PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Boneca, IG; Xu, NX; Gage, DA; deJonge, BLM; Tomasz, A				Boneca, IG; Xu, NX; Gage, DA; deJonge, BLM; Tomasz, A			Structural characterization of an abnormally cross-linked muropeptide dimer that is accumulated in the peptidoglycan of methicillin- and cefotaxime-resistant mutants of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAIN	Laboratory mutants of Staphylococcus aureus strain ATCC 8325 (275) selected for increased minimal inhibitory concentration (MIG) values to methicillin and cefotaxime showed increased rates of cell wall turnover and detergent-induced autolysis in virtual parallel with the increasing MIC for the antibiotic. Also in parallel with the increasing MICs for the particular antibiotic used in the selection was the gradual accumulation of an unusual muropeptide in the peptidoglycan of the mutants, muropeptide 12, which is a minor component of the cell wall of the parental strain. Analysis of muropeptide 12, its peptide derivative, and its lysostaphin degradation products by high pressure liquid chromatography, Edman degradation, and mass spectrometry suggests that muropeptide 12 is a dimer in which the two monomeric components are interlinked by two pentaglycyl crossbridges, thus generating a Ii-member macrocyclic ring structure, This unusual cross-linked structure may be the product of the abnormal activity of penicillin-binding protein 2 which has grossly reduced antibiotic binding capacity in the mutant staphylococci.	ROCKEFELLER UNIV,MICROBIOL LAB,NEW YORK,NY 10021; MICHIGAN STATE UNIV,DEPT BIOCHEM,NIH,MASS SPECTROMETRY FACIL,E LANSING,MI 48824	Rockefeller University; Michigan State University; National Institutes of Health (NIH) - USA			Boneca, Ivo G/H-1677-2014; DeJonge, Boudewijn/AAR-6717-2020	Boneca, Ivo G/0000-0001-8122-509X; 				ATHERTON D, 1989, TECHNIQUES PROTEIN C, V273; DEJONGE BLM, 1991, J BACTERIOL, V173, P1105, DOI 10.1128/jb.173.3.1105-1110.1991; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DELENCASTRE H, 1991, ANTIMICROB AGENTS CH, V35, P632, DOI 10.1128/AAC.35.4.632; GARCIABUSTOS JF, 1987, J BIOL CHEM, V262, P15400; GARCIABUSTOS JF, 1987, ANTIMICROB AGENTS CH, V31, P178, DOI 10.1128/AAC.31.2.178; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; SCHINDLER CA, 1965, BIOCHIM BIOPHYS ACTA, V97, P242, DOI 10.1016/0304-4165(65)90088-7; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; Severin A, 1996, J BACTERIOL, V178, P168, DOI 10.1128/jb.178.1.168-174.1996; TONIN E, 1986, ANTIMICROB AGENTS CH, V30, P577, DOI 10.1128/AAC.30.4.577; Xu NX, 1997, ANAL BIOCHEM, V248, P7, DOI 10.1006/abio.1997.2073	12	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29053	29059		10.1074/jbc.272.46.29053	http://dx.doi.org/10.1074/jbc.272.46.29053			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360979	hybrid			2022-12-27	WOS:A1997YF68400038
J	Diamond, DL; Randall, LL				Diamond, DL; Randall, LL			Kinetic partitioning - Poising SecB to favor association with a rapidly folding ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING-PROTEIN; ESCHERICHIA-COLI SECB; CHAPERONE SECB; SELECTIVE BINDING; EXPORTED PROTEIN; LEADER PEPTIDE; TRANSLOCATION; RECOGNITION; INVITRO; INVIVO	Chaperones are a class of proteins that possess the remarkable ability to selectively bind polypeptides that are in a nonnative state, The selectivity of SecB, a molecular chaperone in Escherichia coli, for its Ligands can be explained in part by a kinetic partitioning between folding of the polypeptide and association with SecB. It has clearly been established that kinetic partitioning can be poised to favor association with SecB by changing the rate constant for folding of the ligand, We now demonstrate that binding to SecB can be given a kinetic advantage over the pathway for folding by modulating the properties of the chaperone. By poising SecB to expose a hydrophobic patch, we were able to detect a complex between SecB and maltose-binding protein under conditions in which rapid folding of the polypeptide otherwise precludes formation of a kinetically stable complex. The data presented here are interpreted within the framework of a kinetic partitioning between binding to SecB and folding of the polypeptide. We propose that exposure of a hydrophobic patch on SecB increases the surface area for binding and thereby increases the rate constant for association. In this way association of SecB with the polypeptide ligand has a kinetic advantage over the pathway for folding.			Diamond, DL (corresponding author), WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,POB 644660,PULLMAN,WA 99164, USA.				NIGMS NIH HHS [GM 29798] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029798, R37GM029798] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHUN SY, 1993, J BIOL CHEM, V268, P20855; DenBlaauwen T, 1996, ARCH MICROBIOL, V165, P1, DOI 10.1007/s002030050289; DIAMOND DL, 1995, PROTEIN SCI, V4, P1118, DOI 10.1002/pro.5560040610; FASMAN GD, 1995, J PROTEIN CHEM, V14, P595, DOI 10.1007/BF01886885; FEKKES P, 1995, BIOCHEMISTRY-US, V34, P10078, DOI 10.1021/bi00031a032; HARDY SJS, 1993, PHILOS T R SOC B, V339, P343, DOI 10.1098/rstb.1993.0033; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; KHISTY VJ, 1995, J BIOL CHEM, V270, P25920, DOI 10.1074/jbc.270.43.25920; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1989, J BIOL CHEM, V264, P2242; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LIU G, 1988, J BIOL CHEM, V263, P14790; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; MILLER DM, 1983, J BIOL CHEM, V258, P3665; MILLS JS, 1988, BIOCHEMISTRY-US, V27, P991, DOI 10.1021/bi00403a023; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; Smith VF, 1996, PROTEIN SCI, V5, P488; SMITH VF, 1997, PROTEIN SCI, V6, P1; TOPPING TB, 1994, PROTEIN SCI, V3, P730; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	30	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28994	28998		10.1074/jbc.272.46.28994	http://dx.doi.org/10.1074/jbc.272.46.28994			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360972	hybrid			2022-12-27	WOS:A1997YF68400031
J	Geiss, GK; Radebaugh, CA; Paule, MR				Geiss, GK; Radebaugh, CA; Paule, MR			The fundamental ribosomal RNA transcription initiation factor-IB (TIF-IB, SL1, factor D) binds to the rRNA core promoter primarily by minor groove contacts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES-SPECIFIC TRANSCRIPTION; PROTEIN-DNA CONTACTS; TATA-BOX COMPLEX; POLYMERASE-I; RDNA TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GENE PROMOTER; DISTAMYCIN-A	Acanthamoeba castellanii transcription initiation factor-IB (TIF-IB) is the TATA-binding protein containing transcription factor that binds the rRNA promoter to form the committed complex. Minor groove-specific drugs inhibit TIF-IB binding, with higher concentrations needed to disrupt preformed complexes because of drug exclusion by bound TIF-IB. TIF-IB/DNA interactions were mapped by hydroxyl radical and uranyl nitrate footprinting. TIF-IB contacts four minor grooves in its binding site. TIF-IB and DNA wrap around each other in a right-handed superhelix of high pitch, so the upstream and downstream contacts are on opposite faces of the helix. Dimethyl sulfate protection assays revealed limited contact with a few guanines in the major groove. This detailed analysis suggests significant DNA conformation dependence of the interaction.	COLORADO STATE UNIV, DEPT BIOCHEM & MOL BIOL, FT COLLINS, CO 80523 USA	Colorado State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022580] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22580] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATEMAN E, 1986, CELL, V47, P445, DOI 10.1016/0092-8674(86)90601-X; BATEMAN E, 1988, MOL CELL BIOL, V8, P1940, DOI 10.1128/MCB.8.5.1940; BATEMAN E, 1985, P NATL ACAD SCI USA, V82, P8004, DOI 10.1073/pnas.82.23.8004; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BELLORINI M, 1995, NUCLEIC ACIDS RES, V23, P1657, DOI 10.1093/nar/23.10.1657; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; BRUZIK JP, 1987, BIOCHEMISTRY-US, V26, P950, DOI 10.1021/bi00377a040; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONS BMG, 1989, NUCLEIC ACIDS RES, V17, P5447, DOI 10.1093/nar/17.14.5447; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; DEVILLIERS J, 1982, NUCLEIC ACIDS RES, V10, P7965, DOI 10.1093/nar/10.24.7965; DOELLING JH, 1995, PLANT J, V8, P683, DOI 10.1046/j.1365-313X.1995.08050683.x; DORN A, 1992, EMBO J, V11, P279, DOI 10.1002/j.1460-2075.1992.tb05050.x; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; FOX KR, 1985, NUCLEIC ACIDS RES, V13, P8695, DOI 10.1093/nar/13.24.8695; FOX KR, 1984, NUCLEIC ACIDS RES, V12, P9271, DOI 10.1093/nar/12.24.9271; GONG XL, 1995, MOL CELL BIOL, V15, P4956; Gourse RL, 1996, ANNU REV MICROBIOL, V50, P645, DOI 10.1146/annurev.micro.50.1.645; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; Heix J, 1997, P NATL ACAD SCI USA, V94, P1733, DOI 10.1073/pnas.94.5.1733; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; IIDA CT, 1985, P NATL ACAD SCI USA, V82, P1668, DOI 10.1073/pnas.82.6.1668; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; IMBODEN MA, 1992, J BIOL CHEM, V267, P24601; JEPPESEN C, 1989, NUCLEIC ACIDS RES, V17, P4947, DOI 10.1093/nar/17.13.4947; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOWNIN P, 1985, NUCLEIC ACIDS RES, V13, P6237, DOI 10.1093/nar/13.17.6237; KOWNIN P, 1988, MOL CELL BIOL, V8, P747, DOI 10.1128/MCB.8.2.747; KOWNIN P, 1987, CELL, V50, P693, DOI 10.1016/0092-8674(87)90327-8; Lalo D, 1996, J BIOL CHEM, V271, P21062, DOI 10.1074/jbc.271.35.21062; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; MANIATIS T, 1982, MOL CLONING LABORATO, P454; Marilley M, 1996, NUCLEIC ACIDS RES, V24, P2204, DOI 10.1093/nar/24.12.2204; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; NEIDLE S, 1987, BIOCHEM J, V243, P1; NIELSEN PE, 1988, FEBS LETT, V235, P122, DOI 10.1016/0014-5793(88)81245-6; NIELSEN PE, 1990, NUCLEIC ACIDS RES, V18, P3847, DOI 10.1093/nar/18.13.3847; NIELSEN PE, 1992, J AM CHEM SOC, V114, P4967, DOI 10.1021/ja00039a003; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Paule Marvin R., 1993, Gene Expression, V3, P1; PAULE MR, 1984, BIOCHEMISTRY-US, V23, P4167, DOI 10.1021/bi00313a025; PAULE MR, 1990, NATURE, V344, P819, DOI 10.1038/344819a0; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PIKAARD CS, 1990, MOL CELL BIOL, V10, P3810, DOI 10.1128/MCB.10.7.3810; PRICE MA, 1992, METHOD ENZYMOL, V212, P194; Pyott A, 1996, BRIT J OPHTHALMOL, V80, P849, DOI 10.1136/bjo.80.9.849; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; RAEEBAUGH CA, 1997, J BIOL CHEM, V272, P3141; REEDER RH, 1992, TRANSCRIPTIONAL REGU, P315; SAFRANY G, 1989, MOL CELL BIOL, V9, P349, DOI 10.1128/MCB.9.1.349; SCHNAPP A, 1991, J BIOL CHEM, V266, P24588; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; Shaw PE, 1994, DNA PROTEIN INTERACT, P79, DOI [10.1385/0-89603-256-6:79, DOI 10.1385/0-89603-256-6:79]; Smith S. David, 1993, Gene Expression, V3, P229; SNOUNOU G, 1983, J MOL BIOL, V167, P211, DOI 10.1016/S0022-2836(83)80043-6; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; Steffan JS, 1996, GENE DEV, V10, P2551, DOI 10.1101/gad.10.20.2551; TOWER J, 1989, MOL CELL BIOL, V9, P1513, DOI 10.1128/MCB.9.4.1513; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WOLFFE AP, 1994, J CELL SCI, V107, P2055; WONG JM, 1992, GENE, V117, P91, DOI 10.1016/0378-1119(92)90494-A; WOYNAROWSKI JM, 1989, BIOCHEMISTRY-US, V28, P3850, DOI 10.1021/bi00435a034; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2; ZWICK MG, 1991, NUCLEIC ACIDS RES, V19, P1681, DOI 10.1093/nar/19.7.1681	75	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29243	29254		10.1074/jbc.272.46.29243	http://dx.doi.org/10.1074/jbc.272.46.29243			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361004	hybrid			2022-12-27	WOS:A1997YF68400063
J	Orlinick, JR; Vaishnaw, A; Elkon, KB; Chao, MV				Orlinick, JR; Vaishnaw, A; Elkon, KB; Chao, MV			Requirement of cysteine-rich repeats of the Fas receptor for binding by the Fas ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; GROWTH-FACTOR RECEPTOR; LYMPHOPROLIFERATIVE SYNDROME; MEDIATED APOPTOSIS; GENE-MUTATIONS; CELL-DEATH; EXPRESSION; ACTIVATION; ANTIGEN; DOMAIN	The Fas receptor is a member of a family of cell death receptors, including tumor necrosis factor receptor I (TNFR I), death receptor 3 and 4 (DR3 and DR4), and cytopathic avian receptor 1 (CAR1), The Fas receptor is composed of several discrete domains, including three cysteine-rich domains (CRDs), a transmembrane do main, and an intracellular domain responsible for transmitting an apoptotic signal, While the mechanism of Fas-mediated cell death has become elucidated, the requirements for Fas ligand binding to the receptor have not been fully defined, Using a series of chimeric F-c-receptor fusion proteins between the human Fas receptor and TNFR I, each cysteine-rich domain of Fas was found to be required for interaction with the Fas ligand, Interestingly, TNFR I CRD1 could partially substitute for the Fas CRD1, The importance of this domain was underscored by the analysis of a Fas extracellular mutation (C66R), which resulted in a complete loss of ligand binding, This mutation was cloned from a human patient suffering from Canale-Smith syndrome, which is characterized by autoimmunity resembling that observed in the lpr and lpr(cg) mice, The localization of essential ligand binding domains in the Fas receptor correlated exactly with the ability of the Fas receptor fusion proteins to prevent cell death mediated by the Fas ligand.	CORNELL UNIV,HOSP SPECIAL SURG,COLL MED,DEPT CELL BIOL,NEW YORK,NY 10021; CORNELL UNIV,HOSP SPECIAL SURG,COLL MED,DEPT MED,NEW YORK,NY 10021	Cornell University; Cornell University				Chao, Moses/0000-0002-6969-3744	NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NCI NIH HHS [CA56490] Funding Source: Medline; NIAMS NIH HHS [P50AR-425888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CASCINO I, 1995, J IMMUNOL, V154, P2706; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; CHU J, 1994, J EXP MED, V178, P723; CORCORAN AE, 1994, EUR J BIOCHEM, V223, P831, DOI 10.1111/j.1432-1033.1994.tb19059.x; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HSU KC, 1993, J BIOL CHEM, V268, P16430; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOBAYASHI S, 1993, BIOCHEM BIOPH RES CO, V191, P617, DOI 10.1006/bbrc.1993.1262; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; MARSTERS SA, 1992, J BIOL CHEM, V267, P5747; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; ONEL KB, 1995, EUR J IMMUNOL, V25, P2940, DOI 10.1002/eji.1830251034; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Starling GC, 1997, J EXP MED, V185, P1487, DOI 10.1084/jem.185.8.1487; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WU JG, 1993, J EXP MED, V178, P461, DOI 10.1084/jem.178.2.461; YAN H, 1991, J BIOL CHEM, V266, P12099	38	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28889	28894		10.1074/jbc.272.46.28889	http://dx.doi.org/10.1074/jbc.272.46.28889			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360957	hybrid			2022-12-27	WOS:A1997YF68400016
J	Accili, EA; Kiehn, J; Wible, BA; Brown, AM				Accili, EA; Kiehn, J; Wible, BA; Brown, AM			Interactions among inactivating and noninactivating Kv beta subunits, and Kv alpha 1.2, produce potassium currents with intermediate inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; K+ CHANNELS; RAT-BRAIN; EXPRESSION; KV-BETA-1	Experiments were carried out to determine whether coinjection of Kv alpha 1.2 with inactivating and noninactivating Kv beta subunits would produce currents with intermediate kinetics and channel complexes containing a mixture of these subunits. Upon coexpression with a saturating amount of Kv beta 1.2 and increasing levels of a noninactivating deletion mutant of Kv beta 1.2, we show that macroscopic Kv alpha 1.2 currents have levels of fractional inactivation and inactivation time constants that are intermediate between those obtained with either the inactivating Kv beta 1.2 or the noninactivating Kv beta 1.2 mutant. We also find that coexpression of Kv alpha 1.2 with saturating amounts of Kv beta 1.2 and the deletion mutant produces a population of single channels with properties intermediate to either the inactivating or noninactivating parental phenotype. Our data can best be explained by the presence of an intermediate population of heterooligomeric channels consisting of Kv alpha 1.2 with different combinations of both types of subunits. Since Kv alpha 1.2 subunits coexist in cells with inactivating and noninactivating Kv beta subunits, our findings suggest that heterooligomeric assembly of these subunits occurs to increase the range of K+ current kinetics and expression levels.	RAMMELKAMP CTR RES,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44109	MetroHealth System; Case Western Reserve University; Case Western Reserve University					NHLBI NIH HHS [HL55404, HL-36930] Funding Source: Medline; NINDS NIH HHS [NS23877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930, R01HL055404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Accili E. A., 1997, Biophysical Journal, V72, pA349; Accili EA, 1997, J BIOL CHEM, V272, P25824, DOI 10.1074/jbc.272.41.25824; KIEHN J, 1996, CIRCULATION, V94, P1151; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rhodes KJ, 1996, J NEUROSCI, V16, P4846; RHODES KJ, 1995, J NEUROSCI, V15, P5360; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; VanDongen AMJ, 1996, BIOPHYS J, V70, P1303, DOI 10.1016/S0006-3495(96)79687-X; Wang ZG, 1996, J BIOL CHEM, V271, P28311, DOI 10.1074/jbc.271.45.28311; Xu J, 1997, J BIOL CHEM, V272, P11728, DOI 10.1074/jbc.272.18.11728; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	16	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28232	28236		10.1074/jbc.272.45.28232	http://dx.doi.org/10.1074/jbc.272.45.28232			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353274	hybrid			2022-12-27	WOS:A1997YF21900014
J	Haribabu, B; Richardson, RM; Fisher, I; Sozzani, S; Peiper, SC; Horuk, R; Ali, H; Snyderman, R				Haribabu, B; Richardson, RM; Fisher, I; Sozzani, S; Peiper, SC; Horuk, R; Ali, H; Snyderman, R			Regulation of human chemokine receptors CXCR4 - Role of phosphorylation in desensitization and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; PLATELET-ACTIVATING-FACTOR; HIV-1 ENTRY; BETA-ARRESTIN; CHEMOATTRACTANT RECEPTORS; PEPTIDE CHEMOATTRACTANTS; INTERLEUKIN-8 RECEPTOR; TRANSDUCTION PATHWAYS; CROSS-DESENSITIZATION; SIGNAL-TRANSDUCTION	Members of the chemokine receptor family CCR5 and CXCR4 have recently been shown to be involved in the entry of human immunodeficiency virus (HIV) into tar; get cells. Here, we investigated the regulation of CXCR4 in rat basophilic leukemia cells (RBL-2H3) stably transfected with wild type (Wt CXCR4) or a cytoplasmic tail deletion mutant (Delta Cyto CXCR4) of CXCR4. The ligand, stromal cell derived factor-1 (SDF-1) stimulated higher G-protein activation, inositol phosphate generation, add a more sustained calcium elevation in cells expressing Delta Cyto CXCR4 relative to Wt CXCR4. SDF-1 and phorbol 12-myristate 13-acetate (PMA), but not a membrane permeable cAMP analog induced rapid phosphorylation as well as desensitization of Wt CXCR4. Phosphorylation of Delta Cyto CXCR4 was not detected under any of these conditions. Despite lack of receptor phosphorylation, calcium mobilization by SDF-1 in Delta Cyto CXCR4 cells was partially desensitized by prior treatment with SDF-1. Of interest, the rapid release of calcium was inhibited without affecting the sustained calcium elevation, indicating independent regulatory pathways for these processes. PMA completely inhibited phosphoinositide hydrolysis and calcium mobilization in Wt CXCR4 but only partially inhibited these responses ill Delta Cyto CXCR4, cAMP also partially inhibited these responses in both, Wt CXCR4, and Delta Cyto CXCR4. SDF-1, PMA, and cAMP caused phosphorylation of phospholipase C beta 3 in Wt add Delta Cyto CXCR4 cells. Both SDF-1 as well as PMA induced rapid internalization of Wt CXCR4. SDF-1 but not PMA induced internalization of Delta Cyto CXCR4 albeit at reduced levels relative: td Wt CXCR4. These results indicate that signaling and internalization of CXCR4 are regulated by receptor phosphorylation dependent and independent mechanisms. Desensitization of CXCR4 signaling, independent of receptor phosphorylation, appears to be a consequence of the phosphorylation of phospholipase C beta 3.	DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710; IST RIC FARMACOL MARIO NEGRI,MILAN,ITALY; UNIV LOUISVILLE,JAMES GRAHAM BROWN CANC CTR,LOUISVILLE,KY 40292; BERLEX BIOSCI,DEPT IMMUNOL,RICHMOND,CA 94804	Duke University; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Louisville	Haribabu, B (corresponding author), DUKE UNIV,MED CTR,DEPT MED,BOX 3680,DURHAM,NC 27710, USA.		Sozzani, Silvano/C-1447-2009; Bodduluri, Haribabu/A-2584-2010	Sozzani, Silvano/0000-0002-3144-8743; Bodduluri, Haribabu/0000-0002-8261-3294	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038910, R01AI038910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54166] Funding Source: Medline; NIAID NIH HHS [AI-38910] Funding Source: Medline; NIDCR NIH HHS [DE-03738] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ALI H, 1993, J BIOL CHEM, V268, P24247; ALI H, 1994, J BIOL CHEM, V269, P24567; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1996, RECENT PROG HORM RES, V51, P352; GIERSCHIK P, 1994, METHOD ENZYMOL, V237, P13; GOLDING H, 1995, J VIROL, V69, P6140, DOI 10.1128/JVI.69.10.6140-6148.1995; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LATTION AL, 1994, J BIOL CHEM, V269, P22887; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Pohl M, 1997, J BIOL CHEM, V272, P18179, DOI 10.1074/jbc.272.29.18179; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; SOZZANI S, 1994, J IMMUNOL, V152, P3615; TAKANO T, 1994, J BIOL CHEM, V269, P22453; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	52	246	252	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28726	28731		10.1074/jbc.272.45.28726	http://dx.doi.org/10.1074/jbc.272.45.28726			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353342	hybrid			2022-12-27	WOS:A1997YF21900082
J	Krishnamurti, U; Rondeau, E; Sraer, JD; Michael, AF; Tsilibary, EC				Krishnamurti, U; Rondeau, E; Sraer, JD; Michael, AF; Tsilibary, EC			Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ACTIVATED PROTEIN-KINASES; SIGNAL-TRANSDUCTION; IV COLLAGEN; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; MESANGIAL CELLS; MESSENGER-RNA; INTEGRINS; EXPRESSION	The glomerular epithelial cells and the glomerular basement membrane are important constituents of the permselective barrier in the kidney. These are affected in diabetic nephropathy, one of the long-term complications in diabetic patients. Nonenzymatic glycosylation resulting in the accumulation of advanced glycosylation end products correlates with the development of longterm complications in diabetes, The interaction of cells with extracellular matrix proteins plays a critical role in a variety of biological processes. Recent studies show that cell-matrix interactions mediated by integrins can transduce biochemical signals to the cell interior and regulate cell behavior. In this paper we demonstrate that interactions of human glomerular epithelial cells with a nonenzymatically glycated matrix are altered with defective cell spreading, reduced phosphorylation of focal adhesion kinase and reduced activity df mitogen-activated protein kinase. These data suggest that matrix glycation interferes with normal cell-matrix interactions and intracellular signaling that can potentially result in differential gene expression contributing to the changes seen in diabetic nephropathy.	UNIV MINNESOTA, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA; HOP TENON, INSERM, U64, F-75970 PARIS, FRANCE; DEMOKRITOS NATL CTR SCI RES, INST BIOL, ATHENS 60228, GREECE	University of Minnesota System; University of Minnesota Twin Cities; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; National Centre of Scientific Research "Demokritos"	Krishnamurti, U (corresponding author), UNIV MINNESOTA, DEPT LAB MED & PATHOL, BOX 609 UMHC, 420 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA.		Krishnamurti, Uma/AAA-1733-2022; Krishnamurti, Uma/AAW-9867-2020		NIAID NIH HHS [AI-10704] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI010704, R37AI010704] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRASS CK, 1988, DIABETES, V37, P1695, DOI 10.2337/diabetes.37.12.1695; Anderson Shane S., 1992, Journal of the American Society of Nephrology, V3, P625; ANDERSON SS, 1994, KIDNEY INT, V46, P1359, DOI 10.1038/ki.1994.405; AYO SH, 1991, AM J PHYSIOL, V260, pF185, DOI 10.1152/ajprenal.1991.260.2.F185; BISELL MJ, 1987, J CELL SCI S, V8, P327; BORDER WA, 1989, SEMIN NEPHROL, V9, P307; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; CHARONIS AS, 1992, DIABETES, V41, P49, DOI 10.2337/diab.41.2.S49; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen Y, 1996, KIDNEY INT, V49, P153, DOI 10.1038/ki.1996.20; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COSIO FG, 1992, AM J KIDNEY DIS, V20, P294, DOI 10.1016/S0272-6386(12)80705-0; COSIO FG, 1995, KIDNEY INT S51, V48, P12; DELARUE F, 1991, KIDNEY INT, V40, P906, DOI 10.1038/ki.1991.292; HAITOGLOU CS, 1992, J BIOL CHEM, V267, P12404; HASEGAWA G, 1995, J BIOL CHEM, V270, P3278, DOI 10.1074/jbc.270.7.3278; HUMPHRIES MJ, 1993, BIOESSAYS, V15, P391, DOI 10.1002/bies.950150605; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KORHONEN M, 1990, J CELL BIOL, V111, P1245, DOI 10.1083/jcb.111.3.1245; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Krishnamurti U, 1996, LAB INVEST, V74, P650; LEDBETTER S, 1990, DIABETES, V39, P196, DOI 10.2337/diabetes.39.2.196; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; ORKIN RW, 1977, J EXP MED, V145, P204, DOI 10.1084/jem.145.1.204; OSTERBY R, 1980, DIABETOLOGIA, V18, P493; OVEREND WG, 1981, J CHEM SCI, P3487; RAHILLY MA, 1992, J PATHOL, V167, P327, DOI 10.1002/path.1711670311; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SETTY S, 1995, CELL ADHES COMMUN, V3, P187, DOI 10.3109/15419069509081286; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; WOLF P, 1983, ANAL BIOCHEM, V129, P145, DOI 10.1016/0003-2697(83)90062-3; Yasuda T., 1996, Journal of the American Society of Nephrology, V7, P1880	44	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27966	27970		10.1074/jbc.272.44.27966	http://dx.doi.org/10.1074/jbc.272.44.27966			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346947	hybrid			2022-12-27	WOS:A1997YD47300073
J	Lima, WF; Crooke, ST				Lima, WF; Crooke, ST			Cleavage of single strand RNA adjacent to RNA-DNA duplex regions by Escherichia coli RNase H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-H; HYDROLYSIS; ENZYME; GENE	RNase H1 from Escherichia coli cleaves single strand RNA extending 3' from an RNA-DNA duplex. Substrates consisting of a 25-mer RNA annealed to complementary DNA ranging in length from 9-17 nucleotides were designed to create overhanging single strand RNA regions extending 5' and 3' from the RNA-DNA duplex. Digestion of single strand RNA was observed exclusively within the 3' overhang region and not the 5' overhang region. RNase H digestion of the 3' overhang region resulted in digestion products with 5'-phosphate and 3'-hydroxyl termini. The number of single strand RNA residues cleaved by RNase H is influenced by the sequence of the single strand RNA immediately adjacent to the RNA-DNA duplex and appears to be a function of the stacking properties of the RNA residues adjacent to the RNA-DNA duplex. RNase H digestion of the 3' overhang region was not observed for a substrate that contained a 2'-methoxy antisense strand. The introduction of 3 de oxynucleotides at the 5' terminus of the 2'-methoxy antisense oligonucleotide resulted in cleavage. These results offer additional insights into the binding directionality of RNase H with respect to the heteroduplex substrate.			Lima, WF (corresponding author), ISIS PHARMACEUT,2280 FARADAY AVE,CARLSBAD,CA 92008, USA.							BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; BUSEN W, 1980, J BIOL CHEM, V255, P9434; CECH TR, 1993, RNA WORLD, P239; CERRITELLI SM, 1995, RNA, V1, P246; CROOKE ST, 1995, BIOCHEM J, V312, P599, DOI 10.1042/bj3120599; Crouch R. J., 1982, NUCLEASES, P211; Daniher AT, 1997, BIOORGAN MED CHEM, V5, P1037, DOI 10.1016/S0968-0896(97)00040-0; HAUSEN P, 1970, EUR J BIOCHEM, V14, P279; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HUANG L, 1994, J BIOL CHEM, V269, P25922; IKEHARA M, 1986, P NATL ACAD SCI USA, V83, P4695, DOI 10.1073/pnas.83.13.4695; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KELLER W, 1972, P NATL ACAD SCI USA, V81, P3993; Lima WF, 1997, J BIOL CHEM, V272, P18191, DOI 10.1074/jbc.272.29.18191; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; MONIA BP, 1993, J BIOL CHEM, V268, P14514; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; ODA Y, 1993, J BIOL CHEM, V268, P88; POSRSCHE D, 1973, EUR J BIOCHEM, V39, P117; REICH C, 1980, BIOPOLYMERS, V19, P833, DOI 10.1002/bip.1980.360190409; ROBERTS GCK, 1969, P NATL ACAD SCI USA, V62, P1151, DOI 10.1073/pnas.62.4.1151; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; UCHIYAMA Y, 1994, J BIOCHEM-TOKYO, V116, P1322, DOI 10.1093/oxfordjournals.jbchem.a124682	26	60	70	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27513	27516		10.1074/jbc.272.44.27513	http://dx.doi.org/10.1074/jbc.272.44.27513			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346880	hybrid			2022-12-27	WOS:A1997YD47300006
J	Murray, NR; Fields, AP				Murray, NR; Fields, AP			Atypical protein kinase C iota protects human leukemia cells against drug-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K562 CELLS; PHOSPHATASE INHIBITOR; OKADAIC ACID; PKC-LAMBDA; IN-VITRO; DIFFERENTIATION; ACTIVATION; ISOZYMES; PROLIFERATION; ISOENZYMES	Protein kinase C (PHC) isozymes play distinct roles in cellular function. In human K562 leukemia cells, PKC alpha is important for cellular differentiation and PKC beta(II) is required for proliferation. In this report, we assess the role of the atypical PKC isoform PKC iota in H562 leukemia cell physiology. K562 cells were stably transfected with expression plasmids containing the cDNA for human PKC iota in sense or antisense orientation to increase or decrease cellular PKC iota levels, respectively. Overexpression or inhibition of expression of PKC iota had no significant effect on the proliferative capacity of K562 cells nor their sensitivity to phorbol myristate acetate-induced cytostasis and megakaryocytic differentiation, suggesting that PKC iota does not play a critical role in these processes, Rather, PKC iota serves to protect K562 cells against drug-induced apoptosis, K562 cells, which are resistant to most apoptotic agents, undergo apoptosis when treated with the protein phosphatase inhibitor okadaic acid (OA). Overexpression of PKC iota leads to increased resistance to OA induced apoptosis whereas inhibition of PKC iota expression sensitizes cells to OA-induced apoptosis, Overexpression of the related atypical PKC zeta has no protective effect, demonstrating that the effect is isotype-specific, PKC iota also protects K562 cells against taxol-induced apoptosis, indicating that it plays a general protective role against apoptotic stimuli. These data support a role for PKC iota in leukemia cell survival.	UNIV TEXAS,MED BRANCH,SEALY CTR ONCOL & HEMATOL,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT PHARMACOL,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston								AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; CLEMENS MJ, 1992, J CELL SCI, V103, P881; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; HOCEVAR BA, 1992, J CELL SCI, V101, P671; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; Mueller Gertraud, 1995, EMBO (European Molecular Biology Organization) Journal, V14, P1961; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; MURRAY NR, 1997, PROTEIN KINASE C, P97; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; RAY S, 1994, CANCER CHEMOTH PHARM, V34, P365, DOI 10.1007/s002800050156; Ray S, 1996, CELL GROWTH DIFFER, V7, P1617; RITKE MK, 1994, MOL PHARMACOL, V46, P605; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868; ZHENG B, 1991, J BIOL CHEM, V266, P10031; ZHENG B, 1994, J BIOL CHEM, V269, P12332	33	155	163	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27521	27524		10.1074/jbc.272.44.27521	http://dx.doi.org/10.1074/jbc.272.44.27521			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346882	hybrid			2022-12-27	WOS:A1997YD47300008
J	Swietnicki, W; Petersen, R; Gambetti, P; Surewicz, WK				Swietnicki, W; Petersen, R; Gambetti, P; Surewicz, WK			pH-dependent stability and conformation of the recombinant human prion protein PrP(90-231)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; MOLECULAR-BIOLOGY; PRP 27-30; SCRAPIE; CONVERSION; INFECTIVITY; MECHANISM; DISEASES	A recombinant protein corresponding to the human prion protein domain encompassing residues 90-231 (huPrP(90-231)) was expressed in Escherichia coli in a soluble form and purified to homogeneity. Spectroscopic data indicate that the conformational properties and the folding pathway of huPrP(90-231) are strongly pH-dependent, Acidic pH induces a dramatic increase in the exposure of hydrophobic patches on the surface of the protein. At pH between 7 and 5, the unfolding of hPrP(90-231) in guanidine hydrochloride occurs as a two-state transition, This contrasts with the unfolding curves at lower pH values, which indicate a three-state transition, with the presence of a stable protein folding intermediate, While the secondary structure of the native huPrP(90-231) is largely alpha-helical, the stable intermediate is rich in beta-sheet structure, These findings have important implications for understanding the initial events on the pathway toward the conversion of the normal into the pathological forms of prion protein.	CASE WESTERN RESERVE UNIV,DEPT PATHOL,CLEVELAND,OH 44106	Case Western Reserve University			Swietnicki, Wieslaw/GOP-2576-2022; Swietnicki, Wieslaw/AAL-2452-2021; Petersen, Robert/B-5075-2011; Swietnicki, Wieslaw/AAU-1536-2020	Petersen, Robert/0000-0002-3154-0072; Swietnicki, Wieslaw/0000-0002-9354-8184				Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; GAJDUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HORNEMANN S, 1996, J MOL BIOL, V262, P614; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1536; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1996, SEMIN VIROL, V7, P181, DOI 10.1006/smvy.1996.0023; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; Safar J, 1996, SEMIN VIROL, V7, P207, DOI 10.1006/smvy.1996.0026; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yehiely F, 1997, NEUROBIOL DIS, V3, P339, DOI 10.1006/nbdi.1997.0130; Zhang H, 1997, BIOCHEMISTRY-US, V36, P3543, DOI 10.1021/bi961965r	37	239	247	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27517	27520		10.1074/jbc.272.44.27517	http://dx.doi.org/10.1074/jbc.272.44.27517			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346881	hybrid			2022-12-27	WOS:A1997YD47300007
J	Watanabe, H; Cheung, SC; Itano, N; Kimata, K; Yamada, Y				Watanabe, H; Cheung, SC; Itano, N; Kimata, K; Yamada, Y			Identification of hyaluronan-binding domains of aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; PIG LARYNGEAL CARTILAGE; LINK PROTEIN; EXTRACELLULAR-MATRIX; KERATAN SULFATE; BIOTINYLATED HYALURONAN; MOLECULAR-CLONING; BOVINE CARTILAGE; ACID; RECEPTOR	Aggrecan, a large cartilage proteoglycan, interacts with hyaluronan (HA), to form aggregates which function to resist compression in joints. The N-terminal region of aggrecan contains two structurally related globular domains, G(1) and G(2) separated by IGD domain. The G(1) domain consists of three subdomains, A, B, and B', structural features characteristic to many other HA-binding proteoglycans. Here, we studied the interaction of aggrecan domains with HA using recombinant proteins expressed in 293 cells, an embryonal kidney cell line. Deglycosylation of the recombinant aggrecan fragment reduced the HA binding activity. We found that both the B and B' subdomains were required for HA binding and that a single module of A, B, or B' was unable to bind HA. The A subdomain increased the HA binding activity of the B-B' region. The G(2) domain had no HA binding activity confirming previous reports. Studies of HA-binding properties using a BIAcore(TM) biosensor system revealed that the K-D of recombinant aggrecan fragment (AgW) consisting of G(1), IGD, and G(2) was 0.226 mu M, whereas the K-D of another HA-binding protein, native bovine link protein, is 0.089 mu M. In contrast, Ag-Mut11 which lacked subdomain A showed little HA binding activity. AgMut12 consisting of only B-B' had a 3.4-fold lower affinity and AgMut13 containing A-B-B' was 1.5-fold lower than AgW. These results suggest that carbohydrates are essential for high level aggrecan binding to HA and that the A subdomain of aggrecan functions in a cooperative manner with subdomains B and B'.	NIDR, CRANIOFACIAL DEV BIOL & REGENERAT BRANCH, NIH, BETHESDA, MD 20892 USA; US FDA, CTR BIOL EVALUAT & RES, DIV HEMATOL, LAB HEMOSTASIS, ROCKVILLE, MD 20852 USA; AICHI MED UNIV, INST MOL SCI MED, NAGAKUTE, AICHI 48011, JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); US Food & Drug Administration (FDA); Aichi Medical University								BARRY FP, 1994, MATRIX BIOL, V14, P323, DOI 10.1016/0945-053X(94)90198-8; BARRY FP, 1995, J BIOL CHEM, V270, P20516, DOI 10.1074/jbc.270.35.20516; BARRY FP, 1992, BIOCHEM J, V286, P761, DOI 10.1042/bj2860761; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; CHEN L, 1994, J BIOL CHEM, V269, P28282; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HOARE K, 1993, CONNECT TISSUE RES, V30, P117, DOI 10.3109/03008209309041327; HORITA DA, 1994, J BIOL CHEM, V269, P1699; HORVATH E, 1989, J NEUROSCI RES, V24, P398, DOI 10.1002/jnr.490240309; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Knudson W, 1996, AM J PATHOL, V148, P1721; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; LESK AM, 1982, J MOL BIOL, V160, P325, DOI 10.1016/0022-2836(82)90179-6; MCCOURT PAG, 1994, J BIOL CHEM, V269, P30081; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; NIEDUSZYNSKI IA, 1980, BIOCHEM J, V185, P107, DOI 10.1042/bj1850107; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PERIN JP, 1987, J BIOL CHEM, V262, P13269; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; RAUCH U, 1992, J BIOL CHEM, V267, P19536; SANDY JD, 1990, J BIOL CHEM, V265, P21108; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; SUGIURA N, 1993, J BIOL CHEM, V268, P15779; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; VARELAS JB, 1995, ARCH BIOCHEM BIOPHYS, V321, P21, DOI 10.1006/abbi.1995.1363; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YANG BH, 1995, ANAL BIOCHEM, V228, P299, DOI 10.1006/abio.1995.1354; YU Q, 1995, BIOTECHNIQUES, V19, P122; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	46	106	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28057	28065		10.1074/jbc.272.44.28057	http://dx.doi.org/10.1074/jbc.272.44.28057			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346959	hybrid			2022-12-27	WOS:A1997YD47300085
J	Cooksey, CJ; Garratt, PJ; Land, EJ; Pavel, S; Ramsden, CA; Riley, PA; Smit, NPM				Cooksey, CJ; Garratt, PJ; Land, EJ; Pavel, S; Ramsden, CA; Riley, PA; Smit, NPM			Evidence of the indirect formation of the catecholic intermediate substrate responsible for the autoactivation kinetics of tyrosinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3,4-DIHYDROXYPHENYLALANINE DOPA; MELANIN BIOSYNTHESIS; PULSE-RADIOLYSIS; OXIDATION; PRECURSORS; PATHWAY; MODEL	Tyrosinase (EC 1.14.18.1) exhibits unusual kinetic properties in the oxidation of monohydric phenol substrates consisting of a lag period that increases with increasing substrate concentration, The cause of this is an autocatalytic process dependent on the generation of a dihydric phenol substrate, which acts as an activator of the enzyme, Experiments with N-substituted dihydric phenol substrate (N-methyldopamine, N-acetyldopamine) demonstrate that oxygen consumption is retarded in the N-acetyl substituted material due to a diminished rate of cyclization, The oxygen uptake exhibited a similar pattern when N-acetyltyramine was oxidized, and this was reflected by a prolongation of the lag period, N,N-Dipropyldopamine was oxidized with. normal kinetics but with an oxygen stoichiometry of 0.5 mol of oxygen/mol of substrate, We show that this is the result of the formation of a stable indoliumolate product with oxidation-reduction properties that prevent the formation of dopaminochrome, thus blocking further stages in the tyrosinase-catalyzed oxidation, Evidence that the indoliumolate product is formed by cyclization of the ortho-quinone is presented by pulse radiolysis studies, which demonstrate the formation of the ortho-quinone (by disproportionation of the corresponding semiquinones), which cyclizes to give the indoliumolate, The rate constant for cyclization was shown to be 48 s(-1) (at pH 6.0), Tyrosinase-catalyzed oxidation of the monohydric phenol analogue, N,N-dimethyltyramine, was shown to require the addition of a dihydric phenol, Oxygen utilization then exhibited a stoichiometry of 1.0, indicating that the reactions proceed only as far as the cyclization. The analogous stable cyclic indoliumolate product was shown to be formed, with UV absorption and NMR spectra closely similar to the indoliumolate derived from N,N-dipropyldopamine. This material was methylated by catechol O-methyltransferase but was unreactive to redox reagents, The formation of the cyclic product accounts for the indefinite lag when N,N-dimethyltyramine is used as the substrate for tyrosinase in the absence of a dihydric phenol cofactor.	UNIV COLL & MIDDLESEX SCH MED, WINDEYER INST, LONDON W1P 6DB, ENGLAND; UNIV LONDON UNIV COLL, CHRISTOPHER INGOLD LABS, DEPT CHEM, LONDON WC1H 0AJ, ENGLAND; CHRISTIE HOSP NHS TRUST, PATERSON INST CANC RES, DEPT BIOPHYS CHEM, CRC, MANCHESTER M20 9BX, LANCS, ENGLAND; LEIDEN UNIV HOSP, DEPT DERMATOL, NL-2333 ZA LEIDEN, NETHERLANDS; UNIV KEELE, DEPT CHEM, KEELE ST5 5BG, STAFFS, ENGLAND	University of London; University College London; University of London; University College London; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Leiden University; Leiden University Medical Center (LUMC); Keele University				Cooksey, Christopher/0000-0002-4151-082X				ADAMS GE, 1965, PULSE RADIOLYSIS, P117; BELL VL, 1986, J CHEM SOC PERK T 1, P1515, DOI 10.1039/p19860001515; BHATNAGAR V, 1993, ARCH BIOCHEM BIOPHYS, V307, P183, DOI 10.1006/abbi.1993.1577; BUTLER J, 1989, RADIAT PHYS CHEM, V34, P633; BUTLER J, 1984, RADIAT PHYS CHEM, V23, P265, DOI 10.1016/0146-5724(84)90118-3; CABANES J, 1987, BIOCHIM BIOPHYS ACTA, V923, P187, DOI 10.1016/0304-4165(87)90003-1; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; CHEDEKEL MR, 1984, J CHEM SOC CHEM COMM, P1170, DOI 10.1039/c39840001170; Cooksey CJ, 1996, QUANT STRUCT-ACT REL, V15, P498, DOI 10.1002/qsar.19960150606; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; Evans WC, 1937, BIOCHEM J, V31, P2162, DOI 10.1042/bj0312162; HEARING VJ, 1981, INT J BIOCHEM, V13, P99, DOI 10.1016/0020-711X(81)90141-5; KEENE JP, 1964, J SCI INSTRUM, V41, P493, DOI 10.1088/0950-7671/41/8/302; LAMBERT C, 1991, J CHEM SOC FARADAY T, V87, P2939, DOI 10.1039/ft9918702939; LAND EJ, 1993, J CHEM SOC FARADAY T, V89, P803, DOI 10.1039/ft9938900803; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; LERNER AB, 1949, J BIOL CHEM, V178, P185; Naish-Byfield S, 1991, Melanoma Res, V1, P273; NAISHBYFIELD S, 1992, BIOCHEM J, V288, P63, DOI 10.1042/bj2880063; RODRIGUEZLOPEZ JN, 1992, J BIOL CHEM, V267, P3801; SMIT NPM, 1990, ANAL BIOCHEM, V190, P286, DOI 10.1016/0003-2697(90)90195-F; SOLOMON EI, 1993, SCIENCE, V259, P1575, DOI 10.1126/science.8384374; SUGUMARAN M, 1992, J BIOL CHEM, V267, P10355; THOMPSON A, 1985, BIOCHIM BIOPHYS ACTA, V843, P49, DOI 10.1016/0304-4165(85)90048-0; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x	25	293	305	3	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26226	26235		10.1074/jbc.272.42.26226	http://dx.doi.org/10.1074/jbc.272.42.26226			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334191	hybrid			2022-12-27	WOS:A1997YB13900025
J	Wang, HY; Singh, D; Fliegel, L				Wang, HY; Singh, D; Fliegel, L			The Na+/H+ antiporter potentiates growth and retinoic acid-induced differentiation of P19 embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH REGULATION; GENE-EXPRESSION; HL-60 CELLS; MONOCYTIC DIFFERENTIATION; PROXIMAL TUBULES; LEUKEMIC-CELLS; EXCHANGER GENE; SMOOTH-MUSCLE; ACTIVATION; PROLIFERATION	The Na+/H+ exchanger is a ubiquitous plasma membrane protein that is responsible for pH regulation and is activated by growth factors. We examined the role of the Na+/H+ exchanger in cell growth and differentiation. Treatment of P19 cells with the Na+/H+ exchanger inhibitor Hoe 694 eliminated retinoic acid-induced differentiation in this cell line. We developed a P19 embryonal carcinoma cell line that was deficient in the Na+/H+ antiporter. Na+/H+ exchanger-deficient cells were reduced in the rate of cell growth and this effect was enhanced by the removal of added HCO(3)(-)1 and by reducing extracellular pH. The antiporter-deficient cells were also markedly deficient in their ability to differentiate to neuronal-like cells and recovered this ability when the Na+/H+ antiporter was reintroduced. The results show that the absence of Na+/H+ antiport as a pH regulatory mechanism can result in deficiencies in both cell growth and differentiation in embryonal carcinoma cells.	UNIV ALBERTA,FAC MED,DEPT PEDIAT,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,FAC MED,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,FAC MED,DEPT ANAT & CELL BIOL,MRC,GRP MOL BIOL MEMBRANES,EDMONTON,AB T6G 2H7,CANADA	University of Alberta; University of Alberta; University of Alberta								ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; ALVAREZ J, 1989, EUR J BIOCHEM, V183, P709, DOI 10.1111/j.1432-1033.1989.tb21102.x; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; BURNS CP, 1983, BIOCHEM BIOPH RES CO, V116, P931; CASSEL D, 1988, J BIOL CHEM, V263, P6122; CHAILLET JR, 1985, J GEN PHYSIOL, V86, P765, DOI 10.1085/jgp.86.6.765; CHURCH JG, 1989, BIOCHEM J, V257, P151, DOI 10.1042/bj2570151; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DYCK JRB, 1995, J BIOL CHEM, V270, P10420, DOI 10.1074/jbc.270.18.10420; DYCK JRB, 1995, CARDIOVASC RES, V29, P203, DOI 10.1016/S0008-6363(96)88571-3; DYCK JRB, 1995, J BIOL CHEM, V270, P1375, DOI 10.1074/jbc.270.3.1375; FLIEGEL L, 1993, MOL CELL BIOCHEM, V125, P137, DOI 10.1007/BF00936442; FLIEGEL L, 1993, BIOCHEM J, V289, P101, DOI 10.1042/bj2890101; GLEESON D, 1989, J CLIN INVEST, V84, P312, DOI 10.1172/JCI114156; GRINSTEIN S, 1983, J GEN PHYSIOL, V82, P619, DOI 10.1085/jgp.82.5.619; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAZAV P, 1989, CANCER RES, V49, P72; HENSLEY CB, 1989, AM J PHYSIOL, V257, pC637, DOI 10.1152/ajpcell.1989.257.4.C637; HORIE S, 1992, J CLIN INVEST, V89, P365, DOI 10.1172/JCI115594; KRAPF R, 1991, J CLIN INVEST, V87, P747, DOI 10.1172/JCI115057; LADOUX A, 1988, EUR J BIOCHEM, V175, P455, DOI 10.1111/j.1432-1033.1988.tb14216.x; LAGARDE AE, 1986, CANCER BIOCHEM BIOPH, V9, P1; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; NEYLON CB, 1990, CIRC RES, V67, P814, DOI 10.1161/01.RES.67.4.814; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; POUYSSEGUR J, 1980, P NATL ACAD SCI-BIOL, V77, P2698, DOI 10.1073/pnas.77.5.2698; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RAO GN, 1990, J BIOL CHEM, V265, P19393; RAO GN, 1992, J CELL PHYSIOL, V151, P361, DOI 10.1002/jcp.1041510217; RAO GN, 1991, J BIOL CHEM, V266, P13485; SINGH G, 1995, BBA-BIOMEMBRANES, V1239, P74, DOI 10.1016/0005-2736(95)00148-V; VAIRO G, 1993, CELL GROWTH DIFFER, V4, P461; VAIRO G, 1992, J BIOL CHEM, V267, P19043; YAMAGATA Y, 1996, NA PLUS H PLUS EXCHA, P269; Yang WD, 1996, BBA-GENE STRUCT EXPR, V1306, P107, DOI 10.1016/0167-4781(95)00236-7	36	61	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26545	26549		10.1074/jbc.272.42.26545	http://dx.doi.org/10.1074/jbc.272.42.26545			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334233	hybrid			2022-12-27	WOS:A1997YB13900067
J	Wu, RC; Schonthal, AH				Wu, RC; Schonthal, AH			Activation of p53-p21(waf1) pathway in response to disruption of cell-matrix interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; ANCHORAGE-INDEPENDENT GROWTH; P21(WAF1/CIP1) EXPRESSION; RETINOBLASTOMA PROTEIN; A EXPRESSION; P53; P21; INHIBITORS; GENES; TRANSCRIPTION	The proliferation of most cells is strictly dependent on cell-matrix interactions, a phenomenon called anchorage dependence, Because tumor cells often are independent of this regulation, it is important to characterize the molecular pathways that control cellular proliferation after detachment of cells from their matrix. In this report, we investigated a possible role of p53 and one of its target genes, p21(waf1/cip1), as components of anchorage-dependent cell growth control, We found that p53 protein is rapidly activated upon the disruption of cellular attachment. This led to p21 transcriptional activation via two p53 binding sites in its promoter. Elevated p21 protein levels blocked transcription and activity of the cell cycle-regulator cyclin A, and cells became arrested in G(1) of the cell cycle. Under the same conditions, fibroblasts from p53 knock out mice did not activate p21 and did not down-regulate cyclin A expression but rather induced another cell cycle inhibitor, p27, Thus, our results characterize a chain of events, starting from the activation of p53 and proceeding via p21 to cyclin A, that is activated in response to the loss of cellular adherence, This p53 regulated pathway may constitute one of a few redundant systems to ensure proper cell control in multicellular organisms.	UNIV SO CALIF,SCH MED,DEPT MOL MICROBIOL & IMMUNOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,LOS ANGELES,CA 90033	University of Southern California; University of Southern California			Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653				Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GRANA X, 1995, ONCOGENE, V11, P211; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Harlow E., 1988, ANTIBODIES LAB MANUA; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUPPI K, 1994, ONCOGENE, V9, P3017; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; Kramer A, 1996, J BIOL CHEM, V271, P6579; Liu Y, 1996, CANCER RES, V56, P31; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nikiforov MA, 1996, ONCOGENE, V13, P1709; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; Sambrook J., 2002, MOL CLONING LAB MANU; SCHONTHAL A, 1993, ONCOGENE, V8, P433; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; Zeng YX, 1996, ONCOGENE, V12, P1557; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	42	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29091	29098		10.1074/jbc.272.46.29091	http://dx.doi.org/10.1074/jbc.272.46.29091			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360984	hybrid			2022-12-27	WOS:A1997YF68400043
J	Bhagwat, M; Hobbs, LJ; Nossal, NG				Bhagwat, M; Hobbs, LJ; Nossal, NG			The 5'-exonuclease activity of bacteriophage T4 RNase H is stimulated by the T4 gene 32 single-stranded DNA-binding protein, but its flap endonuclease is inhibited	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I; REPLICATION; EXONUCLEASE; CLEAVAGE; 3'-EXONUCLEASE; ENCODES; PRIMERS; FAMILY; FEN-1; A737V	Bacteriophage T4 RNase H is a 5'- to 3'-nuclease that has exonuclease activity on RNA DNA and DNA DNA duplexes and can remove the pentamer RNA primers made by the T4 primase-helicase (Hollingsworth, H, C., and Nossal, N. G. (1991) J. Biol. Chem. 266, 1888-1897; Hobbs, L. J., and Nossal, N. G. (1996) J. Bacteriol. 178, 6772-6777). Here we show that this exonuclease degrades du plex DNA nonprocessively, releasing a single oligonucleotide (nucleotides 1-4) with each interaction with the substrate, Degradation continues nonprocessively until the enzyme stops 8-11 nucleotides from the 3'-end of the substrate, T4 gene 32 single-stranded DNA-binding protein strongly stimulates the exonuclease activity of T4 RNase H, converting it into a processive nuclease that removes multiple short oligonucleotides with a combined length of 10-50 nucleotides each time it binds to the duplex substrate, 32 protein must bind on single-stranded DNA behind T4 RNase H for processive degradation, T4 RNase H also has a flap endonuclease activity that cuts preferentially on either side of the junction between single-and double-stranded DNA in flap and fork DNA structures, In contrast to the exonuclease, the endonuclease is inhibited completely by 32 protein binding to the single strand of the flap substrate, These results suggest an important role for T4 32 protein in controlling T4 RNase II degradation of RNA primers and adjacent DNA during each lagging strand cycle.	NIDDK,MOL & CELLULAR BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hobbs LJ, 1996, J BACTERIOL, V178, P6772, DOI 10.1128/jb.178.23.6772-6777.1996; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Nossal Nancy G., 1994, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; ROBINS P, 1994, J BIOL CHEM, V269, P28535; RUSSEL M, 1976, J BIOL CHEM, V251, P7263; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P438; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; Woodworth DL, 1996, GENETICS, V143, P1081; Xu Y, 1997, J MOL BIOL, V268, P284, DOI 10.1006/jmbi.1997.0967	28	22	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28523	28530		10.1074/jbc.272.45.28523	http://dx.doi.org/10.1074/jbc.272.45.28523			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353314	hybrid			2022-12-27	WOS:A1997YF21900054
J	Hampson, R; Humbert, O; Macpherson, P; Aquilina, G; Karran, P				Hampson, R; Humbert, O; Macpherson, P; Aquilina, G; Karran, P			Mismatch repair defects and O-6-methylguanine-DNA methyltransferase expression in acquired resistance to methylating agents in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-PAIR MISMATCHES; TUMOR-CELLS; DNA-REPAIR; MICROSATELLITE INSTABILITY; MUTATOR PHENOTYPE; COLON-CANCER; BINDING; DEFICIENCY; MUTATIONS; EXTRACTS	Fifteen variants with greater than or equal to 30-fold resistance to N-methyl-N-nitrosourea were isolated from the Burkitt's lymphoma Raji cell line. Eight had received a single treatment with a highly cytotoxic dose. The remainder, including the previously described RajiF12 cell line, arose following multiple exposures to initially moderate but escalating doses. Surprisingly, methylation resistance arose in three clones by reactivation of a previously silent O-6-methylguanine-DNA methyltransferase gene, Five clones, including RajiF12, displayed the microsatellite instability and increased spontaneous mutation rates at the hypoxanthine-guanine phosphoribosyltransferase locus, consistent with deficiencies in mismatch repair. Defects in either the hMutS alpha or hMutL alpha mismatch repair complexes were identified in extracts of these resistant clones by in vitro complementation using extracts from colorectal carcinoma cell lines. Defects in hMutL alpha were confirmed by Western blot analysis. Remarkably, five methylation-resistant clones in which mismatch repair defects were demonstrated by biochemical assays did not exhibit significant microsatellite instability.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; IST SUPER SANITA,I-00161 ROME,ITALY	Istituto Superiore di Sanita (ISS)			Aquilina, Gabriele/AAI-7978-2021	Aquilina, Gabriele/0000-0002-3280-7883				Aebi S, 1996, CANCER RES, V56, P3087; Anthoney DA, 1996, CANCER RES, V56, P1374; AQUILINA G, 1994, P NATL ACAD SCI USA, V91, P8905, DOI 10.1073/pnas.91.19.8905; AQUILINA G, 1995, CANCER RES, V55, P2569; Bobola MS, 1996, CLIN CANCER RES, V2, P735; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRANCH P, 1995, CANCER RES, V55, P2304; BROWN R, 1997, ONCOGENE, V15, P42; CAIRNSSMITH S, 1992, CANCER RES, V52, P5257; CATAPANO CV, 1987, CANCER RES, V47, P4884; Ceccotti S, 1996, CURR BIOL, V6, P1528, DOI 10.1016/S0960-9822(96)00758-0; CHU G, 1994, J BIOL CHEM, V269, P787; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUJII H, 1989, J BIOL CHEM, V264, P10057; HESS P, 1994, SOMAT CELL MOLEC GEN, V20, P409, DOI 10.1007/BF02257458; Kane MF, 1997, CANCER RES, V57, P808; Karran P, 1996, CANCER SURV, V28, P69; Karran P, 1996, CHEM BIOL, V3, P875, DOI 10.1016/S1074-5521(96)90175-1; KARRAN P, 1993, J BIOL CHEM, V268, P15878; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOI M, 1994, CANCER RES, V54, P4308; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LENGAUER C, 1997, P NATL ACAD SCI USA, V94, P2245; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MORTEN JEN, 1992, CARCINOGENESIS, V13, P483, DOI 10.1093/carcin/13.3.483; NYCE J, 1989, CANCER RES, V49, P5829; ORegan NE, 1996, J BIOL CHEM, V271, P1789, DOI 10.1074/jbc.271.3.1789; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEGG AE, 1990, CANCER RES, V50, P6119; PIEPER RO, 1991, CANCER COMMUN, V3, P341; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Sambrook J., 2002, MOL CLONING LAB MANU; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; Tomlinson IPM, 1997, MUTAT RES-DNA REPAIR, V383, P177, DOI 10.1016/S0921-8777(96)00058-4; VARLET I, 1990, P NATL ACAD SCI USA, V87, P7883, DOI 10.1073/pnas.87.20.7883; VONWRONSKI MA, 1994, CARCINOGENESIS, V15, P577, DOI 10.1093/carcin/15.4.577	49	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28596	28606		10.1074/jbc.272.45.28596	http://dx.doi.org/10.1074/jbc.272.45.28596			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353325	hybrid			2022-12-27	WOS:A1997YF21900065
J	Joyal, JL; Burks, DJ; Pons, S; Matter, WF; Vlahos, CJ; White, MF; Sacks, DB				Joyal, JL; Burks, DJ; Pons, S; Matter, WF; Vlahos, CJ; White, MF; Sacks, DB			Communication - Calmodulin activates phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; GLUT4 TRANSLOCATION; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; HEXOSE-TRANSPORT; SKELETAL-MUSCLE; INSULIN; IRS-1; CELLS; PHOSPHORYLATION	Calmodulin and phosphatidylinositol 3-kinase are vital components of a number of common intracellular events. Calmodulin, a ubiquitous Ca2+-dependent effector protein, regulates multiple processes in eukaryotic cells, including cytoskeletal organization, vesicular trafficking, and mitogenesis. Phosphatidylinositol 3-kinase participates in events downstream of the receptors for insulin and other growth factors. Here we demonstrate by coimmunoprecipitation and affinity chromatography that Ca2+/calmodulin associates with Src homology 2 domains in the 85-kDa regulatory subunit of phosphatidylinositol 3-kinase, thereby significantly enhancing phosphatidylinositol 3-kinase activity in vitro and in intact cells. Furthermore, CGS9343B, a calmodulin antagonist, inhibited basal and Ca2+-stimulated phosphorylation of phosphatidylinositol in intact cells. These data demonstrate a novel mechanism for modulating phosphatidylinositol 3-kinase and provide a direct link between components of two fundamental signaling pathways.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; ELI LILLY & CO,LILLY RES LABS,INDIANAPOLIS,IN 46285	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Eli Lilly			Pons, Sebastian/K-7794-2014	Pons, Sebastian/0000-0003-1027-0621; Sacks, David/0000-0003-3100-0735	NIDDK NIH HHS [DK47308, DK09062, DK43682] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043682, R01DK047308, F32DK009062] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APODACA G, 1994, J BIOL CHEM, V269, P19005; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Chapin SJ, 1996, J BIOL CHEM, V271, P1336, DOI 10.1074/jbc.271.3.1336; Cohen P, 1988, CALMODULIN; COMMUNI D, 1994, BIOCHEM J, V298, P669, DOI 10.1042/bj2980669; Davidkova G, 1996, NEUROSCIENCE, V75, P1003, DOI 10.1016/0306-4522(96)00230-8; Hasson T, 1996, J BIOL CHEM, V271, P16431, DOI 10.1074/jbc.271.28.16431; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPPELLER R, 1994, BIOESSAYS, V16, P565; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; OKADA T, 1994, J BIOL CHEM, V269, P3568; RADDING W, 1994, J CELL PHYSIOL, V160, P17, DOI 10.1002/jcp.1041600104; RASMUSSEN CD, 1992, CELL MOTIL CYTOSKEL, V21, P45, DOI 10.1002/cm.970210106; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SHASHKIN P, 1995, J BIOL CHEM, V270, P25613, DOI 10.1074/jbc.270.43.25613; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	29	139	140	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28183	28186		10.1074/jbc.272.45.28183	http://dx.doi.org/10.1074/jbc.272.45.28183			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353264	hybrid			2022-12-27	WOS:A1997YF21900004
J	Kurashima, K; Yu, FH; Cabado, AG; Szabo, EZ; Grinstein, S; Orlowski, J				Kurashima, K; Yu, FH; Cabado, AG; Szabo, EZ; Grinstein, S; Orlowski, J			Identification of sites required for down-regulation of Na+/H+ exchanger NHE3 activity by cAMP-dependent protein kinase - Phosphorylation-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL ELECTROLYTE TRANSPORT; INTRACELLULAR PH; H+ EXCHANGER; DIARRHEAL DISEASE; PROXIMAL TUBULES; NA/H EXCHANGER; CELLS; ISOFORM; SENSITIVITY; RECOGNITION	We recently identified a region within the cytoplasmic C-terminal tail of the Na+/H+ exchanger NHE3 isoform (residues 579 to 684) which is essential for inhibition of transport activity by cAMP-dependent protein kinase (PKA) (Cabado, A. G., Yu, F. H., Rapus, A., Gergely, L., Grinstein, S., and Orlowski, J. (1996) J. Biol. Chem. 271, 3590-3599). To further define determinants of PKA regulation, six serine residues located in potential recognition sequences for PKA within, or adjacent to, this region (positions 552, 605, 634, 661, 690, and 691) were altered either independently or in various combinations using site-directed mutagenesis. Wild type and mutant NHE3s tagged with the influenza virus hemagglutinin epitope were stably expressed in exchanger-deficient Chinese hamster ovary cells (AP-1) for functional studies. Of the individual mutations examined, only substitutions at Ser(605) or Ser(634) affected sensitivity to forskolin, an activator of adenylate cyclase, although partial inhibition of NHE3 activity by forskolin remained. By contrast, simultaneous mutation of both these serines completely abolished cAMP-mediated inhibition of NHE3 without greatly affecting basal transport activity. Two-dimensional analysis of tryptic digests of immunoprecipitated NHE3 labeled in vivo with [P-32]orthophosphate revealed several phosphopeptides under basal conditions. Phosphorylation was increased approximately 3-fold in one of these peptides following forskolin treatment, and this change was eliminated by mutation of residue Ser(605). Thus, phosphorylation of Ser(605) is essential for cAMP-mediated inhibition of NHE3. In addition, Ser(634) is also required for the effect of cAMP, even though this residue does not become phosphorylated upon activation of PKA.	MCGILL UNIV, DEPT PHYSIOL, MONTREAL, PQ H3G 1Y6, CANADA; HOSP SICK CHILDREN, RES INST, DIV CELL BIOL, TORONTO, ON M5G 1X8, CANADA	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Yu, Frank/0000-0001-9306-1731; Orlowski, John/0000-0001-7371-175X				Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BINDER HJ, 1990, AM J MED, V88, pS2, DOI 10.1016/0002-9343(90)90267-H; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BORON WF, 1986, ANNU REV PHYSIOL, V48, P377; BROWN D, 1993, J CELL SCI, P49; Cabado AG, 1996, J BIOL CHEM, V271, P3590; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DONOWITZ M, 1987, PHYSL GASTROINTESTIN, P1351; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FIELD M, 1989, NEW ENGL J MED, V321, P879; FIELD M, 1989, NEW ENGL J MED, V321, P800; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HENSLEY CB, 1989, AM J PHYSIOL, V257, pC637, DOI 10.1152/ajpcell.1989.257.4.C637; HILDEN SA, 1990, AM J PHYSIOL, V258, pF1311; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; KNICKELBEIN RG, 1988, J CLIN INVEST, V82, P2158, DOI 10.1172/JCI113838; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marshansky V, 1996, BBA-BIOMEMBRANES, V1284, P171, DOI 10.1016/S0005-2736(96)00123-X; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SABOLIC I, 1990, AM J PHYSIOL, V258, pF1245, DOI 10.1152/ajprenal.1990.258.5.F1245; SCHWARTZ MA, 1991, EXP CELL RES, V195, P533, DOI 10.1016/0014-4827(91)90407-L; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; WEINMAN EJ, 1993, ANNU REV PHYSIOL, V55, P289, DOI 10.1146/annurev.ph.55.030193.001445; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004	39	129	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28672	28679		10.1074/jbc.272.45.28672	http://dx.doi.org/10.1074/jbc.272.45.28672			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353335	hybrid			2022-12-27	WOS:A1997YF21900075
J	Quintana, DG; Hou, ZH; Thome, KC; Hendricks, M; Saha, P; Dutta, A				Quintana, DG; Hou, ZH; Thome, KC; Hendricks, M; Saha, P; Dutta, A			Identification of HsORC4, a member of the human origin of replication recognition complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; YEAST ORIGIN; INITIATION; PROTEINS; ORC	A new member of human origin recognition complex (ORC) has been cloned and identified as the human homologue of Saccharomyces cerevisiae ORC4. HsORC4 is a 45-kDa protein encoded by a 2.2-kilobase mRNA whose amino acid sequence is 29% identical to ScORC4. HsORC4 has a putative nucleotide triphosphate binding motif that is not seen in ScORC4. HsORC4P also reveals an unsuspected homology to the ORC1-Cdc18 family of proteins, HsORC4 mRNA expression and protein levels remain constant through the cell cycle. HsORC4P is coimmunoprecipitated from cell extracts with another subunit of human ORC, HsORC2P, consistent with it being a part of the putative human origin recognition complex.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,DIV MOL ONCOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School			Dutta, Anindya/P-3203-2016; Quintana, David G/M-5628-2018	Quintana, David G./0000-0002-4909-6686; Dutta, Anindya/0000-0002-4319-0073; Saha, Partha/0000-0002-4514-6391	NCI NIH HHS [CA60499, R01 CA060499, R01 CA060499-04A2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018	19	66	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28247	28251		10.1074/jbc.272.45.28247	http://dx.doi.org/10.1074/jbc.272.45.28247			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353276	hybrid			2022-12-27	WOS:A1997YF21900016
J	Bevan, AP; Krook, A; Tikerpae, J; Seabright, PJ; Siddle, K; Smith, GD				Bevan, AP; Krook, A; Tikerpae, J; Seabright, PJ; Siddle, K; Smith, GD			Chloroquine extends the lifetime of the activated insulin receptor complex in endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; DEPENDENT DIABETES-MELLITUS; LOW-DENSITY VESICLES; RAT HEPATOMA-CELLS; KINASE; LIVER; DEGRADATION; INTERNALIZATION; BINDING; INVIVO	Insulin signal transduction, initiated by binding of insulin to its receptor at the plasma membrane, activates the intrinsic receptor tyrosine kinase and leads to internalization of the activated ligand-receptor complex into endosomes, This study addresses the role played by the activated insulin receptor within hepatic endosomes and provides evidence for its central role in insulin-stimulated events in vivo. Rats were treated with chloroquine, an acidotrophic agent that has been shown previously to inhibit endosomal insulin degradation, and then with insulin. Livers were removed and fractionated by density gradient centrifugation to obtain endosomal and plasma membrane preparations, Chloroquine treatment increased the amount of receptor bound insulin in endosomes at 2 min after insulin injection by 93% as determined by exclusion from G-50 columns and by 90% as determined by polyethylene glycol precipitation (p < 0.02), Chloroquine treatment also increased the insulin receptor content of endosomes after insulin injection (integrated over 0-45 min) by 31% when compared with controls (p < 0.05), Similarly, chloroquine increased both insulin receptor phosphotyrosine content and its exogenous tyrosine kinase activity after insulin injection (64%; p < 0.01 and 96% and p < 0.001, respectively), In vivo chloroquine treatment was without any observable effect on insulin binding to plasma membrane insulin receptors, nor did it augment insulin-stimulated receptor autophosphorylation or kinase activity in the plasma membrane. Concomitant with its effects on endosomal insulin receptors, chloroquine treatment augmented insulin-stimulated incorporation of glucose into glycogen in diaphragm (p < 0.001), These observations are consistent with the hypothesis that chloroquine-dependent inhibition of endosomal insulin receptor dissociation and subsequent degradation prolongs the half-life of the active endosomal receptor and potentiates insulin signaling from this compartment.			Bevan, AP (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,HILLS RD,CAMBRIDGE CB2 2QR,ENGLAND.		Krook, Anna/K-1192-2015	Krook, Anna/0000-0002-0891-0258; Bevan, Paul/0000-0002-0656-9164	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Armitage P., 1987, STAT METHODS MED RES; AUTHIER F, 1994, J BIOL CHEM, V269, P3010; Bevan AP, 1996, TRENDS ENDOCRIN MET, V7, P13, DOI 10.1016/1043-2760(95)00179-4; BEVAN AP, 1995, BIOCHEM J, V311, P787, DOI 10.1042/bj3110787; BEVAN AP, 1995, AM J PHYSIOL-ENDOC M, V268, pE60, DOI 10.1152/ajpendo.1995.268.1.E60; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; BEVAN AP, 1997, KEYS S TEMP SPAT DET, P58; BLAZAR BR, 1984, DIABETES, V33, P1133, DOI 10.2337/diabetes.33.12.1133; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHRISTENSEN JR, 1985, CELL BIOCHEM FUNCT, V3, P13, DOI 10.1002/cbf.290030105; CHRISTENSEN JR, 1987, BIOCHEM SOC T, V16, P574; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; DENNIS PA, 1981, ARCH BIOCHEM BIOPHYS, V212, P170, DOI 10.1016/0003-9861(81)90356-8; DESBUQUOIS B, 1992, DIABETES METAB, V18, P104; DEVRIES CP, 1990, DIABETES METAB, V16, P70; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; Drake PG, 1996, ENDOCRINOLOGY, V137, P4960, DOI 10.1210/en.137.11.4960; ECKEL J, 1988, BIOCHEM J, V249, P111, DOI 10.1042/bj2490111; FAURE R, 1992, J BIOL CHEM, V267, P11215; Hansen BF, 1996, BIOCHEM J, V315, P271; IWAMOTO Y, 1982, BIOCHEM BIOPH RES CO, V103, P863; JORGENSEN KH, 1980, DIABETOLOGIA, V19, P546; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; KASUYA J, 1994, BIOCHEM BIOPH RES CO, V200, P777, DOI 10.1006/bbrc.1994.1518; KAY DG, 1986, J BIOL CHEM, V261, P8473; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KLEIN HH, 1987, J BIOL CHEM, V262, P10557; KNUTSON VP, 1991, FASEB J, V5, P2130, DOI 10.1096/fasebj.5.8.2022311; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; MORGAN DO, 1985, ENDOCRINOLOGY, V116, P1224, DOI 10.1210/endo-116-3-1224; MURPHY RF, 1984, J CELL BIOL, V98, P1757, DOI 10.1083/jcb.98.5.1757; PEASE RJ, 1985, BIOCHEM J, V228, P137, DOI 10.1042/bj2280137; PEASE RJ, 1987, EUR J BIOCHEM, V164, P251, DOI 10.1111/j.1432-1033.1987.tb11018.x; POSNER BI, 1980, J BIOL CHEM, V255, P735; POSNER BI, 1982, J BIOL CHEM, V257, P5789; POWRIE JK, 1991, AM J PHYSIOL, V260, pE897, DOI 10.1152/ajpendo.1991.260.6.E897; RAFAELSE.OJ, 1965, DIABETES, V14, P19, DOI 10.2337/diab.14.1.19; RIDEOUT JM, 1985, BIOCHEM SOC T, V13, P1225; Seabright PJ, 1996, BIOCHEM J, V320, P947, DOI 10.1042/bj3200947; SMITH GD, 1982, BIOCHIM BIOPHYS ACTA, V716, P24, DOI 10.1016/0304-4165(82)90198-2; SMITH GD, 1989, EUR J BIOCHEM, V181, P287, DOI 10.1111/j.1432-1033.1989.tb14723.x; SMITH GD, 1987, BRIT MED J, V294, P465, DOI 10.1136/bmj.294.6570.465; SOOS MA, 1992, J BIOL CHEM, V267, P12955; SORIMACHI K, 1987, ENDOCR RES, V13, P49, DOI 10.1080/07435808709023662; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430; YOUN JH, 1990, AM J PHYSIOL, V258, pE899, DOI 10.1152/ajpendo.1990.258.6.E899; ZHANG B, 1991, J BIOL CHEM, V266, P990	55	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26833	26840		10.1074/jbc.272.43.26833	http://dx.doi.org/10.1074/jbc.272.43.26833			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341114	hybrid			2022-12-27	WOS:A1997YC65900010
J	Krueger, KA; Bhatt, H; Landt, M; Easom, RA				Krueger, KA; Bhatt, H; Landt, M; Easom, RA			Calcium-stimulated phosphorylation of MAP-2 in pancreatic beta TC3-cells is mediated by Ca2+/calmodulin-dependent kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; INSULIN-SECRETION; CYCLIC-AMP; BETA-CELL; ASSEMBLY INVITRO; RAT ISLETS; TAU-FACTOR; B-CELL; CALMODULIN; INHIBITOR	An understanding of the role of CaM kinase II in the pancreatic beta-cell is dependent on the identification of its cellular targets, One of the best substrates of CaM kinase II in vitro that could function in secretory events is the microtubule-associated protein, MAP-2. By immuno-blot analysis, a high molecular weight protein with electrophoretic properties characteristic of MAP-2, was identified in rat insulinoma beta TC3 cells and isolated rat islets. In immunoprecipitation experiments employing alpha-toxin-permeabilized beta TC3 cells, elevation of intracellular Ca2+ or addition of forskolin, an adenylate cyclase activator, induced significant phosphorylation of MAP-2 in situ. The effect of Ca2+ was rapid, concentration-dependent and closely correlated with activation of CaM kinase II under similar experimental conditions, H-89, a specific and potent inhibitor of cAMP-dependent protein kinase (PKA),prevented forskolin-induced MAP-2 phosphorylation but had little effect on MAP-2 phosphorylation stimulated by elevated Ca2+. Phosphopeptide mapping revealed that the phosphorylation pattern observed in situ upon incubation of the beta TC3 cells with increased free Ca2+, was strikingly similar to that generated in vitro by CaM kinase Il, most notably with regard to the increased phosphate incorporated into one prominent site, These data provide evidence that MAP-2 is phosphorylated by CaM kinase II in the pancreatic beta-cell in situ, and that this event may provide an important Link in the mediation of Ca2+-dependent insulin secretion.	UNIV N TEXAS,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,FT WORTH,TX 76107; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	University of North Texas System; University of North Texas Health Science Center; Washington University (WUSTL)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047925] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47925] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1994, CELL BIOL LAB HDB, V3, P77; AINSZTEIN AM, 1994, J BIOL CHEM, V269, P28465; Babb EL, 1996, BIOCHEM J, V317, P167, DOI 10.1042/bj3170167; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; CACERES A, 1983, P NATL ACAD SCI-BIOL, V80, P1738, DOI 10.1073/pnas.80.6.1738; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CLYNE CD, 1995, ENDOCR RES, V21, P259, DOI 10.3109/07435809509030441; DECAMILLI P, 1984, NEUROSCIENCE, V11, P761, DOI 10.1016/0306-4522(84)90193-3; DIAZNIDO J, 1993, EUR J NEUROSCI, V5, P818, DOI 10.1111/j.1460-9568.1993.tb00933.x; Easom RA, 1997, ENDOCRINOLOGY, V138, P2359, DOI 10.1210/en.138.6.2359; EASOM RA, 1990, J BIOL CHEM, V265, P14938; FARSHORI PQ, 1997, J SUBMICR CYTOL PATH, V26, P137; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FERREIRA A, 1993, MOL BIOL CELL, V4, P1225, DOI 10.1091/mbc.4.12.1225; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GILON P, 1995, BIOCHEM J, V311, P259, DOI 10.1042/bj3110259; GOLDENRING JR, 1985, J NEUROCHEM, V45, P900, DOI 10.1111/j.1471-4159.1985.tb04078.x; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HARRISON DE, 1982, BIOCHIM BIOPHYS ACTA, V714, P313, DOI 10.1016/0304-4165(82)90339-7; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; Hisatomi M, 1996, ENDOCRINOLOGY, V137, P4644, DOI 10.1210/en.137.11.4644; HUGHES SJ, 1987, MOL CELL ENDOCRINOL, V50, P231, DOI 10.1016/0303-7207(87)90021-9; JEFFERSON AB, 1991, J BIOL CHEM, V266, P346; KOSIK KS, 1988, J NEUROCHEM, V51, P587, DOI 10.1111/j.1471-4159.1988.tb01079.x; KOSZKA C, 1985, EUR J CELL BIOL, V38, P149; LACY PE, 1972, DIABETES, V21, P987, DOI 10.2337/diab.21.10.987; LACY PE, 1975, LAB INVEST, V33, P570; LI GD, 1992, MOL PHARMACOL, V42, P489; LICHTENBERG B, 1988, NATURE, V334, P359, DOI 10.1038/334359a0; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; Mohlig M, 1997, ENDOCRINOLOGY, V138, P2577, DOI 10.1210/en.138.6.2577; NIKI I, 1993, BIOCHEM BIOPH RES CO, V191, P255, DOI 10.1006/bbrc.1993.1210; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; PIPELEERS DG, 1976, SCIENCE, V191, P88, DOI 10.1126/science.1108194; RAFFAELLI N, 1992, FEBS LETT, V296, P21, DOI 10.1016/0014-5793(92)80394-V; SATTILARO RF, 1986, BIOCHEMISTRY-US, V25, P2003, DOI 10.1021/bi00356a025; SCHUIT FC, 1985, ENDOCRINOLOGY, V117, P834, DOI 10.1210/endo-117-3-834; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; SHARP GWG, 1979, DIABETOLOGIA, V16, P287, DOI 10.1007/BF01223617; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; SOMERS G, 1979, ENDOCRINOLOGY, V104, P255, DOI 10.1210/endo-104-1-255; SUPRENANT KA, 1982, J CELL BIOL, V93, P164, DOI 10.1083/jcb.93.1.164; THEURKAUF WE, 1983, J BIOL CHEM, V258, P7883; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; TSUYAMA S, 1987, J BIOL CHEM, V262, P10886; TSUYAMA S, 1986, J BIOL CHEM, V261, P4110; VALDIVIA MM, 1982, BIOCHEM BIOPH RES CO, V105, P1241, DOI 10.1016/0006-291X(82)90920-2; VANDERGEER P, 1994, CELL BIOL LAB HDB, V3, P422; WANG JL, 1990, BIOCHEM BIOPH RES CO, V171, P424, DOI 10.1016/0006-291X(90)91410-T; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; WENHAM RM, 1992, BIOCHEM BIOPH RES CO, V189, P128, DOI 10.1016/0006-291X(92)91534-W; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x	56	40	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27464	27469		10.1074/jbc.272.43.27464	http://dx.doi.org/10.1074/jbc.272.43.27464			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341200	hybrid			2022-12-27	WOS:A1997YC65900096
J	Mitamura, T; Umata, T; Nakano, F; Shishido, Y; Toyoda, T; Itai, A; Kimura, H; Mekada, E				Mitamura, T; Umata, T; Nakano, F; Shishido, Y; Toyoda, T; Itai, A; Kimura, H; Mekada, E			Structure-function analysis of the diphtheria toxin receptor toxin binding site by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; VERO CELLS; MEMBRANE-PROTEIN; MUTANT PROTEINS; CD9 ANTIGEN; EGF; DOMAIN; EXPRESSION; IDENTIFICATION; TRANSLOCATION	Diphtheria toxin (DT) binds to the epidermal growth factor (EGF)-like domain of human membrane-anchored heparin-binding EGF-like growth factor (proHB-EGF), the human DT receptor (DTR). DT does not bind to mouse proHB-EGF because of amino acid substitutions within the EGF-like domain. We made 10 independent mutants, replacing a single amino acid within the EGF-like domain of human DTR/proHB-EGF with the corresponding amino acid residue in mouse proHB-EGF. The mutant proteins were transiently expressed in mouse L cells either expressing or not expressing DRAP27/CD9, and DT binding was measured. DT binding activity of GST fusion proteins containing the mutated EGF-like domain was also determined by a cell-free binding assay. The largest effect was seen with E141H, and second largest effects were seen with F115Y and L127F in all of the assay systems. We conclude that Phe(115), Leu(127), and Glu(141) are critical amino acid residues for DT binding. A computer model of the tertiary structure of the EGF-like domain of human DTR/proHB-EGF was made. The model predicts that three amino acid residues critical for DT binding activity, Phe(115), Leu(127), and Glu(141) are all located on the same face of the EGF-like domain, suggesting that this face of DTR/proHB-EGF interacts with the receptor-binding domain of DT.	KURUME UNIV,INST LIFE SCI,DIV CELL BIOL,KURUME,FUKUOKA 830,JAPAN; KURUME UNIV,SCH MED,DEPT LEGAL MED,KURUME,FUKUOKA 839,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,TOKYO 113,JAPAN	Kurume University; Kurume University; University of Tokyo			Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Mekada, Eisuke/0000-0001-8858-4781				ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; BENEDETTI E, 1983, INT J PEPT PROT RES, V22, P1; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BOQUET P, 1976, P NATL ACAD SCI USA, V73, P4449, DOI 10.1073/pnas.73.12.4449; BROWN JG, 1993, P NATL ACAD SCI USA, V90, P8184, DOI 10.1073/pnas.90.17.8184; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; GABLIKS J, 1962, J IMMUNOL, V88, P505; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HARVEY TS, 1991, EUR J BIOCHEM, V198, P555, DOI 10.1111/j.1432-1033.1991.tb16050.x; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hooper KP, 1996, BIOCHEM BIOPH RES CO, V220, P675, DOI 10.1006/bbrc.1996.0463; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; JORGENSEN WL, 1981, J AM CHEM SOC, V103, P335, DOI 10.1021/ja00392a016; LENNOX ES, 1957, P SOC EXP BIOL MED, V95, P700, DOI 10.3181/00379727-95-23335; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MEKADA E, 1988, J CELL BIOL, V107, P511, DOI 10.1083/jcb.107.2.511; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MONTELIONE GT, 1986, P NATL ACAD SCI USA, V83, P8594, DOI 10.1073/pnas.83.22.8594; MORRIS RE, 1985, INFECT IMMUN, V50, P721, DOI 10.1128/IAI.50.3.721-727.1985; MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PEARLMAN DA, 1995, AMBER VERSION 4 1; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SHEN WH, 1994, J BIOL CHEM, V269, P29077; SHISHIDO Y, 1995, J BIOL CHEM, V270, P29578, DOI 10.1074/jbc.270.49.29578; SILVERMAN JA, 1994, J BIOL CHEM, V269, P22524; UCHIDA T, 1977, NATURE, V266, P839, DOI 10.1038/266839a0; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; VANDERSPEK J, 1994, J BIOL CHEM, V269, P21455	42	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27084	27090		10.1074/jbc.272.43.27084	http://dx.doi.org/10.1074/jbc.272.43.27084			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341148	hybrid			2022-12-27	WOS:A1997YC65900044
J	Osipovich, O; Durum, SK; Muegge, K				Osipovich, O; Durum, SK; Muegge, K			Defining the minimal domain of Ku80 for interaction with Ku70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRAND-BREAK-REPAIR; X-RAY RESISTANCE; V(D)J RECOMBINATION; AUTOANTIGEN-KU; DNA-BINDING; ANTIGEN; SUBUNIT; CELLS; CDNA	The Ku protein has a critical function in the repair of double-strand DNA breaks induced for example by ionizing radiation or during VDJ recombination. Ku serves as the DNA-binding subunit of the DNA-dependent kinase and is a heterodimeric protein composed of 80- and 70-kDa subunits. We used the two hybrid system to analyze the interaction domains of the Ku subunits and to identify possible additional partners for Ku. Screening a human cDNA library with the Ku heterodimer did not reveal any novel partners. Screening with the individual subunits, we detected only Ku70 clones interacting with Ku80 and only Ku80 clones interacting with Ku70, indicating that these are the primary partners for one another. Ku80 and Ku70 formed only heterodimers and did not homodimerize. Ku80 was restricted to interacting with just one Ku70 molecule at a time. The minimal functional interaction domain of Ku80 that interacted with Ku70 was defined. It consisted of a 28-amino acid region extending from amino acid 449 to 477. This region was crucial for interaction with Ku70, since mutation within this critical site at amino acids 453 and 454 abrogated the ability to interact with Ku70. We furthermore verified that the same region is crucial for interaction with Ku70 using in vitro co-translation of both subunits followed by an immunoprecipitation with anti Ku70 antibodies. This interaction domain of Ku80 does not contain any motif previously recognized in protein-protein interactions.	NCI,FREDERICK CANC RES & DEV CTR,MOL IMMUNOREGULAT LAB,SAIC,INTRAMURAL RES SUPPORT PROGRAM,NIH,FREDERICK,MD 21702; NCI,MOL IMMUNOREGULAT LAB,NIH,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				durum, scott/0000-0003-1307-9582				ABUELHEIGA L, 1992, CLIN IMMUNOL IMMUNOP, V64, P145, DOI 10.1016/0090-1229(92)90192-Q; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Errami A, 1996, MOL CELL BIOL, V16, P1519; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRIFFITH AJ, 1992, MOL BIOL REP, V16, P91, DOI 10.1007/BF00419754; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HARPER JW, 1993, CELL, V75, P805; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; KAISER P, 1993, BIOTECHNIQUES, V14, P552; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; MAY G, 1991, J BIOL CHEM, V266, P3052; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; REEVES WH, 1989, J BIOL CHEM, V264, P5047; ROSE MD, 1990, METHODS GENETICS LAB; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHLIESTL RH, 1989, CURR GENET, V16, P339; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SNGLETON BK, 1997, MOL CELL BIOL, V17, P1264; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WANG JS, 1994, J CELL SCI, V107, P3223; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YANEVA M, 1989, J BIOL CHEM, V264, P13407	40	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27259	27265		10.1074/jbc.272.43.27259	http://dx.doi.org/10.1074/jbc.272.43.27259			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341172	hybrid			2022-12-27	WOS:A1997YC65900068
J	Rauch, U; Clement, A; Retzler, C; Frohlich, L; Fassler, R; Gohring, W; Faissner, A				Rauch, U; Clement, A; Retzler, C; Frohlich, L; Fassler, R; Gohring, W; Faissner, A			Mapping of a defined neurocan binding site to distinct domains of tenascin-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX PROTEIN; CELL-ADHESION MOLECULES; NEURITE OUTGROWTH; NERVOUS-TISSUE; EGF-LIKE; N-CAM; FIBRONECTIN; BRAIN; PHOSPHACAN	Neurocan is a member of the aggrecan family of proteoglycans which are characterized by NH2-terminal domains binding hyaluronan, and COOH-terminal domains containing C type lectin like modules, To detect and enhance the affinity for complementary ligands of neurocan, the COOH terminal neurocan domain was fused with the NH2-terminal region of tenascin-C, which contains the hexamerization domain of this extracellular matrix glycoprotein, The fusion protein was designed to contain the last downstream glycosaminoglycan attachment site and was expressed as a proteoglycan, In ligand overlay blots carried out with brain extracts, it recognized tenascin-C. The interaction was abolished by the addition of EDTA, or TNfn4,5, a bacterially expressed tenascin-C fragment comprising the fourth and fifth fibronectin type III module, The fusion protein directly reacted with this fragment in ligand blot and enzyme linked immunosorbent assay procedures, Both tenascin-C and TNfn4,5 were retained on Sepharose 4B-linked carboxyl-terminal neurocan domains, which in BIAcore binding studies yielded a K-D value of 17 nM for purified tenascin-C, We conclude that a divalent cation-dependent interaction between the COOH-terminal domain of neurocan and those fibronectin type III repeats is substantially involved in the binding of neurocan to tenascin-C.	UNIV HEIDELBERG,DEPT NEUROBIOL,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	Rauch, U (corresponding author), MAX PLANCK INST BIOCHEM,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Faissner, Andreas/A-5314-2008	Faissner, Andreas/0000-0002-2211-8259				ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927; CHUNG CY, 1995, J BIOL CHEM, V270, P29012, DOI 10.1074/jbc.270.48.29012; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FAISSNER A, 1995, GLIA, V13, P233, DOI 10.1002/glia.440130402; Faissner A, 1996, SEMIN NEUROSCI, V8, P347, DOI 10.1006/smns.1996.0043; Faissner Andreas, 1995, Seminars in Developmental Biology, V6, P139, DOI 10.1016/S1044-5781(06)80023-X; Forsberg E, 1996, P NATL ACAD SCI USA, V93, P6594, DOI 10.1073/pnas.93.13.6594; FRIEDLANDER DR, 1988, J CELL BIOL, V107, P2329, DOI 10.1083/jcb.107.6.2329; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; Gotz B, 1996, J CELL BIOL, V132, P681, DOI 10.1083/jcb.132.4.681; Gotz M, 1997, EUR J NEUROSCI, V9, P496, DOI 10.1111/j.1460-9568.1997.tb01627.x; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; HUSMANN K, 1992, J CELL BIOL, V116, P1475, DOI 10.1083/jcb.116.6.1475; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; IWATA M, 1993, J NEUROSCI, V13, P195; IWATA M, 1993, J BIOL CHEM, V268, P15061; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kappler J, 1997, EUR J NEUROSCI, V9, P306, DOI 10.1111/j.1460-9568.1997.tb01401.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOCHTER A, 1991, J CELL BIOL, V113, P1159, DOI 10.1083/jcb.113.5.1159; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; Milev P, 1997, J BIOL CHEM, V272, P15501, DOI 10.1074/jbc.272.24.15501; MILEV P, 1995, J BIOL CHEM, V270, P24650, DOI 10.1074/jbc.270.42.24650; MORGELIN M, 1994, BIOPHYS CHEM, V50, P113, DOI 10.1016/0301-4622(94)85024-0; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; RATHJEN FG, 1991, DEVELOPMENT, V113, P151; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Retzler C, 1996, J BIOL CHEM, V271, P27304, DOI 10.1074/jbc.271.44.27304; Retzler C, 1996, J BIOL CHEM, V271, P17107, DOI 10.1074/jbc.271.29.17107; Scholze A, 1996, INT J DEV NEUROSCI, V14, P315, DOI 10.1016/0736-5748(96)00016-0; Schumacher S, 1997, J CELL BIOL, V136, P895, DOI 10.1083/jcb.136.4.895; SEIDENBECHER CI, 1995, J BIOL CHEM, V270, P27206, DOI 10.1074/jbc.270.45.27206; TAYLOR HC, 1989, J CELL BIOCHEM, V41, P71, DOI 10.1002/jcb.240410204; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; Weber P, 1996, FEBS LETT, V389, P304, DOI 10.1016/0014-5793(96)00609-6; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	54	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26905	26912		10.1074/jbc.272.43.26905	http://dx.doi.org/10.1074/jbc.272.43.26905			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341124	hybrid			2022-12-27	WOS:A1997YC65900020
J	Vogt, A; Sun, JZ; Qian, YM; Hamilton, AD; Sebti, SM				Vogt, A; Sun, JZ; Qian, YM; Hamilton, AD; Sebti, SM			The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G(0)/G(1) and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; PROTEIN GERANYLGERANYLATION; RAS TRANSFORMATION; P21; G1; FARNESYLTRANSFERASE; G(1); FARNESYLATION; PRENYLATION; FIBROBLASTS	Recently we have shown that in fibroblasts (NIH 3T3 and Rat-1 cells) inhibition of protein geranylgeranylation leads to a G(0)/G(1) arrest, whereas inhibition of protein farnesylation does not affect cell cycle distribution, Here we demonstrate that in human tumor cells the geranylgeranyltransferase-I (GGTase-I) inhibitor GGTI-298 blocked cells in G(0)/G(1), whereas the farnesyltransferase (FTase) inhibitor FTI-277 showed a differential effect depending on the cell line, FTI-277 accumulated Calu-1 and A-549 lung carcinoma and Cola 357 pancreatic carcinoma cells in G(2)/M, T-24 bladder carcinoma, and HT-1080 fibrosarcoma cells in G(0)/G(1), but had no effect on cell cycle distribution of pancreatic (Panc-1), breast (SKBr 3 and MDAMB-231), and head and neck (A-253) carcinoma cells, Furthermore, treatment of Calu-1, Panc-1, Cole 357, T-24, A-253, SKBr 3, and MDAMB-231 cells with GGTI-298, but not FTI-277, induced the protein expression levels of the cyclin-dependent kinase inhibitor p21(WAF). HT-1080 and A-549 cells had a high basal level of p21(WAF), and GGTI-298 did not further increase these levels, Furthermore, GGTI-298 also induces the accumulation of large amounts of p21(WAF) mRNA in Calu-1 cells, a cell line that lacks the tumor suppressor gene p53. There was little effect of GGTI-298 on the cellular levels of another cyclin-dependent kinase inhibitor p27(KIP) as well as cyclin E and cyclin D1. These results demonstrate that GGTase-I inhibitors arrest cells in G(0)/G(1) and induce accumulation of p21(WAF) in a p53-independent manner and that FTase inhibitors can interfere with cell cycle events by a mechanism that involves neither p21(WAF) nor p27(KIP). The results also point to the potential of GGTase-I inhibitors as agents capable of restoring growth arrest in cells lacking functional p53.	UNIV S FLORIDA,DEPT BIOCHEM & MOL BIOL,H LEE MOFFIT CANC CTR & RES INST,TAMPA,FL 33612; UNIV PITTSBURGH,DEPT CHEM,SCH ARTS & SCI,PITTSBURGH,PA 15261; UNIV PITTSBURGH,DEPT PHARMACOL,SCH MED,PITTSBURGH,PA 15261	State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [U19-CA-67771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALPAN RS, 1996, CELL GROWTH DIFFER; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CASEY PJ, 1992, J LIPID RES, V33, P1731; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crick D C, 1996, SAAS Bull Biochem Biotechnol, V9, P37; CRICK DC, 1994, BIOCHEM BIOPH RES CO, V205, P955, DOI 10.1006/bbrc.1994.2758; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINDER JD, 1997, J BIOL CHEM, V272, P1384; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Macchia M, 1996, J MED CHEM, V39, P1352, DOI 10.1021/jm960127s; McGuire TF, 1997, ONCOGENE, V14, P305, DOI 10.1038/sj.onc.1200819; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; Miguel K., 1997, CANCER RES, V57, P1846; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SUN JZ, 1995, CANCER RES, V55, P4243; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng YX, 1996, ONCOGENE, V12, P1557	46	169	178	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27224	27229		10.1074/jbc.272.43.27224	http://dx.doi.org/10.1074/jbc.272.43.27224			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341167	hybrid			2022-12-27	WOS:A1997YC65900063
J	Zhang, J; Barak, LS; Winkler, KE; Caron, MG; Ferguson, SSG				Zhang, J; Barak, LS; Winkler, KE; Caron, MG; Ferguson, SSG			A central role for beta-arrestins and clathrin-coated vesicle-mediated endocytosis in beta(2)-adrenergic receptor resensitization - Differential regulation of receptor resensitization in two distinct cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HIGH-AFFINITY BINDING; FAILING HUMAN HEART; BETA-2-ADRENERGIC RECEPTOR; SEQUESTRATION; DYNAMIN; KINASE; MUTANT; INTERNALIZATION; EXPRESSION	G protein-coupled receptor (GPCR) sequestration to endosomes is proposed to be the mechanism by which G protein-coupled receptor kinase (GRK)-phosphorylated receptors are dephosphorylated and resensitized. The identification of beta-arrestins as GPCR trafficking molecules suggested that beta-arrestins might represent critical determinants for GPCR resensitization. Therefore, we tested whether beta(2)-adrenergic receptor (beta(2)AR) resensitization was dependent upon beta-arrestins and an intact clathrin coated vesicle endocytic pathway. The overexpression of either the beta-arrestin 1-V53D dominant negative inhibitor of beta(2)AR sequestration or dynamin I-K44A to block, clathrin-coated vesicle-mediated endocytosis impaired both beta(2)AR dephosphorylation and resensitization. In contrast, resensitization of a sequestration impaired beta(2)AR mutant (Y326A) was reestablished following the overexpression of either GRK2 or beta-arrestin 1. Moreover, beta(2)ARs did not resensitize in COS-7 cells as the consequence of impaired sequestration and dephosphorylation. However, beta(2)AR resensitization was restored in these cells following the overexpression of beta-arrestin 2. These findings demonstrate, using both loss and gain of function paradigms, that beta(2)AR dephosphorylation and resensitization are dependent upon an intact sequestration pathway. These studies also indicate that beta-arrestins play an integral role in regulating not only the desensitization and intracellular trafficking of GPCRs but their ability to resensitize. beta-Arrestin expression levels appear to underlie cell type specific differences in the regulation of GPCR resensitization.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 03422] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Ferguson SSG, 1996, BIOCHEM SOC T, V24, P953, DOI 10.1042/bst0240953; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Garland AM, 1996, MOL PHARMACOL, V49, P438; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; ITCKAWA M, 1996, MOL PHARMACOL, V49, P560; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MOORE RH, 1995, J CELL SCI, V108, P2983; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SCHLADOR ML, 1996, 26 ANN M NOV 16 21 1, P1257; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TERWILLIGER RZ, 1994, J NEUROCHEM, V63, P1983; TSUGA H, 1994, J BIOL CHEM, V269, P32522; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; ZHANG J, 1997, IN RPESS RECEPTORS C	49	213	216	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27005	27014		10.1074/jbc.272.43.27005	http://dx.doi.org/10.1074/jbc.272.43.27005			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341139	hybrid, Green Submitted			2022-12-27	WOS:A1997YC65900035
J	Bratton, DL; Fadok, VA; Richter, DA; Kailey, JM; Guthrie, LA; Henson, PM				Bratton, DL; Fadok, VA; Richter, DA; Kailey, JM; Guthrie, LA; Henson, PM			Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; PLASMA-MEMBRANE; TRANSBILAYER MOVEMENT; ERYTHROCYTE-MEMBRANE; TISSUE TRANSGLUTAMINASE; EXTRACELLULAR RELEASE; LEUKEMIA-CELLS; T-LYMPHOCYTES; ICE-LIKE; PHOSPHOLIPIDS	Phosphatidylserine (PS), ordinarily sequestered in the plasma membrane inner leaflet, appears in the outer leaflet during apoptosis, where it triggers non-inflammatory phagocytic recognition of the apoptotic cell, The mechanism of PS appearance during apoptosis is not well understood but has been associated with loss of aminophospholipid translocase activity and nonspecific flip flop of phospholipids of various classes, The human leukemic cell line HL-60, the T cell line Jurkat, and peripheral blood neutrophils, undergoing apoptosis induced either with UV irradiation or anti-Fas antibody, were probed in the cytofluorograph for (i) surface PS using fluorescein isothiocyanate-labeled annexin V, (ii) PS uptake by the aminophospholipid translocase using [6-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino] caproyl] (NBD)-labeled PS, (iii) nonspecific uptake of phospholipids (as a measure of transbilayer flip flop) using NBD-labeled phosphatidylcholine, and (iv) the appearance of hypodiploid DNA, In all three types of cells undergoing apoptosis, the appearance of PS followed loss of aminophospholipid translocase and was accompanied by nonspecific phospholipid flip-flop, Importantly, however, in the absence of extracellular calcium, the appearance of PS was completely inhibited despite DNA fragmentation and loss of aminophospholipid translocase activity, the latter demonstrating that loss of the translocase is insufficient for PS appearance during apoptosis, Furthermore, while both the appearance of PS and nonspecific phospholipid uptake demonstrated identical extracellular calcium requirements with an ED50 of nearly 100 mu m, the magnitude of PS appearance depended on the level of aminophospholipid translocase activity, Taken together, the data strongly suggest that while nonspecific flip-flop is the driving event for PS appearance in the plasma membrane outer leaflet, aminophospholipid translocase activity ultimately modulates its appearance.			Bratton, DL (corresponding author), NATL JEWISH MED & RES CTR, DEPT PEDIAT, 1400 JACKSON ST, DENVER, CO 80206 USA.				NHLBI NIH HHS [HL34303] Funding Source: Medline; NIGMS NIH HHS [GM48211] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048211] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amendola A, 1996, P NATL ACAD SCI USA, V93, P11057, DOI 10.1073/pnas.93.20.11057; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; BEVERS EM, 1989, BIOCHEMISTRY-US, V28, P2382, DOI 10.1021/bi00432a007; BRATTON DL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P24, DOI 10.1016/0005-2736(91)90330-B; BRATTON DL, 1994, J BIOL CHEM, V269, P22517; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; BRATTON DL, 1994, J LIPID MEDIAT CELL, V10, P43; BRATTON DL, 1993, J BIOL CHEM, V268, P3364; BRATTON DL, 1992, J IMMUNOL, V148, P514; CHANG CP, 1993, J BIOL CHEM, V268, P7171; COTTER TG, 1992, CANCER RES, V52, P997; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FADOK VA, 1992, J IMMUNOL, V148, P2207; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HASLETT C, 1985, AM J PATHOL, V119, P101; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; KOK JW, 1995, BIOCHEM J, V309, P905, DOI 10.1042/bj3090905; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LENNON SV, 1992, CLIN EXP IMMUNOL, V87, P465; LESLIE CC, 1990, METHOD ENZYMOL, V187, P216; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; Nagy L, 1996, LEUKEMIA RES, V20, P499, DOI 10.1016/0145-2126(95)00118-2; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; Park HJ, 1996, EUR J CANCER, V32A, P540, DOI 10.1016/0959-8049(95)00606-0; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Squier MKT, 1997, J IMMUNOL, V158, P3690; SUNE A, 1987, BIOCHEMISTRY-US, V26, P2972, DOI 10.1021/bi00385a003; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TILLY RHJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P188, DOI 10.1016/0005-2736(90)90453-U; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; WHYTE MKB, 1993, J CLIN INVEST, V92, P446, DOI 10.1172/JCI116587; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; ZACHOWSKI A, 1986, BIOCHEMISTRY-US, V25, P2585, DOI 10.1021/bi00357a046; Zhu WH, 1996, BIOCHEM PHARMACOL, V51, P1229	39	376	392	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26159	26165		10.1074/jbc.272.42.26159	http://dx.doi.org/10.1074/jbc.272.42.26159			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334182	hybrid			2022-12-27	WOS:A1997YB13900016
J	Elenius, K; Corfas, G; Paul, S; Choi, CJ; Rio, C; Plowman, GD; Klagsbrun, M				Elenius, K; Corfas, G; Paul, S; Choi, CJ; Rio, C; Plowman, GD; Klagsbrun, M			A novel juxtamembrane domain isoform of HER4/ErbB4 - Isoform-specific tissue distribution and differential processing in response to phorbol ester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; GENE ENCODES; PROTEOLYTIC CLEAVAGE; EXTRACELLULAR DOMAIN; TYROSINE KINASE; CARCINOMA-CELLS; ERBB RECEPTORS; TRUNCATED FORM; MESSENGER-RNA; LIGAND	Human epidermal growth factor receptor 4 (HER4) is a member of the epidermal growth factor (EGF) receptor subfamily of receptor tyrosine kinases that is activated by neuregulins (NRG), betacellulin (ETC), and heparin-binding EGF-like growth factor, Sequencing of full-length human HER4 cDNAs revealed the existence of two HER4 isoforms that differed by insertion of either 23 or 13 alternative amino acids in the extracellular juxtamembrane (JM) region, The 23-amino acid form (HERC JM-a) and the 13-amino acid form (HER4 JM-b) were expressed in a tissue-specific manner, as demonstrated by reverse transcriptase-polymerase chain reaction analysis of mouse and human tissues. Both isoforms were expressed in neural tissues such as cerebellum, whereas kidney expressed HER4 JM-a only and heart HER4 JM-b only, In situ hybridization using specific oligonucleotides demonstrated transcription of both JM-a and JM-b isoforms in the mouse cerebellum, Tyro sine phosphorylation analysis indicated that both receptor isoforms were activated to the same extent by NRG-beta 1 and ETC, and to a lesser extent by NRG-alpha 1 and heparin-binding EGF-like growth factor. A functional difference was found, however, in response 60 phorbol ester treatment, Stimulation of cells with phorbol ester resulted in a loss of I-125-NRG-beta 1 binding and in a reduction of total cell-associated HER4 protein in HER4 JM-a transfectants but not in HER4 JM-b transfectants. It was concluded that novel alternatively spliced isoforms of HER4 exist, that they are distributed differentially in vivo in mouse and human tissues, that they are both activated by HER4 ligands, and that they may represent cleavable and noncleavable forms of HER4.	CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115; CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02115; CHILDRENS HOSP,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; SUGEN INC,REDWOOD CITY,CA 94063	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			PLOWMAN, Greg D/E-2012-2011; Río, Carlos/GQA-4045-2022; Corfas, Gabriel/AAH-2378-2020; Elenius, Klaus/AAI-7594-2021	Río, Carlos/0000-0003-2666-7746; Corfas, Gabriel/0000-0001-5412-9473; Elenius, Klaus/0000-0001-5700-0827	NCI NIH HHS [CA 37392] Funding Source: Medline; NICHD NIH HHS [P30-HD 18655] Funding Source: Medline; NIGMS NIH HHS [GM 47397] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA037392, R37CA037392, R56CA037392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baulida J, 1996, J BIOL CHEM, V271, P5251; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, P69; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KATOH M, 1993, BIOCHEM BIOPH RES CO, V192, P1189, DOI 10.1006/bbrc.1993.1542; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEVI E, 1996, P NATL ACAD SCI USA, V93, P7096; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; PUPA SM, 1993, ONCOGENE, V8, P2917; Reiter JL, 1996, NUCLEIC ACIDS RES, V24, P4050, DOI 10.1093/nar/24.20.4050; REITER JL, 1996, MOL CELL BIOL, V24, P4050; Riese DJ, 1996, ONCOGENE, V12, P345; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Strohmaier C, 1996, EMBO J, V15, P3332, DOI 10.1002/j.1460-2075.1996.tb00698.x; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; WARRINGTON AE, 1992, J NEUROSCI RES, V33, P338, DOI 10.1002/jnr.490330218; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YEE NS, 1993, J BIOL CHEM, V268, P14189; Zhang K, 1996, J BIOL CHEM, V271, P3884; ZIMONJIC DB, 1995, ONCOGENE, V10, P1235	57	177	187	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26761	26768		10.1074/jbc.272.42.26761	http://dx.doi.org/10.1074/jbc.272.42.26761			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334263	hybrid			2022-12-27	WOS:A1997YB13900097
J	Kast, C; Gros, P				Kast, C; Gros, P			Topology mapping of the amino-terminal half of multidrug resistance-associated protein by epitope insertion and immunofluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; CONJUGATE EXPORT PUMP; HUMAN TUMOR-CELLS; P-GLYCOPROTEIN; TRANSMEMBRANE ORGANIZATION; MEMBRANE TOPOLOGY; MRP GENE; MONOCLONAL-ANTIBODIES; CANALICULAR ISOFORM; CLINICAL RELEVANCE	The multidrug resistance-associated protein (MRP) is an integral membrane protein that causes multidrug resistance when overexpressed in mammalian cells, Within the ATP-binding cassette superfamily, MRP belongs to a subgroup of structurally and functionally related proteins that includes the yeast cadmium factor 1 and yeast oligomycin resistance I proteins, and the mammalian sulfonylurea receptors SUR1 and SURE, Hydropathy analysis of these proteins predicts a unique membrane-associated region at the amino terminus followed by a structural unit composed of 12 transmembrane (TM) domains and two nucleotide-binding domains that is characteristic of eukaryotic ATP-binding cassette transporters, The topology of the membrane-associated regions of MRP remains largely unknown and was investigated, Small hemagglutinin epitopes (YPYDVPDYAS) were inserted in predicted hydrophilic segments of the membrane-associated regions from the amino-terminal half of MRP and these proteins were expressed in HeLa cells, and tested for their capacity to confer etoposide resistance, The polarity of the inserted tags with respect to plasma membrane was then deduced by immunofluorescence in intact and permeabilized cells, Insertion of epitopes at positions 4, 163, 271, 574, and 653 produced functional proteins while insertions at positions 127, 417, 461, and 529 abrogated the capacity of MRP to confer drug resistance, Epitopes inserted at positions 4, 163, and 574 were localized extracellularly, whereas those inserted at positions 271 and 653 revealed an intracellular location, Although a single epitope inserted at position 461 was compatible with MRP function, it was inaccessible to the anti-epitope antibody and two copies of the tag at that site abrogated MRP function, These results indicate that the amino terminus of MRP is extracellular, while the linker segment joining the first and second membrane-associated regions is intracellular as is the first nucleotide binding domain, Our findings are therefore consistent with a topological model of MRP that contains 5 TM segments in the first membrane-associated region and 6 TM segments in the second membrane region.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA	McGill University								AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ALMQUIST KC, 1995, CANCER RES, V55, P102; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Buchler M, 1996, J BIOL CHEM, V271, P15091; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CHANG XB, 1994, J BIOL CHEM, V269, P18572; COLE SPC, 1993, SCIENCE, V260, P879, DOI 10.1126/science.8098549; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; FLENS MJ, 1994, CANCER RES, V54, P4557; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, 1994, CANCER RES, V54, P357; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; LEE M, 1996, HDB BIOL PHYSICS, P189; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NOOTER K, 1994, LEUKEMIA RES, V18, P233, DOI 10.1016/0145-2126(94)90025-6; OTA E, 1995, BRIT J CANCER, V72, P550, DOI 10.1038/bjc.1995.372; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUSTIK C, 1995, MOL ASPECTS MED, V16, P1, DOI 10.1016/0098-2997(94)00040-A; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; Stride BD, 1996, MOL PHARMACOL, V49, P962; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TANGWAI DF, 1993, BIOCHEMISTRY-US, V32, P6470, DOI 10.1021/bi00076a022; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	55	104	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26479	26487		10.1074/jbc.272.42.26479	http://dx.doi.org/10.1074/jbc.272.42.26479			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334225	hybrid			2022-12-27	WOS:A1997YB13900059
J	Matveeva, EA; He, P; Whiteheart, SW				Matveeva, EA; He, P; Whiteheart, SW			N-ethylmaleimide-sensitive fusion protein contains high and low affinity ATP-binding sites that are functionally distinct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SNAP; VESICULAR TRANSPORT; REGULATED EXOCYTOSIS; SECRETORY PATHWAY; VESICLE FORMATION; GOLGI TRANSPORT; MEMBRANE-FUSION; MDCK CELLS; IN-VITRO; NSF	N-Ethylmaleimide-sensitive factor (NSF) has been shown to be involved in numerous intracellular membrane fusion events of both the regulated and constitutive secretory pathways. Sequence analysis indicates that the NSF subunit contains two nucleotide-binding sites, both with the classical Walker A and B motifs. In this report, we examine the nucleotide binding properties of NSF. The homotrimer contains three high affinity ATP-binding sites with K-d = 30-40 nM for ATP and K-d = 2 mu M for ADP. This class of binding sites did not bind AMP, adenine, or GTP. A second class of lower affinity nucleotide binding sites with a K-d = 15-20 mu M was also detected. Using various mutant forms of NSF, the high affinity nucleotide-binding sites were localized to the D2 domains and the low affinity sites were localized to the D1 domains, Functionally it is these lower affinity sites in D1 that are crucial for NSF activity. Nucleotide concentration greatly affected the ability of NSF to interact with alpha-SNAP SNARE (soluble NSF attachment protein-SNAP receptor) complex, suggesting that only when the D1 domain ATP-binding sites are occupied does NSF bind to the alpha-SNAP SNARE complex.	UNIV KENTUCKY,COLL MED,CHANDLER MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky				Whiteheart, Sidney/0000-0001-5577-0473	NHLBI NIH HHS [HL56652] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056652] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ANTONOFF RS, 1976, PHOTOCHEM PHOTOBIOL, V23, P327, DOI 10.1111/j.1751-1097.1976.tb07256.x; Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hicke L, 1997, MOL BIOL CELL, V8, P13, DOI 10.1091/mbc.8.1.13; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PALLANCK L, 1995, J BIOL CHEM, V270, P18742, DOI 10.1074/jbc.270.32.18742; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steel GJ, 1996, EMBO J, V15, P745, DOI 10.1002/j.1460-2075.1996.tb00410.x; SUMIDA M, 1994, J BIOL CHEM, V269, P20636; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	47	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26413	26418		10.1074/jbc.272.42.26413	http://dx.doi.org/10.1074/jbc.272.42.26413			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334216	hybrid			2022-12-27	WOS:A1997YB13900050
J	Morrione, A; Valentinis, B; Resnicoff, M; Xu, SQ; Baserga, R				Morrione, A; Valentinis, B; Resnicoff, M; Xu, SQ; Baserga, R			The role of mGrb10 alpha in insulin-like growth factor I-mediated growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAIN PROTEINS; RECEPTOR-BINDING-SITES; TUMOR-CELLS; GRB-IR; IGF-I; SUBSTRATE-1; APOPTOSIS; TRANSFORMATION; FIBROBLASTS; EXPRESSION	Several isoforms of Grb10 are known to interact with either the insulin receptor or the insulin-like growth factor I (IGF-I) receptor, or both. Inasmuch as the data in the literature on the function of Grb10 are not-always concordant, we have investigated the role of one of these isoforms, mGrb10 alpha, in cell proliferation. For this pul-pose, a plasmid expressing mGrb10 alpha was stably transfected into p6 cells and other mouse embryo fibroblast cell lines, An overexpressed mGrb10 alpha inhibits IGF-l-mediated growth, causes a delay in the S and G(2) phases of the cell cycle, and partially reverses the transformed phenotype. In contrast, it has no effect on insulin stimulation of cell proliferation These studies indicate that this isoform of Grb10 has an inhibitory effect on IGF-I signaling of cell proliferation.	THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NCI NIH HHS [CA 53424] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Baserga R, 1997, VITAM HORM, V53, P65, DOI 10.1016/S0083-6729(08)60704-9; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DAmbrosio C, 1996, CANCER RES, V56, P4013; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; Hongo A, 1996, ONCOGENE, V12, P1231; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; Morrione A, 1996, CANCER RES, V56, P3165; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; ULLRICH A, 1986, EMBO J, V5, P503; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1	42	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26382	26387		10.1074/jbc.272.42.26382	http://dx.doi.org/10.1074/jbc.272.42.26382			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334212	Green Published, hybrid			2022-12-27	WOS:A1997YB13900046
J	Seok, YJ; Sondej, M; Badawi, P; Lewis, MS; Briggs, MC; Jaffe, H; Peterkofsky, A				Seok, YJ; Sondej, M; Badawi, P; Lewis, MS; Briggs, MC; Jaffe, H; Peterkofsky, A			High affinity binding and allosteric regulation of Escherichia coli glycogen phosphorylase by the histidine phosphorylase protein, HPr	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING PHOSPHOCARRIER PROTEIN; SUGAR PHOSPHOTRANSFERASE SYSTEM; GRAM-POSITIVE BACTERIA; SALMONELLA-TYPHIMURIUM; RESOLUTION STRUCTURE; GENE; PHOSPHOENOLPYRUVATE; PURIFICATION; SEQUENCE; OPERON	The histidine phosphocarrier protein (HPr) is an essential element in sugar transport by the bacterial phosphoenolpyruvate:sugar phosphotransferase system, Ligand fishing, using surface plasmon resonance, was used to show the binding of HPr to a nonphosphotransferase protein in extracts of Escherichia coli; the protein was subsequently identified as glycogen phosphorylase (GP), The high affinity (association constant similar to 10s M-1), species-specific interaction was also demonstrated in electrophoretic mobility shift experiments by polyacrylamide gel electrophoresis, Equilibrium ultracentrifugation analysis indicates that HPr allosterically regulates the oligomeric state of glycogen phosphorylase. HPr binding increases GP activity to 250% of the level in control assays, Kinetic analysis of coupled enzyme as says shows that the binding of HPr to GP causes a decrease in the K-m for glycogen and an increase in the V-max for phosphate, indicating a mixed type activation, The stimulatory effect of E, coli HPr on E, coli GP activity is species-specific, and the unphosphorylated form of HPr activates GP more than does the phosphorylated form, Replacement of specific amino acids in]HPr results in reduced GP activation; HPr residues Arg-17, Lys-24, Lys-27, Lys-40, Ser-46, Gln-51, and Lys-72 were established to be important, This novel mechanism for the regulation of GP provides the first evidence directly linking E, coli HPr to the regulation of carbohydrate metabolism.	NHLBI,NIH,BETHESDA,MD 20892; NIH,NATL CTR RES RESOURCES,BETHESDA,MD 20892; NINCDS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Seok, Yeong-Jae/0000-0003-0379-3619				ANDERSON B, 1971, J BIOL CHEM, V246, P7023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUVIN F, 1996, P NATL ACAD SCI USA, V93, P7038; CHEN GS, 1968, ARCH BIOCHEM BIOPHYS, V127, P164, DOI 10.1016/0003-9861(68)90213-0; CHEN GS, 1968, ARCH BIOCHEM BIOPHYS, V127, P175, DOI 10.1016/0003-9861(68)90214-2; DEREUSE H, 1985, GENE, V35, P199; DEUTSCHER J, 1995, MOL MICROBIOL, V15, P1049, DOI 10.1111/j.1365-2958.1995.tb02280.x; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; Fisher Robert J., 1994, Current Opinion in Biotechnology, V5, P389, DOI 10.1016/0958-1669(94)90047-7; GARRETT D, 1997, BIOCHEMISTRY-US, V36, P4398; GEERSE RH, 1989, MOL GEN GENET, V216, P517, DOI 10.1007/BF00334399; HAMMEN PK, 1991, BIOCHEMISTRY-US, V30, P11842, DOI 10.1021/bi00115a014; HELMREICH E, 1964, P NATL ACAD SCI USA, V51, P131, DOI 10.1073/pnas.51.1.131; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HERZBERG O, 1994, CURR OPIN STRUC BIOL, V4, P812; HUDSON JW, 1993, J MOL BIOL, V234, P700, DOI 10.1006/jmbi.1993.1621; JIA ZC, 1993, J BIOL CHEM, V268, P22490; JOHNSON LN, 1992, FARADAY DISCUSS, V93, P131, DOI 10.1039/fd9929300131; JONES DHA, 1994, MICROBIOL-SGM, V140, P1035, DOI 10.1099/13500872-140-5-1035; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEWIS MS, 1996, EXPLORATION NEWSLETT, V3, P11; LIN K, 1995, J BIOL CHEM, V270, P26833, DOI 10.1074/jbc.270.45.26833; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; LIN K, 1996, J BIOL CHEM, V273, P1539; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; PETERKOFSKY A, 1995, BIOCHEMISTRY-US, V34, P8950, DOI 10.1021/bi00028a003; PIEPER U, 1995, STRUCTURE, V3, P781, DOI 10.1016/S0969-2126(01)00213-1; PLANUTIS KS, 1982, BIOCHEM BIOPH RES CO, V109, P583, DOI 10.1016/0006-291X(82)91761-2; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; PREISS J, 1994, PROG NUCLEIC ACID RE, V47, P299, DOI 10.1016/S0079-6603(08)60255-X; PRIES A, 1991, J BACTERIOL, V173, P5843, DOI 10.1128/jb.173.18.5843-5853.1991; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; REIZER J, 1993, J CELL BIOCHEM, V51, P19, DOI 10.1002/jcb.240510105; REIZER J, 1994, FEMS MICROBIOL LETT, V118, P159, DOI 10.1111/j.1574-6968.1994.tb06819.x; Reizer J, 1996, RES MICROBIOL, V147, P458, DOI 10.1016/0923-2508(96)84000-9; ROMEO T, 1988, GENE, V70, P363, DOI 10.1016/0378-1119(88)90208-9; Seok YJ, 1996, P NATL ACAD SCI USA, V93, P347, DOI 10.1073/pnas.93.1.347; Stone K. L., 1993, PRACTICAL GUIDE PROT, P43; VADEBONCOEUR C, 1995, RES MICROBIOL, V146, P525, DOI 10.1016/0923-2508(96)80558-4; VANNULAND NAJ, 1994, J MOL BIOL, V237, P544, DOI 10.1006/jmbi.1994.1254; WEIGEL N, 1982, J BIOL CHEM, V257, P4499; YU F, 1988, J BIOL CHEM, V263, P13706; ZHU PP, 1993, J BIOL CHEM, V268, P26531	49	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26511	26521		10.1074/jbc.272.42.26511	http://dx.doi.org/10.1074/jbc.272.42.26511			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334229	hybrid			2022-12-27	WOS:A1997YB13900063
J	Csukai, M; Chen, CH; DeMatteis, MA; MochlyRosen, D				Csukai, M; Chen, CH; DeMatteis, MA; MochlyRosen, D			The coatomer protein beta'-COP, a selective binding protein (RACK) for protein kinase C epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PHOSPHOLIPASE-D; INTRACELLULAR RECEPTOR; COATED VESICLES; GOLGI; PHOSPHORYLATION; SUBUNIT; LOCALIZATION; ACTIVATION; CELLS	Distinct subcellular localization of activated protein kinase C (PKC) isozymes is mediated by their binding to isozyme-specific RACKs (receptors for activated C-kinase), Our laboratory has previously isolated one such protein, RACK1, and demonstrated that this protein displays specificity for PKC beta. We have recently shown that at least part of the PKC epsilon RACK-binding site on PKC epsilon lies within the unique V1 region of this isozyme (Johnson, J. A., Gray, M. O., Chen, C.-H., and Mochly-Rosen, D. (1996) J. Biol, Chem. 271, 24962-24966), Here, we have used the PKC epsilon V1 region to clone a PKC epsilon-selective RACK, which was identified as the COPI coatomer protein, beta'-COP. Similar to RACK1, beta'-COP contains seven repeats of the WD40 motif and fulfills the criteria previously established for RACKs. Activated PKC epsilon colocalizes with beta'-COP in cardiac myocytes and binds to Golgi membranes in a beta'-COP-dependent manner, A role for PKC in control of secretion has been previously suggested, but this is the first report of direct protein/protein interaction of PKC epsilon with a protein involved in vesicular trafficking.	STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305; IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,DEPT CELL BIOL & ONCOL,I-66030 SANTA MARIA IMBAR,CHIETI,ITALY	Stanford University; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			De Matteis, Maria Antonietta/AHE-5161-2022	De Matteis, Maria Antonietta/0000-0003-0053-3061; Csukai, Michael/0000-0003-0615-7802; Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [HL52141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Buccione R, 1996, J BIOL CHEM, V271, P3523; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; CSUKAI M, 1997, PROTEIN TARGETING PR; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Eskildsen-Helmond Yvonne E. G., 1996, Journal of Molecular and Cellular Cardiology, V28, pA136; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FORBES MS, 1980, TISSUE CELL, V12, P467, DOI 10.1016/0040-8166(80)90037-3; GRAY MO, 1995, CIRCUALTION S1, V92, P137; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KATOH N, 1983, BIOCHEM J, V209, P189, DOI 10.1042/bj2090189; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Kiss Z, 1996, CHEM PHYS LIPIDS, V80, P81, DOI 10.1016/0009-3084(96)02547-9; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; LIMAS CJ, 1980, BIOCHEM BIOPH RES CO, V96, P1378, DOI 10.1016/0006-291X(80)90103-5; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; Sheff D, 1996, J BIOL CHEM, V271, P7230, DOI 10.1074/jbc.271.12.7230; Simon JP, 1996, J BIOL CHEM, V271, P16952, DOI 10.1074/jbc.271.28.16952; Singer WD, 1996, J BIOL CHEM, V271, P4504; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243	34	209	224	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29200	29206		10.1074/jbc.272.46.29200	http://dx.doi.org/10.1074/jbc.272.46.29200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360998	hybrid			2022-12-27	WOS:A1997YF68400057
J	Hanisch, UK; Lyons, SA; Prinz, M; Nolte, C; Weber, JR; Kettenmann, H; Kirchhoff, F				Hanisch, UK; Lyons, SA; Prinz, M; Nolte, C; Weber, JR; Kettenmann, H; Kirchhoff, F			Mouse brain microglia express interleukin-15 and its multimeric receptor complex functionally coupled to janus kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GROWTH-FACTOR; IL-2 RECEPTOR; NITRIC-OXIDE; ALPHA-CHAIN; BETA-CHAIN; ACTIVATION; SUBUNITS; PROTEIN; JAK3; PHOSPHORYLATION	The cytokine, interleukin (IL)-15, and the T cell growth factor, IL-2, exhibit a similar spectrum of immune effects and share the IL-2 receptor (IL-2R) subunits IL-2R beta and IL-2R gamma for signaling in hematopoietic cells. Numerous neuroregulatory activities of IL-2 have been suggested, but its expression in the normal central nervous system (CNS) is apparently very low and regionally restricted. We show by RNA and protein detection that IL-15, its specific receptor molecule, IL-15R alpha, and the signal-transducing receptor subunits, IL-2R beta and IL-2R gamma, are constitutively present in various regions of the developing and adult mouse brain, We further demonstrate, also at the single-cell level, that IL-15 and the components for IL-15R alpha/IL-2R beta gamma receptors are expressed by microglia, Tyrosine phosphorylation data are presented showing that IL-15 signaling in microglia involves Janus kinase 1 activity, At doses of 0.1-10 ng/ml, IL-15 affected functional properties of these cells, such as the production of nitric oxide, and supported their growth in culture, suggestive of a role as an autocrine growth factor. Microglial IL-15 could thus play a pivotal role in the CNS and may participate in certain CNS and neuroendocrine functions previously ascribed to IL-2.	HUMBOLDT UNIV BERLIN,CHAR MED SCH,DEPT NEUROL,D-10098 BERLIN,GERMANY	Humboldt University of Berlin	Hanisch, UK (corresponding author), MAX DELBRUCK CTR MOL MED,ROBERT ROSSLE STR 10,D-13122 BERLIN,GERMANY.		Kettenmann, Helmut/AAJ-5142-2021; Kirchhoff, Frank/B-9335-2008	Kirchhoff, Frank/0000-0002-2324-2761; Nolte, Christiane/0000-0001-5398-3440; Kettenmann, Helmut/0000-0001-8208-0291				ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BRISCOE J, 1994, CURR BIOL, V4, P1033, DOI 10.1016/S0960-9822(00)00236-0; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; Center DM, 1996, IMMUNOL TODAY, V17, P476, DOI 10.1016/0167-5699(96)10052-I; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; deJong JLO, 1996, J IMMUNOL, V156, P1339; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Elkabes S, 1996, J NEUROSCI, V16, P2508; GIRI JG, 1995, J LEUKOCYTE BIOL, V57, P763, DOI 10.1002/jlb.57.5.763; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Han DS, 1996, ONCOGENE, V12, P1015; HANISCH UK, 1996, BRAIN RES REV, V21, P246; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; Kaplan D, 1996, IMMUNOL TODAY, V17, P303, DOI 10.1016/0167-5699(96)30017-0; KETTENMANN H, 1993, GLIA, V7, P93, DOI 10.1002/glia.440070115; Kirchhoff F, 1996, J NEUROCHEM, V66, P1383; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LAPCHAK PA, 1991, NEUROSCIENCE, V44, P173, DOI 10.1016/0306-4522(91)90259-Q; Lee YB, 1996, NEUROREPORT, V7, P1062, DOI 10.1097/00001756-199604100-00022; McInnes IB, 1996, NAT MED, V2, P175, DOI 10.1038/nm0296-175; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MINAMI Y, 1992, BIOCHIM BIOPHYS ACTA, V1114, P163, DOI 10.1016/0304-419X(92)90013-O; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Moller T, 1997, J NEUROSCI, V17, P615; NAKAJIMA K, 1993, NEUROSCI RES, V17, P187, DOI 10.1016/0168-0102(93)90047-T; NICOLA NA, 1994, GUIDEBOOK CYTOKINES, P1; Nolte C, 1996, NEUROSCIENCE, V73, P1091, DOI 10.1016/0306-4522(96)00106-6; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; PERRY VH, 1994, MACROPHAGES NERVOUS; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SATOH T, 1992, J BIOL CHEM, V267, P25423; SAWADA M, 1995, J NEUROCHEM, V64, P1973; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; WALDMANN TA, 1993, TRENDS PHARMACOL SCI, V14, P159, DOI 10.1016/0165-6147(93)90201-T; WHITTINGTON R, 1993, DRUGS, V46, P446, DOI 10.2165/00003495-199346030-00009; WILKINSON PC, 1995, J EXP MED, V181, P1255, DOI 10.1084/jem.181.3.1255; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X	46	81	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28853	28860		10.1074/jbc.272.46.28853	http://dx.doi.org/10.1074/jbc.272.46.28853			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360952	hybrid			2022-12-27	WOS:A1997YF68400011
J	Tai, GH; Nieduszynski, IA; Fullwood, NJ; Huckerby, TN				Tai, GH; Nieduszynski, IA; Fullwood, NJ; Huckerby, TN			Human corneal keratan sulfates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROTEIN; II DIGESTION; CUPROMERONIC BLUE; LINKAGE-REGION; OLIGOSACCHARIDES; PROTEOGLYCAN; CHAIN; CHROMATOGRAPHY; DISACCHARIDE	The keratan sulfate-containing proteoglycans were isolated from fourteen pooled human corneas (thirteen from 61- to 86-year-olds, plus one from a 12-year-old). These proteoglycans were subjected to digestion with the enzyme keratanase II, and the released oligosaccharides, which included nonreducing termini and repeat region oligosaccharides but not linkage regions, were reduced with alkaline borohydride and identified on two separate ion-exchange columns. Both of the latter had been calibrated with samples, most of which had been derived from bovine corneal keratan sulfate (Tai, G.-H., Huckerby, T. N., and Nieduszynski, I. A. (1996) J. Biol, Chem. 271, 23535-23546) and all of which had been fully characterized by NMR spectroscopic analysis, The capping structures identified in human corneal keratan sulfates occurred in the relative proportions: NeuAc alpha(2-6)- >NeuAc alpha(2-3)- >GaINAc(S)beta(1-3)-. The other groups of capping structures which had been identified in bovine corneal keratan sulfate, i.e. NeuGc alpha(2-3)-, NeuGc alpha(2-6)-, GlcNAc(S)beta(1-3)- were absent, although the possibility of the presence of some Gal alpha(1-3)-structures could not be excluded. In addition, the human sample showed significantly higher levels of alpha(1-3) fucosylated repeat region structures than did the bovine sample, and it is not clear whether this reflects a species or age dependence as the bovine corneas were from young animals, whereas the human corneas were predominantly from an older group. The charge densities and keratan sulfate chain sizes of the human and bovine keratan sulfate-containing proteoglycans were seen to be similar.	UNIV LANCASTER,INST ENVIRONM & NAT SCI,DEPT SCI BIOL,LANCASTER LA1 4YQ,ENGLAND; UNIV LANCASTER,INST ENVIRONM & NAT SCI,SCH PHYS & CHEM,CTR POLYMER,LANCASTER LA1 4YA,ENGLAND	Lancaster University; Lancaster University				Fullwood, Nigel James/0000-0002-9405-8515	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMITAGE WJ, 1990, CURRENT OPHTHALMIC S, P193; BROWN GM, 1994, EUR J BIOCHEM, V224, P281, DOI 10.1111/j.1432-1033.1994.00281.x; BROWN GM, 1994, BIOCHEMISTRY-US, V33, P4836, DOI 10.1021/bi00182a012; BROWN GM, 1995, GLYCOBIOLOGY, V5, P311, DOI 10.1093/glycob/5.3.311; BROWN GM, 1997, LAB GUIDE GLYCOCONJU, P161; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DICKENSON JM, 1990, ANAL BIOCHEM, V190, P271, DOI 10.1016/0003-2697(90)90192-C; FORBES EG, 1994, FEBS LETT, V351, P433, DOI 10.1016/0014-5793(94)00907-4; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1996, INVEST OPHTH VIS SCI, V37, P2989; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; HOUNSELL EF, 1986, EUR J BIOCHEM, V157, P375, DOI 10.1111/j.1432-1033.1986.tb09679.x; KELLER R, 1981, H-S Z PHYSIOL CHEM, V362, P327, DOI 10.1515/bchm2.1981.362.1.327; MEEK KM, 1986, COLLAGEN REL RES, V6, P203; MEEK KM, 1993, BIOPHYS J, V64, P273, DOI 10.1016/S0006-3495(93)81364-X; MEYER K, 1953, J BIOL CHEM, V205, P611; MEYER K, 1970, CHEM MOL BIOL INTERC, P15; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OEBEN M, 1987, BIOCHEM J, V248, P85, DOI 10.1042/bj2480085; SCOTT JE, 1992, J ANAT, V180, P155; SCOTT JE, 1985, BIOSCIENCE REP, V5, P765, DOI 10.1007/BF01119875; Tai GH, 1996, J BIOL CHEM, V271, P23535, DOI 10.1074/jbc.271.38.23535; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25	23	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28227	28231		10.1074/jbc.272.45.28227	http://dx.doi.org/10.1074/jbc.272.45.28227			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353273	hybrid			2022-12-27	WOS:A1997YF21900013
J	Wong, LH; Krauer, KG; Hatzinisiriou, I; Estcourt, MJ; Hersey, P; Tam, ND; Edmondson, S; Devenish, RJ; Ralph, SJ				Wong, LH; Krauer, KG; Hatzinisiriou, I; Estcourt, MJ; Hersey, P; Tam, ND; Edmondson, S; Devenish, RJ; Ralph, SJ			Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3 gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SIGNAL-TRANSDUCTION; STIMULATED-GENE FACTOR-3; TYROSINE PHOSPHORYLATION; ALPHA-INTERFERON; TRANSCRIPTION FACTOR; CELLULAR RESPONSIVENESS; ANTIVIRAL ACTIVITY; MAMMALIAN-CELLS; DOWN-REGULATION; ACTIVATION	The mechanism of IFN resistance was examined in three long-term cell lines, SK-MEL-28, SK-MEL-3, and MM96, exhibiting significant variation in responsiveness to the antiproliferative and antiviral effects of type to IFNs, The JAK-STAT components involved in IFN signal transduction were analyzed in detail, After exposure to IFN, activation of the IFN type I receptor-linked tyrosine kinases, JAk-1 and TYK-2, was detected at similar levels in both IFN-sensitive and IFN-resistant cell types, indicating that IFN resistance did not result from a deficiency in signaling at the level of receptor-associated kinase activation. However, analysis of ISGF3 transcription factor components, STAT1, STAT2, and p48-ISGF3 gamma, revealed that their expression and activation correlated with cellular IFN responsiveness. The analysis was extended to also include IFN-sensitive primary melanocytes, three additional IFN-resistant melanoma cell lines, and seven cell cultures recently established from melanoma patient biopsies, It was consistently observed that the most marked difference in ISGF3 was a lack of STAT1 in the resistant versus the sensitive cells, Transfection of the IFN-resistant MM96 cell line to express increased levels of STAT1 protein partially restored IFN responsiveness in an antiviral assay. We conclude that a defect in the level of STAT1 and possibly all three ISGF3 components in IFN-resistant human melanoma cells may be a general phenomenon responsible for reduced cellular responsiveness of melanomas to IFNs.	MONASH UNIV,DEPT BIOCHEM & MOL BIOL,CLAYTON,VIC 3168,AUSTRALIA; JOHN HUNTER HOSP,IMMUNOL & ONCOL UNIT,NEWCASTLE,NSW 2300,AUSTRALIA; ROYAL CHILDRENS HOSP,CTR HORMONE RES,PARKVILLE,VIC 3052,AUSTRALIA	Monash University; John Hunter Hospital; Royal Children's Hospital Melbourne			Estcourt, Marie/E-6884-2017; Ralph, Stephen J./AAE-4888-2019; Wong, Lee H/H-9757-2012	Estcourt, Marie/0000-0001-8403-6075; Ralph, Stephen J./0000-0002-4335-092X; Wong, Lee H/0000-0002-4005-7330				AMAN P, 1990, EMBO J, V9, P147, DOI 10.1002/j.1460-2075.1990.tb08090.x; [Anonymous], 1982, MOL CLONING LAB MANU; BILLARD C, 1986, BLOOD, V67, P821; COATES AS, 1977, J NATL CANCER I, V59, P1325, DOI 10.1093/jnci/59.4.1325; COLAMONICI OR, 1992, BLOOD, V80, P744; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRON M, 1993, J INTERFERON RES, V13, P377, DOI 10.1089/jir.1993.13.377; EILERS A, 1993, MOL CELL BIOL, V13, P3245, DOI 10.1128/MCB.13.6.3245; ESTROZ Z, 1993, INTERFERONS BASIC PR, P53; GAO PQ, 1993, J BIOL CHEM, V268, P12380; GOUGH NM, 1987, ANAL BIOCHEM, V173, P93; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HASSANAIN HH, 1993, ANAL BIOCHEM, V213, P162, DOI 10.1006/abio.1993.1400; HERTZOG PJ, 1990, BIOCHEM INT, V22, P1095; HEYMAN M, 1994, LEUKEMIA, V8, P425; IMPROTA T, 1992, J INTERFERON RES, V12, P87, DOI 10.1089/jir.1992.12.87; JOHNS TG, 1992, J NATL CANCER I, V84, P1185, DOI 10.1093/jnci/84.15.1185; JOKLIK W K, 1991, P343; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KANDA K, 1992, MOL CELL BIOL, V12, P4930, DOI 10.1128/MCB.12.11.4930; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; KURZROCK R, 1991, BIOL THERAPY CANCER, P247; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MEYSKENS FL, 1984, J CLIN ONCOL, V2, P1223, DOI 10.1200/JCO.1984.2.11.1223; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PAYNE MJ, 1994, BIOCHEM MOL BIOL INT, V33, P283; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PETRICOIN E, 1994, MOL CELL BIOL, V14, P1477, DOI 10.1128/MCB.14.2.1477; PFEFFER LM, 1990, CANCER RES, V50, P2654; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RALPH SJ, 1995, J IMMUNOL, V154, P2248; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHILLER JH, 1986, J INTERFERON RES, V6, P615, DOI 10.1089/jir.1986.6.615; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAQUEZ I, 1994, CELL, V70, P313; Whitehead R, 1973, PIGMENT CELL, V1, P382; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; WINES BD, 1993, BIOCHEM MOL BIOL INT, V31, P1111; XU B, 1994, BLOOD, V84, P1942	48	213	228	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28779	28785		10.1074/jbc.272.45.28779	http://dx.doi.org/10.1074/jbc.272.45.28779			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353349	hybrid			2022-12-27	WOS:A1997YF21900089
J	Dessauer, CW; Gilman, AG				Dessauer, CW; Gilman, AG			The catalytic mechanism of mammalian adenylyl cyclase - Equilibrium binding and kinetic analysis of P-site inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE RECEPTORS; MEDIATED INHIBITION; 2',5'-DIDEOXYADENOSINE; REQUIREMENTS; PURIFICATION; EXPRESSION; FORSKOLIN; DOMAINS; FORM	The mechanism of P-site inhibition of adenylyl cyclase has been probed by equilibrium binding measurements using 2'-[H-3]deoxyadenosine, a P-site inhibitor, and by kinetic analysis of both the forward and reverse reactions (i.e. cyclic BMP and ATP synthesis, respectively). There is one binding site for 2'-deoxyadenosine per C-1/C-2 heterodimer; the K-d is 40 +/- 3 mu M. finding is observed only in the presence of one of the products of the adenylyl cyclase reaction, pyrophosphate (PPi). A substrate analog, Ap(CH2)pp (alpha,beta-methylene adenosine 5'-triphosphate), and cyclic AMP compete for the P-site in the presence of PPi, but P-site analogs do not compete for substrate binding (in the absence of PPi). Kinetic analysis indicates that release of products from the enzyme is random. These facts permit formulation of a model for the adenylyl cyclase reaction, for which we provide substantial kinetic support. We propose that P-site analogs act as dead-end inhibitors of product release, stabilizing an enzyme-product (E-PPi) complex by binding at the active site. Although product release is random, cyclic AMP dissociates from the enzyme preferentially. Release of PPi is slow and partially rate-limiting.			Dessauer, CW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.		Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280	NIGMS NIH HHS [GM34497, GM16905] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSHFIELD M, 1990, MOL PHARMACOL, V38, P848; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; FLORIO VA, 1983, THESIS U VIRGINIA; HAYAISHI O, 1971, J BIOL CHEM, V246, P5840; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; Johnson RA, 1997, J BIOL CHEM, V272, P8962; JOHNSON RA, 1979, J BIOL CHEM, V254, P1094; LEE E, 1994, METHOD ENZYMOL, V237, P146; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; LONDOS C, 1977, J BIOL CHEM, V252, P5957; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; LONDOS C, 1979, PHYSL REGULATORY FUN, P271; Segel I.H., 1975, ENZYME KINETICS; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Takai K, 1974, Methods Enzymol, V38, P160; TAKAI K, 1971, J BIOL CHEM, V246, P5843; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WELTON AF, 1980, BIOCHIM BIOPHYS ACTA, V615, P252, DOI 10.1016/0005-2744(80)90028-5; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WOLFF J, 1978, ARCH BIOCHEM BIOPHYS, V191, P161, DOI 10.1016/0003-9861(78)90078-4; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199; WOLIN MS, 1981, THESIS YALE U; WONG SKF, 1994, J BIOL CHEM, V269, P18968; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; YEUNG SMH, 1990, J BIOL CHEM, V265, P16745; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	34	115	117	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27787	27795		10.1074/jbc.272.44.27787	http://dx.doi.org/10.1074/jbc.272.44.27787			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346923	hybrid			2022-12-27	WOS:A1997YD47300049
J	Nacharaju, P; Roy, RP; White, SP; Nagel, RL; Acharya, AS				Nacharaju, P; Roy, RP; White, SP; Nagel, RL; Acharya, AS			Inhibition of sickle beta-chain (beta(s))-dependent polymerization by nonhuman alpha-chains - A superinhibitory mouse-horse chimeric alpha-chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; DEOXYHEMOGLOBIN-S; INTERMOLECULAR CONTACTS; HEMOGLOBIN FIBERS; MOLECULAR-BASIS; SEMISYNTHESIS	Horse alpha-chain inhibits sickle beta-chain-dependent polymerization; however, its inhibitory potential is not as high as that of mouse alpha-chain. Horse alpha-(1-30) and alpha-(31-141) segments make, respectively, minor and major con tributions to the inhibitory potential of horse alpha-chain. The sum of the inhibitory potential of the two segments does not account for the inhibitory potential of the full-length horse alpha-chain. Although the polymerization inhibitory potential of horse alpha-chain is lower than mouse alpha-chain, the inhibitory potential of horse alpha-(31-141) is comparable to that of mouse alpha-(31-141). When mouse alpha-(1-30) is stitched to horse alpha-(31-141), the product is a chimeric alpha-chain with an inhibitory potential greater than mouse alpha-chain. In contrast, the stitching of horse alpha-(1-30) with mouse alpha-(31-141) had no additional inhibitory potential. Molecular modeling studies of HbS containing the mouse-horse chimeric alpha-chain indicate altered sidechain interactions at the alpha(1) beta(1) interface when compared with HbS, In addition, the AB/GH corner perturbations facilitate a different stereochemistry for the interaction of the epsilon-amino group of Lys-16(alpha) with the beta-carboxyl group of Asp-116(alpha), resulting in a decrease in the accessibility of the side chain of Lys-16(alpha) to the solvent. Based on molecular modeling, we speculate that these perturbations by themselves, or in synergy with the altered conformational aspects of the alpha(1) beta(1) interactions, represent the molecular basis of the superinhibitory potential of the mouse-horse chimeric alpha-chains.	UNIV OKLAHOMA,DEPT BIOCHEM & MOL BIOL,STILLWATER,OK 74078	Oklahoma State University System; Oklahoma State University - Stillwater	Nacharaju, P (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV HEMATOL,BRONX,NY 10461, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038655] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55435-03, HL-38655] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1979, J BIOL CHEM, V254, P7765; BIHOREAU MT, 1990, P NATL ACAD SCI USA, V87, P145; CLEGG JB, 1966, J MOL BIOL, V19, P91, DOI 10.1016/S0022-2836(66)80052-9; CONSTANTINI F, 1986, SCIENCE, V233, P1192; CRETEGNY I, 1993, J MOL BIOL, V230, P733, DOI 10.1006/jmbi.1993.1195; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; ERHART MA, 1987, GENETICS, V115, P511; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12150, DOI 10.1073/pnas.89.24.12150; LADNER RC, 1976, J MOL BIOL, V103, P675, DOI 10.1016/0022-2836(76)90227-8; NAGEL RL, 1980, NATURE, V283, P832, DOI 10.1038/283832a0; PADLAN EA, 1985, J BIOL CHEM, V260, P8272; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; POPP RA, 1967, J MOL BIOL, V27, P916; RHODA MD, 1988, BIOCHIM BIOPHYS ACTA, V952, P208, DOI 10.1016/0167-4838(88)90117-3; ROY RP, 1993, J BIOL CHEM, V268, P16406; ROY RP, 1994, METHOD ENZYMOL, V231, P194; ROY RP, 1995, J PROTEIN CHEM, V14, P81, DOI 10.1007/BF01888365; WATOWICH SJ, 1989, J MOL BIOL, V209, P821, DOI 10.1016/0022-2836(89)90610-4; WATOWICH SJ, 1993, J STRUCT BIOL, V111, P161, DOI 10.1006/jsbi.1993.1047; YIP YK, 1977, P NATL ACAD SCI USA, V74, P64, DOI 10.1073/pnas.74.1.64	20	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27869	27876		10.1074/jbc.272.44.27869	http://dx.doi.org/10.1074/jbc.272.44.27869			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346934	hybrid			2022-12-27	WOS:A1997YD47300060
J	Patterson, B; Ruppel, KM; Wu, Y; Spudich, JA				Patterson, B; Ruppel, KM; Wu, Y; Spudich, JA			Cold-sensitive mutants G680V and G691C of Dictyostelium myosin II confer dramatically different biochemical defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR DOMAIN; MUSCLE-CONTRACTION; NUCLEOTIDE BINDING; CRYSTAL-STRUCTURE; HEAVY-CHAIN; DISCOIDEUM; COMPLEX; ACTIN; SUBFRAGMENT-1; MOVEMENT	Cold-sensitive myosin mutants represent powerful tools for dissecting discrete deficiencies in myosin function. Biochemical characterization of two such mutants, G680V and G691C, has allowed us to identify separate facets of myosin motor function perturbed by each alteration. Compared with wild type, the G680V myosin exhibits a substantially enhanced affinity for several nucleotides, decreased ATPase activity, and overoccupancy or creation of a novel strongly actin-binding state. The properties of the novel strong binding state are consistent with a partial arrest or pausing at the onset of the mechanical stroke. The G691C mutant, on the other hand, exhibits an elevated basal ATPase indicative of premature phosphate release. By releasing phosphate without a requirement for actin binding, the G691C can bypass the part of the cycle involving the mechanical stroke. The two mutants, despite having alterations in glycine residues separated by only 11 residues, have dramatically different consequences on the mechanochemical cycle.	STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305	Stanford University; Stanford University	Patterson, B (corresponding author), UNIV ARIZONA,DEPT MOL & CELL BIOL,LSS452,TUCSON,AZ 85721, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055977, R01GM040509, R01GM033289] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40509, GM33289, GM55977] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURKE M, 1977, BIOCHEMISTRY-US, V16, P5559, DOI 10.1021/bi00644a026; CHAUSSEPIED P, 1988, BIOCHEMISTRY-US, V27, P1778, DOI 10.1021/bi00405a059; CLARKE M, 1974, J MOL BIOL, V86, P209, DOI 10.1016/0022-2836(74)90013-8; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FISHER AJ, 1995, BIOPHYS J, V68, pS19; HUSTON EE, 1988, BIOCHEMISTRY-US, V27, P8945, DOI 10.1021/bi00425a011; Kinose F, 1996, J CELL BIOL, V134, P895, DOI 10.1083/jcb.134.4.895; KUCZMARSKI ER, 1991, J CELL BIOL, V114, P1191, DOI 10.1083/jcb.114.6.1191; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; MANSTEIN DJ, 1995, J MUSCLE RES CELL M, V16, P325, DOI 10.1007/BF00121141; PATTERSON B, 1995, GENETICS, V140, P505; Patterson B, 1996, GENETICS, V143, P801; PHAN BC, 1993, BIOCHEMISTRY-US, V32, P7712, DOI 10.1021/bi00081a016; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, CURR OPIN STRUC BIOL, V3, P944, DOI 10.1016/0959-440X(93)90160-M; Ruppel KM, 1996, MOL BIOL CELL, V7, P1123, DOI 10.1091/mbc.7.7.1123; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SEIDEL JC, 1969, BIOCHIM BIOPHYS ACTA, V180, P216, DOI 10.1016/0005-2728(69)90215-1; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; UE K, 1987, BIOCHEMISTRY-US, V26, P1889, DOI 10.1021/bi00381a016; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V	23	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27612	27617		10.1074/jbc.272.44.27612	http://dx.doi.org/10.1074/jbc.272.44.27612			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346898	hybrid			2022-12-27	WOS:A1997YD47300024
J	Huang, SS; Liu, QJ; Johnson, FE; Konish, Y; Huang, JS				Huang, SS; Liu, QJ; Johnson, FE; Konish, Y; Huang, JS			Transforming growth factor beta peptide antagonists and their conversion to partial agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; V RECEPTOR; CELLS; GROWTH-FACTOR-BETA-1; EXPRESSION; IDENTIFICATION; ANTIBODIES; DISEASE; BINDING	Transforming growth factor beta (TGF-beta) has been implicated in the pathogenesis of various human diseases. Synthetic TGF-beta antagonists therefore could have therapeutic utility. Here we show the development of such compounds. Three synthetic pentacosapeptides designated beta(1)(25)-(41-65), beta(2)(25)-(41-65), and beta(3)(25)-(41-65), whose amino acid sequences correspond to the 41st to 65th amino acid residues of TGF-beta(1), TGF-beta(2), and TGF-beta(3), respectively, inhibit the binding of I-125-labeled TGF-beta isoforms to TGF-beta receptors in mink lung epithelial cells with IC50 of similar to 0.06-2 mu M. beta(1)(25)-(41-65) blocks TGF-beta(1)-induced growth inhibition and TGF-beta(1)-induced plasminogen activator inhibitor-1 expression in these cells. The variants designated beta(1)(25)-(41-65)W52A/D55A and beta(3)(25)-(41-65)R52A/D55A, in which both Trp(52)/Arg(52) and Asp(55) are replaced by alanine residues, do not have TGF-beta antagonist activity. Multiple conjugation of beta(1)(25)-(41-65) to carrier proteins enhances its antagonist activity but also confers partial agonist activity as measured by DNA synthesis inhibition. These results suggest that the (W/R)XXD motif is important for the activities of these TGF-beta peptide antagonists and that this motif may be the active site sequence of TGF-beta.	ST LOUIS UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63104	Saint Louis University; Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA-38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATAYAKULCHANTLER S, 1994, J BIOL CHEM, V269, P27687; BORDER WA, 1995, J CLIN INVEST, V96, P655, DOI 10.1172/JCI118107; BORDER WA, 1995, NAT MED, V1, P1000, DOI 10.1038/nm1095-1000; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; ENGSTROM U, 1992, J BIOL CHEM, V267, P16581; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; LIU QJ, 1994, J BIOL CHEM, V269, P9221; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; MADISON L, 1988, DNA CELL BIOL, V7, P18; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; OGRADY P, 1992, J BIOL CHEM, V267, P21033; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; Qian SW, 1996, J BIOL CHEM, V271, P30656, DOI 10.1074/jbc.271.48.30656; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SHAH M, 1995, J CELL SCI, V108, P985; SHENKAR R, 1994, AM J RESP CELL MOL, V11, P351, DOI 10.1165/ajrcmb.11.3.8086171; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473	27	35	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27155	27159		10.1074/jbc.272.43.27155	http://dx.doi.org/10.1074/jbc.272.43.27155			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341157	hybrid			2022-12-27	WOS:A1997YC65900053
J	Kitajima, I; Hanyu, N; Soejima, Y; Hirano, R; Arahira, S; Yamaoka, S; Yamada, R; Maruyama, I; Kaneda, Y				Kitajima, I; Hanyu, N; Soejima, Y; Hirano, R; Arahira, S; Yamaoka, S; Yamada, R; Maruyama, I; Kaneda, Y			Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan (HVJ)-cationic liposomes - Application for ribozymes that target human T-cell leukemia virus type I tax/rex mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HVJ SENDAI VIRUS; ADULT-RAT LIVER; NF-KAPPA-B; ANTISENSE OLIGONUCLEOTIDES; THERAPEUTIC AGENTS; NUCLEAR-PROTEIN; SELF-CLEAVAGE; CATALYTIC RNA; C-MYB; SEQUENCE	We investigated the usefulness of ribozymes in inhibiting the expression of human T cell leukemia virus type I (HTLV-I) gene, Two hammerhead ribozymes that were against HTLV-I rex (RR) and tax (TR) mRNA were synthesized. Both ribozymes were sequence-specific in the in vitro cleavage analysis of run-off transcripts from tax/rex cDNA. Intracellular activities of the ribozymes were studied in HTLV-I tax cDNA-transfected rat embryonic fibroblasts (Rat/Tax cells), which expressed the Tax but not Rex. Ribozymes were delivered into cells using anionic or cationic liposomes fused with hemagglutinating virus of Japan (HVJ). Cellular uptake of ribozymes complexed with HVJ-cationic liposomes was 15-20 times higher cellular uptake than naked ribozymes, and 4-5 times higher than that of ribozymes complexed with HVJ anionic liposomes. HVJ-cationic liposomes promoted accumulation of ribozymes in cytoplasm and accelerated transport to the nucleus. Tax protein levels were decreased about 95% and were five times lower when the same amount of TR was introduced into the cells using HVJ-cationic, rather than HVJ-anionic liposomes. Inactive ribozyme and tax antisense oligodeoxynucleotides reduced Tax expression by about 20%, whereas RR and tar sense oligodeoxynucleotides had no effect. These results suggest that the ribozymes' effect against tax mRNA was sequence-specific, and HVJ-cationic liposomes can be useful for intracellular introduction of ribozymes.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 60601,JAPAN; HITACHI CHEM CO,TSUKUBA RES & DEV DIV,TSUKUBA,IBARAKI 30042,JAPAN; OSAKA UNIV,INST MOL & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Kyoto University; Hitachi Limited; Osaka University	Kitajima, I (corresponding author), KAGOSHIMA UNIV,DEPT LAB & MOL MED,8-35-1 SAKURAGAOKA,KAGOSHIMA 890,JAPAN.							ASANO K, 1988, BIOCHEMISTRY-US, V27, P1321, DOI 10.1021/bi00404a035; BEIGELMAN L, 1995, J BIOL CHEM, V270, P25702, DOI 10.1074/jbc.270.43.25702; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9137; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISEY L, 1991, ANTISENSE RES DEV, V1, P57, DOI 10.1089/ard.1991.1.57; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; HEIDENREICH O, 1995, NUCLEIC ACIDS RES, V23, P2223, DOI 10.1093/nar/23.12.2223; Jarvis TC, 1996, J BIOL CHEM, V271, P29107, DOI 10.1074/jbc.271.46.29107; Jarvis TC, 1996, RNA, V2, P419; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KANEDA Y, 1987, EXP CELL RES, V173, P56, DOI 10.1016/0014-4827(87)90331-4; KATO K, 1991, J BIOL CHEM, V266, P3361; Kijima H, 1995, PHARMACOL THERAPEUT, V68, P247, DOI 10.1016/0163-7258(95)02008-X; Kitajima I, 1996, J CELL SCI, V109, P609; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KITAJIMA I, 1991, J CLIN INVEST, V88, P1315, DOI 10.1172/JCI115436; KITAJIMA I, 1992, J BIOL CHEM, V267, P25881; KITAJIMA I, 1997, IN RPESS ARTHRITIS R; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; SAEKI Y, 1997, IN PRESS HUM GENE TH; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; Sarver N, 1991, Antisense Res Dev, V1, P373; Scherr M, 1997, J BIOL CHEM, V272, P14304, DOI 10.1074/jbc.272.22.14304; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHARMA HW, 1995, BIOESSAYS, V17, P1055, DOI 10.1002/bies.950171210; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; Wattiaux R, 1996, BIOCHEM BIOPH RES CO, V227, P448, DOI 10.1006/bbrc.1996.1527; WongStaal F, 1995, ADV DRUG DELIVER REV, V17, P363, DOI 10.1016/0169-409X(95)00072-F; XING Z, 1992, J VIROL, V66, P1361, DOI 10.1128/JVI.66.3.1361-1369.1992; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1989, HTLV I NERVOUS SYSTE, P19	41	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27099	27106		10.1074/jbc.272.43.27099	http://dx.doi.org/10.1074/jbc.272.43.27099			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341150	hybrid			2022-12-27	WOS:A1997YC65900046
J	Ohya, K; Kajigaya, S; Yamashita, Y; Miyazato, A; Hatake, K; Miura, Y; Ikeda, U; Shimada, K; Ozawa, K; Mano, H				Ohya, K; Kajigaya, S; Yamashita, Y; Miyazato, A; Hatake, K; Miura, Y; Ikeda, U; Shimada, K; Ozawa, K; Mano, H			SOCS-1/JAB/SSI-1 can bind to and suppress Tec protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; COLONY-STIMULATING FACTOR; CELL LINE; FAMILY; GENE; INTERLEUKIN-3; EXPRESSION; PHOSPHORYLATION; ERYTHROPOIETIN; ASSOCIATION	Tec is the prototype of a recently emerging subfamily among nonreceptor type protein-tyrosine kinases and is known to become tyrosine-phosphorylated and activated by a wide range of cytokine stimulations in hematopoietic cells. Although Tec was recently shown to be involved in the cytokine-driven activation mechanism of c-fos transcription, it is yet obscure how Tec relays the signals from cell surface receptors to the nucleus. To identify signaling molecules: acting downstream of Tec, we have looked for Tec-interacting proteins (TIPs) by using the yeast two-hybrid system. Here we report the identification and characterization of a novel protein, TIP3, which has been simultaneously identified by other groups as SOCS-1, JAB, or SSI-l. TIP3 carries one Src homology 2 domain with a sequence similarity to that of CIS. In 293 cells, TIPB associates with Tec and suppresses its kinase activity. Interestingly, TIPB can also down-regulate the activity of Jak2 but not that of Lyn. We propose that SOCS-1/JAB/SSI-1/TIP3 is a novel type of negative regulator to a subset of protein-tyrosine kinases.	JICHI MED SCH, DEPT MOL BIOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; JICHI MED SCH, DIV CARDIOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; JICHI MED SCH, DIV HEMATOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; NHLBI, HEMATOL BRANCH, NIH, BETHESDA, MD 20892 USA	Jichi Medical University; Jichi Medical University; Jichi Medical University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BAIER G, 1994, BIOTECHNIQUES, V17, P94; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; KIKUCHI Y, 1995, P NATL ACAD SCI USA, V92, P11814, DOI 10.1073/pnas.92.25.11814; KOMATSU N, 1991, CANCER RES, V51, P341; MACHIDE M, 1995, ONCOGENE, V11, P619; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1995, BLOOD, V85, P343; Mano H, 1996, FASEB J, V10, P637, DOI 10.1096/fasebj.10.5.8621063; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Miyazato A, 1996, CELL GROWTH DIFFER, V7, P1135; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; Yamashita Y, 1997, EXP HEMATOL, V25, P211; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	27	99	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27178	27182		10.1074/jbc.272.43.27178	http://dx.doi.org/10.1074/jbc.272.43.27178			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341160	hybrid			2022-12-27	WOS:A1997YC65900056
J	vandeLoo, JWHP; Creemers, JWM; Bright, NA; Young, BD; Roebroek, AJM; VandeVen, WJM				vandeLoo, JWHP; Creemers, JWM; Bright, NA; Young, BD; Roebroek, AJM; VandeVen, WJM			Biosynthesis, distinct post-translational modifications, and functional characterization of lymphoma proprotein convertase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PROCESSING ENZYME FURIN; CYTOPLASMIC DOMAIN; KEX2 PROTEASE; CELL-SURFACE; INTRACELLULAR TRAFFICKING; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; YEAST KEX2	Proprotein convertases are responsible for the endoproteolytic processing of prohormones, neuropeptide precursors, and other proproteins within the constitutive and regulated secretory pathways. Cleavage occurs carboxyl-terminally of basic amino acid motifs, such as RX(K/R)R, RXXR, and (R/K)R. As already available for the other known mammalian members of this enzyme family, we here define structural and functional features of human lymphoma proprotein convertase (LPC). Analysis of expression of recombinant LPC in stably transfected Chinese hamster ovary cells reveals biosynthesis of a 92-kDa nonglycosylated precursor (proLPC) and a 102-kDa endoglycosidase H-sensitive glycosylated form of proLPC. Only the latter is further processed and after propeptide removal converted into a complexly N-glycosylated mature form of LPC of about 92 kDa. Co-expression experiments of truncated LPC with an active site mutant of LPC (LPCS265A) indicate that prodomain removal of LPC occurs via an autoproteolytic, intramolecular mechanism, as was demonstrated before for some of the other members of this enzyme family. Prodomain removal is shown to be required for LPC to exit the endoplasmic reticulum. As far as subcellular localization is concerned, immunocytochemical, ultrastructural, and biochemical analyses show that LPC is concentrated in the trans-Golgi network, associated with membranes, and not secreted. Carboxyl-terminal domains are critically involved in this cellular retention, because removal of both the hydrophobic region and the cytoplasmic tail of LPC results in secretion. Of interest are the observations that LPC is not phosphorylated like furin but is palmitoylated in its cytoplasmic tail. Finally, substrate specificity of LPC is similar to that of furin but not identical. Whereas for furin a basic substrate residue at position P-2 is dispensable, it is essential for LPC. For optimal LPC substrate processing activity, an arginine at position P-6 is preferred over an arginine at P-4.	KATHOLIEKE UNIV LEUVEN,CTR HUMAN GENET,MOL ONCOL LAB,B-3000 LOUVAIN,BELGIUM; FLANDERS INTERUNIV INST BIOTECHNOL,B-3000 LOUVAIN,BELGIUM; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT MED ONCOL,IMPERIAL CANC RES FUND,LONDON EC1 M6BQ,ENGLAND	KU Leuven; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge								AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; Ayoubi TAY, 1996, MOL BIOL REP, V23, P87, DOI 10.1007/BF00424434; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; Griffiths G., 1993, FINE STRUCTURE IMMUN, P1; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; Inocencio NM, 1997, J BIOL CHEM, V272, P1344, DOI 10.1074/jbc.272.2.1344; JANSEN E, 1995, J BIOL CHEM, V270, P15391, DOI 10.1074/jbc.270.25.15391; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOCKER JK, 1995, J BIOL CHEM, V270, P8815, DOI 10.1074/jbc.270.15.8815; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Meerabux J, 1996, CANCER RES, V56, P448; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Nilsson T, 1996, J CELL SCI, V109, P1975; OHAGI S, 1992, P NATL ACAD SCI USA, V89, P4977, DOI 10.1073/pnas.89.11.4977; OHNISHI Y, 1994, J VIROL, V68, P4075, DOI 10.1128/JVI.68.6.4075-4079.1994; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11586, DOI 10.1021/bi00094a015; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; TAKAHASHI S, 1994, J BIOCHEM-TOKYO, V116, P47, DOI 10.1093/oxfordjournals.jbchem.a124501; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VANDUIJNHOVEN HLP, 1992, HYBRIDOMA, V11, P71, DOI 10.1089/hyb.1992.11.71; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; WONG SH, 1993, J BIOL CHEM, V268, P22853; [No title captured]	52	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27116	27123		10.1074/jbc.272.43.27116	http://dx.doi.org/10.1074/jbc.272.43.27116			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341152	hybrid			2022-12-27	WOS:A1997YC65900048
J	Benjannet, S; Savaria, D; Laslop, A; Munzer, JS; Chretien, M; Marcinkiewicz, M; Seidah, NG				Benjannet, S; Savaria, D; Laslop, A; Munzer, JS; Chretien, M; Marcinkiewicz, M; Seidah, NG			alpha 1-antitrypsin portland inhibits processing of precursors mediated by proprotein convertases primarily within the constitutive secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASES; KEX2-LIKE ENDOPROTEASE; SUBTILISIN FAMILY; POLYPEPTIDE 7B2; HUMAN FURIN; PROTEIN; PC2; CELLS; CLEAVAGE; SEQUENCE	We studied the extent of cellular inhibitory activity of alpha 1-antitrypsin Portland (alpha 1-PDX), a patent inhibitor of proprotein convertases of the subtilisin/kexin type. We compared the inhibitory effects of alpha 1-PDX on the intracellular processing of two model precursors (pro ?Ba and POMC) mediated by six of the seven known mammalian convertases, namely furin, PC1, PC2, PACE4, PCB-A, PC5-B, and PC7, The substrates selected were pro7B2, a precursor cleaved within the trans-Golgi network (TGN), and pro-opiomelanocortin, which is processed in the TGN and secretory granules. Biosynthetic analyses were performed using either vaccinia virus expression in BSC40, GH4C1, and AtT20 cells, or stable transfectants of alpha 1-PDX in AtT20 cells. Results revealed that alpha 1-PDX inhibits processing of these precursors primarily within the constitutive secretory pathway and that alpha 1-PDX is cleaved into a shorter form by some convertases. Evidence is presented demonstrating that in contrast to the full-length alpha 1-PDX (64 kDa), the cleaved (56 kDa) secreted product; does not significantly inhibit furin activity in vitro, Cellular expression of alpha 1-PDX results in modified contents of mature secretory granules with increased levels of partially processed products. Biosynthetic and immunocytochemical analyses of AtT20/alpha 1-PDX cells demonstrated that alpha 1-PDX is primarily localized within the TGN, and that a small proportion enters secretory granules where it is mostly stored as the cleaved product.	CLIN RES INST MONTREAL,JA DESEVE LABS BIOCHEM,MONTREAL,PQ H2W 1R7,CANADA; CLIN RES INST MONTREAL,JA DESEVE LABS MOL NEUROENDOCRINOL,MONTREAL,PQ H2W 1R7,CANADA; PROT ENGN NETWORK CTR EXCELLENCE,MONTREAL,PQ H2W 1R7,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; CHRETIEN, Michel/0000-0002-8588-4460				ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRESNAHAN PA, 1993, MECHANISMS INTRACELL, P225; CHRETIEN M, 1995, P ASSOC AM PHYSICIAN, V107, P47; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; DECROLY E, 1994, J BIOL CHEM, V269, P12240; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HUTTON JC, 1994, DIABETOLOGIA, V37, pS48, DOI 10.1007/BF00400826; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Komiyama T, 1996, PROTEIN SCI, V5, P874; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; KURACHI K, 1981, P NATL ACAD SCI-BIOL, V78, P6826, DOI 10.1073/pnas.78.11.6826; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LU WY, 1993, J BIOL CHEM, V268, P14583; Mains RE, 1997, BIOCHEM J, V321, P587, DOI 10.1042/bj3210587; MARTENS GJM, 1988, FEBS LETT, V234, P160, DOI 10.1016/0014-5793(88)81324-3; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MATSUUCHI L, 1988, J CELL BIOL, V106, P239, DOI 10.1083/jcb.106.2.239; MBIKAY M, 1989, INT J PEPT PROT RES, V33, P39; MILGRAM SL, 1994, J CELL SCI, V107, P735; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PAQUET L, 1994, J BIOL CHEM, V269, P19279; PERLMUTTER DH, 1989, AM J PHYSIOL, V257, pL147, DOI 10.1152/ajplung.1989.257.4.L147; REAVES B, 1992, BIOCHEM J, V283, P313, DOI 10.1042/bj2830313; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SEIDAH NG, 1995, INTRAMOLECULAR CHAPE, P181; THOMAS G, 1995, PROPEPTIDE MEDIATED, P157; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; Vollenweider F, 1996, BIOCHEM J, V314, P521, DOI 10.1042/bj3140521; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	50	80	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26210	26218		10.1074/jbc.272.42.26210	http://dx.doi.org/10.1074/jbc.272.42.26210			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334189	hybrid			2022-12-27	WOS:A1997YB13900023
J	Caloca, MJ; Fernandez, N; Lewin, NE; Ching, DX; Modali, R; Blumberg, PM; Kazanietz, MG				Caloca, MJ; Fernandez, N; Lewin, NE; Ching, DX; Modali, R; Blumberg, PM; Kazanietz, MG			beta 2-chimaerin is a high affinity receptor for the phorbol ester tumor promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTPASE-ACTIVATING PROTEIN; CYSTEINE-RICH REGION; MOUSE-BRAIN; N-CHIMAERIN; 12,13-DIBUTYRATE BINDING; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; CALCIUM; ISOZYMES	beta 2-chimaerin, a member of the GTPase-activating proteins for the small GTP-binding protein p21Rac, possesses a single cysteine-rich domain with high homology to those implicated in phorbol ester and diacylglycerol binding in protein kinase C (PKC) isozymes. We have expressed beta 2-chimaerin in Sf9 insect cells using the baculovirus expression system and determined that, like PKCs, beta 2-chimaerin binds phorbol esters with high affinity in the presence of phosphatidylserine as a cofactor. Scatchard plot analysis using the radioligand [H-3]phopbol 12,13-dibutyrate revealed a dissociation constant of 1.9 +/- 0.2 nM for beta 2-chimaerin. Likewise, beta 2-chimaerin is a high affinity receptor for the bryostatins, a class of atypical PHC activators. A detailed comparison of structure activity relations using several phorbol ester analogs revealed striking differences in binding recognition between beta 2-chimaerin and PKC alpha. Although the diacylglycerol 1-oleoyl-2-acetylglycerol binds with similar potency to both beta 2-chimaerin and PKC alpha; the mezerein analog thymeleatoxin has 56-foId less affinity for binding to beta 2-chimaerin. To establish whether beta 2-chimaerin responds to phorbol esters in cellular sys-- tems, we overexpressed beta 2-chimaerin in COS-7 cells and monitored its subcellular distribution after phorbol ester treatment. Interestingly, as described previously for PI(C isozymes, beta 2-chimaerin translocates from cytosolic to particulate fractions as a consequence of phorbol ester treatment. Our results demonstrate that beta 2-chimaerin is a novel target for the phorbol aster tumor promoters. The expansion of the family of phorbol ester receptors strongly suggests a potential for the ''nonkinase'' receptors as cellular mediators of the phorbol ester responses.	UNIV PENN, SCH MED, CTR EXPT THERAPEUT, STELLAR CHANCE LABS 905, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA; NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, NIH, BETHESDA, MD 20892 USA; BIOSERVE BIOTECHNOL, LAUREL, MD 20707 USA	University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Caloca, María-José/K-9357-2014; Fernández, Nieves/N-5426-2018	Fernández, Nieves/0000-0002-9141-3956; Caloca, Maria-Jose/0000-0002-1003-2685	NCI NIH HHS [IROICA74197-OIAI] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; ARECES LB, 1994, J BIOL CHEM, V269, P19553; ASHENDEL CL, 1983, CANCER RES, V43, P4333; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DUNPHY WG, 1981, CANCER RES, V41, P2640; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL C, 1993, MOL CELL BIOL, V13, P4986, DOI 10.1128/MCB.13.8.4986; Hurley JH, 1997, PROTEIN SCI, V6, P477; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P10777, DOI 10.1074/jbc.270.18.10777; KAZANIETZ MG, 1994, MOL PHARMACOL, V46, P374; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KONIG B, 1985, J CELL BIOCHEM, V27, P255, DOI 10.1002/jcb.240270307; Kozma R, 1996, MOL CELL BIOL, V16, P5069; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; Lee J, 1993, Bioorg Med Chem, V1, P119, DOI 10.1016/S0968-0896(00)82109-4; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEUNG T, 1994, J BIOL CHEM, V269, P12888; LEUNG T, 1993, J BIOL CHEM, V268, P3813; LEWIN NE, 1992, BIOCHEM PHARMACOL, V43, P2007, DOI 10.1016/0006-2952(92)90644-X; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; RIDLEY AJ, 1994, J CELL SCI, P127; SANDO JJ, 1983, P NATL ACAD SCI-BIOL, V80, P2642, DOI 10.1073/pnas.80.9.2642; SHARKEY NA, 1985, CANCER RES, V45, P19; Summers MD, 1987, TEXAS AGR EXPT STATI; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; TAKAI Y, 1979, J BIOL CHEM, V254, P3692	42	90	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26488	26496		10.1074/jbc.272.42.26488	http://dx.doi.org/10.1074/jbc.272.42.26488			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334226	hybrid			2022-12-27	WOS:A1997YB13900060
J	Ogino, T; Kobuchi, H; Sen, CK; Roy, S; Packer, L; Maguire, JJ				Ogino, T; Kobuchi, H; Sen, CK; Roy, S; Packer, L; Maguire, JJ			Monochloramine inhibits phorbol ester-inducible neutrophil respiratory burst activation and T cell interleukin-2 receptor expression by inhibiting inducible protein kinase C activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NADPH-OXIDASE; SIGNAL-TRANSDUCTION; POLYMORPHONUCLEAR LEUKOCYTES; SUPEROXIDE PRODUCTION; INTRACELLULAR CA2+; ARACHIDONIC-ACID; BINDING-PROTEINS; ALPHA GENE; PHOSPHORYLATION	Monochloramine derivatives are long lived physiological oxidants produced by neutrophils during the respiratory burst, The effects of chemically prepared monochloramine (NH2Cl) on protein kinase C (PKC) and PKC-mediated cellular responses were studied in elicited rat peritoneal neutrophils and human Jurkat T cells, Neutrophils pretreated with NH2Cl (30-50 mu M) showed a marked decrease in the respiratory burst activity induced by phorbol 12-myristate 13-acetate (PMA), which is a potent PKC activator. These cells, however, were viable and showed a complete respiratory burst upon arachidonic acid stimulation, which induces the respiratory burst by a PKC-independent mechanism, The NH2Cl-treated neutrophils showed a decrease in both PRC activity and PMA-induced phosphorylation of a 47-kDa protein, which corresponds to the cytosolic factor of NADPH oxidase, p47(phox). Jurkat T cells pretreated with NH2Cl (20-70 mu M) showed a decrease in the expression of the interleukin-a receptor a chain following PMA stimulation. This was also accompanied by a decrease in both PKC activity and nuclear transcription factor-kappa B activation, also without loss of cell viability, These results show that NH2Cl inhibits PKC-mediated cellular responses through inhibition of the inducible PKC activity.	UNIV CALIF BERKELEY,ENVIRONM ENERGY TECHNOL DIV,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Ogino, T (corresponding author), UNIV CALIF BERKELEY,DEPT CELLULAR & MOL BIOL,LAWRENCE BERKELEY LAB,251 LSA,BERKELEY,CA 94720, USA.		Sen, Chandan K/A-8762-2013; OGINO, Tetsuya/B-1999-2011; Roy, sashwati/E-3990-2011		NIGMS NIH HHS [GM27345] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM027345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BADWEY JA, 1981, J BIOL CHEM, V256, P2640; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; Bell R M, 1986, Methods Enzymol, V124, P353; Blobe GC, 1996, CANCER SURV, V27, P213; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOHNLEIN E, 1989, J BIOL CHEM, V264, P8475; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BUTTERWORTH RF, 1987, NEUROCHEM PATHOL, V6, P1, DOI 10.1007/BF02833598; COHEN P, 1989, J BIOL CHEM, V264, P21435; COX JA, 1987, J IMMUNOL, V138, P1884; CUNNINGHAM FM, 1979, J PATHOL, V128, P15, DOI 10.1002/path.1711280104; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DING JB, 1992, J BIOL CHEM, V267, P6442; DING JB, 1992, BIOCHIM BIOPHYS ACTA, V1133, P235, DOI 10.1016/0167-4889(92)90074-L; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; GREENE WC, 1984, J IMMUNOL, V133, P1042; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOWANITZ JH, 1984, CLIN CHEM, V30, P906; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; JAMIESON C, 1991, J IMMUNOL, V147, P416; KAKINUMA K, 1976, J BIOCHEM-TOKYO, V79, P795, DOI 10.1093/oxfordjournals.jbchem.a131132; LEARN DB, 1990, J LEUKOCYTE BIOL, V48, P174, DOI 10.1002/jlb.48.2.174; LEVY R, 1994, BBA-MOL CELL RES, V1220, P253, DOI 10.1016/0167-4889(94)90146-5; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MAJUMDAR S, 1993, BIOCHIM BIOPHYS ACTA, V1176, P276, DOI 10.1016/0167-4889(93)90056-U; MAKINO R, 1986, J BIOL CHEM, V261, P1444; Marcinkiewicz J, 1995, J LEUKOCYTE BIOL, V58, P667, DOI 10.1002/jlb.58.6.667; NAKAMURA TY, 1995, J CELL BIOL, V131, P509, DOI 10.1083/jcb.131.2.509; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Ogino T, 1997, FREE RADICAL BIO MED, V23, P445, DOI 10.1016/S0891-5849(97)00115-9; Pero RW, 1996, CARCINOGENESIS, V17, P13, DOI 10.1093/carcin/17.1.13; PILLOUDDAGHER MC, 1992, BIOCHEM BIOPH RES CO, V186, P731, DOI 10.1016/0006-291X(92)90807-W; ROBINSON JM, 1995, HISTOCHEM CELL BIOL, V103, P163, DOI 10.1007/BF01454021; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SALAMINO F, 1991, EUR J BIOCHEM, V200, P573, DOI 10.1111/j.1432-1033.1991.tb16220.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sen CK, 1996, FEBS LETT, V385, P58, DOI 10.1016/0014-5793(96)00346-8; SHACKELFORD DA, 1984, J BIOL CHEM, V259, P1706; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; SUZUKI YJ, 1992, BIOCHEM BIOPH RES CO, V189, P1709, DOI 10.1016/0006-291X(92)90275-P; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; SZAMEL M, 1995, EUR J BIOCHEM, V228, P1; SZAMEL M, 1993, EUR J IMMUNOL, V23, P3072, DOI 10.1002/eji.1830231205; TAUBER AI, 1987, BLOOD, V69, P711; TEST ST, 1984, J CLIN INVEST, V74, P1341, DOI 10.1172/JCI111544; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1983, J CLIN INVEST, V72, P441, DOI 10.1172/JCI110992; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; ZGLICZYNSKI JM, 1988, RESP BURST ITS PHYSL, P315	63	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26247	26252		10.1074/jbc.272.42.26247	http://dx.doi.org/10.1074/jbc.272.42.26247			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334193	hybrid			2022-12-27	WOS:A1997YB13900027
J	Zhang, CY; Gadue, P; Scott, E; Atchison, M; Poncz, M				Zhang, CY; Gadue, P; Scott, E; Atchison, M; Poncz, M			Activation of the megakaryocyte-specific gene platelet basic protein (PBP) by the Ets family factor PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTOR GATA-1; HUMAN BETA-THROMBOGLOBULIN; ERYTHROLEUKEMIA CELL-LINE; ALPHA-GRANULE PROTEINS; FACTOR-IV; REGULATORY ELEMENTS; GLYCOPROTEIN-IIB; FACTOR-RECEPTOR; MYELOID CELLS	Platelet basic protein (PBP) is a chemokine family member that is only found in platelets and their precursors megakaryocytes. The PBP gene is physically linked to the gene for another platelet-specific chemokine, platelet factor 4. While the. biological basis of platelet factor 4 expression has been pursued by others, the regulatory features controlling the platelet specific expression of PBP have not been investigated, In this article, we examined the molecular basis by which this megakaryocyte-specific gene is regulated, Transient expression studies of truncated reporter constructs containing from 4.5 to 0.1 kilobases of the functional PBP gene 5'-flanking region, demonstrated that the proximal 0.1 kilobases of the promoter was sufficient for high levels of expression in human erythroleukemia and CHRF-288 cells, two megakaryocytic cell lines, He-Never, none of these constructs was expressed above background levels in HeLa and 293 cells, two non-megakaryocytic cell lines, Further truncation of this promoter suggested that there was an important regulatory element(s) within a pyrimidine-rich tract. Mobility shift analysis of the pyrimidine-rich tract defined a region between -85 and -64 which bound to a nuclear factor(s), This region contains sequences matching the consensus Ets-binding site from -78 to -75 base pairs, In particular, we noted that this site matched a PU,I consensus sequence known as a PU box, Mobility shift and supershift studies with nuclear extracts as well as recombinant PU.1 protein and anti-PU.1 antibody further confirmed that PU.1 was the specific Ets family factor that bound to this site, Transient expression assays using reporter constructs which contained point mutations that abrogated PU.1 binding also significantly reduced PBP promoter activity in human erythroleukemia and CHRF cells, In addition, while all reporter gene constructs containing PBP promoters were completely inactive in HeLa cells, transactivation experiments using a PU,I expression construct demonstrated that exogenous expression of PU.1 could increase reporter gene expression up to 8-fold in these cells, Finally, the role of PU.1 in PBP gene expression was compared between wild-type and PU.1-null embryonic stem (ES) cells that were differentiated in vitro into cells that resembled megakaryocytes both morphologically and immunologically. We found that PBP gene expression in the differentiated PU.1(-/-) null ES cells (as determined by semi-quantitative reverse transcriptase-polymerase chain reaction) was more that four times lower than that in the wild-type ES cells, while other platelet-specific genes were expressed equally or similarly in the two ES cell lines. Previous reports have shown the PU.1 is expressed in several hematopoietic lineages, including megakaryocytes. However, the functional role of PU.1 has only been previously demonstrated in the myeloid and lymphoid lineages. Therefore, our studies are the first to show the biological importance of this nuclear factor in the regulated expression of a megakaryocyte-specific gene.	UNIV PENN, GRAD GRP PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, IMMUNOL GRAD GRP, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT MOL & CELLULAR ENGN, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT ANIM BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NATIONAL CANCER INSTITUTE [R01CA072769] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037419] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042415] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72769] Funding Source: Medline; NHLBI NIH HHS [HL 37419] Funding Source: Medline; NIGMS NIH HHS [GM 42415] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKRIGG A, 1985, VIRUS RES, V2, P107, DOI 10.1016/0168-1702(85)90242-4; AVRAHAM H, 1993, STEM CELLS, V11, P499, DOI 10.1002/stem.5530110619; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; BEGG GS, 1978, BIOCHEMISTRY-US, V17, P1739, DOI 10.1021/bi00602a024; BIGGS R, 1976, HUMAN BLOOD COAGULAT; BLOCK KL, 1994, BLOOD, V84, P3385; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EISMAN R, 1990, BLOOD, V76, P336; FONG AM, 1994, J BIOL CHEM, V269, P18441; FUGMAN DA, 1990, BLOOD, V75, P1252; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEWIRTZ AM, 1995, THROMB HAEMOSTASIS, V74, P204; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GRIFFIN CA, 1987, CYTOGENET CELL GENET, V45, P67, DOI 10.1159/000132431; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HOLT JC, 1985, SEMIN HEMATOL, V22, P151; HROMAS R, 1993, BLOOD, V82, P2998; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUTER DJ, 1989, BLOOD, V74, P1952; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LONG MW, 1988, EXP HEMATOL, V16, P62; Ludlow LB, 1996, J BIOL CHEM, V271, P22076, DOI 10.1074/jbc.271.36.22076; MAJERUS PW, 1978, ANNU REV MED, V29, P41, DOI 10.1146/annurev.me.29.020178.000353; MAJUMDAR S, 1991, J BIOL CHEM, V266, P5785; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATTILA P, 1991, NUCLEIC ACIDS RES, V19, P4967, DOI 10.1093/nar/19.18.4967; MAZUR EM, 1987, EXP HEMATOL, V15, P340; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PAPAYANNOPOULOU T, 1983, GLOBIN GENE EXPRESSI, P277; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; RAMACHANDRAN B, 1995, EXP HEMATOL, V23, P49; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; RAY D, 1990, ONCOGENE, V5, P663; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; STOECKLE M Y, 1990, New Biologist, V2, P313; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TJIAN R, 1995, SCI AM, V272, P54, DOI 10.1038/scientificamerican0295-54; TUNNACLIFFE A, 1992, BLOOD, V79, P2896; TWEARDY DJ, 1992, BLOOD, V79, P1148, DOI 10.1182/blood.V79.5.1148.bloodjournal7951148; UZAN G, 1991, J BIOL CHEM, V266, P8932; VISVADER J, 1993, BLOOD, V82, P1493; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WENGER RH, 1989, BLOOD, V73, P1498; WENGER RH, 1991, HUM GENET, V87, P367; WORTHINGTON RE, 1984, CYTOMETRY, V5, P501, DOI 10.1002/cyto.990050511; ZUCKER MB, 1991, P SOC EXP BIOL MED, V198, P693	69	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26236	26246		10.1074/jbc.272.42.26236	http://dx.doi.org/10.1074/jbc.272.42.26236			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334192	hybrid			2022-12-27	WOS:A1997YB13900026
J	Cherian, M; Smith, JB; Jiang, XY; Abraham, EC				Cherian, M; Smith, JB; Jiang, XY; Abraham, EC			Influence of protein-glutathione mixed disulfide on the chaperone-like function of alpha-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; B-CRYSTALLIN; HUMAN LENS; MOLECULAR CHAPERONE; A-CRYSTALLIN; POSTTRANSLATIONAL MODIFICATIONS; TISSUES; CATARACTOGENESIS; EXPRESSION; OXIDATION	In an earlier report we showed that incubation of alpha-crystallin with oxidized glutathione results in significant loss of its chaperone-like activity. In the present study, we determined the effect of protein-glutathione mixed disulfides (PSSG), formed at Cys-131 in bovine alpha A-crystallin, and Cys-131 and Cys-142 in human alpha A-crystallin, on the function of alpha-crystallin as a molecular chaperone. After incubation of calf and young human alpha(L)-crystallin fractions with oxidized glutathione, levels of PSSG were determined by performic acid oxidation of the mixed disulfides followed by reversed-phase high pressure liquid chromatography separation of phenylisothiocyanate-derivatized glutathione sulfonic acid, Levels of PSSG increased from 0.01 to 0.14 nmol/nmol (20 kDa) in bovine alpha(L)-crystallin and from 0.022 to 0.25 nmol/nmol in human alpha(L)-crystallin. The presence of glutathione adducts at Cys-131 and Cys-142 mere confirmed by mass spectral analysis. The chaperone-like activity was determined by the heat denaturation assay using beta(L)-crystallin as the target protein, To examine the reversibility of the effect of mixed disulfides on chaperone activity, studies were done before and after reduction with the glutathione reductase system. Increased levels of PSSG resulted in lower chaperone activities, Treatment with the glutathione reductase system led to 80% reduction in PSSG levels with a concomitant recovery of the chaperone activity, These results suggest that cysteine(s) in the alpha A-crystallin subunit play an important role in the function of alpha-crystallin as a molecular chaperone.	MED COLL GEORGIA,DEPT BIOCHEM & MOL BIOL,AUGUSTA,GA 30912; UNIV NEBRASKA,DEPT CHEM,LINCOLN,NE 68588	University System of Georgia; Augusta University; University of Nebraska System; University of Nebraska Lincoln					NEI NIH HHS [EY07394, EY07609, EY11352] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007394, R01EY007609, R01EY011352] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; BOYLE D, 1993, BIOCHEM BIOPH RES CO, V192, P1147, DOI 10.1006/bbrc.1993.1536; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DELCOUR J, 1974, BIOCHEM BIOPH RES CO, V57, P134, DOI 10.1016/S0006-291X(74)80367-0; DICKERSON JE, 1993, BIOCHIM BIOPHYS ACTA, V1157, P141, DOI 10.1016/0304-4165(93)90057-F; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FUJII N, 1994, BBA-PROTEIN STRUCT M, V1204, P157, DOI 10.1016/0167-4838(94)90003-5; GROENEN PJTA, 1993, FEBS LETT, V322, P69, DOI 10.1016/0014-5793(93)81113-E; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HORWITZ J, 1992, CURR EYE RES, V11, P817, DOI 10.3109/02713689209000754; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KUMARI K, 1994, ANAL BIOCHEM, V220, P374, DOI 10.1006/abio.1994.1352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOU MF, 1990, EXP EYE RES, V50, P819, DOI 10.1016/0014-4835(90)90133-F; LOU MF, 1992, EXP EYE RES, V55, P889, DOI 10.1016/0014-4835(92)90015-K; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; Lund AL, 1996, EXP EYE RES, V63, P661, DOI 10.1006/exer.1996.0160; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; ROA PV, 1995, BIOCHIM BIOPHYS ACTA, V1245, P439; SIPPEL THEODORE O., 1966, INVEST OPHTHALMOL, V5, P568; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; SWAMY MS, 1992, EXP EYE RES, V54, P337, DOI 10.1016/0014-4835(92)90046-U; TAKEMOTO L, 1992, CURR EYE RES, V11, P651, DOI 10.3109/02713689209000738; Takemoto LJ, 1996, BIOCHEM BIOPH RES CO, V223, P216, DOI 10.1006/bbrc.1996.0873; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; WANG KY, 1995, INVEST OPHTH VIS SCI, V36, P311	36	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29099	29103		10.1074/jbc.272.46.29099	http://dx.doi.org/10.1074/jbc.272.46.29099			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360985	hybrid			2022-12-27	WOS:A1997YF68400044
J	Nimchinsky, EA; Hof, PR; Janssen, WGM; Morrison, JH; Schmauss, C				Nimchinsky, EA; Hof, PR; Janssen, WGM; Morrison, JH; Schmauss, C			Expression of dopamine D-3 receptor dimers and tetramers in brain and in transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE CYTOPLASMIC DOMAIN; MONKEY PREFRONTAL CORTEX; SF9 CELLS; PRIMATE NEOCORTEX; CEREBRAL-CORTEX; MACAQUE MONKEY; IN-VIVO; PHOSPHORYLATION; PALMITOYLATION; IDENTIFICATION	The expression and characteristics of the dopamine D-3 receptor protein were studied in brain and in stably transfected GH3 cells, Monoclonal antibodies were used for immunoprecipitation and immunoblot experiments. Immunoprecipitates obtained from primate and rodent brain tissues contain a low molecular weight D-3 protein and one or two larger protein species whose molecular mass are integral multiples of the low molecular weight protein and thus appear to have resulted from dimerization and tetramerization of a D-3 monomer, Whereas D-3 receptor multimers were found to be abundantly expressed in brain, the major D-3 immunoreactivity expressed in stable D-3-expressing rat GH3 cells was found to be a monomer, However, multimeric D-3 receptor species with electrophoretic mobilities similar to those expressed in brain were also seen in D-3-expressing GH3 cells when a truncated D-3-like protein (named D-3nf) was coexpressed in these cells, Furthermore, results from immunoprecipitation experiments with D-3- and D-3nf-specific antibodies show that the higher order D-3 proteins extracted from brain and D-3/D-3nf double transfectants also contain D-3nf immunoreactivity, and immunocytochemical studies show that the expression of D-3 and D-3nf immunoreactivities overlaps substantially in monkey and rat cortical neurons. Altogether, these data show oligomeric D-3 receptor protein expression in vivo and they suggest that at least some of these oligomers are heteroligomeric protein complexes containing D-3 and the truncated D-3nf protein.	CUNY MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, FISHBERG RES CTR NEUROBIOL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, NEUROBIOL AGING LABS, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT GERIATR & ADULT DEV, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT OPHTHALMOL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, BROOKDALE CTR DEV & MOL BIOL, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Nimchinsky, Esther/GXF-5277-2022; Morrison, John/F-9229-2012		NIMH NIH HHS [MH45212, MH51623] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALI H, 1994, J BIOL CHEM, V269, P24557; ARIANO MA, 1994, BRAIN RES, V649, P95, DOI 10.1016/0006-8993(94)91052-9; BERGER B, 1991, TRENDS NEUROSCI, V14, P21, DOI 10.1016/0166-2236(91)90179-X; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; GIROS B, 1990, CR ACAD SCI III-VIE, V311, P501; GOLDMANRAKIC PS, 1992, J NEURAL TRANSM-GEN, P163; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HERROELEN L, 1994, BRAIN RES, V648, P222, DOI 10.1016/0006-8993(94)91121-5; HOF PR, 1995, J COMP NEUROL, V352, P161, DOI 10.1002/cne.903520202; HOF PR, 1992, CEREB CORTEX, V2, P456, DOI 10.1093/cercor/2.6.456; HOWE JR, 1995, J BIOL CHEM, V270, P14168, DOI 10.1074/jbc.270.23.14168; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LARSON ER, 1995, SYNAPSE, V20, P325, DOI 10.1002/syn.890200406; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; LEWIS DA, 1986, HUM NEUROBIOL, V5, P181; LEWIS DA, 1988, BRAIN RES, V449, P225, DOI 10.1016/0006-8993(88)91040-2; LEWIS DA, 1987, J NEUROSCI, V7, P279; LIU K, 1994, J BIOL CHEM, V269, P29220; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MURRAY AM, 1992, EUR J PHARM-MOLEC PH, V227, P443, DOI 10.1016/0922-4106(92)90164-Q; MURRAY AM, 1994, P NATL ACAD SCI USA, V91, P11271, DOI 10.1073/pnas.91.23.11271; NG GYK, 1994, J NEUROCHEM, V63, P1589; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; SCHMAUSS C, 1993, P NATL ACAD SCI USA, V90, P8942, DOI 10.1073/pnas.90.19.8942; SCHREURS J, 1995, J NEUROCHEM, V64, P1622; SMILEY JF, 1993, CEREB CORTEX, V3, P223, DOI 10.1093/cercor/3.3.223; SMILEY JF, 1992, J COMP NEUROL, V321, P325, DOI 10.1002/cne.903210302; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; Wang ZZ, 1996, J BIOL CHEM, V271, P27575, DOI 10.1074/jbc.271.44.27575; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488	33	144	145	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29229	29237		10.1074/jbc.272.46.29229	http://dx.doi.org/10.1074/jbc.272.46.29229			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361002	hybrid			2022-12-27	WOS:A1997YF68400061
J	Oligino, L; Lung, FDT; Sastry, L; Bigelow, J; Cao, T; Curran, M; Burke, TR; Wang, SM; Krag, D; Roller, PP; King, CR				Oligino, L; Lung, FDT; Sastry, L; Bigelow, J; Cao, T; Curran, M; Burke, TR; Wang, SM; Krag, D; Roller, PP; King, CR			Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; MITOGENIC SIGNAL-TRANSDUCTION; GUANINE-NUCLEOTIDE EXCHANGE; PHAGE DISPLAY LIBRARIES; TERMINAL SH2 DOMAIN; ADAPTER PROTEIN; EGF RECEPTOR; CRYSTAL-STRUCTURE; RAS PATHWAY; CELL-LINES	Critical intracellular signals in normal and malignant cells are transmitted by the adaptor protein Grb2 by means of its Src homology 2 (SH2) domain, which binds to phosphotyrosyl (pTyr) residues generated by the activation of tyrosine kinases, To understand this important control point and to design inhibitors, previous investigations have focused on the molecular mechanisms by which the Grb2 SH2 domain selectively binds pTyr containing peptides, In the current study, we demonstrate that the Grb2 SH2 domain can also bind in a pTyr independent manner, Using phage display, an 11-amino acid cyclic peptide, G1, has been identified that binds to the Grb2 SH2 domain but not the src SH2 domain, Synthetic G1 peptide blocks GrbP SH2 domain association (IC50 10-25 mu M) with a g-amino acid pTyr-containing peptide derived from the SHC protein (pTyr317), These data and amino acid substitution analysis indicate that G1 interacts in the phosphopeptide binding site, G1 peptide requires a YXN sequence similar to that found in natural pTyr-containing ligands, and phosphorylation of the tyrosine increases G1 inhibitory activity. G1 also requires an internal disulfide bond to maintain the active binding conformation, Since the G1 peptide does not contain pTyr, it defines a new type of SH2 domain binding motif that may advance the design of Grb2 antagonists.	GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA; UNIV VERMONT, VERMONT CANC CTR, BURLINGTON, VT 05405 USA; NCI, MED CHEM LAB, DIV BASIC SCI, NIH, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, MED CTR, DEPT NEUROL, WASHINGTON, DC 20007 USA	Georgetown University; University of Vermont; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University			Burke, Terrence R/N-2601-2014	Wang, Shaomeng/0000-0002-8782-6950; Burke, Terrence/0000-0001-9925-8586				Borg JP, 1996, MOL CELL BIOL, V16, P6229; BRUGGE JS, 1993, SCIENCE, V260, P918, DOI 10.1126/science.8388123; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURKE TR, 1994, BIOCHEMISTRY-US, V33, P6490, DOI 10.1021/bi00187a015; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DALY RJ, 1994, ONCOGENE, V9, P2723; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILMER T, 1994, J BIOL CHEM, V269, P31711; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; HANAZONO Y, 1995, JPN J CANCER RES, V86, P336, DOI 10.1111/j.1349-7006.1995.tb03061.x; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; HENSMANN M, 1994, PROTEIN SCI, V3, P1020, DOI 10.1002/pro.5560030704; JANES PW, 1994, ONCOGENE, V9, P3601; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Li M, 1996, NAT BIOTECHNOL, V14, P986, DOI 10.1038/nbt0896-986; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MALEK SN, 1994, J BIOL CHEM, V269, P33009; MARENGERE LEM, 1994, J CELL SCI, P97; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Metzler WJ, 1996, BIOCHEMISTRY-US, V35, P6201, DOI 10.1021/bi960157x; MIKI H, 1994, J BIOL CHEM, V269, P5489; MIKOL V, 1995, J MOL BIOL, V254, P86, DOI 10.1006/jmbi.1995.0601; MORELOCK MM, 1995, J MED CHEM, V38, P1309, DOI 10.1021/jm00008a009; Nolte RT, 1996, NAT STRUCT BIOL, V3, P364, DOI 10.1038/nsb0496-364; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Raffel GD, 1996, J BIOL CHEM, V271, P4640; Rahuel J, 1996, NAT STRUCT BIOL, V3, P586, DOI 10.1038/nsb0796-586; ROBEY F, 1994, BROMOACETYLATED SYNT; Rojas M, 1997, BIOCHEM BIOPH RES CO, V234, P675, DOI 10.1006/bbrc.1997.6694; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASTRY L, 1995, ONCOGENE, V11, P1107; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Thornton KH, 1996, BIOCHEMISTRY-US, V35, P11852, DOI 10.1021/bi952615s; WAKSMAN G, 1994, CELL MOL BIOL, V40, P611; Wang YS, 1996, J BIOMOL NMR, V7, P89; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; XIAO S, 1994, J BIOL CHEM, V269, P21244; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; XU RX, 1995, BIOCHEMISTRY-US, V34, P2107, DOI 10.1021/bi00007a003; YE B, 1995, J MED CHEM, V38, P4270, DOI 10.1021/jm00021a016; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784	62	99	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29046	29052		10.1074/jbc.272.46.29046	http://dx.doi.org/10.1074/jbc.272.46.29046			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360978	hybrid			2022-12-27	WOS:A1997YF68400037
J	Yang, W; Chan, VC; Kirkpatrick, A; Ramshaw, JAM; Brodsky, B				Yang, W; Chan, VC; Kirkpatrick, A; Ramshaw, JAM; Brodsky, B			Gly-Pro-Arg confers stability similar to Gly-Pro-Hyp in the collagen triple-helix of host-guest peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCCURRING AMINO-ACIDS; THERMODYNAMIC SCALE; FORMING TENDENCIES; HYDROXYPROLINE; STABILIZATION; PARAMETERS; WATER	A set of host-guest peptides of the form Ac(Gly-Pro-Hyp)(3)-Gly-X-Y-(Gly-Pro-Hyp)(4)-Gly-Gly-NH2 has been designed to evaluate the propensity of different Gly-X-Y triplets for the triple-helix conformation (Shah, N, K,, Ramshaw, J. A. M., Kirkpatrick, A., Shah, C., and Brodsky, B, (1996) Biochemistry 35, 10262-10268), All Gly-X-Y guest triplets led to a decrease in melting temperature from the host (Gly-Pro-Hyp), peptide except for Gly-Pro-Arg, In this Gly-Pro-Hyp-rich environment, Gly-Pro-Arg was found to be as stabilizing as Gly-Pro-Hyp. Decreased stability of host-guest peptides containing Gly-Pro-Lys, Gly-Pro-homo-Arg, and Gly Arg-Hyp compared with Gly-Pro-Arg indicated a stabilization that is optimal for Arg and specific to the Y-position, Arg was found to have a similar stabilizing effect when residues other than Pro are in the X-position, Both Arg and Hyp stabilize the triple-helix preferentially in the Y-position in a stereospecific manner and occupy largely Y-positions in collagen, However, contiguous Gly-Pro-Hyp units are highly stable and promote triple helix folding, whereas incorporation of multiple Gly-Pro-Arg triplets was destabilizing and folded slowly due to charge repulsion, In collagen, Gly-Pro-Arg may contribute maximally to local triple-helix stability while also having the potential for electrostatic interactions in fibril formation and binding.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; CSIRO,DIV MOL SCI,PARKVILLE,VIC 3052,AUSTRALIA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			Ramshaw, John AM/A-9411-2011	Ramshaw, John A.M./0000-0002-2131-3685	NIAMS NIH HHS [AR 19626] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019626] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BANSAL M, 1978, INT J PEPT PROT RES, V11, P73; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BELLA J, 1995, STRUCTURE, V3, P393; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5; BURJANADZE TV, 1979, BIOPOLYMERS, V18, P931, DOI 10.1002/bip.1979.360180413; Cappello J., 1994, PLASTICS MICROBES, P35; CHAN VC, 1997, IN PRESS J BIOL CHEM, V272; CHOPRA RK, 1982, P NATL ACAD SCI-BIOL, V79, P7180, DOI 10.1073/pnas.79.23.7180; DOLZ R, 1986, BIOPOLYMERS, V25, P1069, DOI 10.1002/bip.360250607; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; GERMANN HP, 1988, BIOPOLYMERS, V27, P157, DOI 10.1002/bip.360270112; INOUYE K, 1982, ARCH BIOCHEM BIOPHYS, V219, P198, DOI 10.1016/0003-9861(82)90149-7; LINDEBERG EGG, 1976, INT J PEPT PROT RES, V8, P193; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; Ramachandran G.N., 1967, TREATISE COLLAGEN, P103; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; Shah NK, 1997, BIOCHEMISTRY-US, V36, P5878, DOI 10.1021/bi963146c; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023; VITAGLIANO L, 1993, BIOCHEMISTRY-US, V32, P7354, DOI 10.1021/bi00080a004; WOJCIK J, 1990, BIOPOLYMERS, V30, P121, DOI 10.1002/bip.360300113; Yang W, 1997, BIOCHEMISTRY-US, V36, P6930, DOI 10.1021/bi970051h	27	93	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28837	28840		10.1074/jbc.272.46.28837	http://dx.doi.org/10.1074/jbc.272.46.28837			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360948	hybrid			2022-12-27	WOS:A1997YF68400007
J	Chandra, S; Low, PS				Chandra, S; Low, PS			Measurement of Ca2+ fluxes during elicitation of the oxidative burst in aequorin-transformed tobacco cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERSENSITIVE DISEASE RESISTANCE; DEPENDENT PROTEIN-KINASE; HYPHAL WALL COMPONENTS; CYTOSOLIC FREE CALCIUM; CULTURED PLANT-CELLS; ACTIVE OXYGEN; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; PHYTOPHTHORA-INFESTANS; ERWINIA-AMYLOVORA	We have employed suspension cultured aequorin-transformed tobacco cells to examine the involvement of Ca2+ in signal transduction of the oxidative burst. Use of cultured cells for this purpose was validated by demonstrating that the cells responded to cold shock quantitatively and qualitatively similarly to the intact transgenic plants from which they were derived. Stimulation of the oxidative burst in the cell suspension was achieved by administration of oligogalacturonic acid, Mas-7 (a peptide known to activate G proteins and Ca2+ fluxes), hypo-osmotic stress, or harpin (a protein from the pathogenic bacterium Erwinia amylovora). The latter failed to promote any detectable increase ia cytoplasmic Ca2+ concentration, whereas each of the former three triggered a rapid rise in cytosolic Ca2+ followed by a return within seconds to basal Ca2+ levels. Peak Ca2+ concentrations induced by the former three elicitors were similar to 0.7, 1.4, and 1.3 mu M, respectively. Three lines of evidence suggest that the observed Ca2+ pulses are essential to transduction of the oxidative burst signals by their respective elicitors: (i) inhibition of the Ca2+ transients with Ca2+ chelators or Ca2+ channel blockers prevented expression of the oxidative burst, (ii) introduction of exogenous Ca2+ into the same cells initiated the burst even in the absence of other inducers of the response, and (iii) the observed Ca2+ transients often returned to near basal levels well before any H2O2 synthesis could be detected; suggesting that the Ca2+ influx is required to communicate the burst signal but not maintain the defense response. These data suggest that Ca2+ pulses serve frequently, but not invariably, to transduce an oxidative burst signal.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528				ALLEN DG, 1976, SCIENCE, V195, P996; ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; APOSTOL I, 1987, PLANT PHYSIOL, V84, P1276, DOI 10.1104/pp.84.4.1276; ATKINSON MM, 1990, PLANT PHYSIOL, V92, P215, DOI 10.1104/pp.92.1.215; BAKER CJ, 1993, PLANT PHYSIOL, V102, P1341, DOI 10.1104/pp.102.4.1341; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; BUSH DS, 1990, PLANT PHYSIOL, V93, P841, DOI 10.1104/pp.93.3.841; Campbell AK, 1996, CELL CALCIUM, V19, P211, DOI 10.1016/S0143-4160(96)90022-6; Chandra S, 1996, P NATL ACAD SCI USA, V93, P13393, DOI 10.1073/pnas.93.23.13393; Chandra S, 1996, PLANT PHYSIOL, V110, P979, DOI 10.1104/pp.110.3.979; CHANDRA S, 1995, P NATL ACAD SCI USA, V92, P4120, DOI 10.1073/pnas.92.10.4120; DEMARTY M, 1984, PLANT CELL ENVIRON, V7, P441, DOI 10.1111/j.1365-3040.1984.tb01434.x; Desikan R, 1996, FEBS LETT, V382, P213, DOI 10.1016/0014-5793(96)00177-9; DING JP, 1993, PLANT J, V3, P83, DOI 10.1111/j.1365-313X.1993.tb00013.x; DOKE N, 1983, PHYSIOL PLANT PATHOL, V23, P345, DOI 10.1016/0048-4059(83)90019-X; DOKE N, 1983, PHYSIOL PLANT PATHOL, V23, P359, DOI 10.1016/0048-4059(83)90020-6; Dwyer SC, 1996, BBA-GEN SUBJECTS, V1289, P231, DOI 10.1016/0304-4165(95)00156-5; FranklinTong VE, 1996, PLANT CELL, V8, P1305, DOI 10.1105/tpc.8.8.1305; GEHRING CA, 1990, NATURE, V345, P528, DOI 10.1038/345528a0; GILROY S, 1991, PLANT CELL, V3, P333, DOI 10.1105/tpc.3.4.333; Glazener JA, 1996, PLANT PHYSIOL, V110, P759, DOI 10.1104/pp.110.3.759; HALEY A, 1995, P NATL ACAD SCI USA, V92, P4124, DOI 10.1073/pnas.92.10.4124; HARMON AC, 1987, PLANT PHYSIOL, V83, P830, DOI 10.1104/pp.83.4.830; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; JOHNSON CH, 1995, SCIENCE, V269, P1863, DOI 10.1126/science.7569925; Knight H, 1995, METHOD CELL BIOL, V49, P201, DOI 10.1016/S0091-679X(08)61455-7; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; KNIGHT MR, 1992, P NATL ACAD SCI USA, V89, P4967, DOI 10.1073/pnas.89.11.4967; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; LEGENDRE L, 1993, J BIOL CHEM, V268, P24559; LEGENDRE L, 1993, PLANT PHYSIOL, V102, P233, DOI 10.1104/pp.102.1.233; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LEVINE A, 1996, CURR BIOL, V6, P4237; Low PS, 1996, PHYSIOL PLANTARUM, V96, P533, DOI 10.1111/j.1399-3054.1996.tb00469.x; LOW PS, 1997, PLANT MICROBE INTERA; LOW PS, 1994, P 1994 KOR BOT SOC S, P75; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MESSIAEN J, 1993, J CELL SCI, V104, P365; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; OKUDA T, 1991, PLANT PHYSIOL, V97, P1265, DOI 10.1104/pp.97.3.1265; OLSON PD, 1993, PLANT J, V4, P887, DOI 10.1046/j.1365-313X.1993.04050887.x; PENG M, 1992, PHYTOPATHOLOGY, V82, P696, DOI 10.1094/Phyto-82-696; PICAL C, 1992, PLANT PHYSIOL, V100, P1296, DOI 10.1104/pp.100.3.1296; Pierson ES, 1996, DEV BIOL, V174, P160, DOI 10.1006/dbio.1996.0060; PREISIG CL, 1994, PHYTOCHEMISTRY, V36, P857, DOI 10.1016/S0031-9422(00)90451-5; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; SCHROEDER JI, 1991, PLANT CELL, V3, P555, DOI 10.2307/3869184; SCHWACKE R, 1992, PLANTA, V187, P136, DOI 10.1007/BF00201635; Takahashi K, 1997, PLANT PHYSIOL, V113, P587, DOI 10.1104/pp.113.2.587; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; TENHAKEN R, 1995, P NATL ACAD SCI USA, V92, P4158, DOI 10.1073/pnas.92.10.4158; Tucker EB, 1996, PLANT PHYSIOL, V111, P459, DOI 10.1104/pp.111.2.459; VERAESTRELLA R, 1992, PLANT PHYSIOL, V99, P1208, DOI 10.1104/pp.99.3.1208; VIARD MP, 1994, PLANT PHYSIOL, V104, P1245, DOI 10.1104/pp.104.4.1245; WATILLON B, 1993, PLANT PHYSIOL, V101, P1381, DOI 10.1104/pp.101.4.1381; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; WU GS, 1995, PLANT CELL, V7, P1357, DOI 10.1105/tpc.7.9.1357; YAHRAUS T, 1995, PLANT PHYSIOL, V109, P1259, DOI 10.1104/pp.109.4.1259	63	119	133	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28274	28280		10.1074/jbc.272.45.28274	http://dx.doi.org/10.1074/jbc.272.45.28274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353281	hybrid			2022-12-27	WOS:A1997YF21900021
J	Gong, LM; Kamitani, T; Fujise, K; Caskey, LS; Yeh, ETH				Gong, LM; Kamitani, T; Fujise, K; Caskey, LS; Yeh, ETH			Communication - Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEGRADATION; PROTEASOME PATHWAY; HUMAN HOMOLOG; CLONING; IDENTIFICATION; GENE; CDNA	Sentrin is a ubiquitin-like molecule that has been shown to interact with the death domains of Fas and tumor necrosis factor receptor 1 (TNFR1), PML, Rad51, Rad52, and RanGAP1. We have reported previously that sentrin can be conjugated to other proteins in a manner analogous to protein ubiquitination (Kamitani, T., Nguyen, H. P., and Yeh, E. T. H. (1997) J. Biol. Chem. 272, 14001-14004). Furthermore, the conserved C-terminal Gly-Gly residues are required for sentrinization to occur. To identify enzymes which play a role in sentrinization, the yeast two-hybrid system was used to screen a human placenta cDNA library using sentrin as bait. A strong positive interacting clone was found to contain a cDNA insert encoding the ubiquitin-conjugating enzyme, Ubc9. The interaction between sentrin and Ubc9 required the ubiquitin domain and the C-terminal Gly-Gly residues of sentrin. This interaction appears to be specific because sentrin could only interact weakly with UbcH5B, but could not interact with HHR6B, UbcH6 nor E2-EPF. In vitro translated sentrin could be precipitated by a GST-Ubc9 fusion protein, but not by glutathione S-transferase. A beta-mercaptoethanol-sensitive Ubc9-sentrin conjugate could also be identified in the in vitro binding assay. Substitution of the conserved cysteine residue of Ubc9 by serine abolished the formation of the Ubc9-sentrin conjugate. Taken together, Ubc9 is a strong candidate to be the key conjugating enzyme in the sentrinization pathway.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV MOL MED,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,INST MOL MED PREVENT HUMAN DIS,RES CTR CARDIOVASC DIS,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston			Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boddy MN, 1996, ONCOGENE, V13, P971; CENCIARELLI C, 1995, J BIOL CHEM, V271, P8709; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOPKIN K, 1997, J NIH RES, V9, P36; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Jiang WD, 1996, MOL GEN GENET, V251, P153; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; LIU Z, 1992, J BIOL CHEM, V267, P15829; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Okura T, 1996, J IMMUNOL, V157, P4277; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; Wright DA, 1996, J BIOL CHEM, V271, P31037, DOI 10.1074/jbc.271.49.31037; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005	32	164	168	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28198	28201		10.1074/jbc.272.45.28198	http://dx.doi.org/10.1074/jbc.272.45.28198			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353268	hybrid			2022-12-27	WOS:A1997YF21900008
J	Hidari, KIPJ; Weyrich, AS; Zimmerman, GA; McEver, RP				Hidari, KIPJ; Weyrich, AS; Zimmerman, GA; McEver, RP			Engagement of P-selectin glycoprotein ligand-1 enhances tyrosine phosphorylation and activates mitogen-activated protein kinases in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CELL-ADHESION; TUMOR-NECROSIS-FACTOR; MAP KINASE; CYTOPLASMIC DOMAIN; AMINO-TERMINUS; MYELOID CELLS; MONOCYTES; PLATELETS; PSGL-1; BINDING	During inflammation, P-selectin on activated platelets and endothelial cells initiates adhesion of leukocytes through interactions with P-selectin glycoprotein ligand-1 (PSGL-1). We investigated whether ligation of PSGL-1 also transmits signals into leukocytes, Neutrophils incubated with anti-PSGL-1 monoclonal antibodies, but not with Fab fragments of these antibodies, rapidly increased tyrosine phosphorylation of proteins with relative molecular masses of 105-120, 70-84, and 42-44 kDa. PSGL-1-dependent adhesion of neutrophils to P-selectin increased tyrosine phosphorylation of similarly sized proteins, Cytochalasin B did not prevent the tyrosine phosphorylation induced by ligation of PSGL-1, suggesting that an intact cytoskeleton is not required fdr signaling, Engagement of PSGL-1 activated the GTPase Pas through a mechanism that did not require tyrosine phosphorylation of PSGL-1 or association of the Shc-Grbs-Sos1 complex with PSGL-1. Engagement of PSGL-1 activated the 42-44-kDa extracellular signal-regulated kinase family of mitogen-activated protein (MAP) kinases through a pathway that required activation of the MAP kinase kinase, Ligation of PSGL-1 also stimulated secretion of interleukin-8. The tyrosine kinase inhibitor, genistein, blocked tyrosine phosphorylation and secretion of interleukin-8, whereas the MAP kinase kinase inhibitor PD98059 partially inhibited secretion of interleukin-8. Tyrosine phosphorylation stimulated through PSGL-1 on selectin-tethered leukocytes may propagate a signaling cascade that is integrated with signals generated by other mediators.	UNIV OKLAHOMA, HLTH SCI CTR, WK WARREN MED RES INST, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, OKLAHOMA CITY, OK 73104 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV UTAH, HLTH SCI CTR, NORA ECCLES HARRISON CARDIOVASC RES & TRAINING IN, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, DEPT INTERNAL MED, SALT LAKE CITY, UT 84112 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NHLBI NIH HHS [HL 54804, HL 44525, HL 34363] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL044525, P01HL054804, R01HL044525, R01HL034363, R37HL034363] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Brenner B, 1997, BIOCHEM BIOPH RES CO, V231, P802, DOI 10.1006/bbrc.1997.6191; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; CELI A, 1994, P NATL ACAD SCI USA, V91, P8767, DOI 10.1073/pnas.91.19.8767; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; COOPER D, 1994, J IMMUNOL, V153, P3199; DELUCA M, 1995, J BIOL CHEM, V270, P26734, DOI 10.1074/jbc.270.45.26734; ELSTAD MR, 1995, J IMMUNOL, V155, P2109; Evangelista V, 1996, BLOOD, V88, P4183, DOI 10.1182/blood.V88.11.4183.bloodjournal88114183; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Haller H, 1997, J IMMUNOL, V158, P1061; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laszik Z, 1996, BLOOD, V88, P3010, DOI 10.1182/blood.V88.8.3010.bloodjournal8883010; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LORANT DE, 1995, J CLIN INVEST, V96, P171, DOI 10.1172/JCI118018; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Moore Kevin L., 1994, Journal of Tissue Culture Methods, V16, P255, DOI 10.1007/BF01540662; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NAGATA K, 1993, J IMMUNOL, V151, P3267; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; PATEL KD, 1995, J CLIN INVEST, V96, P1887, DOI 10.1172/JCI118234; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Rainger GE, 1997, CURR BIOL, V7, P316, DOI 10.1016/S0960-9822(06)00155-2; Reszka AA, 1997, MOL BIOL CELL, V8, P1219, DOI 10.1091/mbc.8.7.1219; RUF A, 1995, BRIT J HAEMATOL, V90, P791, DOI 10.1111/j.1365-2141.1995.tb05197.x; RUF A, 1992, BLOOD, V80, P1238; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tu LL, 1996, J IMMUNOL, V157, P3995; VAILLANCOURT RR, 1994, METHOD ENZYMOL, V238, P255; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; YEO EL, 1994, BLOOD, V83, P2498; Zimmerman GA, 1996, J CLIN INVEST, V98, P1699, DOI 10.1172/JCI118967; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	71	193	200	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28750	28756		10.1074/jbc.272.45.28750	http://dx.doi.org/10.1074/jbc.272.45.28750			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353345	hybrid			2022-12-27	WOS:A1997YF21900085
J	Lam, YA; DeMartino, GN; Pickart, CM; Cohen, RE				Lam, YA; DeMartino, GN; Pickart, CM; Cohen, RE			Specificity of the ubiquitin isopeptidase in the PA700 regulatory complex of 26 S proteasomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEUBIQUITINATING ENZYME; MULTIUBIQUITIN CHAIN; DEPENDENT PROTEOLYSIS; POLYUBIQUITIN CHAINS; PROTEIN-DEGRADATION; IDENTIFICATION; DIUBIQUITIN; GENE; INHIBITION; RESOLUTION	The specificity of the ubiquitin (Ub) isopeptidase in the PA700 regulatory complex of the bovine 26 S proteasome was investigated. Disassembly of poly-Ub by this enzyme is restricted to the distal-end Ub of the substrate, i.e. the Ub farthest from the site of protein attachment in poly-Ub-protein conjugates. The determinants recognized by the isopeptidase were probed by the use of mutant ubiquitins incorporated into Lys(48)-linked poly-Ub substrates. PA700 could not disassemble poly-Ub chains that contained a distal Ub(L8A,I44A). This suggested either that the enzyme interacts directly with Leu(8) or Ile(44) or that it recognizes a higher order structure that caps the distal end of a poly-Ub substrate and is destabilized by Ub(L8A,I44A). The previously determined di-Ub crystal structure (Cook, W. J., Jeffrey, L. C., Carson, M., Chen, Z., and Pickart, C. M. (1992) J. Biol. Chem. 267, 16467-16471) offered a candidate for such a ''cap.'' In solution, however, this structure was not observed by H-1 NMR spectroscopy. This and the finding that di-Ub with a single proximal Ub(L8A,I44A) is cleaved efficiently suggest that Leu(8) and Ile(44) in the distal-end Ub contact the isopeptidase directly. In addition to Lys(48)-linked chains, PA700 also could disassemble Lys(6)- and Lys-(11)-linked poly-Ub, but, surprisingly, not alpha-linked di-Ub. Results with these and other substrates suggest that specificity determinants for the PA700 isopeptidase include Leu(8), Ile(44), and Lys(48) on the distal Ub and, for poly-Ub, some features of the Ub-Ub linkage itself.	UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA; UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA; JOHNS HOPKINS UNIV, DEPT BIOCHEM, BALTIMORE, MD 21205 USA	University of Iowa; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046984, R56DK046181, R01DK046181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037666] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46181, DK46984] Funding Source: Medline; NIGMS NIH HHS [GM37666] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGELL N, 1988, P NATL ACAD SCI USA, V85, P3693, DOI 10.1073/pnas.85.11.3693; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; COOK WJ, 1992, J BIOL CHEM, V267, P16467; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DISTEFANO DL, 1987, BIOCHEMISTRY-US, V26, P7272, DOI 10.1021/bi00397a012; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; ESPOSITO G, 1992, J MOL BIOL, V224, P659, DOI 10.1016/0022-2836(92)90551-T; FALQUET L, 1995, FEBS LETT, V359, P73, DOI 10.1016/0014-5793(94)01451-6; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1985, PREP BIOCHEM, V15, P49; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HADARI T, 1992, J BIOL CHEM, V267, P719; HAUGLAND RP, 1992, HDB FLUORESCENT PROB, P11; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; MA CP, 1994, J BIOL CHEM, V269, P3539; Melandri F, 1996, BIOCHEMISTRY-US, V35, P12893, DOI 10.1021/bi9612935; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PETROS AM, 1990, BIOCHEMISTRY-US, V29, P10041, DOI 10.1021/bi00495a005; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PICKART CM, 1992, J BIOL CHEM, V267, P14418; PICKART CM, 1988, J BIOL CHEM, V263, P15076; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0; Shaeffer JR, 1997, BLOOD, V90, P1300, DOI 10.1182/blood.V90.3.1300.1300_1300_1308; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; Shaeffer JR, 1996, BIOCHEMISTRY-US, V35, P10886, DOI 10.1021/bi9530705; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WEBER PL, 1987, BIOCHEMISTRY-US, V26, P7282, DOI 10.1021/bi00397a013; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; WOO SK, 1995, J BIOL CHEM, V270, P18766, DOI 10.1074/jbc.270.32.18766; XU W, 1997, THESIS U IOWA; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275	60	89	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28438	28446		10.1074/jbc.272.45.28438	http://dx.doi.org/10.1074/jbc.272.45.28438			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353303	hybrid			2022-12-27	WOS:A1997YF21900043
J	Walter, MJ; Look, DC; Tidwell, RM; Roswit, WT; Holtzman, MJ				Walter, MJ; Look, DC; Tidwell, RM; Roswit, WT; Holtzman, MJ			Targeted inhibition of interferon-gamma-dependent intercellular adhesion molecule-1 (ICAM-1) expression using dominant-negative Stat1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTORS; EPITHELIAL-CELLS; IFN-GAMMA; GENE; ACTIVATION; PROTEIN; ALPHA	A subset of epithelial immune-response genes (including intercellular adhesion molecule-1 (ICAM-1)) depends on an IFN-gamma signal transduction pathway with the Stat1 transcription factor as a critical intermediate, Excessive local activation of this pathway may lead to airway inflammation, so we sought to selectively downregulate the pathway using a dominant-negative strategy for inhibition of epithelial Stat1 in a primary culture airway epithelial cell model. Using a Stat1-deficient cell line, we demonstrated that transfection of wild-type Stat1 expression plasmid restored appropriate Stat1 expression and IFN-gamma-dependent phosphorylation as well as consequent lFN-gamma activation of cotransfected ICAM-1 promoter constructs and endogenous ICAM-1 gene expression. However, mutations of Stat1 at Tyr-701 (JAR kinase phosphorylation site), Glu-428/429 (putative DNA-binding site), His-713 (splice site resulting in Stat1 beta formation), or Ser-727 (MAP kinase phosphorylation site) all decreased Stat1 capacity to activate the ICAM-1 promoter, The Tyr-701 mutant (followed by the His-713 mutant) were most effective in disabling Stat1 function and in overcoming the activating effect of cotransfected wild-type Stat1 in this cell system thereby highlighting the effectiveness of blocking Stat1 homo-and hetero-dimerization. In experiments using primary culture human tracheobronchial epithelial cells (hTBECs) and each of the four Stat1 mutant plasmids, transfection with the Tyr-701 and His-713 mutants again most effectively inhibited IFN-gamma activation of an ICAM-1 gene promoter construct, Then by transfecting hTBECs with wild-type or mutant Stat1 tagged with a Flag reporter sequence, we used dual immunofluorescence to show that hTBECs expressing the Tyr-701 or His-713 mutants were prevented from expressing endogenous ICAM-1 in response to IFN-gamma treatment. The capacity of a specific Stat1 mutations to exert a potent dominant-negative effect on IFN-gamma signal transduction provides for further definition of Statl structure function and a means for natural or engineered expression of mutant Stat1 to selectively down-regulate activity of this pathway in a cell type-or tissue-specific manner during immune and/or inflammatory responses.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CHIANG CM, 1993, PEPTIDE RES, V6, P62; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Holtzman MJ, 1996, AM J RESP CELL MOL, V14, P316, DOI 10.1165/ajrcmb.14.4.8600934; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KOGA T, 1997, AM J RESP CRIT CARE, V155, pA751; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LOOK DC, 1992, AM J PHYSIOL, V263, pL79, DOI 10.1152/ajplung.1992.263.1.L79; LOOK DC, 1994, J BIOL CHEM, V269, P8952; McWilliam AS, 1997, J VIROL, V71, P226, DOI 10.1128/JVI.71.1.226-236.1997; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NAKAJIMA S, 1994, AM J PHYSIOL-LUNG C, V267, pL422, DOI 10.1152/ajplung.1994.267.4.L422; NAKAJIMA S, 1995, J IMMUNOL, V155, P1117; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; SAMPATH D, 1997, J ALLERGY CLIN IMMUN, V99, P475; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHANNON VR, 1993, AM REV RESPIR DIS, V147, P1024, DOI 10.1164/ajrccm/147.4.1024; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TAGUCHI M, 1997, AM J RESP CRIT CARE, V155, pA360; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	41	72	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28582	28589		10.1074/jbc.272.45.28582	http://dx.doi.org/10.1074/jbc.272.45.28582			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353323	hybrid			2022-12-27	WOS:A1997YF21900063
J	Yasui, H; Butscher, W; Cohen, M; Spriggs, N; Wersto, R; Kohn, EC; Liotta, L; Gardner, K				Yasui, H; Butscher, W; Cohen, M; Spriggs, N; Wersto, R; Kohn, EC; Liotta, L; Gardner, K			Selective inhibition of mitogen-induced transactivation of the HIV long terminal repeat by carboxyamidotriazole - Calcium influx blockade represses HIV-1 transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; CELL ANTIGEN RECEPTOR; LYMPHOCYTE-T ACTIVATION; DNA-BINDING ACTIVITY; SIGNAL-TRANSDUCTION; CYCLOSPORINE-A; C-REL; MOLECULAR-BIOLOGY; GENE-EXPRESSION	Carboxyamidotriazole (CAI) is a calcium influx inhibitor that has both antiproliferative and antimetastatic activities, Pretreatment of human T-cells with micromolar concentrations of CAI causes a near complete inhibition of calcium-regulated mitogen-induced transcription from the human immunodeficiency virus (HIV) long terminal repeat (LTR). This inhibition is selective since other mitogen-activated gene regulatory elements, such as the 12-O-tetradecanoylphorbol-13-acetate response element, are not influenced by the drug, HIV LTR transcription inhibition is maximal at 1.0 mu M CAI, requires a pretreatment interval of at least 8 h for optimum inhibition, and shows no acute interference with the growth properties of the cells, Moreover, the inhibition is rapidly reversible upon removal of the drug from the medium, Studies to identify enhancer elements within the HIV LTR that are functionally sensitive to low-dose long-term pretreatment with CAI, indicate that the NF-kappa B-binding sites are among the major targets of drug action, In vitro DNA binding studies with nuclear extracts prepared from mitogen-induced T-cells stimulated in the presence of CAI indicate that the drug differentially influences the calcium-regulated downstream signal transduction pathways necessary for specific NF-KB DNA binding activity at the two KB sites within the HIV LTR, Studies with ionomycin and thapsigargin show that repression is specific for selected modes of inducible calcium entry and indicate that, in T-cells, a major mechanism of CAI action is to modulate calcium influx at a level that is proximal to the regulated release of calcium from intracellular stores, Measurement of calcium influx in CAI-treated cells reveals a dramatic and reversible inhibition of mitogen-induced calcium influx. These results indicate that CAI can be an important and effective pharmacological tool for analysis of the calcium-dependent modulation of HIV LTR transcription.	NCI,DEPT PATHOL,PATHOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANTONI BA, 1994, ADV VIRUS RES, V43, P53, DOI 10.1016/S0065-3527(08)60047-0; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BELL KD, 1993, P NATL ACAD SCI USA, V90, P1411, DOI 10.1073/pnas.90.4.1411; BENNETT V, 1981, P NATL ACAD SCI-BIOL, V78, P7550, DOI 10.1073/pnas.78.12.7550; BIELINSKA A, 1989, J VIROL, V63, P4097, DOI 10.1128/JVI.63.9.4097-4100.1989; BISWAS DK, 1993, P NATL ACAD SCI USA, V90, P11044, DOI 10.1073/pnas.90.23.11044; BISWAS DK, 1994, MOL MED, V1, P31; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; FARINA AR, 1993, J BIOL CHEM, V268, P26466; FELDER CC, 1991, J PHARMACOL EXP THER, V257, P967; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; GARCIA JA, 1994, PROG NUCLEIC ACID RE, V49, P157; GARDNER K, 1994, J BIOL CHEM, V269, P32963; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1985, DNA CLONING PRACTICA, P143; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; GRUMONT RJ, 1993, CELL GROWTH DIFFER, V4, P731; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HASELTINE WA, 1988, SCI AM, V259, P52, DOI 10.1038/scientificamerican1088-52; HOLMES KA, 1993, J CHROMATOGR-BIOMED, V613, P317, DOI 10.1016/0378-4347(93)80148-W; HUSS R, 1995, RES IMMUNOL, V146, P101, DOI 10.1016/0923-2494(96)80243-4; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; KARPAS A, 1992, P NATL ACAD SCI USA, V89, P8351, DOI 10.1073/pnas.89.17.8351; KOHN EC, 1992, CANCER RES, V52, P3208; KOHN EC, 1994, CANCER RES, V54, P935; KOHN EC, 1995, P NATL ACAD SCI USA, V92, P1307, DOI 10.1073/pnas.92.5.1307; KOHN EC, 1990, J NATL CANCER I, V82, P54, DOI 10.1093/jnci/82.1.54; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MODIANO JF, 1988, J CELL PHYSIOL, V135, P451, DOI 10.1002/jcp.1041350312; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; SEI Y, 1995, EXP CELL RES, V216, P222, DOI 10.1006/excr.1995.1028; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; van Oers N S, 1995, Semin Immunol, V7, P227, DOI 10.1006/smim.1995.0027; Venkataraman L, 1996, J IMMUNOL, V157, P1149; VENKATARAMAN L, 1995, J EXP MED, V181, P1091, DOI 10.1084/jem.181.3.1091; Wang WH, 1997, IMMUNITY, V6, P165, DOI 10.1016/S1074-7613(00)80423-9; Weiss A, 1995, ANN NY ACAD SCI, V766, P149, DOI 10.1111/j.1749-6632.1995.tb26658.x; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; ZEICHNER SL, 1994, CLIN PERINATOL, V21, P39, DOI 10.1016/S0095-5108(18)30361-0	57	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28762	28770		10.1074/jbc.272.45.28762	http://dx.doi.org/10.1074/jbc.272.45.28762			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353347	hybrid			2022-12-27	WOS:A1997YF21900087
J	Kuntz, MA; Shapiro, DJ				Kuntz, MA; Shapiro, DJ			Dimerizing the estrogen receptor DNA binding domain enhances binding to estrogen response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTORS; NUCLEAR RECEPTORS; PROTEINS; AFFINITY; GENE; SUBUNITS	In this work, we provide a rationale for the finding that the estrogen receptor (ER) binds to its DNA response element as a homodimer in vivo. Binding of the monomer estrogen receptor DNA binding domain (ER DBD) to a palindromic, consensus estrogen response element (ERE) is increased 5-6-fold when the ER DBD is dimerized either by a monoclonal antibody that recognizes an attached epitope tag or by expressing the ER DBD as a single molecule in which the two monomers are joined by a peptide linker, Most of the increase in binding is due to stabilization of the ER DBD ERE complex. We observed only an approximately 2.5-fold reduction in binding when a consensus ERE was replaced with widely spaced ERE half-sites, suggesting that the interaction between ER DBDs on the ERE is relatively weak, and that in full-length ER the DBDs can move independently of each other, To test binding to an imperfect palindrome, typical of the imperfect EREs found in almost all natural estrogen receptor responsive genes, we used the pS2 ERE. Even at high concentrations of ER DBD, specific binding of the ER DBD to the imperfect pS2 ERE was undetectable, Both of the dimerized ER DBDs exhibited efficient binding to the imperfect pS2 ERE, with an affinity at least 25-fold greater than monomer ER DBD, These data support the View that steroid receptor dimerization provides an important mechanism facilitating the recognition of naturally occurring, imperfect hormone response elements.	UNIV ILLINOIS,DEPT BIOCHEM,B4 RAL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16720] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Carlsson B, 1995, ANAL BIOCHEM, V232, P172, DOI 10.1006/abio.1995.0004; CHIANG CM, 1993, PEPTIDE RES, V6, P62; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; INCE BA, 1993, J BIOL CHEM, V268, P14026; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; KATO S, 1995, MOL CELL BIOL, V15, P5858; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; Kim J, 1997, MOL CELL BIOL, V17, P3173, DOI 10.1128/MCB.17.6.3173; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG H, 1993, P NATL ACAD SCI USA, V90, P7010, DOI 10.1073/pnas.90.15.7010; LUISI B, 1995, NATURE, V375, P359, DOI 10.1038/375359a0; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MURDOCH FE, 1995, BIOCHEMISTRY-US, V34, P9144, DOI 10.1021/bi00028a025; NARDULLI AM, 1991, J BIOL CHEM, V266, P24070; NARDULLI AM, 1993, MOL ENDOCRINOL, V7, P331, DOI 10.1210/me.7.3.331; Nardulli AM, 1996, MOL ENDOCRINOL, V10, P694, DOI 10.1210/me.10.6.694; PERCIPALLE P, 1995, EMBO J, V14, P3200, DOI 10.1002/j.1460-2075.1995.tb07322.x; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; Robinson CR, 1996, BIOCHEMISTRY-US, V35, P109, DOI 10.1021/bi9521194; SASSE J, 1988, CURRENT PROTOCOLS MO, V2; Schodin DJ, 1995, J BIOL CHEM, V270, P31163, DOI 10.1074/jbc.270.52.31163; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; WHITE R, 1991, J STEROID BIOCHEM, V40, P333, DOI 10.1016/0960-0760(91)90199-F	29	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27949	27956		10.1074/jbc.272.44.27949	http://dx.doi.org/10.1074/jbc.272.44.27949			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346945	hybrid			2022-12-27	WOS:A1997YD47300071
J	Behncken, SN; Rowlinson, SW; Rowland, JE; ConwayCampbell, BL; Monks, TA; Waters, MJ				Behncken, SN; Rowlinson, SW; Rowland, JE; ConwayCampbell, BL; Monks, TA; Waters, MJ			Aspartate 171 is the major primate-specific determinant of human growth hormone - Engineering porcine growth hormone to activate the human receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; EXTRACELLULAR DOMAIN; SCANNING MUTAGENESIS; RATIONAL DESIGN; BINDING; DIMERIZATION; IDENTIFICATION; INVOLVEMENT; AFFINITY; MOLECULE	It has been known for more than 4 decades that only primate growth hormones are effective in primate species, but it is only with the availability of the 2.8 A structure of the human growth hormone (hGH). hGH-binding protein (hGHBP)(2) complex that Souza and co-workers (Souza, S. C., Frick, G. P., Wang, X., Kopchick, J. J., Lobo, R. B., and Goodman, H. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 959-963) were able to provide evidence that Arg-43 on the primate receptor is responsible. Here we have examined systematically the interaction between Arg-43 (primate receptor) or Leu-43 (non-primate receptors) and their complementary hormone residues Asp-171 (primate GH) and His-170 (nonprimate hormones) in a four-way comparison involving exchanges of histidine and aspartate and exchanges of arginine and leucine. BAF/BO3 lines were created and characterized which stably expressed hGH receptor, R43L hGH receptor, rabbit GH receptor, and L43R rabbit GH receptor. These were examined for site 1 affinity, for the ability to bind intact cells, and for proliferative biopotency using hGH, D171H hGH, porcine GH, or H170D porcine GH. We find that the single interaction between Arg-43 and His-170/171 is sufficient to explain virtually all of the primate species specificity, and this is congruent with the crystal structure. Accordingly, for the first time we have been able to engineer a nonprimate hormone to bind to and activate the human GH receptor.	UNIV QUEENSLAND,CTR MOL & CELLULAR BIOL,BRISBANE,QLD 4072,AUSTRALIA	University of Queensland	Behncken, SN (corresponding author), UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,BRISBANE,QLD 4072,AUSTRALIA.		waters, michael j/C-9582-2014	Rowland, Jennifer/0000-0003-2313-6106				ASTON R, 1986, J ENDOCRINOL, V110, P381, DOI 10.1677/joe.0.1100381; BARNARD R, 1989, J THEOR BIOL, V140, P355, DOI 10.1016/S0022-5193(89)80092-X; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOBIUS KS, 1992, J MOL ENDOCRINOL, V9, P213, DOI 10.1677/jme.0.0090213; LAUTERIC TJ, 1988, COMP BIOCHEM PHYS A, V91, P15, DOI 10.1016/0300-9629(88)91585-X; LAYTON MJ, 1994, J BIOL CHEM, V269, P29891; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; ROWLINSON SW, 1995, J BIOL CHEM, V270, P16833, DOI 10.1074/jbc.270.28.16833; ROWLINSON SW, 1994, BIOCHEMISTRY-US, V33, P11724, DOI 10.1021/bi00205a008; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; SHANAFELT AB, 1991, J BIOL CHEM, V266, P13804; SOUZA SC, 1995, P NATL ACAD SCI USA, V92, P959, DOI 10.1073/pnas.92.4.959; STATEN NR, 1993, J BIOL CHEM, V268, P18467; Takahashi Y, 1996, NEW ENGL J MED, V334, P432, DOI 10.1056/NEJM199602153340704; WATERS MJ, 1979, J BIOL CHEM, V254, P6815; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1	24	45	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27077	27083		10.1074/jbc.272.43.27077	http://dx.doi.org/10.1074/jbc.272.43.27077			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341147	hybrid			2022-12-27	WOS:A1997YC65900043
J	Flierl, A; Reichmann, H; Seibel, P				Flierl, A; Reichmann, H; Seibel, P			Pathophysiology of the MELAS 3243 transition mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; SODIUM DODECYL-SULFATE; STROKE-LIKE EPISODES; RIBOSOMAL-RNA GENES; MITOCHONDRIAL MYOPATHY; RESPIRATORY-CHAIN; ESCHERICHIA-COLI; LACTIC-ACIDOSIS; TRANSCRIPTION TERMINATION	Single base substitutions of the mitochondrial genome are associated with a variety of metabolic disorders, The myopathy, encephalopathy, lactic acidosis, stroke-like episodes syndrome, most frequently associated with an A to G transition mutation at position 3243 of the mitochondrial tRNA(Leu(UUR)) gene, is characterized by biochemical and structural alterations of mitochondria, To investigate the pathophysiology of the mutation, we established distinct Epstein-Barr virus-transformed B-cell lines for analyses that harbored 30-70% of the mutated genome, Interestingly, neither an alteration of the processing of primary transcripts nor a general impairment of individual mitochondrial protein subunit synthesis rates could be observed, Nevertheless a marked decrease of cytochrome-c oxidase activity and reduced content of mitochondrial encoded subunits in the assembled respiratory complex TV was recorded on the cell line harboring 70% mutated mtDNA, Quantitative analysis of incorporation rates of the amino acid leucine into newly synthesized mitochondrial proteins, representing the functionality of the tRNA(Leu(UUR)) in protein biosynthesis, revealed a specific decrease of this amino acid in distinct mitochondrial translation products, This observation was supported by a variation in the proteolytic fingerprint pattern, Our results suggest that the malfunctioning mitochondrial tRNA(Leu(UUR)) leads to an alteration of amino acid incorporation into the mitochondrially synthesized subunits of the oxidative phosphorylation system, thus altering it's structure and function.	UNIV WURZBURG,BIOZENTRUM,THEODOR BOVERI INST,WISSENSCH NACHWUCHSGRP,D-97074 WURZBURG,GERMANY; UNIV DRESDEN,NEUROL KLIN,KLINIKUM CARL GUSTAV CARUS,D-01307 DRESDEN,GERMANY	University of Wurzburg; Technische Universitat Dresden			Flierl, Adrian/W-3453-2019	Flierl, Adrian/0000-0003-0933-2493				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BANTLE JA, 1976, CELL, V8, P139, DOI 10.1016/0092-8674(76)90195-1; BINDOFF LA, 1993, J BIOL CHEM, V268, P19559; BOURGERON T, 1993, NEUROMUSCULAR DISORD, V3, P605, DOI 10.1016/0960-8966(93)90124-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FOX TD, 1980, NATURE, V288, P60, DOI 10.1038/288060a0; GABRIDGE MG, 1976, J CLIN MICROBIOL, V3, P560; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; GRIVELL LA, 1995, CRIT REV BIOCHEM MOL, V30, P121, DOI 10.3109/10409239509085141; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; ICHIBA T, 1995, BBA-GENE STRUCT EXPR, V1262, P83, DOI 10.1016/0167-4781(95)00062-L; IRWIN B, 1995, J BIOL CHEM, V270, P22801, DOI 10.1074/jbc.270.39.22801; JANKE A, 1993, NUCLEIC ACIDS RES, V21, P1523, DOI 10.1093/nar/21.7.1523; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KOBAYASHI M, 1987, J PEDIATR-US, V110, P223, DOI 10.1016/S0022-3476(87)80158-0; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; MOREADITH RW, 1984, ANAL BIOCHEM, V137, P360, DOI 10.1016/0003-2697(84)90098-8; NAKAMURA M, 1978, J LAB CLIN MED, V91, P568; NYSTROM T, 1994, MOL MICROBIOL, V12, P833, DOI 10.1111/j.1365-2958.1994.tb01069.x; OCONNOR M, 1993, EMBO J, V12, P2559, DOI 10.1002/j.1460-2075.1993.tb05911.x; OFVERSTEDT LG, 1994, CELL, V79, P629, DOI 10.1016/0092-8674(94)90548-7; OLSZEWSKA E, 1988, TRENDS GENET, V4, P92, DOI 10.1016/0168-9525(88)90095-9; PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409; REEDMAN BM, 1972, INT J CANCER, V9, P172; ROJIANI MV, 1990, P NATL ACAD SCI USA, V87, P1511, DOI 10.1073/pnas.87.4.1511; SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/S0005-2728(05)80021-0; SEIBEL P, 1991, J NEUROL SCI, V105, P217, DOI 10.1016/0022-510X(91)90148-Z; TANAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P861, DOI 10.1016/0006-291X(91)91497-Z; TAYLOR RW, 1993, BIOCHIM BIOPHYS ACTA, V1181, P261, DOI 10.1016/0925-4439(93)90030-5; TAYLOR RW, 1993, BIOCHEM SOC T, V21, P804, DOI 10.1042/bst0210804; ULRICH AK, 1991, BIOCHIM BIOPHYS ACTA, V1089, P362, DOI 10.1016/0167-4781(91)90177-N; VOGEL U, 1992, MOL MICROBIOL, V6, P2191, DOI 10.1111/j.1365-2958.1992.tb01393.x; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1995, HUMAN GENE MAPPING 1, P910; WEISS R, 1988, J MOL BIOL, V203, P403, DOI 10.1016/0022-2836(88)90008-3; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WEISS RB, 1990, PROG NUCL ACID RES M, V18, P3529; ZIMMERMANN P, 1992, BIOCHIM BIOPHYS ACTA, V1180, P99, DOI 10.1016/0925-4439(92)90032-I	47	73	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27189	27196		10.1074/jbc.272.43.27189	http://dx.doi.org/10.1074/jbc.272.43.27189			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341162				2022-12-27	WOS:A1997YC65900058
J	Kobayashi, M; Rodriguez, R; Lara, C; Omata, T				Kobayashi, M; Rodriguez, R; Lara, C; Omata, T			Involvement of the C-terminal domain of an ATP-binding subunit in the regulation of the ABC-type nitrate/nitrite transporter of the cyanobacterium Synechococcus sp. strain PCC 7942	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANACYSTIS-NIDULANS; NITRATE TRANSPORT; NITRITE REDUCTASE; ESCHERICHIA-COLI; MALTOSE TRANSPORT; INDUCER EXCLUSION; SP PCC-7942; PROTEIN; GENE; ASSIMILATION	In Synechococcus sp. strain PCC 7942, an ATP-binding cassette transporter encoded by the genes nrtA, nrtB, nrtC, and nrtD mediates active transport of nitrate and nitrite, which is inhibited by ammonium, a preferred source of nitrogen for the cyanobacterium. One of the ATP-binding subunits of the transporter, NrtC, has a distinct C-terminal domain of 380 amino acid residues. A mutant NC2, constructed by removal of this domain using genetic engineering techniques, assimilated low concentrations of nitrate and nitrite and accumulated nitrate intracellularly, showing that the domain is not essential for the transporter activities, Assimilation of low concentrations of nitrite was only partially inhibited by ammonium in NC2 but was completely inhibited in the wild-type cells, Cells of NC2 and its derivative (nitrate reductase-less strain NC4) carrying the truncated NrtC but not the cells with the wild-type NrtC accumulated nitrate intracellularly in the presence of ammonium in medium, These findings indicated that the C-terminal domain of NrtC is involved in the ammonium-promoted inhibition of the nitrate/nitrite transporter, In the presence of ammonium, NC2 could not assimilate nitrate despite its ability to accumulate nitrate intracellularly, which suggested that reduction of intracellular nitrate by nitrate reductase is also subject to inhibition by ammonium.	NAGOYA UNIV, SCH AGR SCI, DEPT APPL BIOL SCI, NAGOYA, AICHI 46401, JAPAN; UNIV SEVILLA, FAC BIOL, DEPT BIOQUIM VEGETAL & BIOL MOL, E-41080 SEVILLE, SPAIN	Nagoya University; University of Sevilla			Lara, Catalina/H-4595-2015	Lara, Catalina/0000-0001-7017-9446				AIBA H, 1981, J BIOL CHEM, V256, P1905; ANDERSON PM, 1986, BIOCHEMISTRY-US, V25, P1621, DOI 10.1021/bi00355a026; ANDRIESSE X, 1990, INORGANIC NITROGEN P, P303; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; CORONIL T, 1991, PLANT PHYSIOL BIOCH, V29, P651; DEAN DA, 1990, J BIOL CHEM, V265, P21005; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; FLORES E, 1987, BIOCHIM BIOPHYS ACTA, V896, P103, DOI 10.1016/0005-2736(87)90361-0; FLORES E, 1980, ARCH MICROBIOL, V128, P137, DOI 10.1007/BF00406150; Guerrero M. G., 1987, The Cyanobacteria., P163; GUERRERO MG, 1981, ANNU REV PLANT PHYS, V32, P169, DOI 10.1146/annurev.pp.32.060181.001125; HERRERO A, 1986, J GEN MICROBIOL, V132, P2463; HERRERO A, 1981, J BACTERIOL, V145, P175, DOI 10.1128/JB.145.1.175-180.1981; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; Kikuchi H, 1996, J BACTERIOL, V178, P5822, DOI 10.1128/jb.178.19.5822-5825.1996; KUHLEMEIER CJ, 1984, J BACTERIOL, V159, P36, DOI 10.1128/JB.159.1.36-41.1984; KUHNAU S, 1991, J BACTERIOL, V173, P2180; LARA C, 1987, J BACTERIOL, V169, P4376, DOI 10.1128/jb.169.9.4376-4378.1987; LARA C, 1993, PHYSIOL PLANTARUM, V89, P582, DOI 10.1111/j.1399-3054.1993.tb05217.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUQUE I, 1993, PLANT MOL BIOL, V21, P1201, DOI 10.1007/BF00023618; LUQUE I, 1994, BBA-BIOENERGETICS, V1184, P296, DOI 10.1016/0005-2728(94)90236-4; MacKinney G, 1941, J BIOL CHEM, V140, P315; Maeda SI, 1997, J BIOL CHEM, V272, P3036, DOI 10.1074/jbc.272.5.3036; OHMORI M, 1977, ARCH MICROBIOL, V114, P225, DOI 10.1007/BF00446866; OMATA T, 1989, P NATL ACAD SCI USA, V86, P6612, DOI 10.1073/pnas.86.17.6612; OMATA T, 1993, MOL GEN GENET, V236, P193, DOI 10.1007/BF00277112; OMATA T, 1991, PLANT CELL PHYSIOL, V32, P151, DOI 10.1093/oxfordjournals.pcp.a078059; RIED JL, 1987, GENE, V57, P239, DOI 10.1016/0378-1119(87)90127-2; RODRIGUEZ R, 1992, BIOCHEM J, V282, P639, DOI 10.1042/bj2820639; RODRIGUEZ R, 1994, FEBS LETT, V350, P19, DOI 10.1016/0014-5793(94)00720-9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; SUZUKI I, 1993, PLANT CELL PHYSIOL, V34, P1311; Suzuki I, 1996, J BACTERIOL, V178, P2688, DOI 10.1128/jb.178.9.2688-2694.1996; SUZUKI I, 1995, PLANT PHYSIOL, V107, P791, DOI 10.1104/pp.107.3.791; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	38	56	59	1	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27197	27201		10.1074/jbc.272.43.27197	http://dx.doi.org/10.1074/jbc.272.43.27197			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341163	Green Published, hybrid			2022-12-27	WOS:A1997YC65900059
J	Kunapuli, P; Lawson, JA; Rokach, J; FitzGerald, GA				Kunapuli, P; Lawson, JA; Rokach, J; FitzGerald, GA			Functional characterization of the ocular prostaglandin F-2 alpha (PGF(2 alpha)) receptor - Activation by the isoprostane, 12-iso-PGF(2 alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; F2-ISOPROSTANE RECEPTORS; INVITRO CHARACTERIZATION; LIPID HYDROPEROXIDES; UVEOSCLERAL OUTFLOW; HUMAN MYOMETRIUM; CORPUS-LUTEUM; FP-RECEPTOR; EXPRESSION	Prostaglandin F-2 alpha (PGF(2) alpha) is a product of cyclooxygenase-catalyzed metabolism of arachidonic acid. Recently, PGF(2) alpha analogs have been hypothesized to reduce intraocular pressure via relaxation of the ciliary muscle. To investigate the molecular basis of PGF(2) alpha receptor (FP) activation in the eye, we cloned the FP from a human ciliary body (hcb) cDNA library. The open reading frame of the hcb-FP cDNA was identical to the uterine FP cDNA, The hcb-FP appeared to be predominantly membrane-localized, as visualized by an FP-specific peptide antibody, and coupled to inositol phosphate formation when stably expressed in HEK 293 cells. Interestingly, the hcb-FP could also be activated by the F-2 isoprostane, 12-iso-PGF(2) alpha, in addition to its cognate ligand, PGF(2) alpha. 12 iso-PGF(2) alpha was less potent (EC50 = 5 mu M) than PGF(2) alpha (EC50 = 10 nM) in generating inositol phosphates via the hcb-FP in HEK 293 cells. Both ligands also stimulated mitogenesis in NIH 3T3 cells. Although 12-iso-PGF(2) alpha caused a dose-dependent activation of the FP, it failed to activate the recombinant human prostacyclin receptor and caused only minimal activation of the thromboxane receptor isoforms stably expressed in HEK 293 cells. Four additional F-2 isoprostanes, 8-iso-PGF(2) alpha, IPF2 alpha,-I, IPF2 alpha-III, and 9 beta,11 beta-PGF(2), caused trivial, or no, activation of the FP. Consistent with these observations, only PGF(2) alpha and 12-iso-PGF(2) alpha caused rapid homologous desensitization of FP and also exhibited cross-desensitization, with PGF(2) alpha resulting in a maximum of similar to 60% desensitization. The human FP may thus be activated specifically, by the free radical-catalyzed F-2 isoprostane, 12-iso-PGF(2) alpha, in addition to the cyclooxygenase product, PGF(2) alpha. Incidental receptor activation by isoprostanes may complement the actions of PGF(2) alpha in clinical syndromes where oxidant stress and augmented prostaglandin biosynthesis coincide.	UNIV PENN, CTR EXPT THERAPEUT, PHILADELPHIA, PA 19104 USA; FLORIDA INST TECHNOL, CLAUDE PEPPER INST, MELBOURNE, FL 32901 USA; FLORIDA INST TECHNOL, DEPT CHEM, MELBOURNE, FL 32901 USA	University of Pennsylvania; Florida Institute of Technology; Florida Institute of Technology			FitzGerald, Garret A/A-4222-2010	Rokach, Joshu/0000-0003-1814-7505	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07843, HL54500] Funding Source: Medline; NIDDK NIH HHS [DK44730] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; Adams JW, 1996, J BIOL CHEM, V271, P1179, DOI 10.1074/jbc.271.2.1179; Adiyaman M, 1996, TETRAHEDRON LETT, V37, P4849, DOI 10.1016/0040-4039(96)00973-2; Adiyaman M, 1997, TETRAHEDRON LETT, V38, P3339, DOI 10.1016/S0040-4039(97)00622-9; ALM A, 1993, OPHTHALMOLOGY, V100, P1312; BARNARD JW, 1992, J APPL PHYSIOL, V72, P2469, DOI 10.1152/jappl.1992.72.6.2469; COLEMAN RA, 1981, BRIT J PHARMACOL, V74, pP913; CRAWFORD K, 1987, ARCH OPHTHALMOL-CHIC, V105, P1112, DOI 10.1001/archopht.1987.01060080114039; CSEPLI J, 1975, PROSTAGLANDINS, V10, P689, DOI 10.1016/S0090-6980(75)80017-7; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DONG YJ, 1986, BRIT J PHARMACOL, V87, P97, DOI 10.1111/j.1476-5381.1986.tb10161.x; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; FUKUNAGA M, 1993, BIOCHEM BIOPH RES CO, V195, P507, DOI 10.1006/bbrc.1993.2075; GABELT BT, 1989, EXP EYE RES, V49, P389, DOI 10.1016/0014-4835(89)90049-3; GOTOH M, 1994, NEUROCHEM RES, V19, P679, DOI 10.1007/BF00967706; GRAVES PE, 1995, ENDOCRINOLOGY, V136, P3430, DOI 10.1210/en.136.8.3430; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; HARDY P, 1994, INVEST OPHTH VIS SCI, V35, P580; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; HORTON EW, 1976, PHYSIOL REV, V56, P595, DOI 10.1152/physrev.1976.56.4.595; Hwang SW, 1996, TETRAHEDRON LETT, V37, P779, DOI 10.1016/0040-4039(95)02390-9; HWANG SW, 1994, J AM CHEM SOC, V116, P10829, DOI 10.1021/ja00102a076; JIMENEZDEASUA L, 1975, P NATL ACAD SCI USA, V72, P2724; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LAKE S, 1994, FEBS LETT, V355, P317, DOI 10.1016/0014-5793(94)01198-2; LINDSEY JD, 1994, INVEST OPHTH VIS SCI, V35, P242; MCCRACKEN JA, 1970, J CLIN ENDOCR METAB, V30, P544, DOI 10.1210/jcem-30-4-544; MEAGHER EA, 1997, ENDOTHERLIUM CLIN PR, P413; MINAMI T, 1992, PAIN, V50, P223, DOI 10.1016/0304-3959(92)90166-9; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; Morrow JD, 1996, BIOCHEM PHARMACOL, V51, P1, DOI 10.1016/0006-2952(95)02072-1; NAKAMURA T, 1983, J BIOCHEM-TOKYO, V94, P1029, DOI 10.1093/oxfordjournals.jbchem.a134444; NAKAO A, 1993, J CELL PHYSIOL, V155, P257, DOI 10.1002/jcp.1041550206; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Pierce KL, 1997, J BIOL CHEM, V272, P883, DOI 10.1074/jbc.272.2.883; PORTER NA, 1984, TETRAHEDRON LETT, V25, P807, DOI 10.1016/S0040-4039(01)80032-0; Pratico D, 1996, J BIOL CHEM, V271, P14916, DOI 10.1074/jbc.271.25.14916; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; SENIOR J, 1993, BRIT J PHARMACOL, V108, P501, DOI 10.1111/j.1476-5381.1993.tb12832.x; SENIOR J, 1992, BRIT J PHARMACOL, V107, P215, DOI 10.1111/j.1476-5381.1992.tb14489.x; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; TACHADO SD, 1993, INVEST OPHTH VIS SCI, V34, P2023; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; Waugh RJ, 1996, J AM SOC MASS SPECTR, V7, P490, DOI 10.1016/1044-0305(95)00709-1; WOODWARD DF, 1989, INVEST OPHTH VIS SCI, V30, P1838; YURA T, 1995, ADV PROSTAG THROMB L, V23, P237; ZIAI N, 1993, ARCH OPHTHALMOL-CHIC, V111, P1351, DOI 10.1001/archopht.1993.01090100059027	57	92	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27147	27154		10.1074/jbc.272.43.27147	http://dx.doi.org/10.1074/jbc.272.43.27147			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341156	hybrid			2022-12-27	WOS:A1997YC65900052
J	Seoane, J; Trinh, K; ODoherty, RM; GomezFoix, AM; Lange, AJ; Newgard, CB; Guinovart, JJ				Seoane, J; Trinh, K; ODoherty, RM; GomezFoix, AM; Lange, AJ; Newgard, CB; Guinovart, JJ			Metabolic impact of adenovirus-mediated overexpression of the glucose-6-phosphatase catalytic subunit in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; RAT-LIVER GLUCOSE-6-PHOSPHATASE; HEPATIC GLYCOGEN-SYNTHESIS; GENE-EXPRESSION; MICROSOMAL GLUCOSE-6-PHOSPHATASE; DIABETIC RATS; HEXOKINASE-I; GLUCOSE; INSULIN; SYNTHASE	Glucose-6-phosphatase (G6Pase) catalyzes the hydrolysis of glucose 6-phosphate (Glu-6-P) to free glucose and, as the last step in gluconeogenesis and glycogenolysis in liver, is thought to play an important role in glucose homeostasis. G6Pase activity appears to be conferred by a set of proteins localized to the endoplasmic reticulum, including a glucose-6-phosphate translocase, a G6Pase phosphohydrolase or catalytic subunit, and glucose and inorganic phosphate transporters in the endoplasmic reticulum membrane. in the current study, we used a recombinant adenovirus containing the cDNA encoding the G6Pase catalytic subunit (AdCMV-G6Pase) to evaluate the metabolic impact of overexpression of the enzyme in primary hepatocytes. We found that AdCMV-G6Pase-treated liver cells contain significantly less glycogen and Glu-6-P, but unchanged UDP-glucose levels, relative to control cans, Further, the glycogen synthase activity state was closely correlated with Glu-6-P levels over a wide range of glucose concentrations in both G6Pase-overexpressing land control cells, The reduction in glycogen synthesis in AdCMV-G6Pase-treated hepatocytes is therefore mot a function of decreased substrate availability but rather occurs because of the regulatory effects of Glu-6-P on glycogen synthase activity, We also found that AdCMV-G6Pase-treated-cells had significantly lower rates of lactate production and [3-H-3]glucose usage, coupled with enhanced rates of gluconeogenesis and Glu-6-P hydrolysis, We conclude that overexpression of the G6Pase catalytic subunit alone is sufficient to activate Bur through the G6Pase system in liver cells, Further, hepatocytes treated with AdCMV-G6Pase exhibit a metabolic profile resembling that of liver cells front patients or animals with non-insulin-dependent diabetes mellitus, suggesting that dysregulation of the catalytic subunit of G6Pase could contribute to the etiology of the disease.	UNIV BARCELONA, FAC QUIM, DEPT BIOQUIM & BIOL MOL, E-08028 BARCELONA, SPAIN; UNIV TEXAS, SW MED CTR, GIFFORD LABS DIABET RES, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, GIFFORD LABS DIABET RES, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV MINNESOTA, SCH MED, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA	University of Barcelona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Minnesota System; University of Minnesota Twin Cities			Seoane, Joan/AAG-9173-2019	Seoane, Joan/0000-0002-6541-5974	PHS HHS [NIH1P50H2598801] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEGRE M, 1988, ANAL BIOCHEM, V173, P185, DOI 10.1016/0003-2697(88)90176-5; Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; ARION WJ, 1980, J BIOL CHEM, V255, P396; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BECKER TC, 1994, METHOD CELL BIOL, V43, P162; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCHELL A, 1985, DIABETOLOGIA, V28, P852, DOI 10.1007/BF00291077; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; CHEN YT, 1994, METABOLIC BASIS INHE, P935; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; ELREFAI M, 1976, AM J PHYSIOL, V231, P1608, DOI 10.1152/ajplegacy.1976.231.5.1608; FernandezNovell JM, 1996, EUR J BIOCHEM, V238, P570, DOI 10.1111/j.1432-1033.1996.0570z.x; Gutmann I., 1974, METHODS ENZYMATIC AN, P1464; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; KEPPLER D, 1974, METHOD ENZYMAT AN, V3, P1464; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LEI KJ, 1995, J CLIN INVEST, V95, P234, DOI 10.1172/JCI117645; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; NOEL RJ, 1996, DIABET ANN, V10, P65; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; Trinh K, 1997, J BIOL CHEM, V272, P24837, DOI 10.1074/jbc.272.40.24837; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; VILLARPALASI C, 1995, BBA-GEN SUBJECTS, V1244, P203, DOI 10.1016/0304-4165(95)00006-W; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173	39	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26972	26977		10.1074/jbc.272.43.26972	http://dx.doi.org/10.1074/jbc.272.43.26972			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341134	hybrid			2022-12-27	WOS:A1997YC65900030
J	Yu, LX; Zhen, L; Dinauer, MC				Yu, LX; Zhen, L; Dinauer, MC			Biosynthesis of the phagocyte NADPH oxidase cytochrome b(558) - Role of heme incorporation and heterodimer formation in maturation and stability of gp91(phox) and p22(phox) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; LEUKEMIA CELL-LINE; SUPEROXIDE PRODUCTION; RESPIRATORY BURST; BINDING-SITE; NEUTROPHIL CYTOCHROME-B558; HL-60 CELLS; MYELOPEROXIDASE; EXPRESSION; PROTEIN	The NADPH oxidase cytochrome b(558) is a membrane heterodimer comprised of a glycosylated 91-kDa subunit, gp91(phox), and a nonglycosylated 22-kDa subunit, p22(phox). The role of heme in cytochrome b(558) biosynthesis was studied using succinyl acetone, an inhibitor of heme synthesis, in PLB-985 myeloid cells undergoing granulocytic differentiation. Succinyl acetone markedly reduced expression of p22(phox) and the mature 91-kDa form of gp91(phox) but not its 65-kDa high mannose precursor, in association with a profound reduction in NADPH oxidase activity, Expression of non-hems-con; taining cytosolic oxidase components was unaffected. The reduction in cytochrome b(558) expression and NADPH oxidase activity was prevented by adding exogenous heme and was reversible upon removal of succinyl acetone. Transgenic expression of gp91(phox) in monkey COS-7 and murine 3T3 cells, both of which lacked endogenous p22(phox) mRNA, demonstrated that p22(phox) was not required for maturation of gp91(phox) carbohydrate to complex oligosaccharides. However, coexpression of transgenic p22(phox) increased the abundance of the mature gp91(phox) glycoprotein. These results suggest that heme incorporation plays an important Pole in cytochrome bass assembly and provide further support fur the concept that stability of p22(phox) and the mature gp91(phox) subunit is increased by heterodimer formation.	INDIANA UNIV,JAMES WHITCOMB RILEY HOSP CHILDREN,SCH MED,DEPT PEDIAT HEMATOL ONCOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL45635] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNLJOTS K, 1987, J BIOL CHEM, V262, P10430; CASTANEDA VL, 1992, EXP HEMATOL, V20, P916; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; CURNUTTE JT, 1994, J BIOL CHEM, V269, P10813; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DINAUER M, 1993, IMMUNODEFICIENCIES, P335; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; DOUSSIERE J, 1993, BIOCHEMISTRY-US, V32, P8880, DOI 10.1021/bi00085a020; DOUSSIERE J, 1995, BIOCHEMISTRY-US, V34, P1760, DOI 10.1021/bi00005a033; EBERT PS, 1979, BIOCHEM BIOPH RES CO, V88, P1382, DOI 10.1016/0006-291X(79)91133-1; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; GREEN SP, 1994, J LEUKOCYTE BIOL, V55, P530, DOI 10.1002/jlb.55.4.530; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; HURST JK, 1991, J BIOL CHEM, V266, P1627; KOMAR AA, 1993, FEBS LETT, V326, P261, DOI 10.1016/0014-5793(93)81803-8; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; KUME A, 1994, BLOOD, V84, P3311; Leusen JHW, 1996, J LAB CLIN MED, V128, P461, DOI 10.1016/S0022-2143(96)90043-8; LEVY R, 1990, J IMMUNOL, V145, P2595; MALY FE, 1993, J EXP MED, V178, P2047, DOI 10.1084/jem.178.6.2047; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; MERLIE JP, 1984, CELL, V36, P573, DOI 10.1016/0092-8674(84)90335-0; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2689; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; NAUSEEF WM, 1992, BLOOD, V80, P2622; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PINNIX IB, 1994, ARCH BIOCHEM BIOPHYS, V312, P447, DOI 10.1006/abbi.1994.1331; PORTER CD, 1994, BLOOD, V84, P2767; Porter CD, 1996, BIOCHEM J, V315, P571, DOI 10.1042/bj3150571; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1992, J BIOL CHEM, V267, P7303; Roos D, 1996, BLOOD, V87, P1663; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SMITH RM, 1991, BLOOD, V77, P673; Smith RM, 1996, J CLIN INVEST, V98, P977, DOI 10.1172/JCI118882; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; TUCKER KA, 1987, BLOOD, V70, P372; UENO I, 1991, FEBS LETT, V281, P130, DOI 10.1016/0014-5793(91)80375-D; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; WIENHUES U, 1992, BIOESSAYS, V14, P17, DOI 10.1002/bies.950140105; YU LX, 1993, BIOCHIM BIOPHYS ACTA, V1178, P73, DOI 10.1016/0167-4889(93)90111-2; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	51	126	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27288	27294		10.1074/jbc.272.43.27288	http://dx.doi.org/10.1074/jbc.272.43.27288			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341176	Green Submitted, hybrid			2022-12-27	WOS:A1997YC65900072
J	Folco, E; Mathur, R; Mori, Y; Buckett, P; Koren, G				Folco, E; Mathur, R; Mori, Y; Buckett, P; Koren, G			A cellular model for long QT syndrome - Trapping of heteromultimeric complexes consisting of truncated Kv1.1 potassium channel polypeptides and native Kv1.4 and Kv1.5 channels in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-CHANNEL; CARDIAC-ARRHYTHMIA; PROTEINS; EXPRESSION; GENE	We demonstrated that overexpression of a cRNA encoding a truncated potassium channel polypeptide that contains the NH, terminus and the first transmembrane segment (Kv1.1206Tag) abolished the expression of Kv1.1 and Kv1.5 outward currents in Xenopus oocytes (Babila, T., Moscucci, A., Wang, H., Weaver, F. E. & Koren, G. (1994) Neuron 12, 615-626), Recently, we showed that expression of Kv1.1N206Tag in the heart of transgenic mice resulted in the creation of mice with prolongation of the surface electrocardiogram's QT interval (London, B., Han, X., Folco, E, & Koren, G. (1996) Biophys, J. 70, A2601), To study the dominant negative mechanism of Kv1.1N206Tag, we overexpressed it in GH3 cells, a pituitary cell line expressing Kv1.5 and Kv1.4, RNase protection analysis comparing the steady-state levels of native Kv1.5 and Kv1.1N206Tag transcripts revealed an excess of Kv1.1N206Tag transcript, Immunoprecipitation analysis using 12CA5 monoclonal antibody detected a 25-kDa polypeptide in the transfected cells, The half-life of Kv1.1N206Tag was 2.6 h, Subcellular fractionation of cell lysates labeled with [S-35]methionine revealed that Kv1.1N206Tag polypeptide is detectable in the particulate (membranous) fraction, but not in the soluble (cytosol) fraction, A series of double immunoprecipitations with 12CA5 and polyclonal antibodies against I(v1.5 and Kv1.4 revealed that Kv1.1N206Tag forms het eromultimeric complexes with the native Kv1.4 and Kv1.5 polypeptides. The steady-state levels of Kv1.5 were not affected by the overexpression of Kv1.1N206Tag, Immunofluorescence colocalization and confocal microscopy analyses revealed that Kv1.1N20gTagFlag did not reach the plasma membrane, and its distribution pattern was characteristic to that of a resident endoplasmic reticulum polypeptide. Our observations establish that the negative effect of Kv1.1N20BTag is mediated by the formation of heteromultimeric complexes with the native channels and by the retention of these complexes in the endoplasmic reticulum.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOVASC,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School								Adelman JP, 1995, NEURON, V15, P1449, DOI 10.1016/0896-6273(95)90022-5; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; CHUNG SW, 1995, P NATL ACAD SCI USA, V92, P5955, DOI 10.1073/pnas.92.13.5955; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; HURTLEY SM, 1989, ANN REV CELL BIOL, V5, P227; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; London B., 1996, Biophysical Journal, V70, pA260; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MORI Y, 1995, J BIOL CHEM, V270, P27788, DOI 10.1074/jbc.270.46.27788; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; PeledZehavi H, 1996, BIOCHEMISTRY-US, V35, P6828, DOI 10.1021/bi952988t; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; TAKIMOTO K, 1993, NEURON, V11, P359, DOI 10.1016/0896-6273(93)90191-S; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904	23	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26505	26510		10.1074/jbc.272.42.26505	http://dx.doi.org/10.1074/jbc.272.42.26505			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334228	hybrid			2022-12-27	WOS:A1997YB13900062
J	Ribbe, M; Gadkari, D; Meyer, O				Ribbe, M; Gadkari, D; Meyer, O			N-2 fixation by Streptomyces thermoautotrophicus involves a molybdenum-dinitrogenase and a manganese-superoxide oxidoreductase that couple N-2 reduction to the oxidation of superoxide produced from O-2 by a molybdenum-CO dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; DISMUTASE GENE; NITROGENASE; PROTEIN; PURIFICATION; BACTERIA	N-2 fixation by Streptomyces thermoautofrophicus follows the equation N-2 + 4-12 MgATP + 8H(+) + 8e(-) --> 2NH(3) + H-2 + 4-12 MgADP + 4-12P(i) and exhibits features which are not obvious in the diazotrophic bacteria studied so far, The reaction is coupled to the oxidation of carbon monoxide (CO) by a molybdenum-containing CO dehydrogenase that transfers the electrons derived from CO oxidation to O-2, thereby producing superoxide anion radicals (O-2(radical anion). A manganese-containing superoxide oxidoreductase reoxidizes the )(2)(radical anion) anions to O-2 and transfers the electrons to a MoFeS-dinitrogenase for the reduction of N-2 to ammonium, Among the most striking properties of the S. thermoautotrophicus nitrogenase system are the dependence on O-2 and O-2(radical anion) the complete insensitivity of all components involved toward O-2 and H2O2, the inability to reduce ethine or ethene, and a low MgATP requirement, In addition, the subunit structure of the S. thermoautotrophicus nitrogenase components and the polypeptides involved seem to be dissimilar from the known nitrogenases.	UNIV BAYREUTH, LEHRSTUHL MIKROBIOL, D-95440 BAYREUTH, GERMANY	University of Bayreuth								BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Blanchard CZ, 1996, BIOCHEMISTRY-US, V35, P472, DOI 10.1021/bi951429j; BOWLER C, 1990, J BACTERIOL, V172, P1539, DOI 10.1128/jb.172.3.1539-1546.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; CARDENAS J, 1974, ANAL BIOCHEM, V60, P372, DOI 10.1016/0003-2697(74)90244-9; CHAMBERS SP, 1992, FEMS MICROBIOL LETT, V91, P277; DALTON H, 1972, BACTERIOL REV, V36, P231, DOI 10.1128/MMBR.36.2.231-260.1972; DALTON H, 1971, BIOCHEMISTRY-US, V10, P2066; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; Eady RR, 1996, CHEM REV, V96, P3013, DOI 10.1021/cr950057h; EADY RR, 1972, BIOCHEM J, V128, P655, DOI 10.1042/bj1280655; Evans HJ, 1992, BIOL NITROGEN FIXATI, P1; GADKARI D, 1984, ZBL MIKROBIOL, V139, P623, DOI 10.1016/S0232-4393(84)80056-6; GADKARI D, 1990, APPL ENVIRON MICROB, V56, P3727, DOI 10.1128/AEM.56.12.3727-3734.1990; GADKARI D, 1992, J BACTERIOL, V174, P6840, DOI 10.1128/JB.174.21.6840-6843.1992; GADKARI D, 1994, BIOENGINEERING, V2, P27; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KRAUT M, 1989, ARCH MICROBIOL, V152, P335, DOI 10.1007/BF00425170; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENGFELDER E, 1979, Z NATURFORSCH C, V34, P374; LOW A, 1993, EUR J BIOCHEM, V215, P473, DOI 10.1111/j.1432-1033.1993.tb18056.x; MEYER O, 1983, ANNU REV MICROBIOL, V37, P277, DOI 10.1146/annurev.mi.37.100183.001425; MEYER O, 1982, J BIOL CHEM, V257, P1333; MEYER O, 1990, FEMS MICROBIOL LETT, V87, P253, DOI 10.1016/0378-1097(90)90463-Z; MEYER O, 1993, ACS SYM SER, V535, P50; MEYER O, 1991, 3 S BIOT COAL COAL D, P111; MEYER O, 1997, KOHLEREI FICHTELGEBI, P1; MISRA HP, 1978, ARCH BIOCHEM BIOPHYS, V189, P317, DOI 10.1016/0003-9861(78)90218-7; RIBBE M, 1994, BIOENGINEERING, V2, P80; Santiago B, 1996, FEMS MICROBIOL LETT, V136, P157; SCHADE AL, 1954, P SOC EXP BIOL MED, V87, P443, DOI 10.3181/00379727-87-21407; SCHMIDT K, 1963, ARCH MIKROBIOL, V46, P117, DOI 10.1007/BF00408204; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; YATES MG, 1972, FEBS LETT, V27, P63, DOI 10.1016/0014-5793(72)80410-1	37	116	127	1	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26627	26633		10.1074/jbc.272.42.26627	http://dx.doi.org/10.1074/jbc.272.42.26627			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334244	hybrid			2022-12-27	WOS:A1997YB13900078
J	Patterson, BC; Sang, QXA				Patterson, BC; Sang, QXA			Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B type IV collagenase (MMP-9)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMINOGEN; MATRIX METALLOPROTEINASES; ANGIOGENESIS INHIBITOR; CANCER METASTASIS; ACTIVATION; PROGELATINASE; SUPPRESSION; EXPRESSION; CARCINOMA	Angiostatin is one of the most potent inhibitors of angiogenesis. Reports have shown that metalloelastase, pancreas elastase, plasmin reductase, and plasmin convert plasminogen to angiostatin. However, the cleavage sites of plasminogen by those enzymes have not been determined. Here we demonstrate that two members of the human matrix metalloproteinase (MMP) family, matrilysin (MMP-7) and gelatinase B/type lV collagenase (MMP-9), hydrolyze human plasminogen to generate angiostatin fragments, The cleavage sites have been determined, The 58-kDa bands derived from plasminogen by MMP-7 and MMP-9 both have the N-terminal sequence KVYLSEXKTG, which corresponds to that of angiostatin. This N terminus is identical to that of the starting plasminogen itself and corresponds to residues 97-106 of prepro-plasminogen. The 42- and 38-kDa bands generated by MMP-7 both have the N-terminal sequence VVLLPNVETP, which corresponds to the amino acid sequence 467-476 of prepro-plasminogen, between kringle domain 4 and 5, MMP-9 cleaves plasminogen to generate a 42-kDa fragment with the N-terminal sequence PVVLLPNVE, 1 residue upstream of the MMP-7 cleavage site, These results indicate that MMP-7 and MMP-9 may regulate new blood vessel formation by cleaving plasminogen and generating angiostatin molecules.	FLORIDA STATE UNIV,DEPT CHEM,TALLAHASSEE,FL 32306	State University System of Florida; Florida State University								ANGLESCANO E, 1994, CHEM PHYS LIPIDS, V67-8, P353, DOI 10.1016/0009-3084(94)90157-0; BUSIEK DF, 1992, J BIOL CHEM, V267, P9087; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, EUR J CANCER, V32A, P2534, DOI 10.1016/S0959-8049(96)00423-6; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; GROSKOPF WR, 1969, J BIOL CHEM, V244, P3590; Heppner KJ, 1996, AM J PATHOL, V149, P273; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PETERSEN TE, 1990, J BIOL CHEM, V265, P6104; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SALAMONSEN LA, 1994, CELL BIOL INT, V18, P1139, DOI 10.1006/cbir.1994.1040; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; Sang QXA, 1996, J PROTEIN CHEM, V15, P243, DOI 10.1007/BF01887112; Sim BKL, 1997, CANCER RES, V57, P1329; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; WIMAN B, 1975, EUR J BIOCHEM, V50, P489, DOI 10.1111/j.1432-1033.1975.tb09887.x; Wu ZG, 1997, BIOCHEM BIOPH RES CO, V236, P651, DOI 10.1006/bbrc.1997.7032	28	359	376	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28823	28825		10.1074/jbc.272.46.28823	http://dx.doi.org/10.1074/jbc.272.46.28823			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360944	hybrid			2022-12-27	WOS:A1997YF68400003
J	Dvir, A; Tan, SY; Conaway, JW; Conaway, RC				Dvir, A; Tan, SY; Conaway, JW; Conaway, RC			Promoter escape by RNA polymerase II - Formation of an escape-competent transcriptional, intermediate is a prerequisite for exit of polymerase from the promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; PREINITIATION COMPLEX; ABORTIVE INITIATION; TERMINAL-DOMAIN; FACTOR-EPSILON; FACTOR-DELTA; RAT-LIVER; ELONGATION; MECHANISM; SELECTION	Shortly after initiating promoter-specific transcription in vitro, mammalian RNA polymerase II becomes highly susceptible td arrest in a promoter-proximal region 9-13 base pairs downstream of the transcriptional start site (Dvir, A., Conaway, R. C., and Conaway, J. W. (1996) J. Biol, Chem, 271, 23352-23356), Arrest by polymerase in this region is suppressed by TFIIH in an ATP-dependent reaction (Dvir, A.; Conaway, R. C., and Conaway, J. W. (1997) Proc. Natl. Acad, Sci, U. S. A. 94, 9006-9010), In this report, we present evidence that, in addition to TFIIH and an ATP cofactor, efficient transcription by RNA polymerase II through this promoter-proximal region requires formation of an ''escape-competent'' transcriptional intermediate, Formation of this intermediate requires template DNA 40-50 base pairs downstream of the transcriptional start site. This requirement for downstream DNA is transient, since template DNA downstream of +40 is dispensable for assembly of the preinitiation complex, for initiation and synthesis of the first 10-12 phosphodiester bonds of nascent transcripts and for further extension of transcripts longer than similar to 14 nucleotides, Thus, promoter escape requires that the RNA polymerase, II transcription complex undergoes a critical structural transition, likely driven by interaction of one or more components of the transcriptional machinery with template DNA 40-50 base pairs downstream of the transcriptional start site.	OAKLAND UNIV,DEPT BIOL SCI,ROCHESTER,MI 48309; STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305; OKLAHOMA MED RES FDN,PROGRAM MOL & CELL BIOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,OKLAHOMA CITY,OK 73190; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104	Oakland University; Stanford University; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LUSE DS, 1987, J BIOL CHEM, V262, P14990; PETERSON MG, 1991, NATURE, V354, P369; REINES D, 1992, J BIOL CHEM, V267, P15516; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAMUELS M, 1984, J BIOL CHEM, V259, P2517; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TAN SY, 1994, BIOTECHNIQUES, V16, P824; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WEIL PA, 1979, CELL, V18, P469	27	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28175	28178		10.1074/jbc.272.45.28175	http://dx.doi.org/10.1074/jbc.272.45.28175			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353262	hybrid			2022-12-27	WOS:A1997YF21900002
J	Koshelnick, Y; Ehart, M; Hufnagl, P; Heinrich, PC; Binder, BR				Koshelnick, Y; Ehart, M; Hufnagl, P; Heinrich, PC; Binder, BR			Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FOS GENE-EXPRESSION; PROTEIN-C INHIBITOR; PLASMINOGEN-ACTIVATOR; DIFFERENTIAL ACTIVATION; INTERLEUKIN-6 FAMILY; ENDOTHELIAL-CELLS; MEMBRANE DOMAINS; TYROSINE KINASE; GP130	The urokinase type plasminogen activator (uPA) binds to cells via a specific receptor attached to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. Despite the lack of a transmembrane domain, the urokinase receptor (uPAR) is capable of transducing extracellular signals affecting growth, migration, and adhesion. Several Tyr kinases of the are family as well as beta 1, beta 2, and beta 3 integrins were found to be associated with the uPAR. We found that in the human kidney epithelial line TCL-598, also components of the JAK1/STAT1 signal transduction pathway including gp130, are associated with uPAR as revealed by coimmunoprecipitation and are co-localized in caveolae. Upon clustering of uPA.uPAR complex by a monoclonal antibody, JAK1 associates with uPAR, which in turn leads to STAT1 phosphorylation, dimerization, specific binding to DNA, and gene activation. To prove the dependence of STAT1 activation on the uPAR, TCL-598 cells were treated with sense and antisense uPAR oligo-nucleotides. In antisense-treated cells in which uPAR expression was reduced to less then one third, activation of STAT1 by the clustering antibody was abolished while STAT1 activation by interferon-gamma was unaffected. Therefore, in this cell line, uPA uPAR also utilizes the JAK1/STAT1 pathway for signaling, and gp130 might be the transmembrane adapter for this signal transduction pathway.	UNIV VIENNA, DEPT VASC BIOL & THROMBOSIS RES, A-1090 VIENNA, AUSTRIA; RHEIN WESTFAL TH AACHEN, INST BIOCHEM, D-5100 AACHEN, GERMANY	University of Vienna; RWTH Aachen University								ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; ANICHINI E, 1994, EXP CELL RES, V213, P438, DOI 10.1006/excr.1994.1221; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUCKNER A, 1992, CANCER RES, V52, P3043; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DUMLER I, 1994, FEBS LETT, V343, P103, DOI 10.1016/0014-5793(94)80298-X; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FALUS A, 1995, IMMUNOL LETT, V44, P221, DOI 10.1016/0165-2478(95)00218-T; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; GEIGER M, 1991, J BIOL CHEM, V266, P11851; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HANSEN JG, 1988, J INVEST DERMATOL, V90, P790; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; KIRCHHEIMER JC, 1989, P NATL ACAD SCI USA, V86, P5424, DOI 10.1073/pnas.86.14.5424; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Li CH, 1995, J BIOL CHEM, V270, P30282, DOI 10.1074/jbc.270.51.30282; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PERALDI SG, 1995, EUR J BIOCHEM, V234, P656; PRIGLINGER U, 1994, J BIOL CHEM, V269, P14705; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; Ruthner M., 1994, Fibrinolysis, V8, P97; Ruthner M., 1996, Fibrinolysis, V10, P17; RUTHNER M, 1995, THROMB HAEMOSTASIS, V73, P1132; SCHNAPER HW, 1995, J CELL PHYSIOL, V165, P107, DOI 10.1002/jcp.1041650114; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; STAHL N, 1994, BRAZ J MED BIOL RES, V27, P297; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WANG N, 1995, AM J PHYSIOL-CELL PH, V268, pC1062, DOI 10.1152/ajpcell.1995.268.4.C1062; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xue W, 1997, CANCER RES, V57, P1682; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016	47	143	151	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28563	28567		10.1074/jbc.272.45.28563	http://dx.doi.org/10.1074/jbc.272.45.28563			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353320	hybrid			2022-12-27	WOS:A1997YF21900060
J	Mao, CG; Wadleigh, M; Jenkins, GM; Hannun, YA; Obeid, LM				Mao, CG; Wadleigh, M; Jenkins, GM; Hannun, YA; Obeid, LM			Identification and characterization of Saccharomyces cerevisiae dihydrosphingosine-1-phosphate phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERAMIDE; QUANTITATION; ARREST; LIVER	We have identified the yeast sphingosine resistance gene (YSR2) of Saccharomyces cerevisiae as encoding a protein that specifically dephosphorylates dihydrosphingosine 1-phosphate (DHS-1-P), and we refer to this protein as dihydrosphingosine-1-phosphate phosphatase. Overexpression of YSR2 conferred sphingosine resistance to the dihydrosphingosine-1-P lyase-defective mutant (JS16) of S. cerevisiae, which is hypersensitive to sphingosine. The ysr2 Delta deletion mutant of S. cerevisiae accumulated DHS-1-P compared with its wild type strain upon labeling with n-erythro-[4,5-H-3]dihydrosphingosine, whereas overexpression of YSR2 increased dephosphorylation of DHS-1-P. An epitope-tagged fusion protein (YSR2-Flag) was partially purified and found to specifically dephosphorylate DHS-1-P to yield dihydrosphingosine. YSR2 failed to dephosphorylate ceramide l-phosphate or phosphatidic acid. Functionally, the mutant bearing the ysr2 Delta deletion decreased labeling of sphingolipids and increased labeling of glycerolipids dramatically following in vivo labeling with D-erythro-[H-3]dihydrosphingosine, but it slightly affected labeling of sphingolipids with inositol. Taken together, these results identify YSR2 as dihydrosphingosine-1-phosphate phosphatase. They also raise the intriguing possibility that phosphorylation followed by dephosphorylation is required for incorporation of exogenous long chain sphingoid bases into sphingolipids.	DUKE UNIV, MED CTR, DEPT MED, DIV GERIATR, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, VET AFFAIRS GERIATR RES EDUC & CLIN CTR, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Geriatric Research Education & Clinical Center				obeid, lina/0000-0002-0734-0847	NIGMS NIH HHS [GM-43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; Badiani K, 1996, BBA-LIPID LIPID MET, V1304, P190, DOI 10.1016/S0005-2760(96)00119-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DECEUSTER P, 1995, BIOCHEM J, V311, P139, DOI 10.1042/bj3110139; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; Gietz RD, 1994, MOL GENETICS YEAST P; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Stukey J, 1997, PROTEIN SCI, V6, P469; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171	26	132	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28690	28694		10.1074/jbc.272.45.28690	http://dx.doi.org/10.1074/jbc.272.45.28690			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353337	hybrid			2022-12-27	WOS:A1997YF21900077
J	Okada, S; Pessin, JE				Okada, S; Pessin, JE			Communication - Insulin and epidermal growth factor stimulate a conformational change in Rap1 and dissociation of the CrkII-C3G complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL-TRANSDUCTION PATHWAY; RECEPTOR TYROSINE KINASES; PROTEIN-KINASE; SH3 DOMAIN; SOS-GRB2 COMPLEX; RAS-P21 GTPASE; RAS ACTIVATION; FACTOR C3G; C-CRK	Insulin and epidermal growth factor (EGF) stimulation of Chinese hamster ovary cells expressing the human insulin and EGF receptors resulted in a time dependent decrease in the ability of a Rap1 antibody (amino acid epitope 121-136) to immunoprecipitate Rap1 from whole cell detergent extracts. This was due to an apparent masking of Rap1 as heat denaturation of the whole cell detergent extracts (5 min at 100 degrees C) resulted in equal immunoprecipitation of Rap1 with this epitope specific antibody. The time-dependent change in Rap1 immunoreactivity was paralleled with an insulin-stimulated dissociation of the CrkII-C3G complex. Similarly, EGF treatment also resulted in a time-dependent dissociation of the CrkII-C3G complex that occurred concomitant with the masking of the 121-136 Rap1 epitope. Furthermore, pretreatment of the cells with the tyrosine kinase inhibitor, genistein, decreased both the basal and insulin-stimulated tyrosine phosphorylation of CrkII that directly correlated with the amount of CrkII that was immunoprecipitated with C3G. Together, these data suggest that insulin and EGF stimulation result in the dissociation of the CrkII-C3G complex, thereby inducing an apparent conformation change in Rap1.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa					NIDDK NIH HHS [DK25295, DK49781, DK33823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R37DK033823, R01DK049781, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Downward J, 1996, CANCER SURV, V27, P87; FELLER SM, 1995, ONCOGENE, V10, P1465; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HATA Y, 1990, J BIOL CHEM, V265, P7104; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Holt KH, 1996, MOL CELL BIOL, V16, P577; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PIZON V, 1988, ONCOGENE, V3, P201; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	47	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28179	28182		10.1074/jbc.272.45.28179	http://dx.doi.org/10.1074/jbc.272.45.28179			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353263	hybrid			2022-12-27	WOS:A1997YF21900003
J	Ford, JM; Hanawalt, PC				Ford, JM; Hanawalt, PC			Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LI-FRAUMENI SYNDROME; XERODERMA-PIGMENTOSUM REVERTANT; DECREASED DNA-REPAIR; C-TERMINAL DOMAIN; MUTANT P53; TRANSCRIBED STRAND; CELL-LINE; PYRIMIDINE DIMERS; ULTRAVIOLET-LIGHT; TUMOR-SUPPRESSOR	We have shown previously that Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in the removal of UV-induced cyclobutane pyrimidine dimers from genomic DNA, but still proficient in the transcription-coupled repair pathway (Ford, J. M., and Hanawalt, P. C. (1995) Proc, Natl, Acad. Sci, U. S. A. 92, 8876-8880), We have now utilized monoclonal antibodies specific for cyclobutane pyrimidine dimers or 6-4 photoproducts, respectively, to measure their repair in UV-irradiated human fibroblasts, Cells homozygous for p53 mutations were deficient in the repair of both photoproducts, whereas cells heterozygous for mutant p53 exhibited normal repair of 6-4 photoproducts, but decreased initial rates of removal of cyclobutane pyrimidine dimers, compared with normal cells, The specificity of the effect of wild-type p53 on nucleotide excision repair was demonstrated in a p53 homozygous mutant cell line containing a tetracycline-regulated wild-type p53 gene, Wild-type p53 expression and activity were suppressed in the presence of tetracycline, whereas withdrawal of tetracycline resulted in the induction of p53 expression, cell cycle checkpoint activation, and DNA damage-induced apoptosis, The regulated expression of wild-type p53 resulted in the recovery of normal levels of repair of both cyclobutane pyrimidine dimers and 6-4 photoproducts in genomic DNA, but did not alter the transcription-coupled repair of cyclobutane pyrimidine dimers, Therefore, the wild-type p53 gene product is an important determinant of nucleotide excision repair activity in human cells.			Ford, JM (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.			Ford, James/0000-0002-2513-7025	NATIONAL CANCER INSTITUTE [K08CA064330, R35CA044349] Funding Source: NIH RePORTER; NCI NIH HHS [K08-CA64330, CA44349] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CLEAVER JE, 1987, MOL CELL BIOL, V7, P3353, DOI 10.1128/MCB.7.9.3353; CLEAVER JE, 1994, SOMAT CELL MOLEC GEN, V20, P327, DOI 10.1007/BF02254721; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ford JM, 1997, CURR TOP MICROBIOL, V221, P47; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FORD JM, 1994, MOL CARCINOGEN, V10, P105, DOI 10.1002/mc.2940100208; FRITSCHE M, 1993, ONCOGENE, V8, P307; HANN BC, 1995, NAT GENET, V9, P221, DOI 10.1038/ng0395-221; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Koehler DR, 1996, NUCLEIC ACIDS RES, V24, P2877, DOI 10.1093/nar/24.15.2877; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Li G, 1996, AM J PATHOL, V148, P1113; Li G, 1997, AM J PATHOL, V150, P1457; Liu PK, 1996, ONCOGENE, V12, P2267; LOMMEL L, 1993, MOL CELL BIOL, V13, P970, DOI 10.1128/MCB.13.2.970; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; MITCHELL DL, 1985, MUTAT RES, V143, P109, DOI 10.1016/S0165-7992(85)80018-X; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; PAN ZQ, 1995, J BIOL CHEM, V270, P2208; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SMITH CA, 1981, DNA REPAIR LABORAT B, V1, P289; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; TAINSKY MA, 1995, CANCER METAST REV, V14, P43, DOI 10.1007/BF00690210; TEITZ T, 1987, P NATL ACAD SCI USA, V84, P8801, DOI 10.1073/pnas.84.24.8801; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	42	315	321	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28073	28080		10.1074/jbc.272.44.28073	http://dx.doi.org/10.1074/jbc.272.44.28073			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346961	hybrid			2022-12-27	WOS:A1997YD47300087
J	Jump, DB; Badin, MV; Thelen, A				Jump, DB; Badin, MV; Thelen, A			The CCAAT box binding factor, NF-Y, is required for thyroid hormone regulation of rat liver S14 gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; RESPONSE ELEMENTS; PRIMARY HEPATOCYTES; SYNERGISTIC ACTION; SEQUENCE IDENTITY; RECEPTOR-BETA; YEAST HAP2; CLASS-II; PROMOTER; PROTEIN	Triiodothyronine (T-3) activates rat liver S14 gene transcription through T-3 receptors (TR beta) binding distal thyroid hormone response elements located between -2.8 and -2.5 kilobase pairs upstream from the transcription start site. Previous studies suggested that proximal promoter elements located between -220 to -80 base pairs upstream from the 5' end of the S14 gene were involve din hormone activation of the S14 gene. This report identifies an inverted CCAAT box (or Y box) at (-104)ATTGG(-100) as a core cis-regulatory element. Gel shift studies using rat liver nuclear proteins show that at least three CCAAT-binding factors interact with this region as follows: NF-Y and c/EBP-related proteins formed major complexes, whereas NF-1/CTF forms a minor complex in gel shift assay. Mutation of the Y box indicated that loss of NF-Y binding, but not c/EBP or NF-1, correlated closely with a decline in basal activity and a loss of T-3-mediated transactivation. Substitution of the S14 Y box in reporter genes with elements binding only NF-Y elevated basal activity and T-3-mediated transactivation, whereas substitution with elements binding c/EBP-related proteins or SP1 displayed low basal activity and T-3-mediated transactivation. These studies indicate that NF-Y and TR beta functionally interact to confer T-3 control to the S14 gene.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University	Jump, DB (corresponding author), MICHIGAN STATE UNIV,DEPT PHYSIOL,E LANSING,MI 48824, USA.				NIDDK NIH HHS [R01 DK043220, DK43220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BRENT GA, 1989, J BIOL CHEM, V264, P178; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DESVERGNE B, 1991, J BIOL CHEM, V266, P1088; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; JUMP DB, 1988, J BIOL CHEM, V263, P7254; JUMP DB, 1986, ENDOCRINOLOGY, V118, P1892, DOI 10.1210/endo-118-5-1892; JUMP DB, 1990, MOL ENDOCRINOL, V4, P1655, DOI 10.1210/mend-4-11-1655; JUMP DB, 1989, J BIOL CHEM, V264, P4698; KAMIE Y, 1996, CELL, V85, P403; LEPAR GJ, 1989, MOL ENDOCRINOL, V3, P1207, DOI 10.1210/mend-3-8-1207; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; MACDOUGALD OA, 1992, BIOCHEM BIOPH RES CO, V182, P631, DOI 10.1016/0006-291X(92)91779-P; MACDOUGALD OA, 1992, BIOCHEM BIOPH RES CO, V188, P470, DOI 10.1016/0006-291X(92)92408-P; MACDOUGALD OA, 1990, BIOCHEM J, V280, P761; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; ONATE SA, 1995, SCIENCE, V270, P1354; Osawa H, 1996, J BIOL CHEM, V271, P17296, DOI 10.1074/jbc.271.29.17296; PARK EA, 1995, BIOCHEM J, V309, P913, DOI 10.1042/bj3090913; Park EA, 1997, BIOCHEM J, V322, P343, DOI 10.1042/bj3220343; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SUDO Y, 1994, ENDOCRINOLOGY, V134, P2532, DOI 10.1210/en.134.6.2532; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; TONE Y, 1994, J BIOL CHEM, V269, P31157; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VOZ ML, 1992, MOL CELL BIOL, V12, P3991, DOI 10.1128/MCB.12.9.3991; VUORIO T, 1990, J BIOL CHEM, V265, P22480; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; YAMAMOTO T, 1980, P NATL ACAD SCI-BIOL, V77, P176, DOI 10.1073/pnas.77.1.176; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	59	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27778	27786		10.1074/jbc.272.44.27778	http://dx.doi.org/10.1074/jbc.272.44.27778			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346922	hybrid			2022-12-27	WOS:A1997YD47300048
J	McCormack, FX; Pattanajitvilai, S; Stewart, J; Possmayer, F; Inchley, K; Voelker, DR				McCormack, FX; Pattanajitvilai, S; Stewart, J; Possmayer, F; Inchley, K; Voelker, DR			The Cys(6) intermolecular disulfide bond and the collagen-like region of rat SP-A play critical roles in interactions with alveolar type II cells and surfactant lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; PULMONARY SURFACTANT; PHOSPHOLIPID SECRETION; HIGH-AFFINITY; LUNG; APOPROTEIN; RECEPTOR; DOMAINS; GENE; PHOSPHATIDYLCHOLINE	Rat pulmonary surfactant protein A is an oligomer of 18 polypeptide chains which are associated by triple helix formation in the collagen-like domain and interchain disulfide bridges at the NH2 terminus. The roles of the intermolecular bond at Cys(6) and the collagen-like domain (Gly(8)-Pro(80)) in the interactions of SP-A with phospholipids and alveolar type II cells were investigated using mutant forms of the protein. Wild type SP-A (SP-A(hyp)), SP-A with the substitution Cys(6) --> Ser to prevent disulfide formation (SP-A(hyp,C6S)), and SP-A with the collagen-domain deleted (SP-A(Delta G8-P80)) were synthesized sized in insect cells using recombinant baculoviruses. The SP-As were glycosylated and secreted from the invertebrate cells and the binding affinities of the wild type and mutant proteins for the mannose-Sepharose matrix used for purification were nearly identical. The SP-A(hyp) and SP-A(Delta G8-P80) were at least nonameric in solution based on gel exclusion chromatography, and demonstrated extensive sulfhydryl-dependent oligomerization under nonreducing conditions. The SP-A(hyp,C6S) was also oligomeric in solution and formed disulfide-dependent dimers, indicating the presence of at least one additional interchain disulfide bond. The SP-A(Delta G8-P80) but not the SP-A(hyp,C6S) aggregated lipid vesicles at 20 degrees C and augmented the surface tension lowering effect of extracts of natural surfactant. The SP-A(Delta G8-P80) competed poorly with native SP-A for receptor occupancy on isolated alveolar type II cells and was a potent but nonspecific (concanavalin A-like) inhibitor of surfactant secretion. In contrast, the SP-A(hyp,C6S) partially competed for receptor occupancy and weakly inhibited surfactant secretion in a specific manner, Neither the SP-A(Delta G8-P80) nor the SP-A(hyp,C6S) supported the association of phospholipid liposomes with type II cells. We conclude that: 1) the Cys(6) interchain disulfide bond of SP-A is required for aggregation of liposomes and for potent inhibition of surfactant secretion, 2) The collagen-like region is required for competition with I-125-SP-A for receptor occupancy and specific inhibition of surfactant secretion in the presence of competing sugars. 3) Both the NH2-terminal disulfide and the collagen-like region are required to enhance the association of phospholipid vesicles with type II cells.	NATL JEWISH MED & RES CTR,LORD & TAYLOR LAB LUNG BIOCHEM,ANNA PERAHIA ADATTO CLIN LABS,DENVER,CO 80206; NATL JEWISH MED & RES CTR,DEPT MED,DENVER,CO 80206; UNIV WESTERN ONTARIO,DEPT OBSTET & GYNECOL,LONDON,ON N6A 5A5,CANADA; UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON,ON N6A 5A5,CANADA; UNIV WESTERN ONTARIO,MRC,GRP FETAL & NEONATAL HLTH & DEV,LONDON,ON N6A 5A5,CANADA; UNIV CINCINNATI,DEPT MED,DIV PULM & CRIT CARE MED,CINCINNATI,OH 45267	National Jewish Health; National Jewish Health; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Cincinnati			McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464	NHLBI NIH HHS [HL-29891, HL-45286] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045286, R37HL029891, R01HL029891] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENSON B, 1985, P NATL ACAD SCI USA, V82, P6379, DOI 10.1073/pnas.82.19.6379; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375, DOI 10.1074/jbc.271.27.16375; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DOBBS LG, 1978, AM REV RESPIR DIS, V118, P705, DOI 10.1164/arrd.1978.118.4.705; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Elhalwagi BM, 1997, BIOCHEMISTRY-US, V36, P7018, DOI 10.1021/bi970100q; ENHORNING G, 1977, J APPL PHYSIOL, V43, P198, DOI 10.1152/jappl.1977.43.2.198; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GAYNOR C, 1994, J IMMUNOL, V155, P5343; Goerke J., 1986, HDB PHYSL RESP SYSTE, P247; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL442; HANIU M, 1994, ARCH BIOCHEM BIOPHYS, V310, P433, DOI 10.1006/abbi.1994.1189; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KING RJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P294, DOI 10.1016/0005-2760(89)90114-8; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KUROKI Y, 1991, BIOCHEM INT, V24, P225; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCORMACK FX, 1990, BIOCHIM BIOPHYS ACTA, V1087, P190, DOI 10.1016/0167-4781(90)90204-F; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P8092, DOI 10.1021/bi970313f; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; MURATA Y, 1993, BIOCHEM J, V291, P71, DOI 10.1042/bj2910071; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V969, P176, DOI 10.1016/0167-4889(88)90073-0; PIKAAR JC, 1995, J INFECT DIS, V172, P481, DOI 10.1093/infdis/172.2.481; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; ROSS GF, 1991, BIOCHEMISTRY-US, V30, P858, DOI 10.1021/bi00217a040; ROSS GF, 1986, J BIOL CHEM, V261, P14283; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; VOELKER DR, 1989, LUNG CELL BIOL, P487; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; YUKITAKE K, 1995, PEDIATR RES, V37, P21, DOI 10.1203/00006450-199501000-00005	52	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27971	27979		10.1074/jbc.272.44.27971	http://dx.doi.org/10.1074/jbc.272.44.27971			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346948	hybrid			2022-12-27	WOS:A1997YD47300074
J	Pal, S; Claffey, KP; Dvorak, HF; Mukhopadhyay, D				Pal, S; Claffey, KP; Dvorak, HF; Mukhopadhyay, D			The von Hippel-Lindau gene product inhibits vascular permeability factor vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; GERMLINE MUTATIONS; RAS ONCOGENES; ANGIOGENESIS; ACTIVATION; IDENTIFICATION; RECEPTORS; INDUCTION; MITOGEN; PHENOTYPE	Mutation or loss of function of the von Hippel-Lindau (VHL) tumor suppressor gene is regularly found in sporadic renal cell carcinomas (RCC), well vascularized malignant tumors that characteristically overexpress vascular permeability factor/vascular endothelial growth factor (VPF/VEGF). The wild-type VHL (wt VHL) gene product acts to suppress VPF/VEGF expression, which is overexpressed when wt-VHL is inactive. The present study investigated the pathways by which VHL regulates VPF/VEGF expression, We found that inhibition of protein kinase C (PKC) represses VPF/VEGF expression in RCC cells that regularly overexpress VPF/VEGF. The wt-VHL expressed by stably transfected RCC cells forms cytoplasmic complexes with two specific PKC isoforms, xi and delta, and prevents their translocation to the cell membrane where they otherwise would engage in signaling steps that lead to VPF/VEGF overexpression. Other experiments implicated mitogen-activated protein kinase (MAPK) phosphorylation as a downstream step in PKC regulation of VPF/VEGF expression. Taken together, these data demonstrate that wt-VHL, by neutralizing PKC isoforms xi and delta and thereby inhibiting MAPK activation, plays an important role in preventing aberrant VPF/VEGF overexpression and the angiogenesis that results from such overexpression.	BETH ISRAEL DEACONESS MED CTR,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R29CA064436, R01CA064436, R01CA050453] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054465] Funding Source: NIH RePORTER; NCI NIH HHS [CA50453, CA64436] Funding Source: Medline; NHLBI NIH HHS [HL54465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARENZANASEISDED.F, 1989, ONCOGENE, V2, P1359; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BROWN LF, 1993, AM J PATHOL, V143, P1255; CHEN F, 1995, CANCER RES, V55, P4804; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSSEY PA, 1994, HUM GENET, V93, P53; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; FUJITA J, 1988, CANCER RES, V48, P5251; GNARRA JR, 1993, UROL CLIN N AM, V20, P207; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1997, KIDNEY INT, V51, P575, DOI 10.1038/ki.1997.82; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; OKA H, 1995, CANCER RES, V55, P4182; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RAK J, 1995, CANCER RES, V55, P4575; RICHARDS FM, 1995, HUM MOL GENET, V4, P2139, DOI 10.1093/hmg/4.11.2139; RICHARDS FM, 1993, HUM MOL GENET, V2, P879, DOI 10.1093/hmg/2.7.879; RICHARDS FM, 1993, J MED GENET, V30, P104, DOI 10.1136/jmg.30.2.104; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TAKAHASHI A, 1994, CANCER RES, V54, P4233; UCHIDA T, 1994, CANCER RES, V54, P3682; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Watts SW, 1996, J PHARMACOL EXP THER, V279, P1541; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358	38	132	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27509	27512		10.1074/jbc.272.44.27509	http://dx.doi.org/10.1074/jbc.272.44.27509			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346879	hybrid			2022-12-27	WOS:A1997YD47300005
J	Smith, CL; Hager, GL				Smith, CL; Hager, GL			Transcriptional regulation of mammalian genes in vivo - A tale of two templates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TUMOR VIRUS PROMOTER; HUMAN ALPHA-1-ANTITRYPSIN GENE; BETA-GLOBIN LOCUS; MMTV PROMOTER; CHROMATIN STRUCTURE; RETINOIC ACID; CELL HYBRIDS; IN-VIVO; DNA; ACTIVATION		NCI,LAB RECEPTOR BIOL & GENE EXPRESS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P865, DOI 10.1093/nar/20.4.865; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BULLA GA, 1992, GENE DEV, V6, P316, DOI 10.1101/gad.6.2.316; CANNON P, 1994, J VIROL, V68, P1993, DOI 10.1128/JVI.68.3.1993-1997.1994; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; CHIN AC, 1987, P NATL ACAD SCI USA, V84, P1614, DOI 10.1073/pnas.84.6.1614; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DANNA KJ, 1982, J VIROL METHODS, V5, P335, DOI 10.1016/0166-0934(82)90025-8; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DUAN LX, 1994, VIROLOGY, V199, P474, DOI 10.1006/viro.1994.1148; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; Fragoso G, 1997, METHODS, V11, P246, DOI 10.1006/meth.1996.0411; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PEARSON SJ, 1983, SOMAT CELL GENET, V9, P567, DOI 10.1007/BF01574259; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; RICHARDFOY H, 1987, MOL ENDOCRINOL, V1, P659, DOI 10.1210/mend-1-9-659; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROBERTS MS, 1995, BIOCHEMISTRY-US, V34, P12470, DOI 10.1021/bi00038a046; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; TONEGUZZO F, 1986, MOL CELL BIOL, V6, P703, DOI 10.1128/MCB.6.2.703; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0	47	215	218	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27493	27496		10.1074/jbc.272.44.27493	http://dx.doi.org/10.1074/jbc.272.44.27493			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346875	hybrid			2022-12-27	WOS:A1997YD47300001
J	Takagi, Y; Pause, A; Conaway, RC; Conaway, JW				Takagi, Y; Pause, A; Conaway, RC; Conaway, JW			Identification of Elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR-SIII; ELONGATION; ACTIVATION; COMPLEX	Elongin C is a 112-amino acid protein that is found in mammalian cells as a positive regulatory subunit of heterotrimeric RNA polymerase ll elongation factor Elongin (Sill) and as a component of a multiprotein complex containing the von Hippel-Lindau (VHL) tumor suppressor protein, As a subunit of the Elongin complex, Elongin C interacts directly with the transcriptionally active Elongin A subunit and potently induces its elongation activity; in addition, Elongin C interacts with the ubiquitin-like Elongin B subunit, which regulates the interaction of Elongin C with Elongin A, As a component of the VHL complex, Elongin C interacts directly with both Elongin B and the VHL, protein. Binding of the VHL protein to Elongin C was found to prevent Elongin C from interacting with and activating. Elongin A in vitro, leading to the proposal that one function of the VHL protein may be to regulate RNA polymerase II elongation by negatively regulating the Elongin complex. In this report, we identify Elongin C sequences required for its interaction with the VHL protein, We previously demonstrated that the ability of Elongin C to hind and activate Elongin A is sensitive to mutations in the C-terminal half of Elongin C, as well as to mutations in an N-terminal Elongin C region needed for formation of the Elongin BC complex. Here we show that interaction of Elongin C with the VHL tumor suppressor protein depends strongly on sequences in the C terminus of Elongin C but is independent of the N-terminal Elongin C region required for binding to Elongin B and for binding and activation of Elongin A. Taken together, our results are consistent with the proposal that the VHL protein negatively regulates Elongin C activation of the Elongin complex by sterically blocking the interaction of C-terminal Elongin C sequences with Elongin A. In addition, our finding that only a subset of Elongin C sequences required for its interaction with Elongin A are critical for binding to VHL may offer the opportunity to develop reagents that selectively interfere with Elongin and VHL function.	OKLAHOMA MED RES FDN,PROGRAM MOL & CELL BIOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,OKLAHOMA CITY,OK 73190; NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Pause A, 1996, METHOD ENZYMOL, V274, P436; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Takagi Y, 1996, J BIOL CHEM, V271, P25562, DOI 10.1074/jbc.271.41.25562; TAN SY, 1994, BIOTECHNIQUES, V16, P824	17	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27444	27449		10.1074/jbc.272.43.27444	http://dx.doi.org/10.1074/jbc.272.43.27444			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341197	hybrid			2022-12-27	WOS:A1997YC65900093
J	Comte, B; Vincent, G; Bouchard, B; Jette, M; Cordeau, S; DesRosiers, C				Comte, B; Vincent, G; Bouchard, B; Jette, M; Cordeau, S; DesRosiers, C			A C-13 mass isotopomer study of anaplerotic pyruvate carboxylation in perfused rat hearts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ACETYL-COA CARBOXYLASE; SUBSTRATE SELECTION; NMR-SPECTROSCOPY; CYCLE METABOLITES; GLUCOSE-OXIDATION; GLOBAL-ISCHEMIA; MALIC ENZYMES; WORKING HEART; CARBON FLUX	Anaplerotic pyruvate carboxylation was examined in hearts perfused with physiological concentrations of glucose, [U-C-13(3)]lactate, and [U-C-13(3)]pyruvate. Also, a fatty acid, [1-C-13]octanoate, or ketone bodies were added at concentrations providing acetyl-CoA at a rate resulting in either low or substantial pyruvate decarboxylation. Relative contributions of pyruvate and fatty acids to citrate synthesis were determined from the C-13 labeling pattern of effluent citrate by gas chromatography-mass spectrometry (see companion article, Comte, B., Vincent, G., Bouchard, B., and Des Rosiers, C. (1997) J. Biol. Chem, 272, 26117-26124). Precision on flux measurements of anaplerotic pyruvate carboxylation depended on the mix of substrates supplied to the heart. Anaplerotic fluxes were precisely determined under conditions where acetyl-CoA was predominantly supplied by beta-oxidation, as it occurred with 0.2 or 1 mM octanoate, Then, anaplerotic pyruvate carboxylation provided 3-8% of the OAA moiety of citrate and was modulated by concentrations of lactate and pyruvate in the physiological range, Also, the contribution of pyruvate to citrate formation through carboxylation was equal to or greater than through decarboxylation. Furthermore, C-13 labeling data on tissue citric acid cycle intermediates and pyruvate suggest that (i) anaplerosis occurs also at succinate and (ii) cataplerotic malate decarboxylation is low, Rather, the presence of citrate in the effluent perfusate of hearts perfused with physiological concentrations of glucose, lactate, and pyruvate and concentrations of octanoate leading to maximal oxidative rates suggests a cataplerotic citrate efflux from mitochondria to cytosol. Taken altogether, our data raise the possibility of a link between pyruvate carboxylation and mitochondrial citrate efflux. In view of the proposed feedback regulation of glycolysis by cytosolic citrate, such a link would support a role of anaplerosis and cataplerosis in metabolic signal transmission between mitochondria and cytosol in the normoxic heart.	UNIV MONTREAL, DEPT NUTR, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, DEPT BIOCHEM, MONTREAL, PQ H3C 3J7, CANADA	Universite de Montreal; Universite de Montreal			Rosiers, Christine Des/O-6285-2014					ATTWOOD PV, 1995, INT J BIOCHEM CELL B, V27, P231, DOI 10.1016/1357-2725(94)00087-R; BARRON JT, 1994, AM J PHYSIOL, V267, pH764, DOI 10.1152/ajpheart.1994.267.2.H764; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, P1836; BRUNET J, 1995, FREE RADICAL BIO MED, V19, P627, DOI 10.1016/0891-5849(95)00077-B; BUNGER R, 1989, EUR J BIOCHEM, V180, P221, DOI 10.1111/j.1432-1033.1989.tb14637.x; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CHATHAM JC, 1995, J BIOL CHEM, V270, P7999, DOI 10.1074/jbc.270.14.7999; CLARK AS, 1987, J CLIN INVEST, V79, P588, DOI 10.1172/JCI112851; COHEN DM, 1995, AM J PHYSIOL-ENDOC M, V268, pE397, DOI 10.1152/ajpendo.1995.268.3.E397; Comte B, 1997, J BIOL CHEM, V272, P26117, DOI 10.1074/jbc.272.42.26117; COMTE B, 1995, CIRCULATION, V92, P3703; COMTE B, 1997, FASEB J, V11, P268; DESROSIERS C, 1990, AM J PHYSIOL, V258, pE519, DOI 10.1152/ajpendo.1990.258.3.E519; FINK G, 1988, J BIOL CHEM, V263, P18036; FORSEY RGP, 1987, CAN J PHYSIOL PHARM, V65, P401, DOI 10.1139/y87-067; GAMBLE J, 1994, BBA-MOL BASIS DIS, V1225, P191, DOI 10.1016/0925-4439(94)90078-7; GARLAND PB, 1963, NATURE, V200, P169, DOI 10.1038/200169a0; GAVVA SR, 1994, BIOCHEM J, V303, P847, DOI 10.1042/bj3030847; GOODWIN GW, 1994, AM J PHYSIOL, V267, pH462, DOI 10.1152/ajpheart.1994.267.2.H462; HILTUNEN JK, 1977, INT J BIOCHEM, V8, P505, DOI 10.1016/0020-711X(77)90112-4; ICHIHARA K, 1980, AM J PHYSIOL, V239, pE430, DOI 10.1152/ajpendo.1980.239.6.E430; Jeffrey FMH, 1996, AM J PHYSIOL-ENDOC M, V271, pE788, DOI 10.1152/ajpendo.1996.271.4.E788; JEFFREY FMH, 1995, BASIC RES CARDIOL, V90, P388, DOI 10.1007/BF00788500; JESSEN ME, 1993, J CLIN INVEST, V92, P831, DOI 10.1172/JCI116657; LANCHA AH, 1994, BIOCHEM MOL BIOL INT, V32, P483; LANOUE K, 1970, J BIOL CHEM, V245, P102; Laplante A, 1997, AM J PHYSIOL-ENDOC M, V272, pE74, DOI 10.1152/ajpendo.1997.272.1.E74; LAPLANTE A, 1995, ANAL BIOCHEM, V224, P580, DOI 10.1006/abio.1995.1090; LATIPAA PM, 1983, BIOCHIM BIOPHYS ACTA, V752, P162, DOI 10.1016/0005-2760(83)90244-8; LERCH R, 1993, BASIC RES CARDIOL, V88, P525, DOI 10.1007/BF00788872; LEWANDOWSKI ED, 1995, CIRCULATION, V91, P2071, DOI 10.1161/01.CIR.91.7.2071; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; LIN RC, 1974, J BIOL CHEM, V249, P3867; LOPASCHUK GD, 1990, CIRC RES, V66, P546, DOI 10.1161/01.RES.66.2.546; LOPASCHUK GD, 1994, CAN J PHYSIOL PHARM, V72, P1101, DOI 10.1139/y94-156; MALLET RT, 1990, EUR J BIOCHEM, V188, P481, DOI 10.1111/j.1432-1033.1990.tb15426.x; MALLOY CR, 1987, FEBS LETT, V212, P58, DOI 10.1016/0014-5793(87)81556-9; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MARKOVITZ LJ, 1985, J SURG RES, V38, P231, DOI 10.1016/0022-4804(85)90031-9; MCVEIGH JJ, 1990, AM J PHYSIOL, V259, pH1079, DOI 10.1152/ajpheart.1990.259.4.H1079; MONTGOMERY JA, 1993, BIOCHEM J, V294, P727, DOI 10.1042/bj2940727; NUUTINEN EM, 1981, BIOCHEM J, V194, P867, DOI 10.1042/bj1940867; PEUHKURINEN KJ, 1984, J MOL CELL CARDIOL, V16, P487, DOI 10.1016/S0022-2828(84)80637-9; PEUHKURINEN KJ, 1982, BIOCHEM J, V202, P67, DOI 10.1042/bj2020067; PEUHKURINEN KJ, 1982, BIOCHEM J, V208, P577, DOI 10.1042/bj2080577; PEUHKURINEN KJ, 1983, AM J PHYSIOL, V244, pH281, DOI 10.1152/ajpheart.1983.244.2.H281; PISARENKO O, 1988, BIOCHIM BIOPHYS ACTA, V934, P55, DOI 10.1016/0005-2728(88)90119-3; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Reed L J, 1981, Curr Top Cell Regul, V18, P95; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; ROSIERS CD, 1988, ANAL BIOCHEM, V173, P96, DOI 10.1016/0003-2697(88)90165-0; RUSSELL RR, 1991, AM J PHYSIOL, V261, pH1756, DOI 10.1152/ajpheart.1991.261.6.H1756; SADDIK M, 1993, J BIOL CHEM, V268, P25836; Saha AK, 1997, AM J PHYSIOL-ENDOC M, V272, pE641, DOI 10.1152/ajpendo.1997.272.4.E641; SCHULZ H, 1994, J NUTR, V124, P165, DOI 10.1093/jn/124.2.165; SLUSE FE, 1971, FEBS LETT, V18, P149, DOI 10.1016/0014-5793(71)80432-5; STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6; SUNDQVIST KE, 1987, BIOCHEM J, V243, P853, DOI 10.1042/bj2430853; SUNDQVIST KE, 1989, BIOCHEM J, V257, P913, DOI 10.1042/bj2570913; SUNDQVIST KE, 1994, EUR HEART J, V15, P561, DOI 10.1093/oxfordjournals.eurheartj.a060543; TAEGTMEYER H, 1978, CIRC RES, V43, P808, DOI 10.1161/01.RES.43.5.808; TAKALA T, 1980, BIOCHEM J, V192, P285, DOI 10.1042/bj1920285; Utter MF, 1969, CURR TOP CELL REGUL, V1, P253, DOI [10.1016/B978-0-12-152801-0.50015-8, DOI 10.1016/B978-0-12-152801-0.50015-8]; VINCENT G, 1997, FASEB J, V11, P269; WEISS RG, 1989, P NATL ACAD SCI USA, V86, P6426, DOI 10.1073/pnas.86.16.6426; WEISS RG, 1993, CIRCULATION, V87, P270, DOI 10.1161/01.CIR.87.1.270; WIESNER RJ, 1988, BIOCHEM MED METAB B, V40, P19, DOI 10.1016/0885-4505(88)90100-4	67	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26125	26131		10.1074/jbc.272.42.26125	http://dx.doi.org/10.1074/jbc.272.42.26125			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334177	hybrid			2022-12-27	WOS:A1997YB13900011
J	ElSayed, NMA; Donelson, JE				ElSayed, NMA; Donelson, JE			African trypanosomes have differentially expressed genes encoding homologues of the Leishmania GP63 surface protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-I; PROTEINASE GP63; HERPETOMONAS-SAMUELPESSOAI; CUTANEOUS LEISHMANIASIS; DONOVANI PROMASTIGOTES; CRITHIDIA-FASCICULATA; CHAGASI PROMASTIGOTES; ANTIGENIC VARIATION; POINT MUTATIONS; CODING GENES	The genomes of various Leishmania parasites contain tandemly arrayed genes encoding an abundant; 63-kDa surface glycoprotein called GP63. Leishmania GP63s are metalloproteases that play an important role in the invasion and survival of the parasites within the macro phage, and their presence on the Leishmania surface has been correlated with resistance to complement;mediated lysis, Here we report the identification of GP63-like genes in African trypanosomes. The predicted trypanosome and Leishmania GP63s share a metalloprotease catalytic site motif of HEXXH as well as 19 cysteines and 10 prolines, implying a conservation of enzymatic activity and secondary/tertiary structure. The trypanosome GP63 genes are. transcribed equally in procyclic and bloodstream trypanosomes, but their mRNAs accumulate to a 50-fold higher steady state level in bloodstream trypanosomes, where the ratio of mRNAs for GP63 and variant surface glycoprotein is about 1:150. Transcription of the GP63 genes is sensitive to alpha-amanitin, indicating that they are transcribed by a different polymerase than the variant, surface glycoprotein genes, These results lead to a reconsideration of the potential functions of GP63, inasmuch as African trypanosomes are not known to interact with macrophages and do not have an intracellular stage during their life cycle.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa			Donelson, John E/F-5795-2010; El-Sayed, Najib M.A./K-7266-2015	El-Sayed, Najib M.A./0000-0001-7970-3312	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032135, R21AI032135] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32135] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOLARIN MO, 1986, T ROY SOC TROP MED H, V80, P618, DOI 10.1016/0035-9203(86)90160-4; ABOLARIN MO, 1982, BRIT MED J, V285, P1380, DOI 10.1136/bmj.285.6352.1380; ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BERBEROF M, 1995, EMBO J, V14, P2925, DOI 10.1002/j.1460-2075.1995.tb07292.x; BORDIER C, 1987, PARASITOL TODAY, V3, P151, DOI 10.1016/0169-4758(87)90199-2; BORST P, 1994, SCIENCE, V264, P1872, DOI 10.1126/science.7516579; BOUVIER J, 1990, BIOCHEMISTRY-US, V29, P10113, DOI 10.1021/bi00495a015; BOUVIER J, 1995, METHOD ENZYMOL, V248, P614; BRITTINGHAM A, 1995, J IMMUNOL, V155, P3102; CARVALHO E. B., 1977, Revista Goiana de Medicina, V23, P41; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; CHAUDHURI G, 1989, J BIOL CHEM, V264, P7483; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON CE, 1992, PROGR NUCLEIC ACID R, P37; CONNELL ND, 1993, P NATL ACAD SCI USA, V90, P11473, DOI 10.1073/pnas.90.24.11473; COQUELET H, 1989, MOL CELL BIOL, V9, P4022, DOI 10.1128/MCB.9.9.4022; COQUELET H, 1991, MOL BIOCHEM PARASIT, V44, P33, DOI 10.1016/0166-6851(91)90218-U; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P93; DEVINE DV, 1986, INFECT IMMUN, V52, P223, DOI 10.1128/IAI.52.1.223-229.1986; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; ElSayed NMA, 1997, MOL BIOCHEM PARASIT, V84, P167, DOI 10.1016/S0166-6851(96)02792-2; EMINI EA, 1983, NATURE, V304, P699, DOI 10.1038/304699a0; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; ETGES R, 1986, EMBO J, V5, P597, DOI 10.1002/j.1460-2075.1986.tb04252.x; ETGES R, 1992, ACTA TROP, V50, P205, DOI 10.1016/0001-706X(92)90077-B; FERNANDES AP, 1993, P NATL ACAD SCI USA, V90, P11608, DOI 10.1073/pnas.90.24.11608; FONG D, 1982, P NATL ACAD SCI-BIOL, V79, P7366, DOI 10.1073/pnas.79.23.7366; GHEORGHIU M, 1995, MICROBIOLOGY, V141, P1585; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; INVERSO JA, 1993, MOL BIOCHEM PARASIT, V57, P47, DOI 10.1016/0166-6851(93)90242-P; LANDWEBER LF, 1994, P NATL ACAD SCI USA, V91, P918, DOI 10.1073/pnas.91.3.918; LEPAY DA, 1983, J EXP MED, V157, P1562, DOI 10.1084/jem.157.5.1562; LIU X, 1992, P NATL ACAD SCI USA, V89, P4991, DOI 10.1073/pnas.89.11.4991; LU Y, 1994, MOL CELL BIOL, V14, P3971, DOI 10.1128/MCB.14.6.3971; LU Y, 1993, CELL, V72, P397, DOI 10.1016/0092-8674(93)90116-8; MCGWIRE B, 1994, MOL BIOCHEM PARASIT, V66, P345, DOI 10.1016/0166-6851(94)90160-0; McGwire BS, 1996, J BIOL CHEM, V271, P7903, DOI 10.1074/jbc.271.14.7903; MEDINAACOSTA E, 1993, INFECT AGENT DIS, V2, P25; Morgan RW, 1996, J BIOL CHEM, V271, P9771, DOI 10.1074/jbc.271.16.9771; MOSSER DM, 1982, EXP PARASITOL, V54, P310, DOI 10.1016/0014-4894(82)90040-6; OLOBO JO, 1995, VET PARASITOL, V60, P199, DOI 10.1016/0304-4017(95)00788-6; ORMEROD WE, 1986, T ROY SOC TROP MED H, V80, P626, DOI 10.1016/0035-9203(86)90161-6; PAYS E, 1990, EMBO J, V9, P3145, DOI 10.1002/j.1460-2075.1990.tb07512.x; PEARSON RD, 1983, REV INFECT DIS, V5, P907; PUENTES SM, 1989, J IMMUNOL, V143, P3743; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; ROBERTS SC, 1993, MOL BIOCHEM PARASIT, V62, P157, DOI 10.1016/0166-6851(93)90106-8; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; RUDENKO G, 1989, EMBO J, V8, P4259, DOI 10.1002/j.1460-2075.1989.tb08611.x; SALLES JM, 1996, MEM I OSWALDO CRUZ S, V91, P269; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER P, 1993, MOL BIOCHEM PARASIT, V58, P277, DOI 10.1016/0166-6851(93)90049-4; SOTERIADOU KP, 1992, J BIOL CHEM, V267, P13980; STEINKRAUS HB, 1993, MOL BIOCHEM PARASIT, V62, P173, DOI 10.1016/0166-6851(93)90107-9; SZARFMAN A, 1981, AM J TROP MED HYG, V30, P43, DOI 10.4269/ajtmh.1981.30.43; TURNER MJ, 1985, BRIT MED BULL, V41, P137, DOI 10.1093/oxfordjournals.bmb.a072040; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VICKERMAN K, 1988, BIOL CELL, V64, P109, DOI 10.1016/0248-4900(88)90070-6; WALLACE FG, 1966, EXP PARASITOL, V18, P124, DOI 10.1016/0014-4894(66)90015-4; WEIDER MK, 1989, PARASITE IMMUNOL, V11, P197; XU D, 1995, IMMUNOLOGY, V85, P1; YANG DM, 1990, J IMMUNOL, V145, P2281; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0	68	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26742	26748		10.1074/jbc.272.42.26742	http://dx.doi.org/10.1074/jbc.272.42.26742			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334260	hybrid			2022-12-27	WOS:A1997YB13900094
J	Huang, XD; Atwood, CS; Moir, RD; Hartshorn, MA; Vonsattel, JP; Tanzi, RE; Bush, AI				Huang, XD; Atwood, CS; Moir, RD; Hartshorn, MA; Vonsattel, JP; Tanzi, RE; Bush, AI			Zinc-induced Alzheimer's A beta 1-40 aggregation is mediated by conformational factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMYLOID PEPTIDES; PROTEIN-PRECURSOR; CORTICAL-NEURONS; DISEASE BRAINS; NEUROTOXICITY; DEPOSITION; PATHOGENESIS; FRAGMENTS; PLATELETS; CLEAVAGE	The heterogeneous precipitates of A beta that accumulate in the brain cortex in Alzheimer's disease possess varying degrees of resistance to resolubilization. We previously found that A beta 1-40 is rapidly precipitated in vitro by physiological concentrations of zinc, a neurochemical that is highly abundant in brain compartments where A beta is most likely to precipitate. We now present evidence that the zinc-induced precipitation of A beta is mediated by a peptide dimer and favored by conditions that promote alpha-helical and diminish beta-sheet conformations. The manner in which the synthetic peptide is solubilized was critical to its behavior in vitro. Zinc-induced A beta aggregation was dependent upon the presence of NaCl, was enhanced when the peptide stock solution was stored frozen. The A beta aggregates induced by zinc were reversible by chelation, but could then be reprecipitated by zinc for several cycles, indicating that the peptide's conformation is probably preserved in the zinc-mediated assembly. In contrast, A beta aggregates induced by low pH (5.5) were not resolubilized by returning the pH milieu to 7.4. The zinc-A beta interaction exhibits features resembling the gelation process of zinc-mediated fibrin assembly, suggesting that, in events such as clot formation or injury, reversible A beta assembly could be physiologically purposive. Such a mechanism is contemplated in the early evolution of diffuse plaques in Alzheimer's disease and suggests a possible therapeutic strategy for the resolubilization of some forms of A beta deposit in the disease.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02114 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL, GENET & AGING UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital			Bush, Ashley/Y-2457-2019; , Craig/AAB-3963-2022; Moir, Robert D./M-7612-2017; Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley I/A-1186-2007	Bush, Ashley/0000-0001-8259-9069; Moir, Robert D./0000-0001-5431-3553; Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley I/0000-0001-8259-9069	NIA NIH HHS [1R29AG126801] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1992, NEUROBIOL AGING, V13, P609, DOI 10.1016/0197-4580(92)90065-6; BUSH AI, 1995, SCIENCE, V268, P1921, DOI 10.1126/science.268.5219.1921; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; BUSH AI, 1990, J BIOL CHEM, V265, P15977; BUSH AI, 1994, J BIOL CHEM, V269, P26618; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CHEN M, 1995, BIOCHEM BIOPH RES CO, V213, P96, DOI 10.1006/bbrc.1995.2103; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 1996, J NEUROCHEM, V66, P723; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; Kuo YM, 1996, J BIOL CHEM, V271, P4077; MACKENZIE I, 1993, J NEUROPATH EXP NEUR, V52, P335, DOI 10.1097/00005072-199305000-00300; MARX G, 1987, THROMB HAEMOSTASIS, V57, P73; MARX G, 1993, J CELL PHYSIOL, V156, P437, DOI 10.1002/jcp.1041560302; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; OTVOS L, 1993, EUR J BIOCHEM, V211, P249, DOI 10.1111/j.1432-1033.1993.tb19893.x; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1991, EUR J PHARM-MOLEC PH, V207, P367, DOI 10.1016/0922-4106(91)90014-9; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROHER AE, 1991, BIOCHEM BIOPH RES CO, V174, P572, DOI 10.1016/0006-291X(91)91455-L; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEN CL, 1994, BIOPHYS J, V67, P1238, DOI 10.1016/S0006-3495(94)80593-4; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SHEN CL, 1993, BIOPHYS J, V65, P2383, DOI 10.1016/S0006-3495(93)81312-2; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; THOLEY G, 1988, NEUROCHEM RES, V13, P45, DOI 10.1007/BF00971853; VANNOSTRAND WE, 1995, THROMB RES, V78, P43, DOI 10.1016/0049-3848(95)00033-X; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	52	303	312	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26464	26470		10.1074/jbc.272.42.26464	http://dx.doi.org/10.1074/jbc.272.42.26464			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334223	hybrid			2022-12-27	WOS:A1997YB13900057
J	Mu, D; Wakasugi, M; Hsu, DS; Sancar, A				Mu, D; Wakasugi, M; Hsu, DS; Sancar, A			Characterization of reaction intermediates of human excision repair nuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; COMPLEMENTATION GROUP-C; RNA-POLYMERASE-II; DNA-REPAIR; XERODERMA-PIGMENTOSUM; TRANSCRIPTION FACTOR; FACTOR TFIIH; DAMAGED DNA; CIS-SYN; COMPLEX	Nucleotide excision repair in humans is a complex reaction involving 14 polypeptides in six repair factors for dual incisions on either sides of a DNA lesion, To identify the reaction intermediates that form by the human excision repair nuclease, we adopted three approaches: purification of functional DNA protein complexes, permanganate footprinting, and the employment as substrate of presumptive DNA reaction intermediates containing unwound sequences 5' to, 3' to, or encompassing the DNA lesion. The first detectable reaction intermediate was formed by substrate binding of XPA, RPA, XPC.HHR23B plus TFIIH (preincision complex 1, PIC1), In this complex the DNA was unwound on either side of the lesion by no more than 10 bases. Independent of the XPG nuclease function, the XPG protein stabilized this complex, forming a long lived preincision complex 2 (PIC2). The XPF.ERCC1 complex bound to PIC2, forming PIC3, which led to dual incisions and the release of the excised oligomer, With partially unwound DNAs, thymine cyclobutane dimer was excised at a fast rate independent of XPC.HHR23B, indicating that a major function of this protein is to stabilize the unwound DNA or to aid lesion unwinding in preincision complexes.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Mu, David/E-8933-2011; Wakasugi, Mitsuo/D-8417-2015	Mu, David/0000-0002-7762-0182; Wakasugi, Mitsuo/0000-0001-9593-0566	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BARSALOU LS, 1994, MUTAT RES, V315, P43, DOI 10.1016/0921-8777(94)90027-2; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; CLUGSTON CK, 1992, CANCER RES, V52, P6375; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; FRIEDBERG EC, 1995, DNA REPAIR; Gunz D, 1996, J BIOL CHEM, V271, P25089, DOI 10.1074/jbc.271.41.25089; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; He ZG, 1997, NUCLEIC ACIDS RES, V25, P1136, DOI 10.1093/nar/25.6.1136; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hwang JR, 1996, J BIOL CHEM, V271, P15898, DOI 10.1074/jbc.271.27.15898; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; LI L, 1995, MOL CELL BIOL, V15, P1993; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Mu D, 1997, J BIOL CHEM, V272, P7570, DOI 10.1074/jbc.272.12.7570; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Mu D, 1997, PROG NUCLEIC ACID RE, V56, P63, DOI 10.1016/S0079-6603(08)61002-8; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SMITH CA, 1993, J BIOL CHEM, V268, P11143; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TAYLOR JS, 1994, ACCOUNTS CHEM RES, V27, P76, DOI 10.1021/ar00039a003; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	52	135	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28971	28979		10.1074/jbc.272.46.28971	http://dx.doi.org/10.1074/jbc.272.46.28971			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360969	Green Published, hybrid			2022-12-27	WOS:A1997YF68400028
J	Wadsworth, SJ; Gebauer, G; vanRossum, GDV; Dhanasekaran, N				Wadsworth, SJ; Gebauer, G; vanRossum, GDV; Dhanasekaran, N			Ras-dependent signaling by the GTPase-deficient mutant of G alpha(12)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NA+/H+ EXCHANGER; PHOSPHOLIPASE-C; ACTIVATION; PATHWAY; CELLS; HYDROLYSIS; TRANSDUCTION; MECHANISMS	G alpha(12) and G alpha(13) regulate diverse responses through the small GTPases Ras, CDC42, Rac, and Rho, Whereas they activate similar responses in many different cell types, they also activate more specific and critical signaling pathways in other cell types, In COS cells, in which both G alpha(12) and G alpha(13) stimulate Na+/H+ exchange, they do so by activating different signaling pathways, Here we report that the differential recruitment of specific small GTPases by G alpha(12) and G alpha(13) defines the molecular basis for their functional differences. We have observed that the stimulation of Na+/H+ exchange by the GTPase-deficient mutant of G alpha(12) (G alpha(12)QL) requires a functional Ras and is independent of Rac/CDC42 and Jun kinase signaling module. By contrast, the stimulation of Na+/H+ exchange by G alpha(13)QL requires a functional Rac/CDC42 CDC42 and the Jun kinase signaling module, Our results also indicate that G alpha(12)QL-Ras stimulation of Na+/H+ exchange involves a D609-sensitive phospholipase and protein kinase C, These studies, for the first time, describe a novel G alpha(12)-specific signaling pathway involving Has, phosphatidylcholine hydrolysis, and protein kinase C in the regulation of Na+/H+ exchange.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NIGMS NIH HHS [GM 49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARNERO A, 1994, ONCOGENE, V9, P1387; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FLIEGEL L, 1993, BIOCHEM J, V296, P273, DOI 10.1042/bj2960273; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; KISS Z, 1995, BBA-LIPID LIPID MET, V1259, P105, DOI 10.1016/0005-2760(95)00148-6; KITAMURA K, 1995, AM J PHYSIOL-CELL PH, V268, pC101, DOI 10.1152/ajpcell.1995.268.1.C101; Li YS, 1996, MOL CELL BIOL, V16, P5947; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MITSUI H, 1997, J BIOL CHEM, V22, P4904; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; vanDijk MCM, 1997, J BIOL CHEM, V272, P11011; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081	30	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28829	28832		10.1074/jbc.272.46.28829	http://dx.doi.org/10.1074/jbc.272.46.28829			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360946	hybrid			2022-12-27	WOS:A1997YF68400005
J	McMahon, GA; Garfinkel, S; Prudovsky, I; Hu, YG; Maciag, T				McMahon, GA; Garfinkel, S; Prudovsky, I; Hu, YG; Maciag, T			Communication - Intracellular precursor interleukin (IL)-1 alpha, but not mature IL-1 alpha, is able to regulate human endothelial cell migration in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; NUCLEAR-LOCALIZATION SEQUENCE; FACTOR RECEPTOR-1; FACTOR-I; C-SRC; ASSOCIATION; CORTACTIN; CLONING; PHOSPHORYLATION; IDENTIFICATION	The human umbilical vein endothelial cell (HUVEC) has a finite lifespan in vitro, and senescent HUVEC contain elevated levels of the negative growth regulator interleukin (IL)-1 alpha, IL-1 alpha is translated as a signal peptide sequence-less cytosolic 31-kDa precursor (IL-1 alpha p), which undergoes proteolytic activation to release the mature carboxyl terminus 17-kDa protein (IL-1 alpha m), Both the IL-1 alpha p and IL-1 alpha m proteins are biologically active as exogenous cytokines. Interestingly, only IL-1 alpha p contains a nuclear localization sequence between residues 79 and 85, To further study the role of intracellular IL-1 alpha in the regulation of human endothelial cell function, a spontaneous HUVEC transformant was stably transfected with IL-1 alpha p, IL-1 alpha m, and the IL-1 alpha p K82N mutant, which attenuates the nuclear traffic of IL-1 alpha p, Interestingly, the IL-1 alpha p transfectants were found to have a lower migratory potential than either IL-1 alpha m or IL-1 alpha p K82N transfectants, and the addition of the IL-1 receptor antagonist did not alter the migration of these cells. Immunofluorescence microscopy demonstrated that only the IL-1 alpha p transfectants exhibited prominent staining for beta-catenin-associated cell-to-cell contacts, as well as pronounced vimentin intermediate filaments and actin cytoskeleton staining, These data suggest that IL-1 alpha p, and not IL-1 alpha m, may function as an intracellular regulator of the migratory capacity of the human endothelial cell and that the nuclear localization sequence present within IL-1 alpha p may be involved in regulating this function.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOL MOL,ROCKVILLE,MD 20855	American Red Cross			Prudovsky, Igor/GVU-1521-2022		NIA NIH HHS [AG07450] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; DUNLEVY JR, 1993, J CELL SCI, V105, P489; FRIEDMAN S, 1994, BIOCHEM BIOPH RES CO, V198, P1203, DOI 10.1006/bbrc.1994.1170; GARFINKEL S, 1992, J BIOL CHEM, V267, P24375; GARFINKEL S, 1994, P NATL ACAD SCI USA, V91, P1559, DOI 10.1073/pnas.91.4.1559; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; GIRI JG, 1985, J IMMUNOL, V134, P343; GRENFELL S, 1989, BIOCHEM J, V264, P813, DOI 10.1042/bj2640813; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; MAIER JAM, 1994, MOL CELL BIOL, V14, P1845, DOI 10.1128/MCB.14.3.1845; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; NAKAI S, 1988, BIOCHEM BIOPH RES CO, V154, P1189, DOI 10.1016/0006-291X(88)90266-5; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SIMS JE, 1994, EUR CYTOKINE NETW, V5, P539; Stevenson FT, 1997, P NATL ACAD SCI USA, V94, P508, DOI 10.1073/pnas.94.2.508; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; TERRANOVA VP, 1985, J CELL BIOL, V101, P2330, DOI 10.1083/jcb.101.6.2330; WANG E, 1985, J CELL BIOL, V100, P1466, DOI 10.1083/jcb.100.5.1466; WESSENDORF JHM, 1993, J BIOL CHEM, V268, P22100; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1994, J BIOL CHEM, V269, P20221	40	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28202	28205		10.1074/jbc.272.45.28202	http://dx.doi.org/10.1074/jbc.272.45.28202			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353269	hybrid			2022-12-27	WOS:A1997YF21900009
J	Schecter, AD; Rollins, BJ; Zhang, YJ; Charo, IF; Fallon, JT; Rossikhina, M; Giesen, PLA; Nemerson, Y; Taubman, MB				Schecter, AD; Rollins, BJ; Zhang, YJ; Charo, IF; Fallon, JT; Rossikhina, M; Giesen, PLA; Nemerson, Y; Taubman, MB			Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; KINASE-C ACTIVATION; SIGNAL-TRANSDUCTION; FUNCTIONAL EXPRESSION; CHEMOTACTIC PROTEIN-1; MOLECULAR-CLONING; MESSENGER-RNA; GROWTH-FACTOR; IN-VITRO; ATHEROSCLEROTIC LESIONS	Monocyte chemoattractant protein-1 (MCP-1) is a C-C chemokine thought to play a major role in recruiting monocytes to the atherosclerotic plaque. Tissue factor (TF), the initiator of coagulation, is found in the atherosclerotic plaque, macrophages, and human aortic smooth muscle cells (SMC). The exposure of TF during plaque rupture likely induces acute thrombosis, leading to myocardial infarction and stroke. This report demonstrates that MCP-1 induces the accumulation of TF mRNA and protein in SMC and in THP-1 myelomonocytic leukemia cells. MCP-1 also induces TF activity on the surface of human SMC. The induction of TF by MCP-1 in SMC is inhibited by pertussis toxin, suggesting that the SMC MCP-1 receptor is coupled to a G(i)-protein. Chelation of intracellular calcium and inhibition of protein kinase C block the induction of TF by MCP-1, suggesting that in SMC it is mediated by activation of phospholipase C. SMC bind MCP-1 with a K-d similar to that previously reported for macrophages. However, mRNA encoding the macrophage MCP-1 receptors, CCR2A and B, is not present in SMC, indicating that they possess a distinct MCP-1 receptor. These data suggest that in addition to being a chemoattractant, MCP-I may have a procoagulant function and raise the possibility of an autocrine pathway in which MCP-1, secreted by SMC and macrophages, induces TF activity in these same cells.	CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,CARDIOVASC INST,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DIV THROMBOSIS RES,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT PATHOL,NEW YORK,NY 10029; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco				Fallon, John/0000-0002-7677-4868	NHLBI NIH HHS [HL09402, HL 54469, HL29019] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054469, F32HL009402, P01HL029019] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREA JE, 1992, HYPERTENSION, V20, P585, DOI 10.1161/01.HYP.20.5.585; ANNEX BH, 1995, CIRCULATION, V91, P619, DOI 10.1161/01.CIR.91.3.619; Bach RR, 1997, BLOOD, V89, P3270, DOI 10.1182/blood.V89.9.3270; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BIZZARRI C, 1995, BLOOD, V86, P2388, DOI 10.1182/blood.V86.6.2388.bloodjournal8662388; Carson SD, 1996, BLOOD COAGUL FIBRIN, V7, P303, DOI 10.1097/00001721-199604000-00004; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; DEMARCO R, 1992, CELL IMMUNOL, V140, P304, DOI 10.1016/0008-8749(92)90198-X; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DONOVANPELUSO M, 1994, J BIOL CHEM, V269, P1361; Dubois PM, 1996, J IMMUNOL, V156, P1356; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; ERNST CA, 1994, J IMMUNOL, V152, P3541; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GRABOWSKI EF, 1993, BLOOD, V81, P3265; Hoogewerf AJ, 1996, BIOCHEM BIOPH RES CO, V218, P337, DOI 10.1006/bbrc.1996.0059; KIRCHHOFER D, 1993, BLOOD, V81, P2050; LE DT, 1994, THROMB HAEMOSTASIS, V72, P848; LEE MW, 1994, AM J PHYSIOL, V267, pC659, DOI 10.1152/ajpcell.1994.267.3.C659; LI YS, 1993, MOL CELL BIOCHEM, V126, P61, DOI 10.1007/BF01772208; Liao DF, 1996, CIRC RES, V79, P1007, DOI 10.1161/01.RES.79.5.1007; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; MAYNARD JR, 1975, J CLIN INVEST, V55, P814, DOI 10.1172/JCI107992; Moreno PR, 1996, CIRCULATION, V94, P3090, DOI 10.1161/01.CIR.94.12.3090; Mulder AB, 1996, BLOOD, V88, P1306, DOI 10.1182/blood.V88.4.1306.bloodjournal8841306; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; NEMERSON Y, 1988, BLOOD, V71, P1; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROLLINS BJ, 1991, BLOOD, V78, P1112; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; SOZZANI S, 1993, J IMMUNOL, V150, P1544; SOZZANI S, 1991, J IMMUNOL, V147, P2215; SOZZANI S, 1995, J LEUKOCYTE BIOL, V57, P788, DOI 10.1002/jlb.57.5.788; SPEIDEL CM, 1995, CIRCULATION, V92, P3323, DOI 10.1161/01.CIR.92.11.3323; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; TAKAHASHI M, 1995, CIRC RES, V76, P750, DOI 10.1161/01.RES.76.5.750; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; TAUBMAN MB, 1993, J CLIN INVEST, V91, P547, DOI 10.1172/JCI116234; TAUBMAN MB, 1992, CIRC RES, V70, P314, DOI 10.1161/01.RES.70.2.314; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; Thiruvikraman SV, 1996, LAB INVEST, V75, P451; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224; VALENTE AJ, 1988, BIOCHEMISTRY-US, V27, P4162, DOI 10.1021/bi00411a039; Wilcox J N, 1992, J Vasc Surg, V15, P913; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YU XH, 1992, P NATL ACAD SCI USA, V89, P6953, DOI 10.1073/pnas.89.15.6953; ZELDIS SM, 1972, SCIENCE, V175, P766, DOI 10.1126/science.175.4023.766; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	64	178	198	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28568	28573		10.1074/jbc.272.45.28568	http://dx.doi.org/10.1074/jbc.272.45.28568			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353321	hybrid			2022-12-27	WOS:A1997YF21900061
J	Aritomi, M; Kunishima, N; Inohara, N; Ishibashi, Y; Ohta, S; Morikawa, K				Aritomi, M; Kunishima, N; Inohara, N; Ishibashi, Y; Ohta, S; Morikawa, K			Crystal structure of rat Bcl-x(L) - Implications for the function of the Bcl-2 protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; X PROTEIN; IN-VIVO; APOPTOSIS; DEAMIDATION; ASPARAGINYL; INHIBITION; GENE; BAX; SURVIVAL	Bcl-x(L) is a member of the Bcl-2 protein family, which regulates apoptosis. Preparation of recombinant rat Bcl-x(L) yielded two forms, one deamidated at -Asn-Gly-sequences to produce isoaspartates and the other not deamidated. The crystal structures of the two forms show that they both adopt an essentially identical backbone structure which resembles the fold of human Bcl-x(L): three layers of two alpha-helices each, capped at one end by two short helices. Both forms have a long disordered region, which contains the potential deamidation sites. The molecular structure exhibits a low level of interhelical interactions, the presence of three cavities, and a notable hydrophobic cleft surrounded by walls rich in basic residues. These unique structural features may be favorable for its accommodation into membranes or for possible rearrangement to modulate homo-/heterodimerization. Homology modeling of Bcl-2 and Bax, based on the Bcl-x(L), structure, suggests that Bax has the strongest potential for membrane insertion. Furthermore, we found a possible interface for interaction with non-Bcl-2 family member proteins, such as CED-4 homologues.	BIOMOL ENGN RES INST, SUITA, OSAKA 565, JAPAN; NIPPON MED COLL, INST GERONTOL, DEPT BIOCHEM & CELL BIOL, NAKAHARA KU, KAWASAKI, KANAGAWA 211, JAPAN	Nippon Medical School			Kunishima, Naoki/N-7464-2015	Aritomi, Masaharu/0000-0003-3002-8779; Kunishima, Naoki/0000-0001-9826-9902				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRUNGER AT, 1992, XPLOR MANUAL VERSION; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Elkins P, 1997, STRUCTURE, V5, P443, DOI 10.1016/S0969-2126(97)00200-1; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GEIGER T, 1987, J BIOL CHEM, V262, P785; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; ISHIKAWA K, 1993, BIOCHEMISTRY-US, V32, P6171, DOI 10.1021/bi00075a009; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JOHNSON BA, 1993, J BIOL CHEM, V268, P6174; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; LURA R, 1988, BIOCHEMISTRY-US, V27, P7671, DOI 10.1021/bi00420a015; MEINWALD YC, 1986, INT J PEPT PROT RES, V28, P79; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Mizuguchi M, 1996, BRAIN RES, V712, P281, DOI 10.1016/0006-8993(95)01453-5; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; MURSHUDOV GN, 1996, P CCP4 STUD WEEK SER, P85; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTWINOSKI Z, 1992, OSCILLATION DATA PRO; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Shimizu S, 1996, ONCOGENE, V13, P21; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Sohma O, 1996, J NEUROSCI RES, V43, P175, DOI 10.1002/(SICI)1097-4547(19960115)43:2<175::AID-JNR5>3.0.CO;2-D; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; TAKEMOTO L, 1991, CURR EYE RES, V10, P865, DOI 10.3109/02713689109013882; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	56	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27886	27892		10.1074/jbc.272.44.27886	http://dx.doi.org/10.1074/jbc.272.44.27886			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346936	hybrid			2022-12-27	WOS:A1997YD47300062
J	Hoffmann, KMV; Tonks, NK; Barford, D				Hoffmann, KMV; Tonks, NK; Barford, D			The crystal structure of domain 1 of receptor protein-tyrosine phosphatase mu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTP-MU; HOMOPHILIC BINDING; KAPPA	Receptor like protein-tyrosine phosphatases (RPTPs) play important roles in regulating intracellular processes, We have been investigating the regulation and function of RPTP mu, a receptor-like PTP related to the Ig superfamily of cell adhesion molecules, Recently, the crystal structure of a dimer of the membrane proximal domain of RPTP alpha (RPTP alpha D1) was described (Bilwes, A. M., den Hertog, J., Hunter, T., and Noel J. P. (1996) Nature 382, 555-559). Within this crystal structure, the catalytic site of each subunit of the dimer is sterically blocked by the insertion of the N-terminal helix-turn-helix segment of the dyad-related monomer, It was proposed that dimerization would lead to inhibition of catalytic activity and may provide a paradigm for the regulation of the RPTP family, We have determined the crystal structure, to 2.3 Angstrom resolution, of RPTP mu D1, which shares 46% sequence identity with that of RPTP alpha D1, Although the tertiary structures of RPTP alpha D1 and RPTP mu D1 are very similar, with a root mean square deviation between equivalent C alpha atoms of 1.1 Angstrom, the quaternary structures of these two proteins are different, Neither the catalytic site nor the N-terminal helix-turn-helix segment of RPTP mu D1 participates in protein-protein interactions, The catalytic site of RPTP mu D1 is unhindered and adopts an open conformation similar to that of the cytosolic PTP, PTP1B (Barford, D., Flint, A. J., and Tonks, N. K. (1994) Science 263, 1397-1404), We propose that dimerization-induced modulation of RPTP activity may not be a general feature of this family of enzymes.	UNIV OXFORD, MOL BIOPHYS LAB, OXFORD OX1 3QU, ENGLAND; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of Oxford; Cold Spring Harbor Laboratory			Hoffmann, Kurt/P-2539-2014	Hoffmann, Kurt/0000-0002-7991-423X	NIGMS NIH HHS [GM 55989] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055989] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; BRUNGER AT, 1992, XPLOR VERSION 3 1; Cheng J, 1997, J BIOL CHEM, V272, P7264, DOI 10.1074/jbc.272.11.7264; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; SAP J, 1994, MOL CELL BIOL, V14, P1; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0	22	100	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27505	27508		10.1074/jbc.272.44.27505	http://dx.doi.org/10.1074/jbc.272.44.27505			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346878	hybrid			2022-12-27	WOS:A1997YD47300004
J	Kovoor, A; Nappey, V; Kieffer, BL; Chavkin, C				Kovoor, A; Nappey, V; Kieffer, BL; Chavkin, C			mu and delta opioid receptors are differentially desensitized by the coexpression of beta-adrenergic receptor kinase 2 and beta-arrestin 2 in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+-CHANNEL; AGONIST-INDUCED DESENSITIZATION; GAMMA-SUBUNITS; RAT-BRAIN; EXPRESSION CLONING; POTASSIUM CHANNEL; PROTEIN-KINASE; I-KACH; MORPHINE; BINDING	The Xenopus oocyte expression system was used to test the hypothesis that homologous opioid receptor desensitization results from receptor phosphorylation by G protein-coupled receptor kinases. Activation of delta (DOR), mu (MOR) opioid, or beta(2)-adrenergic receptors increased K+ conductance in oocytes coexpressing the G protein-gated inwardly rectifying K+ channel subunits GIRK1 and GIRK4, and the intrinsic rate of desensitization was small. Coexpression of beta-adrenergic receptor kinase 2 (beta-ARK2) and beta-arrestin 2 (beta-arr2) synergistically produced a rapid desensitization of both DOR and beta 2-adrenergic receptor signaling with a t(1/2) < 4 min. beta-ARK2 and beta-arr2 more slowly desensitized MOR responses; a similar synergistic effect on MOR required 2-3 h of agonist treatment. DOR mutants lacking serine and threonine residues at the end of the cytoplasmic tail coupled effectively to GIRK channels but were insensitive to beta-ARK2 and beta-arr2. However, a DOR mutant having serine residues mutated to alanine in the third cytoplasmic loop was indistinguishable in coupling and desensitization from the wild type DOR. These studies establish that opioid receptors can be regulated by beta-ARK2 and beta-arr2 and that a portion of the COOH terminus of DOR enhances sensitivity to this modulation.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; UNIV STRASBOURG 1, ECOLE SUPER BIOTECHNOL, F-67085 STRASBOURG, FRANCE	University of Washington; University of Washington Seattle; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Chavkin, Charles/G-2797-2010		NIDA NIH HHS [R37 DA011672, DA04123] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004123, R37DA011672] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Befort K, 1996, MOL PHARMACOL, V49, P216; BLANCHARD G, 1988, OPIATE RECEPTORS, P426; BRADY LS, 1989, BRAIN RES, V477, P382, DOI 10.1016/0006-8993(89)91432-7; BRODSKY M, 1995, BRAIN RES BULL, V38, P135, DOI 10.1016/0361-9230(95)00079-T; CHILDERS SR, 1977, EUR J PHARMACOL, V46, P289, DOI 10.1016/0014-2999(77)90346-6; CHRISTIE MJ, 1987, MOL PHARMACOL, V32, P633; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRAZIANO MP, 1991, METHOD ENZYMOL, V195, P192; GRUDT TJ, 1995, REV NEUROSCIENCE, V6, P279; HAGA K, 1994, J BIOL CHEM, V269, P12594; HARRIS GC, 1991, J NEUROSCI, V11, P2574; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HENRY DJ, 1995, MOL PHARMACOL, V47, P551; HOLLT V, 1975, LIFE SCI, V16, P1823, DOI 10.1016/0024-3205(75)90284-2; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; ISHII K, 1994, J BIOL CHEM, V269, P1125; JEWELLMOTZ EA, 1995, BIOCHEMISTRY-US, V34, P11946, DOI 10.1021/bi00037a036; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Noble F, 1996, BRIT J PHARMACOL, V117, P161, DOI 10.1111/j.1476-5381.1996.tb15169.x; NOMURA K, 1994, J PHARMACOL EXP THER, V270, P466; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PEI G, 1995, MOL PHARMACOL, V48, P173; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; Sim LJ, 1996, J NEUROSCI, V16, P2684; STERNE MR, 1995, VITAM HORM, V51, P193; TAO PL, 1993, EUR J PHARM-MOLEC PH, V246, P233, DOI 10.1016/0922-4106(93)90036-9; TAO PL, 1987, J PHARMACOL EXP THER, V240, P809; TERWILLIGER RZ, 1994, J NEUROCHEM, V63, P1983; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TRUJILLO KA, 1991, NEW BIOL, V3, P915; Wang ZJ, 1996, FEBS LETT, V387, P53, DOI 10.1016/0014-5793(96)00467-X; WERLING LL, 1989, P NATL ACAD SCI USA, V86, P6393, DOI 10.1073/pnas.86.16.6393; Zaki PA, 1996, ANNU REV PHARMACOL, V36, P379; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	47	115	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27605	27611		10.1074/jbc.272.44.27605	http://dx.doi.org/10.1074/jbc.272.44.27605			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346897	hybrid			2022-12-27	WOS:A1997YD47300023
J	Mangiarotti, G; Chiaberge, S; Bulfone, S				Mangiarotti, G; Chiaberge, S; Bulfone, S			rRNA maturation as a ''quality'' control step in ribosomal subunit assembly in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA; PRECURSOR; YEAST; CELLS	In Dictyostelium discoideum, newly assembled ribosomal subunits enter polyribosomes while they still contain immature rRNA. rRNA maturation requires the engagement of the subunits in protein synthesis and leads to stabilization of their structure. Maturation of pre-17 S rRNA occurs only after the newly formed 40 S ribosomal particle has entered an 80 S ribosome and participated at least in the formation of one peptide bond or in one translocation event; maturation of pre-26 S rRNA requires the presence on the 80 S particle of a peptidyl-tRNA containing at least 6 amino acids. Newly assembled particles that cannot fulfill these requirements for structural reasons are disassembled into free immature rRNA and ribosomal proteins.			Mangiarotti, G (corresponding author), OSPED S LUIGI,DEPT CLIN & BIOL SCI,ORBASSANO,TORINO,ITALY.							ADESNIK M, 1969, J MOL BIOL, V46, P281, DOI 10.1016/0022-2836(69)90422-7; APIRION D, 1993, BIOESSAYS, V15, P113, DOI 10.1002/bies.950150207; BLEYMAN M, 1969, J BACTERIOL, V97, P27, DOI 10.1128/JB.97.1.27-31.1969; CECCARELLI A, 1978, FEBS LETT, V93, P348, DOI 10.1016/0014-5793(78)81137-5; DAHLBERG AE, 1971, J MOL BIOL, V55, P61, DOI 10.1016/0022-2836(71)90281-6; DUNN JJ, 1973, P NATL ACAD SCI USA, V70, P3286; EICHLER BC, 1984, PROG NUCL ACIDS RES, V49, P197; FIRTEL RA, 1974, GENETICS, V78, P355; GREINGER RM, 1980, CELL, V20, P619; HAYES D, 1973, CR ACAD SCI III-VIE, V227, P881; HAYES F, 1971, BIOCHIMIE, V53, P369, DOI 10.1016/S0300-9084(71)80104-9; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; HUGES JM, 1991, EMBO J, V10, P4231; KAEMPFER R, 1970, NATURE, V228, P534, DOI 10.1038/228534a0; KOSSMAN CR, 1971, NATURE-NEW BIOL, V234, P102, DOI 10.1038/newbio234102a0; LIAU MC, 1968, BIOCHIM BIOPHYS ACTA, V169, P196, DOI 10.1016/0005-2787(68)90020-8; LINDAHL L, 1973, NATURE-NEW BIOL, V243, P170, DOI 10.1038/newbio243170a0; Maden B.E.H., 1971, PROGR BIOPHYS MOL BI, V22, P127; MADEN BEH, 1972, NATURE-NEW BIOL, V237, P5, DOI 10.1038/newbio237005a0; MANGIAROTTI G, 1975, NATURE, V253, P569, DOI 10.1038/253569a0; MANGIAROTTI G, 1982, DEV BIOL, V89, P82, DOI 10.1016/0012-1606(82)90296-2; MANGIAROTTI G, 1985, P NATL ACAD SCI USA, V82, P5786, DOI 10.1073/pnas.82.17.5786; MANGIAROTTI G, 1967, J MOL BIOL, V29, P395, DOI 10.1016/0022-2836(67)90107-6; MANGIAROTTI G, 1974, NATURE, V247, P147, DOI 10.1038/247147a0; MANGIAROTTI G, 1979, EXP CELL RES, V119, P428, DOI 10.1016/0014-4827(79)90378-1; MANGIAROTTI G, 1980, MOL CELL BIOL, V1, P35; MANGIAROTTI G, 1984, NATURE, V301, P616; MANGIAROTTI G, 1977, J BIOL CHEM, V272, P19682; NIKOLAEV N, 1973, J BIOL CHEM, V248, P7967; NIKOLAEV N, 1973, P NATL ACAD SCI USA, V70, P3361, DOI 10.1073/pnas.70.12.3361; NOMURA M, 1970, NATURE, V228, P744, DOI 10.1038/228744a0; OZAKI T, 1984, NUCLEIC ACIDS RES, V12, P4171, DOI 10.1093/nar/12.10.4171; RAMAGOPAL S, 1980, EUR J BIOCHEM, V105, P245, DOI 10.1111/j.1432-1033.1980.tb04495.x; SCHLESSINGER D, 1967, P NATL ACAD SCI USA, V58, P1782, DOI 10.1073/pnas.58.4.1782; TRAUB P, 1968, P NATL ACAD SCI USA, V59, P777, DOI 10.1073/pnas.59.3.777; TURCO E, 1974, BIOCHEMISTRY-US, V13, P4752, DOI 10.1021/bi00720a011; UDEM SA, 1973, J BIOL CHEM, V248, P1412; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; VELDMAN GM, 1980, NUCLEIC ACIDS RES, V8, P2907, DOI 10.1093/nar/8.13.2907; WEINBERG RA, 1970, J MOL BIOL, V47, P169, DOI 10.1016/0022-2836(70)90337-2	40	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27818	27822		10.1074/jbc.272.44.27818	http://dx.doi.org/10.1074/jbc.272.44.27818			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346927	hybrid			2022-12-27	WOS:A1997YD47300053
J	Rossetti, L; Massillon, D; Barzilai, N; Vuguin, P; Chen, W; Hawkins, M; Wu, J; Wang, JL				Rossetti, L; Massillon, D; Barzilai, N; Vuguin, P; Chen, W; Hawkins, M; Wu, J; Wang, JL			Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC RATS; OBESE GENE; CONSCIOUS RATS; BODY-WEIGHT; FOOD-INTAKE; OB/OB MICE; OB PROTEIN; GLUCOSE; EXPRESSION; MOUSE	Long term administration of leptin decreases caloric intake and fat mass and improves glucose tolerance. Here we examine whether leptin acutely regulates peripheral and hepatic insulin action. Recombinant mouse leptin (0.3 mg/kg.h, Leptin +) or vehicle (Leptin -) were administered for 6 h to 4-month-old rats (n = 20), and insulin (3 milliunits/kg.min) clamp studies were performed. During physiologic hyperinsulinemia (plasma insulin similar to 65 microunits/ml), the rates of whole body glucose uptake, glycolysis, and glycogen synthesis and the rates of 2-deoxyglucose uptake in individual tissues were similar in Leptin - and Leptin +. Post-absorptive hepatic glucose production (HGP) was similar in the two groups. However, leptin enhanced insulin's inhibition of HGP (4.1 +/- 0.7 and 6.2 +/- 0.7 mg/kg.min; p < 0.05). The decreased HGP in the Leptin + group was due to a marked suppression of hepatic glycogenolysis (0.7 +/- 0.1 versus 4.1 +/- 0.6 mg/kg.min, in Leptin + versus Leptin -, respectively; p < 0.001), whereas the % contribution of gluconeogenesis to HGP was markedly increased (82 +/- 3% versus 36 +/- 4% in Leptin + and Leptin -, respectively; p < 0.001). At the end of the 6-h leptin infusion, the hepatic abundance of glucokinase mRNA was decreased, whereas that of phosphoenolpyruvate carboxykinase mRNA was increased compared with Leptin -. We conclude that an acute increase in plasma leptin 1) enhances insulin's ability to inhibit HGP, 2) does not affect peripheral insulin action, and 3) induces a redistribution of intrahepatic glucose fluxes and changes in the gene expression of hepatic enzymes that closely resemble those of fasting.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DIV ENDOCRINOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	Rossetti, L (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,CTR DIABET RES & TRAINING,1300 MORRIS PK AVE,BRONX,NY 10461, USA.			vuguin, patricia/0000-0002-4982-0400	NIDDK NIH HHS [DK 45024, DK 48321] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045024, R37DK048321, R01DK045024, R01DK048321] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai YL, 1996, J BIOL CHEM, V271, P13939, DOI 10.1074/jbc.271.24.13939; BARZILAI N, 1995, BIOCHEM J, V310, P819, DOI 10.1042/bj3100819; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Cinti S, 1997, ENDOCRINOLOGY, V138, P797, DOI 10.1210/en.138.2.797; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Considine RV, 1996, DIABETES, V45, P992, DOI 10.2337/diabetes.45.7.992; CONSIDINE RV, 1996, NEW ENGL J MED, V334, P324; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; FRONTONI S, 1992, HYPERTENSION, V20, P192, DOI 10.1161/01.HYP.20.2.192; GIACCARI A, 1989, J CHROMATOGR-BIOMED, V497, P69, DOI 10.1016/0378-4347(89)80006-4; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Jacob RJ, 1997, DIABETES, V46, P150, DOI 10.2337/diabetes.46.1.150; Kieffer TJ, 1996, BIOCHEM BIOPH RES CO, V224, P522, DOI 10.1006/bbrc.1996.1059; KISSEBAH AH, 1991, INT J OBESITY, V15, P109; Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511; KRAEGEN EW, 1985, AM J PHYSIOL, V248, pE353; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; Massillon D, 1997, DIABETES, V46, P153, DOI 10.2337/diabetes.46.1.153; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RENTSCH J, 1995, BIOCHEM BIOPH RES CO, V214, P131, DOI 10.1006/bbrc.1995.2266; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; Rossetti L, 1996, J BIOL CHEM, V271, P203, DOI 10.1074/jbc.271.1.203; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Sidossis LS, 1996, J CLIN INVEST, V98, P2244, DOI 10.1172/JCI119034; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	38	255	260	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27758	27763		10.1074/jbc.272.44.27758	http://dx.doi.org/10.1074/jbc.272.44.27758			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346919	hybrid			2022-12-27	WOS:A1997YD47300045
J	Fruen, BR; Mickelson, JR; Louis, CF				Fruen, BR; Mickelson, JR; Louis, CF			Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIGNANT-HYPERTHERMIA; CALCIUM-RELEASE; CHANNEL; SODIUM; CALMODULIN; ACTIVATION; AZUMOLENE; CAFFEINE; IDENTIFICATION; DEPOLARIZATION	The skeletal muscle relaxant dantrolene inhibits the release of Ca2+ from the sarcoplasmic reticulum during excitation contraction coupling and suppresses the un controlled Ca2+ release that underlies the skeletal muscle pharmacogenetic disorder malignant hyperthermia; however, the molecular mechanism by which dantrolene selectively affects skeletal muscle Ca2+ regulation remains to be defined, Here we provide evidence of a high-affinity, monophasic inhibition by dantrolene of ryanodine receptor Ca2+ channel function in isolated sarcoplasmic reticulum vesicles prepared from malignant hyperthermia-susceptible and normal pig skeletal muscle. In media simulating resting myoplasm, dantrolene increased the half-time for Ca-45(2+) release from both malignant hyperthermia and normal vesicles approximately 3.5-fold and inhibited sarcoplasmic reticulum vesicle [H-3]ryanodine binding (K-i similar to 150 nM for both malignant hyperthermia and normal). Inhibition of vesicle [H-3]ryanodine binding by dantrolene was associated with a decrease in the extent of activation by both calmodulin and Ca2+, Dantrolene also inhibited [H-3]ryanodine binding to purified skeletal muscle ryanodine receptor protein reconstituted into liposomes, In contrast, cardiac sarcoplasmic reticulum vesicle Ca-45(2+) release and [H-3]ryanodine binding were unaffected by dantrolene. Together, these results demonstrate selective effects of dantrolene on skeletal muscle ryanodine receptors that are consistent with the actions of dantrolene in vivo and suggest a mechanism of action in which dantrolene may act directly at the skeletal muscle ryanodine receptor complex to limit its activation by calmodulin and Ca2+, The potential implications of these results for understanding how dantrolene and malignant hyperthermia mutations may affect the voltage-dependent activation of Ca2+ release in intact skeletal muscle are discussed.	UNIV MINNESOTA,DEPT VET PATHOBIOL,ST PAUL,MN 55108; UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Mickelson, James/0000-0001-6951-0234	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031382] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31382] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PD, 1992, ANESTHESIOLOGY, V76, P132, DOI 10.1097/00000542-199201000-00019; ANDERSON K, 1995, J GEN PHYSIOL, V105, P363, DOI 10.1085/jgp.105.3.363; BULL R, 1994, AM J PHYSIOL, V266, pC391, DOI 10.1152/ajpcell.1994.266.2.C391; DANKO S, 1985, BIOCHIM BIOPHYS ACTA, V816, P18, DOI 10.1016/0005-2736(85)90388-8; DHILLON DS, 1992, DRUG DEVELOP RES, V25, P161, DOI 10.1002/ddr.430250208; Dietze B., 1997, Biophysical Journal, V72, pA273; ELHAYEK R, 1992, BIOCHEM BIOPH RES CO, V187, P894, DOI 10.1016/0006-291X(92)91281-T; ELHAYEK R, 1995, AM J PHYSIOL-CELL PH, V268, pC1381, DOI 10.1152/ajpcell.1995.268.6.C1381; FILL M, 1990, BIOPHYS J, V50, P471; FLEWELLEN EH, 1983, ANESTHESIOLOGY, V59, P275, DOI 10.1097/00000542-198310000-00002; FRANDSEN A, 1992, P NATL ACAD SCI USA, V89, P2590, DOI 10.1073/pnas.89.7.2590; Fratea S, 1997, ANESTHESIOLOGY, V86, P205, DOI 10.1097/00000542-199701000-00025; Fruen BR, 1996, BIOPHYS J, V71, P2522, DOI 10.1016/S0006-3495(96)79445-6; FRUEN BR, 1994, J BIOL CHEM, V269, P192; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GALLANT EM, 1995, J CELL PHYSIOL, V165, P254, DOI 10.1002/jcp.1041650206; GALLANT EM, 1982, NEUROSCI LETT, V28, P181, DOI 10.1016/0304-3940(82)90149-5; HAINAUT K, 1974, NATURE, V252, P728, DOI 10.1038/252728a0; Jong DS, 1997, J PHYSIOL-LONDON, V499, P787, DOI 10.1113/jphysiol.1997.sp021969; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LOUIS CF, 1992, ANESTHESIOLOGY, V77, P114, DOI 10.1097/00000542-199207000-00017; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; MODY I, 1995, TRENDS PHARMACOL SCI, V16, P356, DOI 10.1016/S0165-6147(00)89070-7; MORGAN KG, 1977, J PHARMACOL EXP THER, V201, P138; Nelson TE, 1996, ANESTHESIOLOGY, V84, P1368, DOI 10.1097/00000542-199606000-00013; ODriscoll S, 1996, BIOCHEM J, V319, P421, DOI 10.1042/bj3190421; OHTA T, 1989, AM J PHYSIOL, V256, pC358, DOI 10.1152/ajpcell.1989.256.2.C358; OHTA T, 1990, EUR J PHARMACOL, V178, P11; Palnitkar SS, 1997, BIOCHEM J, V326, P847, DOI 10.1042/bj3260847; PARNESS J, 1995, J BIOL CHEM, V270, P18465, DOI 10.1074/jbc.270.31.18465; Pessah IN, 1996, ANESTHESIOLOGY, V84, P1275, DOI 10.1097/00000542-199606000-00001; PUTNEY JW, 1974, J PHARMACOL EXP THER, V189, P202; Richter M, 1997, J BIOL CHEM, V272, P5256, DOI 10.1074/jbc.272.8.5256; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SHOMER NH, 1993, AM J PHYSIOL, V264, pC125, DOI 10.1152/ajpcell.1993.264.1.C125; SNYDER HR, 1967, J MED CHEM, V10, P807, DOI 10.1021/jm00317a011; SUDA N, 1994, P NATL ACAD SCI USA, V91, P5725, DOI 10.1073/pnas.91.12.5725; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TIAN Q, 1991, BIOCHIM BIOPHYS ACTA, V1094, P27; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; VANWINKLE WB, 1976, SCIENCE, V193, P1130, DOI 10.1126/science.959824; WARD A, 1986, DRUGS, V32, P130, DOI 10.2165/00003495-198632020-00003; Zucchi R, 1997, PHARMACOL REV, V49, P1	45	155	157	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26965	26971		10.1074/jbc.272.43.26965	http://dx.doi.org/10.1074/jbc.272.43.26965			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341133	hybrid			2022-12-27	WOS:A1997YC65900029
J	Ribeiro, CMP; Reece, J; Putney, JW				Ribeiro, CMP; Reece, J; Putney, JW			Role of the cytoskeleton in calcium signaling in NIH 3T3 cells - An intact cytoskeleton is required for agonist-induced [Ca2+](i) signaling, but not for capacitative calcium entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CA2+ RELEASE; PAROTID ACINAR-CELLS; ENDOPLASMIC-RETICULUM; INOSITOL 1,4,5-TRISPHOSPHATE; PLASMA-MEMBRANE; ACTIN-FILAMENTS; RECEPTOR; ANKYRIN; INFLUX; REORGANIZATION	Treatment of NIH 3T3 cells with cytochalasin D (10 mu M, 1 h at 37 degrees C) disrupted the actin cytoskeleton and changed the cells from a planar, extended morphology, to a rounded shape, Calcium mobilization by ATP or by platelet-derived growth factor was abolished, while the ability of thapsigargin (2 mu M) to empty calcium stores and activate calcium influx was unaffected, Similar experiments with nocodazole to depolymerize the tubulin network yielded identical results, Platelet-derived growth factor induced an increase in inositol phosphates, and this increase was undiminished in the presence of cytochalasin D, Therefore, the blockade of agonist responses by this drug does not result from decreased phospholipase C, Injection of inositol 1,4,5-trisphosphate (IP3) released calcium to the same extent in control and cytochalasin D-treated cells. Confocal microscopic studies revealed a significant rearrangement of the endoplasmic reticulum after cytochalasin D treatment, Thus, disruption of the cytoskeleton blocks agonist-elicited [Ca2+](i) mobilization, but this effect does not result from a lower calcium storage capacity, impaired function of the IP3 receptor, or diminished phospholipase C activity, We suggest that cytoskeletal disruption alters the spatial relationship between phospholipase C and IP3 receptors, impairing phospholipase C-dependent calcium signaling, Capacitative calcium entry was not altered under these conditions, indicating that the coupling between depletion of intracellular calcium stores and calcium entry does not depend on a precise structural relationship between intracellular stores and plasma membrane calcium channels.			Ribeiro, CMP (corresponding author), NIEHS, LAB SIGNAL TRANSDUCT, NIH, POB 12233, RES TRIANGLE PK, NC 27709 USA.		Putney, James W/F-7247-2019; Ribeiro, Carla Maria P/A-6955-2009	Putney, James W/0000-0002-3379-4789; 				ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BAUMANN O, 1994, CELL TISSUE RES, V278, P419; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; FJOSE A, 1984, CELL BIOCHEM FUNCT, V2, P38, DOI 10.1002/cbf.290020111; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEDBERG KK, 1991, CELL REGUL, V2, P1067, DOI 10.1091/mbc.2.12.1067; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; KACHAR B, 1988, J CELL BIOL, V106, P1545, DOI 10.1083/jcb.106.5.1545; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; Lobaugh LA, 1996, MOL PHARMACOL, V50, P493; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; Pettit EJ, 1996, BIOCHEM BIOPH RES CO, V229, P109, DOI 10.1006/bbrc.1996.1765; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; RIFKIN DB, 1979, CELL, V18, P361, DOI 10.1016/0092-8674(79)90055-2; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SCHLIWA M, 1984, J CELL BIOL, V99, P1045, DOI 10.1083/jcb.99.3.1045; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; TASAKA K, 1991, BIOCHEM PHARMACOL, V41, P1031; TERASAKI M, 1989, METHOD CELL BIOL, V29, P125; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0	36	138	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26555	26561		10.1074/jbc.272.42.26555	http://dx.doi.org/10.1074/jbc.272.42.26555			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334235	hybrid			2022-12-27	WOS:A1997YB13900069
J	Berditchevski, F; Chang, S; Bodorova, J; Hemler, ME				Berditchevski, F; Chang, S; Bodorova, J; Hemler, ME			Generation of monoclonal antibodies to integrin-associated proteins - Evidence that alpha(3)beta(1) complexes with EMMPRIN/basigin/OX47/M6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; CELL-ADHESION; IMMUNOGLOBULIN SUPERFAMILY; T-CELLS; HISTOCOMPATIBILITY ANTIGENS; UROKINASE RECEPTOR; BETA-1 INTEGRINS; CD9 ANTIGEN; SURFACE; DOMAIN	The alpha(3) beta(1) integrin forms complexes with other cell-surface proteins, including transmembrane-4 superfamily (TM4SF) proteins (e.g. CD9, CD53, CD63, CD81, and CD82). To identify additional cell-surface proteins associated with alpha(3) beta(1) integrin, a monoclonal antibody selection protocol was developed, Mice were immunized with integrin alpha(3) beta(1)-containing complexes isolated from HT1080 fibrosarcoma cells, and then 712 hybridoma clones were produced, and 95 secreted antibodies that recognized the HT1080 cell surface, Among these, 12 antibodies directly recognizing integrin alpha(3) or beta(1) subunits were eliminated, Of the remaining 83, 16 co-immunoprecipitated proteins that resembled integrins under non-stringent detergent conditions. These 16 included 15 monoclonal antibodies recognizing EMMPRIN/basigin/OX-47/M6, a 45-55-kDa transmembrane protein with two immunoglobulin domains. The EMMPRIN protein associated with alpha(3) beta(1) and alpha(6) beta(1), but not alpha(2) beta(1) or alpha(5) beta(1), as shown by reciprocal immunoprecipitation experiments, Also, association with alpha(3) beta(1) was confirmed by cell-surface cross-linking and immunofluorescence co-localization experiments, Importantly, EMMPRIN-alpha(3) beta(1) complexes appear not to contain TM4SF proteins, suggesting that they are distinct from TM4SF protein-alpha(3) beta(1) complexes.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NCI NIH HHS [CA42368] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042368] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTRUDA F, 1989, GENE, V85, P445, DOI 10.1016/0378-1119(89)90438-1; ANDERSON GP, 1991, BRIT J HAEMATOL, V79, P75, DOI 10.1111/j.1365-2141.1991.tb08010.x; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BEHR S, 1995, J EXP MED, V182, P1191, DOI 10.1084/jem.182.5.1191; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BISWAS C, 1995, CANCER RES, V55, P434; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Chintala SK, 1996, CANCER LETT, V103, P201, DOI 10.1016/0304-3835(96)04215-2; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Fadool JM, 1996, BIOCHEM BIOPH RES CO, V229, P280, DOI 10.1006/bbrc.1996.1793; FADOOL JM, 1993, DEV DYNAM, V196, P252, DOI 10.1002/aja.1001960406; FOSSUM S, 1991, EUR J IMMUNOL, V21, P671, DOI 10.1002/eji.1830210320; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; Guo HM, 1997, J BIOL CHEM, V272, P24; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HEMLER ME, 1983, J IMMUNOL, V131, P334; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Igakura T, 1996, BIOCHEM BIOPH RES CO, V224, P33, DOI 10.1006/bbrc.1996.0980; Jones PH, 1996, CELL ADHES COMMUN, V4, P297, DOI 10.3109/15419069609010773; KASINRERK W, 1992, J IMMUNOL, V149, P847; KATAOKA H, 1993, CANCER RES, V53, P3154; LARJAVA H, 1993, J CELL PHYSIOL, V157, P190, DOI 10.1002/jcp.1041570125; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; Mannion BA, 1996, J IMMUNOL, V157, P2039; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MIYAUCHI T, 1990, J BIOCHEM-TOKYO, V107, P316, DOI 10.1093/oxfordjournals.jbchem.a123045; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; NEHME CL, 1993, J CELL BIOL, V120, P687, DOI 10.1083/jcb.120.3.687; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PASQUALINI R, 1993, J CELL SCI, V105, P101; PASQUALINI R, 1994, J CELL BIOL, V125, P477; PATARROYO M, 1994, IMMUNOBIOLOGY, V191, P474, DOI 10.1016/S0171-2985(11)80453-5; Petty HR, 1996, IMMUNOL TODAY, V17, P209, DOI 10.1016/0167-5699(96)30013-3; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Pujades C, 1996, BIOCHEM J, V313, P899, DOI 10.1042/bj3130899; Radford KJ, 1996, BIOCHEM BIOPH RES CO, V222, P13, DOI 10.1006/bbrc.1996.0690; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SCHLOSSHAUER B, 1995, EUR J CELL BIOL, V68, P159; Schmidt C, 1996, J NEUROSCI RES, V43, P12, DOI 10.1002/jnr.490430103; SEULBERGER H, 1990, EMBO J, V9, P2151, DOI 10.1002/j.1460-2075.1990.tb07384.x; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TARONE G, 1988, EUR J BIOCHEM, V172, P713, DOI 10.1111/j.1432-1033.1988.tb13947.x; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WEITZMAN JB, 1995, J CELL SCI, V108, P3635; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651	59	229	244	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29174	29180		10.1074/jbc.272.46.29174	http://dx.doi.org/10.1074/jbc.272.46.29174			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360995	hybrid			2022-12-27	WOS:A1997YF68400054
J	Chang, W; Gelman, MS; Prives, JM				Chang, W; Gelman, MS; Prives, JM			Calnexin-dependent enhancement of nicotinic acetylcholine receptor assembly and surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED COS CELLS; ENDOPLASMIC-RETICULUM; MUSCLE-CELLS; CHAPERONE CALNEXIN; IN-VITRO; DEGRADATION; PROTEIN; SUBUNIT; PROTEASOME; ALPHA	The muscle-type nicotinic acetylcholine receptor (AChR)(2) is a pentameric membrane ion channel assembled in the endoplasmic reticulum from four homologous subunits by mechanisms that are insufficiently understood, Nascent AChR subunits were recently found to form complexes with the endoplasmic reticulum-resident molecular chaperone calnexin, To determine the contribution of this interaction to AChR assembly and surface expression, we have now used transient transfection of mouse AChR subunits and calnexin into nonmuscle cells. Co-transfection of calnexin along with AChR subunits into COS and HEK 293 cells was found to enhance AChR subunit folding and assembly, and to decrease degradation rates of newly synthesized AChR alpha-subunits, resulting in elevated surface expression of assembled AChR. Moreover, inhibition of the interaction between endogenous calnexin and AChR by castanospermine resulted in decreased AChR subunit folding, assembly, and surface expression in muscle and HEK 293 cells. Together, these findings provide evidence that calnexin directly contributes to AChR biogenesis by promoting subunit folding and assembly.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHARMACOL SCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025945] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25945] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; CHANG W, 1995, THESIS STATE U NEW Y; CHAVEZ RA, 1992, J BIOL CHEM, V267, P23028; CONTITRONCONI BM, 1994, CRIT REV BIOCHEM MOL, V29, P69, DOI 10.3109/10409239409086798; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; Gelman MS, 1996, J BIOL CHEM, V271, P10709, DOI 10.1074/jbc.271.18.10709; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MERLIE JP, 1986, J MEMBRANE BIOL, V91, P1, DOI 10.1007/BF01870209; MERLIE JP, 1984, CELL, V36, P573, DOI 10.1016/0092-8674(84)90335-0; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROMAGNOLI P, 1995, J EXP MED, V182, P2027, DOI 10.1084/jem.182.6.2027; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROSS AF, 1987, J BIOL CHEM, V262, P14640; Sambrook J., 2002, MOL CLONING LAB MANU; Shtrom SS, 1996, J BIOL CHEM, V271, P25506, DOI 10.1074/jbc.271.41.25506; SUMIKAWA K, 1992, J BIOL CHEM, V267, P6286; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WADA I, 1991, J BIOL CHEM, V266, P19599; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	47	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28925	28932		10.1074/jbc.272.46.28925	http://dx.doi.org/10.1074/jbc.272.46.28925			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360963	hybrid			2022-12-27	WOS:A1997YF68400022
J	Folberg, A; Kovacs, EN; Featherstone, MS				Folberg, A; Kovacs, EN; Featherstone, MS			Characterization and retinoic acid responsiveness of the murine Hoxd4 transcription unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HOMEOBOX GENE; HOMEOTIC TRANSFORMATIONS; NERVOUS-SYSTEM; MESSENGER-RNAS; HOX-4.2 GENE; MUTANT MICE; EXPRESSION; INITIATION; PROMOTERS; ELEMENT	We have characterized the transcription unit of a murine Hox gene in the fourth paralogous group, Hoxd4, We have identified two HoxdB transcription start sites by S1 analysis, The upstream promoter (P2) is 5.2 kilobase pairs upstream from the coding region, while the downstream promoter (P1) is 1.1 kilobase pairs distant, Both promoters bear a cluster of start sites, Multiple transcripts were identified by Northern blot, originating from both promoters and multiple polyadenylation signals. Expression of P1 transcripts in the neural tube shows an anterior border at the rhombomere 6/7 boundary, corresponding to previous reports (Gaunt, S. J., Krumlauf, R,, and Duboule, D. (1989) Development 107, 131-141; Morrison, A., Moroni, M, C,, Ariza-McNaughton, L,, Krumlauf, R,, and Mavilio, F, (1996) Development 122, 1895-1907), A more posterior boundary in the central nervous system was observed for P2 transcripts, We observed strong expression up to somite 6 and weak expression in somite 5, correlating with the phenotype of Hoxd4 null mutant mice (Horan, G, S. B,, Nagy Kovacs, E,, Behringer, R, R,, and Featherstone, RI, S, (1995) Dev. Biol. 169, 359-372), In response to retinoic acid, expression from P1 in the hindbrain was anteriorized after 4 or 24 h of treatment, P2 transcripts seemed to be less responsive and/or to have an indirect response to retinoic acid, The long 5'-untranslated region found in all Hoxd4 transcripts suggests that translation does not occur by a classical ribosome scanning mechanism.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,DIV EXPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University; McGill University			Featherstone, Mark/E-8057-2010	Featherstone, Mark/0000-0003-1576-046X				AUSUBELL FM, 1989, CURRENT PROTOCOLS MO, V1; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Boulet AM, 1996, DEV BIOL, V177, P232, DOI 10.1006/dbio.1996.0159; BURGLIN TR, 1987, NATURE, V330; CHOW LML, 1992, MOL CELL BIOL, V12, P1226, DOI 10.1128/MCB.12.3.1226; CIANETTI L, 1990, NUCLEIC ACIDS RES, V18, P4361, DOI 10.1093/nar/18.15.4361; CONLON RA, 1992, DEVELOPMENT, V116, P357; COULY GF, 1993, DEVELOPMENT, V117, P409; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GUTMAN A, 1994, MOL CELL BIOL, V14, P8143, DOI 10.1128/MCB.14.12.8143; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HORAN GSB, 1994, P NATL ACAD SCI USA, V91, P12644, DOI 10.1073/pnas.91.26.12644; HORAN GSB, 1995, DEV BIOL, V169, P359, DOI 10.1006/dbio.1995.1150; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KRUMLAUF R, 1987, DEVELOPMENT, V99, P603; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LIPKOWITZ S, 1992, J BIOL CHEM, V267, P21065; MORONI MC, 1993, MECH DEVELOP, V44, P139, DOI 10.1016/0925-4773(93)90063-4; Morrison A, 1996, DEVELOPMENT, V122, P1895; NEDELLEC P, 1994, J VIROL, V68, P4525; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; POPPERL H, 1993, MOL CELL BIOL, V13, P257; Proudfoot N, 1996, CELL, V87, P779, DOI 10.1016/S0092-8674(00)81982-0; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RUDDLE FH, 1994, ANNU REV GENET, V28, P423, DOI 10.1146/annurev.ge.28.120194.002231; SACCOMANNO CF, 1992, BIOTECHNIQUES, V13, P847; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1988, NUCLEIC ACIDS RES, V16, P5379, DOI 10.1093/nar/16.12.5379; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; StJacques B, 1996, CURR OPIN GENET DEV, V6, P439, DOI 10.1016/S0959-437X(96)80065-7; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; Zeltser L, 1996, DEVELOPMENT, V122, P2475	44	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29151	29157		10.1074/jbc.272.46.29151	http://dx.doi.org/10.1074/jbc.272.46.29151			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360992	hybrid			2022-12-27	WOS:A1997YF68400051
J	Mathias, RS; Zhang, SHJ; Wilson, E; Gardner, P; Ives, HE				Mathias, RS; Zhang, SHJ; Wilson, E; Gardner, P; Ives, HE			Non-capacitative calcium entry in Chinese hamster ovary cells expressing the platelet-derived growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; PANCREATIC ACINAR-CELLS; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; JURKAT T-CELLS; RAT MAST-CELLS; MESANGIAL CELLS; PLASMA-MEMBRANE; ANGIOTENSIN-II	Platelet-derived growth factor !PDGF) is believed to produce intracellular calcium (Ca-i(2+)) transients by inositol trisphosphate (InsP(3))-mediated release of intracellular Ca2+ stores followed by ''capacitative'' Ca2+ entry due to emptying of these stores, me examined the roles for the phospholipase C gamma-InsP(3) pathway and the emptying of InsP(3)-dependent intracellular Ca2+ stores In PDGF-mediated Ca2+ entry, Intracellular Ca2+ release and Ca2+ entry were measured with fluorometric methods in Chinese hamster ovary cells expressing wild type or mutant PDGF receptors, Activation of the wild type PDGF receptor caused both intracellular ''Ca2+ release,'' measured in nominally 0 Ca2+ extracellular medium, and ''Ca2+ entry,'' measured upon addition of 2 mM Ca2+ medium, Both phases were absent in Chinese hamster ovary cells expressing a PDGF receptor mutant (Y977F,Y989F) that fails to bind phospholipase C gamma. Blockade of the InsP(3) receptor, by microinjection of single cells with low molecular weight heparin (5-50 mg/ml), blocked only Ca-i(2+) release (following PDGF or flash photolysis of caged InsP(3)) and had no effect on PDGF-induced Ca2+ entry, In whole cell patch-clamp experiments, intracellular heparin also failed to block PDGF-evoked ion currents. Release of InsP(3)-dependent intracellular Ca2+ stores, by flash photolysis of caged InsP(3), was apparently not sufficient to maximally activate Ca2+ entry. Intracellular InsP(3) caused significantly less Ca2+ entry than PDGF alone, These data suggest that InsP(3) alone is not sufficient to maximally activate Ca2+ entry by the capacitative pathway and that products of phosphatidylinositol 4,5-bisphosphate breakdown other than InsP, probably play a role in PDGF-mediated Ca2+ entry.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	Mathias, RS (corresponding author), UNIV CALIF SAN FRANCISCO,MED CTR,DEPT PEDIAT,CHILDRENS RENAL CTR,533 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HL-41210, HL07740] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041210, T32HL007740] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALASUBRAMANYAM M, 1993, AM J PHYSIOL, V265, pC321, DOI 10.1152/ajpcell.1993.265.2.C321; BARANSKA J, 1995, CELL CALCIUM, V17, P207, DOI 10.1016/0143-4160(95)90035-7; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1992, J BIOL CHEM, V267, P17722; BLATTER LA, 1992, AM J PHYSIOL, V263, pH576, DOI 10.1152/ajpheart.1992.263.2.H576; BYRON KL, 1992, J BIOL CHEM, V267, P108; CHOW SC, 1993, BIOCHEM J, V293, P395, DOI 10.1042/bj2930395; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; DAWRA RK, 1993, J BIOL CHEM, V268, P20237; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESTACION M, 1993, CELL CALCIUM, V14, P439, DOI 10.1016/0143-4160(93)90003-O; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRACE AM, 1989, P NATL ACAD SCI USA, V86, P2511, DOI 10.1073/pnas.86.7.2511; Gargus J J, 1993, EXS, V66, P289; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; Graessmann A, 1980, Methods Enzymol, V65, P816; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMADA E, 1993, J GEN PHYSIOL, V102, P667, DOI 10.1085/jgp.102.4.667; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSEN CA, 1991, J BIOL CHEM, V266, P18573; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUANG CL, 1987, J BIOL CHEM, V262, P14134; HUANG CL, 1991, J BIOL CHEM, V266, P4045; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LACY P, 1992, PFLUG ARCH EUR J PHY, V420, P127, DOI 10.1007/BF00374980; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; Lobo E. P., 1996, Molecular Biology of the Cell, V7, p368A; Ma HP, 1996, J CLIN INVEST, V97, P2332, DOI 10.1172/JCI118676; MATSUNAGA H, 1994, AM J PHYSIOL, V267, pC456, DOI 10.1152/ajpcell.1994.267.2.C456; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PREMACK BA, 1994, J IMMUNOL, V152, P5226; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SHIRAKAWA H, 1995, CELL CALCIUM, V17, P1, DOI 10.1016/0143-4160(95)90097-7; STAUDERMAN KA, 1989, J BIOL CHEM, V264, P18349; SZOLLOSI J, 1991, CELL CALCIUM, V12, P477, DOI 10.1016/0143-4160(91)90030-I; THORN P, 1993, J BIOL CHEM, V268, P23219; Tinton SA, 1996, EUR J BIOCHEM, V238, P576, DOI 10.1111/j.1432-1033.1996.0576z.x; Ubl JJ, 1997, PFLUG ARCH EUR J PHY, V433, P312; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; XU YP, 1995, J BIOL CHEM, V270, P23887, DOI 10.1074/jbc.270.41.23887; XUAN YT, 1994, AM J PHYSIOL, V266, pC1550; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	46	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29076	29082		10.1074/jbc.272.46.29076	http://dx.doi.org/10.1074/jbc.272.46.29076			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360982	hybrid			2022-12-27	WOS:A1997YF68400041
J	Han, JH; Cote, HCF; Tollefsen, DM				Han, JH; Cote, HCF; Tollefsen, DM			Inhibition of meizothrombin and meizothrombin(desF1) by heparin cofactor .2.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTHROMBIN ACTIVATION PRODUCTS; HUMAN ALPHA-THROMBIN; ANTITHROMBIN-III; FACTOR-XA; CATALYZED ACTIVATION; BOVINE PROTHROMBIN; DERMATAN SULFATE; BINDING EXOSITE; GLYCOSAMINOGLYCANS; INTERMEDIATE	Meizothrombin and meizothrombin(desF1) are intermediates formed during the conversion of prothrombin to thrombin by factor Xa, factor Va, phospholipids, and Ca2+ (prothrombinase). These intermediates are active toward synthetic peptide substrates but have limited ability to interact with platelets or macromolecular substrates such as fibrinogen, Meizothrombin and meizothrombin(desF1) activate protein C, however, and may exert primarily an anticoagulant effect. In this study, we investigated the inhibition of meizothrombin and meizothrombin(desF1) by two glycosaminoglycan-dependent protease inhibitors, heparin cofactor II (HCII) and antithrombin (AT), Purified recombinant meizothrombin and meizothrombin(desF1) were inhibited by HCII in the presence of dermatan sulfate with maximal second-order rate constants of 8 x 10(6) M-1.min(-1) and 1.8 x 10(7) M-1.min(-1), respectively, but were inhibited less than one-tenth as fast by AT in the presence of heparin, Similarly, the products of the prothrombinase reaction were inhibited in situ more effectively by HCII than by AT, When HCII and dermatan sulfate were present continuously during the prothrombinase reaction, meizothrombin was trapped as a sodium dodecyl sulfate-stable complex with HCII and no amidolytic activity could be detected with a thrombin substrate, Our findings indicate that HCII is an effective inhibitor of meizothrombin and meizothrombin(desF1) and, therefore, might regulate the anticoagulant activity of these proteases.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,DIV HEMATOL,ST LOUIS,MO 63110; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOL BIOL,VANCOUVER,BC V6T 1Z3,CANADA	Washington University (WUSTL); Washington University (WUSTL); University of British Columbia			Cote, Helene/K-7896-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055520] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-55520] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON TR, 1986, SCAND J HAEMATOL, V36, P96; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BERTINA RM, 1987, THROMB HAEMOSTASIS, V57, P196; BOVILL EG, 1995, ARTERIOSCL THROM VAS, V15, P754, DOI 10.1161/01.ATV.15.6.754; COTE HCF, 1994, J BIOL CHEM, V269, P11374; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; COUGHLIN SR, 1994, SEMIN HEMATOL, V31, P270; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1974, J BIOL CHEM, V249, P7782; FERNANDEZ F, 1986, BRIT J HAEMATOL, V64, P309, DOI 10.1111/j.1365-2141.1986.tb04124.x; GAN ZR, 1994, J BIOL CHEM, V269, P1301; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Hackeng TM, 1996, BIOCHEM J, V319, P399, DOI 10.1042/bj3190399; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORITA T, 1981, METHOD ENZYMOL, V80, P303; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NESHEIM ME, 1988, J BIOL CHEM, V263, P1037; OLSON ST, 1991, J BIOL CHEM, V266, P6353; PIETERS J, 1987, THROMB RES, V45, P573, DOI 10.1016/0049-3848(87)90320-3; RAGG H, 1990, J BIOL CHEM, V265, P5211; RAGG H, 1990, J BIOL CHEM, V265, P22386; ROSING J, 1986, J BIOL CHEM, V261, P4224; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; Stevens WK, 1996, J BIOL CHEM, V271, P8062, DOI 10.1074/jbc.271.14.8062; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TOLLEFSEN DM, 1995, METABOLIC MOL BASES, P3313; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WU QY, 1992, J BIOL CHEM, V267, P7083	36	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28660	28665		10.1074/jbc.272.45.28660	http://dx.doi.org/10.1074/jbc.272.45.28660			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353333	hybrid			2022-12-27	WOS:A1997YF21900073
J	Barrero, MJ; Montero, M; Alvarez, J				Barrero, MJ; Montero, M; Alvarez, J			Dynamics of [Ca2+] in the endoplasmic reticulum and cytoplasm of intact HeLa cells - A comparative study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; CYTOSOLIC CA2+; LUMINAL CA2+; CALCIUM; RELEASE; RECEPTOR; STORES; ENTRY; INFLUX; CEREBELLUM	We have measured the [Ca2+] in the endoplasmic reticulum ([Ca2+](er)) of intact HeLa cells at both 22 degrees C and 37 degrees C using endoplasmic reticulum-targeted, low Ca2+ affinity aequorin reconstituted with coelenterazine n. Aequorin consumption was much slower at 22 degrees C, and this allowed performing a much longer study of the dynamics of [Ca2+](er). The steady-state [Ca2+](er) (500-600 mu M) was not modified by the temperature, although both the rates of pumping and leak were decreased at 22 degrees C, The behavior of both [Ca2+](er) and cytoplasmic [Ca2+] ([Ca2+](c)) after the addition of increasing concentrations of agonists and/or Ca2+-ATPase inhibitors, or following incubation in Ca2+-free medium were compared. We show that agonists induce a fast but relatively small decrease in [Ca2+](er), which is enough to produce a sharp increase in [Ca2+](c). Termination of Ca2+ release is controlled by feedback inhibition of the inositol 1,4,5-trisphosphate receptors by [Ca2+](c), a mechanism that appears to be designed to release the minimum amount of Ca2+ necessary to produced the required [Ca2+](c) signal. We also show that Ca2+ release is inhibited progressively when [Ca2+](er) decreases below a threshold of about 150 mu M, even in the absence of Ca2+ pumping or [Ca2+](c) increase. This effect is consistent with a regulation of the inositol 1,4,5-trisphosphate-gated channels by [Ca2+](er).	UNIV VALLADOLID, FAC MED, DEPT BIOQUIM & BIOL MOL & FISIOL, INST MOL BIOL & GENET, E-47005 VALLADOLID, SPAIN; CSIC, E-47005 VALLADOLID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Consejo Superior de Investigaciones Cientificas (CSIC)			Alvarez, Javier/K-8210-2014; Montero, Mayte/K-8212-2014	Alvarez, Javier/0000-0003-0636-5521; Montero, Mayte/0000-0001-7702-6653				BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brini M, 1997, MOL BIOL CELL, V8, P129, DOI 10.1091/mbc.8.1.129; Combettes L, 1996, EMBO J, V15, P2086, DOI 10.1002/j.1460-2075.1996.tb00562.x; COMBETTES L, 1992, FEBS LETT, V301, P287, DOI 10.1016/0014-5793(92)80258-I; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HANNAERTMERAH Z, 1995, CELL CALCIUM, V18, P390, DOI 10.1016/0143-4160(95)90054-3; HIROSE K, 1994, NATURE, V372, P791; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; MARSHALL ICB, 1994, BIOCHEM J, V301, P591, DOI 10.1042/bj3010591; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MONTERO M, 1994, J BIOL CHEM, V269, P29451; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; Montero M, 1997, FASEB J, V11, P881, DOI 10.1096/fasebj.11.11.9285486; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; MONTERO M, 1997, IN PRESS J CELL BIOL; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SHIMOMURA O, 1993, CELL CALCIUM, V14, P373, DOI 10.1016/0143-4160(93)90041-4; SHUTTLEWORTH TJ, 1992, J BIOL CHEM, V267, P3573; VILLALOBOS C, 1995, FASEB J, V9, P815, DOI 10.1096/fasebj.9.9.7601345	31	129	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27694	27699		10.1074/jbc.272.44.27694	http://dx.doi.org/10.1074/jbc.272.44.27694			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346910	hybrid			2022-12-27	WOS:A1997YD47300036
J	Itin, C; Rancano, C; Nakajima, Y; Pfeffer, SR				Itin, C; Rancano, C; Nakajima, Y; Pfeffer, SR			A novel assay reveals a role for soluble N-ethylmaleimide-sensitive fusion attachment protein in mannose 6-phosphate receptor transport from endosomes to the trans Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; MEMBRANE-FUSION; ALPHA-SNAP; ENDOPLASMIC-RETICULUM; TYROSINE SULFATION; NSF; YEAST; CELLS; REQUIRES; COMPLEX	Soluble N-ethylmaleimide sensitive fusion protein (NSF) attachment protein (alpha-SNAP) is a soluble protein that enables the NSF ATPase to associate with membranes and facilitate membrane trafficking events, Although NSF and alpha-SNAP have been shown to be required for many membrane transport processes, their role in the transport of mannose 6-phosphate receptors from endosomes to the trans Golgi network was not established. We present here a novel in vitro assay that monitors the transport of cation-dependent mannose 6-phosphate receptors between endosomes and the trans Golgi network, The assay relies on the trans Golgi network localization of tyrosine sulfotransferase and monitors transport of mannose 6-phosphate receptors engineered to contain a consensus sequence for modification by this enzyme. Using this new assay we show that alpha-SNAP strongly stimulates transport in reactions containing limiting amounts of cytosol. Together with alpha-SNAP, NSF can increase the extent of transport. These data show that alpha-SNAP, a soluble component of the SNAP receptor machinery, facilitates transport from endosomes to the trans Golgi network.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University					NIDDK NIH HHS [DK37332] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037332, R01DK037332, R37DK037332] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BAEUERLE PA, 1986, J CELL BIOL, V129, P577; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; EHRHARDT DW, 1995, J BACTERIOL, V177, P6237, DOI 10.1128/jb.177.21.6237-6245.1995; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFFITHS G, 1990, J CELL SCI, V95, P441; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HIEBSCH RR, 1991, J BIOL CHEM, V266, P20323; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITINGER B, 1994, J BIOL CHEM, V269, P8115; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LUDWIG T, 1992, J BIOL CHEM, V267, P12211; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; ROSA P, 1992, J BIOL CHEM, V267, P12227; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHWARZ JK, 1984, J BIOL CHEM, V259, P3554; SCHWEDOCK JS, 1994, J BACTERIOL, V176, P7055, DOI 10.1128/JB.176.22.7055-7064.1994; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	52	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27737	27744		10.1074/jbc.272.44.27737	http://dx.doi.org/10.1074/jbc.272.44.27737			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346916	hybrid			2022-12-27	WOS:A1997YD47300042
J	Liang, PQ; Wu, JM; Garami, M; Gardner, DG				Liang, PQ; Wu, JM; Garami, M; Gardner, DG			Mechanical strain increases expression of the brain natriuretic peptide gene in rat cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ADHESION MOLECULE-1 EXPRESSION; AORTIC ENDOTHELIAL-CELLS; ADRENERGIC STIMULATION; INDUCED HYPERTROPHY; RIBONUCLEIC-ACID; ANGIOTENSIN-II; C-JUN; ATRIAL; PATHWAYS	Using a device that applies cyclical strain (1 Hz) to ventricular cardiocytes cultured on collagen-coated silicone elastomer surfaces, we have demonstrated strain-dependent increases in brain natriuretic peptide (BNP) secretion, BNP mRNA levels, and expression of a transiently transfected -1595 human BNP-luciferase reporter. When actinomycin D (10 mu M) was introduced concomitantly with the strain stimulus, the strain-induced increase in BNP mRNA was eliminated, and the decay of transcripts was identical in the control and strained cells, indicating the lack of independent effects on transcript stability. Strain-dependent -1595 human BNP-luciferase activity was completely inhibited by chelerythrine, a-aminopurine, genistein, and W-7 and only partially or not at all by KN-62, wortmannin, and H-89. The effects of these individual agents paralleled their effects on mitogen-activated protein kinase (MAPK) activity, but not c-Jun N-terminal kinase (JNK) activity, in the cells. Overexpression of wild-type MAPK and, to a lesser extent, JNK increased strain-dependent BNP promoter activity, whereas dominant-negative mutants of MAPK kinase, JNK kinase, or Ras completely blocked strain-dependent reporter activity. These findings provide the first demonstration that mechanical strain can increase myocardial gene expression through a transcriptional mechanism and suggest important roles for MAPK and JNK in mediating this effect.	UNIV CALIF SAN FRANCISCO, METAB RES UNIT, HSW 1141, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL 35753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AWOLESI MA, 1995, J CLIN INVEST, V96, P1449, DOI 10.1172/JCI118181; BENES AJ, 1985, J CELL SCI, V75, P35; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; Cheng JJ, 1996, HYPERTENSION, V28, P386, DOI 10.1161/01.HYP.28.3.386; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAGNINO L, 1991, MOL ENDOCRINOL, V5, P1292, DOI 10.1210/mend-5-9-1292; DAGNINO L, 1992, HYPERTENSION, V20, P690, DOI 10.1161/01.HYP.20.5.690; DENE H, 1987, MOL ENDOCRINOL, V1, P614, DOI 10.1210/mend-1-9-614; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; GARDNER DG, 1992, AM J PHYSIOL, V263, pE239, DOI 10.1152/ajpendo.1992.263.2.E239; GARDNER DG, 1988, J CLIN INVEST, V82, P1275, DOI 10.1172/JCI113726; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; HANFORD DS, 1994, J BIOL CHEM, V269, P26227; HASEGAWA K, 1993, CIRCULATION, V88, P372, DOI 10.1161/01.CIR.88.2.372; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KNOWLTON KU, 1995, J CLIN INVEST, V96, P1311, DOI 10.1172/JCI118166; KOMURO I, 1990, J BIOL CHEM, V265, P3595; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; KovacicMilivojevic B, 1996, ENDOCRINOLOGY, V137, P1108, DOI 10.1210/en.137.3.1108; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; LaPointe MC, 1996, HYPERTENSION, V27, P715, DOI 10.1161/01.HYP.27.3.715; LAPOINTE MC, 1990, HYPERTENSION, V15, P20, DOI 10.1161/01.HYP.15.1.20; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; MERCADIER JJ, 1989, AM J PHYSIOL, V257, pH979, DOI 10.1152/ajpheart.1989.257.3.H979; MORITA T, 1993, J CLIN INVEST, V92, P1706, DOI 10.1172/JCI116757; MUKOYAMA M, 1990, NEW ENGL J MED, V323, P757; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1995, CIRC RES, V76, P1; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SAITO Y, 1989, J CLIN INVEST, V83, P298, DOI 10.1172/JCI113872; SEI CA, 1991, J BIOL CHEM, V266, P15910; SUDOH T, 1989, BIOCHEM BIOPH RES CO, V159, P1427, DOI 10.1016/0006-291X(89)92269-9; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J BIOL CHEM, V269, P30580; VONHARSDORF R, 1989, CIRC RES, V65, P494, DOI 10.1161/01.RES.65.2.494; WEI YF, 1987, J CLIN INVEST, V79, P1325, DOI 10.1172/JCI112957; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; WU JP, 1988, AM J PHYSIOL, V255, pE388, DOI 10.1152/ajpendo.1988.255.3.E388; WU JP, 1991, MOL ENDOCRINOL, V5, P1311, DOI 10.1210/mend-5-9-1311; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054	50	71	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28050	28056		10.1074/jbc.272.44.28050	http://dx.doi.org/10.1074/jbc.272.44.28050			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346958	hybrid			2022-12-27	WOS:A1997YD47300084
J	Fu, C; Chan, AC				Fu, C; Chan, AC			Identification of two tyrosine phosphoproteins, pp70 and pp68, which interact with phospholipase C gamma, Grb2, and Vav after B cell antigen receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; LYN-DEFICIENT MICE; PROTEIN-KINASE-C; T-CELL; CROSS-LINKING; SIGNAL-TRANSDUCTION; LYMPHOCYTES-B; PROTOONCOGENE PRODUCT; AUTOIMMUNE-DISEASE; MOLECULAR-CLONING	Tyrosine phosphorylation of cellular proteins mediates the assembly and localization of effector proteins through interactions facilitated by modular Src homology 2 (SH2) and phosphotyrosine binding domains. We describe here two tyrosine-phosphorylated proteins with M-r values of 70,000 and 68,000 that interact with Grb2, phospholipase C (PLC gamma 1 and PLC gamma 2), and Vav after B cell receptor cross-linking. The interaction of pp70 and pp68 with PLC and Vav is mediated by the carboxyl-terminal SH2 domain of PLC and the SH2 domain of Vav, In contrast, the interaction of pp70 and pp68 with Grb2 requires cooperative binding of the SH2 and SH3 domains of Grb2. Western blot analysis demonstrated that neither pp70 nor pp68 represented the recently described linker protein SLP-76, which binds Grb2, PLC, and Vav in T cells after T cell receptor activation, However, SLP-76 protein was not detected in a number of B cell lines or in normal mouse B cells. Hence, we propose that pp70 and pp68 likely represent B cell homologs of SLP-76 which facilitate and coordinate B cell activation.	WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,GENET PROGRAM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)								BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DAmbrosio D, 1996, EUR J IMMUNOL, V26, P1960, DOI 10.1002/eji.1830260842; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DeFranco AL, 1995, ANN NY ACAD SCI, V766, P195, DOI 10.1111/j.1749-6632.1995.tb26662.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; Law CL, 1996, MOL CELL BIOL, V16, P1305; LAW CL, 1994, J BIOL CHEM, V269, P12310; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Mizuno K, 1996, J EXP MED, V184, P457, DOI 10.1084/jem.184.2.457; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; ROIFMAN CM, 1992, BIOCHEM BIOPH RES CO, V183, P411, DOI 10.1016/0006-291X(92)90496-8; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; SMIT L, 1994, J BIOL CHEM, V269, P20209; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	60	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27362	27368		10.1074/jbc.272.43.27362	http://dx.doi.org/10.1074/jbc.272.43.27362			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341187	hybrid			2022-12-27	WOS:A1997YC65900083
J	Gorovits, BM; Ybarra, J; Seale, JW; Horowitz, PM				Gorovits, BM; Ybarra, J; Seale, JW; Horowitz, PM			Conditions for nucleotide-dependent GroES-GroEL interactions - GroEL(14)(GroES(7))(2) is favored by an asymmetric distribution of nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONIN GROEL; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ATP HYDROLYSIS; CENTRAL CAVITY; PROTEIN; BINDING; CYCLE; RELEASE; MECHANISM	A still unresolved question regarding the mechanism of chaperonin-assisted protein folding involves the stoichiometry of the GroEL-GroES complex. This is important, because the activities of the Escherichia coli chaperonin GroEL are modulated by the cochaperonin GroES. In this report, the binding of GroES to highly purified GroEL in the presence of ATP, ADP, and the nonhydrolyzable ATP analogue, 5'-adenylyl beta,gamma-imidodiphosphate (AMP-PNP), was investigated by using the fluorescence anisotropy of succinimidyl-1-pyrenebutyrate-labeled GroES. In the presence of Mg2+-ATP and high [KC1] (10 nM), two GroES(7) rings bind per one GroEL(14). In contrast, in the presence of ADP or AMP-PNP only one molecule of oligomeric GroES can be tightly bound by GroEL. With AMP-PNP, binding of a small amount (<20%) of a second GroES can be detected. In the presence of ADP alone, a second GroES ring can bind to GroEL weakly and with negative cooperativity. Strikingly, addition of AMP-PNP to the solution containing preformed GroEL(14)(GroES(7)) complexes formed in the presence of ADP results in an increase in the fluorescence anisotropy. Analysis of this effect indicates that 2 mol of GroES oligomer can be bound in the presence of mixed nucleotides. A similar conclusion follows from studies in which ADP is added to an GroEL(14) (GroES(7)) complex formed in the presence of AMP-PNP. This is the first demonstration of an asymmetric distribution of nucleotides bound on the 1:2 GroEL(14) (GroES(7))(2) complex. The relation of the observed phenomena to the proposed mechanism of the GroEL function is discussed.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; Azem A, 1995, P NATL ACAD SCI USA, V92, P12021, DOI 10.1073/pnas.92.26.12021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; Clark AC, 1996, BIOCHEMISTRY-US, V35, P5893, DOI 10.1021/bi953051v; Corrales FJ, 1996, FOLD DES, V1, P265, DOI 10.1016/S1359-0278(96)00040-5; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V28, P439, DOI 10.1101/SQB.1963.028.01.060; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; FERSHT A, 1977, ENZYME STRUCTURE MEC, P217; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gorovits BM, 1997, J BIOL CHEM, V272, P6842, DOI 10.1074/jbc.272.11.6842; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; LORCA O, 1997, J STRUCT BIOL, V118, P31; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Saibil Helen R., 1996, P245, DOI 10.1016/B978-012237455-5/50010-5; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; Torok Z, 1996, J BIOL CHEM, V271, P16180, DOI 10.1074/jbc.271.27.16180; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YBARRA J, 1995, J BIOL CHEM, V270, P22113, DOI 10.1074/jbc.270.38.22113	42	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26999	27004		10.1074/jbc.272.43.26999	http://dx.doi.org/10.1074/jbc.272.43.26999			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341138	hybrid			2022-12-27	WOS:A1997YC65900034
J	Peracchi, A; Beigelman, L; Scott, EC; Uhlenbeck, OC; Herschlag, D				Peracchi, A; Beigelman, L; Scott, EC; Uhlenbeck, OC; Herschlag, D			Involvement of a specific metal ion in the transition of the hammerhead ribozyme to its catalytic conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-CLEAVAGE REACTION; RNA; MECHANISM; PHOSPHOROTHIOATES; STEREOCHEMISTRY; 1,1-DIOXIDE; REAGENT	Previous crystallographic and biochemical studies of the hammerhead ribozyme suggest that a metal ion is ligated by the pro-R-p oxygen of phosphate 9 and by N-7 of G10.1 and has a functional role in the cleavage reaction, We have tested this model by examining the cleavage properties of a hammerhead containing a unique phosphorothioate at position 9. The R-p-, but not S-p-, phosphorothioate reduces the cleavage rate by 10(3)-fold, and the rate can be fully restored by addition of low concentrations of Cd2+, a thiophilic metal ion. These results strongly suggest that this bound metal ion is critical for catalysis, despite its location similar to 20 Angstrom from the cleavage site in the crystal structure. Analysis of the concentration dependence suggests that Cd2+ binds with a K-d of 25 mu M in the ground state and a K-d of 2.5 nm in the transition state, The much stronger transition state binding suggests that the P9 metal ion adopts at least one additional ligand in the transition state and that this metal ion may participate in a large scale conformational change that precedes hammerhead cleavage.	STANFORD UNIV,DEPT BIOCHEM,BECKMAN CTR B400,STANFORD,CA 94305; RIBOZYME PHARMACEUT INC,BOULDER,CO 80301; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Stanford University; University of Colorado System; University of Colorado Boulder			Peracchi, Alessio/G-5167-2012; Peracchi, Alessio/Q-5173-2019	Peracchi, Alessio/0000-0003-3254-4099; Peracchi, Alessio/0000-0003-3254-4099	NIGMS NIH HHS [GM36944, GM49243] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049243, R37GM036944, R01GM036944, R01GM049243] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGERS PMJ, 1978, P NATL ACAD SCI USA, V75, P4798, DOI 10.1073/pnas.75.10.4798; BUZAYAN JM, 1990, NUCLEIC ACIDS RES, V18, P4447, DOI 10.1093/nar/18.15.4447; ClouetDOrval B, 1996, RNA, V2, P483; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; IYER RP, 1990, J ORG CHEM, V55, P4693, DOI 10.1021/jo00302a039; IYER RP, 1990, J AM CHEM SOC, V112, P1253, DOI 10.1021/ja00159a059; JAFFE EK, 1978, J BIOL CHEM, V253, P4823; Knoll R, 1997, RNA, V3, P132; Kragten J., 1978, ATLAS METAL LIGAND E; McKay DB, 1996, RNA, V2, P395; PABONPENA LM, 1991, MOL CELL BIOL, V11, P6109, DOI 10.1128/MCB.11.12.6109; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; Peracchi A, 1996, P NATL ACAD SCI USA, V93, P11522, DOI 10.1073/pnas.93.21.11522; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1989, GENE, V82, P31, DOI 10.1016/0378-1119(89)90027-9; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Sigel RKO, 1997, J AM CHEM SOC, V119, P744, DOI 10.1021/ja962970l; Sillen L, 1964, STABILITY CONSTANTS; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; TUSCHL T, 1993, P NATL ACAD SCI USA, V90, P6991, DOI 10.1073/pnas.90.15.6991; Warnecke JM, 1996, P NATL ACAD SCI USA, V93, P8924, DOI 10.1073/pnas.93.17.8924; WEINSTEIN LB, 1997, IN PRESS NATURE; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677	31	121	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26822	26826		10.1074/jbc.272.43.26822	http://dx.doi.org/10.1074/jbc.272.43.26822			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341112	hybrid			2022-12-27	WOS:A1997YC65900008
J	Cupane, A; Leone, M; Militello, V; Friedman, FK; Koley, AP; Vasquez, GB; Brinigar, WS; Karavitis, M; Fronticelli, C				Cupane, A; Leone, M; Militello, V; Friedman, FK; Koley, AP; Vasquez, GB; Brinigar, WS; Karavitis, M; Fronticelli, C			Modification of beta-chain or beta-chain heme pocket polarity by Val(E11)->Thr substitution has different effects on the steric, dynamic, and functional properties of human recombinant hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DYNAMICS; OPTICAL SPECTROSCOPY; LIGAND-BINDING; ABSORPTION-SPECTROSCOPY; TEMPERATURE-DEPENDENCE; NEUTRON-SCATTERING; ESCHERICHIA-COLI; FLASH-PHOTOLYSIS; GLOBIN LINKAGE; SORET BAND	The dynamic and functional properties of mutant deoxyhemoglobins in which either the beta-globin Val(67)(E11) or the alpha-globin Val(62)(E11) is replaced by threonine have been investigated through the thermal evolution of the Soret absorption band in the temperature range 300 to 20 K and through the kinetics of CO rebinding after flash photolysis at room temperature. The conformational properties of the modified alpha chain and beta chain distal heme pockets were also studied through x-ray crystallography and molecular modeling. The data obtained with the various techniques consistently indicate that the polar isosteric mutation in the distal side of the alpha chain heme pocket has a larger effect on the investigated properties than the analogous mutation on the beta chain. We attribute the observed differences to the presence of a water molecule in the distal heme pocket of the modified alpha chains, interacting with the hydroxyl of the threonine side chain. This is indicated by molecular modeling which showed that the water molecule present in the cu chain distal heme pocket can bridge by H bonding between Thr(62)(E11) and His(58)(E7) without introducing any unfavorable steric interactions. Consistent with the dynamic and functional data, the presence of a water molecule in the distal heme pocket of the modified beta chains is not observed by x-ray crystallography.	INFM, I-90123 PALERMO, ITALY; NCI, MOL CARCINOGENESIS LAB, NIH, BETHESDA, MD 20892 USA; UNIV MARYLAND, INST BIOTECHNOL, CTR ADV RES BIOTECHNOL, ROCKVILLE, MD 20850 USA; TEMPLE UNIV, DEPT CHEM, PHILADELPHIA, PA 19122 USA; UNIV MARYLAND, SCH MED, DEPT BIOCHEM & MOL BIOL, BALTIMORE, MD 21201 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University System of Maryland; University of Maryland Baltimore	Cupane, A (corresponding author), UNIV PALERMO, IST FIS, VIA ARCHIRAFI 36, I-90123 PALERMO, ITALY.		Friedman, Fred K/D-4208-2016; Friedman, Fred/O-6173-2019; Leone, Maurizio/F-2353-2010; MILITELLO, VALERIA/F-2664-2011	Friedman, Fred/0000-0002-0284-7067; Leone, Maurizio/0000-0002-0292-7657; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048517] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLBI-48517] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; BANGCHAROENPAURPONG O, 1984, J AM CHEM SOC, V106, P5688, DOI 10.1021/ja00331a045; BENESCH RE, 1990, J BIOL CHEM, V265, P14881; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; CASE DA, 1979, J MOL BIOL, V132, P353; CHAN CK, 1983, J CHEM PHYS, V79, P5234, DOI 10.1063/1.445712; CHU AH, 1981, J BIOL CHEM, V256, P1199; CORDONE L, 1986, BIOPHYS CHEM, V24, P259, DOI 10.1016/0301-4622(86)85031-1; CORDONE L, 1988, J MOL BIOL, V199, P213, DOI 10.1016/0022-2836(88)90390-7; CUPANE A, 1995, EUR BIOPHYS J BIOPHY, V23, P385, DOI 10.1007/BF00196825; CUPANE A, 1993, BIOPHYS J, V65, P2461, DOI 10.1016/S0006-3495(93)81311-0; CUPANE A, 1993, EUR BIOPHYS J BIOPHY, V21, P385, DOI 10.1007/BF00185865; DIPACE A, 1992, BIOPHYS J, V63, P475, DOI 10.1016/S0006-3495(92)81606-5; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; DOYLE ML, 1992, BIOCHEMISTRY-US, V31, P8629, DOI 10.1021/bi00151a033; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; FRONTICELLI C, 1994, J BIOL CHEM, V269, P23965; FRONTICELLI C, 1993, BIOCHEMISTRY-US, V32, P1235, DOI 10.1021/bi00056a006; FRONTICELLI C, 1991, J PROTEIN CHEM, V10, P495, DOI 10.1007/BF01025477; Gattoni M, 1996, J BIOL CHEM, V271, P10130, DOI 10.1074/jbc.271.17.10130; Hargrove MS, 1997, J BIOL CHEM, V272, P17385, DOI 10.1074/jbc.272.28.17385; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOTTALAM J, 1988, J AM CHEM SOC, V110, P7690, DOI 10.1021/ja00231a018; LEONE M, 1994, EUR BIOPHYS J BIOPHY, V23, P349; Leone M, 1996, EUR BIOPHYS J BIOPHY, V24, P117, DOI 10.1007/BF00180268; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; MARKOWITZ A, 1992, ANAL INSTRUM, V20, P213; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; Melchers B, 1996, BIOPHYS J, V70, P2092, DOI 10.1016/S0006-3495(96)79775-8; MILITELLO V, 1995, PROTEINS, V22, P12, DOI 10.1002/prot.340220103; MURRAY LP, 1988, BIOPHYS CHEM, V29, P63, DOI 10.1016/0301-4622(88)87025-X; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; PARAK F, 1982, J MOL BIOL, V161, P177, DOI 10.1016/0022-2836(82)90285-6; Pechik I, 1996, BIOCHEMISTRY-US, V35, P1935, DOI 10.1021/bi9519967; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; Sanna MT, 1997, J BIOL CHEM, V272, P3478, DOI 10.1074/jbc.272.6.3478; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; Spiro T.G., 1983, IRON PORPHYRINS P2, P89; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P7390, DOI 10.1021/bi00244a005; SRAJER V, 1986, PHYS REV LETT, V57, P6656	46	12	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26271	26278		10.1074/jbc.272.42.26271	http://dx.doi.org/10.1074/jbc.272.42.26271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334196	hybrid			2022-12-27	WOS:A1997YB13900030
J	Saba, JD; Nara, F; Bielawska, A; Garrett, S; Hannun, YA				Saba, JD; Nara, F; Bielawska, A; Garrett, S; Hannun, YA			The BST1 gene of Saccharomyces cerevisiae is the sphingosine-1-phosphate lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND MESSENGER; SPHINGOSINE; INVASIVENESS; CERAMIDE; GROWTH	Sphingolipids elicit a wide variety of eukaryotic cellular responses, most involving regulation of cell growth, differentiation, and apoptosis, Sphingosine 1-phosphate, a sphingolipid catabolite, is mitogenic in fibroblasts and inhibits the chemotactic mobility and invasiveness of human tumor cells, Sphingosine 1-phosphate degradation requires cleavage at the C2-3 carbon bond by sphingosine phosphate lyase, A yeast genetic approach was used to clone the first sphingosine phosphate lyase gene, BST1, BST1 overexpression conferred resistance to sphingosine in yeast, BST1 deletion produced sensitivity to exogenous D-erythro-sphingosine and phytosphingosine and intracellular accumulation of sphingosine 1-phosphate upon exposure to exogenous sphingosine, This study confirms that sphingoid base metabolism is similar in all eukaryotes and suggests that yeast genetics may be useful in the isolation and identification of other genes involved in sphingolipid signaling and metabolism.	DUKE UNIV,MED CTR,DURHAM,NC 27710	Duke University					NATIONAL CANCER INSTITUTE [K11CA059656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NCI NIH HHS [CA59656-06] Funding Source: Medline; NIGMS NIH HHS [GM 43825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Saba JD, 1996, PHILOS T ROY SOC B, V351, P233, DOI 10.1098/rstb.1996.0021; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SIKORSKI RS, 1989, GENETICS, V122, P19; SPEIGEL S, 1996, FASEB J, V10, P1388; SPIEGEL S, 1994, BREAST CANCER RES TR, V31, P337, DOI 10.1007/BF00666166; VELDHOVEN PV, 1991, J BIOL CHEM, V266, P12502; VELDHOVEN PV, 1993, ADV LIPID RES, V26, P69; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WELLS GB, 1983, J BIOL CHEM, V258, P200	14	201	213	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26087	26090		10.1074/jbc.272.42.26087	http://dx.doi.org/10.1074/jbc.272.42.26087			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334171	hybrid			2022-12-27	WOS:A1997YB13900005
J	Shyur, LF; Poland, BW; Honzatko, RB; Fromm, HJ				Shyur, LF; Poland, BW; Honzatko, RB; Fromm, HJ			Major changes in the kinetic mechanism of AMP inhibition and AMP cooperativity attend the mutation of Arg(49) in fructose-1,6-bisphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RABBIT LIVER FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; PORCINE FRUCTOSE-1,6-BISPHOSPHATASE; BISPHOSPHATASE; BINDING; 1,6-BISPHOSPHATASE; 6-PHOSPHATE; TRANSITION; CATIONS	The significance of subunit interface residues Arg(49) and Lys(50) in the function of porcine liver fructose-1,6-bisphosphatase was explored by site-directed mutagenesis, initial rate kinetics, and circular dichroism spectroscopy. The Lys(50) --> Met mutant had kinetic properties similar to the wild-type enzyme but was more thermostable. Mutants Arg(49) --> Leu, Arg(49) --> Asp, Arg(49) --> Cys were less thermostable than the wild-type enzyme yet exhibited wild-type values for k(cat) and K-m. The K-i for the competitive inhibitor fructose 2, 6-bisphosphate increased 3- and 8-fold in Arg(49) --> Leu and Arg(49) --> Asp, respectively, The K-a for Mg2+ increased 4-8-fold for the Arg(49) mutants, with no alteration in the cooperativity of Mg2+ binding, Position 49 mutants had 4-10-fold lower AMP affinity, Most significantly, the mechanism of AMP inhibition with respect to fructose 1,6-bisphosphate changed from noncompetitive (wild-type enzyme) to competitive (Arg(49) --> Leu and Arg(49) --> ASP mutants) and to uncompetitive (Arg(49) --> Cys mutant), In addition, AMP cooperativity was absent in the Arg(49) mutants, The R and T-state circular dichroism spectra of the position 49 mutants were identical and superimposable on only the R-state spectrum of the wild-type enzyme. Changes from noncompetitive to competitive inhibition by AMP can be accommodated within the framework of a steady-state Random Ri Ri mechanism, The appearance of uncompetitive inhibition, however, suggests that a more complex mechanism may be necessary to account for the kinetic properties of the enzyme.	IOWA STATE UNIV,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, XPLOR SYSTEM CRYSTAL; BURTON VA, 1993, BIOCHEM BIOPH RES CO, V192, P511, DOI 10.1006/bbrc.1993.1445; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KE HM, 1991, BIOCHEMISTRY-US, V30, P4412, DOI 10.1021/bi00232a007; KITAJIMA S, 1983, J BIOL CHEM, V258, P7352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3371, DOI 10.1021/bi00794a009; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; Lu GQ, 1997, J BIOL CHEM, V272, P5076, DOI 10.1074/jbc.272.8.5076; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; RUDOLPH FB, 1971, J BIOL CHEM, V246, P6611; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; SHYUR LF, 1995, ARCH BIOCHEM BIOPHYS, V319, P123, DOI 10.1006/abbi.1995.1273; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; Shyur LF, 1996, J BIOL CHEM, V271, P3005, DOI 10.1074/jbc.271.6.3005; SIANO DB, 1975, ARCH BIOCHEM BIOPHYS, V170, P587, DOI 10.1016/0003-9861(75)90154-X; SOLA MM, 1993, INT J BIOCHEM, V25, P1963, DOI 10.1016/0020-711X(88)90332-1; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TAKETA K, 1965, J BIOL CHEM, V240, P651; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Ulm E H, 1975, Methods Enzymol, V42, P369; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; XUE YF, 1994, P NATL ACAD SCI USA, V91, P12482, DOI 10.1073/pnas.91.26.12482; Zhang RL, 1996, BIOCHEMISTRY-US, V35, P3038, DOI 10.1021/bi952188i; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	35	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26295	26299		10.1074/jbc.272.42.26295	http://dx.doi.org/10.1074/jbc.272.42.26295			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334199	hybrid			2022-12-27	WOS:A1997YB13900033
J	Vogan, KJ; Gros, P				Vogan, KJ; Gros, P			The C-terminal subdomain makes an important contribution to the DNA binding activity of the Pax-3 paired domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR BSAP; CRYSTAL-STRUCTURE; HOMEODOMAIN; RECOGNITION; MUTATION; PROTEIN; GENE; IDENTIFICATION; SEQUENCE; FAMILY	The recognition of DNA targets by Pax-3 is achieved through the coordinate use of two distinct helix-turn-helix-based DNA-binding modules: a paired domain, composed of two structurally independent subdomains joined by a short linker, and a paired-type homeodomain, In mouse, the activity of the Pax-3 paired domain is modulated by an alternative splicing event in the paired domain linker region that generates isoforms (Q(+) and Q(-)) with distinct C-terminal subdomain-mediated DNA-binding properties, In this study, we have used derivatives of a classical high affinity paired domain binding site (CD19-2/A) to derive an improved consensus recognition sequence for the Pax-3 C-terminal subdomain, This new consensus differs at six out of eight positions from the C-terminal subdomain recognition motif present in the parent CD19-2/A sequence, and includes a 5'-TT-3' dinucleotide at base pairs 15 and 16 that promotes high affinity binding by both Pax-3 isoforms, However, with a less favorable guanine at position 15, only the Q(-) isoform retains high affinity binding to this sequence, suggesting that this alternative splicing event might serve to stabilize binding to suboptimal recognition sequences. Finally, mutagenic analysis of the linker demonstrates that both the sequence and the spacing in this region contribute to the enhanced DNA-binding properties of the Pax-3/Q(-) isoform. Altogether, our studies establish a clear role for the Pax-3 C-terminal subdomain in DNA recognition and, thus, provide insights into an important mechanism by which Pax proteins achieve distinct target specificities.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University				Vogan, Kyle/0000-0001-9565-9665				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Azuma N, 1996, NAT GENET, V13, P141, DOI 10.1038/ng0696-141; Bertuccioli C, 1996, DEVELOPMENT, V122, P2673; BOBER E, 1994, DEVELOPMENT, V120, P603; CALZONE FJ, 1988, GENE DEV, V2, P1074, DOI 10.1101/gad.2.9.1074; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; Fujioka M, 1996, DEVELOPMENT, V122, P2697; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Holst BD, 1997, P NATL ACAD SCI USA, V94, P1465, DOI 10.1073/pnas.94.4.1465; Jun S, 1996, DEVELOPMENT, V122, P2639; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; NELSON HCM, 1995, CURR OPIN GENET DEV, V5, P180, DOI 10.1016/0959-437X(95)80006-9; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; Phelps DE, 1996, J BIOL CHEM, V271, P7978, DOI 10.1074/jbc.271.14.7978; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tang HK, 1997, HUM MOL GENET, V6, P381, DOI 10.1093/hmg/6.3.381; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	38	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28289	28295		10.1074/jbc.272.45.28289	http://dx.doi.org/10.1074/jbc.272.45.28289			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353283	hybrid			2022-12-27	WOS:A1997YF21900023
J	Funderburgh, JL; Corpuz, LM; Roth, MR; Funderburgh, ML; Tasheva, ES; Conrad, GW				Funderburgh, JL; Corpuz, LM; Roth, MR; Funderburgh, ML; Tasheva, ES; Conrad, GW			Mimecan, the 25-kDa corneal keratan sulfate proteoglycan, is a product of the gene producing osteoglycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOINDUCTIVE FACTOR; BOVINE BONE; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; PROTEIN; UNIQUE; PURIFICATION; ISOFORMS; SEQUENCE; LUMICAN	Bovine cornea contains three unique keratan sulfate proteoglycans (KSPGs), of which two (lumican and keratocan) have been characterized using molecular cloning, The gene for the third protein (KSPG25) has not been identified, This study examined the relationship between the KSPG25 protein and the gene for osteoglycin, a 12-kDa bone glycoprotein, The N-terminal amino acid sequence of KSPG25 occurs in osteoglycin cDNA cloned from bovine cornea, The osteoglycin amino acid sequence makes up the C-terminal 47% of the deduced sequence of the KSPG25 protein, Antibodies to osteoglycin reacted with intact corneal KSPG, with KSPG25 protein, and with a 36-kDa protein, distinct from lumican and keratocan, KSPG25-related proteins, not modified with keratan sulfate, were also detected in several connective tissues, Northern blot analysis showed mRNA transcripts of 2.4, 2.5, and 2.6 kilobases in numerous tissues with the 2.4-kilobase transcript enriched in ocular tissues, Ribonuclease protection analysis detected several protected KSPG25 mRNA fragments, suggesting alternate splicing of KSPG25 transcripts, We conclude that the full-length translation product of the gene producing osteoglycin is a corneal keratan sulfate proteoglycan, also present in many non-corneal tissues without keratan sulfate chains, The multiple size protein products of this gene appear to result from ia situ proteolytic processing and/or alternative splicing of mRNA, The name mimecan is proposed for this gene and its products.			Funderburgh, JL (corresponding author), KANSAS STATE UNIV,DIV BIOL,ACKERT HALL,MANHATTAN,KS 66506, USA.				NATIONAL EYE INSTITUTE [R01EY009368, R01EY000952] Funding Source: NIH RePORTER; NEI NIH HHS [EY09368, EY00952] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BENTZ H, 1989, J BIOL CHEM, V264, P20805; BENTZ H, 1991, MATRIX, V11, P269, DOI 10.1016/S0934-8832(11)80234-9; BENTZ H, 1990, J BIOL CHEM, V265, P5024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONRAD GW, 1982, J BIOL CHEM, V257, P464; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DASCH JR, 1993, CONNECT TISSUE RES, V30, P11, DOI 10.3109/03008209309032927; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUNDERBURGH JL, 1983, CURR EYE RES, V2, P769; FUNDERBURGH JL, 1991, BIOCHEM SOC T, V19, P871, DOI 10.1042/bst0190871; Funderburgh JL, 1996, J BIOL CHEM, V271, P31431, DOI 10.1074/jbc.271.49.31431; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; Hascall V C, 1982, Prog Clin Biol Res, V110 Pt B, P3; Hassell J. R., 1997, Investigative Ophthalmology and Visual Science, V38, pS681; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P3705, DOI 10.1073/pnas.77.6.3705; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; JOST CJ, 1991, J BIOL CHEM, V266, P13336; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; PIATIGORSKY J, 1994, EXS, V71, P241; Sax CM, 1996, J BIOL CHEM, V271, P33568, DOI 10.1074/jbc.271.52.33568; Suzuki M., 1939, J BIOCHEM, V30, P185, DOI [10.1093/oxfordjournals.jbchem.a125896, DOI 10.1093/OXFORDJOURNALS.JBCHEM.A125896]; TASHEVA ES, 1995, GENE DEV, V9, P304, DOI 10.1101/gad.9.3.304	27	152	160	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28089	28095		10.1074/jbc.272.44.28089	http://dx.doi.org/10.1074/jbc.272.44.28089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346963	hybrid			2022-12-27	WOS:A1997YD47300089
J	Iivanainen, A; Kortesmaa, J; Sahlberg, C; Morita, T; Bergmann, U; Thesleff, I; Tryggvason, K				Iivanainen, A; Kortesmaa, J; Sahlberg, C; Morita, T; Bergmann, U; Thesleff, I; Tryggvason, K			Primary structure, developmental expression, and immunolocalization of the murine laminin alpha 4 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; HEPARAN-SULFATE PROTEOGLYCAN; HOMOZYGOUS NONSENSE MUTATION; A-CHAIN; MULTIDOMAIN PROTEIN; GENE LAMC2; CHROMOSOMAL ASSIGNMENT; NEUROMUSCULAR-JUNCTION; TISSUE DISTRIBUTION; MUSCULAR-DYSTROPHY	The complete primary structure of the mouse laminin alpha 4 chain was derived from cDNA clones. The translation product contains a 24-residue signal peptide preceding the mature alpha 4 chain of 1,792 residues. Northern analysis on whole mouse embryos revealed that the expression was weak at day 7, but it later increased and peaked at day 15. In adult tissues the strongest expression was observed in lung and cardiac and skeletal muscles. Weak expression was also seen in other adult tissues such as brain, spleen, liver, kidney, and testis. By in situ hybridization of fetal and newborn tissues, expression of the laminin alpha 4 chain was mainly localized to mesenchymal cells. Strong expression was seen in the villi and submucosa of the developing intestine, the mesenchymal stroma surrounding the branching lung epithelia, and the external root sheath of vibrissae follicles, as well as in cardiac and skeletal muscle fibers. In the developing kidney, intense but transient expression was associated with the differentiation of epithelial kidney tubules from the nephrogenic mesenchyme. Immunohistologic staining with affinity-purified IgG localized the laminin alpha 4 chain primarily to lung septa, heart, and skeletal muscle, capillaries, and perineurium.	KAROLINSKA INST, DEPT MED BIOCHEM & BIOPHYS, DIV MATRIX BIOL, S-17177 STOCKHOLM, SWEDEN; UNIV OULU, BIOCTR, SF-90570 OULU, FINLAND; UNIV OULU, DEPT BIOCHEM, SF-90570 OULU, FINLAND; UNIV HELSINKI, FAC VET MED, DEPT ANAT & EMBRYOL, FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, INST BIOTECHNOL, FIN-00014 HELSINKI, FINLAND	Karolinska Institutet; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Helsinki; University of Helsinki								ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; Airenne T, 1996, GENOMICS, V32, P54, DOI 10.1006/geno.1996.0076; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BERNIER SM, 1995, MATRIX BIOL, V14, P447, DOI 10.1016/0945-053X(95)90002-0; BREITSCHOPF H, 1992, ACTA NEUROPATHOL, V84, P581; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; EHRIG K, 1989, P NATL ACAD SCI USA, V85, P3264; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; GALLIANO MF, 1995, J BIOL CHEM, V270, P21820, DOI 10.1074/jbc.270.37.21820; GARRISON K, 1991, J BIOL CHEM, V266, P22899; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GILBERT SF, 1991, DEV BIOL, P582; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; IIVANAINEN A, 1995, MATRIX BIOL, V14, P489, DOI 10.1016/0945-053X(95)90006-3; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KLEIN G, 1990, DEVELOPMENT, V110, P823; KLEINMAN HK, 1985, J CELL BIOCHEM, V27, P317, DOI 10.1002/jcb.240270402; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; MCGRATH JA, 1995, GENOMICS, V29, P282, DOI 10.1006/geno.1995.1246; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Nielsen H, 1996, PROTEINS, V24, P165, DOI 10.1002/(SICI)1097-0134(199602)24:2<165::AID-PROT4>3.0.CO;2-I; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; NOAKES PG, 1995, NAT GENET, V10, P400, DOI 10.1038/ng0895-400; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; RICHARDS AJ, 1994, GENOMICS, V22, P237, DOI 10.1006/geno.1994.1372; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Sambrook J., 2002, MOL CLONING LAB MANU; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SUGIYAMA S, 1995, EUR J BIOCHEM, V228, P120, DOI 10.1111/j.1432-1033.1995.0120o.x; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; UTANI A, 1995, LAB INVEST, V72, P300; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WEWER UM, 1994, GENOMICS, V24, P243, DOI 10.1006/geno.1994.1612; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; [No title captured]	59	65	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27862	27868		10.1074/jbc.272.44.27862	http://dx.doi.org/10.1074/jbc.272.44.27862			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346933	hybrid			2022-12-27	WOS:A1997YD47300059
J	Kurachi, H; Wada, Y; Tsukamoto, N; Maeda, M; Kubota, H; Hattori, M; Iwai, K; Minato, N				Kurachi, H; Wada, Y; Tsukamoto, N; Maeda, M; Kubota, H; Hattori, M; Iwai, K; Minato, N			Human SPA-1 gene product selectively expressed in lymphoid tissues is a specific GTPase-activating protein for Rap1 and Rap2 - Segregate expression profiles from a rap1GAP gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; BINDING PROTEIN; SH3 DOMAIN; RAS; GRB2; VAV; TRANSFORMATION; IDENTIFICATION	Mouse Spa-1 gene with a region homologous to the human rap1GAP gene is transcriptionally induced in the lymphocytes by mitogenic stimulation, Herein we have cloned a cDNA for its human counterpart. SPA-1 cDNA encodes a 130-kDa protein (p130(SPA-1)) consisting of proline-rich regions and rap1GAP-related domain followed by a coiled coil stretch. Baculovirally expressed p130(SPA-1) exhibited GTPase-activating protein (GAP) activity for Rap1 and Rap2, but not for Ras, Rho, Cdc42, Pac, and Ran, with comparable specific activity to the rap1GAP gene product (p85/95(rap1GAP)). In the cells, p130(SPA-1) was mostly localized at the perinuclear membranous region co-localizing with Rap1 and Rap2, Expression of SPA-1 and rap1GAP genes tended to be segregate in various tissues, lymphoid tissues expressing abundant SPA-1 transcript without rap1GAP, while those such as brain, kidney, and pancreas exhibiting rap1GAP mRNA with little SPA-1, Promyelocytic HL-60 cells, which expressed p130(SPA-1) With little p85/95(rap1GAP) in uninduced state, showed progressive decline in p130(SPA-1) and conversely drastic increase in p85/95(rap1GAP) as they ceased from proliferation and differentiated into macrophages by 12-O-tetradecanoylphorbol-13-acetate. These results suggested that products of SPA-1 and rap1GAP genes, albeit comparable GAP activity for Rap1 and Rap2, functioned in the distinct contexts depending on cell types and/or states.	KYOTO UNIV,GRAD SCH MED,DEPT IMMUNOL & CELL BIOL,SAKYO KU,KYOTO 606,JAPAN; CHUGAI RES INST MOL MED,IBARAKI,OSAKA 30014,JAPAN	Kyoto University			IWAI, KAZUHIRO/GSN-7385-2022	Iwai, Kazuhiro/0000-0001-5620-5951				ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HATTORI M, 1995, MOL CELL BIOL, V15, P552, DOI 10.1128/MCB.15.1.552; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; JANOUEIXLEROSEY I, 1992, BIOCHEM BIOPH RES CO, V189, P455, DOI 10.1016/0006-291X(92)91580-J; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; *TECTS, 1993, CELL, V75, P1305; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; Wada Y, 1997, GENOMICS, V39, P66, DOI 10.1006/geno.1996.4464; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS J, 1994, CYTOGENET CELL GENET, V66, P18, DOI 10.1159/000133655; Wienecke R, 1997, AM J PATHOL, V150, P43; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	47	104	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28081	28088		10.1074/jbc.272.44.28081	http://dx.doi.org/10.1074/jbc.272.44.28081			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346962	hybrid			2022-12-27	WOS:A1997YD47300088
J	Szardenings, M; Tornroth, S; Mutulis, F; Muceniece, R; Keinanen, K; Kuusinen, A; Wikberg, JES				Szardenings, M; Tornroth, S; Mutulis, F; Muceniece, R; Keinanen, K; Kuusinen, A; Wikberg, JES			Phage display selection on whole cells yields a peptide specific for melanocortin receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; INSECT CELLS; COMBINATORIAL LIBRARIES; RADIOLIGAND BINDING; FILAMENTOUS PHAGE; EXPRESSION SYSTEM; LIGAND-BINDING; AFFINITY; IDENTIFICATION; ANTAGONISTS	A phage display system for the selection of peptides binding to heterologously expressed human melanocortin receptor 1 on the surface of insect cells has been established. It could be shown that phage particles displaying the natural ligand alpha-melanocyte-stimulating hormone bind selectively to cells expressing this receptor and that these phages exhibit biological activity on mouse B16F1 melanoma cells. Insect cells were superior to other cell lines tested and have been used to select binders from a small library, in which critical determinants (Phe(7)-Arg(8)-Trp(9)) were kept, whereas the flanking regions where allowed to variate freely. One peptide displaying little similarity with native hormone was found that binds to the receptor also in its free form with an affinity of 7 nM. It showed a remarkable selectivity for this receptor, because it binds to the other melanocortin receptor subtypes with a maximum affinity of 21 mu M. This is the first time phage display has been used successfully with G-protein-coupled receptors lacking an extracellular binding domain.	LATVIAN INST ORGAN SYNTH,DEPT MED CHEM,LV-1006 RIGA,LATVIA; LATVIAN INST ORGAN SYNTH,PHARMACOL LAB,LV-1006 RIGA,LATVIA; VTT BIOTECHNOL & FOOD RES,FIN-02044 ESPOO,FINLAND	Latvian Institute of Organic Synthesis; Latvian Institute of Organic Synthesis; VTT Technical Research Center Finland	Szardenings, M (corresponding author), UNIV UPPSALA,CTR BIOMED,DEPT PHARMACEUT PHARMACOL,BOX 591,S-75124 UPPSALA,SWEDEN.		Keinanen, Kari/E-9122-2010; Törnroth-Horsefield, Susanna/B-2702-2010	Tornroth-Horsefield, Susanna/0000-0002-9435-8243; Szardenings, Michael/0000-0003-1553-9765				ADAN RAH, 1994, EUR J PHARM-MOLEC PH, V269, P331, DOI 10.1016/0922-4106(94)90041-8; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BOYLE JS, 1995, TRENDS GENET, V11, P8, DOI 10.1016/S0168-9525(00)88977-5; CAMPBELL MJ, 1995, BIOTECHNIQUES, V18, P1027; Chhajlani V, 1996, BIOCHEM MOL BIOL INT, V38, P73; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; CHUNG CT, 1993, METHOD ENZYMOL, V218, P621; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; Cortese Riccardo, 1995, Current Opinion in Biotechnology, V6, P73, DOI 10.1016/0958-1669(95)80012-3; DOOLEY CT, 1995, PEPTIDE RES, V8, P124; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; DOOLEY CT, 1994, SCIENCE, V266, P2019, DOI 10.1126/science.7801131; DOORBAR J, 1994, J MOL BIOL, V244, P361, DOI 10.1006/jmbi.1994.1736; DOYLE MV, 1995, COMBINATORIAL LIB SY, P159; EBERLE AN, 1988, MELANOTROPINS CHEM P, P210; EISINGER DP, 1996, BIOTECHNIQUES, V22, P250; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAM H, 1993, J IMMUNOL METHODS, V161, P169, DOI 10.1016/0022-1759(93)90292-F; HaskellLuevano C, 1996, J MED CHEM, V39, P432, DOI 10.1021/jm950407s; Hidajat R, 1997, BIOTECHNIQUES, V22, P32, DOI 10.2144/97221bm04; Hirschmann R, 1996, J MED CHEM, V39, P2441, DOI 10.1021/jm960281e; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HRUBY VJ, 1995, J MED CHEM, V38, P3454, DOI 10.1021/jm00018a005; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; JACOBSSON K, 1995, BIOTECHNIQUES, V18, P878; JACOBSSON K, 1997, MICROBIOL RES, V152, P1; Kay B. K, 1996, PHAGE DISPLAY PEPTID; KAY BK, 1993, GENE, V128, P59, DOI 10.1016/0378-1119(93)90153-T; KUUSINEN A, 1995, EUR J BIOCHEM, V233, P720, DOI 10.1111/j.1432-1033.1995.720_3.x; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; LUNEC J, 1992, MELANOMA RES, V2, P5, DOI 10.1097/00008390-199205000-00002; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MCCAFFERTY J, 1991, PROTEIN ENG, V4, P955, DOI 10.1093/protein/4.8.955; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; NORDSTEDT C, 1990, ANAL BIOCHEM, V189, P231, DOI 10.1016/0003-2697(90)90113-N; ODONOHUE TL, 1982, PEPTIDES, V3, P353, DOI 10.1016/0196-9781(82)90098-5; ONEIL KT, 1994, METHOD ENZYMOL, V245, P370; PARMLEY SF, 1989, ADV EXP MED BIOL, V251, P215; PRUSIS P, 1995, BIOCHEM BIOPH RES CO, V210, P205, DOI 10.1006/bbrc.1995.1647; QUILLAN JM, 1995, P NATL ACAD SCI USA, V92, P2894, DOI 10.1073/pnas.92.7.2894; ROBERTS BL, 1992, GENE, V121, P9, DOI 10.1016/0378-1119(92)90156-J; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; SAGGIO I, 1995, EMBO J, V14, P3045, DOI 10.1002/j.1460-2075.1995.tb07307.x; SAGGIO I, 1995, GENE, V152, P35, DOI 10.1016/0378-1119(94)00733-9; SAHM UG, 1994, PEPTIDES, V15, P1297, DOI 10.1016/0196-9781(94)90157-0; Schioth HB, 1996, BIOCHEM BIOPH RES CO, V221, P807, DOI 10.1006/bbrc.1996.0678; Schioth HB, 1996, PHARMACOL TOXICOL, V79, P161, DOI 10.1111/j.1600-0773.1996.tb00261.x; SCHIOTH HB, 1995, EUR J PHARM-MOLEC PH, V288, P311, DOI 10.1016/0922-4106(95)90043-8; Schioth HB, 1996, LIFE SCI, V59, P797, DOI 10.1016/0024-3205(96)00370-0; Schioth HB, 1996, EUR J PHARMACOL, V314, P381, DOI 10.1016/S0014-2999(96)00566-3; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SZARDENINGS M, 1990, GENE, V94, P1, DOI 10.1016/0378-1119(90)90460-9; TESAR M, 1995, IMMUNOTECHNOLOGY, V1, P53, DOI 10.1016/1380-2933(95)00005-4; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WICKHAM TJ, 1992, BIOTECHNOL PROGR, V8, P391, DOI 10.1021/bp00017a003; WIDERSTEN M, 1995, J MOL BIOL, V250, P115, DOI 10.1006/jmbi.1995.0362; ZUCKERMANN RN, 1994, J MED CHEM, V37, P2678, DOI 10.1021/jm00043a007	65	72	91	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27943	27948		10.1074/jbc.272.44.27943	http://dx.doi.org/10.1074/jbc.272.44.27943			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346944	hybrid			2022-12-27	WOS:A1997YD47300070
J	Wang, L; Fast, DG; Attie, AD				Wang, L; Fast, DG; Attie, AD			The enzymatic and non-enzymatic roles of protein-disulfide isomerase in apolipoprotein B secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY-LIPOPROTEIN; HUMAN PROLYL 4-HYDROXYLASE; RETINOL-BINDING PROTEIN; ACTIVE-SITE CYSTEINE; RAT HEPATOMA-CELLS; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; HEPG2 CELLS; FATTY-ACIDS	Secretion of apolipoprotein B (apoB) from mammalian cells requires the presence of functional microsomal triglyceride transfer protein (MTP). We previously reported that co-expressing the human intestinal form of apoB, B48, with both subunits of human MTP in oleate-treated Sf21 cells led to a dramatic induction of B48 secretion. Deletion mutagenesis studies showed that the cysteine-enriched amino terminus of apoB was necessary for the MTP responsiveness (Gretch, D. G., Sturley, S. L., Wang, L., Dunning, A., Grunwald, K. A. A., Wetterau, J. R., Yao, Z., Talmud, P., and Attie, A. D. (1996) J. Biol. Chem. 271, 8682-8691). We therefore hypothesized that the small subunit of MTP, protein-disulfide isomerase (PDI), plays a role in apoB secretion by facilitating correct disulfide bond formation. To determine whether the enzymatic activities of PDI are important for MTP-stimulated apoB secretion, the wild type PDI subunit was replaced with an active site mutant, mPDI (Cys(36)--> Ser/Cys(380) --> Ser), lacking both disulfide shuffling and redox activities. MTP containing mPDI was fully functional in promoting apoB and triglyceride secretion. Therefore, the shufflase and redox activities of PDI are not necessary for the function of MTP. Since PDI exists in large molar excess over the other subunit of MTP, the role of free PDI (independent of the MTP complex) was investigated. PDI or mPDI was co-expressed with B48 and B17, a fragment encompassing the amino-terminal 17% of apoB. Mutant PDI significantly and specifically reduced the accumulation of the B17 and E48 both intracellularly and in the culture medium. The reduction was partially eliminated by the protease inhibitor N-acetyl-leucyl-leucyl-norleucinal, consistent with rapid co-or post-translational degradation of apoB in the presence of mPDI. Treating the cells with oleate reversed the effect of mPDI on B48 secretion in a dose-dependent manner, but had no effect on B17. In conclusion: 1) the role of PDI in the MTP complex involves functions other than its known enzymatic activities; 2) one or both of the enzymatic activities of free PDI is/are important for the MTP-independent steps of apoB secretion; 3) oleate can affect apoB secretion at high physiological concentrations and compensate for the insufficiency of PDI activities.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT COMPARAT BIOSCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NHLBI NIH HHS [HL37251] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; BONIFACINO JS, 1994, MODERN CELL BIOL CEL, V15, P137; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BRANDES HK, 1993, J BIOL CHEM, V268, P18411; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHIVERS PT, 1995, EMBO J, V15, P2559; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; DAVIS RA, 1982, J BIOL CHEM, V257, P908; Dirlam KA, 1996, PROTEIN EXPRES PURIF, V8, P489, DOI 10.1016/S1046-5928(96)90129-1; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; Du EZ, 1996, J LIPID RES, V37, P1309; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; GRETCH DG, 1991, P NATL ACAD SCI USA, V88, P8530, DOI 10.1073/pnas.88.19.8530; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; KAJI EH, 1993, J BIOL CHEM, V268, P22188; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LABOISSIERE MCA, 1995, PROTEIN EXPRES PURIF, V6, P700, DOI 10.1006/prep.1995.1092; Lamberg A, 1996, BIOCHEM J, V315, P533, DOI 10.1042/bj3150533; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; MELHUS H, 1992, J BIOL CHEM, V267, P12036; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PATSCH W, 1983, J CLIN INVEST, V72, P371, DOI 10.1172/JCI110977; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RICCI B, 1995, J BIOL CHEM, V270, P14281, DOI 10.1074/jbc.270.24.14281; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SALAM WH, 1988, BIOCHEM J, V251, P809, DOI 10.1042/bj2510809; SAUNDERS AJ, 1993, PROTEIN SCI, V2, P1183, DOI 10.1002/pro.5560020713; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Shelness GS, 1996, J LIPID RES, V37, P408; SINGH R, 1990, J AM CHEM SOC, V112, P1190, DOI 10.1021/ja00159a046; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1984, J BIOL CHEM, V259, P863; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801; WHITE AL, 1992, J BIOL CHEM, V267, P15657; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Wu XJ, 1997, J BIOL CHEM, V272, P11575; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; YAO ZM, 1991, J BIOL CHEM, V266, P3300; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	69	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27644	27651		10.1074/jbc.272.44.27644	http://dx.doi.org/10.1074/jbc.272.44.27644			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346903	hybrid			2022-12-27	WOS:A1997YD47300029
J	Fan, JQ; Lee, YC				Fan, JQ; Lee, YC			Detailed studies on substrate structure requirements of glycoamidases A and F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-GLYCOSIDASE-F; PEPTIDE-N-4-(N-ACETYL-BETA-D-GLUCOSAMINYL)ASPARAGINE AMIDASE-F; ASPARAGINE-LINKED GLYCANS; ANIMAL-CELLS; PEPTIDE; OLIGOSACCHARIDES; GLYCOPEPTIDES; DERIVATIVES; ACETYLGLUCOSAMINIDASE; DEGLYCOSYLATION	Glycoamidases (peptide-N-4-(N-acetyl-beta-glucosaminyl)-asparagine amidase, EC 3.5.1.52; also known as peptide: N-glycanases (PNGases) release N-linked oligosaccharides from glycopeptides and/or glycoproteins by hydrolyzing the glycosylated beta-amide bond of the asparagine side chain. The most widely used glycoamidases are those from Flavobacterium meningosepticum (glycoamidase F or PNGase F) and almond emulsin (glycoamidase A or PNGase A). The study the substrate structure requirement of these enzymes systematically, we synthesized >30 glycopeptides containing cellobiose, lactose, GlcNAc, and di-N,N'-acetylchitobiose (CTB). The length of the peptide was varied from one to five amino acids, and glycosylamines were linked to either Asn or Gln located at different positions in the peptide, including NH2 and COOH termini. Neither enzyme could cleave cellobiose and lactose glycopeptides, indicating that the 2-acetamido group on the Asn-linked GlcNAc is important in the recognition by both glycoamidases A and F. GlcNAc peptides could be cleaved by both enzymes, albeit not as effectively as CTB glycopeptides. Neither enzyme requires the Asn-Xaa-(Ser/Thr) sequence (required for N-glycosylation) for activity. Glycoamidase A could even hydrolyze a Gln-bound CTB glycopeptide, whereas the action of glycoamidase A could act on CTB dipeptides, glycoamidase A could act on CTB dipeptides, glycoamidase F preferred a tripeptide or longer. The K-m and V-max values of glycoamidase A for t-butoxycarbonyl-(CTB)-Asn-Ala-Ser-OMe were 2.1 nM and 0.66 mu mol/min/mg, respectively. A natural glycodipeptide, Man(9)-GlcNAc(2)-Asn-Phe, was also completely hydrolyzed by glycoamidase A.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; TOKYO METROPOLITAN INST MED SCI,DEPT CLIN GENET,TOKYO 113,JAPAN	Johns Hopkins University; Tokyo Metropolitan Institute of Medical Science								ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P84, DOI 10.1007/BF00731873; ANISFELD ST, 1990, J ORG CHEM, V55, P5560, DOI 10.1021/jo00308a009; CHU FK, 1986, J BIOL CHEM, V261, P172; DUNSTAN D, 1972, CARBOHYD RES, V23, P17, DOI 10.1016/S0008-6215(00)81572-4; EBERT RF, 1986, ANAL BIOCHEM, V154, P431, DOI 10.1016/0003-2697(86)90010-2; FAN JQ, 1994, ANAL BIOCHEM, V219, P224, DOI 10.1006/abio.1994.1261; FAN JQ, 1995, J BIOL CHEM, V270, P17723, DOI 10.1074/jbc.270.30.17723; FAYE L, 1989, PHYSIOL PLANTARUM, V75, P309, DOI 10.1111/j.1399-3054.1989.tb06187.x; GARG HG, 1975, CARBOHYD RES, V43, P371, DOI 10.1016/S0008-6215(00)83502-8; GARG HG, 1985, ADV CARBOHYD CHEM BI, V43, P135, DOI 10.1016/S0065-2318(08)60068-2; GARG HG, 1972, CARBOHYD RES, V23, P437, DOI 10.1016/S0008-6215(00)82696-8; HIRANI S, 1987, ANAL BIOCHEM, V162, P485, DOI 10.1016/0003-2697(87)90424-6; ISHIHARA H, 1979, J BIOL CHEM, V254, P715; KALLIN E, 1986, GLYCOCONJUGATE J, V3, P311, DOI 10.1007/BF01049500; KARTHA KPR, 1990, J CARBOHYD CHEM, V9, P777, DOI 10.1080/07328309008543873; KHORLIN AY, 1980, CARBOHYD RES, V85, P201, DOI 10.1016/S0008-6215(00)84671-6; KITAJIMA K, 1995, ARCH BIOCHEM BIOPHYS, V319, P393, DOI 10.1006/abbi.1995.1309; KUHN P, 1994, BIOCHEMISTRY-US, V33, P11699, DOI 10.1021/bi00205a005; KUHN P, 1995, J BIOL CHEM, V270, P29493, DOI 10.1074/jbc.270.49.29493; KUNZ H, 1987, ANGEW CHEM INT EDIT, V26, P294, DOI 10.1002/anie.198702941; LEE KB, 1995, ANAL BIOCHEM, V230, P31, DOI 10.1006/abio.1995.1433; LHERNOULD S, 1992, GLYCOCONJUGATE J, V9, P191, DOI 10.1007/BF00731164; MANGER ID, 1992, BIOCHEMISTRY-US, V31, P10724, DOI 10.1021/bi00159a012; MUSSAR KJ, 1989, J BIOCHEM BIOPH METH, V20, P53, DOI 10.1016/0165-022X(89)90081-X; NISHIMURA SI, 1989, CARBOHYD RES, V194, P223, DOI 10.1016/0008-6215(89)85021-9; PLUMMER TH, 1987, EUR J BIOCHEM, V163, P167, DOI 10.1111/j.1432-1033.1987.tb10751.x; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; PLUMMER TH, 1981, J BIOL CHEM, V256, P243; SEKO A, 1991, J BIOL CHEM, V266, P22110; SPINOLA M, 1970, CARBOHYD RES, V15, P361, DOI 10.1016/S0008-6215(00)80452-8; SPINOLA M, 1970, J BIOL CHEM, V245, P4158; STAUDACHER E, 1992, GLYCOCONJUGATE J, V9, P82, DOI 10.1007/BF00731703; SUGIYAMA K, 1983, BIOCHEM BIOPH RES CO, V112, P155, DOI 10.1016/0006-291X(83)91810-7; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V194, P1124, DOI 10.1006/bbrc.1993.1938; SUZUKI T, 1994, GLYCOCONJUGATE J, V11, P469, DOI 10.1007/BF00731283; SUZUKI T, 1995, J BIOL CHEM, V270, P15181, DOI 10.1074/jbc.270.25.15181; SUZUKI T, 1994, GLYCOBIOLOGY, V4, P777, DOI 10.1093/glycob/4.6.777; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; TAKAHASHI N, 1978, J BIOCHEM-TOKYO, V84, P1467, DOI 10.1093/oxfordjournals.jbchem.a132270; TAKAHASHI N, 1986, BIOCHEMISTRY-US, V25, P388, DOI 10.1021/bi00350a018; TAKAHASHI N, 1992, HDB ENDOGLYCOSIDASES, P199; TAKAHASHI N, 1992, HDB ENDOGLYCOSIDASES, P183; TAMURA T, 1994, ANAL BIOCHEM, V216, P335, DOI 10.1006/abio.1994.1050; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; Wang LX, 1996, TETRAHEDRON LETT, V37, P1975; WONG SYC, 1993, GLYCOCONJUGATE J, V10, P227, DOI 10.1007/BF00702204	48	55	63	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27058	27064		10.1074/jbc.272.43.27058	http://dx.doi.org/10.1074/jbc.272.43.27058			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341145	hybrid			2022-12-27	WOS:A1997YC65900041
J	Nadeau, OW; Sacks, DB; Carlson, GM				Nadeau, OW; Sacks, DB; Carlson, GM			The structural effects of endogenous and exogenous Ca2+/calmodulin on phosphorylase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT-SKELETAL-MUSCLE; GAMMA-SUBUNIT; CATALYTIC SUBUNIT; MOLECULAR-BASIS; PROTEIN-KINASE; CDNA CLONING; BETA-SUBUNIT; B KINASE; CALMODULIN; ACTIVATION	The activity of phosphorylase b kinase (PbK) is stimulated by Ca2+ ions, which act through its endogenous calmodulin subunit (delta), and further stimulated by the Ca2+-dependent binding of exogenous calmodulin (delta'). In contrast to their highly characterized effects on activity, little is known regarding the structural effects on the (alpha beta gamma delta)(4) PbK. holoenzyme induced by Ca2+ and delta'/Ca2+, We have used mono- and bifunctional chemical modifiers as conformational probes to compare how the two effecters influence the structure of the catalytic gamma subunit and the interactions among all of the subunits. As determined by reductive methylation and carboxymethylation, Ca2+ increased She accessibility of the gamma subunit; it also increased the formation by phenylenedimaleimide of an alpha gamma gamma conjugate that is characteristic of activated conformations of PbK (Nadeau, O.W., Sacks, D.M., and Carlson, G.M. (1997) J. Biol. Chem:. 272, 26196-26201); however; Ca2+ also had structural effects that were clearly distinct fi om other activators, Moreover, similar structural effects of Ca2+ were observed with PbK that had been activated by phosphorylation, consistent with the fact that such activation does not eliminate the catalytic dependence of the enzyme on Ca2+, Our results suggest tiers of conformational transitions in the activation of PbK, with the most fundamental being induced by Ca2+. Analysis of the various cross-linked conjugates formed in the presence of Ca2+ by o-phenylenedimaleimide or m-maleimidobenzoyl-N-hydroxysuccinimide ester showed that the binding of Ca2+ to the delta subunit triggers changes in the interactions among all subunits, including between protomers, indicating an extensive communication network throughout the PbK complex. Most of the structural effects of delta'/Ca2+ were qualitatively similar to, but quantitatively greater than, the effects of Ca2+ alone; but delta'/Ca2+ also had distinct effects, especially involving cross-linking of the delta subunit.	UNIV TENNESSEE, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Sacks, David/0000-0003-3100-0735	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032953, R56DK032953] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32953] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROSTROM CO, 1971, J BIOL CHEM, V246, P1961; CHAN KFJ, 1982, J BIOL CHEM, V257, P5948; CHENG A, 1985, J BIOL CHEM, V260, P2535; COHEN P, 1979, FEBS LETT, V104, P25, DOI 10.1016/0014-5793(79)81078-9; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; COHEN P, 1980, EUR J BIOCHEM, V111, P563, DOI 10.1111/j.1432-1033.1980.tb04972.x; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEPAOLIROACH AA, 1979, FEBS LETT, V105, P321, DOI 10.1016/0014-5793(79)80639-0; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P10274, DOI 10.1021/bi00106a027; FARRAR YJK, 1993, J BIOL CHEM, V268, P4120; FITZGERALD TJ, 1984, J BIOL CHEM, V259, P3266; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRAND RJA, 1981, EUR J BIOCHEM, V113, P359, DOI 10.1111/j.1432-1033.1981.tb05074.x; HALLENBECK PC, 1983, J BIOL CHEM, V258, P3493; HEILMEYER LMG, 1991, BIOCHIM BIOPHYS ACTA, V1094, P168, DOI 10.1016/0167-4889(91)90005-I; HEILMEYER LMG, 1993, MOL CELL BIOCHEM, V128, P19, DOI 10.1007/BF01076754; JAMES P, 1991, J BIOL CHEM, V266, P7087; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KEE SM, 1987, J BIOL CHEM, V262, P9448; KEE SM, 1986, J BIOL CHEM, V261, P4732; KILIMANN MW, 1988, P NATL ACAD SCI USA, V85, P9381, DOI 10.1073/pnas.85.24.9381; KING MM, 1982, J BIOL CHEM, V257, P4058; KING MM, 1982, FEBS LETT, V140, P131, DOI 10.1016/0014-5793(82)80537-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN DM, 1989, J BIOL CHEM, V264, P2373; Nadeau OW, 1997, J BIOL CHEM, V272, P26196, DOI 10.1074/jbc.272.42.26196; NADEAU OW, 1995, FASEB J, V9, pA1304; NADEAU OW, 1994, J BIOL CHEM, V269, P29670; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; PAUDEL HK, 1990, P NATL ACAD SCI USA, V87, P7285, DOI 10.1073/pnas.87.18.7285; Pickett-Gies CA., 1986, ENZYMES, V17, P395; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SANCHEZ VE, 1992, FASEB J, V6, pA339; SHENOLIKAR S, 1979, EUR J BIOCHEM, V100, P329, DOI 10.1111/j.1432-1033.1979.tb04175.x; TREMPE MR, 1987, J BIOL CHEM, V262, P4333; WALSH DA, 1971, J BIOL CHEM, V246, P1968; WALSH KX, 1980, J BIOL CHEM, V255, P5036; Wangsgard WP, 1997, BIOCHEM BIOPH RES CO, V230, P179, DOI 10.1006/bbrc.1996.5927; Wilkinson DA, 1997, J MOL BIOL, V265, P319, DOI 10.1006/jmbi.1996.0739; WILKINSON DA, 1993, THESIS U TENNESSEE M, P107; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5014, DOI 10.1021/bi9528107; YOSHIKAWA K, 1983, EUR J BIOCHEM, V136, P413, DOI 10.1111/j.1432-1033.1983.tb07758.x; ZANDER NF, 1988, P NATL ACAD SCI USA, V85, P2929, DOI 10.1073/pnas.85.9.2929	46	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26202	26209		10.1074/jbc.272.42.26202	http://dx.doi.org/10.1074/jbc.272.42.26202			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334188	hybrid			2022-12-27	WOS:A1997YB13900022
J	Hunt, JE; Friend, DS; Gurish, MF; Feyfant, E; Sali, A; Huang, CF; Ghildyal, N; Stechschulte, S; Austen, KF; Stevens, RL				Hunt, JE; Friend, DS; Gurish, MF; Feyfant, E; Sali, A; Huang, CF; Ghildyal, N; Stechschulte, S; Austen, KF; Stevens, RL			Mouse mast cell protease 9, a novel member of the chromosome 14 family of serine proteases that is selectively expressed in uterine mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTES-T; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; NEUTRAL PROTEASES; MOLECULAR-CLONING; GLOBIN GENE; MICE; DIFFERENTIATION; IDENTIFICATION; SEQUENCE	Mouse mast cell protease (mMCP) 1, mMCP-2, mMCP-4, and mMCP-5 are members of a family of related serine proteases whose genes reside within an similar to 850 kilobase (kb) complex on chromosome 14 that does not readily undergo crossover events, While mapping the mMCP-1 gene, we isolated a novel gene that encodes a homologous serine protease designated mMCP-9. The mMCP-9 and mMCP-1 genes are only similar to 7 kb apart on the chromosome and are oriented back to back, The proximity of the mMCP-1 and mMCP-9 genes now suggests that the low recombination frequency of the complex is due to the closeness of some of its genes, The mMCP-9 transcript and protein were observed in the jejunal submucosa of Trichinella spiralis-infected BALB/c mice, However, in normal BALB/c mice, mMCP-9 transcript and protein were found only in those mast cells that reside in the uterus, Thus, the expression of mMCP-9 differs from that of all other chymases. The observation that BALB/c mouse bone marrow-derived mast cells developed with interleukin (IL) 10 and c-kif ligand contain mMCP-9 transcript, whereas those developed with IL-3 do not, indicates that the expression of this particular chymase is regulated by the cytokine microenvironment, Comparative protein structure modeling revealed that mMCP-9 is the only known granule protease with three positively charged regions on its surface. This property may allow mMCP-9 to form multimeric complexes with serglycin proteoglycans and other negatively charged proteins inside the granule, Although mMCP-9 exhibits a >50% overall amino acid sequence identity with its homologous chymases, it has a unique substrate-binding cleft, This finding suggests that each member of the chromosome 14 family of serine proteases evolved to degrade a distinct group of proteins.	BRIGHAM & WOMENS HOSP, DIV RHEUMATOL ALLERGY & IMMUNOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Rockefeller University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022531, R01AI023483, R37AI022531, T32AI007306] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-07306, AI-23483, AI-22531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BECKSTEAD JH, 1981, BLOOD, V57, P1088; BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BOENISH T, 1989, IMMUNOLOGICAL STAINI, P11; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; DEYOUNG MB, 1987, ARCH BIOCHEM BIOPHYS, V254, P222, DOI 10.1016/0003-9861(87)90098-1; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GURISH MF, 1993, J BIOL CHEM, V268, P11372; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; HEUSEL JW, 1993, BLOOD, V81, P1614; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; JENNE D, 1988, P NATL ACAD SCI USA, V85, P4814, DOI 10.1073/pnas.85.13.4814; JENNE D, 1988, J IMMUNOL, V140, P318; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liao YB, 1997, J BIOL CHEM, V272, P2969, DOI 10.1074/jbc.272.5.2969; LOBE CG, 1988, BIOCHEMISTRY-US, V27, P6941, DOI 10.1021/bi00418a040; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MELOUN B, 1966, BIOCHIM BIOPHYS ACTA, V130, P543, DOI 10.1016/0304-4165(66)90258-3; MIKES O, 1966, BIOCHEM BIOPH RES CO, V24, P346, DOI 10.1016/0006-291X(66)90162-8; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; MURAKAMI M, 1995, J BIOL CHEM, V270, P2218, DOI 10.1074/jbc.270.5.2218; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; RAZIN E, 1984, J IMMUNOL, V132, P1479; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1993, J BIOL CHEM, V268, P9023; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; STECHSCHULTE DJ, 1987, J CELL PHYSIOL, V132, P565, DOI 10.1002/jcp.1041320321; STEVENS RL, 1996, FASEB J, V10, pA1307; TRONG HL, 1987, BIOCHEMISTRY-US, V26, P6988; TRONG HL, 1989, BIOCHEMISTRY-US, V28, P391; WOODBURY RG, 1978, BIOCHEMISTRY-US, V17, P811, DOI 10.1021/bi00598a010; Xia ZN, 1996, J BIOL CHEM, V271, P8747, DOI 10.1074/jbc.271.15.8747; YOKOI H, 1994, BIOL REPROD, V50, P1034, DOI 10.1095/biolreprod50.5.1034; ZON LI, 1991, J BIOL CHEM, V266, P22948	60	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29158	29166		10.1074/jbc.272.46.29158	http://dx.doi.org/10.1074/jbc.272.46.29158			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360993	hybrid			2022-12-27	WOS:A1997YF68400052
J	IacobuzioDonahue, CA; Shuja, S; Cai, JG; Peng, P; Murnane, MJ				IacobuzioDonahue, CA; Shuja, S; Cai, JG; Peng, P; Murnane, MJ			Elevations in cathepsin B protein content and enzyme activity occur independently of glycosylation during colorectal tumor progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG-CANCER; HUMAN BREAST; CELLS; CARCINOMAS; OLIGOSACCHARIDES; DEGLYCOSYLATION; GLYCOPROTEINS; ASSOCIATION; FIBROBLASTS; ACTIVATION	Western blots, enzyme assays, protein glycosylation studies, and immunohistochemical staining were used to characterize cathepsin B expression at successive stages of colorectal tumor progression, In normal colon mucosa and premalignant adenomas, cathepsin B expression was predominantly due to mature two-chain protein detected on Western blots as the nonglycosylated 27-kDa form, with overexpression of this protein occurring in only 4 of 18 adenomas, Overexpression increased significantly in Dukes A and B carcinomas (26 of 37 cases), with cathepsin B protein generally detectable in carcinomas as a combination of both 27-kDa nonglycosylated and 28-kDa glycosylated mature two-chain forms, Glycosylated cathepsin B protein in carcinoma extracts was sensitive to PNGase F but resistant to Endo H, indicating a pattern consistent with complex rather than high mannose type glycosylation, When sorted by advancing tumor stage, peak expression of cathepsin B protein occurred in carcinomas involved in local invasion compared with adenomas or metastatic cancers, At all stages, cathepsin B activity correlated significantly with the levels of heavy chain mature cathepsin B protein (r = 0.6682, p < 0.0001) irrespective of glycosylation, Immunohistochemical staining of cathepsin B protein revealed fine diffuse cytoplasmic staining in both adenomas and carcinomas compared with coarse granular cytoplasmic staining (typical of lysosomes) seen in matched normal mucosa, Our results demonstrate several sequential, apparently independent changes in cathepsin B expression during colorectal tumor progression including early changes in subcellular localization, up-regulation of cathepsin B protein and activity in invasive cancers, and altered protein glycosylation detected in malignant tumors at all stages.	BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; MALLORY INST PATHOL,BOSTON,MA 02118	Boston University; Boston University					NCI NIH HHS [CA67719, CA51865] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA067719] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CAMPO E, 1994, AM J PATHOL, V145, P301; CAPONY F, 1987, J CELL BIOL, V104, P253, DOI 10.1083/jcb.104.2.253; CAPONY F, 1989, CANCER RES, V49, P3904; CASTIGLIONI T, 1994, HUM PATHOL, V25, P857, DOI 10.1016/0046-8177(94)90003-5; CHU FK, 1981, ANAL BIOCHEM, V116, P152, DOI 10.1016/0003-2697(81)90338-9; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; Farinati F, 1996, CARCINOGENESIS, V17, P2581, DOI 10.1093/carcin/17.12.2581; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FERNANDES B, 1991, CANCER RES, V51, P718; GORDON JI, 1985, J BIOL CHEM, V260, P4824; HALBAN PA, 1994, BIOCHEM J, V299, P1; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; HASILIK A, 1982, EUR J BIOCHEM, V125, P317, DOI 10.1111/j.1432-1033.1982.tb06685.x; KEPPLER D, 1988, CANCER RES, V48, P6855; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KREPELA E, 1995, INT J CANCER, V61, P44, DOI 10.1002/ijc.2910610109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO G, 1994, INT J ONCOL, V5, P509; Leto G., 1994, In Vivo (Attiki), V8, P231; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACGREGOR RR, 1979, J BIOL CHEM, V254, P4423; MACH L, 1993, BIOCHEM J, V293, P437, DOI 10.1042/bj2930437; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MATSUOKA Y, 1992, NEOPLASMA, V39, P107; MOIN K, 1992, BIOCHEM J, V285, P427, DOI 10.1042/bj2850427; MURNANE MJ, 1991, CANCER RES, V51, P1137; Murnane MJ, 1997, IN VIVO, V11, P209; MURNANE MJ, 1994, PROTEASES INVOLVED C, P11; OHTA T, 1994, BRIT J CANCER, V69, P152, DOI 10.1038/bjc.1994.25; PAGANO M, 1989, CANCER LETT, V45, P13, DOI 10.1016/0304-3835(89)90030-X; ROZHIN J, 1994, CANCER RES, V54, P6517; ROZHIN J, 1990, CANCER RES, V50, P6278; SHEAHAN K, 1989, CANCER RES, V49, P3809; SHUJA S, 1991, INT J CANCER, V49, P341, DOI 10.1002/ijc.2910490305; SIVAPARVATHI M, 1995, CLIN EXP METASTAS, V13, P49, DOI 10.1007/BF00144018; SLOANE BF, 1994, J CELL SCI, V107, P373; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; SPEISS E, 1994, J HISTOCHEM CYTOCHEM, V42, P917; SUKOH N, 1994, CANCER, V74, P46, DOI 10.1002/1097-0142(19940701)74:1<46::AID-CNCR2820740109>3.0.CO;2-G; TAKAHASHI T, 1984, J BIOL CHEM, V259, P6059; TANIGUCHI T, 1985, J BIOCHEM-TOKYO, V97, P973, DOI 10.1093/oxfordjournals.jbchem.a135141; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TSUSHIMA H, 1991, MELANOMA RES, V1, P341; TURNBULL RB, 1967, ANN SURG, V166, P420; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	49	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29190	29199		10.1074/jbc.272.46.29190	http://dx.doi.org/10.1074/jbc.272.46.29190			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360997	hybrid			2022-12-27	WOS:A1997YF68400056
J	Nolan, DP; Jackson, DG; Windle, HJ; Pays, A; Geuskens, M; Micheli, A; Voorheis, HP; Pays, E				Nolan, DP; Jackson, DG; Windle, HJ; Pays, A; Geuskens, M; Micheli, A; Voorheis, HP; Pays, E			Characterization of a novel, stage-specific, invariant surface protein in Trypanosoma brucei containing an internal, serine-rich, repetitive motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; MICROTUBULE-ASSOCIATED PROTEIN; AFRICAN TRYPANOSOMES; PLASMODIUM-FALCIPARUM; CELL-SURFACE; CULTURE FORMS; GENE; ANTIGEN; IDENTIFICATION; GLYCOPROTEIN	A new surface membrane protein, invariant surface glycoprotein termed ISG(100), was identified in Trypanosoma brucei, using catalyzed surface, radioiodination of intact cells, This integral membrane glycoprotein was purified by a combination of detergent extraction, lectin-affinity, and ion exchange chromatography followed by preparative SDS-polyacrylamide gel electrophoresis. The protein was expressed only in bloodstream forms of the parasite, was heavily N-glycosylated, and was present in different clonal variants of the same serodeme as well as in different serodemes. The gene for this protein was isolated by screening a cDNA expression library with antibodies against the purified protein followed by screening of a genomic library. The nucleotide sequence of the gene (4050 base pairs) predicted a highly reiterative polypeptide containing three distinct domains, a unique N-terminal domain of about 10 kDa containing three potential N-glycosylation sites, which was followed by a large internal domain consisting entirely of 72 consecutive copies of a serine-rich, 17-amino acid motif (similar to 113 kDa) and terminated with an apparent transmembrane spanning region of about 3.3 kDa, The internal repeat region of this gene (3672 base pairs) represents the largest reiterative coding sequence to be fully characterized in any species of trypanosome. There was no significant homology with other known proteins, and overall the predicted protein was extremely hydrophobic, Unlike the genes for other surface proteins, the gene encoding ISG(100) was present as a single copy. Although present in the flagellar pocket, ISG(100) was predominantly associated with components of the pathways for endo/exocytosis, such as intracellular vesicles located in the proximity of the pocket as web a large, electron-lucent perinuclear digestive vacuole.	JOHN RADCLIFFE HOSP, INST MOL MED, OXFORD OX3 9DU, ENGLAND; UNIV DUBLIN TRINITY COLL, DEPT BIOCHEM, DUBLIN 2, IRELAND; UNIV MONS, CHIM BIOL LAB, B-7000 MONS, BELGIUM	University of Oxford; Trinity College Dublin; University of Mons	Nolan, DP (corresponding author), UNIV BRUSSELS, DEPT MOL BIOL, 67 RUE CHEVAUX, B-1640 RHODE ST GENESE, BELGIUM.			Nolan, Derek/0000-0002-3742-4304; , david/0000-0002-4133-9364				ALEXANDRE S, 1988, MOL CELL BIOL, V8, P2367, DOI 10.1128/MCB.8.6.2367; ANDERS RF, 1986, PARASITE IMMUNOL, V8, P529, DOI 10.1111/j.1365-3024.1986.tb00867.x; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; Bastin P, 1996, MOL BIOCHEM PARASIT, V76, P43, DOI 10.1016/0166-6851(95)02537-5; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOGNER W, 1986, EUR J BIOCHEM, V161, P611, DOI 10.1111/j.1432-1033.1986.tb10485.x; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BRICKMAN MJ, 1994, J CELL SCI, V107, P3191; BRINGAUD F, 1993, MOL CELL BIOL, V13, P1146, DOI 10.1128/MCB.13.2.1146; BRUN R, 1979, ACTA TROP, V36, P289; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CHAUDHRI M, 1994, P NATL ACAD SCI USA, V91, P6443, DOI 10.1073/pnas.91.14.6443; COPPENS I, 1991, BIOCHEM BIOPH RES CO, V178, P185, DOI 10.1016/0006-291X(91)91797-G; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; COWMAN AF, 1985, CELL, V40, P775, DOI 10.1016/0092-8674(85)90337-X; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FLAVERLORO JM, 1986, NUCLEIC ACIDS RES, V14, P8265; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Hager KM, 1997, NATURE, V385, P823, DOI 10.1038/385823a0; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HEMPHILL A, 1992, J CELL BIOL, V117, P95, DOI 10.1083/jcb.117.1.95; HOBBS RN, 1989, J IMMUNOL METHODS, V117, P257, DOI 10.1016/0022-1759(89)90148-8; IMBODEN M, 1995, PARASITOLOGY, V110, P249, DOI 10.1017/S0031182000080835; JACKSON DG, 1990, BIOCHEM SOC T, V18, P1032, DOI 10.1042/bst0181032; JACKSON DG, 1993, J BIOL CHEM, V268, P8085; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGRETH SG, 1975, J PROTOZOOL, V22, P40, DOI 10.1111/j.1550-7408.1975.tb00943.x; LEE MGS, 1994, J BIOL CHEM, V269, P8408; LEE MGS, 1990, MOL CELL BIOL, V10, P4506, DOI 10.1128/MCB.10.9.4506; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; MCLAUGHLIN J, 1982, J IMMUNOL, V128, P2656; MULLER N, 1992, PARASITOLOGY, V104, P111, DOI 10.1017/S0031182000060856; NOLAN DP, 1994, J BIOL CHEM, V269, P26045; OVERATH P, 1994, PARASITOL TODAY, V10, P53, DOI 10.1016/0169-4758(94)90393-X; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PAYS E, 1980, NUCLEIC ACIDS RES, V8, P5965, DOI 10.1093/nar/8.24.5965; PAYS E, 1988, ANNU REV GENET, V22, P107, DOI 10.1146/annurev.ge.22.120188.000543; POLLEVICK GD, 1991, MOL BIOCHEM PARASIT, V47, P247, DOI 10.1016/0166-6851(91)90185-9; RODITI I, 1990, PARASITOL TODAY, V6, P79, DOI 10.1016/0169-4758(90)90216-Q; ROLIN S, 1990, EXP PARASITOL, V71, P350, DOI 10.1016/0014-4894(90)90041-A; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHELL D, 1990, FEBS LETT, V271, P67, DOI 10.1016/0014-5793(90)80373-Q; SCHNEIDER A, 1988, SCIENCE, V241, P459, DOI 10.1126/science.3393912; SCHOFIELD L, 1991, PARASITOL TODAY, V7, P99, DOI 10.1016/0169-4758(91)90166-L; STAHL HD, 1985, P NATL ACAD SCI USA, V82, P543, DOI 10.1073/pnas.82.2.543; VOORHEIS HP, 1979, BIOCHEM J, V180, P11, DOI 10.1042/bj1800011; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; ZIEGELBAUER K, 1995, MOL BIOCHEM PARASIT, V69, P53, DOI 10.1016/0166-6851(94)00194-R; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10791; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	55	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29212	29221		10.1074/jbc.272.46.29212	http://dx.doi.org/10.1074/jbc.272.46.29212			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361000	hybrid			2022-12-27	WOS:A1997YF68400059
J	Tachibana, K; Urano, T; Fujita, H; Ohashi, Y; Kamiguchi, K; Iwata, S; Hirai, H; Morimoto, C				Tachibana, K; Urano, T; Fujita, H; Ohashi, Y; Kamiguchi, K; Iwata, S; Hirai, H; Morimoto, C			Tyrosine phosphorylation of Crk-associated substrates by focal adhesion kinase - A putative mechanism for the integrin-mediated tyrosine phosphorylation of Crk-associated substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC FAMILY KINASES; CELL-ADHESION; EXTRACELLULAR-MATRIX; V-SRC; SIGNAL TRANSDUCTION; T-CELLS; PROTEIN; PP125(FAK); P130(CAS); BINDING	Integrin-ligand binding induces the tyrosine phosphorylation of various proteins including focal adhesion kinase (pp125(FAK)) and Crk-associated substrate (Gas). FAK is activated and autophosphorylated by the ligation of integrins, although the substrate of FAK has not been revealed. We show here that p130(Cas) and Cas-L are FAX substrates. FAK directly phosphorylates Cas proteins primarily at the YDYVHL sequence that is conserved among all Cas proteins. Furthermore, the phosphorylated YDYVHL sequence is a binding site for Src family protein-tyrosine kinases, and the recruited Src family kinase phosphorylates the other tyrosine residues within Gas. The Cas-L YDYVHL sequence is phosphorylated upon integrin-ligand binding, and this integrin-mediated tyrosine phosphorylation is inhibited by the cotransfection of the FAX COOH-terminal domain that does not contain a kinase domain, These findings strongly suggest that FAK initiates integrin-mediated tyrosine phosphorylation of Cas proteins; then, Src family tyrosine kinases, which are recruited to phosphorylated Cas and FAK, further phosphorylate Cas proteins.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,INST MED SCI,DEPT CLIN IMMUNOL,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MED SCI,AIDS RES CTR,MINATO KU,TOKYO 108,JAPAN	Tufts University; University of Tokyo; University of Tokyo; University of Tokyo	Tachibana, K (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT CANC IMMUNOL & AIDS,44 BINNEY ST,BOSTON,MA 02115, USA.		Iwata, Satoshi/A-8819-2011	Urano, Takeshi/0000-0003-3383-3554	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033713] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-29530] Funding Source: Medline; NIAMS NIH HHS [AR-33713] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALALB MB, 1995, MOL CELL BIOL, V15, P954; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ishino M, 1995, ONCOGENE, V11, P2331; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Law SF, 1996, MOL CELL BIOL, V16, P3327; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; NOJIMA Y, 1995, CELL IMMUNOL, V161, P8, DOI 10.1006/cimm.1995.1002; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TAPLEY P, 1989, ONCOGENE, V4, P325; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TURNER CE, 1994, J CELL SCI, V107, P1583; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413	50	138	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29083	29090		10.1074/jbc.272.46.29083	http://dx.doi.org/10.1074/jbc.272.46.29083			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360983	hybrid			2022-12-27	WOS:A1997YF68400042
J	JahngenHodge, J; Obin, MS; Gong, X; Shang, F; Nowell, TR; Gong, JX; Abasi, H; Blumberg, J; Taylor, A				JahngenHodge, J; Obin, MS; Gong, X; Shang, F; Nowell, TR; Gong, JX; Abasi, H; Blumberg, J; Taylor, A			Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-ANHYDRASE-III; LENS EPITHELIAL-CELLS; PROTEIN S-THIOLATION; SACCHAROMYCES-CEREVISIAE; DEPENDENT PROTEOLYSIS; POLYUBIQUITIN GENE; ACTIVATING ENZYME; HYDROGEN-PEROXIDE; CARRIER PROTEINS; INDUCED CATARACT	Upon oxidative stress cells show an increase in the oxidized glutathione (GSSG) to reduced glutathione (GSH) ratio with a concomitant decrease in activity of the ubiquitinylation pathway, Because most of the enzymes involved in the attachment of ubiquitin to substrate proteins contain active site sulfhydryls that might be covalently modified (thiolated) upon enhancement of GSSG levels (glutathiolation), it appeared plausible that glutathiolation might alter ubiquitinylation rates upon cellular oxidative stress. This hypothesis was explored using intact retina and retinal pigment epithelial (RPE) cell models, Exposure of intact bovine retina and RPE cells to H2O2 (0.1-1.7 mu mol/mg) resulted in a dose-dependent increase in the GSSG:GSH ratio and coincident dose-dependent reductions in the levels of endogenous ubiquitin-activating enzyme (E1)-ubiquitin thiol esters and endogenous protein-ubiquitin conjugates and in the ability to form de novo retinal protein(125)I-labeled ubiquitin conjugates. Oxidant-induced decrements in ubiquitin conjugates were associated with 60-80% reductions in El and ubiquitin-conjugating enzyme (E2) activities as measured by formation of ubiquitin thiol esters, When GSH levels in RPE cells recovered to preoxidation levels following H2O2 removal, endogenous El activity and protein-ubiquitin conjugates were restored, Evidence that S thiolation of El and E2 enzymes is the biochemical link between cellular redox state and E1/E2 activities includes: (i) 5-fold increases in levels of immunoprecipitable, dithiothreitollabile S-35-E1 adducts in metabolically labeled, H2O2-treated, RPE cells; (ii) diminished formation of El-and E2-I-125-labeled ubiquitin thiol esters, oligomerization of E2(25K), and coincident reductions in protein-I-125-labeled ubiquitin conjugates in supernatants from nonstressed retinas upon addition of levels of GSSG equivalent to levels measured in oxidatively stressed retinas; and (iii) partial restoration of El and E2 activities and levels of protein-I-125-labeled ubiquitin conjugates in supernatants from H2O2-treated retinas when GSSG:GSH ratios were restored to preoxidation levels by the addition of physiological levels of GSH. These data suggest that the cellular redox status modulates protein ubiquitinylation via reversible S thiolation of El and E2 enzymes, presumably by glutathione.	TUFTS UNIV, USDA, JMHNRCA, LAB NUTR & VIS RES, BOSTON, MA 02111 USA; TUFTS UNIV, USDA, JMHNRCA, ANTIOXIDANT RES LAB, BOSTON, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA); Tufts University; United States Department of Agriculture (USDA)					NATIONAL EYE INSTITUTE [R29EY011735] Funding Source: NIH RePORTER; NEI NIH HHS [EY11735-01] Funding Source: Medline; PHS HHS [8566] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BENZI G, 1995, FREE RADICAL BIO MED, V19, P77, DOI 10.1016/0891-5849(94)00244-E; BRIGELIUS R, 1982, BIOCHEM PHARMACOL, V31, P1637, DOI 10.1016/0006-2952(82)90393-8; CABISCOL E, 1995, J BIOL CHEM, V270, P14742, DOI 10.1074/jbc.270.24.14742; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; CHENG L, 1994, MOL GEN GENET, V243, P358, DOI 10.1007/BF00301072; CHIN DT, 1982, P NATL ACAD SCI-BIOL, V79, P5857, DOI 10.1073/pnas.79.19.5857; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; COLLISON MW, 1987, BIOCHIM BIOPHYS ACTA, V928, P121, DOI 10.1016/0167-4889(87)90112-1; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Forster MJ, 1996, P NATL ACAD SCI USA, V93, P4765, DOI 10.1073/pnas.93.10.4765; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HAYASHI T, 1993, BRAIN RES, V620, P171, DOI 10.1016/0006-8993(93)90288-X; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HUANG LE, 1994, J BIOL CHEM, V269, P30718; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; JANERO DR, 1995, BIOCHEM J, V306, P421, DOI 10.1042/bj3060421; KOWLURU R, 1994, CURR EYE RES, V13, P891, DOI 10.3109/02713689409015092; KUCK JFR, 1990, EXP EYE RES, V50, P659, DOI 10.1016/0014-4835(90)90110-G; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LII CK, 1994, ARCH BIOCHEM BIOPHYS, V308, P231, DOI 10.1006/abbi.1994.1033; Liu H, 1996, J BIOL CHEM, V271, P4805; LOU MF, 1995, CURR EYE RES, V14, P951, DOI 10.3109/02713689508995135; MEDRANO CJ, 1995, EXP EYE RES, V61, P273, DOI 10.1016/S0014-4835(05)80122-8; MILLER RM, 1990, ARCH BIOCHEM BIOPHYS, V276, P355, DOI 10.1016/0003-9861(90)90732-E; Mune M, 1995, AGE, V18, P43, DOI 10.1007/BF02432518; MURPHY ME, 1992, EUR J BIOCHEM, V210, P139, DOI 10.1111/j.1432-1033.1992.tb17401.x; NAASH M, 1991, J NEUROSCI RES, V30, P433, DOI 10.1002/jnr.490300220; OBIN M, 1995, CURR EYE RES, V14, P751, DOI 10.3109/02713689508995796; OBIN M, 1994, BIOCHEM BIOPH RES CO, V200, P1169, DOI 10.1006/bbrc.1994.1574; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1988, J BIOL CHEM, V263, P12028; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SEMPLEROWLAND SL, 1991, ELECTROPHORESIS, V12, P307, DOI 10.1002/elps.1150120414; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176; SIES H, 1987, ADV ENZYME REGUL, V26, P175, DOI 10.1016/0065-2571(87)90013-6; SIEZEN RJ, 1989, EXP EYE RES, V48, P225, DOI 10.1016/S0014-4835(89)80072-7; SPECTOR A, 1993, CURR EYE RES, V12, P163, DOI 10.3109/02713689308999484; Strack PR, 1996, BIOCHEMISTRY-US, V35, P7142, DOI 10.1021/bi9518048; Taylor A, 1997, Adv Pharmacol, V38, P515; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; VESSEY DA, 1992, J INVEST DERMATOL, V99, P859, DOI 10.1111/1523-1747.ep12614831; WALTERS DW, 1986, J BIOL CHEM, V261, P3135; WHITLEY TJ, 1995, BT TELECOMM, V5, P218; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; YAMASHITA H, 1992, RETINA-J RET VIT DIS, V12, P59, DOI 10.1097/00006982-199212010-00012	60	234	240	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28218	28226		10.1074/jbc.272.45.28218	http://dx.doi.org/10.1074/jbc.272.45.28218			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353272	hybrid			2022-12-27	WOS:A1997YF21900012
J	Rybakova, IN; Ervasti, JM				Rybakova, IN; Ervasti, JM			Dystrophin-glycoprotein complex is monomeric and stabilizes actin filaments in vitro through a lateral association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; ALPHA-ACTININ; EXTRACELLULAR-MATRIX; MUSCULAR-DYSTROPHY; BINDING DOMAIN; MUSCLE ACTIN; PROTEIN; DEPOLYMERIZATION; SARCOGLYCAN; EXPRESSION	The native molecular weight of the dystrophin-glycoprotein complex and its effect on actin depolymerization and polymerization were examined, First, we determined that the native molecular weight of purified dystrophin-glycoprotein complex is only large enough (M-r 1,200,000) to contain one copy of each protein in the complex, including dystrophira. Using different approaches, we also demonstrated that dystrophin-glycoprotein complex significantly protected a fraction of actin filaments from disassembly, while individual recombinant actin binding fragments of dystrophin or calpain-digested dystrophin-glycoprotein complex had no effect on F-actin depolymerization. The protective effect of dystrophin-glycoprotein complex on F-actin depolymerization saturated at a dystrophin:actin molar ratio of 0.04, corresponding to 1 dystrophin/25 actin monomers, which is highly consistent with the 1:24 stoichiometry of dystrophin-glycoprotein complex binding to F actin previously measured at equilibrium, However, dystrophin-glycoprotein complex did not bind G-actin or alter the kinetics or extent of actin polymerization, This excluded the possibility that dystrophin-glycoprotein complex inhibited actin depolymerization by capping the ends of actin filaments, It therefore appears that actin binding domains separated on the dystrophin molecule from each other by almost 1,200 amino acids act in concert to protect F-actin from depolymerization, Our data suggest that dystrophin stabilizes F-actin in vitro by binding alongside an actin filament and bridging actin monomers in a manner analogous to the actin side binding protein tropomyosin, It is noteworthy that we did not find any effect of skeletal muscle tropomyosin on dystrophin-glycoprotein complex binding to F-actin, This indicates that dystrophin-glycoprotein complex and tropomyosin may simultaneously bind the same actin filament and identifies another feature that distinguishes dystrophin from the other proteins in the actin-cross-linking superfamily.	UNIV WISCONSIN, DEPT PHYSIOL, SCH MED, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison			Ervasti, James/AAZ-4786-2020		NIAMS NIH HHS [AR42423, AR01985] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR001985, R01AR042423] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; BROSCHAT KO, 1990, J BIOL CHEM, V265, P21323; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CANO ML, 1992, J CELL BIOL, V116, P1123, DOI 10.1083/jcb.116.5.1123; Carugo KD, 1997, NAT STRUCT BIOL, V4, P175, DOI 10.1038/nsb0397-175; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; COLUMBO R, 1993, J MOL BIOL, V230, P1151; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; CORRADO K, 1994, FEBS LETT, V344, P255, DOI 10.1016/0014-5793(94)00397-1; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; DAVIS J, 1983, J BIOL CHEM, V258, P7757; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ervasti JM, 1997, SOC GEN PHY, V52, P31; FABBRIZIO E, 1993, BIOCHEMISTRY-US, V32, P10457, DOI 10.1021/bi00090a023; FABBRIZIO E, 1995, BIOCHEM BIOPH RES CO, V213, P295, DOI 10.1006/bbrc.1995.2129; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; HORI S, 1995, BIOCHEM BIOPH RES CO, V209, P1062, DOI 10.1006/bbrc.1995.1605; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KAHANA E, 1994, J MOL BIOL, V235, P1271, DOI 10.1006/jmbi.1994.1080; Kahana E, 1997, CELL MOTIL CYTOSKEL, V36, P246; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; Law D. J., 1996, Molecular Biology of the Cell, V7, p382A; LEBART MC, 1995, J MUSCLE RES CELL M, V16, P543, DOI 10.1007/BF00126438; LEBART MC, 1990, BIOCHEM BIOPH RES CO, V173, P120, DOI 10.1016/S0006-291X(05)81030-7; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MAN NT, 1990, FEBS LETT, V262, P237, DOI 10.1016/0014-5793(90)80199-S; MARUYAMA K, 1978, J BIOCHEM-TOKYO, V84, P1017, DOI 10.1093/oxfordjournals.jbchem.a132184; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; Murray JW, 1996, J CELL BIOL, V135, P1309, DOI 10.1083/jcb.135.5.1309; Nigro V, 1996, HUM MOL GENET, V5, P1179, DOI 10.1093/hmg/5.8.1179; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHTAKI T, 1985, EUR J BIOCHEM, V153, P609, DOI 10.1111/j.1432-1033.1985.tb09344.x; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PONS F, 1990, P NATL ACAD SCI USA, V87, P7851, DOI 10.1073/pnas.87.20.7851; PUSZKIN S, 1978, BIOCHIM BIOPHYS ACTA, V513, P205, DOI 10.1016/0005-2736(78)90174-8; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; Root DD, 1997, P NATL ACAD SCI USA, V94, P5685, DOI 10.1073/pnas.94.11.5685; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; SATO M, 1987, NATURE, V325, P828, DOI 10.1038/325828a0; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; SENTER L, 1993, BIOCHEM BIOPH RES CO, V192, P899, DOI 10.1006/bbrc.1993.1500; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TIDBALL JG, 1991, AM J PATHOL, V138, P17; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; WEBER A, 1994, BIOCHEMISTRY-US, V33, P4780, DOI 10.1021/bi00182a005; WINDER SJ, 1995, J CELL SCI, V108, P63; WINDER SJ, 1995, FEBS LETT, V369, P27, DOI 10.1016/0014-5793(95)00398-S; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755; YANG B, 1994, J BIOL CHEM, V269, P6040; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; ZIGMOND SH, 1992, J CELL BIOL, V119, P559, DOI 10.1083/jcb.119.3.559	62	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28771	28778		10.1074/jbc.272.45.28771	http://dx.doi.org/10.1074/jbc.272.45.28771			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353348	hybrid			2022-12-27	WOS:A1997YF21900088
J	Sakuma, H; Ikeda, A; Oka, S; Kozutsumi, Y; Zanetta, JP; Kawasaki, T				Sakuma, H; Ikeda, A; Oka, S; Kozutsumi, Y; Zanetta, JP; Kawasaki, T			Molecular cloning and functional expression of a cDNA encoding a new member of mixed lineage protein kinase from human brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER-BEARING KINASE; SH3 DOMAIN; C-JUN; CIRCULAR-DICHROISM; TERMINAL DOMAIN; CYCLIC-GMP; PHOSPHORYLATION; ACTIVATION; PATHWAY; FAMILY	We have cloned a novel protein kinase from human cerebellum and named it LZK (leucine zipper-bearing kinase). The LZK cDNA encoded a 966-amino acid polypeptide that contains a kinase catalytic domain and double leucine/isoleucine zippers separated by a short spacer region. The amino acid sequence of the kinase catalytic domain was a hybrid between those in serine/ threonine and tyrosine protein kinases, indicating that LZK belongs to the subfamily of the mixed lineage kinase (MLK) family. The kinase catalytic domain of LZK was most similar to DLK (Holtzman, L. B., Merritt, S.E., and Fan, G. (1994) J. Biol Chem. 269, 3080-30817), MUK (Hirai, S., Izawa, M., Osada, S., Spyrou, G., and Ohno, S. (1996) Oncogene 12, 641-650), and ZPK (Reddy, U. R., and Presure, D. (1994) Biochem. Biophys. Res. Commun. 202, 613-620), which belong to the same subfamily of the MLK family. However, besides the kinase catalytic domain and double leucine/isoleucine zippers, there was no significant homology with known proteins. The recombinant LZK autophosphorylated in the presence of ATP and divalent cations, and exhibited serine/threonine kinase catalytic activity. Northern blot analysis revealed that LZK is expressed most strongly in the pancreas, with a pattern that differs from other MLKs. Expression of LZK in COS7 cells induced phosphorylation of c-Jun and activation of JNK-1, indicating the association of LZK in the c-Jun amino-terminal kinase/ stress-activated protein kinase pathway. The expressed LZK was detected primarily in the membrane fraction, suggesting that LZK interacts with other cellular components in vivo.	KYOTO UNIV, FAC PHARMACEUT SCI, DEPT BIOL CHEM, SAKYO KU, KYOTO 606, JAPAN; UNIV SCI & TECH LILLE FLANDRES ARTOIS, CHIM BIOL LAB, F-59655 VILLENEUVE DASCQ, FRANCE	Kyoto University; Universite de Lille - ISITE; Universite de Lille								ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1995, SCIENCE, V249, P1266; DERJARD B, 1994, CELL, V76, P1025; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; DOROW DS, 1994, J PROTEIN CHEM, V13, P458; EZOE K, 1994, ONCOGENE, V9, P935; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Frederickson R M, 1992, Semin Cell Biol, V3, P107; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; Hirai S, 1996, ONCOGENE, V12, P641; Holtzman LB, 1994, J BIOL CHEM, V269, P30808; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; HUSAINCHISHTI A, 1988, NATURE, V334, P718, DOI 10.1038/334718a0; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; ING YL, 1994, ONCOGENE, V9, P1745; KATOH M, 1995, ONCOGENE, V10, P1447; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LINBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; WOLFE L, 1989, J BIOL CHEM, V264, P7734; YAN MH, 1994, NATURE, V372, P798; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	47	72	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28622	28629		10.1074/jbc.272.45.28622	http://dx.doi.org/10.1074/jbc.272.45.28622			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353328	hybrid			2022-12-27	WOS:A1997YF21900068
J	Takaki, Y; Muta, T; Iwanaga, S				Takaki, Y; Muta, T; Iwanaga, S			A peptidyl-prolyl cis/trans-isomerase (cyclophilin G) in regulated secretory granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE ZYMOGEN; TACHYPLEUS-TRIDENTATUS HEMOCYTES; CIS-TRANS ISOMERASE; A-BINDING-PROTEIN; HORSESHOE-CRAB; FACTOR-C; LIMULUS-POLYPHEMUS; CYCLOSPORIN-A; HOMOLOG NINAA; S-CYCLOPHILIN	A 27-kDa protein (p27) in horseshoe crab hemocyte that cross-reacts with antiserum against a beta-glucan-sensitive protease zymogen was purified to homogeneity, and its cDNA was cloned, The 1.7-kilobase pair cDNA contains an open reading frame of 660 base pairs, encoding a 23 amino acid signal sequence followed by a mature protein of 197 residues. The sequence of p27 exhibits strong similarity to that of cyclophilin B, a peptidyl-prolyl cis/trans-isomerase. p27 exhibits isomerase activity with a k(cat)/K-m of 0.18 mu m(-1) s(-1) for a peptide substrate; this activity is inhibited by cyclosporin A but is not affected by FK506. Although the p27 precursor possesses an amino-terminal secretory hydrophobic signal sequence, unlike other cyclophilin B molecules, it lacks a conserved carboxyl-terminal endoplasmic reticulum retention signal and it contains a central 8-amino acid insertion, Although p27 is secreted into the culture media of transiently expressed COS cells, it is not detected in horseshoe crab hemolymph plasma brit rather is localized to the hemocyte large granules, the regulated secretory granules that are exocytosed upon stimulation. These results indicate that p27 is a new peptidyl-prolyl cis/trans-isomerase in the regulated secretory granules, and is thus designated cyclophilin G. This first report of a cyclophilin homologue in the secretory granule of the horseshoe crab hemocyte suggests that such chaperon-like proteins may constitute a key quality control system for stored proteins in exocytotic granules.	KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT BIOL MOL,FUKUOKA 81281,JAPAN; KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 81281,JAPAN	Kyushu University; Kyushu University								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Bergner A, 1996, EMBO J, V15, P6789, DOI 10.1002/j.1460-2075.1996.tb01070.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARONI P, 1991, J BIOL CHEM, V266, P10739; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; Guggenheim EA, 1926, PHILOS MAG, V2, P538; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARLOW E, 1989, ANTIBODIES LABORATOR, P471; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HEITMAN J, 1993, METHODS COMPANION ME, V5, P178; HOLMBERG L, 1976, BIOCHIM BIOPHYS ACTA, V445, P215, DOI 10.1016/0005-2744(76)90174-1; IWAI N, 1990, KIDNEY INT, V37, P1460, DOI 10.1038/ki.1990.136; Kawabata Shun-ichiro, 1996, P255; KOSER PL, 1990, NUCLEIC ACIDS RES, V18, P1643, DOI 10.1093/nar/18.6.1643; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; Lui J., 1991, CELL, V66, P807; MURER EH, 1975, J CELL PHYSIOL, V86, P533, DOI 10.1002/jcp.1040860310; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; MUTA T, 1991, J BIOL CHEM, V266, P6554; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; Ornberg R.L., 1979, Progress in Clinical and Biological Research, V29, P125; Page AP, 1996, BIOCHEM J, V317, P179, DOI 10.1042/bj3170179; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SEKI N, 1994, J BIOL CHEM, V269, P1370; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720; TOKUNAGA F, 1991, J BIOCHEM, V109, P150, DOI 10.1093/oxfordjournals.jbchem.a123337; TOKUNAGA F, 1987, EUR J BIOCHEM, V167, P405, DOI 10.1111/j.1432-1033.1987.tb13352.x	45	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28615	28621		10.1074/jbc.272.45.28615	http://dx.doi.org/10.1074/jbc.272.45.28615			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353327	hybrid			2022-12-27	WOS:A1997YF21900067
J	Chow, KS; Singh, DP; Roper, JM; Smith, AG				Chow, KS; Singh, DP; Roper, JM; Smith, AG			A single precursor protein for ferrochelatase-I from Arabidopsis is imported in vitro into both chloroplasts and mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-PLANTS; PORPHOBILINOGEN DEAMINASE; GLUTATHIONE-REDUCTASE; SUBCELLULAR LOCATION; PARTIAL-PURIFICATION; MALIC ENZYME; GENE; PEA; POLYPEPTIDES; OXIDASE	Ferrochelatase is the last enzyme of heme biosynthesis and in higher plants is found in both chloroplasts and mitochondria, We have isolated cDNAs for two isoforms of ferrochelatase from Arabidopsis thaliana, both of which are imported into isolated chloroplasts. In this paper we show that ferrochelatase-I is also imported into isolated pea mitochondria with approximately the same efficiency as into chloroplasts. Processing of the precursor was observed with both chloroplast stroma and mitochondrial matrix extracts. This was inhibited by EDTA, indicating it was due to the specific processing proteases, The specificity of import was verified by the fact that the mitochondrial preparation did not import the precursor of the light-harvesting chlorophyll alb protein precursor or the precursor of porphobilinogen deaminase, an earlier enzyme of tetrapyrrole biosynthesis, both of which are exclusively chloroplast-located, Furthermore, import of ferrochelatase-I precursor into mitochondria was inhibited by valinomycin, but this had no effect on its import into chloroplasts. Thus a single precursor molecule is recognized by the import machinery of the two organelles, The implications for the targeting of ferrochelatase in a possible protective role against photooxidative stress are discussed.	UNIV CAMBRIDGE,DEPT PLANT SCI,CAMBRIDGE CB2 3EA,ENGLAND	University of Cambridge			Singh, Davinder P/B-4056-2009	Smith, Alison Gail/0000-0001-6511-5704				APREES T, 1983, ARCH BIOCHEM BIOPHYS, V227, P511, DOI 10.1016/0003-9861(83)90480-0; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; BOUTRY M, 1987, NATURE, V328, P340, DOI 10.1038/328340a0; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; Camp W. van, 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P317; CHAUMONT F, 1990, J BIOL CHEM, V265, P16856; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CREISSEN G, 1995, PLANT J, V8, P167, DOI 10.1046/j.1365-313X.1995.08020167.x; CUMSKY MG, 1987, MOL CELL BIOL, V7, P3511, DOI 10.1128/MCB.7.10.3511; DAY DA, 1979, J EXP BOT, V30, P539, DOI 10.1093/jxb/30.3.539; DUKE SO, 1991, ACS SYM SER, V449, P371; EDWARDS EA, 1990, PLANTA, V180, P278, DOI 10.1007/BF00194008; FANG TK, 1987, CURR TOP PLANT BIOCH, V6, P175; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; GIETL C, 1992, BIOCHIM BIOPHYS ACTA, V1100, P217, DOI 10.1016/0167-4838(92)90476-T; HARBIN BM, 1985, BIOCHEMISTRY-US, V24, P366, DOI 10.1021/bi00323a019; HUANG JT, 1990, PLANT CELL, V2, P1249, DOI 10.1105/tpc.2.12.1249; HURT EC, 1986, EMBO J, V5, P1343, DOI 10.1002/j.1460-2075.1986.tb04365.x; JACOBS JM, 1995, ARCH BIOCHEM BIOPHYS, V32, P274; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM SH, 1994, PLANT MOL BIOL, V26, P863, DOI 10.1007/BF00028854; LITTLE HN, 1976, BIOCHEM J, V156, P309, DOI 10.1042/bj1560309; MARTIN NC, 1994, BIOCHIMIE, V76, P1161, DOI 10.1016/0300-9084(94)90045-0; MATRINGE M, 1989, BIOCHEM J, V260, P231, DOI 10.1042/bj2600231; Mireau H, 1996, PLANT CELL, V8, P1027, DOI 10.1105/tpc.8.6.1027; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; PRASAD ARK, 1995, J BIOL CHEM, V270, P18198, DOI 10.1074/jbc.270.31.18198; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; Roper JM, 1997, EUR J BIOCHEM, V246, P32, DOI 10.1111/j.1432-1033.1997.t01-1-00032.x; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SMITH AG, 1993, BIOCHEM J, V292, P503, DOI 10.1042/bj2920503; SMITH AG, 1994, J BIOL CHEM, V269, P13405; STITT M, 1982, PLANT PHYSIOL, V70, P971, DOI 10.1104/pp.70.4.971; SUZUKI T, 1992, EUR J BIOCHEM, V207, P767, DOI 10.1111/j.1432-1033.1992.tb17107.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; Waegemann K, 1995, METHOD CELL BIOL, V50, P255, DOI 10.1016/S0091-679X(08)61035-3; WHELAN J, 1990, PLANT MOL BIOL, V14, P977, DOI 10.1007/BF00019394; WHELAN J, 1991, PLANT MOL BIOL, V16, P283, DOI 10.1007/BF00020559; WINNING BM, 1994, J BIOL CHEM, V269, P4780; WINNING BM, 1992, PLANT J, V2, P763, DOI 10.1046/j.1365-313X.1992.t01-15-00999.x; WITOWSKI DA, 1988, PLANT PHYSIOL, V87, P632; Witty M, 1996, PLANTA, V199, P557, DOI 10.1007/BF00195187	44	88	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27565	27571		10.1074/jbc.272.44.27565	http://dx.doi.org/10.1074/jbc.272.44.27565			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346891	hybrid			2022-12-27	WOS:A1997YD47300017
J	Cutler, NS; Heitman, J; Cardenas, ME				Cutler, NS; Heitman, J; Cardenas, ME			STT4 is an essential phosphatidylinositol 4-kinase that is a target of wortmannin in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C GENE; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; VACUOLAR PROTEIN; MAMMALIAN-CELLS; RAT ADIPOCYTES; YEAST; INHIBITOR; 5-KINASE; ACTIVATION	Wortmannin is a natural product that inhibits signal transduction. One target of wortmannin in mammalian cells is the 110-kDa catalytic subunit of phosphatidylinositol S-kinase (PI 3-kinase). We show that wortmannin is toxic to the yeast Saccharomyces cerevisiae and present genetic and biochemical evidence that a phosphatidylinositol 4-kinase (PI 4-kinase), STT4, is a target of wortmannin in yeast. In a strain background in which stt4 mutants are rescued by osmotic support with sorbitol, the toxic effects of wortmannin are similarly prevented by sorbitol. In contrast, in a different strain background, STT4 is essential under all conditions and wortmannin toxicity is not mitigated by sorbitol. Overexpression of STT4 confers wortmannin resistance, but overexpression of PIK1, a related PI 4-kinase, does not. In vitro, the PI 4-kinase activity of STT4, but not of PIK1, was potently inhibited by wortmannin. Overexpression of the phosphatidylinositol 4-phosphate 5-kinase homolog MSS4 conferred wortmannin resistance, as did deletion of phospholipase C-1. These observations support a model for a phosphatidylinositol metabolic cascade involving STT4, MSS4, and phospholipase C-1 and provide evidence that an essential product of this pathway is the lipid phosphatidylinositol 4,5-bisphosphate.	DUKE UNIV, MED CTR, DEPT GENET, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute			Heitman, Joseph/ABC-6006-2021		NHLBI NIH HHS [P01-HL50985-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL050985] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; STACK JH, 1994, J BIOL CHEM, V269, P31552; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WONG K, 1994, J BIOL CHEM, V269, P28878; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YANO H, 1993, J BIOL CHEM, V268, P25846; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	47	66	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27671	27677		10.1074/jbc.272.44.27671	http://dx.doi.org/10.1074/jbc.272.44.27671			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346907	hybrid			2022-12-27	WOS:A1997YD47300033
J	Adams, CM; Snyder, PM; Welsh, MJ				Adams, CM; Snyder, PM; Welsh, MJ			Interactions between subunits of the human epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; SHAKER POTASSIUM CHANNEL; CAENORHABDITIS-ELEGANS; ACETYLCHOLINE-RECEPTOR; PSEUDOHYPOALDOSTERONISM TYPE-1; MEMBRANE TOPOLOGY; LIDDLES SYNDROME; GAMMA-SUBUNIT; NEURODEGENERATION; MUTATIONS	The human epithelial sodium channel (hENaC) mediates Na+ transport across the apical membrane of epithelia, and mutations in hENaC result in hypertensive and salt-wasting diseases. In heterologous expression systems, maximal hENaC function requires co-expression of three homologous proteins, the alpha, beta, and gamma hENaC subunits, suggesting that hENaC subunits interact to form a multimeric channel complex. Using a co immunoprecipitation assay, we found that hENaC subunits associated tightly to form home-and heteromeric complexes and that the association between subunits occurred early in channel biosynthesis. Deletion analysis of gamma hENaC revealed that the N terminus was sufficient but not necessary for co precipitation of alpha hENaC, and that both the N terminus and the second transmembrane segment (M2) were required for gamma subunit function. The biochemical studies were supported by functional studies. Go-expression of gamma subunits lacking M2 with full-length hENaC subunits revealed an inhibitory effect on hENaC channel function that appeared to be mediated by the cytoplasmic N terminus of gamma, and was consistent with the assembly of nonfunctional subunits into the channel complex. We conclude that the N terminus of gamma hENaC is involved in channel assembly.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa				Welsh, Michael/0000-0002-1646-6206; Adams, Christopher/0000-0002-5795-7212	NHLBI NIH HHS [HL-07344, HL-03575] Funding Source: Medline; NIA NIH HHS [T32 AG 00214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; Bubien JK, 1996, AM J PHYSIOL-CELL PH, V270, pC208, DOI 10.1152/ajpcell.1996.270.1.C208; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHALFIE M, 1989, NATURE, P1027; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Ostedgaard LS, 1997, BIOCHEMISTRY-US, V36, P1287, DOI 10.1021/bi962174s; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; RENARD S, 1994, J BIOL CHEM, V269, P12981; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; Tavernarakis N, 1997, NEURON, V18, P107, DOI 10.1016/S0896-6273(01)80050-7; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; Tucker SJ, 1996, J BIOL CHEM, V271, P5866, DOI 10.1074/jbc.271.10.5866; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	43	66	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27295	27300		10.1074/jbc.272.43.27295	http://dx.doi.org/10.1074/jbc.272.43.27295			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341177	hybrid			2022-12-27	WOS:A1997YC65900073
J	Giuriato, S; Payrastre, B; Drayer, AL; Plantavid, M; Woscholski, R; Parker, P; Erneux, C; Chap, H				Giuriato, S; Payrastre, B; Drayer, AL; Plantavid, M; Woscholski, R; Parker, P; Erneux, C; Chap, H			Tyrosine phosphorylation and relocation of SHIP are integrin-mediated in thrombin-stimulated human blood platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 5-PHOSPHATASE; INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; PHOSPHOINOSITIDE 3-KINASE; PHOSPHOLIPASE-C; SIGNAL-TRANSDUCTION; PROTEIN; ACTIVATION; RECEPTOR; IDENTIFICATION; AGGREGATION	The SH2 domain-containing inositol 5-phosphatase, SHIP, known to dephosphorylate inositol 1,3,4,5-tetrakisphosphate and phosphatidylinositol 3,4,5-trisphosphate has recently been shown to be expressed in a variety of hemopoietic cells. This 145-kDa protein is induced to associate with Shc by multiple cytokines and may play an important role in the negative regulation of immunocompetent cells mediated by Fc gamma RIIB receptor. We report here that SHIP is present in human blood platelets and may be involved in platelet activation evoked by thrombin. Platelet SHIP was identified by Western blotting as a single 145-kDa protein, Both phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activities could be demonstrated in anti-SHIP immunoprecipitates of platelet lysate. Thrombin stimulation induced a tyrosine phosphorylation of SHIP, this effect being pre vented if platelets were not shaken or if RGD-containing peptides were present, indicating an aggregation-dependent, integrin-mediated event. Moreover, although the intrinsic phosphatase activity of SHIP did not appear to be significantly increased, tyrosine-phosphorylated SHIP was relocated to the actin cytoskeleton upon activation in an aggregation-and integrin engagement-dependent manner. Finally, the striking correlation observed between phosphatidylinositol 3,4-bisphosphate production and the tyrosine phosphorylation of SHIP, as well as its relocation to the cytoskeleton upon thrombin stimulation, suggest a role for SHIP in the aggregation-dependent and GpIIb-IIIa-mediated accumulation of this important phosphoinositide.	HOP PURPAN,INST FEDERAT RECH 30,INSERM U326,F-31059 TOULOUSE,FRANCE; FREE UNIV BRUSSELS,INTERDISCIPLINARY RES INST,IRIBHN,B-1070 BRUSSELS,BELGIUM; IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,LONDON WC2A 3PX,ENGLAND	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Libre de Bruxelles; Vrije Universiteit Brussel; Cancer Research UK			Parker, Peter j/D-5192-2013; Giuriato, Sylvie/A-9113-2010	Giuriato, Sylvie/0000-0003-3274-3397; parker, peter/0000-0002-6218-2933; , Bernard/0000-0002-8693-0190				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; CAZENAVE JP, 1983, ANN BIOL CLIN-PARIS, V41, P167; Chacko GW, 1996, J IMMUNOL, V157, P2234; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; Drayer AL, 1996, BIOCHEM SOC T, V24, P1001, DOI 10.1042/bst0241001; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; ERNEUX C, 1987, BIOCHEM J, V247, P635, DOI 10.1042/bj2470635; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gachet C, 1997, J BIOL CHEM, V272, P4850, DOI 10.1074/jbc.272.8.4850; GAUDETTE DC, 1993, J BIOL CHEM, V268, P13773; Gironcel D, 1996, FEBS LETT, V389, P253, DOI 10.1016/0014-5793(96)00595-9; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; KING WG, 1989, J BIOL CHEM, V264, P6070; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Matsuo T, 1996, BIOCHEM J, V315, P505, DOI 10.1042/bj3150505; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; PAYRASTRE B, 1994, FEBS LETT, V341, P113, DOI 10.1016/0014-5793(94)80251-3; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; Shock DD, 1997, BIOCHEM J, V321, P525, DOI 10.1042/bj3210525; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SULTAN C, 1991, J BIOL CHEM, V266, P23554; Tan Z, 1997, J BIOL CHEM, V272, P2285; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; Woscholski R, 1997, J BIOL CHEM, V272, P9625; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; ZHANG J, 1993, J BIOL CHEM, V268, P22251	57	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26857	26863		10.1074/jbc.272.43.26857	http://dx.doi.org/10.1074/jbc.272.43.26857			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341117	hybrid			2022-12-27	WOS:A1997YC65900013
J	Herrera, JE; Bergel, M; Yang, XJ; Nakatani, Y; Bustin, M				Herrera, JE; Bergel, M; Yang, XJ; Nakatani, Y; Bustin, M			The histone acetyltransferase activity of human GCN5 and PCAF is stabilized by coenzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOMAL DNA; ACETYLATION; TRANSCRIPTION; H4; CHROMOSOME; CHROMATIN; YEAST; H3	Here we report that PCAF and human GCN5, two related type A histone acetyltransferases, are unstable enzymes that under the commonly used assay conditions are rapidly and irreversibly inactivated, Ire addition, we report that free histone H1, although not acetylated in vivo, is a preferred and convenient in vitro substrate for the study of PCAF, human GCN5, and possibly other type A histone acetyltransferases, Using either histone H1 or histone H3 as substrates, we find that preincubation with either acetyl-CoA or CoA stabilizes the acetyltransferase activities of PCAF, human GCN5 and an enzymatically active PCAF deletion mutant containing the C-terminal half of the protein. The stabilization requires the continuous presence of coenzyme, suggesting that the acetyltransferase-coenzyme complexes are stable, while the isolated apoenzymes are not, Human GCN5 and the N-terminal deletion mutant of PCAF are stabilized equally well by preincubation with either CoA or acetyl-CoA, while intact PCAF is better stabilized by acetyl-CoA than by CoA, Intact PCAF, but not the N-terminal truncation mutant or human GCN5, is auto-acetylated. These findings raise the possibility that the intracellular concentrations of the coenzymes affect the stability and therefore the nuclear activity of these acetyltransferases.	NICHHD,LAB MOL GROWTH REGULAT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Herrera, JE (corresponding author), NCI,MOL CARCINOGENESIS LAB,DIV BASIC SCI,NIH,BLDG 37,ROOM 3D-12,BETHESDA,MD 20892, USA.		Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242				ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Belyaev ND, 1996, HUM GENET, V97, P573; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; BUSTIN M, 1973, Nature New Biology, V245, P207; Garrard W T, 1978, Methods Cell Biol, V17, P27, DOI 10.1016/S0091-679X(08)61132-2; HORIUCHI K, 1975, ANAL BIOCHEM, V69, P491, DOI 10.1016/0003-2697(75)90151-7; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LOIDL P, 1994, CHROMOSOMA, V103, P441; MARZLUFF WF, 1972, J BIOL CHEM, V247, P2026; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ROMANI M, 1979, J BIOL CHEM, V254, P2918; ROTH SY, 1966, CELL, V87, P5; Tauton J, 1996, SCIENCE, V272, P408; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; van Holde K.E., 1988, CHROMATIN; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	24	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27253	27258		10.1074/jbc.272.43.27253	http://dx.doi.org/10.1074/jbc.272.43.27253			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341171	hybrid			2022-12-27	WOS:A1997YC65900067
J	Kral, AM; Diehl, RE; deSolms, SJ; Williams, TM; Kohl, NE; Omer, CA				Kral, AM; Diehl, RE; deSolms, SJ; Williams, TM; Kohl, NE; Omer, CA			Mutational analysis of conserved residues of the beta-subunit of human farnesyl:protein transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYLTRANSFERASE TYPE-I; GLUTATHIONE-S-TRANSFERASE; METAL REQUIREMENTS; ALPHA-SUBUNIT; CDNA CLONING; RAT-BRAIN; FARNESYLTRANSFERASE; EXPRESSION; BINDING; INHIBITION	The roles of 11 conserved amino acids of the beta-subunit of human farnesyl:protein transferase (FTase) were examined by performing kinetic and biochemical analyses of site-directed mutants. This biochemical information along with the x-ray crystal structure of rat FTase indicates that residues His-248, Arg-291, Lys-294, and Trp-303 are involved with binding and utilization of the sub strate farnesyl diphosphate. Our data confirm structural evidence that amino acids Cys-299, Asp-297, and His-362 are ligands for the essential Zn2+ ion and suggest that Asp-359 may also play a role in Zn2+ binding. Additionally, we demonstrate that Arg-202 is important for binding the essential C-terminal carboxylate of the protein substrate.	MERCK RES LABS,DEPT CANC RES,W POINT,PA 19486; MERCK RES LABS,DEPT MED CHEM,W POINT,PA 19486; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	Merck & Company; Merck & Company; University of Pennsylvania								ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BUKHTIYAROV YE, 1995, J BIOL CHEM, V270, P19035, DOI 10.1074/jbc.270.32.19035; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DelVillar K, 1997, J BIOL CHEM, V272, P680; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; Fu HW, 1996, J BIOL CHEM, V271, P28541, DOI 10.1074/jbc.271.45.28541; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOFFMAN R, 1992, ANAL BIOCHEM, V203, P70, DOI 10.1016/0003-2697(92)90044-8; Huang CC, 1997, J BIOL CHEM, V272, P20; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KOBLAN KS, 1995, PROTEIN SCI, V4, P681; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LIU SX, 1992, J BIOL CHEM, V267, P4296; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NAGASU T, 1995, CANCER RES, V55, P5310; NELSON N, 1987, ANAL BIOCHEM, V165, P287, DOI 10.1016/0003-2697(87)90271-5; OHYA Y, 1991, J BIOL CHEM, V266, P12356; OMER CA, 1995, METHOD ENZYMOL, V250, P3; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; PEMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800; POMPLIANO DL, 1993, BIOCHEMISTRY-US, V32, P8341, DOI 10.1021/bi00083a038; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Schmitt D, 1996, PLANT PHYSIOL, V112, P767, DOI 10.1104/pp.112.2.767; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; WILLIAMS TM, 1996, J MED CHEM, V39, P13455; YING WL, 1994, J BIOL CHEM, V269, P470; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	42	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27319	27323		10.1074/jbc.272.43.27319	http://dx.doi.org/10.1074/jbc.272.43.27319			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341181	hybrid			2022-12-27	WOS:A1997YC65900077
J	Schwanbeck, R; Wisniewski, JR				Schwanbeck, R; Wisniewski, JR			Cdc2, and mitogen-activated protein kinases modulate DNA binding properties of the putative transcriptional regulator Chironomus high mobility group protein I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY JUNCTION DNA; HMG-I; SIGNAL-TRANSDUCTION; HISTONE H1; PHOSPHORYLATION; DOMAIN; SPECIFICITY; CHROMOSOMES; CHROMATIN; AFFINITY	Cells of the dipteran insect Chironomus contain a high mobility group protein that is homologous to the mammalian high mobility group proteins I/Y (HMGI/Y). These proteins facilitate the assembly of higher order nucleoprotein complexes, In proliferating cells, >30% of Chironomus HMGI was found to be phosphorylated, The phosphorylation sites were mapped to Ser(3), Ser(22), and Ser(72) and were found to be substrates for the kinases Cdc2 (and mitogen-activated protein (MAP)), MAP, and Ca2+/phospholipid-dependent protein kinase, respectively, In mitotically arrested cells, the extent of phosphorylation at Ser(3) increased, whereas phosphorylation at Ser(22) remained unchanged, In nondividing cells, phosphorylation at Ser(3) and Ser(22) was strongly reduced, The DNA binding affinity of Chironomus HMGI was not influenced by single phosphorylation at Sers or Ser(22). In contrast, phosphorylation at both of these sites resulted in a 10-fold weakening of the binding activity and altered the mode of protein-DNA interaction. Since both human and murine HMGI/Y proteins, similarly to the insect HMGI protein, possess phosphorylation sites for Cdc2 and MAP kinases that intersperse the AT-hook DNA-binding motifs, our results may reflect a general mechanism that regulates the properties and function of this class of putative transcriptional regulators.	UNIV GOTTINGEN, ZOOL INST ENTWICKLUNGSBIOL 3, D-37073 GOTTINGEN, GERMANY	University of Gottingen			Schwanbeck, Ralf/A-2648-2008	Schwanbeck, Ralf/0000-0003-0925-929X				AlamiOuahabi N, 1996, MOL CELL BIOL, V16, P3720; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CLAUS P, 1994, J BIOL CHEM, V269, P33042; COBB M, 1996, PROTEIN KINASE FACTS, P214; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; ELTON TS, 1986, ANAL BIOCHEM, V157, P53, DOI 10.1016/0003-2697(86)90195-8; Fiske CH, 1925, J BIOL CHEM, V66, P375; Ghidelli S, 1997, CHROMOSOMA, V105, P369, DOI 10.1007/BF02529752; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; LUND T, 1985, FEBS LETT, V180, P275, DOI 10.1016/0014-5793(85)81085-1; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAMACHANDRAN C, 1984, J BIOL CHEM, V259, P3495; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; RINGER DP, 1991, METHOD ENZYMOL, V201, P3; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANHOLDE K, 1994, CHROMATIN STRUCTURE, P1; VARGAWEISZ P, 1993, J BIOL CHEM, V268, P20699; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; WISNIEWSKI JR, 1992, J BIOL CHEM, V267, P17170; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 1997, EUR J BIOCHEM, V243, P151, DOI 10.1111/j.1432-1033.1997.0151a.x; Wisniewski JR, 1996, INT J DEV BIOL, V40, P177; WISNIEWSKI JR, 1994, EUR J BIOCHEM, V225, P687, DOI 10.1111/j.1432-1033.1994.00687.x; WYSS C, 1982, EXP CELL RES, V139, P309, DOI 10.1016/0014-4827(82)90255-5; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	38	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27476	27483		10.1074/jbc.272.43.27476	http://dx.doi.org/10.1074/jbc.272.43.27476			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341202	hybrid			2022-12-27	WOS:A1997YC65900098
J	Lin, S; Naim, HY; Roth, MG				Lin, S; Naim, HY; Roth, MG			Tyrosine-dependent basolateral sorting signals are distinct from tyrosine dependent internalization signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; AMINO-ACID CHANGE; MDCK CELLS; CYTOPLASMIC DOMAIN; COATED PITS; GOLGI-COMPLEX; FC-RECEPTORS; ENDOCYTOSIS	Converting cysteine 543 to tyrosine in the influenza virus hemagglutinin (HA) introduces both a basolateral sorting signal and an internalization signal into the HA cytoplasmic domain. Another RA mutant, HA+8, contains eight additional amino acids at the end of the cytoplasmic domain that include a powerful internalization signal, HA+8 was also sorted efficiently to the basolateral surface of Madin-Darby canine kidney cells, The simplest explanation for the observation that multiple sorting phenotypes depend upon the same small amino acid sequence is that certain tyrosine-based internalization signals might also function as basolateral sorting signals. To test this hypothesis, second-site mutations were introduced into HA C543Y or HA+8 to determine if the internalization and basolateral sorting functions can be separated, For HA C543Y, the same sequence positions were important for both basolateral sorting and internalization, but the two functions responded differently to individual amino acid replacements, indicating that they were distinct. For HA+8, the basolateral sorting signal required the same tyrosine as the internalization signal, but did not share any other characteristics. Thus, even when basolateral sorting signals that depend on tyrosine overlap or are co-linear with internalizations signals, the two sorting processes are sensitive to different characteristics of the sequence.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Roth, Michael/0000-0002-9056-332X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BREWER CB, 1995, J CELL SCI, V108, P789; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NAIM HY, 1995, J CELL BIOL, V129, P1241, DOI 10.1083/jcb.129.5.1241; NAIM HY, 1992, J VIROL, V66, P7585, DOI 10.1128/JVI.66.12.7585-7588.1992; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; Reich V, 1996, J CELL SCI, V109, P2133; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Zwart DE, 1996, J BIOL CHEM, V271, P907, DOI 10.1074/jbc.271.2.907	32	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26300	26305		10.1074/jbc.272.42.26300	http://dx.doi.org/10.1074/jbc.272.42.26300			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334200	hybrid			2022-12-27	WOS:A1997YB13900034
J	Pinson, B; Napias, C; Chevallier, J; VandenBroek, PJA; Brethes, D				Pinson, B; Napias, C; Chevallier, J; VandenBroek, PJA; Brethes, D			Characterization of the Saccharomyces cerevisiae cytosine transporter using energizable plasma membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-MOTIVE FORCE; CYTOCHROME-C OXIDASE; CHAIN AMINO-ACIDS; STREPTOCOCCUS-CREMORIS; TRANSLOCATING ATPASE; PERMEASE; RECONSTITUTION; PROTEIN; BINDING; SYSTEM	The purine-cytosine permease is a carrier localized in the plasma membrane of the yeast Saccharomyces cerevisiae. The energetics of cytosine transport catalyzed by this permease has been studied in an artificial system obtained by fusion between proteoliposomes containing beef heart cytochrome c oxidase and plasma membrane-enriched fractions of a S. cerevisiae strain overexpressing the permease, Upon addition of an energy donor, a proton-motive force (inside alkaline and negative) is created in this system and promotes cytosine accumulation, By using different phospholipids, it is shown that cytosine uptake is dependent on the phospholipids surrounding the carrier, It was demonstrated that the purine-cytosine permease is able to catalyze a secondary active transport of cytosine, By using nigericin and valinomycin. the Delta pH component of the proton-motive force is shown to be the only force driving nucleobase accumulation, Moreover, transport measurements done at two pH values have shown that alkalinization of intravesicular pH leads to a significant increase in cytosine uptake rate. Finally, no specific role of K+ ions on cytosine transport could be demonstrated in this system.	CNRS,INST BIOCHIM GENET CELLULAIRE,UPR 9026,F-33077 BORDEAUX,FRANCE; LEIDEN UNIV,DEPT MOL CELL BIOL,SYLVIUS LAB,NL-2333 AL LEIDEN,NETHERLANDS	Centre National de la Recherche Scientifique (CNRS); Leiden University; Leiden University - Excl LUMC				Pinson, Benoit/0000-0003-2936-9058				Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BRETHES D, 1992, EUR J BIOCHEM, V210, P785, DOI 10.1111/j.1432-1033.1992.tb17481.x; BRETHES D, 1992, EUR J BIOCHEM, V204, P699, DOI 10.1111/j.1432-1033.1992.tb16684.x; CHEVALLIER MR, 1975, J BACTERIOL, V122, P629, DOI 10.1128/JB.122.2.629-641.1975; CHIRIO MC, 1990, EUR J BIOCHEM, V194, P293, DOI 10.1111/j.1432-1033.1990.tb19456.x; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; DEVRIJ W, 1986, EUR J BIOCHEM, V156, P431; DRIESSEN AJM, 1987, J BIOL CHEM, V262, P12438; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; DRIESSEN AJM, 1987, J BACTERIOL, V169, P5193, DOI 10.1128/jb.169.11.5193-5200.1987; DRIESSEN AJM, 1985, P NATL ACAD SCI USA, V82, P7555, DOI 10.1073/pnas.82.22.7555; FOLCH J, 1957, J BIOL CHEM, V226, P497; Geros H, 1996, YEAST, V12, P1263; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GUERIN M, 1982, EUR J BIOCHEM, V124, P457; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HOPKINS P, 1988, FEMS MICROBIOL LETT, V49, P173; HOPKINS P, 1992, YEAST, V8, P1053, DOI 10.1002/yea.320081208; Liu CE, 1997, J BIOL CHEM, V272, P859, DOI 10.1074/jbc.272.2.859; LOLKEMA JS, 1982, BIOCHIM BIOPHYS ACTA, V681, P85, DOI 10.1016/0005-2728(82)90281-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; ONGJOCO R, 1987, J BACTERIOL, V169, P2926, DOI 10.1128/jb.169.7.2926-2931.1987; OPEKAROVA M, 1993, EUR J BIOCHEM, V211, P683, DOI 10.1111/j.1432-1033.1993.tb17596.x; POLAK A, 1973, EUR J BIOCHEM, V32, P276, DOI 10.1111/j.1432-1033.1973.tb02608.x; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; REICHERT U, 1977, FEBS LETT, V83, P325, DOI 10.1016/0014-5793(77)81033-8; SCHMIDT R, 1984, P NATL ACAD SCI-BIOL, V81, P6276, DOI 10.1073/pnas.81.20.6276; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHINBO T, 1978, ARCH BIOCHEM BIOPHYS, V187, P414, DOI 10.1016/0003-9861(78)90052-8; vandenBroek PJA, 1997, BIOCHEM J, V321, P487, DOI 10.1042/bj3210487; VANDERREST ME, 1995, MICROBIOL REV, V59, P304, DOI 10.1128/MMBR.59.2.304-322.1995; VANLEEUWEN CCM, 1991, J BIOL CHEM, V266, P12146; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; WEBER E, 1990, MOL MICROBIOL, V4, P585, DOI 10.1111/j.1365-2958.1990.tb00627.x; YU CA, 1975, J BIOL CHEM, V250, P1383	37	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28918	28924		10.1074/jbc.272.46.28918	http://dx.doi.org/10.1074/jbc.272.46.28918			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360962	hybrid			2022-12-27	WOS:A1997YF68400021
J	Acs, P; Wang, QMJ; Bogi, K; Marquez, AM; Lorenzo, PS; Biro, T; Szallasi, Z; Mushinski, JF; Blumberg, PM				Acs, P; Wang, QMJ; Bogi, K; Marquez, AM; Lorenzo, PS; Biro, T; Szallasi, Z; Mushinski, JF; Blumberg, PM			Both the catalytic and regulatory domains of protein kinase C chimeras modulate the proliferative properties of NIH 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; SIGNAL-TRANSDUCTION; PHORBOL ESTER; TYROSINE PHOSPHORYLATION; RAT FIBROBLASTS; PKC-DELTA; BETA-II; ALPHA; EPSILON; EXPRESSION	Protein kinase C (PKC) isozymes exhibit important differences in terms of their regulation and biological functions, Not only may some PKC isoforms be active and others not for a given response, but the actions of different isoforms may even be antagonistic, In NIH 3T3 cells, for example, PKC delta arrests cell growth whereas PKC epsilon stimulates it, To probe the contribution of the regulatory and the catalytic domains of PKC isozymes to isozyme-specific responses, we prepared chimeras between the regulatory and the catalytic domains of PKC alpha, -delta, and -epsilon. These chimeras, which preserve the overall structure of the native PKC enzymes, were stably expressed in mouse fibroblasts. A major objective was to characterize the growth properties of the cells that overexpress the various PKC constructs. Our data demonstrate that both the regulatory and the catalytic domains play roles in cell proliferation, The regulatory domain of PKC epsilon enhanced cell growth in the absence or presence of phorbol 12-myristate 13-acetate (PMA), and, in the presence of PMA, all chimeras with the PKC epsilon regulatory domain also gave rise to colonies in soft agar; the role of the catalytic domain of PKC epsilon was evident in the PMA-treated cells that overexpressed the PKC chimera containing the delta regulatory and the epsilon catalytic domains (PKC delta/epsilon). The important contribution of the PKC epsilon catalytic domain to the growth of PKC delta/epsilon-expressing cells was also evident in terms of a significantly increased saturation density in the presence of PMA, their formation of foci upon PMA treatment, and the induction of anchorage-independent growth. Aside from the growth-promoting effect of PKC epsilon, we have shown that most chimeras with PKC alpha and -delta regulatory domains inhibit cell growth. These results underscore the complex contributions of the regulatory and catalytic domains to the overall behavior of PKC.	NCI, MOL MECH TUMOR PROMOT SECT, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, NIH, BETHESDA, MD 20892 USA; NCI, GENET LAB, NIH, BETHESDA, MD 20892 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT PHARMACOL, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA			Wang, Qiming Jane/B-6064-2012	Wang, Qiming Jane/0000-0002-9502-4851; Szallasi, Zoltan/0000-0001-5395-7509				Acs P, 1997, J BIOL CHEM, V272, P22148, DOI 10.1074/jbc.272.35.22148; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CACACE AM, 1993, ONCOGENE, V8, P2095; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; FlorinChristensen J, 1996, BIOCHEM J, V315, P513, DOI 10.1042/bj3150513; Herbert JM, 1996, J BIOL CHEM, V271, P25928; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hurley JH, 1997, PROTEIN SCI, V6, P477; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KILEY S, 1997, 88 ANN M AM ASS CANC; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; LUO JH, 1993, J BIOL CHEM, V268, P23580; Manni A, 1996, CELL GROWTH DIFFER, V7, P1187; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; ONO Y, 1988, J BIOL CHEM, V263, P6927; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; RAZIN E, 1994, P NATL ACAD SCI USA, V91, P7722, DOI 10.1073/pnas.91.16.7722; RIEDEL H, 1993, MOL CELL BIOL, V13, P4728, DOI 10.1128/MCB.13.8.4728; Singer WD, 1996, J BIOL CHEM, V271, P4504; SZALLASI Z, 1994, J BIOL CHEM, V269, P27159; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Wang WJ, 1997, J BIOL CHEM, V272, P76; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	42	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28793	28799		10.1074/jbc.272.45.28793	http://dx.doi.org/10.1074/jbc.272.45.28793			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353351	hybrid			2022-12-27	WOS:A1997YF21900091
J	Lu, M; Seufert, J; Habener, JF				Lu, M; Seufert, J; Habener, JF			Pancreatic beta-cell-specific repression of insulin gene transcription by CCAAT enhancer-binding protein beta - Inhibitory interactions with basic helix-loop-helix transcription factor E47	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH GLUCOSE-CONCENTRATIONS; REGULATED NUCLEAR-PROTEIN; HOMEOBOX FACTOR STF-1; HIT CELLS; SOMATOSTATIN GENE; CHRONIC EXPOSURE; MESSENGER-RNA; C/EBP-BETA; FACTOR EXPRESSION; LEUCINE ZIPPER	Chronic exposure of beta-cells to supraphysiologic glucose concentrations results in decreased insulin gene transcription, Here we identify the basic leucine zipper transcription factor, CCAAT/enhancer-binding protein beta (C/EBP beta), as a repressor of insulin gene transcription in conditions of supraphysiological glucose levels. C/EBP beta is expressed in primary rat islets, Moreover, after exposure to high glucose concentrations the beta-cell lines HIT-TIS and INS-1 express increased levels of C/EBP beta. The rat insulin I gene promoter contains a consensus binding motif for C/EBP beta (CEB box) that binds C/EBP beta. In non-beta-cells C/EBP beta stimulates the activity of the rat insulin I gene promoter through the CEB box. Paradoxically, in beta-cells C/EBP beta inhibits transcription, directed by the promoter of the rat insulin I gene by direct protein-protein interaction with a heptad leucine repeat sequence within activation domain 2 of the basic helix-loop-helix transcription factor E47. This interaction leads to the inhibition of both dimerization and DNA binding of E47 to the E-elements of the insulin promoter, thereby reducing functionally the transactivation potential of E47 on insulin gene transcription. We suggest that the induction of C/EBP beta in pancreatic beta-cells by chronically elevated glucose levels may contribute to the impaired insulin secretion in severe type II diabetes mellitus.	HARVARD UNIV, MOL ENDOCRINOL LAB,MASSACHUSETTS GEN HOSP,SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030834] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30834] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1992, CHEM IMMUNOL, V51, P299; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BAILLAR JC, 1992, MED USES STAT; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GIDDINGS SJ, 1985, DIABETOLOGIA, V28, P343; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; HENDERSON E, 1994, MOL CELL BIOL, V14, P655, DOI 10.1128/MCB.14.1.655; HOCHHUTH C, 1994, ENDOCRINE, V2, P833; ItkinAnsari P, 1996, ENDOCRINOLOGY, V137, P3540, DOI 10.1210/en.137.8.3540; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Moran A, 1997, J CLIN INVEST, V99, P534, DOI 10.1172/JCI119190; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OHLSSON H, 1988, P NATL ACAD SCI USA, V85, P4228, DOI 10.1073/pnas.85.12.4228; OLSON LK, 1995, P NATL ACAD SCI USA, V92, P9127, DOI 10.1073/pnas.92.20.9127; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; Olson LK, 1996, DIABETES, V45, P896; Osada S, 1996, J BIOL CHEM, V271, P3891; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PARK EA, 1993, J BIOL CHEM, V268, P613; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PHILIPPE J, 1994, ENDOCR REV, V2, P21; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; REGAZZI R, 1990, J BIOL CHEM, V265, P15003; ROBERTSON RP, 1992, J CLIN INVEST, V90, P320, DOI 10.1172/JCI115865; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Sharma S, 1996, J BIOL CHEM, V271, P2294, DOI 10.1074/jbc.271.4.2294; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; VASSEUR-COGNET M, 1993, P NATL ACAD SCI USA, V90, P7312, DOI 10.1073/pnas.90.15.7312; WEBSTER NJG, 1994, DIABETES, V43, P305, DOI 10.2337/diabetes.43.2.305; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	66	105	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28349	28359		10.1074/jbc.272.45.28349	http://dx.doi.org/10.1074/jbc.272.45.28349			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353292	hybrid			2022-12-27	WOS:A1997YF21900032
J	Bloom, LB; Chen, XL; Fygenson, DK; Turner, F; ODonnell, M; Goodman, MF				Bloom, LB; Chen, XL; Fygenson, DK; Turner, F; ODonnell, M; Goodman, MF			Fidelity of Escherichia coli DNA polymerase III holoenzyme - The effects of beta,gamma complex processivity proteins and epsilon proofreading exonuclease on nucleotide misincorporation efficiencies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID POLYMERASES; SPONTANEOUS MUTATION; ACCESSORY PROTEINS; BIOCHEMICAL BASIS; WILD-TYPE; TRANSIENT MISALIGNMENT; REVERSE-TRANSCRIPTASE; INSERTION FIDELITY; KINETIC-ANALYSIS; REPLICATION	The fidelity of Escherichia coli DNA polymerase III (pol III), is measured and the effects of beta, gamma processivity and epsilon proofreading subunits are evaluated using a gel kinetic assay, Pol III holoenzyme synthesizes DNA with extremely high fidelity, misincorporating dTMP, dAMP, and dGMP opposite a template G target with efficiencies f(inc) = 5.6 x 10(-6), 4.2 x 10(-7) and 7 x 10(-7), respectively. Elevated dGMP.G and dTMP.G misincorporation efficiencies of 3.2 x 10(-5) and 5.8 x 10(-4), attributed to a ''dNTP-stabilized'' DNA misalignment mechanism, occur when C and A, respectively, are located one base downstream from the template target G. At least 92% of mis-inserted nucleotides are excised by pol III holoenzyme in the absence of a next correct ''rescue'' nucleotide, As rescue dNTP concentrations are increased, pol III holoenzyme suffers a maximum 8-fold reduction in fidelity as proofreading of mispaired primer termini are reduced in competition with incorporation of a next correct nucleotide, Compared with pol III holoenzyme, the alpha holoenzyme, which cannot proofread, has 47-, 32-, and 13-fold higher misincorporation rates for dGMP.G, dTMP.G, and dAMP.G mispairs. Both the beta, gamma complex and the downstream nucleotide have little effect on the fidelity of catalytic alpha subunit, An analysis of the gel kinetic fidelity assay when multiple polymerase-DNA encounters occur is presented in the ''Appendix'' (see Fygenson, D. K., and Goodman, M. F. (1997) J. Biol. Chem, 272, 27931-27935 (accompanying paper)).	UNIV SO CALIF,DEPT BIOL SCI,HEDCO MOL BIOL LABS,LOS ANGELES,CA 90089; CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; HEARST RES FDN,DEPT MICROBIOL,NEW YORK,NY	University of Southern California; Cornell University; Howard Hughes Medical Institute			Bloom, Linda B/F-3684-2014; Fygenson, Deborah K/U-3105-2017	Fygenson, Deborah K/0000-0002-5681-3938	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM021422, R01GM042554] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42554, GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESSMAN MJ, 1974, J MOL BIOL, V88, P409, DOI 10.1016/0022-2836(74)90491-4; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRENOWITZ S, 1991, J BIOL CHEM, V266, P7888; BROWN T, 1989, J MOL BIOL, V207, P455, DOI 10.1016/0022-2836(89)90268-4; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CAI H, 1993, J BIOL CHEM, V268, P23567; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; Creighton S, 1995, METHOD ENZYMOL, V262, P232; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; DONG ZM, 1993, J BIOL CHEM, V268, P11758; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Efrati E, 1997, J BIOL CHEM, V272, P2559; FAY PJ, 1981, J BIOL CHEM, V256, P976; FERSHT A, 1985, ENZYME STRUCTURE MEC, P112; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; FERSHT AR, 1981, P NATL ACAD SCI-BIOL, V78, P4251, DOI 10.1073/pnas.78.7.4251; FERSHT AR, 1983, J MOL BIOL, V165, P669, DOI 10.1016/S0022-2836(83)80273-3; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; FERSHT AR, 1983, J MOL BIOL, V165, P633, DOI 10.1016/S0022-2836(83)80271-X; FREESE E., 1959, PROC NATL ACAD SCI, V45, P622, DOI 10.1073/pnas.45.4.622; FREESE E, 1959, J MOL BIOL, V1, P87, DOI 10.1016/S0022-2836(59)80038-3; Fygenson DK, 1997, J BIOL CHEM, V272, P27931, DOI 10.1074/jbc.272.44.27931; GALAS DJ, 1978, J MOL BIOL, V88, P653; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; KAN LS, 1983, P NATL ACAD SCI-BIOL, V80, P4263, DOI 10.1073/pnas.80.14.4263; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; Mo JY, 1996, J BIOL CHEM, V271, P18947, DOI 10.1074/jbc.271.31.18947; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; Nossal Nancy G., 1994, P43; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; PATEL DJ, 1984, FED PROC, V43, P2663; PETRUSKA J, 1985, J BIOL CHEM, V260, P7533; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TABOR S, 1987, J BIOL CHEM, V262, P16212; TRAUTNER TA, 1962, P NATL ACAD SCI USA, V48, P449, DOI 10.1073/pnas.48.3.449; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WATANABE SM, 1982, P NATL ACAD SCI-BIOL, V79, P6429, DOI 10.1073/pnas.79.21.6429; WATANABE SM, 1978, J VIROL, V25, P73, DOI 10.1128/JVI.25.1.73-77.1978; XIAO H, 1993, J BIOL CHEM, V268, P11773; YU H, 1992, J BIOL CHEM, V267, P10888	60	110	110	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27919	27930		10.1074/jbc.272.44.27919	http://dx.doi.org/10.1074/jbc.272.44.27919			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346941	hybrid			2022-12-27	WOS:A1997YD47300067
J	Johnson, GD; Bond, JS				Johnson, GD; Bond, JS			Activation mechanism of meprins, members of the astacin metalloendopeptidase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZYMOGEN ACTIVATION; BETA-SUBUNIT; MEMBRANE; PROCOLLAGENASE; KIDNEY; COLLAGENASES; EXPRESSION; PROTEINASE; SEQUENCE; TRYPSIN	Meprins are mammalian zinc metalloendopeptidases with protease domains structurally related to astacin, the prototype of the ''astacin family'' of metalloproteases. Mature, active astacins are produced by proteolytic removal of an activation peptide to generate a new NH2-terminal residue. Structural studies indicate that the NH2-terminal ammonium group inserts into a water-filled cavity adjacent to the active site to form a salt bridge with a Glu residue that is conserved in all astacins. A similar interaction is known to play a crucial role in the activation of trypsin, resulting in the hypothesis that this salt bridge is required for the activation of astacin-like proteases. In this study, we have used the mouse meprin alpha subunit as a model to test this hypothesis of zymogen activation of the astacins. Mutants were generated to vary the NH2-terminal residue of the mature meprin alpha subunit (Asn(78)) and its putative salt bridge partner (Glu(178)). In addition, mutants-creating NH2-terminal extensions and truncations were expressed in human embryonic kidney 293 cells. The recombinant proteins were activated by limited protease digestion and assayed for enzymatic activity and thermal stability. Point mutations of Asn(78) resulted in enzymes with activity comparable to the wild-type enzyme, indicating that the structure of this side chain is not essential for activity. NH2-terminal extension mutants of meprin alpha retained partial activity, with greater decreases against peptide relative to protein substrates. A mutant with a deletion of Asn(78) to disrupt salt bridge formation with Glu(178) had full activity, indicating that the putative salt bridge with Glu(178) is not essential for enzyme activity. However, all changes in meprin alpha subunit NH2-terminal structure were found to decrease the thermal stability of the enzyme. These observations and additional data indicate that the zymogen activation mechanism of meprin and other astacins differs from that of the trypsin family of enzymes, and has some features in common with matrixins. It is proposed that prosequence removal of astacins allows the formation of hydrogen bonds involving the two NH2-terminal residues that are critical for enzyme structure.	PENN STATE UNIV,COLL MED,DEPT BIOCHEM & MOL BIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NIDDK NIH HHS [DK19691, DK09238] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019691, R56DK019691, R01DK019691, F32DK009238] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARNES K, 1989, BIOCHEM J, V264, P335, DOI 10.1042/bj2640335; Benbow U, 1996, J BIOL CHEM, V271, P10715, DOI 10.1074/jbc.271.18.10715; Beynon RJ, 1996, BIOCHEM J, V315, P461, DOI 10.1042/bj3150461; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BRUNGER AT, 1987, BIOCHEMISTRY-US, V26, P5153; Chestukhin A, 1996, J BIOL CHEM, V271, P30272, DOI 10.1074/jbc.271.47.30272; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANT GA, 1987, J BIOL CHEM, V262, P5886; Hedstrom L, 1996, BIOCHEMISTRY-US, V35, P4515, DOI 10.1021/bi951928k; HITE LA, 1992, BIOCHEMISTRY-US, V31, P6203, DOI 10.1021/bi00142a005; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; KAUSHAL GP, 1994, J CELL BIOL, V126, P1319, DOI 10.1083/jcb.126.5.1319; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KNAUPER V, 1993, BIOCHEM J, V295, P581; KNAUPER V, 1990, EUR J BIOCHEM, V189, P295, DOI 10.1111/j.1432-1033.1990.tb15489.x; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; STOCKER W, 1993, EUR J BIOCHEM, V214, P215, DOI 10.1111/j.1432-1033.1993.tb17915.x; STOCKER W, 1995, PROTEIN SCI, V4, P823; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WANG JY, 1995, PROTEIN SCI, V4, P1758, DOI 10.1002/pro.5560040911; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325; YAMAGUCHI T, 1991, EUR J BIOCHEM, V200, P563, DOI 10.1111/j.1432-1033.1991.tb16219.x	38	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28126	28132		10.1074/jbc.272.44.28126	http://dx.doi.org/10.1074/jbc.272.44.28126			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346968	hybrid			2022-12-27	WOS:A1997YD47300094
J	Li, JP; HagnerMcWhirter, A; Kjellen, L; Palgi, J; Jalkanen, M; Lindahl, U				Li, JP; HagnerMcWhirter, A; Kjellen, L; Palgi, J; Jalkanen, M; Lindahl, U			Biosynthesis of heparin/heparan sulfate - DNA cloning and expression of D-glucuronyl C5-epimerase from bovine lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEACETYLASE N-SULFOTRANSFERASE; ESCHERICHIA-COLI K5; HEPARAN-SULFATE; CAPSULAR POLYSACCHARIDE; AZOTOBACTER-VINELANDII; MOLECULAR-CLONING; ACID; PURIFICATION; EPIMERASE; BINDING	Glucuronyl C5-epimerases catalyze the conversion of D-glucuronic acid (GlcUA) to L-iduronic acid (IdceA) units during the biosynthesis of glycosaminoglycans. An epimerase implicated in the generation of heparin/heparan sulfate was previously purified to homogeneity from bovine liver (Campbell, P., Hannesson, H. H., Sandback, D., Roden, L., Lindahl, U., and Li, J.-p, (1994) J. Biol. Chem. 269, 2695-26958). The present report describes the molecular cloning and functional expression of the lung enzyme, The cloned enzyme contains 444 amino acid residues and has a molecular mass of 49,905 Da, N-terminal sequence analysis of the isolated liver enzyme showed this species to be a truncated form lacking a 73-residue N-terminal domain of the deduced amino acid sequence. The coding cDNA insert was cloned into a baculovirus expression vector and expressed in Sf9 insect cells, Cells infected with recombinant epimerase showed a 20-30-fold increase in enzyme activity, measured as release of (H2O)-H-3 from a polysaccharide substrate containing C5-H-3-labeled hexuronic acid units. Furthermore, incubation of the expressed protein with the appropriate (GlcUA-GlcNSO(3))(n) substrate resulted in conversion of similar to 20% of the GlcUA units into IdceA residues, Northern analysis implicated two epimerase transcripts in both bovine lung and liver tissues, a dominant similar to 9-kilobase (kb) mRNA and a minor similar to 5-kb species, Mouse mastocytoma cells showed only the similar to 5-kb transcript. A comparison of the cloned epimerase with the enzymes catalyzing an analogous reaction in alginate biosynthesis revealed no apparent amino acid sequence similarity.	SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT VET MED CHEM,S-75123 UPPSALA,SWEDEN; UNIV TURKU,CTR BIOTECHNOL,FIN-20520 TURKU,FINLAND; ABO AKAD UNIV,FIN-20520 TURKU,FINLAND	Swedish University of Agricultural Sciences; University of Turku; Abo Akademi University	Li, JP (corresponding author), UNIV UPPSALA,DEPT MED & PHYSIOL CHEM,POB 575,S-75123 UPPSALA,SWEDEN.		Kjellen, Lena/F-1362-2011					BACKSTROM G, 1979, J BIOL CHEM, V254, P2975; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; CASU B, 1994, CARBOHYD RES, V263, P271, DOI 10.1016/0008-6215(94)00172-3; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; ERTESVAG H, 1995, MOL MICROBIOL, V16, P719, DOI 10.1111/j.1365-2958.1995.tb02433.x; ERTESVAG H, 1994, J BACTERIOL, V176, P2846; FRANKLIN MJ, 1994, J BACTERIOL, V176, P1821, DOI 10.1128/JB.176.7.1821-1830.1994; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; HANNESSON HH, 1995, BIOCHEM J, V313, P589; HARLOW E, 1989, ANTIBODIES LAB MANUA, P78; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HAUG A, 1969, BIOCHIM BIOPHYS ACTA, V192, P557, DOI 10.1016/0304-4165(69)90414-0; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; JACOBSSON KG, 1985, J BIOL CHEM, V260, P2154; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Lindahl U., 1989, HEPARIN, P159; MALMSTROM A, 1982, BIOCHEM J, V201, P1; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; PODUSLO JF, 1981, ANAL BIOCHEM, V114, P131, DOI 10.1016/0003-2697(81)90463-2; RAZI N, 1995, BIOCHEM J, V309, P465, DOI 10.1042/bj3090465; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Sambrook J., 2002, MOL CLONING LAB MANU; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SILBERT JE, 1963, J BIOL CHEM, V238, P3542; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	33	83	94	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28158	28163		10.1074/jbc.272.44.28158	http://dx.doi.org/10.1074/jbc.272.44.28158			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346972	hybrid			2022-12-27	WOS:A1997YD47300098
J	Muthukkumar, S; Han, SS; Muthukkumar, S; Rangnekar, VM; Bondada, S				Muthukkumar, S; Han, SS; Muthukkumar, S; Rangnekar, VM; Bondada, S			Role of Egr-1 gene expression in B cell receptor-induced apoptosis in an immature B cell lymphoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; GROWTH-INHIBITION; LYMPHOCYTES-B; PROTEIN; PROMOTER; TRANSCRIPTION; ACTIVATION; SURVIVAL; ELEMENT; STAGE	Ligation of B cell receptor (BCR) on BKS-2, an immature B cell lymphoma by anti-IgM antibodies (Ab) caused apoptosis. Here we report that signaling through B cell receptor in wild type BKS-2 cells down-regulated the expression of Egr-1, a zinc finger-containing transcription factor. A reduction in the level of Egr-1 mRNA could be demonstrated as early as 30 min after the ligation of BCR on BKS-2 cells. Immunocytochemical and Western blot analysis revealed that the expression of EGR-1 protein was also inhibited by anti-IgM treatment. Antisense oligonucleotides to Egr-1 caused growth inhibition and apoptosis in BKS-2 cells, suggesting that expression of Egr-1 is important for the survival of these B lymphoma cells. In contrast to wild type BKS-2 cells, the mutant 1.B5 cell line, which is refractory to B cell receptor-mediated growth-inhibitory signals, showed an increased expression of Egr-1 upon treatment with anti-IgM. These results implicate a role for Egr-1 in blocking B cell receptor-mediated apoptosis in immature B cells.	UNIV KENTUCKY,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; UNIV KENTUCKY,SANDERS BROWN RES CTR AGING,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT SURG,DIV UROL,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky; University of Kentucky				Han, Seong-Su/0000-0001-9824-6751	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21490] Funding Source: Medline; NIA NIH HHS [AG 05731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Bikah G, 1996, SCIENCE, V274, P1906, DOI 10.1126/science.274.5294.1906; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Carman JA, 1996, J IMMUNOL, V156, P4562; CHEN C, 1995, NATURE, V373, P252, DOI 10.1038/373252a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DAY ML, 1993, CANCER RES, V53, P5597; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GOLD MR, 1994, ADV IMMUNOL, V55, P221; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; HUANG RP, 1995, ONCOGENE, V10, P467; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; LAMAIRE P, 1989, P NATL ACAD SCI USA, V85, P4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEPTIN M, 1985, EUR J IMMUNOL, V15, P131, DOI 10.1002/eji.1830150206; LIM RW, 1987, ONCOGENE, V1, P263; MADEN SL, 1991, SCIENCE, V253, P1550; Maltzman JS, 1996, J EXP MED, V183, P1747, DOI 10.1084/jem.183.4.1747; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MONROE JG, 1993, ADV MOL CELL IMMUN B, V1, P1; MUTHUKKUMAR S, 1995, TRANSPLANTATION, V60, P264, DOI 10.1097/00007890-199508000-00010; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; MUTHUKKUMAR S, 1993, EUR J IMMUNOL, V23, P2419, DOI 10.1002/eji.1830231007; MUTHUKKUMAR S, 1994, INT IMMUNOL, V7, P305; NAMAZEE DA, 1989, NATURE, V337, P562; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; RACHAL MJ, 1989, NUCLEIC ACIDS RES, V17, P5135, DOI 10.1093/nar/17.13.5135; RANGNEKAR VV, 1991, J BIOL CHEM, V266, P2415; Reid S, 1996, J IMMUNOL METHODS, V192, P43, DOI 10.1016/0022-1759(96)00004-X; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SEIFERT VL, 1989, MOL CELL BIOL, V9, P2083; SELLS SF, 1995, MOL CELL BIOL, V15, P682; SEYFERT VL, 1990, J IMMUNOL, V145, P3647; SIDEROVSKI DP, 1990, DNA CELL BIOL, V9, P579, DOI 10.1089/dna.1990.9.579; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; Sonenshein GE, 1997, J IMMUNOL, V158, P1994; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; UDHAYAKUMAR V, 1991, J IMMUNOL, V146, P4120; UDHAYAKUMAR V, 1989, CLIN IMMUNOL IMMUNOP, V51, P240, DOI 10.1016/0090-1229(89)90023-8; WANG ZY, 1992, BIOCHEM BIOPH RES CO, V188, P433, DOI 10.1016/0006-291X(92)92403-K; YELLEN AJ, 1991, J IMMUNOL, V146, P1446	53	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27987	27993		10.1074/jbc.272.44.27987	http://dx.doi.org/10.1074/jbc.272.44.27987			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346950	Green Published, hybrid			2022-12-27	WOS:A1997YD47300076
J	Park, MS; Valdez, J; Gurley, L; Kim, CY				Park, MS; Valdez, J; Gurley, L; Kim, CY			Characterization of a putative helix-loop-helix motif in nucleotide excision repair endonuclease, XPG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-G; NONPOLYPOSIS COLON-CANCER; COMPLEMENTATION GROUP-G; XERODERMA-PIGMENTOSUM; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; CHROMOSOMAL LOCALIZATION; MAMMALIAN-CELLS; YEAST RAD2	Complementation group G of xeroderma pigmentosum (XPG) is one of the most rare and pathophysiologically heterogeneous forms of this inherited disease. XPG patients exhibit varying phenotypes, from having a very mild defect in DNA repair to being severely affected, and a few cases are also associated with the neurological degeneracy and growth retardation of Cockayne's syndrome. The XPG gene encodes a 134-kDa nuclear protein that is essential for the incision steps of nucleotide excision repair. XPG protein contains a putative helix-loop-helix (HLH) motif in the region that is most conserved among the members of structure-specific endonuclease family. To establish the functional significance of the HLH motif, we used several approaches, including theoretical modeling, functional complementation assay, structure-specific endonuclease assay, and DNA binding assay. A secondary structure of the motif was predicted by energy minimization and the Monte Carlo simulation and empirically proven using the circular dichroism to contain a high content of alpha-helix. When an XPG mutant lacking the HLH was overexpressed in UV135 cells, which have defects in the hamster homolog of XPG, the mutant gene failed to confer to the hamster cells the resistance to UV light. A recombinant XPG protein lacking the HLH motif was purified from insect cells and tested for a structure-specific endonuclease activity. The mutant protein failed to cleave the flap strand. A recombinant peptide containing the HLH (amino acids 758-871) was expressed in and purified from bacteria, tested for DNA binding activity, and found to bind to a DNA substrate with the flap structure. These results suggest that the HLH motif is required for the catalytic and DNA binding activities of XPG.			Park, MS (corresponding author), LOS ALAMOS NATL LAB,DIV LIFE SCI,M888,LOS ALAMOS,NM 87545, USA.		Park, Min Sung/HCH-2207-2022	Kim, Chang-Yub/0000-0001-9353-5909	NATIONAL CANCER INSTITUTE [R29CA071630] Funding Source: NIH RePORTER; NCI NIH HHS [CA71630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; CLOUD KG, 1995, MUTAT RES LETT, V347, P55, DOI 10.1016/0165-7992(95)90070-5; DELEAGE G, 1989, PREDICTION PROTEIN S, P587; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLETCHER R, 1984, PRACTICAL METHODS OP, V1; FRIEDBERG EC, 1995, DNA REPAIR; GRAM FL, 1973, VIROLOGY, V52, P456; GUPTA G, PEPTIDES DESIGN SYNT, P324; GUPTA G, 1990, 5 C CENT GARD, V99, P143; HABRAKEN Y, 1994, NUCLEIC ACIDS RES, V22, P3312, DOI 10.1093/nar/22.16.3312; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HARADA YN, 1995, GENOMICS, V28, P59, DOI 10.1006/geno.1995.1106; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MACINNES MA, 1993, MOL CELL BIOL, V13, P6393, DOI 10.1128/MCB.13.10.6393; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; MUDGETT JS, 1990, GENOMICS, V8, P623, DOI 10.1016/0888-7543(90)90248-S; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MUSER TC, 1996, CELL, V85, P1101; NORRIS PG, 1987, BRIT J DERMATOL, V116, P861, DOI 10.1111/j.1365-2133.1987.tb04906.x; NOUSPIKEL T, 1994, HUM MOL GENET, V3, P963, DOI 10.1093/hmg/3.6.963; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SHIOMI T, 1994, MUTAT RES, V314, P167, DOI 10.1016/0921-8777(94)90080-9; SIPPL MJ, 1984, J PHYS CHEM-US, V88, P6231, DOI 10.1021/j150669a035; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; VERMEULEN W, 1986, MUTAT RES, V165, P199, DOI 10.1016/0167-8817(86)90055-6; VERMEULEN W, 1993, AM J HUM GENET, V53, P185; WOOD RD, 1995, PHILOS T ROY SOC B, V347, P69, DOI 10.1098/rstb.1995.0011	52	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27823	27829		10.1074/jbc.272.44.27823	http://dx.doi.org/10.1074/jbc.272.44.27823			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346928	hybrid			2022-12-27	WOS:A1997YD47300054
J	Croniger, C; Trus, M; LysekStupp, K; Cohen, H; Liu, Y; Darlington, GJ; Poli, V; Hanson, RW; Reshef, L				Croniger, C; Trus, M; LysekStupp, K; Cohen, H; Liu, Y; Darlington, GJ; Poli, V; Hanson, RW; Reshef, L			Role of the isoforms of CCAAT/enhancer-binding protein in the initiation of phosphoenolpyruvate carboxykinase (GTP) gene transcription at birth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-ALPHA-GENE; MESSENGER-RNA; RAT-LIVER; REGULATORY ELEMENTS; 3T3-L1 ADIPOCYTES; TRANSGENIC MICE; NUCLEAR FACTORS; ADIPOSE-TISSUE; RESPONSE UNIT; EXPRESSION	The gene for phosphoenolpyruvate carboxykinase (PEPCK), a target of CCAAT/enhancer-binding protein-alpha (C/EBP alpha) and -beta (C/EBP beta), begins to be expressed in the liver at birth. Mice homozygous for a deletion in the gene for CEBP alpha (C/EBP alpha(-)/(-) mice) die shortly after birth of hypoglycemia, with no detectable hepatic PEPCK mRNA and negligible hepatic glycogen stores. Half of the mice homozygous for a deletion in the gene for CEBP beta(C/EBP beta(-)/(-) mice) have normal glucose homeostasis (phenotype A), and the other half die at birth of hypoglycemia due to a failure to express the gene for PEPCK and to mobilize hepatic glycogen (phenotype B). Insulin deficiency induces C/EBP alpha and PEPCK gene transcription in the livers of 19-day fetal rats, whereas dibutyryl cyclic AMP (Bt(2)cAMP) increases the expression of the gene for C/EBP beta and causes a transient burst of PEPCK mRNA. Bt(2)cAMP induces PEPCK mRNA in the livers of control animals; however, there is no induction of PEPCK mRNA if the cyclic nucleotide is injected into C/EBP alpha(-)/(-) mice immediately after delivery. The expression of the gene for C/EBP beta is markedly induced in the livers of C/EBP alpha(-)/(-) mice within 2 h after the administration of Bt(2)cAMP. C/EBP beta(-)/(-) mice injected at 20 days of fetal life with Bt(2)cAMP have a normal pattern of induction of hepatic PEPCK mRNA. In C/EBP beta(-)/(-) mice with phenotype B, the administration of Bt(2)cAMP immediately after delivery induces PEPCK mRNA, causes the mobilization of hepatic glycogen, and maintains normal glucose homeostasis for up to 4 h (duration of the experiment). We conclude that C/EBP alpha is required for the cAMP induction of PEPCK gene expression in the liver and that C/EBP beta can compensate for the loss of C/EBP alpha if its concentration is induced to appropriate levels.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT DEV BIOCHEM,IL-91120 JERUSALEM,ISRAEL; BAYLOR COLL MED,DEPT PATHOL & HUMAN GENET,HOUSTON,TX 77030; IST RIC BIOL MOL P ANGELETTI,I-00040 POMEZIA,ITALY	Case Western Reserve University; Hebrew University of Jerusalem; Baylor College of Medicine; Merck & Company			Poli, Valeria/A-9215-2012	Poli, Valeria/0000-0002-3739-3966	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011089, P01HD011089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025541] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-11089] Funding Source: Medline; NIDDK NIH HHS [DK-25541, DK-07319] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONI R, 1992, MOL CELL BIOL, V12, P2203, DOI 10.1128/MCB.12.5.2203; ANG SL, 1993, DEVELOPMENT, V119, P1301; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALLARD FJ, 1967, BIOCHEM J, V104, P866, DOI 10.1042/bj1040866; BALLARD FJ, 1970, PHYSIOLOGY PERINATAL, V1, P417; BENVENISTY N, 1987, P NATL ACAD SCI USA, V84, P1132, DOI 10.1073/pnas.84.5.1132; BERKENMEIER EH, 1989, GENE DEV, V3, P1146; CASCIO S, 1991, DEVELOPMENT, V113, P217; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRABTREE GR, 1992, TRANSCRIPTIONAL REGU, P1063; De Simone V, 1991, CURR OPIN CELL BIOL, V3, P960, DOI 10.1016/0955-0674(91)90114-E; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; Friedman A. D., 1989, GENE DEV, V3, P767; GARCIARUIZ JP, 1978, P NATL ACAD SCI USA, V75, P4189; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GIRARD JR, 1973, J CLIN INVEST, V52, P3190, DOI 10.1172/JCI107519; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREENGARD O, 1970, BIOCHEMICAL ACTIONS, V1, P53; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUNNING P, 1984, CELL, V36, P709, DOI 10.1016/0092-8674(84)90351-9; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HANSON RW, 1975, FED PROC, V34, P166; HOPGOOD MF, 1973, BIOCHEM J, V134, P445, DOI 10.1042/bj1340445; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KIOUSSIS D, 1979, P NATL ACAD SCI USA, V76, P4370, DOI 10.1073/pnas.76.9.4370; LOOSE DS, 1986, P NATL ACAD SCI USA, V83, P5184, DOI 10.1073/pnas.83.14.5184; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; MENCHER D, 1979, EUR J BIOCHEM, V102, P489, DOI 10.1111/j.1432-1033.1979.tb04264.x; MENCHER D, 1979, EUR J BIOCHEM, V94, P581, DOI 10.1111/j.1432-1033.1979.tb12928.x; MENCHER D, 1984, EUR J BIOCHEM, V141, P199, DOI 10.1111/j.1432-1033.1984.tb08175.x; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PARK K, 1993, J BIOL CHEM, V268, P17811; PATEL YM, 1994, J BIOL CHEM, V269, P5619; PHILIPPIDIS H, 1969, BIOCHEM J, V113, P651, DOI 10.1042/bj1130651; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POWELL DJ, 1984, J MOL BIOL, V179, P21, DOI 10.1016/0022-2836(84)90304-8; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; SHERMAN L, 1983, P NATL ACAD SCI-BIOL, V80, P5465, DOI 10.1073/pnas.80.18.5465; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUS M, 1990, MOL CELL BIOL, V10, P2418, DOI 10.1128/MCB.10.5.2418; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; YANUKAKASHLES O, 1994, MOL CELL BIOL, V14, P7124, DOI 10.1128/MCB.14.11.7124; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656; Zaret Kenneth S., 1993, P135; ZORZOLI A, 1969, BIOCHEM J, V111, P181, DOI 10.1042/bj1110181	61	90	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26306	26312		10.1074/jbc.272.42.26306	http://dx.doi.org/10.1074/jbc.272.42.26306			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334201	hybrid			2022-12-27	WOS:A1997YB13900035
J	deVargas, LM; Sobolewski, J; Siegel, R; Moss, LG				deVargas, LM; Sobolewski, J; Siegel, R; Moss, LG			Individual beta cells within the intact islet differentially respond to glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN-FLUORESCENT PROTEIN; INSULIN GENE-EXPRESSION; HUMAN ADENOVIRUS TYPE-5; PANCREATIC B-CELLS; RECOMBINANT ADENOVIRUS; TRANSCRIPTION; HETEROGENEITY; OSCILLATIONS; SECRETION; LINE	Insulin production by the pancreatic islet is tightly coupled to the concentration of blood glucose. The mechanism by which glucose controls proinsulin biosynthesis in beta cells is poorly understood. Analysis of insulin gene expression in individual cells within whole, living islets using adenovirus gene transfer and direct observation of insulin promoter-directed green fluorescent protein activity indicates that beta cells are functionally heterogeneous. An increase in glucose concentration not only stimulates expression within individual beta cells, but unexpectedly acts to increase the total number of positive cells. The net islet response to a given glucose stimulus reflects an integrated action of beta cells with individually differing behaviors. This additional level of functional complexity may provide new insights into the pathophysiology and treatment of diabetes mellitus.	TUFTS UNIV NEW ENGLAND MED CTR,DEPT MED,BOSTON,MA 02111; TUFTS UNIV NEW ENGLAND MED CTR,DEPT PHYSIOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,BOSTON,MA 02111	Tufts Medical Center; Tufts Medical Center; Tufts University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051111, R01DK034447, P30DK034928, R55DK034447] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34928, DK51111, DK34447] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amsterdam A, 1996, GENE, V173, P99, DOI 10.1016/0378-1119(95)00719-9; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BECKER TC, 1994, J BIOL CHEM, V269, P21234; Bennett BD, 1996, J BIOL CHEM, V271, P3647; BERGSTEN P, 1994, J BIOL CHEM, V269, P8749; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; BOSCO D, 1991, DEVELOPMENT CAMB, V113, P1257; Castano JP, 1996, MOL ENDOCRINOL, V10, P599, DOI 10.1210/me.10.5.599; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CSETE ME, 1994, TRANSPLANT P, V26, P756; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; KIEKENS R, 1992, J CLIN INVEST, V89, P117, DOI 10.1172/JCI115551; LEAHY JL, 1990, DIABETES CARE, V13, P992, DOI 10.2337/diacare.13.9.992; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MEDA P, 1981, P NATL ACAD SCI USA, V78, P293; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; ORCI L, 1985, DIABETOLOGIA, V28, P528, DOI 10.1007/BF00281987; PERMUTT MA, 1972, J BIOL CHEM, V247, P1200; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; REDMON JB, 1994, DIABETES, V43, P546, DOI 10.2337/diabetes.43.4.546; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SORIA B, 1991, DIABETES, V40, P1069, DOI 10.2337/diabetes.40.8.1069; STEFAN Y, 1987, J CLIN INVEST, V80, P175, DOI 10.1172/JCI113045; VALDEOLMILLOS M, 1993, DIABETES, V42, P1210, DOI 10.2337/diabetes.42.8.1210; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0	38	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26573	26577		10.1074/jbc.272.42.26573	http://dx.doi.org/10.1074/jbc.272.42.26573			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334237	hybrid			2022-12-27	WOS:A1997YB13900071
J	Huang, CS; Ma, WY; Hanenberger, D; Cleary, MP; Bowden, GT; Dong, ZG				Huang, CS; Ma, WY; Hanenberger, D; Cleary, MP; Bowden, GT; Dong, ZG			Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GREEN TEA; INDUCED TRANSFORMATION; CELL LINES; JB6 CELLS; BLACK TEA; C-FOS; JUN; UV; CANCER	Aspirin is under consideration as a promising chemopreventative agent for human cancers, To study the use fulness of aspirin as a chemopreventative agent for UV-induced human skin cancer, we investigated the effect of aspirin on UVB induced activator protein-1 (AP-1) activity, In the JB6 cell culture system, aspirin or sodium salicylate (SA) inhibited UVB-induced AP-1 activity in a dose-dependent manner; this inhibitory effect occurred only in cells pretreated with aspirin or SA before UVB irradiation but not cells treated with aspirin or SA after UVB irradiation. Furthermore, these inhibitory effects on UVB-induced AP-1 activity appeared to be mediated through blocking of activation of MAP kinase family members, including extracellular signal-regulated protein kinases, c-Jun N-terminal kinases, and p38, It was not due to absorption of UVB light by aspirin, In the skin of AP-l-luciferase transgenic mice, UVB irradiation induced a rapid increase in AP-1 activity, which reached the peak at 48 h post-UVB irradiation, The topical pretreatment of mouse skin with aspirin markedly blocked the UVB induced AP-1 transactivation in vivo, These data provide the first evidence that aspirin and SA are inhibitors of W-induced signal transduction and thus could be used as a chemopreventative agent for skin cancer.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912; UNIV ARIZONA,HLTH SCI CTR,DEPT RADIAT ONCOL,TUCSON,AZ 85724	University of Minnesota System; University of Arizona; University of Arizona Health Sciences				Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R29CA074916, P01CA027502] Funding Source: NIH RePORTER; NCI NIH HHS [CA74916-01, CA27502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; BUSCHER M, 1988, ONCOGENE, V3, P301; BUZZELL RA, 1993, OTOLARYNG CLIN N AM, V26, P1; CRAVEN PA, 1992, CARCINOGENESIS, V13, P541, DOI 10.1093/carcin/13.4.541; DANPURE HJ, 1976, PHOTOCHEM PHOTOBIOL, V23, P171, DOI 10.1111/j.1751-1097.1976.tb07238.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1995, INT J ONCOL, V7, P359; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Flower R. J., 1985, PROSTAGLANDINS LEUKO, P583; FLOWER RJ, 1980, PHARMACOL BASIS THER, P682; Gensler HL, 1996, NUTR CANCER, V26, P325, DOI 10.1080/01635589609514488; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HIGGS GA, 1976, ADV PROSTAGLANDIN TH, P105; HUANG C, 1997, IN PRESS P NATL ACAD, V94; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; Huang CS, 1996, INT J ONCOL, V8, P389; HUMUS JL, 1981, P NATL ACAD SCI USA, V78, P2053; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Li JJ, 1996, CANCER RES, V56, P483; MATSUI MS, 1995, PHOTOCARCINOGENESIS, P21; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORHAM SG, 1995, CELL, V83, P437; PEDERSEN AK, 1984, NEW ENGL J MED, V311, P1206, DOI 10.1056/NEJM198411083111902; PELAGE II, 1994, ARCH INTERN MED, V154, P394; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; RONAI ZA, 1988, J VIROL, V62, P1057, DOI 10.1128/JVI.62.3.1057-1060.1988; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; SCOTTO J, 1983, PUBLICATION NIH; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WANG ZY, 1992, CANCER RES, V52, P1943; WANG ZY, 1994, CANCER RES, V54, P3428; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063	56	124	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26325	26331		10.1074/jbc.272.42.26325	http://dx.doi.org/10.1074/jbc.272.42.26325			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334204	hybrid			2022-12-27	WOS:A1997YB13900038
J	Kristie, TM				Kristie, TM			The mouse homologue of the human transcription factor C1 (host cell factor) - Conservation of forms and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; VP16 ACCESSORY PROTEIN; ALPHA-GENES; DNA COMPLEX; POU DOMAIN; CIS SITE; OCT-1; BINDING; INDUCTION; RECOGNITION	The assembly of the herpes simplex virus (HSV) alpha/IE gene enhancer complex is determined by the interactions of the Oct-1 POU domain protein, the viral alpha TIF (alpha-trans-induction factor, VP16, ICP25, VMW65), and the C1 factor (host cell factor, HCF). A unique transcription factor, C1 consists of a family of polypeptides derived from a common precursor by site-specific proteolytic processing. To analyze the role of this factor in the determination of HSV lytic-latent infection, cDNAs and genomic DNAs encoding the mouse homologue have been isolated. This factor is nearly identical to the human protein, contains multiple consensus proteolytic processing sites, and functions efficiently in the assembly of a specific HSV enhancer complex. Interestingly, the differential expression of the C1 factors in both human and mouse tissues may be important for the determination of HSV tissue tropism in these two organisms.			Kristie, TM (corresponding author), NIAID,VIRAL DIS LAB,NIH,BLDG 4,RM 133,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BATTERSON W, 1983, J VIROL, V46, P371, DOI 10.1128/JVI.46.2.371-377.1983; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRATTINI A, 1994, GENOMICS, V23, P30, DOI 10.1006/geno.1994.1455; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; KRISTIE TM, 1988, J VIROL, V62, P1145, DOI 10.1128/JVI.62.4.1145-1157.1988; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MCKNIGHT JLC, 1986, CANCER CELL CONTROL, V4, P163; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OReilly D, 1997, EMBO J, V16, P2420, DOI 10.1093/emboj/16.9.2420; PELLETT PE, 1985, P NATL ACAD SCI USA, V82, P5870, DOI 10.1073/pnas.82.17.5870; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; Roizman B., 1985, VIROLOGY, P497; Roizman Bernard, 1996, P1043; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; WERSTUCK G, 1989, J VIROL, V63, P5509, DOI 10.1128/JVI.63.12.5509-5513.1989; Whitley RJ, 1996, FIELDS VIROLOGY, P2297; WILSON AC, 1995, GENOMICS, V25, P462, DOI 10.1016/0888-7543(95)80046-O; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974	38	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26749	26755		10.1074/jbc.272.42.26749	http://dx.doi.org/10.1074/jbc.272.42.26749			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334261	hybrid			2022-12-27	WOS:A1997YB13900095
J	Cain, D; Hutson, SM; Wallin, R				Cain, D; Hutson, SM; Wallin, R			Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; PROTEIN DISULFIDE-ISOMERASE; DEPENDENT CARBOXYLASE; EPOXIDE REDUCTASE; 5-LIPOXYGENASE-ACTIVATING PROTEIN; GLUTATHIONE TRANSFERASE; SOLUBILIZATION; IDENTIFICATION; PROTHROMBIN; METABOLISM	gamma-Carboxylation of vitamin K-dependent proteins requires a functional vitamin K cycle to produce the active vitamin Ii cofactor for the gamma-carboxylase which posttranslationally modifies precursors of these proteins to contain gamma-carboxyglutamic acid residues, The warfarin-sensitive enzyme vitamin K epoxide reductase CVI(OR) of the cycle reduces vitamin K 2,3-epoxide to the active vitamin K hydroquinone cofactor, Because of the importance of warfarin as an anticoagulant in prophylactic medicine and as a poison in rodent pest control, numerous attempts have been made to understand the molec molecular mechanism underlying warfarin-sensitive vitamin K 2,3-epoxide reduction. In search for protein components that could be involved in this reaction we designed an in vitro gamma-carboxylation test system where the warfarin-sensitive VKOR produces the cofactor for the gamma-carboxylase. Dissection of this system by chromatographic techniques has identified a member(s) of the glutathione S-transferase gene family as one component of the VKOR enzyme complex in the endoplasmic reticulum membrane, The affinity-purified glutathione S-transferase(s) was sensitive to warfarin but lost its warfarin sensitivity and glutathione S-transferase activity upon association with lipids in the presence of Mn2+ or Ca2+. In the gamma-carboxylation test system, loss of warfarin-sensitive glutathione S-transferase activity coincided with formation of the VKOR enzyme complex, It is proposed that formation of VKOR in the endoplasmic reticulum membrane resembles formation of the Lipoxygenase enzyme complex where the glutathione S-transferase-related FLAP protein binds cytosolic lipoxygenase to form a membrane enzyme complex.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT INTERNAL MED,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center								ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; ANDERSON C, 1994, BIOCHIM BIOPHYS ACTA, V1240, P298; ANDERSSON C, 1995, BBA-PROTEIN STRUCT M, V1247, P277, DOI 10.1016/0167-4838(94)00239-D; BELL R G, 1970, Archives of Biochemistry and Biophysics, V141, P473, DOI 10.1016/0003-9861(70)90164-5; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; FASCO MJ, 1983, BIOCHEMISTRY-US, V22, P5655, DOI 10.1021/bi00293a031; FASCO MJ, 1983, J BIOL CHEM, V258, P4372; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FRIEDBERG T, 1994, BIOCHEM J, V303, P967, DOI 10.1042/bj3030967; FRIEDBERG T, 1979, J BIOL CHEM, V254, P2028; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GUENTHNER TM, METHOD ENZYMOL, V77, P344; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HAYES JD, 1995, CRIT REV BIOCHEM MOL, V30, P446; HILDEBRANDT EF, 1984, ARCH BIOCHEM BIOPHYS, V228, P480, DOI 10.1016/0003-9861(84)90014-6; Jackson WB, 1988, CURRENT ADV VITAMIN, P381; Jakobsson PJ, 1996, J BIOL CHEM, V271, P22203, DOI 10.1074/jbc.271.36.22203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JJ, 1984, BIOCHEMISTRY-US, V23, P2246, DOI 10.1021/bi00305a024; LENAZ G, 1977, MOL BIOL MEMBRANES, P137; LIND C, 1981, ARCH BIOCHEM BIOPHYS, V207, P217, DOI 10.1016/0003-9861(81)90027-8; MAILLARD C, 1992, ENDOCRINOLOGY, V130, P1599, DOI 10.1210/en.130.3.1599; MORGENSTERN R, 1983, FEBS LETT, V160, P264, DOI 10.1016/0014-5793(83)80979-X; MORGENSTERN R, 1985, J BIOL CHEM, V260, P3976; ROSS D, 1985, CHEM-BIOL INTERACT, V55, P177, DOI 10.1016/S0009-2797(85)80126-5; SADOWSKI JA, 1976, J BIOL CHEM, V251, P2770; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SOUTE BAM, 1992, BIOCHEM J, V281, P255, DOI 10.1042/bj2810255; STANTON C, 1991, BIOCHEM J, V277, P59, DOI 10.1042/bj2770059; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Suttie J W, 1987, Adv Exp Med Biol, V214, P3; Suttie J. W., 1978, Handbook of lipid research. Volume 2. The fat-soluble vitamins, P211; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; THIJSSEN HHW, 1994, BIOCHEM J, V297, P277, DOI 10.1042/bj2970277; Tishler M, 1940, J AM CHEM SOC, V62, P2866, DOI 10.1021/ja01867a066; VERKLEIJ AJ, 1984, BIOCHIM BIOPHYS ACTA, V779, P43, DOI 10.1016/0304-4157(84)90003-0; WALLIN R, 1978, BIOCHEM J, V169, P95, DOI 10.1042/bj1690095; WALLIN R, 1988, J BIOL CHEM, V263, P9994; WALLIN R, 1985, J CLIN INVEST, V76, P1879, DOI 10.1172/JCI112182; WALLIN R, 1984, P NATL ACAD SCI-BIOL, V81, P4095, DOI 10.1073/pnas.81.13.4095; Wallin R, 1997, METHOD ENZYMOL, V282, P395; WALLIN R, BIOCHEM J, V241, P389	44	93	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29068	29075		10.1074/jbc.272.46.29068	http://dx.doi.org/10.1074/jbc.272.46.29068			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360981	hybrid			2022-12-27	WOS:A1997YF68400040
J	Costello, LC; Liu, YY; Franklin, RB; Kennedy, MC				Costello, LC; Liu, YY; Franklin, RB; Kennedy, MC			Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTOSTERONE; SECRETION; OXIDATION; BINDING	Prostate epithelial cells possess a uniquely limiting mitochondrial (m-) aconitase activity that minimizes their ability to oxidize citrate, These cells also possess uniquely high cellular and mitochondrial zinc levels, Correlations among zinc, citrate, and m-aconitase in prostate indicated that zinc might be an inhibitor of prostate m-aconitase activity and citrate oxidation, The present studies reveal that zinc at near physiological levels inhibited m-aconitase activity of mitochondrial sonicate preparations obtained from rat ventral prostate epithelial cells, Corresponding studies conducted with mitochondrial sonicates of rat kidney cells revealed that zinc also inhibited the kidney m-aconitase activity, However the inhibitory effect of zinc was more sensitive with the prostate m-aconitase activity. Zinc inhibition fit the competitive inhibitor model, The inhibitory effect of zinc occurred only with citrate as substrate and was specific for the citrate --> cis-aconitate reaction. Other cations (Ca2+, Mn2+, Cd2+) did not result in the inhibitory effects obtained with zinc, The presence of endogenous zinc inhibited the m-aconitase activity of the prostate mitochondrial preparations, Kidney preparations that contain lower endogenous zinc levels exhibited no endogenous inhibition of m-aconitase activity, Studies with pig prostate and seminal vesicle mitochondrial preparations also revealed that zinc was a competitive inhibitor against citrate of m-aconitase activity, The effects of zinc on purified beef heart m-aconitase verified the competitive inhibitor action of zinc, In contrast, zinc had no inhibitory effect on purified cytosolic aconitase, These studies reveal for the first time that zinc is a specific inhibitor of m-aconitase of mammalian cells, In prostate epithelial cells, in situ mitochondrial zinc levels inhibit m-aconitase activity, which provides a mechanism by which citrate oxidation is limited.	MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	Medical College of Wisconsin	Costello, LC (corresponding author), UNIV MARYLAND,SCH DENT,CELLULAR & MOL BIOL SECT,666 W BALTIMORE ST,BALTIMORE,MD 21201, USA.				NATIONAL CANCER INSTITUTE [R01CA071207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051831] Funding Source: NIH RePORTER; NCI NIH HHS [CA-71207] Funding Source: Medline; NIDDK NIH HHS [DK-28015] Funding Source: Medline; NIGMS NIH HHS [GM-51831] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Costello LC, 1997, UROLOGY, V50, P3, DOI 10.1016/S0090-4295(97)00124-6; COSTELLO LC, 1995, MOL CELL ENDOCRINOL, V112, P45, DOI 10.1016/0303-7207(95)03582-R; Costello LC, 1996, UROLOGY, V48, P654, DOI 10.1016/S0090-4295(96)00217-8; COSTELLO LC, 1991, PROSTATE, V19, P181, DOI 10.1002/pros.2990190302; COSTELLO LC, 1991, PROSTATE, V18, P25, DOI 10.1002/pros.2990180104; COSTESCU A, 1981, REV ROUM PHYS, V26, P281; Franklin R. B., 1997, PROSTATE BASIC CLIN, P115; Frishman D, 1996, EUR J BIOCHEM, V239, P197, DOI 10.1111/j.1432-1033.1996.0197u.x; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; LAUBLE H, 1994, J MOL BIOL, V237, P437, DOI 10.1006/jmbi.1994.1246; Lauble H, 1996, P NATL ACAD SCI USA, V93, P13699, DOI 10.1073/pnas.93.24.13699; Liu Y, 1996, METABOLISM, V45, P442, DOI 10.1016/S0026-0495(96)90217-6; LIU Y, 1996, PROSTATE, V30, P26; LUTZ RA, 1986, ENZYME, V36, P197, DOI 10.1159/000469292; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Sillen L, 1964, STABILITY CONSTANTS; WESTERGAARD N, 1995, P NATL ACAD SCI USA, V92, P3367, DOI 10.1073/pnas.92.8.3367	18	182	218	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28875	28881		10.1074/jbc.272.46.28875	http://dx.doi.org/10.1074/jbc.272.46.28875			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360955	hybrid			2022-12-27	WOS:A1997YF68400014
J	Gurevich, VV; PalsRylaarsdam, R; Benovic, JL; Hosey, MM; Onorato, JJ				Gurevich, VV; PalsRylaarsdam, R; Benovic, JL; Hosey, MM; Onorato, JJ			Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; CHOLINERGIC RECEPTORS; BINDING; PHOSPHORYLATION; RHODOPSIN	The rapid decrease of a response to a persistent stimulus, often termed desensitization, is a widespread biological phenomenon, Signal transduction by numerous G protein-coupled receptors appears to be terminated by a strikingly uniform two-step mechanism, most extensively characterized for the beta(2)-adrenergic receptor (beta(2)AR), m2 muscarinic cholinergic receptor (m2 mAChR), and rhodopsin, The model predicts that activated receptor is initially phosphorylated and then tightly binds an arrestin protein that effectively blocks further G protein interaction, Here we report that complexes of beta(2)AR-arrestin and m2 mAChR-arrestin have a higher affinity for agonists (but not antagonists) than do receptors not complexed with arrestin. The percentage of phosphorylated beta(2)AR in this high affinity state in the presence of full agonists varied with different arrestins and was enhanced by selective mutations in arrestins, The percentage of high affinity sites also was proportional to the intrinsic activity of an agonist, and the coefficient of proportionality varies for different arrestin proteins. Certain mutant arrestins can form these high affinity complexes with unphosphorylated receptors, Mutations that enhance formation of the agonist-receptor-arrestin complexes should provide useful tools for manipulating both the efficiency of signaling and rate and specificity of receptor internalization.	NORTHWESTERN UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,CHICAGO,IL 60611; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; UNIV WISCONSIN,DEPT MED,MADISON,WI 53706	Northwestern University; Jefferson University; University of Wisconsin System; University of Wisconsin Madison	Gurevich, VV (corresponding author), SUN HLTH RES INST,10515 W SANTA FE DR,SUN CITY,AZ 85372, USA.		Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NEI NIH HHS [EY11500] Funding Source: Medline; NHLBI NIH HHS [HL50201] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL050201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GOODMAN OB, 1997, J BIOL CHEM, V272, P15016; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; LEFKOWITZ RJ, 1982, FED PROC, V41, P2664; LIMBIRD LE, 1978, P NATL ACAD SCI USA, V75, P228, DOI 10.1073/pnas.75.1.228; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1170; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0	18	149	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28849	28852		10.1074/jbc.272.46.28849	http://dx.doi.org/10.1074/jbc.272.46.28849			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360951	hybrid			2022-12-27	WOS:A1997YF68400010
J	Yu, YK; Zhang, L; Yin, XX; Sun, H; Uhl, GR; Wang, JB				Yu, YK; Zhang, L; Yin, XX; Sun, H; Uhl, GR; Wang, JB			mu opioid receptor phosphorylation, desensitization, and ligand efficacy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; OPIATE RECEPTOR; FUNCTIONAL DESENSITIZATION; DIFFERENTIAL REGULATION; POTASSIUM CHANNEL; CYCLIC-AMP; AGONIST; CELLS; METHADONE	mu opioid receptors are subject to phosphorylation and desensitization through actions of at least two distinct biochemical pathways: agonist-dependent mu receptor phosphorylation and desensitization induced by a biochemically distinct second pathway dependent on protein kinase C activation (1), To better understand the nature of the agonist-induced mu receptor phosphorylation events, we have investigated the effects of a variety of opiate ligands of varying potencies and intrinsic activities on mu receptor phosphorylation and desensitization, Exposure to the potent full agonists sufentanil, dihydroetorphine, etorphine, etonitazine, and [D-Ala2, MePhe4, Glyol5]enkephalin (DAMGO) led to strong receptor phosphorylation, while methadone, l-alpha-acetyl-methadone (LAAM), morphine, meperidine, DADL, beta-endorphin((1-31)), enkephalins, and dynorphin A((1-17)) produced intermediate effects, The partial agonist buprenorphine minimally enhanced receptor phosphorylation while antagonists failed to alter phosphorylation, Buprenorphine and full antagonists each antagonized the enhanced mu receptor phosphorylation induced by morphine or DAMGO, The rank order of opiate ligand efficacies in producing mu receptor-mediated functional desensitization generally paralleled their rank order of efficacies in producing receptor phosphorylation, Interestingly, the desensitization and phosphorylation mediated by methadone and LAAM were disproportionate to their efficacies in two distinct test systems, This generally good fit between the efficacies of opiates in mu receptor activation, phosphorylation, and desensitization supports the idea that activated receptor/agonist/G-protein complexes and/or receptor conformational changes induced by agonists are required for agonist-induced mu receptor phosphorylation, Data for methadone and LAAM suggest possible contribution from their enhanced desensitizing abilities to their therapeutic efficacies.	UNIV MARYLAND,SCH PHARM,DEPT PHARMACEUT SCI,BALTIMORE,MD 21201; NIAAA,LAB MOL & CELLULAR NEUROBIOL,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21224; NIDA,MOL NEUROBIOL BRANCH,BALTIMORE,MD 21224	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)			Zhang, Li/W-2104-2019					ARDEN JR, 1995, J NEUROCHEM, V65, P1636; BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; BROWN BL, 1972, ADV CYCL NUCL RES<D>, V2, P25; CARTER BD, 1992, J NEUROCHEM, V58, P1611, DOI 10.1111/j.1471-4159.1992.tb10032.x; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CLAUDE PA, 1996, P NATL ACAD SCI USA, V83, P5715; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; Fiorillo CD, 1996, J NEUROSCI, V16, P1479; INGLESE J, 1993, J BIOL CHEM, V268, P23735; IZENWASSER S, 1993, J PHARMACOL EXP THER, V267, P145; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; KREEK MJ, 1994, ANN MED INTERNE, V145, P9; KREEK MJ, 1991, DRUG ADDICTION AIDS, P153; LAW PY, 1983, MOL PHARMACOL, V24, P413; LING W, 1994, J PSYCHOACTIVE DRUGS, V26, P119, DOI 10.1080/02791072.1994.10472259; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; ONOGI T, 1995, FEBS LETT, V357, P93, DOI 10.1016/0014-5793(94)01341-W; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PRATHER PL, 1994, J PHARMACOL EXP THER, V270, P177; REISINE T, 1995, NEUROPHARMACOLOGY, V34, P463, DOI 10.1016/0028-3908(95)00025-2; ROTHMAN RB, 1995, SYNAPSE, V21, P60, DOI 10.1002/syn.890210109; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; Wang ZJ, 1996, FEBS LETT, V387, P53, DOI 10.1016/0014-5793(96)00467-X; YU VC, 1990, J NEUROCHEM, V55, P1390, DOI 10.1111/j.1471-4159.1990.tb03151.x; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449	28	190	191	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28869	28874		10.1074/jbc.272.46.28869	http://dx.doi.org/10.1074/jbc.272.46.28869			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360954	hybrid			2022-12-27	WOS:A1997YF68400013
J	Anafi, M; Kiefer, F; Gish, GD; Mbamalu, G; Iscove, NN; Pawson, T				Anafi, M; Kiefer, F; Gish, GD; Mbamalu, G; Iscove, NN; Pawson, T			SH2/SH3 adaptor proteins can link tyrosine kinases to a Ste20-related protein kinase, HPK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; CELL-DEATH; SH3-LIGAND INTERACTIONS; GENERAL-MODEL; CRK ADAPTER; BINDING; STRESS; PATHWAY; ACTIVATION; APOPTOSIS	Ste20-related protein kinases have been implicated as regulating a range of cellular responses, including stress-activated protein kinase pathways and the control of cytoskeletal architecture. An important issue involves the identities of the upstream signals and regulators that might control the biological functions of mammalian Ste20-related protein kinases. HPK1 is a protein-serine/threonine kinase that possesses a Ste20-like kinase domain, and in transfected cells activates a protein kinase pathway leading to the stress-activated protein kinase SAPK/JNK. Here we have investigated candidate upstream regulators that might interact with HPK1. HPK1 possesses an N-terminal catalytic domain and an extended C-terminal tail with four proline-rich motifs. The SH3 domains of Grb2 bound in vitro to specific proline-rich motifs in the HPK1 tail and functioned synergistically to direct the stable binding of Grb2 to HPK1 in transfected Cos1 cells. Epidermal growth factor (EGF) stimulation did not affect the binding of Grb2 to HPK1 but induced recruitment of the Grb2-HPK1 complex to the autophosphorylated EGF receptor and to the Shc docking protein. Several activated receptor and cytoplasmic tyrosine kinases, including the EGF receptor, stimulated the tyrosine phosphorylation of the HPK1 serine/threonine kinase. These results suggest that HPK1, a mammalian Ste20-related protein-serine/threonine kinase, can potentially associate with protein-tyrosine kinases through interactions mediated by SH2/SH3 adaptors such as Grb2. Such interaction may provide a possible mechanism for cross-talk between distinct biochemical pathways following the activation of tyrosine kinases.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAMME MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, ONTARIO CANC INST, TORONTO, ON M5G 2M9, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M5G 2M9, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto			Pawson, Tony J/E-4578-2013; Gish, Gerald D/C-7228-2017	Kiefer, Friedemann/0000-0002-3002-8237				Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Chook YM, 1996, J BIOL CHEM, V271, P30472, DOI 10.1074/jbc.271.48.30472; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIN N, 1993, NATURE, V863, P85; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SALCINI AE, 1994, ONCOGENE, V9, P2827; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; Smit L, 1996, ONCOGENE, V13, P381; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	57	71	73	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27804	27811		10.1074/jbc.272.44.27804	http://dx.doi.org/10.1074/jbc.272.44.27804			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346925	hybrid			2022-12-27	WOS:A1997YD47300051
J	Duckworth, BC; Cantley, LC				Duckworth, BC; Cantley, LC			Conditional inhibition of the mitogen-activated protein Kinase cascade by wortmannin - Dependence of signal strength	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; PLASMA-MEMBRANE; MAMMALIAN-CELLS; RAS; PDGF; PHOSPHORYLATION; INSULIN; RAF-1	Phosphoinositide (PI) 3-kinase and the mitogen-activated protein (MAP) kinase cascades are activated by many of the same ligands, Several groups have reported involvement of PI 3-kinase in the activation of Erk1 and Erk2, whereas many other groups have shown that activation of Erk1 and Erk2 is not sensitive to inhibitors of PI 3-kinase such as wortmannin, Here we show that wortmannin inhibition of the MAP kinase pathway is cell type-and ligand-specific. Wortmannin blocks platelet derived growth factor (PDGF) dependent activation of Raf-l and the MAP kinase cascade in Chinese hamster ovary cells, which have few PDGF receptors, but has no significant effect on Erk activation in Swiss 3T3 cells, which have high levels of PDGF receptors. However, wortmannin blocks activation of Erk proteins if Swiss 3T3 cells are stimulated with lower, physiological levels of PDGF, These results suggest that PI 3-kinase is in an efficient pathway for activation of MAP kinase, but that MAP kinase can be stimulated by a redundant pathway when a large number of receptors are activated. We present evidence that a protein kinase C family member downstream of phospholipase C gamma is involved in the redundant pathway.	BETH ISRAEL HOSP, DEPT MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tufts University			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHUANG LM, 1994, J BIOL CHEM, V269, P27645; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DUCKWORTH BC, 1996, LIPID 2 MESSENGERS H, V8, P125; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; HUANG JS, 1982, J BIOL CHEM, V257, P8130; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nakamura K, 1996, AM J PHYSIOL-GASTR L, V271, pG640, DOI 10.1152/ajpgi.1996.271.4.G640; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Nishioka N, 1995, FEBS LETT, V377, P393, DOI 10.1016/0014-5793(95)01382-2; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SINGH JP, 1982, J CELL BIOL, V95, P667, DOI 10.1083/jcb.95.2.667; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807	45	178	182	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27665	27670		10.1074/jbc.272.44.27665	http://dx.doi.org/10.1074/jbc.272.44.27665			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346906	hybrid			2022-12-27	WOS:A1997YD47300032
J	Hashimoto, R; Ono, M; Fujiwara, H; Higashihashi, N; Yoshida, M; EnjohKimura, T; Sakano, K				Hashimoto, R; Ono, M; Fujiwara, H; Higashihashi, N; Yoshida, M; EnjohKimura, T; Sakano, K			Binding sites and binding properties of binary and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; ADULT-RAT SERUM; EXPRESSION; MUTANTS; PURIFICATION; RECEPTORS; DELETION; IGFBP-3; MAC25; CELLS	We have examined regions of rat IGF-binding protein-3 (IGFBP-3) important for complex formations using two kinds of deletion mutants, three kinds of chimera molecules between rat IGFBP-3 and rat IGFBP-2, and a synthetic peptide (41 residues, Glu(52)-Ala(92)) derived from rat IGFBP-3. Solid-phase binding assays using 96-well microtiter plates were designed to quantitate the relative binding affinities. It was found that not only the IGFBP-3 derivatives with the amino-terminal, cysteine-rich domain (N domain) but also the synthetic peptide maintained affinity for IGF-II. Ternary complex formation was observed with full-length IGFBP-3 and chimera IGFBP, the carboxyl-terminal cysteine-rich domain (C domain) of which was derived from IGFBP-3, unlike the mutants lacking the C domain and the chimera IGFBPs, the C domain of which was derived from IGFBP-2. These results were confirmed by affinity crosslinking experiments. Furthermore, the IGFBP-3 derivatives that possessed the C domain of IGFBP-3 bound to the acid-labile subunit, even in the absence of IGFs. Finally, we observed sites in IGF-II important for the ternary complex formation using various IGF-II mutants. These IGF-II mutants, which contained a substitution of Tyr(27) for Leu, had extremely reduced activity. These results strongly suggest that: 1) the N domain, containing at least Glu(52)-Ala(92), of rat IGFBP-3 is important for binding to IGF-II; 2) the C domain of IGFBP-3 is essential for binding to the acid-labile subunit both in the presence and absence of IGF-II; and 3) Tyr(27) of TGF-II is important for the ternary complex formation.			Hashimoto, R (corresponding author), DAIICHI PHARMACEUT CO LTD,BASIC TECHNOL RES LAB,EDOGAWA KU,16-13 KITAKASAI 1 CHOME,TOKYO 134,JAPAN.							BACH LA, 1993, J BIOL CHEM, V268, P9246; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1992, J BIOL CHEM, V267, P60; BAXTER RC, 1994, ENDOCRINOLOGY, V134, P848, DOI 10.1210/en.134.2.848; BINOUX M, 1991, MODERN CONCEPTS INSU, P329; BROWN AL, 1989, J BIOL CHEM, V264, P5148; CASCIERI MA, 1989, MOLECULAR AND CELLULAR BIOLOGY OF INSULIN-LIKE GROWTH FACTORS AND THEIR RECEPTORS, P285; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; DODSON EJ, 1979, CAN J BIOCHEM CELL B, V57, P469, DOI 10.1139/o79-060; FRANCIS GL, 1993, BIOCHEM J, V293, P713, DOI 10.1042/bj2930713; HASHIMOTO R, 1995, J BIOL CHEM, V270, P18013, DOI 10.1074/jbc.270.30.18013; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1995, ENDOCRINOLOGY, V136, P668, DOI 10.1210/en.136.2.668; LEE CY, 1995, ENDOCRINOLOGY, V136, P4982, DOI 10.1210/en.136.11.4982; LUTHI C, 1992, EUR J BIOCHEM, V205, P483, DOI 10.1111/j.1432-1033.1992.tb16804.x; MARUMOTO Y, 1992, BIOSCI BIOTECH BIOCH, V56, P13, DOI 10.1271/bbb.56.13; MARUMOTO Y, 1987, J GEN VIROL, V68, P2599, DOI 10.1099/0022-1317-68-10-2599; NAKAGAWA SH, 1991, J BIOL CHEM, V266, P11502; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; SAKANO KI, 1991, J BIOL CHEM, V266, P20626; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID C, 1991, BIOCHEM BIOPH RES CO, V179, P579, DOI 10.1016/0006-291X(91)91410-E; SHIMASAKI S, 1989, BIOCHEM BIOPH RES CO, V165, P907, DOI 10.1016/S0006-291X(89)80052-X; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; SHIMONAKA M, 1989, BIOCHEM BIOPH RES CO, V165, P189, DOI 10.1016/0006-291X(89)91053-X; SOMMER A, 1991, MODERN CONCEPTS INSU, P715; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TERASAWA H, 1994, EMBO J, V13, P5590, DOI 10.1002/j.1460-2075.1994.tb06896.x; ZAPF J, 1988, BIOCHEM BIOPH RES CO, V156, P1187, DOI 10.1016/S0006-291X(88)80758-7; ZAPF J, 1990, J BIOL CHEM, V265, P14892	35	44	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27936	27942		10.1074/jbc.272.44.27936	http://dx.doi.org/10.1074/jbc.272.44.27936			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346943	hybrid			2022-12-27	WOS:A1997YD47300069
J	Aguilar, RC; Ohno, H; Roche, KW; Bonifacino, JS				Aguilar, RC; Ohno, H; Roche, KW; Bonifacino, JS			Functional domain mapping of the clathrin-associated adaptor medium chains mu 1 and mu 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; COATED VESICLES; BINDING SUBUNIT; PLASMA-MEMBRANE; SORTING SIGNALS; AP-2 COMPLEXES; DELTA-COP; GOLGI; IDENTIFICATION; PREDICTION	The clathrin-associated adaptors AP-1 and AP-2 are heterotetrameric complexes involved in the recognition of sorting signals present within the cytosolic domain of integral membrane proteins. The medium chains of these complexes, mu 1 and mu 2, have been implicated in two types of interaction: assembly with the beta 1 and beta 2 chains of the corresponding complexes and recognition of tyrosine-based sorting signals. In this study, we report the results of a structure-function analysis of the mu 1 and mu 2 chains aimed at identifying regions of the molecules that, ape responsible for each of the two interactions. Analyses using the yeast two-hybrid system and proteolytic digestion experiments suggest that mu 1 and mu 2 have a bipartite structure, with the amino-terminal one-third (residues 1-145 of mu 1 and mu 2) being involved in assembly with the beta chains and the carboxyl-terminal two-thirds (residues 147-423 of mu 1 and 164-435 of mu 2) binding tyrosine-based sorting signals, These observations support a model in which the amino-terminal one-third of mu 2 is embedded within the core of the AP-2 complex, while the carboxyl-terminal two-thirds of the protein are exposed to the medium, placing this region in a position to interact with tyrosine-based sorting signals.	NICHHD,CBMB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Roche, Katherine/W-9893-2019; Ohno, Hiroshi/L-7899-2014	Ohno, Hiroshi/0000-0001-8776-9661; Bonifacino, Juan S./0000-0002-5673-6370; Roche, Katherine/0000-0001-7282-6539				AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Faulstich D, 1996, J CELL BIOL, V135, P53, DOI 10.1083/jcb.135.1.53; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; NAKAYAMA Y, 1991, EUR J BIOCHEM, V202, P569, DOI 10.1111/j.1432-1033.1991.tb16409.x; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Ooi CE, 1997, EMBO J, V16, P4508; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PEVSNER J, 1994, GENE, V146, P279, DOI 10.1016/0378-1119(94)90306-9; PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; RADICE P, 1995, GENOMICS, V26, P101, DOI 10.1016/0888-7543(95)80087-3; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1993, J CELL BIOL, V123, P67, DOI 10.1083/jcb.123.1.67; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Traub LM, 1997, TRENDS CELL BIOL, V7, P43, DOI 10.1016/S0962-8924(96)20042-X; Wang XL, 1997, FEBS LETT, V402, P57, DOI 10.1016/S0014-5793(96)01500-1; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108	43	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27160	27166		10.1074/jbc.272.43.27160	http://dx.doi.org/10.1074/jbc.272.43.27160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341158	hybrid			2022-12-27	WOS:A1997YC65900054
J	Daniel, R; Caminade, E; Martel, A; LeGoffic, F; Canosa, D; Carrascal, M; Abian, J				Daniel, R; Caminade, E; Martel, A; LeGoffic, F; Canosa, D; Carrascal, M; Abian, J			Mass spectrometric determination of the cleavage sites in Escherichia coli dihydroorotase induced by a cysteine-specific reagent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; MAMMALIAN DIHYDROOROTASE; PYRC GENE; PROTEINS; RESIDUES; ZINC; CATALYSIS; ENZYMES; BINDING	Escherichia coli dihydroorotase contains six cysteines/subunit, which are potential ligands of structural and catalytic zinc metals at protein sites of the enzyme, Specific thiol reagents modify, in nondenaturing conditions only, two of these cysteines; these two residues are thought to be ligands of structural zinc. We report here ore the localization of these two cysteines on the polypeptide chain through their cyanylation by 2-nitro-thiocyanobenzoic acid (NTCB) and the analysis by mass spectrometry of the protein adducts. This is the first study of E. coli dihydroorotase by mass spectrometry, allowing the accurate determination of the subunit molecular weight (38,695). Treatment of dihydroorotase by NTCB induced a cleavage N-terminal to the cyanylated cysteines. The resulting fragments visualized on electrophoresis gel have been N-terminal sequenced, and their masses were determined by electrospray-ionizing mass spectrometry. This allowed the identification of cysteines 221 and 265 as the two residues cyanylated by the reagent NTCB. Results from gel filtration of dihydroorotase cyanylated on the two cysteines indicate that these residues are involved in subunit interactions leading to the active dimer. Consistent with literature data, we assume that cysteine 221 and cysteine 265, along with the neighboring cysteines 263 and 268 arranged in cluster, are potential ligands of structural zinc of E. coli dihydroorotase.	ECOLE NATL SUPER CHIM PARIS, CNRS, LAB BIOORGAN & BIOTECHNOL, F-75231 PARIS 05, FRANCE; CSIC, DEPT MED BIOANAL, ES-08034 BARCELONA, SPAIN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Chimie ParisTech; Consejo Superior de Investigaciones Cientificas (CSIC)			Abian, Joaquin/M-1965-2014; Daniel, Regis/S-7890-2016; Carrascal, Montserrat/M-1913-2014	Abian, Joaquin/0000-0003-2823-5429; Daniel, Regis/0000-0003-0725-5439; Carrascal, Montserrat/0000-0002-0205-2176				BACKSTROM D, 1986, EUR J BIOCHEM, V160, P77, DOI 10.1111/j.1432-1033.1986.tb09942.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DC, 1986, J BIOL CHEM, V261, P5917; BROWN DC, 1991, J BIOL CHEM, V266, P1597; Carrey EA, 1995, BIOCHEM SOC T, V23, P899, DOI 10.1042/bst0230899; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CHRISTIANSON DW, 1989, J AM CHEM SOC, V254, P12506; Daniel R, 1996, ANAL BIOCHEM, V239, P130, DOI 10.1006/abio.1996.0307; DEGANI Y, 1974, BIOCHEMISTRY-US, V13, P1, DOI 10.1021/bi00698a001; GIBBS P, 1981, Biochemical Society Transactions, V9, P232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OGILVIE JW, 1980, BIOCHIM BIOPHYS ACTA, V622, P277, DOI 10.1016/0005-2795(80)90038-0; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; SANDER EG, 1965, J BIOL CHEM, V240, P3628; SIMMER JP, 1990, P NATL ACAD SCI USA, V87, P174, DOI 10.1073/pnas.87.1.174; Stark G R, 1977, Methods Enzymol, V47, P129; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WASHABAUGH MW, 1984, J BIOL CHEM, V259, P3293; WASHABAUGH MW, 1986, J BIOL CHEM, V261, P5920; WILLIAMS NK, 1995, BIOCHEMISTRY-US, V34, P11344, DOI 10.1021/bi00036a007; WILSON HR, 1987, J BACTERIOL, V169, P3051, DOI 10.1128/jb.169.7.3051-3058.1987; Wu J, 1996, ANAL BIOCHEM, V235, P161, DOI 10.1006/abio.1996.0108; ZIMMERMANN BH, 1995, BIOCHEMISTRY-US, V34, P7038, DOI 10.1021/bi00021a015; ZIMMERMANN BH, 1995, ADV EXP MED BIOL, V370, P699	25	11	12	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26934	26939		10.1074/jbc.272.43.26934	http://dx.doi.org/10.1074/jbc.272.43.26934			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341128	hybrid			2022-12-27	WOS:A1997YC65900024
J	Krupenko, NI; Wagner, C				Krupenko, NI; Wagner, C			Transport of rat liver glycine N-methyltransferase into rat liver nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE-BINDING-PROTEIN; PURIFICATION; DNA; COMPONENTS; SUBUNIT; IMPORT	Rat liver cytosolic glycine N-methyltransferase (GNMT) catalyzes the S-adenosylmethionine-dependent methylation of glycine to sarcosine. It is comprised of four identical 292-amino acid residue subunits. Recently, evidence has been provided to show that GNMT is identical to the cytosolic receptor for benzo[a]pyrene, which induces cytochrome P450 1A1 gene expression. In the present study we show that chemical modification of purified rat Liver GNMT with fluorescein isothiocyanate (FITC) resulted in dissociation of the tetrameric enzyme and was accompanied by loss of enzyme activity. Amino acid sequence analysis of the FITC-labeled peptides obtained by hydrolysis of the modified protein with Staphylococcus aureus V8 protease revealed that lysines 45, 89, 92, 96, 122, and 147 were modified. Lys-122 and Lys-147 were derivatized in tetrameric, dimeric, and monomeric forms of the enzyme. Lysines 45, 89, 92, and 96 were derivatized only in monomeric GNMT, suggesting that modification of these residues resulted in GNMT dissociation. The modified monomeric GNMT was quickly transported into isolated rat liver nuclei. This transport was specific for the GNMT monomer, since neither tetramer nor dimer was able to enter the nuclei, Bovine carbonic anhydrase, similar in size to the GNMT monomer, was labeled with FITC to a similar extent but was not transported into the nuclei. Disruption of the nuclei containing fluorescein-labeled GNMT and subsequent extraction of the nuclear lysate with both high and low salt buffers recovered FITC-GNMT only in the chromatin pellet. Our study supports the suggestion of an additional function for GNMT, probably connected with regulation of cytochrome P450 1A1 gene expression.	VET AFFAIRS MED CTR,NASHVILLE,TN 37232	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Krupenko, NI (corresponding author), VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,221 KIRKLAND HALL,614 LH,NASHVILLE,TN 37232, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015289, R01DK046788, R01DK015289] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46788, DK15289] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLFREY V, 1951, J BIOL CHEM, V226, P529; BERNHARDT R, 1983, BIOCHIM BIOPHYS ACTA, V745, P140, DOI 10.1016/0167-4838(83)90042-0; Bhat R, 1996, J BIOL CHEM, V271, P32551, DOI 10.1074/jbc.271.51.32551; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CANTONI GL, 1978, TRANSMETHYLATION, P155; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; Drapeau G R, 1977, Methods Enzymol, V47, P189; ElSeaidy AZ, 1997, AM J PHYSIOL-GASTR L, V272, pG298, DOI 10.1152/ajpgi.1997.272.2.G298; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P19; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; JINDAL HK, 1990, J BIOL CHEM, V265, P6540; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KERR SJ, 1972, J BIOL CHEM, V247, P4248; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; Ogawa H, 1997, BIOCHEM BIOPH RES CO, V233, P300, DOI 10.1006/bbrc.1997.6444; OGAWA H, 1982, J BIOL CHEM, V257, P3447; RAHA A, 1994, J BIOL CHEM, V269, P5750; RAHA A, 1995, ARCH BIOCHEM BIOPHYS, V322, P395, DOI 10.1006/abbi.1995.1480; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RONAI Z, 1993, INT J BIOCHEM, V25, P1073, DOI 10.1016/0020-711X(93)90123-V; SMITH DS, 1981, ANN CLIN BIOCHEM, V18, P253, DOI 10.1177/000456328101800501; SPELSBERG TC, 1971, J BIOL CHEM, V246, P4188; WAGNER C, 1989, J BIOL CHEM, V264, P9638; WAGNER C, 1985, BIOCHEM BIOPH RES CO, V127, P746, DOI 10.1016/S0006-291X(85)80006-1; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010; YEO EJ, 1994, P NATL ACAD SCI USA, V91, P210, DOI 10.1073/pnas.91.1.210; YEO EJ, 1992, J BIOL CHEM, V267, P24669	34	13	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27140	27146		10.1074/jbc.272.43.27140	http://dx.doi.org/10.1074/jbc.272.43.27140			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341155	hybrid			2022-12-27	WOS:A1997YC65900051
J	Babiker, A; Andersson, O; Lund, E; Xiu, RJ; Deeb, S; Reshef, A; Leitersdorf, E; Diczfalusy, U; Bjorkhem, I				Babiker, A; Andersson, O; Lund, E; Xiu, RJ; Deeb, S; Reshef, A; Leitersdorf, E; Diczfalusy, U; Bjorkhem, I			Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism - Comparison with high density lipoprotein-mediated reverse cholesterol transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBROTENDINOUS XANTHOMATOSIS; ACID; 25-HYDROXYCHOLESTEROL; 26-HYDROXYLASE; HOMEOSTASIS; PROTEINS; ENZYME; BRAIN	Cultured macrophages and endothelial cells have been reported to secrete 27-oxygenated metabolites of cholesterol, This mechanism was compared with the classical high density lipoprotein (HDL)-dependent reverse cholesterol transport, Under standard conditions, macrophage preparations had considerably higher capacity to secrete 27-hydroxycholesterol and 3 beta-hydroxy-5-cholestenoic acid than had endothelial cells and fibroblasts, Western blotting showed that lung macrophages contained the most sterol 27-hydroxylase protein of the cells tested, The relative amounts of 3 beta-hydroxy-5-cholestenoic acid produced by the macrophages were also highest, Macrophages derived from monocytes of patients with sterol 27-hydroxylase deficiency did not secrete 27-oxygenated products, demonstrating that sterol 27-hydroxylase is the critical enzyme for the conversion of cholesterol into the 27-oxygenated steroids, That sterol 27-hydroxylase is responsible not only for 27-hydroxylation of cholesterol but also for time further oxidation of this steroid into 3 beta-hydroxy-5-cholestenoic acid was shown with use of tritium-labeled 27-hydroxy-cholesterol and an inhibitor of sterol 27-hydroxylase. Secretion of 27-oxygenated products by the cultured macrophages as well as the ratio between the alcohol and the acid appeared to be dependent upon total 27-hydroxylase activity, the availability of substrate cholesterol, and the presence of an acceptor for 27-hydroxy-cholesterol in the medium, With albumin as extracellular acceptor, the major secreted product was 3 beta-hydroxy-5-cholestenoic acid. Under such conditions, secretion of labeled 27-oxygenated products was higher than that of labeled cholesterol from lung alveolar macrophages preloaded with [4-C-14]cholesterol. With HDL as acceptor, 27-hydroxycholesterol was the major secreted product, and the total secretion of labeled 27-oxygenated products was only about 10% of that of labeled cholesterol, Thus, 27-hydroxycholesterol and cholesterol may compete for HDL-mediated efflux from the cells. The results support the contention that the sterol 27-hydroxylase-mediated elimination of cholesterol is more important in macrophages than in endothelial cell. This mechanism may be an alternative and/or a complement to the classical HDL-mediated reverse cholesterol transport in macrophages, in particular when the concentration of HDL is low.	KAROLINSKA INST,DEPT MED LAB SCI & TECHNOL,SE-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,CLIN RES CTR,SE-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,DEPT LUNG MED,SE-14186 HUDDINGE,SWEDEN; HADASSAH UNIV HOSP,DIV MED,CTR RES PREVENT & TREATMENT ATHEROSCLEROSIS,IL-91120 JERUSALEM,ISRAEL	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Hebrew University of Jerusalem			Diczfalusy, Ulf/A-5336-2008	Xiu, Ruijuan/0000-0002-1446-2711; Bjorkhem, Ingemar/0000-0002-0575-9425; Diczfalusy, Ulf/0000-0001-6643-3763; Bjorkhem, Ingemar/0000-0001-6087-9190				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BJORKHEM I, 1992, BIOCHIM BIOPHYS ACTA, V1128, P73, DOI 10.1016/0005-2760(92)90259-X; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BJORKHEM I, 1974, J BIOL CHEM, V249, P2528; BJORKHEM I, 1994, METABOLIC BASIS INHE, P2073; Crisby M, 1997, BBA-LIPID LIPID MET, V1344, P278, DOI 10.1016/S0005-2760(96)00152-X; GRANT MM, 1992, AM J PHYSIOL, V263, P370; HARIKKHAN R, 1990, J STEROID BIOCHEM, V35, P351; HOLMBERGBETSHOLTZ I, 1993, J BIOL CHEM, V268, P11079; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAVITT NB, 1994, FASEB J, V8, P1308, DOI 10.1096/fasebj.8.15.8001744; KURIYAMA M, 1991, J NEUROL SCI, V102, P225, DOI 10.1016/0022-510X(91)90073-G; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE Y, 1995, J LIPID RES, V36, P1092; Lange Y, 1996, TRENDS CELL BIOL, V6, P205, DOI 10.1016/0962-8924(96)20016-9; LEITERSDORF E, 1993, J CLIN INVEST, V91, P2488, DOI 10.1172/JCI116484; LIN CY, 1995, J NUTR BIOCHEM, V6, P618, DOI 10.1016/0955-2863(95)00122-G; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; LUND J, 1986, TOXICOL APPL PHARM, V83, P486, DOI 10.1016/0041-008X(86)90231-0; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Martinez F, 1997, Subcell Biochem, V28, P205; Ohvo H, 1996, BIOCHEMISTRY-US, V35, P8018, DOI 10.1021/bi9528816; Oram JF, 1996, J LIPID RES, V37, P2473; PEDERSEN JI, 1989, BIOCHEM INT, V18, P615; REISS AB, 1994, J LIPID RES, V35, P1026; SKREDE S, 1986, J CLIN INVEST, V78, P729, DOI 10.1172/JCI112633; SLOOP CH, 1993, BIOCHIM BIOPHYS ACTA, V1169, P196, DOI 10.1016/0005-2760(93)90206-O; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VESSBY B, 1987, J LIPID RES, V28, P629; ZHANG J, 1994, 13 INT BIL AC M FALK, P86	31	198	201	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26253	26261		10.1074/jbc.272.42.26253	http://dx.doi.org/10.1074/jbc.272.42.26253			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334194	hybrid			2022-12-27	WOS:A1997YB13900028
J	Han, JD; Baker, NE; Rubin, CS				Han, JD; Baker, NE; Rubin, CS			Molecular characterization of a novel A kinase anchor protein from Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; REGULATORY SUBUNIT RII; A-KINASE; II-BETA; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; EXPRESSION; LOCALIZATION; CLONING; CYTOSKELETON	Activation of protein kinase A (PKA) at discrete intracellular sites facilitates oogenesis and development in Drosophila, Thus, PKA-anchor protein complexes may involved in controlling these crucial biological processes, Evaluation of this proposition requires knowledge of PKA binding/targeting proteins in the fly, We now report the discovery and characterization of cDNAs encoding a novel, Drosophila A kinase anchor protein, DAKAP550, DAKAP550 is a large (>2300 amino acids) acidic protein that is maximally expressed in anterior tissues, It binds regulatory subunits (RII) of both mammalian and Drosophila PKAII isoforms. The tethering region of DAKAP550 includes two proximal, but noncontiguous RII-binding sites (B1 and B2), The B1 domain (residues 1406-1425) binds RII similar to 20-fold more avidly than B2 (amino acids 1350-1369). Affinity-purified anti-DAKAP550 IgGs were exploited to demonstrate that the anchor protein is expressed in many cells in nearly all tissues throughout the lifespan of the fly, However, DAKAP550 is highly enriched and asymmetrically positioned in subpopulations of neurons and in apical portions of cells in gut and trachea. The combination of RII (PKAII) binding activity with differential expression polarized localization is consistent with a role for DAKAP550 in creating target loci for the reception of signals carried by cAMP. The DAKAP550 gene was mapped to the 4F1.2 region of the X chromosome; flies that carry a deletion for this portion of the X chromosome lack DAKAP550 protein.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,ATRAN LABS,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,DEPT MOL GENET,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				Han, Jing-Dong J./0000-0002-9270-7139	NIGMS NIH HHS [GM47892, GM22792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792, R01GM047892] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ashburner M, 1989, DROSOPHILA LABORATOR, P44; BEEBE SJ, 1986, ENZYMES, P44; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, J BIOL CHEM, V267, P16816; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FEUCHTER AE, 1992, GENOMICS, V13, P1237, DOI 10.1016/0888-7543(92)90041-P; FOSTER JL, 1984, J BIOL CHEM, V259, P3049; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P1256; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; LAND M, 1994, J BIOL CHEM, V269, P9234; LANE ME, 1995, MECH DEVELOP, V49, P191, DOI 10.1016/0925-4773(94)00317-G; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LU XY, 1990, J BIOL CHEM, V265, P3293; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SHORT JM, 1992, METHOD ENZYMOL, V216, P495; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	40	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26611	26619		10.1074/jbc.272.42.26611	http://dx.doi.org/10.1074/jbc.272.42.26611			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334242	hybrid			2022-12-27	WOS:A1997YB13900076
J	Kuo, HJ; Maslen, CL; Keene, DR; Glanville, RW				Kuo, HJ; Maslen, CL; Keene, DR; Glanville, RW			Type VI collagen anchors endothelial basement membranes by interacting with type IV collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; BETHLEM MYOPATHY; EXTRACELLULAR-MATRIX; BINDING-PROPERTIES; 2-HYBRID SYSTEM; HUMAN PLACENTA; ALPHA-3 CHAIN; CELL-ADHESION; TRIPLE-HELIX; HYALURONAN	Type VI collagen filaments are found associated with interstitial collagen fibers, around cells, and in contact with endothelial basement membranes, To identify type VI collagen binding proteins, the amino-terminal domains of the alpha 1(VI) and alpha 2(VI) chains and a part of the carboxyl-terminal domain of the alpha 3(VI) chain were used as bait in a yeast two-hybrid system to screen a human placenta library. Eight persistently positive clones were identified, two coding the known matrix proteins fibronectin and basement membrane type IV collagen and the rest coding new proteins. The amino-terminal domain of alpha 1(VI) was shown to interact with the carboxyl-terminal globular domain of type IV collagen. The specificity of this interaction was further studied using the yeast two-hybrid system in a one-on-one format and confirmed by using isolated protein domains in immunoprecipitation, affinity blots, and enzyme-linked immunosorbent assay-based binding studies. Co-distribution of type. VI and type IV collagens in human muscle was demonstrated using double labeling immunofluorescent microscopy and immunoelectron microscopy, The strong interaction of type VI collagen filaments with basement membrane collagen provided a possible molecular pathogenesis for the heritable disorder Bethlem myopathy.	SHRINERS HOSP CRIPPLED CHILDRENS, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT MED, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOL BIOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, CONGENITAL HEART RES CTR, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University					NIAMS NIH HHS [R29AR41846-03] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041846] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, P1; BETHLEM J, 1976, BRAIN, V99, P91, DOI 10.1093/brain/99.1.91; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BRINKER JM, 1985, P NATL ACAD SCI USA, V82, P3649, DOI 10.1073/pnas.82.11.3649; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARTER WG, 1982, J BIOL CHEM, V257, P13805; CARTER WG, 1984, J CELL BIOL, V99, P105, DOI 10.1083/jcb.99.1.105; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FITCH JM, 1991, DEV BIOL, V144, P379, DOI 10.1016/0012-1606(91)90430-B; HAGIWARA H, 1993, CELL TISSUE RES, V272, P155, DOI 10.1007/BF00323581; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HNATOWICH DJ, 1987, J NUCL MED, V28, P1294; IIDA K, 1994, J ELECTRON MICROSC, V43, P367; Jobsis GJ, 1996, NEUROLOGY, V46, P779, DOI 10.1212/WNL.46.3.779; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; KIELTY CM, 1992, J CELL BIOL, V118, P979, DOI 10.1083/jcb.118.4.979; KIELTY CM, 1991, J CELL SCI, V99, P797; KUO HJ, 1995, EUR J BIOCHEM, V232, P364, DOI 10.1111/j.1432-1033.1995.364zz.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; MCDEVITT CA, 1991, FEBS LETT, V294, P167, DOI 10.1016/0014-5793(91)80660-U; MOHIRE MD, 1988, NEUROLOGY, V38, P573, DOI 10.1212/WNL.38.4.573; Nagase T, 1996, DNA Res, V3, P43, DOI 10.1093/dnares/3.1.43; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OZEBBERGER BA, 1995, MOL ENDOCRINOL, V9, P1321; PERRIS R, 1993, EXP CELL RES, V209, P103, DOI 10.1006/excr.1993.1290; Pessier AP, 1996, LAB INVEST, V75, P87; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; QIAN RG, 1984, BIOCHEM J, V222, P447, DOI 10.1042/bj2220447; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; SENGA K, 1995, ANAT REC, V243, P294, DOI 10.1002/ar.1092430303; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; Speer MC, 1996, HUM MOL GENET, V5, P1043, DOI 10.1093/hmg/5.7.1043; SPISSINGER T, 1995, MATRIX BIOL, V14, P499, DOI 10.1016/0945-053X(95)90007-1; STALLCUP WB, 1990, J CELL BIOL, V111, P3177, DOI 10.1083/jcb.111.6.3177; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; WEBER S, 1984, EUR J BIOCHEM, V139, P401, DOI 10.1111/j.1432-1033.1984.tb08019.x; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; ZHU D, 1994, J HISTOCHEM CYTOCHEM, V42, P577, DOI 10.1177/42.5.8157929	49	226	234	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26522	26529		10.1074/jbc.272.42.26522	http://dx.doi.org/10.1074/jbc.272.42.26522			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334230	hybrid			2022-12-27	WOS:A1997YB13900064
J	Nemoto, T; Sato, N; Iwanari, H; Yamashita, H; Takagi, T				Nemoto, T; Sato, N; Iwanari, H; Yamashita, H; Takagi, T			Domain structures and immunogenic regions of the 90-kDa heat-shock protein (HSP90) - Probing with a library of anti-HSP90 monoclonal antibodies and limited proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONHORMONE-BINDING-COMPONENT; STEROID-RECEPTORS; GLUCOCORTICOID RECEPTOR; HORMONE-BINDING; CASEIN KINASE; RAT-LIVER; SEQUENCE; GROWTH	Domain structures of the 90-kDa heat shock protein (HSP90) have been investigated with a library of anti-HSP90 monoclonal antibodies (mAbs) and by limited proteolysis with trypsin and chymotrypsin. Thirty-three mAbs were obtained by immunization with bacterially expressed human HSP90 alpha and HSP90 beta isoforms, Among them, ten and three mAbs reacted specifically with HSP90 alpha and HSP90 beta, respectively. Immunoblotting and enzyme-linked immunosorbent analyses revealed that major immunogenic domains were located at two restricted regions of HSP90 alpha, i.e. amino acids 227-310 (designated Region I) and 702-716 (Region II), corresponding to a highly charged region and a region near the C terminus, respectively, Taken together with the characteristics of the amino acid sequences, these two immunogenic regions appeared to be exposed at the outer surface of HSP90. We further investigated the domain structures of HSP90 by limited proteolysis in combination with N-terminal sequencing and immunoblotting analyses, Tryptic cleavages of HSP90 alpha at low concentrations revealed the existence of major susceptible sites at Arg(400)-Glu(401), Lys(615)-Ala(616), and Arg(620)-Asp(621). Proteolysis at higher trypsin concentrations caused successive cleavages only toward the N-terminal direction from these sites, and Region I was included in the region selectively deleted during this process, thereby further suggesting its surface location, From these results, we propose three domain structures of HSP90 consisting of amino acids 1-400, 401-615, and 621-732. Differences in the protease sensitivity and immunogenicity further suggest that every domain is composed of two subdomains, This is the first study describing the domain structures and the immunogenic regions of HSP90.	INST IMMUNOL CO,ISHIBASHI,TOCHIGI 32905,JAPAN; TOHOKU UNIV,FAC SCI,INST BIOL,SENDAI,MIYAGI 98077,JAPAN	Tohoku University	Nemoto, T (corresponding author), IWATE UNIV,SCH DENT,DEPT BIOCHEM,19-1 UCHIMARU,MORIOKA,IWATE 020,JAPAN.			Nemoto, Takayuki K./0000-0002-5007-6260				BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; BINART N, 1989, J STEROID BIOCHEM, V34, P369, DOI 10.1016/0022-4731(89)90110-6; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; CADEPOND F, 1994, J STEROID BIOCHEM, V48, P361, DOI 10.1016/0960-0760(94)90076-0; DOUGHERTY JJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P74, DOI 10.1016/0167-4889(87)90067-X; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KYAKUMOTO S, 1994, ARCH ORAL BIOL, V39, P569, DOI 10.1016/0003-9969(94)90132-5; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; NEMOTO T, 1987, J BIOCHEM-TOKYO, V102, P513, DOI 10.1093/oxfordjournals.jbchem.a122083; Nemoto T, 1996, J BIOCHEM-TOKYO, V120, P249; NEMOTO T, 1995, STEROID BIOCH LIFE S, V14, P59; OLI VT, 1984, SELECTED METHODS CEL, P351; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641	24	58	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26179	26187		10.1074/jbc.272.42.26179	http://dx.doi.org/10.1074/jbc.272.42.26179			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334185	hybrid			2022-12-27	WOS:A1997YB13900019
J	Springer, C; Valerius, O; Strittmatter, A; Braus, GH				Springer, C; Valerius, O; Strittmatter, A; Braus, GH			The adjacent yeast genes ARO4 and HIS7 carry no intergenic region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COMPLEMENT GENES; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION TERMINATION; POLYADENYLATION SITES; TRANSFORMATION; SEQUENCES; END	The region between the open reading frames of the adjacent yeast genes ARO4 and HIS7 consists of 417 base pairs (bp), Termination of ARO4 transcription and initiation of HIS7 transcription has to take place within this interval, because both genes are transcribed into the same direction, We show that, the ARO4 terminator acid the HIS7 promoter are spatially separated, nonoverlapping units. The ARO4 terminator includes 84 bp of the ARO4 3'-untranslated region with several redundant ARO4 3' end processing signals. Deletion of the ARO4 terminator does reduce but not completely shut down its expression, The adjacent region of 40 bp is neither required for correct: ARO4 3' end formation nor for HIS7 initiation but contains the nucleotides corresponding to the wild type mRNA 3' ends, The following 280 bp are required for the HIS7 promoter, Replacement of the housekeeping ARO4 promoter by the stronger ACT1 promoter leads to: reduced HIS7 expression due to transcriptional interference, This underlines the compactness of the yeast genome carrying virtually no intergenic regions between adjacent genes.	UNIV GOTTINGEN,INST MICROBIOL & GENET,D-37077 GOTTINGEN,GERMANY	University of Gottingen			Braus, Gerhard/ABC-6293-2021; Braus, Gerhard H/G-3999-2012	Braus, Gerhard/0000-0002-3117-5626; Braus, Gerhard H/0000-0002-3117-5626				ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASHFIELD R, 1991, EMBO J, V10, P4197, DOI 10.1002/j.1460-2075.1991.tb04998.x; BRAUS G, 1985, ARCH MICROBIOL, V142, P383, DOI 10.1007/BF00491908; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; EGLI CM, 1995, MOL CELL BIOL, V15, P2466; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GIEBEL LB, 1990, NUCLEIC ACIDS RES, V18, P4947, DOI 10.1093/nar/18.16.4947; GUO ZJ, 1995, MOL CELL BIOL, V15, P5983; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEIDMANN S, 1994, MOL CELL BIOL, V14, P4633, DOI 10.1128/MCB.14.7.4633; HENIKOFF S, 1984, MOL CELL BIOL, V4, P1515, DOI 10.1128/MCB.4.8.1515; HYMAN LE, 1993, MOL CELL BIOL, V13, P5159, DOI 10.1128/MCB.13.9.5159; IRNIGER S, 1992, MOL CELL BIOL, V12, P2322, DOI 10.1128/MCB.12.5.2322; IRNIGER S, 1991, MOL CELL BIOL, V11, P3060, DOI 10.1128/MCB.11.6.3060; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KUNZLER M, 1992, GENE, V113, P67, DOI 10.1016/0378-1119(92)90670-K; KUNZLER M, 1993, J BACTERIOL, V175, P5548; MIOZZARI G, 1978, J BACTERIOL, V153, P163; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPRINGER C, 1996, J BIOL CHEM, V270, P29637; TAKAHASHI M, 1971, CAN J BIOCHEM CELL B, V49, P1015, DOI 10.1139/o71-149; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	28	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26318	26324		10.1074/jbc.272.42.26318	http://dx.doi.org/10.1074/jbc.272.42.26318			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334203	hybrid			2022-12-27	WOS:A1997YB13900037
J	ToyamaSorimachi, N; Kitamura, F; Habuchi, H; Tobita, Y; Kimata, K; Miyasaka, M				ToyamaSorimachi, N; Kitamura, F; Habuchi, H; Tobita, Y; Kimata, K; Miyasaka, M			Widespread expression of chondroitin sulfate-type serglycins with CD44 binding ability in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTES-T; BONE-MARROW; MAST-CELLS; PROTEOGLYCANS; ACTIVATION; RECEPTOR; SURFACE; HYALURONATE; ANTIBODIES; ADHERENCE	Serglycin is a family of small proteoglycans with Ser-Gly dipeptide repeats and is modified with various types of glycosaminoglycan side chains, We previously demonstrated that chondroitin sulfate-modified serglycin is a navel ligand for CD44 involved in the adherence and activation of lymphoid cells, In this study, we investigated the production and distribution of CD44 binding serglycins in various hematopoietic cells and characterized their carbohydrate side chains. Immunoprecipitation analysis using CD44-IgG; and polyclonal antibody against the serglycin core peptide demonstrated that, various serglycin species capable of binding CD44 are produced by a variety of hematopoietic cells including lymphoid cells, myeloid cells, and a few tumor cell lines, Glycosaminoglycans on these serglycins, which are essential for CD44 binding, are composed of chondroitin 4-sulfate or a mixture of chondroitin 4-sulfate and chondroitin B-sulfate, but no heparin or heparan sulfate side chain was detected. The serglycins are also secreted by normal splenocytes, lymph node lymphocytes, and bone marrow cells, whereas they are secreted in very small amounts by normal thymocytes, Secretion of serglycins is greatly enhanced by mitogenic stimulation with concanavalin A or lipopolysaccharide. Our results showed that serglycin, unlike hyaluronate, is produced and secreted in a functional (CD44 binding) form by many members of the hematopoietic system including various lymphocyte subsets, Our data suggest that serglycin may serve as a major Ligand for CD44 in various events in the lymphohematopoietic system.	AICHI MED UNIV,INST MOL SCI MED,AICHI 48011,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT BIOREGULAT,OSAKA 565,JAPAN	Aichi Medical University; Osaka University	ToyamaSorimachi, N (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT IMMUNOL,BUNKYO KU,3-18-22 HON KOMAGOME,TOKYO 113,JAPAN.		Miyasaka, Masayuki/AAM-6343-2020					ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DELFINO DV, 1994, J IMMUNOL, V152, P5171; FYMAN R, 1991, IMMUNOGENETICS, V33, P392; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; Kolset SO, 1996, J LEUKOCYTE BIOL, V59, P545, DOI 10.1002/jlb.59.4.545; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; KOOPMAN G, 1990, J IMMUNOL, V145, P3589; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LEVITT D, 1989, CELL IMMUNOL, V98, P78; MASSON D, 1990, BIOCHEMISTRY-US, V29, P11229, DOI 10.1021/bi00503a011; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; STELLRECHT CM, 1991, DIFFERENTIATION, V48, P127, DOI 10.1111/j.1432-0436.1991.tb00251.x; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; STEVENS RL, 1988, CURR TOP MICROBIOL I, V140, P93; STEWARD WP, 1990, BIOCHIM BIOPHYS ACTA, V1052, P416, DOI 10.1016/0167-4889(90)90151-3; Tanaka Y, 1993, Curr Top Microbiol Immunol, V184, P99; TOYAMASORIMACHI N, 1993, EUR J IMMUNOL, V23, P439, DOI 10.1002/eji.1830230221; TOYAMASORIMACHI N, 1994, INT IMMUNOL, V6, P655, DOI 10.1093/intimm/6.4.655; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	32	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26714	26719		10.1074/jbc.272.42.26714	http://dx.doi.org/10.1074/jbc.272.42.26714			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334256	hybrid			2022-12-27	WOS:A1997YB13900090
J	Apostol, I; Levine, J; Lippincott, J; Leach, J; Hess, E; Glascock, CB; Weickert, MJ; Blackmore, R				Apostol, I; Levine, J; Lippincott, J; Leach, J; Hess, E; Glascock, CB; Weickert, MJ; Blackmore, R			Incorporation of norvaline at leucine positions in recombinant human hemoglobin expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; AMINO-ACIDS; PROTEIN; NORLEUCINE; METHIONINE; REPLACEMENT; SUBSTITUTIONS; RESIDUES	We report here a novel finding that norvaline can be incorporated in place of leucine in recombinant human hemoglobin expressed in Escherichia coli, The presence of the norvaline was confirmed by several analytical methods such as amino acid analysis, peptide mapping, electrospray mass spectrometry, and Edman protein sequencing, It appears that substitution is distributed across both the beta- and di-alpha-globins in purified recombinant hemoglobin, The level of misincorporation correlated with the ratio of the free norvaline/leucine pool available in the cell culture, This suggests that the incorporation of norvaline for leucine occurs through misaminoacylation of tRNA(Leu), similar to the misincorporation of norleucine for methionine found in many recombinant proteins expressed in E. coli.			Apostol, I (corresponding author), SOMATOGEN INC,2545 CENT AVE,BOULDER,CO 80301, USA.							APOSTOL I, 1995, PROTEIN SCI, V4, P2616, DOI 10.1002/pro.5560041219; BARKER DG, 1979, J MOL BIOL, V133, P217, DOI 10.1016/0022-2836(79)90531-X; BIGLER TL, 1993, PROTEIN SCI, V2, P786, DOI 10.1002/pro.5560020509; BOGOSIAN G, 1989, J BIOL CHEM, V264, P531; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; DAVIS MT, 1995, ANAL BIOCHEM, V224, P235, DOI 10.1006/abio.1995.1035; FIORINO A, 1989, J CHROMATOGR, V476, P83, DOI 10.1016/S0021-9673(01)93858-0; FLEMING J, 1992, 228212 HEWL PACK; GILLES AM, 1988, J BIOL CHEM, V263, P8204; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; KISUMI M, 1976, J BIOCHEM-TOKYO, V79, P1021, DOI 10.1093/oxfordjournals.jbchem.a131142; KISUMI M, 1977, J ANTIBIOT, V30, P111, DOI 10.7164/antibiotics.30.111; Lippincott J, 1997, ANAL BIOCHEM, V252, P314, DOI 10.1006/abio.1997.2334; LOOKER D, 1994, METHOD ENZYMOL, V231, P364; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; LU HS, 1988, BIOCHEM BIOPH RES CO, V156, P807, DOI 10.1016/S0006-291X(88)80916-1; MENDEL D, 1992, SCIENCE, V256, P1798, DOI 10.1126/science.1615324; MIYAZAWA T, 1989, Patent No. 4879223; NANDI P, 1953, NATURE, V172, P841; Neidhardt F.C., 1996, ESCHERICHIA COLI SAL, Vvol. 1; PICUR B, 1994, ARCH BIOCHEM BIOPHYS, V315, P533, DOI 10.1006/abbi.1994.1534; PLOMER JJ, 1996, Patent No. 15151; RANDHAWA ZI, 1994, BIOCHEMISTRY-US, V33, P4352, DOI 10.1021/bi00180a032; SEMMES OJ, 1985, PEPTIDES, V6, P491, DOI 10.1016/0196-9781(85)90115-9; SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207; Strydom D. J., 1993, TECHNIQUES PROTEIN C, VIV, P299; TERASAWA M, 1991, APPL MICROBIOL BIOT, V35, P348, DOI 10.1007/BF00172724; TSAI LB, 1988, BIOCHEM BIOPH RES CO, V156, P733, DOI 10.1016/S0006-291X(88)80904-5; VIOLAND BN, 1989, TECHNIQUES PROTEIN C, P315; WALLACE CJA, 1986, PROTEIN ENG, V1, P23, DOI 10.1093/protein/1.1.23	32	67	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28980	28988		10.1074/jbc.272.46.28980	http://dx.doi.org/10.1074/jbc.272.46.28980			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360970	hybrid			2022-12-27	WOS:A1997YF68400029
J	Bour, S; Geleziunas, R; Wainberg, MA				Bour, S; Geleziunas, R; Wainberg, MA			Inhibition of CD4 translation mediated by human immunodeficiency virus type 1 envelope protein in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYADENYLATED RNA SEQUENCES; INDEPENDENT DOWN-REGULATION; CYTOPLASMIC DOMAIN; MESSENGER-RNA; VPU PROTEIN; SURFACE CD4; ENDOPLASMIC-RETICULUM; DEPENDENT KINASE; HIV-1 INFECTION; BINDING-SITE	The human immunodeficiency virus type 1 (HIV-1) employs a number of complex strategies to interfere with the synthesis, stability, and subcellular localization of its specific cellular receptor CD4, To define better the mechanisms of inhibition of CD4 expression, we used a rabbit reticulocyte lysate in vitro system, in which cDNAs derived from HIV-1-infected cells were used to generate mRNA for the Tat, Vpu, and gp160 envelope proteins that were translated together with CD4-encoding mRNA, In the presence of microsomal membranes, we observed that cotranslation of Env mRNA resulted in a dose-dependent inhibition of CD4 translation, This effect was enhanced further when an mRNA-encoding Vpu in addition to Env mRNA was utilized, However, the activity of Vpu was mostly posttranslational, since translation of Vpu alone, but not Env, was able to destabilize CD4 molecules presynthesized into microsomes, The Env-mediated inhibitory effect was specifically targeted at CD4 and did not affect the synthesis or stability of the CD8 molecule, Interestingly, mutated CD4 species, with a 26-fold lower affinity for HIV-1 Env than wild-type, were less sensitive to cotranslational inhibition, Our report identifies the envelope as the HIV-1 protein responsible for down-regulation of CD4 translation, We further propose a mechanism whereby direct interactions between gp160 and nascent CD4 molecules can cause interference with and premature termination of CD4 protein elongation.	MCGILL UNIV,JEWISH GEN HOSP,LADY DAVIS INST,AIDS CTR,MONTREAL,PQ H3T 1E2,CANADA	Lady Davis Institute; McGill University				Bour, Stephan/0000-0002-0211-0110				AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ANDERSON SJ, 1994, J VIROL, V68, P3092, DOI 10.1128/JVI.68.5.3092-3101.1994; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; BOUR S, 1995, J VIROL, V69, P1510, DOI 10.1128/JVI.69.3.1510-1520.1995; BOUR S, 1991, J VIROL, V65, P6387, DOI 10.1128/JVI.65.12.6387-6396.1991; BOUR S, 1995, MICROBIOL REV, V59, P65; BRADFORD AJ, 1988, SCIENCE, V240, P1335; BUTERA ST, 1991, J VIROL, V65, P4645, DOI 10.1128/JVI.65.9.4645-4653.1991; CACOULLOS N, 1991, VIROLOGY, V184, P747, DOI 10.1016/0042-6822(91)90445-H; CHEN MY, 1993, J VIROL, V67, P3877, DOI 10.1128/JVI.67.7.3877-3884.1993; CLARKE PA, 1990, EUR J BIOCHEM, V193, P635, DOI 10.1111/j.1432-1033.1990.tb19381.x; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; DAVIES MV, 1991, J BIOL CHEM, V266, P14714; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; ELLERBROK H, 1992, J VIROL, V66, P5114, DOI 10.1128/JVI.66.8.5114-5118.1992; FENNIE C, 1989, J VIROL, V63, P639, DOI 10.1128/JVI.63.2.639-646.1989; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GARCIA JV, 1992, J CELL BIOCH E S, V16, P21; GELEZIUNAS R, 1991, AIDS, V5, P29, DOI 10.1097/00002030-199101000-00004; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAFFAR OK, 1988, J CELL BIOL, V107, P1677, DOI 10.1083/jcb.107.5.1677; HOXIE JA, 1986, SCIENCE, V234, P1123, DOI 10.1126/science.3095925; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; KATZE MG, 1990, ENZYME, V44, P332, DOI 10.1159/000468769; KAWAMURA I, 1989, J VIROL, V63, P3748, DOI 10.1128/JVI.63.9.3748-3754.1989; KOGA Y, 1990, J IMMUNOL, V144, P94; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MAITRA RK, 1994, VIROLOGY, V204, P823, DOI 10.1006/viro.1994.1601; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; PETIT AJC, 1987, J CLIN INVEST, V79, P1883, DOI 10.1172/JCI113032; RICHARDSON NE, 1988, P NATL ACAD SCI USA, V85, P6102, DOI 10.1073/pnas.85.16.6102; SALMON P, 1988, J EXP MED, V168, P1953, DOI 10.1084/jem.168.6.1953; Sambrook J., 2002, MOL CLONING LAB MANU; SANFRIDSON A, 1994, J BIOL CHEM, V269, P3917; SCHEPPLER JA, 1989, J IMMUNOL, V143, P2858; SCHWARTZ S, 1990, J VIROL, V64, P5448, DOI 10.1128/JVI.64.11.5448-5456.1990; SCHWARTZ S, 1992, MOL CELL BIOL, V12, P207, DOI 10.1128/MCB.12.1.207; SERPENTE N, 1993, INT IMMUNOL, V5, P939, DOI 10.1093/intimm/5.8.939; SOSA MAG, 1991, AIDS RES HUM RETROV, V7, P859, DOI 10.1089/aid.1991.7.859; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; STEVENSON M, 1987, J VIROL, V61, P3741, DOI 10.1128/JVI.61.12.3741-3748.1987; SU MJ, 1990, VIROLOGY, V179, P679, DOI 10.1016/0042-6822(90)90135-E; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; VINCENT MJ, 1993, J VIROL, V67, P5538, DOI 10.1128/JVI.67.9.5538-5549.1993; WILLEY RL, 1992, J VIROL, V66, P226, DOI 10.1128/JVI.66.1.226-234.1992; WILLEY RL, 1994, J VIROL, V68, P1207, DOI 10.1128/JVI.68.2.1207-1212.1994; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; YUILLE MAR, 1988, J ACQ IMMUN DEF SYND, V1, P131	56	2	2	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29005	29014		10.1074/jbc.272.46.29005	http://dx.doi.org/10.1074/jbc.272.46.29005			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360974	hybrid			2022-12-27	WOS:A1997YF68400033
J	Chen, JG; Sachpatzidis, A; Rudnick, G				Chen, JG; Sachpatzidis, A; Rudnick, G			The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER TRANSPORTERS; CYSTEINE-SUBSTITUTION; AMINO-ACID; CHANNEL; RECEPTOR; MUTANTS; EXPRESSION; REUPTAKE; SEGMENT	Twenty residues in the third transmembrane domain of the serotonin transporter (SERT) were mutated, one at a time, to cysteine, Almost all of these mutants were fully active for serotonin (5-HT) transport and insensitive to inactivation by the positively charged cysteine reagent [2-(trimethylammonium)ethyl]methanethiosulfonate (MTSET), Two active mutants, I172C and I179C, were sensitive to rapid inactivation by MTSET but were relatively insensitive to the negatively charged reagent (2-sulfonatoethyl)methanethiosulfonate (MTSES). Inactivation of I172C was blocked by 5-HT and cocaine, but I179C was not similarly protected, Replacement of Tyr-175 with cysteine resulted in a mutant with low transport activity, and, at the neighboring Tyr-176, cysteine replacement completely blocked transport, The Y175C and Y176C mutants were expressed on the cell surface at levels 84% and 69%, respectively, that of wild type (C109A) SERT, Mutants Y175C and Y176C had lower cocaine affinity than C109A, as measured by displacement of the high affinity cocaine analog 2 beta-carbomethoxy-3 beta-(4-[I-125]iodophenyl)tropane (beta-CIT). For Y176C, 5-HT affinity also was decreased, MTSET inactivated beta-CIT binding to I172C and Y176C, but only slightly inhibited binding to I179C and C109A, The MTSET sensitivity of cysteine replacements at positions 172, 176, and 179 was not observed when these positions were replaced with alanine, serine, or methionine, The results suggest that Ile-172, Tyr-176 and Ile-l79 are on one face of an alpha-helical transmembrane element, and that Ile-172 and Tyr-176 are in proximity to the binding site for 5-HT and cocaine.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University				Sachpatzidis, Aristidis/0000-0002-5237-0842				AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Barker EL, 1996, MOL PHARMACOL, V50, P957; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; BLAKELY RD, 1993, SOC GEN PHY, V48, P283; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; Borowsky B, 1995, INT REV NEUROBIOL, V38, P139, DOI 10.1016/S0074-7742(08)60526-7; BOYER WF, 1992, INT CLIN PSYCHOPHARM, V6, P5, DOI 10.1097/00004850-199206005-00001; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; GOTTARDI C, 1995, AM J PHYSIOL, V37, pE285; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; HUMPHREYS CJ, 1994, BIOCHEMISTRY-US, V33, P9118, DOI 10.1021/bi00197a014; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; KITAYAMA S, 1993, SYNAPSE, V15, P58, DOI 10.1002/syn.890150107; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; Lester HA, 1996, NEURON, V17, P807, DOI 10.1016/S0896-6273(00)80213-5; Lin F, 1996, BIOPHYS J, V71, P3126, DOI 10.1016/S0006-3495(96)79506-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NELSON N, 1994, J EXP BIOL, V196, P213; NELSON PJ, 1979, J BIOL CHEM, V254, P84; RUDNICK G, 1991, MOL PHARMACOL, V40, P421; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; TATE CG, 1994, J BIOL CHEM, V269, P26303; UHL GR, 1994, J EXP BIOL, V196, P229; WALL SC, 1995, MOL PHARMACOL, V47, P544; WANG JB, 1995, J NEUROCHEM, V64, P1416; XU M, 1993, J BIOL CHEM, V268, P21505	31	156	159	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28321	28327		10.1074/jbc.272.45.28321	http://dx.doi.org/10.1074/jbc.272.45.28321			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353288	hybrid			2022-12-27	WOS:A1997YF21900028
J	Qin, WS; Pappan, K; Wang, XM				Qin, WS; Pappan, K; Wang, XM			Molecular heterogeneity of phospholipase D (PLD) - Cloning of PLD gamma and regulation of plant PLD gamma, -beta, and -alpha by polyphosphoinositides and calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDIC-ACID; C2 DOMAIN; FAMILY; PURIFICATION; IDENTIFICATION; PROTEINS; BINDING; EXPRESSION; ACYLATION; GELSOLIN	Phospholipase D (PLD) has emerged as an important enzyme involved in signal transduction, Vesicle trafficking, and membrane metabolism. This report describes the cloning and expression of a new Arabidopsis PLD cDNA, designated PLD gamma, and the regulation of PLD gamma, -beta, and -alpha by phosphatidylinositol 4,5-bisphosphate (PIP2) and Ca2+, The PLD gamma cDNA is 3.3 kilobases in length and codes for an 855-amino acid protein of 95,462 Da with a pi of 6.9. PLD gamma shares a 66% amino acid sequence identity with PLD beta, but only a 41% identity with PLD alpha. A potential N-terminal myristoylation site is found in PLD gamma, but not in PLD alpha and -beta. Catalytically active PLD gamma was expressed in Escherichia coli, and its activity requires polyphosphoinositides. Both PLD gamma and -beta are most active at mu M Ca2+ concentrations, whereas the optimal PLD alpha activity requires mM Ca2+ concentrations. Binding studies showed that the PLDs bound PIP2 in the order of PLD beta > PLD gamma > PLD alpha. This binding ability correlates with the degree of conservation of a basic PIP2-binding motif located near the putative catalytic site. The binding of [H-3]PIP, was saturable and could be competitively decreased by addition of unlabeled PIP2. Neomycin inhibited the activities of PLD gamma and -beta, but not PLD alpha. These results demonstrate that PLD is ancoded by a heterogeneous gene family and that direct polyphosphoinositide binding is required for the activities of PLD gamma and -beta, but not PLD alpha. The different structural and biochemical properties suggest that PLD alpha, -beta, and -gamma are regulated differently and may mediate unique cellular functions.	KANSAS STATE UNIV,DEPT BIOCHEM,MANHATTAN,KS 66506	Kansas State University			Wang, Xuemin/M-2853-2013; Pappan, Kirk/AAV-5946-2021	Pappan, Kirk/0000-0002-2341-8798; wang, xuemin/0000-0002-6251-6745				BRIEVIARIO D, 1995, PLANT MOL BIOL, V27, P953; CAMILLI PD, 1996, SCIENCE, V271, P1533; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Dyer JH, 1995, PLANT PHYSIOL, V109, P1497; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; MARCU MG, 1994, MOL CELL BIOCHEM, V141, P153, DOI 10.1007/BF00926179; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MICHAYLOVA V, 1971, ANAL CHIM ACTA, V53, P194, DOI 10.1016/S0003-2670(01)80088-X; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Pappan K, 1997, J BIOL CHEM, V272, P7055, DOI 10.1074/jbc.272.11.7055; Pappan K, 1997, J BIOL CHEM, V272, P7048, DOI 10.1074/jbc.272.11.7048; Ponting CP, 1996, PROTEIN SCI, V5, P914; Ponting CP, 1996, PROTEIN SCI, V5, P162; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; UEKI J, 1995, PLANT CELL PHYSIOL, V36, P903, DOI 10.1093/oxfordjournals.pcp.a078837; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; WANG XM, 1994, J BIOL CHEM, V269, P20312; WANG XM, 1993, ARCH BIOCHEM BIOPHYS, V306, P486, DOI 10.1006/abbi.1993.1541; YU FX, 1992, J BIOL CHEM, V267, P14616; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	33	146	163	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28267	28273		10.1074/jbc.272.45.28267	http://dx.doi.org/10.1074/jbc.272.45.28267			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353280	hybrid			2022-12-27	WOS:A1997YF21900020
J	Zhao, SM; Lee, EYC				Zhao, SM; Lee, EYC			A protein phosphatase-1-binding motif identified by the panning of a random peptide display library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 CATALYTIC SUBUNIT; PHOSPHORYLASE-PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; REGULATORY SUBUNIT; MOLECULAR-CLONING; ESCHERICHIA-COLI; SEQUENCE; ENCODES; MUSCLE; PURIFICATION	An unusually large number of regulatory or targeting proteins that bind to the catalytic subunit of protein phosphatase-1 have been recently reported. This can be explained by their possession of a common protein motif that interacts with a binding site on protein phosphatase-1. The existence of such a motif was established by the panning of a random peptide library in which peptide sequences are displayed on the Escherichia coli bacterial flagellin protein for bacteria that bound to protein phosphatase-1. There were 79 isolates containing 46 unique sequences with the conserved motif VXF or VXW, where X was most frequently His or Arg. In addition, this sequence was commonly preceded by 2-5 basic residues and followed by 1 acidic residue. This study demonstrates that binding to protein phosphatase-1 can be conferred to a protein by the presentation of a peptide motif on a surface loop. This binding motif is found in a number of protein phosphatase-1-binding proteins.	UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOL BIOL, MIAMI, FL 33101 USA	University of Miami					NIDDK NIH HHS [DK18512] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018512] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BRANDT H, 1975, J BIOL CHEM, V250, P8038; BRAUTIGAN DL, 1994, RECENT PROG HORM RES, V49, P197; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CHUN YS, 1994, P NATL ACAD SCI USA, V91, P3319, DOI 10.1073/pnas.91.8.3319; Cori GT, 1943, J BIOL CHEM, V151, P31; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; FENG ZH, 1991, J BIOL CHEM, V266, P23796; GRATECOS D, 1977, BIOCHEMISTRY-US, V16, P4812, DOI 10.1021/bi00641a009; Hausken ZE, 1996, BIOCHEM SOC T, V24, P986, DOI 10.1042/bst0240986; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; HIRANO K, 1995, J BIOL CHEM, V270, P19786, DOI 10.1074/jbc.270.34.19786; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KHANDELWAL RL, 1976, J BIOL CHEM, V251, P4820; KILLILEA SD, 1978, BIOCHEM BIOPH RES CO, V81, P1040, DOI 10.1016/0006-291X(78)91455-9; KONDOH H, 1974, BIOCHIM BIOPHYS ACTA, V336, P117, DOI 10.1016/0005-2795(74)90390-0; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LEE EYC, 1995, ZOOL STUD, V34, P149; LU Z, 1995, BIOTECHNOLOGY, V13, P266; MACKINTOSH RW, 1990, FEBS LETT, V276, P156, DOI 10.1016/0014-5793(90)80531-M; MERLEVEDE W, 1984, CURR TOP CELL REGUL, V23, P177; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; STUART JS, 1994, MOL CELL BIOL, V14, P896, DOI 10.1128/MCB.14.2.896; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; Tu JL, 1996, MOL CELL BIOL, V16, P4199; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; Wu J, 1996, BIOCHEMISTRY-US, V35, P13858, DOI 10.1021/bi961669e; ZHANG AJ, 1992, J BIOL CHEM, V267, P1784; ZHANG SR, 1995, MOL CELL BIOL, V15, P2037; ZHANG ZJ, 1993, ARCH BIOCHEM BIOPHYS, V303, P402, DOI 10.1006/abbi.1993.1301	43	121	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28368	28372		10.1074/jbc.272.45.28368	http://dx.doi.org/10.1074/jbc.272.45.28368			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353294	hybrid			2022-12-27	WOS:A1997YF21900034
J	Butler, AA; Blakesley, VA; Koval, A; DeJong, R; Groffen, J; LeRoith, D				Butler, AA; Blakesley, VA; Koval, A; DeJong, R; Groffen, J; LeRoith, D			In vivo regulation of CrkII and CrkL proto-oncogenes in the uterus by insulin-like growth factor-I - Differential effects on tyrosine phosphorylation and association with paxillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-CRK; V-CRK; RECEPTOR SUBSTRATE-1; SIGNALING PATHWAYS; DEPENDENT MANNER; ADAPTER PROTEINS; ENDOGENOUS CRK; BINDING; PRODUCT; CELLS	Changes in CrkII and CrkL phosphorylation are associated with insulin-like growth factor receptor activation in cultured cells. We examined whether similar changes also occur following administration of recombinant human insulin-like growth factor-I to the intact animal. In female rats starved overnight, CrkL phosphorylation was significantly increased 12 min after insulin-like growth factor-I administration. Tyrosine phosphorylation of CrkII was not detectable in either control or treated animals. Paxillin, a 65-70-kDa phosphoprotein containing high affinity binding sites common for the Src homology 2 (SH2) domains of CrkII and CrkL, was observed in both CrkII and CrkL immunoprecipitates. Insulin-like growth factor-I treatment stimulated the association of CrkII with paxillin. In contrast, the same treatment resulted in the dissociation of the CrkL-paxillin complex. Similar effects of insulin-like growth factor-I treatment on the association of CrkL with tyrosine phosphorylated paxillin were observed in fibroblasts overexpressing CrkL. This study demonstrates that the activation of the insulin-like growth factor-I receptor induces changes in the tyrosine phosphorylation and protein-protein interactions of the Crk proteins in vivo. The different responses of CrkL and CrkII to insulin-like growth factor-I receptor activation suggest distinct roles for these two adapter proteins in signal transduction.	NIDDK, DIABET BRANCH, NIH, BETHESDA, MD 20892 USA; CHILDRENS HOSP, DEPT PATHOL, SECT MOL CARCINOGENESIS, LOS ANGELES, CA 90027 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Butler, Andrew/0000-0001-7196-0170				Baker J, 1996, MOL ENDOCRINOL, V10, P903, DOI 10.1210/me.10.7.903; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ribon V, 1996, MOL CELL BIOL, V16, P45; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Richards RG, 1996, P NATL ACAD SCI USA, V93, P12002, DOI 10.1073/pnas.93.21.12002; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469	32	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27660	27664		10.1074/jbc.272.44.27660	http://dx.doi.org/10.1074/jbc.272.44.27660			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346905	hybrid			2022-12-27	WOS:A1997YD47300031
J	Grondin, B; Cote, F; Bazinet, M; Vincent, M; Aubry, M				Grondin, B; Cote, F; Bazinet, M; Vincent, M; Aubry, M			Direct interaction of the KRAB/Cys(2)-His(2) zinc finger protein ZNF74 with a hyperphosphorylated form of the RNA polymerase II largest subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; PRE-MESSENGER-RNA; DISCRETE NUCLEAR DOMAINS; SPLICING FACTORS; TRANSCRIPTIONAL REPRESSION; DNA RECOGNITION; IN-VIVO; MATRIX; PHOSPHORYLATION; BINDING	We previously identified ZNF74 as a developmentally expressed gene commonly deleted in DiGeorge syndrome. ZNF74 encodes an RNA-binding protein tightly associated with the nuclear matrix and belongs to a large subfamily of Cys(2)-His(2) zinc finger proteins containing a KRAB (Kruppel-associated box) repressor motif, We now report on the multifunctionality of the zinc finger domain of ZNF74, This nucleic acid binding domain is shown here to function as a nuclear matrix targeting sequence and to be involved in protein-protein interaction, Ey far-Western analysis and coimmunoprecipitation studies, we demonstrate that ZNF74 interacts, via its zinc finger domain, with the hyperphosphorylated largest subunit of RNA polymerase II (pol IIo) but not with the hypophosphorylated form. The importance of the phosphorylation in this interaction is supported by the observation that phosphatase treatment inhibits ZNF74 binding. Double immunofluorescence experiments indicate that ZNF74 colocalizes with the pol IIo and the SC35 splicing factor in irregularly shaped subnuclear domains, Thus, ZNF74 sublocalization in nuclear domains enriched in pre-mRNA maturating factors, its RNA binding activity, and its direct phosphodependent interaction with the pol IIo, a form of the RNA polymerase functionally associated with pre-mRNA processing, suggest a role for this member of the KRAB multifinger protein family in RNA processing.	INST RECH CLIN MONTREAL, MONTREAL, PQ H2W 1R7, CANADA; UNIV MONTREAL, DEPT MED, MONTREAL, PQ H2W 1R7, CANADA; UNIV LAVAL, Ste Foy, PQ G1K 7P4, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Laval University								AUBRY M, 1993, HUM MOL GENET, V2, P1583, DOI 10.1093/hmg/2.10.1583; AUBRY M, 1992, GENOMICS, V13, P641, DOI 10.1016/0888-7543(92)90135-F; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BISOTTO S, 1995, J CELL SCI, V108, P1873; Bourquin JP, 1997, NUCLEIC ACIDS RES, V25, P2055, DOI 10.1093/nar/25.11.2055; BRANCOLINI C, 1991, P NATL ACAD SCI USA, V88, P6936, DOI 10.1073/pnas.88.16.6936; BREGMAN DB, 1994, J CELL SCI, V107, P387; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; CHABOT B, 1995, NUCLEIC ACIDS RES, V23, P3206, DOI 10.1093/nar/23.16.3206; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CICCHETTI P, 1995, METHOD ENZYMOL, V256, P140; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLBEREGARAPIN F, 1983, DEV BIOLOGICALS, V55, P267; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GLOVER TW, 1995, NAT GENET, V10, P257, DOI 10.1038/ng0795-257; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; Huang S, 1996, J CELL BIOL, V133, P719, DOI 10.1083/jcb.133.4.719; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; KARAYIORGOU P, 1995, P NATL ACAD SCI USA, V92, P7612, DOI 10.1073/pnas.92.17.7612; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KIM WY, 1986, J BIOL CHEM, V261, P14219; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KRAMER A, 1980, MOL GEN GENET, V180, P193, DOI 10.1007/BF00267369; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MARINEAU C, 1992, NUCLEIC ACIDS RES, V20, P1430, DOI 10.1093/nar/20.6.1430; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; PIELER T, 1994, MOL BIOL REP, V20, P1, DOI 10.1007/BF00999848; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; SUZUKI M, 1994, NUCLEIC ACIDS RES, V22, P3397, DOI 10.1093/nar/22.16.3397; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; THIBODEAU A, 1991, EXP CELL RES, V195, P145, DOI 10.1016/0014-4827(91)90510-2; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; Vincent M, 1996, NUCLEIC ACIDS RES, V24, P4649, DOI 10.1093/nar/24.23.4649; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401; ZHANG GH, 1994, NATURE, V372, P809	65	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27877	27885		10.1074/jbc.272.44.27877	http://dx.doi.org/10.1074/jbc.272.44.27877			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346935	hybrid			2022-12-27	WOS:A1997YD47300061
J	JosephLiauzun, E; Farges, R; Delmas, P; Ferrara, P; Loison, G				JosephLiauzun, E; Farges, R; Delmas, P; Ferrara, P; Loison, G			The M-r 18,000 subunit of the peripheral-type benzodiazepine receptor exhibits both benzodiazepine and isoquinoline carboxamide binding sites in the absence of the voltage-dependent anion channel or of the adenine nucleotide carrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP TRANSLOCATOR; LEYDIG TUMOR-CELLS; SACCHAROMYCES-CEREVISIAE; DIRECTED MUTAGENESIS; MOLECULAR-CLONING; HIGH-LEVEL; YEAST; EXPRESSION; DIETHYLPYROCARBONATE; LOCALIZATION	The peripheral type benzodiazepine receptor (PBR) binds benzodiazepines such as R05-4864 and isoquinoline carboxamide derivatives such as PK11195. This receptor includes an M-r 18,000 isoquinoline-binding subunit predominantly located in mitochondrial membranes. This protein has been found to copurify with two other mitochondrial proteins, namely the outer membrane voltage-dependent anion channel (VDAC), also known as mitochondrial porin, and the inner membrane adenine nucleotide carrier. In vitro reconstitution experiments suggested that the PBR was a multimeric complex in which the isoquinoline binding site was on the M-r 18,000 subunit, denoted pk18, whereas the benzodiazepine binding site required the association of this subunit with VDAC to be expressed. Untransformed cells of the yeast Saccharomyces cerevisiae are devoid of specific binding sites for isoquinolines and benzodiazepines, whereas yeast cells transformed with a pk18-expressing vector exhibit R05-4864 and PK11195 binding sites that are pharmacologically identical to those of the PBR. To clarify the role of VDAC and of the adenine nucleotide carrier, if any, in the constitution of the benzodiazepine binding site, yeast host strains were constructed in which the corresponding genes had been knocked out, Mitochondria prepared from pk18-producing cells devoid of either VDAC or adenine nucleotide carrier exhibit both benzodiazepine and isoquinoline carboxamide binding sites with little or no change in the K-d values as compared with the wild-type background. These results rule out the contention that VDAC is indispensable for establishing the benzodiazepine binding site and are in agreement with the hypothesis that the M-r 18,000 subunit carries both the isoquinoline carboxamide and benzodiazepine binding domains.	SANOFI RECH, DEPT PROT BIOCHEM, F-31676 LABEGE, FRANCE	Sanofi-Aventis; Sanofi France	JosephLiauzun, E (corresponding author), SANOFI RECH, DEPT MICROBIOL, BP 137, F-31676 LABEGE, FRANCE.							Amri H, 1996, ENDOCRINOLOGY, V137, P5707, DOI 10.1210/en.137.12.5707; AWAD M, 1989, BIOCHEM PHARMACOL, V38, P3843, DOI 10.1016/0006-2952(89)90594-7; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BENAVIDES J, 1984, LIFE SCI, V35, P1249, DOI 10.1016/0024-3205(84)90095-X; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Boujrad N, 1996, ENDOCRINOLOGY, V137, P5727, DOI 10.1210/en.137.12.5727; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; COSTA E, 1979, ANNU REV PHARMACOL, V19, P531, DOI 10.1146/annurev.pa.19.040179.002531; DOBLE A, 1987, MOL PHARMACOL, V31, P42; DRGON T, 1992, FEBS LETT, V304, P277, DOI 10.1016/0014-5793(92)80637-V; Dussossoy D, 1996, CYTOMETRY, V24, P39; FARGES R, 1993, FEBS LETT, V335, P305, DOI 10.1016/0014-5793(93)80407-L; FARGES R, 1994, MOL PHARMACOL, V46, P1160; GARNIER M, 1994, MOL PHARMACOL, V45, P201; HEINEMANN JA, 1989, NATURE, V340, P205, DOI 10.1038/340205a0; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; JOSEPHLIAUZUN E, 1994, GENE, V155, P195; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; LEPLATOIS P, 1992, GENE, V122, P139, DOI 10.1016/0378-1119(92)90041-M; LOISON G, 1989, YEAST, V5, P497, DOI 10.1002/yea.320050609; LUEDDENS HWM, 1986, MOL PHARMACOL, V29, P540; MCENERY MW, 1992, J BIOENERG BIOMEMBR, V24, P63, DOI 10.1007/BF00769532; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; NELSON DR, 1993, J MOL BIOL, V230, P1159, DOI 10.1006/jmbi.1993.1233; PAROLA AL, 1991, J BIOL CHEM, V266, P14082; RIOND J, 1991, EUR J PHARM-MOLEC PH, V208, P307, DOI 10.1016/0922-4106(91)90076-T; RIOND J, 1991, EUR J BIOCHEM, V195, P305, DOI 10.1111/j.1432-1033.1991.tb15707.x; RIOND J, 1989, FEBS LETT, V245, P238, DOI 10.1016/0014-5793(89)80229-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SKOWRONSKI R, 1987, EUR J PHARMACOL, V143, P305, DOI 10.1016/0014-2999(87)90454-7; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; Woods MJ, 1996, BIOCHEM PHARMACOL, V52, P1805, DOI 10.1016/S0006-2952(96)00558-8	34	57	57	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28102	28106		10.1074/jbc.272.44.28102	http://dx.doi.org/10.1074/jbc.272.44.28102			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346965	hybrid			2022-12-27	WOS:A1997YD47300091
J	Koch, RO; Wanner, SG; Koschak, A; Hanner, M; Schwarzer, C; Kaczorowski, GJ; Slaughter, RS; Garcia, ML; Knaus, HG				Koch, RO; Wanner, SG; Koschak, A; Hanner, M; Schwarzer, C; Kaczorowski, GJ; Slaughter, RS; Garcia, ML; Knaus, HG			Complex subunit assembly of neuronal voltage-gated K+ channels - Basis for high-affinity toxin interactions and pharmacology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; RAT-BRAIN; XENOPUS-OOCYTES; MAMMALIAN BRAIN; NERVE-TERMINALS; BOVINE BRAIN; LOCALIZATION; PROTEINS; KV1.2; CHARYBDOTOXIN	Neurons require specific patterns of K+ channel subunit expression as well as the precise coassembly of channel subunits into heterotetrameric structures for proper integration and transmission of electrical signals, In vivo subunit coassembly was investigated by studying the pharmacological profile, distribution, and subunit composition of voltage-gated Shaker family K+ (K(v)1) channels in rat cerebellum that are labeled by I-125-margatoxin (I-125-MgTX; K-d, 0.08 pm), High-resolution receptor autoradiography showed spatial receptor expression mainly in basket cell terminals (52% of all cerebellar sites) and the molecular layer (39% of sites), Sequence directed antibodies indicated overlapping expression of K(v)1.1 and K(v)1.2 in basket cell terminals, whereas the molecular layer expressed K(v)1.1, K(v)1.2, K(v)1.3, and K(v)1.6 proteins, Immunoprecipitation experiments revealed that all I-125-MgTX receptors contain at least one K(v)1.2 subunit and that 83% of these receptors are heterotetramers of K(v)1.1 and K(v)1.2 subunits, Moreover, 33% of these K(v)1.1/K(v)1.2-containing receptors possess either an additional K(v)1.3 or K(v)1.6 subunit, Only a minority of the I-125-MgTX receptors (<20%) seem to be homotetrameric K(v)1.2 channels, Heterologous coexpression of K(v)1.1 and K(v)1.2 subunits in COS-1 cells leads to the formation of a complex that combines the pharmacological profile of both parent subunits, reconstituting the native MgTX receptor phenotype, Subunit assembly provides the structural basis for toxin binding pharmacology and can lead to the association of as many as three distinct channel subunits to form functional K+ channels in vivo.	UNIV INNSBRUCK, INST BIOCHEM PHARMACOL, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST PHARMACOL, A-6020 INNSBRUCK, AUSTRIA; MERCK RES LABS, DEPT MEMBRANE BIOCHEM & BIOPHYS, RAHWAY, NJ 07065 USA	University of Innsbruck; University of Innsbruck; Merck & Company				Schwarzer, Christoph/0000-0002-6373-3717				CALVO MG, 1993, J BIOL CHEM, V268, P18866; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; Hanner M, 1997, P NATL ACAD SCI USA, V94, P2853, DOI 10.1073/pnas.94.7.2853; HARVEY AL, 1995, TOXICON, V33, P425, DOI 10.1016/0041-0101(94)00181-7; Helms LMH, 1997, BIOCHEMISTRY-US, V36, P3737, DOI 10.1021/bi962351p; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KNAUS HG, 1995, BIOCHEMISTRY-US, V34, P13627, DOI 10.1021/bi00041a043; Knaus HG, 1996, J NEUROSCI, V16, P955; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; MCNAMARA NMC, 1993, NEUROSCIENCE, V57, P1039, DOI 10.1016/0306-4522(93)90047-J; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; SHENG M, 1994, J NEUROSCI, V14, P2408; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; VAZQUEZ J, 1990, J BIOL CHEM, V265, P15564; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WANG H, 1994, J NEUROSCI, V14, P4588; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8	30	110	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27577	27581		10.1074/jbc.272.44.27577	http://dx.doi.org/10.1074/jbc.272.44.27577			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346893	hybrid			2022-12-27	WOS:A1997YD47300019
J	Tarcsa, E; Marekov, LN; Andreoli, J; Idler, WW; Candi, E; Chung, SI; Steinert, PM				Tarcsa, E; Marekov, LN; Andreoli, J; Idler, WW; Candi, E; Chung, SI; Steinert, PM			The fate of trichohyalin - Sequential, post-translational modifications by peptidyl-arginine deiminase and transglutaminases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ENVELOPE PRECURSOR; HAIR FOLLICLE; SUBSTRATE-SPECIFICITY; HUMAN EPIDERMIS; HUMAN LORICRIN; CROSS-LINKING; GUINEA-PIG; PROTEIN; EXPRESSION; CITRULLINE	Trichohyalin (THH) is a major structural protein of the inner root sheath cells and medulla layer of the hair follicle and, to a lesser extent, of other specialized epithelia, THH is a high molecular weight insoluble alpha-helix-rich protein that forms rigid structures as a result of postsynthetic modifications by two Ca2+-dependent enzymes, transglutaminases (TGases) (protein cross-linking) and peptidyl-arginine deiminase (conversion of arginines to citrullines with loss of organized structure), The modified THH is thought to serve as a keratin intermediate filament matrix protein and/or as a constituent of the cell envelope, In this paper, we have explored in vitro the order of processing of THH to fulfill these functions, using an expressed truncated, more soluble form THH-8, THH-8 is a complete substrate for three known TGases expressed in epithelia, but the kinetic efficiency with TGase 3 is by far the greatest. Following maximal conversion of its arginines to citrullines, THH-8 is cross-linked even more efficiently by TGase 3, using most glutamines partially and all lysines, In addition, we show that insoluble aggregates of THH-8 or native pig tongue THH can be solubilized following peptidyl-arginine deiminase modification. Together, these data suggest an in vivo model in which THH located in insoluble cytoplasmic droplets is first modified by peptidyl-arginine deiminase which denatures it and makes it more soluble. This renders it available for efficient cross-linking by TGase 3 to form highly crosslinked rigid structures in the cells, This temporal order of reaction is supported by the observation that THH is expressed in hair follicle cells before the TGase 3 enzyme.	NIAMS, SKIN BIOL LAB, NIH, BETHESDA, MD 20892 USA; KOREA GREEN CROSS CORP, KYUNGGI GI DO 449900, SOUTH KOREA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Green Cross Corporation								AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; BIRBECK MSC, 1957, J BIOPHYS BIOCHEM CY, V3, P223, DOI 10.1083/jcb.3.2.223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; CHUNG SI, 1972, P NATL ACAD SCI USA, V69, P303, DOI 10.1073/pnas.69.2.303; DEVIRAGH PA, 1994, J INVEST DERMATOL, V103, P815, DOI 10.1111/1523-1747.ep12413482; FIETZ MJ, 1993, J CELL BIOL, V121, P855, DOI 10.1083/jcb.121.4.855; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; Fraser R.D.B., 1972, KERATINS THEIR COMPO; HAMILTON EH, 1991, J INVEST DERMATOL, V96, P666, DOI 10.1111/1523-1747.ep12470590; HAMILTON EH, 1992, J INVEST DERMATOL, V98, P881, DOI 10.1111/1523-1747.ep12459412; HARDING HWJ, 1972, BIOCHEMISTRY-US, V11, P2858, DOI 10.1021/bi00765a019; HARDING HWJ, 1976, BIOCHIM BIOPHYS ACTA, V427, P315, DOI 10.1016/0005-2795(76)90307-X; HARDING HWJ, 1971, BIOCHEMISTRY-US, V10, P624, DOI 10.1021/bi00780a013; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HOHL D, 1991, J BIOL CHEM, V266, P6626; Kartasova T, 1996, J INVEST DERMATOL, V106, P294, DOI 10.1111/1523-1747.ep12340741; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KIM SY, 1994, J BIOL CHEM, V269, P27979; KUBILUS J, 1980, BIOCHIM BIOPHYS ACTA, V615, P246, DOI 10.1016/0005-2744(80)90027-3; LEE SC, 1993, J BIOL CHEM, V268, P12164; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MANABE M, 1994, DIFFERENTIATION, V58, P65, DOI 10.1046/j.1432-0436.1994.5810065.x; OGUIN WM, 1992, J INVEST DERMATOL, V98, P24, DOI 10.1111/1523-1747.ep12494172; OGUIN WM, 1991, ANN NY ACAD SCI, V642, P51; OKEEFE EJ, 1993, J INVEST DERMATOL, V101, pS65, DOI 10.1111/1523-1747.ep12362866; PARENTEAU NL, 1986, DIFFERENTIATION, V33, P130, DOI 10.1111/j.1432-0436.1986.tb00418.x; PETERSON LL, 1984, MOL CELL BIOCHEM, V58, P99, DOI 10.1007/BF00240609; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; ROGERS GE, 1977, BIOCHIM BIOPHYS ACTA, V495, P159, DOI 10.1016/0005-2795(77)90250-1; ROGERS GE, 1963, J HISTOCHEM CYTOCHEM, V11, P700, DOI 10.1177/11.6.700; ROGERS GE, 1983, NORMAL ABNORMAL EPID, P171; ROGERS GE, 1977, ADV EXPT MED BIOL A, V86, P282; ROTHNAGEL JA, 1986, J CELL BIOL, V102, P1419, DOI 10.1083/jcb.102.4.1419; SENSHU T, 1995, J INVEST DERMATOL, V105, P163, DOI 10.1111/1523-1747.ep12317070; SIMON M, 1988, J BIOL CHEM, V263, P18093; STEINERT PM, 1978, BIOCHEMISTRY-US, V17, P5045, DOI 10.1021/bi00616a029; STEINERT PM, 1971, J INVEST DERMATOL, V56, P49, DOI 10.1111/1523-1747.ep12291902; STEINERT PM, 1969, BIOCHIM BIOPHYS ACTA, V175, P1, DOI 10.1016/0005-2795(69)90138-X; STEVEN AC, 1994, J CELL SCI, V107, P693; TAKAHARA H, 1983, J BIOCHEM, V94, P1945, DOI 10.1093/oxfordjournals.jbchem.a134548; TAKAHARA H, 1989, J BIOL CHEM, V264, P13361; TAMADA Y, 1995, ACTA DERM-VENEREOL, V75, P190; Tarcsa E, 1996, J BIOL CHEM, V271, P30709, DOI 10.1074/jbc.271.48.30709; TERAKAWA H, 1991, J BIOCHEM, V110, P661, DOI 10.1093/oxfordjournals.jbchem.a123636; VORNER H, 1903, DERMATOL Z BERLIN, V10, P357; WATANABE K, 1988, BIOCHIM BIOPHYS ACTA, V966, P375, DOI 10.1016/0304-4165(88)90088-8	50	124	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27893	27901		10.1074/jbc.272.44.27893	http://dx.doi.org/10.1074/jbc.272.44.27893			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346937	hybrid			2022-12-27	WOS:A1997YD47300063
J	Croteau, DL; apRhys, CMJ; Hudson, EK; Dianov, GL; Hansford, RG; Bohr, VA				Croteau, DL; apRhys, CMJ; Hudson, EK; Dianov, GL; Hansford, RG; Bohr, VA			An oxidative damage-specific endonuclease from rat liver mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMAMIDOPYRIMIDINE DNA GLYCOSYLASE; HAMSTER OVARY CELLS; ESCHERICHIA-COLI; CATALYTIC MECHANISM; FPG PROTEIN; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; IONIZING-RADIATION; BETA-ELIMINATION; REPAIR	Reactive oxygen species have been shown to generate mutagenic lesions in DNA, One of the most abundant lesions in both nuclear and mitochondrial DNA is 7,8-dihydro-8-oxoguanine (8-oxoG). We report here the partial purification and characterization of a mitochondrial oxidative damage endonuclease (mtODE) from rat liver that recognizes and incises at 8-oxoG and abasic sites in duplex DNA. Rat liver mitochondria were purified by differential and Percoll gradient centrifugation, and mtODE was extracted from Triton X-100-solubilized mitochondria. Incision activity was measured using a radiolabeled double-stranded DNA oligonucleotide containing a unique 8-oxoG, and, reaction products were separated by polyacrylamide gel electrophoresis. Gel filtration chromatography predicts mtODE's molecular mass to be between 25 and 30 kDa. mtODE has a monovalent cation optimum between 50 and 100 mM KCl and a pH optimum between 7.5 and 8. mtODE does not require any co-factors and is active in the presence of 5 mM EDTA. It is specific for 8-oxoG and preferentially incises at S-oxoG:C base pairs. mtODE is a putative S-oxoG glycosylase/lyase enzyme, because it can be covalently linked to the 8-oxoG oligonucleotide by sodium borohydride reduction, Comparison of mtODE's activity with other known 8-oxoG glycosglases/lyases and mitochondrial enzymes reveals that this may be a novel protein.	NIA,MOL GENET LAB,NIH,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University			Bohr, Vilhelm/AAP-5931-2020; Croteau, Deb/AAP-5933-2020	Croteau, Deborah/0000-0002-6094-4084				Aburatani H, 1997, CANCER RES, V57, P2151; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; ANDERSON CTM, 1980, NUCLEIC ACIDS RES, V8, P875; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BESSHO T, 1993, J BIOL CHEM, V268, P19416; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; CLAYTON DA, 1974, P NATL ACAD SCI USA, V89, P7370; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; DEOLIVEIRA R, 1994, NUCLEIC ACIDS RES, V22, P3760, DOI 10.1093/nar/22.18.3760; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; GASNIER F, 1993, ANAL BIOCHEM, V212, P173, DOI 10.1006/abio.1993.1309; GERSCHENSON M, 1995, NUCLEIC ACIDS RES, V23, P88, DOI 10.1093/nar/23.1.88; GERSCHENSON M, 1994, J MOL CELL CARDIOL, V26, P31, DOI 10.1006/jmcc.1994.1005; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KIM J, 1995, J BIOL CHEM, V270, P13620, DOI 10.1074/jbc.270.23.13620; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; LEDOUX SP, 1993, CARCINOGENESIS, V14, P913, DOI 10.1093/carcin/14.5.913; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; MYERS KA, 1988, CARCINOGENESIS, V9, P285, DOI 10.1093/carcin/9.2.285; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; PIRSEL M, 1993, CARCINOGENESIS, V14, P2105, DOI 10.1093/carcin/14.10.2105; RAGAN CI, 1987, PRACTICAL APPROACH S, P80; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SATOH MS, 1988, J BIOL CHEM, V263, P6854; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; TOMKINSON AE, 1990, NUCLEIC ACIDS RES, V18, P929, DOI 10.1093/nar/18.4.929; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210; Yacoub A, 1996, EMBO J, V15, P2306, DOI 10.1002/j.1460-2075.1996.tb00584.x; YAMAMOTO F, 1992, JPN J CANCER RES, V83, P351, DOI 10.1111/j.1349-7006.1992.tb00114.x	49	130	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27338	27344		10.1074/jbc.272.43.27338	http://dx.doi.org/10.1074/jbc.272.43.27338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341184	hybrid			2022-12-27	WOS:A1997YC65900080
J	Kim, JY; Soede, RDM; Schaap, P; Valkema, R; Borleis, JA; VanHaastert, PJM; Devreotes, PN; Hereld, D				Kim, JY; Soede, RDM; Schaap, P; Valkema, R; Borleis, JA; VanHaastert, PJM; Devreotes, PN; Hereld, D			Phosphorylation of chemoattractant receptors is not essential for chemotaxis or termination of G-protein-mediated responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED PHOSPHORYLATION; DICTYOSTELIUM CAMP RECEPTOR; ADENYLYL-CYCLASE; SIGNALING PATHWAYS; GUANINE-NUCLEOTIDES; MOLECULAR-BIOLOGY; CAR1; DISCOIDEUM; CELLS; IDENTIFICATION	In several G-protein-coupled signaling systems, ligand-induced receptor phosphorylation by specific kinases is suggested to lead to desensitization via mechanisms including receptor/G-protein uncoupling, receptor internalization, and receptor down-regulation. We report here that elimination of phosphorylation of a chemoattractant receptor of Dictyostelium, either by site-directed substitution of the serines or by truncation of the C-terminal cytoplasmic domain, completely prevented agonist-induced loss of ligand binding but did not impair the adaptation of several receptor-mediated responses including the activation of adenylyl and guanylyl cyclases and actin polymerization, In addition, the phosphorylation deficient receptors were capable of mediating chemotaxis, aggregation, and differentiation. We propose that for chemoattractant receptors agonist-induced phosphorylation regulates surface binding activity but other phosphorylation-independent mechanisms mediate response adaptation.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; LEIDEN UNIV, INST MOL PLANT SCI, LEIDEN, NETHERLANDS; UNIV GRONINGEN, DEPT BIOCHEM, GRONINGEN, NETHERLANDS	Johns Hopkins University; Leiden University; Leiden University - Excl LUMC; University of Groningen			Schaap, Pauline/M-5355-2019; Schaap, Pauline/A-3682-2009	Schaap, Pauline/0000-0003-4500-2555; Schaap, Pauline/0000-0003-4500-2555	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034933] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34933] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CATERINA MJ, 1994, J BIOL CHEM, V269, P1523; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; CATERINA MJ, 1995, J BIOL CHEM, V270, P4418, DOI 10.1074/jbc.270.9.4418; CATERINA MJ, 1995, J BIOL CHEM, V270, P8667, DOI 10.1074/jbc.270.15.8667; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CHEN MY, 1994, J BIOL CHEM, V269, P20925; Chen QJ, 1996, MOL CELL BIOL, V16, P247; CONDEELIS J, 1991, METHOD ENZYMOL, V196, P486; DEVREOTES PN, 1979, J CELL BIOL, V80, P291, DOI 10.1083/jcb.80.2.291; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; GUNDERSEN RE, 1990, SCIENCE, V248, P591, DOI 10.1126/science.2110382; HERELD D, 1994, J BIOL CHEM, V269, P7036; INGLESE J, 1993, J BIOL CHEM, V268, P23735; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; KLEIN P, 1987, J BIOL CHEM, V262, P358; KONIJN TM, 1970, EXPERIENTIA, V26, P367, DOI 10.1007/BF01896891; LILLY PJ, 1995, J CELL BIOL, V129, P1659, DOI 10.1083/jcb.129.6.1659; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; SOEDE RDM, 1994, DEVELOPMENT, V120, P1997; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; VANHAASTERT PJM, 1983, J CELL BIOL, V96, P1559, DOI 10.1083/jcb.96.6.1559; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VANHAASTERT PJM, 1987, J CELL BIOL, V105, P2301, DOI 10.1083/jcb.105.5.2301; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171	35	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27313	27318		10.1074/jbc.272.43.27313	http://dx.doi.org/10.1074/jbc.272.43.27313			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341180	Green Published, hybrid			2022-12-27	WOS:A1997YC65900076
J	Akita, K; Ohtsuki, T; Nukada, Y; Tanimoto, T; Namba, M; Okura, T; TakakuraYamamoto, R; Torigoe, K; Gu, Y; Su, MSS; Fujii, M; SatohItoh, M; Yamamoto, K; Kohno, K; Ikeda, M; Kurimoto, M				Akita, K; Ohtsuki, T; Nukada, Y; Tanimoto, T; Namba, M; Okura, T; TakakuraYamamoto, R; Torigoe, K; Gu, Y; Su, MSS; Fujii, M; SatohItoh, M; Yamamoto, K; Kohno, K; Ikeda, M; Kurimoto, M			Involvement of caspase-1 and caspase-3 in the production and processing of mature human interleukin 18 in monocytic THP.1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASE; CONVERTING-ENZYME; INTERLEUKIN-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE; GAMMA PRODUCTION; T-CELLS; IDENTIFICATION; ACTIVATION; APOPTOSIS; CYTOKINE	Recently, human interleukin 18 (hIL-18) cDNA was cloned, and the recombinant protein with a tentatively assigned NH2-terminal amino acid sequence was generated. However, natural hIL-18 has not yet been isolated, and its cellular processing is therefore still unclear. To clarify this, we purified natural hIL-18 from the cytosolic extract of monocytic THP.1 cells. Natural hIL-18 exhibited a molecular mass of 18.2 kDa, and the NH2-terminal amino acid was Tyr(37). Biological activities of the purified protein were identical to those of recombinant hIL-18 with respect to the enhancement of natural killer cell cytotoxicity and interferon-gamma production by human peripheral blood mononuclear cells. We also found two precursor hIL-18 (prohIL-18)-processing activities in the cytosol of THP.1 cells, These activities were blocked separately by the caspase inhibitors Ac-YVAD-CHO and Ac-DEVD-CHO. Further analyses of the partially purified enzymes revealed that one is caspase-1, which cleaves prohIL-18 at the Asp(36)-Tyr(37) Site to generate the mature hIL-18, and the other is caspase-3, which cleaves both precursor and mature hIL-18 at Asp(71)-Ser(72) and Asp(76)-Asn(77) to generate biologically inactive products, These results suggest that the production and processing of natural hIL-18 are regulated by two processing enzymes, caspase-1 and caspase-3, in THP.1 cells.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139	Vertex Pharmaceuticals	Akita, K (corresponding author), HAYASHIBARA BIOCHEM LABS INC,FUJISAKI INST,675-1 FUJISAKI,OKAYAMA 702,JAPAN.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANDO S, 1988, JPN J CANCER RES, V79, P757, DOI 10.1111/j.1349-7006.1988.tb02233.x; Bazan JF, 1996, NATURE, V379, P591, DOI 10.1038/379591a0; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FUKUDA S, 1988, LYMPHOKINE RES, V7, P175; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; Kohno K, 1997, J IMMUNOL, V158, P1541; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KURTJONES EA, 1985, P NATL ACAD SCI USA, V82, P1204, DOI 10.1073/pnas.82.4.1204; LICHTMAN AH, 1988, P NATL ACAD SCI USA, V85, P9699, DOI 10.1073/pnas.85.24.9699; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OKAMURA H, 1995, INFECT IMMUN, V63, P3966, DOI 10.1128/IAI.63.10.3966-3972.1995; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SIDERS WM, 1995, J BIOL CHEM, V270, P16258, DOI 10.1074/jbc.270.27.16258; Takeuchi M, 1997, CELL TISSUE RES, V289, P499, DOI 10.1007/s004410050895; TANIGUCHI M, 1997, IN PRESS J IMMUNOL M; TASTUTA T, 1996, J IMMUNOL, V157, P3949; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1995, PROTEIN SCI, V4, P3; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; Thornberry Nancy A., 1995, Perspectives in Drug Discovery and Design, V2, P389, DOI 10.1007/BF02172032; Ushio S, 1996, J IMMUNOL, V156, P4274; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	36	179	190	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26595	26603		10.1074/jbc.272.42.26595	http://dx.doi.org/10.1074/jbc.272.42.26595			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334240	hybrid			2022-12-27	WOS:A1997YB13900074
J	McCormack, T; Baumeister, W; Grenier, L; Moomaw, C; Plamondon, L; Pramanik, B; Slaughter, C; Soucy, F; Stein, R; Zuhl, F; Dick, L				McCormack, T; Baumeister, W; Grenier, L; Moomaw, C; Plamondon, L; Pramanik, B; Slaughter, C; Soucy, F; Stein, R; Zuhl, F; Dick, L			Active site-directed inhibitors of Rhodococcus 20 S proteasome - Kinetics and mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING ENZYME-INHIBITORS; THERMOPLASMA-ACIDOPHILUM; COMPLEX; LACTACYSTIN	We have studied the mechanism of inhibition of the recombinant Rhodococcus proteasome by four different chemical classes of active site-directed small molecule inhibitors, Clasto-lactacystin beta-lactone is a time-dependent inhibitor of the Rhodococcus proteasome's ability to hydrolyze Suc-Leu-Leu-Val-Tyr-AMC, a substrate for this proteasome's single type of active site, and proceeds with a k(inact)[I] of 1,700 m(-1) s(-1). Using peptide mapping of tryptic digests, LC/MS, and amino acid sequence analysis, we have established that the O gamma of the hydroxyl group on the N terminal threonine of the beta-subunit is the sole modification made by the beta-lactone. Active site titrations of the Rhodococcus proteasome with reversible peptide aldehydes show the expected stoichiometry of one inhibitor molecule per beta-subunit. Prior modification with beta-lactone completely abrogates the binding of peptidyl boronic acid inhibitors, suggesting that these inhibitors also inactivate the enzyme by reacting with the O gamma moiety on Thr(1), High performance liquid chromatography analysis of peptidyl vinyl sulfone-modified intact Rhodococcus proteasome beta-subunit and its tryptic peptides suggests that the peptidyl vinyl sulfone modifies a residue in the N-terminal 20 amino acids, This modification is also blocked by prior treatment with beta-lactone.	PROSCRIPT INC,CAMBRIDGE,MA 02139; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society			Dick, Lawrence/ABA-8831-2021	Dick, Larry/0000-0002-6880-0405				Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Cantor, 1980, BIOPHYS CHEM; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DITZEL L, 1997, J BIOL CHEM, V378, P239; FENG R, 1991, J AM SOC MASS SPECTR, V2, P387, DOI 10.1016/1044-0305(91)85005-Q; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GRECO WR, 1979, J BIOL CHEM, V254, P2104; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GUTFREUND H, 1975, ENZYMES PHYSICAL PRI; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SHENVI AB, 1986, BIOCHEMISTRY-US, V25, P1286, DOI 10.1021/bi00354a014; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; UNO H, 1994, J AM CHEM SOC, V116, P2139, DOI 10.1021/ja00084a062; WEBER PC, 1995, BIOCHEMISTRY-US, V34, P3750, DOI 10.1021/bi00011a033; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; Zuhl F, 1997, FEBS LETT, V400, P83, DOI 10.1016/S0014-5793(96)01403-2	25	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26103	26109		10.1074/jbc.272.42.26103	http://dx.doi.org/10.1074/jbc.272.42.26103			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334174	hybrid			2022-12-27	WOS:A1997YB13900008
J	Tomashek, JJ; Graham, LA; Hutchins, MU; Stevens, TH; Klionsky, DJ				Tomashek, JJ; Graham, LA; Hutchins, MU; Stevens, TH; Klionsky, DJ			V-1-situated stalk subunits of the yeast vacuolar proton-translocating ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; GENE DISRUPTION; 13-KDA SUBUNIT; ENZYME COMPLEX; ENCODES; PUMP; EVOLUTION; CONTAINS	The proton-translocating ATPase of the yeast vacuole is an enzyme complex consisting of a large peripheral membrane sector (V-1) and an integral membrane sector (V-0), each composed of multiple subunits. The V-1 sector contains subunits that hydrolyze ATP, whereas the V-0 sector contains subunits that translocate protons across the membrane. Additional subunits in both sectors couple these activities. Here we have continued our examination of intermediate subunits primarily associated with the V-1 but also implicated in interactions with the V-0. Interactions between Vma7p (F) and Vma8p (D) and between Vma4p (E) and Vma10p (G) are described. Although Vma7p and Vma10p have been observed to interact with the V-0 sector, our results indicate that these subunits behave primarily as canonical V-1 sector subunits. We categorize these four subunits as ''stalk'' subunits to distinguish them from the known catalytic (A and B) and proton-translocating (c, c', and Vma16p) subunits and to highlight their intermediate nature. Furthermore, we show that the in vivo stability of Vma4p is dependent upon interaction with Vma10p. This may be important in the regulation of assembly, since these two subunits add to the V-1 during later stages of V-1 assembly. This is the first demonstration of interdependence between ATPase subunits for structural stability.	UNIV CALIF DAVIS, MICROBIOL SECT, DAVIS, CA 95616 USA; UNIV OREGON, INST MOL BIOL, EUGENE, OR 97403 USA	University of California System; University of California Davis; University of Oregon				Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006, R01GM053396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53396, GM38006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BOWMAN BJ, 1992, J EXP BIOL, V172, P57; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1995, BBA-BIOMEMBRANES, V1237, P95, DOI 10.1016/0005-2736(95)00108-F; Crider BP, 1997, J BIOL CHEM, V272, P10721; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KASHO VN, 1989, P NATL ACAD SCI USA, V86, P8708, DOI 10.1073/pnas.86.22.8708; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Lepier A, 1996, J BIOL CHEM, V271, P8502, DOI 10.1074/jbc.271.14.8502; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SIKORSKI RS, 1989, GENETICS, V122, P19; Supekova L, 1996, J EXP BIOL, V199, P1147; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618	33	93	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26787	26793		10.1074/jbc.272.42.26787	http://dx.doi.org/10.1074/jbc.272.42.26787			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334266	hybrid			2022-12-27	WOS:A1997YB13900100
J	Tong, JF; Oyamada, H; Demaurex, N; Grinstein, S; McCarthy, TV; MacLennan, DH				Tong, JF; Oyamada, H; Demaurex, N; Grinstein, S; McCarthy, TV; MacLennan, DH			Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; TWITCH SKELETAL-MUSCLE; CONTRACTURE-TEST; RYR1 GENE; CA-2+ RELEASE; CELLS; SUBSTITUTION; IDENTIFICATION; DISCORDANCE; CYSTEINE	Malignant hyperthermia (MH) and central core disease (CCD) are autosomal dominant disorders of skeletal muscle in which a potentially fatal hypermetabolic crisis can be triggered by commonly used anesthetic agents, To date, 17 mutations in the human RYR1 gene encoding the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum (the ryanodine receptor) have been associated with MH and/or CCD, Although many of these mutations have been linked to MH and/or CCD, with high Iod (log of the odds favoring linkage versus nonlinkage) scopes, others have been found in single, small families, Independent biochemical evidence for a causal role for these mutations in MH is available for only two mutants, Mutations corresponding to the human MH mutations were made in a full-length rabbit RYR1 cDNA, and wild type. and mutant cDNAs were transected into HEK-293 cells, After about 48 h, intact cells were loaded with the fluorescent Ca2+ indicator, fura-2, and intracellular Ca2+ release, induced by caffeine or halothane, was measured by photometry. Ca2+ release in cells expressing MH or CCD mutant ryanodine receptors was invariably significantly more sensitive to low concentrations of caffeine and halothane than Ca2+ release in cells expressing wild type receptors or receptors mutated in other regions of the molecule, Linear regression analysis showed that there is a strong correlation (r = 0.95, p < 0.001) between caffeine sensitivity of different RYR1 mutants measured by the cellular Ca2+ photometry assay and by the clinical in vitro caffeine halothane contracture test (IVCT). The correlation was weaker, however for halothane (r = 0.49, p > 0.05), Abnormal sensitivity in the Ca2+ photometry assay provides supporting evidence for a causal role in MH for each of 15 single amino acid mutations in the ryanodine receptor, The study demonstrates the usefulness of the cellular Ca2+ photometpy assay in the assessment of the sensitivity to caffeine and halothane of specific ryanodine receptor mutants.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M6S 1A1, CANADA; HOSP SICK CHILDREN, RES INST, DIV CELL BIOL, TORONTO, ON M5G 1X8, CANADA; NATL UNIV IRELAND UNIV COLL CORK, DEPT BIOCHEM, CORK, IRELAND	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University College Cork				Demaurex, Nicolas/0000-0002-9933-6772; McCarthy, Tommie/0000-0003-4884-6972				AIREY JA, 1990, J BIOL CHEM, V265, P14187; BRITT BA, 1991, THERMOREGULATION PAT, P179; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; Chen SRW, 1997, BIOPHYS J, V73, P1904, DOI 10.1016/S0006-3495(97)78221-3; DENBOROUGH MA, 1973, BMJ-BRIT MED J, V1, P272, DOI 10.1136/bmj.1.5848.272; DEUFEL T, 1995, AM J HUM GENET, V56, P1334; DUBOWITZ V, 1960, LANCET, P23; ELLIS FR, 1984, BRIT J ANAESTH, V56, P1267; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GILLARD EF, 1991, GENOMICS, V11, P751, DOI 10.1016/0888-7543(91)90084-R; GILLARD EF, 1992, GENOMICS, V13, P1247, DOI 10.1016/0888-7543(92)90042-Q; GROMADA J, 1995, FEBS LETT, V373, P182, DOI 10.1016/0014-5793(95)01070-U; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOGAN K, 1992, ANESTH ANALG, V75, P441; KEATING KE, 1994, HUM MOL GENET, V3, P1855, DOI 10.1093/hmg/3.10.1855; Keating KE, 1997, J MED GENET, V34, P291, DOI 10.1136/jmg.34.4.291; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARACH MG, 1989, ANESTH ANALG, V69, P511; Lynch PJ, 1997, ANESTHESIOLOGY, V86, P620, DOI 10.1097/00000542-199703000-00014; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MACLENNAN DH, 1995, SOC GEN PHY, V50, P89; MACLENNAN DH, 1995, CURR OPIN NEUROL, V8, P397, DOI 10.1097/00019052-199510000-00013; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MICKELSON JR, 1987, BIOCHIM BIOPHYS ACTA, V897, P364, DOI 10.1016/0005-2736(87)90434-2; MICKELSON JR, 1994, AM J PHYSIOL, V267, pC282, DOI 10.1152/ajpcell.1994.267.1.C282; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; OHNISHI ST, 1983, FEBS LETT, V161, P103; Ording H, 1997, ACTA ANAESTH SCAND, V41, P955, DOI 10.1111/j.1399-6576.1997.tb04820.x; OTSU K, 1994, J BIOL CHEM, V269, P9413; OTSU K, 1991, GENOMICS, V11, P744, DOI 10.1016/0888-7543(91)90083-Q; PHILLIPS MS, 1994, HUM MOL GENET, V3, P2181, DOI 10.1093/hmg/3.12.2181; QUANE KA, 1994, GENOMICS, V23, P236, DOI 10.1006/geno.1994.1483; QUANE KA, 1993, NAT GENET, V5, P51, DOI 10.1038/ng0993-51; QUANE KA, 1994, HUM MOL GENET, V3, P471, DOI 10.1093/hmg/3.3.471; Quane KA, 1997, BRIT J ANAESTH, V79, P332, DOI 10.1093/bja/79.3.332; Richter M, 1997, J BIOL CHEM, V272, P5256, DOI 10.1074/jbc.272.8.5256; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Serfas KD, 1996, ANESTHESIOLOGY, V84, P322, DOI 10.1097/00000542-199602000-00009; SHOMER NH, 1993, AM J PHYSIOL, V264, pC125, DOI 10.1152/ajpcell.1993.264.1.C125; SHY GM, 1956, BRAIN, V79, P610, DOI 10.1093/brain/79.4.610; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREVES S, 1994, BIOCHEM J, V301, P661, DOI 10.1042/bj3010661; ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	48	194	196	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26332	26339		10.1074/jbc.272.42.26332	http://dx.doi.org/10.1074/jbc.272.42.26332			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334205	hybrid			2022-12-27	WOS:A1997YB13900039
J	Brown, AM; Lemke, G				Brown, AM; Lemke, G			Multiple regulatory elements control transcription of the peripheral myelin protein zero gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED SCHWANN-CELLS; BOX-BINDING PROTEINS; NERVOUS-SYSTEM; DNA-BINDING; IN-VIVO; NF-Y; NEGATIVE REGULATION; DEJERINE-SOTTAS; TRANSGENIC MICE; MAJOR MYELIN	The gene encoding protein zero (P-0), the most abundant protein of peripheral nervous system myelin, is expressed uniquely in Schwann cells. Previous studies have demonstrated that much of the cell type specificity of this expression is due to transcriptional control elements in the 1.1-kilobase pair 5'-regulatory region of the gene. We have now analyzed this region and have identified a set of functional elements in the 500 base pairs proximal to the transcription start site. DNA sequence conservation within the 5' regions of the human, mouse, and rat P-0 genes correlates closely with the results of promoter deletion analysis of the 1.1-kilobase pair region assayed in Schwann cell cultures and reveals a potent proximal region from position -350 to +45. Sites of protein/DNA interaction within the proximal 500 base pairs of the promoter were identified by footprinting assays. Functional transcriptional elements were identified within the protected regions in the proximal promoter by mutation and transient transfection analysis in P-0-expressing cell lines, The core (or basal) P-0 promoter is identified as two regulatory elements, a G/C-rich element that binds nuclear factor Sp1 and a CAAT box that binds NF-Y. These core elements are essential for the transcription observed from the transfected promoter in cultured Schwann cells.			Brown, AM (corresponding author), SALK INST BIOL STUDIES,MOL NEUROBIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NINDS NIH HHS [NS23896] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023896] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel FM, 1988, MOL REPROD DEV; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BROCKES JP, 1980, J BIOL CHEM, V255, P8374; BROWN AM, 1993, J BIOL CHEM, V268, P26328; BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; HAYASAKA K, 1993, NAT GENET, V5, P31, DOI 10.1038/ng0993-31; HAYASAKA K, 1993, NAT GENET, V5, P266, DOI 10.1038/ng1193-266; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; KUHN R, 1991, MOL CELL BIOL, V11, P4642, DOI 10.1128/MCB.11.9.4642; KULKENS T, 1993, NAT GENET, V5, P35, DOI 10.1038/ng0993-35; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1988, NEURON, V1, P535, DOI 10.1016/0896-6273(88)90103-1; LEMKE G, 1988, DEVELOPMENT, V102, P499; LEMKE G, 1985, CELL, V40, P501, DOI 10.1016/0092-8674(85)90198-9; LEMKE G, 1986, TRENDS NEUROSCI, V9, P266, DOI 10.1016/0166-2236(86)90076-7; Lemke G., 1992, INTRO MOL NEUROBIOLO, P281; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MARTINI R, 1995, NAT GENET, V11, P281, DOI 10.1038/ng1195-281; MESSING A, 1994, J NEUROSCI, V14, P3533; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; Morell, 1984, MYELIN; MORGAN L, 1994, DEVELOPMENT, V120, P1399; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; POLITIS MJ, 1982, J NEUROSCI, V2, P1252; PORTER S, 1986, J NEUROSCI, V6, P3070; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; STAHL N, 1990, MOL BRAIN RES, V8, P209, DOI 10.1016/0169-328X(90)90018-9; SU Y, 1993, P NATL ACAD SCI USA, V90, P10856, DOI 10.1073/pnas.90.22.10856; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Warner LE, 1996, NEURON, V17, P451, DOI 10.1016/S0896-6273(00)80177-4; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978	50	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28939	28947		10.1074/jbc.272.46.28939	http://dx.doi.org/10.1074/jbc.272.46.28939			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360965	hybrid			2022-12-27	WOS:A1997YF68400024
J	Miyashita, T; OkamuraOho, Y; Mito, Y; Nagafuchi, S; Yamada, M				Miyashita, T; OkamuraOho, Y; Mito, Y; Nagafuchi, S; Yamada, M			Dentatorubral pallidoluysian atrophy (DRPLA) protein is cleaved by caspase-3 during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE-LIKE; ICE/CED-3 PROTEASE; CELL-LINE; IN-VITRO; DEATH; MICE; IDENTIFICATION; SUBSTRATE; DISEASE; BCL-2	Dentatorubral pallidoluysian atrophy (DRPLA) is an autosomal dominant neurodegenerative disorder. It is associated with an abnormal CAG repeat expansion resulting in formation of a protein with an elongated poly glutamine stretch, However, neither the physiological roles of the DRPLA gene product nor molecular mechanisms of its pathogenesis have yet been elucidated. Here we report that the DRPLA protein is cleaved at a site near the N terminus during apoptosis induced by VP-16, staurosporine, or glucocorticoid. Moreover, the in vitro translated DRPLA protein is cleaved by recombinant caspase-3, a member of the cysteine protease family, which is thought to be a main executioner of apoptosis, Using mutant DRPLA proteins, the cleavage site was identified as (106)DSLDG(110). The cleavage, however, was not modulated by the length of the polyglutamine stretch, These findings suggest that the DRPLA protein is one of the physiological substrates of caspase-3, and its cleavage may result in structural and biochemical alterations associated with apoptosis.	NATL CHILDRENS MED RES CTR,DEPT GENET,TOKYO 154,JAPAN; TOHO UNIV,FAC SCI,DEPT BIOMOL SCI,FUNABASHI,CHIBA 274,JAPAN	National Center for Child Health & Development - Japan; Toho University								Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CAILLIAU CP, 1995, J NEUROSCI, V15, P3775; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MIYASHITA T, 1993, BLOOD, V81, P151; Miyashita T, 1997, BIOCHEM BIOPH RES CO, V233, P781, DOI 10.1006/bbrc.1997.6559; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; YAZAWA I, 1995, NAT GENET, V10, P99, DOI 10.1038/ng0595-99; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	34	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29238	29242		10.1074/jbc.272.46.29238	http://dx.doi.org/10.1074/jbc.272.46.29238			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361003	hybrid			2022-12-27	WOS:A1997YF68400062
J	Yu, M; Yang, XY; Schmidt, T; Chinenov, Y; Wang, R; Martin, ME				Yu, M; Yang, XY; Schmidt, T; Chinenov, Y; Wang, R; Martin, ME			GA-binding protein-dependent transcription initiator elements - Effect of helical spacing between polyomavirus enhancer a factor 3(PEA3)/Ets-binding sites on initiator activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; SUBUNIT-IV GENE; DIHYDROFOLATE-REDUCTASE PROMOTER; MURINE TISSUE INHIBITOR; ETS DOMAIN; COOPERATIVE BINDING; COLLAGENASE GENE; MAMMALIAN-CELLS; TATA BOX; DNA	Many eukaryotic RNA polymerase II promoters contain initiator elements which direct accurate transcription in a TATA-independent manner, The PEA3/Ets-binding site (PEA3/EBS) is a common enhancer element in eukaryotic genes and is also found near the transcriptional start sites of many TATA-less promoters. We demonstrate that two PEA3/EBSs driving expression of the luciferase reporter gene, function as a minimal transcriptional initiator element, Maximal levels of transcription was achieved when two PEA3/EBSs, in either orientation, were located on the same face of the DNA helix, and the sites could be separated by up to three helical turns, In vitro transcription start sites directed by PEA3/EBS elements were clustered on either side of the upstream PEA3/EBS and were abolished by immunodepletion of GA-binding protein (GABP) from FM3A cell nuclear extracts. In vivo, co-transfection of GABP alpha and GABP beta expression vectors enhanced reporter gene expression driven from PEA3/EBS initiator elements, Like other initiator elements, the PEA3/EBS elements were activated synergistically by upstream Spl-binding sites. Thus, our results establish GABP as both a transcriptional activator factor and as an initiator factor.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027200, R55HD027200] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27200] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BASU A, 1993, J BIOL CHEM, V268, P4188; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CLEVERS HC, 1988, P NATL ACAD SCI USA, V85, P8156, DOI 10.1073/pnas.85.21.8156; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FLORES O, 1992, J BIOL CHEM, V267, P2786; GRIFFITH J, 1986, NATURE, V322, P750, DOI 10.1038/322750a0; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARVEY C, 1991, MOL ENDOCRINOL, V5, P836, DOI 10.1210/mend-5-6-836; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JIANG Y, 1993, J BIOL CHEM, V268, P6535; Kadonaga JT, 1990, CURR OPIN CELL BIOL, V2, P496, DOI 10.1016/0955-0674(90)90133-Y; KANG ME, 1993, J BIOL CHEM, V268, P25033; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; LEDNICKY J, 1992, J VIROL, V66, P6379, DOI 10.1128/JVI.66.11.6379-6390.1992; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; Martin ME, 1996, J BIOL CHEM, V271, P25617, DOI 10.1074/jbc.271.41.25617; MARTIN ME, 1992, MOL CELL BIOL, V12, P2213, DOI 10.1128/MCB.12.5.2213; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OGAWA K, 1988, J BIOL CHEM, V263, P8384; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PETERSON MG, 1992, NATURE, V358, P620, DOI 10.1038/358620a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4396; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Sucharov C, 1995, GENE EXPRESSION, V5, P93; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOOZE J, 1981, MOL BIOL TUMOUR VIRU; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; VILLENA JA, 1994, J BIOL CHEM, V269, P32649; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; XU LC, 1991, NUCLEIC ACIDS RES, V19, P6699, DOI 10.1093/nar/19.24.6699; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	64	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29060	29067		10.1074/jbc.272.46.29060	http://dx.doi.org/10.1074/jbc.272.46.29060			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360980	hybrid			2022-12-27	WOS:A1997YF68400039
J	Choi, YH; Lee, SJ; Nguyen, P; Jang, JS; Lee, J; Wu, ML; Takano, E; Maki, M; Henkart, PA; Trepel, JB				Choi, YH; Lee, SJ; Nguyen, P; Jang, JS; Lee, J; Wu, ML; Takano, E; Maki, M; Henkart, PA; Trepel, JB			Regulation of cyclin D1 by calpain protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA FAMILY PROTEINS; ACTIVATED NEUTRAL PROTEASE; PROGRAMMED CELL-DEATH; INHIBITOR P27; G1 PHASE; DEGRADATION; PATHWAY; G(1); PROGRESSION; TRANSITION	Cyclin D1, a critical positive regulator of G(1) progression, has been implicated in the pathogenesis of certain cancers. Regulation of cyclin D1 occurs at the transcriptional and posttranscriptional level. Here we present evidence that cyclin D1 levels are regulated at the posttranscriptional level by the Ca2+-activated protease calpain. Serum starvation of NIH 3T3 cells resulted in rapid loss of cyclin D1 protein that was completely reversible by calpain inhibitors. Actinomycin D and lovastatin induced rapid loss of cyclin D1 in prostate and breast cancer cells that was reversible by calpain inhibitors and not by phenylmethylsulfonyl fluoride, caspase inhibitors, or lactacystin, a specific inhibitor of the 26 S proteasome. Treatment of intact NIH 3T3, prostate, and breast cancer cells with a calpain inhibitor dramatically increased the half-life of cyclin D1 protein, Addition of purified calpain to PC-3-M lysates resulted in Ca2+-dependent cyclin D1 degradation. Transient expression of the calpain inhibitor calpastatin increased cyclin D1 protein in serum-starved NIR 3T3 cells. Cyclins A, E, and El have been reported to be regulated by proteasome-associated proteolysis. The data presented here implicate calpain in cyclin D1 posttranslational regulation.	NCI, MED BRANCH, DIV CLIN SCI, NIH, BETHESDA, MD 20892 USA; NCI, DIV BASIC SCI, EXPT IMMUNOL BRANCH, NIH, BETHESDA, MD 20892 USA; NATL KYOTO HOSP, KYOTO 612, JAPAN; NAGOYA UNIV, NAGOYA, AICHI 46401, JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Nagoya University			Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491				ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bates S, 1996, ONCOGENE, V13, P1103; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Geng Y, 1996, ONCOGENE, V12, P1173; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KEYOMARSI K, 1991, CANCER RES, V51, P3602; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUKAS J, 1994, ONCOGENE, V9, P707; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAGAO S, 1994, J BIOCHEM, V115, P1178, DOI 10.1093/oxfordjournals.jbchem.a124476; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Pusch O, 1996, FEBS LETT, V385, P143, DOI 10.1016/0014-5793(96)00369-9; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	61	148	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28479	28484		10.1074/jbc.272.45.28479	http://dx.doi.org/10.1074/jbc.272.45.28479			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353308	hybrid			2022-12-27	WOS:A1997YF21900048
J	Li, XQ; Zhang, GH; Ngo, N; Zhao, XN; Kain, SR; Huang, CC				Li, XQ; Zhang, GH; Ngo, N; Zhao, XN; Kain, SR; Huang, CC			Deletions of the Aequorea victoria green fluorescent protein define the minimal domain required for fluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CODON USAGE; CHROMOPHORE; MUTATIONS	The Green Fluorescent Protein (GFP) from the jellyfish Aequorea victoria is a widely used marker for gene expression and protein localization studies. Dissection of the structure of the protein would be expected to shed light on its potential applications to other fields such as the detection of protease activity. Using deletion analysis, we have defined the minimal domain in GFP required for fluorescence to amino acids 7-229. This domain starts at the middle of the first small cy helix at the N terminus of GFP and ends immediately following the last beta sheet. Studies of the amino acids at both termini of the minimal domain revealed that positions 6 and 7 at the N terminus are Glu-specific. Change of the Glu residues to other amino acids results in reduction of GFP fluorescence. Position 229 at the C terminus of GFP, however, is nonspecific: the De can be replaced with other amino acids with no measurable loss of fluorescence. A total of only 15 terminal amino acids can be deleted from GFP without disrupting fluorescence, consistent with findings of a previous study of GFP crystal structure (Ormo, M., Cubitt, A. B., Kallio, K., Gross, L. A., Tsien, R. Y., Remington, S. J. (1996) Science 273, 1392-1395 and Yang, F., Moss, L. G., and Phillips, G. N., Jr. (1996) Not. Biotechnol. 14, 1246-1251) that a tightly packed structure exists in the protein. We also generated internal deletions within the loop regions of GFP according to its crystal structure and found that all such deletions eliminated GFP fluorescence.			Li, XQ (corresponding author), CLONTECH LABS INC,1020 E MEADOW CIRCLE,PALO ALTO,CA 94303, USA.							CHALFIE M, 1995, PHOTOCHEM PHOTOBIOL, V62, P651, DOI 10.1111/j.1751-1097.1995.tb08712.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Dopf J, 1996, GENE, V173, P39, DOI 10.1016/0378-1119(95)00692-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INOUYE S, 1994, FEBS LETT, V351, P211, DOI 10.1016/0014-5793(94)00859-0; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yang TT, 1996, NUCLEIC ACIDS RES, V24, P4592, DOI 10.1093/nar/24.22.4592; YING DX, 1996, ANAL BIOCHEM, V235, P195	17	99	111	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28545	28549		10.1074/jbc.272.45.28545	http://dx.doi.org/10.1074/jbc.272.45.28545			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353317	hybrid			2022-12-27	WOS:A1997YF21900057
J	Yao, SYM; Ng, AML; Muzyka, WR; Griffiths, M; Cass, CE; Baldwin, SA; Young, JD				Yao, SYM; Ng, AML; Muzyka, WR; Griffiths, M; Cass, CE; Baldwin, SA; Young, JD			Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELLS; GUINEA-PIG; PYRIMIDINE NUCLEOSIDES; INHIBITOR SPECIFICITY; XENOPUS-LAEVIS; ERYTHROCYTES; BINDING; IDENTIFICATION; EXPRESSION; SYSTEM	Equilibrative nucleoside transport processes in mammalian cells are either nitrobenzylthioinosine (NBMPR)-sensitive (es) or NBMPR-insensitive (ei), Previously, we isolated a cDNA from human placenta encoding the 456-residue glycoprotein hENT1, When expressed in Xenopus oocytes, hENT1 mediated es-type transport activity and was inhibited by coronary vasoactive drugs (dipyridamole and dilazep) that may compete with nucleosides and NBMPR for binding to the substrate binding site, We now report the molecular cloning and functional expression of es and ei homologs of hENT1 from rat tissues; rENT1 (457 residues) was 78% identical to hENT1 in amino acid sequence, and rENT2 (456 residues) was 49-50% identical to rENT1/hENT1 and corresponded to a full-length form of the delayed-early proliferative response gene product HNP36, a protein of unknown function previously cloned in truncated form, rENT1 was inhibited by NBMPR (IC50 = 4.6 nM at 10 mu M uridine), whereas rENT2 was NBMPR-insensitive (IC50 > 1 mu M). Both proteins mediated saturable uridine influx (K-m = 0.15 and 0.30 mM, respectively), were broadly selective for purine and pyrimidine nucleosides, including adenosine, and were relatively insensitive to inhibition by dipyridamole and dilazep (IC50 > 1 mu M). These observations demonstrate that es and ei nucleoside transport activities are mediated by separate, but homologous, proteins and establish a function for the HNP36 gene product.	UNIV ALBERTA,DEPT PHYSIOL,MEMBRANE TRANSPORT RES GRP,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,DEPT ONCOL,EDMONTON,AB T6G 2H7,CANADA; UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Alberta; University of Alberta; University of Alberta; University of Leeds					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARROS LF, 1995, PFLUG ARCH EUR J PHY, V429, P394, DOI 10.1007/BF00374155; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; BELT JA, 1985, BIOCHEM J, V232, P681, DOI 10.1042/bj2320681; Boleti H, 1997, NEUROPHARMACOLOGY, V36, P1167, DOI 10.1016/S0028-3908(97)00136-6; CASS CE, 1974, BIOCHIM BIOPHYS ACTA, V345, P1, DOI 10.1016/0005-2736(74)90239-9; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CLUMECK N, 1993, J ANTIMICROB CHEMOTH, V32, P133, DOI 10.1093/jac/32.suppl_A.133; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; CRAWFORD CR, 1990, BIOCHIM BIOPHYS ACTA, V1024, P289, DOI 10.1016/0005-2736(90)90357-T; DAGNINO L, 1990, CANCER RES, V50, P6549; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Fang X, 1996, BIOCHEM J, V317, P457, DOI 10.1042/bj3170457; GATI WP, 1986, BIOCHEM J, V236, P665, DOI 10.1042/bj2360665; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; HAMMOND JR, 1992, BIOCHEM J, V287, P431, DOI 10.1042/bj2870431; HOGUE DL, 1990, BIOCHEM CELL BIOL, V68, P199, DOI 10.1139/o90-026; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; Jacobson K.A., 1990, PURINES CELLULAR SIG; JARVIS SM, 1980, BIOCHIM BIOPHYS ACTA, V597, P183, DOI 10.1016/0005-2736(80)90162-5; JARVIS SM, 1986, J MEMBRANE BIOL, V93, P1, DOI 10.1007/BF01871013; JARVIS SM, 1982, J PHYSIOL-LONDON, V324, P31, DOI 10.1113/jphysiol.1982.sp014099; JARVIS SM, 1986, MOL PHARMACOL, V30, P659; JARVIS SM, 1980, BIOCHEM J, V190, P377, DOI 10.1042/bj1900377; KWONG FYP, 1988, BIOCHEM J, V255, P243; KWONG FYP, 1993, J BIOL CHEM, V268, P22127; KWONG FYP, 1992, J BIOL CHEM, V267, P21954; LEE CW, 1988, NEUROCHEM INT, V12, P483, DOI 10.1016/0197-0186(88)90032-0; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; SHI MM, 1986, BIOCHEM J, V240, P879, DOI 10.1042/bj2400879; SHI MM, 1984, BIOCHEM BIOPH RES CO, V118, P584; WILLIAMS JB, 1995, BIOCHEM BIOPH RES CO, V213, P325, DOI 10.1006/bbrc.1995.2133; WU JSR, 1983, J BIOL CHEM, V258, P3745; WU JSR, 1984, BIOCHEM J, V220, P499, DOI 10.1042/bj2200499; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 1996, MOL PHARMACOL, V50, P388	40	187	194	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28423	28430		10.1074/jbc.272.45.28423	http://dx.doi.org/10.1074/jbc.272.45.28423			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353301	hybrid			2022-12-27	WOS:A1997YF21900041
J	Carr, JF; Hinshaw, JE				Carr, JF; Hinshaw, JE			Dynamin assembles into spirals under physiological salt conditions upon the addition of GDP and gamma-phosphate analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; GTP-BINDING PROTEINS; MECHANOCHEMICAL ENZYME; NERVE-TERMINALS; SH3 DOMAINS; MICROTUBULES; ENDOCYTOSIS; DROSOPHILA; MECHANISM; MUTANT	Dynamin is a 100-kDa GTPase that is believed to be involved in the constriction of clathrin-coated pits and the fission of clathrin-coated vesicles during receptor-mediated endocytosis and during membrane retrieval in nerve termini. It has been shown that purified dynamin incubated under low salt conditions forms rings and spirals that, in dimension and appearance, resemble the dense material occasionally observed at the necks of coated pits. In this report we show that purified dynamin forms spirals under physiological salt conditions when incubated with GDP and gamma-phosphate analogues (beryllium and aluminum fluoride) or when dialyzed into guanosine 5'-3-O-(thio)triphosphate. Moreover, spirals still form when dynamin is proteolyzed to either a predominant similar to 90-kDa species, lacking the C terminus, or to two smaller fragments, a similar to 55-kDa species originating from the N-terminal half of the protein and a similar to 30-kDa species lacking both the N and C termini. This work indicates that the addition of GDP and gamma-phosphate analogues arrests dynamin in a GTP or transition state that markedly stabilizes the spiral conformation under physiological ionic strength conditions and thereby suggests that dynamin in the absence of a receptor is capable of assembly into spirals at the necks of coated pits prior to vesicle fission.			Carr, JF (corresponding author), NIDDK,LAB CELL BIOCHEM & BIOL,NIH,BETHESDA,MD 20892, USA.							Baba T, 1995, COLD SPRING HARB SYM, V60, P235, DOI 10.1101/SQB.1995.060.01.027; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRIGLIATTI TA, 1973, MOL GEN GENET, V120, P107, DOI 10.1007/BF00267238; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HINSHAW JE, 1996, MOL BIOL CELL, V7, P83; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; NAKATA T, 1993, J CELL SCI, V105, P1; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TSURUHARA T, 1983, CELL TISSUE RES, V259, P199; TUMA PL, 1994, J BIOL CHEM, V269, P30842; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310	41	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28030	28035		10.1074/jbc.272.44.28030	http://dx.doi.org/10.1074/jbc.272.44.28030			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346955	hybrid			2022-12-27	WOS:A1997YD47300081
J	FernandezBusquets, X; Burger, MM				FernandezBusquets, X; Burger, MM			The main protein of the aggregation factor responsible for species-specific cell adhesion in the marine sponge Microciona prolifera is highly polymorphic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; IMMUNE-SYSTEM; TRANSPLANTATION IMMUNITY; INVERTEBRATE IMMUNITY; PERIPLANETA-AMERICANA; RECOGNITION MOLECULES; SELF-INCOMPATIBILITY; NATURAL-POPULATIONS; GEODIA-CYDONIUM; NICOTIANA-ALATA	Species-specific cell recognition in sponges, the oldest living metazoans, is based on a proteoglycan-like aggregation factor. We have screened individual sponge cDNA libraries, identifying multiple related forms for the aggregation factor core protein (MAFp3). Northern blots show the presence in several human tissues of transcripts strongly binding a MAFp3-specific probe. The open reading frame for MAFp3 is not interrupted in the 5' direction, revealing variable protein sequences that contain numerous introns equally spaced. We have studied tissue histocompatibility within a sponge population, finding 100% correlation between rejection behavior and the individual-specific restriction fragment length polymorphism pattern using aggregation factor-related probes. PCR amplifications with specific primers showed that at least some of the MAFp3 forms are allelic and distribute in the population used. A pronounced polymorphism is also observed when analyzing purified aggregation factor in polyacrylamide gels. Protease digestion of the polymorphic glycosaminoglycan-containing bands indicates that glycans are also responsible for the variability. The data presented reveal a high polymorphism of aggregation factor components, which matches the elevated sponge alloincompatibility, suggesting an involvement of the cell adhesion system in sponge allogeneic reactions.	MARINE BIOL LAB, WOODS HOLE, MA 02543 USA	Marine Biological Laboratory - Woods Hole	FernandezBusquets, X (corresponding author), FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND.		Fernàndez-Busquets, Xavier/K-1323-2014	Fernàndez-Busquets, Xavier/0000-0002-4622-9631				AHO S, 1993, P NATL ACAD SCI USA, V90, P7288, DOI 10.1073/pnas.90.15.7288; AYALA FJ, 1978, SCI AM, V239, P56, DOI 10.1038/scientificamerican0978-56; BERGQUIST PR, 1978, SPONGES, P202; BERTHEUSSEN K, 1979, EXP CELL RES, V120, P373, DOI 10.1016/0014-4827(79)90397-5; BIGGER CH, 1980, BIOL BULL, V159, P117, DOI 10.2307/1541013; BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; BODMER WF, 1972, NATURE, V237, P139, DOI 10.1038/237139a0; BURNET FM, 1971, NATURE, V232, P230, DOI 10.1038/232230a0; CHENG TC, 1970, J INVERTEBR PATHOL, V15, P177, DOI 10.1016/0022-2011(70)90232-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFARO KA, 1977, SCIENCE, V197, P1389, DOI 10.1126/science.331476; COOPER EL, 1992, SCAND J IMMUNOL, V35, P247, DOI 10.1111/j.1365-3083.1992.tb02857.x; COOPER EL, 1969, J EXP ZOOL, V171, P69, DOI 10.1002/jez.1401710110; COOPER EL, 1990, BIOSCIENCE, V40, P720, DOI 10.2307/1311503; COOPER EL, 1969, SCIENCE, V166, P1414, DOI 10.1126/science.166.3911.1414; CURTIS ASG, 1982, TRANSPLANTATION, V33, P127, DOI 10.1097/00007890-198202000-00005; CURTIS ASG, 1971, J EMBRYOL EXP MORPH, V26, P295; DANSKA JS, 1990, INT IMMUNOL, V2, P796, DOI 10.1093/intimm/2.9.795; DESUTTER D, 1979, DEV COMP IMMUNOL, V3, P389, DOI 10.1016/S0145-305X(79)80036-1; EDELMAN GM, 1982, P NATL ACAD SCI-BIOL, V79, P7036, DOI 10.1073/pnas.79.22.7036; EDELMAN GM, 1987, IMMUNOL REV, V100, P11, DOI 10.1111/j.1600-065X.1987.tb00526.x; EXPOSITO JY, 1991, J BIOL CHEM, V266, P21923; FernandezBusquets X, 1996, J BIOL CHEM, V271, P23558, DOI 10.1074/jbc.271.38.23558; FLAJNIK MF, 1994, CIBA F SYMP, V186, P224; FUKE MT, 1985, BIOL BULL-US, V169, P631, DOI 10.2307/1541305; GEORGE JF, 1987, TRANSPLANTATION, V43, P514, DOI 10.1097/00007890-198704000-00012; GROSBERG RK, 1986, NATURE, V322, P456, DOI 10.1038/322456a0; HANSON AN, 1983, ANAL BIOCHEM, V130, P32, DOI 10.1016/0003-2697(83)90646-2; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HILDEMAN.WH, 1972, TRANSPLANTATION, V14, P624, DOI 10.1097/00007890-197211000-00015; HILDEMANN WH, 1980, TRANSPLANTATION, V30, P297, DOI 10.1097/00007890-198010000-00012; HILDEMANN WH, 1979, SCIENCE, V204, P420, DOI 10.1126/science.441730; HOOD L, 1985, CELL, V40, P225, DOI 10.1016/0092-8674(85)90133-3; HOWCROFT TK, 1987, TRANSPLANTATION, V44, P129, DOI 10.1097/00007890-198707000-00026; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; HUMPHREYS T, 1994, IMMUNOL TODAY, V15, P316, DOI 10.1016/0167-5699(94)90079-5; HUMPHREYS T, 1994, ANN NY ACAD SCI, V712, P342, DOI 10.1111/j.1749-6632.1994.tb33590.x; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KELLY KL, 1992, J EXP ZOOL, V262, P202, DOI 10.1002/jez.1402620210; KLEIN J, 1989, SCAND J IMMUNOL, V29, P499, DOI 10.1111/j.1365-3083.1989.tb01152.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBBOCK R, 1980, P NATL ACAD SCI-BIOL, V77, P6667, DOI 10.1073/pnas.77.11.6667; MARCHALONIS JJ, 1994, ANN NY ACAD SCI, V712, P1; MARCHALONIS JJ, 1990, BIOSCIENCE, V40, P758, DOI 10.2307/1311509; MATSUNAGA T, 1987, SCAND J IMMUNOL, V25, P485, DOI 10.1111/j.1365-3083.1987.tb02220.x; MCCOY J P JR, 1991, Glycobiology, V1, P321, DOI 10.1093/glycob/1.4.321; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; MOSCONA AA, 1968, DEV BIOL, V18, P250, DOI 10.1016/0012-1606(68)90035-3; MUCHMORE AV, 1987, J IMMUNOL, V138, P2547; MUKAI H, 1975, P JPN ACAD, V51, P44, DOI 10.2183/pjab1945.51.44; MULLER WEG, 1981, EUR J BIOCHEM, V116, P573, DOI 10.1111/j.1432-1033.1981.tb05374.x; MULLER WEG, 1978, DIFFERENTIATION, V10, P45, DOI 10.1111/j.1432-0436.1978.tb00944.x; MULLER WEG, 1973, EXP CELL RES, V80, P95, DOI 10.1016/0014-4827(73)90279-6; NEIGEL JE, 1985, EVOLUTION, V39, P724, DOI 10.1111/j.1558-5646.1985.tb00415.x; Oka H., 1957, Proceedings of the Japan Academy, V33, P657; OTTILIE S, 1992, ONCOGENE, V7, P1625; OXLEY D, 1995, GLYCOBIOLOGY, V5, P517, DOI 10.1093/glycob/5.5.517; Pancer Z, 1996, CELL ADHES COMMUN, V4, P327, DOI 10.3109/15419069609010776; PFEIFER K, 1993, J CELL SCI, V106, P545; PIMLOTT NJG, 1986, J IMMUNOL, V137, P2455; RATCLIFFE NA, 1985, INT REV CYTOL, V97, P183, DOI 10.1016/S0074-7696(08)62351-7; REINISCH CL, 1989, IMMUNOL TODAY, V10, P278, DOI 10.1016/0167-5699(89)90142-4; RINKEVICH B, 1993, BIOL BULL, V184, P79, DOI 10.2307/1542381; ROTHBARD JB, 1982, J BIOL CHEM, V257, P1064; ROTHENBERG BE, 1978, DEV COMP IMMUNOL, V2, P23, DOI 10.1016/S0145-305X(78)80022-6; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; SAJDERA S, 1969, J BIOL CHEM, V244, P77; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; Schaecke Heike, 1994, Journal of Molecular Recognition, V7, P273, DOI 10.1002/jmr.300070406; SCHLUTER SF, 1994, ANN NY ACAD SCI, V712, P74, DOI 10.1111/j.1749-6632.1994.tb33563.x; SCOFIELD VL, 1982, NATURE, V295, P499, DOI 10.1038/295499a0; SEEGER MA, 1988, CELL, V55, P589, DOI 10.1016/0092-8674(88)90217-6; SMITH LC, 1992, IMMUNOL TODAY, V13, P356, DOI 10.1016/0167-5699(92)90172-4; SOLECAVA AM, 1991, BIOL J LINN SOC, V44, P65, DOI 10.1111/j.1095-8312.1991.tb00607.x; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; SPILLMANN D, 1995, J BIOL CHEM, V270, P5089, DOI 10.1074/jbc.270.10.5089; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; THEODOR JL, 1970, NATURE, V227, P690, DOI 10.1038/227690a0; Van de Vyver G., 1975, Transactions Congr int Un Game Biol, V10, P123; van de Vyver G., 1970, Annls Embryol. Morphogen., V3, P251; Varner JA, 1996, J BIOL CHEM, V271, P16119; Weissman I L, 1988, Int Rev Immunol, V3, P397, DOI 10.3109/08830188809051207; WEISSMAN IL, 1990, IMMUNOL REV, V113, P227, DOI 10.1111/j.1600-065X.1990.tb00043.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS AF, 1988, IMMUNOGENETICS, V27, P265, DOI 10.1007/BF00376121; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554; WOODWARD JR, 1992, GLYCOBIOLOGY, V2, P241, DOI 10.1093/glycob/2.3.241; WYMAN AR, 1980, P NATL ACAD SCI-BIOL, V77, P6754, DOI 10.1073/pnas.77.11.6754; Yin CQ, 1996, BIOL BULL, V191, P159, DOI 10.2307/1542919	94	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27839	27847		10.1074/jbc.272.44.27839	http://dx.doi.org/10.1074/jbc.272.44.27839			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346930	hybrid			2022-12-27	WOS:A1997YD47300056
J	Kawaguchi, T; Qin, L; Shimomura, T; Kondo, J; Matsumoto, K; Denda, K; Kitamura, N				Kawaguchi, T; Qin, L; Shimomura, T; Kondo, J; Matsumoto, K; Denda, K; Kitamura, N			Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MESSENGER-RNA; MOLECULAR-CLONING; CDNA; GLYCOSYLATION; SIMILARITY; MITOGEN; DOMAINS; CELLS	Hepatocyte growth factor (HGF) activator is a serine protease responsible for proteolytic activation of HGF in response to tissue injury and thus plays an important role in the regulation of biological functions of HGF in regenerating tissue, We previously purified an inhibitor of HGF activator (HGF activator inhibitor type 1, HAI-1) from the conditioned medium of a human stomach carcinoma cell line MKN45 and cloned its cDNA, HAI-1 is a novel member of the Kunitz family of serine protease inhibitors, In the present study, we purified a second type of HGF activator inhibitor (HAI-2) from the conditioned medium of MKN45 cells and molecularly cloned its cDNk The cDNA sequence revealed that HAI-2 is derived from a precursor protein of 252 amino acids and contains two Kunitz domains, indicating that HAI-2 is also a member of the Kunitz family of serine protease inhibitors, The primary translation product of HAI-S has a hydrophobic sequence in the COOH-terminal region, suggesting that, like HAI-1, HAI-2 is produced in a membrane-associated form and secreted in a proteolytically truncated form, Because HAI-2 and HAI-1 are potent inhibitors specific for HGF activator, they may be involved in regulation of proteolytic activation of HGF in injured tissues.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; MITSUBISHI CHEM CORP,YOKOHAMA RES CTR,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical								BIELINSKA M, 1989, J BIOL CHEM, V264, P17113; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; DUBE S, 1988, J BIOL CHEM, V263, P17516; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; KATAOKA H, 1989, VIRCHOWS ARCH B, V57, P157, DOI 10.1007/BF02899077; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MURAYAMA T, 1991, VIRCHOWS ARCH B, V60, P263, DOI 10.1007/BF02899556; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; Okajima A, 1997, HEPATOLOGY, V25, P97, DOI 10.1002/hep.510250118; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAILER JP, 1990, TRENDS BIOCHEM SCI, V15, P435; SAITO F, 1995, BIOCHEM BIOPH RES CO, V210, P703, DOI 10.1006/bbrc.1995.1716; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; SINHA S, 1990, J BIOL CHEM, V265, P8983; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; WEST CM, 1986, MOL CELL BIOCHEM, V72, P3; WUN TC, 1988, J BIOL CHEM, V263, P6001	28	166	182	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27558	27564		10.1074/jbc.272.44.27558	http://dx.doi.org/10.1074/jbc.272.44.27558			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346890	hybrid			2022-12-27	WOS:A1997YD47300016
J	Mu, J; Skurat, AV; Roach, PJ				Mu, J; Skurat, AV; Roach, PJ			Glycogenin-2, a novel self-glucosylating protein involved in liver glycogen biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; PHOSPHORYLATION SITES; MOLECULAR-CLONING; RAT-HEART; SYNTHASE; BIOGENESIS; INITIATION; IDENTIFICATION; REQUIREMENT; MECHANISM	Glycogenin is a self-glucosylating protein involved in the initiation phase of glycogen biosynthesis. A single mammalian gene had been reported to account for glycogen biogenesis in Liver and muscle, the two major repositories of glycogen, We describe the characterization of novel forms of glycogenin, designated glycogenin-2 (GN-2), encoded by a second gene that is expressed preferentially in certain tissues, including liver, heart, and pancreas. Cloning of cDNAs encoding glycogenin-a indicated the existence of multiple species, including three liver forms (GN-2 alpha, GN-2 beta, and GN-2 gamma) generated in part by alternative splicing. Overall, GN-2 has 40-45% identity to muscle glycogenin but is 72% identical over a 200-residue segment thought to contain the catalytic domain. GN-2 expressed in Escherichia coli or COS cells is active in self-glucosylation assays, and self-glucosylated GN-2 can be elongated by skeletal muscle glycogen synthase. Antibodies raised against GN-2 produced in E. coli recognized proteins of M-r similar to 66,000 present in extracts of rat liver and in cultured H4IIEC3 hepatoma cells. In H4IIEC3 cells, most of the GN-2 was present as a free protein but some was covalently associated with glycogen fractions and was only released by treatment with alpha-amylase, H4IIEC3 cells also expressed the muscle form of glycogenin (glycogenin-1), which was attached to a chromatographically separable glycogen fraction.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis				Mu, James/0000-0001-8081-2401	NIDDK NIH HHS [DK27221] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R01DK027221, R56DK027221] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO MD, 1995, FEBS LETT, V359, P110, DOI 10.1016/0014-5793(95)00018-5; ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; BLUMENFELD ML, 1986, EUR J BIOCHEM, V156, P163, DOI 10.1111/j.1432-1033.1986.tb09562.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDER PC, 1988, BIOCHEM INT, V17, P711; CAMICI M, 1982, J BIOL CHEM, V257, P9898; CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; CAO YJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P293, DOI 10.1006/abbi.1995.1295; CAO YJ, 1993, J BIOL CHEM, V268, P14687; CHENG C, 1995, MOL CELL BIOL, V15, P6632; ERCAN N, 1994, J BIOL CHEM, V269, P22328; GANNON MC, 1996, TRENDS GLYCOSCI GLYC, V8, P163; KRISMAN CR, 1975, EUR J BIOCHEM, V52, P117, DOI 10.1111/j.1432-1033.1975.tb03979.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1983, J BIOL CHEM, V258, P710; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MANZELLA S, 1995, ARCH BIOCHEM BIOPHYS, V320, P361, DOI 10.1016/0003-9861(95)90020-9; Mu J, 1996, J BIOL CHEM, V271, P26554, DOI 10.1074/jbc.271.43.26554; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; Preiss J., 1981, BIOL CARBOHYDRATES, V1, P199; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; Roach PJ, 1997, PROG NUCLEIC ACID RE, V57, P289, DOI 10.1016/S0079-6603(08)60284-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; Skurat AV, 1997, EUR J BIOCHEM, V245, P147, DOI 10.1111/j.1432-1033.1997.t01-1-00147.x; SKURAT AV, 1995, DIABETES MELLITUS FU, P213; SMYTHE C, 1989, EUR J BIOCHEM, V183, P205, DOI 10.1111/j.1432-1033.1989.tb14914.x; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1990, EUR J BIOCHEM, V189, P199, DOI 10.1111/j.1432-1033.1990.tb15477.x; STETTEN MR, 1961, J AM CHEM SOC, V83, P2912, DOI 10.1021/ja01474a029; THON VJ, 1993, J BIOL CHEM, V268, P7509; Tolmasky DS, 1996, CELL MOL BIOL, V42, P589; VISKUPIC E, 1992, J BIOL CHEM, V267, P25759; WANG YH, 1986, BIOCHIM BIOPHYS ACTA, V888, P225, DOI 10.1016/0167-4889(86)90025-X; YANG BZ, 1992, J BIOL CHEM, V267, P9294	37	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27589	27597		10.1074/jbc.272.44.27589	http://dx.doi.org/10.1074/jbc.272.44.27589			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346895	hybrid			2022-12-27	WOS:A1997YD47300021
J	Sanchez, X; CousinsHodges, B; Aguilar, T; Gosselink, P; Lu, ZJ; Navarro, J				Sanchez, X; CousinsHodges, B; Aguilar, T; Gosselink, P; Lu, ZJ; Navarro, J			Activation of HIV-1 coreceptor (CXCR4) mediates myelosuppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; LYMPHOCYTE CHEMOATTRACTANT; CLONING; CHEMOKINES; RECEPTOR; SDF-1; 7-TRANSMEMBRANE; INTERLEUKIN-8; PROLIFERATION; LESTR/FUSIN	Chemokines are cytokines that activate and induce the migration of leukocytes. Stroma-derived factor-1 (SDF-1) is a novel chemokine that blocks the entry of T-tropic HIV-1 mediated by fusin/CXCR4/LESTR (leukocyte-derived seven-transmembrane domain receptor). In this work we demonstrate that SDF-1 triggers increases in intracellular calcium and inhibits the proliferation of myeloid progenitor cell line 32D. By contrast, SDF-1 neither triggers a calcium response nor affects the proliferation of the myeloid progenitor cell line 32D GR that is deficient in CXCR4. Responsiveness to SDF-1 was rescued by transfection of 32D-GR cells with a cDNA encoding the human CXCR4. The data indicate that SDF-1 induces myelosuppression by activation of CXCR4. The constitutive production of SDF-1 by bone marrow stromal cells argues for a major role of SDF-1 on the regulation of myelopoiesis.	UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,SEALY CTR MOL SCI,GALVESTON,TX 77555; GENET INST INC,CAMBRIDGE,MA 02140	University of Texas System; University of Texas Medical Branch Galveston				Navarro, Javier/0000-0001-7098-4373	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034031] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 34031] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; BROXMEYER HE, 1995, ANN HEMATOL, V71, P235, DOI 10.1007/s002770050112; BROXMEYER HE, 1993, J IMMUNOL, V150, P3448; DALY TJ, 1995, J BIOL CHEM, V270, P23282, DOI 10.1074/jbc.270.40.23282; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Lu ZJ, 1996, J BIOL CHEM, V271, P5059; METCALF D, 1985, BLOOD, V65, P357; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OTHA M, 1989, PATHOL IMMUNOPATH R, V8, P1; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535	22	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27529	27531		10.1074/jbc.272.44.27529	http://dx.doi.org/10.1074/jbc.272.44.27529			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346884	hybrid			2022-12-27	WOS:A1997YD47300010
J	Yang, Y; Yang, Y; Kovalski, K; Smith, HC				Yang, Y; Yang, Y; Kovalski, K; Smith, HC			Partial characterization of the auxiliary factors involved in apolipoprotein B mRNA editing through APOBEC-1 affinity chromatography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CATALYTIC SUBUNIT; IN-VITRO; CYTIDINE DEAMINASE; PROTEIN; ENZYME; BINDING; COMPLEX; SITE; MUTAGENESIS	APOBEC-1-catalyzed apolipoprotein B (apoB) mRNA editing requires auxiliary factors, but the number and functions of these factors are unknown, We have partially purified the editing activity from extracts of a McArdle cell line overexpressing His(6)-hemagglutinin-tagged, rat APOBEC-1 using metal-chelating affinity chromatography, The 1,200-fold purification achieved by this approach was partially dependent on exogenously added RNA containing a mooring sequence for editosome assembly, Affinity-purified editing activity could be separated by 300 mM NaCl extraction into two fractions, a salt-resistant fraction (editing fraction 1; EF1) and a salt-soluble fraction (EF2). Neither EF1 nor EF2 alone could edit apoB RNA, but when added together they reconstituted full editing activity, Previously identified candidate auxiliary factors including the p66/p44 apoB RNA binding proteins and the presumptive editosome assembly factor p240 were all present in the affinity-purified editing complex, Moreover, virtually all of p66, p240, and APOBEC-1 were present in EF1, whereas p44 was quantitatively recovered in EF2, This is the first demonstration that p66 and p44 can bind to apoB RNA independently of one another. In addition, 100- and 55-kDa apoB RNA cross-linking proteins have been identified in the APOBEC-1 affinity-purified material. RNA competition studies demonstrated that p100, p66, and p55 bound selectively to apoB RNA, whereas p44 had general RNA cross-linking characteristics. The data underscore the multiplicity of auxiliary factors potentially involved in apoB RNA editing and suggest an editosome far more complicated than may have been previously appreciated.	UNIV ROCHESTER, DEPT BIOCHEM & BIOPHYS, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, DEPT PATHOL, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester				Smith, Harold/0000-0001-6257-6791	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043739] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43739] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1217, P65; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1219, P1, DOI 10.1016/0167-4781(94)90240-2; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; FUNAHASHI T, 1995, J LIPID RES, V36, P414; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; INUI Y, 1994, J LIPID RES, V35, P1477; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Mehta A, 1996, J BIOL CHEM, V271, P28294, DOI 10.1074/jbc.271.45.28294; NAGAI K, 1994, RNA PROTEIN INTERACT; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; Oka K, 1997, J BIOL CHEM, V272, P1456, DOI 10.1074/jbc.272.39.24387; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Schock D, 1996, P NATL ACAD SCI USA, V93, P1097, DOI 10.1073/pnas.93.3.1097; SHAH RR, 1991, J BIOL CHEM, V266, P16301; Smith H C, 1993, Semin Cell Biol, V4, P267, DOI 10.1006/scel.1993.1032; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; Smith HC, 1997, RNA, V3, P1105; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; Yang Y, 1996, BIOCHEM BIOPH RES CO, V218, P797, DOI 10.1006/bbrc.1996.0142	30	37	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27700	27706		10.1074/jbc.272.44.27700	http://dx.doi.org/10.1074/jbc.272.44.27700			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346911	hybrid			2022-12-27	WOS:A1997YD47300037
J	Komissarov, AA; Marchbank, MT; Calcutt, MJ; Quinn, TP; Deutscher, SL				Komissarov, AA; Marchbank, MT; Calcutt, MJ; Quinn, TP; Deutscher, SL			Site-specific mutagenesis of a recombinant anti-single-stranded DNA Fab - Role of heavy chain complementarity-determining region 3 residues in antigen interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE DISPLAY LIBRARIES; 3-DIMENSIONAL STRUCTURE; NUCLEIC-ACIDS; ACTIVE-SITE; BINDING; ANTIBODIES; AUTOANTIBODY; AFFINITY; PROTEIN; CONSTRUCTION	The heavy chain complementarity-determining region 3 (HCDR3) of the anti-oligo(dT) recombinant antibody fragment, DNA-1, contributes significantly to antigen binding (Komissarov, A. A., Calcutt, M. J., Marchbank, M. T., Peletskaya, E. N., and Deutscher, S. L. (1996) J. Biol, Chem, 271, 12241-12246), in the present study, the role of separate HCDR3 residues of DNA-1 in interaction with oligo(dT) was elucidated. Based on a molecular model of the combining site, residues at the base (Arg(98) and Asp(108)) and in the middle (Tyr(101)-Arg-Pro-Tyr-Tyr(105)) Of HCDR3 were predicted to support the loop conformation and directly contact the ligand, respectively. Twenty-five site-specific mutants were produced as hexahistidine-tagged proteins, purified, and examined for binding to (dT)(15) using two independent methods, All mutations in the middle of HCDR3 led to either abolished or diminished affinity, Tyr(101) likely participates in hydrogen bonding, while Tyr(104) and Tyr(105) may be involved in aromatic-aromatic interactions with the ligand. The residues Arg(102) and Pro(103) were not as critical as the tyrosines. It is speculated that HCDR3 interacts with the thymines, rather than the phosphates, of the ligand. A 3-fold increase in affinity was observed by mutation of Asp(108) to alanine. The highly conserved Arg(98) and Asp(108) do not appear to form a salt bridge.	UNIV MISSOURI,SCH MED,DEPT BIOCHEM,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047979] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-47979] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; BARBAS SM, 1995, P NATL ACAD SCI USA, V92, P2529, DOI 10.1073/pnas.92.7.2529; BRUMMELL DA, 1993, BIOCHEMISTRY-US, V32, P1180, DOI 10.1021/bi00055a024; CALCUTT MJ, 1993, GENE, V137, P77, DOI 10.1016/0378-1119(93)90254-Z; Calcutt MJ, 1996, GENE, V168, P9, DOI 10.1016/0378-1119(95)00717-2; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CHIEN NC, 1989, P NATL ACAD SCI USA, V86, P5532, DOI 10.1073/pnas.86.14.5532; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; COLLET TA, 1992, P NATL ACAD SCI USA, V89, P10026, DOI 10.1073/pnas.89.21.10026; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; Deutscher SL, 1996, ARCH BIOCHEM BIOPHYS, V333, P207, DOI 10.1006/abbi.1996.0382; EIGENBROT C, 1993, J MOL BIOL, V229, P969, DOI 10.1006/jmbi.1993.1099; EILAT D, 1994, MOL IMMUNOL, V31, P1377, DOI 10.1016/0161-5890(94)90154-6; GULLIVER GA, 1994, J BIOL CHEM, V269, P7934; GULLIVER GA, 1995, BIOCHEMISTRY-US, V34, P5158, DOI 10.1021/bi00015a029; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; Higuchi R., 1990, PCR PROTOCOLS GUIDE; Hoffman RW, 1995, ARTHRITIS RHEUM-US, V38, P1837, DOI 10.1002/art.1780381218; HOROVITZ A, 1987, J MOL BIOL, V196, P733, DOI 10.1016/0022-2836(87)90045-3; JACKSON JR, 1995, J IMMUNOL, V154, P3310; KABAT EA, 1989, P NATL ACAD SCI USA, V85, P6885; Komissarov AA, 1997, ANAL BIOCHEM, V247, P123, DOI 10.1006/abio.1997.2051; Komissarov AA, 1996, J BIOL CHEM, V271, P12241, DOI 10.1074/jbc.271.21.12241; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; MARION TN, 1992, IMMUNOL REV, V128, P123, DOI 10.1111/j.1600-065X.1992.tb00835.x; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; NOVOTNY J, 1990, PROTEINS, V7, P93, DOI 10.1002/prot.340070109; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PANKA DJ, 1988, P NATL ACAD SCI USA, V85, P3080, DOI 10.1073/pnas.85.9.3080; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PEWZNERJUNG Y, 1996, J IMMUNOL, V154, P2198; PISETSKY DS, 1990, ARTHRITIS RHEUM, V33, P153, DOI 10.1002/art.1780330202; POLYMENIS M, 1995, J IMMUNOL, V156, P3065; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; RUMBLEY CA, 1993, J BIOL CHEM, V268, P13667; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; STENZELJOHNSON PR, 1994, BIOCHEMISTRY-US, V33, P14400, DOI 10.1021/bi00252a005; STOLLAR BD, 1994, FASEB J, V8, P337, DOI 10.1096/fasebj.8.3.7511550; STOLLAR BD, 1986, CRC CRIT REV BIOCH, V21, P1; TAN EM, 1989, ADV IMMUNOL, V44, P93; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551	46	13	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26864	26870		10.1074/jbc.272.43.26864	http://dx.doi.org/10.1074/jbc.272.43.26864			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341118	hybrid			2022-12-27	WOS:A1997YC65900014
J	Loudon, RP; Benovic, JL				Loudon, RP; Benovic, JL			Altered activity of palmitoylation-deficient and isoprenylated forms of the G protein-coupled receptor kinase GRK6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; LIGHT-DEPENDENT PHOSPHORYLATION; HETEROTRIMERIC G-PROTEINS; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; RHODOPSIN KINASE; ACTIVATION; FAMILY; IDENTIFICATION; DESENSITIZATION	G protein-coupled receptor kinases (GRKs) utilize diverse mechanisms to associate with the plasma membrane and mediate phosphorylation of agonist-occupied receptors, For example, two members of this family, GRK4 and CRK6, contain C-terminal cysteine residues that are palmitoylated, To address whether the activity and membrane association of GRK6 is regulated by palmitoylation, we overexpressed and characterized wild-type GRK6 and two GRK6 mutants, one with the palmitoylation sites mutated to serines (GRK6-pal(-)) and one containing a C-terminal CAAX motif to promote geranylgeranylation (GRK6-GG). Compared with wildtype GRK6, GRK6-pal(-) had a similar to 5-fold higher K-m and similar to 2-fold lower V-max for phosphorylating rhodopsin, whereas GRRG-GG exhibited a similar to 2-fold lower K, and similar to 14-fold higher V-max for rhodopsin, In contrast, wildtype GRR6 and GRK6-pal(-) displayed similar activity toward the nonreceptor substrate phosvitin, indicating that nonpalmitoylated GRK6 is catalytically active, Wild-type GRK6 and GRK6-GG, but not GRK6-pal(-), also bound significantly to phosphatidylcholine vesicles (36 +/- 3, 79 +/- 4, and 4 +/- 2%, respectively) suggesting that GRK6 activity is dependent upon its ability to interact with the plasma membrane, When assayed in COS-1 cells GRK6-pal(-) promoted minimal agonist-dependent sequestration of the beta(2)-adrenergic receptor, while sequestration was significantly increased in cells expressing either wild-type GRKG or GRK6-GG. These data demonstrate an important functional Link between the ability of GRK6 to bind to the plasma membrane, a process that appears to be regulated by palmitoylation, and its activity toward receptor substrates.	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; GOMEZ J, 1992, MOL BIOL RECEPTORS T, P1; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAGA K, 1992, J BIOL CHEM, V267, P2222; HARGRAVE PA, 1992, MOL BIOL RECEPTORS T, P49; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KIM CM, 1993, J BIOL CHEM, V268, P15412; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUHN H, 1973, BIOCHEMISTRY-US, V12, P2495; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; Loudon RP, 1996, BLOOD, V88, P4547, DOI 10.1182/blood.V88.12.4547.bloodjournal88124547; LUODON RP, 1994, J BIOL CHEM, V269, P22691; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	37	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27422	27427		10.1074/jbc.272.43.27422	http://dx.doi.org/10.1074/jbc.272.43.27422			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341194	hybrid			2022-12-27	WOS:A1997YC65900090
J	Martincic, I; Peralta, ME; Ngsee, JK				Martincic, I; Peralta, ME; Ngsee, JK			Isolation and characterization of a dual prenylated Rab and VAMP2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SYNAPTIC VESICLES; 2-HYBRID SYSTEM; GERANYLGERANYL TRANSFERASE; CA2+-DEPENDENT EXOCYTOSIS; FUNCTIONAL INTERACTION; ENDOPLASMIC-RETICULUM; TARGETING SIGNAL; N-TYPE; YEAST	Rab GTPases have been implicated in intracellular vesicle trafficking. Using the yeast two-hybrid screen, we have isolated a rat clone that interacts with Rab3A as well as with Rab1. The gene encodes a 20.6-kDa protein with two extensive hydrophobic domains and is broadly expressed in all tissues. This protein binds to prenylated Rab GTPases but not to other small Ras like GTPases such as the Rho/Rac family. This prenylated Rab acceptor (PRA1) also binds specifically to the synaptic vesicle protein VAMPS (or synaptobrevin II) but shows no affinity for VAMP1 or cellubrevin in both the yeast two-hybrid system and in vitro binding assays. This specificity resides, in part, in the proline-rich domain of VAMPS as a chimera containing this domain of VAMPS fused to VAMP1 is able to bind to PRA1. The transmembrane domain of VAMPS is also essential as its deletion abolished binding to PRA1. Replacement of the deleted VAMPS transmembrane domain by a CAAX prenylation signal can not restore binding to PRA1. This interaction is therefore distinct from that required for VAMPS binding to either syntaxin or both syntaxin and SNAP-25, Deletion analysis on PRA1 indicates that the critical Rab-and VAMP2-interacting residues reside in two regions: the amino-terminal residues 30-54 and the extreme carboxyl-terminal domain. This dual Rab and VAMPS binding characteristic suggests that PRA1 may serve to link these two protein families in the control of vesicle docking and fusion.	UNIV OTTAWA,LOEB RES INST,DEPT MED & BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; Ottawa Hospital Research Institute								ANDRES DA, 1993, J BIOL CHEM, V268, P1383; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Grote E, 1996, J CELL BIOL, V132, P537, DOI 10.1083/jcb.132.4.537; Hao JC, 1997, J NEUROSCI, V17, P1596; HARPER JW, 1993, CELL, V75, P805; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MIYAZAKI A, 1994, FEBS LETT, V350, P333, DOI 10.1016/0014-5793(94)00804-3; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; OMER CA, 1994, MOL MICROBIOL, V11, P219, DOI 10.1111/j.1365-2958.1994.tb00302.x; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Rose M, 1990, LAB COURSE MANUAL ME; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1995, J BIOL CHEM, V270, P25541, DOI 10.1074/jbc.270.43.25541; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STETTLER O, 1995, EUR J NEUROSCI, V7, P702, DOI 10.1111/j.1460-9568.1995.tb00674.x; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Weber E, 1996, J BIOL CHEM, V271, P6963, DOI 10.1074/jbc.271.12.6963; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; ZHANG FL, 1994, J BIOL CHEM, V269, P3175	51	102	109	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26991	26998		10.1074/jbc.272.43.26991	http://dx.doi.org/10.1074/jbc.272.43.26991			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341137	hybrid			2022-12-27	WOS:A1997YC65900033
J	McCullough, AK; Dodson, ML; Scharer, OD; Lloyd, RS				McCullough, AK; Dodson, ML; Scharer, OD; Lloyd, RS			The role of base flipping in damage recognition and catalysis by T4 endonuclease V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL-DNA GLYCOSYLASE; EXCISION-REPAIR ENZYME; NUCLEOTIDE ANALOG 2-AMINOPURINE; CRYSTAL-STRUCTURE; PYRIMIDINE DIMER; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; KLENOW FRAGMENT; ACTIVE-SITE; MECHANISM	The process of moving a DNA base extrahelical (base flipping) has been shown in the co-crystal structure of a W-induced pyrimidine dimer-specific glycosylase, T4 endonuclease V, with its substrate DNA. Compared with other enzymes known to use base flipping, endonuclease V is unique in that it moves the base opposite the target site extrahelical, rather than moving the target base itself. Utilizing substrate analogs and catalytically inactive mutants of T4 endonuclease V, this study investigates the discrete steps involved in damage recognition by this DNA repair enzyme. Specifically, fluorescence spectroscopy analysis shows that fluorescence changes attributable to base flipping are specific for only the base directly opposite either abasic site analogs or the 5'-thymine of a pyrimidine dimer, and no changes are detected if the S-aminopurine is moved opposite the 3'-thymine of the pyrimidine dimer. Interestingly, base flipping is not detectable with every specific binding event suggesting that damage recognition can be achieved without base flipping. Thus, base flipping does not add to the stability of the specific enzyme-DNA complex but rather induces a conformational change to facilitate catalysis at the appropriate target site, When used in conjunction with structural information, these types of analyses can yield detailed mechanistic models and critical amino acid residues for extrahelical base movement as a mode of damage recognition.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	University of Texas System; University of Texas Medical Branch Galveston; Harvard University			Schärer, Orlando D./AAF-8613-2021; Scharer, Orlando/B-8908-2008	Scharer, Orlando/0000-0003-2425-2715; Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [F32 ES05780-01, R01 ES04091, P30 ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004091, F32ES005780, P30ES006676] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BLOOM LB, 1993, BIOCHEMISTRY-US, V32, P11247, DOI 10.1021/bi00092a039; Cheng XD, 1996, STRUCTURE, V4, P639, DOI 10.1016/S0969-2126(96)00068-8; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOI T, 1992, P NATL ACAD SCI USA, V89, P9420, DOI 10.1073/pnas.89.20.9420; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HOCHSTRASSER RA, 1994, BIOCHEMISTRY-US, V33, P11971, DOI 10.1021/bi00205a036; INAOKA T, 1989, J BIOL CHEM, V264, P2609; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P258; LATHAM KA, 1994, DNA DAMAGE, P181; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; Marquez LA, 1996, J BIOL CHEM, V271, P28903, DOI 10.1074/jbc.271.46.28903; McCullough AK, 1996, J BIOL CHEM, V271, P32147, DOI 10.1074/jbc.271.50.32147; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MORIKAWA K, 1995, J MOL BIOL, V249, P360, DOI 10.1006/jmbi.1995.0302; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PRINCE MA, 1991, J BIOL CHEM, V266, P10686; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; Sastry SS, 1996, BIOCHEMISTRY-US, V35, P15715, DOI 10.1021/bi960729d; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SCHARER OD, 1995, J AM CHEM SOC, V117, P6623, DOI 10.1021/ja00129a039; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; Vassylyev DG, 1997, CURR OPIN STRUC BIOL, V7, P103, DOI 10.1016/S0959-440X(97)80013-9; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; WARD DC, 1969, J BIOL CHEM, V244, P1228	38	61	61	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27210	27217		10.1074/jbc.272.43.27210	http://dx.doi.org/10.1074/jbc.272.43.27210			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341165	hybrid, Green Published			2022-12-27	WOS:A1997YC65900061
J	Schwarz, G; Boxer, DH; Mendel, RR				Schwarz, G; Boxer, DH; Mendel, RR			Molybdenum cofactor biosynthesis - The plant protein Cnx1 binds molybdopterin with high affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVOLVEMENT; REDUCTASE; CINNAMON; GEPHYRIN; LOCI	The molybdenum cofactor is an essential part of all eukaryotic molybdoenzymes. It is a molybdopterin (RIFT) revealing the same core structure in all organisms, The plant protein Cnx1 from Arabidopsis thaliana is involved in the multi step biosynthesis of molybdenum cofactor, Previous studies (Stallmeyer, B., Nerlich, A., Schiemann, J., Brinkmann, H., and Mendel, R, R, (1995) Plant J, 8, 751-762) suggested a function of Cnx1 in a late step of cofactor biosynthesis distal to the formation of MPT, i.e, conversion of MPT into molybdenum cofactor, Here we present the first biochemical evidences confirming this assumption, The protein Cnx1 consists of two domains (E and G) homologous to two distinct Escherichia coli proteins involved in cofactor synthesis. Binding studies with recombinantly expressed and purified Cnx1 and with its single domains revealed a high affinity of the G domain to MPT (kD = 0.1 mu M) with equimolar binding, In contrast, the E domain of Cnx1 binds MPT with lower affinity (kD = 1.6 mu M) and in a cooperative manner (n(H) = 1.5), The entire Cnx1 showed a tight and cooperative MPT binding. Based on these data providing a common link between both domains that matches the previous characterization of plant and bacterial Cnx1 homologous mutants, we present a model for the function of Cnx1.	TECH UNIV CAROLO WILHELMINA BRAUNSCHWEIG,INST BOT,D-38023 BRAUNSCHWEIG,GERMANY; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD 4HN,SCOTLAND	Braunschweig University of Technology; University of Dundee			Schwarz, Guenter/ABE-9643-2021	Schwarz, Guenter/0000-0002-2118-9338				BRAAKSMA FJ, 1973, MUTAT RES, V19, P175; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; Joshi MS, 1996, J BACTERIOL, V178, P4310, DOI 10.1128/jb.178.14.4310-4312.1996; KAMDAR KP, 1994, GENETICS, V137, P791; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; MENDEL RR, 1997, IN PRESS PLANTA; MENDEL RR, 1981, MOL GEN GENET, V18, P395; Muller A. J., 1989, Molecular and genetic aspects of nitrate assimilation., P166; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; STALLMEYER B, 1995, PLANT J, V8, P751, DOI 10.1046/j.1365-313X.1995.08050751.x; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982	15	89	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26811	26814		10.1074/jbc.272.43.26811	http://dx.doi.org/10.1074/jbc.272.43.26811			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341109	hybrid			2022-12-27	WOS:A1997YC65900005
J	Soyombo, AA; Hofmann, SL				Soyombo, AA; Hofmann, SL			Molecular cloning and expression of palmitoyl-protein thioesterase 2 (PPT2), a homolog of lysosomal palmitoyl-protein thioesterase with a distinct substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; INFANTILE TYPE; ENZYME; PURIFICATION; CDNA; SITES	Palmitoyl-protein thioesterase is a lysosomal hydrolase that, removes long chain fatty acyl groups from modified cysteine residues in proteins, Mutations in this enzyme were recently shown to underlie the hereditary neurodegenerative disorder, infantile neuronal ceroid lipofuscinosis, and lipid thioesters derived from acylated proteins were found to accumulate in lymphoblasts from individuals with the disorder. In the current study, we describe the cloning and expression of a second lysosomal thioesterase, palmitoyl-protein thioesterase 2 (PPT2), that shares an 18% identity with palmitoyl-protein thioesterase, Transient expression of a PPT2 cDNA led to the production of a glycosylated lysosomal protein with palmitoyl-CoA hydrolase activity comparable with palmitoyl-protein thioesterase, However, PPT2 did not remove palmitate groups from palmitoylated proteins that are substrates for palmitoyl-protein thioesterase, In cross-correction experiments, PPT2 did not abolish the accumulation of protein-derived lipid thioesters in palmitoyl-protein thioesterase-deficient cell lines, These results indicate that PPT2 is a lysosomal thioesterase that possesses a substrate specificity that is distinct from that of palmitoyl-protein thioesterase.	UNIV TEXAS, SW MED CTR, HAMON CTR THERAPEUT ONCOL RES, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Soyombo, Abigail/0000-0003-0850-2593	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035323] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35323] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BUTOR C, 1995, J CELL SCI, V108, P2213; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; DUNCAN JR, 1993, J NUCL MED, V34, P1728; HALTIA M, 1973, ACTA NEUROPATHOL, V26, P157, DOI 10.1007/BF00697751; HALTIA M, 1973, J NEUROL SCI, V18, P269, DOI 10.1016/0022-510X(73)90076-2; HARLOW E, 1988, ANTIBODIES LABORATOR, P61; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; HIGA HH, 1989, J BIOL CHEM, V264, P19435; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAWSON DM, 1994, BIOCHEMISTRY-US, V33, P9382, DOI 10.1021/bi00198a003; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MORREAU H, 1989, J BIOL CHEM, V264, P20655; NAGGERT J, 1988, J BIOL CHEM, V263, P1146; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; SAMBROOK J, 1989, MOL CLONING LAB MENA; SAVUKOSKI M, 1994, AM J HUM GENET, V55, P965; SCHLESINGER MJ, 1992, LIPID MODIFICATIONS, P1; Schriner JE, 1996, GENOMICS, V34, P317, DOI 10.1006/geno.1996.0292; Sharp JD, 1997, HUM MOL GENET, V6, P591, DOI 10.1093/hmg/6.4.591; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TOLLERSRUD OK, 1989, BIOCHEM J, V260, P101, DOI 10.1042/bj2600101; Verkruyse LA, 1996, J BIOL CHEM, V271, P15831, DOI 10.1074/jbc.271.26.15831; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	33	76	79	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27456	27463		10.1074/jbc.272.43.27456	http://dx.doi.org/10.1074/jbc.272.43.27456			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341199	hybrid			2022-12-27	WOS:A1997YC65900095
J	Tagliavacca, L; Moon, N; Dunham, WR; Kaufman, RJ				Tagliavacca, L; Moon, N; Dunham, WR; Kaufman, RJ			Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER-TRANSPORTING ATPASE; PORCINE FACTOR-VIII; FACTOR-V; MAMMALIAN-CELLS; MENKES DISEASE; ISOLATED SUBUNITS; CANDIDATE GENE; PROCOAGULANT ACTIVITY; BLUE OXIDASES; CERULOPLASMIN	Coagulation factor VIII (FVIII) is a heterodimer consisting of a light chain of 80 kDa (domains A3-C1-C2) in a metal ion-dependent association with a 220-kDa heavy chain (domains A1-A2-B). The nature of the metal ion-dependent association be between the heavy and light chains was investigated using atomic absorption spectroscopy, electron paramagnetic resonance spectroscopy (EPR), and site-directed mutagenesis and expression of the FVIII cDNA, Whereas copper ion was not detected in intact recombinant FVIII, EDTA dissociation of the chains yielded an EPR signal consistent with 1 mol of Cu(I)/mol of active protein, supporting the hypothesis that a single molecule of reduced copper ion is hurled within intact FVIII and is released and oxidized upon treatment with EDTA. Cu(I), and not Cu(II), was able to reconstitute FVIII activity from dissociated chains, demonstrating a requirement for Cu(I) in FVIII function, Three potential copper ion binding sites exist within FVIII: one type-2 site and two type-1 sites. The importance of these potential copper ion ligands was tested by studying the effect of site-directed mutants. Of the two histidines that compose the type-a binding site, the His-1957 --> Ala mutant displayed secretion, light and heavy chain assembly, and activity similar to wild-type FVIII, while mutant His-99 --> Ala was partially defective for secretion and had low levels of heavy and light chain association and activity, In contrast, FVIII: having the mutation Cys-310 --> Ser within the type-1 copper binding site in the Al domain was inactive and partially defective for secretion from the cell, and the heavy and light chains of the secreted protein were not associated, Mutant Cys-2000 --> Ser within the A3 domain displayed secretion, assembly, and activity similar to that for wildtype FVIII. These results support the hypothesis that Cu(I) is buried within the type-1 copper binding site within the A1 domain and is required for FVIII chain association and activity.	UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NHLBI NIH HHS [HL52173] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; BIHOREAU N, 1994, EUR J BIOCHEM, V222, P41, DOI 10.1111/j.1432-1033.1994.tb18839.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUWER M, 1992, BIOCHEMISTRY-US, V31, P4096, DOI 10.1021/bi00131a028; CANTERS GW, 1993, FEBS LETT, V325, P39, DOI 10.1016/0014-5793(93)81410-2; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CIRIOLO MR, 1990, J BIOL CHEM, V265, P11030; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; Erlich H.A., 1989, PCR TECHNOLOGY PRINC; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FREEDMAN JH, 1989, J BIOL CHEM, V264, P5598; HUNZIKER PE, 1985, TOPICS MOL STRUCTURA, V7, P149; JENNY RJ, 1987, P NATL ACAD SCI USA, V81, P390; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MALKIN R, 1970, ADV ENZYMOL REL S BI, V33, P177; MALMSTROM BG, 1982, ANNU REV BIOCHEM, V51, P21, DOI 10.1146/annurev.bi.51.070182.000321; MANN KG, 1984, J BIOL CHEM, V259, P2949; MARQUETTE KA, 1995, J BIOL CHEM, V270, P10297, DOI 10.1074/jbc.270.17.10297; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; Musci G, 1996, J BIOL CHEM, V271, P1972, DOI 10.1074/jbc.271.4.1972; NORDFANG O, 1989, EUR J HAEMATOL, V43, P1; NORDFANG O, 1988, J BIOL CHEM, V263, P1115; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; Pipe SW, 1996, J BIOL CHEM, V271, P25671, DOI 10.1074/jbc.271.41.25671; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; PITTMAN DD, 1992, BLOOD, V79, P389; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; RYDEN L, 1982, P NATL ACAD SCI-BIOL, V79, P6767, DOI 10.1073/pnas.79.22.6767; RYDEN LG, 1993, J MOL EVOL, V36, P41, DOI 10.1007/BF02407305; SCHEINBERG IH, 1984, MAJOR PROBLEMS INT A, V22; Sudhakar K, 1996, J BIOL CHEM, V271, P23015, DOI 10.1074/jbc.271.38.23015; Swaroop M, 1997, J BIOL CHEM, V272, P24121, DOI 10.1074/jbc.272.39.24121; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P390, DOI 10.1073/pnas.81.2.390; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WISE RJ, 1991, J BIOL CHEM, V266, P21948; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018; ZATLOUKAL K, 1994, P NATL ACAD SCI USA, V91, P5148, DOI 10.1073/pnas.91.11.5148	52	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27428	27434		10.1074/jbc.272.43.27428	http://dx.doi.org/10.1074/jbc.272.43.27428			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341195	hybrid			2022-12-27	WOS:A1997YC65900091
J	Wang, D; Sul, HS				Wang, D; Sul, HS			Upstream stimulatory factor binding to the E-box at -65 is required for insulin regulation of the fatty acid synthase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; GLUCOSE RESPONSE COMPLEX; MAJOR LATE PROMOTER; PHOSPHOENOLPYRUVATE CARBOXYKINASE; GENE-EXPRESSION; HORMONAL-REGULATION; PROTEIN-KINASE; DNA; IDENTIFICATION; FAMILY	Fatty acid synthase (FAS) plays a central role in de novo lipogenesis in mammals. We have shown that FAS transcription rate is induced dramatically when fasted animals are refed with a high carbohydrate diet or when streptozotocin-diabetic mice are given insulin, We also reported that FAS gene transcription was up regulated by insulin through the proximal promoter region from -71 to -50 and that upstream stimulatory factors (USFs), including USF1 and USF2, interact with this region in vitro, In the present study, by using site-directed mutagenesis of the -71/-50 region and correlating functional assays of the mutated promoter with USF binding activities, we demonstrate that the -65/-60 E-box motif (5'-CATGTG-3') is functionally required for insulin regulation and that USFs are in vivo components of the insulin response complex, Mutation of the -65/-60 E-box sequence abolished insulin response in both transiently and stably transfected 3T3-L1 adipocytes in the -2.1 kb promoter context, which contains all the necessary regulatory elements of the promoter based on our previous transgenic mice studies, and in the minimal -67 promoter context, Gel mobility shift assays demonstrated that USFs can no longer bind to the -71/-50 promoter region when the E-box is mutated. Cotransfection of USF1 and USF2 expression vectors with the FAS promoter-luciferase reporter constructs increased insulin-stimulated FAS promoter activity, Moreover, cotransfection of dominant negative USF1 and USF2 mutants lacking the DNA binding domain inhibited the insulin stimulation of the FAS promoter activity, On the other hand, site-directed mutagenesis of the -65/-60 E-box surrounding sequences within the overlapped tandem copies of sterol regulatory element-binding protein (SREBP) binding sites prevented SREBP from binding to -71/-50 promoter region in vitro but had no effect on insulin regulation of the FAS promoter in vivo, When rat liver nuclear extracts were used in gel mobility shift assays, only USF-containing protein-DNA complexes that can be supershifted by specific USF antibodies were observed, These results demonstrate that upstream stimulatory factor binding to the E-box at -65 is required for insulin regulation of the fatty acid synthase promoter.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Han, Zaiqi/AAI-2233-2019		NIDDK NIH HHS [DK-36264] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036264] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; DATTA PK, 1995, J BIOL CHEM, V270, P8637, DOI 10.1074/jbc.270.15.8637; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Ghosh AK, 1997, ONCOGENE, V14, P589, DOI 10.1038/sj.onc.1200866; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; KOZLOWSKI MT, 1991, DEV BIOL, V148, P625, DOI 10.1016/0012-1606(91)90280-G; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LIU ZR, 1993, J BIOL CHEM, V268, P12787; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; Mezey E, 1993, Alcohol Alcohol Suppl, V2, P57; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Soncini M, 1995, J BIOL CHEM, V270, P30339, DOI 10.1074/jbc.270.51.30339; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; Wang D, 1997, BIOTECHNIQUES, V22, P70, DOI 10.2144/97221bm14; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	39	126	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26367	26374		10.1074/jbc.272.42.26367	http://dx.doi.org/10.1074/jbc.272.42.26367			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334210	hybrid			2022-12-27	WOS:A1997YB13900044
J	Kaneto, H; Miyagawa, J; Kajimoto, Y; Yamamoto, K; Watada, H; Umayahara, Y; Hanafusa, T; Matsuzawa, Y; Yamasaki, Y; Higashiyama, S; Taniguchi, N				Kaneto, H; Miyagawa, J; Kajimoto, Y; Yamamoto, K; Watada, H; Umayahara, Y; Hanafusa, T; Matsuzawa, Y; Yamasaki, Y; Higashiyama, S; Taniguchi, N			Expression of heparin-binding epidermal growth factor-like growth factor during pancreas development - A potential role of PDX-1 in transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INSULIN GENE; HOMEOBOX FACTOR; FACTOR-I; PROMOTER ELEMENTS; ISLET CELLS; EGF; INDUCTION; PROTEIN; MITOGEN	The development of the pancreas appears to be regulated by various growth factors, We report here the expression of heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) in the developing pancreas, Immunostaining of fetal and neonatal rat pancreata, in which endocrine cells are visible as cell clusters often associated with primitive ducts or ductular cells, revealed that most of the cluster-forming cells and primitive ducts or ductular cells express HB-EGF protein, In contrast, the exocrine pancreas lacked HB-EGF expression, Based on findings that the expression pat tern was similar to that of the homeodomain-containing transcription factor PDX-1 (IDX-1/STF-1/IPF1) and that the regulatory region of the HB-EGF gene contained sequences similar to the PDX-1-binding A element, we examined whether PDX-1 could be a potential activator of HB-EGF gene expression, The results of reporter gene analyses suggested that the HB-EGF gene promoter is PDX-1-responsive and that the activity of the promoter in pancreatic beta cell-derived beta TC1 cells depends on the PDX-1 binding site-like sequences, Gel-mobility shift analyses using an anti-PDX-l antibody indicated that PDX-1 is a specific and dominant binding factor for an A element-like sequence in the HB-EGF gene. These observations suggest the possible involvement of HB-EGF in pancreas development, While PDX-1 is essential for pancreas development, HB-EGF may function as a mediator of PDX-1 and thus be involved in the development of the endocrine pancreas.	OSAKA UNIV,SCH MED,DEPT MED 2,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University	Kaneto, H (corresponding author), OSAKA UNIV,SCH MED,DEPT MED 1,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.		Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968; Watada, Hirotaka/0000-0001-5961-1816				AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; CHEN XR, 1995, J BIOL CHEM, V270, P18285, DOI 10.1074/jbc.270.31.18285; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GUZ Y, 1995, DEVELOPMENT, V121, P11; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; INUI Y, 1994, GASTROENTEROLOGY, V107, P1799, DOI 10.1016/0016-5085(94)90823-0; ITO N, 1994, BIOCHEM BIOPH RES CO, V198, P25, DOI 10.1006/bbrc.1994.1004; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KAJIMOTO Y, 1991, J BIOL CHEM, V266, P9724; KANAKAGANTENBEIN C, 1995, ENDOCRINOLOGY, V136, P3154, DOI 10.1210/en.136.7.3154; KOBRIN MS, 1994, BIOCHEM BIOPH RES CO, V202, P1705, DOI 10.1006/bbrc.1994.2131; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Mashima H, 1996, J CLIN INVEST, V97, P1647, DOI 10.1172/JCI118591; MIETTINEN PJ, 1992, DEVELOPMENT, V114, P833; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OTONKOSKI T, 1994, DIABETES, V43, P947, DOI 10.2337/diabetes.43.7.947; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SANVITO F, 1994, DEVELOPMENT, V120, P3451; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Waguri M, 1997, DIABETES, V46, P1281, DOI 10.2337/diabetes.46.8.1281; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478	36	59	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29137	29143		10.1074/jbc.272.46.29137	http://dx.doi.org/10.1074/jbc.272.46.29137			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360990	hybrid			2022-12-27	WOS:A1997YF68400049
J	Yu, R; Tan, TH; Kong, ANT				Yu, R; Tan, TH; Kong, ANT			Butylated hydroxyanisole and its metabolite tert-butylhydroquinone differentially regulate mitogen-activated protein kinases - The role of oxidative stress in the activation of mitogen-activated protein kinases by phenolic antioxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; N-TERMINAL KINASE-1; C-JUN; MAP KINASE; GROWTH-FACTOR; SYNTHETIC ANTIOXIDANTS; HORSERADISH-PEROXIDASE; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; HYDROGEN-PEROXIDE	Phenolic antioxidant butylated hydroxyanisole (BRA) is a commonly used food preservative with broad biological activities, including protection against acute toxicity of chemicals, modulation of macromolecule synthesis and immune response, induction of phase II detoxifying enzymes, and especially its potential tumor-promoting activities. Understanding the molecular basis underlying these diverse biological actions of BRA is thus of great importance, Here we demonstrate that BRA is capable of activating distinct mitogen-activated protein kinases (MAPKs), extracellular signal-regulated protein kinase 2 (ERK2), and c-Jun N-terminal kinase 1 (JNK1). Activation of ERK2 by BHA was rapid and transient, whereas the JNK1 activation was relatively delayed and persistent. A major metabolite of BHA, tert-butylhydroquinone (tBHQ), also activated ERK2 but weakly stimulated JNK1 activity, Furthermore, tBHQ activation of ERK2 was late and prolonged, showing a kinetics different from that induced by BHA. ERK2 activation by both compounds required the involvement of an upstream signaling kinase MAPK/ERK, kinase (MEK), as evidenced by the inhibitory effect of a MEK inhibitor, PD98059, Pretreatment with N-acetyl-L-cysteine, glutathione, or vitamin E attenuated ERK2 but not JNK1 activation by BHA and tBHQ. Modulation of intracellular H2O2 levels by direct addition of catalase or pretreatment with a catalase inhibitor, aminotriazole, also affected BHA-and tBHQ-stimulated ERK2 activity but not JNK1, indicating the involvement of oxidative stress in the ERK2 activation by these two compounds. However, we did not observe any generation of H2O2 after exposure of cells to BHA or tBHQ using a H2O2-sensitive fluorescent probe, 2',7'-dichlorofluorescein diacetate. Instead, BRA and tBHQ substantially reduced the amount of intracellular H2O2, Furthermore, BHA and tBHQ activation of ERK2 was strongly inhibited by ascorbic acid and a peroxidase inhibitor, sodium azide, suggesting the potential role of phenoxyl radicals and/or their derivatives, Taken together, our results indicate that (i) BHA and its metabolite tBHQ differentially regulate MAPK pathways, and (ii) oxidative stress due to the generation of reactive intermediates, possibly phenoxyl radicals but not H2O2, is responsible for the ERK2 activation by BHA and tBHQ, whereas the JNK1 activation may require a distinct yet unknown mechanism.	UNIV ILLINOIS,CTR PHARMACEUT BIOTECHNOL,DEPT PHARMACEUT & PHARMACODYNAM MC 865,COLL PHARM,CHICAGO,IL 60612; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Baylor College of Medicine			Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021; Kong, Ah-Ng Tony/AAX-2828-2020	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049875, R29GM049172] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ES06887] Funding Source: Medline; NIGMS NIH HHS [R29-GM49172, R01-GM49875] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTILL BD, 1962, J AGR FOOD CHEM, V10, P315, DOI 10.1021/jf60122a015; BENSON AM, 1978, CANCER RES, V38, P4486; BOULIKAS T, 1995, INT J ONCOL, V6, P271; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHA YN, 1978, CANCER RES, V38, P4496; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CLAYSON DB, 1990, ANNU REV PHARMACOL, V30, P441; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; CUMMINGS SW, 1983, J BIOL CHEM, V258, P2315; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EASTMOND DA, 1986, MOL PHARMACOL, V30, P674; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIROSE M, 1987, CARCINOGENESIS, V8, P1555, DOI 10.1093/carcin/8.10.1555; ITO N, 1983, JNCI-J NATL CANCER I, V70, P343; IVERSON F, 1985, CANCER LETT, V26, P43, DOI 10.1016/0304-3835(85)90171-5; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAGAN VE, 1990, ARCH BIOCHEM BIOPHYS, V280, P33, DOI 10.1016/0003-9861(90)90514-Y; KAGAN VE, 1994, BIOCHEMISTRY-US, V33, P9651, DOI 10.1021/bi00198a034; KAHL R, 1989, TOXICOLOGY, V59, P179, DOI 10.1016/0300-483X(89)90056-5; KAHL R, 1984, TOXICOLOGY, V33, P185, DOI 10.1016/0300-483X(84)90038-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LUI Y, 1996, FREE RADICAL BIO MED, V21, P771; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MNSOUR SJ, 1994, SCIENCE, V265, P966; MOLDEUS P, 1982, BIOCHEM PHARMACOL, V31, P1907, DOI 10.1016/0006-2952(82)90496-8; MONROE DH, 1987, TOXICOL APPL PHARM, V90, P401, DOI 10.1016/0041-008X(87)90132-3; NAKAGAWA Y, 1994, EUR J PHARM-ENVIRON, V270, P341, DOI 10.1016/0926-6917(94)90010-8; NERA EA, 1988, TOXICOLOGY, V53, P251, DOI 10.1016/0300-483X(88)90218-1; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; Peters MMCG, 1996, CANCER RES, V56, P1006; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; RAHIMTULA A, 1983, CHEM-BIOL INTERACT, V45, P125, DOI 10.1016/0009-2797(83)90048-0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO DNR, 1989, J BIOL CHEM, V265, P844; REHWOLDT R, 1986, FOOD CHEM TOXICOL, V24, P1039, DOI 10.1016/0278-6915(86)90286-3; ROGERS CG, 1992, MUTAT RES, V280, P17, DOI 10.1016/0165-1218(92)90014-Q; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROSSING D, 1985, TOXICOLOGY, V34, P67, DOI 10.1016/0300-483X(85)90079-4; SAKAI A, 1990, CARCINOGENESIS, V11, P1985, DOI 10.1093/carcin/11.11.1985; SCHILDERMAN PAEL, 1993, CARCINOGENESIS, V14, P347, DOI 10.1093/carcin/14.3.347; SCHILDERMAN PAEL, 1995, CARCINOGENESIS, V16, P507, DOI 10.1093/carcin/16.3.507; SCHILDERMAN PAEL, 1992, CARCINOGENESIS, V13, P585, DOI 10.1093/carcin/13.4.585; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TAJIMA K, 1992, DRUG METAB DISPOS, V20, P816; THOMPSON D, 1988, BIOCHEM PHARMACOL, V37, P2201, DOI 10.1016/0006-2952(88)90582-5; THOMPSON DC, 1989, J BIOL CHEM, V264, P3957; VERHAGEN H, 1991, CHEM-BIOL INTERACT, V80, P109, DOI 10.1016/0009-2797(91)90019-4; VERHAGEN H, 1989, CARCINOGENESIS, V10, P1947, DOI 10.1093/carcin/10.10.1947; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WATTENBERG LW, 1980, CANCER RES, V40, P2820; WATTENBERG LW, 1983, RADIOPROTECTORS ANTI, P461; *WHO, 1987, WHO FOOD ADDITIVE SE, V21, P25; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WURTZEN G, 1986, FOOD CHEM TOXICOL, V24, P1229, DOI 10.1016/0278-6915(86)90311-X; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu R, 1996, CANCER RES, V56, P2954; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5	73	101	101	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28962	28970		10.1074/jbc.272.46.28962	http://dx.doi.org/10.1074/jbc.272.46.28962			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360968	hybrid, Green Submitted			2022-12-27	WOS:A1997YF68400027
J	Destoumieux, D; Bulet, P; Loew, D; VanDorsselaer, A; Rodriguez, J; Bachere, E				Destoumieux, D; Bulet, P; Loew, D; VanDorsselaer, A; Rodriguez, J; Bachere, E			Penaeidins, a new family of antimicrobial peptides isolated from the shrimp Penaeus vannamei (decapoda)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ANTIBACTERIAL PEPTIDE; HORSESHOE-CRAB HEMOCYTES; HONEYBEE APIS-MELLIFERA; AMINO-ACID-SEQUENCE; INSECT DEFENSIN-A; SECONDARY STRUCTURE; INNATE IMMUNITY; CARCINUS-MAENAS; JAPONICUS BATE; SHORE CRAB	We report here the isolation of three members of a new family of antimicrobial peptides from the hemolymph of shrimps Penaeus vannamei in which immune response has not been experimentally induced. The three molecules display antimicrobial activity against fungi and bacteria with a predominant activity against Gram-positive bacteria. The complete sequences of these peptides were determined by a combination of enzymatic cleavages, Edman degradation, mass spectrometry, and cDNA cloning using a hemocyte cDNA library. The mature molecules (50 and 62 residues) are characterized by an NH2-terminal domain rich in proline residues and a COOH-terminal domain containing three intramolecular disulfide bridges. One of these molecules is post-translationally modified by a pyroglutamic acid at the first position. Comparison of the data obtained from the cDNA clones and mass spectrometry showed that two of these peptides are probably COOH-terminally amidated by elimination of a glycine residue. These molecules with no evident homology to other hitherto described antimicrobial peptides were named penaeidins.	UNIV MONTPELLIER 2, IFREMER, CNRS, F-34095 MONTPELLIER, FRANCE; INST BIOL MOL & CELLULAIRE, CNRS, UPR REPONSE IMMUNITAIRE & DEV CHEZ INSECTES 9022, F-67084 STRASBOURG, FRANCE; UNIV STRASBOURG 1, LAB SPECTROMETRIE MASSE BIOORGAN,URA 31,CNRS, FAC CHIM, F-67008 STRASBOURG, FRANCE; ESCUELA SUPER POLITECN LITORAL, CTR NACL ACUICULTURE & INVEST MARINAS, GUAYAQUIL, ECUADOR	Centre National de la Recherche Scientifique (CNRS); Ifremer; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Escuela Superior Politecnica del Litoral			Destoumieux-Garzón, Delphine/O-3328-2014; Bachere, Evelyne/O-6117-2014; BULET, Philippe/C-8557-2014	Destoumieux-Garzón, Delphine/0000-0002-8793-9138; BULET, Philippe/0000-0001-9016-265X; Damarys, Loew/0000-0002-9111-8842; Rodriguez, Jenny/0000-0002-4773-0700				BACHERE E, 1995, FISH SHELLFISH IMMUN, V5, P597, DOI 10.1016/S1050-4648(95)80044-1; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; BULET P, 1991, J BIOL CHEM, V266, P24520; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; BULET P, 1993, J BIOL CHEM, V268, P14893; BURNS CD, 1979, AQUACULTURE, V16, P193, DOI 10.1016/0044-8486(79)90107-8; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1990, EUR J BIOCHEM, V187, P381, DOI 10.1111/j.1432-1033.1990.tb15315.x; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; Charlet M, 1996, J BIOL CHEM, V271, P21808, DOI 10.1074/jbc.271.36.21808; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; CHISHOLM JRS, 1992, J MAR BIOL ASSOC UK, V72, P529, DOI 10.1017/S0025315400059324; COCKLE SM, 1989, J BIOL CHEM, V264, P7788; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; CRISP LM, 1989, MYCOLOGIA, V81, P709, DOI 10.2307/3759875; DIMARCQ JL, 1988, EUR J BIOCHEM, V171, P17, DOI 10.1111/j.1432-1033.1988.tb13752.x; EhretSabatier L, 1996, J BIOL CHEM, V271, P29537, DOI 10.1074/jbc.271.47.29537; FALICK AM, 1993, J AM SOC MASS SPECTR, V4, P882, DOI 10.1016/1044-0305(93)87006-X; FANT F, 1994, P 12 EUR EXPT NMR C; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; FISCHER WH, 1987, P NATL ACAD SCI USA, V84, P3628, DOI 10.1073/pnas.84.11.3628; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Hetru Charles, 1994, P43; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Hubert F, 1996, EUR J BIOCHEM, V240, P302, DOI 10.1111/j.1432-1033.1996.0302h.x; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; ISHIMARU K, 1995, INT J SYST BACTERIOL, V45, P134, DOI 10.1099/00207713-45-1-134; IWANAGA S, 1994, ANN NY ACAD SCI, V712, P102, DOI 10.1111/j.1749-6632.1994.tb33566.x; JAYNES JM, 1993, PLANT SCI, V89, P43, DOI 10.1016/0168-9452(93)90169-Z; KANAI A, 1990, MOL CELL BIOL, V10, P6114, DOI 10.1128/MCB.10.12.6114; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; KOPACEK P, 1993, EUR J BIOCHEM, V213, P591, DOI 10.1111/j.1432-1033.1993.tb17798.x; Landon C, 1996, EUR J BIOCHEM, V236, P395, DOI 10.1111/j.1432-1033.1996.00395.x; LEVASHINA EA, 1995, EUR J BIOCHEM, V233, P694, DOI 10.1111/j.1432-1033.1995.694_2.x; LI ZQ, 1988, FEBS LETT, V231, P299, DOI 10.1016/0014-5793(88)80837-8; Lightner D.V., 1983, CRC HDB MARICULTURE, P289; MIYATA T, 1989, J BIOCHEM, V106, P663, DOI 10.1093/oxfordjournals.jbchem.a122913; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NORELLI JL, 1994, EUPHYTICA, V77, P123, DOI 10.1007/BF02551474; RHOOBUNJONGDE W, 1991, NIPPON SUISAN GAKK, V57, P629, DOI 10.2331/suisan.57.629; RODRIGUEZ J, 1995, J CELL SCI, V108, P1043; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; Schnapp D, 1996, EUR J BIOCHEM, V240, P532, DOI 10.1111/j.1432-1033.1996.0532h.x; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SONG YL, 1993, B I ZOOL ACAD SINICA, V32, P217; SOSERHALL K, 1996, NEW DIRECTIONS INVER, P229; VEGAVILLASANTE F, 1993, PREV VET MED, V17, P271, DOI 10.1016/0167-5877(93)90035-R; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	56	362	409	2	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28398	28406		10.1074/jbc.272.45.28398	http://dx.doi.org/10.1074/jbc.272.45.28398			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353298	Green Published, hybrid			2022-12-27	WOS:A1997YF21900038
J	Weinstein, J				Weinstein, J			Cell cycle-regulated expression, phosphorylation, and degradation of p55Cdc - A mammalian homolog of CDC20/Fizzy/slp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; PROTEIN-KINASE; MITOTIC SPINDLE; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; ANAPHASE TRANSITION; PROMOTING FACTOR; GENE-EXPRESSION; TELOPHASE DISC; CDC20 GENE	p55Cdc is a mammalian protein that shows high homology to the cell cycle proteins Cdc20p of Saccharomyces cerevisiae and the product of the Drosophila fizzy (fly) gene, both of which contain WD repeats and are thought to be required for the metaphase-anaphase transition. The fzy mutants exhibit a metaphase arrest phenotype, which is accompanied by stabilization of cyclins A and B, leading to the hypothesis that fzy function is required for cell cycle-regulated ubiquitin-mediated proteolysis. p55Cdc expression was initiated at the G(1)/S transition and steady state levels of p55Cdc were highest at M and lowest in G(1). Inhibition of the 26 S proteasome prevented both mitotic exit and loss of p55Cdc at the M/G(1) transition, suggesting that p55Cdc degradation was mediated by the cell cycle-regulated proteolytic pathway. Immune complexes of p55Cdc obtained at different cell cycle stages showed a variety of proteins with dramatic differences observed in the pattern of associated proteins during the transition from G(2) to M. Immunolocalization of p55Cdc demonstrated dynamic changes in p55Cdc localization as the cells transit mitosis. p55Cdc appears to act as a regulatory protein interacting with several other proteins, perhaps via its seven WD repeats, at multiple points in the cell cycle.			Weinstein, J (corresponding author), AMGEN INC, 14-1-B, 1840 DEHAVILLAND DR, THOUSAND OAKS, CA 91320 USA.							AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; Clapham DE, 1996, NATURE, V379, P297, DOI 10.1038/379297a0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; COMPTON DA, 1991, J CELL BIOL, V112, P1083, DOI 10.1083/jcb.112.6.1083; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EARNSHAW WC, 1991, CHROMOSOMA, V100, P139, DOI 10.1007/BF00337241; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GORBSKY GJ, 1995, TRENDS CELL BIOL, V5, P143, DOI 10.1016/S0962-8924(00)88968-0; Hall LL, 1996, CANCER RES, V56, P3551; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; Kao CT, 1996, ONCOGENE, V13, P1221; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; MARGOLIS RL, 1993, BIOESSAYS, V15, P201, DOI 10.1002/bies.950150310; MARTINEAU SN, 1995, J CELL BIOL, V131, P191, DOI 10.1083/jcb.131.1.191; MASTRONARDE DN, 1993, J CELL BIOL, V123, P1475, DOI 10.1083/jcb.123.6.1475; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NAGELE R, 1995, SCIENCE, V270, P1831, DOI 10.1126/science.270.5243.1831; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OToole ET, 1997, MOL BIOL CELL, V8, P1, DOI 10.1091/mbc.8.1.1; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Saunders William S., 1993, Trends in Cell Biology, V3, P432, DOI 10.1016/0962-8924(93)90032-V; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; VERNOS I, 1995, TRENDS CELL BIOL, V5, P297, DOI 10.1016/S0962-8924(00)89045-5; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Wheatley SP, 1996, J CELL BIOL, V135, P981, DOI 10.1083/jcb.135.4.981; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201	74	116	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28501	28511		10.1074/jbc.272.45.28501	http://dx.doi.org/10.1074/jbc.272.45.28501			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353311	hybrid			2022-12-27	WOS:A1997YF21900051
J	Xiong, HS; Stanley, BA; Tekwani, BL; Pegg, AE				Xiong, HS; Stanley, BA; Tekwani, BL; Pegg, AE			Processing of mammalian and plant S-adenosylmethionine decarboxylase proenzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT HISTIDINE-DECARBOXYLASE; L-METHIONINE DECARBOXYLASE; ESCHERICHIA-COLI; MESSENGER-RNA; RAT-LIVER; EXPRESSION; PUTRESCINE; SITE; GENE; CDNA	S-Adenosylmethionine decarboxylase (AdoMetDC) is a pyruvoyl enzyme, and the pyruvate is formed in an intramolecular reaction that cleaves a proenzyme precursor and converts a serine residue into pyruvate, The wild type potato AdoMetDC proenzyme processed much faster than the human proenzyme and did not require putrescine for an optimal rate of processing despite the presence of three acidic residues (equivalent to Glu(11), Glu(178), and Glu(256)) that were demonstrated in previous studies to be required for the putrescine activation of human AdoMetDC proenzyme processing (Stanley, B. A., Shantz, L. M., and Pegg, A. E. (1994) J. Biol, Chem. 269, 7901-7907), A fourth residue that is also needed for the putrescine stimulation of human AdoMetDC proenzyme processing was identified in the present studies, and this residue (Asp(174)) is not present in the potato sequence, The site of potato AdoMetDC proenzyme processing was found to be Ser(73) in the conserved sequence, YVLSE (S) under bar S, which is the equivalent of Ser(68) in the human sequence, Replacement of the serine precursor with threonine or cysteine by site-directed mutagenesis in either the potato or the human AdoMetDC proenzyme did not prevent processing but caused a significant reduction in the rate, Although the COOH-terminal regions of the known eukaryotic AdoMetDCs are not conserved, only relatively small truncations of 8 residues from the human protein and 25 residues from the potato proenzyme were compatible with processing. The maximally truncated proteins show no similarity in COOH-terminal amino acid sequence but each contained 46 amino acid residues after the last conserved sequence, suggesting that the length of this section of the protein is essential for maintaining the proenzyme conformation needed for autocatalytic processing.	PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT CELLULAR & MOL PHYSIOL, COLL MED, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health			Stanley, Bruce/R-9856-2019	Stanley, Bruce/0000-0003-1338-2928	NATIONAL CANCER INSTITUTE [R01CA018138, R37CA018138] Funding Source: NIH RePORTER; NCI NIH HHS [CA 18138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIF SAM, 1994, PLANT MOL BIOL, V26, P327, DOI 10.1007/BF00039543; COPPOC GL, 1971, INT J BIOCHEM, V2, P673, DOI 10.1016/0020-711X(71)90058-9; DADara AA, 1996, BIOCHEM J, V320, P519, DOI 10.1042/bj3200519; DEZEURE F, 1989, INT J BIOCHEM, V21, P889, DOI 10.1016/0020-711X(89)90288-7; Dresselhaus T, 1996, PLANT MOL BIOL, V30, P1021, DOI 10.1007/BF00020812; GALLAGHER T, 1993, J MOL BIOL, V230, P516, DOI 10.1006/jmbi.1993.1168; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; HACKERT ML, 1997, IN PRESS COMPREHENSI; HUYNH QK, 1984, J BIOL CHEM, V259, P2826; KAMEJI T, 1987, BIOCHEM J, V243, P285, DOI 10.1042/bj2430285; KASHIWAGI K, 1990, J BIOL CHEM, V265, P22321; Lee MM, 1997, PLANT MOL BIOL, V34, P371, DOI 10.1023/A:1005811229988; LI QX, 1990, J BIOL CHEM, V265, P4111; MACH M, 1986, J BIOL CHEM, V261, P1697; PAJUNEN A, 1988, J BIOL CHEM, V263, P17040; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1984, CELL BIOCHEM FUNCT, V2, P11, DOI 10.1002/cbf.290020105; PERSSON K, 1995, J BIOL CHEM, V270, P5642, DOI 10.1074/jbc.270.10.5642; PULKKA A, 1993, GENOMICS, V16, P342, DOI 10.1006/geno.1993.1195; RECSEI PA, 1984, ANNU REV BIOCHEM, V53, P357, DOI 10.1146/annurev.bi.53.070184.002041; SCHRODER G, 1995, EUR J BIOCHEM, V228, P74, DOI 10.1111/j.1432-1033.1995.tb20231.x; Shao D, 1996, J CELL PHYSIOL, V166, P43; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; Shinga J, 1996, BBA-GENE STRUCT EXPR, V1308, P31, DOI 10.1016/0167-4781(96)00020-6; SHIRAHATA A, 1985, J BIOL CHEM, V260, P9583; STANLEY BA, 1994, BIOCHEM SOC T, V22, P863, DOI 10.1042/bst0220863; STANLEY BA, 1991, J BIOL CHEM, V266, P18502; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; STANLEY BA, 1994, J BIOL CHEM, V269, P7901; STANLEY BA, 1995, POLYAMINES REGULATIO, P27; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; TABOR CW, 1987, J BIOL CHEM, V262, P16037; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; TAYLOR MA, 1992, PLANT MOL BIOL, V20, P641, DOI 10.1007/BF00046449; TEKWANI BL, 1992, BIOCHIM BIOPHYS ACTA, V1130, P221, DOI 10.1016/0167-4781(92)90533-6; VANDERSLICE P, 1988, J BIOL CHEM, V263, P10583; VASNPOELJE PD, 1990, ANN REV BIOCH, V59, P29; YAMANOHA B, 1985, PLANT PHYSIOL, V78, P784, DOI 10.1104/pp.78.4.784; YANG YG, 1991, BIOCHEM BIOPH RES CO, V181, P1181, DOI 10.1016/0006-291X(91)92063-P	39	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28342	28348		10.1074/jbc.272.45.28342	http://dx.doi.org/10.1074/jbc.272.45.28342			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353291	hybrid			2022-12-27	WOS:A1997YF21900031
J	Huang, CS; Ma, WY; Ding, M; Bowden, GT; Dong, ZG				Huang, CS; Ma, WY; Ding, M; Bowden, GT; Dong, ZG			Direct evidence for an important role of sphingomyelinase in ultraviolet-induced activation of c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; ZETA-ISOFORM; CERAMIDE; STRESS; AP-1; ACID; PHOSPHORYLATION; TRANSFORMATION	Sphingomyelinase (SMase) and its product ceramide have recently attracted a great deal of attention because of their possible role in the signal transduction pathway. However, the role of sphingomyelinase in W-induced c-June N-terminal kinase (JNK) activation is still unclear. Thus, we investigated this issue directly using a genetic SMase-deficient (2 similar to 3% residual acid SMase activity) lymphoblast cell line, MS1418. The results showed that while UV irradiation markedly induces JNK activation in a normal human lymphoblast cell line, JY, it induces only weak JNK activation in MS1418 cells. This difference of JNK response to UV irradiation between these two cell lines was further observed in time course and dose response studies. In contrast, 12-0-tetradecanoylphorbol-13 acetate-induced JNK activation could be observed in both JY and MS1418 cells. Furthermore, significant JNK activation can be observed in MS1418 cells by exposure of the cells to SMase or C-2-ceramide, whereas phospholipase A(2) or phospholipase C did not show significant induction of JNK activity, and C-2-dihydroceramide and sphingosine induce only much weaker JNK activation in MS1418 cells than that by C-2-ceramide. These data demonstrated that SMase plays an essential role in UV-induced JNK activation.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912; NIOSH,NIH,MORGANTOWN,WV 26505; UNIV ARIZONA,HLTH SCI CTR,DEPT RADIAT ONCOL,TUCSON,AZ 85724	University of Minnesota System; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); National Institutes of Health (NIH) - USA; University of Arizona; University of Arizona Health Sciences				Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R29CA074916] Funding Source: NIH RePORTER; NCI NIH HHS [1R29CA74916-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; GUBINS E, 1994, MOL CELL BIOL, V14, P906; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; Huang CS, 1996, INT J ONCOL, V8, P389; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RONAI ZA, 1988, J VIROL, V62, P1057, DOI 10.1128/JVI.62.3.1057-1060.1988; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	31	104	106	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27753	27757		10.1074/jbc.272.44.27753	http://dx.doi.org/10.1074/jbc.272.44.27753			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346918	hybrid			2022-12-27	WOS:A1997YD47300044
J	Keyer, K; Imlay, JA				Keyer, K; Imlay, JA			Inactivation of dehydratase [4Fe-4S] clusters and disruption of iron homeostasis upon cell exposure to peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; ESCHERICHIA-COLI; NITRIC-OXIDE; DNA-DAMAGE; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; OXIDATION; ACONITASE; PROTEIN	Phagocytes produce both nitric oxide and superoxide as components of the oxidative defense against pathogens. Neither molecule is likely at physiological concentrations to kill cells. However, two of their reaction products, hydrogen peroxide and peroxynitrite, are strong oxidants, cell-permeant, and toxic. Hydrogen peroxide generates oxidative DNA damage, while the primary mechanism of toxicity of peroxynitrite has not yet been determined. Recent in vitro studies indicated that peroxynitrite is capable of oxidizing the [4Fe-4S] clusters of a family of dehydratases (Hausladen, A., and Fridovich, I. (1994) J. Biol. Chem. 269, 29405-29408; Castro, L., Rodriguez, M., and Radi, R. (1994) J. Biol. Chem. 269, 29409-29415). We demonstrate here that peroxynitrite at 1% of its lethal dose almost fully inactivated the labile dehydratases in Escherichia coli. The rate at which peroxynitrite inactivated the clusters substantially exceeded the rate at which it oxidized thiols or spontaneously decomposed. These results suggest that these dehydratases may be primary targets of peroxynitrite in vivo. Another consequence of the cluster damage was the release of 100 mu m iron into the cytosol. During phagocytosis, this intracellular free iron could increase lethal DNA damage by hydrogen peroxide or protein modification by additional peroxynitrite. In response to peroxynitrite challenges, E. coli rapidly sequestered the intracellular free iron using an undefined scavenging system. The iron-sulfur clusters were more gradually repaired by a process that drew iron from its iron-storage proteins. These are likely to be critical events in the struggle between phagocyte and pathogen.	UNIV ILLINOIS, DEPT MICROBIOL, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign								BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BERNLOHR DA, 1981, BIOCHEMISTRY-US, V20, P5675, DOI 10.1021/bi00523a006; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; BUCHMEIER NA, 1993, MOL MICROBIOL, V7, P933, DOI 10.1111/j.1365-2958.1993.tb01184.x; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CASTRO L, 1994, J BIOL CHEM, V269, P29409; COLMAN RF, 1968, J BIOL CHEM, V243, P2454; CORBIER C, 1992, BIOCHEMISTRY-US, V31, P12532, DOI 10.1021/bi00164a033; CSONKA LN, 1980, J BACTERIOL, V143, P529, DOI 10.1128/JB.143.1.529-530.1980; DALESSIO G, 1971, J BIOL CHEM, V246, P4326; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; Epe B, 1996, NUCLEIC ACIDS RES, V24, P4105, DOI 10.1093/nar/24.21.4105; FLINT D H, 1990, P285; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Flint DH, 1996, J BIOL CHEM, V271, P16068; FRAENKEL DG, 1964, J BIOL CHEM, V239, P2765; FUCHS JA, 1975, J BACTERIOL, V124, P140, DOI 10.1128/JB.124.1.140-148.1975; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; Goldstein S, 1996, FREE RADICAL BIO MED, V21, P965, DOI 10.1016/S0891-5849(96)00280-8; GRUER MJ, 1994, MICROBIOL-SGM, V140, P2531, DOI 10.1099/00221287-140-10-2531; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HILLMAN JD, 1975, J BACTERIOL, V122, P1175, DOI 10.1128/JB.122.3.1175-1179.1975; HUDSON AJ, 1993, EUR J BIOCHEM, V218, P985, DOI 10.1111/j.1432-1033.1993.tb18457.x; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; IMLAY JA, 1992, J BACTERIOL, V174, P953, DOI 10.1128/jb.174.3.953-961.1992; IMLAY JA, 1986, J BACTERIOL, V166, P519, DOI 10.1128/jb.166.2.519-527.1986; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KAO SM, 1985, J BIOL CHEM, V260, P478; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KUO CF, 1987, J BIOL CHEM, V262, P4724; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LIU RH, 1995, MUTAT RES-REV GENET, V339, P73, DOI 10.1016/0165-1110(95)90004-7; LUO YZ, 1994, P NATL ACAD SCI USA, V91, P12438, DOI 10.1073/pnas.91.26.12438; LYNCH RE, 1978, J BIOL CHEM, V253, P1838; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MILLER DM, 1992, ARCH BIOCHEM BIOPHYS, V295, P240, DOI 10.1016/0003-9861(92)90513-V; Miller J. H, 1972, EXPT MOL GENETICS; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; OHNISHI T, 1976, J BIOL CHEM, V251, P2105; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; Reed L.J., 1966, METHOD ENZYMOL, V9, P247; REEVES WJ, 1966, METHOD ENZYMOL, V9, P288; Rutter W.J., 1966, METHODS ENZYMOL, V9, P479; SALGO MG, 1995, BIOCHEM BIOPH RES CO, V210, P1025, DOI 10.1006/bbrc.1995.1759; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; SZABO C, 1995, BIOCHEM BIOPH RES CO, V209, P739, DOI 10.1006/bbrc.1995.1561; THOMSON L, 1995, ARCH BIOCHEM BIOPHYS, V319, P491, DOI 10.1006/abbi.1995.1321; THORNELEY RNF, 1989, BIOCHEM J, V261, P181, DOI 10.1042/bj2610181; TORRIANI A, 1960, BIOCHIM BIOPHYS ACTA, V38, P460, DOI 10.1016/0006-3002(60)91281-6; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; Weitzman PDJ, 1969, METHOD ENZYMOL, V8, P22, DOI 10.1016/0076-6879(69)13009-8; WU JY, 1991, J BACTERIOL, V173, P325, DOI 10.1128/jb.173.1.325-333.1991; YARIV J, 1981, BIOCHEM J, V197, P171, DOI 10.1042/bj1970171	71	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27652	27659		10.1074/jbc.272.44.27652	http://dx.doi.org/10.1074/jbc.272.44.27652			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346904	hybrid			2022-12-27	WOS:A1997YD47300030
J	Bruneau, N; Nganga, A; Fisher, EA; Lombardo, D				Bruneau, N; Nganga, A; Fisher, EA; Lombardo, D			O-glycosylation of C-terminal tandem-repeated sequences regulates the secretion of rat pancreatic bile salt-dependent lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL ESTERASE GENE; LINKED GLYCOSYLATION; STIMULATED LIPASE; PEST SEQUENCES; CDNA CLONING; PROTEIN; EXPRESSION; HYDROLASE; CELLS; PURIFICATION	Amino acid sequences rich in Pro, Glu, Ser, and Thr (PEST) are common to rapidly degraded proteins (Rogers, S., Wells, R. & Rechsteiner, M. (1986) Science 234, 364-368), On pancreatic bile salt-dependent lipase (BSDL), PEST sequences are present in the C-terminal region of the enzyme to which is associated the O-glycosylation, We have postulated that the O-glycosylation of BSDL may contribute to mask PEST sequences and to trigger the secretion of this enzyme instead of its delivery into a degradative pathway (Bruneau, N., and Lombardo, D. (1995) J. Biol. Chem. 270, 13524-13525). To further examine the role of the O-linked glycosylation on BSDL metabolism, rat pancreatic BSDL cDNA was stably transfected into two Chinese hamster ovary (CHO) cell lines, the CHO K1 wild-type line and the O-glycosylation defective CHO IdlD line. In these latter cells, O-glycosylation can be reversibly modulated by culture conditions. Results indicate that the rate of BSDL synthesis by transfected CHO K1 or CHO IdlD cells reflects, independently of culture conditions, the amount of mRNA specific for BSDL present in these transfected cells. Nevertheless, the rate of secretion of the enzyme depends upon cell culture conditions and increases with the cell capability to O-glycosylate C-terminal tandem-repeated sequences, Immunoprecipitation experiments performed on cell lysates suggested that a rapid degradation of BSDL occurred particularly when transfected CHO IdlD cells were cultured under non-permissive conditions. We further showed that BSDL secreted by CHO IdlD cells grown under nonpermissive conditions that normally prevent O-glycosylation incorporated galactose and was reactive with peanut agglutinin, which recognizes the core structure of O-linked glycans, We concluded that the BSDL expressed by CHO IdlD cells grown under non-permissive conditions was rapidly degraded but a fraction of the enzyme was allowed to O-glycosylate and consequently was secreted.	INSERM, U260, UNITE RECH PHYSIOPATHOL REGULAT HORMONONUTR, F-13385 MARSEILLE, FRANCE; MT SINAI SCH MED, CARDIOVASC INST, NEW YORK, NY 10021 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Icahn School of Medicine at Mount Sinai			Bruneau, Nadine/O-2100-2016	Bruneau, Nadine/0000-0002-1523-3128; Fisher, Edward/0000-0001-9802-143X				ABOUAKIL N, 1993, J BIOL CHEM, V268, P25755; ABOUAKIL N, 1988, BIOCHIM BIOPHYS ACTA, V961, P299, DOI 10.1016/0005-2760(88)90077-X; BARNES JA, 1995, MOL CELL BIOCHEM, V149, P17, DOI 10.1007/BF01076559; BRUNEAU N, 1995, EUR J BIOCHEM, V233, P209, DOI 10.1111/j.1432-1033.1995.209_1.x; BRUNEAU N, 1995, J BIOL CHEM, V270, P13524, DOI 10.1074/jbc.270.22.13524; CALAME KB, 1975, ARCH BIOCHEM BIOPHYS, V168, P57, DOI 10.1016/0003-9861(75)90227-1; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DIPERSIO LP, 1994, BIOCHEMISTRY-US, V33, P3442, DOI 10.1021/bi00177a038; DOOLITTLE MH, 1991, ANAL BIOCHEM, V195, P364, DOI 10.1016/0003-2697(91)90342-Q; FONTAINE RN, 1991, BIOCHEMISTRY-US, V30, P7008, DOI 10.1021/bi00242a028; GJELLESVIK DR, 1992, BIOCHIM BIOPHYS ACTA, V1124, P123, DOI 10.1016/0005-2760(92)90088-D; GJELLESVIK DR, 1994, EUR J BIOCHEM, V226, P603, DOI 10.1111/j.1432-1033.1994.tb20086.x; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HANSSON L, 1993, J BIOL CHEM, V268, P26692; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOLTSBERG FW, 1995, BIOCHEM J, V309, P141, DOI 10.1042/bj3090141; HUANG Y, 1991, J BIOL CHEM, V266, P6720; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; KUMAR BV, 1992, BIOCHEMISTRY-US, V31, P6077, DOI 10.1021/bi00141a017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1984, J BIOL CHEM, V259, P4616; LOMBARDO D, 1978, BIOCHIM BIOPHYS ACTA, V527, P142, DOI 10.1016/0005-2744(78)90263-2; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P147, DOI 10.1016/0005-2744(80)90050-9; LOOMES KM, 1995, EUR J BIOCHEM, V230, P607; MAS E, 1993, BIOCHEM J, V289, P609, DOI 10.1042/bj2890609; Mas E, 1997, GLYCOBIOLOGY, V7, P745, DOI 10.1093/glycob/7.6.745; MORLOCKFITZPATRICK KR, 1995, P SOC EXP BIOL MED, V208, P186; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REUE K, 1991, J LIPID RES, V32, P267; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUDANI S, 1994, EUR J CELL BIOL, V65, P132; ROUDANI S, 1995, BBA-GENE STRUCT EXPR, V1264, P141, DOI 10.1016/0167-4781(95)00141-3; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WANG CS, 1995, BIOCHEMISTRY-US, V34, P10639, DOI 10.1021/bi00033a039; WINKLER KE, 1992, BIOCHIM BIOPHYS ACTA, V1126, P151; YE SQ, 1993, J BIOL CHEM, V268, P8497; ZOLFAGHARI R, 1993, J BIOL CHEM, V268, P13532	40	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27353	27361		10.1074/jbc.272.43.27353	http://dx.doi.org/10.1074/jbc.272.43.27353			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341186	hybrid			2022-12-27	WOS:A1997YC65900082
J	Cvejic, S; Devi, LA				Cvejic, S; Devi, LA			Dimerization of the delta opioid receptor: Implication for a role in receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NG108-15 HYBRID-CELLS; OPIATE ENKEPHALIN RECEPTORS; NEURO-BLASTOMA CELLS; DOWN-REGULATION; BINDING-SITES; CROSS-TALK; IN-VIVO; PHOSPHORYLATION; MORPHINE; COEXPRESSION	Dimerization of G protein-coupled receptors has been increasingly noted in the regulation of their biological activity, However, its involvement in agonist-induced receptor internalization is not well understood. In this study, we examined the ability of mouse delta-opioid receptors to dimerize and the role of receptor dimerization in agonist induced internalization. Using differentially (Flag and c-Myc) epitope-tagged receptors we show that delta-opioid receptors exist as dimers, The level of dimerization is agonist dependent, Increasing concentrations of agonists reduce the levels of dimer with a corresponding increase in the levels of monomer, Interestingly, morphine does not affect the levels of either form, It has been shown that morphine, unlike other opioid agonists, does not induce receptor internalization. This suggests a relationship between the ability of agonists to reduce the levels of dimer and to induce receptor internalization, The time course of the agonist-induced decrease of delta-opioid receptor dimers is shorter than the time course of internalization, suggesting that monomerization precedes the agonist-induced internalization of the receptor, Furthermore, we found that a mutant delta-opioid receptor, with a 15-residue C-terminal deletion, does not exhibit dimerization. This mutant receptor has been shown to lack the ability to undergo agonist-induced internalization. These results suggest that the interconversion between the dimeric and monomeric forms plays a role in opioid receptor internalization.	NYU,SCH MED,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NIDA NIH HHS [DA08863] Funding Source: Medline; NINDS NIH HHS [NS1788] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R56DA008863, R37DA008863, R01DA008863] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ALI H, 1994, J BIOL CHEM, V269, P24557; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BOWEN WD, 1981, P NATL ACAD SCI-BIOL, V78, P4818, DOI 10.1073/pnas.78.8.4818; Cvejic S, 1996, J BIOL CHEM, V271, P4073; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; HAZUM E, 1979, SCIENCE, V206, P1077, DOI 10.1126/science.227058; HAZUM E, 1982, BIOCHEM BIOPH RES CO, V104, P347, DOI 10.1016/0006-291X(82)91981-7; HAZUM E, 1979, NATURE, V282, P626, DOI 10.1038/282626a0; HAZUM E, 1980, P NATL ACAD SCI-BIOL, V77, P3038, DOI 10.1073/pnas.77.5.3038; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; JIANG Q, 1990, EUR J PHARMACOL, V186, P137; JIANG Q, 1990, Journal of Pharmacology and Experimental Therapeutics, V254, P683; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAW PY, 1994, J PHARMACOL EXP THER, V271, P1686; LAW PY, 1982, MOL PHARMACOL, V22, P1; LAW PY, 1984, J BIOL CHEM, V259, P4096; LAW PY, 1995, J PHARMACOL EXP THER, V272, P322; LAW PY, 1983, MOL PHARMACOL, V24, P413; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; ROTHMAN RB, 1986, EUR J PHARMACOL, V124, P113, DOI 10.1016/0014-2999(86)90130-5; ROTHMAN RB, 1987, PEPTIDES, V8, P1015, DOI 10.1016/0196-9781(87)90130-6; ROTHMAN RB, 1989, EUR J PHARMACOL, V160, P71, DOI 10.1016/0014-2999(89)90655-9; ROTHMAN RB, 1988, J PHARMACOL EXP THER, V247, P405; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U	36	404	414	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26959	26964		10.1074/jbc.272.43.26959	http://dx.doi.org/10.1074/jbc.272.43.26959			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341132	hybrid			2022-12-27	WOS:A1997YC65900028
J	Jbilo, O; Vidal, H; Paul, R; DeNys, N; Bensaid, M; Silve, S; Carayon, P; Davi, D; Galiegue, S; Bourrie, B; Guillemot, JC; Ferrara, P; Loison, G; Maffrand, JP; LeFur, G; Casellas, P				Jbilo, O; Vidal, H; Paul, R; DeNys, N; Bensaid, M; Silve, S; Carayon, P; Davi, D; Galiegue, S; Bourrie, B; Guillemot, JC; Ferrara, P; Loison, G; Maffrand, JP; LeFur, G; Casellas, P			Purification and characterization of the human SR 31747A-binding protein - A nuclear membrane protein related to yeast sterol isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG BRAIN; ETORPHINE-INACCESSIBLE SITES; SIGMA-BINDING SITES; AUTORADIOGRAPHIC LOCALIZATION; <H-3>-LABELED SKF-10047; RAT-LIVER; IN-VIVO; RECEPTOR; SR-31747; LIGAND	SR 31747A, defined as a sigma ligand, is a novel immunosuppressive agent that blocks proliferation of human and mouse lymphocytes. Using a radiolabeled chemical probe, we here purified a target of SR 31747A and called it SR 31747A-binding protein (SR-BP). Purified SR-BP retained its binding properties and migrated on SDS-polyacrylamide gel as a M-r 28,000 protein. Cloning of the cDNA encoding human SR-BP shows an open reading frame for a 223-amino acid protein, which is homologous to the recently cloned sigma 1 receptor. Interestingly, the deduced amino acid sequence was found to be related to fungal C8-C7 sterol isomerase, encoded by the ERG2 gene. The ERG2 gene product has been identified recently as the molecular target of SR 31747A that mediates antiproliferative effects of the drug in yeast. Northern blot analysis of SR-BP gene expression revealed a single transcript of 2 kilobases which was widely expressed among organs, with the highest abundance in liver and the lowest abundance in brain. Subcellular localization analysis in various cells, using a specific monoclonal antibody raised against SR-BP, demonstrated that this protein was associated with the nuclear envelope. When studying the binding of SR 31747A on membranes from yeast expressing SR-BP, we found a pharmacological profile of sigma 1 receptors; binding was displaced by (+)-pentazocine, haloperidol, and (+)-SKF 10,047, with (+)-SKF 10,047 being a more potent competitor than (-)-SKF 10,047. Scatchard plot analysis revealed K-d values of 7.1 nM and 0.15 nM for (+)-pentazocine and SR 31747A, respectively, indicating an affinity of SR-BP 50-fold higher for SR 31747A than for pentazocine. Additionally, we showed that pentazocine, a competitive inhibitor of SR 31747A binding, also prevents the immunosuppressive effect of SR 31747A. Taken together, these findings strongly suggest that SR-BP represents the molecular target for SR 31747A in mammalian tissues, which could be critical for T cell proliferation.	SANOFI RECH, F-34184 MONTPELLIER 04, FRANCE; SANOFI RECH, F-31676 LABEGE, FRANCE; SANOFI RECH, F-31036 TOULOUSE, FRANCE; SANOFI RECH, F-75374 PARIS 08, FRANCE	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], 1991, Methods Enzymol, V194, P1; ASHMAN WH, 1991, LIPIDS, V26, P628, DOI 10.1007/BF02536427; BOURRIE B, 1995, EUR J IMMUNOL, V25, P2882, DOI 10.1002/eji.1830251026; BOWEN WD, 1989, EUR J PHARMACOL, V163, P309, DOI 10.1016/0014-2999(89)90200-8; CASELLAS P, 1994, J NEUROIMMUNOL, V52, P193, DOI 10.1016/0165-5728(94)90113-9; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEROCQ JM, 1995, J PHARMACOL EXP THER, V272, P224; Dussossoy D, 1996, CYTOMETRY, V24, P39; GUNDLACK AL, 1996, J NEUROSCI, V6, P1757; Hanner M, 1996, P NATL ACAD SCI USA, V93, P8072, DOI 10.1073/pnas.93.15.8072; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HELLEWELL SB, 1990, BRAIN RES, V527, P244, DOI 10.1016/0006-8993(90)91143-5; HELLEWELL SB, 1994, EUR J PHARM-MOLEC PH, V268, P9, DOI 10.1016/0922-4106(94)90115-5; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KARBON EW, 1991, EUR J PHARMACOL, V193, P21; Kekuda R, 1996, BIOCHEM BIOPH RES CO, V229, P553, DOI 10.1006/bbrc.1996.1842; KEON JPR, 1994, CURR GENET, V25, P531, DOI 10.1007/BF00351674; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YH, 1995, J NEUROIMMUNOL, V59, P143, DOI 10.1016/0165-5728(95)00032-W; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Moebius FF, 1997, TRENDS PHARMACOL SCI, V18, P67, DOI 10.1016/S0165-6147(96)01037-1; MYERS AM, 1994, J MED CHEM, V37, P4109, DOI 10.1021/jm00050a008; PAUL R, 1994, J NEUROIMMUNOL, V52, P183, DOI 10.1016/0165-5728(94)90112-0; ROBINSON GW, 1993, MOL CELL BIOL, V13, P2706, DOI 10.1128/MCB.13.5.2706; ROMAN F, 1989, GASTROENTEROLOGY, V97, P76, DOI 10.1016/0016-5085(89)91418-2; ROTHMAN RB, 1991, MOL PHARMACOL, V39, P222; SAMOVILOVA NN, 1988, EUR J PHARMACOL, V147, P259, DOI 10.1016/0014-2999(88)90784-4; Silve S, 1996, MOL CELL BIOL, V16, P2719; Silve S, 1996, J BIOL CHEM, V271, P22434, DOI 10.1074/jbc.271.37.22434; SU TP, 1981, EUR J PHARMACOL, V75, P81, DOI 10.1016/0014-2999(81)90352-6; SU TP, 1982, J PHARMACOL EXP THER, V223, P284; Whitlock BB, 1996, J NEUROIMMUNOL, V67, P83; Wolfe SA, 1997, J NEUROIMMUNOL, V72, P45, DOI 10.1016/S0165-5728(96)00140-3; WOLFE SA, 1989, ENDOCRINOLOGY, V124, P1160, DOI 10.1210/endo-124-3-1160; WOLFE SA, 1988, J PHARMACOL EXP THER, V247, P1114; WOLFE SA, 1994, SIGMA RECEPTORS, P287; WOLFE SA, 1992, MULTIPLE SIGMA PCP R, P927; WU XZ, 1991, J PHARMACOL EXP THER, V257, P351; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	41	62	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27107	27115		10.1074/jbc.272.43.27107	http://dx.doi.org/10.1074/jbc.272.43.27107			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341151	hybrid			2022-12-27	WOS:A1997YC65900047
J	Liu, WM; Wang, D; Chen, P; Halpern, M				Liu, WM; Wang, D; Chen, P; Halpern, M			Cloning and expression of a gene encoding a protein obtained from earthworm secretion that is a chemoattractant for garter snakes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOMERONASAL SYSTEM; CHEMICAL SENSES	The protein ES20, derived from earthworm shock secretion, is a vomeronasally mediated chemoattractant for garter snakes (Jiang, X. C., Lnouchi, J., Wang, D., and Halpern, M. (1990) J. Biol. Chem. 265, 8736-8744). Based on its 15-residue N-terminal amino acid sequence, degenerative oligodeoxynucleotide probes were synthesized and used to screen a cDNA library that was constructed in sense orientation using a Uni-ZAP(TM) XR vector and XL1-Blue MRF' host, A gene was cloned from a polymerase chain reaction as well as from the cDNA library. A combination of the forward degenerative primer and T7 primer was used to obtain gene-specific DNA fragments, from which probes were synthesized and successfully used in screening the cDNA Library, The ES20 gene is about 700 base pairs long and encodes 208 amino residues, The ES20, gene was excised from a recombinant plasmid pSK-ES20, ligated to pQE30 expression vector, and transformed into Escherichia coli strain JM109. The selected recombinant plasmids were transformed into expression host cell, E. coli M15[pREP4]. Three transformants were selected, induced with isopropyl-1-thio-beta-D-galactopyranoside for fusion gene expression and an expressed 20-kDa fusion protein purified under denaturing conditions, This protein was refolded and gave a positive reaction against ES20-specific polyclonal antibodies. The fusion protein that had not been denatured remained as an aggregate and was an active chemoattractant for garter snakes.	SUNY HLTH SCI CTR,DEPT BIOCHEM,BROOKLYN,NY 11203; SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NIDCD NIH HHS [DC 00104] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Burghardt G. M., 1966, PSYCHON SCI, V4, P37; BURGHARDT GM, 1975, PHYSIOL BEHAV, V14, P185, DOI 10.1016/0031-9384(75)90164-X; GABE M, 1976, Memoires du Museum National d'Histoire Naturelle Serie A Zoologie, V98, P1; HALPERN M, 1979, PHYSIOL BEHAV, V22, P1183, DOI 10.1016/0031-9384(79)90274-9; INOUCHI J, 1993, BRAIN BEHAV EVOLUT, V41, P171, DOI 10.1159/000113835; JIANG XC, 1990, J BIOL CHEM, V265, P8736; KUBIE JL, 1979, J COMP PHYSIOL PSYCH, V93, P648, DOI 10.1037/h0077606; KUBIE JL, 1978, J COMP PHYSIOL PSYCH, V92, P362, DOI 10.1037/h0077456; LI CS, 1993, SOC NEUROSCI, V23, P122; LUO YQ, 1994, J BIOL CHEM, V269, P16867; PARSONS TS, 1970, BIOLOGY REPTILIA, V2, P99; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WANG D, 1993, BRAIN BEHAV EVOLUT, V41, P246, DOI 10.1159/000113846; WANG D, 1988, ARCH BIOCHEM BIOPHYS, V267, P459, DOI 10.1016/0003-9861(88)90051-3; WANG D, 1992, COMP BIOCH PHYSL B, V102, P601; WANG D, 1992, CHEM SIGNALS VERTEBR, V6, P107; WANG D, 1997, IN PRESS ARCH BIOCH; Wilde W, 1938, J EXP ZOOL, V77, P445, DOI 10.1002/jez.1400770307	19	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27378	27381		10.1074/jbc.272.43.27378	http://dx.doi.org/10.1074/jbc.272.43.27378			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341189	hybrid			2022-12-27	WOS:A1997YC65900085
J	Luo, GY; YuLee, LY				Luo, GY; YuLee, LY			Transcriptional inhibition by Stat5 - Differential activities at growth-related versus differentiation-specific promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY FACTOR-I; MAMMARY-GLAND FACTOR; SINGLE PHOSPHOTYROSINE RESIDUE; COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASES; DNA-BINDING ACTIVITY; NB2 T-CELLS; PROLACTIN RECEPTOR; GENE-EXPRESSION; SIGNAL-TRANSDUCTION	Prolactin (PRL) induces transcriptional activation of not only growth-related genes such as interferon regulatory factor-1 (LRF-1) but also differentiation-specific genes such as beta-casein through a signaling cascade consisting of Janus kinases and Stat (signal transducer and activator of transcription) factors. To understand better the role of Stats in PRL signaling, we cloned rat Stat5b from a PRL-responsive T cell line Nb2. A Stat5b-specific peptide antibody was generated. In PRL receptor reconstituted COS cells cotransfected with Stat5b or Stat5a, both Stat5 proteins become tyrosine phosphorylated and bind to the IRF-1 GAS (interferon-gamma activation sequence) element in a PRL-inducible manner. Unexpectedly, both Stat5b and Stat5a inhibit PRL induction of the IRF-1 promoter, but they mediate PRL stimulation of the beta-casein promoter. Stat5-mediated inhibition was observed only at the native IRF-1 promoter and not at the isolated IRF-1 GAS element linked to a heterologous thymidine kinase promoter. Mutational analyses showed that the DNA binding activity of Stat5b is not required, but the carboxyl terminal transactivation domain is essential for Stat5b to inhibit PRL induction of the IRF-1 promoter. These results suggest that Stat5b mediates inhibition via protein protein interactions. In contrast, both DNA binding and transactivation domains of Stat5b are required to mediate PRL induction of the beta-casein promoter. Furthermore, at carboxyl-terminal truncated dominant negative Stat5b can reverse Stat5b inhibition at the IRF-1 promoter, These studies suggest that Stat proteins can act as not only positive but also negative regulators of gene transcription. Further, Stat5 can modulate gene expression without binding to DNA but via protein-protein interactions.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT IMMUNOL & MICROBIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NIDDK NIH HHS [DK-44625] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044625] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXTELL SM, 1995, MOL ENDOCRINOL, V9, P312, DOI 10.1210/me.9.3.312; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CHUAI K, 1996, MOL CELL BIOL, V16, P4932; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; Dajee M, 1996, MOL ENDOCRINOL, V10, P171, DOI 10.1210/me.10.2.171; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DEMMER J, 1995, MOL CELL ENDOCRINOL, V107, P113, DOI 10.1016/0303-7207(94)03432-S; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; EDERY M, 1994, MOL CELL ENDOCRINOL, V102, P39, DOI 10.1016/0303-7207(94)90095-7; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; GILMOUR KC, 1995, P NATL ACAD SCI USA, V92, P10772, DOI 10.1073/pnas.92.23.10772; GILMOUR KC, 1994, P NATL ACAD SCI USA, V91, P6850, DOI 10.1073/pnas.91.15.6850; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GOUT PW, 1980, CANCER RES, V40, P2433; HOOGHE R, 1993, IMMUNOL TODAY, V14, P212, DOI 10.1016/0167-5699(93)90165-H; HORSEMAN ND, 1994, ENDOCR REV, V15, P627, DOI 10.1210/er.15.5.627; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hou XS, 1997, TRENDS GENET, V13, P105, DOI 10.1016/S0168-9525(97)01006-8; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LEE KF, 1994, MOL ENDOCRINOL, V3, P447; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURPHY WJ, 1995, LIFE SCI, V57, P1, DOI 10.1016/0024-3205(95)00237-Z; ONEAL KD, 1994, J BIOL CHEM, V269, P26076; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SAVINO W, 1995, IMMUNOL TODAY, V16, P318, DOI 10.1016/0167-5699(95)80144-8; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHWARZ LA, 1992, MOL CELL ENDOCRINOL, V86, P103, DOI 10.1016/0303-7207(92)90180-E; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; STEVENS AM, 1995, MOL ENDOCRINOL, V9, P513, DOI 10.1210/me.9.4.513; STEVENS AM, 1994, MOL ENDOCRINOL, V8, P345, DOI 10.1210/me.8.3.345; STEVENS AM, 1992, MOL ENDOCRINOL, V6, P2236, DOI 10.1210/me.6.12.2236; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; STRUELI HC, 1995, J BIOL CHEM, V270, P21639; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wang YF, 1997, MOL ENDOCRINOL, V11, P1353, DOI 10.1210/me.11.9.1353; Wang YF, 1996, MOL CELL ENDOCRINOL, V121, P19, DOI 10.1016/0303-7207(96)03840-3; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; YuLee LY, 1997, P SOC EXP BIOL MED, V215, P35, DOI 10.3181/00379727-215-44111; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	76	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26841	26849		10.1074/jbc.272.43.26841	http://dx.doi.org/10.1074/jbc.272.43.26841			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341115	hybrid			2022-12-27	WOS:A1997YC65900011
J	Scheirer, KE; Higgins, NP				Scheirer, KE; Higgins, NP			The DNA cleavage reaction of DNA gyrase - Comparison of stable ternary complexes formed with enoxacin and CcdB protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TOPOISOMERASE-IV; BINDING-SITE; QUINOLONE ANTIBACTERIALS; NALIDIXIC-ACID; LETD CCDB; MECHANISM; INHIBITION; ENZYME; REPLICATION	The potent synthetic fluoroquinolones and the natural CcdB protein encoded by the F plasmid both inhibit bacterial growth by attacking DNA gyrase and by stimulating enzyme-induced breaks in bacterial DNA. The cleavage mechanisms of these structurally diverse compounds were analyzed by purifying and characterizing stable ternary complexes of enoxacin and CcdB protein with gyrase bound to a strong gyrase binding site from bacteriophage Mu. Three differences between enoxacin-and CcdB-derived complexes were discovered. 1) Enoxacin binds to the DNA active site and alters the breakage/reunion activity of the enzyme. CcdB binds gyrase-DNA complexes but does not influence enzymatic activity directly. 2) Complexes that produce DNA cleavage with enoxacin are reversible, whereas similar complexes made with CcdB protein are not. 3) Enoxacin stimulates cleavage of both relaxed and supercoiled forms of DNA in the absence of ATP, whereas CcdB induces cleavage only after many cycles of ATP-dependent breakage and reunion. These differences in mechanisms can be explained by a model in which enoxacin induces formation of a novel ''cleavable'' complex, whereas CcdB protein traps a very rare ''cleaved'' conformation of the enzyme.	UNIV ALABAMA,DEPT BIOCHEM & MOL GENET,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [AI07150, AI35170] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007150] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; BERNARD P, 1993, J MOL BIOL, V234, P534, DOI 10.1006/jmbi.1993.1609; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Chen CR, 1996, J MOL BIOL, V258, P627, DOI 10.1006/jmbi.1996.0274; Critchlow SE, 1996, BIOCHEMISTRY-US, V35, P7387, DOI 10.1021/bi9603175; DOMAGALA JM, 1986, J MED CHEM, V29, P394, DOI 10.1021/jm00153a015; Drlica K, 1994, Adv Pharmacol, V29A, P263; ELLEDGE SJ, 1997, SCIENCE, V274, P1663; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Gari E, 1996, MOL MICROBIOL, V21, P111, DOI 10.1046/j.1365-2958.1996.6221338.x; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Hiasa H, 1996, J BIOL CHEM, V271, P26424, DOI 10.1074/jbc.271.42.26424; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; LOCKSHON D, 1985, J MOL BIOL, V181, P63, DOI 10.1016/0022-2836(85)90324-9; Maki S, 1996, J MOL BIOL, V256, P473, DOI 10.1006/jmbi.1996.0102; Marians KJ, 1997, J BIOL CHEM, V272, P9401; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MORRISON A, 1980, J BIOL CHEM, V255, P2211; MORRISON A, 1979, CELL, V17, P175, DOI 10.1016/0092-8674(79)90305-2; MORRISON A, 1981, P NATL ACAD SCI-BIOL, V78, P1416, DOI 10.1073/pnas.78.3.1416; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PATO ML, 1990, P NATL ACAD SCI USA, V87, P8716, DOI 10.1073/pnas.87.22.8716; PATO ML, 1995, J BACTERIOL, V177, P5937, DOI 10.1128/jb.177.20.5937-5942.1995; Shen L L, 1994, Adv Pharmacol, V29A, P285; SHEN LL, 1989, J BIOL CHEM, V264, P2973; SHEN LL, 1985, P NATL ACAD SCI USA, V82, P307, DOI 10.1073/pnas.82.2.307; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3886, DOI 10.1021/bi00435a039; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; VANMELDEREN L, 1994, MOL MICROBIOL, V11, P1151; WILLMOTT CJR, 1994, J MOL BIOL, V242, P351, DOI 10.1006/jmbi.1994.1586; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; YORGEY P, 1994, P NATL ACAD SCI USA, V91, P4519, DOI 10.1073/pnas.91.10.4519; YOSHIDA H, 1991, ANTIMICROB AGENTS CH, V35, P1647, DOI 10.1128/AAC.35.8.1647; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	44	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27202	27209		10.1074/jbc.272.43.27202	http://dx.doi.org/10.1074/jbc.272.43.27202			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341164	hybrid			2022-12-27	WOS:A1997YC65900060
J	Wendler, F; Bergler, H; Prutej, K; Jungwirth, H; Zisser, G; Kuchler, K; Hogenauer, G				Wendler, F; Bergler, H; Prutej, K; Jungwirth, H; Zisser, G; Kuchler, K; Hogenauer, G			Diazaborine resistance in the yeast Saccharomyces cerevisiae reveals a link between YAP1 and the pleiotropic drug resistance genes PDR1 and PDR3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; ESCHERICHIA-COLI; TRANSCRIPTIONAL ACTIVATION; MULTIDRUG TRANSPORTER; MOLECULAR-CLONING; OXIDATIVE STRESS; PLASMA-MEMBRANE; ENCODING GENE; TARGET GENE; PROTEIN	We have investigated the mechanisms underlying resistance to the drug diazaborine in Saccharomyces cerevisiae. We used UV mutagenesis to generate resistant mutants, which were divided into three different complementation groups. The resistant phenotype in these groups was found to be caused by allelic forms of the genes AFG2, PDR1, and PDR3. The AFG2 gene encodes an AAA (ATPases associated to a variety of cellular activities) protein of unknown function, while PDR1 and PDR3 encode two transcriptional regulatory proteins involved in pleiotropic drug resistance development. The isolated PDR1-12 and PDR3-33 alleles carry mutations that lead to a L1044Q and a Y276H exchange, respectively. In addition, we report that overexpression of Yap1p, the yeast homologue of the transcription factor AP1, results in a diazaborine-resistant phenotype. The YAP1-mediated diazaborine resistance is dependent on the presence of functional PDR1 and PDR3 genes, although PDR3 had a more pronounced effect. These results provide the first evidence for a functional link between the Yap1p-dependent stress response pathway and Pdr1p/Pdr3p-dependent development of pleiotropic drug resistance.	KARL FRANZENS UNIV GRAZ, INST MIKROBIOL, A-8010 GRAZ, AUSTRIA; UNIV VIENNA, DEPT MOL GENET, A-1030 VIENNA, AUSTRIA; BIOCTR VIENNA, A-1030 VIENNA, AUSTRIA	University of Graz; University of Vienna; Vienna Biocenter (VBC)			kuchler, karl/AAL-6937-2020	kuchler, karl/0000-0003-2719-5955; Jungwirth, Helmut/0000-0003-4868-4571; Bergler, Helmut/0000-0002-7724-309X				Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1994, J BIOL CHEM, V269, P2206; BALZI E, 1994, BIOCHIM BIOPHYS ACTA, V1187, P151; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERGLER H, 1994, J BIOL CHEM, V269, P5493; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; EGNER R, 1995, MOL CELL BIOL, V15, P5879; *GEN COMP GROUP, 1991, PROGR MAN GCG PACK V; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; GRASSBERGER MA, 1984, J MED CHEM, V27, P947, DOI 10.1021/jm00374a003; HOGENAUER G, 1981, NATURE, V293, P662, DOI 10.1038/293662a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANDROSITZ A, 1991, GENE, V107, P155, DOI 10.1016/0378-1119(91)90310-8; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Mahe Y, 1996, J BIOL CHEM, V271, P25167, DOI 10.1074/jbc.271.41.25167; Martens JA, 1996, J BIOL CHEM, V271, P15884, DOI 10.1074/jbc.271.27.15884; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SALMERON JM, 1990, GENETICS, V125, P21; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SCHWEIZER M, 1984, MOL GEN GENET, V194, P457, DOI 10.1007/BF00425558; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; Sherman F, 1979, METHODS YEAST GENETI; SUBIK J, 1986, CURR GENET, V10, P665, DOI 10.1007/BF00410914; THORSNESS PE, 1993, YEAST, V9, P1267, DOI 10.1002/yea.320091114; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	44	63	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27091	27098		10.1074/jbc.272.43.27091	http://dx.doi.org/10.1074/jbc.272.43.27091			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341149	hybrid			2022-12-27	WOS:A1997YC65900045
J	Yiu, GK; Hecht, NB				Yiu, GK; Hecht, NB			Novel testis-specific protein-DNA interactions activate transcription of the mouse protamine 2 gene during spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM-CELL DEVELOPMENT; RNA-BINDING PROTEINS; Y-BOX PROTEINS; MESSENGER-RNA; TRANSGENIC MICE; INVITRO TRANSCRIPTION; RECEPTOR SUPERFAMILY; ESTROGEN-RECEPTOR; MOLECULAR-CLONING; THYROID-HORMONE	The mouse protamines ape expressed exclusively in postmeiotic male germ cells and are crucial for the compaction of chromatin during the late stages of spermatogenesis, The temporal expression of the two mouse protamines is transcriptionally regulated in the testis. Recent studies have demonstrated that ubiquitous and testis-specific proteins bind to the promoter of the mouse protamine 2 (mP2) gene, We have performed in vitro transcription and mobility shift assays to characterize the functional significance of the protein-DNA interactions within 180 base pairs upstream of the mP2 transcription start site. Deletion and mutational analyses reveal two positive regulatory sequences for mP2 transcription at positions -59/-47 and -83/-72 of the mP2 promoter, The proximal element at -59/-47 binds to a novel testis-specific protein we name protamine-activating factor 1 (PAF-1). PAF-1 reaches high levels in round spermatids at the time of mP2 transcription. Deletion of the -59/-47 sequence results in about a 3-fold reduction of mP2 transcription in vitro, Although the PAF-1 binding site (PAF-responsive element, PAF-RE), contains the sequence GTCA present in the cAMP-responsive element and is very similar to the estrogen-responsive element, mobility shift assays revealed that neither the cAMP-responsive element modulator nor the estrogen receptor is the protein(s) binding to PAF-RE, Competition mobility shift assays reveal that the second positive regulatory element at -88/-72 binds a Y-box-binding protein, Using in vitro transcription assays, a 5-fold decrease in mP2 transcription is seen when both the PAF-RE and this Y-box are deleted, These data suggest that the testis-specific PAF-1 and a Y-box-binding protein are needed to activate mP2 transcription in postmeiotic male germ cells.	TUFTS UNIV, DEPT BIOL, MEDFORD, MA 02155 USA	Tufts University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011878] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 11878] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Balhorn R., 1989, P366; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Borgmeyer U, 1997, EUR J BIOCHEM, V244, P120, DOI 10.1111/j.1432-1033.1997.00120.x; BUNICK D, 1990, P NATL ACAD SCI USA, V87, P891, DOI 10.1073/pnas.87.3.891; CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Eddy EM, 1993, MOL BIOL MALE REPROD, P181; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GOLDBERG E, 1977, ISOENZYMES CURRENT T, V1, P79; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Ha H, 1997, J CELL BIOCHEM, V64, P94, DOI 10.1002/(SICI)1097-4644(199701)64:1<94::AID-JCB12>3.3.CO;2-H; HAKE LE, 1990, DEVELOPMENT, V110, P249; HECHT NB, 1995, DEV GENET, V16, P95, DOI 10.1002/dvg.1020160202; Hecht NB, 1989, HISTONES OTHER BASIC, P347; Hecht NB., 1986, EXPT APPROACHES MAMM, P151; HESS RA, 1995, ENVIRON HEALTH PERSP, V103, P59, DOI 10.2307/3432509; HIROSE T, 1995, GENE, V152, P247, DOI 10.1016/0378-1119(94)00656-D; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; JOHNSON PA, 1991, BIOL REPROD, V44, P127, DOI 10.1095/biolreprod44.1.127; KLEENE KC, 1983, DEV BIOL, V98, P455, DOI 10.1016/0012-1606(83)90375-5; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KWON YK, 1993, DEV BIOL, V158, P90, DOI 10.1006/dbio.1993.1170; Lee CH, 1996, MOL REPROD DEV, V44, P305, DOI 10.1002/(SICI)1098-2795(199607)44:3&lt;305::AID-MRD4&gt;3.0.CO;2-Q; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NIKOLAJCZYK BS, 1995, BIOL REPROD, V52, P524, DOI 10.1095/biolreprod52.3.524; Oko R, 1996, MOL REPROD DEV, V44, P1, DOI 10.1002/(SICI)1098-2795(199605)44:1&lt;1::AID-MRD1&gt;3.0.CO;2-S; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Sommerville J, 1996, CHROMOSOMA, V104, P469, DOI 10.1007/s004120050139; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WOLFFE AP, 1992, NEW BIOL, V4, P290; Yan ZH, 1997, J BIOL CHEM, V272, P10565; Yiu GK, 1997, BIOL REPROD, V56, P1439, DOI 10.1095/biolreprod56.6.1439; ZAMBROWICZ BP, 1994, BIOL REPROD, V50, P65, DOI 10.1095/biolreprod50.1.65; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071; Zhou YD, 1996, P NATL ACAD SCI USA, V93, P12262, DOI 10.1073/pnas.93.22.12262	50	41	43	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26926	26933		10.1074/jbc.272.43.26926	http://dx.doi.org/10.1074/jbc.272.43.26926			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341127	hybrid			2022-12-27	WOS:A1997YC65900023
J	Dusing, MR; Brickner, AC; Thomas, MB; Wiginton, DA				Dusing, MR; Brickner, AC; Thomas, MB; Wiginton, DA			Regulation of duodenal specific expression of the human adenosine deaminase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; ACID-BINDING-PROTEIN; HORMONE FUSION GENES; TRANSGENIC MICE; DEVELOPMENTAL EXPRESSION; REPORTER GENE; ENHANCER; DNA; DIFFERENTIATION; TISSUES	Formation of the mammalian gastrointestinal tract is an ordered process of development and differentiation. Yet, the adult small intestine also retains the plasticity to respond to cues both internal and environmental to modulate intestinal function. The components that regulate this development, differentiation, and modulation at the molecular level are only now being elucidated. We have used the human adenosine deaminase (ADA) gene as a model to identify potential cis-regulatory components involved in these processes within the small intestine. In mammals, high levels of ADA in the small intestine are limited, specifically 60 the differentiated enterocytes within the duodenal region. These studies describe the identification of a region of the human ADA. gene, completely distinct from the previously identified T-cell enhancer, which is capable of directing the human intestinal expression pattern in the intestine of transgenic mice. The reporter gene expression pattern observed in these transgenic mice is identical to the endogenous gene along both the cephalocaudal and crypt/villus axis of development. Timing of this transgene activation, however, varies from that of the endogenous mouse gene in that the transgene is activated approximately 2 weeks earlier in development. Even so, this precocious activation is also limited to the epithelium of the developing villi strictly within the duodenal region of the small intestine.	UNIV CINCINNATI, COLL MED, DEPT PEDIAT, DIV DEV BIOL, CINCINNATI, OH 45229 USA; CHILDRENS HOSP RES FDN, CINCINNATI, OH 45229 USA	University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation								ADAMS A, 1976, CLIN EXP IMMUNOL, V26, P647; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; ARONOW BJ, 1995, MOL CELL BIOL, V15, P123; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRADY TG, 1965, COMP BIOCHEM PHYSIOL, V14, P101, DOI 10.1016/0010-406X(65)90011-3; Brickner AG, 1995, GENE, V167, P261, DOI 10.1016/0378-1119(95)00673-7; BUSTAMANTE S, 1981, TXB GASTROENTEROLOGY, P49; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; CIRILLO LA, 1995, DEV BIOL, V168, P395, DOI 10.1006/dbio.1995.1089; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; DUSING MR, 1994, NUCLEIC ACIDS RES, V22, P669, DOI 10.1093/nar/22.4.669; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; ESS KC, 1995, MOL CELL BIOL, V15, P5707; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HAYASHI S, 1978, J HISTOCHEM CYTOCHEM, V26, P677, DOI 10.1177/26.8.99471; Haynes TL, 1996, NUCLEIC ACIDS RES, V24, P5034, DOI 10.1093/nar/24.24.5034; HE YP, 1993, J NUTR, V123, P1017; HENNING SJ, 1987, PHYSL GASTROINTESTIN, V1, P285; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; KIZAKI H, 1988, J IMMUNOL, V141, P1652; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1989, TERATOLOGY, V40, P615, DOI 10.1002/tera.1420400609; KNUDSEN TB, 1988, BIOL REPROD, V39, P937, DOI 10.1095/biolreprod39.4.937; KREDICH NM, 1989, METABOLIC BASIS INHE, V1, P1045; LEE PC, 1973, DEV BIOL, V31, P227, DOI 10.1016/0012-1606(73)90259-5; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; MOHAMEDALI KA, 1993, J BIOL CHEM, V268, P23728; MOOG F, 1981, TXB GASTROENTEROLOGY, P139; OLSEN J, 1991, J BIOL CHEM, V266, P18089; POTTEN CS, 1979, BIOCHIM BIOPHYS ACTA, V560, P281, DOI 10.1016/0304-419X(79)90022-2; ROSE SD, 1994, MOL CELL BIOL, V14, P2048, DOI 10.1128/MCB.14.3.2048; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; TRABER PG, 1994, J LAB CLIN MED, V123, P467; VANDERWEYDEN MB, 1976, J BIOL CHEM, V251, P5448; WAKADE AR, 1995, J BIOL CHEM, V270, P17986, DOI 10.1074/jbc.270.30.17986; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WALSH A, 1993, J LIPID RES, V34, P617; WIGINTON D, 1991, ADV EXP MED BIOL, V309, P57; WIGINTON DA, 1986, BIOCHEMISTRY-US, V25, P8234, DOI 10.1021/bi00373a017; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; WINSTON JH, 1995, ADV EXP MED BIOL, V370, P579; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	56	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26634	26642		10.1074/jbc.272.42.26634	http://dx.doi.org/10.1074/jbc.272.42.26634			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334245	hybrid			2022-12-27	WOS:A1997YB13900079
J	Nadeau, OW; Sacks, DB; Carlson, GM				Nadeau, OW; Sacks, DB; Carlson, GM			Differential affinity cross-linking of phosphorylase kinase conformers by the geometric isomers of phenylenedimaleimide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT-SKELETAL-MUSCLE; ALPHA-SUBUNIT; BETA-SUBUNIT; MOLECULAR-BASIS; CALMODULIN; BINDING; ACTIVATION; SPECIFICITY; MELITTIN; PROTEINS	Phosphorylase b kinase (PbK) from skeletal muscle is a highly regulated oligomer consisting of four copies of four distinct subunits (alpha beta gamma)delta(4). The gamma subunit is catalytic, and the remaining subunits are regulatory, To characterize effector-induced changes in the quaternary structure of the enzyme, we utilized the ortho-, meta, and para-isomers of phenylenedimaleimide (PDM), which in addition to having different geometries, also vary 2.5-fold in their cross-linking spans, Even at concentrations equivalent to the alpha beta gamma delta protomers of PbK, all three isomers caused specific, rapid, and extensive cross-linking of the holoenzyme to farm primarily alpha beta dimers, plus smaller amounts of beta gamma gamma and alpha gamma gamma trimers, The formation of these three conjugates was nearly totally inhibited by a 10-fold molar excess over PDM of N-(o- and p-tolyl)succinimide, which are chemically inert structural analogs of PDM. This inhibition suggests that PbK has binding sites for PDM and that PDM acts as an affinity cross linker in binding to these sites prior to forming crosslinked conjugates. The largest effect on cross-linking in progressing from o- to p-PDM was on the alpha gamma gamma trimer, which is preferentially formed by the p-isomer. Activation tion of the enzyme by either phosphorylation or the allosteric activators ADP and GDP resulted in large increases in the amount of alpha gamma gamma formed, small increases in beta gamma gamma, and little change in alpha beta. When cross-linked in the presence of the reversibly activating nucleoside diphosphates, PbK remained activated after their removal, indicating-that cross-linking had locked it in the active conformation. Our results provide direct evidence for perturbations in the interactions of the catalytic gamma subunit with the regulatory alpha and beta subunits upon activation of PbK.	UNIV TENNESSEE, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Sacks, David/0000-0003-3100-0735	NIDDK NIH HHS [DK32953] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032953, R56DK032953] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENESCH RE, 1991, J PROTEIN CHEM, V10, P503, DOI 10.1007/BF01025478; CARLSON GM, 1984, BIOCHIM BIOPHYS ACTA, V789, P347, DOI 10.1016/0167-4838(84)90191-2; CHANG FN, 1972, J MOL BIOL, V68, P177, DOI 10.1016/0022-2836(72)90272-0; CHENG A, 1988, J BIOL CHEM, V263, P5534; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; FISCHER EH, 1978, VERSATILITY PROTEINS, P133; FITZGERALD TJ, 1984, J BIOL CHEM, V259, P3266; HEILMEYER LMG, 1991, BIOCHIM BIOPHYS ACTA, V1094, P168, DOI 10.1016/0167-4889(91)90005-I; HESSOVA Z, 1985, EUR J BIOCHEM, V146, P107, DOI 10.1111/j.1432-1033.1985.tb08626.x; ISHII Y, 1986, BIOPHYS J, V50, P75, DOI 10.1016/S0006-3495(86)83440-3; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KILIMANN MW, 1988, P NATL ACAD SCI USA, V85, P9381, DOI 10.1073/pnas.85.24.9381; KING MM, 1983, J BIOL CHEM, V258, P9925; KING MM, 1981, J BIOL CHEM, V256, P1058; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOOY PK, 1982, ARCH BIOCHEM BIOPHYS, V213, P551, DOI 10.1016/0003-9861(82)90583-5; LEE JH, 1992, BIOCHEMISTRY-US, V31, P10616, DOI 10.1021/bi00158a026; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MILLER S, 1989, PROTEIN ENG, V3, P77, DOI 10.1093/protein/3.2.77; MORTON A, 1995, BIOCHEMISTRY-US, V34, P8576, DOI 10.1021/bi00027a007; Nadeau OW, 1997, J BIOL CHEM, V272, P26202, DOI 10.1074/jbc.272.42.26202; NADEAU OW, 1994, J BIOL CHEM, V269, P29670; PAUDEL HK, 1988, ARCH BIOCHEM BIOPHYS, V264, P641, DOI 10.1016/0003-9861(88)90330-X; PAUDEL HK, 1993, BIOCHEMISTRY-US, V32, P11865, DOI 10.1021/bi00095a015; PAUDEL HK, 1987, J BIOL CHEM, V262, P11912; Pickett-Gies CA., 1986, ENZYMES, V17, P395; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SANCHEZ V, 1993, THESIS U TENNESSEE M, P79; SANCHEZ VE, 1993, J BIOL CHEM, V268, P17889; SMYTH DG, 1964, BIOCHEM J, V91, P589, DOI 10.1042/bj0910589; TREMPE MR, 1987, J BIOL CHEM, V262, P4333; Wilkinson DA, 1997, J MOL BIOL, V265, P319, DOI 10.1006/jmbi.1996.0739; WILKINSON DA, 1994, J MOL BIOL, V235, P974, DOI 10.1006/jmbi.1994.1051; Wold F, 1972, Methods Enzymol, V25, P623, DOI 10.1016/S0076-6879(72)25061-3; YANG T, 1991, BIOCHEM BIOPH RES CO, V174, P518, DOI 10.1016/0006-291X(91)91447-K	41	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26196	26201		10.1074/jbc.272.42.26196	http://dx.doi.org/10.1074/jbc.272.42.26196			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334187	hybrid			2022-12-27	WOS:A1997YB13900021
J	Saito, F; Yamada, H; Sunada, Y; Hori, H; Shimizu, T; Matsumura, K				Saito, F; Yamada, H; Sunada, Y; Hori, H; Shimizu, T; Matsumura, K			Characterization of a 30-kDa peripheral nerve glycoprotein that binds laminin and heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; TERMINAL GLOBULAR DOMAIN; SCHWANN-CELL MIGRATION; BASAL LAMINA; BASEMENT-MEMBRANES; MEROSIN DEFICIENCY; SYNTHETIC PEPTIDES; NEURITE GROWTH; CHAIN GENE; EXPRESSION	We have shown previously that a bovine peripheral nerve protein with a molecular mass of about 30 kDa binds laminin in blot overlay assay, In this paper, we have characterized this 30-kDa laminin-binding protein (LBP30), LBP30 was extracted from the crude bovine peripheral nerve membranes at pH 12 or by 0.5 M NaCl but not; by 2% Triton X-100. LBP30 bound to heparin-Sepharose in the presence of 0.5 M NaCl. The results of lectin staining indicated that LBP30 contained both terminally sialylated and nonsialylated Ser/Thr-linked oligosaccharides. LBP30 bound laminin-a as well as laminin-1 but not fibronectin or collagen type IV, When immoobilized LBP30 was incubated with the crude peripheral nerve membrane extracts, all of the endogenous peripheral nerve laminin chain isoforms, the alpha 1, alpha 2, beta 1, beta 2, and gamma 1 chains, were detected bound to LBP30. The binding of LBP30 to laminin was inhibited by heparin, heparan sulfate, dextran sulfate, or NaCl but was not affected significantly by chondroitin sulfate, dextran, or EDTA. Although LBP30 bound to laminin-1 denatured with SDS in a nonreducing condition, the binding was reduced drastically when laminin-1 was denatured with SDS in a reducing condition, suggesting that the binding of LBP30 is somewhat dependent on the high order structure of laminin-1, Immunohistochemical analysis demonstrated the broad distribution of LBP30 in the perineurium and endoneurium of bovine peripheral nerve, These results indicate that LBP30 is a laminin-and heparin-binding glycoprotein localized in the perineurium and endoneurium of bovine peripheral nerve.	TEIKYO UNIV,SCH MED,DEPT NEUROL & NEUROSCI,TOKYO 173,JAPAN; TOKYO MED & DENT UNIV,MED RES INST,DEPT TISSUE PHYSIOL,TOKYO 101,JAPAN	Teikyo University; Tokyo Medical & Dental University (TMDU)								ANTON ES, 1994, DEV BIOL, V164, P133, DOI 10.1006/dbio.1994.1186; ARAHATA K, 1993, P JPN ACAD B-PHYS, V69, P259, DOI 10.2183/pjab.69.259; BAILEY SB, 1993, J NEUROCYTOL, V22, P176, DOI 10.1007/BF01246356; BRADLEY WG, 1973, J NEUROL SCI, V18, P227, DOI 10.1016/0022-510X(73)90009-9; Bunge R P, 1993, Curr Opin Neurobiol, V3, P805, DOI 10.1016/0959-4388(93)90157-T; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ELDRIDGE CF, 1989, J NEUROSCI, V9, P625; FELTRI ML, 1994, DEVELOPMENT, V120, P1287; FERNANDEZVALLE C, 1994, J NEUROBIOL, V25, P1207, DOI 10.1002/neu.480251004; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HORI H, 1994, J BIOCHEM-TOKYO, V116, P1212, DOI 10.1093/oxfordjournals.jbchem.a124666; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JAAKKOLA S, 1993, J NEUROCYTOL, V22, P215, DOI 10.1007/BF01246360; LEIVO L, 1988, P NATL ACAD SCI USA, V85, P1554; MADRID RE, 1975, NATURE, V257, P319, DOI 10.1038/257319a0; Matsumura K, 1997, NEUROMUSCULAR DISORD, V7, P7, DOI 10.1016/S0960-8966(96)00402-6; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; Mercurio AM, 1990, CURR OPIN CELL BIOL, V2, P845, DOI 10.1016/0955-0674(90)90082-P; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; Mora M, 1996, NEUROMUSCULAR DISORD, V6, P377, DOI 10.1016/0960-8966(96)00359-8; NIESSEN CM, 1994, J CELL SCI, V107, P543; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; OBREMSKI VJ, 1995, DEV BIOL, V168, P124, DOI 10.1006/dbio.1995.1066; Pall EA, 1996, J BIOL CHEM, V271, P3817; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; Ryan MC, 1996, MATRIX BIOL, V15, P369, DOI 10.1016/S0945-053X(96)90157-2; SANDROCK AW, 1987, P NATL ACAD SCI USA, V84, P6934, DOI 10.1073/pnas.84.19.6934; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SHARP AH, 1989, J BIOL CHEM, V264, P2816; SHORER Z, 1995, J CHILD NEUROL, V10, P472, DOI 10.1177/088307389501000610; SKUBITZ APN, 1991, J CELL BIOL, V115, P1137, DOI 10.1083/jcb.115.4.1137; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; WANG GY, 1992, BRAIN RES, V570, P116, DOI 10.1016/0006-8993(92)90571-P; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; Yamada H, 1996, J NEUROCHEM, V66, P1518; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981	46	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26708	26713		10.1074/jbc.272.42.26708	http://dx.doi.org/10.1074/jbc.272.42.26708			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334255	hybrid			2022-12-27	WOS:A1997YB13900089
J	Bendall, HH; Scherer, DC; Edson, CR; Ballard, DW; Oltz, EM				Bendall, HH; Scherer, DC; Edson, CR; Ballard, DW; Oltz, EM			Transcription factor NF-kappa B regulates inducible Oct-2 gene expression in precursor B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL DIFFERENTIATION; PROTEIN; ACTIVATION; DEFECTS; DOMAIN	The POU transcription factors Oct-1 and Oct-2 regulate the activity of octamer-dependent promoters, including those that direct transcription from rearranged immunoglobulin genes, Unlike Oct-1, which is constitutively expressed in many cell types, Oct-2 expression is restricted primarily to B lymphocytes and can be induced in precursor B cells by stimulation with bacterial Lipopolysaccharide (LPS), However, the precise factors that mediate this induction mechanism remain unknown. In the present study, we monitored Oct-2; expression in cells arrested for the activation of NF-kappa B, an LPS-responsive member of the Rel transcription factor family. Despite stimulation with LPS, disruption of the NF-kappa B signaling pathway in precursor B cells led to the loss of inducible Oct-2 DNA binding activity in vitro and the suppression of Oct-2-directed transcription in vivo. This biochemical defect correlated with a specific block to Oct-2 gene expression at the level of transcription, whereas the expression of Oct-1 was unaffected. The finding that Oct-2 is under NF-kappa B control highlights an important cross-talk mechanism involving two distinct transcription factor families that regulate B lymphocyte function.	VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232	Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University					NIAID NIH HHS [AI01412, AI36944, AI33839] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036944, R21AI036944, R01AI033839] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BAUERLE PA, 1988, SCIENCE, V242, P540; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; GSTAIGER M, 1995, NATURE, V373, P60; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; KEMLER I, 1990, FASEB J, V4, P1444, DOI 10.1096/fasebj.4.5.2407588; KONIG H, 1995, GENE DEV, V9, P1598, DOI 10.1101/gad.9.13.1598; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MILLER CL, 1991, MOL CELL BIOL, V11, P4885, DOI 10.1128/MCB.11.10.4885; OBrien DP, 1997, MOL CELL BIOL, V17, P3477, DOI 10.1128/MCB.17.7.3477; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; Scherer DC, 1996, IMMUNITY, V5, P563, DOI 10.1016/S1074-7613(00)80271-X; Schubart DB, 1996, NUCLEIC ACIDS RES, V24, P1913, DOI 10.1093/nar/24.10.1913; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Shaffer AL, 1997, IMMUNITY, V6, P131, DOI 10.1016/S1074-7613(00)80420-3; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0	22	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28826	28828		10.1074/jbc.272.46.28826	http://dx.doi.org/10.1074/jbc.272.46.28826			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360945				2022-12-27	WOS:A1997YF68400004
J	DaSilva, J; Pierrat, B; Mary, JL; Lesslauer, W				DaSilva, J; Pierrat, B; Mary, JL; Lesslauer, W			Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; INFLAMMATORY CYTOKINES; FACTOR RECEPTORS; MAMMALIAN-CELLS; MAPKAP KINASE-2; MESSENGER-RNA; MICE LACKING; TNF RECEPTOR; STRESS	Treatment of mouse astrocyte cultures with combined interleukin (IL)-1 alpha and tumor necrosis factor (TNF)-alpha induced expression of inducible nitric-oxide synthase (iNOS), resulting in sustained release of large amounts of nitric oxide, whereas TNF-alpha and IL-1 alpha individually were unable to induce iNOS expression in astrocytes. The role of MAPK cascades and of NF-kappa B activation in the early intracellular signal transduction involved in iNOS transcription in TNF-alpha/IL-1 alpha-stimulated astrocytes was investigated. TNF-alpha and IL-1 alpha activated all p42/44(MAPK), p38(MAPK), and p54(JNK) pathways as determined by immunoprecipitation kinase assays using specific antibodies and substrates, The p38(MAPK) pathway is specifically involved in TNF-alpha/IL-1 alpha-induced iNOS expression, since iNOS protein and nitric oxide release in the presence of a specific inhibitor of p38(MAPK), 4-(4-fluorophenyl)-2 -2-(4-hydroxyphenyl)-5-(4-pyridyl)-imidazole (FHPI), were dramatically diminished. In contrast, PD98059, a specific inhibitor of MEK1 had no effect on iNOS expression, p38(MAPK) did not couple NF-kappa B to iNOS transcription, but NF-KB had a clear role in NOS transcription regulation, Northern blot analysis showed that the p38(MAPK) pathway controlled iNOS expression at the transcriptional level, since iNOS mRNA was reduced in the presence of FHPI in TNF-alpha/IL-1 alpha-stimulated astrocytes. iNOS expression was investigated with TNF receptor (TNFR)-1- and TNFR-2-deficient mice, The TNF-alpha activity in TNF-alpha/IL-1 alpha-stimulated astrocytes was exclusively mediated through TNFR-1, most likely because TNFR-2-mediated signals in astrocytes did not connect to the p38(MAPK) pathway. These data suggest that TNF-alpha/IL-1 alpha-induced iNOS expression depends on a yet undetermined second pathway in addition to p38(MAPK).			DaSilva, J (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PRPN,DEPT CENT NERVOUS SYST DIS,CH-4070 BASEL,SWITZERLAND.							Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU SC, 1995, J BIOL CHEM, V270, P10625, DOI 10.1074/jbc.270.18.10625; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P32028, DOI 10.1074/jbc.271.50.32028; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding MZ, 1997, J BIOL CHEM, V272, P11327; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EBERHARDT W, 1994, BIOCHEM BIOPH RES CO, V200, P163, DOI 10.1006/bbrc.1994.1429; Farivar RS, 1996, J BIOL CHEM, V271, P31585, DOI 10.1074/jbc.271.49.31585; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; FISCHER G, 1985, EXP CELL RES, V159, P273, DOI 10.1016/S0014-4827(85)80001-X; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; KANNO K, 1994, AM J PHYSIOL-HEART C, V267, pH2318, DOI 10.1152/ajpheart.1994.267.6.H2318; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; Kopnisky KL, 1997, J NEUROCHEM, V68, P935; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEIST M, 1995, J IMMUNOL, V154, P1307; Liu J, 1996, J IMMUNOL, V157, P3569; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nishiya T, 1997, FEBS LETT, V408, P33, DOI 10.1016/S0014-5793(97)00383-9; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Pietersma A, 1997, BIOCHEM BIOPH RES CO, V230, P44, DOI 10.1006/bbrc.1996.5886; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Ridley SH, 1997, J IMMUNOL, V158, P3165; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salkowski CA, 1997, J IMMUNOL, V158, P905; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; SHERMAN MP, 1993, BIOCHEM BIOPH RES CO, V191, P1301, DOI 10.1006/bbrc.1993.1359; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Vieira LQ, 1996, J IMMUNOL, V157, P827; WANG X, 1996, SCIENCE, V272, P1247; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; XIE QW, 1994, J BIOL CHEM, V269, P4705; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531	61	258	266	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28373	28380		10.1074/jbc.272.45.28373	http://dx.doi.org/10.1074/jbc.272.45.28373			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353295	hybrid			2022-12-27	WOS:A1997YF21900035
J	Deloche, O; Liberek, K; Zylicz, M; Georgopoulos, C				Deloche, O; Liberek, K; Zylicz, M; Georgopoulos, C			Purification and biochemical properties of Saccharomyces cerevisiae Mdj1p, the mitochondrial DnaJ homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; ATPASE ACTIVITY; INNER MEMBRANE; NMR STRUCTURE; J-DOMAIN; GRPE; BINDING; HSP70	The DnaK/DnaJ/GrpE heat shock proteins of Escherichia coli constitute the prototype DnaK chaperone machine. Various studies have shown that these three proteins work synergistically in a diverse array of biological functions, including protein folding and disaggregation, proteolysis, and transport across biological membranes, We have overexpressed and purified the mitochondrial Saccharomyces cerevisiae DnaJ homologue, Mdj1p Delta 55, which lacks the mitochondrial presequence, and studied its biochemical properties in well defined in vitro systems, We find that Mdj1p Delta 55 interacts with DnaK as judged both by an enzyme-linked immunosorbent assay, as well as stimulation of DnaK's weak ATPase activity in the presence of GrpE, In addition, Mdj1p Delta 55 not only interacts with denatured firefly luciferase on its own, but also enables DnaK to bind to it in an ATP-dependent mode, Using co-immunoprecipitation assays we can demonstrate the presence of a stable Mdj1p Delta 55-luciferase-DnaK complex. However, in contrast to DnaJ, Mdj1p Delta 55 does not appear to interact well with certain seemingly folded proteins, such as the sigma (32) heat shock transcription factor or the lambda P DNA replication protein, Finally, Mdj1p Delta 55 can substitute perfectly well for DnaJ in the refolding of denatured firefly luciferase by the DnaK chaperone machine. These studies demonstrate that Mdj1p Delta 55 has conserved most of DnacJ's known biological properties, thus supporting an analogous functional role in yeast mitochondria.	UNIV GDANSK, DEPT CELLULAR & MOL BIOL, PL-80822 GDANSK, POLAND	Fahrenheit Universities; University of Gdansk	Deloche, O (corresponding author), CTR MED UNIV GENEVA, DEPT BIOCHIM MED, 1 RUE MICHEL SERVET, CH-1211 GENEVA 4, SWITZERLAND.		Liberek, Krzysztof/F-5812-2011	Liberek, Krzysztof/0000-0002-7532-9279				Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Deloche O, 1996, J BIOL CHEM, V271, P23960, DOI 10.1074/jbc.271.39.23960; Deloche O, 1997, J BACTERIOL, V179, P6066, DOI 10.1128/jb.179.19.6066-6075.1997; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1994, BIOL HEAT SHOCK PROT, P53; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; Miao BJ, 1997, J MOL BIOL, V265, P541, DOI 10.1006/jmbi.1996.0762; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; PripBuus C, 1996, FEBS LETT, V380, P142, DOI 10.1016/0014-5793(96)00049-X; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; WALL D, 1994, J BIOL CHEM, V269, P5446; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; Westermann B, 1996, MOL CELL BIOL, V16, P7063; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; [No title captured]	36	20	22	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28539	28544		10.1074/jbc.272.45.28539	http://dx.doi.org/10.1074/jbc.272.45.28539			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353316	hybrid			2022-12-27	WOS:A1997YF21900056
J	Glover, CJ; Hartman, KD; Felsted, RL				Glover, CJ; Hartman, KD; Felsted, RL			Human N-myristoyltransferase amino-terminal domain involved in targeting the enzyme to the ribosomal subcellular fraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MYRISTOYL-COA; DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BOVINE BRAIN; GENE-PRODUCT; RNA-BINDING; SUBSTRATE-SPECIFICITY; TRANSFERASE-ACTIVITY; CANDIDA-ALBICANS	N-Myristoyltransferase (NMT) catalyzes the cotranslational acylation with myristic acid of the NH2-terminal glycines of a number of cellular and viral proteins. Most of the in vitro NMT activity (60-85%) in isoosmotic cell homogenates of human lymphoblastic leukemia (i.e. CEM and MOLT-4) and cervical carcinoma (i.e. HeLa) cells was shown to be associated with the ribosomal subcellular fractions by differential centrifugation. Also found in the ribosomal fractions was a approximate to 60-kDa protein that was specifically immunoblotted with an anti-human NMT (hNMT) peptide antibody. This approximate to 60-kDa protein was stable in the presence of proteolytic enzyme inhibitors but was gradually converted into a approximate to 46-kDa species when stored in the absence of protease inhibitors. Sucrose density gradient centrifugation of the ribosomal fraction resulted in the hNMT activity sedimenting exactly coincident with the 260 nm absorption profile and exhibiting A(260)/A(260) absorption ratios >1.8, indicating an association of NMT with putative ribosomal particle (s)/subunit(s), The subcellular targeting of hNMT was also examined by immunoblotting subcellular fractions from HeLa cells transfected with plasmids containing FLAG epitope-tagged hNMT inserts corresponding either to the originally assigned hNMT gene or to an alternative open reading frame initiated from an in-frame start site upstream from the assumed hNMT start site. Anti-FLAG immunoblotting of cells transfected with a plasmid containing the larger insert revealed FLAG-NMT primarily in the ribosomal fraction with an apparent molecular mass similar to the approximate to 60-kDa native hNMT. In contrast, immunoblotting of cells transfected with a plasmid containing the smaller insert identified a approximate to 50-kDa FLAG-NMT predominantly in the cytosolic fraction. An analysis of mixtures of CEM ribosomes and serial dilutions of purified recombinant FLAG-NMTs demonstrated that the approximate to 60-kDa FLAG-NMT binds ribosomes with higher affinity than the approximate to 50-kDa FLAG-NMT. These in vivo and-in vitro subcellular targeting and recombinant expression experiments identify a native hNMT that is 10-12 kDa larger than the enzyme predicted by the originally assigned hNMT gene and which is apparently translated from an alternative up stream start site. The data also indicate that although the unique NH2-terminal residues encoded by this larger open reading frame are not required for in vitro catalytic activity, they do provide signal(s) involved in targeting hNMT to the ribosomal subcellular fraction where cotranslational N-myristoylation occurs.			Glover, CJ (corresponding author), NCI,PHARMACOL & EXPT THERAPEUT SECT,NIH,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,FREDERICK,MD 21702, USA.							AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; BHARUCHA AD, 1992, METHOD ENZYMOL, V216, P168; Borgese N, 1996, J CELL BIOL, V135, P1501, DOI 10.1083/jcb.135.6.1501; BOUTIN JA, 1991, EUR J BIOCHEM, V201, P257, DOI 10.1111/j.1432-1033.1991.tb16282.x; BOUTIN JA, 1993, EUR J BIOCHEM, V214, P853, DOI 10.1111/j.1432-1033.1993.tb17989.x; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CLARK RJ, 1971, NATURE-NEW BIOL, V229, P101, DOI 10.1038/newbio229101a0; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FELSTED RL, 1995, J NATL CANCER I, V87, P1571, DOI 10.1093/jnci/87.21.1571; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLOVER CJ, 1988, BIOCHEM J, V250, P485, DOI 10.1042/bj2500485; GLOVER CJ, 1995, J BIOL CHEM, V270, P23226, DOI 10.1074/jbc.270.39.23226; GLOVER CJ, 1991, BIOCHEM PHARMACOL, V41, P1067, DOI 10.1016/0006-2952(91)90215-Q; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GRAHAM JM, 1993, BIOMEMBRANE PROTOCOL, V19, P1; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; KING MJ, 1992, MOL CELL BIOCHEM, V113, P77; KING MJ, 1991, FASEB J, V5, pA1157; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; KNOLL LJ, 1995, METHOD ENZYMOL, V250, P405; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODGE JK, 1994, J BIOL CHEM, V269, P2996; MAGNUSON BA, 1995, J NATL CANCER I, V87, P1630, DOI 10.1093/jnci/87.21.1630; Magnuson BA, 1996, BBA-LIPID LIPID MET, V1300, P119, DOI 10.1016/0005-2760(95)00240-5; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MCILHINNEY RAJ, 1994, EUR J BIOCHEM, V222, P137, DOI 10.1111/j.1432-1033.1994.tb18851.x; MCILHINNEY RAJ, 1993, BIOCHEM J, V290, P405, DOI 10.1042/bj2900405; McIlhinney RAJ, 1996, EXP CELL RES, V223, P348, DOI 10.1006/excr.1996.0090; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NOLL H, 1967, NATURE, V215, P360, DOI 10.1038/215360a0; Ntwasa M, 1997, J CELL SCI, V110, P149; OLSON EN, 1986, J BIOL CHEM, V261, P2458; PALMITER RD, 1974, BIOCHEMISTRY-US, V13, P3606, DOI 10.1021/bi00714a032; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; RAJU RVS, 1995, MOL CELL BIOCHEM, V149, P191, DOI 10.1007/BF01076577; Raju RVS, 1996, MOL CELL BIOCHEM, V155, P69, DOI 10.1007/BF00714335; RAJU RVS, 1994, J BIOL CHEM, V269, P12080; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; Rigacci S, 1996, J BIOL CHEM, V271, P1278, DOI 10.1074/jbc.271.3.1278; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SPEDDING G, 1990, RIBOSOMES PROTEIN SY, P1; STEENSGAARD J, 1970, EUR J BIOCHEM, V16, P66, DOI 10.1111/j.1432-1033.1970.tb01054.x; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; VANDERZEIJST BAM, 1975, HDB BIOCH MOL BIOL, V1, P426; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; Watanabe Y, 1996, BIOCHEMISTRY-US, V35, P562, DOI 10.1021/bi951703+; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; Wu SY, 1996, BIOCHEMISTRY-US, V35, P8275, DOI 10.1021/bi953028+; WU SY, 1993, J BIOL CHEM, V268, P10796; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; YU G, 1992, VIROLOGY, V187, P46, DOI 10.1016/0042-6822(92)90293-X; YU G, 1995, J BIOL CHEM, V270, P4792, DOI 10.1074/jbc.270.9.4792; Zwerner R K, 1979, Methods Enzymol, V58, P221	78	73	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28680	28689		10.1074/jbc.272.45.28680	http://dx.doi.org/10.1074/jbc.272.45.28680			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353336	hybrid			2022-12-27	WOS:A1997YF21900076
J	Mehta, DP; Etchison, JR; Wu, RR; Freeze, HH				Mehta, DP; Etchison, JR; Wu, RR; Freeze, HH			UDP-GlcNAc:Ser-protein N-acetylglucosamine-1-phosphotransferase from Dictyostelium discoideum recognizes serine-containing peptides and eukaryotic cysteine proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; LINKED OLIGOSACCHARIDES; IDENTIFICATION; GLYCOSYLATION; SPECIFICITY; PHOSPHORYLATION; PURIFICATION; TRANSFERASE; ANALOGS; GALNAC	Phosphoglycosylation catalyzed by UDP-GlcNAc:Ser-protein N-acetylglucosamine-1-phosphotransferase (Ser:GlcNAc phosphotransferase) adds GlcNAc alpha-1-P to peptidyl-Ser of selected Dictyostelium discoideum proteins, Lysosomal cysteine proteinase (CP), proteinase-1(CP7), is the major phosphoglycosylated protein in bacterially grown amoebae. GlcNAc-1-P is added within a Ser-rich domain containing SSS, SGSG, or SGSQ repeated motifs that are not found in other papain-like CPs, We studied the substrate specificity. of the transferase using peptides containing these motifs and 12 other peptides with one or more Ser residues, Phosphoglycosylation is comparable for all three Dictyostelium CP motifs, but it is not restricted to them, Flanking residues in the other peptides strongly influence phosphoglyco, sylation efficiency, Dictyostelium microsomal membranes also phosphoglycosylate endogenous accepters, and some of these accepters occur as an 18 S complex with the transferase, CP-serine motif peptides inhibit endogenous acceptor phosphoglycosylation weakly (30-40%) at 800 mu M, whereas catalytically inactive proteinase-1(CP7) and other non-phosphoglycosylated eukaryotic CPs, lacking the serine domain, inhibit transferase activity at 1-4 mu M. SDS denaturation destroys the inhibitory potential of all CPs showing that transferase recognizes a conformation-dependent feature that is shared by all, Proteinase-1(CP7) expressed in Escherichia coli lacks GlcNAc-1-P, but it is a substrate for Ser:GlcNAc phosphotransferase, K-m = 5.6 mu M. Thus, Ser: GlcNAc phosphotransferase recognizes both acceptor peptide sequences and a conformational feature of eukaryotic CPs, This may be physiologically important for establishing or maintaining non-overlapping groups of GlcNAc-1-P- and Man-6-P-modified Dictyostelium proteins that reside in functionally distinct endo-lysosomal vesicles.	BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute				Freeze, Hudson/0000-0001-6316-0501	PHS HHS [R01 32485] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANASTASI A, 1983, BIOCHEM J, V211, P129, DOI 10.1042/bj2110129; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Capasso JM, 1996, BBA-BIOMEMBRANES, V1281, P15, DOI 10.1016/0005-2736(95)00298-7; DAWSON RMC, 1986, DATA BIOCH RES, P485; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; Etchison JR, 1996, GLYCOBIOLOGY, V6, P177, DOI 10.1093/glycob/6.2.177; FREEZE HH, 1992, J BIOL CHEM, V267, P4431; FREEZE HH, 1995, BIOCHEM BIOPH RES CO, V208, P384, DOI 10.1006/bbrc.1995.1349; FREEZE HH, 1997, NEW COMPREHENSIVE BI, V29, P91; GUSTAFSON GL, 1984, METHOD ENZYMOL, V107, P172; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1986, J BIOL CHEM, V261, P6320; LANG L, 1984, J BIOL CHEM, V259, P4663; MAEDA K, 1971, J ANTIBIOT, V24, P402, DOI 10.7164/antibiotics.24.402; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Mehta DP, 1996, J BIOL CHEM, V271, P10897, DOI 10.1074/jbc.271.18.10897; MEHTA DP, 1995, ARCH BIOCHEM BIOPHYS, V321, P191, DOI 10.1006/abbi.1995.1385; MERELLO S, 1995, J BIOL CHEM, V270, P7281, DOI 10.1074/jbc.270.13.7281; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; Ord T, 1997, ARCH BIOCHEM BIOPHYS, V339, P64, DOI 10.1006/abbi.1996.9870; RITONJA A, 1989, FEBS LETT, V247, P419, DOI 10.1016/0014-5793(89)81383-3; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Souza GM, 1997, J CELL SCI, V110, P2239; SOUZA GM, 1995, J BIOL CHEM, V270, P28938, DOI 10.1074/jbc.270.48.28938; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9	31	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28638	28645		10.1074/jbc.272.45.28638	http://dx.doi.org/10.1074/jbc.272.45.28638			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353330	hybrid			2022-12-27	WOS:A1997YF21900070
J	Oluwatosin, YE; Kane, PM				Oluwatosin, YE; Kane, PM			Mutations in the CYS4 gene provide evidence for regulation of the yeast vacuolar H+-ATPase by oxidation and reduction in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; CYSTATHIONINE BETA-SYNTHASE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CYSTEINE BIOSYNTHESIS; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; SHUTTLE VECTORS; ENZYME COMPLEX; ACIDIFICATION	The vma41-1 mutant was identified in a genetic screen designed to identify novel genes required for vacuolar H+-ATPase activity in Saccharomyces cerevisiae. The VMA41 gene was cloned and shown to be allelic to the CYS4 gene, The CYS4 gene encodes the first enzyme: in cysteine biosynthesis, and in addition to cysteine auxotrophy, cys4 mutants have much lower levels of intracellular glutathione than wild-type cells. cys4 mutants display the pH-dependent growth phenotypes characteristic of vma mutants and are unable to accumulate quinacrine in the vacuole, indicating loss of vacuolar acidification in vivo. The vacuolar proton-translocating ATPases (V-ATPase) is synthesized at normal levels and assembled at the vacuolar membrane in cys4 mutants, but its specific activity is reduced (47% of wild type) and the activity is unstable. Addition of reduced glutathione to the growth medium complements the pH-dependent growth phenotype, partially restores vacuolar acidification, and restores wild type levels of ATPase activity. The CYS4 gene was deleted in a strain in which the catalytic site cysteine residue implicated in oxidative inhibition of the yeast V-ATPase has been mutagenized (Liu, Q., Leng, X.-H., Newman, P., Vasilyeva, E., Kane, P. M., and Forgac, M. (1997) J. Biol. Chem. 272, 11750-11756). This catalytic site point mutation suppresses the effects of the cys4 mutation. The data indicate that the acidification defect of cys4 mutants arises from inactivation of the vacuolar ATPase in the less reducing cytosol resulting from loss of Cys4p activity and provide the first evidence for the modulation of V-ATPase activity by the redox state of the environment in vivo.	SUNY HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NIGMS NIH HHS [R01 GM050322, R01-GM50322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; Chaudhuri B, 1997, GENETICS, V145, P75; CHEREST H, 1993, J BACTERIOL, V175, P5366, DOI 10.1128/JB.175.17.5366-5374.1993; Ciriolo MR, 1997, J BIOL CHEM, V272, P2700, DOI 10.1074/jbc.272.5.2700; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DSCHIDA WJA, 1995, J BIOL CHEM, V270, P1557, DOI 10.1074/jbc.270.4.1557; ELSKENS MT, 1991, J GEN MICROBIOL, V137, P637, DOI 10.1099/00221287-137-3-637; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Forgac M, 1996, SOC GEN PHY, V51, P121; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KIBAK H, 1993, J BIOL CHEM, V268, P23325; KLAPHOLZ S, 1982, GENETICS, V100, P387; KRUGER WD, 1994, P NATL ACAD SCI USA, V91, P6614, DOI 10.1073/pnas.91.14.6614; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; ONO B, 1992, CURR GENET, V21, P285, DOI 10.1007/BF00351684; ONO BI, 1988, J BACTERIOL, V170, P5883, DOI 10.1128/jb.170.12.5883-5889.1988; PASZEWSKI A, 1992, CURR GENET, V22, P273, DOI 10.1007/BF00317920; RANDOLPH E, 1992, BIOTECHNIQUES, V13, P18; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHERMAN F, 1982, METHODS YEAST GENETI, P177; SIKORSKI RS, 1989, GENETICS, V122, P19; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; TAIZ L, 1994, BBA-BIOMEMBRANES, V1194, P329, DOI 10.1016/0005-2736(94)90315-8; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	57	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28149	28157		10.1074/jbc.272.44.28149	http://dx.doi.org/10.1074/jbc.272.44.28149			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346971	hybrid			2022-12-27	WOS:A1997YD47300097
J	Souchelnytskyi, S; Tamaki, K; Engstrom, U; Wernstedt, C; tenDijke, P; Heldin, CH				Souchelnytskyi, S; Tamaki, K; Engstrom, U; Wernstedt, C; tenDijke, P; Heldin, CH			Phosphorylation of Ser(465) and Ser(467) in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE KINASE RECEPTORS; MAD-RELATED PROTEIN; TGF-BETA; ACTS DOWNSTREAM; FAMILY SIGNALS; I RECEPTORS; COMPLEX; MOTHERS; ACTIVIN; DPP	Members of the Smad family of intracellular signal transducers are essential for transforming growth factor-beta (TGF-beta) to exert its multifunctional effects. After activation of TGF-beta receptors, Smad2 and Smad3 be come phosphorylated and form heteromeric complexes with Smad4. Thereafter, these activated Smad complexes translocate to the nucleus, where they may direct transcriptional responses, Here we report that TGF-beta mediates phosphorylation of Smad2 at two serine residues in the C terminus, i.e. Ser(465) and Ser(467), which are phosphorylated in an obligate order; phosphorylation of Ser(465) requires that Ser467 be phosphorylated. Transfection of Smad2 with mutation of Ser(465) and/or Ser(467) to alanine residues into Mv1Lu cells resulted in dominant-negative inhibition of TGF-beta signaling. These Smad2 mutants were found to stably interact with an activated TGF-beta receptor complex, in contrast to wild-type Smad2, which interacts only transiently, Mutation of Ser(465) and Ser(467) in Smad2 abrogated complex formation of this mutant with Smad4 and blocked the nuclear accumulation not only of Smad2, but also of Smad4. Thus, heteromeric complex formation of Smad2 with Smad4 is required for nuclear translocation of Smad4. Moreover, peptides from the C terminus of Smad2 containing phosphorylated Ser(465) and Ser467 were found to bind Smad4 in vitro, whereas the corresponding unphosphorylated peptides were less effective, Thus, phosphorylated Ser(465) and Ser(467) in Smad2 may provide a recognition site for interaction with Smad4, and phosphorylation of these sites is a key event in Smad2 activation.			Souchelnytskyi, S (corresponding author), LUDWIG INST CANC RES, BOX 595, S-75124 UPPSALA, SWEDEN.		Dijke, Peter ten/AAG-4660-2021; Souchelnytskyi, Serhiy/J-9446-2014; Souchelnytskyi, Serhiy/G-6491-2011	Dijke, Peter ten/0000-0002-7234-342X; Souchelnytskyi, Serhiy/0000-0001-8243-9276				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; LIN HY, 1993, TRENDS CELL BIOL, V11, P972; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CANCER SURV, V27, P41; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Meersseman G, 1997, MECH DEVELOP, V61, P127, DOI 10.1016/S0925-4773(96)00629-6; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	46	325	347	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28107	28115		10.1074/jbc.272.44.28107	http://dx.doi.org/10.1074/jbc.272.44.28107			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346966	hybrid			2022-12-27	WOS:A1997YD47300092
J	Yamauchi, JJ; Nagao, M; Kaziro, Y; Itoh, H				Yamauchi, JJ; Nagao, M; Kaziro, Y; Itoh, H			Activation of p38 mitogen-activated protein kinase by signaling through G protein-coupled receptors - Involvement of G beta gamma and G alpha(q/11) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; C-JUN KINASE; MAP KINASE; TRANSDUCTION PATHWAY; DEPENDENT ACTIVATION; REGULATED KINASE; ALPHA-SUBUNITS; MESSENGER-RNAS; CDNA CLONING; COS-7 CELLS	Various extracellular stimuli activate three classes of mitogen-activated protein kinases (MAPKs): extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 MAPK. In mammalian cells, p38 MAPK is activated by endotoxins, inflammatory cytokines, and environmental stresses, We show here that p38 MAPK is also activated upon stimulation of G protein-coupled receptors (G(q)/G(11)-coupled m1 and G(i)-coupled m2 muscarinic acetylcholine and G(s)-coupled beta-adrenergic receptors) in human embryonal kidney 293 cells. The activation of p38 MAPK through the m2 and beta-adrenergic receptors was completely inhibited by coexpression of G alpha(o), whereas the activation by the mi receptor was only partially inhibited. Furthermore, we show that overexpression of G beta gamma or a constitutively activated mutant of G alpha(11), but not G alpha(s) and G alpha(i), can stimulate p38 MAPK. These results suggest that the signal from the m2 and beta-adrenergic receptors to p38 MAPK is mediated by G beta gamma, whereas the signal from the m1 receptor is mediated by both G beta gamma and G alpha(q/11).	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology								ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FAURE M, 1994, J BIOL CHEM, V269, P7851; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1993, J BIOL CHEM, V268, P25009; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; ITOH H, 1988, J BIOL CHEM, V263, P6656; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LUTHIN GR, 1984, MOL PHARMACOL, V26, P164; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PERELTA EG, 1987, EMBO J, V6, P3923; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SHREEVE SM, 1984, J BIOL CHEM, V259, P2398; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamauchi J, 1997, J BIOL CHEM, V272, P7602, DOI 10.1074/jbc.272.12.7602; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	62	126	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27771	27777		10.1074/jbc.272.44.27771	http://dx.doi.org/10.1074/jbc.272.44.27771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346921	hybrid			2022-12-27	WOS:A1997YD47300047
J	Bennett, KL; Bradshaw, J; Youngman, T; Rodgers, J; Greenfield, B; Aruffo, A; Linsley, PS				Bennett, KL; Bradshaw, J; Youngman, T; Rodgers, J; Greenfield, B; Aruffo, A; Linsley, PS			Deleted in colorectal carcinoma (DCC) binds heparin via its fifth fibronectin type III domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; RECEPTOR; CELLS; ADHESION; MOLECULE; HOMOLOG; ENCODES; CANCER	DCC (deleted in colorectal carcinoma) is a broadly expressed cell-surface receptor. Netrin-1 was recently identified as a DCC ligand in brain, but the possibility of other DCC ligands was suggested by the finding that an anti-DCC antibody (clone AF5) neutralized netrin-1-dependent commissural axon outgrowth without blocking DCC/netrin-1 interactions. Here we have searched for alternative cell-surface DCC ligands. A DCC-Ig fusion protein bound to neural and epithelial derived cell lines, indicating that these lines express ligand(s) for DCC. The cell-surface binding activity was mediated by the loop between beta-strands F and G of the fifth fibronectin type III repeat FNIII-D5. The loop included the sequence KNRR, which resembles heparin-binding motifs in other proteins. Heparinase and heparitinase treatment of cells reduced binding of DCC-Ig, suggesting that heparan sulfate proteoglycans are cell-surface DCC ligand(s). This was further supported by heparin blocking experiments and by binding of DCC-Ig to immobilized heparan sulfate. The interaction between DCC-Ig and heparan sulfate/heparin, both on the surface of cells and immobilized on plastic, was blocked by the same anti-DCC antibody that blocks netrin-1-dependent commissural axon outgrowth. Taken together, these findings suggest that the DCC-Ig/heparin interaction may contribute to the biological activity to DCC.			Bennett, KL (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,POB 4000,OFF K4430B,PRINCETON,NJ 08543, USA.							ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; DRAKE SL, 1993, J BIOL CHEM, V268, P15859; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1996, BIOCHIM BIOPHYS ACTA, V1288, P17; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; WEBER P, 1995, J BIOL CHEM, V270, P4619, DOI 10.1074/jbc.270.9.4619	20	60	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26940	26946		10.1074/jbc.272.43.26940	http://dx.doi.org/10.1074/jbc.272.43.26940			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341129	hybrid			2022-12-27	WOS:A1997YC65900025
J	Falcon, CM; SwintKruse, L; Matthews, KS				Falcon, CM; SwintKruse, L; Matthews, KS			Designed disulfide between N-terminal domains of lactose repressor disrupts allosteric linkage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSIN-RESISTANT CORE; LAC REPRESSOR; CRYSTAL-STRUCTURE; DNA-BINDING; OPERATOR; PROTEIN; TETRAMER; HEADPIECE; SEQUENCE; INDUCER	Substitution of Cys for Val at position 52 of the lac repressor was designed to permit disulfide bond formation between the two N-terminal DNA binding domains that comprise an operator DNA binding site. This position marks the closest approach of these domains based on the x-ray crystallographic structures of the homologous purine holorepressor-operator complex and lac repressor-operator complex (Schumacher, M. A., Choi, R. Y,, Zalkin, H., and Brennan, R, G, (1994) Science 266, 763-710; Lewis, M., Chang, G., Horton, N.C., Kercher, M. A., Pace, H. C., Schumacher, M. A., Brennan, R. G., and Lu, P. (1996) Science 271, 1247-1254), The V52C mutation was generated by site-specific methods, and the mutant protein was purified and characterized. In the reduced form, V52C bound operator DNA with slightly increased affinity, Exposure to oxidizing conditions resulted in disulfide bond formation, and the oxidized protein bound operator DNA with similar to 6-fold higher affinity than wild-type protein, Inducer binding for both oxidized and reduced forms of V52C was comparable to wild-type bac repressor, In the presence of inducer, the reduced protein exhibited wild-type, diminished DNA binding. In contrast, DNA binding for the oxidized form was unaffected by inducer, even at 1 mM. Thus, the formation of the designed disulfide between Cys(52) Side chains within each dimer renders the protein-operator complex unresponsive to sugar binding, presumably by disrupting the allosteric linkage between operator and inducer binding.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005	Rice University				Swint-Kruse, Liskin/0000-0002-5925-9741	NIGMS NIH HHS [GM 22441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER K, 1972, NATURE, V237, P322, DOI 10.1038/237322a0; ALBERTI S, 1991, NEW BIOL, V3, P57; BETZ JL, 1986, GENE, V42, P283, DOI 10.1016/0378-1119(86)90232-5; BEYREUTHER K, 1975, BIOCHEM SOC T, V3, P1125, DOI 10.1042/bst0031125; BOURGEOIS S, 1971, METHODS ENZYMOLOGY D, V21, P491; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5468, DOI 10.1021/bi00367a018; FILES JG, 1976, J BIOL CHEM, V251, P3386; Frank DE, 1997, J MOL BIOL, V267, P1186, DOI 10.1006/jmbi.1997.0920; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; GILBERT W, 1973, P NATL ACAD SCI USA, V70, P3581, DOI 10.1073/pnas.70.12.3581; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KANIA J, 1977, EUR J BIOCHEM, V79, P381, DOI 10.1111/j.1432-1033.1977.tb11819.x; KANIA J, 1976, P NATL ACAD SCI USA, V73, P3529, DOI 10.1073/pnas.73.10.3529; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LAMERICHS RMJN, 1989, BIOCHEMISTRY-US, V28, P2985, DOI 10.1021/bi00433a037; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; MATTHEWS KS, 1997, IN PRESS PROG NUCL A, V58; Miller J. H., 1980, OPERON; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MULLERHILL B, 1977, NUCLEIC ACID PROTEIN, P219; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; PFAHL M, 1974, GENETICS, V76, P669; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Spronk CAEM, 1996, NAT STRUCT BIOL, V3, P916, DOI 10.1038/nsb1196-916; Suckow J, 1996, J MOL BIOL, V261, P509, DOI 10.1006/jmbi.1996.0479; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428	37	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26818	26821		10.1074/jbc.272.43.26818	http://dx.doi.org/10.1074/jbc.272.43.26818			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341111	hybrid			2022-12-27	WOS:A1997YC65900007
J	Li, XM; LopezGuisa, JM; Ninan, N; Weiner, EJ; Rauscher, FJ; Marmorstein, R				Li, XM; LopezGuisa, JM; Ninan, N; Weiner, EJ; Rauscher, FJ; Marmorstein, R			Overexpression, purification, characterization, and crystallization of the BTB/POZ domain from the PLZF oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PROTEIN INTERACTION MOTIF; ZINC-FINGER PROTEINS; TRANSCRIPTION FACTOR; CONSERVED DOMAIN; DNA-BINDING; ALPHA LOCUS; BTB DOMAIN; POZ-DOMAIN; DROSOPHILA	The BTB/POZ domain defines a conserved region of about 120 residues and has been found in over 40 proteins to date. It is located predominantly at the N terminus of Zn-finger DNA-binding proteins, where it may function as a repression domain, and less frequently in actin-binding and poxvirus-encoded proteins, where it may function as a protein-protein interaction interface, A prototypic human BTB/POZ protein, PLZF (promyelocytic Leukemia zinc finger) is fused to RAR alpha (retinoic acid receptor alpha) in a subset of acute promyeloeytic leukemias (APLs), where it acts as a potent oncogene, The exact role of the BTB/POZ domain in protein-protein interactions and/or transcriptional regulation is unknown. We have overexpressed, purified, characterized, and crystallized the BTB/POZ domain from PLZF (PLZF-BTB/POZ). Gel filtration, dynamic light scattering, and equilibrium sedimentation experiments show that PLZF-BTB/POZ forms a homodimer with a K-d below 200 nM. Differential scanning calorimetry and equilibrium denaturation experiments are consistent with the PLZF-BTB/POZ dimer undergoing a two-state unfolding-transition with a T-m of 70.4 degrees C, and a Delta G of 12.8 +/- 0.4 kcal/mel. Circular dichroism shows that the PLZF-BTB/POZ dimer has significant secondary structure including about 45% helix and 20% beta-sheet, The have prepared crystals of the PLZF-BTB/POZ that are suitable for a high resolution structure determination using x-ray crystallography, The crystals form in the space group I222 or I2(1)2(1)2(1) with a = 38.8, b = 77.7, and c = 85.3 Angstrom and contain 1 protein subunit per asymmetric unit, with approximately 40% solvent. Our data support the hypothesis that the ETB/POZ domain mediates a functionally relevant dimerization function in vivo. The crystal structure of the PLZF-BTB/POZ domain will provide a paradigm for understanding the structural basis underlying BTB/POZ domain function.	UNIV PENN,WISTAR INST,PHILADELPHIA,PA 19104; UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			li, xinmin/C-6173-2011					ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BAVISOTTO L, 1991, J EXP MED, V174, P1097, DOI 10.1084/jem.174.5.1097; BROOKS I, 1994, METHOD ENZYMOL, V240, P459; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CUDNEY R, 1994, ACTA CRYSTALLOGR D, V50, P414; DIBELLO PR, 1991, GENETICS, V129, P385; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; FREEMONT PS, 1993, ZINC FINGER PROTEINS; GEWIRTH D, 1993, HKL VERSION 1 0 MANU; GODT D, 1993, DEVELOPMENT, V119, P799; GUIDEZ F, 1994, LEUKEMIA, V8, P312; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEMONS RS, 1995, J PEDIAT HEMATOL ONC, V17, P198, DOI 10.1097/00043426-199508000-00002; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; McPherson A, 1982, PREPARATION ANAL PRO; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; ROWLEY JD, 1977, LANCET, V1, P549; SCOTT WG, 1995, J MOL BIOL, V250, P327, DOI 10.1006/jmbi.1995.0380; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; ZELENT A, 1994, BRIT J HAEMATOL, V86, P451, DOI 10.1111/j.1365-2141.1994.tb04773.x; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	37	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27324	27329		10.1074/jbc.272.43.27324	http://dx.doi.org/10.1074/jbc.272.43.27324			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341182	hybrid			2022-12-27	WOS:A1997YC65900078
J	Scaffidi, C; Medema, JP; Krammer, PH; Peter, ME				Scaffidi, C; Medema, JP; Krammer, PH; Peter, ME			FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; CELL-DEATH; CYSTEINE PROTEASE; MOLECULAR-CLONING; APOPTOSIS; IDENTIFICATION; FAMILY; GENE; INTERACTS; INDUCTION	Induction of apoptosis by the cell surface receptor CD95 (APO-1/Fas) has been shown to involve activation of a family of cysteine proteases (caspases). Recently, a new member of this family has been identified, designated FLICE (caspase-8/MACH/Mch5). FLICE is part of the CD95 death-inducing signaling complex and is therefore the most upstream caspase in the CD95 apo ptotic pathway. A total of eight different isoforms of FLICE (caspase-8/a-h) have been described. To determine which isoforms are expressed in different cells we have generated a panel of monoclonal antibodies directed against all functional domains of FLICE. Using these antibodies we could show that only two of the FLICE isoforms (caspase-8/a and caspase-8/b) were predominantly expressed in cells of different origin. Both isoforms were recruited to the CD95 death-inducing signaling complex and were activated upon CD95 stimulation with similar kinetics. Taken together, only two of the eight published caspase-8 isoforms could be detected in significant amounts at the protein level.	GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Watzl, Carsten/B-4911-2013	Watzl, Carsten/0000-0001-5195-0995; Medema, Jan Paul/0000-0003-3045-2924; Peter, Marcus Ernst/0000-0003-3216-036X				ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Faucheu C, 1996, EUR J BIOCHEM, V236, P207, DOI 10.1111/j.1432-1033.1996.t01-1-00207.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; MUZIO M, 1996, CELL, V85, P807; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; PETER ME, 1997, APOPTOSIS PROBLEMS D; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580	35	362	373	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26953	26958		10.1074/jbc.272.43.26953	http://dx.doi.org/10.1074/jbc.272.43.26953			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341131	hybrid			2022-12-27	WOS:A1997YC65900027
J	Beyer, K; Dandekar, T; Keller, W				Beyer, K; Dandekar, T; Keller, W			RNA ligands selected by cleavage stimulation factor contain distinct sequence motifs that function as downstream elements in 3'-end processing of pre-mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 DNA-POLYMERASE; GROWTH-HORMONE GENE; 3' END FORMATION; MESSENGER-RNA; POLYADENYLATION FACTOR; POLY(A) SITE; BINDING; AAUAAA; REGION; EFFICIENCY	Critical events in 3'-end processing of pre-mRNA are the recognition of the AAUAAA polyadenylation signal by cleavage and polyadenylation specificity factor (CPSF) and the binding of cleavage stimulation factor (CstF) via its 64-kDa subunit to the downstream element. The stability of this CPSF CstF.RNA complex is thought to determine the efficiency of 3'-end processing. Since downstream elements reveal high sequence variability, in vitro selection experiments with highly purified CstF were performed to investigate the sequence requirements for CstF RNA interaction. CstF was purified from calf thymus and from HeLa cells. Surprisingly, calf thymus CstF contained an additional, novel form of the 64-kDa subunit with a molecular mass of 70 kDa. RNA ligands selected by HeLa and calf thymus CstF contained three highly conserved sequence elements as follows: element 1 (AUGCGUUCCUCGUCC) and two closely related elements, element 2a (YGUGUYN(0-4)UUYAYUGYGU) and element 2b (UUGYUN(0-4)AUUUACU(U/G)N0-2YCU). All selected sequences tested functioned as downstream elements in 3'-end processing in vitro. A computer survey of the EMBL data library revealed significant homologies to all selected elements in naturally occurring 3'-untranslated regions. The majority of element 2a homologies was found downstream of coding sequences. Therefore, we postulate that this element represents a novel consensus sequence for downstream elements in 3'-end processing of pre-mRNA.	UNIV BASEL, BIOZENTRUM, DEPT CELL BIOL, CH-4056 BASEL, SWITZERLAND; EUROPEAN MOL BIOL LAB, D-69117 HEIDELBERG, GERMANY	University of Basel; European Molecular Biology Laboratory (EMBL)			Dandekar, Thomas/A-4431-2017	Dandekar, Thomas/0000-0003-1886-7625				BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHEN JS, 1992, NUCLEIC ACIDS RES, V20, P2565, DOI 10.1093/nar/20.10.2565; CHOU ZF, 1994, NUCLEIC ACIDS RES, V22, P2525, DOI 10.1093/nar/22.13.2525; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; DANDEKAR T, 1995, TRENDS GENET, V11, P45, DOI 10.1016/S0168-9525(00)88996-9; DAY INM, 1992, GENE, V110, P245, DOI 10.1016/0378-1119(92)90656-A; EDWALDSGILBERT G, 1995, MOL CELL BIOL, V15, P6420; GIL A, 1987, CELL, V49, P399, DOI 10.1016/0092-8674(87)90292-3; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GIMMI ER, 1988, NUCLEIC ACIDS RES, V16, P8977, DOI 10.1093/nar/16.18.8977; GOODWIN EC, 1992, J BIOL CHEM, V267, P16330; KAHN P, 1990, METHOD ENZYMOL, V183, P23; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; Keller W, 1997, CURR OPIN CELL BIOL, V9, P329, DOI 10.1016/S0955-0674(97)80004-X; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; Manley JL, 1996, SCIENCE, V274, P1481, DOI 10.1126/science.274.5292.1481; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MANN KP, 1993, MOL CELL BIOL, V13, P2411, DOI 10.1128/MCB.13.4.2411; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; MASON PJ, 1986, CELL, V46, P263, DOI 10.1016/0092-8674(86)90743-9; MCDEVITT MA, 1986, EMBO J, V5, P2907, DOI 10.1002/j.1460-2075.1986.tb04586.x; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; RYNER LC, 1989, MOL CELL BIOL, V9, P1759, DOI 10.1128/MCB.9.4.1759; SADOFSKY M, 1985, MOL CELL BIOL, V5, P2713, DOI 10.1128/MCB.5.10.2713; SITTLER A, 1994, NUCLEIC ACIDS RES, V22, P222, DOI 10.1093/nar/22.2.222; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; TAYA Y, 1982, EMBO J, V1, P953, DOI 10.1002/j.1460-2075.1982.tb01277.x; TUERK C, 1990, J MOL BIOL, V213, P749, DOI 10.1016/S0022-2836(05)80261-X; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WAHLE E, 1994, RNA PROCESSING PRACT, P1; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; WOYCHIK RP, 1984, P NATL ACAD SCI-BIOL, V81, P3944, DOI 10.1073/pnas.81.13.3944; Yoshio TD, 1997, MOL CELL BIOL, V17, P3907, DOI 10.1128/MCB.17.7.3907; ZARKOWER D, 1988, J BIOL CHEM, V263, P5780; ZHANG F, 1986, MOL CELL BIOL, V6, P4611, DOI 10.1128/MCB.6.12.4611	48	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26769	26779		10.1074/jbc.272.42.26769	http://dx.doi.org/10.1074/jbc.272.42.26769			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334264	Green Accepted, hybrid			2022-12-27	WOS:A1997YB13900098
J	Verdier, F; Chretien, S; Billat, C; Gisselbrecht, S; Lacombe, C; Mayeux, P				Verdier, F; Chretien, S; Billat, C; Gisselbrecht, S; Lacombe, C; Mayeux, P			Erythropoietin induces the tyrosine phosphorylation of insulin receptor substrate-2 - An alternate pathway for erythropoietin-induced phosphatidylinositol 3-kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; LEUKEMIC-CELL-LINE; SERUM-FREE MEDIUM; GROWTH FACTOR-I; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; INTERFERON-GAMMA; PROTEIN; IRS-1; DIFFERENTIATION	In this report, we demonstrate that insulin receptor substrate-a (IRS-P) is phosphorylated on tyrosine following treatment of UT-7 cells with erythropoietin. We have investigated the expression of IRS-1 and IRS-S in several cell lines with erythroid and/or megakaryocytic features, and we observed that IRS-P was expressed in all cell lines tested. In contrast, we did not detect the expression of IRS-1 in these cells. In response to erythropoietin, IRS-2 was immediately phosphorylated on tyrosine, with maximal phosphorylation between 1 and 5 min. Tyrosine-phosphorylated IRS-P was associated with phosphatidylinositol 3-kinase and with a 140-kDa protein that comigrated with the phosphatidylinositol-3,4,5-trisphosphate B-phosphatase, SHIP. Moreover, IRS-2 was constitutively associated with the erythropoietin receptor. We did not observe the association of IRS-2 with JAK2, Grb2, or PTP1D. Using BaF3 cells transfected with mutated erythropoietin receptors, we demonstrate that neither the tyrosine residues of the intracellular domain nor the last 109 amino acids of the erythropoietin receptor are required for erythropoietin-induced IRS-P tyrosine phosphorylation. Altogether, our results indicate that erythropoietin-induced IRS-S tyrosine phosphorylation could account for the previously reported activation of phosphatidylinositol 3-kinase mediated by erythropoietin receptors mutated in the phosphatidylinositol 3-kinase-binding site.	UNIV PARIS 05, INSERM U363, INST COCHIN GENET MOL, F-75014 PARIS, FRANCE; INST NATL TRANSFUS SANGUINE, F-75015 PARIS, FRANCE; UNIV REIMS, UFR SCI EXACTES & NAT, CNRS UPRES A6021, BIOCHIM LAB, F-51687 REIMS 2, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Reims Champagne-Ardenne			Chretien, Stany/M-5166-2018					ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Berlanga JJ, 1997, J BIOL CHEM, V272, P2050; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; CORREA PN, 1991, BLOOD, V78, P2823; CORREA PN, 1994, BLOOD, V83, P99; DAMEN J, 1992, BLOOD, V80, P1923; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HE TC, 1993, BLOOD, V82, P3530; HE TC, 1994, J BIOL CHEM, V269, P18291; HERMINE O, 1992, BLOOD, V80, P3060; Hilton CJ, 1995, GROWTH FACTORS, V12, P263, DOI 10.3109/08977199509028965; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IKAWA Y, 1976, GANN, V67, P767; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KITAMURA T, 1989, BLOOD, V73, P375; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KOMATSU N, 1991, CANCER RES, V51, P341; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA Y, 1994, J BIOL CHEM, V269, P29962; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Porteu F, 1996, MOL CELL BIOL, V16, P2473; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Welham MJ, 1997, J BIOL CHEM, V272, P1377, DOI 10.1074/jbc.272.2.1377; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	61	76	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26173	26178		10.1074/jbc.272.42.26173	http://dx.doi.org/10.1074/jbc.272.42.26173			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334184	hybrid			2022-12-27	WOS:A1997YB13900018
J	Xie, M; Shao, G; Buyse, IM; Huang, S				Xie, M; Shao, G; Buyse, IM; Huang, S			Transcriptional repression mediated by the PR domain zinc finger gene RIZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-TRANSFORMING GENE; ADENOVIRUS E1A PROTEIN; MAMMALIAN-CELLS; IDENTIFICATION; ACTIVATION; EXPRESSION; PROMOTER; BINDING; TRANSLOCATIONS; MATURATION	The RIZ (G3B or MTB-Zf) zinc finger gene is structurally related to the myeloid leukemia gene, MDS1-EVI1, and the transcription repressor/differentiation factor, PRDI-BF1/BLIMP1, through a conserved amino-terminal motif, the TR domain, Similar-to MDS1-EVI1, RIZ gene normally produces two protein product: that differ by the PR domain, The smaller protein RIZ2 lacks the PR domain of RIZ1 but is otherwise identical to RIZ1. Here we show that RIZ proteins bind to GC-rich or Sp-1-binding elements and repress transcription, Both RIZ1 and RIZ2 repressed the herpes simplex virus thymidine kinase (HSV-TK) promoter, one of the best characterized eukaryotic promoters. Recombinant RIZ1 proteins were able to bind tit HSV-TK promoter. This binding was mediated by the GC-rich Sp-l elements of the promoter and the first three zinc finger motifs of RIZ1. RIZ also encodes a repressor domain that was mapped to the central region of the protein, Fusion of this region to the GAL4 DNA-binding domain generated GAL4 site-dependent transcriptional repressors. We also show that RIZ1 protein can efficiently repress the simian virus 40 (SV40) early promoter, which primarily consists of Sp-l sites; RIZ2, however only weakly repressed this promoter, suggesting a role for PR in modulating RIZ protein function. The data have implications for a role of RIZ proteins in the regulation of cellular gene promoters, many of which are characterized by GC-rich elements.	BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA057496] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA57496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Buyse IM, 1996, GENOMICS, V34, P119, DOI 10.1006/geno.1996.0249; Buyse IM, 1997, J VIROL, V71, P6200, DOI 10.1128/JVI.71.8.6200-6203.1997; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; Mock BA, 1996, GENOMICS, V37, P24, DOI 10.1006/geno.1996.0516; MORISHITA K, 1995, ONCOGENE, V10, P1961; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Muraosa Y, 1996, EUR J BIOCHEM, V235, P471, DOI 10.1111/j.1432-1033.1996.00471.x; MURAOSA Y, 1993, MOL CELL BIOL, V13, P7881, DOI 10.1128/MCB.13.12.7881; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHAPIRO VS, 1995, GENE, V163, P329, DOI 10.1016/0378-1119(95)00420-B; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2	37	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26360	26366		10.1074/jbc.272.42.26360	http://dx.doi.org/10.1074/jbc.272.42.26360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334209	hybrid			2022-12-27	WOS:A1997YB13900043
J	Bhat, MK; Yu, CL; Yap, N; Zhan, QM; Hayashi, Y; Seth, P; Cheng, SY				Bhat, MK; Yu, CL; Yap, N; Zhan, QM; Hayashi, Y; Seth, P; Cheng, SY			Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CO-REPRESSOR; NUCLEAR; PROTEIN; CELLS; GENE; EXPRESSION; PROMOTER; BINDING	Thyroid hormone nuclear receptors (TRs) are ligand-dependent transcription factors which regulate growth, differentiation, and development, The molecular mechanisms by which TRs mediate these diverse effects are unclear, One emerging hypothesis suggests that TRs could mediate these diverse effects via cooperation with different transcription factors/receptors, Indeed, we have recently shown that the human TR subtype beta 1 (h-TR beta 1) interacts with the tumor suppressor p53, p53 is a transcription factor that plays a critical role in cell cycle regulation and tumor development, To assess the physiological relevance of the interaction of h-TR beta 1 with p53, the present study addressed the question as to whether the functions of h-TR beta 1 could be modulated by p53, We first compared the h-TR beta 1-mediated transcriptional activity in two pairs of isogenic cell lines, RKO/RKO E6 and MCF-7/MCF-7 E6, RKO and MCF-7 cells are colon and breast carcinoma cell lines, respectively, that contain p53 but lack TR beta 1, The isogenic RKO E6 and MCF-7 E6 cells are stable clones expressing high levels of papillomavirus type 16 E6 protein, In these cells, the level of p53 protein was lower than the parental cells, The impairment of p53 functions in these EG-containing cells led to an activation of TR beta 1-mediated transcriptional activity, Furthermore, in a growth hormone-producing cell line in which the expression of the growth hormone gene is positively regulated by TRs, overexpression of the wild-type p53 led to repression in the expression of the growth hormone gene, Thus, TRs could cross-talk with p53 in its signaling pathways to regulate gene regulatory functions, The present findings further strengthen the hypothesis that mediation of the pleiotropic effects of T-3 requires the cooperation of TRs with a large network of transcription factors.	NCI, MOL BIOL LAB, MED BRANCH, NIH, BETHESDA, MD 20892 USA; NCI, MOL PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA; NAGOYA UNIV, ENVIRONM MED RES INST, DEPT ENDOCRINOL & METAB, NAGOYA, AICHI 464, JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Nagoya University			Hayashi, Yoshitaka/I-6168-2014	Hayashi, Yoshitaka/0000-0002-7557-4303				BHAT MK, 1995, BIOCHEMISTRY-US, V34, P10591, DOI 10.1021/bi00033a034; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cheng Sheue-Yann, 1995, Journal of Biomedical Science, V2, P77, DOI 10.1007/BF02253060; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DESESI CR, 1986, ENDOCRINOLOGY, V116, P2026; DESESI CR, 1981, ENDOCRINOLOGY, V108, P259; DESESI CR, 1984, ENDOCRINOLOGY, V114, P293; DOBNER PR, 1981, P NATL ACAD SCI-BIOL, V78, P2230, DOI 10.1073/pnas.78.4.2230; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FAN SJ, 1995, CANCER RES, V55, P1649; GUERNSEY D L, 1990, Critical Reviews in Oncogenesis, V1, P389; Hayashi Y, 1996, MOL ENDOCRINOL, V10, P100, DOI 10.1210/me.10.1.100; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Katayose D, 1995, CLIN CANCER RES, V1, P889; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; MAXWELL SA, 1994, CRIT REV ONCOGENESIS, V5, P23, DOI 10.1615/CritRevOncog.v5.i1.20; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; ONATE SA, 1995, SCIENCE, V270, P1354; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Ting YT, 1997, J BIOL CHEM, V272, P4129, DOI 10.1074/jbc.272.7.4129; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; YAFFE BM, 1984, J BIOL CHEM, V259, P6284; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; Zhu XG, 1997, J BIOL CHEM, V272, P9048	34	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28989	28993		10.1074/jbc.272.46.28989	http://dx.doi.org/10.1074/jbc.272.46.28989			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360971	hybrid			2022-12-27	WOS:A1997YF68400030
J	Newport, G; Agabian, N				Newport, G; Agabian, N			KEX2 influences Candida albicans proteinase secretion and hyphal formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SACCHAROMYCES-CEREVISIAE; ASPARTIC PROTEINASE; SHARED FUNCTIONS; SHUTTLE VECTOR; GENE ENCODES; IN-VIVO; EXPRESSION; YEAST; SEQUENCE	Candida albicans possesses at least seven differentially expressed genes that encode virulence-related secretory aspartyl proteinases (Saps), Sap DNA sequences predict post-translational processing at lysine arginine residues in the preproteins, reminiscent of the maturation of Saccharomyces cerevisiae alpha-factor, where a prepropolypeptide is converted into a biologically active pheromone by Kex2, a subtilisin-like proprotein convertase. To investigate involvement of a C. albicans KEX2 homologue in Sap activation, a genetic selection was performed based on KEX2 function, A kex2 strain of S. cerevisiae was transformed with a C. albicans genomic DNA library and screened for the production of active alpha-factor. Positive clones were assayed for killer toxin activity, another Kex2-dependent phenotype. Plasmids that rescued both defects contained a sequence encoding a protein homologous to S. cerevisiae Kex2. Both alleles of the C. albicans REX2 were inactivated by successive mutations, Null mutants continued to secrete active Sap2; however, the enzyme was abnormally processed and secreted at reduced levels, Unexpectedly, null mutants were incapable of forming hyphae, instead differentiating into aberrantly shaped cells. The ability to normally process Sap2 and form hyphae was restored upon transformation of null mutants with a KEX2-containing plasmid.	UNIV CALIF SAN FRANCISCO, DEPT STOMATOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [R01 AI33317] Funding Source: Medline; NIDCR NIH HHS [P01 DE07946] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE007946] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGABIAN N, 1994, J MED VET MYCOL, V32, P229; AKASHI T, 1993, J GEN MICROBIOL, V139, P2185, DOI 10.1099/00221287-139-9-2185; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANGLIKER H, 1995, J MED CHEM, V38, P4014, DOI 10.1021/jm00020a016; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; CHAMBERS RS, 1993, J GEN MICROBIOL, V139, P325, DOI 10.1099/00221287-139-2-325; CRANDALL M, 1987, J GEN MICROBIOL, V133, P2817; CUTFIELD SM, 1995, STRUCTURE, V3, P1261, DOI 10.1016/S0969-2126(01)00261-1; DAVEY J, 1994, EMBO J, V13, P5910, DOI 10.1002/j.1460-2075.1994.tb06936.x; DeBernardis F, 1996, INFECT IMMUN, V64, P466, DOI 10.1128/IAI.64.2.466-471.1996; ENDERLIN CS, 1994, YEAST, V10, P67, DOI 10.1002/yea.320100107; FONZI WA, 1993, GENETICS, V134, P717; GILLUM AM, 1984, MOL GEN GENET, V198, P179, DOI 10.1007/BF00328721; GLEE PM, 1995, INFECT IMMUN, V63, P1373, DOI 10.1128/IAI.63.4.1373-1379.1995; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; Hoegl L, 1996, J MOL MED, V74, P135, DOI 10.1007/BF01575445; HUBE B, 1994, MOL MICROBIOL, V14, P87, DOI 10.1111/j.1365-2958.1994.tb01269.x; Inoue H, 1996, EUR J BIOCHEM, V237, P719, DOI 10.1111/j.1432-1033.1996.0719p.x; JONES S, 1994, J CLIN MICROBIOL, V32, P2869, DOI 10.1128/JCM.32.11.2869-2870.1994; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Kohler GA, 1997, J BACTERIOL, V179, P2331; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; LARRIBA G, 1995, FEMS MICROBIOL LETT, V125, P121; LEIBOWITZ MJ, 1976, P NATL ACAD SCI USA, V73, P2061, DOI 10.1073/pnas.73.6.2061; LIN XL, 1993, J BIOL CHEM, V268, P20143; Lubkowitz MA, 1997, MICROBIOL-UK, V143, P387, DOI 10.1099/00221287-143-2-387; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MONOD M, 1994, MOL MICROBIOL, V13, P357, DOI 10.1111/j.1365-2958.1994.tb00429.x; MORRISON CJ, 1993, INFECT IMMUN, V61, P2030, DOI 10.1128/IAI.61.5.2030-2036.1993; Odds FC., 1988, CANDIDA CANDIDOSIS; OLLERT MW, 1995, J CLIN MICROBIOL, V33, P2543, DOI 10.1128/JCM.33.10.2543-2549.1995; OLLERT MW, 1993, INFECT IMMUN, V61, P4560, DOI 10.1128/IAI.61.11.4560-4568.1993; PFALLER MA, 1994, J CLIN MICROBIOL, V32, P59, DOI 10.1128/JCM.32.1.59-64.1994; PLA J, 1995, GENE, V165, P115, DOI 10.1016/0378-1119(95)00492-O; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Redding K, 1996, MOL CELL BIOL, V16, P6208; Reichard U, 1996, MYCOSES, V39, P99, DOI 10.1111/j.1439-0507.1996.tb00109.x; ROGERS DT, 1979, BIOCHEM BIOPH RES CO, V90, P187, DOI 10.1016/0006-291X(79)91607-3; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rose MD., 1990, METHODS YEAST GENETI; RUCHEL R, 1992, J MED VET MYCOL, V30, P123; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SLUTSKY B, 1985, SCIENCE, V230, P666, DOI 10.1126/science.3901258; Staab JF, 1996, J BIOL CHEM, V271, P6298, DOI 10.1074/jbc.271.11.6298; Staib F, 1965, Sabouraudia, V4, P187; STINCHCOMB DT, 1982, J MOL BIOL, V158, P157, DOI 10.1016/0022-2836(82)90427-2; SWEET SP, 1995, J MED MICROBIOL, V43, P452, DOI 10.1099/00222615-43-6-452; TANGUYROUGEAU C, 1988, FEBS LETT, V234, P464, DOI 10.1016/0014-5793(88)80139-X; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Togni G, 1996, MICROBIOL-SGM, V142, P493, DOI 10.1099/13500872-142-3-493; West RW, 1996, GENE, V169, P119, DOI 10.1016/0378-1119(95)00774-1; WHITE TC, 1993, J BACTERIOL, V175, P6126, DOI 10.1128/JB.175.19.6126-6133.1993; WHITE TC, 1995, J BACTERIOL, V177, P5215, DOI 10.1128/jb.177.18.5215-5221.1995; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; Wosten HAB, 1996, EMBO J, V15, P4274, DOI 10.1002/j.1460-2075.1996.tb00802.x; Wu T, 1996, J MED MICROBIOL, V44, P311, DOI 10.1099/00222615-44-4-311	57	90	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28954	28961		10.1074/jbc.272.46.28954	http://dx.doi.org/10.1074/jbc.272.46.28954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360967	hybrid			2022-12-27	WOS:A1997YF68400026
J	Reddy, SAG; Huang, JH; Liao, WSL				Reddy, SAG; Huang, JH; Liao, WSL			Phosphatidylinositol 3-kinase in interleukin 1 signaling - Physical interaction with the interleukin 1 receptor and requirement in NF kappa B and AP-1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOINOSITIDE 3-KINASE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; C/EBP-LIKE; IN-VITRO; CELLS; BINDING; ASSOCIATION; WORTMANNIN	The signaling mechanisms utilized by the proinflammatory cytokine interleukin-l (IL-1) to activate the transcription factors NF kappa B and activator protein-1 (AP-1) are poorly defined. We present evidence here that IL-1 not only stimulates a dramatic increase in phosphatidylinositol 3-kinase (PI 3-kinase) activity but also induces the physical interaction of its type I receptor with the p85 regulatory subunit of PI 3-kinase. Furthermore, two PI S-kinase-specific inhibitors, wortmannin and a dominant-negative mutant of the p85 subunit, inhibited IL-induced activation of both NF kappa B and AP-1. Transient transfection experiments indicated that whereas overexpression of PI S-kinase may be sufficient to induce AP-1 and increase nuclear c-Fos protein levels, PI 3-kinase may need to cooperate with other IL-l-inducible signals to fully activate NF kappa B-dependent gene expression. In this regard, cotransfection studies suggested that PI 3-kinase may functionally interact with the recently-identified IL-l-receptor-associated kinase to activate NF kappa B. Our results thus indicate that PI 3-kinase is a novel signal transducer in IL-1 signaling and that it may differentially mediate the activation of NF kappa B and AP-1.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NIAMS NIH HHS [AR38858] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038858, R01AR038858] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHEN HM, 1993, MOL CELL BIOL, V13, P6766, DOI 10.1128/MCB.13.11.6766; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GARCIA P, 1993, J BIOL CHEM, V268, P25146; GUNTHER R, 1989, IMMUNOPHARM IMMUNOT, V11, P559, DOI 10.3109/08923978909005385; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HEGUY A, 1992, J BIOL CHEM, V267, P2605; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LI XX, 1991, J BIOL CHEM, V266, P15192; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Rzymkiewicz DM, 1996, J BIOL CHEM, V271, P17241, DOI 10.1074/jbc.271.29.17241; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	45	211	220	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29167	29173		10.1074/jbc.272.46.29167	http://dx.doi.org/10.1074/jbc.272.46.29167			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360994	hybrid			2022-12-27	WOS:A1997YF68400053
J	Kakinuma, A; Chazenbalk, GD; Tanaka, K; Nagayama, Y; McLachlan, SM; Rapport, B				Kakinuma, A; Chazenbalk, GD; Tanaka, K; Nagayama, Y; McLachlan, SM; Rapport, B			An N-linked glycosylation motif from the noncleaving luteinizing hormone receptor substituted for the homologous region (Gly(367) to Glu(369)) of the thyrotropin receptor prevents cleavage at its second, downstream site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TSH RECEPTOR; MOLECULAR-CLONING; EXTRACELLULAR DOMAIN; MAMMALIAN-CELLS; EXPRESSION; BINDING; GENE; ACID; MEMBRANES; SEQUENCE	The thyrotropin receptor (TSHR) exists in two forms (single polypeptide and two subunits), whereas the lutropin/chorionic gonadotropin receptor (LH/CGR) is a single chain, Recent data suggest that the TSHR cleaves at two sites, We mutagenized selected chimeric TSH-LH/CGR to localize the cleavage sites in the TSHR, All 23 receptors mutated in the estimated vicinity of the upstream site cleaved into two subunits as determined by I-125-TSH cross-linking to intact cells, In contrast, in a series of mutations homologous to the noncleaving LH/GGR, the downstream TSHR cleavage site localized to three amino acids (GQE(367-369)). Remarkably, group substitution of these residues, but not substitution of individual residues, abolished cleavage, Moreover, the mutation that prevented cleavage (GQE(367-369)NET) transposed a motif (NET291-293) that is glycosylated in the LH/CGR, TSHR cleavage or noncleavage after substitution of GQE(367-369) with Other triplets (AAA, NQE, and NQT) was consistent with a role for N-linked glycosylation at this site. In summary, our data (i) support the concept that the TSHR cleaves at two sites, (ii) relate TSHR residues GQE(367-369) to cleavage at the second, downstream site, and (iii) suggest that cleavage or noncleavage at site two is related to N-linked glycosylation. These findings provide new insight into the evolutionary divergence of two closely related receptors.	VET ADM MED CTR,THYROID MOL BIOL UNIT 111T,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94121	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019289] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19289] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAN T, 1992, ENDOCRINOLOGY, V131, P815, DOI 10.1210/en.131.2.815; BUCKLAND PR, 1982, FEBS LETT, V145, P245, DOI 10.1016/0014-5793(82)80176-2; CHAZENBALK GD, 1994, J BIOL CHEM, V269, P32209; Chazenbalk GD, 1997, ENDOCRINOLOGY, V138, P2893, DOI 10.1210/en.138.7.2893; Chazenbalk GD, 1996, ENDOCRINOLOGY, V137, P4586, DOI 10.1210/en.137.11.4586; Chazenbalk GD, 1996, BIOCHEM BIOPH RES CO, V225, P479, DOI 10.1006/bbrc.1996.1198; Couet J, 1996, J BIOL CHEM, V271, P4545; Davis DP, 1997, MOL ENDOCRINOL, V11, P550, DOI 10.1210/me.11.5.550; FURMANIAK J, 1987, FEBS LETT, V215, P316, DOI 10.1016/0014-5793(87)80169-2; Graves PN, 1996, ENDOCRINOLOGY, V137, P3915, DOI 10.1210/en.137.9.3915; GROSS B, 1991, BIOCHEM BIOPH RES CO, V177, P679, DOI 10.1016/0006-291X(91)91842-Z; Kakinuma A, 1996, ENDOCRINOLOGY, V137, P2664, DOI 10.1210/en.137.7.2664; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NAGAYAMA Y, 1992, ENDOCRINOLOGY, V131, P548, DOI 10.1210/en.131.2.548; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; POTTER E, 1994, BIOCHEM BIOPH RES CO, V205, P361, DOI 10.1006/bbrc.1994.2673; RUSSO D, 1991, MOL ENDOCRINOL, V5, P1607, DOI 10.1210/mend-5-11-1607; RUSSO D, 1992, ENDOCRINOLOGY, V130, P2135, DOI 10.1210/en.130.4.2135; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649	30	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28296	28300		10.1074/jbc.272.45.28296	http://dx.doi.org/10.1074/jbc.272.45.28296			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353284	hybrid			2022-12-27	WOS:A1997YF21900024
J	Li, LT; Kaplan, J				Li, LT; Kaplan, J			Characterization of two homologous yeast genes that encode mitochondrial iron transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ALCALIGENES-EUTROPHUS; EFFLUX SYSTEM; ZINC; OXIDASE; PROTEIN; IDENTIFICATION; EXPRESSION; RESISTANCE; COBALT	Two different yeast genes were identified that when overexpressed suppressed the low iron growth defect of a mutation in the endoplasmic reticulum iron binding enzyme methyl sterol oxidase. These genes were determined to be novel and highly related, The deduced amino acid sequences indicated that both were membrane proteins having two identical histidine-rich motifs. The predicted proteins, while not ABC transporters, are homologous to a widely distributed family of transition metal transporters present in all kingdoms. Subcellular fractionation and fluorescence microscopy localized these gene products to mitochondria. Based on this result we term these genes Mitochondrial Fe Transporters (MFT). Cells with disruptions in both genes show a growth defect on low iron medium, suggesting that these genes have redundant function and can affect cytosolic iron levels. Measurement of mitochondrial iron in cells grown in iron-rich medium overexpressing MFT1 or MFT2 show a 25-fold increase in iron compared with mitochondria from control cells, These results suggest that the mitochondria may act as a reservoir for iron that can be mobilized and used for cytosolic purposes.	UNIV UTAH,SCH MED,DEPT PATHOL,DIV CELL BIOL & IMMUNOL,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah								AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; EIDE D, 1992, J BIOL CHEM, V267, P20774; GEITZ RD, 1988, GENE, V74, P527; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li LT, 1996, J BIOL CHEM, V271, P16927, DOI 10.1074/jbc.271.28.16927; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; NIES DH, 1995, J BACTERIOL, V177, P2707, DOI 10.1128/jb.177.10.2707-2712.1995; NIES DH, 1989, P NATL ACAD SCI USA, V86, P7351, DOI 10.1073/pnas.86.19.7351; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Sambrook J., 2002, MOL CLONING LAB MANU; Sherman F, 1979, METHODS YEAST GENETI; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203	23	67	72	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28485	28493		10.1074/jbc.272.45.28485	http://dx.doi.org/10.1074/jbc.272.45.28485			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353309	hybrid			2022-12-27	WOS:A1997YF21900049
J	Schinkmann, K; Blenis, J				Schinkmann, K; Blenis, J			Cloning and characterization of a human STE20-like protein kinase with unusual cofactor requirements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNAL-TRANSDUCTION; C-JUN; SACCHAROMYCES-CEREVISIAE; CASCADE; PATHWAY; STRESS; YEAST; ACTIVATION; GROWTH	We cloned and characterized a novel human member of the STE20 serine/threonine protein kinase family named mst-3. Based on its domain structure, mst-3 belongs to the SPS1 subgroup of STE20-like proteins, which includes germinal center (GC) kinase, hematopoietic progenitor kinase (HPK), kinase homologous to STE20/SPS-1 (KHS), kinases responsive to stress (KRS1/2), the mammalian STE20-like kinases (mst1/2), and the recently published STE20/oxidant stress response kinase SOK-1. mst-3 is most closely related to SOK-1, with 88% amino acid similarity in the kinase domain. The similarity of the mst-3 kinase domain to STE20 is 42%. The mst-3 transcript is ubiquitously expressed, and the protein was found in all human, mouse, and monkey cell lines tested. An in vitro kinase assay showed that mst-3 can phosphorylate! basic exogenous substrates as well as itself. Interestingly, mst-3 prefers Mn2+ to Mg2+ as a divalent cation and can use both GTP and ATP as phosphate donors. Like SOK-1, mst-3 is activated by autophosphorylation. However, a physiological stimulus of mst-3 activity was not identified. mst-3 activity does not change upon exposure to several mitogenic and stress stimuli. Overexpression of mst b wild-type or kinase dead protein affects neither the extracellular signal-regulated kinases (ERK1/2 or ERK6, c-Jun N-terminal kinase (JNK), p38, nor pp70S6 kinase, suggesting that mst-3 is part of a novel signaling pathway.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA046595, R37CA046595] Funding Source: NIH RePORTER; NCI NIH HHS [CA46595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMMERER G, 1994, CURR OPIN CELL BIOL, V5, P254; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; CARPENTER G, 1978, NATURE, V276, P409, DOI 10.1038/276409a0; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATZ P, 1994, J BIOL CHEM, V269, P16802; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NG TI, 1992, VIROLOGY, V191, P9, DOI 10.1016/0042-6822(92)90161-H; Pelech SL, 1996, CURR BIOL, V6, P551, DOI 10.1016/S0960-9822(02)00540-7; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1992, J BIOL CHEM, V267, P14373; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; WHITE MF, 1984, J BIOL CHEM, V259, P255; WHITE MF, 1986, ENZYMES, V17, P248	48	95	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28695	28703		10.1074/jbc.272.45.28695	http://dx.doi.org/10.1074/jbc.272.45.28695			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353338	hybrid			2022-12-27	WOS:A1997YF21900078
J	Barak, LS; Ferguson, SSG; Zhang, J; Caron, MG				Barak, LS; Ferguson, SSG; Zhang, J; Caron, MG			A beta-arrestin green fluorescent protein biosensor for detecting G protein-coupled receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSED SEQUENCE TAGS; BETA(2)-ADRENERGIC RECEPTOR; SEQUESTRATION; BINDING; PHOSPHORYLATION; SUPERFAMILY; RHODOPSIN	G protein-coupled receptors (GPCR) represent the single most important drug targets for medical therapy, and information from genome sequencing and genomic data bases has substantially accelerated their discovery. The lack of a systematic approach either to identify the function of a new GPCR or to associate it with a cognate ligand has added to the growing number of orphan receptors. In this work we provide a novel approach to this problem using a beta-arrestin2/green fluorescent protein conjugate (beta arr2-GFP). It provides a real-time and single cell based assay to monitor GPCR activation and GPCR-Gr protein-coupled receptor kinase or GPCR-arrestin interactions, Confocal microscopy demonstrates the translocation of beta arr2-GFP to more than 15 different ligand-activated GPCRs, These data clearly support the common hypothesis that the beta-arrestin binding of an activated receptor is a convergent step of GPCR signaling, increase by 5-fold the number of GPCRs known to interact with beta-arrestins, demonstrate that the cytosol is the predominant reservoir of biologically active beta-arrestins, and provide the first direct demonstration of the critical importance of G protein-coupled receptor kinase phosphorylation to the biological regulation of beta-arrestin activity and GPCR signal transduction in living cells, The use of beta arr2-GFP as a biosensor to recog- nize the activation of pharmacologically distinct GPCRs should accelerate the identification of orphan receptors and permit the optical study of their signal transduction biology intractable to ordinary biochemical methods.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 03422] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; KAETHER C, 1995, FEBS LETT, V369, P267, DOI 10.1016/0014-5793(95)00765-2; LopezNieto CE, 1996, NAT BIOTECHNOL, V14, P857, DOI 10.1038/nbt0796-857; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; OLSON KR, 1995, J CELL BIOL, V130, P639, DOI 10.1083/jcb.130.3.639; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAYMOND JR, 1990, HYPERTENSION, V15, P119, DOI 10.1161/01.HYP.15.2.119; ROSS E M, 1990, P33; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; TSUGA H, 1994, J BIOL CHEM, V269, P522; VALETTE F, 1989, NUCLEIC ACIDS RES, V17, P723; Wells TNC, 1997, J LEUKOCYTE BIOL, V61, P545, DOI 10.1002/jlb.61.5.545	26	369	448	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27497	27500		10.1074/jbc.272.44.27497	http://dx.doi.org/10.1074/jbc.272.44.27497			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346876	hybrid			2022-12-27	WOS:A1997YD47300002
J	Yang, WM; Yao, YL; Sun, JM; Davie, JR; Seto, E				Yang, WM; Yao, YL; Sun, JM; Davie, JR; Seto, E			Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; TRANSCRIPTIONAL REPRESSION; NUCLEAR MATRIX; YEAST; ACETYLTRANSFERASE; REGULATOR; RPD3; ACETYLATION; EXPRESSION; PROTEINS	Several human cDNAs encoding a histone deacetylase protein, HDAC3, have been isolated. Analysis of the predicted amino acid sequence of HDAC3 revealed an open reading frame of 428 amino acids with a predicted molecular mass of 49 kDa. The HDAC3 protein is 50% identical in DNA sequence and 53% identical in protein sequence compared with the previously cloned human HDAC1, Comparison of the HDAC3 sequence with human HDAC2 also yielded similar results, with 51% identity in DNA sequence and 52% identity in protein sequence. The expressed HDAC3 protein is functionally active because it possesses histone deacetylase activity, represses transcription when tethered to a promoter, and binds transcription factor YY1. Similar to HDAC1 and HDAC2, HDAC3 is ubiquitously expressed in many different cell types.	UNIV S FLORIDA,H LEE MOFFIT CANC CTR & RES INST,DEPT MED MICROBIOL & IMMUNOL,MOL ONCOL PROGRAM,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOL BIOL,TAMPA,FL 33612; UNIV MANITOBA,DEPT BIOCHEM & MOL BIOL,WINNIPEG,MB R3E 0W3,CANADA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Manitoba				Davie, James/0000-0002-0420-6888; Yang, Wen-Ming/0000-0002-5871-5979				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Davie JR, 1996, J CELL BIOCHEM, V62, P149, DOI 10.1002/(SICI)1097-4644(199608)62:2<149::AID-JCB2>3.0.CO;2-S; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1983, ANTIBODIES LAB MANUA; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Lusser A, 1997, SCIENCE, V277, P88, DOI 10.1126/science.277.5322.88; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; RON D, 1992, BIOTECHNIQUES, V13, P866; RUBERTIS FD, 1996, NATURE, V384, P589; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sambrook J., 2002, MOL CLONING LAB MANU; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; ZHU XL, 1995, MOL CELL BIOL, V15, P5017	35	392	431	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28001	28007		10.1074/jbc.272.44.28001	http://dx.doi.org/10.1074/jbc.272.44.28001			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346952	hybrid			2022-12-27	WOS:A1997YD47300078
J	Chen, D; Elmendorf, JS; Olson, AL; Li, X; Earp, S; Pessin, JE				Chen, D; Elmendorf, JS; Olson, AL; Li, X; Earp, S; Pessin, JE			Osmotic shock stimulates GLUT4 translocation in 3T3L1 adipocytes by a novel tyrosine kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; INSULIN-RECEPTOR SUBSTRATE-1; RAT ADIPOSE-CELLS; ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT ACTIVITY; 3T3-L1 ADIPOCYTES; PROTEIN-KINASE; SKELETAL-MUSCLE; OKADAIC ACID; GLUCOSE-TRANSPORTER-4 TRANSLOCATION	Similar to insulin, osmotic shock of 3T3L1 adipocytes stimulated an increase in glucose transport activity and translocation of GLUT4 protein from intracellularly localized vesicles to the plasma membrane, The docking/ fusion of GLUT4 vesicles with the plasma membrane appeared to utilize a similar mechanism, since expression of a dominant interfering mutant of syntaxin-4 prevented both insulin-and osmotic shock-induced GLUT4 translocation, However, although the insulin stimulation of GLUT4 translocation and glucose transport activity was completely inhibited by wortmannin, activation by osmotic shock was wortmannin-insensitive, Furthermore, insulin stimulated the phosphorylation and activation of the Akt kinase, whereas osmotic shock was completely without effect, Surprisingly, treatment of cells with the tyrosine kinase inhibitor, genistein, or microinjection of phosphotyrosine antibody prevented both the insulin-and osmotic shock stimulated translocation of GLUT4, In addition, osmotic shock induced the tyrosine phosphorylation of several discrete proteins including Cbl, p130(cas), and the recently identified soluble tyrosine kinase, calcium-dependent tyrosine kinase (CADTK), In contrast, insulin had no effect on CADTK but stimulated the tyrosine phosphorylation of Cbl and the tyrosine dephosphorylation of pp125(FAK) and p130(cas), These data demonstrate that the osmotic shock stimulation of GLUT4 translocation in adipocytes occurs through a novel tyrosine kinase pathway that is independent of both the phosphatidylinositol S-kinase and the Akt kinase.	UNIV IOWA,PROGRAM MOL BIOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT PHYSIOL,IOWA CITY,IA 52242; UNIV N CAROLINA,CTR COMPREHENS CANC,CHAPEL HILL,NC 27599	University of Iowa; University of Iowa; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033823, R37DK033823, R01DK049012] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25925, DK49012, DK33823] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BIRNBAUM MJ, 1995, CURR OPIN ENDOCRINOL, V2, P383; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; CLAUSEN T, 1975, BIOCHIM BIOPHYS ACTA, V375, P292, DOI 10.1016/0005-2736(75)90197-2; CLAUSEN T, 1968, BIOCHIM BIOPHYS ACTA, V150, P56, DOI 10.1016/0005-2736(68)90008-4; CLAUSEN T, 1970, BIOCHIM BIOPHYS ACTA, V211, P233, DOI 10.1016/0005-2736(70)90096-9; CORVERA S, 1991, J BIOL CHEM, V266, P9271; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Kishi K, 1996, J BIOL CHEM, V271, P26561, DOI 10.1074/jbc.271.43.26561; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KUZUYA T, 1965, J BIOL CHEM, V240, P2277; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LEMARCHANDBRUSTEL Y, 1995, ENDOCRINOLOGY, V136, P3564, DOI 10.1210/en.136.8.3564; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLEFSKY JM, 1976, BIOCHEM BIOPH RES CO, V71, P106, DOI 10.1016/0006-291X(76)90255-2; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Rondinone CM, 1996, J BIOL CHEM, V271, P18148, DOI 10.1074/jbc.271.30.18148; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TSAKIRIDIS T, 1995, BIOCHEM J, V309, P1; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WHEELER TJ, 1994, BBA-BIOMEMBRANES, V1196, P191, DOI 10.1016/0005-2736(94)00211-8; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; YANG J, 1993, J BIOL CHEM, V268, P4600; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	90	136	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27401	27410		10.1074/jbc.272.43.27401	http://dx.doi.org/10.1074/jbc.272.43.27401			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341192	hybrid			2022-12-27	WOS:A1997YC65900088
J	Johnson, ES; Blobel, G				Johnson, ES; Blobel, G			Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING ENZYME; YEAST; DEGRADATION; GENE; PURIFICATION; CYCLINS; SACCHAROMYCES; INTERACTS; HOMOLOG; ENCODES	At least one essential function of Smt3p, a Saccharomyces cerevisiae ubiquitin-like protein similar to the mammalian protein SUMO-1, involves its posttranslational covalent attachment to other proteins, Using Smt3p affinity chromatography, we have isolated the second enzyme of the Smt3p conjugation pathway and have found that it is identical to Ubc9p, a previously identified protein that has extensive sequence similarity to the ubiquitin-conjugating enzymes (E2s) and that is required for yeast to progress through mitosis, A hallmark of E2s is the ability to form a thioester bond-containing covalent intermediate with ubiquitin (Ub). While we were unable to detect formation of a Ub similar to Ubc9p thioester, Ubc9p was found to form a thioester with Smt3p, indicating that Ubc9p is the functional analog of E2s in the Smt3p pathway and that this step is distinct from the ubiquitin pathway. Ubc9p is required for attachment of Smt3p to other proteins in vitro, suggesting that it is the only such enzyme in S. cerevisiae. These results suggest that, like ubiquitination, Smt3p conjugation may be a critical modification in cell cycle regulation.			Johnson, ES (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,BOX 168,1230 YORK AVE,NEW YORK,NY 10021, USA.							Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Betting J, 1996, J BIOL CHEM, V271, P25790, DOI 10.1074/jbc.271.42.25790; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; Boddy MN, 1996, ONCOGENE, V13, P971; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Gharahdaghi F, 1996, ANAL BIOCHEM, V233, P94, DOI 10.1006/abio.1996.0012; Gonen H, 1996, ADV EXP MED BIOL, V389, P209; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jiang WD, 1996, MOL GEN GENET, V251, P153; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Okura T, 1996, J IMMUNOL, V157, P4277; PICKART CM, 1994, J BIOL CHEM, V269, P7115; PICKART CM, 1988, UBIQUITIN, P77; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; STRAMBIODECASTILLIA C, 1995, J CELL BIOL, V131, P19, DOI 10.1083/jcb.131.1.19; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4	34	320	332	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26799	26802		10.1074/jbc.272.43.26799	http://dx.doi.org/10.1074/jbc.272.43.26799			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341106	hybrid			2022-12-27	WOS:A1997YC65900002
J	Yurieva, O; Skangalis, M; Kuriyan, J; ODonnell, M				Yurieva, O; Skangalis, M; Kuriyan, J; ODonnell, M			Thermus thermophilis dnaX homolog encoding gamma- and tau-like proteins of the chromosomal replicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI; ACCESSORY PROTEINS; SLIDING CLAMPS; SUBUNIT; SEQUENCE; GENE; IDENTIFICATION; STRAND; REGION	This report identifies the dnaX homolog from Thermus thermophilis. Replicases from bacteria to humans contain subunits that are homologous to one another. These homologs are subunits of a clamp loading apparatus that loads sliding clamps onto DNA, which in turn act as mobile tethers for the replication machinery. In Escherichia coli, two of these subunits (gamma and tau) are encoded by one gene (dnaX) in nearly equal amounts by way of an efficient translational frameshift. The gamma and tau subunits form the central touchpoint that holds together two DNA polymerases with one clamp loading apparatus to form the E. coli chromosomal replicase, DNA polymerase III holoenzyme. The E. coli holoenzyme is an efficient replication machine that simultaneously replicates both strands of duplex DNA. The T. thermophilis dnaX homolog also contains a frameshift signature and produces both tau- and gamma-like proteins. Recombinant T. thermophilis tau- and gamma-like proteins, expressed in E. coli, have an oligomeric state similar to that of their E. coli counterparts and display ATPase activity that is stimulated by DNA. These results imply that T. thermophilis utilizes a DNA polymerase III holoenzyme replication machinery similar to that of E. coli.	ROCKEFELLER UNIV,LAB DNA REPLICAT,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOL BIOPHYS LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University				O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM38839, GM 45547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO JC, 1990, NUCLEIC ACIDS RES, V18, P6771, DOI 10.1093/nar/18.23.6771; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; CHEN M, 1992, P NATL ACAD SCI USA, V89, P5211, DOI 10.1073/pnas.89.12.5211; CULLMAN G, 1995, MOL CELL BIOL, V150, P4661; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gesteland RF, 1996, ANNU REV BIOCHEM, V65, P741, DOI 10.1146/annurev.bi.65.070196.003521; GUENTHER BD, 1996, THESIS ROCKEFELLER U; GUIBUS JM, 1996, CELL, V87, P297; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LARSEN B, 1994, J BACTERIOL, V176, P6842, DOI 10.1128/JB.176.22.6842-6851.1994; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; MAKI H, 1988, J BIOL CHEM, V263, P6570; Maniatis T., 1982, MOL CLONING LABORATO, P76; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; TSUCHIHASHI Z, 1992, GENE DEV, V6, P511, DOI 10.1101/gad.6.3.511; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WU CA, 1992, J BIOL CHEM, V267, P4064; YIN KC, 1986, NUCLEIC ACIDS RES, V14, P6541, DOI 10.1093/nar/14.16.6541; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	36	15	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27131	27139		10.1074/jbc.272.43.27131	http://dx.doi.org/10.1074/jbc.272.43.27131			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341154	hybrid			2022-12-27	WOS:A1997YC65900050
J	CoskunAri, FF; Hill, TM				CoskunAri, FF; Hill, TM			Sequence-specific interactions in the Tus-Ter complex and the effect of base pair substitutions on arrest of DNA replication in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATOR PROTEIN; BACILLUS-SUBTILIS; LAC REPRESSOR; OPERATOR DNA; IDENTIFICATION; TRANSLOCATION; EQUILIBRIUM; COMPETITION; HELICASES; PLASMID	Arrest of DNA replication in Escherichia coli is mediated by specific interactions between the Tus protein and terminator (Ter) sequences, Binding of Tus to a Ter site forms a asymmetric protein-DNA complex that arrests DNA replication in an orientation-dependent fashion, In this study, mutant Ter sites carrying single base pair substitutions at 16 different positions were examined for their ability to bind purified Tus protein and arrest DNA replication, In vitro competition assays demonstrated that base pair substitutions at positions 8-19 had significant effects on the free energy of Tus binding (Delta Delta G(0) Of 1.5 to >4.0 kcal/mol). Concomitant with loss of binding affinity, mutations at these positions also showed significantly lower or undetectable replication arrest activities in vivo, Substitutions at positions 6, 20, and 21 had moderate effects on Tus-Ter interactions, suggesting that these base pairs contribute to, but are. not absolutely critical for, Tus binding. Even though the effects on binding were minimal, these Ter mutants were not as efficient as wild type Tus-TerB complexes at arresting replication forks. Three new potential Ter sites, referred to as TerH, TerI, and TerJ, were identified by searching the E. coli genome for sequence similarity to a consensus Ter site sequence.	UNIV N DAKOTA,SCH MED & HLTH SCI,DEPT MICROBIOL & IMMUNOL,GRAND FORKS,ND 58202; DREXEL UNIV,DEPT BIOSCI & BIOTECHNOL,PHILADELPHIA,PA 19104	University of North Dakota Grand Forks; Drexel University					NIGMS NIH HHS [GM43193] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043193, R01GM043193] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIERNE H, 1995, PLASMID, V33, P101, DOI 10.1006/plas.1995.1012; BIERNE H, 1994, J BACTERIOL, V176, P4165, DOI 10.1128/JB.176.13.4165-4167.1994; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COSKUNARI FF, 1994, J BIOL CHEM, V269, P4027; Duggan LJ, 1996, BIOCHEMISTRY-US, V35, P15391, DOI 10.1021/bi962208w; DUGGAN LJ, 1995, J BIOL CHEM, V270, P28049; FRANKS AH, 1995, MOL MICROBIOL, V17, P13, DOI 10.1111/j.1365-2958.1995.mmi_17010013.x; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HILL TM, 1996, ESCHERICHIA COLI SAL, V2, P1602; JENJACOBSON L, 1991, NUCL ACIDS MOL BIOL, V5, P142; Kamada K, 1996, NATURE, V383, P598, DOI 10.1038/383598a0; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; Messing J, 1979, RECOMBINANT DNA TECH, V2, P43; SAHOO T, 1995, J BIOL CHEM, V270, P29138, DOI 10.1074/jbc.270.49.29138; SHARMA B, 1992, J BACTERIOL, V174, P7854, DOI 10.1128/JB.174.23.7854-7858.1992; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SKOKOTAS A, 1994, J BIOL CHEM, V269, P20446; Skokotas A, 1995, J BIOL CHEM, V270, P30941, DOI 10.1074/jbc.270.52.30941; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439	27	51	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26448	26456		10.1074/jbc.272.42.26448	http://dx.doi.org/10.1074/jbc.272.42.26448			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334221	hybrid			2022-12-27	WOS:A1997YB13900055
J	Domanski, P; Fish, E; Nadeau, OW; Witte, M; Platanias, LC; Yan, H; Krolewski, J; Pitha, P; Colamonici, OR				Domanski, P; Fish, E; Nadeau, OW; Witte, M; Platanias, LC; Yan, H; Krolewski, J; Pitha, P; Colamonici, OR			A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; ERYTHROPOIETIN RECEPTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; CYTOKINE RECEPTORS; ASSOCIATION; BINDING; CELLS; EXPRESSION; PROTEINS	Coexpression of the alpha and beta(L) subunits of the human interferon alpha (IFN alpha) receptor is required for the induction of an antiviral state by human IFN alpha. To explore the role of the different domains of the beta(L) subunit in IFN alpha signaling, we coexpressed wild-type alpha subunit and truncated forms of the beta(L) chain in L-929 cells. Our results demonstrated that the first 82 amino acids (AAs) (AAs 265-346) of the cytoplasmic domain of the beta(L) chain are sufficient to activate the Jak-Stat pathway and trigger an antiviral state after IFN alpha 2 binding to the receptor. This region of the beta(L) chain, required for Jak1 binding and activation, contains the Bos 1 motif that is important; for the interaction of some cytokine receptors with Jak kinases, However, using glutathione S-transferase fusion proteins containing amino-and carboxyl-terminal deletions of the beta(L) cytoplasmic domain, we demonstrate that the main Jak1-binding region (corresponding to AAs 300-346 on the beta subunit) is distinct from the Box 1 domain (AAs 287-295).	UNIV TENNESSEE,DEPT PATHOL,MEMPHIS,TN 38163; UNIV TORONTO,DEPT MED GENET & MICROBIOL,TORONTO,ON M5S 1A8,CANADA; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231; UNIV ILLINOIS,HEMATOL ONCOL SECT,CHICAGO,IL; VET ADM W SIDE MED CTR,CHICAGO,IL 60607; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032	University of Tennessee System; University of Tennessee Health Science Center; University of Toronto; Johns Hopkins University; Johns Hopkins Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Columbia University; Columbia University			, Otto/P-4127-2018	, Otto/0000-0003-2101-4105	NATIONAL CANCER INSTITUTE [R01CA055079, R29CA073381] Funding Source: NIH RePORTER; NCI NIH HHS [CA73381, CA55079] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEUNG SC, 1991, J IMMUNOL, V146, P121; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1995, J BIOL CHEM, V270, P15974, DOI 10.1074/jbc.270.27.15974; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLOSI P, 1993, J BIOL CHEM, V268, P12617; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; HE TC, 1994, J BIOL CHEM, V269, P18291; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jiang N, 1996, J BIOL CHEM, V271, P16472, DOI 10.1074/jbc.271.28.16472; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Platanias LC, 1996, J BIOL CHEM, V271, P23630, DOI 10.1074/jbc.271.39.23630; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SCHINDLER S, 1995, ANNU REV BIOCHEM, V64, P621; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WANG XZ, 1995, J BIOL CHEM, V270, P6261, DOI 10.1074/jbc.270.11.6261; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yan H, 1996, MOL CELL BIOL, V16, P2074	36	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26388	26393		10.1074/jbc.272.42.26388	http://dx.doi.org/10.1074/jbc.272.42.26388			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334213	hybrid			2022-12-27	WOS:A1997YB13900047
J	Lindahl, B; Lindahl, U				Lindahl, B; Lindahl, U			Amyloid-specific heparan sulfate from human liver and spleen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; MONOCLONAL-ANTIBODY; AA-AMYLOIDOSIS; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; CELLS; DEPOLYMERIZATION; ANTITHROMBIN; DEPOSITION; AFFINITY	Heparan sulfate proteoglycans are consistently accumulated in tissues afflicted by amyloidosis and have been implicated in the mechanism of amyloid deposition. To study this relationship, heparan sulfate was isolated from liver and spleen of patients with AA amyloidosis and from normal organs and subjected to struc tural analysis, The polysaccharides were deaminated with nitrous acid, and the products were reduced with (NaBH4)-H-3 to yield labeled oligosaccharides. Disaccharides obtained by selective deamination of intact or N-deacetylated polysaccharides were separated and quantified by anion-exchange high performance liquid chromatography and thus defined the composition of N-sulfated block regions or the entire heparan sulfate chains, respectively, The heparan sulfate samples derived from liver or spleen with AA-type amyloidosis were all similar in composition, regardless of tissue source, but differed from either control material, These findings suggest that secondary amyloidosis is associated with the deposition in the affected tissues of a heparan sulfate with a specifically modified structure.	UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN	Uppsala University								AILLES L, 1993, LAB INVEST, V69, P443; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BITTER T, 1966, J CLIN INVEST, V45, P963, DOI 10.1172/JCI105412; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; KISILEVSKY R, 1992, J INTERN MED, V232, P515, DOI 10.1111/j.1365-2796.1992.tb00628.x; KJELLEN L, 1983, DIABETES, V32, P337, DOI 10.2337/diabetes.32.4.337; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINKER A, 1987, LAB INVEST, V57, P297; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MAGNUS JH, 1997, IN PRESS AMYLOID INT, V4; NAKANISHI H, 1992, BIOCHEM J, V288, P215, DOI 10.1042/bj2880215; NELSON SR, 1991, BIOCHEM J, V275, P67, DOI 10.1042/bj2750067; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PEJLER G, 1987, J BIOL CHEM, V262, P5036; RIESENFELD J, 1982, J BIOL CHEM, V257, P421; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; SKINNER M, 1992, J INTERN MED, V232, P513, DOI 10.1111/j.1365-2796.1992.tb00627.x; SNOW AD, 1987, LAB INVEST, V56, P665; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; SNOW AD, 1985, LAB INVEST, V53, P37; STENSTAD T, 1994, BIOCHEM J, V303, P663, DOI 10.1042/bj3030663; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; vandenBorn J, 1996, J BIOL CHEM, V271, P22802, DOI 10.1074/jbc.271.37.22802; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310	30	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26091	26094		10.1074/jbc.272.42.26091	http://dx.doi.org/10.1074/jbc.272.42.26091			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334172	hybrid			2022-12-27	WOS:A1997YB13900006
J	Nass, R; Cunningham, KW; Rao, R				Nass, R; Cunningham, KW; Rao, R			Intracellular sequestration of sodium by a novel Na+/H+ exchanger in yeast is enhanced by mutations in the plasma membrane H+-ATPase - Insights into mechanisms of sodium tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT PMA1 MUTANTS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; POTASSIUM-TRANSPORT; SALT TOLERANCE; GENE; STRESS; CALCINEURIN; ANTIPORTER; VESICLES	Sodium tolerance in yeast is disrupted by mutations in calcineurin, a Ca2+/calmodulin dependent protein phosphatase, which is required for modulation of Na+ uptake and efflux mechanisms, Five Na+-tolerant mutants were isolated by selecting for suppressors of calcineurin mutations, and mapped to the PMA1 gene, encoding the plasma membrane H+-ATPase, One mutant, pma1-alpha 4, which has the single amino acid change Glu(367) --> Lys at a highly conserved site within the catalytic domain of the ATPase, was analyzed in detail to determine the mechanism of Na+ tolerance. After exposure to Na+ in the culture medium, Na-22 influx in the pma1 mutant was reduced 2-fold relative to control, consistent with a similar decrease in ATPase activity, Efflux of Na-22 from intact cells was relatively unchanged in the pma1 mutant, However, selective permeabilization of the plasma membrane revealed that mutant cells retained up to 80% of intracellular Na+ within a slowly exchanging pool, We show that NHX1, a novel gene homologous to the mammalian NHE family of Na+/H+ exchangers, is required for Na+ sequestration in yeast and contributes to the Na+-tolerant phenotype of pma1-alpha 4.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053082, R01GM052414] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53082, GM 52414] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; Barkla B J, 1994, Symp Soc Exp Biol, V48, P141; BASSILANA M, 1984, BIOCHEMISTRY-US, V23, P5288, DOI 10.1021/bi00317a029; BLUMWALD E, 1987, PLANT PHYSIOL, V83, P884, DOI 10.1104/pp.83.4.884; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GARBARINO J, 1988, PLANT PHYSIOL, V86, P231, DOI 10.1104/pp.86.1.231; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HAJIBAGHERI MA, 1993, MICROSC RES TECHNIQ, V24, P395, DOI 10.1002/jemt.1070240505; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HARO R, 1993, PHYSIOL PLANTARUM, V89, P868, DOI 10.1111/j.1399-3054.1993.tb05298.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KO CH, 1990, GENETICS, V125, P305; LATTERICH M, 1993, BIOCHEM BIOPH RES CO, V191, P1111, DOI 10.1006/bbrc.1993.1331; MARTINUSSEN J, 1994, J BACTERIOL, V176, P6457, DOI 10.1128/JB.176.21.6457-6463.1994; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; Mendoza I, 1996, J BIOL CHEM, V271, P23061, DOI 10.1074/jbc.271.38.23061; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; MISOGA T, 1994, YEAST, V10, P965; MUNRO AW, 1991, MOL MICROBIOL, V5, P607, DOI 10.1111/j.1365-2958.1991.tb00731.x; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; ORTEGA M D, 1988, Microbiologia (Madrid), V4, P61; PANARETOU B, 1990, J GEN MICROBIOL, V136, P1763, DOI 10.1099/00221287-136-9-1763; PERKINS J, 1993, FEMS MICROBIOL LETT, V107, P255; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; RAMOS J, 1994, J BACTERIOL, V176, P249, DOI 10.1128/JB.176.1.249-252.1994; RAO R, 1996, MYCOTA, V3, P29; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SERRANO R, 1994, CRIT REV PLANT SCI, V13, P121, DOI 10.1080/713608057; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; TSE CM, 1994, CELL PHYSIOL BIOCHEM, V4, P282, DOI 10.1159/000154731; ULASZEWSKI S, 1983, EUR J BIOCHEM, V130, P235, DOI 10.1111/j.1432-1033.1983.tb07141.x; VALLEJO CG, 1989, YEAST, V5, P307, DOI 10.1002/yea.320050411; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WASER M, 1992, J BIOL CHEM, V267, P5396; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x	49	205	224	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26145	26152		10.1074/jbc.272.42.26145	http://dx.doi.org/10.1074/jbc.272.42.26145			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334180	hybrid			2022-12-27	WOS:A1997YB13900014
J	Ramalingam, R; Ennis, HL				Ramalingam, R; Ennis, HL			Characterization of the Dictyostelium discoideum cellulose-binding protein CelB and regulation of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORE GERMINATION; FAMILY; DOMAINS; RNA	Similar to other stages of Dictyostelium development, spore germination is a particularly suitable model for studying regulation of gene expression. The transition from spore to amoeba is accompanied by developmentally regulated changes in both protein and mRNA synthesis. A number of spore germination-specific cDNAs have been isolated previously. Among these are two members of the 270 gene family, a group of four genes defined by the presence of a common tetrapeptide repeat of Thr-Glu-Thr-Pro, celA (formerly called 270-6) and celB (formerly 270-11) are expressed solely and coordinately during spore germination, the levels of the respective mRNAs being low in dormant spores, rising during gemination to a maximum level at about 2 h, and then rapidly declining as amoebae are released from spores. The mRNAs are not found in growing cells or during multicellular development. The rapidity with which these transcripts accumulate and then disappear during germination implies that the respective products may be important for the process. We reported previously that the CelA protein is a cellulase (endo-1,4-beta-glucanase (EC 3.2.1.4)). In the present investigation, properties of the CelB protein, a glycosylated protein of 532 amino acids, 36% of which are serine or threonine, were examined, and the upstream sequences involved in the developmental regulation of the expression of the gene have been determined. The CelB protein does not demonstrate cellulase activity, but it has a cellulose-binding domain. Its role, if any, in degradation of the cellulose-containing spore wall is unknown. To identify cis-acting elements in the celB promoter, unidirectional 5' deletions of the celB upstream noncoding region were constructed and used to transform amoebae. Analysis of promoter activity during different stages of development shows that a short, very APT-rich sequence of approximately 81 base pairs is sufficient for spore-specific celB transcription. Contained in this sequence is the Myb oncogene protein binding site, TAACTG, which was shown previously to be a negative regulator of celA transcription. Dictyostelium and mouse Myb proteins bind to this region of the promoter, suggesting that Myb might regulate celB gene expression negatively as it does in celA.	ROCHE INST MOL BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA	Roche Holding								ALEXANDER A, 1982, METHOD ENZYMOL, V179, P505; ALEXANDER S, 1988, DIFFERENTIATION, V38, P82, DOI 10.1111/j.1432-0436.1988.tb00201.x; BLUME JE, 1991, J BIOL CHEM, V266, P15432; COTTER DA, 1966, P NATL ACAD SCI USA, V69, P1402; DASILVA AM, 1990, DEV BIOL, V140, P139, DOI 10.1016/0012-1606(90)90061-M; DIN N, 1994, P NATL ACAD SCI USA, V91, P11383, DOI 10.1073/pnas.91.24.11383; DIN N, 1991, BIO-TECHNOL, V9, P1096, DOI 10.1038/nbt1191-1096; DOWBENKO DJ, 1980, P NATL ACAD SCI-BIOL, V77, P1791, DOI 10.1073/pnas.77.4.1791; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GIORDA R, 1990, BIOCHEMISTRY-US, V29, P7264, DOI 10.1021/bi00483a015; GIORDA R, 1987, MOL CELL BIOL, V6, P2097; GIRI JG, 1978, DEV BIOL, V67, P189, DOI 10.1016/0012-1606(78)90308-1; GIRI JG, 1977, BIOCHEM BIOPH RES CO, V77, P282, DOI 10.1016/S0006-291X(77)80194-0; KELLY LJ, 1983, MOL CELL BIOL, V3, P1943, DOI 10.1128/MCB.3.11.1943; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI, P3; MAY T, 1989, MOL CELL BIOL, V9, P4653, DOI 10.1128/MCB.9.11.4653; MEINKE A, 1991, Protein Sequences and Data Analysis, V4, P349; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; RAMALINGAM R, 1992, J BACTERIOL, V174, P7834, DOI 10.1128/JB.174.23.7834-7837.1992; RAMALINGAM R, 1995, NUCLEIC ACIDS RES, V23, P3018, DOI 10.1093/nar/23.15.3018; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; SHOSEYOV O, 1990, P NATL ACAD SCI USA, V87, P2192, DOI 10.1073/pnas.87.6.2192; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; WONG WKR, 1986, GENE, V44, P315	24	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26166	26172		10.1074/jbc.272.42.26166	http://dx.doi.org/10.1074/jbc.272.42.26166			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334183	hybrid			2022-12-27	WOS:A1997YB13900017
J	Satlin, LM; Amin, V; Wolkoff, AW				Satlin, LM; Amin, V; Wolkoff, AW			Organic anion transporting polypeptide mediates organic anion/HCO3- exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; ACID COTRANSPORT SYSTEM; PERFUSED-RAT-LIVER; INTRACELLULAR PH; EXPRESSION CLONING; HELA-CELLS; HEPATOCYTES; CHLORIDE; BINDING; CHOLATE	Organic anion transporting polypeptide (oatp) is an integral membrane protein cloned from rat liver that mediates Na+-independent transport of organic anions such as sulfobromophthalein and taurocholic acid, Previous studies in rat hepatocytes suggested that organic anion uptake is associated with base exchange, To better characterize the mechanism of oatp-mediated organic anion uptake, we examined transport of taurocholate in a HeLa cell line stably transfected with oatp under the regulation of a zinc-inducible promoter (Shi, X., Bai, S., Forci, A. C., Burk, R. D., Jacquemin, E., Hagenbuch, B., Meier, P. J., and Wolkoff, A. W. (1995) J. Biol. Chem. 270, 25591-25595). Whereas noninduced transfected cells showed virtually no uptake of [H-3]taurocholate, taurocholate uptake by induced cells was Na+-independent and saturable (K-m = 19.4 +/- 3.3 mu M; V-max = 62.2 +/- 1.4 pmol/min/mg protein; n = 3). To test whether organic anion transport is coupled to HCO3- extrusion, we compared the rates of taurocholate-dependent HCO3- efflux from alkali-loaded noninduced and induced cells. Monolayers grown on glass coverslips were loaded with the pH-sensitive dye 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein; intracellular pH (pH(I)) was measured by excitation ratio fluorometry, Noninduced and induced cells were alkalinized to an equivalent pH(i) (similar to 7.7) by transient exposure to a 50 mM HCO3- Cl--free solution. In the absence of extracellular Cl- and taurocholate , isohydric reduction of superfusate HCO3- concentration from 50 to 25 mM resulted in an insignificant change in pH(i) over time (dpH(i)/dt) in both groups. Addition of 25 mu M taurocholate to the superfusate led to a rapid fall in pH(i) in induced (-0.037 +/- 0.011 pH units/min to pH(i) of 7.41 +/- 0.14) but not in noninduced (0.003 +/- 0.006 pH units/min to pH(i) of 7.61 +/- 0.08) cells (p < 0.03). These data indicate that oatp-mediated taurocholate transport is Na+-independent, saturable, and accompanied by HCO, exchange, We conclude that organic anion/base exchange is an important, potentially regulatable component of oatp function.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	Satlin, LM (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,RM 721 RFK,1410 PELHAM PKWY S,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK023026] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK23026, DK41296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENEDETTI A, 1991, AM J PHYSIOL, V261, pG512, DOI 10.1152/ajpgi.1991.261.3.G512; Bergwerk AJ, 1996, AM J PHYSIOL-GASTR L, V271, pG231, DOI 10.1152/ajpgi.1996.271.2.G231; BLITZER BL, 1986, J BIOL CHEM, V261, P2042; BOYER JL, 1994, AM J PHYSIOL, V266, pG382, DOI 10.1152/ajpgi.1994.266.3.G382; FITZ JG, 1991, J MEMBRANE BIOL, V122, P1, DOI 10.1007/BF01872734; FITZ JG, 1987, AM J PHYSIOL, V252, pG56, DOI 10.1152/ajpgi.1987.252.1.G56; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GLEESON D, 1989, J CLIN INVEST, V84, P312, DOI 10.1172/JCI114156; GRAF J, 1987, J MEMBRANE BIOL, V95, P241, DOI 10.1007/BF01869486; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HOLSEY C, 1990, J CELL PHYSIOL, V142, P586, DOI 10.1002/jcp.1041420319; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; JACQUEMIN E, 1991, J CLIN INVEST, V88, P2146, DOI 10.1172/JCI115546; Kanai N, 1996, AM J PHYSIOL-RENAL, V270, pF319, DOI 10.1152/ajprenal.1996.270.2.F319; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUKACS GL, 1993, AM J PHYSIOL, V265, pC3, DOI 10.1152/ajpcell.1993.265.1.C3; Meier PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG801, DOI 10.1152/ajpgi.1995.269.6.G801; MIN AD, 1991, J CLIN INVEST, V87, P1496, DOI 10.1172/JCI115159; MOSELEY RH, 1986, AM J PHYSIOL, V250, pG35, DOI 10.1152/ajpgi.1986.250.1.G35; RENNER EL, 1989, J CLIN INVEST, V83, P1225, DOI 10.1172/JCI114005; SATLIN LM, 1992, AM J PHYSIOL, V262, pF199, DOI 10.1152/ajprenal.1992.262.2.F199; SCHARSCHMIDT BF, 1975, J CLIN INVEST, V56, P1280, DOI 10.1172/JCI108204; SHI XY, 1995, J BIOL CHEM, V270, P25591, DOI 10.1074/jbc.270.43.25591; Silver RB, 1996, AM J PHYSIOL-RENAL, V270, pF539, DOI 10.1152/ajprenal.1996.270.3.F539; STOLLMAN YR, 1983, J CLIN INVEST, V72, P718, DOI 10.1172/JCI111021; VEITH CM, 1992, BIOCHIM BIOPHYS ACTA, V1103, P51, DOI 10.1016/0005-2736(92)90056-R; Wolkoff Allan W., 1994, P179; WOLKOFF AW, 1987, J CLIN INVEST, V79, P1259, DOI 10.1172/JCI112946	28	125	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26340	26345		10.1074/jbc.272.42.26340	http://dx.doi.org/10.1074/jbc.272.42.26340			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334206	hybrid			2022-12-27	WOS:A1997YB13900040
J	Guy, HI; Bouvier, A; Evans, DR				Guy, HI; Bouvier, A; Evans, DR			The smallest carbamoyl-phosphate synthetase - A single catalytic subdomain catalyzes all three partial reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; INITIATES PYRIMIDINE BIOSYNTHESIS; ESCHERICHIA-COLI; DOMAIN-STRUCTURE; LARGE SUBUNIT; AMIDOTRANSFERASE DOMAIN; REVERSIBLE DISSOCIATION; CONTROLLED PROTEOLYSIS; NUCLEOTIDE-SEQUENCE; LIMITED PROTEOLYSIS	Escherichia coli carbamoyl-phosphate synthetase (CPSase) is comprised of a 40-kDa glutaminase (GLN) and a 120-kDa synthetase (CPS) subunit, The CPS subunit consists of two homologous domains, CPS.A and CPS.B, which catalyze the two different ATP-dependent partial reactions involved in carbamoyl phosphate synthesis, Sequence similarities and controlled proteolysis experiments suggest that the CPS subdomains consist, in turn, of three subdomains, designated Al, A2, A3 and B1, B2, B3 for CPS.A and CPS.B, respectively, Previous studies of individually cloned CPS.A and CPS.B from E. coli and mammalian CPSase have shown that homologous dimers of either of these ''half-molecules'' could catalyze all three reactions involved in ammonia-dependent carbamoyl phosphate synthesis, Four smaller recombinant proteins were made for this study as follows: 1) A1-A2 in which the A3 subdomain was deleted from CPS.A, 2) B1-B2 lacking subdomain B3 of CPS.B, 3) the A2 subdomain of CPS.A, and 4) the B2 subdomain of CPS.B. When associated with the GLN subunit, A1-A2 and B1-B2 had both glutamine-and ammonia-dependent CPSase activities comparable to the wild-type protein, In contrast, the 27-kDa A2 and B2 recombinant proteins, which represent only 17% of the mass of the parent protein, were unable to use glutamine as a nitrogen donor, but the ammonia-dependent activity was enhanced 14-16-fold. The hyperactivity suggests that A2 and B2 are the catalytic subdomains and that Al and B1 are attenuation domains which suppress the intrinsically high activity and are required for the physical association with the GLN subunit.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, DETROIT, MI 48201 USA	Wayne State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47399] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELAL AT, 1982, J BACTERIOL, V151, P1411, DOI 10.1128/JB.151.3.1411-1419.1982; ALONSO E, 1992, J BIOL CHEM, V267, P4524; ALONSO E, 1995, EUR J BIOCHEM, V229, P377, DOI 10.1111/j.1432-1033.1995.tb20478.x; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; BEIN K, 1991, J BIOL CHEM, V266, P3791; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; EVANS DR, 1988, BIOCHIM BIOPHYS ACTA, V953, P185, DOI 10.1016/0167-4838(88)90023-4; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GHIM SY, 1994, MICROBIOL-UK, V140, P479, DOI 10.1099/00221287-140-3-479; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GUADALAJARA A, 1987, EUR J BIOCHEM, V165, P163, DOI 10.1111/j.1432-1033.1987.tb11207.x; GUILLOU F, 1992, BIOCHEMISTRY-US, V31, P1656, DOI 10.1021/bi00121a012; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; GUY HI, 1995, J BIOL CHEM, V270, P2190, DOI 10.1074/jbc.270.5.2190; Guy HI, 1997, J BIOL CHEM, V272, P19913, DOI 10.1074/jbc.272.32.19913; Guy HI, 1996, J BIOL CHEM, V271, P13762, DOI 10.1074/jbc.271.23.13762; GUY HI, 1994, J BIOL CHEM, V269, P7702; Hanahan D, 1985, DNA CLONING PRACTICA; HELBING CC, 1994, J BIOL CHEM, V269, P11743; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; HONG J, 1995, J BIOL CHEM, V270, P14130, DOI 10.1074/jbc.270.23.14130; HUTTER R, 1986, ANNU REV MICROBIOL, V40, P55, DOI 10.1146/annurev.mi.40.100186.000415; JavidMajd F, 1996, BIOCHEMISTRY-US, V35, P14362, DOI 10.1021/bi961184q; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; KIM HS, 1992, J BIOL CHEM, V267, P7177; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRAIN C, 1995, MICROBIOL-SGM, V141, P1093, DOI 10.1099/13500872-141-5-1093; LIM F, 1988, J BIOL CHEM, V263, P11493; LUSTY CJ, 1992, FEBS LETT, V314, P135, DOI 10.1016/0014-5793(92)80959-K; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING; MAREYA SM, 1995, BIOORGAN MED CHEM, V3, P525, DOI 10.1016/0968-0896(95)00042-F; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MILES BW, 1993, BIOCHEMISTRY-US, V32, P232, DOI 10.1021/bi00052a030; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, P NATL ACAD SCI USA, V82, P2244, DOI 10.1073/pnas.82.8.2244; NYUNOYA H, 1984, J BIOL CHEM, V259, P9790; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POTTER MD, 1993, ARCH BIOCHEM BIOPHYS, V306, P377, DOI 10.1006/abbi.1993.1526; POWERSLEE SG, 1986, J BIOL CHEM, V261, P5349; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; Purcarea C, 1996, EUR J BIOCHEM, V236, P189, DOI 10.1111/j.1432-1033.1996.00189.x; QUINN CL, 1991, J BIOL CHEM, V266, P9113; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; Rubio V, 1995, BIOCHEM SOC T, V23, P879, DOI 10.1042/bst0230879; RUMSBY PC, 1984, BIOCHEM J, V217, P435, DOI 10.1042/bj2170435; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; Stapleton MA, 1996, BIOCHEMISTRY-US, V35, P14352, DOI 10.1021/bi961183y; TAKAI T, 1988, J BIOL CHEM, V263, P2651; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P492; ZIMMERMANN BH, 1993, BIOCHEMISTRY-US, V32, P1519, DOI 10.1021/bi00057a016	64	15	15	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29255	29262		10.1074/jbc.272.46.29255	http://dx.doi.org/10.1074/jbc.272.46.29255			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361005	hybrid			2022-12-27	WOS:A1997YF68400064
J	Wang, J; Giacomini, KM				Wang, J; Giacomini, KM			Molecular determinants of substrate selectivity in Na+-dependent nucleoside transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; COTRANSPORTERS; PROTEINS; ANALOGS; BIOLOGY; RABBIT; CELLS	In mammalian cells, the salvage of purine and pyrimidine nucleosides is mediated by both facilitated and Na+-dependent nucleoside transporters. These transporters also play important roles in the transmembrane flux of therapeutic nucleoside analogs, which are widely used in the treatment of cancer and viral infections, The N1, N2, and N3 Na+-dependent nucleoside transporters differ in terms of their transport selectivity for purine and pyrimidine nucleosides. N1 is purine-selective, N2 is pyrimidine-selective, and N3 is broadly selective, To identify structural domains involved in substrate binding and molecular determinants responsible for distinct transport selectivity, chimeric transporters were made from the cloned rat N1 and N2 transporters, Of the 14 transmembrane domains (TM) of N1 and N2, transplanting TM8-9 of N1 into N2 converted N2 from a pyrimidine- to a purine-selective transporter. Transplanting only TM8 generated a chimera with characteristics similar to the N3 transporter that has yet to be cloned. These data suggest that TRZ8-9 confer substrate selectivity and may form at least part of a substrate-binding site in Na+-dependent nucleoside transporters.	UNIV CALIF SAN FRANCISCO,DEPT BIOPHARMACEUT SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Giacomini, Kathleen/AEF-2452-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042230] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42230] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELT JA, 1993, ADV ENZYME REGUL, V33, P235; Borgland SL, 1997, J PHARMACOL EXP THER, V281, P347; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CARON MG, 1993, NATURE, V366, P409, DOI 10.1038/366409a0; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; GUTIERREZ MM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P202, DOI 10.1016/0005-2736(93)90202-B; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; KAPLAN JH, 1993, CELL, V72, P13, DOI 10.1016/0092-8674(93)90045-R; LERMAN BB, 1991, CIRCULATION, V83, P1499, DOI 10.1161/01.CIR.83.5.1499; Mani Sridhar, 1996, Current Opinion in Oncology, V8, P525; MORSE GD, 1993, CLIN PHARMACOKINET, V24, P101, DOI 10.2165/00003088-199324020-00002; PanayotovaHeiermann M, 1996, J BIOL CHEM, V271, P10029, DOI 10.1074/jbc.271.17.10029; Redlak MJ, 1996, BIOCHEM BIOPH RES CO, V225, P106, DOI 10.1006/bbrc.1996.1137; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Roovers KI, 1996, J CELL PHYSIOL, V166, P593, DOI 10.1002/(SICI)1097-4652(199603)166:3<593::AID-JCP14>3.0.CO;2-8; Sadee W, 1995, PHARM RES-DORDR, V12, P1823, DOI 10.1023/A:1016211015926; Schaner ME, 1997, PHARMACEUT RES, V14, P1316, DOI 10.1023/A:1012148016794; WANG J, 1997, IN PRESS AM J PHYSL; Wiley JS, 1997, NAT MED, V3, P25, DOI 10.1038/nm0197-25; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6; WU XC, 1992, J BIOL CHEM, V267, P8813; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 1996, MOL PHARMACOL, V50, P388; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	27	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28845	28848		10.1074/jbc.272.46.28845	http://dx.doi.org/10.1074/jbc.272.46.28845			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360950	hybrid			2022-12-27	WOS:A1997YF68400009
J	Adler, HT; Nallaseth, FS; Walter, G; Tkachuk, DC				Adler, HT; Nallaseth, FS; Walter, G; Tkachuk, DC			HRX leukemic fusion proteins form a heterocomplex with the leukemia-associated protein SET and protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD SHOCK DOMAINS; 11Q23 TRANSLOCATIONS; DNA-BINDING; ALL-1 GENE; MYELOID LEUKEMOGENESIS; DROSOPHILA-TRITHORAX; PUTATIVE ONCOGENE; POTENT INHIBITOR; CRUCIFORM DNA; OKADAIC ACID	One of the most common chromosomal abnormalities in acute leukemia is a reciprocal translocation involving the HRX gene at chromosome locus 11q23, resulting in HRX fusion proteins. Using the yeast two-hybrid system, in vitro binding studies, and human cell culture coimmunoprecipitation experiments, we show here that a region of the HRX protein that is consistently retained in HRX leukemic fusion proteins interacts directly with SET, another protein implicated in leukemia. We have identified the binding sites on HRX for SET and show that these sequences are clustered near the A.T hooks that have been shown to bind DNA. We also show that carboxyl-terminal SET sequences, possibly the acidic tail of SET, bind to HRX. We have also found serine/threonine-specific protein phosphatase activity in anti-HRX coimmunoprecipitates. Using the phosphatase inhibitor okadaic acid and Western blotting, the phosphatase was identified as protein phosphatase 2A (PP2A). Mutation of a single amino acid in one of the SET binding sites of HRX resulted in lower amounts of both coimmunoprecipitated SET protein and coimmunoprecipitated PP2A. These results suggest that the leukemogenic effects of HRX fusion proteins may be related to interactions with SET and PP2A.	UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV WASHINGTON, SCH MED, DEPT PATHOL, SEATTLE, WA 98195 USA	University of California System; University of California San Diego; University of Washington; University of Washington Seattle	Adler, HT (corresponding author), VA PUGET SOUND HLTH CARE SYST, SEATTLE DIV, 1660 S COLUMBIAN WAY, RES MAIL STOP 151, SEATTLE, WA 98108 USA.							ADACHI Y, 1994, J BIOL CHEM, V269, P2258; ASHAR HR, 1995, CELL, V82, P57; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BREEN TR, 1993, DEVELOPMENT, V117, P119; Broeker PL, 1996, CURR TOP MICROBIOL, V211, P259; Burns LG, 1997, BBA-GENE STRUCT EXPR, V1350, P159; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Fidanza V, 1996, CANCER RES, V56, P1179; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORNEROD M, 1995, ONCOGENE, V10, P1739; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HUNGER SP, 1993, BLOOD, V81, P3197; ISHIMI Y, 1983, J BIOCHEM-TOKYO, V94, P735, DOI 10.1093/oxfordjournals.jbchem.a134414; Ito T, 1996, MOL CELL BIOL, V16, P3112; JACQUEMINSABLON H, 1994, NUCLEIC ACIDS RES, V22, P2643, DOI 10.1093/nar/22.13.2643; Joh T, 1996, ONCOGENE, V13, P1945; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KOBAYASHI H, 1993, BLOOD, V81, P3027; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Leshkowitz D, 1996, ONCOGENE, V13, P2027; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Lochner K, 1996, CANCER RES, V56, P2171; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Rasio D, 1996, CANCER RES, V56, P1766; Reeves R, 1996, BIOCHEMISTRY-US, V35, P5063, DOI 10.1021/bi952424p; REEVES R, 1990, J BIOL CHEM, V265, P8573; Rogaia D, 1997, CANCER RES, V57, P799; RUBNITZ JE, 1994, BLOOD, V84, P1747; Rubnitz JE, 1996, LEUKEMIA, V10, P74; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SCHICHMAN SA, 1995, JAMA-J AM MED ASSOC, V273, P571, DOI 10.1001/jama.273.7.571; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; TAMKUN JW, 1995, CURR OPIN GENET DEV, V5, P473, DOI 10.1016/0959-437X(95)90051-H; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tkachenko A, 1997, CANCER RES, V57, P2276; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; Williams AJ, 1997, AM J PATHOL, V150, P911; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; Young BD, 1996, CANCER SURV, V28, P225; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	68	87	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28407	28414		10.1074/jbc.272.45.28407	http://dx.doi.org/10.1074/jbc.272.45.28407			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353299	hybrid			2022-12-27	WOS:A1997YF21900039
J	Hamilton, BJN; Burns, CM; Nichols, RC; Rigby, WFC				Hamilton, BJN; Burns, CM; Nichols, RC; Rigby, WFC			Modulation of AUUUA response element binding by heterogeneous nuclear ribonucleoprotein A1 in human T lymphocytes - The roles of cytoplasmic location, transcription, and phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; HNRNP PROTEINS; TERMINAL DOMAIN; OKADAIC ACID; CALF THYMUS; IN-VIVO; GM-CSF; SEQUENCE; DEGRADATION	The heterogeneous nuclear ribonucleoprotein Al (hnRNP A1) shuttles between the cytoplasm and nucleus and plays important roles in RNA metabolism, Whereas nuclear hnRNP Al has been shown to bind intronic sequences and modulate splicing, cytoplasmic hnRNP Al is associated with poly(A)(+) RNA, indicating different RNA ligand specificity. Previous studies indicated that cytoplasmic hnRNP Al is capable of high-affinity binding of reiterated AUUUA sequences (ARE) that have been shown to modulate mRNA turnover and translation. Through a combination of two-dimensional gel and proteolysis studies, we establish hnRNP Al (or structurally related proteins that are post-translationally regulated in an identical manner) as the dominant cytoplasmic protein in human T lymphocytes capable of interacting with the ARE contained within the context of full-length granulocyte-macrophage colony-stimulating factor mRNA. We additionally demonstrate that cytoplasmic hnRNP Al preferentially binds ARE relative to pre-mRNAs in both cross-linking and mobility shift experiments. RNA polymerase II inhibition increased the binding of ARE (AUBP activity) and poly(U)-Sepharose by cytoplasmic hnRNP Al, while nuclear hnRNP Al binding was unaffected. Nuclear and cytoplasmic hnRNP Al could be distinguished by the differential sensitivity of their RNA binding to diamide and N-ethyhmaleimide. The increase in AUBP activity of cytoplasmic hnRNP Al following RNA polymerase II inhibition correlated with serine-threonine dephosphorylation, as determined by inhibitor and metabolic labeling studies, Thus, cytoplasmic and nuclear hnRNP Al exhibit different RNA binding profiles, perhaps transduced through serine-threonine phosphorylation. These findings are relevant to the specific ability of hnRNP Al to serve distinct roles in post-transcriptional regulation of gene expression in both the nucleus and cytoplasm.	DARTMOUTH HITCHCOCK MED CTR,DEPT MED,SECT CONNECT TISSUE DIS,DARTMOUTH MED SCH,LEBANON,NH 03756; DARTMOUTH HITCHCOCK MED CTR,DEPT MICROBIOL,SECT CONNECT TISSUE DIS,DARTMOUTH MED SCH,LEBANON,NH 03756; VET ADM MED CTR,WHITE RIVER JCT,VT 05009	Dartmouth College; Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007576] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI34928] Funding Source: Medline; NIAMS NIH HHS [T32 AR07576] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMERO SA, 1993, MOL CELL BIOL, V13, P5323, DOI 10.1128/MCB.13.9.5323; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; BUVOLI M, 1990, NUCLEIC ACIDS RES, V18, P6595, DOI 10.1093/nar/18.22.6595; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CASASFINET JR, 1991, J MOL BIOL, V221, P693, DOI 10.1016/0022-2836(91)80081-5; CHEN SJ, 1985, P NATL ACAD SCI USA, V82, P7284, DOI 10.1073/pnas.82.21.7284; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; COBIANCHI F, 1993, NUCLEIC ACIDS RES, V21, P949, DOI 10.1093/nar/21.4.949; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ELZINGA SDJ, 1993, NUCLEIC ACIDS RES, V21, P5328, DOI 10.1093/nar/21.23.5328; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HENICS T, 1994, J BIOL CHEM, V269, P5377; HERRICK G, 1976, J BIOL CHEM, V251, P2124; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUMAR A, 1986, J BIOL CHEM, V261, P1266; KUMAR A, 1990, J BIOL CHEM, V265, P17094; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MATUNIS EL, 1993, J CELL BIOL, V121, P219, DOI 10.1083/jcb.121.2.219; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYRAND SH, 1990, NUCLEIC ACIDS RES, V18, P3307, DOI 10.1093/nar/18.11.3307; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; MYER VE, 1992, P NATL ACAD SCI USA, V89, P1296, DOI 10.1073/pnas.89.4.1296; NAGY E, 1994, CELL IMMUNOL, V159, P140, DOI 10.1006/cimm.1994.1303; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; ROSENBERGER U, 1995, BIOCHEM J, V305, P269, DOI 10.1042/bj3050269; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Tsukamoto H, 1996, J CLIN INVEST, V97, P2823, DOI 10.1172/JCI118738; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; WEIGHARDT F, 1997, IN PRESS J CELL SCI; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; ZANDOMENI R, 1983, J MOL BIOL, V167, P561, DOI 10.1016/S0022-2836(83)80098-9; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	68	85	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28732	28741		10.1074/jbc.272.45.28732	http://dx.doi.org/10.1074/jbc.272.45.28732			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353343	hybrid			2022-12-27	WOS:A1997YF21900083
J	Hassel, B; Rathjen, FG; Volkmer, H				Hassel, B; Rathjen, FG; Volkmer, H			Organization of the neurofascin gene and analysis of developmentally regulated alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; N-CAM GENE; IMMUNOGLOBULIN SUPERFAMILY; VASE EXON; SURFACE RECOGNITION; NEURITE OUTGROWTH; GENOMIC STRUCTURE; AXONAL SURFACE; SPINAL-CORD; L1 FAMILY	Neurofascin is an axonal member of the L1 subgroup of the immunoglobulin superfamily implicated in neurite extension in the course of embryonic development. Here we have isolated and characterized the gene encoding chicken neurofascin. Comparison of genomic sequences with cDNA sequences provides the structure and localization of intron/exon boundaries and indicates that neurofascin isoforms are generated by alternative splicing of its pre-mRNA. The neurofascin gene is composed of 33 exons distributed over 72 kilobases. Each of the six immunoglobulin- and five fibronectin-type III-like domains is encoded by two exons. While introns between domains are of phase 1, others are of phase 0, 1, or 2. Alternative splicing of neurofascin is developmentally regulated as shown by polymerase chain reaction analysis. Furthermore, plasmid libraries from long range polymerase chain reaction-amplified cDNA of neurofascin were used to examine and quantify the distribution of alternatively spliced exons in individual neurofascin molecules; We found 50. different neurofascin isoforms at different developmental stages and revealed the existence of one major ''early'' in comparison with multiple ''late'' neurofascin isoforms.	MAX DELBRUCK CTR MOL MED, D-13122 BERLIN, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Volkmer, Hansjuergen/AAU-9641-2021	Volkmer, Hansjuergen/0000-0002-3867-0603				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bateman A, 1996, EMBO J, V15, P6050, DOI 10.1002/j.1460-2075.1996.tb00993.x; BRUMMENDORF T, 1995, PROTEIN PROFILE, V2, P963; Brummendorf T, 1996, CURR OPIN NEUROBIOL, V6, P584, DOI 10.1016/S0959-4388(96)80089-4; Burmeister M, 1996, MAMM GENOME, V7, P558, DOI 10.1007/s003359900168; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; COLWELL G, 1992, GENOMICS, V14, P875, DOI 10.1016/S0888-7543(05)80108-9; CUNNINGHAM BA, 1995, CURR OPIN CELL BIOL, V7, P628, DOI 10.1016/0955-0674(95)80103-0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; FRANSEN E, 1995, EUR J HUM GENET, V3, P273; GIGER RJ, 1995, EUR J BIOCHEM, V227, P617, DOI 10.1111/j.1432-1033.1995.tb20181.x; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Holm J, 1996, EUR J NEUROSCI, V8, P1613, DOI 10.1111/j.1460-9568.1996.tb01306.x; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; JOUET M, 1995, MOL BRAIN RES, V30, P378, DOI 10.1016/0169-328X(95)00027-P; KAYYEM JF, 1992, J CELL BIOL, V118, P1259, DOI 10.1083/jcb.118.5.1259; Kenwrick S, 1996, J MED GENET, V33, P59, DOI 10.1136/jmg.33.1.59; KOHL A, 1992, J NEUROSCI RES, V32, P167, DOI 10.1002/jnr.490320206; KOZLOV SV, 1995, GENOMICS, V30, P141, DOI 10.1006/geno.1995.9892; KROGER S, 1990, J NEUROSCI, V10, P3118; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LIU L, 1993, J NEUROSCI RES, V35, P327, DOI 10.1002/jnr.490350313; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; MOSCOSO LM, 1995, J COMP NEUROL, V352, P321, DOI 10.1002/cne.903520302; NAKANO R, 1991, BIOCHEM BIOPH RES CO, V178, P282, DOI 10.1016/0006-291X(91)91811-P; OGRADY P, 1994, J BIOL CHEM, V269, P25193; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; Plagge A, 1997, GENE, V192, P215, DOI 10.1016/S0378-1119(97)00066-8; RATHJEN FG, 1987, CELL, V51, P841, DOI 10.1016/0092-8674(87)90107-3; REID RA, 1992, J MOL NEUROSCI, V3, P127, DOI 10.1007/BF02919404; REYES AA, 1991, MOL CELL BIOL, V11, P1654, DOI 10.1128/MCB.11.3.1654; ROSENTHAL A, 1993, CYTOGENET CELL GENET, V64, P185; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SCHREWE H, 1990, MOL CELL BIOL, V10, P2738, DOI 10.1128/MCB.10.6.2738; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHIGA T, 1991, J COMP NEUROL, V310, P234, DOI 10.1002/cne.903100208; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; SMALL SJ, 1988, NEURON, V1, P1007, DOI 10.1016/0896-6273(88)90158-4; VOLKMER H, 1992, J CELL BIOL, V118, P149, DOI 10.1083/jcb.118.1.149; Volkmer H, 1996, J CELL BIOL, V135, P1059, DOI 10.1083/jcb.135.4.1059; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; Walsh F. S., 1991, SEMIN NEUROSCI, V3, P271; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	61	50	52	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28742	28749		10.1074/jbc.272.45.28742	http://dx.doi.org/10.1074/jbc.272.45.28742			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353344	hybrid			2022-12-27	WOS:A1997YF21900084
J	Nusse, O; Serrander, L; FoyouziYoussefi, R; Monod, A; Lew, DP; Krause, KH				Nusse, O; Serrander, L; FoyouziYoussefi, R; Monod, A; Lew, DP; Krause, KH			Store-operated Ca2+ influx and stimulation of exocytosis in HL-60 granulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED HUMAN-NEUTROPHILS; PROTEIN-KINASE-C; PHOSPHOLIPASE-D; INTRACELLULAR CALCIUM; SIGNAL-TRANSDUCTION; ENZYME-SECRETION; CHROMAFFIN CELLS; ACTIVATION; RECEPTOR; RELEASE	This study addresses the role of store-operated Ca2+ influx in the regulation of exocytosis in inflammatory cells. In HL-60 granulocytes, which do not possess voltage-operated Ca2+ channels, the chemotactic peptide fMet-Leu-Phe (fMLP) was able to stimulate store-operated Ca2+ influx and to trigger exocytosis of primary granules. An efficient triggering of exocytosis by fMLP required the presence of extracellular Ca2+ and was inhibited by blockers of store-operated Ca2+ influx. However, receptor-independent activation of store-operated Ca2+ influx through thapsigargin did not trigger exocytosis. fMLP was unable to stimulate exocytosis in the absence of cytosolic free Ca2+ concentration [Ca2+](c) elevations. However, a second signal generated by fMLP synergized with store-operated Ca2+ influx to trigger exocytosis and led to a left shift of the exocytosis/[Ca2+], relationship in ionomycin-stimulated cells. The synergistic fMLP-generated signaling cascade was long-lasting, involved a pertussis toxin-sensitive G protein and a phosphatidylinositol 3-kinase. In summary, store-operated Ca2+ influx is crucial for the efficient triggering of exocytosis in HL-60 granulocytes, but, as opposed to Ca2+ influx through voltage-operated Ca2+ channels in neurons, it is not a sufficient stimulus by itself and requires synergistic receptor-generated signals.			Nusse, O (corresponding author), UNIV GENEVA,HOP CANTONAL,DIV INFECT DIS,CH-1211 GENEVA 14,SWITZERLAND.		Krause, Karl-Heinz/E-8030-2011; Nüsse, Oliver/J-8645-2013; Serrander, Lena/W-4117-2017	Krause, Karl-Heinz/0000-0002-9033-6768; Nüsse, Oliver/0000-0003-0068-8346; Serrander, Lena/0000-0002-9058-3582				ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; Brandolini L, 1996, J LEUKOCYTE BIOL, V59, P427, DOI 10.1002/jlb.59.3.427; BRANDT SJ, 1985, P NATL ACAD SCI USA, V82, P3277, DOI 10.1073/pnas.82.10.3277; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; COCKCROFT S, 1981, BIOCHEM J, V200, P501, DOI 10.1042/bj2000501; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1991, BIOCHEM J, V275, P127, DOI 10.1042/bj2750127; DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; DEWALD B, 1988, J BIOL CHEM, V263, P16179; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FAVRE CJ, 1994, BIOCHEM J, V302, P155, DOI 10.1042/bj3020155; Favre CJ, 1996, J LAB CLIN MED, V128, P19, DOI 10.1016/S0022-2143(96)90110-9; FoyouziYoussefi R, 1997, BIOCHEM J, V322, P709, DOI 10.1042/bj3220709; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KRAUSE KH, 1992, EUR J PHARM-MOLEC PH, V227, P221, DOI 10.1016/0922-4106(92)90131-E; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEW PD, 1981, J CLIN INVEST, V67, P1, DOI 10.1172/JCI110000; LEW PD, 1984, J CELL BIOL, V99, P1212, DOI 10.1083/jcb.99.4.1212; LEW PD, 1986, J CELL BIOL, V102, P2197, DOI 10.1083/jcb.102.6.2197; Merritt JE, 1997, CELL SIGNAL, V9, P53, DOI 10.1016/S0898-6568(96)00097-6; NACCACHE PH, 1985, J CELL PHYSIOL, V122, P273, DOI 10.1002/jcp.1041220217; NOVICK SF, 1994, NATURE, V370, P191; NUSSE O, 1988, J CELL BIOL, V107, P2117, DOI 10.1083/jcb.107.6.2117; PAI JK, 1988, J BIOL CHEM, V263, P12472; PARSONS TD, 1994, NEURON, V13, P875, DOI 10.1016/0896-6273(94)90253-4; Pizzo P, 1997, J CELL BIOL, V136, P355, DOI 10.1083/jcb.136.2.355; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V161, P276, DOI 10.1016/0006-291X(89)91592-1; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SMOLEN JE, 1987, J LEUKOCYTE BIOL, V41, P8, DOI 10.1002/jlb.41.1.8; SMOLEN JE, 1990, BIOCHIM BIOPHYS ACTA, V1052, P133, DOI 10.1016/0167-4889(90)90068-O; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3	49	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28360	28367		10.1074/jbc.272.45.28360	http://dx.doi.org/10.1074/jbc.272.45.28360			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353293	hybrid			2022-12-27	WOS:A1997YF21900033
J	Stam, JC; Sander, EE; Michiels, F; vanLeeuwen, FN; Kain, HET; vanderKammen, RA; Collard, JG				Stam, JC; Sander, EE; Michiels, F; vanLeeuwen, FN; Kain, HET; vanderKammen, RA; Collard, JG			Targeting of Tiam1 to the plasma membrane requires the cooperative function of the N-terminal pleckstrin homology domain and an adjacent protein interaction domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; BRUTON TYROSINE KINASE; RHO-LIKE PROTEINS; PH DOMAIN; RAS TRANSFORMATION; CDC42 GTPASES; BINDING; ACTIVATION; ASSOCIATION; RAC1	The Rho-like GTPases Cdc42, Rac, and Rho play key roles in the regulation of the actin cytoskeleton and are implicated in transcriptional activation and cell transformation. We have previously identified the invasion-inducing Tiam1 gene, which encodes an activator of Pac, In fibroblasts, Tiam1 induces Rac-mediated membrane ruffling, which requires the N-terminal pleckstrin homology (PHn) domain. Here we show that this PHn domain is part of a protein interaction domain, which mediates membrane localization of Tiam1. After subcellular fractionation, up to 50% of Tiam1 is recovered in the Triton X-100-insoluble high speed pellet that contains small protein complexes. The regions in Tiam1 that are responsible for these protein interactions comprise the PHn domain, an adjacent putative coiled coil region (CC), and an additional flanking region (Ex). Deletions in each of these regions abolish membrane localization of Tiam1 and membrane ruffling, suggesting that they function cooperatively. Indeed, only polypeptides encompassing the PHn-CC-Ex region, and not the PHn-CC or the Ex region, localize at the membrane. These results indicate that the N-terminal PH domain is part of a larger functional Tiam1 domain that mediates protein complex formation and membrane localization of Tiam1.	NETHERLANDS CANC INST,DIV CELL BIOL H1,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute			van Leeuwen, Frank/AAQ-6799-2020	van Leeuwen, Frank/0000-0003-1107-6513				BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Collard JG, 1996, INT J ONCOL, V8, P131; COOK S, 1994, NATURE, V369, P361, DOI 10.1038/369361a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FOX JE, 1992, METHODS ENZYMOL, V42; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HILL CS, 1995, CELL, V70, P419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; VANBERGEN H, 1992, EXP CELL RES, V199, P90; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; Wang DS, 1995, BIOCHEM BIOPH RES CO, V217, P608, DOI 10.1006/bbrc.1995.2818; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Yan SR, 1996, FEBS LETT, V380, P198; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; ZHANG J, 1992, J BIOL CHEM, V267, P4686; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	47	128	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28447	28454		10.1074/jbc.272.45.28447	http://dx.doi.org/10.1074/jbc.272.45.28447			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353304	hybrid			2022-12-27	WOS:A1997YF21900044
J	Wells, MJ; Hatton, MWC; Hewlett, B; Podor, TJ; Sheffield, WP; Blajchman, MA				Wells, MJ; Hatton, MWC; Hewlett, B; Podor, TJ; Sheffield, WP; Blajchman, MA			Cytokeratin 18 is expressed on the hepatocyte plasma membrane surface and interacts with thrombin-antithrombin complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED-PROTEIN; TISSUE-PLASMINOGEN ACTIVATOR; AMYLOID-BETA PEPTIDE; HEPARIN-COFACTOR; ALPHA(2)-MACROGLOBULIN RECEPTOR; INTERMEDIATE FILAMENTS; UROKINASE RECEPTOR; KERATIN FILAMENTS; EPITHELIAL-CELLS; CARCINOMA CELLS	During experiments to identify putative hepatic receptors for thrombin-antithrombin (TAT) complexes, a 45-kDa protein was identified by ligand blotting. Following gel purification, amino acid sequencing revealed the 45-kDa TAT-binding polypeptide to be cytokeratin 18 (CK18). The presence of CK18 on the surface of intact rat hepatoma cells was demonstrated by binding of I-125-anti-CK18 antibodies. Anti-CR18 antibodies reduced the binding and internalization of I-125-TAT by rat hepatoma cells. Immunocytochemical analysis, to determine the location of CK18 in vivo, revealed a periportal gradient of CK18 staining; with hepatocytes around the portal triads demonstrating striking pericellular staining. In addition, anti-CK18 IgG associated with perfused livers to a significantly greater extent than preimmune IgG. Taken together, these data provide evidence that CK18 is found on the extracellular surface of hepatocytes and could play a role in TAT removal. Finally, these data, in conjunction with recent reports of CK8 (Hembrough, T. A., Li, L., and Gonias, S. L. (1996) J. Biol. Chem. 271, 25684-25691) and CK1 cell membrane surface expression (Schmaier, A. H. (1997) Thromb. Hemostasis 78, 101-107), indicate a novel role for these proteins as putative cellular receptors or cofactors to cellular receptors.	MCMASTER UNIV,MED CTR,DEPT PATHOL,HAMILTON,ON L8N 3Z5,CANADA	McMaster University				Sheffield, William Peter/0000-0002-5870-8189				ABE M, 1990, J CELL BIOL, V111, P1197, DOI 10.1083/jcb.111.3.1197; BLAJCHMAN MA, 1992, BLOOD, V80, P2159; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CHEN M, 1993, NEUROLOGY, V43, P1223, DOI 10.1212/WNL.43.6.1223; CHOU CF, 1994, BIOCHEM J, V298, P457, DOI 10.1042/bj2980457; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; CONESE M, 1994, J BIOL CHEM, V269, P17886; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Coulombe PA, 1993, CURR OPIN CELL BIOL, V5, P17, DOI 10.1016/S0955-0674(05)80004-3; DONALD PJ, 1991, OTOLARYNG HEAD NECK, V105, P781, DOI 10.1177/019459989110500603; DUBERNARD V, 1995, FEBS LETT, V364, P109, DOI 10.1016/0014-5793(95)00362-D; Dudani AK, 1996, BRIT J HAEMATOL, V95, P168, DOI 10.1046/j.1365-2141.1996.7482367.x; FAIR DS, 1986, THROMB RES, V41, P67, DOI 10.1016/0049-3848(86)90280-X; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRANKE WW, 1981, EXP CELL RES, V131, P299, DOI 10.1016/0014-4827(81)90234-2; FRENCH SW, 1989, ELECTRON MICROSC REV, V2, P17, DOI 10.1016/0892-0354(89)90009-9; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FURMANIAKKAZMIERCZAK E, 1995, BIOCHEM CELL BIOL, V73, P105, DOI 10.1139/o95-012; GEORGE JN, 1978, J LAB CLIN MED, V92, P430; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P161; GODFROID E, 1991, J CELL SCI, V99, P595; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HATTON MWC, 1994, METABOLISM, V43, P1430, DOI 10.1016/0026-0495(94)90040-X; HEMBROUGH TA, 1995, J CELL SCI, V108, P1071; Hembrough TA, 1996, J BIOL CHEM, V271, P25684, DOI 10.1074/jbc.271.41.25684; Hembrough TA, 1996, BIOCHEM J, V317, P763, DOI 10.1042/bj3170763; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUBBARD AL, 1983, J CELL BIOL, V96, P230, DOI 10.1083/jcb.96.1.230; HUNT LT, 1982, BIOCHEM BIOPH RES CO, V95, P866; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; Lundblad R L, 1976, Methods Enzymol, V45, P156; Maekawa H, 1996, J BIOL CHEM, V271, P18604, DOI 10.1074/jbc.271.31.18604; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOROIANU J, 1993, P NATL ACAD SCI USA, V90, P3815, DOI 10.1073/pnas.90.9.3815; OKANOUE T, 1985, HEPATOLOGY, V5, P1, DOI 10.1002/hep.1840050102; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PIZZO SV, 1990, AM J MED, V87, pS10; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; POLSON A, 1990, IMMUNOL INVEST, V19, P253; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; Schmaier AH, 1997, THROMB HAEMOSTASIS, V78, P101; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; Sheffield WP, 1995, MOL BASIS THROMBOSIS, P355; Stefansson S, 1996, J BIOL CHEM, V271, P8215, DOI 10.1074/jbc.271.14.8215; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1993, J INVEST DERMATOL, V100, P729, DOI 10.1111/1523-1747.ep12475665; TAKEYA H, 1994, BIOCHEM BIOPH RES CO, V200, P1334, DOI 10.1006/bbrc.1994.1597; VOORSCHUUR AH, 1994, BIOCHEM J, V303, P809, DOI 10.1042/bj3030809; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	57	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28574	28581		10.1074/jbc.272.45.28574	http://dx.doi.org/10.1074/jbc.272.45.28574			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353322	hybrid			2022-12-27	WOS:A1997YF21900062
J	Okamoto, H; Fujita, H; Matsuyama, S; Tsuyama, S				Okamoto, H; Fujita, H; Matsuyama, S; Tsuyama, S			Purification, characterization, and localization of an ADP-ribosylactin hydrolase that uses ADP-ribosylated actin from rat brains as a substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE-SPECIFIC MONO(ADP-RIBOSYL)ATION; ADENYLATE-CYCLASE SYSTEM; RIBOSYLARGININE HYDROLASE; TURKEY ERYTHROCYTES; BOTULINUM-C2 TOXIN; PROTEIN-KINASE; BOVINE BRAIN; 2 PROTEINS; RIBOSYLTRANSFERASE; BINDING	Mammalian ADP-ribosylation is poorly understood, An ADP-ribosylprotein hydrolase that acted on ADP-ribosylated actin was purified from rat brain. The molecular weight of this enzyme was 62,000 as determined by SDS-polyacrylamide gel electrophoresis and gel filtration, Enzyme activity with ADP-ribosylated actin as a substrate was inhibited by NAD, ATP, ADP, and ADP-ribose, but not by AMP, Mg2+ increased V-max, Purified ADP-ribosylactin hydrolase catalyzed the hydrolysis of ADP-ribosylated subunits G(s) alpha, G(i) alpha, and G(o) alpha and elongation factor-2, After de-ADP-ribosylation by the purified ADP-ribosylactin hydrolase, the proteins were re-ADP-ribosylated by brain mono-ADP-ribosyltransferases and bacterial toxins, The actin that was de-modified by ADP-ribosylactin hydrolase could form actin filaments, Two kinds of monoclonal antibodies against ADP-ribosylactin hydrolase were prepared and characterized, In an immunohistochemical study, the plasma membranes and cytoplasmic regions of the nerve cells in the rat brain were immunoreactive. In subcellular fractionation of the brains, most of the ADP-ribosylactin hydrolase activity was found in the cytosol and synaptosome fractions. When the synaptosomes were treated with a hypotonic solution, ADP-ribosylactin hydrolase activity was found in the supernatant, Our findings suggest that brain ADP-ribosylactin hydrolase has the important function of polymerizing actin for signal transduction in the cytosol of nerve cells and synaptosomes.	UNIV OSAKA PREFECTURE,DEPT VET SCI,MOL BIOL LAB,SAKAI,OSAKA 593,JAPAN	Osaka Metropolitan University								AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1987, BIOSCIENCE REP, V7, P281, DOI 10.1007/BF01121449; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; EARL DCN, 1965, BIOCHEM J, V94, P721, DOI 10.1042/bj0940721; FUJITA H, 1995, INT J BIOCHEM CELL B, V27, P1065, DOI 10.1016/1357-2725(95)00070-6; GEIPEL U, 1989, EUR J BIOCHEM, V179, P229, DOI 10.1111/j.1432-1033.1989.tb14545.x; Goding J., 1986, MONOCLONAL ANTIBODIE, P108; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HONJO T, 1968, J BIOL CHEM, V243, P3553; HUANG KP, 1976, ANAL BIOCHEM, V72, P593, DOI 10.1016/0003-2697(76)90571-6; JUST I, 1994, EUR J BIOCHEM, V221, P1047, DOI 10.1111/j.1432-1033.1994.tb18823.x; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE H, 1984, P NATL ACAD SCI-BIOL, V81, P2703, DOI 10.1073/pnas.81.9.2703; LELKES PI, 1986, FEBS LETT, V208, P357, DOI 10.1016/0014-5793(86)81049-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUYAMA S, 1991, J NEUROCHEM, V57, P1380, DOI 10.1111/j.1471-4159.1991.tb08304.x; MATTER K, 1989, J NEUROCHEM, V52, P370, DOI 10.1111/j.1471-4159.1989.tb09131.x; MOSS J, 1980, J BIOL CHEM, V255, P5838; MOSS J, 1986, BIOCHEMISTRY-US, V25, P5408, DOI 10.1021/bi00367a010; MOSS J, 1992, J BIOL CHEM, V267, P10481; MOSS J, 1985, P NATL ACAD SCI USA, V82, P5603, DOI 10.1073/pnas.82.17.5603; OBARA S, 1989, BIOCHEM BIOPH RES CO, V163, P452, DOI 10.1016/0006-291X(89)92157-8; OHISHI I, 1986, BIOCHEM BIOPH RES CO, V136, P802, DOI 10.1016/0006-291X(86)90511-5; PATERSON JE, 1990, J BIOL CHEM, V265, P17062; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; QUIST EE, 1994, J MOL CELL CARDIOL, V26, P251, DOI 10.1006/jmcc.1994.1028; SAYHAN O, 1986, BIOCHEM BIOPH RES CO, V139, P1210, DOI 10.1016/S0006-291X(86)80306-0; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAKADA T, 1993, J BIOL CHEM, V268, P17837; TANIGAWA Y, 1984, J BIOL CHEM, V259, P2022; TANUMA S, 1988, J BIOL CHEM, V263, P5485; TITANJI VPK, 1977, BIOCHIM BIOPHYS ACTA, V481, P140, DOI 10.1016/0005-2744(77)90145-0; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; WEGNER A, 1988, J BIOL CHEM, V263, P13739; WEIR JP, 1982, METHOD ENZYMOL, V85, P371; WOOD T, 1964, BIOCHEM J, V91, P453, DOI 10.1042/bj0910453; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	46	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28116	28125		10.1074/jbc.272.44.28116	http://dx.doi.org/10.1074/jbc.272.44.28116			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346967	hybrid			2022-12-27	WOS:A1997YD47300093
J	vandePut, FHMM; Elliott, AC				vandePut, FHMM; Elliott, AC			The endoplasmic reticulum can act as a functional Ca2+ in all subcellular regions of the pancreatic acinar cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL-TRISPHOSPHATE; CALRETICULIN INCREASES; EXOCRINE PANCREAS; GUINEA-PIG; RELEASE; STORES; OSCILLATIONS; CA-2+; OVEREXPRESSION; SECRETION	Stimulation of pancreatic acinar cells raises [Ca2+](i) via Ca2+ release from inositol-1,4,5-trisphosphate (InsP(3))-sensitive intracellular Ca2+ stores, generally considered to reside within the endoplasmic reticulum (ER), However, with physiological doses of cholinergic agonists, the [Ca2+](i) increase is localized to the apical (secretory) pole of the cell, leading to suggestions that zymogen (secretory) granules themselves may constitute an InsP(3)-sensitive Ca2+ store responsible for localized Ca2+ release, We have therefore re-investigated whether the ER in pancreatic acinar cells is capable of acting as a functional Ca2+ store in all, or only some, cellular regions. In streptolysin 0-permeabilized cells, the ER accumulated up to 25 mmol of Ca-45(2+) per liter ER volume by an ATP-dependent, thapsigargin-sensitive, process, This tracer Ca2+ uptake was dependent on ambient (loading) [Ca2+], as was the intra-ER free [Ca2+], assessed by imaging the fluorescence of Magfura-8 within the Ca2+ stores, Comparison of free and total intra-ER [Ca2+] indicated that 200-300 Ca2+ ions are bound within the ER lumen for every Ca2+ ion remaining free. Subcellular analysis showed that EB stores in all regions of the permeabilized cell took up Ca2+ at loading [Ca2+] between 60 nM and 1 mu M. Thapsigargin released Ca2+ from stores in all cellular regions, as did InsP(3). Immunofluorescence with antibodies against sarco(endo)plasmic reticulum-2b type Ca2+,Mg2+-ATP-ase or calreticulin confirmed that ER Ca2+ stores were present throughout the cytoplasm. In summary, these results clearly show that the endoplasmic reticulum can act as a functional Ca2+ store in all regions of the acinar cell, including the apical pole.	UNIV MANCHESTER,SCH BIOL SCI,CELL PHYSIOL GRP,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester				Elliott, Austin/0000-0003-3569-9002	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CASE RM, 1973, J PHYSIOL-LONDON, V235, P75, DOI 10.1113/jphysiol.1973.sp010379; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; DELAAGE M, 1967, BIOCHEM BIOPH RES CO, V28, P390, DOI 10.1016/0006-291X(67)90323-3; DORMER RL, 1981, AM J PHYSIOL, V240, pG38, DOI 10.1152/ajpgi.1981.240.1.G38; DORMER RL, 1993, BIOCHIM BIOPHYS ACTA, V1152, P225, DOI 10.1016/0005-2736(93)90253-V; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; ELLIOTT AC, 1992, EUR J PHYSL, V422, P245; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KHANNA NC, 1986, BIOCHEMISTRY-US, V25, P1078, DOI 10.1021/bi00353a020; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; MELDOLESI J, 1971, J CELL BIOL, V49, P109, DOI 10.1083/jcb.49.1.109; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Muallem S, 1997, CELL CALCIUM, V22, P1, DOI 10.1016/S0143-4160(97)90083-X; Roderick HL, 1997, FEBS LETT, V405, P181, DOI 10.1016/S0014-5793(97)00183-X; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SCHREURS VVAM, 1976, BIOCHIM BIOPHYS ACTA, V436, P664, DOI 10.1016/0005-2736(76)90448-X; SCHREURS VVAM, 1975, BIOCHIM BIOPHYS ACTA, V404, P257, DOI 10.1016/0304-4165(75)90332-3; SCHREURS VVAM, 1976, BIOCHIM BIOPHYS ACTA, V419, P320, DOI 10.1016/0005-2736(76)90358-8; STEIN EA, 1964, BIOCHEMISTRY-US, V3, P56, DOI 10.1021/bi00889a010; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TAN YP, 1992, P NATL ACAD SCI USA, V89, P11229, DOI 10.1073/pnas.89.23.11229; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; vandePut FHMM, 1996, J BIOL CHEM, V271, P4999; VANDEPUT FHMM, 1993, J MEMBRANE BIOL, V135, P153, DOI 10.1007/BF00231441; VANDEPUT FHMM, 1994, J BIOL CHEM, V269, P12438; WILLEMS PHGM, 1994, PFLUG ARCH EUR J PHY, V427, P233, DOI 10.1007/BF00374529; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; Yule DI, 1997, J BIOL CHEM, V272, P9093	38	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27764	27770		10.1074/jbc.272.44.27764	http://dx.doi.org/10.1074/jbc.272.44.27764			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346920	hybrid			2022-12-27	WOS:A1997YD47300046
J	Hocker, M; Henihan, RJ; Rosewicz, S; Riecken, EO; Zhang, ZS; Koh, TJ; Wang, TC				Hocker, M; Henihan, RJ; Rosewicz, S; Riecken, EO; Zhang, ZS; Koh, TJ; Wang, TC			Gastrin and phorbol 12-myristate 13-acetate regulate the human histidine decarboxylase promoter through raf-dependent activation of extracellular signal-regulated kinase-related signaling pathways in gastric cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MAP KINASE; C-JUN; IN-VIVO; HA-RAS; CHOLECYSTOKININ; RECEPTOR; PHOSPHORYLATION; EXPRESSION; TRANSFORMATION	Gastrin stimulates transcription of the human histidine decarboxylase (HDC) gene through binding to the G-protein-coupled cholecystokinin-B/gastrin receptor. We have explored the possibility that mitogen-activated protein kinase cascades play a role in mediating the effects of gastrin on transcription in a gastric cancer (AGS-B) cell line. Gastrin and phorbol 12-myristate 13-acetate (PMA) treatment of AGS-B cells was found to increase the phosphorylation of tyrosine residues of extracellular signal-regulated kinases (ERKs) 1 and 2 and increase ERK activity as determined by the in vitro phosphorylation of myelin basic protein. Reporter gene assays also demonstrated that gastrin and PMA stimulated Elk-1- and c-Myc-dependent transactivation, consistent with gastrin and PMA-induced activation of ERKs. Overexpression of wild type ERK-1 and ERK-2 or activation of endogenous ERKs using activated MEK-1 (mitogen-activated protein kinase kinase or ERK kinase) overexpression stimulated HDC promoter activity in a dose-dependent fashion. Interruption of the ERK-related pathway using expression vectors for kinase-deficient ERKs or an ERK-specific phosphatase (PAC-1) blocked gastrin and PMA-stimulated HDC promoter activity. In contrast, inhibition of the Jun kinase pathway using an interfering dominant negative SEK-1 (stress-activated protein kinase/ERK-1) mutant did not inhibit HDC promoter activity. Furthermore, whereas gastrin stimulated phosphorylation of She proteins and association with Grb2, activation of the HDC promoter was not influenced by expression of dominant negative Ras (N15 or N17) proteins. However, gastrin stimulated Raf-1 kinase activity, and activation of the HDC promoter was blocked by coexpression of a dominant negative Raf-1 construct. Overall, these data demonstrate that gastrin regulates HDC transcription in a Raf-dependent, Ras-independent fashion predominantly through activation of the ERK-related pathway.	MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [R01CA067463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048077] Funding Source: NIH RePORTER; NCI NIH HHS [CA67463] Funding Source: Medline; NIDDK NIH HHS [DK48077] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BERTRAND V, 1994, INT J CANCER, V56, P427, DOI 10.1002/ijc.2910560324; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CHEN D, 1994, GASTROENTEROLOGY, V107, P18, DOI 10.1016/0016-5085(94)90056-6; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIMALINE R, 1991, FEBS LETT, V281, P20, DOI 10.1016/0014-5793(91)80348-7; DUAN RD, 1994, AM J PHYSIOL, V267, pG401, DOI 10.1152/ajpgi.1994.267.3.G401; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hocker M, 1996, AM J PHYSIOL-GASTR L, V270, pG619, DOI 10.1152/ajpgi.1996.270.4.G619; HOCKER M, 1997, AM J PHYSIOL, V35, P6822; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; Langhans N, 1997, GASTROENTEROLOGY, V112, P280, DOI 10.1016/S0016-5085(97)90000-7; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; NAKATA H, 1992, BIOCHEM BIOPH RES CO, V187, P1151, DOI 10.1016/0006-291X(92)91317-J; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3755; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANDVIK AK, 1994, AM J PHYSIOL, V267, pG254, DOI 10.1152/ajpgi.1994.267.2.G254; Seva C, 1996, FEBS LETT, V378, P74, DOI 10.1016/0014-5793(95)01414-4; SEVA C, 1994, REGUL PEPTIDES, V52, P31, DOI 10.1016/0167-0115(94)90018-3; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANIGUCHI T, 1994, ONCOGENE, V9, P861; TODISCO A, 1995, J BIOL CHEM, V270, P28337; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WINITZ S, 1993, J BIOL CHEM, V268, P19196; Zhang ZS, 1996, J BIOL CHEM, V271, P14188, DOI 10.1074/jbc.271.24.14188	43	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27015	27024		10.1074/jbc.272.43.27015	http://dx.doi.org/10.1074/jbc.272.43.27015			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341140	hybrid			2022-12-27	WOS:A1997YC65900036
J	Ito, K; Groudine, M				Ito, K; Groudine, M			A new member of the cationic amino acid transporter family is preferentially expressed in adult mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRAL RECEPTOR; CULTURED ANIMAL-CELLS; L-ARGININE TRANSPORT; SMOOTH-MUSCLE CELLS; GENE-EXPRESSION; NOREPINEPHRINE TRANSPORTER; PLASMA-MEMBRANE; MAMMALIAN-CELLS; MESSENGER-RNA; SYSTEM Y(+)	We have isolated and characterized a novel member (CAT3) of the cationic amino acid transporter (CAT) family, In oocyte injection assays, CAT3 cRNA exhibited a saturable, sodium ion-independent transport activity with high affinity for L-arginine and L-lysine (K-m = 40-60 and 115-165 mu M, respectively), Transport of L-arginine was effectively competed only by cationic amino acids in L-form: arginine, lysine, ornithine, and 2,4-diamino-n-butyric acid but not by 2,3-diaminopropionic acid. The presence of L-arginine in the incubation medium stimulated the efflux rate of L-arginine, indicating that CAT3 is subject to trails-stimulation. All these re suits are consistent with the idea that CAT3, along with CAT1 and CAT2, constitutes the transport activity originally assigned to system y(+). Like CAT2, but unlike CAT1, the expression of CAT3 is regulated in a highly tissue-specific manner; when various adult tissues were examined, significant levels of CAT3 transcript were detectable only in brain, In situ hybridization oil brain sections revealed that CAT3 transcripts were localized predominantly along the midbrain-thalamus-hypothalamus axis, whereas neither CAT1 nor CAT2 transcripts demonstrated a similar localization, In contrast to its highly localized expression during the primitive streak stage and in the adult stage, CAT3 expression was detected more widely in 13.5 day post-coitum mouse embryos.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT RADIAT ONCOL,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle								AHMED A, 1995, J BIOL CHEM, V270, P8482, DOI 10.1074/jbc.270.15.8482; ALBRITTON LM, 1992, GENOMICS, V12, P430, DOI 10.1016/0888-7543(92)90431-Q; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; CHRISTENSEN HN, 1973, MEMBRANE STRUCTURE M, P233; CHRISTENSEN HN, 1975, CURRENT TOPICS MEMBR, V6, P227; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; Durante W, 1996, J BIOL CHEM, V271, P11838, DOI 10.1074/jbc.271.20.11838; ELENO N, 1994, J PHYSIOL-LONDON, V479, P291, DOI 10.1113/jphysiol.1994.sp020296; Gill DJ, 1996, J BIOL CHEM, V271, P11280, DOI 10.1074/jbc.271.19.11280; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hosokawa H, 1997, J BIOL CHEM, V272, P8717, DOI 10.1074/jbc.272.13.8717; Ing BL, 1996, BIOCHEM BIOPH RES CO, V218, P76, DOI 10.1006/bbrc.1996.0015; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KIM JW, 1993, J BIOL CHEM, V268, P16316; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LOW BC, 1995, J BIOL CHEM, V270, P27577, DOI 10.1074/jbc.270.46.27577; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Melikian HE, 1996, MOL PHARMACOL, V50, P266; Nguyen TT, 1996, J NEUROCHEM, V67, P645; OPRESKO LK, 1991, METHOD CELL BIOL, V36, P117; PUPPI M, 1995, P SOC EXP BIOL MED, V209, P38, DOI 10.3181/00379727-209-43875; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Simmons WW, 1996, J BIOL CHEM, V271, P11694, DOI 10.1074/jbc.271.20.11694; Stevens BR, 1996, J BIOL CHEM, V271, P24017, DOI 10.1074/jbc.271.39.24017; STOLL J, 1993, J NEUROCHEM, V60, P1956, DOI 10.1111/j.1471-4159.1993.tb13428.x; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WHITE MF, 1982, J BIOL CHEM, V257, P4443; WHITE MF, 1982, J BIOL CHEM, V257, P69; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; YOSHIMOTO T, 1991, VIROLOGY, V185, P10, DOI 10.1016/0042-6822(91)90748-Z; YOSHIMOTO T, 1992, J VIROL, V66, P4377, DOI 10.1128/JVI.66.7.4377-4381.1992	45	90	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26780	26786		10.1074/jbc.272.42.26780	http://dx.doi.org/10.1074/jbc.272.42.26780			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334265	hybrid			2022-12-27	WOS:A1997YB13900099
J	Shimoaraiso, M; Nakanishi, T; Kubo, T; Natori, S				Shimoaraiso, M; Nakanishi, T; Kubo, T; Natori, S			Identification of the region in yeast S-II that defines species specificity in its interaction with RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-SII; ASCITES TUMOR-CELLS; PROMOTE READ-THROUGH; TRANSCRIPTION ELONGATION; SACCHAROMYCES-CEREVISIAE; DEPENDENT TRANSCRIPTION; NASCENT TRANSCRIPT; STIMULATORY FACTOR; FACTOR TFIIS; ZINC-FINGER	Yeast S-II was found to stimulate yeast RNA polymerase II only and not mouse RNA polymerase II, To identify the molecular region of S-II that defines species specificity, we constructed six hybrid S-II molecules consisting of three regions from yeast: and/or Ehrlich cell S-II and examined their activity in terms of RNA polymerase II specificity and suppression of 6-azauracil. sensitivity in the yeast S-II null mutant. We found that the region 132-270 (amino acid positions) of yeast S-II is indispensable for specific interaction with yeast RNA polymerase II in vitro and for suppression of 6-azauracil sensitivity in vivo. The corresponding region of Ehrlich cell S-II, the region 132-262, was also shown to be essential for its interaction with mouse RNA polymerase II. This region is known to be less conserved than the Nand C-terminal regions in the S-II family suggesting that it is important in the interaction with transcription machinery proteins in a tissue and/or species-specific manner.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo				Kubo, Takeo/0000-0002-5914-5269				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BITTER GA, 1983, ANAL BIOCHEM, V128, P294, DOI 10.1016/0003-2697(83)90378-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HOMMA K, 1994, J BIOL CHEM, V269, P15258; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KANE CM, 1993, TRANSCRIPTION MECH R, P279; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, FASEB J, V5, P777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; Morin PE, 1996, P NATL ACAD SCI USA, V93, P10604, DOI 10.1073/pnas.93.20.10604; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P265; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SEKIMIZU K, 1983, J BIOCHEM-TOKYO, V93, P1523, DOI 10.1093/oxfordjournals.jbchem.a134290; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SEKIMIZU K, 1982, J BIOL CHEM, V257, P2719; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SEKIMIZU K, 1979, EXP CELL RES, V124, P68; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SPENCER CA, 1990, ONCOGENE, V5, P777; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UENO K, 1979, NATURE, V277, P145, DOI 10.1038/277145a0	50	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26550	26554		10.1074/jbc.272.42.26550	http://dx.doi.org/10.1074/jbc.272.42.26550			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334234	hybrid			2022-12-27	WOS:A1997YB13900068
J	Knauer, MF; Kridel, SJ; Hawley, SB; Knauer, DJ				Knauer, MF; Kridel, SJ; Hawley, SB; Knauer, DJ			The efficient catabolism of thrombin-protease nexin 1 complexes is a synergistic mechanism that requires both the LDL receptor-related protein and cell surface heparins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; HUMAN ANTITHROMBIN-III; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; BINDING-SITE; INTERNALIZATION; DEGRADATION; PROTEOGLYCANS; PURIFICATION	Protease nexin 1 (PN1) is a serine protease inhibitor (SERPIN) that acts as a suicide substrate for thrombin (Th) and urokinase-type plasminogen activator (uPA), PN1 forms 1:1 stoichiometric complexes with these proteases, which are then rapidly bound, internalized, and degraded, The low density lipoprotein receptor-related protein (LRP) is the receptor responsible for the internalization of protease-PN1 complexes, However, we found that the LRP is not significantly involved in the initial cell surface binding of thrombin-PN1, leading us to investigate what cellular component was responsible for this initial interaction, Since Th-PN1 complexes retain a high-affinity for heparin after complex formation, unlike several of the other SERPINs, we tested the possibility that cell surface heparins were involved in initial complex binding, Soluble heparin was found to be a potent inhibitor of the binding of Th-PN1 to the cell surface and greatly facilitated the dissociation of Th-PN1 complexes pre-bound in the absence of soluble heparin, To ascertain the role of cell surface heparins, further studies were done using complexes of thrombin and PN1(K7E), a variant of PN1 in which the heparin binding site was rendered non-functional, When added at equal initial concentrations of complexes, Th-PN1(K7E) was catabolized B-to 10-fold less efficiently than Th-PN1, a direct result of the greatly diminished initial binding of the Th-PN1(K7E) complexes, These data demonstrate the sizable contribution of cell surface heparins to Thrombin-PN1 complex binding and support a model in which these heparins act to concentrate the complexes at the cell surface facilitating their subsequent LRP-dependent endocytosis.	UNIV CALIF IRVINE, SCH BIOL SCI, DEPT DEV & CELL BIOL, IRVINE, CA 92697 USA; Scripps Res Inst, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA	University of California System; University of California Irvine; Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034001] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM34001-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CONESE M, 1994, J BIOL CHEM, V269, P17886; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; EVANS DL, 1991, J BIOL CHEM, V266, P22307; GILLESPIE LS, 1991, J BIOL CHEM, V266, P3995; Hardy MM, 1997, J BIOL CHEM, V272, P6812, DOI 10.1074/jbc.272.10.6812; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOWARD EW, 1986, J BIOL CHEM, V261, P684; HOWARD EW, 1987, J CELL PHYSIOL, V131, P276, DOI 10.1002/jcp.1041310219; KAPLAN J, 1980, CELL, V19, P197, DOI 10.1016/0092-8674(80)90401-8; KNAUER DJ, 1983, J CELL PHYSIOL, V117, P385, DOI 10.1002/jcp.1041170314; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; Nielsen MS, 1997, J BIOL CHEM, V272, P5821, DOI 10.1074/jbc.272.9.5821; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLSON D, 1992, J BIOL CHEM, V267, P9129; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P1774, DOI 10.1172/JCI113519; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SMITH JW, 1987, J BIOL CHEM, V262, P11964; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; Veiga SS, 1997, J BIOL CHEM, V272, P12529, DOI 10.1074/jbc.272.19.12529; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLNOW TE, 1994, J CELL SCI, V107, P719	30	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29039	29045		10.1074/jbc.272.46.29039	http://dx.doi.org/10.1074/jbc.272.46.29039			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360977	hybrid			2022-12-27	WOS:A1997YF68400036
J	Hunter, T; Bannister, WH; Hunter, GJ				Hunter, T; Bannister, WH; Hunter, GJ			Cloning, expression, and characterization of two manganese superoxide dismutases from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; METHYL VIOLOGEN; LIFE-SPAN; C-ELEGANS; DOSAGE COMPENSATION; SEX DETERMINATION; OXIDATIVE DAMAGE; SENSITIVE MUTANT; GENE; NEMATODE	Two genes encoding manganese superoxide dismutase (sod-2 and sod-3) have been identified in the nematode Caenorhabditis elegans. Each gene is composed of five exons, and intron positions are identical; however, intron sizes and sequences are not the same, The predicted protein sequences are 86.3% homologous (91.8% conservative), and the cDNAs are only 75.2% homologous, Both deduced protein sequences contain the expected N-terminal mitochondrial transit peptides. Reverse transcriptase polymerase chain reaction analysis shows that both genes are expressed under normal growth conditions and that their RNA transcripts are trans-spliced to the SL-1 leader sequence. The latter result together with Northern blot analysis indicate that both genes have mono-cistronic transcripts, The sod-3 gene was mapped to chromosome X, and the location of sod-2 was confirmed to be chromosome I, Polymerase chain reaction was used to amplify the cDNA regions encoding the predicted mature manganese superoxide dismutase proteins and each was cloned and expressed to high levels in Escherichia coli cells deficient in cytosolic superoxide dismutases. Both proteins were shown to be active in E. coli, providing similar protection against methyl viologen-induced oxidative stress. The expressed enzymes, which were not inhibited by hydrogen peroxide or cyanide, are dimeric, show quite different electrophoretic mobilities and isoelectric points, but exhibit comparable specific activities.	UNIV MALTA, DEPT PHYSIOL & BIOCHEM, MSIDA MSD06, MALTA	University of Malta				Hunter, Therese/0000-0002-3447-5800; Hunter, Gary/0000-0002-0336-6556				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANDERSON GL, 1982, CAN J ZOOL, V60, P288, DOI 10.1139/z82-038; ARPAGAUS M, 1994, J BIOL CHEM, V269, P9957; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BEYER WF, 1991, J BIOL CHEM, V266, P303; BLUM J, 1983, ARCH BIOCHEM BIOPHYS, V222, P35, DOI 10.1016/0003-9861(83)90499-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1974, GENETICS, V77, P71; COMPAN I, 1993, J BACTERIOL, V175, P1687, DOI 10.1128/JB.175.6.1687-1696.1993; DARR D, 1995, FREE RADICAL BIO MED, V18, P195, DOI 10.1016/0891-5849(94)00118-4; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; FRIEDMAN DB, 1988, GENETICS, V118, P75; FRIEDMAN DB, 1988, J GERONTOL, V43, pB102, DOI 10.1093/geronj/43.4.B102; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GIGLIO AM, 1994, BIOCHEM MOL BIOL INT, V33, P41; GIGLIO MP, 1994, BIOCHEM MOL BIOL INT, V33, P37; HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HARTMAN P, 1995, J GERONTOL A-BIOL, V50, pB322, DOI 10.1093/gerona/50A.6.B322; HASSAN HM, 1978, J BIOL CHEM, V253, P8143; HASSAN HM, 1977, J BIOL CHEM, V252, P7667; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; HONDA S, 1993, J GERONTOL, V48, pB57, DOI 10.1093/geronj/48.2.B57; HOPKIN KA, 1992, J BIOL CHEM, V267, P24253; HUANG XY, 1989, J MOL BIOL, V206, P411, DOI 10.1016/0022-2836(89)90490-7; Hunter T, 1997, BIOCHEMISTRY-US, V36, P4925, DOI 10.1021/bi9629541; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; ISHII N, 1993, MECH AGEING DEV, V68, P1, DOI 10.1016/0047-6374(93)90135-E; JONES PL, 1995, GENE, V153, P155, DOI 10.1016/0378-1119(94)00666-G; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lithgow GJ, 1996, BIOESSAYS, V18, P809, DOI 10.1002/bies.950181007; MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MEYER BJ, 1988, TRENDS GENET, V4, P337, DOI 10.1016/0168-9525(88)90053-4; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; MUIRAS ML, 1993, MUTAT RES, V295, P47, DOI 10.1016/0921-8734(93)90010-Z; NUSBAUM C, 1989, GENETICS, V122, P579; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PARKER MW, 1988, FEBS LETT, V229, P377, DOI 10.1016/0014-5793(88)81160-8; PARKER MW, 1988, J MOL BIOL, V199, P649, DOI 10.1016/0022-2836(88)90308-7; PRIVALLE CT, 1992, J BIOL CHEM, V267, P9140; REED DJ, 1986, FUND APPL TOXICOL, V6, P591, DOI 10.1016/0272-0590(86)90171-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STENICO M, 1994, NUCLEIC ACIDS RES, V22, P2437, DOI 10.1093/nar/22.13.2437; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Suzuki N, 1996, DNA Res, V3, P171, DOI 10.1093/dnares/3.3.171; TOUATI D, 1988, J BACTERIOL, V170, P2511, DOI 10.1128/jb.170.6.2511-2520.1988; VANFLETEREN JR, 1992, COMP BIOCHEM PHYS B, V102, P219, DOI 10.1016/0305-0491(92)90114-7; VANFLETEREN JR, 1995, FASEB J, V9, P1355, DOI 10.1096/fasebj.9.13.7557026; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WAGNER UG, 1993, PROTEIN SCI, V2, P814, DOI 10.1002/pro.5560020511; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991; YSEBAERTVANNESTE M, 1980, ANAL BIOCHEM, V107, P86, DOI 10.1016/0003-2697(80)90496-0; ZHU DH, 1993, P NATL ACAD SCI USA, V90, P9310, DOI 10.1073/pnas.90.20.9310; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	69	112	125	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28652	28659		10.1074/jbc.272.45.28652	http://dx.doi.org/10.1074/jbc.272.45.28652			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353332	hybrid			2022-12-27	WOS:A1997YF21900072
J	Kamitani, T; Kito, K; Nguyen, HP; Yeh, ETH				Kamitani, T; Kito, K; Nguyen, HP; Yeh, ETH			Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME PATHWAY; DEGRADATION; IDENTIFICATION; CONJUGATION; COMPLEX; HOMOLOG	NEDD8 is a novel 81 amino acid polypeptide which is 60% identical and 80% homologous to ubiquitin, Northern blot analysis showed that the NEDD8 message was developmentally down-regulated, In adult tissues, NEDD8 expression was mostly restricted to the heart and skeletal muscle. Antiserum specific for NEDD8 detected a 6-kDa monomer in SK-N-SH, BJAB, and HL60 cell lysates, A 14-kDa band was also detected in BJAB, HL60, and SK-MEL28 but not in SK-N-SH and K562 cell lysates, An approximately 90-kDa band was detected in all cell lines tested, Thus, NEDD8 is likely to be conjugated to other proteins in a manner analogous to ubiquitination. However, the conjugation pattern of NEDD8 is entirely different from that of ubiquitin in all cell lines tested, To study NEDD8 conjugation in more detail, hemagglutinin-epitope-tagged NEDD8 was expressed in COS cells. Western blot analysis revealed an NEDD8 monomer and a series of higher molecular weight NEDD8-conjugated proteins or NEDD8 multimers, Immunocytochemical analysis showed that NEDD8 expression was highly enriched in the nucleus and was much weaker in the cytosol, In contrast, ubiquitin expression was detectable equally well in the nucleus and cytosol, Mutational analysis showed that the C terminus of NEDD8 was efficiently cleaved and that Gly-76 was required for conjugation of NEDD8 to other proteins, Taken together, NEDD8 provides another substrate for covalent protein modification and may play a unique role during development.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV MOL MED,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,INST MOL MED PREVENT HUMAN DIS,RES CTR CARDIOVASC DIS,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston			Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NHLBI NIH HHS [HL-45851] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boddy MN, 1996, ONCOGENE, V13, P971; Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOPKIN K, 1997, J NIH RES, V9, P36; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KAMITANI T, 1991, CLIN IMMUNOL IMMUNOP, V58, P217, DOI 10.1016/0090-1229(91)90138-Z; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Okura T, 1996, J IMMUNOL, V157, P4277; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113	26	348	357	4	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28557	28562		10.1074/jbc.272.45.28557	http://dx.doi.org/10.1074/jbc.272.45.28557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353319	hybrid			2022-12-27	WOS:A1997YF21900059
J	Mitchell, AG; Martin, CE				Mitchell, AG; Martin, CE			Fah1p, a Saccharomyces cerevisiae cytochrome b(5) fusion protein, and its Arabidopsis thaliana homolog that lacks the cytochrome b(5) domain both function in the alpha-hydroxylation of sphingolipid-associated very long chain fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEAROYL-COA DESATURASE; RICINUS-COMMUNIS L; XYLENE MONOOXYGENASE; ALKANE HYDROXYLASE; GENE; EXPRESSION; B5; SEQUENCE; SEGMENT; STRAINS	A search of the Saccharomyces cerevisiae genome data base for cytochrome b(5)-like sequences identified a 1.152-kilobase pair open reading frame, located on chromosome XIII at locus YMR272C (FAH1). That gene encodes a putative 384-amino acid protein with an amino-terminal cytochrome b(5) domain, The b(5) core domain shows a 52% identity and 70% similarity to that of the yeast microsomal cytochrome b(5) and a 35% identity and 54% similarity to the b(5) core domain of OLE1, the S. cerevisiae Delta-9 fatty acid desaturase, Expression of the S. cerevisiae FAH1 cytochrome b(5) domain in Escherichia coli produces a soluble protein that exhibits the typical oxidized versus reduced differential absorbance spectra of cytochrome b(5). Sequence analysis of Fah1p reveals other similarities to Ole1p, Both proteins are predicted to have two hydrophobic domains, each capable of spanning the membrane twice, and both have the HX(2-3)(XH)H motifs that are characteristic of membrane-bound fatty acid desaturases, These similarities to Ole1p suggested that Fah1p played a role in the biosynthesis or modification of fatty acids. Disruption of the FAH1 gene in S. cerevisiae did not give any visible phenotype, and there was no observable difference in content or distribution of the most abundant long chain saturated and unsaturated 14-18-carbon fatty acid species, Northern blot analysis, however, showed that this gene is expressed at much lower levels (similar to 150-fold) than the OLE1 gene, suggesting that it might act on a smaller subset of fatty acids, Analysis of sphingolipid-derived very long chain fatty acids revealed an approximately 40 fold reduction of alpha-HO 26:0 and a complementary increase in 26:0 in the gene-disrupted fah1 Delta strain, GAL1 expression of the S. cerevisiae FAH1 genes in the fah1 Delta strain restores alpha-HO 26:0 fatty acids to wild type levels, Also identified are a number of homologs to this gene in other Species, Expression of an Arabidopsis thaliana FAH1 gene, which does not contain the cytochrome b(5) domain, in the fah1 Delta strain produced an approximately 25-fold increase in alpha-HO 26:0 and reduced the levels of its 26-carbon precursor, suggesting that it functions in very long chain fatty acid hydroxylation using an alternate electron transfer mechanism.	RUTGERS STATE UNIV,DEPT BIOL SCI,NELSON LABS,PISCATAWAY,NJ 08855; RUTGERS STATE UNIV,BUR BIOL RES,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick								Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BESSOULE JJ, 1988, EUR J BIOCHEM, V177, P207, DOI 10.1111/j.1432-1033.1988.tb14363.x; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; DAILEY HA, 1980, J BIOL CHEM, V255, P5184; DAILEY HA, 1978, J BIOL CHEM, V253, P8203; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; GARGANO S, 1995, LIPIDS, V30, P899, DOI 10.1007/BF02537480; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUIARD B, 1979, J MOL BIOL, V135, P639, DOI 10.1016/0022-2836(79)90169-4; KAYA K, 1984, J BIOL CHEM, V259, P3548; KOK M, 1989, J BIOL CHEM, V264, P5435; LEDERER F, 1994, BIOCHIMIE, V76, P674, DOI 10.1016/0300-9084(94)90144-9; LESTER RL, 1993, J BIOL CHEM, V268, P845; LIANGTAO L, 1996, J BIOL CHEM, V271, P16927; MANIATIS T, 1998, MOL CLONING; MATHEWS FS, 1972, J MOL BIOL, V64, P449, DOI 10.1016/0022-2836(72)90510-4; MITCHELL AG, 1995, J BIOL CHEM, V270, P29766; NISHIMOTO M, 1989, BIOCHEMISTRY-US, V32, P8863; NURMINEN T, 1971, BIOCHEM J, V125, P963, DOI 10.1042/bj1250963; OZOLS J, 1974, BIOCHEMISTRY-US, V13, P426, DOI 10.1021/bi00700a005; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; Sayanova O, 1997, P NATL ACAD SCI USA, V94, P4211, DOI 10.1073/pnas.94.8.4211; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Sherman F., 1982, METHODS YEAST GENETI; SHIGEMATSU H, 1987, INT J BIOCHEM, V19, P41, DOI 10.1016/0020-711X(87)90121-2; SMITH MA, 1992, BIOCHEM J, V287, P141, DOI 10.1042/bj2870141; SMITH MA, 1994, BIOCHEM J, V303, P73, DOI 10.1042/bj3030073; SPERLING P, 1995, EUR J BIOCHEM, V232, P798, DOI 10.1111/j.1432-1033.1995.0798a.x; STORCH EM, 1995, BIOCHEMISTRY-US, V34, P9682, DOI 10.1021/bi00030a005; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; SUZUKI M, 1991, J BACTERIOL, V173, P1690, DOI 10.1128/jb.173.5.1690-1695.1991; TRUAN G, 1994, GENE, V149, P123; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743; VERGERES G, 1992, J BIOL CHEM, V267, P12583	39	82	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28281	28288		10.1074/jbc.272.45.28281	http://dx.doi.org/10.1074/jbc.272.45.28281			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353282	hybrid			2022-12-27	WOS:A1997YF21900022
J	Stephens, KM; McMacken, R				Stephens, KM; McMacken, R			Functional properties of replication fork assemblies established by the bacteriophage lambda O and P replication proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; SINGLE-STRANDED-DNA; HEAT-SHOCK PROTEINS; SPECIALIZED NUCLEOPROTEIN STRUCTURES; COORDINATED LEADING-STRAND; OKAZAKI FRAGMENT SIZE; ESCHERICHIA-COLI; PHAGE-LAMBDA; PLASMID DNA; INITIATION	We have used a set of bacteriophage lambda and Escherichia coli replication proteins to establish rolling circle DNA replication in vitro to permit characterization of the functional properties of lambda replication forks. We demonstrate that the lambda replication fork assembly synthesizes leading strand DNA chains at a physiological rate of 650-750 nucleotides/s at 30 degrees C. This rate is identical to the fork movement rate we obtained using a minimal protein system, composed solely off. coli DnaB helicase and DNA polymerase III holoenzyme. Our data are consistent with the conclusion that these two key bacterial replication proteins constitute the basic functional unit of a lambda replication fork, A comparison of rolling circle DNA replication in the minimal and lambda replication systems indicated that DNA synthesis proceeded for more extensive periods in the lambda system and produced longer DNA chains, which averaged nearly 200 kilobases in length. The higher potency of the lambda replication system is believed to result from its capacity to mediate efficient reloading of DnaB helicase onto rolling circle replication products, thereby permitting reinitiation of DNA chain elongation following spontaneous termination events. E. coli single-stranded DNA-binding protein and primase individually stimulated rolling circle DNA replication, but they apparently act indirectly by blocking accumulation of inhibitory free single-stranded DNA product. Finally, in the course of this work, we discovered that E. coli DNA polymerase III holoenzyme is itself capable of carrying out significant strand displacement DNA synthesis at about 50 nucleotides/s when it is supplemented with E. coli single-stranded DNA-binding protein.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University					NIEHS NIH HHS [ES-03819] Funding Source: Medline; NIGMS NIH HHS [GM32253] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032253] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1968, COLD SPRING HARB SYM, V33, P289, DOI 10.1101/SQB.1968.033.01.033; ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI K, 1981, J BIOL CHEM, V256, P5253; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BASTIA D, 1975, J MOL BIOL, V98, P305, DOI 10.1016/S0022-2836(75)80120-3; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CARTER BJ, 1969, BIOCHIM BIOPHYS ACTA, V195, P494, DOI 10.1016/0005-2787(69)90656-X; DENTE L, 1987, METHOD ENZYMOL, V155, P111; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DODSON M, 1989, J BIOL CHEM, V264, P10719; ERDILE L, 1984, VIROLOGY, V139, P97, DOI 10.1016/0042-6822(84)90333-7; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KLEIN A, 1980, EUR J BIOCHEM, V105, P1, DOI 10.1111/j.1432-1033.1980.tb04467.x; KLINKERT J, 1978, J VIROL, V25, P730, DOI 10.1128/JVI.25.3.730-737.1978; Kornberg A., 1992, DNA REPLICATION; KUHN B, 1979, J BIOL CHEM, V254, P1343; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAMED R, 1973, BIOCHIM BIOPHYS ACTA, V305, P163, DOI 10.1016/0005-2728(73)90241-7; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LEBOWITZ JH, 1985, P NATL ACAD SCI USA, V82, P3988, DOI 10.1073/pnas.82.12.3988; LEBOWITZ JH, 1984, ADV EXP MED BIOL, V179, P77; LEBOWITZ JH, 1984, NUCLEIC ACIDS RES, V12, P3069, DOI 10.1093/nar/12.7.3069; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P7545, DOI 10.1093/nar/16.15.7545; MAKI H, 1988, J BIOL CHEM, V263, P6570; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; MARIANS KJ, 1996, ESCHERICHIA COLI SAL, P749; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCMACKEN R, 1977, P NATL ACAD SCI USA, V74, P4190, DOI 10.1073/pnas.74.10.4190; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; MOK M, 1987, J BIOL CHEM, V262, P16644; ODONNELL ME, 1985, J BIOL CHEM, V260, P2884; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; ROWEN L, 1978, J BIOL CHEM, V253, P758; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SKALKA A, 1972, J MOL BIOL, V64, P541, DOI 10.1016/0022-2836(72)90081-2; TAKAHASHI S, 1975, MOL GEN GENET, V142, P137, DOI 10.1007/BF00266095; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; Tougu K, 1996, J BIOL CHEM, V271, P21391, DOI 10.1074/jbc.271.35.21391; TOUGU K, 1994, J BIOL CHEM, V269, P4675; TSURIMOTO T, 1981, NUCLEIC ACIDS RES, V9, P1789, DOI 10.1093/nar/9.8.1789; UEDA K, 1978, J BIOL CHEM, V253, P261; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WICKNER SH, 1979, COLD SPRING HARB SYM, V43, P303, DOI 10.1101/SQB.1979.043.01.037; WU CA, 1992, J BIOL CHEM, V267, P4030; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	67	15	15	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28800	28813		10.1074/jbc.272.45.28800	http://dx.doi.org/10.1074/jbc.272.45.28800			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353352	hybrid			2022-12-27	WOS:A1997YF21900092
J	Sung, P				Sung, P			Communication - Function of yeast Rad52 protein as a mediator between replication protein A and the Rad51 recombinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; ESCHERICHIA-COLI; REPAIR; RECA; FILAMENT; ENCODES; GENE	The RAD51 and RAD52 genes of Saccharomyces cerevisiae are key members of the RAD52 epistasis group required for genetic recombination and the repair of DNA double-stranded breaks. The RAD51 encoded product mediates the DNA strand exchange reaction. Efficient strand exchange is contingent upon the addition of the heterotrimeric single-stranded DNA binding factor replication protein A (RPA) after Rad51 has nucleated onto the single-stranded DNA However, if the single-stranded DNA is incubated with Rad51 and RPA simultaneously to mimic what may be expected to occur in vivo, the efficiency of strand exchange decreases dramatically, revealing an inhibitory effect of RPA that is distinct from its stimulatory function. Interestingly, the inclusion of Rad52 protein, which has been purified in this study from yeast cells, restores the efficiency of strand exchange. Thus, Rad52 functions as a co-factor for the Rad51 recombinase, acting specifically to overcome the apparent competition by RPA for binding to single-stranded DNA.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,SAN ANTONIO,TX 78245; SEALY CTR MOL SCI,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,GALVESTON,TX 77555	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Sung, P (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MOL MED,15355 LAMBDA DR,SAN ANTONIO,TX 78245, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES07061] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		COX MM, 1987, ANN REV BIOCH, V56, P29; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; JIANG H, 1993, J BIOL CHEM, V268, P7904; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; MORRICAL SW, 1990, J BIOL CHEM, V265, P15096; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875	18	435	442	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28194	28197		10.1074/jbc.272.45.28194	http://dx.doi.org/10.1074/jbc.272.45.28194			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353267	hybrid			2022-12-27	WOS:A1997YF21900007
J	DeMaria, CT; Sun, Y; Long, L; Wagner, BJ; Brewer, G				DeMaria, CT; Sun, Y; Long, L; Wagner, BJ; Brewer, G			Structural determinants in AUF1 required for high affinity binding to A+U-rich elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; PROTEIN-PROTEIN-INTERACTION; RNA-BINDING; POLY(A)-BINDING PROTEIN; DOMAIN; MOTIFS; TETRAMERS; CLONING; KINASE; SITE	AUF1 is an RNA binding protein that contains two nonidentical RNA recognition motifs (RRMs), AUF1 binds to A + U-rich elements (AREs) with high affinity. The binding of AUF1 to AREs is believed to serve as a signal to an mRNA-processing pathway that degrades mRNAs encoding many cytokines, oncoproteins, and G protein-coupled receptors, Because the ARE binding activity of AUF1 appears central to the regulation of many important genes, we analyzed the domains of the protein that are important for this activity. Examination of the RNA binding affinity of various AUF1 mutants suggests that both RRMs may be required for binding to the human c-fos ARE. However, the two RRMs together are not sufficient, Highest affinity binding of AUF1 to an ARE requires an alanine-rich region of the N terminus and a short glutamine-rich region in the C terminus. In addition, the N terminus is required for dimerization of AUF1, However, AUF1 binds an ARE as a hexameric protein. Thus, protein-protein interactions are important for high affinity ARE binding activity of AUF1.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MICROBIOL & IMMUNOL, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PLAST & RECONSTRUCT SURG, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center					NCI NIH HHS [CA12197, CA52443] Funding Source: Medline; NIAID NIH HHS [T32-AI07401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052443, P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERS GK, 1964, BIOCHEMISTRY-US, V3, P723, DOI 10.1021/bi00893a021; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BARNETT SF, 1989, MOL CELL BIOL, V9, P492, DOI 10.1128/MCB.9.2.492; BARNETT SF, 1991, MOL CELL BIOL, V11, P864, DOI 10.1128/MCB.11.2.864; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; EHRENMAN K, 1994, GENE, V149, P315, DOI 10.1016/0378-1119(94)90168-6; FREIFELDER D, 1982, PHYSICAL BIOCH APPLI, P460; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; HUANG M, 1994, MOL CELL BIOL, V14, P518, DOI 10.1128/MCB.14.1.518; Kiledjian M, 1997, MOL CELL BIOL, V17, P4870, DOI 10.1128/MCB.17.8.4870; Kim MK, 1996, MOL CELL BIOL, V16, P4366; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LU JR, 1995, J MOL BIOL, V247, P739, DOI 10.1016/S0022-2836(05)80152-4; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Pace C N, 1986, Methods Enzymol, V131, P266; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Parks JS, 1997, J LIPID RES, V38, P266; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SERING, 1997, J BIOL CHEM, V272, P13109; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; Yeung K, 1997, MOL CELL BIOL, V17, P36, DOI 10.1128/MCB.17.1.36; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; Zeng QY, 1997, RNA, V3, P303; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	41	79	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27635	27643		10.1074/jbc.272.44.27635	http://dx.doi.org/10.1074/jbc.272.44.27635			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346902	hybrid			2022-12-27	WOS:A1997YD47300028
J	Huang, XF; Compans, RW; Chen, SY; Lamb, RA; Arvan, P				Huang, XF; Compans, RW; Chen, SY; Lamb, RA; Arvan, P			Polarized apical targeting directed by the signal/anchor region of simian virus 5 hemagglutinin-neuraminidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CANINE KIDNEY-CELLS; EPITHELIAL-CELLS; MDCK CELLS; SURFACE EXPRESSION; SORTING SIGNAL; INFLUENZA HEMAGGLUTININ; ENDOPLASMIC-RETICULUM; CYTOPLASMIC DOMAINS; VIRAL GLYCOPROTEINS	To examine the possibility of independent cytoplasmic/transmembrane domain-based apical sorting, we have investigated paramyxovirus SV5 hemagglutinin-neuraminidase (HN), a type II membrane protein with a small N-terminal signal/anchor region. In SV5-infected Madin-Darby canine kidney (MDCK) cells, >90% of HN is found on the apical surface. We have expressed chimeric proteins in which the N terminus of HN, including its signal/anchor region, is attached to a (normally cytosolic) reporter pyruvate kinase (Ph). PK itself expressed immediately downstream from a cleavable signal peptide was converted to a 58-kDa N-linked glycosylated form, which was secreted predominantly (80%) to the basolateral surface of MDCK cells. By contrast, Stably expressed PK chimeras, now anchored as type II membrane proteins with either the first 48 or 72 amino acids of HN, received similar N-linked glycosylation, yet exhibited polarized transport with a preferentially (75%) apical distribution. These results suggest that the N-terminal signal/anchor region of HN contains independent sorting information for apical specific targeting in MDCK cells.	UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35209 USA; EMORY UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, ATLANTA, GA 30322 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, CTR COMPREHENS CANC, DEPT CANC BIOL, WINSTON SALEM, NC 27157 USA; NORTHWESTERN UNIV, HOWARD HUGHES MED INST, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, EVANSTON, IL 60208 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DIV ENDOCRINOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT DEV & MOL BIOL, BRONX, NY 10461 USA	University of Alabama System; University of Alabama Birmingham; Emory University; Wake Forest University; Wake Forest Baptist Medical Center; Howard Hughes Medical Institute; Northwestern University; Northwestern University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			Compans, Richard W/I-4087-2013	Compans, Richard W/0000-0003-2360-335X	NIAID NIH HHS [AI-12680] Funding Source: Medline; NIDDK NIH HHS [DK-40344] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012680, R01AI012680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040344, R29DK040344] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; BOULAN ER, 1980, CELL, V20, P45, DOI 10.1016/0092-8674(80)90233-0; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHEN SY, 1991, J VIROL, V65, P5902, DOI 10.1128/JVI.65.11.5902-5909.1991; COMPLANS RW, 1991, CURR TOP MICROBIOL I, V170, P142; COMPTON T, 1989, P NATL ACAD SCI USA, V86, P4112, DOI 10.1073/pnas.86.11.4112; CORBEIL D, 1992, J BIOL CHEM, V267, P2798; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, J CELL SCI, V105, P481; GREEN RF, 1981, J CELL BIOL, V89, P230, DOI 10.1083/jcb.89.2.230; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HIEBERT SW, 1988, J CELL BIOL, V107, P865, DOI 10.1083/jcb.107.3.865; HIEBERT SW, 1985, J VIROL, V54, P1; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JONES LV, 1985, MOL CELL BIOL, V5, P2181, DOI 10.1128/MCB.5.9.2181; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KUNDU A, 1994, J VIROL, V68, P1812, DOI 10.1128/JVI.68.3.1812-1818.1994; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; Leser GP, 1996, MOL BIOL CELL, V7, P155, DOI 10.1091/mbc.7.1.155; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; LONBERG N, 1983, P NATL ACAD SCI-BIOL, V80, P3661, DOI 10.1073/pnas.80.12.3661; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCQUEEN N, 1986, P NATL ACAD SCI USA, V83, P9318, DOI 10.1073/pnas.83.24.9318; MCQUEEN NL, 1987, J BIOL CHEM, V262, P16233; MELLMAN I, 1993, J CELL SCI, P1; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P17202; OWENS RJ, 1989, J VIROL, V63, P978, DOI 10.1128/JVI.63.2.978-982.1989; PATERSON RG, 1985, P NATL ACAD SCI USA, V82, P7520, DOI 10.1073/pnas.82.22.7520; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; RACCHI M, 1993, J BIOL CHEM, V268, P5735; RANDALL RE, 1987, J GEN VIROL, V68, P2769, DOI 10.1099/0022-1317-68-11-2769; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; ROTH MG, 1983, CELL, V33, P435, DOI 10.1016/0092-8674(83)90425-7; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; ROTH MG, 1979, P NATL ACAD SCI USA, V76, P6430, DOI 10.1073/pnas.76.12.6430; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; STEPHENS EB, 1986, CELL, V47, P1053, DOI 10.1016/0092-8674(86)90820-2; STEPHENS EB, 1986, EMBO J, V5, P237, DOI 10.1002/j.1460-2075.1986.tb04204.x; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; Wada I, 1997, EMBO J, V16, P5420, DOI 10.1093/emboj/16.17.5420; WAGNER M, 1995, EUR J CELL BIOL, V67, P84; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	56	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27598	27604		10.1074/jbc.272.44.27598	http://dx.doi.org/10.1074/jbc.272.44.27598			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346896	hybrid			2022-12-27	WOS:A1997YD47300022
J	Schaller, F; Weiler, EW				Schaller, F; Weiler, EW			Molecular cloning and characterization of 12-oxophytodienoate reductase, an enzyme of the octadecanoid signaling pathway from Arabidopsis thaliana - Structural and functional relationship to yeast old yellow enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID HYDROPEROXIDES; ALLENE OXIDE SYNTHASE; JASMONIC ACID; TENDRIL COILING; LIFE-CYCLE; PROTEINS; BIOSYNTHESIS; INHIBITORS; METABOLISM; MECHANISM	Using partial amino acid sequence information for 12-oxophytodienoate-10,11-reductase obtained from Corydalis sempervirens we have cloned the homologous enzyme from Arabidopsis thaliana. The open reading frame of the cDNA encodes a polypeptide of 372 amino acids (M-r = 41,165) with significant similarity to the sequence of Old Yellow Enzyme from Saccharomyces carlsbergensis (Saito, K., Thiele, D. J., Davio, M., Lockridge, O., and Massey, V. (1991) J. Biol. Chem. 266, 20720-20724), a flavin (FMN)-protein catalyzing the NADPH-dependent reduction of the olefinic bond of alpha,beta-unsaturated carbonyls. Specifically, all residues required for binding of FMN in Old Yellow Enzyme are conserved in the A. thaliana sequence, as are all residues associated with catalytic activity. The enzyme was functionally expressed from its cDNA in Escherichia coli and thus proven to encode OPDA reductase. Further similarities of OPDA reductase and yeast Old Yellow Enzyme include their binding to and elution by reductant from N-(4-hydroxybenzoyl)aminohexyl-Sepharose the immunoreactivity of yeast Old Yellow Enzyme with an antiserum raised against plant OPDA reductase and the demonstration that Old Yellow Enzyme is an active OPDA reductase. It is thus conceivable that the physiological role of Old Yellow Enzymes now known from bacteria, yeasts, and higher plants, is in oxylipin metabolism.	RUHR UNIV BOCHUM,LEHRSTUHL PFLANZENPHYSIOL,D-44780 BOCHUM,GERMANY	Ruhr University Bochum								ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5321; BELL E, 1995, P NATL ACAD SCI USA, V92, P8675, DOI 10.1073/pnas.92.19.8675; Blee E, 1996, PLANT PHYSIOL, V110, P445, DOI 10.1104/pp.110.2.445; BOLAND W, 1995, ANGEW CHEM, V107, P1715; BOTHA A, 1994, S AFR J SCI, V90, P604; BRUIN J, 1992, EXPERIENTIA, V48, P525, DOI 10.1007/BF01928181; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; COETZEE DJ, 1992, SYST APPL MICROBIOL, V15, P311, DOI 10.1016/S0723-2020(11)80105-0; FALKENSTEIN E, 1991, PLANTA, V185, P316, DOI 10.1007/BF00201050; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; French CE, 1995, BIOCHEM J, V312, P671, DOI 10.1042/bj3120671; GUNDLACH H, 1992, P NATL ACAD SCI USA, V89, P2389, DOI 10.1073/pnas.89.6.2389; HAMBERG M, 1988, LIPIDS, V23, P469, DOI 10.1007/BF02535522; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Howe GA, 1996, PLANT CELL, V8, P2067, DOI 10.1105/tpc.8.11.2067; Karplus PA, 1995, FASEB J, V9, P1518, DOI 10.1096/fasebj.9.15.8529830; KEY G, 1988, PLANTA, V176, P472, DOI 10.1007/BF00397653; KINOSITA K, 1977, BIOCHIM BIOPHYS ACTA, V471, P227, DOI 10.1016/0005-2736(77)90252-8; KOCK JLF, 1991, S AFR J SCI, V87, P73; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krumm T, 1995, FEBS LETT, V377, P523, DOI 10.1016/0014-5793(95)01398-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laudert D, 1997, ANAL BIOCHEM, V246, P211, DOI 10.1006/abio.1997.2012; Laudert D, 1996, PLANT MOL BIOL, V31, P323, DOI 10.1007/BF00021793; MADANI ND, 1994, P NATL ACAD SCI USA, V91, P922, DOI 10.1073/pnas.91.3.922; MIRANDA M, 1995, YEAST, V11, P459, DOI 10.1002/yea.320110509; NIINO YS, 1995, J BIOL CHEM, V270, P1983, DOI 10.1074/jbc.270.5.1983; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Peters W, 1996, J PLANT PHYSIOL, V149, P233, DOI 10.1016/S0176-1617(96)80202-1; SAITO K, 1991, J BIOL CHEM, V266, P20720; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schaller F, 1997, EUR J BIOCHEM, V245, P294, DOI 10.1111/j.1432-1033.1997.t01-1-00294.x; SEMBDNER G, 1993, ANNU REV PLANT PHYS, V44, P569, DOI 10.1146/annurev.pp.44.060193.003033; Smith B J, 1988, Methods Mol Biol, V3, P71, DOI 10.1385/0-89603-126-8:71; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; STOTT K, 1993, J BIOL CHEM, V268, P6097; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA J, 1980, PLANT PHYSIOL, V66, P246, DOI 10.1104/pp.66.2.246; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; VICK BA, 1984, PLANT PHYSIOL, V75, P458, DOI 10.1104/pp.75.2.458; Warburg O, 1933, BIOCHEM Z, V266, P377; WEILER EW, 1994, FEBS LETT, V345, P9, DOI 10.1016/0014-5793(94)00411-0; WEILER EW, 1993, PHYTOCHEMISTRY, V32, P591, DOI 10.1016/S0031-9422(00)95142-2	46	117	127	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28066	28072		10.1074/jbc.272.44.28066	http://dx.doi.org/10.1074/jbc.272.44.28066			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346960	hybrid			2022-12-27	WOS:A1997YD47300086
J	Song, XL; vonKampen, J; Slaughter, CA; DeMartino, GN				Song, XL; vonKampen, J; Slaughter, CA; DeMartino, GN			Relative functions of the alpha and beta subunits of the proteasome activator, PA28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE; THERMOPLASMA-ACIDOPHILUM; 20-S PROTEASOME; 20S PROTEASOME; HOMOLOGOUS SUBUNITS; MOLECULAR-CLONING; 26-S PROTEASE; 26S PROTEASE; PURIFICATION; COMPLEX	PA28 is a 180,000-dalton protein that activates hydrolysis of small nonubiquitinated peptides by the 20 S proteasome. PA28 is composed of two homologous subunits, alpha and beta arranged in alternating positions in a ring-shaped oligomer with a likely stoichiometry of (alpha beta)(3). Our previous work demonstrated that the carboxyl terminus of the alpha subunit was necessary for PA28 to bind to and activate the proteasome. The goals of this work were to define the exact structural basis for this effect and to determine the relative roles of the alpha and beta subunits in proteasome activation. Each subunit and various mutants of the alpha subunit were expressed in Escherichia coli and purified. PA28 alpha stimulated the proteasome, but had a much greater K-act than native heteromeric PA28. In contrast, PA28 beta was unable to stimulate the proteasome. Mutants of the alpha subunit in which the carboxyl-terminal tyrosine residue was deleted or substituted with charged amino acids could neither bind to nor activate the proteasome. However, substitution of the carboxyl-terminal tyrosine with other amino acids resulted in proteins which could stimulate the proteasome to various extents. Tryptophan mutants stimulated the proteasome as well as did native PA28, whereas serine or phenylalanine mutants stimulated the proteasome much poorer than did wild type PA28 alpha. Deletion of the ''KEKE'' motif, a 28-amino acid domain near the amino terminus of PA28 alpha, had no effect on proteasome stimulatory activity. Hetero-oligomeric PA28 proteins were reconstituted from isolated wild type and mutant subunits. PA28 reconstituted from wild type subunits had structural and functional properties that were indistinguishable from those of the native hetero-oligomeric protein. PA28 molecules reconstituted from inactive a subunits and wild type beta subunits remained inactive. However, PA28 molecules reconstituted from suboptimally active alpha mutants and wild type beta subunits had the same activity as native heteromeric PA28. These results indicate that the beta subunit modulates PA28 activity, perhaps by influencing the affinity of PA28 for the proteasome.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046181, R01DK046181] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46181] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARTINO GN, 1993, ENZYME PROTEIN, V47, P314, DOI 10.1159/000468689; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; Ferrell K, 1996, FEBS LETT, V381, P143, DOI 10.1016/0014-5793(96)00101-9; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; Kuehn L, 1996, FEBS LETT, V394, P183, DOI 10.1016/0014-5793(96)00946-5; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1993, J BIOL CHEM, V268, P22514; MA CP, 1992, J BIOL CHEM, V267, P10515; MOTT JD, 1994, J BIOL CHEM, V269, P31466; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Song XL, 1996, J BIOL CHEM, V271, P26410, DOI 10.1074/jbc.271.42.26410; Tanahashi N, 1997, GENES CELLS, V2, P195, DOI 10.1046/j.1365-2443.1997.d01-308.x; TANAKA K, 1992, NEW BIOL, V4, P173; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	41	67	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27994	28000		10.1074/jbc.272.44.27994	http://dx.doi.org/10.1074/jbc.272.44.27994			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346951	hybrid			2022-12-27	WOS:A1997YD47300077
J	Sudbeck, P; Scherer, G				Sudbeck, P; Scherer, G			Two independent nuclear localization signals are present in the DNA-binding high-mobility group domains of SRY and SOX9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL SEX REVERSAL; DETERMINING GENE SRY; CAMPOMELIC DYSPLASIA; TRANSCRIPTION FACTOR; MOLECULAR-BASIS; EXPRESSION; SEQUENCE; MUTATIONS; FAMILY; CONSENSUS	SRY and SOX9, members of the family of high-mobility group (HMG) domain transcription factors, are both essential for testis formation during human embryonic development. The HMG domain is a DNA-binding and DNA-bending motif comprising about 80 amino acid residues. It has been shown that SRY and SOX9 are nuclear proteins. Using normal or mutant SRY-beta-galactosidase and SOX9-beta-galactosidase fusion proteins in transfection studies involving COS-7 cells, we have identified two nuclear localization signals (NLSs) within the HMG domains of both proteins that can independently direct the fusion proteins into the nucleus. Only mutational inactivation of both NLS motifs resulted in complete exclusion of the fusion proteins from the nucleus. The NLS sequences are located at the N and C termini of the HMG domain and are a bipartite NLS motif and a basic cluster NLS motif, respectively. Both NLS motifs are conserved in the HMG domains of other transcription factors. The implications of the present results are discussed regarding (a) the apparent dual function of certain basic amino acid residues in the HMG domain of SRY in both DNA binding and in nuclear localization and (b) the possible control of SOX9 in early gonadal differentiation at the level of nuclear translocation.	UNIV FREIBURG, INST HUMAN GENET, D-79106 FREIBURG, GERMANY	University of Freiburg								AFFARA NA, 1993, HUM MOL GENET, V2, P785, DOI 10.1093/hmg/2.6.785; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUNN TL, 1995, GENE, V161, P223, DOI 10.1016/0378-1119(95)00280-J; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; Kent J, 1996, DEVELOPMENT, V122, P2813; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Meyer J, 1997, HUM MOL GENET, V6, P91, DOI 10.1093/hmg/6.1.91; Meyer J, 1996, CYTOGENET CELL GENET, V72, P246, DOI 10.1159/000134200; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WOLF U, 1995, J MOL MED-JMM, V73, P325; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744	34	147	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27848	27852		10.1074/jbc.272.44.27848	http://dx.doi.org/10.1074/jbc.272.44.27848			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346931	hybrid			2022-12-27	WOS:A1997YD47300057
J	Wang, ZY; Melmed, S				Wang, ZY; Melmed, S			Identification of an upstream enhancer within a functional promoter of the human leukemia inhibitory factor receptor gene and its alternative promoter usage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-6 SIGNAL TRANSDUCER; ALPHA-SUBUNIT GENE; NF-KAPPA-B; BINDING PROTEINS; LIF RECEPTOR; CYTOKINE RECEPTORS; CNTF RECEPTOR; MESSENGER-RNA; ONCOSTATIN-M; EXPRESSION	Knockout of the leukemia inhibitory factor receptor (LIFR) gene results in disrupted placental architecture, imbalanced bone development, and losses of functional neurons. We here report the identification df an enhancer in a functional human LIFR gene promoter and alternative promoter usage by this gene. A single transcription start site was identified in placental JEG-3 cells and a genomic clone containing 4876-nucleotide upstream sequences was found to have promoter activity in JEG-3 cells. However, in osteogenic sarcoma U-2 OS cell, Northern blot using a probe of the first exon detected in JEG-3 cells failed to detect LIFR transcripts. 5'-Rapid amplification of cDNA ends (RACE) revealed an alternative first exon and a 0.6-kilobase pair (kb) 5'-flanking region possessed promoter activity in U-2 OS cells. For the 4.8-kb promoter active in placental cells, a minimal promoter was localized within -162 nucleotides. Three regions increased and one inhibited promoter activity. Subcloning of an activation region (-4876 to -3453 nucleotides) into SV40 promoter either upstream or downstream in either orientation to the luciferase reporter resulted in 10-35-fold luciferase induction, demonstrating the characteristics of an enhancer. Transfections into nine cell lines of different tissue origin indicated that the cloned promoter and enhancer in the 4.8-kb fragment was placental tissue-specific. A 226-base pair fragment (-4625 to -4400 nucleotides) was further localized as the minimal enhancer region, in which deletion of either element A (-4625 to -4581 nucleotides) or element B (-4418 to -4400 nucleotides) resulted in the loss of enhancer activity. Electrophoretic mobility shift assay confirmed that these two elements bind to specific nuclear proteins individually. In the middle region between element A and B, disruption of enhancer integrity also led to a loss of enhancer activity, although two SP1 and three NF-kappa B/c-Rel binding sites did not contribute to enhancer function. These results demonstrate a complex regulation of the human LIFR gene, including alternative promoter usage and tissue-specific elements at the transcription level.	UNIV CALIF LOS ANGELES,SCH MED,CEDARS SINAI MED CTR,DIV ENDOCRINOL,B131,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIDDK NIH HHS [DK50238] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050238] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bousquet C, 1997, J BIOL CHEM, V272, P10551; CHAMBERLIN ME, 1994, J BIOL CHEM, V269, P17152; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOJIMA K, 1995, HUM REPROD, V10, P1907, DOI 10.1093/oxfordjournals.humrep.a136205; KOJIMA K, 1995, MOL HUM REPROD, V1, P1907; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LIU ZY, 1995, MOL ENDOCRINOL, V9, P1477, DOI 10.1210/me.9.11.1477; MANDL CW, 1991, BIOTECHNIQUES, V10, P485; MARUSIC A, 1993, J BONE MINER RES, V8, P617; MARUYAMA K, 1994, GENE, V138, P171; Michaelson JS, 1996, J IMMUNOL, V156, P2828; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; Owczarek CM, 1996, J BIOL CHEM, V271, P5495, DOI 10.1074/jbc.271.10.5495; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PITTMAN RH, 1994, J BIOL CHEM, V269, P19360; Ray DW, 1996, J CLIN INVEST, V97, P1852, DOI 10.1172/JCI118615; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; Sambrook J., 2002, MOL CLONING LAB MANU; Sheng ZL, 1996, DEVELOPMENT, V122, P419; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; Stefana B, 1996, P NATL ACAD SCI USA, V93, P12502, DOI 10.1073/pnas.93.22.12502; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TOMIDA M, 1993, FEBS LETT, V334, P193, DOI 10.1016/0014-5793(93)81710-H; Wang ZY, 1996, ENDOCRINOLOGY, V137, P2947, DOI 10.1210/en.137.7.2947; WARE CB, 1995, DEVELOPMENT, V121, P1283	46	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27957	27965		10.1074/jbc.272.44.27957	http://dx.doi.org/10.1074/jbc.272.44.27957			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346946	hybrid			2022-12-27	WOS:A1997YD47300072
J	Sekine, M; Nara, K; Suzuki, A				Sekine, M; Nara, K; Suzuki, A			Tissue-specific regulation of mouse core 2 beta-1,6-N-acetylglucosaminyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; MOLECULAR-CLONING; TRANSCRIPTION FACTORS; GENE FAMILY; O-GLYCANS; ORGANIZATION; BIOSYNTHESIS; TRANSPORTER; TRANSFERASE; KIDNEY	Mouse kidney beta-1,6-GlcNAc-transferase (GNT) is the key enzyme for the synthesis of a glycosphingolipid (Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-6(Gal beta 1-3)Gal-NAc beta 1-3Gal alpha 1-4Gal beta 1-4Glc beta 1-ceramide) that contains the Le(X) trisaccharide epitope at its nonreducing terminus, The expression of this glycolipid in the kidney is polymorphic; it is expressed in BALB/c but not DBA/2 mice; and a single autosomal gene (Gsl5) is responsible for this polymorphism We report here the cDNA sequence that encodes the kidney GNT of BALB/c mice, which possess a wild-type Gsl5 gene, The deduced amino acid sequence exhibits 84% identity to that of human core 2 beta-1,6-GlcNAc-transferase, which suggests that kidney GNT is a mouse homologue of human core 2 beta-1,6-GlcNAc-transferase. The GNT mRNA is expressed. abundantly in the kidney, but was not detected in other BALB/c organs or in the kidneys of DBA/2 mice by Northern blot analysis, In addition, we were able to clone and sequence another homologous cDNA from the submandibular gland, The two sequences differ only in their 5'-untranslated region, The submandibular gland type of cDNA was detected in various organs of DBA/2 mice by reverse transcription-polymerase chain reaction, which indicates that the submandibular gland type is ubiquitous and that its expression is not regulated by the Gsl5 gene, Results obtained using the long accurate polymerase chain reaction method indicate that the GNT gene is -45 kilobases long, and the order of the exons from the 5'-end is exon 1 of the kidney type, exon 1 of the ubiquitous type, exon 2, and exon 3. Exons 2 and 3 are present in both transcripts, and the translated region is in exon 3. These data suggest that the expression of GNT is regulated by an alternative splicing mechanism and also probably by tissue-specific enhancers and that Gsl5 regulates the expression of GNT only in the kidney.	TOKYO METROPOLITAN INST MED SCI, DEPT MEMBRANE BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN; MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN	Tokyo Metropolitan Institute of Medical Science								AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; BIERHUIZEN MFA, 1995, GLYCOCONJUGATE J, V12, P857, DOI 10.1007/BF00731248; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROCKHAUSEN I, 1991, CANCER RES, V51, P1257; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; EARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; Gao LY, 1996, BIOCHEM BIOPH RES CO, V224, P103, DOI 10.1006/bbrc.1996.0991; Granovsky M, 1995, GLYCOBIOLOGY, V5, P797, DOI 10.1093/glycob/5.8.797; GU XB, 1995, J NEUROCHEM, V64, P2295; HAKOMORI S, 1983, JNCI-J NATL CANCER I, V71, P231; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; Igarashi P, 1996, J BIOL CHEM, V271, P9666, DOI 10.1074/jbc.271.16.9666; Ishida N, 1996, J BIOCHEM, V120, P1074; Kitagawa H, 1996, J BIOL CHEM, V271, P931, DOI 10.1074/jbc.271.2.931; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; PILLER F, 1988, J BIOL CHEM, V263, P15146; Rajput B, 1996, J BIOL CHEM, V271, P5131, DOI 10.1074/jbc.271.9.5131; SAITO H, 1995, EUR J BIOCHEM, V233, P18, DOI 10.1111/j.1432-1033.1995.018_1.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHTER H, 1994, MOL GLYCOBIOLOGY, P87; SEKINE M, 1994, J BIOL CHEM, V269, P31143; SEKINE M, 1990, J BIOCHEM-TOKYO, V108, P103, DOI 10.1093/oxfordjournals.jbchem.a123147; SHAPER NL, 1994, J BIOL CHEM, V269, P25165; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; VALLET V, 1995, EXP CELL RES, V216, P363, DOI 10.1006/excr.1995.1046; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WEN DX, 1992, J BIOL CHEM, V267, P2512; YANG J, 1994, GLYCOBIOLOGY, V4, P703, DOI 10.1093/glycob/4.5.703; [No title captured]	36	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27246	27252		10.1074/jbc.272.43.27246	http://dx.doi.org/10.1074/jbc.272.43.27246			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341170	hybrid			2022-12-27	WOS:A1997YC65900066
J	Hecht, K; CarlstedtDuke, J; Stierna, P; Gustafsson, JA; Bronnegard, M; Wikstrom, AC				Hecht, K; CarlstedtDuke, J; Stierna, P; Gustafsson, JA; Bronnegard, M; Wikstrom, AC			Evidence that the beta-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAIN; TRANSCRIPTION; EXPRESSION; ANTIBODIES; PROTEINS; RNA	Alternative splicing of the human glucocorticoid receptor (hGR) primary transcript generates two receptor isoforms, hGR alpha and hGR beta, with different carboxyl termini diverging at amino acid 727, By reverse transcriptase-polymerase chain reactions it was previously demonstrated that the hGR beta message had a widespread tissue distribution, To demonstrate the presence of hGR beta as protein we produced specific rabbit antisera to hGR beta, as well as a hGR beta-specific mouse monoclonal IgM antibody, by peptide immunizations, By SDS-polyacrylamide gel electrophoresis and Western immunoblotting we showed that hGR beta is endogenously expressed at the protein level in HeLa cells and human lymphatic leukemia cells. Using an antibody directed against an epitope shared by both isoforms we showed a relatively lower expression of the hGR beta form, We also showed that hGR beta bound to hsp90 by immunoprecipitation of in vitro translated hGR beta in reticulocyte lysate with hsp90-specific antibodies, a coprecipitation occurring also in the presence of dexamethasone. We could not demonstrate that hGR beta inhibited the effects of dexamethasone-activated hGR alpha on a glucocorticoid-responsive reporter gene. In conclusion, low hGR beta expression levels and hGR beta-hsp90 interaction maintained in the presence of ligand and lack of inhibition of hormone-activated hGR alpha effects challenge the concept of the hGR beta isoform as a proposed dominant negative inhibitor of hGR alpha activity.	HUDDINGE UNIV HOSP,KAROLINSKA INST,NOVUM,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,KAROLINSKA INST,NOVUM,DEPT OTORHINOLARYNGOL,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,KAROLINSKA INST,NOVUM,DEPT PEDIAT,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet								ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; BRONNEGARD M, 1987, BIOCHEMISTRY-US, V26, P1697; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; deCastro M, 1996, MOL MED, V2, P597, DOI 10.1007/BF03401643; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; MCEWAN IJ, 1994, J BIOL CHEM, V269, P25629; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; URDA LA, 1989, MOL ENDOCRINOL, V3, P251, DOI 10.1210/mend-3-2-251; VEGATO E, 1993, MOL ENDOCRINOL, V7, P1244; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	21	122	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26659	26664		10.1074/jbc.272.42.26659	http://dx.doi.org/10.1074/jbc.272.42.26659			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334248	hybrid			2022-12-27	WOS:A1997YB13900082
J	Hinson, DD; Chambliss, KL; Hoffmann, GF; Krisans, S; Keller, RK; Gibson, KM				Hinson, DD; Chambliss, KL; Hoffmann, GF; Krisans, S; Keller, RK; Gibson, KM			Identification of an active site alanine in mevalonate kinase through characterization of a novel mutation in mevalonate kinase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CHOLESTEROL-BIOSYNTHESIS; SYNTHASE GENE; RAT-LIVER; ACIDURIA; FIBROBLASTS; PROMOTER; PATHWAY	Sequencing of polymerase chain reaction-amplified cDNAs from cultured cells of three patients with mevalonate kinase deficiency revealed a G --> A transversion at nucleotide 1000 of the coding region, converting alanine to threonine at position 331 (A334T). To characterize this defect, we expressed wild-type and mutant cDNAs in Escherichia coli as the glutathione S-transferase fusion proteins, with purification by affinity chromatography. SDS-polyacrylamide gel electrophoresis analysis for wild-type and mutant fusion proteins indicated an expected molecular mass of 12-43 kDa. Kinetic characterization of the wild-type fusion protein yielded K-m values of 150 +/- 23 and 440 +/- 190 mu m (mean +/- S.E.) for substrates (RS)-mevalonate and ATP, respectively. Expressed wild-type mevalonate kinase (MKase) had a maximum velocity of 13.6 +/- 1.4 units/mg of protein (n = 22, +/- S.E.), whereas the A334T mutation yielded an enzyme with average V-max of 0.26 +/- 0.02 unit/mg of protein (n = 6, +/-S.E.), representing a decrease to 1.4% of control V-max. Restriction digestion with HhaI, in conjunction with direct sequencing of cDNAs, revealed that two patients were homozygous and one heterozygous for the A334T allele, establishing autosomal recessive inheritance within families. Although the A334T enzyme had a normal K-m for ATP of 680 +/- 226 mu m (n = 3, +/-S.E.), the Michaelis constant for (RS)-mevalonate was increased >30-fold to 4623 +/- 1167 mu M (n = 4, +/-S.E.) under standard assay conditions. Comparable kinetic results were obtained using extracts of lymphoblasts, which were homozygous for the A334T allele. Alanine 334 is invariant in MKase from bacteria to mall and located in a glycine-rich region postulated to have homology with ATP-binding sequences. Our results indicate that the bacterial expression system for human MKase will provide a useful model system in which to analyze inherited mutations and identify the first active site residue in MKase associated with stabilization of mevalonate binding.	UNIV MARBURG, DEPT METAB DIS & NEUROPEDIAT, D-35033 MARBURG, GERMANY; SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, INST MOL BIOL, SAN DIEGO, CA 92182 USA; UNIV S FLORIDA, COLL MED, DEPT BIOCHEM & MOL BIOL, TAMPA, FL 33612 USA; UNIV TEXAS, SW MED CTR, DEPT NEUROL, DALLAS, TX 75235 USA	Philipps University Marburg; California State University System; San Diego State University; California State University System; San Diego State University; State University System of Florida; University of South Florida; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hinson, DD (corresponding author), BAYLOR UNIV, MED CTR, INST METAB DIS, 3812 ELM ST, DALLAS, TX 75226 USA.		Keller, Ronald/A-1386-2012					BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Clayton P, 1996, LANCET, V348, P404, DOI 10.1016/S0140-6736(05)65020-9; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GIBSON KM, 1988, EUR J PEDIATR, V148, P250, DOI 10.1007/BF00441413; GIBSON KM, 1989, ENZYME, V41, P47, DOI 10.1159/000469050; GIBSON KM, 1990, J LIPID RES, V31, P515; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRAEF E, 1995, VIROLOGY, V208, P696, DOI 10.1006/viro.1995.1201; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HINSON DD, 1997, IN PRESS J LIPID RES; HOFFMANN GF, 1993, PEDIATRICS, V91, P915; HUBNER C, 1993, PEDIATR RES, V34, P129; JABALQUINTO AM, 1981, ARCH BIOCHEM BIOPHYS, V210, P132, DOI 10.1016/0003-9861(81)90173-9; Potter D, 1997, J BIOL CHEM, V272, P5741, DOI 10.1074/jbc.272.9.5741; Salen G, 1996, J LIPID RES, V37, P1169; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; SOLER M, 1979, INT J BIOCHEM, V10, P931, DOI 10.1016/0020-711X(79)90126-5; TANAKA RD, 1990, J BIOL CHEM, V265, P2391; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; Weinberger C, 1996, TRENDS ENDOCRIN MET, V7, P1, DOI 10.1016/1043-2760(95)00180-8	20	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26756	26760		10.1074/jbc.272.42.26756	http://dx.doi.org/10.1074/jbc.272.42.26756			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334262	hybrid			2022-12-27	WOS:A1997YB13900096
J	Ramirez, MI; Rishi, AK; Cao, YX; Williams, MC				Ramirez, MI; Rishi, AK; Cao, YX; Williams, MC			TGT3, thyroid transcription factor I, and Sp1 elements regulate transcriptional activity of the 1.3-kilobase pair promoter of T1 alpha, a lung alveolar type I cell gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-B; DNA-BINDING SPECIFICITY; SECRETORY PROTEIN; EPITHELIAL-CELLS; EXPRESSION PATTERNS; TRANSGENIC MICE; A PROMOTER; CC10 GENE; C GENE; TTF-1	Alveolar type I epithelial cells form the major surface for gas exchange in the lung. To explore how type I cells differ in gene expression from their progenitor alveolar type II cells, we analyzed transcriptional regulation of T1 alpha, a gene expressed by adult type I but not type II cells. In vivo developmental patterns of T1 alpha expression in lung and brain suggest active gene regulation. We cloned and sequenced 1.25 kilobase pairs of the T1 alpha promoter that can drive reporter expression in lung epithelial cell lines. Deletion analyses identified regions important for lung cell expression. The base pair (bp) -100 to -170 fragment conferred differential regulation in lung epithelial cells compared with fibroblasts. Sequence alignment of this fragment with type II-specific surfactant protein B and C promoters shows similar consensus elements arranged in a different order, Gel retardation studies with alveolar epithelial cell line nuclear extracts, thyroid transcription factor I (TTF-1) homeodomain, hepatic nuclear factor (HNF)-3 beta, or Sp1 proteins, and supershift assays were used to characterize TTF-1, HNF-3 (TGT3), and Sp1/Sp3 binding sites. The TGT3 site binds factors with binding properties similar to HNF-3/Fkh (hepatic nuclear factor-3/forkhead) proteins but different from HNF-3 alpha or HNF-3 beta. Co-transfection with a TTF-1 expression vector moderately transactivated the -170 bp-reporter construct. Mutational analysis of these three binding sites showed reduced transcriptional activity of the -170 bp promoter. Therefore, several regulatory sequences involved in type II cell gene regulation are also present in the T1 alpha promoter, suggesting that genes of the peripheral lung epithelium may be regulated by similar factors.	BOSTON UNIV,SCH MED,PULM CTR R3,DEPT ANAT,BOSTON,MA 02118	Boston University	Ramirez, MI (corresponding author), BOSTON UNIV,SCH MED,PULM CTR R3,DEPT MED,80 E CONCORD ST,BOSTON,MA 02118, USA.			Ramirez, Maria Isabel/0000-0001-6294-4419	NHLBI NIH HHS [P01 HL047049, HL47049] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047049] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benvenuto G, 1996, MOL CELL BIOL, V16, P2736; BINGLE CD, 1993, BIOCHEM J, V295, P227, DOI 10.1042/bj2950227; BOAM DSW, 1995, J BIOL CHEM, V270, P19487, DOI 10.1074/jbc.270.33.19487; BOGGARAM V, 1989, J BIOL CHEM, V264, P11421; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BOROK Z, 1995, AM J RESP CELL MOL, V12, P50, DOI 10.1165/ajrcmb.12.1.7811470; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CLEMENT A, 1991, EXP CELL RES, V196, P198, DOI 10.1016/0014-4827(91)90251-O; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COSTA RH, 1994, LIVER GENE EXPRESSIO, V10, P183; CRAPO JD, 1982, AM REV RESPIR DIS, V125, P332; DOBBS LG, 1988, BIOCHIM BIOPHYS ACTA, V970, P146, DOI 10.1016/0167-4889(88)90173-5; ENERBACK S, 1992, MOL CELL BIOL, V12, P4622, DOI 10.1128/MCB.12.10.4622; EVANS MJ, 1975, EXP MOL PATHOL, V22, P142, DOI 10.1016/0014-4800(75)90059-3; Fabbro D, 1996, NUCLEIC ACIDS RES, V24, P3283, DOI 10.1093/nar/24.17.3283; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HACKETT BP, 1994, AM J RESP CELL MOL, V11, P123, DOI 10.1165/ajrcmb.11.2.8049073; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; Kamakaka RT, 1997, TRENDS BIOCHEM SCI, V22, P124, DOI 10.1016/S0968-0004(96)10074-8; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; KANG BH, 1993, AM J RESP CELL MOL, V9, P350, DOI 10.1165/ajrcmb/9.4.350; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KELLY SE, 1995, AM J RESP CRIT CARE, V151, P163; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kovarik A, 1996, J BIOL CHEM, V271, P18140, DOI 10.1074/jbc.271.30.18140; LACAZEMASMONTEIL T, 1992, EUR J BIOCHEM, V206, P613, DOI 10.1111/j.1432-1033.1992.tb16966.x; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LI F, 1995, AM J PHYSIOL-LUNG C, V269, pL241, DOI 10.1152/ajplung.1995.269.2.L241; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; LUZI P, 1995, BIOCHEM BIOPH RES CO, V208, P153, DOI 10.1006/bbrc.1995.1317; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; Michael LF, 1996, MOL ENDOCRINOL, V10, P159, DOI 10.1210/me.10.2.159; Minoo P, 1995, DEV BIOL, V172, P694, DOI 10.1006/dbio.1995.8080; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; NAGAE A, 1993, AM J RESP CELL MOL, V9, P221, DOI 10.1165/ajrcmb/9.2.221; NOSE K, 1990, CELL GROWTH DIFFER, V1, P511; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RISHI AK, 1995, DEV BIOL, V167, P294, DOI 10.1006/dbio.1995.1024; Rust K, 1996, AM J RESP CELL MOL, V14, P121, DOI 10.1165/ajrcmb.14.2.8630261; SAIARDI A, 1995, BIOCHEM J, V310, P491, DOI 10.1042/bj3100491; Sambrook J., 2002, MOL CLONING LAB MANU; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; SAWAYA PL, 1994, J BIOL CHEM, V269, P22211; Stahlman MT, 1996, J HISTOCHEM CYTOCHEM, V44, P673, DOI 10.1177/44.7.8675988; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; VENKATESH VC, 1995, AM J PHYSIOL-LUNG C, V268, pL674, DOI 10.1152/ajplung.1995.268.4.L674; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Wetterwald A, 1996, BONE, V18, P125, DOI 10.1016/8756-3282(95)00457-2; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Williams MC, 1996, AM J RESP CELL MOL, V14, P577, DOI 10.1165/ajrcmb.14.6.8652186; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Young PP, 1996, AM J PHYSIOL-LUNG C, V271, pL287, DOI 10.1152/ajplung.1996.271.2.L287; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	70	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26285	26294		10.1074/jbc.272.42.26285	http://dx.doi.org/10.1074/jbc.272.42.26285			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334198	hybrid			2022-12-27	WOS:A1997YB13900032
J	Regan, LM; Mollica, JS; Rezaie, AR; Esmon, CT				Regan, LM; Mollica, JS; Rezaie, AR; Esmon, CT			The interaction between the endothelial cell protein C receptor and protein C is dictated by the gamma-carboxyglutamic acid domain of protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-THROMBOMODULIN COMPLEX; GROWTH-FACTOR DOMAIN; FACTOR-X ACTIVATION; HUMAN FACTOR-IX; BINDING PROPERTIES; PROTEOLYTIC FORMATION; ESCHERICHIA-COLI; HOMOLOGY DOMAIN; FACTOR-VIIIA; FACTOR-VA	The endothelial cell protein C receptor (EPCR) binds to both protein C and activated protein C (APC) with similar affinity. Removal of the Gla domain of protein C results in the loss of most of the binding affinity. This observation is compatible with at least two models: 1) the Gla domain of protein C interacts with phospholipid on cell surfaces to stabilize interaction with EPCR or 2) the Gla domain of protein C makes specific protein protein interactions with EPCR. The latter model predicts that chimeric proteins containing the protein C Gla domain should interact with EPCR, To test this, we constructed a prothrombin chimera in which the Gla domain and aromatic stack of prothrombin were replaced with the corresponding region of protein C. The I-125-labeled chimera (K-d = 176 nM) and I-125-APC (K-d = 65 nM) both bound specifically to 293 cells stably transfected with EPCR, but both bound poorly to sham-transfected cells. The chimera also blocked APC binding to EPCR-transfected cells in a dose-dependent fashion (K-i approximate to 139 nM) similarly to protein C (K-i approximate to 75 nM). Chimera binding to EPCR-transfected cells was blocked by soluble EPCR, demonstrating direct protein-protein interaction between the chimera and EPCR, Consistent with this conclusion, the isolated Gla domain of protein C blocked APC binding to EPCR-transfected cells (IC50 = 2 mu M). No inhibition was observed with the isolated prothrombin Gla domain, A protein C chimera with the prothrombin Gla domain and aromatic stack failed to bind to EPCR detectably. These data suggest that the Gla domain of protein C is responsible for much of the binding energy and specificity of the protein C-EPCR interaction.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOL MOL,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	Regan, LM (corresponding author), OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1992, J BIOL CHEM, V267, P8571; APPELLA E, 1987, J BIOL CHEM, V262, P4437; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; BANGALORE N, 1994, THROMB HAEMOSTASIS, V72, P465; BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; Bevington P.R., 1969, DATA REDUCTION ERROR; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; CASTELLINO FJ, 1995, TRENDS CARDIOVAS MED, V5, P55, DOI 10.1016/1050-1738(94)00031-X; Cheung WF, 1996, P NATL ACAD SCI USA, V93, P11068, DOI 10.1073/pnas.93.20.11068; CHEUNG WF, 1992, J BIOL CHEM, V267, P20529; CHRISTIANSEN WT, 1994, BIOCHEMISTRY-US, V33, P5901, DOI 10.1021/bi00185a030; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; COMP PC, 1982, J CLIN INVEST, V70, P127, DOI 10.1172/JCI110584; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; ESMON CT, 1995, TRENDS CARDIOVAS MED, V5, P141, DOI 10.1016/1050-1738(95)00054-D; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; Fukudome K, 1996, J BIOL CHEM, V271, P17491, DOI 10.1074/jbc.271.29.17491; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; FURMANIAKKAZMIERCZAK E, 1993, BLOOD, V81, P405; GENG JP, 1995, BIOCHEMISTRY-US, V34, P8449, DOI 10.1021/bi00026a028; GILES AR, 1982, BLOOD, V9, P401; GREY ST, 1994, J IMMUNOL, V153, P3664; HANSON SR, 1993, J CLIN INVEST, V92, P2003, DOI 10.1172/JCI116795; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P651; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MILETICH JP, 1977, P NATL ACAD SCI USA, V74, P4035; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; OWEN WG, 1974, J BIOL CHEM, V249, P594; REGAN LM, 1994, J BIOL CHEM, V269, P9445; Regan LM, 1996, J BIOL CHEM, V271, P17499, DOI 10.1074/jbc.271.29.17499; REZAIE AR, 1993, J BIOL CHEM, V268, P19943; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; RIVARD GE, 1995, J PEDIATR-US, V126, P646, DOI 10.1016/S0022-3476(95)70369-1; SHEN L, 1994, J BIOL CHEM, V269, P18735; SMALLEY DM, 1988, ANAL BIOCHEM, V172, P241, DOI 10.1016/0003-2697(88)90438-1; SMIRNOV M, 1996, CIRCULATION, V94, P694; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; SUGO T, 1984, J BIOL CHEM, V259, P5705; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	51	68	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26279	26284		10.1074/jbc.272.42.26279	http://dx.doi.org/10.1074/jbc.272.42.26279			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334197	hybrid			2022-12-27	WOS:A1997YB13900031
J	Allan, CM; Taylor, S; Taylor, JM				Allan, CM; Taylor, S; Taylor, JM			Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; E MESSENGER-RNA; TRANSGENIC MICE; C-I; CONTROL REGION; PERIPHERAL-TISSUES; NONHUMAN-PRIMATES; ELEMENTS CONTROL; A-I; LOCUS	We show that the liver-specific expression of all four genes in the human apolipoprotein (ape) E/C-I/C-IV/C-II gene cluster in transgenic mice is determined by the coordinate action of two distinct hepatic control regions (HCR). These enhancers are positioned 15 kilobases (kb) (HCR.1) and 26 kb (HCR.2) downstream of the apoE gene. To investigate the action of each HCR, transgenic mice were generated with a 70-kb human genomic fragment that contained the complete apoE gene cluster or with this fragment modified by the specific deletion of HCR.1, HCR.2, or both HCR domains. Hepatic expression of all four apolipoprotein genes was observed in transgenic mice in which either HCR,I or HCR.2 was deleted, but no transgene expression was found in the liver in the absence of both HCR domains. The overall patterns of transgene expression suggested that HCR.2 was the dominant element for apoC-IV and apoC-II expression and that HCR.1 was dominant for the apoE/C-I expression, No liver-specific transcriptional activity was identified for the proximal promoter of any gene in the cluster; all liver-specific activity was associated with HCR.1 and HCR.2. Thus, the HCRs of the apoE gene cluster constitute unique regulatory domains for determining the requirements for apolipoprotein gene expression in the liver.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL-37063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1995, J BIOL CHEM, V270, P26278, DOI 10.1074/jbc.270.44.26278; ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; Allan CM, 1996, J LIPID RES, V37, P1510; ANDERSSON Y, 1991, J LIPID RES, V32, P1805; BASU SK, 1982, J BIOL CHEM, V257, P9788; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Boren J, 1996, GENOME RES, V6, P1123, DOI 10.1101/gr.6.11.1123; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; Dang Q, 1996, J BIOL CHEM, V271, P28667, DOI 10.1074/jbc.271.45.28667; DAWSON PA, 1989, J LIPID RES, V30, P403; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GILMAN M, 1993, CURRENT PROTOCOLS MO, V1; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HOFFER MJV, 1993, GENOMICS, V15, P62, DOI 10.1006/geno.1993.1010; JI ZS, 1994, J BIOL CHEM, V269, P2764; Kostenis E, 1997, J BIOL CHEM, V272, P19107, DOI 10.1074/jbc.272.31.19107; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; LI WH, 1988, J LIPID RES, V29, P245; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LUO CC, 1989, J LIPID RES, V30, P1735; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MYKLEBOST O, 1984, J BIOL CHEM, V259, P4401; MYKLEBOST O, 1988, HUM GENET, V78, P244, DOI 10.1007/BF00291670; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; NOSSEL HL, 1976, J CLIN INVEST, V58, P1136, DOI 10.1172/JCI108566; PESCHLE C, 1985, NATURE, V313, P235, DOI 10.1038/313235a0; PETERSON KR, 1995, P NATL ACAD SCI USA, V92, P5655, DOI 10.1073/pnas.92.12.5655; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; POLANCO JI, 1995, LIFE SCI, V56, P1865, DOI 10.1016/0024-3205(95)00161-X; PROTTER AA, 1984, DNA-J MOLEC CELL BIO, V3, P449, DOI 10.1089/dna.1.1984.3.449; RAISONNIER A, 1991, J MOL EVOL, V32, P211; REARDON CA, 1986, J BIOL CHEM, V261, P9858; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SCHONFELD G, 1980, J CELL BIOL, V86, P562, DOI 10.1083/jcb.86.2.562; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SHEN PY, 1992, ARCH BIOCHEM BIOPHYS, V297, P345, DOI 10.1016/0003-9861(92)90683-N; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; TAYLOR JM, 1991, CURR OPIN LIPIDOL, V2, P73; VANECK MM, 1994, GENOMICS, V21, P110, DOI 10.1006/geno.1994.1231; VORGIA P, 1996, CIRCULATION, V94, P397; WEI CF, 1985, J BIOL CHEM, V260, P5211; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WU AL, 1979, J BIOL CHEM, V254, P7316; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Zhang LH, 1996, J BIOL CHEM, V271, P1776, DOI 10.1074/jbc.271.3.1776	55	91	96	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29113	29119		10.1074/jbc.272.46.29113	http://dx.doi.org/10.1074/jbc.272.46.29113			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360987	hybrid			2022-12-27	WOS:A1997YF68400046
J	Park, SK; Provost, JJ; Bae, CD; Ho, WT; Exton, JH				Park, SK; Provost, JJ; Bae, CD; Ho, WT; Exton, JH			Cloning and characterization of phospholipase D from rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; GTP-BINDING PROTEIN; KINASE-C; REGULATORY PROTEIN; HL-60 CELLS; D ACTIVATION; RHOB P20; MEMBRANE; ARF; PURIFICATION	The regulation of phospholipase D cloned from rat brain (rPLD) was examined in vivo and in vitro. The enzyme was a shorter splice variant of human phospholipase D 1 (Hammond, S. M., Altshuller, Y. M., Sung, T.-C., Rudge, S. M., Rose, K., Engebrecht, J. A., Morris, A. J., and Frohman, M. A. (1995) J. Biol. Chem. 270, 29640-29643). Its expression in COS-7 cells led to increased phospholipase D (PLD) activity that was further stimulated by constitutively active V14RhoA. V14RhoA had no effect on the endogenous PLD of the COS-7 cells, but constitutively active L71ARF3 increased its activity. In contrast, L71ARF3 did not activate rPLD expressed in the cells. Addition of phorbol ester markedly increased the endogenous PLD activity of COS-7 cells, and there was a further increase in the cells expressing rPLD. In membranes from COS-7 cells expressing rPLD, addition of myristoylated ADP-ribosylation factor (ARF) and RhoA in vitro stimulated PLD activity. The effect of ARF was greater than that of RhoA, although the concentrations for half-maximal stimulation (0.08-0.2 mu M) were similar. Membranes isolated from cells expressing rPLD plus L71ARF3 and/or V14RhoA also showed higher PLD activity but no synergism between the two G proteins. Addition of phorbol ester and protein kinase C alpha (PKC alpha) also stimulated PLD activity in membranes from COS-7 cells expressing rPLD, but it had no effect on the activity in control (vector) membranes and did not enhance the effects of constitutively active ARF or Rho. The stimulation by PKC alpha did not require ATP and was not increased by addition of this nucleotide. No synergism between ARF and Rho and between these and PKC alpha on PLD activity was observed when these were added to membranes from cells expressing rPLD. Oleate inhibited the PLD activity of membranes from both control and rPLD-expressing cells. In summary, these results indicate that in vitro, rPLD is stimulated by ARF, RhoA, and PKC alpha and inhibited by oleate. However, in intact COS-7 cells, ARF activates endogenous PLD but not rPLD, whereas the reverse is true for RhoA, In addition, the effects of phorbol ester are much greater in the intact cells. It is concluded that the regulation of rPLD in intact COS-7 cells differs significantly from that seen in vitro; possible reasons for this are discussed.	VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MOL PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047448] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47448] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; GENY B, 1995, EUR J BIOCHEM, V231, P31, DOI 10.1111/j.1432-1033.1995.tb20666.x; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; ISOMURA M, 1991, ONCOGENE, V6, P119; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; Kim JH, 1996, J BIOL CHEM, V271, P25213, DOI 10.1074/jbc.271.41.25213; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KUSNER DJ, 1994, BIOCHEM J, V304, P485, DOI 10.1042/bj3040485; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; Liscovitch M, 1996, CHEM PHYS LIPIDS, V80, P37, DOI 10.1016/0009-3084(96)02544-3; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; Lukowski S, 1996, J BIOL CHEM, V271, P24164, DOI 10.1074/jbc.271.39.24164; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; Provost JJ, 1996, BIOCHEM J, V319, P285, DOI 10.1042/bj3190285; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Shimooku K, 1996, FEBS LETT, V387, P141, DOI 10.1016/0014-5793(96)00483-8; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; UEDA T, 1990, J BIOL CHEM, V265, P9373; Vinggaard AM, 1997, CELL SIGNAL, V9, P189, DOI 10.1016/S0898-6568(96)00140-4	40	127	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29263	29271		10.1074/jbc.272.46.29263	http://dx.doi.org/10.1074/jbc.272.46.29263			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361006	hybrid			2022-12-27	WOS:A1997YF68400065
J	Wang, SX; Nakamura, N; Mure, M; Klinman, JP; SandersLoehr, J				Wang, SX; Nakamura, N; Mure, M; Klinman, JP; SandersLoehr, J			Characterization of the native lysine tyrosylquinone cofactor in lysyl oxidase by Raman spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPA QUINONE COFACTOR; AMINE OXIDASE; PURIFICATION; ENZYME	Lysine tyrosylquinone (LTQ) recently has been identified as the active site cofactor in lysyl oxidase by isolation and characterization of a derivatized active site peptide, Reported in this study is the first characterization of the underivatized cofactor in native lysyl oxidase by resonance Raman (RR) spectrometry. The spectrum is characterized by a unique set of vibrational modes in the 1200 to 1700 cm(-1) region. We show that the RR spectrum of lysyl oxidase closely matches that of a synthetic LTQ model compound, 4-n-butylamino-5-ethyl-1,2-benzoquinone, in aqueous solutions but differs significantly from those of other topa quinone-containing amine oxidases under similar conditions, Furthermore, we have observed the same O-18 shift of the C=O stretch in both the lysyl oxidase enzyme and the LTQ cofactor model compound, The RR spectra of different model compounds and their D shifts give additional evidence for the protonation state of LTQ cofactor in the enzyme, The overall similarity of these spectra and their shifts shows that the lysyl oxidase cofactor and the model LTQ compound have the same structure and properties. These data provide strong and independent support for the new cofactor structure, unambiguously ruling out the possibility that the structure originally reported had been derived from a spurious side reaction during the derivatization of the protein and isolation of the active site peptide.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CELL & MOL BIOL,BERKELEY,CA 94720; OREGON GRAD INST SCI & TECHNOL,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97291	University of California System; University of California Berkeley; University of California System; University of California Berkeley			Nakamura, Nobuhumi/C-1972-2013	Nakamura, Nobuhumi/0000-0002-5373-2972	NIGMS NIH HHS [GM-39296, GM-34468] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034468, R01GM039296] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; Kumar V, 1996, STRUCTURE, V4, P943, DOI 10.1016/S0969-2126(96)00101-3; LOEHR TM, 1993, METHOD ENZYMOL, V226, P431; LORD RC, 1970, J MOL BIOL, V50, P509, DOI 10.1016/0022-2836(70)90208-1; MOENNELOCCOZ P, 1995, BIOCHEMISTRY-US, V34, P7020, DOI 10.1021/bi00021a013; Nakamura N, 1996, J BIOL CHEM, V271, P4718; Nakamura N, 1997, BIOCHEMISTRY-US, V36, P11479, DOI 10.1021/bi9708139; Patai S, 1988, CHEM QUINONOID COMPO, V2; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9	13	53	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28841	28844		10.1074/jbc.272.46.28841	http://dx.doi.org/10.1074/jbc.272.46.28841			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360949	hybrid, Green Accepted			2022-12-27	WOS:A1997YF68400008
J	Engel, E; Richter, K; Obermeyer, G; Briza, P; Kungl, AJ; Simon, B; Auer, M; Ebner, C; Rheinberger, HJ; Breitenbach, M; Ferreira, F				Engel, E; Richter, K; Obermeyer, G; Briza, P; Kungl, AJ; Simon, B; Auer, M; Ebner, C; Rheinberger, HJ; Breitenbach, M; Ferreira, F			Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; IGE CROSS-REACTIVITIES; REGULATORY LIGHT-CHAIN; MAJOR ALLERGEN; MONOCLONAL-ANTIBODIES; LILIUM-LONGIFLORUM; ACTIN-BINDING; PROTEIN; CALMODULIN; IDENTIFICATION	We have isolated a cDNA clone coding for a birch pollen allergen, Bet v 4. The deduced amino acid sequence of Bet v 4 contained two typical EF-hand calcium-binding domains, Sequence similarities of Bet v 4 to calmodulin are primarily confined to the calcium-binding domains, However, significant sequence similarities extending outside the Ca2+-binding sites were found with a recently described group of pollen-specific allergens of Brassica and Bermuda grass, Both EF-hand domains of Bet v 4 are able to bind Ca2+, as demonstrated by Ca-45(2+) blot overlay of wild type and calcium-binding deficient mutants of Bet v 4, Among pollen-allergic patients, protein-bound Ca2+ was not an absolute requirement for IgE recognition of Bet v 4, However, disruption of the carboxyl-terminal Ca2+-binding domain indicated that most IgE antibodies from allergic patients are directed against this site. IgE inhibition experiments suggested that Bet v 4 represents a high;ly cross-reactive pollen allergen. Pre-absorption of allergic sera with Bet v 4 drastically reduced IgE binding to proteins of similar molecular weight in pollen extracts from distantly related plant species (e.g. timothy grass, mugwort, lily) but not in extracts from plant-derived foodstuff, To test for a possible biological role in pollen germination and tube growth, we introduced recombinant Bet v 4 protein into growing lily pollen tubes by iontophoresis. As a result, cytoplasmic streaming stopped in the vicinity of the electrode tip, and a slight depolarization of the membrane voltage was measured. These effects were not observed with Ca2+-binding deficient mutants of Bet v 4, Thus, Bet v 4 and homologous proteins represent a new class of pollen-specific Ca2+-binding allergens that may have a physiological role as inhibitors of cytoplasmic streaming in outgrowing pollen tubes.	SALZBURG UNIV,INST GENET & ALLGEMEINE BIOL,A-5020 SALZBURG,AUSTRIA; SALZBURG UNIV,INST PFLANZENPHYSIOL,A-5020 SALZBURG,AUSTRIA; NOVARTIS FORSCHUNGSINST,A-1235 VIENNA,AUSTRIA; INST ALLGEMEINE & EXPT PATHOL,A-1090 VIENNA,AUSTRIA	Salzburg University; Salzburg University; Novartis			Ferreira, Fatima/AAB-4321-2019; Obermeyer, Gerhard/G-4061-2013; Ferreira, Fatima/E-4889-2011; Briza, Peter/D-7309-2012; ENGEL, Erwan/HHC-1529-2022; Obermeyer, Gerhard/M-5942-2019	Ferreira, Fatima/0000-0003-0989-2335; Obermeyer, Gerhard/0000-0001-8102-6322; Ferreira, Fatima/0000-0003-0989-2335; Briza, Peter/0000-0002-4941-6782; Obermeyer, Gerhard/0000-0001-8102-6322; Kungl, Andreas/0000-0003-3362-797X; Auer, Manfred/0000-0001-8920-3522				BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BREWBAKE JL, 1963, AM J BOT, V50, P859, DOI 10.2307/2439772; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASILVA ACR, 1995, J BIOL CHEM, V270, P6773, DOI 10.1074/jbc.270.12.6773; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DIRKSEN A, 1978, ALLERGY, V33, P299; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FELL PJ, 1992, CLIN EXP ALLERGY, V22, P501, DOI 10.1111/j.1365-2222.1992.tb00154.x; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FINN BE, 1995, NAT STRUCT BIOL, V2, P777, DOI 10.1038/nsb0995-777; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; Kretsinger R.H., 1991, NOVEL CALCIUM BINDIN, P17; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; Kungl AJ, 1996, BIOCHEM BIOPH RES CO, V223, P187, DOI 10.1006/bbrc.1996.0867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LING V, 1993, PLANT MOL BIOL, V22, P207, DOI 10.1007/BF00014929; LOEWENSTEIN H, 1983, ALLERGY CPH, V38, P162; MARINI F, 1993, NUCLEIC ACIDS RES, V21, P2277, DOI 10.1093/nar/21.9.2277; NOBILING R, 1987, PROTOPLASMA, V139, P20, DOI 10.1007/BF01417531; OBERMEYER G, 1995, J EXP BOT, V46, P803, DOI 10.1093/jxb/46.7.803; OBERMEYER G, 1991, EUR J CELL BIOL, V56, P319; PEDROCCHI M, 1994, BIOCHEMISTRY-US, V33, P6732, DOI 10.1021/bi00187a045; RATHORE KS, 1991, DEV BIOL, V148, P612, DOI 10.1016/0012-1606(91)90278-B; REINACH FC, 1986, NATURE, V322, P80, DOI 10.1038/322080a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SISTRUNK ML, 1994, PLANT CELL, V6, P1553, DOI 10.1105/tpc.6.11.1553; SORENSON MM, 1995, J BIOL CHEM, V270, P9770, DOI 10.1074/jbc.270.17.9770; Spieksma F., 1991, ALLERGENIC POLLEN PO, P203; Spitzauer S, 1995, J ALLERGY CLIN IMMUN, V96, P951, DOI 10.1016/S0091-6749(95)70233-4; STEER MW, 1989, NEW PHYTOL, V111, P323, DOI 10.1111/j.1469-8137.1989.tb00697.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Suphioglu C, 1997, FEBS LETT, V402, P167, DOI 10.1016/S0014-5793(96)01520-7; Toriyama K, 1995, PLANT MOL BIOL, V29, P1157, DOI 10.1007/BF00020459; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VALENTA R, 1992, J EXP MED, V175, P365; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VIANDER M, 1979, ALLERGY, V34, P289; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x	59	113	117	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28630	28637		10.1074/jbc.272.45.28630	http://dx.doi.org/10.1074/jbc.272.45.28630			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353329	hybrid			2022-12-27	WOS:A1997YF21900069
J	Razik, MA; Lee, K; Price, RR; Williams, MR; Ongjoco, RR; Dole, MK; Rudner, SL; Kwatra, MM; Schwinn, DA				Razik, MA; Lee, K; Price, RR; Williams, MR; Ongjoco, RR; Dole, MK; Rudner, SL; Kwatra, MM; Schwinn, DA			Transcriptional regulation of the human alpha(1a)-adrenergic receptor gene - Characterization of the 5'-regulatory and promoter region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(1B) ADRENERGIC-RECEPTOR; GROWTH-FACTOR-I; ALPHA(1)-ADRENERGIC RECEPTOR; MESSENGER-RNA; MOLECULAR-CLONING; HUMAN PROSTATE; ALPHA-1-ADRENERGIC RECEPTOR; DIHYDROFOLATE-REDUCTASE; EXPRESSION; IDENTIFICATION	We recently cloned cDNAs encoding three subtypes of human alpha(1)-adrenergic receptors (alpha(1)ARs), alpha(1a), alpha(1b), and alpha(1d) (Schwinn, D. A., Johnston, G. L., Page, S. O., Mosley, M. J., Wilson, K. H., Worman, N. P., Campbell, S., Fidock, M. D., Furness, L. M., Parry-Smith, D. J., Peter, B., and Bailey, D. S. (1995) J. Pharmacol. Exp. Ther. 272, 134-142) and demonstrated predominance of alpha(1a)ARs in many human tissues (Price, D. T., Lefkowitz, R. J., Caron, M. G., Berkowitz, D., and Schwinn, D. A. (1994) Mol. Pharmacol. 45, 171-175). Several lines of evidence indicate that alpha(1a)ARs are important in clinical diseases such as myocardial hypertrophy and benign prostatic hyperplasia. Therefore, we initiated studies to understand mechanisms underlying regulation of alpha(1a)AR gene transcription, A genomic clone containing 6.2 kb of 5'-untranslated region of the human alpha(1a)AR gene was recently isolated. Ribonuclease protection and primer extension assays indicate that alpha(1a)AR gene transcription occurs at multiple initiation sites with the major site located 696 base pairs upstream of the ATG, where a classic initiator sequence is located. Transfection of luciferase reporter constructs containing varying amounts of 5'-untranslated region into human SK-N-MC neuroblastoma cells indicate that a region extending 125 base pairs upstream from the main transcription initiation site contains full alpha(1a)AR promoter activity. Furthermore, distinct activator and suppressor elements lie 2-3 and 3-5 kilobase pairs upstream, respectively. Although the alpha(1a)AR promoter contains neither TATA or CAAT elements, gel shift mobility assays targeting three GC boxes immediately upstream of the main transcription initiation site confirm binding of Spl. Activity of the alpha(1a)AR promoter is cell-specific, demonstrating highest activity in cells endogenously expressing alpha(1a)ARs. The human alpha(1a)AR gene also contains several cis regulatory elements, including several insulin and cAMP response elements. Consistent with these observations, we provide the first evidence that treatment of SK-N-MC cells with insulin and cAMP elevating agents leads to an increase in alpha(1a)AR expression. In conclusion, these data represent the first characterization of the alpha(1a)AR gene; our findings should facilitate further studies designed to understand mechanisms regulating alpha(1)AR subtype-specific expression in healthy and diseased human tissue.	DUKE UNIV, MED CTR, DEPT ANESTHESIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PEDIAT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Duke University			Kwatra, Madan/ABD-2008-2020	Schwinn, Debra/0000-0002-9696-5231	NIA NIH HHS [AG13853, AG00745] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013853] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chen LQ, 1995, J BIOL CHEM, V270, P30980, DOI 10.1074/jbc.270.52.30980; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DENG CL, 1994, J RECEPTOR RES, V14, P119, DOI 10.3109/10799899409067000; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FORRAY C, 1994, MOL PHARMACOL, V45, P703; GAO B, 1995, J BIOL CHEM, V270, P5614, DOI 10.1074/jbc.270.10.5614; GAO B, 1993, GENE, V131, P243, DOI 10.1016/0378-1119(93)90300-R; GAO B, 1994, J BIOL CHEM, V269, P15762; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; Granneman JG, 1997, MOL PHARMACOL, V51, P644, DOI 10.1124/mol.51.4.644; HAENDLER B, 1990, EUR J BIOCHEM, V190, P477, DOI 10.1111/j.1432-1033.1990.tb15598.x; HIEBLE JP, 1995, PHARMACOL REV, V47, P267; HOD Y, 1988, J BIOL CHEM, V263, P7747; Hu ZW, 1996, J CLIN INVEST, V98, P1826, DOI 10.1172/JCI118983; KANASAKI M, 1994, J CLIN INVEST, V94, P2245, DOI 10.1172/JCI117587; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LEE K, 1997, IN PRESS DNA SEQ; Lee SH, 1996, J BIOL CHEM, V271, P25292, DOI 10.1074/jbc.271.41.25292; Litts J C, 1991, DNA Seq, V1, P263, DOI 10.3109/10425179109020781; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MARSHALL I, 1995, BRIT J PHARMACOL, V115, P781, DOI 10.1111/j.1476-5381.1995.tb15001.x; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; PARK K, 1993, J BIOL CHEM, V268, P17811; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PRICE DT, 1994, MOL PHARMACOL, V45, P171; PRICE DT, 1994, MOL PHARMACOL, V46, P221; PRICE DT, 1993, J UROLOGY, V150, P546, DOI 10.1016/S0022-5347(17)35544-1; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; Richardson CD, 1997, PROSTATE, V33, P55; Rokosh DG, 1996, J BIOL CHEM, V271, P5839, DOI 10.1074/jbc.271.10.5839; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SEARLES RP, 1995, J BIOL CHEM, V270, P157, DOI 10.1074/jbc.270.1.157; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TERZIC A, 1993, PHARMACOL REV, V45, P147; TITUS DE, 1991, PROTOCOLS APPLICATIO, P58; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; WEINBERG DH, 1994, BIOCHEM BIOPH RES CO, V201, P1296, DOI 10.1006/bbrc.1994.1845; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WOOD KV, 1991, BIOLUMINESCENCE CHEM; Yamazaki T, 1997, CIRCULATION, V95, P1260; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	58	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28237	28246		10.1074/jbc.272.45.28237	http://dx.doi.org/10.1074/jbc.272.45.28237			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353275	hybrid			2022-12-27	WOS:A1997YF21900015
J	Chagovetz, AM; Sweasy, JB; Preston, BD				Chagovetz, AM; Sweasy, JB; Preston, BD			Increased activity and fidelity of DNA polymerase beta on single-nucleotide gapped DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; KINETIC-ANALYSIS; NUCLEAR EXTRACT; PROCESSIVITY; REQUIREMENT; MECHANISM; ALPHA	DNA polymerase beta (pol beta) is an error-prone polymerase that plays a central role in mammalian base excision repair. To better characterize the mechanisms governing rat pol beta activity, we examined polymerization on synthetic primer-templates of different structure. Steady-state kinetic analyses revealed that the catalytic efficiency of pol beta (k(cat)/K-m,dNTP(app)) is strongly influenced by gap size and the presence of a phosphate group at the 5'-margin of the gap. pol beta exhibited the highest catalytic efficiency on 5'-phosphorylated 1-nucleotide gapped DNA. This efficiency was greater than or equal to 500 times higher than on non-phosphorylated 1-nucleotide and 6-nucleotide (with or without PO4) gapped DNAs and 2,500 times higher than on primer-template with no gaps, The nucleotide insertion fidelity of pol beta, as judged by its ability to form G-N mispairs, was also higher (10-100 times) on 5'-phosphorylated single nucleotide gapped DNA compared with the other DNA substrates studied. These data suggest that a primary function of mammalian pol beta is to fill 5'-phosphorylated 1-nucleotide gaps.	UNIV UTAH,ECCLES INST HUMAN GENET,PROGRAM HUMAN MOL BIOL & GENET,DEPT BIOCHEM,SALT LAKE CITY,UT 84112; UNIV UTAH,ECCLES INST HUMAN GENET,PROGRAM HUMAN MOL BIOL & GENET,DEPT RADIAT ONCOL,SALT LAKE CITY,UT 84112; YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06520	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Yale University; Yale University								BAMBARA RA, 1978, J BIOL CHEM, V253, P413; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; CHANG LMS, 1975, J MOL BIOL, V93, P219, DOI 10.1016/0022-2836(75)90129-1; FRIEDBERG EC, 1996, DNA REPLICATION EUKA, P249; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; MATSUKAGE A, 1979, J BIOCHEM-TOKYO, V85, P1551, DOI 10.1093/oxfordjournals.jbchem.a132487; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; Nealon K, 1996, NUCLEIC ACIDS RES, V24, P3763, DOI 10.1093/nar/24.19.3763; Oda N, 1996, J BIOL CHEM, V271, P13816, DOI 10.1074/jbc.271.23.13816; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; PRASAD R, 1994, J BIOL CHEM, V269, P18096; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Roberts J.D., 1996, DNA REPLICATION EUKA, P217; SIEDLECKI JA, 1980, NUCLEIC ACIDS RES, V8, P361, DOI 10.1093/nar/8.2.361; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009; Washington SL, 1997, P NATL ACAD SCI USA, V94, P1321, DOI 10.1073/pnas.94.4.1321; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202	26	93	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27501	27504		10.1074/jbc.272.44.27501	http://dx.doi.org/10.1074/jbc.272.44.27501			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346877	hybrid			2022-12-27	WOS:A1997YD47300003
J	Ma, JJ; Zhao, JY; Drumm, ML; Xie, JX; Davis, PB				Ma, JJ; Zhao, JY; Drumm, ML; Xie, JX; Davis, PB			Function of the R domain in the cystic fibrosis transmembrane conductance regulator chloride channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; CL CHANNEL; ATP HYDROLYSIS; MOLECULAR MECHANISMS; CFTR; PHOSPHORYLATION; PROTEIN; PYROPHOSPHATE; INACTIVATION; STATES	For a cystic fibrosis transmembrane conductance regulator (CFTR) channel to enter its open state, serine residues in the R domain must be phosphorylated by cAMP-dependent protein kinase, and intracellular ATP must bind to the nucleotide-binding folds and subsequently be hydrolyzed, CFTR with its It domain partially removed, Delta R(708-835)-CFTR, forms a chloride channel that opens independently of protein kinase A phosphorylation, with open probability approximately one-third that of the wild type CFTR channel, Deletion of this portion of the R domain from CFTR alters the response of the channel to 5'-adenylylimidodiphosphate, pyrophosphate, and vanadate, compounds that prolong burst duration of the wild type CFTR channel but fail to do so in the Delta R-CFTR. In addition, the addition of exogenous unphosphorylated R domain protein, which blocks the wild type CFTR channel, has no effect on the Delta R-CFTR channel, However, when the exogenous R domain is phosphorylated, significant stimulation of the Delta R-CFTR channel results; P-o increases from 0.10 to 0.22. These data are consistent with a model for CFTR function in which the R domain in the unphosphorylated state interacts with the first nucleotide binding fold to inhibit either binding or hydrolysis of ATP or transduction of the effect to open the pore, but when the R domain is phosphorylated, it undergoes conformational change and interacts at a separate site in the first nucleotide binding fold to stimulate either binding or hydrolysis of ATP or transduction of the effect to open the pore.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PEDIAT,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651, R01DK045965] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL/DK49003] Funding Source: Medline; NIDDK NIH HHS [DK27651, DK45965] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CIACCIA AV, 1994, PEDIATR PULM, V10, P180; DULHANTY AM, 1994, FEBS LETT, V343, P109, DOI 10.1016/0014-5793(94)80300-5; FRIZZELL RA, 1995, AM J RESP CRIT CARE, V151, pS54, DOI 10.1164/ajrccm/151.3_Pt_2.S54; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; MA J, 1995, J BIOL CHEM, V271, P7351; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Tao T, 1996, BIOPHYS J, V70, P743, DOI 10.1016/S0006-3495(96)79614-5; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WINTER MC, 1996, PEDIATR PULM, V13, P212; XIE JX, 1995, J BIOL CHEM, V270, P28084; Xie JX, 1996, BIOPHYS J, V71, P3148, DOI 10.1016/S0006-3495(96)79508-5; Zhao Jiying, 1997, Biophysical Journal, V72, pA33	36	65	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28133	28141		10.1074/jbc.272.44.28133	http://dx.doi.org/10.1074/jbc.272.44.28133			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346969	hybrid			2022-12-27	WOS:A1997YD47300095
J	Swanson, DJ; Zellmer, E; Lewis, EJ				Swanson, DJ; Zellmer, E; Lewis, EJ			The homeodomain protein Arix interacts synergistically with cyclic AMP to regulate expression of neurotransmitter biosynthetic genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE GENE; DOPAMINE-BETA-HYDROXYLASE; CAMP-RESPONSE-ELEMENT; REPEATED IMMOBILIZATION STRESS; PHEOCHROMOCYTOMA CELL-LINE; DNA-BINDING SPECIFICITY; NERVE GROWTH-FACTOR; MESSENGER-RNA; PC12 CELLS; COOPERATIVE INTERACTIONS	Transcription of the neurotransmitter biosynthetic genes tyrosine hydroxylase and dopamine beta-hydroxylase (DBH) is regulated by cell type-specific transcription factors, including the homeoprotein Arix, and second messengers, including cyclic AMP. The cis-acting regulatory sites of the DBH gene which respond to Arix and cAMP lie adjacent to each other, between bases -180 and -150, in a regulatory element named DBI. Neither Arix nor cyclic AMP analogs alone effectively stimulate transcription from the DBH promoter in nonneuronal cell cultures. However, when Arix is present together with cAMP, transcription is substantially activated, Synergistic transcription from the DBH promoter can also be elicited by cotransfection of Arix with an expression vector encoding the catalytic subunit of protein kinase A. Nuclear extracts from PC12 cells display a cAMP-induced complex binding to the DB1 element, and antisera to transcription factors CREB, CREM, Fos, and Jun indicate that these proteins, or closely related family members, interact with DB1. A dominant negative construct of CREB inhibits the response of the DBH promoter to protein kinase A. These results demonstrate a synergistic interaction between a homeodomain protein and the cAMP signal transduction system and suggest that similar interactions may regulate the tissue-specific expression of neuroendocrine genes.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOL BIOL, PORTLAND, OR 97201 USA	Oregon Health & Science University					NIGMS NIH HHS [GM38696] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038696, R29GM038696] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; Afar R, 1996, MOL BRAIN RES, V36, P79, DOI 10.1016/0169-328X(95)00247-P; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; Ausbel F.M., 1995, CURRENT PROTOCOLS MO; BEST JA, 1995, J NEUROCHEM, V65, P1934; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHU HM, 1994, MOL ENDOCRINOL, V8, P59, DOI 10.1210/me.8.1.59; COLLINSHICOK J, 1994, MOL CELL BIOL, V14, P2837, DOI 10.1128/MCB.14.5.2837; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU XY, 1995, J NEUROSCI, V15, P5420; ERNSBERGER U, 1995, MECH DEVELOP, V52, P125, DOI 10.1016/0925-4773(95)00396-I; FADER D, 1990, MOL BRAIN RES, V8, P25, DOI 10.1016/0169-328X(90)90005-X; FOSSOM LH, 1992, MOL PHARMACOL, V42, P898; FOSSOM LH, 1991, MOL PHARMACOL, V40, P193; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GROVES AK, 1995, DEVELOPMENT, V121, P887; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HIREMAGALUR B, 1993, J BIOL CHEM, V268, P23704; HWANG O, 1995, J NEUROCHEM, V65, P1988; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KIM KS, 1994, J NEUROSCI, V14, P7200; KIM KS, 1993, J BIOL CHEM, V268, P15689; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KONRADI C, 1993, P NATL ACAD SCI USA, V90, P7005, DOI 10.1073/pnas.90.15.7005; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LAMOUROUX A, 1993, J NEUROCHEM, V60, P364, DOI 10.1111/j.1471-4159.1993.tb05861.x; LAZAROFF M, 1995, J BIOL CHEM, V270, P21579, DOI 10.1074/jbc.270.37.21579; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIU JS, 1991, J BIOL CHEM, V266, P19095; MacArthur L, 1996, J NEUROCHEM, V67, P2256; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MCMAHON A, 1992, J NEUROCHEM, V58, P2124, DOI 10.1111/j.1471-4159.1992.tb10954.x; MCMAHON A, 1992, J NEUROCHEM, V59, P2040; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; NANKOVA B, 1993, J NEUROCHEM, V61, P776; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; RICHARD F, 1988, J NEUROSCI RES, V20, P32, DOI 10.1002/jnr.490200106; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; Seo HM, 1996, J NEUROSCI, V16, P4102; SHASKUS J, 1995, J NEUROCHEM, V64, P52; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; STACHOWIAK MK, 1987, BRAIN RES, V359, P256; TANK AW, 1986, MOL PHARMACOL, V30, P497; TANK AW, 1985, J NEUROCHEM, V45, P1030, DOI 10.1111/j.1471-4159.1985.tb05519.x; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; Tiveron MC, 1996, J NEUROSCI, V16, P7649; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WESSELSREIKER M, 1993, J NEUROCHEM, V60, P1018, DOI 10.1111/j.1471-4159.1993.tb03250.x; Zellmer E, 1995, J NEUROSCI, V15, P8109; ZURN AD, 1993, MOL BRAIN RES, V20, P125, DOI 10.1016/0169-328X(93)90117-8	64	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27382	27392		10.1074/jbc.272.43.27382	http://dx.doi.org/10.1074/jbc.272.43.27382			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341190	hybrid			2022-12-27	WOS:A1997YC65900086
J	Zhang, LT; Strickland, DK; Cines, DB; Higazi, AAR				Zhang, LT; Strickland, DK; Cines, DB; Higazi, AAR			Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; SARCOMA-CELLS; TYPE-1; COMPLEX; PROUROKINASE; VITRONECTIN; PROENZYME; RESISTANT; ADHESION	The internalization and degradation of cell associated urokinase type plasminogen activator (uPA) through the alpha(2)-macroglobulin receptor/low density lipoprotein-related receptor (alpha(2)MR/LRP) represent important steps in the control of plasmin formation. Complexes between two chain urokinase (tcuPA) and plasminogen activator type 1 are degraded rapidly whereas single chain urokinase (scuPA) is not, suggesting that alpha(2)MR/LRP requires specific epitopes in the serpin for effective function. We report an alternative mechanism that may contribute to this process. The binding of scuPA to LM-TK- cells that lack the uPA receptor was stimulated by the hexapeptide EEIIMD, corresponding to amino acids 350-355 of plasminogen activator type 1, which contacts the sequence RHRGGS, corresponding to amino acids 179-184 in uPA. EEIIMD increased the B-max of scuPA binding 4-fold with the half-maximal effect achieved at a peptide concentration of 50 mu M. Stimulation was dependent on the charge on the COOH-terminal amino acid but not on the NH2 terminus of the peptide. EEIIMD also stimulated the internalization and degradation of scuPA. Both the binding and internalization of scuPA in the presence of EEIIMD were blocked by recombinant, 39-kDa alpha(2)MR/LRP-associated protein as well as by an anti-alpha(2)MR/LRP antibody. EEIIMD also stimulated the binding of scuPA to purified alpha(2)MR/LRP. EEIIMD had no effect on the binding of tcuPA or of complexes between scuPA and its receptor. These results suggest that EEIIMD regulates the binding of scuPA with alpha(2)MR/LRP. These findings also suggest a potential mechanism by which scuPA can be cleared which is independent of activation by plasmin or binding to uPA receptor.	UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT LAB MED,PHILADELPHIA,PA 19104; AMER RED CROSS,DEPT BIOCHEM,ROCKVILLE,MD 20855; HADASSAH HEBREW UNIV HOSP,DEPT CLIN BIOCHEM,IL-91120 JERUSALEM,ISRAEL	University of Pennsylvania; University of Pennsylvania; American Red Cross; Hebrew University of Jerusalem; Hadassah University Medical Center					NHLBI NIH HHS [HL50790, HL49517, HL40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050790, R01HL049517, P01HL040387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS DS, 1991, J BIOL CHEM, V266, P8476; ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; COLLEN D, 1986, J BIOL CHEM, V261, P1259; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; ELLIS V, 1987, J BIOL CHEM, V262, P14998; ELLIS V, 1990, J BIOL CHEM, V265, P9904; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; Higazi AAR, 1997, J BIOL CHEM, V272, P5348, DOI 10.1074/jbc.272.8.5348; Higazi AAR, 1996, THROMB RES, V84, P243, DOI 10.1016/S0049-3848(96)00184-3; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; Higazi AAR, 1996, BLOOD, V87, P3545, DOI 10.1182/blood.V87.9.3545.bloodjournal8793545; HUSAIN SS, 1991, BIOCHEM, V30, P5707; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KRUITHOF EKO, 1984, BLOOD, V64, P907; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; LI H, 1994, J BIOL CHEM, V269, P8153; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P567, DOI 10.1111/j.1432-1033.1994.00567.x; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MANCHANDA N, 1995, J BIOL CHEM, V270, P20032, DOI 10.1074/jbc.270.34.20032; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; Shapiro RL, 1997, AM J PATHOL, V150, P359; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035	35	18	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27053	27057		10.1074/jbc.272.43.27053	http://dx.doi.org/10.1074/jbc.272.43.27053			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341144				2022-12-27	WOS:A1997YC65900040
J	Geiszt, M; Kapus, A; Nemet, K; Farkas, L; Ligeti, E				Geiszt, M; Kapus, A; Nemet, K; Farkas, L; Ligeti, E			Regulation of capacitative Ca2+ influx in human neutrophil granulocytes - Alterations in chronic granulomatous disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CA-2+; PROTEIN-KINASE-C; MEMBRANE-POTENTIAL CHANGES; NADPH OXIDASE; CHEMOTACTIC PEPTIDE; PLASMA-MEMBRANE; CALCIUM-ENTRY; INTRACELLULAR CALCIUM; TRANSIENT INHIBITION; RESPIRATORY BURST	Ca2+ entry through the capacitative (store regulated) pathway was shown to be inhibited in neutrophil granulocytes by the protein kinase C activator phorbol 12-myristate 13-acetate and the chemoattractant N-formylmethionyl-leucyl-phenylalanine (fMLP) by a hitherto unknown mechanism, Measuring both Ca2+ and Mn2+ entry into store-depleted cells we show in the present study that inhibition of the capacitative pathway is absent in various forms of chronic granulomatous disease, To establish the possible relationship between inhibition of the capacitative pathway and ability of O-2(.-) production and consequent membrane depolarization, gradual changes of the membrane potential were evoked in neutrophils of healthy individuals. This was accomplished by pharmacological manipulation of the membrane potential and by variations of the concentration and type of the stimulant, Close relationship was observed between membrane depolarization and inhibition of Mn2+ entry through the capacitative transport route, Our results provide an explanation for the inhibitory action of fMLP and phorbol la-myristate 13-acetate on capacitative cation influx and reveal that upon physiological stimulation, Ca2+ entry into neutrophils is restricted by the depolarization accompanying O-2(.-) production.	SEMMELWEIS UNIV MED,DEPT PHYSIOL,H-1444 BUDAPEST 8,HUNGARY; SEMMELWEIS UNIV MED,LAB CELLULAR & MOL PHYSIOL,H-1444 BUDAPEST 8,HUNGARY; NATL INST HAEMATOL & BLOOD TRANSFUS,H-1113 BUDAPEST,HUNGARY	Semmelweis University; Semmelweis University								AHLIN A, 1995, J LAB CLIN MED, V125, P392; ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; Alonso MT, 1996, J LEUKOCYTE BIOL, V60, P323, DOI 10.1002/jlb.60.3.323; DEMAUREX N, 1992, J CLIN INVEST, V90, P830, DOI 10.1172/JCI115958; DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595; DEWALD B, 1986, BIOCHIM BIOPHYS ACTA, V888, P42, DOI 10.1016/0167-4889(86)90069-8; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P4574; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; Etter EF, 1996, P NATL ACAD SCI USA, V93, P5368, DOI 10.1073/pnas.93.11.5368; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; FURUYA W, 1986, AM J PHYSIOL, V251, pC55; GARCIA RC, 1992, BIOCHEM J, V286, P687, DOI 10.1042/bj2860687; GEISZT M, 1995, BIOCHEM J, V305, P525, DOI 10.1042/bj3050525; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; HJORTH R, 1981, J IMMUNOL METHODS, V43, P95, DOI 10.1016/0022-1759(81)90040-5; JOHANSEN KS, 1983, ACTA PATH MICRO IM C, V91, P349; KAPUS A, 1994, J BIOL CHEM, V269, P4736; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; KOVACS T, 1990, FEBS LETT, V266, P171, DOI 10.1016/0014-5793(90)81532-S; LEVY R, 1990, J IMMUNOL, V145, P2595; LEW PD, 1984, BLOOD, V63, P231; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; LU DJ, 1992, AM J PHYSIOL, V262, pC39, DOI 10.1152/ajpcell.1992.262.1.C39; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; MCCARTHY SA, 1989, BIOCHEM J, V264, P357, DOI 10.1042/bj2640357; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1993, J BIOL CHEM, V268, P26911; MONTERO M, 1993, J BIOL CHEM, V268, P13055; MONTERO M, 1994, J BIOL CHEM, V269, P3963; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; NANDA A, 1991, Cellular Physiology and Biochemistry, V1, P65, DOI 10.1159/000154595; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Roos D, 1996, BLOOD, V87, P1663; SARKADI B, 1990, BIOCHIM BIOPHYS ACTA, V1027, P130, DOI 10.1016/0005-2736(90)90076-Z; SCHARFF O, 1993, PHYSIOL REV, V73, P547, DOI 10.1152/physrev.1993.73.3.547; Segal AW, 1996, MOL MED TODAY, V2, P129, DOI 10.1016/1357-4310(96)88723-5; SELIGMANN BE, 1980, J MEMBRANE BIOL, V52, P257, DOI 10.1007/BF01869194; SELIGMANN BE, 1980, J CLIN INVEST, V66, P493, DOI 10.1172/JCI109880; SENGELOV H, 1993, J IMMUNOL, V150, P1535; SMITH RM, 1991, BLOOD, V77, P673; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; WATSON F, 1991, J BIOL CHEM, V266, P7432; WHITIN JC, 1980, J BIOL CHEM, V255, P1874	49	97	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26471	26478		10.1074/jbc.272.42.26471	http://dx.doi.org/10.1074/jbc.272.42.26471			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334224	hybrid			2022-12-27	WOS:A1997YB13900058
J	Giannini, G; Dawson, MI; Zhang, XK; Thiele, CJ				Giannini, G; Dawson, MI; Zhang, XK; Thiele, CJ			Activation of three distinct RXR/RAR heterodimers induces growth arrest and differentiation of neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; HUMAN NEURO-BLASTOMA; X-RECEPTOR; N-MYC; BINDING-PROTEINS; THYROID-HORMONE; NUCLEAR RECEPTORS; RESPONSE ELEMENT; RXR-ALPHA; RAR-ALPHA	Naturally occurring retinoids, like all-trans retinoic acid and 9-cis retinoic acid, are known to affect proliferation and differentiation of sensitive neuroblastoma cell lines. Cellular responsiveness to retinoic acid depends on its interaction with two distinct classes of receptors, the retinoic acid receptors (RARs) and the retinoic X receptors (RXRs). Both receptor classes have three different subtypes (RAR alpha, RAR beta, and RAR gamma and RXR alpha, RAR beta, and RAR gamma) that act as ligand-dependent transcription factors. To examine the involvement of the different receptor classes and subtypes in the biological responses of neuroblastoma cells to retinoids, we analyzed the effects of a panel of receptor selective retinoids on cell growth, differentiation, and gene expression on in vitro cultured KCNR cells. Any association of per se inactive RXR-selective with RAR-selective ligands efficiently regulates growth inhibition, differentiation (neurite extension), and expression of RAR beta, TrkB, and N-myc. SR11383 alone, a very potent retinoid, entirely reproduces the pattern of biological responses induced by naturally occurring retinoids, In contrast to other tumor cell lines, the growth of neuroblastoma cell lines is not altered using AP1-antagonistic retinoids. These studies raise the possibility that three distinct RXR/RAR heterodimers mediate the effects of retinoids on neuroblastoma cells through an AP-1 antagonism-independent mechanism.	NCI,CELL & MOL BIOL SECT,PEDIAT ONCOL BRANCH,NIH,BETHESDA,MD 20892; SRI INT,RETINOID PROGRAM,MENLO PK,CA 94025; BURNHAM INST,LA JOLLA,CA 92037	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); SRI International; Sanford Burnham Prebys Medical Discovery Institute			Giannini, Giuseppe/B-5672-2013	Giannini, Giuseppe/0000-0003-0299-4056				ALBEMAYOR E, 1989, ENV HLTH PERSPECT, V80, P3; ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOLANDE RP, 1985, SURV SYN PATHOL RES, V4, P296; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Brooks SC, 1996, BLOOD, V87, P227; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Cheung B, 1996, BIOCHEM BIOPH RES CO, V229, P349, DOI 10.1006/bbrc.1996.1804; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; HAN GY, 1995, DIFFERENTIATION, V59, P61, DOI 10.1046/j.1432-0436.1995.5910061.x; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kizaki M, 1996, BLOOD, V87, P1977; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LAVSITAPICARD N, 1996, MOL CELL BIOL, V16, P4137; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; Lutz W, 1996, ONCOGENE, V13, P803; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARSHALL GM, 1995, ONCOGENE, V11, P485; MATSUMOTO K, 1995, CANCER RES, V55, P1798; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; Peverali FA, 1996, ONCOGENE, V12, P457; REDFERN CPF, 1994, BIOCHEM J, V304, P147, DOI 10.1042/bj3040147; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; REYNOLDS CP, 1991, PROG CLIN BIOL RES, V366, P203; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUBERTE E, 1993, DEVELOPMENT, V118, P267; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1991, CANCER METAST REV, V10, P311, DOI 10.1007/BF00554793; WADA RK, 1992, ONCOGENE, V7, P711; Willhite CC, 1996, DRUG METAB REV, V28, P105, DOI 10.3109/03602539608993994; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	55	49	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26693	26701		10.1074/jbc.272.42.26693	http://dx.doi.org/10.1074/jbc.272.42.26693			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334253	hybrid			2022-12-27	WOS:A1997YB13900087
J	Jones, BE; Dossonnet, V; Kuster, E; Hillen, W; Deutscher, J; Klevit, RE				Jones, BE; Dossonnet, V; Kuster, E; Hillen, W; Deutscher, J; Klevit, RE			Binding of the catabolite repressor protein CcpA to its DNA target is regulated by phosphorylation of its corepressor HPr	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; PHOSPHOCARRIER PROTEIN; PHOSPHOTRANSFERASE SYSTEM; PURINE REPRESSOR; SEQUENCE; PHOSPHOENOLPYRUVATE; EXPRESSION; KINASE	Catabolite repression of a number of catabolic operons in bacilli is mediated by the catabolite control protein CcpA, the phosphocarrier protein HPr from the phosphoenolpyruvate-dependent sugar transport system (PTS), and a cis-acting DNA sequence termed the catabolite-responsive element (cre), We present evidence that CcpA interacts with HPr that is phosphorylated at Ser(46) (Ser(P) HPr) and that these proteins form a specific ternary complex with cre DNA, Titration experiments following the circular dichroism signal of the cre DNA indicate that this complex consists of two molecules of Ser(P) HPr, a CcpA dimer, and the cre sequence, Limited proteolysis experiments indicate that the domain structure of CcpA is similar to other members of the LacI/GalR family of helix-turn-helix proteins, comprised of a helix-turn-helix DNA domain and a C-terminal effector domain, NMR titration of Ser(P) HPr demonstrates that the isolated C-terminal domain of CcpA. forms a specific complex with Ser(P) HPr but not with unphosphorylated HPr. Based upon perturbations to the NMR spectrum, we propose that the binding site of the C-terminal domain of CcpA on Ser(P) HPr forms a contiguous surface that encompasses both Sep(P)(46) and His(15), the site of phosphorylation by enzyme I of the PTS. This allows CcpA to recognize the phosphorylation state of HPr, effectively linking the process of sugar import via the PTS to catabolite repression in bacilli.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,BIOMOL STRUCT CTR,SEATTLE,WA 98195; UNIV ERLANGEN NURNBERG,INST MIKROBIOL BIOCHEM & GENET,D-91058 ERLANGEN,GERMANY; CNRS,INST BIOL CHIM PROT,F-69367 LYON 07,FRANCE	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Erlangen Nuremberg; Centre National de la Recherche Scientifique (CNRS)				Kuster-Schock, Elke/0000-0002-9487-6948; Jones, Bryan/0000-0003-4764-6290	NIDDK NIH HHS [R01 DK35187] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035187] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chambliss Glenn H., 1993, P213; Chauvaux S, 1996, RES MICROBIOL, V147, P518, DOI 10.1016/0923-2508(96)84006-X; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; CHOI KY, 1994, J BACTERIOL, V176, P1767, DOI 10.1128/jb.176.6.1767-1772.1994; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DEUTSCHER J, 1994, J BACTERIOL, V176, P3336, DOI 10.1128/jb.176.11.3336-3344.1994; DEUTSCHER J, 1995, MOL MICROBIOL, V15, P1049, DOI 10.1111/j.1365-2958.1995.tb02280.x; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUJITA Y, 1995, MOL MICROBIOL, V17, P953, DOI 10.1111/j.1365-2958.1995.mmi_17050953.x; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gosseringer R, 1997, J MOL BIOL, V266, P665, DOI 10.1006/jmbi.1996.0820; GRAY DM, 1992, METHOD ENZYMOL, V211, P389; HUECK CJ, 1994, RES MICROBIOL, V145, P503, DOI 10.1016/0923-2508(94)90028-0; HUECK CJ, 1995, MOL MICROBIOL, V16, P855, DOI 10.1111/j.1365-2958.1995.tb02313.x; JONES BE, 1997, IN PRESS PROTEIN SCI, V6; KIM JH, 1995, J BACTERIOL, V177, P5129, DOI 10.1128/jb.177.17.5129-5134.1995; Kowalak JA, 1996, PROTEIN SCI, V5, P1625, DOI 10.1002/pro.5560050816; Kruger S, 1996, J BACTERIOL, V178, P2637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; MARTINVERSTRAETE I, 1995, J BACTERIOL, V177, P6919, DOI 10.1128/jb.177.23.6919-6927.1995; MIWA Y, 1994, MICROBIOL-UK, V140, P2567, DOI 10.1099/00221287-140-10-2567; PLATT T, 1973, J BIOL CHEM, V248, P110; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PULLEN K, 1995, PROTEIN SCI, V4, P2478, DOI 10.1002/pro.5560041204; RAJAGOPAL P, 1994, TECHNIQUES PROTEIN C, V5, P439; REIZER J, 1992, J BIOL CHEM, V267, P9158; Reizer J, 1996, J BACTERIOL, V178, P5480, DOI 10.1128/jb.178.18.5480-5486.1996; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; VANNULAND NAJ, 1995, J MOL BIOL, V246, P180, DOI 10.1006/jmbi.1994.0075; VANNULAND NAJ, 1993, FEBS LETT, V315, P11, DOI 10.1016/0014-5793(93)81122-G; Voskuil MI, 1996, J BACTERIOL, V178, P7014, DOI 10.1128/jb.178.23.7014-7015.1996; WEICKERT MJ, 1990, P NATL ACAD SCI USA, V87, P6238, DOI 10.1073/pnas.87.16.6238; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005	38	123	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26530	26535		10.1074/jbc.272.42.26530	http://dx.doi.org/10.1074/jbc.272.42.26530			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334231	hybrid			2022-12-27	WOS:A1997YB13900065
J	Pazdernik, NJ; Cain, SM; Brooker, RJ				Pazdernik, NJ; Cain, SM; Brooker, RJ			An analysis of suppressor mutations suggests that the two halves of the lactose permease function in a symmetrical manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; LAC CARRIER PROTEIN; SUGAR-TRANSPORT PROTEINS; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; SEQUENCE MOTIF; GENE; EXPRESSION; SEGMENT-2; MUTANT	A conserved motif, GXXX(D/E)(R/K)XG[X](R/K)(R/K), is located in loop 2/3 and loop 8/9 in the lactose permease, and also in hundreds of evolutionarily related transporters, The importance of conserved residues in loop 8/9 was previously investigated (Pazdernik, N. J., Jessen-Marshall, A, E., and Brooker, R. J, (1997) J, Bacteriol. 179, 735-741), Although this loop was tolerant of many substitutions, a few mutations in the first position of the motif were shown to dramatically decrease lactose transport, In the current study, a mutant at the first position in the motif having very low lactose transport, Leu(230), was used as it parental strain to isolate second-site revertants that restore function, A total of 23 independent mutants were sequenced and found to have a second amino acid substitution at several locations (G46C, G46S, F49L, A50T, L212Q, L216Q, S233P, C333G, F354C, G370C, G370S, and G370V). A kinetic analysis revealed that the first-site mutation, Leu(230), had a slightly better affinity for lactose compared with the wild-type strain, but its V-max for lactose transport was over 30-fold lower. The primary effect of the second-site mutations was to increase the V-max for lactose transport, in some cases, to levels that were near the wild-type value. When comparing this study to second-site mutations obtained from loop 2/3 defective strains, a striking observation was made, Mutations in three regions of the protein, codons 45-50, 234-241, and 366-370, were able to restore functionality to both loop 2/3 and loop 8/9 defects, These results are discussed within the context of a C1/C2 alternating conformation model in which lactose translocation occurs by a conformational change at the interface between the two halves of the protein.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities				Pazdernik, Nanette/0000-0002-1037-6437	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1982, P NATL ACAD SCI-BIOL, V79, P6894, DOI 10.1073/pnas.79.22.6894; COPE DL, 1994, BIOCHEM J, V300, P291, DOI 10.1042/bj3000291; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GOSWITZ VC, 1995, PROTEIN SCI, V4, P543; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; HERZLINGER D, 1984, BIOCHEMISTRY-US, V23, P3688, DOI 10.1021/bi00311a018; JESSENMARSHALL AE, 1995, J BIOL CHEM, V270, P16251, DOI 10.1074/jbc.270.27.16251; JessenMarshall AE, 1996, J BIOL CHEM, V271, P1400, DOI 10.1074/jbc.271.3.1400; JessenMarshall AE, 1997, J BACTERIOL, V179, P2616, DOI 10.1128/jb.179.8.2616-2622.1997; JUNG K, 1993, BIOCHEMISTRY-US, V32, P12272; KIMURA T, 1995, FEBS LETT, V362, P47, DOI 10.1016/0014-5793(95)00205-N; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; LEE JI, 1993, J BIOL CHEM, V268, P20007; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Mandel M, 1970, J MOL BIOL, V53, P154; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Miller J. H., 1972, EXPT MOL GENETICS, P433; Pazdernik NJ, 1997, J BACTERIOL, V179, P735, DOI 10.1128/jb.179.3.735-741.1997; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; Sambrook J., 2002, MOL CLONING LAB MANU; SEGAL IH, 1975, ENZYME KINETICS; Sun JZ, 1996, BIOCHEMISTRY-US, V35, P990, DOI 10.1021/bi952166w; TEATHER RM, 1978, MOL GEN GENET, V159, P239, DOI 10.1007/BF00268260; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; YAMAGUCHI A, 1993, J BIOL CHEM, V268, P6496; YAMAGUCHI A, 1993, FEBS LETT, V324, P131, DOI 10.1016/0014-5793(93)81378-D; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAMAGUCHI A, 1995, BIOCHEMISTRY-US, V34, P11800, DOI 10.1021/bi00037a018	38	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26110	26116		10.1074/jbc.272.42.26110	http://dx.doi.org/10.1074/jbc.272.42.26110			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334175	hybrid			2022-12-27	WOS:A1997YB13900009
J	Aichinger, G; Karlsson, L; Jackson, MR; Vestberg, M; Vaughan, JH; Teyton, L; Lechler, RI; Peterson, PA				Aichinger, G; Karlsson, L; Jackson, MR; Vestberg, M; Vaughan, JH; Teyton, L; Lechler, RI; Peterson, PA			Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; DROSOPHILA-MELANOGASTER CELLS; HLA-DR MOLECULES; INVARIANT-CHAIN; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; ANTIGEN PRESENTATION; SURFACE EXPRESSION; PEPTIDE BINDING; MHC MOLECULES	We have analyzed the ability of major histocompatibility (MHC) class II molecules to capture proteins in the biosynthetic pathway and whether this may be associated with MHC class II dependent antigen processing, When coexpressed with HLA-DR 4 molecules in HeLa cells, influenza hemagglutinin was inhibited from folding and trimerization in the biosynthetic pathway, targeted to endosomal compartments, and rapidly degraded. Due to the interaction with MHC class II molecules, therefore, unfolded forms of hemagglutinin were bypassing the quality control mechanism of the secretory pathway, More important, however, the transport, endocytosis, and rapid degradation of unfolded hemagglutinin in the presence of MHC class II molecules suggest that proteins captured in the endoplasmic reticulum by class II molecules may become substrates for antigen processing and presentation to CD4-positive T cells. In insect cells we show that this phenomenon is not restricted to a few proteins such as hemagglutinin. A highly heterogeneous mixture of proteins from the endoplasmic reticulum including coexpressed hemagglutinin can form stable complexes with soluble HLA DR alpha and beta chains that were transported into the supernatant. This mechanism may gain biological significance in abnormal situations associated with accumulation of unfolded or malfolded proteins in the endoplasmic reticulum, for example during viral infections.	RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, LA JOLLA, CA 92039 USA; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT IMMUNOL, LONDON W12 0NN, ENGLAND	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute; University of California System; University of California San Diego; Imperial College London								ANDERSON MS, 1993, J EXP MED, V178, P1959, DOI 10.1084/jem.178.6.1959; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BIKOFF EK, 1995, IMMUNITY, V2, P301, DOI 10.1016/1074-7613(95)90054-3; BODMER H, 1994, SCIENCE, V263, P1258; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BONNEROT C, 1994, EMBO J, V13, P934, DOI 10.1002/j.1460-2075.1994.tb06338.x; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BUSCH R, 1995, EUR J IMMUNOL, V25, P48, DOI 10.1002/eji.1830250110; Busch R, 1996, EMBO J, V15, P418, DOI 10.1002/j.1460-2075.1996.tb00372.x; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CLAESSONWELSH L, 1985, J IMMUNOL, V135, P3551; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DENG H, 1993, J EXP MED, V187, P1675; DODI AI, 1994, EUR J IMMUNOL, V24, P1632, DOI 10.1002/eji.1830240727; DOMS RW, 1985, J BIOL CHEM, V260, P2973; DONERMEYER DL, 1989, J IMMUNOL, V142, P1063; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GETHING MJ, 1982, NATURE, V300, P598, DOI 10.1038/300598a0; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GORGA JC, 1986, CELL IMMUNOL, V103, P160, DOI 10.1016/0008-8749(86)90077-8; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HELENIUS A, 1987, CHEM SCRIPTA, V27B, P229; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JENSEN PE, 1993, J IMMUNOL, V150, P3347; KITTLESEN DJ, 1993, J EXP MED, V177, P1021, DOI 10.1084/jem.177.4.1021; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEE P, 1988, J IMMUNOL, V140, P1063; Lightstone L, 1997, P NATL ACAD SCI USA, V94, P5772, DOI 10.1073/pnas.94.11.5772; Lindner R, 1996, EMBO J, V15, P6910, DOI 10.1002/j.1460-2075.1996.tb01083.x; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARKS MS, 1995, J BIOL CHEM, V270, P10475, DOI 10.1074/jbc.270.18.10475; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MOURITSEN S, 1992, J IMMUNOL, V149, P1987; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NOWELL J, 1985, J EXP MED, V162, P1371, DOI 10.1084/jem.162.4.1371; PATERA AC, 1995, EUR J IMMUNOL, V25, P1803, DOI 10.1002/eji.1830250702; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; Quaratino S, 1996, J EXP MED, V183, P349, DOI 10.1084/jem.183.2.349; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SCHULZEGAHMEN U, 1988, J BIOL CHEM, V263, P17100; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SETTE A, 1993, J IMMUNOL, V151, P3163; SETTE A, 1989, J IMMUNOL, V143, P1265; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.iy.08.040190.003513; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	74	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29127	29136		10.1074/jbc.272.46.29127	http://dx.doi.org/10.1074/jbc.272.46.29127			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360989	hybrid			2022-12-27	WOS:A1997YF68400048
J	Bin, OY; Pan, HQ; Lu, L; Li, J; Stambrook, P; Li, B; Dai, W				Bin, OY; Pan, HQ; Lu, L; Li, J; Stambrook, P; Li, B; Dai, W			Human prk is a conserved protein serine/threonine kinase involved in regulating M phase functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS CDC25 PHOSPHATASE; DROSOPHILA POLO; CELL-DIVISION; CYCLE; GENE; HOMOLOG; YEAST; PHOSPHORYLATION; LOCALIZATION; INHIBITORS	Human prk encodes a novel protein serine/threonine kinase capable of strongly phosphorylating casein but not histone HL in vitro. prk expression is tightly regulated at various levels during different stages of the cell cycle in lung fibroblasts. The Prk kinase activity is relatively low during mitosis, G(1), and G(1)/S, and peaks during late S and G(2) stages of the cell cycle. Recombinant human Prk expressed through the baculoviral vector system is capable of phosphorylating Cdc25C, a positive regulator for the G(2)/M transition. Human prk shares significant sequence homology with Saccharomyces cerevisiae CDC5 and Drosophila melanogaster polo, both of which are essential for mitosis and meiosis. Full-length prk, transcripts greatly potentiate progesterone-induced meiotic maturation of Xenopus laevis oocytes. Oh the other hand, antisense prk transcripts significantly delay and reduce the rate of oocyte maturation. When expressed in ii CDC5 mutant strain of S. cerevisiae, human Prk, but not a deletional mutant protein, fully rescues the temperature-sensitive phenotype of the budding yeast. Taken together, prk may represent a new protein kinase, playing an important role in regulating the onset and/or progression of mitosis' in mammalian cells.	UNIV CINCINNATI,COLL MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT CELL BIOL,CINCINNATI,OH 45267; WRIGHT STATE UNIV,DEPT PHYSIOL & BIOPHYS,DAYTON,OH 45435	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; Wright State University Dayton					NATIONAL CANCER INSTITUTE [R01CA059985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032483] Funding Source: NIH RePORTER; NCI NIH HHS [CA59985] Funding Source: Medline; NIAID NIH HHS [AI32483] Funding Source: Medline; NIGMS NIH HHS [GM48634] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREASSEN PR, 1992, P NATL ACAD SCI USA, V89, P2272, DOI 10.1073/pnas.89.6.2272; CAPLEN HS, 1988, J BIOL CHEM, V263, P332; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; DONAHUE PJ, 1995, J BIOL CHEM, V270, P10351; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HARTWELL LH, 1973, GENETICS, V74, P267; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IWASAKI T, 1995, INT J CANCER, V63, P282, DOI 10.1002/ijc.2910630223; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; LU L, 1990, J BIOL CHEM, V265, P16190; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SCHWARTS RM, 1979, ATLAS PROTEIN SEQUEN; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281	31	112	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28646	28651		10.1074/jbc.272.45.28646	http://dx.doi.org/10.1074/jbc.272.45.28646			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353331	hybrid			2022-12-27	WOS:A1997YF21900071
J	Dairaghi, DJ; Oldham, ER; Bacon, KB; Schall, TJ				Dairaghi, DJ; Oldham, ER; Bacon, KB; Schall, TJ			Communication - Chemokine receptor CCR3 function is highly dependent on local pH and ionic strength	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; CHEMOATTRACTANT; EOSINOPHILS; EOTAXIN	The CC chemokine receptor 3 (CCR3) plays an important role in the regulation of the migration of eosinophils, a leukocyte population involved in many inflammatory pathologies including asthma. CCR3 binds to the CC chemokine eotaxin, a promigratory cytokine originally isolated as the key component in a model of eosinophil-induced airway inflammation. We show here that eotaxin/CCR3 binding interactions exhibit a marked sensitivity to relatively small changes in the extracellular environment. In particular, modest variations in the pH and the level of sodium chloride over a range of physiologic and near physiologic conditions had dramatic effects on eotaxin binding and CCR3-mediated cytoplasmic Ca2+ mobilization. These biochemical indices were reflected at the functional level as well; small changes in pH and salt also resulted in striking changes in the migration of primary human eosinophils in vitro. These results reveal that relatively small perturbations in extracellular buffer conditions can yield widely disparate interpretations of CCR3 ligand binding and affinities and suggest that modulation of the tissue microenvironment might be utilized to control the affinity and efficacy of chemokine-mediated cell migration.	DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOBIOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.								BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; BANGIA N, 1994, MOL IMMUNOL, V31, P1303, DOI 10.1016/0161-5890(94)90048-5; BOSWORTH N, 1989, NATURE, V341, P167, DOI 10.1038/341167a0; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUTTERFIELD JH, 1994, SAMTERS IMMUNOLOGIC, P501; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GLEICH GJ, 1994, SAMTERS IMMUNOLOGICA, P205; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; KAY AB, 1992, BRIT MED BULL, V48, P51, DOI 10.1093/oxfordjournals.bmb.a072541; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Samson M, 1996, GENOMICS, V36, P522, DOI 10.1006/geno.1996.0498; Williams AJ, 1997, MOL PHARMACOL, V51, P1060, DOI 10.1124/mol.51.6.1060	17	48	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28206	28209		10.1074/jbc.272.45.28206	http://dx.doi.org/10.1074/jbc.272.45.28206			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353270	hybrid			2022-12-27	WOS:A1997YF21900010
J	Elser, B; Kriz, W; Bonventre, JV; Englert, C; Witzgall, R				Elser, B; Kriz, W; Bonventre, JV; Englert, C; Witzgall, R			The Kruppel-associated box (KRAB) zinc finger protein Kid-1 and the Wilms' tumor protein WT1, two transcriptional repressor proteins, bind to heteroduplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; DOMAIN; SUBFAMILY; SEQUENCE; SITES	Zinc finger proteins of the Cys(2)His(2) class represent a large group of DNA-binding proteins. A major subfamily of those proteins, the Kruppel-associated box (KRAB) domain-containing Cys(2)His(2)-zinc finger proteins, have been described as potent transcriptional repressors. So far, however, no DNA-binding sites for KRAB domain-containing zinc finger proteins have been isolated. Using a polymerase chain reaction-based selection strategy with double-and single-stranded DNA, we failed to reveal a binding site for Kid-1, one member of KRAB-zinc finger proteins. Binding of Kid-1 both to single-and homoduplex double-stranded DNA was negligible. We now present evidence that Kid-1 binds to heteroduplex DNA. Similar to Kid-1, the non-KRAB-zinc finger protein WT1 also bound avidly to heteroduplex DNA (both the -KTS and +KTS splice variant of WT1), whereas the POU domain protein Oct-6, the ets domain protein Ets-1 and the RING finger of BRCA-1 did not bind to heteroduplex DNA. Binding of WT1 to heteroduplex DNA was markedly reduced in naturally occurring mutants. The recognition of certain DNA structures by transcriptional repressor proteins may therefore represent a more common phenomenon than previously thought.	UNIV HEIDELBERG,INST ANAT & CELL BIOL 1,D-69120 HEIDELBERG,GERMANY; HARVARD UNIV,SCH MED,DEPT MED,CHARLESTOWN,MA 02129; MASSACHUSETTS GEN HOSP,RENAL UNIT,CHARLESTOWN,MA 02129; FORSCHUNGSZENTRUM KARLSRUHE,INST GENET,D-76021 KARLSRUHE,GERMANY	Ruprecht Karls University Heidelberg; Harvard University; Harvard University; Massachusetts General Hospital; Helmholtz Association; Karlsruhe Institute of Technology				Englert, Christoph/0000-0002-5931-3189; Witzgall, Ralph/0000-0002-5283-4846				Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; PIERROU S, 1995, ANAL BIOCHEM, V229, P99, DOI 10.1006/abio.1995.1384; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; ROSATI M, 1991, NUCLEIC ACIDS RES, V19, P5661, DOI 10.1093/nar/19.20.5661; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WITZGALL R, 1993, MOL CELL BIOL, V13, P1933, DOI 10.1128/MCB.13.3.1933; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	32	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27908	27912		10.1074/jbc.272.44.27908	http://dx.doi.org/10.1074/jbc.272.44.27908			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346939	hybrid			2022-12-27	WOS:A1997YD47300065
J	Melford, SK; Turner, M; Briddon, SJ; Tybulewicz, VLJ; Watson, SP				Melford, SK; Turner, M; Briddon, SJ; Tybulewicz, VLJ; Watson, SP			Syk and Fyn are required by mouse megakaryocytes for the rise in intracellular calcium induced by a collagen-related peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; PROTEIN-TYROSINE KINASES; CELL ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA; HUMAN PLATELETS; SH2 DOMAINS; INDEPENDENT PATHWAYS; CYTOSOLIC CALCIUM; CA2+ MOBILIZATION; IMMUNOGLOBULIN-E	Stimulation of platelets by collagen leads to activation of a tyrosine kinase cascade resulting in secretion and aggregation. We have recently shown that this pathway involves rapid tyrosine phosphorylation of an Fc receptor gamma chain, which contains an immunoreceptor tyrosine-based activation motif(ITAM), enabling interaction with the tandem SH2 domains of the tyrosine kinase Syk. Activation of Syk lies upstream of tyrosine phosphorylation of phospholipase C gamma 2. In the present study we sought to test directly the role of the ITAM/Syk interaction and the role of the Src-related kinases in collagen receptor signaling using mouse megakaryocytes. We demonstrate that the calcium-mobilizing action of a collagen-related peptide (CRP) is kinase-dependent, in hibited by the microinjection of the tandem SH2 domains of Syk and abolished in Syk-deficient mice. Furthermore, the CRP response is abolished by the Src family kinase inhibitor PPI and inhibited in Fyn-deficient mice. In contrast, the calcium response to the G-protein-linked receptor agonist thrombin is not significantly altered under these conditions. These results provide direct evidence of the functional importance of Fyn and Syk in collagen receptor signaling and support the megakaryocyte as a model for the study of proteins involved in this pathway.	UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	University of Oxford; MRC National Institute for Medical Research			Turner, Martin/N-9976-2014; Watson, Stephen P/Q-6292-2016	Turner, Martin/0000-0002-3801-9896; Watson, Stephen P/0000-0002-7846-7423; Briddon, Stephen/0000-0001-8514-0827	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aroca P, 1996, ONCOGENE, V13, P1839; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; BLAKE RA, 1993, BIOCHEM J, V290, P471, DOI 10.1042/bj2900471; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; BRASS LF, 1993, THROMB HAEMOSTASIS, V70, P217; BRETONGORIUS J, 1986, SEMIN HEMATOL, V23, P43; Chen T, 1996, J BIOL CHEM, V271, P25308, DOI 10.1074/jbc.271.41.25308; Costello PS, 1996, ONCOGENE, V13, P2595; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DECKMYN H, 1992, BLOOD, V79, P1466, DOI 10.1182/blood.V79.6.1466.bloodjournal7961466; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; GIBBINS J, 1997, FEBS LETT, V1413, P255; Graessmann A, 1980, Methods Enzymol, V65, P816; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; Ichinohe T, 1997, J BIOL CHEM, V272, P63; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; Jackson SP, 1996, THROMB HAEMOSTASIS, V76, P640; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nishizumi H, 1997, J IMMUNOL, V158, P2350; Northrop JP, 1996, MOL CELL BIOL, V16, P2255; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; POOLE AW, 1995, BRIT J PHARMACOL, V115, P101, DOI 10.1111/j.1476-5381.1995.tb16326.x; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; Tertyshnikova S, 1997, CELL CALCIUM, V21, P331, DOI 10.1016/S0143-4160(97)90026-9; Uneyama C, 1995, EUR J PHARM-MOLEC PH, V291, P381, DOI 10.1016/0922-4106(95)90080-2; WATSON SP, 1989, BIOCHEM J, V258, P479, DOI 10.1042/bj2580479; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471	44	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27539	27542		10.1074/jbc.272.44.27539	http://dx.doi.org/10.1074/jbc.272.44.27539			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346887	hybrid			2022-12-27	WOS:A1997YD47300013
J	Raso, V; Brown, M; McGrath, J; Liu, S; Stafford, WF				Raso, V; Brown, M; McGrath, J; Liu, S; Stafford, WF			Antibodies capable of releasing diphtheria toxin in response to the low pH found in endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; BOUNDARY ANALYSIS; ENTRY; CELLS	Diphtheria toxin (DT) undergoes a rapid conformational change in response to the acidity encountered within endosomes. That transition is integral to the passage of its catalytic domain into the cytosol and thus its lethal action. The importance of this translocation mechanism led us to develop several monoclonal antibodies that bind DT at neutral pH but spontaneously release the toxin when critical epitopes denature or unfold upon lowering the pH to 4.5-5.5. Hybridomas were selected using a microtiter plate assay that measured the pH-dependent detachment of antibody from immobilized toxin. The acid-sensitive epitopes involved were on the catalytic, transmembrane, and receptor binding domains of DT. This pH-induced disruption of the binding of toxin to these monoclonal antibodies was analyzed by sedimentation velocity ultracentrifugation. Antibody combining sites were fully occupied at pH 5.5, partially bound at pH 5.0, and totally empty at pH 4.5. It was estimated that the K-alpha for antibody-toxin binding was similar to 1000-fold lower at pH 5.0 than at neutral pH. This novel acid-triggered release mechanism provides a basis for delivery of antibody-bound toxin into cells accompanied by its immediate dissociation as the complex enters acidic vesicles.			Raso, V (corresponding author), BOSTON BIOMED RES INST, 20 STANIFORD ST, BOSTON, MA 02114 USA.		Stafford, Walter/ABC-6553-2020		NATIONAL CANCER INSTITUTE [R01CA049254, R01CA049856] Funding Source: NIH RePORTER; NCI NIH HHS [CA49856, CA49254] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; Cann J. R., 1970, INTERACTING MACROMOL; CARROLL SF, 1988, METHOD ENZYMOL, V165, P68; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GEISOW MJ, 1984, EXP CELL RES, V150, P29, DOI 10.1016/0014-4827(84)90698-0; GEISOW MJ, 1984, EXP CELL RES, V150, P36, DOI 10.1016/0014-4827(84)90699-2; GIGLIOTTI F, 1984, J INFECT DIS, V149, P43, DOI 10.1093/infdis/149.1.43; HAYAKAWA S, 1983, J BIOL CHEM, V258, P4311; KENNETT RH, 1980, MONOCLONAL ANTIBODIE, P365; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; OVERLY CC, 1995, P NATL ACAD SCI USA, V92, P3156, DOI 10.1073/pnas.92.8.3156; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; Raso V, 1990, Semin Cancer Biol, V1, P227; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; Yphantis D, 1994, MODERN ANAL ULTRACEN, P209; ZUCKER DR, 1984, MOL IMMUNOL, V21, P785, DOI 10.1016/0161-5890(84)90165-2	21	2	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27618	27622		10.1074/jbc.272.44.27618	http://dx.doi.org/10.1074/jbc.272.44.27618			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346899	hybrid			2022-12-27	WOS:A1997YD47300025
J	Takeshita, A; Cardona, GR; Koibuchi, N; Suen, CS; Chin, WW				Takeshita, A; Cardona, GR; Koibuchi, N; Suen, CS; Chin, WW			TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; IDENTIFICATION	Nuclear hormone receptors (NRs) are ligand-dependent transcription factors that regulate target gene transcription, We report the molecular cloning and characterization of a novel human cDNA encoding TRAM-1, a thyroid hormone receptor activator molecule, a similar to 160-kDa protein homologous with SRC-1/TIF2, by far-Western-based expression screening. TRAM-1 binds to thyroid hormone receptor (TR) and other NRs in a ligand-dependent manner and enhances ligand-induced transcriptional activity of TR. The AF-2 region in NRs has been thought to play a critical role in mediating ligand-dependent transactivation by the interaction with coactivators. Surprisingly, TRAM-1 retains strong ligand-dependent interaction with an AF-2 mutant of TR (E457A), while SRC-1 fails to interact with this mutant. Furthermore, we identified a critical TRAM-1 binding site in rat TR beta 1 outside of AF-2, as TRAM-1 shows weak ligand-dependent interaction with a helix 3 ligand binding domain TR mutant (K288A), compared with SRC-1. These results suggest that TRAM-1 is a coactivator that may exhibit its activity by interacting with subdomains of NRs other than the AF-2 region, in contrast to SRC-1/TIF2.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; WYETH AYERST RES,WOMENS HLTH RES INST,RADNOR,PA 19087	Harvard University; Harvard Medical School; Pfizer	Takeshita, A (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV GENET,GW THORN RES BLDG,ROOM 905,20 SHATTUCK ST,BOSTON,MA 02115, USA.			Koibuchi, Noriyuki/0000-0002-2247-9740				BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DOUARIN BL, 1995, EMBO J, V14, P2020; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; ONATE SA, 1995, SCIENCE, V270, P1354; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RON D, 1992, BIOTECHNIQUES, V13, P866; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; TONE Y, 1994, J BIOL CHEM, V269, P31157; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YEN PM, 1992, J BIOL CHEM, V267, P3565; Yen PM, 1996, J BIOL CHEM, V271, P10910, DOI 10.1074/jbc.271.18.10910	22	311	316	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27629	27634		10.1074/jbc.272.44.27629	http://dx.doi.org/10.1074/jbc.272.44.27629			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346901	hybrid			2022-12-27	WOS:A1997YD47300027
J	Lohr, D				Lohr, D			Nucleosome transactions on the promoters of the yeast GAL and PHO genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CYCLIN-CDK COMPLEX; SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; REGULATORY PROTEINS; ACTIVATION DOMAIN; HISTONE H4; IN-VIVO; TRANSCRIPTION; INVIVO; MODEL		ARIZONA STATE UNIV,MOL CELLULAR BIOL PROGRAM,TEMPE,AZ 85287	Arizona State University; Arizona State University-Tempe	Lohr, D (corresponding author), ARIZONA STATE UNIV,DEPT CHEM BIOCHEM,TEMPE,AZ 85287, USA.							ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BARBARIC S, 1992, NUCLEIC ACIDS RES, V20, P1031, DOI 10.1093/nar/20.5.1031; Barbaric S, 1996, NUCLEIC ACIDS RES, V24, P4479, DOI 10.1093/nar/24.22.4479; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; COOK PR, 1995, J CELL SCI, V108, P2927; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; HAGER G, 1995, CHROMATIN STRUCTURE, P89; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; Hartzog GA, 1997, CURR OPIN GENET DEV, V7, P192, DOI 10.1016/S0959-437X(97)80128-1; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; Krude T, 1996, CURR BIOL, V6, P511, DOI 10.1016/S0960-9822(02)00529-8; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LOHR D, 1993, P NATL ACAD SCI USA, V90, P10628, DOI 10.1073/pnas.90.22.10628; LOHR D, 1983, NUCLEIC ACIDS RES, V11, P6755, DOI 10.1093/nar/11.19.6755; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; LOHR D, 1985, NUCLEIC ACIDS RES, V13, P8409, DOI 10.1093/nar/13.23.8409; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; LOHR D, 1995, J BIOL CHEM, V20, P27671; LUSE D, 1995, CHROMATIN STRUCTURE, P104; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; Shao DL, 1996, MOL GEN GENET, V251, P358, DOI 10.1007/BF02172527; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Svaren J, 1996, CURR OPIN GENET DEV, V6, P164, DOI 10.1016/S0959-437X(96)80046-3; SVAREN J, 1995, SEMIN CELL BIOL, V6, P177, DOI 10.1006/scel.1995.0025; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; TRAUB P, 1994, BIOESSAYS, V16, P349, DOI 10.1002/bies.950160510; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; van Holde K.E., 1988, CHROMATIN; VANHOLDE K, 1995, CHROMATIN STRUCTURE, P1; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x	52	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26795	26798		10.1074/jbc.272.43.26795	http://dx.doi.org/10.1074/jbc.272.43.26795			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341105	hybrid			2022-12-27	WOS:A1997YC65900001
J	Raats, CJI; Bakker, MAH; vandenBorn, J; Berden, JHM				Raats, CJI; Bakker, MAH; vandenBorn, J; Berden, JHM			Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE-REDUCTIVE DEPOLYMERIZATION; DOXORUBICIN HYDROCHLORIDE NEPHROSIS; BASEMENT-MEMBRANE; SUPEROXIDE-DISMUTASE; MONOCLONAL-ANTIBODY; HYALURONIC-ACID; ANIONIC SITES; AMINONUCLEOSIDE NEPHROSIS; INCREASED PERMEABILITY; DIABETIC NEPHROPATHY	Heparan sulfate, the polysaccharide side chain of heparan sulfate proteoglycan, is important for the permselective properties of the glomerular basement-membrane, In this report, we show a role for hydroxyl radicals in heparan sulfate degradation and an enhanced glomerular basement membrane permeability, First, in enzyme-linked immunosorbent assay, exposure of coated heparan sulfate (proteoglycan) to reactive oxygen species resulted in a +/-50% decrease of binding of a monoclonal antibody against heparan sulfate, whereas binding of an antibody against the cope protein remained unaltered, Second, on polyacrylamide gel electrophoresis, the molecular weight of heparan sulfate exposed to radicals was reduced which indicates depolymepization. Both in enzyme-linked immunosorbent assay and gel electrophoresis, hydroxyl radicals are instrumental for heparan sulfate degradation as shown by the addition of various radical scavengers, Third, in an experimental model for human nephpotic syndrome (Adriamycin nephropathy in rats), glomerular basement membrane staining of two recently described anti-heparan sulfate antibodies (JM403 and KJ865) was reduced by 24 and 43%, Treatment of Adriamycin-exposed rats with the hydroxyl radical scavenger dimethylthiourea both reduced albuminuria by 37% (p < 0.01) and partly prevented loss of heparan sulfate staining by 53% (JM403) and 39% (KJ865) (p < 0.03) In contrast to the heparan sulfate side chains, the core protein expression and the extent of glycanation did not change in Adriamycin nephropathy, We conclude that glomerular basement membrane heparan sulfate is susceptible to depolymerization hydroxyl radicals leading to loss of glomerular basement membrane integrity and albuminuria.			Raats, CJI (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP, DIV NEPHROL, POB 9101, NL-6500 HB NIJMEGEN, NETHERLANDS.		Berden, J.H.M./H-8009-2014					BARBEY MM, 1989, FREE RADICAL RES COM, V7, P195, DOI 10.3109/10715768909087942; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BERTANI T, 1982, LAB INVEST, V46, P16; BERTOLATUS JA, 1991, J LAB CLIN MED, V118, P435; COTRAN RS, 1983, NEW ENGL J MED, V309, P1050, DOI 10.1056/NEJM198310273091709; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Desassis JF, 1997, NEPHRON, V75, P336, DOI 10.1159/000189558; DIAMOND JR, 1986, KIDNEY INT, V29, P478, DOI 10.1038/ki.1986.24; FARQUHAR MG, 1985, NEPHROLOGY, P580; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; HIEBERT LM, 1990, ATHEROSCLEROSIS, V83, P47, DOI 10.1016/0021-9150(90)90129-7; KANWAR YS, 1980, J CELL BIOL, V86, P688, DOI 10.1083/jcb.86.2.688; KANWAR YS, 1991, SEMIN NEPHROL, V11, P390; KANWAR YS, 1982, J CELL BIOL, V93, P489, DOI 10.1083/jcb.93.2.489; KASHIHARA N, 1992, P NATL ACAD SCI USA, V89, P6309, DOI 10.1073/pnas.89.14.6309; KLEBANOFF SJ, 1993, AM J PATHOL, V143, P907; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LELONGT B, 1987, KIDNEY INT, V31, P1299, DOI 10.1038/ki.1987.143; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LIU ZC, 1994, CARBOHYD RES, V255, P183, DOI 10.1016/S0008-6215(00)90978-9; LYON M, 1990, ANAL BIOCHEM, V185, P63, DOI 10.1016/0003-2697(90)90255-8; METCALFE DD, 1990, BIOCHEM J, V272, P51, DOI 10.1042/bj2720051; MICHELSON AM, 1980, ACTA PHYSIOL SCAND, P67; MILNER LS, 1991, J LAB CLIN MED, V118, P427; MOSELEY R, 1995, BBA-GEN SUBJECTS, V1244, P245, DOI 10.1016/0304-4165(95)00010-9; NAGASAWA K, 1992, CARBOHYD RES, V236, P165, DOI 10.1016/0008-6215(92)85014-Q; NEALE TJ, 1993, P NATL ACAD SCI USA, V90, P3645, DOI 10.1073/pnas.90.8.3645; OKASORA T, 1992, NEPHRON, V60, P199, DOI 10.1159/000186739; PANASYUK A, 1994, FREE RADICAL BIO MED, V16, P157, DOI 10.1016/0891-5849(94)90139-2; PYATAK PS, 1980, RES COMMUN CHEM PATH, V29, P113; RAATS CJI, 1995, J AM SOC NEPHROL, V6, P850; REHAN A, 1984, LAB INVEST, V51, P396; RICARDO SD, 1994, J AM SOC NEPHROL, V4, P1974; ROSENZWEIG LJ, 1982, LAB INVEST, V47, P177; SAARI H, 1993, INFLAMMATION, V17, P403, DOI 10.1007/BF00916581; SATO H, 1988, ARTHRITIS RHEUM, V31, P63, DOI 10.1002/art.1780310110; SCHNEEBERGER EE, 1983, LAB INVEST, V49, P445; SHAH SV, 1989, KIDNEY INT, V35, P1093, DOI 10.1038/ki.1989.96; TAMSMA JT, 1994, DIABETOLOGIA, V37, P313, DOI 10.1007/BF00398060; TAY M, 1990, BIOCHEM INT, V20, P767; THAKUR V, 1988, KIDNEY INT, V34, P494, DOI 10.1038/ki.1988.208; UCHIYAMA H, 1990, J BIOL CHEM, V265, P7753; VANBRUGGEN MCJ, 1995, AM J PATHOL, V146, P753; vanBruggen MCJ, 1997, NEPHROL DIAL TRANSPL, V12, P57, DOI 10.1093/ndt/12.1.57; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; VANDENBORN J, 1993, KIDNEY INT, V43, P454, DOI 10.1038/ki.1993.67; vandenBorn J, 1996, J BIOL CHEM, V271, P22802, DOI 10.1074/jbc.271.37.22802; VANDENBORN J, 1995, DIABETOLOGIA, V38, P1169, DOI 10.1007/BF00422365; VANDENBORN J, 1994, J HISTOCHEM CYTOCHEM, V42, P89, DOI 10.1177/42.1.8263327; VANDENHEUVEL LPWJ, 1989, BIOCHEM J, V264, P457, DOI 10.1042/bj2640457; VOLPI N, 1992, ANAL BIOCHEM, V200, P100, DOI 10.1016/0003-2697(92)90283-D; YOSHIOKA T, 1991, J AM SOC NEPHROL, V2, P902; YURCHENCO PD, 1990, ANN NY ACAD SCI, V580, P195, DOI 10.1111/j.1749-6632.1990.tb17929.x; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	57	100	100	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26734	26741		10.1074/jbc.272.42.26734	http://dx.doi.org/10.1074/jbc.272.42.26734			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334259	hybrid, Green Published			2022-12-27	WOS:A1997YB13900093
J	Dubois, T; Rommel, C; Howell, S; Steinhussen, U; Soneji, Y; Morrice, N; Moelling, R; Aitken, A				Dubois, T; Rommel, C; Howell, S; Steinhussen, U; Soneji, Y; Morrice, N; Moelling, R; Aitken, A			14-3-3 is phosphorylated by casein kinase I on residue 233 - Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; T-CELLS; 14-3-3-PROTEINS ASSOCIATE; TRYPTOPHAN-HYDROXYLASE; SIGNALING PROTEINS; MOLECULAR-CLONING; FAMILY; IDENTIFICATION; EXPRESSION; ISOFORM	14-3-3 proteins mediate interactions between proteins involved in signal transduction and cell cycle regulation, Phosphorylation of target proteins as well as 14-3-3 are important for protein-protein interactions, Here, we describe the purification of a protein kinase from porcine brain that phosphorylates 14-3-3 zeta on Thr-233, This protein kinase has been identified as casein kinase I alpha (CKI alpha) by peptide mapping analysis and sequencing, Among mammalian 14-3-3, only 14-3-3 tau possesses a phosphorylatable residue at the same position (Ser-233), and we show that this residue is also phosphorylated by CKI. In addition, we show that 14-3-3 zeta is exclusively phosphorylated on Thr-233 in human embryonic kidney 293 cells. The residue 233 is located within a region shown to be important for the association of 14-3-3 to target proteins, me showed previously that, in 293 cells, only the unphosphorylated form of 14-3-3 zeta associates with the regulatory domain of c-Raf, me have now shown that in vivo phosphorylation of 14-3-3 zeta at the CKI alpha site (Thr-233) negatively regulates its binding to c-Raf, and may be important in Raf-mediated signal transduction.	UNIV ZURICH, INST MED VIROL, CH-8028 ZURICH, SWITZERLAND; MRC, PROT PHOSPHORYLAT UNIT, DUNDEE DD1 4HN, SCOTLAND	University of Zurich	Dubois, T (corresponding author), NATL INST MED RES, DIV PROT STRUCT, MILL HILL, LONDON NW7 1AA, ENGLAND.		; Dubois, Thierry/D-2852-2017	Soneji, Yasmina/0000-0001-9189-6348; Dubois, Thierry/0000-0003-4739-6164				AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; CELIS A, 1988, FEBS LETT, V227, P14, DOI 10.1016/0014-5793(88)81404-2; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Craparo A, 1997, J BIOL CHEM, V272, P11663; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Dubois T, 1997, J PROTEIN CHEM, V16, P513, DOI 10.1023/A:1026321813463; Estrada E, 1996, J BIOL CHEM, V271, P32064, DOI 10.1074/jbc.271.50.32064; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; GROSS SD, 1995, J CELL BIOL, V130, P711, DOI 10.1083/jcb.130.3.711; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOEKSTRA MF, 1995, J CELL BIOCH SA, V21; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; JONES DHA, 1995, J MOL BIOL, V245, P375, DOI 10.1006/jmbi.1994.0031; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; MEGIDISH T, 1995, BIOCHEM BIOPH RES CO, V216, P739, DOI 10.1006/bbrc.1995.2684; Meller N, 1996, MOL CELL BIOL, V16, P5782; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MILNE DM, 1992, ONCOGENE, V7, P1361; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Pietromonaco SF, 1996, BLOOD CELL MOL DIS, V22, P225, DOI 10.1006/bcmd.1996.0103; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Rommel C, 1996, ONCOGENE, V12, P609; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TUAZON PT, 1991, ADV 2 MESSENGER PHOS, V23, P123; VARELA I, 1988, FEBS LETT, V231, P361, DOI 10.1016/0014-5793(88)80850-0; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang JR, 1996, BIOCHEMISTRY-US, V35, P16319, DOI 10.1021/bi9614444	65	121	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28882	28888		10.1074/jbc.272.46.28882	http://dx.doi.org/10.1074/jbc.272.46.28882			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360956	hybrid			2022-12-27	WOS:A1997YF68400015
J	Emsley, J; King, SL; Bergelson, JM; Liddington, RC				Emsley, J; King, SL; Bergelson, JM; Liddington, RC			Crystal structure of the I domain from integrin alpha 2 beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADHESION; LIGAND-BINDING; A-DOMAIN; LAMININ RECEPTOR; VLA-2; IDENTIFICATION; COLLAGEN; SITE; CD11B/CD18; PLATELETS	We have determined the high resolution crystal structure of the I domain from the alpha-subunit of the integrin alpha 2 beta 1, a cell surface adhesion receptor for collagen and the human pathogen echovirus-1. The domain, as expected, adopts the dinucleotide-binding fold, and contains a metal ion-dependent adhesion site motif with bound Mg2+ at the top of the beta-sheet. Comparison with the crystal structures of the leukocyte integrin I domains reveals a new helix (the C-helix) protruding from the metal ion-dependent adhesion site face of the domain which creates a groove centered on the magnesium ion. Modeling of a collagen triple helix into the groove suggests that a glutamic acid side chain from collagen can coordinate the metal ion, and that the C-helix insert is a major determinant of binding specificity. The binding site for echovirus-1 maps to a distinct surface of the alpha 2-I domain (one edge of the beta-sheet), consistent with data showing that virus and collagen binding occur by different mechanisms. Comparison with the homologous von Willebrand factor A3 domain, which also binds collagen, suggests that the two domains bind collagen in different ways.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND; DANA FARBER CANC INST,DIV INFECT DIS,BOSTON,MA 02115	University of Leicester; Harvard University; Dana-Farber Cancer Institute			emsley, jonas/A-8509-2016	emsley, jonas/0000-0002-8949-8030				BAHOU WF, 1994, BLOOD, V84, P3734, DOI 10.1182/blood.V84.11.3734.bloodjournal84113734; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CHAMPE M, 1995, J BIOL CHEM, V270, P1388, DOI 10.1074/jbc.270.3.1388; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1994, J BIOL CHEM, V269, P22811; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; MAY ACW, 1994, PROTEIN ENG, V7, P475, DOI 10.1093/protein/7.4.475; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Nicholls A., 1992, GRASP GRAPHICAL REPR; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rieu P, 1996, J BIOL CHEM, V271, P15858, DOI 10.1074/jbc.271.27.15858; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tuckwell D, 1996, SEMIN CELL DEV BIOL, V7, P649, DOI 10.1006/scdb.1996.0079	27	247	259	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28512	28517		10.1074/jbc.272.45.28512	http://dx.doi.org/10.1074/jbc.272.45.28512			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353312	hybrid			2022-12-27	WOS:A1997YF21900052
J	Gabrielli, BG; Clark, JM; McCormack, AK; Ellem, KAO				Gabrielli, BG; Clark, JM; McCormack, AK; Ellem, KAO			Hyperphosphorylation of the N-terminal domain of Cdc25 regulates activity toward cyclin B1/Cdc2 but not cyclin A/Cdk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; CYTOPLASMIC ACCUMULATION; DEPENDENT KINASES; PROTEIN-KINASE; HELA-CELLS; ACTIVATION; PHOSPHORYLATION; PHOSPHATASE; MITOSIS; P34(CDC2)	Cdc25 regulates entry into mitosis by regulating the activation of cyclin B/cdc2. In humans, at least two cdc25 isoforms have roles in controlling the G(2)/M transition. Here we show, using bacterially expressed recombinant proteins, that two cdc25B splice variants, cdc25B2 and cdc25B3, are capable of activating cyclin A/cdk2 and cyclin B/cdc2, but that mitotic hyperphosphorylation of these proteins increases their activity toward only cyclin B1/cdc2, Cdc25C has only very low activity in its unphosphorylated form, add following hyperphosphorylation it will efficiently catalyze the activation of only cyclin B/cdc2, This was reflected by the in vivo activity of the immunoprecipitated cdc25B and cdc25C from interphase and mitotic HeLa cells. The increased activity of the hyperphosphorylated cdc25s toward cyclin B1/cdc2 was in large part due to increased binding of this substrate. The substrate specificity, activities; and timing of the hyperphosphorylation of cdc25B and cdc25C during G(2) and M suggest that these two mitotic cdc25 isoforms are activated by different kinases and perform different functions during progression through G(2) into mitosis.	UNIV QUEENSLAND,ROYAL BRISBANE HOSP,JOINT ONCOL PROGRAM,HERSTON,QLD 4029,AUSTRALIA	Royal Brisbane & Women's Hospital; University of Queensland	Gabrielli, BG (corresponding author), UNIV QUEENSLAND,ROYAL BRISBANE HOSP,HYDRO QUEBEC RES INST,QUEENSLAND CANC FUND,RES LABS,HERSTON,QLD 4029,AUSTRALIA.		Gabrielli, Brian G/B-3655-2011	Gabrielli, Brian G/0000-0003-3933-1651				ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BAILLY E, 1992, J CELL SCI, V101, P529; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kovelman R, 1996, MOL CELL BIOL, V16, P86; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; OGG S, 1994, J BIOL CHEM, V269, P30461; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SEKI T, 1992, MOL BIOL CELL, V3, P1373, DOI 10.1091/mbc.3.12.1373; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; VILLAMORUZZI E, 1993, BIOCHEM BIOPH RES CO, V196, P1248, DOI 10.1006/bbrc.1993.2386; Xu X, 1996, J BIOL CHEM, V271, P5118; ZHENG XF, 1993, CELL, V75, P155, DOI 10.1016/S0092-8674(05)80092-3	26	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28607	28614		10.1074/jbc.272.45.28607	http://dx.doi.org/10.1074/jbc.272.45.28607			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353326	hybrid			2022-12-27	WOS:A1997YF21900066
J	He, CZ; Burch, JBE				He, CZ; Burch, JBE			The chicken GATA-6 locus contains multiple control regions that confer distinct patterns of heart region-specific expression in transgenic mouse embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SKELETAL-MUSCLE; GENE-EXPRESSION; HOMEOBOX GENES; MESODERM; IDENTIFICATION; EMBRYOGENESIS; MORPHOGENESIS; GATA-4/5/6; CHROMATIN	The GATA-6 transcription factor is expressed in cardiogenic cells and during subsequent stages of heart development in diverse vertebrate species. To gain insights into the molecular events that govern this heart-restricted expression, we isolated the chicken GATA-6 gene and used several approaches to screen for associated control regions. Our analysis of two chicken GATA-6/lacZ constructs in transgenic mouse embryos was particularly revealing. One GATA-6/lacZ construct, which has 1.5 kilobase pairs of upstream sequences along with the promoter and first intron, was expressed exclusively in the atrioventricular canal region of the heart. This expression pattern is novel and appears to mark specialized myocardial cells that induce underlying endocardial cells to initiate valve formation. The other GATA-6/ lacZ construct, which has an additional 7.7 kilobase pairs of upstream sequences, was expressed in the ventricle and outflow tract in addition to the atrioventricular canal. The failure of these GATA-6 control regions to function as enhancers in transfected cardiac myocyte cultures underscores the importance of using transgenic approaches to elucidate transcriptional controls that function in the developing heart. Although the endogenous GATA-6 gene is expressed throughout the heart, our results indicate that this is effected in a heart region-specific manner.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA-06927] Funding Source: Medline; NHLBI NIH HHS [HL55373] Funding Source: Medline; NIGMS NIH HHS [GM35535] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035535] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; CHANTHOMAS PS, 1993, DEV DYNAM, V197, P203, DOI 10.1002/aja.1001970305; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; Davis DL, 1996, ANTISENSE NUCLEIC A, V6, P259, DOI 10.1089/oli.1.1996.6.259; DEHAAN RL, 1967, DEV BIOL, V16, P216, DOI 10.1016/0012-1606(67)90025-5; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GRIESHAMMER U, 1995, DEVELOPMENT, V121, P2245; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HOGAN B, 1994, MANIPULATING MOUSE E, P373; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HUANG JX, 1995, ANN NY ACAD SCI, V752, P317, DOI 10.1111/j.1749-6632.1995.tb17441.x; Jiang YM, 1996, DEV BIOL, V174, P258, DOI 10.1006/dbio.1996.0071; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; KELLEY C, 1993, DEVELOPMENT, V118, P817; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; KILEDJIAN M, 1990, NUCLEIC ACIDS RES, V18, P957, DOI 10.1093/nar/18.4.957; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kuisk IR, 1996, DEV BIOL, V174, P1, DOI 10.1006/dbio.1996.0046; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LITVIN J, 1993, DEV BIOL, V156, P409, DOI 10.1006/dbio.1993.1088; Lough J, 1996, DEV BIOL, V178, P198, DOI 10.1006/dbio.1996.0211; Lyons GE, 1996, CURR OPIN GENET DEV, V6, P454, DOI 10.1016/S0959-437X(96)80067-0; MacNeill C, 1997, J BIOL CHEM, V272, P8396, DOI 10.1074/jbc.272.13.8396; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Ross RS, 1996, DEVELOPMENT, V122, P1799; Sambrook J., 2002, MOL CLONING LAB MANU; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STERN CD, 1993, ESSENTIAL DEV BIOL P, P195; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; TRIEZENBERG SJ, 1992, CURRENT PROTOCOLS MO; Wang GF, 1996, J BIOL CHEM, V271, P19836, DOI 10.1074/jbc.271.33.19836; Wei Y, 1996, DEVELOPMENT, V122, P2779; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Zhang HB, 1996, DEVELOPMENT, V122, P2977; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276	51	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28550	28556		10.1074/jbc.272.45.28550	http://dx.doi.org/10.1074/jbc.272.45.28550			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353318	hybrid			2022-12-27	WOS:A1997YF21900058
J	Murphy, MEP; Turley, S; Adman, ET				Murphy, MEP; Turley, S; Adman, ET			Structure of nitrite bound to copper-containing nitrite reductase from Alcaligenes faecalis - Mechanistic implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; X-RAY STRUCTURE; ACHROMOBACTER-CYCLOCLASTES; DISSIMILATORY NITRITE; CRYSTAL-STRUCTURES; PROTEIN STRUCTURES; SUBSTRATE ADDUCT; STRAIN S-6; SITE; CENTERS	The structures of oxidized, reduced, nitrite-soaked oxidized and nitrite-soaked reduced nitrite reductase from Alcaligenes faecalis have been determined at 1.8-2.0 Angstrom resolution using data collected at -160 degrees C. The active site at cryogenic temperature, as at room temperature, contains a tetrahedral type II copper site liganded by three histidines and a water molecule. The solvent site is empty when crystals are reduced with ascorbate. A fully occupied oxygen-coordinate nitrite occupies the solvent site in crystals soaked in nitrite. Ascorbate-reduced crystals soaked in a glycerol-methanol solution and nitrite at -40 degrees C remain colorless at -160 degrees C but turn amber-brown when warmed, suggesting that NO is released. Nitrite is found at one-half occupancy. Five new solvent sites in the oxidized nitrite bound form exhibit defined but different occupancies in the other three forms. These results support a previously proposed mechanism by which nitrite is bound primarily by a single oxygen atom that is protonable, and after reduction and cleavage of that N-O bond, NO is released leaving the oxygen atom bound to the Cu site as hydroxide or water.	UNIV WASHINGTON,SCH MED,DEPT BIOL STRUCT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Murphy, Michael/R-6805-2017	Murphy, Michael/0000-0003-2589-0014	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031770] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31770] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM ZHL, 1993, BIOCHEM J, V295, P587, DOI 10.1042/bj2950587; ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; ARGOS P, 1978, J MOL BIOL, V126, P141, DOI 10.1016/0022-2836(78)90356-X; ARNEZ JG, 1994, J APPL CRYSTALLOGR, V27, P649, DOI 10.1107/S0021889894001858; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, XPLOR VERSION 3 1; COYNE MS, 1989, APPL ENVIRON MICROB, V55, P2924, DOI 10.1128/AEM.55.11.2924-2931.1989; Dodd FE, 1997, ACTA CRYSTALLOGR D, V53, P406, DOI 10.1107/S0907444997002667; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; GOMISRUTH FX, 1994, J BIOL CHEM, V269, P17111; Halfen JA, 1996, J AM CHEM SOC, V118, P763, DOI 10.1021/ja952691i; HALFEN JA, 1994, J AM CHEM SOC, V116, P5475, DOI 10.1021/ja00091a064; HIGASHI T, 1990, J APPL CRYSTALLOGR, V23, P253, DOI 10.1107/S0021889890002461; HOWES BD, 1994, BIOCHEMISTRY-US, V33, P3171, DOI 10.1021/bi00177a005; HULSE CL, 1989, J AM CHEM SOC, V111, P2322, DOI 10.1021/ja00188a067; JACKSON MA, 1991, FEBS LETT, V291, P41, DOI 10.1016/0014-5793(91)81099-T; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; KAKUTANI T, 1981, J BIOCHEM, V89, P453, DOI 10.1093/oxfordjournals.jbchem.a133220; KIM CH, 1984, J BIOL CHEM, V259, P2092; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LIBBY E, 1992, BIOCHEM BIOPH RES CO, V187, P1529, DOI 10.1016/0006-291X(92)90476-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURPHY MEP, 1995, BIOCHEMISTRY-US, V34, P12107, DOI 10.1021/bi00038a003; Murphy MEP, 1997, PROTEIN SCI, V6, P761; NISHIYAMA M, 1993, J GEN MICROBIOL, V139, P725, DOI 10.1099/00221287-139-4-725; OTWINOWSKI Z, 1993, P CCP4 STUDY WEEKEND, P87; PETERSLIBEU CA, 1997, IN PRESS BIOCHEMISTR; Stibrany RT, 1996, INORG CHIM ACTA, V243, P33, DOI 10.1016/0020-1693(95)04889-8; STRANGE RW, 1995, NAT STRUCT BIOL, V2, P287, DOI 10.1038/nsb0495-287; SUZUKI S, 1994, J AM CHEM SOC, V116, P11145, DOI 10.1021/ja00103a035; TOLMAN WB, 1991, INORG CHEM, V30, P4877, DOI 10.1021/ic00026a005; Tolman WB, 1993, BIOINORGANIC CHEM CO, P406; TURLEY S, 1988, J MOL BIOL, V200, P417, DOI 10.1016/0022-2836(88)90251-3; 1994, ACTA CRYSTALLOGR, V50, P760	40	182	184	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28455	28460		10.1074/jbc.272.45.28455	http://dx.doi.org/10.1074/jbc.272.45.28455			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353305	hybrid			2022-12-27	WOS:A1997YF21900045
J	Venema, VJ; Ju, H; Zou, R; Venema, RC				Venema, VJ; Ju, H; Zou, R; Venema, RC			Communication - Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle - Identification of a novel caveolin scaffolding/inhibitory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PROTEIN; CELLS; ENZYME; LOCALIZATION; DYSTROPHIN; SARCOLEMMA; INHIBITION; ISOFORMS	Neuronal nitric-oxide synthase (nNOS) has been shown previously to interact with alpha(1)-syntrophin in the dystrophin complex of skeletal muscle. In the present study, we have examined whether nNOS also interacts with caveolin-3 in skeletal muscle. nNOS and caveolin-3 are coimmunoprecipitated from rat skeletal muscle homogenates by antibodies directed against either of the two proteins. Synthetic peptides corresponding to the membrane-proximal caveolin-3 residues 65-84 and 109-130 and homologous caveolin-1 residues 82-101 and 135-156 potently inhibit the catalytic activity of purified, recombinant nNOS. Purified nNOS also binds to a glutathione S-transferase-caveolin-1 fusion protein in in vitro binding assays. In vitro binding is completely abolished by preincubation of nNOS with either of the two caveolin-3 inhibitory peptides. Interactions between nNOS and caveolin-3, therefore, appear to be direct and to involve two distinct caveolin scaffolding/inhibitory domains. Other caveolin-interacting enzymes, including endothelial nitric-oxide synthase and the c-Src tyrosine kinase, are also potently inhibited by each of the four caveolin peptides. Inhibitory interactions mediated by two different caveolin domains may thus be a general feature of enzyme docking to caveolin proteins in plasmalemmal caveolae.	MED COLL GEORGIA, VASC BIOL CTR, AUGUSTA, GA 30912 USA; MED COLL GEORGIA, DEPT PEDIAT, AUGUSTA, GA 30912 USA; MED COLL GEORGIA, DEPT PHARMACOL & TOXICOL, AUGUSTA, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057201, R01HL057201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57201] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bredt DS, 1996, P SOC EXP BIOL MED, V211, P41; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; VENEMA RC, 1993, J BIOL CHEM, V268, P2705; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; Venema VJ, 1996, BIOCHEM BIOPH RES CO, V226, P703, DOI 10.1006/bbrc.1996.1417	27	213	215	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28187	28190		10.1074/jbc.272.45.28187	http://dx.doi.org/10.1074/jbc.272.45.28187			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353265	hybrid			2022-12-27	WOS:A1997YF21900005
J	Vito, P; Ghayur, T; DAdamio, L				Vito, P; Ghayur, T; DAdamio, L			Generation of anti-apoptotic presenilin-2 polypeptides by alternative transcription, proteolysis, and caspase-3 cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; T-CELL HYBRIDOMAS; MISSENSE MUTATIONS; ICE/CED-3 PROTEASE; DEATH; ACTIVATION; GENE; APOPAIN/CPP32; REQUIREMENT; ALG-3	PS2, the chromosome 1 familial Alzheimer's disease gene, has been shown to be involved in programmed cell death by three complementary experimental approaches, Reduction of PS2 protein levels by antisense RNA protects from apoptosis, whereas overexpression of an Alzheimer's PS2 mutant increases cell death induced by several stimuli, In addition, ALG-3, a truncated PS2 cDNA, encodes an artificial COOH-terminal PS2 segment that dominantly inhibits apoptosis, Here we describe a physiological COOH-terminal PS2 polypeptide (PS2s, Met(298)-Ile(448)) generated by both an alternative PS2 transcript and proteolytic cleavage, We find that PS2s protects transfected cells from Fas-and tumor necrosis factor alpha (TNF alpha)-induced apoptosis, Furthermore, a similar anti-apoptotic COOH-terminal PS2 polypeptide (PS2Ccas) is generated by caspase-3 cleavage at Asp(329). These results suggest that caspase-3 not only activates pro-apoptotic substrates but also generates a negative feedback signal in which PS2Ccas antagonizes the progression of cell death. Thus, whereas PS2 is required for apoptosis, PS2s and PS2Ccas oppose this process, and the balance between PS2 and these COOH-terminal fragments may dictate the cell fate.	NIAID, T CELL MOL BIOL UNIT, CELLULAR & MOL IMMUNOL LAB, NIH, BETHESDA, MD 20892 USA; 3 BASF RES CORP, WORCESTER, MA 01605 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); BASF			vito, pasquale/ABF-5505-2020	vito, pasquale/0000-0002-5721-7716; D'Adamio, Luciano/0000-0002-2204-9441; D'Adamio, Luciano/0000-0002-9820-4882				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lacana E, 1997, J IMMUNOL, V158, P5129; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHI YF, 1990, J IMMUNOL, V144, P3326; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710	33	104	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28315	28320		10.1074/jbc.272.45.28315	http://dx.doi.org/10.1074/jbc.272.45.28315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353287	hybrid			2022-12-27	WOS:A1997YF21900027
J	Yu, R; Hinkle, PM				Yu, R; Hinkle, PM			Desensitization of thyrotropin-releasing hormone receptor-mediated responses involves multiple steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE FORMATION; PITUITARY-TUMOR CELLS; PROTEIN-KINASE-C; PHOSPHOINOSITIDE HYDROLYSIS; GENE-TRANSFER; GH4C1 CELLS; CALCIUM; MECHANISM; TRH; PHOSPHODIESTERASE	Desensitization and recovery of the inositol 1,4,5-trisphosphate (IP3) and intracellular free calcium concentration ([Ca2+](i)) responses to thyrotropin-releasing hormone (TRH) were measured in HEK298 cells stably expressing the G protein coupled TRH receptor, TRH caused a large, rapid, and transient increase in IP3 and a biphasic increase in [Ca2+](i). Desensitization of the TRH response was measured by exposing cells to TRH, washing, and then incubating the cells in hormone-free medium before reintroducing TRH and measuring IP3, [Ca2+](i), and intracellular Ca2+ pool size, When cells were incubated with 1 mu M TRH for 10 s or 10 min and reexposed to TRH, there was almost no IP3, or [Ca2+](i) increase, The IP3, response recovered first, followed by the [Ca2+](i) response, The ionomycin-releasable intracellular Ca2+ pool was almost completely depleted by TRH, and pool refilling was slow, Thrombin, endothelin, and carbachol, when combined, stimulated large increases in IP3 and [Ca2+](i), but did not block the IP3 or [Ca2+](i) responses to TRH measured 10 min later. In contrast, cells exposed to TRH first responded to combined agonists with a nearly normal increase in IP3, but no rise in [Ca2+](i), Thus, the IP3 response to TRH displays homologous desensitization, whereas the [Ca2+](i) response displays heterologous desensitization because depletion of intracellular Ca2+ pools prevents responses to other hormones.	UNIV ROCHESTER, SCH MED & DENT, DEPT PHYSIOL & PHARMACOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, CTR CANC, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester					NCI NIH HHS [CA11198] Funding Source: Medline; NIDDK NIH HHS [DK19974] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019974] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERMAN SN, 1991, ENDOCRINOLOGY, V129, P475, DOI 10.1210/endo-129-1-475; ANDERSON L, 1995, BIOCHEM J, V311, P385, DOI 10.1042/bj3110385; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Bohm SK, 1997, BIOCHEM J, V322, P1; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; DRUMMOND AH, 1986, J EXP BIOL, V124, P337; DRUMMOND AH, 1984, MOL PHARMACOL, V25, P201; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; FISHER SK, 1995, EUR J PHARM-MOLEC PH, V288, P231, DOI 10.1016/0922-4106(95)90035-7; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GERSHENGORN MC, 1994, J BIOL CHEM, V269, P6779; HINKLE PM, 1982, J BIOL CHEM, V257, P5462; Hinkle PM, 1996, TRENDS ENDOCRIN MET, V7, P370, DOI 10.1016/S1043-2760(96)00188-9; IMAI A, 1985, J BIOL CHEM, V260, P536; KOSHIYAMA H, 1991, BIOCHEM BIOPH RES CO, V177, P551, DOI 10.1016/0006-291X(91)92019-G; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MARTIN TFJ, 1986, J BIOL CHEM, V261, P2918; NELSON EJ, 1994, ENDOCRINOLOGY, V135, P1084, DOI 10.1210/en.135.3.1084; NELSON EJ, 1994, J BIOL CHEM, V269, P30854; PARKER I, 1995, CIBA F SYMP, V188, P50; PERLMAN JH, 1991, ENDOCRINOLOGY, V129, P2679, DOI 10.1210/endo-129-5-2679; RAMSDELL JS, 1986, J BIOL CHEM, V261, P5301; REBECCHI MJ, 1983, BIOCHEM J, V216, P287, DOI 10.1042/bj2160287; Shupnik MA, 1996, MOL ENDOCRINOL, V10, P90, DOI 10.1210/me.10.1.90; TASHJIAN AH, 1987, BIOCHEM J, V243, P305, DOI 10.1042/bj2430305; TORJESEN PA, 1988, MOL CELL ENDOCRINOL, V56, P107, DOI 10.1016/0303-7207(88)90014-7; VILLALOBOS C, 1995, PFLUG ARCH EUR J PHY, V430, P923, DOI 10.1007/BF01837406; WAGNER KA, 1993, BIOCHEM J, V292, P175, DOI 10.1042/bj2920175; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3	32	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28301	28307		10.1074/jbc.272.45.28301	http://dx.doi.org/10.1074/jbc.272.45.28301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353285	hybrid			2022-12-27	WOS:A1997YF21900025
J	Howard, KM; Miller, JE; Miwa, M; Olson, MS				Howard, KM; Miller, JE; Miwa, M; Olson, MS			Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT KUPFFER CELLS; TUMOR-NECROSIS-FACTOR; ACETYLGLYCERYL ETHER PHOSPHORYLCHOLINE; AGGREGATED IMMUNOGLOBULIN-G; FACTOR PAF ACETYLHYDROLASE; SIGNAL-TRANSDUCTION; INTESTINAL ISCHEMIA; CALCIUM IONOPHORE; PURIFICATION; LIPOPOLYSACCHARIDE	Platelet-activating factor (PAF) is a potent proinflammatory phospholipid mediator that causes hypotension, increases vascular permeability, and has been implicated in anaphylaxis, septic shock and several other inflammatory responses. PAF is hydrolyzed and inactivated by the enzyme PAF-acetylhydrolase. In the intact rat, a mesenteric vein infusion of lipopolysaccharide (LPS) served as an acute, liver-focused model of endotoxemia, Plasma PAF-acetylhydrolase activity increased 2-fold by 24 h following LPS administration. Ribonuclease protection experiments demonstrated very low levels of plasma-type PAF-acetylhydrolase mRNA transcripts in the livers of saline-infused rats; however, 24 h following LPS exposure, a 20-fold induction of PAF-acetylhydrolase mRNA was detected. In cells isolated from endotoxin-exposed rat Livers, Northern blot analyses demonstrated that Kupffer cells but not hepatocytes or endothelial cells were responsible for the increased PAF-acetylhydrolase mRNA levels, In Kupffer cells, plasma-type PAF-acetylhydrolase mRNA was induced by 12 h, peaked at 24 h, and remained substantially elevated at 48 h, Induction of neutropenia prior to LPS administration had no effect on the increase in PAF-acetylhydrolase mRNA seen at 24 h. Although freshly isolated Kupffer cells contain barely detectable levels of plasma-type PAF-acetylhydrolase mRNA when Kupffer cells were established in culture, PAF-acetylhydrolase expression became constitutively activated concomitant with cell adherence to the culture plates, Alterations in plasma-type PAF-acetylhydrolase expression may constitute an important mechanism for elevating plasma PAF-acetylhydrolase levels and an important component in minimizing PAF-mediated pathophysiology in livers exposed to endotoxemia.	UNIV TEXAS, HLTH SCI CTR, DEPT SURG, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Howard, KM (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033538] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33538] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTTERY LDK, 1994, LAB INVEST, V71, P755; BUXTON DB, 1984, J BIOL CHEM, V259, P3758; BUXTON DB, 1984, J BIOL CHEM, V259, P1468; BUXTON DB, 1986, J BIOL CHEM, V261, P644; BUXTON DB, 1987, BIOCHEM J, V243, P493, DOI 10.1042/bj2430493; CAPLAN MS, 1990, J PEDIATR-US, V116, P960, DOI 10.1016/S0022-3476(05)80661-4; CAPLAN MS, 1990, AM REV RESPIR DIS, V142, P1258, DOI 10.1164/ajrccm/142.6_Pt_1.1258; CHAO W, 1989, BIOCHEM J, V261, P77, DOI 10.1042/bj2610077; CHAO W, 1989, J BIOL CHEM, V264, P13591; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHAO W, 1989, BIOCHEM J, V257, P823, DOI 10.1042/bj2570823; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENDO S, 1994, RES COMMUN CHEM PATH, V83, P289; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURUKAWA M, 1993, PEDIATR RES, V34, P237, DOI 10.1203/00006450-199308000-00027; GANDHI CR, 1992, BIOCHEM J, V281, P485, DOI 10.1042/bj2810485; GATHIRAM P, 1989, CIRC SHOCK, V27, P103; GRAHAM RM, 1994, CRIT CARE MED, V22, P204, DOI 10.1097/00003246-199402000-00009; GRUN M, 1977, ACTA HEPATO-GASTRO, V24, P64; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; KARASAWA K, 1994, J BIOCHEM-TOKYO, V116, P374, DOI 10.1093/oxfordjournals.jbchem.a124534; KNOOK DL, 1976, EXP CELL RES, V99, P444, DOI 10.1016/0014-4827(76)90605-4; KORTH R, 1993, LIPIDS, V28, P193, DOI 10.1007/BF02536639; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; LEMANSKE RF, 1983, J IMMUNOL, V130, P2837; MEADE CJ, 1994, J LIPID MEDIAT CELL, V9, P205; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; MOCHIDA S, 1992, J HEPATOL, V16, P266, DOI 10.1016/S0168-8278(05)80656-7; Mustafa SB, 1996, HEPATOLOGY, V23, P1622, DOI 10.1053/jhep.1996.v23.pm0008675186; NARAHARA H, 1993, ARCH BIOCHEM BIOPHYS, V301, P275, DOI 10.1006/abbi.1993.1144; NIJSSEN JG, 1986, BIOCHIM BIOPHYS ACTA, V876, P611, DOI 10.1016/0005-2760(86)90050-0; OLOFSSON P, 1985, ACTA CHIR SCAND, V151, P635; OLSON MS, 1996, LIVER INNERVATION, P75; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; SATOH K, 1991, J CLIN INVEST, V87, P476, DOI 10.1172/JCI115020; SATOH K, 1989, PROSTAGLANDINS, V37, P673; SATOH K, 1993, METABOLISM, V42, P672, DOI 10.1016/0026-0495(93)90231-C; SHENG ZY, 1992, J TRAUMA, V32, P148, DOI 10.1097/00005373-199202000-00006; SHUKLA SD, 1983, J BIOL CHEM, V258, P212; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1993, J BIOL CHEM, V268, P3857; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; Svetlov SI, 1996, ARCH BIOCHEM BIOPHYS, V327, P113, DOI 10.1006/abbi.1996.0099; TAFFET SM, 1989, CELL IMMUNOL, V120, P291, DOI 10.1016/0008-8749(89)90198-6; TARBET EB, 1991, J BIOL CHEM, V266, P16667; TETTA C, 1990, INT ARCH ALLER A IMM, V91, P244, DOI 10.1159/000235124; Tew DG, 1996, ARTERIOSCL THROM VAS, V16, P591, DOI 10.1161/01.ATV.16.4.591; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Tsukioka Kazuharu, 1993, Japanese Journal of Allergology, V42, P167; YU SF, 1990, J LEUKOCYTE BIOL, V48, P412, DOI 10.1002/jlb.48.5.412; ZHOU WG, 1992, HEPATOLOGY, V16, P1236; ZHOU WG, 1992, AM J PHYSIOL, V263, pG587, DOI 10.1152/ajpgi.1992.263.5.G587	58	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27543	27548		10.1074/jbc.272.44.27543	http://dx.doi.org/10.1074/jbc.272.44.27543			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346888	hybrid			2022-12-27	WOS:A1997YD47300014
J	Masui, R; Mikawa, T; Kuramitsu, S				Masui, R; Mikawa, T; Kuramitsu, S			Local folding of the N-terminal domain of Escherichia coli RecA controls protein-protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; AMINO-ACID-RESIDUES; BINDING; COMPLEXES; RECOMBINATION; ASSOCIATION; GENE; L2	To obtain structural information about the self-association of the protein RecA, we studied urea denaturation of RecA by circular dichroism spectroscopy and gelfiltration. Gel filtration analysis showed that urea at low concentrations, 1.0-1.2 M, dissociated the RecA oligomer to almost a monomeric state prior to the unfolding of each molecule, Upon treatment with 1.0 M urea, the circular dichroism spectrum showed a decrease in the a-helical content of RecA, A similar decrease was observed in the absence of urea for RecA at an extremely low protein concentration; the RecA oligomer dissociated to an almost completely monomeric state, The properties of RecA at low urea concentrations were similar to those of a truncated RecA lacking the first 33 N-terminal residues (Delta 33RecA). Addition of a synthetic peptide corresponding to the 33 N-terminal residues to Delta 33RecA increased the alpha-helical content, These results suggest that local folding of the N-terminal domain is coupled to protein-protein interactions of monomeric RecA, which are involved in the regulation of filament formation, The dissociation constant for interaction between RecA monomers was determined from the ellipticity data to be 0.1 mu M.	OSAKA UNIV,GRAD SCH SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN	Osaka University			Mikawa, Tsutomu/E-6510-2013	Mikawa, Tsutomu/0000-0003-2325-5084				BRENNER SL, 1990, J MOL BIOL, V216, P949, DOI 10.1016/S0022-2836(99)80013-8; BRENNER SL, 1988, J MOL BIOL, V204, P959, DOI 10.1016/0022-2836(88)90055-1; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; HORII T, 1980, P NATL ACAD SCI-BIOL, V77, P313, DOI 10.1073/pnas.77.1.313; KURAMITSU S, 1984, BIOCHEMISTRY-US, V23, P2363, DOI 10.1021/bi00306a006; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; Maraboeuf F, 1995, J BIOL CHEM, V270, P30927, DOI 10.1074/jbc.270.52.30927; MIKAWA T, 1995, J MOL BIOL, V250, P471, DOI 10.1006/jmbi.1995.0391; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SANCAR A, 1980, P NATL ACAD SCI-BIOL, V77, P2611, DOI 10.1073/pnas.77.5.2611; STASIAK A, 1994, EXPERIENTIA, V50, P192, DOI 10.1007/BF01924002; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Voloshin ON, 1996, SCIENCE, V272, P868, DOI 10.1126/science.272.5263.868; Wang Y, 1996, BIOCHEMISTRY-US, V35, P3563, DOI 10.1021/bi952438v; WATANABE R, 1994, J BIOCHEM-TOKYO, V116, P960, DOI 10.1093/oxfordjournals.jbchem.a124653; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9; Yu X, 1995, BIOPHYS J, V69, P2728, DOI 10.1016/S0006-3495(95)80144-X; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101; ZLOTNICK A, 1988, J MOL BIOL, V209, P447	23	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27707	27715		10.1074/jbc.272.44.27707	http://dx.doi.org/10.1074/jbc.272.44.27707			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346912	hybrid			2022-12-27	WOS:A1997YD47300038
J	Salazar, D; Zhang, LN; deGala, GD; Frerman, FE				Salazar, D; Zhang, LN; deGala, GD; Frerman, FE			Expression and characterization of two pathogenic mutations in human electron transfer flavoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA DEHYDROGENASE; ACIDEMIA TYPE-II; PIG-LIVER; UBIQUINONE OXIDOREDUCTASE; PEPTOSTREPTOCOCCUS-ELSDENII; CIRCULAR-DICHROISM; REDUCTION; PURIFICATION; FIBROBLASTS; MUTAGENESIS	Defects in electron transfer flavoprotein (ETF) or its electron acceptor, electron transfer flavoprotein-ubiquinone oxidoreductase (ETF-QO), cause the human inherited metabolic disease glutaric acidemia type II, In this disease, electron transfer from nine primary flavoprotein dehydrogenases to the main respiratory chain is impaired, Among these dehydrogenases are the four chain length-specific flavoprotein dehydrogenases of fatty acid beta-oxidation. In this investigation, two mutations in the alpha subunit that have been identified in patients were expressed in Escherichia coli, Of the two mutant alleles, alpha T266M and alpha G116R, the former is the most frequent mutation found in patients with ETF deficiency, The crystal structure of human ETF shows that alpha G116 lies in a hydrophobic pocket, under a contact residue of the alpha/beta subunit interface, and that the hydroxyl hydrogen of alpha T266 is hydrogen bonded to N(5) of the FAD; the amide backbone hydrogen of alpha T266 is hydrogen-bonded to C(4)-O of the flavin prosthetic group (Roberts, D, L,, Frerman, F, E, and Kim, J-J. P, (1996) Proc, Natl, Acad, Sci, U.S.A. 93, 14355-14360). Stable expression of the alpha G116R ETF required coexpression of the chaperonins, GroEL and GroES, alpha G116R ETF folds into a conformation different from the wild type, and is catalytically inactive in crude extracts, It is unstable and could not be extensively purified, The alpha T266M ETF was purified and characterized after stabilization to proteolysis in crude extracts, Although the global structure of this mutant protein is unchanged, its flavin environment is altered as indicated by absorption and circular dichroism spectroscopy and the kinetics of flavin release from the oxidized and reduced protein, The loss of the hydrogen bond at N(5) of the flavin and the altered flavin binding increase the thermodynamic stability of the flavin semiquinone by 10-fold relative to the semiquinone of wild type ETF. The mutation has relatively little effect on the reductive half-reaction of ETF catalyzed by sarcosine and medium chain acyl CoA dehydrogenases which reduce the flavin to the semiquinone, However, k(cat)/K-m of ETF-QO in a coupled acyl-CoA:ubiquinone reductase assay with oxidized alpha T266M ETF as substrate is reduced 33-fold; this decrease is due in largest part to a decrease in the rate of disproportionation of the alpha T266M ETF semiquinone catalyzed by ETF-QO.	UNIV COLORADO,SCH MED,DEPT PEDIAT,DENVER,CO 80262; UNIV COLORADO,SCH MED,PROGRAM CELLULAR & DEV BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NICHD NIH HHS [P30 HD04024] Funding Source: Medline; NIDDK NIH HHS [R01 DK49726] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD004024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049726] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKMANN JD, 1985, BIOCHEMISTRY-US, V24, P3913, DOI 10.1021/bi00336a016; BEDZYK LA, 1993, J BIOL CHEM, V268, P20211; BLAUER G, 1993, BIOCHEMISTRY-US, V32, P6674, DOI 10.1021/bi00077a021; Clark W.M., 1960, OXIDATION REDUCTION, P184; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; EDMONDSO.DE, 1971, BIOCHEMISTRY-US, V10, P113; EWEG JK, 1980, J AM CHEM SOC, V102, P51, DOI 10.1021/ja00521a010; FRENEAUX E, 1992, J CLIN INVEST, V90, P1670; FRERMAN FE, 1985, BIOCHEM MED METAB B, V33, P38, DOI 10.1016/0006-2944(85)90124-3; FRERMAN FE, 1985, P NATL ACAD SCI USA, V82, P4517, DOI 10.1073/pnas.82.13.4517; GATENBY AA, 1992, PLANT MOL BIOL, V19, P677, DOI 10.1007/BF00026793; GHISLA S, 1989, EUR J BIOCHEM, V18, P1; GORELICK RJ, 1985, BIOCHEMISTRY-US, V24, P6830, DOI 10.1021/bi00345a015; Griffin KJ, 1997, BIOCHEMISTRY-US, V36, P4194, DOI 10.1021/bi962572v; GUSTAFSON WG, 1986, J BIOL CHEM, V26, P7733; HERRICK KR, 1994, J BIOL CHEM, V269, P32239; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HSU MC, 1971, J AM CHEM SOC, V93, P3515; HUSAIN M, 1983, BIOCHEM J, V209, P541, DOI 10.1042/bj2090541; HUSAIN M, 1984, BIOCHEM J, V219, P1043, DOI 10.1042/bj2191043; KOZIOL J, 1965, BIOCHIM BIOPHYS ACTA, V102, P289, DOI 10.1016/0926-6585(65)90221-9; LOEHR JP, 1990, PEDIATR RES, V27, P311, DOI 10.1203/00006450-199003000-00024; MADDEN M, 1984, BIOCHEM J, V224, P577, DOI 10.1042/bj2240577; MASSEY V, 1963, BIOCHEM Z, V338, P474; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; MAYHEW SG, 1974, EUR J BIOCHEM, V44, P579, DOI 10.1111/j.1432-1033.1974.tb03515.x; MCILWAIN H, 1937, J CHEM SOC, V2, P1704; MCKEAN MC, 1983, J BIOL CHEM, V258, P1866; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; RAMSAY RR, 1987, BIOCHEM J, V241, P883, DOI 10.1042/bj2410883; ROBERTS DL, 1996, P NATL ACAD SCI USA, V90, P14355; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1993, J BIOCHEM, V114, P215, DOI 10.1093/oxfordjournals.jbchem.a124157; SWENSON RP, 1994, BIOCHEMISTRY-US, V33, P8505, DOI 10.1021/bi00194a015; TATWAWADI SV, 1968, J ELECTROANAL CHEM, V17, P411, DOI 10.1016/S0022-0728(68)80221-9; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; WHITFIELD CD, 1974, J BIOL CHEM, V249, P2801	37	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26425	26433		10.1074/jbc.272.42.26425	http://dx.doi.org/10.1074/jbc.272.42.26425			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334218	hybrid			2022-12-27	WOS:A1997YB13900052
J	Furie, BC; Ratcliffe, JV; Tward, J; Jorgensen, MJ; Blaszkowsky, LS; DiMichele, D; Furie, B				Furie, BC; Ratcliffe, JV; Tward, J; Jorgensen, MJ; Blaszkowsky, LS; DiMichele, D; Furie, B			The gamma-carboxylation recognition site is sufficient to direct vitamin K-dependent carboxylation on all adjacent glutamate-rich region of thrombin in a propeptide-thrombin chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROTEIN-C; INVITRO ANTICOAGULANT ACTIVITY; CARBOXYGLUTAMIC ACID RESIDUES; PHOSPHOLIPID-BINDING SITE; HAMSTER OVARY CELLS; MATRIX GLA PROTEIN; HUMAN FACTOR-IX; BLOOD-COAGULATION; NUCLEOTIDE-SEQUENCE; HUMAN-PROTHROMBIN	The propeptides of the vitamin K-dependent proteins contain gamma-carboxylation recognition site that is required for gamma-glutamyl carboxylation. To determine whether the propeptide is sufficient to direct carboxylation, two mutant prothrombin species were expressed and characterized with regard to posttranslational gamma-carboxylation. A double point mutant, in which serine substituted for cysteines 17 and 22 disrupted a conserved loop formed by a disulfide bond, was fully carboxylated when expressed in Chinese hamster ovary cells. A propeptide/thrombin chimeric protein, constructed by deleting the Cia, aromatic amino acid stack, and kringle domains of prothrombin, has the signal peptide and propeptide juxtaposed to a glutamate-rich COOH-terminal region Of prothrombin, residues 249-530. Of the 8 glutamic acid residues contained within the first 40 residues of the NH2 terminus adjacent to the propeptide, at least seven were fully carboxylated as demonstrated by direct gamma-carboxyglutamic acid analysis of the alkaline hydrolysate and by NH2-terminal sequence analysis. These results indicate that the gamma-carboxylation recognition site within the prothrombin propeptide in a prothrombin propeptide-thrombin chimeric protein is sufficient to direct gamma-carboxylase-catalyzed carboxylation of adjacent glutamic acid residues in a glutamate-rich region of thrombin that is not normally gamma-carboxylated. Furthermore, the disulfide loop in the Gla domain of prothrombin is not required for complete carboxylation.	TUFTS UNIV NEW ENGLAND MED CTR,DIV HEMATOL ONCOL,CTR HEMOSTASIS & THROMBOSIS RES,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Tufts University				Tward, Jonathan/0000-0001-7765-4473	NHLBI NIH HHS [HL42443, HL18834, HL38216] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038216, P01HL042443, R01HL018834, R37HL038216, R37HL018834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASAKAI R, 1987, BIOCHEMISTRY-US, V26, P7221, DOI 10.1021/bi00397a004; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLANCHARD RA, 1983, J LAB CLIN MED, V101, P242; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; Bristol JA, 1996, BLOOD, V88, P2585, DOI 10.1182/blood.V88.7.2585.bloodjournal8872585; BROWN MA, 1997, THROMB HAEMOSTASIS S, V78, pA639; CAIRNS JR, 1991, ANAL BIOCHEM, V199, P93, DOI 10.1016/0003-2697(91)90274-W; CARLISLE TL, 1980, BIOCHEMISTRY-US, V19, P1161, DOI 10.1021/bi00547a019; CHASIN LA, 1980, P NATL ACAD SCI USA, V77, P4216; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHOO KH, 1982, NATURE, V299, P178, DOI 10.1038/299178a0; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FRIEZNERDEGEN SJ, 1987, BIOCHEMISTRY-US, V26, P6165; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; HUBBARD BR, 1989, P NATL ACAD SCI USA, V86, P6893, DOI 10.1073/pnas.86.18.6893; HUBER P, 1990, J BIOL CHEM, V265, P12467; IRWIN DM, 1985, BIOCHEMISTRY-US, V24, P6854, DOI 10.1021/bi00345a018; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; JORGENSEN MJ, 1987, J BIOL CHEM, V262, P6729; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; KOTKOW KJ, 1993, METHOD ENZYMOL, V222, P435; KULIOPULOS A, 1992, BIOCHEMISTRY-US, V31, P9436, DOI 10.1021/bi00154a016; KULIOPULOS A, 1994, J BIOL CHEM, V269, P21364; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; KUWADA M, 1983, ANAL BIOCHEM, V131, P173, DOI 10.1016/0003-2697(83)90150-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; Lingenfelter SE, 1996, BIOCHEMISTRY-US, V35, P8234, DOI 10.1021/bi9523318; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; OHARA PJ, 1987, P NATL ACAD SCI USA, V84, P5158, DOI 10.1073/pnas.84.15.5158; OOSTRA BA, 1983, NATURE, V304, P456, DOI 10.1038/304456a0; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRICE PA, 1985, J BIOL CHEM, V260, P4971; RATCLIFFE JV, 1993, J BIOL CHEM, V268, P24339; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; SANFORD DG, 1991, BIOCHEMISTRY-US, V30, P9835, DOI 10.1021/bi00105a004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; WU SM, 1990, J BIOL CHEM, V265, P13124; Wu SM, 1997, J BIOL CHEM, V272, P11718, DOI 10.1074/jbc.272.18.11718; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236; YAMADA M, 1995, BIOCHEMISTRY-US, V34, P481, DOI 10.1021/bi00002a012; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHANG L, 1992, BLOOD, V80, P942; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	62	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28258	28262		10.1074/jbc.272.45.28258	http://dx.doi.org/10.1074/jbc.272.45.28258			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353278	hybrid			2022-12-27	WOS:A1997YF21900018
J	Harris, CM; Massey, V				Harris, CM; Massey, V			The oxidative half-reaction of xanthine dehydrogenase with NAD; Reaction kinetics and steady-state mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-2-DEPENDENT TYPES; RAPID REACTION; OXIDASE; REDOX; PURIFICATION; INACTIVATION; FLAVIN; SITE; FAD	The reaction between reduced xanthine dehydrogenase (XDH) from bovine milk and NAD has been studied in detail. An understanding of this reaction is necessary for a complete description of XDH turnover with its presumed natural electron acceptor and to address the preference of WH for NAD over oxygen as a substrate. The reaction between pre-reduced XDH and NAD was studied by stopped-flow spectrophotometry. The reaction was found to involve two rounds of oxidation with 2 eq of NAD. The first round goes to completion, and the second round reaches a slightly disfavored equilibrium. Rapid binding of NAD with an apparent K-d of 25 +/- 2 mu M is followed by NAD reduction at a rate constant of 130 +/- 13 s(-1). NADH dissociation at a rate constant of 42 +/- 12 s(-1) completes a round of oxidation. These steps have been successfully tested and modeled to repeat themselves in the second round of oxidation. The association rate constant for NAD binding was estimated to be much greater than any rate constant measured in the oxidation by molecular oxygen, thus explaining how NAD competes with oxygen for reducing equivalents. Rate constants for NAD reduction and NADH dissociation are respectively 21- and 7-fold greater than k(cat), indicating that the reductive half-reaction of the enzyme by xanthine is mostly rate-limiting in xanthine/NAD turnover. A steady-state mechanism for XDH is discussed.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM08270] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008270] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATTELLI MG, 1973, BIOCHEM J, V131, P191, DOI 10.1042/bj1310191; BRAY RC, 1964, J BIOL CHEM, V239, P2667; DARDENNE SC, 1990, BIOCHEMISTRY-US, V29, P9046, DOI 10.1021/bi00490a023; GASSNER G, 1994, BIOCHEMISTRY-US, V33, P12184, DOI 10.1021/bi00206a022; Harris CM, 1997, J BIOL CHEM, V272, P22514, DOI 10.1074/jbc.272.36.22514; Harris CM, 1997, J BIOL CHEM, V272, P8370, DOI 10.1074/jbc.272.13.8370; HUNT J, 1992, J BIOL CHEM, V267, P21479; HUNT J, 1994, J BIOL CHEM, V269, P18904; HUNT J, 1993, J BIOL CHEM, V268, P18685; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; KOBAYASHI K, 1993, J BIOL CHEM, V268, P24642; KOMAI H, 1969, J BIOL CHEM, V244, P1692; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MASSEY V, 1969, J BIOL CHEM, V244, P1682; Massey V., 1970, PYRIDINE NUCLEOTIDE, P393; MAYHEW SG, 1969, J BIOL CHEM, V244, P803; NISHINO T, 1989, J BIOL CHEM, V264, P5468; NISHINO T, 1991, ADV EXP MED BIOL, V309, P327; NISHINO T, 1989, J BIOL CHEM, V264, P6075; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; SAITO T, 1989, J BIOL CHEM, V264, P10015; SAITO T, 1989, J BIOL CHEM, V264, P15930; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; Segel I. H., 1976, BIOCH CALCULATIONS, P414; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048	29	41	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28335	28341		10.1074/jbc.272.45.28335	http://dx.doi.org/10.1074/jbc.272.45.28335			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353290	hybrid			2022-12-27	WOS:A1997YF21900030
J	Paudel, HK				Paudel, HK			Phosphorylation by neuronal cdc2-like protein kinase promotes dimerization of tau protein in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; NEUROFIBRILLARY PATHOLOGY; GLUTATHIONE METABOLISM; ANTIPARALLEL DIMERS; SELF-ASSOCIATION; BOVINE BRAIN; ISOFORMS; PURIFICATION	In Alzheimer's disease, the microtubule-associated protein tau forms paired helical filaments (PHFs) that are the major structural component of neurofibrillary tangles. Although tau isolated from PHFs (PHF-tau) is abnormally phosphorylated, the role of this abnormal phosphorylation in PHF assembly is not known. Previously, neuronal cdc2-like protein kinase (NCLK) was shown to phosphorylate tau on sites that are abnormally phosphorylated in PHF-tau (Paudel, H. g., Lew, J., All, Z., and Wang, J. H. (1993) J. Biol. Chem. 268, 23512-23518). In this study, phosphorylation by NCLK was found to promote dimerization of recombinant human tau (R-tau) and brain tau (B-tau) purified from brain extract. Chemical cross-linking by disuccinimidyl suberate (DSS), a homobifunctional chemical cross-linker that specifically cross-linked R-tau dimers, and a Superose 12 gel filtration chromatography revealed that R-tau preparations contain mixtures of monomeric and dimeric R-tau species. When the structure of NCLK-phosphorylated R-tau was studied by a similar approach, DSS preferentially cross-linked the phosphorylated R-tau over the nonphosphorylated R-tau, and the phosphorylated R-tau eluted as a dimeric species from the gel filtration column. Phosphorylated R-tau became resistant to DSS upon dephosphorylation and was recovered as a monomeric species from the gel filtration column. In the presence of a low concentration of dithiothreitol (1.65 mu M), R-tau formed disulfide crosslinked R-tau dimers. When compared, phosphorylated R-tau formed more disulfide cross-linked dimers than the nonphosphorylated R-tau. B-tau also was specifically cross-linked to dimers by DSS. When B-tau and NCLK-phosphorylated B-tau were treated with DSS, phosphorylated B-tau was preferentially cross-linked over nonphosphorylated counterpart. Taken together, these results suggest that phosphorylation by NCLK promotes dimerization and formation of disulfide crosslinked tau dimers, which is suggested to be the key step leading to PHF assembly (Schweers, O., Mandelkow, E.M., Biernat, J., and Mandelkow, E. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 8463-8467).	SIR MORTIMER B DAVIS JEWISH HOSP, LADY DAVIS INST MED RES, BLOOMFIELD CTR RES AGING, MONTREAL, PQ H3T 1E2, CANADA; MCGILL UNIV, DEPT NEUROL & NEUROSURG, MONTREAL, PQ H3T 1E2, CANADA	Lady Davis Institute; McGill University; McGill University								ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BANCHER C, 1991, BRAIN RES, V539, P11, DOI 10.1016/0006-8993(91)90681-K; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; DEANCOS JG, 1993, J BIOL CHEM, V268, P7976; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GUTTMANN RP, 1995, J NEUROCHEM, V64, P1209; HOSOI T, 1995, J BIOCHEM-TOKYO, V117, P711; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, NEUROBIOL AGING, V16, P263, DOI 10.1016/0197-4580(95)00014-6; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; Paudel HK, 1997, J BIOL CHEM, V272, P1777; PAUDEL HK, 1993, J BIOL CHEM, V268, P6207; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WILLE H, 1992, J BIOL CHEM, V267, P10737	34	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28328	28334		10.1074/jbc.272.45.28328	http://dx.doi.org/10.1074/jbc.272.45.28328			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353289	hybrid			2022-12-27	WOS:A1997YF21900029
J	Tang, SQ; Morgan, KG; Parker, C; Ware, JA				Tang, SQ; Morgan, KG; Parker, C; Ware, JA			Requirement for protein kinase C theta for cell cycle progression and formation of actin stress fibers and filopodia in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; CDC42 GTPASES; ANGIOGENESIS; GROWTH; RHO; EXPRESSION; BINDING; FAMILY; ACTIVATION	Activation of the protein kinase C (PKC) family with phorbol esters induces endothelial proliferation and angiogenesis, but which of the events that constitute angiogenesis are affected by individual members of the PMC family is unknown. In rat capillary endothelial (BCE) cells, serum stimulation increased expression of a single PKC isoenzyme, PKC theta, and its translocation to the periphery. Conditional overexpression of a dominant-negative mutant of PKC theta markedly inhibited RCE proliferation, as well as closure of a ''wound'' by RCE migration and formation of capillary rings and tubules in vitro. PKC theta inhibition delayed the endothelial cell cycle at the G(2)/M phase and prevented formation of actin stress fibers and filopodia but not lamellipodia. The defect in cell morphology and wound closure in PKC theta-kn cells was reversed by overexpressing kinase-active PKC theta, indicating that these RCE functions depend upon PKC theta substrates. Thus, PKC theta is required for multiple processes essential for angiogenesis and wound repair, including endothelial mitosis, maintenance of a normal actin cytoskeleton, and formation of an enclosed tube.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DIV CARDIOL,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,VASC BIOL UNIT,BRONX,NY 10461; HARVARD UNIV,SCH MED,HARVARD THORNDIKE LAB,BOSTON,MA 02115; BOSTON BIOMED RES INST,BOSTON,MA 02114	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Boston Biomedical Research Institute				Morgan, Kathleen/0000-0003-3300-3630	NHLBI NIH HHS [HL51043, HL47032] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051043, R01HL047032] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BAIER G, 1993, J BIOL CHEM, V268, P4997; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; CHANG JD, 1993, J BIOL CHEM, V268, P14208; COOMBER BL, 1991, EXP CELL RES, V194, P42, DOI 10.1016/0014-4827(91)90127-G; COOMBER BL, 1990, ARTERIOSCLEROSIS, V10, P215, DOI 10.1161/01.ATV.10.2.215; DAVIET I, 1989, BIOCHEM BIOPH RES CO, V158, P584, DOI 10.1016/S0006-291X(89)80089-0; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; DOCTROW SR, 1987, J CELL BIOL, V104, P679, DOI 10.1083/jcb.104.3.679; FAN TPD, 1995, TRENDS PHARMACOL SCI, V16, P57, DOI 10.1016/S0165-6147(00)88979-8; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FUJISE A, 1994, J BIOL CHEM, V269, P31642; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOOCK TC, 1991, J CELL BIOL, V112, P654; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; Kosaka C, 1996, AM J PHYSIOL-CELL PH, V270, pC170, DOI 10.1152/ajpcell.1996.270.1.C170; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHNO S, 1990, J BIOL CHEM, V265, P6296; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PRESTA M, 1991, CELL REGUL, V199, P719; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; TANG DG, 1993, PROSTAG OTH LIPID M, V45, P249, DOI 10.1016/0090-6980(93)90051-8; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9158; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WHITE GE, 1983, J CELL BIOL, V97, P416, DOI 10.1083/jcb.97.2.416; WONG AJ, 1983, SCIENCE, V219, P867, DOI 10.1126/science.6681677; WONG MKK, 1990, ARTERIOSCLEROSIS, V10, P76, DOI 10.1161/01.ATV.10.1.76; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZHOU W, 1993, J BIOL CHEM, V268, P23041; ZIGIMOND SH, 1996, CURR OPIN CELL BIOL, V8, P66	47	85	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28704	28711		10.1074/jbc.272.45.28704	http://dx.doi.org/10.1074/jbc.272.45.28704			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353339	hybrid			2022-12-27	WOS:A1997YF21900079
J	Burks, DJ; Pons, S; Towery, H; SmithHall, J; Myers, MG; Yenush, L; White, MF				Burks, DJ; Pons, S; Towery, H; SmithHall, J; Myers, MG; Yenush, L; White, MF			Heterologous pleckstrin homology domains do not couple IRS-1 to the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; PH DOMAINS; SUBSTRATE-1; DYNAMIN; BINDING; PROTEIN; ACTIVATION; SUBUNITS; REGION	Pleckstrin homology (PH) domains occur in many signaling proteins, including substrates for the insulin receptor tyrosine kinase (IRS proteins). Based on the hypothesis that PH domains may have a common function such as membrane targeting we tested the ability of PH domains from other signaling molecules to link IRS-1 to the insulin receptor. Chimeric IRS-1 proteins containing a homologous PH domain derived from other HRS proteins (IRS-2 or Gab-1) were tyrosine phosphorylated normally in response to insulin. In contrast, heterologous PH domains from the beta-adrenergic receptor kinase, phospholipase C gamma, or spectrin failed to mediate tyrosine phosphorylation of chimeric IRS-1 proteins, even in cells expressing high levels of insulin receptor. Moreover, IRS-1 proteins containing heterologous PH domains did not bind phosphorylated NPEY motifs derived from the insulin receptor, suggesting that the presence of these structures interfered with the function of the adjacent PTB binding domain. Thus, tyrosine phosphorylation of IRS-1 by the insulin receptor specifically requires a PH domain derived from IRS proteins.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Yenush, Lynne/J-8815-2014; Pons, Sebastian/K-7794-2014	Yenush, Lynne/0000-0001-8589-7002; Pons, Sebastian/0000-0003-1027-0621	NIDDK NIH HHS [T32 DK 07260, DK43808, P30 DK36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808, T32DK007260, P30DK036836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HEIDENREICH KA, 1985, J NEUROCHEM, V45, P1642, DOI 10.1111/j.1471-4159.1985.tb07237.x; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; JENNY TF, 1994, PROTEINS, V20, P1, DOI 10.1002/prot.340200102; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OWERBACH D, 1982, DIABETES, V31, P275, DOI 10.2337/diabetes.31.3.275; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PONS S, 1995, MOL CELL BIOL, V15, P4453; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	34	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27716	27721		10.1074/jbc.272.44.27716	http://dx.doi.org/10.1074/jbc.272.44.27716			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346913	hybrid			2022-12-27	WOS:A1997YD47300039
J	Ding, YM; Davisson, RL; Hardy, DO; Zhu, LJ; Merrill, DC; Catterall, JF; Sigmund, CD				Ding, YM; Davisson, RL; Hardy, DO; Zhu, LJ; Merrill, DC; Catterall, JF; Sigmund, CD			The kidney androgen-regulated protein promoter confers renal proximal tubule cell-specific and highly androgen-responsive expression on the human angiotensinogen gene in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BLOOD-PRESSURE; MOUSE KIDNEY; HUMAN RENIN; CONVERTING ENZYME; KAP GENE; RAT; SYSTEM; HYPERTENSION; LOCALIZATION	Transgenic mice were generated containing a 1542-base pair fragment of the kidney androgen-regulated protein (KBP) promoter fused to the human angiotensinogen (HAGT) gene with the goal of specifically targeting inducible expression of renin-angiotensin system components to the kidney. High level expression of both KAP-HAGT and endogenous KAP mRNA was evident in the kidney of male mice from two independent transgenic lines. Renal expression of the transgene in female mice was undetectable under basal conditions but could be strongly induced by administration of testosterone. Testosterone treatment did not cause a transcriptional induction id any ether tissues examined. However, an analysis of Six androgen target tissues in males revealed that the transgene was expressed in epididymis. No other extra-renal expression of the transgene was detected. In situ hybridization demonstrated that expression of HAGT (and KAP) mRNA in males and testosterone-treated females was restricted to proximal tubule epithelial cells in the renal cortex. Although there was no detectable human angiotensinogen protein in plasma, it was evident in the urine, consistent with a pathway of synthesis in proximal tubule cells and release into the tubular lumen. These results demonstrate that 1542 base pairs of the KAP promoter is sufficient to drive expression of a heterologous reporter gene in a tissue-specific, cell-specific, and androgen-regulated fashion in transgenic mice.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, TRANSGEN ANIM FACIL, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, GENET PROGRAM, IOWA CITY, IA 52242 USA; ROCKEFELLER UNIV, POPULAT COUNCIL, NEW YORK, NY 10021 USA	University of Iowa; University of Iowa; University of Iowa; Population Council; Rockefeller University			Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NHLBI NIH HHS [HL55006, HL48058] Funding Source: Medline; NICHD NIH HHS [HD13541] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055006, R01HL048058, R37HL048058] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1988, MOL REPROD DEV; BUNNEMANN B, 1992, J CARDIOVASC PHARM, V19, pS51, DOI 10.1097/00005344-199219006-00010; BURSON JM, 1994, AM J PHYSIOL, V267, pE260, DOI 10.1152/ajpendo.1994.267.2.E260; CATTERALL JF, 1986, RECENT PROG HORM RES, V42, P71; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DZAU VJ, 1986, HYPERTENSION, V8, P553, DOI 10.1161/01.HYP.8.7.553; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; GOMEZ RA, 1988, AM J PHYSIOL, V254, pF582, DOI 10.1152/ajprenal.1988.254.4.F582; HALL J E, 1991, Comprehensive Therapy, V17, P8; HALL JE, 1977, AM J PHYSIOL, V232, pF538, DOI 10.1152/ajprenal.1977.232.6.F538; HALL JE, 1990, ACTA PHYSIOL SCAND, V139, P48; HATAE T, 1994, MOL CELL BIOCHEM, V131, P43, DOI 10.1007/BF01075723; HOGAN E, 1986, MANIPULATING MOUSE E; INGELFINGER JR, 1990, J CLIN INVEST, V85, P417, DOI 10.1172/JCI114454; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JOHNSTON CI, 1993, KIDNEY INT, V44, pS59; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; KAKINUMA Y, 1993, KIDNEY INT, V43, P1229, DOI 10.1038/ki.1993.174; KASIK JW, 1993, MOL CELL ENDOCRINOL, V90, P239, DOI 10.1016/0303-7207(93)90157-F; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; LEVENS NR, 1981, CIRC RES, V48, P157, DOI 10.1161/01.RES.48.2.157; LINDPAINTNER K, 1991, CARDIOLOGY, V79, P32, DOI 10.1159/000174905; LINDPAINTNER K, 1991, ACTA CARDIOL, V46, P385; LINDZEY J, 1994, VITAM HORM, V49, P383; MATTSON DL, 1991, AM J PHYSIOL, V260, pR1200, DOI 10.1152/ajpregu.1991.260.6.R1200; Merrill DC, 1996, J CLIN INVEST, V97, P1047, DOI 10.1172/JCI118497; MESEGUER A, 1987, MOL ENDOCRINOL, V1, P535, DOI 10.1210/mend-1-8-535; MESEGUER A, 1990, MOL ENDOCRINOL, V4, P1240, DOI 10.1210/mend-4-8-1240; MESEGUER A, 1992, MOL CELL ENDOCRINOL, V89, P153, DOI 10.1016/0303-7207(92)90221-Q; NIU EM, 1991, DNA CELL BIOL, V10, P41, DOI 10.1089/dna.1991.10.41; PAGE MJ, 1982, MOL CELL ENDOCRINOL, V27, P343, DOI 10.1016/0303-7207(82)90099-5; PENG Y, 1995, AM J PHYSIOL-RENAL, V269, pF40, DOI 10.1152/ajprenal.1995.269.1.F40; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; SIGMUND CD, 1992, CIRC RES, V70, P1070, DOI 10.1161/01.RES.70.5.1070; SIGMUND CD, 1991, AM J PHYSIOL, V260, pF249, DOI 10.1152/ajprenal.1991.260.2.F249; SIGMUND CD, 1993, HYPERTENSION, V22, P599, DOI 10.1161/01.HYP.22.4.599; TAN JA, 1992, J BIOL CHEM, V267, P4456; TAUGNER R, 1982, KLIN WOCHENSCHR, V60, P1218, DOI 10.1007/BF01716726; TOOLE JJ, 1979, CELL, V17, P441, DOI 10.1016/0092-8674(79)90170-3; TUFROMCREDDIE A, 1993, J CLIN INVEST, V91, P530, DOI 10.1172/JCI116232; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; YANG GY, 1994, J BIOL CHEM, V269, P32497	42	107	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28142	28148		10.1074/jbc.272.44.28142	http://dx.doi.org/10.1074/jbc.272.44.28142			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346970	hybrid			2022-12-27	WOS:A1997YD47300096
J	Okada, S; Kao, AW; Ceresa, BP; Blaikie, P; Margolis, B; Pessin, JE				Okada, S; Kao, AW; Ceresa, BP; Blaikie, P; Margolis, B; Pessin, JE			The 66-kDa Shc isoform is a negative regulator of the epidermal growth factor-stimulated mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; PHOSPHOTYROSINE INTERACTION DOMAIN; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; PHOSPHORYLATED PROTEINS; SH2-CONTAINING PROTEINS; INSULIN-RECEPTOR; SEVENLESS GENE; PTB DOMAIN	In addition to tyrosine phosphorylation of the 66-, 52-, and 46-kDa Shc isoforms, epidermal growth factor (EGF) treatment of Chinese hamster ovary cells expressing the human EGF receptor also resulted in the serine/ threonine phosphorylation of approximately 50% of the 66-kDa Shc proteins. The serine/threonine phosphorylation occurred subsequent to tyrosine phosphorylation and was prevented by pretreatment of the cells with the MEK-specific inhibitor PD98059. Surprisingly, only the gel-shifted 66-kDa Shc isoform (serine/threonine phosphorylated) was tyrosine phosphorylated and associated with Grb2. In contrast, only the non-serine/threonine-phosphorylated fraction of 66-kDa Shc was associated with the EGF receptor. To assess the relationship between the three Shc isoforms in EGF-stimulated signaling, the cDNA encoding the 66-kDa Shc species was cloned from a 16-day-old mouse embryo library. Sequence alignment confirmed that the 66-kDa Shc cDNA resulted from alternative splicing of the primary Shc transcript generating a 110-amino acid extension at the amino terminus. Co-immunoprecipitation of Shc and Grb2 from cells overexpressing the 52/46-kDa Shc isoforms versus the 66-kDa Shc species directly demonstrated a competition of binding for a limited pool of Grb2 proteins. Furthermore, expression of the 66-kDa Shc isoform markedly accelerated the inactivation of ERK following EGF stimulation. Together, these data indicate that the serine/threonine phosphorylation of 66-kDa Shc impairs its ability to associate with the tyrosine-phosphorylated EGF receptor and can function in a dominant-interfering manner by inhibiting EGF receptor downstream signaling pathways.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV MICHIGAN,HOWARD HUGHES MED INST,DEPT INTERNAL MED & BIOL CHEM,ANN ARBOR,MI 48109	University of Iowa; Howard Hughes Medical Institute; University of Michigan System; University of Michigan					NIDDK NIH HHS [DK33823, DK25925] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER LN, 1993, NATURE, V363, P85; BENJAMIN CW, 1994, J BIOL CHEM, V269, P30911; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GiorgettiPeraldi S, 1997, MOL CELL BIOL, V17, P1180, DOI 10.1128/MCB.17.3.1180; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Holt KH, 1996, MOL CELL BIOL, V16, P577; Kao AW, 1997, ENDOCRINOLOGY, V138, P2474, DOI 10.1210/en.138.6.2474; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMIT L, 1994, J BIOL CHEM, V269, P20209; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107	50	120	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28042	28049		10.1074/jbc.272.44.28042	http://dx.doi.org/10.1074/jbc.272.44.28042			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346957	hybrid			2022-12-27	WOS:A1997YD47300083
J	Yan, ZF; Deng, XB; Chen, MX; Xu, Y; Ahram, M; Sloane, BF; Friedman, E				Yan, ZF; Deng, XB; Chen, MX; Xu, Y; Ahram, M; Sloane, BF; Friedman, E			Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; INTERCELLULAR-ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN; ANTISENSE OLIGONUCLEOTIDES; COLORECTAL CARCINOMAS; TUMOR PROGRESSION; CATHEPSIN-B; DIFFERENTIATION; MUTATIONS; ASSOCIATION	Colon carcinomas commonly contain mutations in Ki-ras4B, but very rarely in Ha-ras, suggesting that different Ras isoforms may have distinct functions in colon epithelial cell biology, In an earlier study we had demonstrated that oncogenic Ki-ras4B(Val-12), but not oncogenic Ha-ras(Val-12), blocks the apicobasal polarization of colon epithelial cells by preventing normal glycosylation of the integrin beta 1 chain of the collagen receptor, As a result, only the Ki-ras mutated cells exhibited altered cell to substratum attachment, whereas mutation of either Res isoform activated mitogen-activated protein kinases. We have now asked whether intercellular adhesion proteins implicated in establishing basolateral polarity in colon epithelial cells are modulated by oncogenic Ki-Ras4B(Val-12) proteins but not oncogenic Ha-Ras(Val-12) proteins, The embryonic adhesion protein carcinoembryonic antigen (CEA) was up-regulated on the mRNA and protein levels in each of three stable Ki-ras(Val-12) transfectant lines but in none of three stable Ha-ras(Val-12) transfectant lines. The elevated protein levels of CEA in Ki-ras4B(Val-12) transfectant cells were decreased by blocking expression of Ki-ras4B(Val-12) with antisense oligonucleotides. N-cadherin levels were decreased in only the Ki-ras transfectants, whereas E-cadherin levels were unchanged. Immunohistochemical analysis demonstrated that Ki-ras4B(Val-12) transfectant cells did not polarize into cells with discrete apical and basal regions and so could not restrict expression of CEA to the apical region, These unpolarized cells displayed elevated levels of CEA all along their surface membrane where CEA mediated random, multilayered associations of tumor cells, This aggregation was both calcium-independent and blocked by Fab' fragments of anti-CEA monoclonal antibody col-1. Trafficking of the lysosomal cysteine protease cathepsin B may also be altered when cell polarity cannot be established. Ki-ras4B(Val-12) transfectant cells expressed 2-fold elevated protein levels of the lysosomal cysteine protease cathepsin B but did not up-regulate cathepsin B mRNA expression. One function of oncogenic c-Ki-Ras proteins in colon cancer progression may be to up-regulate CEA and thus to prevent the lateral adhesion of adjacent colon epithelial cells that normally form a monolayer in vivo.	SUNY HLTH SCI CTR,DEPT PATHOL,SYRACUSE,NY 13210; WAYNE STATE UNIV,DEPT PHARMACOL,DETROIT,MI 48201; WAYNE STATE UNIV,CANC BIOL PROGRAM,DETROIT,MI 48201	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Wayne State University; Wayne State University			Ahram, Mamoun/D-8497-2015; Sloane, Bonnie F/A-1050-2009	Ahram, Mamoun/0000-0003-4457-3604; 	NATIONAL CANCER INSTITUTE [R01CA067405, R01CA045783] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA67405, R01 CA45783] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CAMPO E, 1994, AM J PATHOL, V145, P301; Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; EIDELMAN FJ, 1993, J CELL BIOL, V123, P467, DOI 10.1083/jcb.123.2.467; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GRIMM T, 1995, CANCER RES, V55, P3254; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; HUANG F, 1994, ONCOGENE, V9, P3701; JESSUP JM, 1993, BRIT J CANCER, V67, P464, DOI 10.1038/bjc.1993.88; KUROKI M, 1989, INT J CANCER, V44, P208, DOI 10.1002/ijc.2910440204; MAHER J, 1995, ONCOGENE, V11, P1639; MONIA BP, 1992, J BIOL CHEM, V267, P19954; OJAKIAN GK, 1994, J CELL SCI, V107, P561; SHIBATA D, 1993, J NATL CANCER I, V85, P1058, DOI 10.1093/jnci/85.13.1058; SLOANE BF, 1994, J CELL SCI, V107, P373; SUCHY B, 1992, INT J CANCER, V52, P30, DOI 10.1002/ijc.2910520107; TIBBETTS LM, 1993, CANCER, V71, P315, DOI 10.1002/1097-0142(19930115)71:2<315::AID-CNCR2820710208>3.0.CO;2-B; WANG AZ, 1990, J CELL SCI, V95, P153; YAN Z, 1993, CELL GROWTH DIFFER, V4, P1; YAN ZF, 1994, J BIOL CHEM, V269, P13231	25	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27902	27907		10.1074/jbc.272.44.27902	http://dx.doi.org/10.1074/jbc.272.44.27902			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346938	hybrid			2022-12-27	WOS:A1997YD47300064
J	Arbuzova, A; Wang, JY; Murray, D; Jacob, J; Cafiso, DS; McLaughlin, S				Arbuzova, A; Wang, JY; Murray, D; Jacob, J; Cafiso, DS; McLaughlin, S			Kinetics of interaction of the myristoylated alanine-rich C kinase substrate, membranes, and calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE UNILAMELLAR VESICLES; MARCKS-RELATED PROTEIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOLIPID-VESICLES; ELECTROSTATIC SWITCH; CALCIUM-CALMODULIN; DEPENDENT BINDING; ASSOCIATION; PHOSPHORYLATION; PEPTIDES	Membrane binding of the myristoylated alanine-rich C kinase substrate (MARCKS) requires both its myristate chain and basic ''effector'' region. Previous studies with a peptide corresponding to the effector region, MARCKS-(151-175), showed that the 13 basic residues interact electrostatically with acidic lipids and that the 5 hydrophobic phenylalanine residues penetrate the polar head group region of the bilayer, Here we describe the kinetics of the membrane binding of fluorescent (acrylodan-labeled) peptides measured with a stopped-flow technique, Even though the peptide penetrates the polar head group region, the association of MARCKS-(151-175) with membranes is extremely rapid; association occurs with a diffusion-limited association rate constant, For example, k(on) = 10(11) M-1 s(-1) for the peptide binding to 100-nm diameter phospholipid vesicles, As expected theoretically, k(on) is independent of factors that affect the molar partition coefficient, such as the mole fraction of acidic lipid in the vesicle and the salt concentration The dissociation rate constant (k(off)) is similar to 10 s(-1) (lifetime = 0.1 s) for vesicles with 10% acidic lipid in 100 mM KCl. Ca2+-calmodulin (Ca2+. CaM) decreases markedly the lifetime of the peptide on vesicles, e.g. from 0.1 to 0.01 s in the presence of 5 mu M Ca2+. CaM. Our results suggest that Ca2+. CaM collides with the membrane-bound MARCKS (151-175) peptide and pulls the peptide off rapidly, We discuss the biological implications of this switch mechanism, speculating that an increase in the level of Ca2+-calmodulin could rapidly release phosphatidylinositol 4,5-bisphosphate that previous work has suggested is sequestered in lateral domains formed by MARCKS and MARCKS-(151-175).	SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,HLTH SCI CTR,STONY BROOK,NY 11794; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901; UNIV VIRGINIA,BIOPHYS PROGRAM,CHARLOTTESVILLE,VA 22901	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Virginia; University of Virginia				Arbuzova, Anna/0000-0003-2462-147X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024971, R37GM024971, R01GM035215] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24971, GM35215] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; BERG HC, 1983, RANDOM WALKS BIOL, P17; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; COBURN C, 1993, BIOPHYS J, V64, P60; DIEBLER H, 1969, Pure and Applied Chemistry, V20, P93, DOI 10.1351/pac196920010093; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; ERTEL A, 1993, BIOPHYS J, V64, P426, DOI 10.1016/S0006-3495(93)81383-3; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; KOELCHENS S, 1993, CHEM PHYS LIPIDSA, V65, P1; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; KUZELOVA K, 1994, BIOCHEMISTRY-US, V33, P9447, DOI 10.1021/bi00198a010; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LU Y, 1995, BIOCHEMISTRY-US, V34, P10777, DOI 10.1021/bi00034a010; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MCINTOSH TJ, 1986, BIOCHEMISTRY-US, V25, P4058, DOI 10.1021/bi00362a011; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MUI BLS, 1993, BIOPHYS J, V64, P443, DOI 10.1016/S0006-3495(93)81385-7; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOYES RM, 1961, PROG REACT KINET MEC, V1, P129; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROUX M, 1988, EUR BIOPHYS J BIOPHY, V16, P267, DOI 10.1007/BF00254062; Schleiff E, 1996, J BIOL CHEM, V271, P26794, DOI 10.1074/jbc.271.43.26794; SCHWARZ G, 1989, BIOCHIM BIOPHYS ACTA, V979, P82, DOI 10.1016/0005-2736(89)90526-9; SCHWARZ G, 1987, BIOPHYS CHEM, V26, P163, DOI 10.1016/0301-4622(87)80019-4; SCHWARZ G, 1987, BIOPHYS J, V52, P685, DOI 10.1016/S0006-3495(87)83263-0; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361	53	69	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27167	27177		10.1074/jbc.272.43.27167	http://dx.doi.org/10.1074/jbc.272.43.27167			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341159	hybrid			2022-12-27	WOS:A1997YC65900055
J	Karlsson, M; Contreras, JA; Hellman, U; Tornqvist, H; Holm, C				Karlsson, M; Contreras, JA; Hellman, U; Tornqvist, H; Holm, C			cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase - Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; ALPHA/BETA-HYDROLASE FOLD; RAT ADIPOSE-TISSUE; NUCLEOTIDE-SEQUENCE; LIPOPROTEIN LIPASE; PURIFICATION; MUTAGENESIS; PROTEINS; SERINE; GENE	Monoglyceride lipase catalyzes the last step in the hydrolysis of stored triglycerides in the adipocyte and presumably also complements the action of lipoprotein lipase in degrading triglycerides from chylomicrons and very low density lipoproteins. Monoglyceride Lipase was cloned from a mouse adipocyte cDNA library. The predicted amino acid sequence consisted of 302 amino acids, corresponding to a molecular weight. of 33,218, The sequence showed no extensive homology to other known mammalian proteins, but a number of microbial proteins, including two bacterial lysophospholipases and a family of haloperoxidases, were found to be distantly related to this enzyme, By means of multiple sequence alignment and secondary structure prediction, the structural elements in monoglyceride lipase, as well as the putative catalytic triad, were identified, The residues of the proposed triad, Ser-122, in a GXSXG motif, Asp-239, and His-269, were confirmed by site-directed mutagenesis experiments. Northern blot analysis revealed that monoglyceride lipase is ubiquitously expressed among tissues, with a transcript size of about 4 kilobases.	LUND UNIV,DEPT CELL & MOL BIOL,SECT MOL SIGNALLING,S-22100 LUND,SWEDEN; LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN; UNIV LUND HOSP,DEPT PEDIAT,S-22185 LUND,SWEDEN; NOVO NORDISK AS,DK-2820 GENTOFTE,DENMARK	Lund University; Ludwig Institute for Cancer Research; Lund University; Skane University Hospital; Novo Nordisk								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CYGLER M, 1993, PROTEIN SCI, V2, P366; DEREWENDA ZS, 1993, ADV PROTEIN CHEM, V45, P1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FELLER G, 1991, DNA CELL BIOL, V10, P381, DOI 10.1089/dna.1991.10.381; FREDRIKSON G, 1986, BIOCHIM BIOPHYS ACTA, V876, P288, DOI 10.1016/0005-2760(86)90286-9; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; HECHT HJ, 1994, NAT STRUCT BIOL, V1, P532, DOI 10.1038/nsb0894-532; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HOLM C, 1986, J BIOL CHEM, V261, P5659; HOLM C, 1994, FEBS LETT, V344, P234, DOI 10.1016/0014-5793(94)00403-X; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; NILSSONEHLE P, 1971, BIOCHIM BIOPHYS ACTA, V248, P114, DOI 10.1016/0005-2760(71)90081-6; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; OZAKI E, 1995, BIOSCI BIOTECH BIOCH, V59, P1204, DOI 10.1271/bbb.59.1204; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SHIRAI K, 1982, J BIOL CHEM, V257, P1253; TORNQVIST H, 1978, J LIPID RES, V19, P654; TORNQVIST H, 1972, J LIPID RES, V13, P424; TORNQVIST H, 1974, J LIPID RES, V15, P291; TORNQVIST H, 1976, J BIOL CHEM, V251, P813; TORNQVIST H, 1978, BIOCHIM BIOPHYS ACTA, V530, P474, DOI 10.1016/0005-2760(78)90167-4	27	319	333	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27218	27223		10.1074/jbc.272.43.27218	http://dx.doi.org/10.1074/jbc.272.43.27218			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341166	hybrid			2022-12-27	WOS:A1997YC65900062
J	Lin, Q; Taylor, SJ; Shalloway, D				Lin, Q; Taylor, SJ; Shalloway, D			Specificity and determinants of Sam68 RNA binding - Implications for the biological function of K homology domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X SYNDROME; ACTIN MESSENGER-RNA; PROTEIN SAM68; C-SRC; MITOSIS; GENE; SIGNAL; ACTIVATION; POLYMERASE; FMR1	Sam68, a specific target of the Src tyrosine kinase in mitosis, possesses features common to RNA-binding proteins, including a K homology (KH) domain, To elucidate its biological function, we first set out to identify RNA species that bound to Sam68 with high affinity using in vitro selection, From a degenerate 40-mer pool, 15 RNA sequences were selected that bound to Sam68 with K-d values of 12-140 nM. The highest affinity RNA sequences (K-d similar to 12-40 nM) contained a UAAA motif; mutation to UACA abolished binding to Sam68, Binding of the highest affinity ligand, G8-5, was assessed to explore the role of different regions of Sam68 in RNA binding, The KH domain alone did not bind G8-5, but a fragment containing the KH domain and a region of homology within the Sam68 subgroup of KH-containing proteins was sufficient for G8-5 binding, Deletion of the KH domain or mutation of RR domain residues analogous to loss-of-function mutations in the human Fragile X syndrome gene product and the Caenorhabditis elegans tumor suppressor protein Gld-l abolished G8-5 binding, Our results establish that a RB domain-containing protein can bind RNA with specificity and high affinity and suggest that specific RNA binding is integral to the functions of some regulatory proteins in growth and development.	CORNELL UNIV,BIOCHEM MOL & CELL BIOL SECT,ITHACA,NY 14853	Cornell University					NCI NIH HHS [CA32317] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032317] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arning S, 1996, RNA, V2, P794; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; Fischer U, 1996, TRENDS CELL BIOL, V6, P290, DOI 10.1016/0962-8924(96)20030-3; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GIBSON TJ, 1993, TRENDS BIOCHEM SCI, V18, P331, DOI 10.1016/0968-0004(93)90068-X; HILL MA, 1994, J CELL BIOL, V126, P1221, DOI 10.1083/jcb.126.5.1221; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; Kislauskis Edward H., 1992, Current Opinion in Cell Biology, V4, P975, DOI 10.1016/0955-0674(92)90128-Y; LATHAM VM, 1994, J CELL BIOL, V126, P1211, DOI 10.1083/jcb.126.5.1211; LIU KB, 1995, P NATL ACAD SCI USA, V92, P5012, DOI 10.1073/pnas.92.11.5012; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; NEEL H, 1995, CURR BIOL, V5, P413, DOI 10.1016/S0960-9822(95)00082-0; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; Sambrook J., 1989, MOL CLONING LAB MANU, V3, P18; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Shi H, 1997, MOL CELL BIOL, V17, P2649, DOI 10.1128/MCB.17.5.2649; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TODA T, 1994, HUM MOL GENET, V3, P465, DOI 10.1093/hmg/3.3.465; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H	42	139	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27274	27280		10.1074/jbc.272.43.27274	http://dx.doi.org/10.1074/jbc.272.43.27274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341174	hybrid			2022-12-27	WOS:A1997YC65900070
J	Linnekin, D; DeBerry, CS; Mou, S				Linnekin, D; DeBerry, CS; Mou, S			Lyn associates with the Juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CYTOKINE SIGNAL-TRANSDUCTION; FACTOR-INDUCED PROLIFERATION; SRC-FAMILY KINASES; GROWTH-FACTOR; PROTOONCOGENE PRODUCT; AUTOIMMUNE-DISEASE; ESCHERICHIA-COLI; DEFICIENT MICE; RECEPTOR	Stem cell factor (SCF) is a cytokine critical for normal hematopoiesis. The receptor for SCF is c-Kit, a receptor tyrosine kinase. Our laboratory is interested in delineating critical components of the SCF signal transduction pathway in hematopoietic tissue. The present study examines activation of Src family members in response to SCF. Stimulation of cell lines as well as normal progenitor cells with SCF rapidly increased tyrosine phosphorylation of the Src family member Lyn. Peak responses were noted 10-20 min after SCF treatment, and phosphorylation of Lyn returned to basal levels 60-90 min after stimulation, SCF also induced increases in Lyn kinase activity in, vitro. Lyn coimmunoprecipitated with c-Kit, and studies with GST fusion proteins demonstrated that Lyn readily associated with the juxtamembrane region of c-Kit. Treatment of cells with either Lyn antisense oligonucleotides or PPI, a Src family inhibitor, resulted in dramatic inhibition of SCF-induced proliferation. These data demonstrate that SCF rapidly activates Lyn and suggest that Lyn is critical in SCF-induced proliferation in hematopoietic cells.	NCI,FREDERICK CANC RES & DEV CTR,INTRAMURAL RES & SUPPORT PROGRAM,SAIC FREDERICK,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Linnekin, D (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,LAB LEUKOCYTE BIOL,DIV BASIC SCI,BLDG 567,RM 226,FREDERICK,MD 21702, USA.							ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ANDERSON SM, 1995, J IMMUNOL, V155, P1660; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KAPLAN M, 1996, IMMUNITY, V3, P313; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI Y, 1995, J IMMUNOL, V154, P2165; LI ZH, 1992, BIOCHEM BIOPH RES CO, V187, P1536, DOI 10.1016/0006-291X(92)90477-3; LINNEKIN D, 1994, BLOOD, V84, P94, DOI 10.1182/blood.V84.1.94.bloodjournal84194; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Paulson R F, 1995, Semin Immunol, V7, P267, DOI 10.1006/smim.1995.0031; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SCHEUERMANN RH, 1994, P NATL ACAD SCI USA, V91, P4048, DOI 10.1073/pnas.91.9.4048; SHIMODA L, 1996, NATURE, V380, P627; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; TORIGOE T, 1992, BLOOD, V80, P617; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688	40	140	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27450	27455		10.1074/jbc.272.43.27450	http://dx.doi.org/10.1074/jbc.272.43.27450			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341198	hybrid			2022-12-27	WOS:A1997YC65900094
J	Scheper, GC; Mulder, J; Kleijn, M; Voorma, HO; Thomas, AAM; vanWijk, R				Scheper, GC; Mulder, J; Kleijn, M; Voorma, HO; Thomas, AAM; vanWijk, R			Inactivation of eIF2B and phosphorylation of PHAS-I in heat-shocked rat hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INITIATION-FACTOR 4E; NUCLEOTIDE EXCHANGE FACTOR; CAP-DEPENDENT TRANSLATION; HELA-CELLS; RABBIT RETICULOCYTES; RIBOSOMAL-PROTEINS; GLYCOGEN-SYNTHASE; FACTOR EIF-4E; INSULIN	Various factors are involved in the heat shock-induced inhibition of protein synthesis, Changes upon heat shock in phosphorylation, leading to inactivation, of eukaryotic initiation factors (eIFs) eIF2 and eIF4E have been shown for several cell types, However, in mammalian cells these changes occur at temperatures of 43 degrees C or higher while protein synthesis is already affected at milder heat shock temperatures, In searching far the cranes for the inhibition of protein synthesis, the regulation of eIF2 and eIF4E by additional factors was analyzed. In this respect, the activity of eIF2B was measured during and after heat shook. A very clear correlation was found between the activity of this guanine exchange factor and the levels of protein synthesis, also at mild heat shock conditions. Changes in the phosphorylation of eIF4E and of the eIF4E-binding protein PHAS-I were also analyzed. Surprisingly, in H35 cells as well as in some other cell lines, PHAS-I phosphorylation was increased by heat shock, whereas in others it was decreased, Therefore, decreasing the eIF4E availability under stressful conditions does not seem to be a general mechanism to inhibit protein synthesis by heat shack, Regulation of eIF2B activity appears to be the main mechanism to control translation initiation after heat shock at mild temperatures.			Scheper, GC (corresponding author), UNIV UTRECHT,DEPT MOL CELL BIOL,PADUALAAN 8,NL-3584 CH UTRECHT,NETHERLANDS.		Scheper, Gert C/D-7001-2014					Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; DUNCAN RF, 1995, BIOCHEMISTRY-US, V34, P2985, DOI 10.1021/bi00009a030; DUNCAN RF, 1996, TRANSLATIONAL CONTRO, P271; ERNST V, 1982, HEAT SHOCK BACTERIA, P215; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HICKEY ED, 1982, BIOCHEMISTRY-US, V21, P1513, DOI 10.1021/bi00536a008; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JOHNSTON AM, 1984, EUR J BIOCHEM, V150, P507; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KENNEDY IM, 1984, FEBS LETT, V169, P267, DOI 10.1016/0014-5793(84)80331-2; Kleijn M, 1995, J CELL BIOCHEM, V59, P443, DOI 10.1002/jcb.240590405; Kleijn M, 1996, FEBS LETT, V396, P165, DOI 10.1016/0014-5793(96)01097-6; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MARIANO TM, 1986, BIOCHEM BIOPH RES CO, V138, P519, DOI 10.1016/S0006-291X(86)80527-7; MCCORMICK W, 1969, J MOL BIOL, V39, P315, DOI 10.1016/0022-2836(69)90320-9; MEHTA HB, 1983, J BIOL CHEM, V258, P3438; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MIZZEN LA, 1988, J CELL BIOL, V109, P1467; NOVER L, 1991, HEAT SHOCK RESPONSE, P299; OLSEN AS, 1983, MOL CELL BIOL, V3, P2017, DOI 10.1128/MCB.3.11.2017; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PANNIERS R, 1988, J BIOL CHEM, V263, P5519; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; SCHAMHART DHJ, 1984, RADIAT RES, V98, P82, DOI 10.2307/3576053; SCHARF KD, 1982, CELL, V30, P427, DOI 10.1016/0092-8674(82)90240-9; TAS PWL, 1987, EUR J BIOCHEM, V163, P553, DOI 10.1111/j.1432-1033.1987.tb10903.x; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; VANWIJK R, 1993, INT J HYPERTHER, V9, P137, DOI 10.3109/02656739309061486; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625	54	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26850	26856		10.1074/jbc.272.43.26850	http://dx.doi.org/10.1074/jbc.272.43.26850			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341116	hybrid			2022-12-27	WOS:A1997YC65900012
J	Wenderoth, I; Scheibe, R; vonSchaewen, A				Wenderoth, I; Scheibe, R; vonSchaewen, A			Identification of the cysteine residues involved in redox modification of plant plastidic glucose-6-phosphate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCONOSTOC-MESENTEROIDES; MALATE-DEHYDROGENASE; CHLOROPLAST ENZYMES; LIGHT-MODULATION; SEQUENCE; SYSTEM; GENE; DITHIOTHREITOL; INACTIVATION; PRINCIPLE	The cDNA sequences encoding cytosolic and light-modulated plastidic glucose-6-phosphate dehydrogenase (G6PDH) from potato were modified by polymerase chain reaction and subsequently overexpressed in Escherichia coli. Characterization of the recombinant enzymes showed that they closely resembled their native counterparts. Treatment with reduced dithiothreitol or glutathione led to inactivation of plastidic G6PDH, whereas the activity of the cytosolic isoenzyme was not influenced by reduction. As for the native enzyme, inactivation of recombinant plastidic G6PDH was accelerated by thioredoxin m and could be fully reversed by subsequent addition of oxidant, To identify the residues which are involved in redox regulation of plastidic G6PDH, each of the six cysteines in the mature protein sequence was exchanged separately for serine by site-directed mutagenesis. Two mutant proteins exhibited characteristics of the reduced wild-type enzyme. Exchange of either Cys(149) or Cys(157) to serine abolished the regulatory properties, suggesting that these cysteine residues are the sites responsible for redox-mediated inactivation of plastidic G6PDH.	UNIV OSNABRUCK,FB BIOL CHEM 5,D-49069 OSNABRUCK,GERMANY	University Osnabruck								ANDERSON LE, 1977, FEBS LETT, V76, P64, DOI 10.1016/0014-5793(77)80121-X; ANDERSON LE, 1976, PLANT PHYSIOL, V58, P135, DOI 10.1104/pp.58.2.135; ANDERSON LE, 1974, PLANT PHYSIOL, V53, P835, DOI 10.1104/pp.53.6.835; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; GRAEVE K, 1994, PLANT J, V5, P353, DOI 10.1111/j.1365-313X.1994.00353.x; HEBER U, 1967, Z NATURFORSCH PT B, VB 22, P1200; ISSAKIDIS E, 1994, J BIOL CHEM, V269, P3511; Jacquot JP, 1997, FEBS LETT, V401, P143, DOI 10.1016/S0014-5793(96)01459-7; JOHNSON HS, 1972, PLANTA, V106, P273, DOI 10.1007/BF00388105; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WT, 1991, J BIOL CHEM, V266, P13028; LEE WT, 1992, PROTEIN SCI, V1, P329; LENDZIAN K, 1970, PLANTA, V94, P27, DOI 10.1007/BF00386606; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NEWMAN J, 1995, FEMS MICROBIOL LETT, V133, P187, DOI 10.1111/j.1574-6968.1995.tb07882.x; ROWLAND P, 1994, STRUCTURE, V2, P1073, DOI 10.1016/S0969-2126(94)00110-3; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCANLAN DJ, 1992, PLANT MOL BIOL, V19, P877, DOI 10.1007/BF00027085; SCHEIBE R, 1991, PLANT PHYSIOL, V96, P1, DOI 10.1104/pp.96.1.1; SCHEIBE R, 1981, BIOCHIM BIOPHYS ACTA, V636, P58, DOI 10.1016/0005-2728(81)90075-X; SCHEIBE R, 1989, ARCH BIOCHEM BIOPHYS, V274, P290, DOI 10.1016/0003-9861(89)90441-4; SCHNARRENBERGER C, 1973, ARCH BIOCHEM BIOPHYS, V154, P438, DOI 10.1016/0003-9861(73)90077-5; SUMMERS ML, 1995, PLANT PHYSIOL, V107, P267, DOI 10.1104/pp.107.1.267; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VONSCHAEWEN A, 1995, PLANT PHYSIOL, V109, P1327, DOI 10.1104/pp.109.4.1327; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; YUAN XH, 1987, PLANT PHYSIOL, V85, P598, DOI 10.1104/pp.85.2.598	32	128	136	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26985	26990		10.1074/jbc.272.43.26985	http://dx.doi.org/10.1074/jbc.272.43.26985			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341136	hybrid			2022-12-27	WOS:A1997YC65900032
J	Jin, G; Howe, PH				Jin, G; Howe, PH			Regulation of clusterin gene expression by transforming growth factor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TGF-BETA; APOLIPOPROTEIN J/CLUSTERIN; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; BINDING SEQUENCE; CELLS; RECEPTORS; ELEMENTS	Transforming growth factor beta (TGF beta) induces the expression of a wide variety of genes in many cell types. Our previous studies have shown that TGF beta stimulates both clusterin mRNA and protein levels, and induces its accumulation in the nucleus of CCL64 cells. To further investigate the molecular mechanism of clusterin mRNA induction by TGF beta, we created a 1.3-kilobase rat clusterin promoter/luciferase reporter construct. We demonstrate that TGF beta enhances luciferase activity 2.5-6fold in transient transfection assays of epithelial, endothelial, and fibroblast cell lines. Deletional analysis reveals that an AP-1-binding site (5'-TGAGTCA) in the minimal promoter region is necessary for initiating transactivation by TGF beta. A single T to G base mutation in the AP-1 site (5'-TGAGGCA) abolishes TGF beta-induced clusterin promoter transactivation. In transcription factor decoy experiments, 23-mer oligonucleotides of wild type AP-1 reduce TGF beta induction of clusterin mRNA levels and promoter transactivation, while all oligonucleotide containing the mutated AP-1 site has no effect. Two specific protein kinase C inhibitors, GF109203X and calphostin C, block TGF beta-induced clusterin mRNA levels and promoter transactivation. Together these results indicate that TGF beta regulates clusterin gene expression through an AP-1 site and its cognate transcription factor AP-1, and requires the involvement of protein kinase C.	CLEVELAND CLIN FDN,DEPT CELL BIOL NC1,LERNER RES INST,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University					NATIONAL CANCER INSTITUTE [R01CA055536, R29CA055536] Funding Source: NIH RePORTER; NCI NIH HHS [CA55536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Atfi A, 1995, P NATL ACAD SCI USA, V92, P12110, DOI 10.1073/pnas.92.26.12110; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BETTUZZI S, 1991, BIOCHEM BIOPH RES CO, V175, P810, DOI 10.1016/0006-291X(91)91637-R; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRANDES ME, 1991, J IMMUNOL, V147, P1600; Brown TL, 1996, BIOL REPROD, V55, P740, DOI 10.1095/biolreprod55.4.740; BROWN TL, 1995, BIOL REPROD, V52, P1038, DOI 10.1095/biolreprod52.5.1038; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BURKEY BF, 1991, J LIPID RES, V32, P1039; CAMPBELL MJ, 1995, BIOTECHNIQUES, V18, P1027; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; HALSTEAD J, 1995, J BIOL CHEM, V270, P13600, DOI 10.1074/jbc.270.23.13600; HARDARDOTTIR I, 1994, J CLIN INVEST, V94, P1304, DOI 10.1172/JCI117449; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERAULT Y, 1992, NUCLEIC ACIDS RES, V20, P6377, DOI 10.1093/nar/20.23.6377; Hocevar BA, 1996, P NATL ACAD SCI USA, V93, P7655, DOI 10.1073/pnas.93.15.7655; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI L, 1990, J BIOL CHEM, V265, P1556; LI Q, 1994, J BIOL CHEM, V269, P17508; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; MICHEL D, 1995, EUR J BIOCHEM, V229, P215, DOI 10.1111/j.1432-1033.1995.0215l.x; MILLER DA, 1989, MOL ENDOCRINOL, V3, P1108, DOI 10.1210/mend-3-7-1108; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MORGAN TE, 1995, J NEUROIMMUNOL, V58, P101, DOI 10.1016/0165-5728(94)00194-S; MOSES HL, 1989, ADV GROWTH HORMONE G, P191; MUID RE, 1991, FEBS LETT, V293, P169, DOI 10.1016/0014-5793(91)81178-B; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P6157, DOI 10.1021/bi952981b; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P309, DOI 10.1021/bi951880a; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; ROSEMBLIT N, 1994, J MOL ENDOCRINOL, V13, P69, DOI 10.1677/jme.0.0130069; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TAKESHITA A, 1995, J IMMUNOL, V155, P419; THOMASSALGAR S, 1994, J BIOL CHEM, V269, P17879; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WONG P, 1994, EUR J BIOCHEM, V221, P917, DOI 10.1111/j.1432-1033.1994.tb18807.x; WONG P, 1993, J BIOL CHEM, V268, P5021; WONG P, 1994, BIOCH CELL BIOL, V72, P449; ZWAIN IH, 1994, MOL CELL NEUROSCI, V5, P229, DOI 10.1006/mcne.1994.1027	63	85	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26620	26626		10.1074/jbc.272.42.26620	http://dx.doi.org/10.1074/jbc.272.42.26620			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334243	hybrid			2022-12-27	WOS:A1997YB13900077
J	Li, YT; Wang, LX; Pavlova, NV; Li, SC; Lee, YC				Li, YT; Wang, LX; Pavlova, NV; Li, SC; Lee, YC			alpha-KDOase activity in oyster and synthesis of alpha- and beta-4-methylumbelliferyl ketosides of 3-deoxy-D-manno-octulosonic acid (KDO)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; N-ACETYLNEURAMINIC ACID; FLUOROMETRIC ASSAY; ESCHERICHIA-COLI; NEURAMINIDASE; C-13; LIPOPOLYSACCHARIDES; POLYSACCHARIDE; SUBSTRATE	Although alpha- and beta-linked 3-deoxy-D-manno-octulosonic acid (KDO) is found in lipopolysaccharides (LPSs) of Gram-negative bacteria, capsular polysaccharides of microorganisms, and plants, very little is known about its degradation, Using both thin-layer chromatography and the periodate-thiobarbituric acid reaction, we found that the hepatopancreas of oyster (Crassostrea virginica) contained an enzyme (alpha-KDOase) capable of releasing alpha-linked KDO from LPSs, To facilitate the studies of alpha-KDOase, we have carried out the synthesis of 4-methylumbelliferyl-alpha-KDO (alpha-KDO-MU) by conjugating the glycosyl chloride of the per-O-acetylated methylester of KDO with methylumbelliferone by the S(N)2 type reaction and the catalyzed phase-transfer, In both cases, the beta-anomer was obtained as the major product with a yield of about 80%, whereas the yield of alpha-anomer was only about 7%, Attempts to increase the yield of alpha-anomer were not successful, alpha-BDO-MU was used as substrate to follow the purification of alpha-KDOase from oyster hepatopancreas. The pH optimum for oyster alpha-KDOase was determined to be 4.5 using Re-LPS as substrate and 3.0 using alpha-KDO-MU as substrate. The enzyme was found to be stable in the pH range of 3-8, This enzyme released KDO from different LPSs, including Re-LPS from Escherichia coli and Salmonella minnesota, Rd-LPS from S. minnesota, and de-O-acyl-Re-LPS (Kiang, J., Szu, S, C., Wang, L.X., Tang, M., and Lee, Y. C. (1997) Anal, Biochem, 245, 97-101).	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University	Li, YT (corresponding author), TULANE UNIV,SCH MED,DEPT BIOCHEM SL43,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.		wang, xl/Y-8251-2019; Wang, Lai-Xi/E-8755-2019; Wang, Lai-Xi/E-8790-2019	Wang, Lai-Xi/0000-0003-4293-5819	NIDDK NIH HHS [DK 09970] Funding Source: Medline; NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009970, R01DK009970] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BHATTACHARJEE AK, 1978, BIOCHEMISTRY-US, V17, P645, DOI 10.1021/bi00597a013; CLAESSON A, 1982, ACTA CHEM SCAND B, V36, P719, DOI 10.3891/acta.chem.scand.36b-0719; DROGE W, 1970, EUR J BIOCHEM, V14, P175, DOI 10.1111/j.1432-1033.1970.tb00276.x; FURUHATA K, 1986, CHEM PHARM BULL, V34, P2725; GHALAMBOR MA, 1966, J BIOL CHEM, V241, P3207; HARRIS G, 1954, CHEM IND-LONDON, P249; HORI H, 1988, TETRAHEDRON LETT, V29, P6317, DOI 10.1016/S0040-4039(00)82335-7; ITOH M, 1986, CHEM PHARM BULL, V34, P1479; Kiang J, 1997, ANAL BIOCHEM, V245, P97, DOI 10.1006/abio.1996.9951; LEDUR A, 1978, EUR J BIOCHEM, V84, P579, DOI 10.1111/j.1432-1033.1978.tb12201.x; MYERS RW, 1980, ANAL BIOCHEM, V101, P166, DOI 10.1016/0003-2697(80)90056-1; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; ROTHERMEL J, 1990, CARBOHYD RES, V196, P29, DOI 10.1016/0008-6215(90)84104-3; SCHWARCZ JA, 1972, CAN J CHEMISTRY, V50, P3667, DOI 10.1139/v72-581; STRAIN SM, 1983, J BIOL CHEM, V258, P2906; STRAIN SM, 1983, J BIOL CHEM, V258, P3466; TAYLOR PW, 1974, BIOCHEM BIOPH RES CO, V61, P148, DOI 10.1016/0006-291X(74)90546-4; Unger F. M., 1981, ADV CARBOHYD CHEM BI, V38, P323; UNGER FM, 1980, CARBOHYD RES, V80, P191, DOI 10.1016/S0008-6215(00)85325-2; YORK WS, 1985, CARBOHYD RES, V138, P109, DOI 10.1016/0008-6215(85)85228-9	20	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26419	26424		10.1074/jbc.272.42.26419	http://dx.doi.org/10.1074/jbc.272.42.26419			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334217	hybrid			2022-12-27	WOS:A1997YB13900051
J	Obata, H; Hayashi, K; Nishida, W; Momiyama, T; Uchida, A; Ochi, T; Sobue, K				Obata, H; Hayashi, K; Nishida, W; Momiyama, T; Uchida, A; Ochi, T; Sobue, K			Smooth muscle cell phenotype-dependent transcriptional regulation of the alpha 1 integrin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; CHICKEN CALDESMON GENE; LONG TERMINAL REPEAT; PROMOTER ELEMENTS; TRANSGENIC MICE; C-FOS; EXPRESSION; ACTIN; IDENTIFICATION; COLLAGEN	The expressional regulation of chicken alpha 1 integrin in smooth muscle cells was studied. The alpha 1 integrin mRNA was expressed developmentally and was distributed dominantly in vascular and visceral smooth muscles in chick embryos. In a primary culture of smooth muscle cells, alpha 1 integrin expression was dramatically down-regulated during serum-induced dedifferentiation. Promoter analyses revealed that the 5'-upstream region (-516 to +281) was sufficient for transcriptional activation in differentiated smooth muscle cells but not in dedifferentiated smooth muscle cells or chick embryo fibroblasts. Like other alpha integrin promoters, the promoter region of the alpha 1 integrin gene lacks TATA and CCAAT boxes and contains binding sites for AP1 and AP2. The essential difference from other alpha integrin promoters is the presence of a CArG box-like motif. Deletion and site-directed mutation analyses revealed that the CArG box-like motif was an essential cis-element for transcriptional activation in differentiated smooth muscle cells, whereas the binding sites for AP1 and AP2 were not. Using specific antibodies, a nuclear protein factor specifically bound to the CArG; box-like motif was identified as serum response factor. These results indicate that (yl integrin expression in smooth muscle cells is regulated transcriptionally in a phenotype-dependent manner and that serum response factor binding plays a crucial role in this regulation.	OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT NEUROCHEM & NEUROPHARMACOL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT ORTHOPAED SURG, SUITA, OSAKA 565, JAPAN; MIE UNIV, SCH MED, DEPT ORTHOPAED SURG, TSU, MIE 514, JAPAN	Osaka University; Osaka University; Mie University								AUDET JF, 1994, DNA CELL BIOL, V13, P1071, DOI 10.1089/dna.1994.13.1071; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; BELKIN VM, 1990, J CELL BIOL, V111, P2159, DOI 10.1083/jcb.111.5.2159; BIRUKOV KG, 1991, CELL TISSUE RES, V266, P579, DOI 10.1007/BF00318599; BLANK RS, 1992, J BIOL CHEM, V267, P984; BORRIONE AC, 1989, EUR J BIOCHEM, V183, P413, DOI 10.1111/j.1432-1033.1989.tb14943.x; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; DUBAND JL, 1992, DEVELOPMENT, V116, P585; GILGENKRANTZ H, 1992, J BIOL CHEM, V267, P10823; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HARUNA M, 1993, BIOCHEM BIOPH RES CO, V197, P145, DOI 10.1006/bbrc.1993.2453; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HEDIN U, 1990, DIFFERENTIATION, V44, P222, DOI 10.1111/j.1432-0436.1990.tb00621.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; IGNATIUS MJ, 1988, NEURON, V1, P713, DOI 10.1016/0896-6273(88)90170-5; Kashiwada K, 1997, J BIOL CHEM, V272, P15396, DOI 10.1074/jbc.272.24.15396; KATOH Y, 1994, J BIOL CHEM, V269, P30538; KEMP PR, 1995, BIOCHEM J, V310, P1037, DOI 10.1042/bj3101037; KORHONEN M, 1990, J CELL BIOL, V111, P1245, DOI 10.1083/jcb.111.3.1245; KOTELIANSKY VE, 1985, FEBS LETT, V182, P67, DOI 10.1016/0014-5793(85)81155-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; LIU SH, 1995, DEV GENET, V16, P229, DOI 10.1002/dvg.1020160303; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; MECHTERSHEIMER G, 1994, AM J PATHOL, V144, P1172; Moessler H, 1996, DEVELOPMENT, V122, P2415; NAKANO Y, 1991, GENE, V99, P285; NUEDA A, 1993, J BIOL CHEM, V268, P19305; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Samaha FF, 1996, J BIOL CHEM, V271, P395, DOI 10.1074/jbc.271.1.395; SEALEY L, 1987, MOL CELL BIOL, V7, P787, DOI 10.1128/MCB.7.2.787; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SKINNER MP, 1994, AM J PATHOL, V145, P1070; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Soulez M, 1996, BIOCHEM BIOPH RES CO, V219, P418, DOI 10.1006/bbrc.1996.0248; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; UEKI N, 1987, P NATL ACAD SCI USA, V84, P9049, DOI 10.1073/pnas.84.24.9049; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661; YANO H, 1994, BIOCHEM BIOPH RES CO, V201, P618, DOI 10.1006/bbrc.1994.1746; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	52	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26643	26651		10.1074/jbc.272.42.26643	http://dx.doi.org/10.1074/jbc.272.42.26643			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334246	hybrid			2022-12-27	WOS:A1997YB13900080
J	Pourquier, P; Pilon, AA; Kohlhagen, G; Mazumder, A; Sharma, A; Pommier, Y				Pourquier, P; Pilon, AA; Kohlhagen, G; Mazumder, A; Sharma, A; Pommier, Y			Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps - Importance of DNA end phosphorylation and camptothecin effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ILLEGITIMATE RECOMBINATION; EUKARYOTIC TOPOISOMERASE; BINDING SEQUENCE; CLEAVAGE SITES; DUPLEX DNA; STRAND; INHIBITORS; CELL; BASE; REPLICATION	We used purified mammalian topoisomerases I (top1) and oligonucleotides containing a unique top1 cleavage site to study top1-mediated cleavage and recombination in the presence of nicks and short gaps mimicking DNA damage, In general, top1 cleavage was not induced opposite to the nicks, and nicks upstream from the top1 cleavage site suppressed top1 activity, Irreversible top1 cleavage complexes (''suicide products'' or ''aborted complexes'') were produced in DNA containing nicks or short gaps just opposite to the normal top1 cleavage site, Camptothecin enhanced the formation of the aborted top1 complexes only for nicks downstream from the cleavage site, These aborted (suicide) complexes can mediate DNA recombination and promote illegitimate recombination by catalyzing the ligation of nonhomologous DNA fragments (accepters), We report for the first time that top1-mediated recombination is greatly en enhanced by the presence of a phosphate at the 5' terminus of the top1 aborted complex (donor DNA), By contrast, phosphorylation of the 3' terminus of the gap did not affect recombination, At concentrations that strongly enhanced inhibition of intramolecular religation, resulting in an increase of top1 cleavable complexes, camptothecin did not reduce recombination (intermolecular religation). Nicks or gaps with 5'-phosphate termini would be expected to be produced directly by ionizing radiations or by processing of abasic sites and DNA lesions induced by carcinogens or drugs used in cancer chemotherapy, Thus, these results further demonstrate that DNA damage can efficiently trap top1-cleavable complexes and enhance top1 mediated DNA recombination.	NCI,MOL PHARMACOL LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Pourquier, Philippe/O-8030-2018	Pourquier, Philippe/0000-0001-5326-3005				ANDERSON RD, 1994, MUTAT RES-FUND MOL M, V309, P109, DOI 10.1016/0027-5107(94)90048-5; [Anonymous], 1985, DNA REPAIR; BACKER LC, 1990, MUTAGENESIS, V5, P541, DOI 10.1093/mutage/5.6.541; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; CHAMPOUX JJ, 1988, GENETIC RECOMBINATIO, P655; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; Chen AY, 1997, CANCER RES, V57, P1529; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; DEGRASSI F, 1989, MUTAT RES, V211, P125, DOI 10.1016/0027-5107(89)90112-7; DENNY CT, 1986, SCIENCE, V234, P197, DOI 10.1126/science.3092355; FUJIMORI A, 1995, CANCER RES, V55, P1339; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HENNINGFELD KA, 1995, BIOCHEMISTRY-US, V34, P6120, DOI 10.1021/bi00018a015; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1989, CANCER RES, V49, P5077; JAXEL C, 1991, J BIOL CHEM, V266, P20418; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LETEURTRE F, 1994, J BIOL CHEM, V269, P7893; MCCOUBREY WK, 1986, J BIOL CHEM, V261, P5130; POMMIER Y, 1995, MUTAT RES-DNA REPAIR, V337, P135, DOI 10.1016/0921-8777(95)00019-G; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; POMMIER Y, 1993, CAUSES CONSEQUENCES, P277; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; RABBITTS TH, 1984, CHROMOSOMAL TRANSLOC, P164; Roth D., 1988, GENETIC RECOMBINATIO, P621; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5157, DOI 10.1093/nar/21.22.5157; WANG HP, 1991, J VIROL, V65, P2381, DOI 10.1128/JVI.65.5.2381-2392.1991; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; YEH YC, 1994, J BIOL CHEM, V269, P15498; ZHELKOVSKY AM, 1994, PROTEIN EXPRES PURIF, V5, P364, DOI 10.1006/prep.1994.1053; ZHOU W, 1995, CELL, V82, P577, DOI 10.1016/0092-8674(95)90030-6; Zhu J, 1996, MOL CELL BIOL, V16, P1805	47	151	154	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26441	26447		10.1074/jbc.272.42.26441	http://dx.doi.org/10.1074/jbc.272.42.26441			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334220	Green Published, hybrid			2022-12-27	WOS:A1997YB13900054
J	Wang, RH; Tao, L; Trumbore, MW; Berger, SL				Wang, RH; Tao, L; Trumbore, MW; Berger, SL			Turnover of the acyl phosphates of human and murine prothymosin alpha in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEAR-PROTEIN; MESSENGER-RNA; GENE; PHOSPHORYLATION; EXPRESSION; PRODUCTS; TISSUES; PROLIFERATION; PARATHYMOSIN	Prothymosin alpha is a small, highly acidic, abundant, nuclear, mammalian protein which is essential for cell growth, Our laboratory has recently shown that primate prothymosin alpha contains stoichiometric amounts of phosphate on the glutamyl groups of the protein and that in vitro the phosphate undergoes rapid hydrolysis or transfer to a nearby serine residue, Here an assay for the presence of acyl phosphates in vivo has been developed by measuring stable phosphoserine and phosphothreonine in. vitro, The assay was used to determine the half-life of the acyl phosphates on prothymosin alpha in vivo by pulse-labeling HeLa cells with [P-32]orthophosphate and chasing using three different techniques: permeabilization with digitonin to allow extracellular ATP to equilibrate with the intracellular pool; electroporation in the presence of ATP to reduce the specific activity of [P-32]ATP by expansion of the pool; and incubation with inorganic phosphate, Regardless of the method, the phosphate turned over with a half-life of 75-90 min. The ability of cells to phosphorylate old prothymosin alpha molecules was established by demonstrating equivalent labeling of the protein with [P-32]orthophosphate in the presence and absence of cycloheximide. The half-life of the acyl phosphates was also studied in resting and growing NIH3T3 cells, with measured values of 30-35 and 70 min, respectively. Our data suggest that the ''activity'' of prothymosin alpha involves the turnover of its acyl phosphates and that it participates in a function common to all nucleated mammalian cells regardless of whether they are quiescent or undergoing rapid proliferation, This is the first measurement of the stability of protein-bound acyl phosphates in vivo.	NCI,SECT GENES & GENE PROD,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BARCIA MG, 1992, FEBS LETT, V312, P152, DOI 10.1016/0014-5793(92)80924-6; BERGER SL, 1987, METHOD ENZYMOL, V152, P49; BUSTELO XR, 1991, J BIOL CHEM, V266, P1443; CLINTON M, 1989, ARCH BIOCHEM BIOPHYS, V269, P256, DOI 10.1016/0003-9861(89)90107-0; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; COHENSOLAL L, 1979, P NATL ACAD SCI USA, V76, P4327, DOI 10.1073/pnas.76.9.4327; COHENSOLAL L, 1985, ANAL BIOCHEM, V151, P82, DOI 10.1016/0003-2697(85)90055-7; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEGANI C, 1973, J BIOL CHEM, V248, P8222; ECONOMOU M, 1988, FEBS LETT, V233, P342, DOI 10.1016/0014-5793(88)80456-3; ERIKSSON AM, 1991, EUR J BIOCHEM, V198, P471; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; FRILLINGOS S, 1991, MOL CELL BIOCHEM, V109, P85; GAST K, 1995, BIOCHEMISTRY-US, V34, P13211, DOI 10.1021/bi00040a037; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1391, DOI 10.1073/pnas.81.5.1391; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOSHLAND DE, 1993, SCIENCE, V262, P532, DOI 10.1126/science.8211179; KOSHLAND DE, 1952, J AM CHEM SOC, V74, P2286, DOI 10.1021/ja01129a035; KUBOTA S, 1995, EUR J BIOCHEM, V233, P48, DOI 10.1111/j.1432-1033.1995.048_1.x; LEE JJ, 1992, DEV BIOL, V149, P415, DOI 10.1016/0012-1606(92)90296-S; MANROW RE, 1991, J BIOL CHEM, V266, P3916; MOL PC, 1995, MOL CELL BIOL, V15, P6999; PALVIMO J, 1990, FEBS LETT, V277, P257, DOI 10.1016/0014-5793(90)80860-L; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; SASVARISZEKELY M, 1975, BIOCHIM BIOPHYS ACTA, V395, P221, DOI 10.1016/0005-2787(75)90192-6; Sburlati A R, 1990, Protein Expr Purif, V1, P184, DOI 10.1016/1046-5928(90)90014-P; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SBURLATI AR, 1993, BIOCHEMISTRY-US, V32, P4587, DOI 10.1021/bi00068a015; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT G, 1991, BIOCHIM BIOPHYS ACTA, V1088, P442, DOI 10.1016/0167-4781(91)90141-8; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; Trumbore MW, 1997, J BIOL CHEM, V272, P26394, DOI 10.1074/jbc.272.42.26394; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; WATTS JD, 1989, FEBS LETT, V245, P17, DOI 10.1016/0014-5793(89)80182-6; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; ZUURENDONK PF, 1974, BIOCHIM BIOPHYS ACTA, V333, P393, DOI 10.1016/0005-2728(74)90022-X	40	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26405	26412		10.1074/jbc.272.42.26405	http://dx.doi.org/10.1074/jbc.272.42.26405			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334215	hybrid			2022-12-27	WOS:A1997YB13900049
J	Wo, YYP; Stewart, J; Greenlee, WF				Wo, YYP; Stewart, J; Greenlee, WF			Functional analysis of the promoter for the human CYP1B1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	34th Annual Meeting of the Society-of-Toxicology	MAR 05-09, 1995	BALTIMORE, MD	Soc Toxicol			TRANSCRIPTION FACTOR; REGULATORY ELEMENTS; ADRENAL CYTOCHROME-P450; HYDROCARBON METABOLISM; INDUCIBLE EXPRESSION; NUCLEAR FACTOR; MESSENGER-RNA; DNA-SEQUENCES; RAT CYP1B1; TATA	Our laboratory has cloned the cDNA (Sutter, T. R., Tang Y, M., Hayes, C. L., Wo, Y.-Y. P., Jabs, E. W., Li, X., Yin, H., Cody, C. W., and Greenlee, W. P. (1994) J. Biol. Chem. 269, 13092-13099) and gene (Tang, Y. M., Wo, Y.-Y.P., Jabs, E. pi,, Stewart, J. C., Sutter, T. R. and Greenlee, W. F. (1996) J. Biol. Chem. 271, 28324-28350) for human CYP1B1, a new member of the cytochrome P450 superfamily, Here, we report on the mapping and function of the CYP1B1 promoter, The CYP1B1 promoter is fully functional, when if: is uncoupled from upstream enhancer elements. Deletion analysis and site-directed mutagenesis identified four regulatory elements required for maximum promoter activity: two antisense Spl sites (-84 to -89 and -68 to -73), a TATA-like box (-84 to -29), and an initiator motif (-5 to +3). The initiator and the TATA-like elements are both required for basal promoter activity, with enhanced activity mediated by the two antisense Sp1 elements. The GYP1B1 initiator was demonstrated by in vitro transcription analysis to be a positioning element that maintained fidelity of transcription from a single site. Specific binding to a CYP1B1 initiator probe by human nuclear extract proteins was competed either by the highly homologous murine terminal deoxynucleotidyl transferase initiator or, to a lesser extent, by the adenovirus major late initiator. Taken together, these results indicate that the structure and function of the CYP1B1 promoter confers constitutive expression of the gene and assures fidelity of transcription initiation from a single site, The CYP1B1 promoter is distinct from the promoters of the closely related cytochrome P450s CYP1A1 and CYP1A2 and is structurally and functionally similar to the promoters of constitutively expressed genes and at least two viruses.	UNIV MASSACHUSETTS, MED CTR, DEPT MOL PHARMACOL & TOXICOL, WORCESTER, MA 01655 USA; PURDUE UNIV, DEPT MOL PHARMACOL & MED CHEM, W LAFAYETTE, IN 47907 USA	University of Massachusetts System; University of Massachusetts Worcester; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIEHS NIH HHS [ES07009] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007009] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ATCHISON ML, 1989, MOL CELL BIOL, V9, P2067, DOI 10.1128/MCB.9.5.2067; AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BHATTACHARYYA KK, 1995, J BIOL CHEM, V270, P11595, DOI 10.1074/jbc.270.19.11595; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUSING MR, 1994, NUCLEIC ACIDS RES, V22, P669, DOI 10.1093/nar/22.4.669; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FABER PW, 1993, J BIOL CHEM, V268, P9296; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; GAATA BA, 1994, BIOCHIM BIOPHYS ACTA, V1219, P307; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; GROSVELD GC, 1981, CELL, V25, P215, DOI 10.1016/0092-8674(81)90246-4; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HILDEBRAND CE, 1985, NUCLEIC ACIDS RES, V13, P2009, DOI 10.1093/nar/13.6.2009; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JAISWAL A K, 1987, Journal of Experimental Pathology (New York), V3, P1; JONES KW, 1990, MOL CELL BIOL, V10, P5098, DOI 10.1128/MCB.10.10.5098; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; KUDO S, 1994, EUR J BIOCHEM, V223, P319, DOI 10.1111/j.1432-1033.1994.tb18997.x; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; LANS MS, 1994, J BIOL CHEM, V269, P14170; MANOHAR A, 1994, BBA-GENE STRUCT EXPR, V1219, P233, DOI 10.1016/0167-4781(94)90279-8; MCKINNON RA, 1991, HEPATOLOGY, V14, P848, DOI 10.1002/hep.1840140517; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; OTTO S, 1991, ENDOCRINOLOGY, V129, P970, DOI 10.1210/endo-129-2-970; QUATTROCHI LC, 1989, MOL PHARMACOL, V36, P66; RITTNER K, 1995, J MOL BIOL, V248, P562, DOI 10.1006/jmbi.1995.0243; SAGAMI I, 1994, J BIOCHEM-TOKYO, V116, P801, DOI 10.1093/oxfordjournals.jbchem.a124599; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAS U, 1994, J BIOL CHEM, V269, P14905; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SHEN ZY, 1993, P NATL ACAD SCI USA, V90, P11483, DOI 10.1073/pnas.90.24.11483; Shimada T, 1996, CANCER RES, V56, P2979; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; Tang WM, 1996, J BIOL CHEM, V271, P28324, DOI 10.1074/jbc.271.45.28324; WALKER NJ, 1995, CARCINOGENESIS, V16, P1319, DOI 10.1093/carcin/16.6.1319; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470	51	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26702	26707		10.1074/jbc.272.42.26702	http://dx.doi.org/10.1074/jbc.272.42.26702			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	YB139	9334254	hybrid			2022-12-27	WOS:A1997YB13900088
J	Bassilana, F; Champigny, G; Waldmann, R; deWeille, JR; Heurteaux, C; Lazdunski, M				Bassilana, F; Champigny, G; Waldmann, R; deWeille, JR; Heurteaux, C; Lazdunski, M			The acid-sensitive ionic channel subunit ASIC and the mammalian degenerin MDEG form a heteromultimeric H+-gated Na+ channel with novel properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED SODIUM CURRENT; ROOT GANGLION NEURONS; CAENORHABDITIS-ELEGANS; HOMOLOGOUS SUBUNITS; SENSORY NEURONS; NEURODEGENERATION; EXPRESSION; RECEPTOR; PROTONS; CLONING	Proton-gated cation channels are acid sensors that are present in both sensory neurons and in neurons of the central nervous system. One of these acid sensing ion channels (ASIC) has been recently cloned. This paper shows that ASIC and the mammalian degenerin MDEG, which are colocalized in the same brain regions, can directly associate with each other. Immunoprecipitation of MDEG causes coprecipitation of ASIC. Moreover, coexpression of ASIC and MDEG subunits in Xenopus oocytes generates an amiloride-sensitive H+-gated Na+ channel with novel properties (different kinetics, ionic selectivity, and pH sensitivity). In addition, coexpression of MDEG with mutants of the ASIC subunit can create constitutively active channels that become completely nonselective for Na+ versus K+ and H+-gated channels that have a drastically altered pH sensitivity compared with MDEG. These data clearly show that ASIC and MDEG can form heteromultimeric assemblies with novel properties. Heteromultimeric assembly is probably used for creating a diversity of H+-gated cation channels acting as neuronal acid sensors in different pH ranges.	CNRS,INST PHARMACOL MOL & CELLULAIRE,UPR 411,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Waldmann, Rainer/Q-2108-2016; de Weille, Jan R/F-8103-2014; HEURTEAUX, Catherine/M-4947-2016	Waldmann, Rainer/0000-0002-4599-2926; de Weille, Jan R/0000-0002-0505-3166; HEURTEAUX, Catherine/0000-0002-9741-9777; Bassilana, Frederic/0000-0003-2063-8450				AKAIKE N, 1994, PROG NEUROBIOL, V43, P73, DOI 10.1016/0301-0082(94)90016-7; Barnard EA, 1996, TRENDS PHARMACOL SCI, V17, P305, DOI 10.1016/0165-6147(96)10041-9; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; DAVIES NW, 1988, J PHYSIOL-LONDON, V400, P159, DOI 10.1113/jphysiol.1988.sp017116; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GARTY H, 1994, FASEB J, V8, P522, DOI 10.1096/fasebj.8.8.8181670; Gu GQ, 1996, P NATL ACAD SCI USA, V93, P6577, DOI 10.1073/pnas.93.13.6577; HERMAN RK, 1996, BIOESSAYS, V48, P199; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KRISHTAL OA, 1981, BRAIN RES, V214, P150, DOI 10.1016/0006-8993(81)90446-7; KRISHTAL OA, 1987, BRAIN RES, V436, P352, DOI 10.1016/0006-8993(87)91678-7; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; UENO S, 1992, J PHYSIOL-LONDON, V447, P309, DOI 10.1113/jphysiol.1992.sp019004; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411	26	179	194	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28819	28822		10.1074/jbc.272.46.28819	http://dx.doi.org/10.1074/jbc.272.46.28819			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360943	hybrid			2022-12-27	WOS:A1997YF68400002
J	Brooks, EE; Gray, NS; Joly, A; Kerwar, SS; Lum, R; Mackman, RL; Norman, TC; Rosete, J; Rowe, M; Schow, SR; Schultz, PG; Wang, XB; Wick, MM; Shiffman, D				Brooks, EE; Gray, NS; Joly, A; Kerwar, SS; Lum, R; Mackman, RL; Norman, TC; Rosete, J; Rowe, M; Schow, SR; Schultz, PG; Wang, XB; Wick, MM; Shiffman, D			CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; OLIGONUCLEOTIDES	The activity of cyclin-dependent kinase 2 (CDK2) is essential for progression of cells from G(1) to the S phase of the mammalian cell cycle. CVT-313 is a potent CDK2 inhibitor, which was identified from a purine analog library with an IC50 of 0.5 mu M in vitro. Inhibition was competitive with respect to ATP (K-i = 95 nM), and selective CVT-313 had no effect on other, nonrelated ATP-dependent serine/threonine kinases, When added to CDK1 or CDK4, a 8.5- and 430-fold higher concentration of CVT-313 was required for half-maximal inhibition of the enzyme activity. In cells exposed to CVT-313, hyperphosphorylation of the retinoblastoma gene product was inhibited, and progression through the cell cycle was arrested at the G(1)/S boundary, The growth of mouse, rat, and human cells in culture was also inhibited by CVT-313 with the IC50 for growth arrest ranging from 1.25 to 20 mu M. To evaluate the effects of CVT-313 in vivo, we tested this agent in a rat carotid artery model of restenosis, A brief intraluminal exposure of CVT-313 to a denuded rat carotid artery resulted in more than 80% inhibition of neointima formation. These observations suggest that CVT-313 is a promising candidate for evaluation in other disease models related to aberrant cell proliferation.	CV THERAPEUT, PALO ALTO, CA 94304 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley								ABE J, 1994, BIOCHEM BIOPH RES CO, V198, P16, DOI 10.1006/bbrc.1994.1003; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; Norman TC, 1996, J AM CHEM SOC, V118, P7430, DOI 10.1021/ja9614934; Nugiel DA, 1997, J ORG CHEM, V62, P201, DOI 10.1021/jo961909w; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wei GL, 1997, CIRC RES, V80, P418, DOI 10.1161/01.res.0000435858.35902.ea; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	16	130	149	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29207	29211		10.1074/jbc.272.46.29207	http://dx.doi.org/10.1074/jbc.272.46.29207			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360999	hybrid			2022-12-27	WOS:A1997YF68400058
J	Galione, A; Jones, KT; Lai, FA; Swann, K				Galione, A; Jones, KT; Lai, FA; Swann, K			A cytosolic sperm protein factor mobilizes Ca2+ from intracellular stores by activating multiple Ca2+ release mechanisms independently of low molecular weight messengers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; SEA-URCHIN EGGS; INOSITOL TRISPHOSPHATE; CALCIUM OSCILLATIONS; MAMMALIAN EGGS; FERTILIZATION; WAVES; THAPSIGARGIN; RECEPTORS; RYANODINE	Ca2+ oscillations can be induced in mammalian eggs and somatic cells by microinjection of a cytosolic sperm protein factor. The nature of the sperm factor-induced Ca2+ signaling was investigated by adding sperm protein extracts to homogenates of sea urchin eggs, which contain multiple classes of Ca2+ release mechanisms. We show that the sperm factor mobilizes Ca2+ from nonmitochondrial Ca2+ stores in egg homogenates after a distinct latency. This latency is abolished by preincubation of sperm extracts with egg cytosol. The preincubation step is highly temperature-dependent and generates a high molecular weight, protein-based Ca2+-releasing agent that can also mobilize Ca2+ from purified egg microsomes. This Ca2+ release appears to be mediated via both inositol 1,4,5-trisphosphate and ryanodine receptors, since homologous desensitization of these two release mechanisms by their respective agonists inhibits further release by the sperm factor. However, sperm factor-induced Ca2+ release by these channels is independent of inositol 1,4,5-trisphosphate or cADPR since antagonists of either of these two messengers did not block the Ca2+ release effected by the sperm factor. The sperm protein factor may cause Ca2+ release via an enzymatic step that generates a protein-based Ca2+-releasing agent.	UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; NATL INST MED RES,MRC,LONDON NW7 1AA,ENGLAND	University of Oxford; MRC National Institute for Medical Research	Galione, A (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Jones, Keith/AAA-3479-2021; Jones, Keith/C-9821-2013; Galione, Antony/E-5884-2011	Jones, Keith/0000-0002-0294-0851; Jones, Keith/0000-0002-0294-0851; Swann, Karl/0000-0002-4355-1449; Galione, Antony/0000-0002-4132-7646; Lai, Tony/0000-0003-2852-8547	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAMSON JJ, 1995, J BIOL CHEM, V270, P29644; ALLEN RD, 1958, EXP CELL RES, V15, P163, DOI 10.1016/0014-4827(58)90072-7; BERRIE CP, 1996, BIOCHEM J, V311, P369; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DALE B, 1978, NATURE, V275, P217, DOI 10.1038/275217a0; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1997, TRENDS PHARMACOL SCI, V18, P108, DOI 10.1016/S0165-6147(96)01036-X; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; GUTFREUND H, 1996, KINETICS LIFE SCI; HOMA ST, 1994, HUM REPROD, V9, P2356, DOI 10.1093/oxfordjournals.humrep.a138452; JONES KT, 1995, J BIOL CHEM, V270, P6671, DOI 10.1074/jbc.270.12.6671; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; Lawrence Y, 1997, DEVELOPMENT, V124, P233; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; MCCULLOH DH, 1992, J GEN PHYSIOL, V99, P137, DOI 10.1085/jgp.99.2.137; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; Palermo GD, 1997, MOL HUM REPROD, V3, P367, DOI 10.1093/molehr/3.4.367; Parrington J, 1996, NATURE, V379, P364, DOI 10.1038/379364a0; Sette C, 1997, DEVELOPMENT, V124, P2267; Stricker SA, 1997, DEV BIOL, V186, P185, DOI 10.1006/dbio.1997.8594; Stricker SA, 1996, DEV BIOL, V176, P243, DOI 10.1006/dbio.1996.0131; SWANN K, 1990, DEVELOPMENT, V110, P1295; Swann K, 1997, BIOESSAYS, V19, P371, DOI 10.1002/bies.950190504; SWANN K, 1994, CELL CALCIUM, V15, P331, DOI 10.1016/0143-4160(94)90072-8; SWANN K, 1994, INT REV CYTOL, V152, P183, DOI 10.1016/S0074-7696(08)62557-7; TESARIK J, 1994, HUM REPROD, V9, P511, DOI 10.1093/oxfordjournals.humrep.a138537; WHITAKER M, 1993, DEVELOPMENT, V117, P1; Wu H, 1997, MOL REPROD DEV, V46, P176, DOI 10.1002/(SICI)1098-2795(199702)46:2&lt;176::AID-MRD8&gt;3.0.CO;2-N	31	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28901	28905		10.1074/jbc.272.46.28901	http://dx.doi.org/10.1074/jbc.272.46.28901			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360959	hybrid, Green Published			2022-12-27	WOS:A1997YF68400018
J	PazElizur, T; Barak, P; Livneh, Z				PazElizur, T; Barak, P; Livneh, Z			Anti-mutagenic activity of DNA damage-binding proteins mediated by direct inhibition of translesion replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI; EXCISION-REPAIR; UV MUTAGENESIS; DEOXYRIBONUCLEIC-ACID; INVITRO REPLICATION; BETA SUBUNIT; RECA PROTEIN; ABASIC SITES	DNA lesions that block replication can be bypassed in Escherichia coli by a special DNA synthesis process termed translesion replication, This process is mutagenic due to the miscoding nature of the DNA lesions, We report that the repair enzyme formamido-pyrimidine DNA glycosylase and the general DNA damage recognition protein UvrA each inhibit specifically translesion replication through an abasic site analog by purified DNA polymerases I and II, and DNA polymerase III (alpha subunit) from E. coli. In vice experiments suggest that a similar inhibitory mechanism prevents at least 70% of the mutations caused by ultraviolet light DNA lesions in E. coli. These results suggest that DNA damage-binding proteins regulate mutagenesis by a novel mechanism that involves direct inhibition of translesion replication. This mechanism provides anti-mutagenic defense against DNA lesions that have escaped DNA repair.	WEIZMANN INST SCI,FAC BIOCHEM,DEPT BIOL CHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BOITEUX S, 1993, J PHOTOCH PHOTOBIO B, V19, P87, DOI 10.1016/1011-1344(93)87101-R; BONNER CA, 1988, J BIOL CHEM, V263, P18946; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; CHAMBERS RW, 1985, P NATL ACAD SCI USA, V82, P7173, DOI 10.1073/pnas.82.21.7173; COX MM, 1981, J BIOL CHEM, V256, P4676; FRIEDBERG EC, 1995, DNA REPAIR; HEVRONI D, 1988, P NATL ACAD SCI USA, V85, P5046, DOI 10.1073/pnas.85.14.5046; HORSFALL MJ, 1994, J MOL BIOL, V235, P465, DOI 10.1006/jmbi.1994.1006; Horsfall MJ, 1997, J BACTERIOL, V179, P2835, DOI 10.1128/jb.179.9.2835-2839.1997; KUNKEL TA, 1983, BIOCHEMISTRY-US, V22, P2378, DOI 10.1021/bi00279a012; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MAKI H, 1985, J BIOL CHEM, V260, P2987; Miller J.H., 1972, EXPT MOL GENETICS; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; PazElizur T, 1997, BIOCHEMISTRY-US, V36, P1766, DOI 10.1021/bi9621324; PazElizur T, 1996, J BIOL CHEM, V271, P24662, DOI 10.1074/jbc.271.40.24662; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; RUIZRUBIO M, 1988, J BACTERIOL, V170, P5371, DOI 10.1128/jb.170.11.5371-5374.1988; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SANCAR GB, 1987, J BIOL CHEM, V262, P478; SCHAAPER RM, 1982, MUTAT RES, V106, P1, DOI 10.1016/0027-5107(82)90186-5; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SHAVITT O, 1989, J BIOL CHEM, V264, P11275; SHWARTZ H, 1987, J BIOL CHEM, V262, P10518; SHWARTZ H, 1988, J BIOL CHEM, V263, P18277; SNOWDEN A, 1990, BIOCHEMISTRY-US, V29, P7251, DOI 10.1021/bi00483a013; TADMOR Y, 1992, J BACTERIOL, V174, P2517, DOI 10.1128/jb.174.8.2517-2524.1992; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; Tomer G, 1996, P NATL ACAD SCI USA, V93, P1376, DOI 10.1073/pnas.93.4.1376; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535	40	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28906	28911		10.1074/jbc.272.46.28906	http://dx.doi.org/10.1074/jbc.272.46.28906			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360960	hybrid			2022-12-27	WOS:A1997YF68400019
J	Pinner, E; Gruenheid, S; Raymond, M; Gros, P				Pinner, E; Gruenheid, S; Raymond, M; Gros, P			Functional complementation of the yeast divalent cation transporter family SMF by NRAMP2, a member of the mammalian natural resistance-associated macrophage protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-BOVIS BCG; INTRACELLULAR PARASITES; GENETIC-CONTROL; H+-ATPASE; EXPRESSION; INFECTION; MICE; SUSCEPTIBILITY; SEQUENCE; MUTATION	The mammalian NRAMP gene family has two members, NRAMP1 and NRAMP2 that encode integral membrane proteins, Nramp1 is expressed exclusively in macrophages where it is found in the phagosomal membrane, and NRAMP1 mutations cause susceptibility to infection by abrogating the capacity of macrophages to control intracellular microbial replication. Nramp2 is highly similar to Nramp1, but is expressed in several tissues and cell types, The Nramp protein family is remarkably conserved throughout evolution, and recent data suggest that the mammalian Nramp2 and the yeast homologues Smf1 and Smf2 transport divalent cations, We tested whether structural similarity between the mammalian Nramp and the yeast Smf proteins results in functional complementation in yeast, Wild-type and mutant variants of the Nramp1 and Nramp2 proteins were expressed in a yeast mutant bearing null alleles at the SMF1 and SMF2 loci, and complementation of the phenotypes of this yeast mutant was investigated, Nramp2, but not Nramp1, was found to complement hypersensitivity to EGTA of the smf1/smf2 mutant under oxidative stress conditions (methyl viologen), We also observed that the smf1/smf2 double mutant is hypersensitive to growth at alkaline pH (pH 7.9) and that Nramp2 could complement this phenotype as well, Complementation by Nramp2 was specific and required a functional protein as independent mutations in residues highly conserved in all members of the Nramp family abrogated Nramp2 complementation. Since Mn2+ was the only divalent cation capable of completely suppressing both the EGTA and pH phenotypes, our results suggest that Nramp2 can transport Mn2+ in yeast.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; CLIN RES INST MONTREAL,MONTREAL,PQ H2W 1R7,CANADA	McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal				Gruenheid, Samantha/0000-0002-0908-6715	NIAID NIH HHS [AI35237-04A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI035237, R01AI035237] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097, DOI 10.1093/nar/21.13.3097; Belouchi A, 1997, PLANT MOL BIOL, V33, P1085, DOI 10.1023/A:1005723304911; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BRADLEY DJ, 1977, CLIN EXP IMMUNOL, V30, P130; Cellier M, 1996, TRENDS GENET, V12, P201, DOI 10.1016/0168-9525(96)30042-5; Cellier M, 1997, J LEUKOCYTE BIOL, V61, P96, DOI 10.1002/jlb.61.1.96; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; CROCKER PR, 1984, INFECT IMMUN, V43, P1033, DOI 10.1128/IAI.43.3.1033-1040.1984; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DESCOTEAUX S, 1994, INFECT IMMUN, V62, P3572, DOI 10.1128/IAI.62.8.3572-3575.1994; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Govoni G, 1996, INFECT IMMUN, V64, P2923, DOI 10.1128/IAI.64.8.2923-2929.1996; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GROS P, 1983, J IMMUNOL, V131, P1966; GROS P, 1981, J IMMUNOL, V127, P2417; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; LISSNER CR, 1983, J IMMUNOL, V131, P3006; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PLANT J, 1976, J INFECT DIS, V133, P72, DOI 10.1093/infdis/133.1.72; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SHERMAN F, 1982, METHODS YEAST GENETI, P163; STACH JL, 1984, J IMMUNOL, V132, P888; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; Vidal SM, 1996, J IMMUNOL, V157, P3559; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WEST AH, 1992, J BIOL CHEM, V267, P24625; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882	36	104	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28933	28938		10.1074/jbc.272.46.28933	http://dx.doi.org/10.1074/jbc.272.46.28933			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360964	hybrid			2022-12-27	WOS:A1997YF68400023
J	Diviani, D; Lattion, AL; Cotecchia, S				Diviani, D; Lattion, AL; Cotecchia, S			Characterization of the phosphorylation sites involved in G protein-coupled receptor kinase- and protein kinase C-mediated desensitization of the alpha(1B)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; RHODOPSIN KINASE; MULTIPLE PHOSPHORYLATION; CARBOXYL-TERMINUS; 48-KDA PROTEIN; IN-VIVO; IDENTIFICATION; SPECIFICITY; ACTIVATION; TRUNCATION	Catecholamines as well as phorbol esters can induce the phosphorylation and desensitization of the alpha(1B)-adrenergic receptor (alpha(1B)AR). In this study, phosphoamino acid analysis of the phosphorylated alpha(1B)AR revealed that both epinephrine-and phorbol ester-induced phosphorylation predominantly occurs at serine residues of the receptor, The findings obtained with receptor mutants in which portions of the C-tail were truncated or deleted indicated that a region of 21 amino acids (393-413) of the carboxyl terminus including seven serines contains the main phosphorylation sites involved in agonist-as well as phorbol ester-induced phosphorylation and desensitization of the alpha(1B)AR. To identify the serines invoved in agonist-versus phorbol ester-dependent regulation of the receptor, two different strategies were adopted, the seven serines were either substituted with alanine or reintroduced into a mutant lacking all of them, Our findings indicate that Ser(394) and Ser(400) were phosphorylated following phorbol ester-induced activation of protein kinase C, whereas Ser(404), Ser(408), and Ser(410) were phosphorylated upon stimulation of the alpha(1B)AR with epinephrine, The observation that overexpression of G protein-coupled kinase 2 (GRK2) could increase agonist-induced phosphorylation of Ser(404), Ser(408), and Ser(410), strongly suggests that these serines are the phosphorylation sites of the alpha(1B)AR for kinases of the GRK family, Phorbol ester-induced phosphorylation of the Ser(394) and Ser(400) as well as GRK2-mediated phosphorylation of the Ser(404), Ser(408), and Ser(410), resulted in the desensitization of cu,BAR-mediated inositol phosphate response, This study provides generalities about the biochemical mechanisms underlying homologous and heterologous desensitization of G protein-coupled receptors linked to the activation of phospholipase C.	INST PHARMACOL & TOXICOL, FAC MED, CH-1005 LAUSANNE, SWITZERLAND	University of Geneva				Diviani, Dario/0000-0003-4375-3718				ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Diviani D, 1996, J BIOL CHEM, V271, P5049; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; Greene NM, 1997, J BIOL CHEM, V272, P10341; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1994, J BIOL CHEM, V269, P1125; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; LATTION AL, 1994, J BIOL CHEM, V269, P22887; Lembo PMC, 1995, MOL PHARMACOL, V48, P1024; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1995, J BIOL CHEM, V270, P15294, DOI 10.1074/jbc.270.25.15294; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Widmann C, 1996, J BIOL CHEM, V271, P19957, DOI 10.1074/jbc.271.33.19957; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YUAN NY, 1994, J BIOL CHEM, V269, P23032	35	113	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28712	28719		10.1074/jbc.272.45.28712	http://dx.doi.org/10.1074/jbc.272.45.28712			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353340	hybrid			2022-12-27	WOS:A1997YF21900080
J	Tiger, CF; Champliaud, MF; PedrosaDomellof, F; Thornell, LE; Ekblom, P; Gullberg, D				Tiger, CF; Champliaud, MF; PedrosaDomellof, F; Thornell, LE; Ekblom, P; Gullberg, D			Presence of laminin alpha 5 chain and lack of laminin alpha 1 chain during human muscle development and in muscular dystrophies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHAIN; EXTRACELLULAR-MATRIX; DIFFERENTIAL EXPRESSION; MONOCLONAL-ANTIBODIES; SKELETAL-MUSCLE; MOLECULAR-CLONING; MYOGENIC CELLS; MEROSIN; KIDNEY; MYOBLASTS	There is currently a great interest in identifying laminin isoforms expressed in developing and regenerating skeletal muscle. Laminin alpha 1 has been reported to localize to human fetal muscle and to be induced in muscular dystrophies based on immunohistochemistry with the monoclonal antibody 4C7, suggested to recognize the human laminin alpha 1 chain. Nevertheless, there seems to be no expression of laminin alpha 1 protein or mRNA in developing or dystrophic mouse skeletal muscle fibers. To address the discrepancy between the results obtained in developing and dystrophic human and mouse muscle we expressed the E3 domain of human laminin alpha 1 chain as a recombinant protein and made antibodies specific for human laminin alpha 1 chain (anti-hLN-alpha 1G4/G5). We also made antibodies to the human laminin alpha 5 chain purified from placenta. In the present report we show that hLN-alpha 1G4/G5 antibodies react with a 400-kDa laminin alpha 1 chain and that 4C7 reacts with a 380-kDa laminin alpha 5 chain. Immunohistochemistry with the hLN-alpha 1G4/G5 antibody and 4C7 revealed that the two antibodies stained human kidney, developing and dystrophic muscle in distinct patterns. Our data indicate that the previously reported expression patterns in developing, adult, and dystrophic human muscle tissues with 4C7 should be re-interpreted as an expression of laminin alpha 5 chain. Our data are also consistent with earlier work in mouse, indicating that laminin alpha 1 is largely an epithelial laminin chain not present in developing or dystrophic muscle fibers.	UPPSALA UNIV,DEPT ANIM PHYSIOL,BMC,S-75124 UPPSALA,SWEDEN; HARVARD UNIV,MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,SCH MED,CHARLESTOWN,MA 02142; UMEA UNIV,DEPT ANAT,S-90187 UMEA,SWEDEN	Uppsala University; Harvard University; Massachusetts General Hospital; Umea University			Thornell, Lars-Eric/L-8358-2019; Gullberg, Donald/H-2495-2016	Gullberg, Donald/0000-0002-7245-4437; Pedrosa Domellof, Fatima/0000-0002-0648-4996				Allamand V, 1997, HUM MOL GENET, V6, P747, DOI 10.1093/hmg/6.5.747; BIROC SL, 1993, DEV BRAIN RES, V75, P119, DOI 10.1016/0165-3806(93)90071-H; BISCHOFF R, 1990, DEVELOPMENT, V109, P943; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; De Arcangelis A, 1996, J CELL BIOL, V133, P417, DOI 10.1083/jcb.133.2.417; Durbeej M, 1996, MATRIX BIOL, V15, P397, DOI 10.1016/S0945-053X(96)90159-6; Durkin ME, 1997, FEBS LETT, V411, P296, DOI 10.1016/S0014-5793(97)00686-8; Echtermeyer F, 1996, J BIOL CHEM, V271, P2071, DOI 10.1074/jbc.271.4.2071; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; Ekblom P, 1996, CURR OPIN CELL BIOL, V8, P700, DOI 10.1016/S0955-0674(96)80112-8; EKBLOM P, 1980, DEV BIOL, V74, P263, DOI 10.1016/0012-1606(80)90429-7; Eng H, 1997, DIFFERENTIATION, V61, P169, DOI 10.1046/j.1432-0436.1997.6130169.x; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; ENGVALL E, 1986, J CELL BIOL, V103, P2457, DOI 10.1083/jcb.103.6.2457; EVELLING T, 1996, DEV DYNAM, V207, P355; GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799; Gullberg D, 1995, INT J DEV BIOL, V39, P845; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; JAFFREDO T, 1988, DEVELOPMENT, V103, P431; Jaspars LH, 1996, CELL ADHES COMMUN, V4, P269, DOI 10.3109/15419069609010771; JIN P, 1993, DIFFERENTIATION, V54, P47; KLEIN G, 1990, DEVELOPMENT, V110, P823; Korhonen M, 1997, J HISTOCHEM CYTOCHEM, V45, P569, DOI 10.1177/002215549704500409; MCCOURT PAG, 1994, J BIOL CHEM, V269, P30081; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; MUNDEGAR RR, 1995, MUSCLE NERVE, V18, P992, DOI 10.1002/mus.880180911; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; ROSE O, 1994, DEV DYNAM, V201, P245, DOI 10.1002/aja.1002010308; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SCHULER F, 1995, J CELL SCI, V108, P3795; SEWRY CA, 1995, HISTOCHEM J, V27, P497; SEWRY CA, 1995, NEUROMUSCULAR DISORD, V5, P307, DOI 10.1016/0960-8966(94)00072-H; SOROKIN LM, 1992, EXP CELL RES, V201, P137, DOI 10.1016/0014-4827(92)90357-E; SOROKIN LM, 1997, IN PRESS DEV BIOL; SUNADA Y, 1995, NEUROLOGY, V45, P2084, DOI 10.1212/WNL.45.11.2084; TALTS JF, 1993, INT J CANCER, V54, P868, DOI 10.1002/ijc.2910540524; TIGER CF, 1997, IN PRESS MUSCLE NERV; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; VACHON PH, 1995, AM J PHYSIOL-GASTR L, V268, pG857, DOI 10.1152/ajpgi.1995.268.5.G857; VIRTANEN I, 1995, J HISTOCHEM CYTOCHEM, V43, P621, DOI 10.1177/43.6.7769233; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755	52	188	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28590	28595		10.1074/jbc.272.45.28590	http://dx.doi.org/10.1074/jbc.272.45.28590			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353324	hybrid			2022-12-27	WOS:A1997YF21900064
J	Elble, RC; Widom, J; Gruber, AD; AbdelGhany, M; Levine, R; Goodwin, A; Cheng, HC; Pauli, BU				Elble, RC; Widom, J; Gruber, AD; AbdelGhany, M; Levine, R; Goodwin, A; Cheng, HC; Pauli, BU			Cloning and characterization of lung endothelial cell adhesion molecule-1 suggest it is an endothelial chloride channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE TRACHEA; METASTASIS; GLYCOPROTEIN; RECOGNITION; EXPRESSION; LU-ECAM-1; SEQUENCE; PROTEINS	Lung-endothelial cell adhesion molecule-1 (Lu-ECAM-1) is an endothelial cell surface molecule that mediates adhesion of metastatic melanoma cells to lung endothelium, Here we analyze the organization of the Lu-ECAM-1 protein complex, report the sequence of Lu-ECAM-1 cDNAs, and reveal a novel function of the protein, Lu-ECAM-1 immunopurified from bovine aortic endothelial cells (BAEC) consists of tightly associated glycoproteins of 90, 38, and 32 kDa, with minor components of 130 and 120 kDa, We present evidence that all of these protein species are encoded by a single open reading frame whose initial translation product is proteolytically processed to yield the other products, Correct processing in. vitro was demonstrated by transfection of the longest cDNA into human embryonic kidney 293 cells; immunoblot analysis showed that the similar to 120-kDa precursor gave rise to 90- and 38-kDa products, RNA blots of BAEC mRNA detected messages in agreement with the sizes of the cDNA clones in addition to several of high molecular weight, DNA blot analysis showed that Lu-ECAM-1 is conserved throughout its length in all mammals tested, usually as a single or low copy gene, In the bovine, Lu-ECAM-1 protein is 88% identical to a calcium-dependent chloride channel described recently in tracheal epithelium, Ca-CC, Probes for Lu-ECAM-1 mRNA and protein confirmed the presence of a homolog in this tissue, We show that messages for both proteins are present in lung while only Ca-CC is present in trachea and only Lu-ECAM-1 is present in BAEC, These results suggest that endothelial cells express a chloride channel that is related to, but distinct from, that expressed in tracheal epithelium, They further suggest that an adhesion molecule can also be a chloride channel.	CORNELL UNIV,COLL VET MED,DEPT PATHOL,CANC BIOL LABS,ITHACA,NY 14853	Cornell University			Gruber, Achim D./ABA-4514-2021		NATIONAL CANCER INSTITUTE [T32CA009682, R01CA047668] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09682, CA 47668] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1993, LAB INVEST, V68, P4; ALBELDA SM, 1991, AM J RESP CELL MOL B, V4, P193; AUGUSTINVOSS HG, 1991, EXP CELL RES, V192, P346, DOI 10.1016/0014-4827(91)90051-U; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCKCROFT VB, 1990, PROTEINS, V8, P386, DOI 10.1002/prot.340080412; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; Elble RC, 1996, CURR TOP MICROBIOL, V213, P107; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P330; Goetz DJ, 1996, INT J CANCER, V65, P192, DOI 10.1002/(SICI)1097-0215(19960117)65:2<192::AID-IJC11>3.0.CO;2-G; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; JOVOV B, 1995, J BIOL CHEM, V270, P1521, DOI 10.1074/jbc.270.4.1521; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Kunz S, 1996, J CELL BIOL, V135, P253, DOI 10.1083/jcb.135.1.253; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PAULI BU, 1988, LAB INVEST, V58, P379; PAULI BU, 1997, ENCY CANC, V1, P464; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; QIAN LA, 1993, MOL CELL BIOL, V13, P1686, DOI 10.1128/MCB.13.3.1686; RAN S, 1992, J BIOL CHEM, V267, P3618; Sambrook J., 2002, MOL CLONING LAB MANU; TAKADA A, 1993, CANCER RES, V53, P354; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; ZHU DZ, 1993, INT J CANCER, V53, P628; ZHU DZ, 1991, J HISTOCHEM CYTOCHEM, V39, P1137, DOI 10.1177/39.8.1856462; ZHU DZ, 1992, J CLIN INVEST, V89, P1718, DOI 10.1172/JCI115773; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	31	82	90	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27853	27861		10.1074/jbc.272.44.27853	http://dx.doi.org/10.1074/jbc.272.44.27853			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346932	hybrid			2022-12-27	WOS:A1997YD47300058
J	Nikaido, K; Liu, PQ; Ames, GFL				Nikaido, K; Liu, PQ; Ames, GFL			Purification and characterization of HisP, the ATP-binding subunit of a traffic ATPase (ABC transporter), the histidine permease of Salmonella typhimurium - Solubility, dimerization, and ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; MALTOSE TRANSPORT; CYSTIC-FIBROSIS; PERIPLASMIC TRANSPORT; CONFORMATIONAL CHANGE; MULTIDRUG-RESISTANCE; PROTEIN CONFORMATION; MEMBRANE-COMPONENTS; CIRCULAR-DICHROISM	The nucleotide-binding subunit, HisP, of the histidine permease, a traffic ATPase (ABC transporter), has been purified as a soluble protein and characterized. Addition of a 6-histidine extension (HisP((His6))) allows a rapid and effective metal affinity purification, giving a 30-fold purification with a yield of 50%. HisP((his6)) is indistinguishable from underivatized HisP when incorporated into the permease membrane-bound complex, HisQMP(2). Purified HisP((his6)) has a strong tendency to precipitate; 5 mM ATP and 20% glycerol maintain it in solution at a high protein concentration. HisP((his6)) is active as a dimer, binds ATP with a K-d value of 205 mu M, and hydrolyzes it at a rate comparable to that of HisQMP(2); in contrast to the latter, it does not display cooperativity for ATP. HisP((his6)) has been characterized with respect to substrate and inhibitor specificity and Various physico-chemical characteristics. Its pH optimum is 7 and it requires a cation for activity, with Co(2+)and Mn2+ being more effective than Mg2+ at lower concentrations but inhibitory in the higher concentration range. In contrast to the intact complex, HisP((his6)) is not inhibited by vanadate but is inhibited by N-ethylmaleimide. Neither the soluble receptor, HisJ, nor the transport substrate, histidine, has any effect on the activity.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NIDDK NIH HHS [DK12121] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012121, R01DK012121] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES GF, 1968, J BACTERIOL, V96, P1742, DOI 10.1128/JB.96.5.1742-1749.1968; AMES GF, 1989, J BIOL CHEM, V264, P3998; AMES GF, 1968, J BACTERIOL, V95, P833, DOI 10.1128/JB.95.3.833-843.1968; AMES GF, 1964, ARCH BIOCHEM BIOPHYS, V104, P1, DOI 10.1016/S0003-9861(64)80028-X; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; AMES GFL, 1978, P NATL ACAD SCI USA, V75, P5447, DOI 10.1073/pnas.75.11.5447; AMES GFL, 1981, EUR J BIOCHEM, V115, P525; AMES GFL, 1990, BACTERIAL ENERGETICS, P225; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Liu CE, 1997, J BIOL CHEM, V272, P859, DOI 10.1074/jbc.272.2.859; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MORBACH S, 1993, J BIOL CHEM, V268, P18617; NIKAIDO H, 1994, FEBS LETT, V346, P55, DOI 10.1016/0014-5793(94)00315-7; PARCZEL A, 1992, ANAL BICHEM, V203, P83; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WALTER C, 1992, J BIOL CHEM, V267, P8863; WEICHELMAN K, 1988, ANAL BIOCHEM, V175, P231; WOLF A, 1995, J BIOL CHEM, V270, P16097, DOI 10.1074/jbc.270.27.16097; YANG JT, 1986, METHOD ENZYMOL, V130, P208	42	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27745	27752		10.1074/jbc.272.44.27745	http://dx.doi.org/10.1074/jbc.272.44.27745			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346917	hybrid			2022-12-27	WOS:A1997YD47300043
J	Dickinson, JR; Lanterman, MM; Danner, DJ; Pearson, BM; Sanz, P; Harrison, SJ; Hewlins, MJE				Dickinson, JR; Lanterman, MM; Danner, DJ; Pearson, BM; Sanz, P; Harrison, SJ; Hewlins, MJE			A C-13 nuclear magnetic resonance investigation of the metabolism of leucine to isoamyl alcohol in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXOSE-MONOPHOSPHATE PATHWAY; ACETYL-COA HYDROLASE; SOLE NITROGEN-SOURCE; CHAIN AMINO-ACIDS; PYRUVATE DECARBOXYLASE; DEHYDROGENASE; GENE; ENZYMES; PURIFICATION; SPORULATION	The metabolism of leucine to isoamyl alcohol in yeast was examined by C-13 nuclear magnetic resonance spectroscopy. The product of leucine transamination, alpha-ketoisocaproate had four potential routes to isoamyl alcohol. The first, via branched-chain alpha-keto acid dehydrogenase to isovaleryl-CoA with subsequent conversion to isovalerate by acyl-CoA hydrolase operates in wild-type cells where isovalerate appears to be an end product. This pathway is not required for the synthesis of isoamyl alcohol because abolition of branched-chain alpha-keto acid dehydrogenase activity in an lpd1 disruption mutant did not prevent the formation of isoamyl alcohol. A second possible route was via pyruvate decarboxylase; however, elimination of pyruvate decarboxylase activity in a pdc1 pdc5 pdc6 triple mutant did not decrease the levels of isoamyl alcohol produced. A third route utilizes alpha-ketoisocaproate reductase (a novel activity in Saccharomyces cerevisiae) but with no role in the formation of isoamyl alcohol from alpha-hydroxyisocaproate because cell homogenates could not convert alpha-hydroxyisocaproate to isoamyl alcohol. The final possibility was that a pyruvate decarboxylase-like enzyme encoded by YDL080c appears to be the major route of decarboxylation of alpha-ketoisocaproate to isoamyl alcohol although disruption of this gene reveals that at least one other unidentified decarboxylase can substitute to a minor extent.	EMORY UNIV, SCH MED, DEPT GENET, ATLANTA, GA 30322 USA; INST FOOD RES, NORWICH NR4 7UA, NORFOLK, ENGLAND; CSIC, INST AGROQUIM & TECNOL ALIMENTOS, E-46010 VALENCIA, SPAIN; UNIV WALES COLL CARDIFF, DEPT CHEM, CARDIFF CF1 3TB, S GLAM, WALES	Emory University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA); Cardiff University	Dickinson, JR (corresponding author), UNIV WALES COLL CARDIFF, SCH PURE & APPL BIOL, POB 915, CARDIFF CF1 3TL, S GLAM, WALES.		Sanz, Pascual/K-2751-2014	Sanz, Pascual/0000-0002-2399-4103; Pearson, Bruce/0000-0002-9223-7712				Bender D.A., 1975, AMINO ACID METABOLIS; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; DERRICK S, 1993, J GEN MICROBIOL, V139, P2783, DOI 10.1099/00221287-139-11-2783; DICKINSON JR, 1991, J GEN MICROBIOL, V137, P1033, DOI 10.1099/00221287-137-5-1033; DICKINSON JR, 1983, P NATL ACAD SCI-BIOL, V80, P5847, DOI 10.1073/pnas.80.19.5847; DICKINSON JR, 1993, FEBS LETT, V326, P29, DOI 10.1016/0014-5793(93)81754-N; DICKINSON JR, 1986, MOL GEN GENET, V204, P103; DICKINSON JR, 1992, J GEN MICROBIOL, V138, P2029, DOI 10.1099/00221287-138-10-2029; DICKINSON JR, 1988, J GEN MICROBIOL, V134, P333; Dickinson JR, 1996, MICROBIOL-UK, V142, P1391, DOI 10.1099/13500872-142-6-1391; DICKINSON JR, 1995, MICROBIOL-UK, V141, P385, DOI 10.1099/13500872-141-2-385; DICKINSON JR, 1988, J GEN MICROBIOL, V133, P135; Ehrlich F, 1907, BER DTSCH CHEM GES, V40, P1027, DOI 10.1002/cber.190704001156; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HOHMANN S, 1990, EUR J BIOCHEM, V188, P615, DOI 10.1111/j.1432-1033.1990.tb15442.x; HOHMANN S, 1991, J BACTERIOL, V173, P7963, DOI 10.1128/jb.173.24.7963-7969.1991; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; Lanterman MM, 1996, HUM MOL GENET, V5, P1643, DOI 10.1093/hmg/5.10.1643; Large P. J., 1986, YEAST, V2, P1; LEE FJS, 1990, J BIOL CHEM, V265, P7413; LEE FJS, 1989, EUR J BIOCHEM, V184, P21, DOI 10.1111/j.1432-1033.1989.tb14985.x; LERCH HP, 1989, GENE, V78, P47, DOI 10.1016/0378-1119(89)90313-2; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; Neubauer O, 1911, H-S Z PHYSIOL CHEM, V70, P326; NISHIMURA H, 1992, J BACTERIOL, V174, P4701, DOI 10.1128/JB.174.14.4701-4706.1992; REPTTO B, 1991, MOL CELL BIOL, V11, P3931; SCHMITT HD, 1982, J BACTERIOL, V151, P1146, DOI 10.1128/JB.151.3.1146-1152.1982; Sherman F, 1975, Methods Cell Biol, V11, P189, DOI 10.1016/S0091-679X(08)60323-4; SINCLAIR DA, 1995, GENETICS, V140, P1213; SINCLAIR DA, 1993, BIOCHEM MOL BIOL INT, V31, P911; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; WEBB A. DINSMOOR, 1963, ADVAN APPL MICROBIOL, V5, P317, DOI 10.1016/S0065-2164(08)70014-5	32	157	172	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26871	26878		10.1074/jbc.272.43.26871	http://dx.doi.org/10.1074/jbc.272.43.26871			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341119	hybrid			2022-12-27	WOS:A1997YC65900015
J	Arata, Y; Hirabayashi, J; Kasai, K				Arata, Y; Hirabayashi, J; Kasai, K			Structure of the 32-kDa galectin gene of the nematode Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; CARBOHYDRATE-RECOGNITION DOMAINS; MACROPHAGE MANNOSE RECEPTOR; AMINO-ACID-SEQUENCE; SITE-DIRECTED MUTAGENESIS; NEGATIVE GROWTH-FACTOR; FULL-LENGTH CDNA; C-ELEGANS; ANIMAL LECTINS; MESSENGER-RNA	Galectins are a family of soluble beta-galacto side-binding lectins distributed in both vertebrates and invertebrates and, more recently, found also in fungus, The 32-kDa galectin isolated from the nematode Caenorhabditis elegans (Hirabayashi, J., Satoh, M., and Kasai, K. (1992) J. Biol. Chem. 267, 15485-15490) was the first ''tandem repeat-type'' galectin, containing two homologous carbohydrate-binding sites. Here, we report the structure of the nematode 32-kDa galectin gene, Physical mapping by yeast artificial chromosome polytene filter hybridization revealed that the 32-kDa galectin gene is located on chromosome II. Analysis of the transcript (1.4 kilobases) showed the presence at its 5'-end of a 22-nucleotide trans-spliced leader sequence (SL1), The entire genomic structure spanning >5 kilobase pairs (kbp), including the 5'-noncoding region, two intervening sequences (introns 1 and 2), and the 3'-noncoding region, was completely determined by the combination of genomic polymerase chain reaction and conventional colony hybridization, Intron 1 was relatively long (2.4 kbp) and was found to be inserted after the ninth codon (TAG) from the initiation codon, This position proved to be almost homologous to the conserved first intron insertion position in the vertebrate galectin genes (i.e. genes of mammalian galectin-1, -2, and -3 and chick 14-kDa galectin), On the other hand, intron 2 was much shorter (0.6 kbp), and it was inserted into the central region of the second carbohydrate-binding site. Although such an insertion pattern has never been observed in the vertebrate galectin genes, it seems to be common in C. elegans tandem repeat-type galectin genes, as predicted by the C. elegans genome project (Coulson, A., and the C. elegans Genome Consortium (1996) Biochem, Sec. Trans, 24, 289-291), Based on extensive sequence comparison, the origin and molecular evolution of the tandem repeat-type galectins are discussed.			Arata, Y (corresponding author), TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,SAGAMIKO,KANAGAWA 19901,JAPAN.							ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; ACKERMAN SJ, 1993, J IMMUNOL, V150, P456; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arata Y, 1997, J BIOCHEM-TOKYO, V121, P1002, DOI 10.1093/oxfordjournals.jbchem.a021686; Arata Y, 1996, HISTOCHEM J, V28, P201, DOI 10.1007/BF02331444; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRENNER S, 1974, GENETICS, V77, P71; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHIARIOTTI L, 1991, BIOCHIM BIOPHYS ACTA, V1089, P54, DOI 10.1016/0167-4781(91)90084-Y; CHIU ML, 1994, J BIOL CHEM, V269, P31770; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; CONRAD R, 1993, EMBO J, V12, P1249, DOI 10.1002/j.1460-2075.1993.tb05766.x; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; Cooper DNW, 1997, J BIOL CHEM, V272, P1514, DOI 10.1074/jbc.272.3.1514; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; Coulson A, 1996, BIOCHEM SOC T, V24, P289, DOI 10.1042/bst0240289; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; Epstein HF, 1995, METHODS CELL BIOL, V48; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; GITT MA, 1995, GLYCOCONJUGATE J, V12, P548; GRITZMACHER CA, 1992, BIOCHEMISTRY-US, V31, P9533, DOI 10.1021/bi00155a004; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HARRIS N, 1994, BIOCHEM BIOPH RES CO, V198, P682, DOI 10.1006/bbrc.1994.1099; HARRIS N, 1992, BLOOD, V80, P2363; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; Hirabayashi J, 1996, J BIOL CHEM, V271, P2497, DOI 10.1074/jbc.271.5.2497; HIRABAYASHI J, 1988, J BIOCHEM-TOKYO, V104, P1; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; HIRABAYASHI J, 1989, BIOCHIM BIOPHYS ACTA, V1008, P85, DOI 10.1016/0167-4781(89)90173-5; HIRABAYASHI J, 1994, GLYCOCONJUGATE J, V11, P437, DOI 10.1007/BF00731280; HIRABAYASHI J, 1992, J BIOCHEM-TOKYO, V111, P553, DOI 10.1093/oxfordjournals.jbchem.a123794; Hirabayashi J, 1997, TRENDS GLYCOSCI GLYC, V9, P1; HIRABAYASHI J, 1993, TRENDS GLYCOSCI GLYC, V5, P251; JIA SH, 1988, J BIOL CHEM, V263, P6009; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KIM SJ, 1992, GENOMICS, V14, P721, DOI 10.1016/S0888-7543(05)80174-0; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; ODA Y, 1993, J BIOL CHEM, V268, P5929; ODA Y, 1991, GENE, V99, P279; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Sambrook J., 2002, MOL CLONING LAB MANU; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; Wood WB, 1988, NEMATODE CAENORHABDI	63	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26669	26677		10.1074/jbc.272.42.26669	http://dx.doi.org/10.1074/jbc.272.42.26669			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334250	hybrid			2022-12-27	WOS:A1997YB13900084
J	Katahira, J; Sugiyama, H; Inoue, N; Horiguchi, Y; Matsuda, M; Sugimoto, N				Katahira, J; Sugiyama, H; Inoue, N; Horiguchi, Y; Matsuda, M; Sugimoto, N			Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERO CELLS; RABBIT ILEUM; TOXIN; BINDING; GENE; RAT; PERMEABILITY; TRANSCRIPTS; CALCIUM; HELA	Human and mouse cDNAs showing homology to the Clostridium perfringens enterotoxin (CPE) receptor gene (CPE-R) from Vero cells (DDBJ/EMBL/GenBank(TM) accession no. D88492) (Katahira, J,, Inoue, N., Horiguchi, Y., Matsuda, M., and Sugimoto, N. (1997) J. Cell Biol. 136, 1239-1247) were cloned, They were classified into two groups, the Vero cell CPE receptor homologues and rat androgen withdrawal apoptosis protein (RVP1; accession no. M74067) homologues, based on the similarities of primary amino acid sequences. L929 cells that were originally insensitive to CPE became sensitive to CPE on their transfection with cDNAs encoding either the CPE receptor or RVP1 homologues, indicating that these gene products are not only structurally similar but also functionally active as receptors for CPE. Ey binding assay, the human RVP1 homologue showed differences in affinity and capacity of binding from those of the human CPE receptor, Northern blot analysis showed that mouse homologues of the CPE receptor and RVP1 are expressed abundantly in mouse small intestine. The expression of CPE-R mRNA in the small intestine was restricted to cryptic enterocytes, indicating that the CPE receptor is expressed in intestinal epithelial cells. These results are consistent with reports that CPE binds to the small intestinal cells via two different kinds of receptors, High levels of expression of CPE-R and/or RVP1 mRNA were also detected in other organs, including the lungs, liver, and kidneys, but only low levels were expressed in heart; and skeletal muscles. These results indicate that CPE uses structurally related cellular proteins as functional receptors in vivo and that organs that have not so far been recognized as CPE-sensitive have the potential to be targets of CPE.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT BACTERIAL TOXICOL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT IMMUNOREGULAT,SUITA,OSAKA 565,JAPAN; NATL INST HLTH,DEPT PARASITOL,SHINJUKU KU,TOKYO 162,JAPAN	Osaka University; Osaka University				Katahira, Jun/0000-0001-5188-0368				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRIEHL MM, 1991, MOL ENDOCRINOL, V5, P1381, DOI 10.1210/mend-5-10-1381; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HORIGUCHI Y, 1985, FEMS MICROBIOL LETT, V28, P131; Katahira J, 1997, J CELL BIOL, V136, P1239, DOI 10.1083/jcb.136.6.1239; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MATSUDA M, 1979, BIOCHEM BIOPH RES CO, V91, P629, DOI 10.1016/0006-291X(79)91568-7; MATSUDA M, 1986, BIOCHEM BIOPH RES CO, V141, P704, DOI 10.1016/S0006-291X(86)80229-7; MCCLANE BA, 1981, BIOCHIM BIOPHYS ACTA, V641, P401, DOI 10.1016/0005-2736(81)90496-X; MCCLANE BA, 1979, J CELL PHYSIOL, V99, P191, DOI 10.1002/jcp.1040990205; MCCLANE BA, 1987, MICROB PATHOGENESIS, V3, P195, DOI 10.1016/0882-4010(87)90096-9; McDonel J. L., 1986, Pharmacology of bacterial toxins, P477; MCDONEL JL, 1979, BIOCHEM BIOPH RES CO, V87, P497, DOI 10.1016/0006-291X(79)91823-0; MCDONEL JL, 1975, INFECT IMMUN, V12, P1214, DOI 10.1128/IAI.12.5.1214-1218.1975; MCDONEL JL, 1980, BIOCHEMISTRY-US, V19, P4801, DOI 10.1021/bi00562a014; MCDONEL JL, 1978, LAB INVEST, V39, P210; Ohishi K, 1996, GENOMICS, V34, P340, DOI 10.1006/geno.1996.0296; SAKAGUCHI G, 1973, APPL MICROBIOL, V27, P762; SKJELKVALE R, 1980, ACTA PATH MICRO IM B, V88, P95; STARK RL, 1971, INFECT IMMUN, V4, P89, DOI 10.1128/IAI.4.2.89-96.1971; SUGIMOTO N, 1988, BIOCHEM BIOPH RES CO, V156, P551, DOI 10.1016/S0006-291X(88)80877-5; SUGIMOTO N, 1985, European Journal of Epidemiology, V1, P264; TOLLESHAUG H, 1982, INFECT IMMUN, V37, P486, DOI 10.1128/IAI.37.2.486-491.1982; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; Watanabe R, 1996, J BIOL CHEM, V271, P26868, DOI 10.1074/jbc.271.43.26868; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WNEK AP, 1986, MICROB PATHOGENESIS, V1, P89, DOI 10.1016/0882-4010(86)90035-5	29	211	223	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26652	26658		10.1074/jbc.272.42.26652	http://dx.doi.org/10.1074/jbc.272.42.26652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334247	hybrid			2022-12-27	WOS:A1997YB13900081
J	Muresan, Z; Arvan, P				Muresan, Z; Arvan, P			Thyroglobulin transport along the secretory pathway - Investigation of the role of molecular chaperone, GRP94, in protein export from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; IMMUNOGLOBULIN HEAVY-CHAIN; INFLUENZA HEMAGGLUTININ; CONGENITAL GOITER; SEQUENTIAL INTERACTION; SELECTIVE PROTEINS; GOLGI-COMPLEX; BIP; CELLS; GLYCOPROTEIN	GRP94 serves as a molecular chaperone in the endoplasmic reticulum (ER), In normal thyrocytes, GRP94 interacts transiently with thyroglobulin (Tg), and in thyrocytes of animals suffering from congenital hypothyroid goiter with defective thyroglobulin, GRP94 and thyroglobulin associate in a protracted fashion. In order explore possible consequences of GRP94 binding, we have studied recombinant nonmutant thyroglobulin expressed in control Chinese hamster ovary (CHO) cells in comparison to that produced in CHO cells genetically manipulated for selectively increased GRP94 expression. Levels of ER chaperones other than GRP94 did not detectably differ, and thyroglobulin achieved transport competence in both kinds of CHO cells. However, increased availability of GRP94 caused the residence time of Tg in the ER to be remarkably prolonged, This was accompanied by a major increase in Tg directly associated with GRP94 and an increase in the ER pool size of Tg. Importantly, co-immunoprecipitation analysis revealed disulfide-linked Tg complexes (previously reported as an early Tg-folding intermediate) especially associated with GRP94. Indeed, non-native Tg, GRP94, and a 78-kDa protein likely to be BiP, appeared in ternary complexes. Under these conditions, GRP94 association appears directly involved in prolongation of Tg folding and export, consistent with a role in quality control in the ER.	HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02215	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040344, F32DK009411, R29DK040344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09411, DK40344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arvan P, 1997, THYROID, V7, P89, DOI 10.1089/thy.1997.7.89; ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BEAMER WG, 1987, ENDOCRINOLOGY, V120, P838, DOI 10.1210/endo-120-2-838; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; DORNER AJ, 1994, BIOLOGICALS, V22, P103, DOI 10.1006/biol.1994.1016; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GRAVES PN, 1990, MOL ENDOCRINOL, V4, P155, DOI 10.1210/mend-4-1-155; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HURTLEY SM, 1989, J CELL BIOL, V108, P2116; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KIM PS, 1991, J BIOL CHEM, V266, P12412; KIM PS, 1993, AM J PHYSIOL, V265, pC704, DOI 10.1152/ajpcell.1993.265.3.C704; KIM PS, 1993, J BIOL CHEM, V268, P4873; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MAKI RG, 1990, P NATL ACAD SCI USA, V87, P5658, DOI 10.1073/pnas.87.15.5658; MALTHIERY Y, 1989, BIOCHIMIE, V71, P195, DOI 10.1016/0300-9084(89)90057-6; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; MAYDRHOFER A, 1988, J HERED, V79, P200; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MedeirosNeto G, 1996, J CLIN INVEST, V98, P2838, DOI 10.1172/JCI119112; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MERCKEN L, 1985, NATURE, V316, P647, DOI 10.1038/316647a0; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RAJASEKARAN AK, 1993, J CELL SCI, V105, P333; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHMITZ A, 1995, EMBO J, V14, P1091, DOI 10.1002/j.1460-2075.1995.tb07092.x; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; TAYLOR BA, 1987, P NATL ACAD SCI USA, V84, P1986, DOI 10.1073/pnas.84.7.1986; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WATOWICH SS, 1991, J VIROL, V65, P3590, DOI 10.1128/JVI.65.7.3590-3597.1991; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WIEST DL, 1990, J CELL BIOL, V110, P1501, DOI 10.1083/jcb.110.5.1501	67	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26095	26102		10.1074/jbc.272.42.26095	http://dx.doi.org/10.1074/jbc.272.42.26095			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334173	hybrid			2022-12-27	WOS:A1997YB13900007
J	Lu, DS; Boyd, B; Lingwood, CA				Lu, DS; Boyd, B; Lingwood, CA			Identification of the key protein for zinc uptake in Hemophilus influenzae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PARASANGUIS; HAEMOPHILUS-INFLUENZAE; GENE ENCODES; TRANSPORT; BACTERIA; PURIFICATION; VIRULENCE; SYSTEMS; ADHESIN; YEAST	Very little is known about specific mechanisms for zinc accumulation and transport in bacteria, In this study a putative adhesin B in Hemophilus influenzae, the product of gene HI0119, has been identified as a periplasmic zinc-binding protein (PZP1), A pzp1-deficient mutant has been constructed which is defective for growth under aerobic conditions and grows poorly under anaerobic conditions, The growth defect is specifically rescued by supplementing the growth medium with high concentrations of zinc. Subcellular fractionation was used to localize PZP1 to the periplasmic region in a nontypeable H, influenzae strain and in a transfected recombinant Escherichia coli strain (TApzp1). Recombinant PZP1, purified from a periplasmic extract off. coli strain TApzp1, contained similar to two zinc atoms/protein molecule as determined by neutron activation analysis and atomic absorption spectroscopy, The zinc atoms could be removed by incubation with EDTA, and, by further addition of zinc, a total of five zinc atoms/PZP1 could be bound. Direct binding of Zn-65 to the recombinant protein by Western blot was demonstrated, Taken together, these results provide direct evidence that PZP1 plays a key role in zinc uptake by H, influenzae.	UNIV TORONTO, HOSP SICK CHILDREN, DIV MICROBIOL, RES INST, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT MED GENET & MICROBIOL BIOCHEM, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT LAB MED & PATHOBIOL, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto			Lu, desheng/E-4822-2013	Lu, desheng/0000-0002-3616-6657; Lu, Desheng/0000-0002-0314-5649				AMES GFL, 1994, METHOD ENZYMOL, V235, P234; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; Berry AM, 1996, INFECT IMMUN, V64, P5255, DOI 10.1128/IAI.64.12.5255-5262.1996; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUCHEDER F, 1974, EUR J BIOCHEM, V45, P555, DOI 10.1111/j.1432-1033.1974.tb03581.x; BURNETTECURLEY D, 1995, INFECT IMMUN, V63, P4669, DOI 10.1128/IAI.63.12.4669-4674.1995; CHIPLEY JR, 1972, CAN J MICROBIOL, V84, P297; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; FAILLA ML, 1977, ZINC FUNCTIONS TRANS, P151; FENNO JC, 1995, MOL MICROBIOL, V15, P849, DOI 10.1111/j.1365-2958.1995.tb02355.x; FENNO JC, 1989, INFECT IMMUN, V57, P3527, DOI 10.1128/IAI.57.11.3527-3533.1989; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HUGHES MN, 1989, METALS MICROORGANISM, P120; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KY, 1971, MICROBIOS, V3, P215; MOXON ER, 1989, HAEMOPHILUS INFLUENZ, P1722; OLIGINO L, 1993, INFECT IMMUN, V61, P1016, DOI 10.1128/IAI.61.3.1016-1022.1993; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4191; SCHMIEDESKAMP M, 1994, CURR OPIN STRUC BIOL, V4, P28, DOI 10.1016/S0959-440X(94)90056-6; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; SWANCUTT MA, 1989, INFECT IMMUN, V57, P3314, DOI 10.1128/IAI.57.11.3314-3323.1989; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURK DC, 1985, J MED MICROBIOL, V18, P1; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; WEBB M, 1970, BIOCHIM BIOPHYS ACTA, V222, P428, DOI 10.1016/0304-4165(70)90133-9; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; [No title captured]	31	49	50	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29033	29038		10.1074/jbc.272.46.29033	http://dx.doi.org/10.1074/jbc.272.46.29033			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360976	hybrid			2022-12-27	WOS:A1997YF68400035
J	Wu, C				Wu, C			Chromatin remodeling and the control of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							YEAST SWI/SNF COMPLEX; PUTATIVE TRANSCRIPTIONAL ADAPTER; DNA-BINDING PROPERTIES; CELL-FREE SYSTEM; SACCHAROMYCES-CEREVISIAE; HISTONE ACETYLATION; NUCLEOSOME DISRUPTION; IN-VITRO; MULTISUBUNIT COMPLEX; AMINO-TERMINUS				Wu, C (corresponding author), NCI,MOL CELL BIOL LAB,NIH,BLDG 37,RM 5E-26,BETHESDA,MD 20892, USA.							ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, MOL CELL BIOL, V16, P593; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; Chavez S, 1997, P NATL ACAD SCI USA, V94, P2885, DOI 10.1073/pnas.94.7.2885; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414; DeRubertis F, 1996, NATURE, V384, P589; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; FELSENFELD G, 1996, BROW, V86, P13; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17928; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; HONG L, 1993, J BIOL CHEM, V268, P305; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; IMBALZANO AN, 1996, NATURE, V271, P20726; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Krude T, 1996, CURR BIOL, V6, P511, DOI 10.1016/S0960-9822(02)00529-8; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LOIDL P, 1994, CHROMOSOMA, V103, P441; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakatani Y, 1996, J BIOL CHEM, V271, P6575, DOI 10.1074/jbc.271.12.6575; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Ramakrishnan V, 1997, ANNU REV BIOPH BIOM, V26, P83, DOI 10.1146/annurev.biophys.26.1.83; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; Stokes DG, 1996, P NATL ACAD SCI USA, V93, P7137, DOI 10.1073/pnas.93.14.7137; STOKES DG, 1995, MOL CELL BIOL, V15, P2745; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tauton J, 1996, SCIENCE, V272, P408; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; VANHOLDE K, 1995, CHROMATIN STRUCTURE, P1; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	110	186	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28171	28174		10.1074/jbc.272.45.28171	http://dx.doi.org/10.1074/jbc.272.45.28171			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353261	hybrid			2022-12-27	WOS:A1997YF21900001
J	Enyedi, A; Elwess, NL; Filoteo, AG; Verma, AK; Paszty, K; Penniston, JT				Enyedi, A; Elwess, NL; Filoteo, AG; Verma, AK; Paszty, K; Penniston, JT			Protein kinase C phosphorylates the ''a'' forms of plasma membrane Ca2+ pump isoforms 2 and 3 and prevents binding of calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ PUMP; DEPENDENT PHOSPHORYLATION; SARCOLEMMAL CA-2+-ATPASE; HUMAN-ERYTHROCYTES; SMOOTH-MUSCLE; CALCIUM-PUMP; DOMAIN; CA2+-ATPASE; EXPRESSION; PRODUCTS	Phosphorylation by protein kinase C of the ''a'' and ''b'' variants of plasma membrane Ca2+ pump isoforms 2 and 3 was studied. Full-length versions of these isoforms were assembled and expressed in COS cells, Whereas the ''a'' forms were phosphorylated easily with PKC, isoform 2b was phosphorylated only a little, and isoform 3b was not phosphorylated at all. Phosphorylation of isoforms 2a and 3a did not affect their basal activity, but pre vented the stimulation of their activity by calmodulin and their binding to calmodulin-Sepharose. This indicated that phosphorylation prevented activation of these isoforms by preventing calmodulin binding. Based on these results, phosphorylation of the pump with PHC would be expected to increase free intracellular Ca2+ levels in those cells where isoforms 2a and 3a are expressed.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; NATL INST HAEMATOL & IMMUNOL,H-1113 BUDAPEST,HUNGARY	Mayo Clinic			Pászty, Katalin/X-3785-2019; Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376; Paszty, Katalin/0000-0003-2457-8555	NIGMS NIH HHS [GM 28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURK SE, 1992, J BIOL CHEM, V267, P19683; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FARRAR YJK, 1994, FASEB J, V8, pA1390; FUKUDA T, 1990, J BIOCHEM-TOKYO, V108, P629, DOI 10.1093/oxfordjournals.jbchem.a123254; FURUKAWA KI, 1989, J BIOL CHEM, V264, P4844; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; JAMES P, 1988, J BIOL CHEM, V263, P2905; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KUO TH, 1991, J BIOL CHEM, V266, P2520; OGURUSU T, 1990, J BIOCHEM-TOKYO, V108, P222, DOI 10.1093/oxfordjournals.jbchem.a123184; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; Verma AK, 1996, J BIOL CHEM, V271, P3714; VERMA AK, 1994, J BIOL CHEM, V269, P1687; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WANG KKW, 1991, J BIOL CHEM, V266, P9078	22	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27525	27528		10.1074/jbc.272.44.27525	http://dx.doi.org/10.1074/jbc.272.44.27525			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346883	hybrid			2022-12-27	WOS:A1997YD47300009
J	Ha, JH; Hellman, U; Johnson, ER; Li, LS; McKay, DB; Sousa, MC; Takeda, S; Wernstedt, C; Wilbanks, SM				Ha, JH; Hellman, U; Johnson, ER; Li, LS; McKay, DB; Sousa, MC; Takeda, S; Wernstedt, C; Wilbanks, SM			Destabilization of peptide binding and interdomain communication by an E543K mutation in the bovine 70-kDa heat shock cognate protein, a molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; ATPASE ACTIVITY; UNCOATING PROTEIN; ESCHERICHIA-COLI; HSC70 ATPASE; DNAK; AUTOPHOSPHORYLATION; HYDROLYSIS; CLATHRIN; PHOSPHORYLATION	We have compared 70-kDa heat shock cognate protein (Hsc70) isolated from bovine brain with recombinant wild type protein and mutant E543K protein (previously studied as wild type in our laboratory), Wild type bovine and recombinant protein differ by posttranslational modification of lysine 561 but interact similarly with a short peptide (fluorescein-labeled FYQLALT) and with denatured staphylococcal nuclease-(Delta 135-149). Mutation E543K results in 4.5-fold faster release of peptide and lower stability of complexes with staphylococcal nuclease-(Delta 135-149). ATP hydrolysis rates of the wild type proteins are enhanced 6-10-fold by the addition of peptide. The E543K mutant has a peptide-stimulated hydrolytic rate similar to that of wild type protein but a higher unstimulated rate, yielding a mere 2-fold enhancement. All three versions of Hsc70 possess similar ATP-dependent conformational shifts, and all show potassium ion dependence. These data support the following model: (i) in the presence of K+, Mg2+, and ATP, the peptide binding domain inhibits the ATPase; (ii) binding of peptide relieves this inhibition; and (iii) the E543K mutation significantly attenuates the inhibition by the peptide binding domain and destabilizes Hsc70-peptide complexes.	STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,STANFORD,CA 94305; LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN	Stanford University; Ludwig Institute for Cancer Research				Wilbanks, Sigurd/0000-0001-7565-8913; Takeda, Shigeki/0000-0001-8979-1133	NIGMS NIH HHS [GM-39928] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; DALIE BL, 1990, BIOCHEM BIOPH RES CO, V166, P1284, DOI 10.1016/0006-291X(90)91005-D; DELUCAFLAHERTY C, 1990, NUCLEIC ACIDS RES, V18, P5569, DOI 10.1093/nar/18.18.5569; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GAUT JR, 1993, J BIOL CHEM, V268, P12691; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HA JH, 1994, BIOCHEMISTRY-US, V33, P14625, DOI 10.1021/bi00252a031; HA JH, 1995, BIOCHEMISTRY-US, V34, P11635, DOI 10.1021/bi00036a040; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; KAMATHLOEB AS, 1995, J BIOL CHEM, V270, P30051; LEUSTEK T, 1991, ARCH BIOCHEM BIOPHYS, V289, P256, DOI 10.1016/0003-9861(91)90469-Y; LEUSTEK T, 1992, CELL MOL BIOL, V38, P1; LOOMIS WF, 1982, MOL CELL BIOL, V2, P484, DOI 10.1128/MCB.2.5.484; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PANAGIOTIDIS CA, 1994, J BIOL CHEM, V269, P16643; RICE M, SSRL SLAC USER MANUA; RIEUL C, 1987, EUR J BIOCHEM, V168, P621, DOI 10.1111/j.1432-1033.1987.tb13461.x; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; WANG C, 1992, ARCH BIOCHEM BIOPHYS, V297, P169, DOI 10.1016/0003-9861(92)90656-H; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P1209; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412	40	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27796	27803		10.1074/jbc.272.44.27796	http://dx.doi.org/10.1074/jbc.272.44.27796			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346924	hybrid			2022-12-27	WOS:A1997YD47300050
J	Neznanov, N; Umezawa, A; Oshima, RG				Neznanov, N; Umezawa, A; Oshima, RG			A regulatory element within a coding exon modulates keratin 18 gene expression in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; SEQUENCES DOWNSTREAM; GLOBIN GENE; C-FOS; REGION; TRANSCRIPTION; ACTIVATION; CELLS; MOUSE; PROMOTER	Multiple tissue specific, DNase-hypersensitive sites are correlated with known or potential regulatory regions of the human keratin 18 (R18) gene. One of these sites is found within exon 6, close to a potential AP-1 binding site. Footprint analysis confirmed that this site is capable of binding c-Jun and c-Fos in vitro. However, exon 6 can stimulate expression of a reporter gene driven by the R18 proximal promoter independent of AP-1 in F9 cells and additionally modulates AP-1 responsiveness when in combination with an intron enhancer. Analysis in transgenic mice and by transient transfections of mutant forms of the K18 gene showed that exon 6 contributes to the expression of the K18 gene, However, substitution of part of exon 6 with the corresponding part of the keratin 19 gene which lacks an AP-1 site decreased but did not destroy the regulatory activity of the exon, Furthermore, this mutation did not alter either the tissue specificity or the position-independent and copy number-dependent behavior of the K18 gene. In contrast, a frameshift mutation within exon 6 dramatically decreased the expression of the gene. K18 RNA expression from the frameshift mutation was less than 10% of the wild type K18 transgene, This decline in expression was the result of a combination of decreased stability of mutant K18 RNA and the creation of a negative regulatory element that can interact with the first intron regulatory elements and actively suppress K18 expression. These results demonstrate that a protein-coding portion of the K18 gene also has a regulatory function.	BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [P30 CA30199, R01 CA42302] Funding Source: Medline; NICHD NIH HHS [N01-HD-0-2911] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002911] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042302, P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1990, J CELL BIOL, V111, P1197, DOI 10.1083/jcb.111.3.1197; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOEBEN RC, 1995, BLOOD, V85, P2447, DOI 10.1182/blood.V85.9.2447.bloodjournal8592447; HURT MM, 1989, P NATL ACAD SCI USA, V86, P4450, DOI 10.1073/pnas.86.12.4450; HURT MM, 1991, MOL CELL BIOL, V11, P2929, DOI 10.1128/MCB.11.6.2929; JAMESPEDERSON M, 1995, J BIOL CHEM, V270, P3965, DOI 10.1074/jbc.270.8.3965; JONES BK, 1995, MOL CELL BIOL, V15, P7010; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; KULESH DA, 1989, MOL CELL BIOL, V9, P1553, DOI 10.1128/MCB.9.4.1553; KULESH DA, 1989, GENOMICS, V4, P339, DOI 10.1016/0888-7543(89)90340-6; KULESH DA, 1988, MOL CELL BIOL, V8, P267; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MANIATIS T, 1989, MOL CLONING LAB MANU, P14; MOUS J, 1985, MOL CELL BIOL, V5, P2764, DOI 10.1128/MCB.5.10.2764; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; NAKATANI Y, 1990, P NATL ACAD SCI USA, V87, P4289, DOI 10.1073/pnas.87.11.4289; NEZNANOV N, 1993, MOL CELL BIOL, V13, P2214, DOI 10.1128/MCB.13.4.2214; Neznanov N, 1996, MOL BIOL CELL, V7, P541, DOI 10.1091/mbc.7.4.541; NEZNANOV NS, 1993, MOL CELL BIOL, V13, P1815, DOI 10.1128/MCB.13.3.1815; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; STOVER DM, 1992, MOL CELL BIOL, V12, P2230, DOI 10.1128/MCB.12.5.2230; THOREY IS, 1993, DEV BIOL, V160, P519, DOI 10.1006/dbio.1993.1326; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; YANG-YEN H-F, 1990, New Biologist, V2, P351	37	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27549	27557		10.1074/jbc.272.44.27549	http://dx.doi.org/10.1074/jbc.272.44.27549			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346889	hybrid			2022-12-27	WOS:A1997YD47300015
J	Tilton, B; Andjelkovic, M; Didichenko, SA; Hemmings, BA; Thelen, M				Tilton, B; Andjelkovic, M; Didichenko, SA; Hemmings, BA; Thelen, M			G-protein-coupled receptors and Fc gamma-receptors mediate activation of Akt protein kinase B in human phagocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL LEUKOCYTES; MYELOID-DERIVED CELLS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; RESPIRATORY BURST; GRO-ALPHA; INTERLEUKIN-8 RECEPTORS; BETA-GAMMA; CHEMOTACTIC CYTOKINES	Activation of the serine/threonine kinase Akt, also called protein kinase B (PRE), was investigated in human neutrophils. Stimulation of the cells with the chemoattractant fMet-Leu-Phe or the chemokines IL-8 and GRO alpha leads to the rapid and transient activation of PKB. Maximum PKB activation correlates with the well documented kinetics of respiratory burst and exocytosis. Wortmannin, a selective inhibitor of phosphoinositide 3-kinases (PI 3-kinases) in neutrophils; abrogates PKB activation. Similarly homo and heterotypic crosslinking of Fc gamma IIA and Fc gamma IIIB causes a transient activation of PKB that is sensitive to wortmannin treatment. Kinase activity measurements in immunoprecipitates from lysates of the myelocytic GM-1 cells or GM-1/CXCR1 cells, which are transfected with the IL-8 receptor 1, confirmed the transient activation of PKB observed in neutrophils. Stimulation of human monocytes with the CC chemokine RANTES (regulated on activation normal T cell expressed and secreted) also results in the activation of PKB. Preincubation of monocytes and neutrophils with Bordetella pertussis toxin inhibits fMet-Leu-Phe and RANTES-stimulated PKB activation, demonstrating that coupling of the receptors to heterotrimeric Gi-protein is required. The data show, that activation of PKB by G(i)-protein-coupled receptors is mediated by PI 3-kinase and suggest that PRE is a constituent of neutrophil activating pathways.	UNIV BERN,THEODOR KOCHER INST,CH-3000 BERN 9,SWITZERLAND; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	University of Bern; Friedrich Miescher Institute for Biomedical Research								Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Allen LAH, 1996, CURR OPIN IMMUNOL, V8, P36, DOI 10.1016/S0952-7915(96)80102-6; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini Marco, 1992, News in Physiological Sciences, V7, P215; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHAUDHRY A, 1994, CELL SIGNAL, V6, P457, DOI 10.1016/0898-6568(94)90093-0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damaj BB, 1996, J BIOL CHEM, V271, P20540, DOI 10.1074/jbc.271.34.20540; Dewald B, 1986, Methods Enzymol, V132, P267; DEWALD B, 1988, J BIOL CHEM, V263, P16179; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EDBERG JC, 1995, J BIOL CHEM, V270, P22301, DOI 10.1074/jbc.270.38.22301; EDBERG JC, 1992, IMMUNOL RES, V11, P239, DOI 10.1007/BF02919130; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; GAROTTA G, 1991, J LEUKOCYTE BIOL, V49, P294, DOI 10.1002/jlb.49.3.294; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; KANAKARAJ P, 1994, J EXP MED, V179, P551, DOI 10.1084/jem.179.2.551; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; LIN CT, 1994, J CLIN IMMUNOL, V14, P1, DOI 10.1007/BF01541170; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; Moser B, 1997, TRENDS MICROBIOL, V5, P88, DOI 10.1016/S0966-842X(97)01019-6; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; Popik W, 1996, MOL CELL BIOL, V16, P6532; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; SALMON JE, 1991, J IMMUNOL, V146, P997; Santana C, 1996, J LEUKOCYTE BIOL, V60, P433, DOI 10.1002/jlb.60.4.433; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; Trotta R, 1996, J EXP MED, V184, P1027, DOI 10.1084/jem.184.3.1027; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Unkeless J C, 1995, Semin Immunol, V7, P37, DOI 10.1016/1044-5323(95)90006-3; VOSSEBELD PJM, 1995, J BIOL CHEM, V270, P10671, DOI 10.1074/jbc.270.18.10671; WYMANN MP, 1987, J BIOL CHEM, V262, P12048; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553	70	131	132	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28096	28101		10.1074/jbc.272.44.28096	http://dx.doi.org/10.1074/jbc.272.44.28096			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346964	hybrid			2022-12-27	WOS:A1997YD47300090
J	Venning, JD; Grimley, RL; Bizouarn, T; Cotton, NPJ; Jackson, JB				Venning, JD; Grimley, RL; Bizouarn, T; Cotton, NPJ; Jackson, JB			Evidence that the transfer of hydride ion equivalents between nucleotides by proton-translocating transhydrogenase is direct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOSPIRILLUM-RUBRUM; ESCHERICHIA-COLI; DINUCLEOTIDE TRANSHYDROGENASE; RHODOBACTER-CAPSULATUS; ADENINE-DINUCLEOTIDE; ENERGY; RESOLUTION; ENZYME; MITOCHONDRIA; REDUCTION	The molecular masses of the purified, recombinant nucleotide-binding domains (domains I and III) of transhydrogenase from Rhodospirillum rubrum were determined by electrospray mass spectrometry, The values obtained, 40,273 and 21,469 Da, for domains I and III, respectively, are similar to those estimated from the amino acid sequences of the proteins, Evidently, there are no prosthetic groups or metal centers that can serve as reducible intermediates in hydride transfer between nucleotides bound to these proteins. The transient-state kinetics of hydride transfer catalyzed by mixtures of recombinant domains I and III were studied by stopped-flow spectrophotometry, The data indicate that oxidation of NADPH, bound to domain III, and reduction of acetylpyridine adenine dinucleotide (an NAD(+) analogue), bound to domain I, are simultaneous and very fast. The transient-state reaction proceeds as a biphasic burst of hydride transfer before establishment of a steady state, which is limited by slow release of NADP(+). Hydride transfer between the nucleotides is evidently direct, This conclusion indicates that the nicotinamide rings of the nucleotides are in close apposition during the hydride transfer reaction, and it imposes firm constraints on the mechanism by which transhydrogenation is linked to proton translocation.	UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham			bizouarn, tania/W-6782-2019		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bizouarn T, 1996, EUR J BIOCHEM, V239, P737, DOI 10.1111/j.1432-1033.1996.0737u.x; Bizouarn T, 1997, BBA-BIOENERGETICS, V1320, P265, DOI 10.1016/S0005-2728(97)00030-3; BIZOUARN T, 1997, IN PRESS BIOCH BIOPH; CUNNINGHAM IJ, 1992, BIOCHIM BIOPHYS ACTA, V1100, P332, DOI 10.1016/0167-4838(92)90490-5; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; ENANDER K, 1982, J BIOL CHEM, V257, P4760; FISHER R. R., 1982, PYRIDINE NUCLEOTIDE, P279; FISHER RR, 1971, J BIOL CHEM, V246, P4687; HANSON RL, 1979, J BIOL CHEM, V254, P888; Hatefi Y, 1996, FASEB J, V10, P444, DOI 10.1096/fasebj.10.4.8647343; Hojeberg B, 1979, Methods Enzymol, V55, P275; HOMYK M, 1979, BIOCHIM BIOPHYS ACTA, V571, P201, DOI 10.1016/0005-2744(79)90091-3; HU X, 1995, BBA-BIOENERGETICS, V1229, P64, DOI 10.1016/0005-2728(94)00187-A; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; JACKSON JB, 1991, J BIOENERG BIOMEMBR, V23, P715, DOI 10.1007/BF00785998; JACOBS E, 1979, BIOCHEMISTRY-US, V18, P4315, DOI 10.1021/bi00587a009; LEVER TM, 1991, EUR J BIOCHEM, V197, P247, DOI 10.1111/j.1432-1033.1991.tb15905.x; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; MEULLER J, 1997, BIOCHEM J, V234, P681; OLAUSSON T, 1995, BBA-BIOENERGETICS, V1231, P1, DOI 10.1016/0005-2728(95)00058-Q; PALMER T, 1992, BIOCHIM BIOPHYS ACTA, V1099, P157, DOI 10.1016/0304-4173(92)90022-7; PERSSON B, 1987, BIOCHEM BIOPH RES CO, V142, P573, DOI 10.1016/0006-291X(87)90312-3; RIZZO V, 1987, PYRIDINE NUCLEOTID A, P99; SIEGEL JM, 1959, ARCH BIOCHEM BIOPHYS, V82, P288, DOI 10.1016/0003-9861(59)90124-9; Stilwell SN, 1997, BBA-BIOENERGETICS, V1320, P83, DOI 10.1016/S0005-2728(97)00016-9; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; WILLIAMS R, 1994, MICROBIOL-UK, V140, P1595, DOI 10.1099/13500872-140-7-1595; Woenckhaus C., 1987, PYRIDINE NUCLEOTID A, P449; Yamaguchi M, 1997, BBA-BIOENERGETICS, V1318, P225, DOI 10.1016/S0005-2728(96)00139-9	30	40	40	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27535	27538		10.1074/jbc.272.44.27535	http://dx.doi.org/10.1074/jbc.272.44.27535			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346886	hybrid			2022-12-27	WOS:A1997YD47300012
J	Byzova, TV; Plow, EF				Byzova, TV; Plow, EF			Networking in the hemostatic system - Integrin alpha(IIIb)beta(3) binds prothrombin and influences its activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE MONOCLONAL-ANTIBODY; GLYCOPROTEIN-IIB-IIIA; HUMAN-PLATELETS; FACTOR-X; VONWILLEBRAND-FACTOR; CLINICAL RESTENOSIS; FIBRINOGEN BINDING; THROMBIN; RECEPTOR; SITE	Prothrombin activation is a pivotal event in thrombosis and hemostasis because thrombin can mediate fibrin formation and can activate and aggregate platelets. Platelet aggregation depends upon the binding of adhesive proteins to integrin alpha(IIb)beta(3) on the platelet surface. In the present study, a novel interface between the blood coagulation system and platelets is demonstrated by showing that 1) prothrombin binds to alpha(IIb)beta(3) and 2) this interaction accelerates prothrombin activation. Prothrombin bound to purified alpha(IIb)beta(3) in a specific, saturable, and divalent cation-dependent manner, This interaction was inhibited by certain monoclonal antibodies to alpha(IIb)beta(3), by the alpha(IIb)beta(3) ligands fibrinogen and RGD peptides, but not by thrombin or unrelated proteins, Prothrombin also interacted with alpha(IIb)beta(3) on resting and stimulated platelets as demonstrated by soluble ligand binding and platelet adhesion assays, Activation of prothrombin by Factor Xa alone or Factor Xa-Va was accelerated by alpha(IIb)beta(3), and this enhancement was blocked by a monoclonal antibody that inhibited prothrombin binding to the receptor, Taken together, these data identify a previously unrecognized linkage between platelets and the blood coagulation system that may have a significant regulatory consequence.	CLEVELAND CLIN FDN, JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL, DEPT MOL CARDIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation				Byzova, Tatiana/0000-0002-2615-875X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054924] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54924] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BARSHAVIT R, 1995, ISRAEL J MED SCI, V31, P86; BARSHAVIT R, 1991, J CELL BIOL, V112, P335, DOI 10.1083/jcb.112.2.335; BODE W, 1992, PROTEIN SCI, V1, P426; BOVILL EG, 1995, ARTERIOSCL THROM VAS, V15, P754, DOI 10.1161/01.ATV.15.6.754; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHARO IF, 1991, J BIOL CHEM, V266, P1415; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; DACHARYPRIGENT J, 1993, BLOOD, V81, P2554; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; HAVERSTICK DM, 1985, BLOOD, V66, P946; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; Mazurov AV, 1996, FEBS LETT, V391, P84, DOI 10.1016/0014-5793(96)00709-0; PIOTROWICZ RS, 1988, J CELL BIOL, V106, P1359, DOI 10.1083/jcb.106.4.1359; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1985, BLOOD, V66, P724; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; Reverter JC, 1996, J CLIN INVEST, V98, P863, DOI 10.1172/JCI118859; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SMITH JW, 1994, J BIOL CHEM, V269, P960; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; Weiss HJ, 1997, BLOOD, V89, P1599, DOI 10.1182/blood.V89.5.1599.1599_1599_1611	37	105	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27183	27188		10.1074/jbc.272.43.27183	http://dx.doi.org/10.1074/jbc.272.43.27183			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341161	hybrid			2022-12-27	WOS:A1997YC65900057
J	Eskandari, S; Loo, DDF; Dai, G; Levy, O; Wright, EM; Carrasco, N				Eskandari, S; Loo, DDF; Dai, G; Levy, O; Wright, EM; Carrasco, N			Thyroid Na+/I- symporter - Mechanism, stoichiometry, and specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTES; GLUCOSE COTRANSPORTER; ELECTROGENIC PROPERTIES; MEMBRANE-VESICLES; TRANSPORT; CHANNELS; IODIDE; KINETICS; CELLS	The rat thyroid Na+/l(-) symporter (NIS) was expressed in Xenopus laevis oocytes and characterized using electrophysiological, tracer uptake, and electron microscopic methods, MS activity was found to be electrogenic and Na+-dependent (Na+ much greater than Li+ much greater than H+). The apparent affinity constants for Na+ and I- were 28 +/- 3 mM and 33 +/- 9 mu M, respectively, Stoichiometry of Na+/anion cotransport was 2:1. MS was capable of transporting a wide variety of anions (I-, ClO3-, SCN-, SeCN-, NO3-, Br-, BF4-, IO4-, BrO3-, but perchlorate (ClO4-) was not transported, In the absence of anion substrate, NIS exhibited a Na+-dependent leak current (similar to 35% of maximum substrate-induced current) with an apparent Na+ affinity of 74 +/- 14 mM and a Hill coefficient (n) of 1. In response to step voltage changes, MS exhibited current transients that relaxed with a time constant of 8-14 ms, Presteady-state charge movements (integral of the current transients) versus voltage relations obey a Boltzmann relation, The voltage for half-maximal charge translocation (V-0.5) was -15 +/- 3 mV, and the apparent valence of the movable charge was 1. Total charge was insensitive to [Na+](o), but V-0.5 shifted to more negative potentials as [Na+](o) was reduced. MS charge movements are attributed to the conformational changes of the empty transporter within the membrane electric field, The turnover rate of NIS was greater than or equal to 22 s(-1) in the Na+ uniport mode and greater than or equal to 36 s(-1) in the Na+/I- cotransport mode, Transporter density in the plasma membrane was determined using freeze-fracture electron microscopy, Expression of NIS in oocytes led to a similar to 2,5-fold increase in the density of plasma membrane protoplasmic face intramembrane particles. On the basis of the kinetic results, we propose an ordered simultaneous transport mechanism in which the binding of Na+ to NIS occurs first.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	Eskandari, S (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90095, USA.		Carrasco, Nancy/AAH-1053-2019	Carrasco, Nancy/0000-0003-4137-6162	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041544, R01DK019567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS025554] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19567, DK41544] Funding Source: Medline; NINDS NIH HHS [NS25554] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANBAR M, 1959, J APPL RADIAT ISOT, V7, P87; BEZANILLA F, 1994, ANNU REV BIOPH BIOM, V23, P819, DOI 10.1146/annurev.bb.23.060194.004131; BOORER KJ, 1994, J BIOL CHEM, V269, P20417; Cao Yongwei, 1997, Biophysical Journal, V72, pA407; CARRASCO N, 1993, BIOCHIM BIOPHYS ACTA, V1154, P65, DOI 10.1016/0304-4157(93)90017-I; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; HALMI NS, 1961, VITAM HORM, V19, P138; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; Hirayama BA, 1997, J BIOL CHEM, V272, P2110; HIRAYAMA BA, 1994, J BIOL CHEM, V269, P21407; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; KAMINSKY SM, 1991, EUR J BIOCHEM, V200, P203, DOI 10.1111/j.1432-1033.1991.tb21068.x; Lauger P., 1991, ELECTROGENIC ION PUM; Loo DDF, 1996, FEBS LETT, V392, P250, DOI 10.1016/0014-5793(96)00823-X; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; NAKAMURA Y, 1988, J BIOCHEM-TOKYO, V104, P544, DOI 10.1093/oxfordjournals.jbchem.a122507; ONEILL B, 1987, BIOCHIM BIOPHYS ACTA, V896, P263, DOI 10.1016/0005-2736(87)90187-8; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Segel I.H., 1975, ENZYME KINETICS; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1108, DOI 10.1210/endo-114-4-1108; WOLFF J, 1964, PHYSIOL REV, V44, P45, DOI 10.1152/physrev.1964.44.1.45; WRIGHT EM, 1977, PHYSIOL REV, V57, P109, DOI 10.1152/physrev.1977.57.1.109; WRIGHT EM, 1974, J PHYSIOL-LONDON, V240, P535, DOI 10.1113/jphysiol.1974.sp010622; Yoshida A, 1997, BIOCHEM BIOPH RES CO, V231, P731, DOI 10.1006/bbrc.1997.6178; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	34	359	376	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27230	27238		10.1074/jbc.272.43.27230	http://dx.doi.org/10.1074/jbc.272.43.27230			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341168	hybrid			2022-12-27	WOS:A1997YC65900064
J	Giasson, E; Servant, MJ; Meloche, S				Giasson, E; Servant, MJ; Meloche, S			Cyclic AMP-mediated inhibition of angiotensin II-induced protein synthesis is associated with suppression of tyrosine phosphorylation signaling in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C ACTIVATION; SWISS 3T3 CELLS; CELLULAR HYPERTROPHY; HAMSTER FIBROBLASTS; JAK/STAT PATHWAY; MESANGIAL CELLS; GENE-EXPRESSION; FACTOR RECEPTOR; FOS EXPRESSION; MESSENGER-RNA	In the present study, we have examined the effect of increased cyclic AMP (cAMP) levels on the stimulatory action of angiotensin II (Ang II) on protein synthesis. Treatment with cAMP-elevating agents potently inhibited Ang II-induced protein synthesis in rat aortic smooth muscle cells and in rat fibroblasts expressing the human AT(1) receptor, The inhibition was dose-dependent and was observed at all concentrations of the peptide, To explore the mechanism of cAMP action, we have analyzed the effects of forskolin and 3-isobutyl-1-methylxanthine on various receptor-mediated re sponses. Elevation of cAMP did not alter the binding properties of the AT(1) receptor and did not interfere with the activation of phospholipase C or the induction of early growth response genes by Ang II. Likewise, Ang II-dependent activation of the mitogen-activated protein kinases ERK1/ERK2 and p70 S6 kinase was unaffected by cAMP, In contrast, we found that increased concentration of cAMP strongly inhibited the stimulatory effect of Ang II on protein tyrosine phosphorylation. Specifically, cAMP abolished Ang II-induced tyrosine phosphorylation of the focal adhesion-associated protein paxillin and of the tyrosine kinase Tyk2. These results identify a novel mechanism by which the cAMP signaling system may exert growth-inhibitory effects in specific cell types.	HOP HOTEL DIEU,CTR RECH,MONTREAL,PQ H2W 1T8,CANADA; UNIV MONTREAL,DEPT PHARMACOL,MONTREAL,PQ H2W 1T8,CANADA	Universite de Montreal; Universite de Montreal								BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BLOMHOFF HK, 1987, J CELL PHYSIOL, V131, P426, DOI 10.1002/jcp.1041310315; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Catt KJ, 1993, CELLULAR MOL BIOL RE, P307; Chiu A T, 1991, Receptor, V1, P133; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; David M, 1996, J BIOL CHEM, V271, P4585; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; EARP HS, 1995, J BIOL CHEM, V270, P28440; FORCE T, 1991, J BIOL CHEM, V266, P6650; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HELDIN NE, 1989, J CELL PHYSIOL, V138, P17, DOI 10.1002/jcp.1041380104; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAHARA Y, 1988, BIOCHEM BIOPH RES CO, V150, P52, DOI 10.1016/0006-291X(88)90485-8; LALLI E, 1994, J BIOL CHEM, V269, P17359; LAMBERT C, 1995, CIRC RES, V77, P1001, DOI 10.1161/01.RES.77.5.1001; LEDUC I, 1995, J BIOL CHEM, V270, P4401, DOI 10.1074/jbc.270.9.4401; LEDUC I, 1995, MOL PHARMACOL, V48, P582; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MELOCHE S, 1986, MOL PHARMACOL, V30, P537; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAFTILAN AJ, 1989, HYPERTENSION, V13, P706, DOI 10.1161/01.HYP.13.6.706; PASTAN I, 1978, NATURE, V274, P645, DOI 10.1038/274645a0; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PRATT RE, 1993, CELLULAR MOL BIOL RE, P471; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROTHMAN A, 1994, J BIOL CHEM, V269, P6399; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SACHINIDIS A, 1992, FEBS LETT, V313, P109, DOI 10.1016/0014-5793(92)81423-J; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SCHELLING P, 1991, J HYPERTENS, V9, P3; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SECKL M, 1993, J BIOL CHEM, V268, P9548; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TOVEY KC, 1974, CLIN CHIM ACTA, V56, P221, DOI 10.1016/0009-8981(74)90133-8; TREPEL JB, 1987, MOL CELL BIOL, V7, P2644, DOI 10.1128/MCB.7.7.2644; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; TURNER CE, 1995, J CELL SCI, V108, P333; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WOLF G, 1991, CELL REGUL, V2, P219, DOI 10.1091/mbc.2.3.219; WOLF G, 1993, NEPHROL DIAL TRANSPL, V8, P128; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	71	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26879	26886		10.1074/jbc.272.43.26879	http://dx.doi.org/10.1074/jbc.272.43.26879			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341120	hybrid			2022-12-27	WOS:A1997YC65900016
J	JandrotPerrus, M; Lagrue, AH; Okuma, M; Bon, C				JandrotPerrus, M; Lagrue, AH; Okuma, M; Bon, C			Adhesion and activation of human platelets induced by convulxin involve glycoprotein VI and integrin alpha(2)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROTALUS-DURISSUS-CASCAVELLA; COLLAGEN-INDUCED AGGREGATION; PHOSPHOLIPASE C-GAMMA-2; TYROSINE PHOSPHORYLATION; MEMBRANE; VENOM; PROTEINS; DEFICIENCY; THROMBIN; RECEPTOR	We analyzed the interaction of convulxin (Cvx), a 72-kDa protein isolated from the venom of Crotalus durissus terrificus, with human platelets. Cvx is a potent platelet agonist that induces an increase in the intracellular Ca2+ concentration ([Ca2+](i)), granule exocytosis and aggregation. I-125-Labeled Cvx binds specifically and rapidly to platelets at binding sites of high and moderate affinity. Platelets adhere to immobilized Cvx in a time-dependent but cation-independent manner. Platelet exocytosis and aggregation induced by Cvx were inhibited by an anti-integrin alpha(2) beta(1) monoclonal antibody (6F1) and by the Fab fragments of a polyclonal antiglycoprotein VI (GPVI) antibody. Both the adhesion of platelets to Cvx and the Cvx-induced increase in [Ca2+](i) were inhibited by anti-GPVI Fab fragments but not by 6F1. Ligand blotting assay showed that I-125-CvX binds to a 57-kDa platelet protein with an electrophoretic mobility identical to that of GPVI. In addition, we observed the following: (i) I-125-CvX binds to GPVI immunoprecipitated by the anti-GPVI antibody from a platelet lysate, and (ii) Cvx inhibits the binding of anti-GPVI IgG to GPVI. Taken together, these results demonstrate that GPVI behaves as a Cvx receptor and that the alpha(2) beta(1) integrin appears to be involved in the later stages of Cvx-induced platelet activation, i.e. exocytosis and aggregation.	INST PASTEUR,UNITE VENINS,F-75724 PARIS 15,FRANCE; KYOTO UNIV,FAC MED,DEPT INTERNAL MED,SAKYO KU,KYOTO 60601,JAPAN	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Kyoto University	JandrotPerrus, M (corresponding author), UNIV PARIS 07,LAB RECH HEMOSTASE & THROMBOSE,BP 416,F-75870 PARIS 18,FRANCE.		Jandrot-Perrus, Martine/GZM-1526-2022	JANDROT-PERRUS, Martine/0000-0002-8450-9247				BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; Brinkhous K.M., 1988, Hematology (New York), V7, P363; CLEMETSON KJ, 1995, THROMB HAEMOSTASIS, V74, P111; COLLER BS, 1989, BLOOD, V74, P182; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; FAILI A, 1994, BIOCHEM J, V298, P87, DOI 10.1042/bj2980087; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Fujimura Y, 1996, THROMB HAEMOSTASIS, V76, P633; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; JANDROTPERRUS M, 1987, THROMB HAEMOSTASIS, V58, P915; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; KEHREL B, 1988, BLOOD, V71, P1074; KROLL MH, 1989, BLOOD, V74, P1181; KUNICKI TJ, 1993, BLOOD, V82, P2693; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARLAS G, 1983, BIOCHIMIE, V65, P619; MARLAS G, 1983, BIOCHIMIE, V65, P405, DOI 10.1016/S0300-9084(83)80060-1; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; NIEUWENHUIS HK, 1986, BLOOD, V68, P692; NURDEN P, 1994, SEMIN HEMATOL, V31, P240; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; PRADOFRANCESCHI J, 1981, TOXICON, V19, P875, DOI 10.1016/0041-0101(81)90085-4; RYO R, 1992, AM J HEMATOL, V39, P25, DOI 10.1002/ajh.2830390107; SANOMARTINS IS, 1992, TOXICON, V30, P141, DOI 10.1016/0041-0101(92)90467-J; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SUGIYAMA T, 1987, BLOOD, V69, P1712; VARGAFTIG BB, 1980, EUR J PHARMACOL, V68, P451, DOI 10.1016/0014-2999(80)90420-3; VARGAFTIG BB, 1983, EUR J PHARMACOL, V92, P57, DOI 10.1016/0014-2999(83)90108-5; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; ZINGALI RB, 1991, ANN I PASTEUR, V4, P267	32	148	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27035	27041		10.1074/jbc.272.43.27035	http://dx.doi.org/10.1074/jbc.272.43.27035			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341142	hybrid			2022-12-27	WOS:A1997YC65900038
J	Peters, JM; Hennuyer, N; Staels, B; Fruchart, JC; Fievet, C; Gonzalez, FJ; Auwerx, J				Peters, JM; Hennuyer, N; Staels, B; Fruchart, JC; Fievet, C; Gonzalez, FJ; Auwerx, J			Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN C-III; COENZYME-A OXIDASE; FATTY-ACIDS; GENE-EXPRESSION; PPAR; HYPERCHOLESTEROLEMIA; DIFFERENTIATION; FENOFIBRATE; INDUCTION; LIGAND	The peroxisome proliferator-activated receptor-alpha (PPAR alpha) controls gene expression in response to a diverse class of compounds collectively referred to as peroxisome proliferators. Whereas most known peroxisome proliferators are of exogenous origin and include hypolipidemic drugs and other industrial chemicals, several endogenous PPAR alpha activators have been identified such as fatty acids and steroids, The latter finding and the fact that PPAR alpha modulates target genes encoding enzymes involved in lipid metabolism suggest a role for PPAR alpha in lipid metabolism, This was investigated in the PPAR alpha-deficient mouse model, Basal levels of total serum cholesterol, high density lipoprotein cholesterol, hepatic apolipoprotein A-I mRNA, and serum apolipoprotein A-I in PPAR alpha-deficient mice are significantly higher compared with wild type controls, Treatment with the fibrate Wy 14,643 decreased apoA-I serum levels and hepatic mRNA levels in wild-type mice, whereas no effect was detected in the PPAR alpha-deficient mice, Administration of the fibrate Wy 14,643 to wild-type mice results in marked depression of hepatic apolipoprotein C-III mRNA and serum triglycerides compared with un treated controls, In contrast, PPAR alpha-deficient mice were unaffected by Wy 14,643 treatment, These studies demonstrate that PPAR alpha modulates basal levels of serum cholesterol, in particular high density lipoprotein cholesterol, and establish that fibrate induced modulation in hepatic apolipoprotein A-I, C-III mRNA, and serum triglycerides observed in wild-type mice is mediated by PPAR alpha.	INST PASTEUR,U325 INSERM,DEPT ATHEROSCLEROSE,F-59019 LILLE,FRANCE; NCI,LAB METAB,NIH,BETHESDA,MD 20892	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Peters, Jeffrey/D-8847-2011; Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503; Auwerx, Johan/0000-0002-5065-5393; HENNUYER, Nathalie/0000-0003-0303-7258; Peters, Jeffrey/0000-0003-2782-2998				AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; BERTHOU L, 1995, EUR J BIOCHEM, V232, P179, DOI 10.1111/j.1432-1033.1995.tb20797.x; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; BROUSSEAU T, 1993, CLIN CHEM, V39, P960; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESVERGNE B, 1994, INDUCIBLE GENE EXPRE, P253; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DUVERGER N, 1993, BIOCHEMISTRY-US, V32, P12372, DOI 10.1021/bi00097a014; FIELDING CJ, 1995, J LIPID RES, V36, P211; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Green S, 1995, MUTAT RES-FUND MOL M, V333, P101, DOI 10.1016/0027-5107(95)00136-0; Haubenwallner S, 1995, J LIPID RES, V36, P2541; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALMENDIER CL, 1985, ATHEROSCLEROSIS, V55, P161, DOI 10.1016/0021-9150(85)90095-4; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MELLIES MJ, 1987, ATHEROSCLEROSIS, V63, P57, DOI 10.1016/0021-9150(87)90082-7; MILLER NE, 1987, AM HEART J, V112, P825; SAAD MJA, 1994, MOL ENDOCRINOL, V8, P545, DOI 10.1210/me.8.5.545; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SCHOONJANS K, 1993, EUR J BIOCHEM, V216, P615, DOI 10.1111/j.1432-1033.1993.tb18181.x; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Schoonjans K, 1996, J LIPID RES, V37, P907; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118	33	369	386	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27307	27312		10.1074/jbc.272.43.27307	http://dx.doi.org/10.1074/jbc.272.43.27307			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341179	hybrid			2022-12-27	WOS:A1997YC65900075
J	Comte, B; Vincent, G; Bouchard, B; DesRosiers, C				Comte, B; Vincent, G; Bouchard, B; DesRosiers, C			Probing the origin of acetyl-CoA and oxaloacetate entering the citric acid cycle from the C-13 labeling of citrate released by perfused rat hearts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; FATTY-ACID; PYRUVATE CARBOXYLATION; SUBSTRATE SELECTION; ISOTOPOMER ANALYSIS; GLUCOSE-METABOLISM; NMR-SPECTROSCOPY; CORONARY FLOW; OXIDATION; GLUCONEOGENESIS	We present a strategy for simultaneous assessment of the relative contributions of anaplerotic pyruvate carboxylation, pyruvate decarboxylation, and fatty acid oxidation to citrate formation in the perfused rat heart, This requires perfusing with a mix of C-13-substrates and determining the C-13 labeling pattern of a single metabolite, citrate, by gas chromatography-mass spectrometry, The mass isotopomer distributions of the oxaloacetate and acetyl moieties of citrate allow calculation of the flux ratios: (pyruvate carboxylation)/(pyruvate decarboxylation), (pyruvate carboxylation)/(citrate synthesis), (pyruvate decarboxylation)/(citrate synthesis) (pyruvate carboxylation)/(fatty acid oxidation), and (pyruvate decarboxylation)/(fatty acid oxidation), Calculations, based on precursor-product relationship, are independent of pool size, The utility of our method was demonstrated for hearts perfused under normoxia with [U-C-13(3)](lactate + pyruvate) and [1-C-13]octanoate under steady-state conditions, Under these conditions, effluent and tissue citrate were similarly enriched in all C-13 mass isotopomers, The use of effluent citrate instead of tissue citrate allows probing substrate fluxes through the various reactions non-invasively in the intact heart, The methodology should also be applicable to hearts perfused with other C-13-substrates, such as 1-C-13-labeled long chain fatty acid, and under various conditions, provided that assumptions on which equations are developed are valid.	UNIV MONTREAL, DEPT NUTR, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, DEPT BIOCHEM, MONTREAL, PQ H3C 3J7, CANADA	Universite de Montreal; Universite de Montreal			Rosiers, Christine Des/O-6285-2014					Abdelaleem S, 1996, J MOL CELL CARDIOL, V28, P825, DOI 10.1006/jmcc.1996.0077; BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; BARRON JT, 1994, AM J PHYSIOL, V267, pH764, DOI 10.1152/ajpheart.1994.267.2.H764; BEYLOT M, 1995, J BIOL CHEM, V270, P1509, DOI 10.1074/jbc.270.4.1509; BROSNAN JT, 1985, METABOLISM, V34, P588, DOI 10.1016/0026-0495(85)90199-4; BRUNET J, 1995, FREE RADICAL BIO MED, V19, P627, DOI 10.1016/0891-5849(95)00077-B; BUNGER R, 1989, EUR J BIOCHEM, V180, P221, DOI 10.1111/j.1432-1033.1989.tb14637.x; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CHATHAM JC, 1995, J BIOL CHEM, V270, P7999, DOI 10.1074/jbc.270.14.7999; CLINE GW, 1995, J BIOL CHEM, V270, P28062; COHEN DM, 1994, AM J PHYSIOL, V266, pE341, DOI 10.1152/ajpendo.1994.266.3.E341; COMTE B, 1995, CIRCULATION, V92, P3703; COMTE B, 1997, FASEB J, V11, P268; COMTE B, 1997, J BIOL CHEM, V272, P46145; DAVID F, 1994, ANAL BIOCHEM, V218, P143, DOI 10.1006/abio.1994.1153; DESROSIERS C, 1994, J BIOL CHEM, V269, P27179; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; FERNANDEZ CA, 1995, J BIOL CHEM, V270, P10037, DOI 10.1074/jbc.270.17.10037; GAMBLE J, 1994, BBA-MOL BASIS DIS, V1225, P191, DOI 10.1016/0925-4439(94)90078-7; HEATH DF, 1985, BIOCHEM J, V227, P851, DOI 10.1042/bj2270851; JEFFREY FMH, 1995, BASIC RES CARDIOL, V90, P388, DOI 10.1007/BF00788500; JESSEN ME, 1993, J CLIN INVEST, V92, P831, DOI 10.1172/JCI116657; KATZ J, 1989, J BIOL CHEM, V264, P12994; KELLEHER JK, 1985, AM J PHYSIOL, V248, pE252, DOI 10.1152/ajpendo.1985.248.2.E252; KELLEHER JK, 1986, AM J PHYSIOL, V250, pE296, DOI 10.1152/ajpendo.1986.250.3.E296; KELLEHER JK, 1994, AM J PHYSIOL, V266, pE384, DOI 10.1152/ajpendo.1994.266.3.E384; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; LANOUE K, 1970, J BIOL CHEM, V245, P102; Laplante A, 1997, AM J PHYSIOL-ENDOC M, V272, pE74, DOI 10.1152/ajpendo.1997.272.1.E74; LAPLANTE A, 1995, ANAL BIOCHEM, V224, P580, DOI 10.1006/abio.1995.1090; Lee W. N. P., 1989, J BIOL CHEM, V264, P13002; LEE WNP, 1993, J BIOL CHEM, V268, P25522; LEWANDOWSKI ED, 1990, AM J PHYSIOL, V258, pH1357, DOI 10.1152/ajpheart.1990.258.5.H1357; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; LOPASCHUK GD, 1992, MOL CELL BIOCHEM, V116, P111, DOI 10.1007/BF01270577; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MARTIN G, 1994, J BIOL CHEM, V269, P26034; MCVEIGH JJ, 1990, AM J PHYSIOL, V259, pH1079, DOI 10.1152/ajpheart.1990.259.4.H1079; MULLHOFER G, 1977, EUR J BIOCHEM, V75, P331, DOI 10.1111/j.1432-1033.1977.tb11533.x; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; PEUHKURINEN KJ, 1982, BIOCHEM J, V202, P67, DOI 10.1042/bj2020067; PEUHKURINEN KJ, 1982, BIOCHEM J, V208, P577, DOI 10.1042/bj2080577; PEUHKURINEN KJ, 1983, BIOCHEM J, V210, P193, DOI 10.1042/bj2100193; PLUMMER DT, 1971, INTRO PRACTICAL BIOC, P313; RENSTROM B, 1990, CIRC RES, V66, P282, DOI 10.1161/01.RES.66.2.282; ROGNSTAD R, 1993, BIOCHEM ARCH, V9, P15; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; ROSIERS CD, 1988, ANAL BIOCHEM, V173, P96, DOI 10.1016/0003-2697(88)90165-0; ROSIERS CD, 1991, J BIOL CHEM, V266, P1574; RUSSELL RR, 1991, AM J PHYSIOL, V261, pH1756, DOI 10.1152/ajpheart.1991.261.6.H1756; SADDIK M, 1993, J BIOL CHEM, V268, P25836; SCHULZ H, 1994, J NUTR, V124, P165, DOI 10.1093/jn/124.2.165; SLUSE FE, 1971, FEBS LETT, V18, P149, DOI 10.1016/0014-5793(71)80432-5; SUNDQVIST KE, 1989, BIOCHEM J, V257, P913, DOI 10.1042/bj2570913; VINCENT G, 1997, FASEB J, V11, P269; WEISS RG, 1989, P NATL ACAD SCI USA, V86, P6426, DOI 10.1073/pnas.86.16.6426; WEISS RG, 1992, CIRC RES, V70, P392, DOI 10.1161/01.RES.70.2.392; WEISS RG, 1989, J MOL CELL CARDIOL, V21, P469, DOI 10.1016/0022-2828(89)90787-6	60	43	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26117	26124		10.1074/jbc.272.42.26117	http://dx.doi.org/10.1074/jbc.272.42.26117			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334176	hybrid			2022-12-27	WOS:A1997YB13900010
J	Mishima, Y; Kaizu, H; Kominami, R				Mishima, Y; Kaizu, H; Kominami, R			Pairing of DNA fragments containing (GGA:TCC)(n) repeats and promotion by high mobility group protein 1 and histone H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKER HISTONES; NUCLEOPROTEIN STRUCTURES; 4-STRANDED COMPLEXES; BINDING PROTEIN; TELOMERIC DNA; STRANDED DNA; HMG-D; CHROMATIN; CONFORMATION; DISTAMYCIN	Tandemly repealed DNA sequences of(GGA:TCC)(n) are found in tracts up to 50 base pairs long, dispersed at thousands of sites throughout the genomes of eukaryotes, Here we demonstrate the formation of complexes paired between two DNAs containing such repeats in vitro and show enhancement of the pairing by glutathione S-transferase fusion proteins of high mobility group protein 1 and histone H1, This assembly depends on incubation time at 37 degrees C and concentrations of the proteins and DNA, and the enhancement is inhibited by distamycin and actinomycin D interacting DNA through the minor groove, Structure of the DNA-DNA complex is deduced by comparison of its mobility in gel electrophoresis with those of synthetic markers of heterotetramers. Three synthetic and genomic DNA fragments containing repeats that have different arrangements exhibit different efficiencies of DNA pairing, implying that the pairing is affected by the number of repeat units and the arrangement of repeats in a sequence, Intriguingly, pairing occurs between homologous fragments but not between heterologous DNAs among the three, These results suggest that the repeat-mediated DNA pairing plays a role in organization of higher order architecture of chromatin and possibly chromosome segregation requiring sequence-specific association events of DNA molecules.			Mishima, Y (corresponding author), NIIGATA UNIV,SCH MED,DEPT BIOCHEM,ASAHIMACHI DORI 1-757,NIIGATA 951,JAPAN.							BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BELLORINI M, 1995, NUCLEIC ACIDS RES, V23, P1657, DOI 10.1093/nar/23.10.1657; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BONNEANDREA C, 1984, EMBO J, V3, P1193, DOI 10.1002/j.1460-2075.1984.tb01950.x; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; DRESCHER U, 1987, DNA-J MOLEC CELL BIO, V6, P307, DOI 10.1089/dna.1987.6.307; FALCIOLA L, 1994, NUCLEIC ACIDS RES, V22, P285, DOI 10.1093/nar/22.3.285; FESEN M, 1989, J BIOL CHEM, V264, P11354; GAILLARD C, 1994, SCIENCE, V264, P433, DOI 10.1126/science.8153633; GE H, 1994, J BIOL CHEM, V269, P17136; GOODWIN GH, 1977, FEBS LETT, V73, P85, DOI 10.1016/0014-5793(77)80021-5; GRAZIANO V, 1994, NATURE, V368, P351, DOI 10.1038/368351a0; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; ISACKSON PJ, 1980, FEBS LETT, V119, P337, DOI 10.1016/0014-5793(80)80284-5; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; KUEHL L, 1984, J CELL BIOL, V99, P648, DOI 10.1083/jcb.99.2.648; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; Mishima Y, 1996, J BIOCHEM, V119, P805; MORTENSEN UH, 1990, NUCLEIC ACIDS RES, V18, P1983, DOI 10.1093/nar/18.8.1983; MURAISO T, 1992, NUCLEIC ACIDS RES, V20, P6631, DOI 10.1093/nar/20.24.6631; NER SS, 1994, EMBO J, V13, P1817, DOI 10.1002/j.1460-2075.1994.tb06450.x; Nightingale K, 1996, EMBO J, V15, P548, DOI 10.1002/j.1460-2075.1996.tb00387.x; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; READ CM, 1994, EMBO J, V13, P5369; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SOBELL HM, 1974, SCI AM, V231, P82, DOI 10.1038/scientificamerican0874-82; Suda T, 1996, NUCLEIC ACIDS RES, V24, P4733, DOI 10.1093/nar/24.23.4733; SUDA T, 1995, NUCLEIC ACIDS RES, V23, P3771, DOI 10.1093/nar/23.18.3771; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; Takayanagi K, 1997, DNA Res, V4, P241, DOI 10.1093/dnares/4.3.241; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; WAGA S, 1989, BIOCHIM BIOPHYS ACTA, V1007, P209, DOI 10.1016/0167-4781(89)90041-9; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WOLFFE A, 1995, CHROMATIN STRUCTURE, P6; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X	50	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26578	26584		10.1074/jbc.272.42.26578	http://dx.doi.org/10.1074/jbc.272.42.26578			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334238	hybrid			2022-12-27	WOS:A1997YB13900072
J	Surinya, KH; Cox, TC; May, BK				Surinya, KH; Cox, TC; May, BK			Transcriptional regulation of the human erythroid 5-aminolevulinate synthase gene - Identification of promoter elements and role of regulatory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; KRUPPEL-LIKE FACTOR; DELTA-AMINOLEVULINATE SYNTHASE; LINKED SIDEROBLASTIC ANEMIA; IRON-RESPONSIVE ELEMENT; LEUCINE ZIPPER PROTEIN; BETA-GLOBIN PROMOTER; FACTOR GATA-1; BINDING PROTEINS; HYPERSENSITIVE SITES	We have characterized the 5'-flanking region of the human erythroid-specific 5-amino levulinate synthase (ALAS) gene (the ALAS2 gene) and shown that the first 300 base pairs of promoter sequence gives maximal expression in erythroid cells, Transcription factor binding sites clustered within this promoter sequence include GATA motifs and CACCC boxes, critical regulatory sequences of many erythroid cell-expressed genes, GATA sites at -126/-121 (on the noncoding strand) and -102/-97 were each recognized by GATA-1 protein in vitro using erythroid cell nuclear extracts, Promoter mutagenesis and transient expression assays in erythroid cells established that both GATA-1 binding sites were functional and exogenously expressed GATA-1 increased promoter activity through these sites in transactivation experiments, A noncanonical TATA sequence at the expected TATA box location (-30/-23) bound GATA-1- or TATA-binding protein (TBP) in vitro, Conversion of this sequence to a canonical TATA box reduced expression in erythroid cells, suggesting a specific role for GATA-1 at this site. However, expression was also markedly reduced when the -30/-23 sequence was converted to a consensus GATA-1 sequence (that did not bind TBP in vitro), suggesting that a functional interaction of both factors with this sequence is important. A sequence comprising two overlapping CACCC boxes at -59/-48 (on the noncoding strand) was demon strated by mutagenesis to be functionally important. This CACCC sequence bound Spl, erythroid Kruppel-like factor, and basic Kruppel-like factor in vitro, while in transactivation experiments erythroid Kruppel-like factor activated ALAS2 promoter expression through this sequence, A sequence at -49/-39 with a 9/11 match to the consensus for the erythroid specific factor NF-E2 was not functional, Promoter constructs with 5'-flanking sequence from 293 base pairs to 10.3 kilobase pairs expressed efficiently in COS-1 cells as well as in erythroid cells, indicating that an enhancer sequence located elsewhere or native chromatin structure may be required for the tissue-restricted expression of the gene in vivo.	UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5005,AUSTRALIA; UNIV ADELAIDE,DEPT GENET,ADELAIDE,SA 5005,AUSTRALIA	University of Adelaide; University of Adelaide				Surinya, Kathy/0000-0003-0507-2962				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARTON MC, 1993, GENE DEV, V7, P1796, DOI 10.1101/gad.7.9.1796; BEAUMONT C, 1984, EXP CELL RES, V154, P474, DOI 10.1016/0014-4827(84)90171-X; BHASKER CR, 1993, J BIOL CHEM, V268, P12699; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BOTTOMLEY SS, 1995, J BIOENERG BIOMEMBR, V27, P161, DOI 10.1007/BF02110031; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; CONBOY JG, 1992, J BIOL CHEM, V267, P18753; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; COX TC, 1994, NEW ENGL J MED, V330, P675, DOI 10.1056/NEJM199403103301004; COX TC, 1990, AM J HUM GENET, V46, P107; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; Dierks P, 1990, BIOSYNTHESIS HEME CH, P201; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FENG WC, 1994, J BIOL CHEM, V269, P1493; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; JAMESPEDERSON M, 1995, J BIOL CHEM, V270, P3965, DOI 10.1074/jbc.270.8.3965; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kappas A, 1995, METABOLIC MOL BASES, P2103; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KAYA AH, 1994, GENOMICS, V19, P242, DOI 10.1006/geno.1994.1054; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KULOZIK AE, 1991, BLOOD, V77, P2054; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; LIM KC, 1994, NUCLEIC ACIDS RES, V22, P1226, DOI 10.1093/nar/22.7.1226; MAGUIRE DJ, 1986, NUCLEIC ACIDS RES, V14, P1379, DOI 10.1093/nar/14.3.1379; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; ORKIN SH, 1984, J BIOL CHEM, V259, P8679; Partington GA, 1997, DEV BIOL, V181, P144, DOI 10.1006/dbio.1996.8432; PERKINS AC, 1995, NATURE, V375, P318; PORCHER C, 1991, J BIOL CHEM, V266, P10562; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOENHAUT DS, 1989, NUCLEIC ACIDS RES, V17, P7013, DOI 10.1093/nar/17.17.7013; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUTHERLAND GR, 1988, AM J HUM GENET, V43, P331; Sutherland HGE, 1997, MOL CELL BIOL, V17, P1607, DOI 10.1128/MCB.17.3.1607; TAKETANI S, 1995, GENOMICS, V29, P698, DOI 10.1006/geno.1995.9949; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; TUGORES A, 1994, J BIOL CHEM, V269, P30789; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; YOMOGIDA K, 1993, J BIOCHEM-TOKYO, V113, P364, DOI 10.1093/oxfordjournals.jbchem.a124052; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	72	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26585	26594		10.1074/jbc.272.42.26585	http://dx.doi.org/10.1074/jbc.272.42.26585			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334239	hybrid			2022-12-27	WOS:A1997YB13900073
J	Zahringer, U; Wagner, F; Rietschel, ET; BenMenachem, G; Deutsch, J; Rottem, S				Zahringer, U; Wagner, F; Rietschel, ET; BenMenachem, G; Deutsch, J; Rottem, S			Primary structure of a new phosphocholine-containing glycoglycerolipid of Mycoplasma fermentans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINE PHOSPHATE; LIPOTEICHOIC ACID; C-POLYSACCHARIDE; MEMBRANE-LIPIDS	The chemical structure of a novel phosphocholine-containing glycoglycerolipid, the major polar lipid in the cell membrane of Mycoplasma fermentans PG18, was investigated by chemical analyses, gas-liquid chromatography-mass spectrometry, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, as well as one-and two-dimensional homo-and heteronuclear NMR spectroscopy and identified as 6'-O-(3 ''-phosphocholine-2 ''-amino-1 ''-phospho- 1 '',3 ''-propanediol)-alpha-D-glucopyranosyl-(1'-->3)-1,2-diacyl-glycerol (MfGL-II), Palmitate (16:0) and stearate (18:0), in a 3.6:1 molar ratio, constitute the major fatty acids present, MALDI-TOF mass spectrometry revealed two major pseudomolecular ions at m/z 1049.5 [M-I + H](+) and 1077.3 [M-II + H](+) representing a dipalmitoyl as the major component and a palmitoyl-stearoyl structure as a minor component. This is the first report of 2-amino-1,3-propanediol-1,3-bisphosphate present in a natural product, This glycoglycerolipid is the second phosphocholine-containing glycoglycerolipid found in M. fermentans.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MEMBRANE & ULTRASTRUCT RES,IL-91010 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,DEPT PHARMACEUT CHEM,SCH PHARM,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Zahringer, U (corresponding author), RES CTR BORSTEL,CTR MED & BIOSCI,PK ALLEE 22,D-23845 BORSTEL,GERMANY.							BEHR T, 1992, EUR J BIOCHEM, V207, P1063, DOI 10.1111/j.1432-1033.1992.tb17143.x; BLANCHARD A, 1994, ANNU REV MICROBIOL, V48, P687, DOI 10.1146/annurev.mi.48.100194.003351; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DEUTSCH J, 1995, EUR J BIOCHEM, V227, P897, DOI 10.1111/j.1432-1033.1995.tb20216.x; DITTMER JC, 1964, J LIPID RES, V5, P126; FISCHER W, 1994, EUR J BIOCHEM, V223, P879, DOI 10.1111/j.1432-1033.1994.tb19065.x; FISCHER W, 1993, EUR J BIOCHEM, V215, P851, DOI 10.1111/j.1432-1033.1993.tb18102.x; FRANZOSO G, 1992, FEBS LETT, V303, P251, DOI 10.1016/0014-5793(92)80531-K; JOHNSTON NC, 1994, MICROBIOL-UK, V140, P105, DOI 10.1099/13500872-140-1-105; MATSUDA K, 1994, J BIOL CHEM, V269, P33123; MATSUDA K, 1995, MICROBIOL IMMUNOL, V39, P307, DOI 10.1111/j.1348-0421.1995.tb02206.x; Risberg A, 1997, EUR J BIOCHEM, V243, P701, DOI 10.1111/j.1432-1033.1997.00701.x; SALMAN M, 1994, FEMS MICROBIOL LETT, V123, P255, DOI 10.1111/j.1574-6968.1994.tb07233.x; SHIELDS R, 1960, ANAL CHEM, V32, P885, DOI 10.1021/ac60163a053; SLOMIANY BL, 1977, EUR J BIOCHEM, V78, P33, DOI 10.1111/j.1432-1033.1977.tb11711.x; SUGITA M, 1992, J BIOL CHEM, V267, P22595; VINOGRADOV EV, 1992, EUR J BIOCHEM, V210, P491, DOI 10.1111/j.1432-1033.1992.tb17447.x; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612; Weiser JN, 1997, INFECT IMMUN, V65, P943, DOI 10.1128/IAI.65.3.943-950.1997; WISE KS, 1993, INFECT IMMUN, V61, P3327, DOI 10.1128/IAI.61.8.3327-3333.1993	22	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26262	26270		10.1074/jbc.272.42.26262	http://dx.doi.org/10.1074/jbc.272.42.26262			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334195	hybrid			2022-12-27	WOS:A1997YB13900029
J	Bergwitz, C; Jusseaume, SA; Luck, MD; Juppner, H; Gardella, TJ				Bergwitz, C; Jusseaume, SA; Luck, MD; Juppner, H; Gardella, TJ			Residues in the membrane-spanning and extracellular loop regions of the parathyroid hormone (PTH)-2 receptor determine signaling selectivity for PTH and PTH-related peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PTH)/PTH-RELATED PEPTIDE; CHIMERIC RECEPTORS; ADENYLATE-CYCLASE; BINDING-AFFINITY; COMMON RECEPTOR; INDIAN HEDGEHOG; PROTEIN; EXPRESSION; ACTIVATION; SECRETIN	The parathyroid hormone (PTH)-2 receptor displays strong ligand selectivity in that it responds fully to PTH but not at all to PTH-related peptide (PTHrP), In contrast, the PTH-1 receptor (PTH/PTHrP receptor) responds fully to both ligands, Previously it was shown that two divergent residues in PTH and PTHrP account for PTH-2 receptor selectivity; position 23 (Trp in PTH and Phe in PTHrP) determines binding selectivity and position 5 (Ile in PTH and His in PTHrP) determines signaling selectivity, To identify sites in the PTH-2 receptor involved in discriminating between His(5) and Ile(5), we constructed PTH-S receptor/PTH-1 receptor chimeras, expressed them in COS-7 cells, and tested for cAMP responsiveness to [Trp(23)] PTHrP-(1-36), and to the nondiscriminating peptide [Ile(5),Trp(23)]PTHrP-(1-36) (the Phe(23) --> Trp modification enabled high affinity binding of each ligand to the PTH-2 receptor), The chimeras revealed that the membrane-spanning/loop region of the receptor determined His(5)/Ile(5) signaling selectivity, Subsequent analysis of smaller cassette substitutions and then individual point mutations led to the identification of two single residues that function as major determinants of residue 5 signaling selectivity, These residues, Ile(244) at the extracellular end of transmembrane helix 3, and Tyr(318) at the COOH-terminal portion of extracellular loop 2, are replaced by Leu and Ile in the PTH-1 receptor, respectively, The results thus indicate a functional interaction between two residues in the core region of the PTH-2 receptor and residue 5 of the ligand.	MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CHILDRENS SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-11794] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell A, 1996, J BIOL CHEM, V271, P4518; ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2215, DOI 10.1210/endo-125-4-2215; Behar V, 1996, ENDOCRINOLOGY, V137, P4217, DOI 10.1210/en.137.10.4217; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; NISSENSON RA, 1988, J BIOL CHEM, V263, P12866; ROST B, 1995, PROTEIN SCI, V4, P521; SCHERTLER G, 1995, NATURE, V362, P770; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCHWARTZ TW, 1995, CURR PHARM DESIGN, V1, P325; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SHIGENO C, 1988, J BIOL CHEM, V263, P3872; STROOP S, 1994, BIOCHEMISTRY-US, V34, P1050; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; Turner PR, 1996, MOL ENDOCRINOL, V10, P132, DOI 10.1210/me.10.2.132; Usdin TB, 1997, ENDOCRINOLOGY, V138, P831, DOI 10.1210/en.138.2.831; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; Usdin TB, 1996, ENDOCRINOLOGY, V137, P4285, DOI 10.1210/en.137.10.4285; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	32	68	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28861	28868		10.1074/jbc.272.46.28861	http://dx.doi.org/10.1074/jbc.272.46.28861			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360953	hybrid			2022-12-27	WOS:A1997YF68400012
J	Hayes, F; Hallet, B; Cao, YH				Hayes, F; Hallet, B; Cao, YH			Insertion mutagenesis as a tool in the modification of protein function - Extended substrate specificity conferred by pentapeptide insertions in the Omega-LOOP of TEM-1 beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-ENZYME INTERMEDIATE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; RESOLUTION; SPECTRUM; MUTANTS; CEPHALOSPORINS; RESISTANCE; HYDROLYSIS; EVOLUTION	The TEM-1 beta-lactamase enzyme efficiently hydrolyzes beta-lactam antibiotics such as ampicillin but cleaves third generation cephalosporin antibiotics poorly. Variant beta-lactamases that conferred elevated levels of resistance to the cephalosporin ceftazidime were identified in a set of beta-lactamase derivatives previously generated by pentapeptide scanning mutagenesis in which a variable 5-amino acid cassette was introduced randomly in the target protein, This mutagenesis procedure was also modified to allow the direct selection of variant beta-lactamases with pentapeptide insertions that conferred extended substrate specificities, All insertions associated with enhanced resistance to ceftazidime were targetted to the 19-amino acid Omega-loop region, which forms part of the catalytic pocket of the beta-lactamase enzyme. However, pentapeptide insertions in the C-and N-terminal halves of this region had different effects on the ability of the enzyme to hydrolyze ampicillin in vivo. Larger insertions that increased the length of the Omega-loop by up to 2-fold also retained catalytic activity toward ampicillin and/or ceftazidime in vivo. In accord with previous substitution mutation studies, these results emphasize the extreme flexibility of the Omega-loop with regards the primary structure requirements for ceftazidime hydrolysis by beta-lactamase. The potential of pentapeptide scanning mutagenesis in mimicking evolution events that result from the insertion and excision of transposons in nature is discussed.			Hayes, F (corresponding author), UNIV OXFORD,DEPT BIOCHEM,MICROBIOL UNIT,S PARKS RD,OXFORD OX1 3QU,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADACHI H, 1991, J BIOL CHEM, V266, P3186; AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; Berg DE, 1989, MOBILE DNA; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Cao YH, 1997, J MOL BIOL, V274, P39, DOI 10.1006/jmbi.1997.1380; DELAIRE M, 1991, PROTEIN ENG, V4, P805, DOI 10.1093/protein/4.7.805; ESCOBAR WA, 1991, BIOCHEMISTRY-US, V30, P10783, DOI 10.1021/bi00108a025; FISHER J, 1980, BIOCHEMISTRY-US, V19, P2895, DOI 10.1021/bi00554a012; FOSTER PL, 1994, EMBO J, V13, P5240, DOI 10.1002/j.1460-2075.1994.tb06855.x; FRERE JM, 1995, MOL MICROBIOL, V16, P385, DOI 10.1111/j.1365-2958.1995.tb02404.x; Guillaume G, 1997, J BIOL CHEM, V272, P5438, DOI 10.1074/jbc.272.9.5438; Hallet B, 1997, NUCLEIC ACIDS RES, V25, P1866, DOI 10.1093/nar/25.9.1866; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAENHAUTMICHEL G, 1994, EMBO J, V13, P5229, DOI 10.1002/j.1460-2075.1994.tb06854.x; MAHILLON J, 1988, EMBO J, V7, P1515, DOI 10.1002/j.1460-2075.1988.tb02971.x; Maveyraud L, 1996, J BIOL CHEM, V271, P10482, DOI 10.1074/jbc.271.18.10482; NUKAGA M, 1995, J BIOL CHEM, V270, P5729, DOI 10.1074/jbc.270.11.5729; PALZKILL T, 1994, MOL MICROBIOL, V12, P217, DOI 10.1111/j.1365-2958.1994.tb01011.x; Petrosino JF, 1996, J BACTERIOL, V178, P1821, DOI 10.1128/jb.178.7.1821-1828.1996; RAQUET X, 1994, J MOL BIOL, V244, P625, DOI 10.1006/jmbi.1994.1756; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO JA, 1993, CURR OPIN GENET DEV, V3, P845, DOI 10.1016/0959-437X(93)90003-8; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; SUMMERS DK, 1988, EMBO J, V7, P851, DOI 10.1002/j.1460-2075.1988.tb02884.x; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469	31	34	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28833	28836		10.1074/jbc.272.46.28833	http://dx.doi.org/10.1074/jbc.272.46.28833			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360947	hybrid			2022-12-27	WOS:A1997YF68400006
J	MacLennan, DH; Rice, WJ; Green, NM				MacLennan, DH; Rice, WJ; Green, NM			The mechanism of Ca2+ transport by sarco(endo)plasmic reticulum Ca2+-ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MUSCLE SARCOPLASMIC-RETICULUM; SITE-DIRECTED MUTAGENESIS; NUCLEOTIDE-BINDING DOMAIN; AMINO-ACIDS; FUNCTIONAL CONSEQUENCES; ACTIVE-SITE; ATPASE; CA-2+-ATPASE; MEMBRANE; MUTATION		NATL INST MED RES, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research	MacLennan, DH (corresponding author), UNIV TORONTO, BANTING & BEST DEPT MED RES, CHARLES H BEST INST, 112 COLL ST, TORONTO, ON M5G 1L6, CANADA.		Tuluc, Petronel/C-2527-2011	Rice, William/0000-0002-5187-255X				ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; Barth A, 1996, J BIOL CHEM, V271, P30637, DOI 10.1074/jbc.271.48.30637; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; BIGELOW DJ, 1992, BIOCHIM BIOPHYS ACTA, V1113, P323, DOI 10.1016/0304-4157(92)90005-U; BLASIE JK, 1985, BIOPHYS J, V48, P9, DOI 10.1016/S0006-3495(85)83756-5; Canet D, 1996, J BIOL CHEM, V271, P20566, DOI 10.1074/jbc.271.34.20566; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; Cheong GW, 1996, BIOPHYS J, V70, P1689, DOI 10.1016/S0006-3495(96)79731-X; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; GIRARDET JL, 1992, FEBS LETT, V296, P103, DOI 10.1016/0014-5793(92)80413-B; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; JENCKS WP, 1992, ANN NY ACAD SCI, V671, P49, DOI 10.1111/j.1749-6632.1992.tb43783.x; LEE AG, 1996, BIOMEMBRANES, V5; LIU LH, 1997, IN PRESS J BIOL CHEM, V272; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; Martonosi AN, 1995, BIOSCIENCE REP, V15, P263, DOI 10.1007/BF01788359; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MATA AM, 1992, BIOCHEM J, V286, P567, DOI 10.1042/bj2860567; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; RICE WJ, 1997, IN PRESS J BIOL CHEM, V272; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; STOKES DL, 1994, J BIOL CHEM, V269, P11606; STOKES DL, 1990, J MOL BIOL, V213, P529, DOI 10.1016/S0022-2836(05)80213-X; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; Troullier A, 1996, BIOPHYS J, V71, P2970, DOI 10.1016/S0006-3495(96)79537-1; VILSEN B, 1992, J BIOL CHEM, V267, P25739; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Yonekura K, 1997, BIOPHYS J, V72, P997, DOI 10.1016/S0006-3495(97)78752-6; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9	49	423	433	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28815	28818		10.1074/jbc.272.46.28815	http://dx.doi.org/10.1074/jbc.272.46.28815			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360942	hybrid			2022-12-27	WOS:A1997YF68400001
J	Bhagwat, M; Meara, D; Nossal, NG				Bhagwat, M; Meara, D; Nossal, NG			Identification of residues of T4 RNase H required for catalysis and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POLYMERASE-I; ENDONUCLEASE; REPLICATION; EXONUCLEASE; MUTAGENESIS; SUBSTRATE; PROTEINS; CLEAVAGE; INVITRO	Bacteriophage T4 RNase H, which removes the RNA primers that initiate lagging strand fragments, has a 5'-to 3'-exonuclease activity on DNA DNA and RNA DNA duplexes and an endonuclease activity on flap or forked DNA structures (Bhagwat, M., Hobbs, L. J., and Nossal, N. J. (1997) J. Biol. Chem. 272, 28523-28530). It is a member of the RAD2 family of prokaryotic and eukaryotic replication and repair nucleases, The crystal structure of T4 RNase H, in the absence of DNA, shows two Mg2+ ions coordinated to the amino acids highly conserved in this family, It also shows a disordered region proposed to be involved in DNA binding (Mueser, T. C., Nossal, N. G., and Hyde, C. C. Cell (1996) 85, 1101-1112). To identify the amino acids essential for catalysis and DNA binding, we have constructed and characterized three kinds of T4 RNase H mutant proteins based on the possible roles of the amino acid residues: mutants of acidic residues coordinated to each of the two Mg2+ ions (Mg2+ - 1: D19N, D71N, D132N, and D155N; and Mg2+ - 2: D157N and D200N); mutants of conserved basic residues in or near the disordered region (K87A and R90A); and mutants of residues with hydroxyl side chains involved in the hydrogen bonding network (Y86F and S153A), Our studies show that Mg2+- 1 and the residues surrounding it are important for catalysis and that Lys(87) is necessary for DNA binding.	NIDDK,MOL & CELLULAR BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bhagwat M, 1997, J BIOL CHEM, V272, P28523, DOI 10.1074/jbc.272.45.28523; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; COZZARELLI NR, 1969, J MOL BIOL, V45, P513, DOI 10.1016/0022-2836(69)90309-X; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; Gerlt J. A., 1993, NUCLEASES, P1; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hobbs LJ, 1996, J BACTERIOL, V178, P6772, DOI 10.1128/jb.178.23.6772-6777.1996; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Mizrahi V, 1996, NUCLEIC ACIDS RES, V24, P4845, DOI 10.1093/nar/24.24.4845; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; ODA Y, 1993, J BIOL CHEM, V268, P88; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6089, DOI 10.1021/bi00141a019; Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030; XU SY, 1991, J BACTERIOL, V173, P5030, DOI 10.1128/jb.173.16.5030-5035.1991; Xu Y, 1997, J MOL BIOL, V268, P284, DOI 10.1006/jmbi.1997.0967; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	29	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28531	28538		10.1074/jbc.272.45.28531	http://dx.doi.org/10.1074/jbc.272.45.28531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353315	hybrid			2022-12-27	WOS:A1997YF21900055
J	Eggert, M; Michel, J; Schneider, S; Bornfleth, H; Baniahmad, A; Fackelmayer, FO; Schmidt, S; Renkawitz, R				Eggert, M; Michel, J; Schneider, S; Bornfleth, H; Baniahmad, A; Fackelmayer, FO; Schmidt, S; Renkawitz, R			The glucocorticoid receptor is associated with the RNA-binding nuclear matrix protein hnRNP U	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATES TRANSCRIPTIONAL ACTIVATION; THYROID-HORMONE RECEPTOR; CHICKEN LYSOZYME GENE; IN-VITRO; MONOCLONAL-ANTIBODY; DNA-REPLICATION; CO-REPRESSOR; DOMAIN; CELLS; ACID	The glucocorticoid receptor (GR) is a ligand-dependent transcription factor that is able to modulate gene activity by binding to its response element, interacting with other transcription factors, and contacting several accessory proteins such as coactivators. Here we show that GRIP120, one of the factors we have identified to interact with the glucocorticoid receptor, is identical to the heterogeneous nuclear ribonucleoprotein U (hnRNP U), a nuclear matrix protein binding to RNA as well as to scaffold attachment regions, GR hnRNP U complexes were identified by blotting and coimmunoprecipitation. The subnuclear distribution of GR and hnRNP U was characterized by indirect immunofluorescent labeling and confocal laser microscopy demonstrating a colocalization of both proteins, Using a nuclear transport-deficient deletion of hnRNP U, nuclear translocation was seen to be dependent on GR and dexamethasone. Transient transfections were used to identify possible interaction domains, Overexpressed hnRNP U interfered with glucocorticoid induction, and the COOH-terminal domains of both proteins were sufficient in mediating the transcriptional interference, A possible functional role for this GR binding-protein in addition to its binding to the nuclear matrix, to RNA, and to scaffold attachment regions is discussed.	UNIV GIESSEN, GENET INST, D-35392 GIESSEN, GERMANY; UNIV HEIDELBERG, INST ANGEW PHYS, D-69120 HEIDELBERG, GERMANY; UNIV CONSTANCE, FAK BIOL, D-78646 CONSTANCE, GERMANY	Justus Liebig University Giessen; Ruprecht Karls University Heidelberg; University of Konstanz								BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1997, STEROID THYROID RETI; BANIAHMAD C, 1991, J MOL BIOL, V222, P155, DOI 10.1016/0022-2836(91)90202-H; BARRACK ER, 1980, J BIOL CHEM, V255, P7265; BARRACK ER, 1982, RECENT PROG HORM RES, V38, P133; BASKIN Y, 1995, SCIENCE, V268, P1564, DOI 10.1126/science.7777854; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berezney R, 1976, Adv Enzyme Regul, V14, P63, DOI 10.1016/0065-2571(76)90008-X; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BORNFLETH H, 1996, MODELLGESTUTZTE SEGM, P408; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Eggert M, 1995, J BIOL CHEM, V270, P30755, DOI 10.1074/jbc.270.51.30755; EGGERT M, 1993, EUR J BIOCHEM, V213, P659, DOI 10.1111/j.1432-1033.1993.tb17806.x; EISEN LP, 1985, J BIOL CHEM, V260, P1805; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; FACKELMAYER FO, 1994, BIOCHEMISTRY-US, V33, P10416, DOI 10.1021/bi00200a024; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Hughes TA, 1995, J CELL SCI, P59; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAUFMANN SH, 1986, J BIOL CHEM, V261, P1962; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim MK, 1996, MOL CELL BIOL, V16, P4366; KIRSCH TM, 1986, BIOCHEM BIOPH RES CO, V137, P640, DOI 10.1016/0006-291X(86)91126-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauber AH, 1995, INT REV CYTOL, V162B, P337; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; MUNKEL C, 1995, BIOIMAGING, V3, P108; NELKIN BD, 1980, NUCLEIC ACIDS RES, V8, P5623, DOI 10.1093/nar/8.23.5623; Nickel J, 1995, NUCLEIC ACIDS RES, V23, P4785, DOI 10.1093/nar/23.23.4785; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; ONATE SA, 1995, SCIENCE, V270, P1354; PALMITER RD, 1974, P NATL ACAD SCI USA, V71, P2357, DOI 10.1073/pnas.71.6.2357; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; SCHMITT J, 1993, NUCLEIC ACIDS RES, V21, P2673, DOI 10.1093/nar/21.11.2673; SCHUCHARD M, 1991, BIOCHEMISTRY-US, V30, P4535, DOI 10.1021/bi00232a024; SCHUTZ G, 1977, COLD SPRING HARB SYM, V42, P617, DOI 10.1101/SQB.1978.042.01.064; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; STUURMAN N, 1992, J CELL SCI, V101, P773; SWANECK GE, 1979, P NATL ACAD SCI USA, V76, P1049, DOI 10.1073/pnas.76.3.1049; Tang YT, 1996, MOL CELL BIOL, V16, P1989; VANSTEENSEL B, 1995, J CELL SCI, V108, P3003; VANSTEENSEL B, 1995, J CELL BIOCHEM, V57, P465, DOI 10.1002/jcb.240570312; VANSTEENSEL B, 1991, FEBS LETT, V292, P229, DOI 10.1016/0014-5793(91)80873-2; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VOGELSTEIN B, 1980, CELL, V22, P79, DOI 10.1016/0092-8674(80)90156-7; VONKRIES JP, 1994, NUCLEIC ACIDS RES, V22, P1215, DOI 10.1093/nar/22.7.1215; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	63	72	76	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28471	28478		10.1074/jbc.272.45.28471	http://dx.doi.org/10.1074/jbc.272.45.28471			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353307	hybrid			2022-12-27	WOS:A1997YF21900047
J	Li, F; Hui, DY				Li, F; Hui, DY			Modified low density lipoprotein enhances the secretion of bile salt-stimulated cholesterol esterase by human monocyte-macrophages - Species-specific difference in macrophage cholesteryl ester hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; DEPENDENT PROTEIN-KINASE; UNESTERIFIED CHOLESTEROL; RAT-LIVER; MOLECULAR-CLONING; PORCINE PANCREAS; MESSENGER-RNA; FOAM CELLS; EXPRESSION; GENE	Reverse transcriptase-polymerase chain reaction was used to study the biosynthesis of two different cholesteryl ester hydrolases by human and mouse macrophages. Oligonucleotide primers for bile salt-stimulated cholesterol esterase yielded positive reactions with RNA isolated from human peripheral blood monocytes, monocyte-derived macrophages, the human monocytic THP-1 cells, and phorbol ester-induced THP-1 macrophages. In contrast, oligonucleotide primers for hormone-sensitive lipase yielded positive reactions only with RNA isolated from non-differentiated human THP-1 monocytic cells and peripheral blood monocytes, but not those obtained from differentiated THP-1 macrophages or monocyte-derived macrophages, Thus, while human monocytes were capable of synthesizing both enzymes, human macrophages synthesized only bile salt-stimulated cholesterol esterase and not the hormone-sensitive lipase. The synthesis of bile salt-stimulated cholesterol esterase by human macrophages was confirmed by detection of bile salt-stimulated cholesteryl ester hydrolytic activity in conditioned media of differentiated THP-1 cells and human peripheral blood monocyte-derived macrophages, Moreover, incubating human macrophages with oxidized low density lipoprotein (LDL) or acetylated LDL increased bile salt-stimulated cholesterol esterase activity in the conditioned media of these cells. These results with human macrophages were contrasted with results of studies with mouse macrophages, which showed the presence of hormone-sensitive lipase mRNA but not the bile salt-stimulated cholesterol esterase mRNA, Taken together, these results demonstrated species-specific differences in expression of cholesteryl ester hydrolytic enzymes in macrophages. The expression of bile salt-stimulated cholesterol esterase by human macrophages, in a proc ess inducible by modified LDL, suggests a role of this protein in atherogenesis.	UNIV CINCINNATI, COLL MED, DEPT PATHOL & LAB MED, CINCINNATI, OH 45267 USA	University of Cincinnati					NIDDK NIH HHS [DK46405, DK40917] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046405, R01DK040917] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRODTEPPLEY J, 1995, BBA-MOL BASIS DIS, V1272, P69, DOI 10.1016/0925-4439(95)00083-G; BRODTEPPLEY J, 1994, J LIPID RES, V35, P27; BROWN MS, 1983, J CLIN INVEST, V72, P743, DOI 10.1172/JCI111044; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTRERAS JA, 1994, ARTERIOSCLER THROMB, V14, P443, DOI 10.1161/01.ATV.14.3.443; FONTAINE RN, 1991, BIOCHEMISTRY-US, V30, P7008, DOI 10.1021/bi00242a028; Ghosh S, 1995, BBA-LIPID LIPID MET, V1259, P305, DOI 10.1016/0005-2760(95)00184-0; GHOSH S, 1992, BIOCHEM CELL BIOL, V70, P800, DOI 10.1139/o92-121; GHOSH S, 1991, LIPIDS, V26, P793, DOI 10.1007/BF02536160; GHOSH S, 1989, LIPIDS, V24, P733, DOI 10.1007/BF02535213; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; HAKAMATA H, 1994, ARTERIOSCLER THROMB, V14, P1860, DOI 10.1161/01.ATV.14.11.1860; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERNELL O, 1994, J PEDIATR-US, V125, pS56, DOI 10.1016/S0022-3476(06)80737-7; HOLTSBERG FW, 1995, BIOCHEM J, V309, P141, DOI 10.1042/bj3090141; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; HUANG Y, 1991, J BIOL CHEM, V266, P6720; HUI DY, 1990, FEBS LETT, V276, P131, DOI 10.1016/0014-5793(90)80525-N; Hui DY, 1996, BBA-LIPID LIPID MET, V1303, P1, DOI 10.1016/0005-2760(96)00085-9; HYUN J, 1969, J BIOL CHEM, V244, P1937; Innerarity T L, 1986, Methods Enzymol, V129, P542; ISHII I, 1992, ARTERIOSCLER THROMB, V12, P1139, DOI 10.1161/01.ATV.12.10.1139; KHOO JC, 1993, J LIPID RES, V34, P1969; KHOO JC, 1981, J BIOL CHEM, V256, P2659; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KRUTH HS, 1985, ATHEROSCLEROSIS, V57, P337, DOI 10.1016/0021-9150(85)90045-0; KUMAR BV, 1992, BIOCHEMISTRY-US, V31, P6077, DOI 10.1021/bi00141a017; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; Li F, 1996, BIOCHEMISTRY-US, V35, P6657, DOI 10.1021/bi952313q; LIDBERG U, 1992, GENOMICS, V13, P630, DOI 10.1016/0888-7543(92)90134-E; LIDMER AS, 1995, GENOMICS, V29, P115, DOI 10.1006/geno.1995.1221; LOMBARDO D, 1978, BIOCHIM BIOPHYS ACTA, V527, P142, DOI 10.1016/0005-2744(78)90263-2; MOMSEN WE, 1977, BIOCHIM BIOPHYS ACTA, V486, P103, DOI 10.1016/0005-2760(77)90074-1; MORA R, 1987, ATHEROSCLEROSIS, V67, P143, DOI 10.1016/0021-9150(87)90274-7; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; REMAURY A, 1995, BIOCHEM BIOPH RES CO, V207, P175, DOI 10.1006/bbrc.1995.1169; REUE K, 1991, J LIPID RES, V32, P267; ROUDANI S, 1994, EUR J CELL BIOL, V65, P132; Rudd E.A., 1984, P185; RUDD EA, 1987, BIOCHIM BIOPHYS ACTA, V918, P106, DOI 10.1016/0005-2760(87)90184-6; Shamir R, 1996, J CLIN INVEST, V97, P1696, DOI 10.1172/JCI118596; SMALL CA, 1989, FEBS LETT, V247, P205, DOI 10.1016/0014-5793(89)81335-3; Smith E B, 1974, Adv Lipid Res, V12, P1; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; ZOLFAGHARI R, 1992, ARTERIOSCLER THROMB, V12, P295, DOI 10.1161/01.ATV.12.3.295; ZOLFAGHARI R, 1993, J BIOL CHEM, V268, P13532	50	85	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28666	28671		10.1074/jbc.272.45.28666	http://dx.doi.org/10.1074/jbc.272.45.28666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353334	hybrid			2022-12-27	WOS:A1997YF21900074
J	Scott, DA; Docampo, R; Dvorak, JA; Shi, SL; Leapman, RD				Scott, DA; Docampo, R; Dvorak, JA; Shi, SL; Leapman, RD			In situ compositional analysis of acidocalcisomes in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PROBE MICROANALYSIS; ELEMENTAL COMPOSITION; CYSTEINE PROTEINASE; LYSOSOMAL COMPARTMENT; CRITHIDIA-FASCICULATA; AFRICAN TRYPANOSOMES; GRANULES INSITU; CA-2+ TRANSPORT; CALCIUM STORES; CA2+ RELEASE	We measured the elemental content of different compartments in Trypanosoma cruzi epimastigotes using quick freezing, ultracryomicrotomy, and electron probe microanalysis. Vacuoles identified by high electron density contained (in units of mmol/kg dry weight +/- S.E.) large amounts of phosphorus (1390 +/- 13), magnesium (646 +/- 19), calcium (171 +/- 5), sodium (161 +/- 18), and zinc (148 +/- 6). No other compartment had appreciable calcium or zinc content. Iron (128 +/- 16 mmol/kg) was detected only in vacuoles distinct from the electron-dense vacuoles and other organelles. Incubation of cells for 70 min in culture medium in the presence of ionomycin plus nigericin led to a very significant 3- or 2-fold increase in potassium in the electron-dense vacuoles and the iron-rich vacuoles, respectively, with no significant change in the other elements investigated, This indicated the acidic nature of the vacuoles and demonstrated that the electron-dense vacuoles correspond to what were described previously as acidocalcisomes, i.e. acidic compartments rich in Ca2+. The acidocalcisomes were investigated by separation of epimastigote fractions on Percoll gradients in combination with Triton WR-1339 treatment. This detergent caused a rapid vacuolation; these vacuoles were shown by electron microscopy to be largely transparent, with a diffuse matrix. Percoll gradient fractionation demonstrated decreases in the density of various organelle markers in detergent-treated cells compared with controls. Large decreases in the density of the acidocalcisome and the mitochondrion were seen, as well as smaller decreases in the density of the other markers. Conventional electron microscopy of epimastigotes loaded with gold-labeled transferrin indicated that the endosomal system was separate from vacuoles that probably corresponded to the calcium-containing organelles detected by electron probe microanalysis. The combined results provide evidence that acidocalcisomes are organelles different from lysosomes or other organelles previously described in these parasites.	UNIV ILLINOIS, COLL VET MED, DEPT VET PATHOBIOL, MOL PARASITOL LAB, URBANA, IL 61802 USA; NIAID, PARASIT DIS LAB, BETHESDA, MD 20892 USA; NIH, NATL CTR RES RESOURCES, BIOMED ENGN & INSTRUMENTAT PROGRAM, BETHESDA, MD 20892 USA	University of Illinois System; University of Illinois Urbana-Champaign; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA				Scott, David/0000-0002-8668-2449; Leapman, Richard/0000-0002-8575-4084	NIAID NIH HHS [AI-23259] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023259, R21AI023259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi T, 1996, BIOL PHARM BULL, V19, P1291; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; ARAI K, 1991, J BIOCHEM, V110, P541, DOI 10.1093/oxfordjournals.jbchem.a123616; ATKINSON AW, 1974, PROTOPLASMA, V81, P77, DOI 10.1007/BF02055775; Avila Jose Luis, 1992, V18, P189; BEAUMELLE BD, 1990, J CELL BIOL, V111, P1811, DOI 10.1083/jcb.111.5.1811; Bode HP, 1996, PFLUG ARCH EUR J PHY, V432, P97, DOI 10.1007/s004240050110; BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; BONTEMPI E, 1989, MOL BIOCHEM PARASIT, V33, P43, DOI 10.1016/0166-6851(89)90040-6; BOVERIS A, 1986, MOL BIOCHEM PARASIT, V19, P163, DOI 10.1016/0166-6851(86)90121-0; CANNATA JJB, 1982, MOL BIOCHEM PARASIT, V6, P151, DOI 10.1016/0166-6851(82)90074-3; CARVALHO TUD, 1977, J PARASITOL, V63, P1116, DOI 10.2307/3279861; CAZZULO JJ, 1990, BIOCHIM BIOPHYS ACTA, V1037, P186, DOI 10.1016/0167-4838(90)90166-D; DESOUZA W, 1979, ACTA TROP, V36, P253; DOCAMPO R, 1989, J BIOL CHEM, V264, P108; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; DVORAK JA, 1988, MOL BIOCHEM PARASIT, V31, P19, DOI 10.1016/0166-6851(88)90141-7; Egerton R.F., 1996, ELECT ENERGY LOSS SP, P245; FIORI CD, 1992, NIST NIH DESKTOP SPE; FOSTER MC, 1993, BIOPHYS J, V64, P525, DOI 10.1016/S0006-3495(93)81397-3; FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HALL TA, 1983, Q REV BIOPHYS, V16, P279, DOI 10.1017/S0033583500005114; Haller T, 1996, CELL CALCIUM, V19, P157, DOI 10.1016/S0143-4160(96)90084-6; HEALY N, 1992, PARASITOLOGY, V104, P315, DOI 10.1017/S003118200006176X; Hensgens CMH, 1996, EUR J BIOCHEM, V242, P327, DOI 10.1111/j.1432-1033.1996.0327r.x; HORISBERGER M, 1985, HISTOCHEMISTRY, V82, P219, DOI 10.1007/BF00501398; KRIVANEK OL, 1987, ULTRAMICROSCOPY, V22, P103, DOI 10.1016/0304-3991(87)90054-4; KUNDMANN M, 1990, EL P SOFTWARE MACINT; LEAPMAN RD, 1988, ULTRAMICROSCOPY, V24, P251, DOI 10.1016/0304-3991(88)90314-2; LEAPMAN RD, 1991, J MICROSC-OXFORD, V161, P3, DOI 10.1111/j.1365-2818.1991.tb03070.x; LEFURGEY A, 1990, MOL BIOCHEM PARASIT, V40, P77, DOI 10.1016/0166-6851(90)90081-V; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LIMA MF, 1990, MOL BIOCHEM PARASIT, V38, P245, DOI 10.1016/0166-6851(90)90027-J; LIU CM, 1978, J BIOL CHEM, V253, P5892; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; Moreno SNJ, 1996, BIOCHEM J, V313, P655, DOI 10.1042/bj3130655; OPPERDOES FR, 1982, MOL BIOCHEM PARASIT, V6, P181, DOI 10.1016/0166-6851(82)90077-9; ORNBERG RL, 1988, J BIOL CHEM, V263, P1488; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Reyes JG, 1996, AM J PHYSIOL-CELL PH, V270, pC401, DOI 10.1152/ajpcell.1996.270.2.C401; SCHLATTERER C, 1994, CELL CALCIUM, V16, P101, DOI 10.1016/0143-4160(94)90005-1; SCOTT DA, 1995, BIOCHEM J, V310, P789, DOI 10.1042/bj3100789; SCOTT DA, 1995, INT J PARASITOL, V25, P657, DOI 10.1016/0020-7519(95)99370-X; Shi SL, 1996, MICROSC RES TECHNIQ, V33, P241; SHUMAN H, 1976, ULTRAMICROSCOPY, V1, P317, DOI 10.1016/0304-3991(76)90049-8; Silva LHP, 1953, FOLIA CLIN BIOL, V20, P191; Silveira FT, 1979, HILEIA MED BELEM, V1, P61; SOARES MJ, 1991, PARASITOL RES, V77, P461, DOI 10.1007/BF00928410; SOARES MJ, 1992, J CELL SCI, V102, P157; SOMLYO AV, 1988, P NATL ACAD SCI USA, V85, P6222, DOI 10.1073/pnas.85.16.6222; SOMLYO AV, 1977, J CELL BIOL, V74, P828, DOI 10.1083/jcb.74.3.828; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SOUTOPADRON T, 1990, J CELL SCI, V96, P485; STEINERT M, 1965, EXP CELL RES, V39, P69, DOI 10.1016/0014-4827(65)90008-X; TONER JJ, 1972, BIOCHEM BIOPH RES CO, V46, P652, DOI 10.1016/S0006-291X(72)80190-6; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; VICKERMAN K, 1977, ANN SOC BELG MED TR, V57, P441; VIRK SS, 1985, BIOCHEM J, V226, P741, DOI 10.1042/bj2260741; WADA Y, 1994, J BIOENERG BIOMEMBR, V26, P631, DOI 10.1007/BF00831538; WEBSTER P, 1989, EUR J CELL BIOL, V49, P303; WILLIAMSON J, 1981, J PROTOZOOL, V28, P460, DOI 10.1111/j.1550-7408.1981.tb05320.x; Xu CW, 1996, MOL CELL BIOL, V16, P564; ZIEROLD K, 1988, METHOD MICROBIOL, V20, P91, DOI 10.1016/S0580-9517(08)70049-7	71	92	94	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28020	28029		10.1074/jbc.272.44.28020	http://dx.doi.org/10.1074/jbc.272.44.28020			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346954	hybrid			2022-12-27	WOS:A1997YD47300080
J	Asano, K; Vornlocher, HP; RichterCook, NJ; Merrick, WC; Hinnebusch, AG; Hershey, JWB				Asano, K; Vornlocher, HP; RichterCook, NJ; Merrick, WC; Hinnebusch, AG; Hershey, JWB			Structure of cDNAs encoding human eukaryotic initiation factor 3 subunits - Possible roles in RNA binding and macromolecular assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN PROTEIN-SYNTHESIS; SACCHAROMYCES-CEREVISIAE; RABBIT RETICULOCYTES; TRANSLATIONAL INITIATION; FACTOR EIF-3; MOV-34 GENE; HELA-CELLS; COMPLEX; CLONING; YEAST	The mammalian translation initiation factor 3 (eIF3), is a multiprotein complex of similar to 600 kDa that binds to the 40 S ribosome and promotes the binding of methionyl-tRNA(i) and mRNA. cDNA encoding 5 of the 10 subunits, namely eIF3-p170,-p116,-110,-p48, and -p36, have been isolated previously. Here we report the cloning and characterization of human cDNAs encoding the major RNA binding subunit, eIF3-p66, and two additional sub-units, eIF3-p47 and eIF3-p40. Each of these proteins is present in immunoprecipitates formed with affinity-purified anti-eIF3-p170 antibodies. Human eIF3-p66 shares 64% sequence identity with a hypothetical Caenorhabditis elegans protein, presumably the p66 homolog. Deletion analyses of recombinant derivatives of eIF3-p66 show that the RNA-binding domain lies within an N-terminal 71-amino acid region rich in lysine and arginine. The N-terminal regions of human eIF3-p40 and eIF3-p47 are related to each other and to 17 other erkaryotic proteins, including murine Mov-34, a subunit of the 26 S proteasome. Phylogenetic analyses of the 19 related protein sequences, called the Mov-34 family, distinguish five major subgroups, where eIF3-p40, eIF3-p47, and Mov-34 are each found in a different subgroup. The subunit composition of eIF3 appears to be highly conserved in Drosophila melanogaster, C. elegans, and Arabidopsis thaliana, whereas only 5 homologs of the 10 subunits of mammalian eIF3 are encoded in S. cerevisiae.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; NICHHD,LAB EUKARYOT GENE REGULAT,NIH,BETHESDA,MD 20892	University of California System; University of California Davis; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135, R01GM036467, R01GM026796] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36467, GM26796, GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; BENNE R, 1976, J BIOL CHEM, V251, P7675; BENNE R, 1978, J BIOL CHEM, V253, P3078; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; DUBIEL W, 1995, FEBS LETT, V363, P97, DOI 10.1016/0014-5793(95)00288-K; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; GRIDLEY T, 1991, GENOMICS, V11, P501, DOI 10.1016/0888-7543(91)90056-K; GU ZY, 1992, P NATL ACAD SCI USA, V89, P10355, DOI 10.1073/pnas.89.21.10355; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; Johnson KR, 1997, J BIOL CHEM, V272, P7106, DOI 10.1074/jbc.272.11.7106; KENRICK S, 1992, HUM MOL GENET, V1, P179; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Maniatis T., 1982, MOL CLONING; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; METHOT N, 1994, MOL CELL BIOL, V14, P3207; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MILBURN SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P6, DOI 10.1016/0003-9861(90)90002-G; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; *NAT CTR BIOT INF, SUMM DBEST HUM LIB; NYGARD O, 1982, NUCLEIC ACIDS RES, V10, P1327, DOI 10.1093/nar/10.4.1327; RINALDI T, 1995, GENE, V160, P135, DOI 10.1016/0378-1119(95)00212-O; SHIMANUKI M, 1995, J CELL SCI, V108, P569; TABER S, 1985, P NATL ACAD SCI USA, V82, P1074; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; TSURUMI C, 1995, BIOCHEM BIOPH RES CO, V210, P600, DOI 10.1006/bbrc.1995.1701; WEI CL, 1995, J BIOL CHEM, V270, P5764, DOI 10.1074/jbc.270.11.5764; WEI CL, 1995, J BIOL CHEM, V270, P22788, DOI 10.1074/jbc.270.39.22788; WESTERMANN P, 1984, NUCLEIC ACIDS RES, V12, P887; Wool I. G., 1996, TRANSLATIONAL CONTRO, P685; Yang WM, 1996, MOL CELL BIOL, V16, P6603	43	145	164	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27042	27052		10.1074/jbc.272.43.27042	http://dx.doi.org/10.1074/jbc.272.43.27042			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341143	hybrid			2022-12-27	WOS:A1997YC65900039
J	Lange, A; Gebremedhin, D; Narayanan, J; Harder, D				Lange, A; Gebremedhin, D; Narayanan, J; Harder, D			20-hydroxyeicosatetraenoic acid-induced vasoconstriction and inhibition of potassium current in cerebral vascular smooth muscle is dependent on activation of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SPECIFIC SUBSTRATE; RENAL ARCUATE ARTERIES; ARACHIDONIC-ACID; PHORBOL 12,13-DIBUTYRATE; BASILAR ARTERY; FATTY-ACIDS; CELLS; TRANSDUCTION; METABOLITES; K+	20-Hydroxyeicosatetraenoic acid (20-HETE), a cytochrome P450 metabolite of arachidonic acid, is a potent vasoconstrictor, and has been implicated in the myogenic activation of renal and cerebral arteries. We examined the role of protein kinase C (PKC) in the signal transduction pathway by which 20-HETE induces vasoconstriction and inhibition of whole-cell K+ current in cat cerebral vascular smooth muscle, 20-HETE induced a concentration-dependent constriction in isolated pressurized cat middle cerebral arteries (-29 +/- 8% at 1 mu M). However, in the presence of an N-myristoylated PKC pseudosubstrate inhibitor peptide (Myr Psi PKC-I(19-27)) 20-HETE induced a concentration-dependent vasodilation (26 +/- 4% at 1 mu M). In whole-cell voltage clamp studies, application of 20-HETE inhibited whole-cell K+ current recorded in cat cerebral vascular smooth muscle cells, an effect that was attenuated by Myr Psi PKC-I(19-27). Further evidence for the role of PKC activation in response to 20-HETE is the finding that 20-HETE increased the phosphorylation of myristoylated, alanine rich PKC substrate in cultured cat cerebral vascular smooth muscle cells in a concentration-and PKC-dependent manner. These data provide evidence that PKC is an integral part of the signal transduction pathway by which 20-HETE elicits vasoconstriction of cerebral arteries and inhibition of whole-cell K+ current in cat cerebral vascular smooth muscle.	MED COLL WISCONSIN, CARDIOVASC RES CTR, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT PHYSIOL, MILWAUKEE, WI 53226 USA; CLEMENT J ZABLOCKI VET AFFAIRS MED CTR, MILWAUKEE, WI 53295 USA	Medical College of Wisconsin; Medical College of Wisconsin					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032321] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33883-13] Funding Source: Medline; NINDS NIH HHS [R01 NS 32321-03] Funding Source: Medline; VA [VA 3440-06P] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); VA(US Department of Veterans Affairs)		ABRAHAM NG, 1991, BLOOD, V78, P1461; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; Amlal H, 1996, AM J PHYSIOL-CELL PH, V271, pC455, DOI 10.1152/ajpcell.1996.271.2.C455; Birks EK, 1997, AM J PHYSIOL-LUNG C, V272, pL823, DOI 10.1152/ajplung.1997.272.5.L823; BLOBE GC, 1995, PROSTAG LEUKOTR ESS, V52, P129, DOI 10.1016/0952-3278(95)90011-X; CAROLL MA, 1996, AM J PHYSIOL, V271, pR863; CAROLL MA, 1993, CIRC RES, V72, P126; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CLARK AH, 1991, BRIT J PHARMACOL, V102, P415, DOI 10.1111/j.1476-5381.1991.tb12188.x; CROOK RB, 1992, J CELL PHYSIOL, V153, P214, DOI 10.1002/jcp.1041530126; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; ENCABO A, 1993, J PHARM PHARMACOL, V45, P274, DOI 10.1111/j.2042-7158.1993.tb05552.x; ESCALANTE B, 1994, AM J PHYSIOL, V266, pC1775, DOI 10.1152/ajpcell.1994.266.6.C1775; FERRER M, 1992, BRAIN RES, V599, P186, DOI 10.1016/0006-8993(92)90390-U; GEBREMEDHIN D, 1997, IN PRESS J PHYSL LON; Goodman AI, 1997, P SOC EXP BIOL MED, V214, P54; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSSON A, 1986, BIOCHEM BIOPH RES CO, V134, P1215, DOI 10.1016/0006-291X(86)90380-3; Harder DR, 1997, J VASC RES, V34, P237, DOI 10.1159/000159228; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HARDER DR, 1994, AM J PHYSIOL, V266, pH2098, DOI 10.1152/ajpheart.1994.266.5.H2098; HARDER DR, 1995, TRENDS CARDIOVAS MED, V5, P7, DOI 10.1016/1050-1738(94)00026-R; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; HORSBURGH K, 1990, EUR J PHARMACOL, V191, P205, DOI 10.1016/0014-2999(90)94148-Q; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Imig JD, 1996, AM J PHYSIOL-REG I, V270, pR217, DOI 10.1152/ajpregu.1996.270.1.R217; KAUSER K, 1991, CIRC RES, V68, P1154, DOI 10.1161/01.RES.68.4.1154; KAZUSHI M, 1993, BIOCHEM BIOPH RES CO, V190, P263; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; Lin FM, 1995, AM J PHYSIOL-RENAL, V269, pF806, DOI 10.1152/ajprenal.1995.269.6.F806; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; MA YH, 1993, CIRC RES, V72, P126, DOI 10.1161/01.RES.72.1.126; MACICA C, 1993, AM J PHYSIOL, V265, pG735, DOI 10.1152/ajpgi.1993.265.4.G735; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; MURRAY MA, 1992, HYPERTENSION, V19, P739, DOI 10.1161/01.HYP.19.6.739; Nowicki S, 1997, J CLIN INVEST, V99, P1224, DOI 10.1172/JCI119279; Ominato M, 1996, J MEMBRANE BIOL, V152, P235, DOI 10.1007/s002329900101; RIBALET B, 1995, J MEMBRANE BIOL, V148, P111; RIBEIRO CMP, 1994, AM J PHYSIOL, V266, pF497, DOI 10.1152/ajprenal.1994.266.3.F497; ROBINSON PJ, 1993, ANAL BIOCHEM, V210, P172, DOI 10.1006/abio.1993.1169; ROMAN RJ, 1993, J AM SOC NEPHROL, V4, P986; SALAICES M, 1990, J PHARMACOL EXP THER, V255, P66; SEKIGUCHI K, 1987, BIOCHEM BIOPH RES CO, V145, P797, DOI 10.1016/0006-291X(87)91035-7; Shipston MJ, 1996, J PHYSIOL-LONDON, V493, P665, DOI 10.1113/jphysiol.1996.sp021413; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; WALSH MP, 1994, CAN J PHYSIOL PHARM, V72, P1392, DOI 10.1139/y94-201; WANG WH, 1995, J GEN PHYSIOL, V106, P727, DOI 10.1085/jgp.106.4.727; ZHANG H, 1995, PHARMACOLOGY, V50, P247, DOI 10.1159/000139289; ZOU AP, 1994, AM J PHYSIOL, V266, pF275, DOI 10.1152/ajprenal.1994.266.2.F275; Zou AP, 1996, AM J PHYSIOL-REG I, V270, pR228, DOI 10.1152/ajpregu.1996.270.1.R228	51	146	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27345	27352		10.1074/jbc.272.43.27345	http://dx.doi.org/10.1074/jbc.272.43.27345			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341185	hybrid			2022-12-27	WOS:A1997YC65900081
J	Mueller, GA; Smith, AM; Williams, DC; Hakkaart, GAJ; Aalberse, RC; Chapman, MD; Rule, GS; Benjamin, DC				Mueller, GA; Smith, AM; Williams, DC; Hakkaart, GAJ; Aalberse, RC; Chapman, MD; Rule, GS; Benjamin, DC			Expression and secondary structure determination by NMR methods of the major house dust mite allergen Der p 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGKISTRODON-PISCIVORUS-PISCIVORUS; 3-DIMENSIONAL SOLUTION STRUCTURE; MAGNETIC-RESONANCE SPECTROSCOPY; SITE-DIRECTED MUTAGENESIS; GROUP-II DERMATOPHAGOIDES; SIDE-CHAIN RESONANCES; C-13/N-15-ENRICHED PROTEINS; C-13-LABELED PROTEINS; ANTIGENIC STRUCTURE; C-13 MAGNETIZATION	There exists a strong correlation between asthma and sensitization to indoor allergens, This study reports on the secondary structure of the major house dust mite allergen Der p 2, determined using heteronuclear NMR methods, The DNA was subcloned from the yeast expression vector pSAY1 into the high yield bacterial expression vector pET21a, resulting in yields of 50 mg/liter, The recombinant protein was shown to have immunoreactivity comparable with that of the natural mite protein using competitive inhibition enzyme-linked immunosorbent assay (ELISA) and a modified monoclonal radioallergosorbent test (RAST), The secondary structure was determined by examining chemical shifts, short and long range NOESYs, J(HN-HA) coupling constants, and amide exchange rates, From these data, it is clear that Der p 2 is composed of beta-sheets and random coil, Based on long range distance constraints, a number of beta strands were aligned into two three-stranded, antiparallel beta-sheets.	UNIV VIRGINIA,HLTH SCI CTR,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,ASTHMA & ALLERG DIS CTR,CHARLOTTESVILLE,VA 22908; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,NL-1006 AD AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,CLIN & EXPT IMMUNOL LAB,NL-1006 AD AMSTERDAM,NETHERLANDS; CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	University of Virginia; University of Virginia; University of Amsterdam; Carnegie Mellon University			Mueller, Geoffrey A/I-2909-2017; Rule, Gordon S/Q-2422-2015	Mueller, Geoffrey A/0000-0001-8361-5323; Rule, Gordon S/0000-0002-4396-3363; Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034607, U01AI034607] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-34607] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRIERCHECK DM, 1997, J BIOMOL NMR, V8, P429; CHUA KY, 1991, CLIN EXP ALLERGY, V21, P161, DOI 10.1111/j.1365-2222.1991.tb00825.x; CLUBB RT, 1992, J BIOMOL NMR, V2, P203, DOI 10.1007/BF01875531; DRISCOLL PC, 1990, J MAGN RESON, V88, P425; FRENKIEL T, 1990, J MAGN RESON, V90, P420, DOI 10.1016/0022-2364(90)90152-Y; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; Jerala R, 1996, J MAGN RESON SER B, V110, P87, DOI 10.1006/jmrb.1996.0013; Jerala R, 1996, J BIOMOL NMR, V7, P107; KAY LE, 1993, J AM CHEM SOC, V115, P2055, DOI 10.1021/ja00058a072; LATHROP BK, 1992, PROTEIN EXPRES PURIF, V3, P512, DOI 10.1016/1046-5928(92)90069-9; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; MAJUMDAR A, 1993, J MAGN RESON SER B, V102, P242, DOI 10.1006/jmrb.1993.1093; METZLER WJ, 1992, BIOCHEMISTRY-US, V31, P5117, DOI 10.1021/bi00137a005; METZLER WJ, 1992, BIOCHEMISTRY-US, V31, P8697, DOI 10.1021/bi00152a003; NISHIYAMA C, 1994, INT ARCH ALLERGY IMM, V105, P62, DOI 10.1159/000236804; Nishiyama C, 1995, MOL IMMUNOL, V32, P1021, DOI 10.1016/0161-5890(95)00091-7; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; PENNINGTON CJ, 1992, BIOCHEMISTRY-US, V11, P2912; PLATTSMILLS TAE, 1997, IN PRESS J ALLERGY C; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1111/j.1365-2222.1997.tb00667.x; Sambrook J., 2002, MOL CLONING LAB MANU; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; SMITH AM, 1991, J IMMUNOL, V146, P1254; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEWART GA, 1992, J ALLERGY CLIN IMMUN, V90, P141, DOI 10.1016/S0091-6749(06)80029-1; THOMAS W, 1996, MOL ANAL IMMEDIATE H, P77; THOMAS WR, 1995, CLIN EXP ALLERGY, V25, P667, DOI 10.1111/j.1365-2222.1995.tb01117.x; TOPHAM CM, 1994, PROTEIN ENG, V7, P869, DOI 10.1093/protein/7.7.869; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033	44	51	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26893	26898		10.1074/jbc.272.43.26893	http://dx.doi.org/10.1074/jbc.272.43.26893			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341122	hybrid, Green Published			2022-12-27	WOS:A1997YC65900018
J	Ren, B; Thelen, AP; Peters, JM; Gonzalez, FJ; Jump, DB				Ren, B; Thelen, AP; Peters, JM; Gonzalez, FJ; Jump, DB			Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X RECEPTOR; COA DESATURASE-1 GENE; HYDROGENATED FISH OIL; RAT-LIVER; BETA-OXIDATION; MESSENGER-RNA; CROSS-TALK; DIFFERENTIAL EXPRESSION; EICOSAPENTAENOIC ACID; SIGNALING PATHWAYS	Dietary polyunsaturated fatty acids (PUFA) induce hepatic peroxisomal and microsomal fatty acid oxidation and suppress lipogenic gene expression. The peroxisome proliferator-activated receptor alpha (PPAR alpha) has been implicated as a mediator of fatty acid effects on gene transcription. This report uses the PPAR alpha-deficient mouse to examine the role of PPAR alpha in the PUFA regulation of mRNAs encoding hepatic lipogenic (fatty acid synthase (FAS) and the 514 protein (514)), microsomal (cytochrome P450 4A2 (CYP4A2)), and peroxisomal (acyl-CoA oxidase (AOX)) enzymes, PUFA ingestion induced mRNA(AOX) (2.3-fold) and mRNA(CYP4A2) (8-fold) and suppressed mRNA(FAS) and mRNA(S14) by greater than or equal to 80% in wild type mice, In PPAR alpha-deficient mice, PUFA did not induce mRNA(AOX) or mRNA(CYP4A2), indicating a requirement for PPAR alpha in the PUFA-mediated induction of these enzymes, However, PUFA still suppressed mRNA(FAS) and mRNA(S14) in the PPAR alpha-deficient mice, Studies in rats provided additional support for the differential regulation of lipogenic and peroxisomal enzymes by PUFA. These studies provide evidence for two distinct pathways for PUFA control of hepatic lipid metabolism. One requires PPAR alpha and is involved in regulating peroxisomal and microsomal enzymes, The other pathway does not require PPAR alpha and is involved in the PUFA mediated suppression of lipogenic gene expression.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT PHYSIOL, E LANSING, MI 48824 USA; NCI, LAB METAB, NIH, BETHESDA, MD 20892 USA	Michigan State University; Michigan State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Peters, Jeffrey/D-8847-2011	Peters, Jeffrey/0000-0003-2782-2998	NIDDK NIH HHS [R01 DK043220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARSLAND A, 1990, LIPIDS, V25, P546, DOI 10.1007/BF02537162; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CHU RY, 1995, P NATL ACAD SCI USA, V92, P11593, DOI 10.1073/pnas.92.25.11593; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; CLARKE SD, 1990, J NUTR, V120, P218, DOI 10.1093/jn/120.2.218; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; FLATMARK T, 1988, BIOCHIM BIOPHYS ACTA, V962, P122, DOI 10.1016/0005-2760(88)90103-8; GEARING KL, 1994, CELL, V79, P1147; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; Hertz R, 1996, J BIOL CHEM, V271, P218, DOI 10.1074/jbc.271.1.218; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; HUANG Q, 1994, J BIOL CHEM, V269, P8493; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; JUMP DB, 1994, J LIPID RES, V35, P1076; JUMP DB, 1995, PROSTAG LEUKOTR ESS, V52, P107, DOI 10.1016/0952-3278(95)90007-1; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; KAIKAUS RM, 1993, J BIOL CHEM, V268, P26866; KELLER H, 1995, MOL ENDOCRINOL, V9, P794, DOI 10.1210/me.9.7.794; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LALWANI ND, 1983, HUM TOXICOL, V2, P27, DOI 10.1177/096032718300200103; LANDSCHULZ KT, 1994, BIOCHEM BIOPH RES CO, V200, P763, DOI 10.1006/bbrc.1994.1516; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Miller CW, 1996, P NATL ACAD SCI USA, V93, P9443, DOI 10.1073/pnas.93.18.9443; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEAT CE, 1980, BIOCHEM J, V186, P369, DOI 10.1042/bj1860369; NILSSON A, 1987, BIOCHIM BIOPHYS ACTA, V920, P114, DOI 10.1016/0005-2760(87)90250-5; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; RAMB, 1996, LIPIDS, V31, pS45; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; RUSTAN AC, 1992, BIOCHEM J, V283, P333, DOI 10.1042/bj2830333; RUSTAN AC, 1988, J LIPID RES, V29, P1417; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schoonjans K, 1996, J LIPID RES, V37, P907; THOMASSEN MS, 1982, BIOCHEM J, V206, P195, DOI 10.1042/bj2060195; TOUSSANT MJ, 1981, J NUTR, V111, P146, DOI 10.1093/jn/111.1.146; VALDES E, 1995, LIPIDS, V30, P955, DOI 10.1007/BF02537488; WILLUMSEN N, 1993, J LIPID RES, V34, P13; YOKOMIZO T, 1995, J LIPID MEDIAT CELL, V12, P321, DOI 10.1016/0929-7855(95)00041-N	52	208	215	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26827	26832		10.1074/jbc.272.43.26827	http://dx.doi.org/10.1074/jbc.272.43.26827			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341113	hybrid			2022-12-27	WOS:A1997YC65900009
J	Vernallis, AB; Hudson, KR; Heath, JK				Vernallis, AB; Hudson, KR; Heath, JK			An antagonist for the leukemia inhibitory factor receptor inhibits leukemia inhibitory factor, cardiotrophin-1, ciliary neurotrophic factor, and oncostatin M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; SIGNAL TRANSDUCER GP130; HUMAN MYELOMA CELLS; CNTF RECEPTOR; HUMAN INTERLEUKIN-6; LIF RECEPTOR; SYMPATHETIC NEURONS; ALPHA COMPONENT; RATIONAL DESIGN; GROWTH-FACTORS	The leukemia inhibitory factor receptor (LIF-R) is activated not only by LlF, but also by cardiotrophin-1, ciliary neurotrophic factor with its receptor, and oncostatin M (OSM). Each of these cytokines induces the hetero oligomerization of LIF-R with gp130, a signal-transducing subunit shared with interleukin-6 and interleukin-11. The introduction of mutations into human LIF that reduced the affinity for gp130 while retaining affinity for LIF-R has generated antagonists for LIF. In the current study, a LIF antagonist that was free of detectable agonistic activity was tested for antagonism against the family of LIF-R ligands. On cells that express LIF-R and gp130, all LIF-R ligands were antagonized. On cells that also express OSM receptor, OSM was not antagonized, demonstrating that the antagonist is specific for LIF-R. Ligand-triggered tyrosine phosphorylation of both LIF-R and gp130 was blocked by the antagonist. The antagonist is therefore likely to work by preventing receptor oligomerization.	UNIV BIRMINGHAM,SCH BIOCHEM,CRC,GROWTH FACTOR GRP,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham								AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; BANNER LR, 1994, P NATL ACAD SCI USA, V91, P7109, DOI 10.1073/pnas.91.15.7109; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; Bellido T, 1996, J CLIN INVEST, V97, P431, DOI 10.1172/JCI118432; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BROWN MA, 1994, CYTOKINE, V6, P300, DOI 10.1016/1043-4666(94)90027-2; CORDINGLEY MG, 1990, J BIOL CHEM, V265, P9062; Crichton MB, 1996, MOL CELL ENDOCRINOL, V118, P215, DOI 10.1016/0303-7207(96)03761-6; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DEHON FD, 1994, J EXP MED, V180, P2395, DOI 10.1084/jem.180.6.2395; DiMarco A, 1996, P NATL ACAD SCI USA, V93, P9247, DOI 10.1073/pnas.93.17.9247; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1992, CIBA F SYMP, V167, P245; Grunewald SM, 1997, J BIOL CHEM, V272, P1480, DOI 10.1074/jbc.272.3.1480; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kurek JB, 1996, MUSCLE NERVE, V19, P1291, DOI 10.1002/(SICI)1097-4598(199610)19:10<1291::AID-MUS6>3.0.CO;2-9; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; LECRON JC, 1993, CLIN EXP IMMUNOL, V92, P23; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LONG AC, 1989, FEBS LETT, V258, P75, DOI 10.1016/0014-5793(89)81619-9; LOTZ M, 1992, J CLIN INVEST, V90, P888, DOI 10.1172/JCI115964; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Neophytou C, 1997, DEVELOPMENT, V124, P2345; ODORISIO MS, 1992, REGUL PEPTIDES, V37, P213; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; Omori N, 1996, LAB INVEST, V75, P15; Owczarek CM, 1996, J BIOL CHEM, V271, P5495, DOI 10.1074/jbc.271.10.5495; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PIQUETPELLORCE C, 1994, EXP CELL RES, V213, P340, DOI 10.1006/excr.1994.1208; Rajan P, 1996, J NEUROSCI RES, V43, P403, DOI 10.1002/(SICI)1097-4547(19960215)43:4<403::AID-JNR2>3.0.CO;2-J; RAO MS, 1992, NEUROREPORT, V3, P865, DOI 10.1097/00001756-199210000-00011; ROBINSON RC, 1994, CELL, V77, P1; RUDGE JS, 1994, EUR J NEUROSCI, V6, P693, DOI 10.1111/j.1460-9568.1994.tb00981.x; SAGGIO I, 1994, ANAL BIOCHEM, V221, P387, DOI 10.1006/abio.1994.1430; Sambrook J., 2002, MOL CLONING LAB MANU; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sporeno E, 1996, BLOOD, V87, P4510, DOI 10.1182/blood.V87.11.4510.bloodjournal87114510; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Sun Y, 1996, EUR J NEUROSCI, V8, P2213, DOI 10.1111/j.1460-9568.1996.tb00744.x; SUN Y, 1994, J NEUROBIOL, V25, P415, DOI 10.1002/neu.480250407; Sun Y, 1996, J NEUROCHEM, V67, P1751; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Taga T, 1996, J NEUROCHEM, V67, P1; THOMA B, 1994, J BIOL CHEM, V269, P6215; Thompson SWN, 1997, EUR J NEUROSCI, V9, P1244, DOI 10.1111/j.1460-9568.1997.tb01479.x; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; ULICH TR, 1994, AM J PHYSIOL-LUNG C, V267, pL442, DOI 10.1152/ajplung.1994.267.4.L442; WARE CB, 1995, DEVELOPMENT, V121, P1283; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; YANG YC, 1986, CELL, V47, P8; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	76	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26947	26952		10.1074/jbc.272.43.26947	http://dx.doi.org/10.1074/jbc.272.43.26947			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341130	hybrid, Green Accepted			2022-12-27	WOS:A1997YC65900026
J	Birn, H; Verroust, PJ; Nexo, E; Hager, H; Jacobsen, C; Christensen, EI; Moestrup, SK				Birn, H; Verroust, PJ; Nexo, E; Hager, H; Jacobsen, C; Christensen, EI; Moestrup, SK			Characterization of an epithelial similar to 460-kDa protein that facilitates endocytosis of intrinsic factor-vitamin B-12 and binds receptor-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHRITIS ANTIGENIC COMPLEX; BRUSH-BORDER MEMBRANE; FACTOR-COBALAMIN; TRANSCOBALAMIN-II; ALPHA-2-MACROGLOBULIN RECEPTOR; MONOCLONAL-ANTIBODIES; RAT-KIDNEY; GP330; LIPOPROTEIN; IDENTIFICATION	By using receptor-associated protein (RAP) as an affinity target, an intrinsic factor-vitamin B-12 (IF-B-12)-binding renal epithelial protein of similar to 460 kDa was copurified together with the transcobalamin-B-12-binding 600-kDa receptor, megalin, IF-B-12 affinity chromatography of renal cortex membrane from rabbit and man yielded the same similar to 460-kDa protein. Binding studies including surface plasmon resonance analyses of the protein demonstrated a calcium-dependent and high affinity binding of IF-B-12 to a site distinct from the RAP binding site. The high affinity binding of IF-B-12 was dependent on complex formation with vitamin B-12. Light and electron microscope autoradiography of rat renal cortex cryosections incubated directly with IF-Co-57-B-12 and rat proximal tubules microinjected in vivo with the radioligand demonstrated binding of the ligand to endocytic invaginations of proximal tubule membranes followed by endocytosis and targeting of vitamin B-12 to lysosomes. Polyclonal antibodies recognizing the similar to 460-kDa receptor inhibited the uptake, Immunohistochemistry of kidney and intestine showed colocalization of the IF-B-12 receptor and megalin in both tissues. In conclusion, we have identified the epithelial IF-B-12-binding receptor as a similar to 460-kDa RAP-binding protein facilitating endocytosis.	AARHUS UNIV,DEPT BIOCHEM MED,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,DEPT CELL BIOL,DK-8000 AARHUS C,DENMARK; AARHUS KOMMUNE HOSP,DEPT CLIN BIOCHEM,DK-8000 AARHUS C,DENMARK; HOP TENON,INSERM,U64,F-75020 PARIS,FRANCE	Aarhus University; Aarhus University; Aarhus University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite			Moestrup, Søren Kragh/AAD-1735-2019; Birn, Henrik/C-3931-2009; Moestrup, Søren Kragh/A-1403-2014	Birn, Henrik/0000-0003-3715-7266; Moestrup, Søren Kragh/0000-0003-3862-2107; Nexo, Ebba/0000-0001-9406-9081				BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; COOPER BA, 1968, BRIT J HAEMATOL, V14, P73, DOI 10.1111/j.1365-2141.1968.tb01474.x; DAN N, 1994, J BIOL CHEM, V269, P18849; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; FYFE JC, 1991, J BIOL CHEM, V266, P4489; GRASBECK R, 1960, ACTA MED SCAND, V167, P289; HAKAMI N, 1971, NEW ENGL J MED, V285, P1163, DOI 10.1056/NEJM197111182852103; Hjalm G, 1996, EUR J BIOCHEM, V239, P132, DOI 10.1111/j.1432-1033.1996.0132u.x; HOOPER DC, 1973, J CLIN INVEST, V52, P3074, DOI 10.1172/JCI107506; IMERSLUND O, 1960, Acta Paediatr Suppl, V49(Suppl 119), P1; JACOBSEN DW, 1994, ADV T ADDISONS DIS, V1, P229; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LePanse S, 1997, EUR J CELL BIOL, V72, P257; LEPANSE S, 1994, AM J PATHOL, V145, P1526; MACKENZIE IL, 1968, J EXP MED, V123, P375; MAUNSBACH AB, 1966, J ULTRA MOL STRUCT R, V15, P197, DOI 10.1016/S0022-5320(66)80108-9; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; NEXO E, 1975, BIOCHIM BIOPHYS ACTA, V379, P189, DOI 10.1016/0005-2795(75)90021-5; NEXO E, 1977, BIOCHIM BIOPHYS ACTA, V494, P395, DOI 10.1016/0005-2795(77)90168-4; NEXO E, 1982, B12 BIOCH MED, P57; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; RACHOWDURY R, 1989, SCIENCE, V244, P1163; RAMANUJAM KS, 1992, BIOCHEM BIOPH RES CO, V182, P439, DOI 10.1016/0006-291X(92)91751-B; RAMANUJAM KS, 1990, BIOCHIM BIOPHYS ACTA, V1030, P157, DOI 10.1016/0005-2736(90)90251-I; ROTHENBERG SP, 1968, J CLIN INVEST, V47, P913, DOI 10.1172/JCI105783; SAHALI D, 1988, J EXP MED, V167, P213, DOI 10.1084/jem.167.1.213; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SEETHARAM B, 1981, J BIOL CHEM, V256, P3785; SEETHARAM B, 1983, BIOCHEM BIOPH RES CO, V115, P238, DOI 10.1016/0006-291X(83)90995-6; Seetharam B, 1997, J CLIN INVEST, V99, P2317, DOI 10.1172/JCI119411; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; SEETHARAM B, 1994, ADV T ADDISONS DISEA, V2, P293; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; VANKAPEL J, 1988, CLIN CHIM ACTA, V172, P297, DOI 10.1016/0009-8981(88)90336-1; WAHLSTEDT V, 1985, J LAB CLIN MED, V106, P439; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; YANG YM, 1985, J CLIN INVEST, V76, P2037	47	118	123	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26497	26504		10.1074/jbc.272.42.26497	http://dx.doi.org/10.1074/jbc.272.42.26497			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334227	hybrid			2022-12-27	WOS:A1997YB13900061
J	Phalipou, S; Cotte, N; Carnazzi, E; Seyer, R; Mahe, E; Jard, S; Barberis, C; Mouillac, B				Phalipou, S; Cotte, N; Carnazzi, E; Seyer, R; Mahe, E; Jard, S; Barberis, C; Mouillac, B			Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; P NK-1 RECEPTOR; MOLECULAR-CLONING; SUBSTANCE-P; FUNCTIONAL EXPRESSION; OXYTOCIN; SITE; AGONISTS; LIGAND; CELLS	The study of antagonist binding domains of the hu man Via vasopressin receptor was performed using a radioiodinated photoreactive peptide antagonist, This ligand displayed a high affinity for the receptor expressed in Chinese hamster ovary cell membranes, and specifically labeled two protein bands with apparent molecular mass at 85-90 and 46 kDa. Our results clearly show that the V1a receptor is degraded during incubation with the ligand and that the 46-kDa. species is probably the result of the 65-90-kDa species proteolytic cleavage, Truncation of the receptor was then confirmed by deglycosylation with N-glycosidase F, A monoclonal antibody directed against a c-Myc epitope added at the receptor NH,terminus allowed. immunoprecipitation of the 85-90-kDa photolabeled species, The 46 kDa photolabeled protein never immunoprecipitated, indicating that the truncated form of the receptor lacks the NN, terminus region. To localize photolabeled domains of the receptor, the 46 kDa protein was cleaved with V8 and/or Lys-C endoproteinases, The identity of the smallest photolabeled fragment, observed at approximately 6 kDa, was then confirmed by mutation of the potential V8 cleavage sites, Our results indicate that covalent labeling of the vasopressin Via receptor with the photoreactive antagonist: occurs in a region including transmembrane domain VII (residues Asn(327)-Lys(370)).	CNRS, INSERM, U469, CCIPE, F-34094 MONTPELLIER 05, FRANCE; CNRS, CCIPE, UPR 9023, F-34094 MONTPELLIER 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS)			MOUILLAC, Bernard/M-3896-2014	MOUILLAC, Bernard/0000-0002-3906-8673				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARBEAU D, 1992, J MED CHEM, V35, P151, DOI 10.1021/jm00079a020; BARBERIS C, 1995, NEUROENDOCRINOLOGY, V62, P135, DOI 10.1159/000126998; Barberis C, 1996, CRIT REV NEUROBIOL, V10, P119; BERDE B, 1968, HDB EXPERIMENTAL PHA, V23, P802; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BOER R, 1985, J BIOL CHEM, V260, P5051; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; CARNAZZI E, 1994, J MED CHEM, V37, P1841, DOI 10.1021/jm00038a013; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAHRENHOLZ F, 1986, EUR J BIOCHEM, V161, P321, DOI 10.1111/j.1432-1033.1986.tb10450.x; FONG TM, 1994, J BIOL CHEM, V269, P2728; Girault S, 1996, EUR J BIOCHEM, V240, P215, DOI 10.1111/j.1432-1033.1996.0215h.x; HRUBY VJ, 1987, PEPTIDES, V8, P77; JARD S, 1988, INT CONGR SER, V799, P1183; KASSIS S, 1984, J BIOL CHEM, V259, P4910; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; MAHE L, 1992, J AM CHEM SOC, V114, P7904, DOI 10.1021/ja00046a042; MAHLMANN S, 1994, P NATL ACAD SCI USA, V91, P1342, DOI 10.1073/pnas.91.4.1342; MANNING M, 1988, INT J PEPT PROT RES, V32, P455; MANNING M, 1993, J RECEPTOR RES, V13, P195, DOI 10.3109/10799899309073655; MANNING M, 1992, INT J PEPT PROT RES, V40, P261; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MOUILLAC B, 1995, J BIOL CHEM, V270, P25774; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Park C, 1996, BIOCHEMISTRY-US, V35, P9807, DOI 10.1021/bi9602223; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHAMBYE HT, 1995, MOL PHARMACOL, V47, P425; SCHMIDT A, 1991, FEBS LETT, V282, P77, DOI 10.1016/0014-5793(91)80448-C; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; TURCATTI G, 1995, BIOCHEMISTRY-US, V34, P3972, DOI 10.1021/bi00012a015; UFER E, 1995, FEBS LETT, V362, P19, DOI 10.1016/0014-5793(95)00150-8; VANKESTEREN RE, 1995, NEURON, V15, P897, DOI 10.1016/0896-6273(95)90180-9	48	46	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26536	26544		10.1074/jbc.272.42.26536	http://dx.doi.org/10.1074/jbc.272.42.26536			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334232	hybrid			2022-12-27	WOS:A1997YB13900066
J	Brandsma, M; Janssen, GMC; Moller, W				Brandsma, M; Janssen, GMC; Moller, W			Termination of quiescence in crustacea - The role of transfer RNA aminoacylation in the brine shrimp Artemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; MESSENGER-RNA; SALINA EMBRYOS; SYNTHETASE; PURIFICATION; TRANSLATION	In quiescent embryos of the brine shrimp Artemia, the level of aminoacylation of transfer RNAs is low, During resumption of development the charging level of transfer RNAs increases, concomitant with the activation of protein synthesis. The total level of charging rises dramatically from an average of 4% to 50% within a period of 24 h of development. The restriction of in vitro translation of the quiescent embryo extract can be partially released by the addition of charged aminoacyl-tRNA, which apparently starts the flow of ribosomes into polyribosome structures, Complete reactivation of translation by aminoacyl-tRNA occurs when mRNA from preformed mRNA-ribosome complexes, like the polyribosomes extracted from developing embryos or poly(U)-programmed ribosomes, are offered to quiescent embryo extracts, With respect to the mechanism of in vivo recharging of tRNAs, are observed that the level of several aminoacyl-tRNA synthetases increase during development. Methionyl-tRNA synthetase rises more than 10-fold. In the case of valyl-tRNA synthetase, the activation is lower and shown to be due to the de novo synthesis of its mRNA and the corresponding protein product as well, We conclude that protein synthesis and thereby the gradual animation of cryptobiotic Artemia embryos is determined to a large extent by the rate by which aminoacyl-tRNAs are replenished during development at both the initiation and elongation level.	LEIDEN UNIV,DEPT MED BIOCHEM,NL-2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAGSHAW JC, 1970, DEV BIOL, V23, P23, DOI 10.1016/S0012-1606(70)80005-7; BRANDSMA M, 1995, EUR J BIOCHEM, V233, P277, DOI 10.1111/j.1432-1033.1995.277_1.x; CHANG PK, 1990, J BIOL CHEM, V265, P20898; Clegg JS, 1996, PHYSIOL ZOOL, V69, P49, DOI 10.1086/physzool.69.1.30164200; CLEGG JS, 1980, BRINE SHRIMP ARTEMIA, V2, P11; CLEMENS MJ, 1990, TRENDS BIOCHEM SCI, V15, P172, DOI 10.1016/0968-0004(90)90153-3; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; CROWE JH, 1987, ARTEMIA RES ITS APPL, V2, P19; DINTZIS HM, 1961, P NATL ACAD SCI USA, V47, P247, DOI 10.1073/pnas.47.3.247; FINNAMORE, 1969, CELL CYCLE, P249; GOLUB A, 1968, DEV BIOL, V17, P644, DOI 10.1016/0012-1606(68)90011-0; GROSFELD H, 1976, EUR J BIOCHEM, V70, P589, DOI 10.1111/j.1432-1033.1976.tb11050.x; HENKIN TM, 1994, MOL MICROBIOL, V13, P381, DOI 10.1111/j.1365-2958.1994.tb00432.x; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HULTIN T, 1968, DEV BIOL, V17, P143, DOI 10.1016/0012-1606(68)90058-4; IWASAKI K, 1981, RNA PROTEIN SYNTHESI, P435; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; JANSSEN GMC, 1990, RIBOSOMES PROTEIN SY, P51; JANSSEN GMC, 1994, THESIS LEIDEN U NETH; KELLERMANN O, 1978, EUR J BIOCHEM, V88, P197, DOI 10.1111/j.1432-1033.1978.tb12438.x; KENMOCHI N, 1989, J BIOCHEM-TOKYO, V106, P289, DOI 10.1093/oxfordjournals.jbchem.a122846; KNECHT R, 1986, ADV METHODS PROTEIN, P56; LANKER S, 1992, CELL, V70, P647, DOI 10.1016/0092-8674(92)90433-D; Lavens P., 1987, P27; LEEHUANG S, 1977, ARCH BIOCHEM BIOPHYS, V180, P276, DOI 10.1016/0003-9861(77)90039-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACRAE TH, 1979, EUR J BIOCHEM, V100, P67, DOI 10.1111/j.1432-1033.1979.tb02034.x; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MOLLER W, 1987, ARTEMIA RES ITS APPL, V2, P451; MORENO A, 1991, BIOCHEM J, V276, P809, DOI 10.1042/bj2760809; OGILVIE A, 1979, BIOCHIM BIOPHYS ACTA, V565, P293, DOI 10.1016/0005-2787(79)90206-5; PUTZER H, 1995, MOL MICROBIOL, V16, P709, DOI 10.1111/j.1365-2958.1995.tb02432.x; REDDINGTON MA, 1978, DEV BIOL, V63, P402, DOI 10.1016/0012-1606(78)90144-6; ROJIANI MV, 1990, P NATL ACAD SCI USA, V87, P1511, DOI 10.1073/pnas.87.4.1511; Sambrook J., 2002, MOL CLONING LAB MANU; SETLOW P, 1974, J BACTERIOL, V118, P1067, DOI 10.1128/JB.118.3.1067-1074.1974; SIERRA JM, 1974, P NATL ACAD SCI USA, V71, P2693, DOI 10.1073/pnas.71.7.2693; THOMAS G, 1979, CELL BIOL INT REP, V3, P307, DOI 10.1016/S0309-1651(79)80001-6; TOCKMAN J, 1977, J BACTERIOL, V130, P1091, DOI 10.1128/JB.130.3.1091-1097.1977; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	41	12	12	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28912	28917		10.1074/jbc.272.46.28912	http://dx.doi.org/10.1074/jbc.272.46.28912			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360961	Green Published, hybrid			2022-12-27	WOS:A1997YF68400020
J	Cantu, C; Huang, WZ; Palzkill, T				Cantu, C; Huang, WZ; Palzkill, T			Cephalosporin substrate specificity determinants of TEM-1 beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-STRUCTURE; EXTENDED-SPECTRUM; MUTAGENESIS; SELECTION; ENZYME; HYDROLYSIS; RESOLUTION; MUTATIONS; REVEALS; PROTEIN	beta-lactamase is a bacterial enzyme that catalyzes the hydrolysis of beta-lactam antibiotics such as penicillins and cephalosporins. TEM-1 beta-lactamase is a prevalent beta-lactamase found in Gram-negative bacteria and is capable of hydrolyzing both penicillins and cephalosporins, except for the extended-spectrum cephalosporins, To identify the sequence determinants in the active site for a given antibiotic substrate, random libraries were constructed that each contain all possible amino acid combinations for the designated region of TEM-1 beta-lactamase, To establish the determinants of substrate specificity for cephalosporins versus those for penicillins, these active site Libraries have been screened for mu tants with high levels of activity for the second generation cephalosporin cephaloridine, Based on the sequence results, substitutions of W165S, A237T, and E240C were identified as cephalosporin-specific. Kinetic analysis of these mutants was done to determine whether each is capable of distinguishing between the two classes of antibiotics. Both the A237T and E240C substitutions, alone or in combination, exhibited increased cephalosporinase activity and decreased penicillinase activity relative to the wild-type enzyme. A sequence comparison between functional mutants selected for cephaloridine hydrolytic activity and functional mutants previously selected for ampicillin hydrolytic activity suggests that TEM-1 beta-lactamase has greater restrictions in maintaining cephalosporinase activity versus maintaining penicillinase activity.	BAYLOR COLL MED, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, STRUCT & COMPUTAT BIOL & MOL BIOPHYS PROGRAM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NIAID NIH HHS [AI32956] Funding Source: Medline; NIGMS NIH HHS [GM17581] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI032956, R01AI032956, R56AI032956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM017581] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; Bevington P. R, 1969, DATA REDUCTION ERROR; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Cantu C, 1996, J BIOL CHEM, V271, P22538, DOI 10.1074/jbc.271.37.22538; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Fersht A., 1985, ENZYME STRUCTURE MEC, P99; HALL A, 1976, NATURE, V264, P803, DOI 10.1038/264803a0; HEALEY WJ, 1989, PROTEINS, V6, P275, DOI 10.1002/prot.340060310; Huang WZ, 1996, J MOL BIOL, V258, P688, DOI 10.1006/jmbi.1996.0279; HULETSKY A, 1993, J BIOL CHEM, V268, P3690; IMTIAZ U, 1993, ANTIMICROB AGENTS CH, V37, P2438, DOI 10.1128/AAC.37.11.2438; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; JUTEAU JM, 1992, PROTEIN ENG, V5, P693, DOI 10.1093/protein/5.7.693; KELLY JA, 1989, J MOL BIOL, V209, P281, DOI 10.1016/0022-2836(89)90277-5; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUZIN AP, 1995, BIOCHEMISTRY-US, V34, P9532, DOI 10.1021/bi00029a030; MATAGNE A, 1995, BBA-PROTEIN STRUCT M, V1246, P109, DOI 10.1016/0167-4838(94)00177-I; MINAMI S, 1980, ANTIMICROB AGENTS CH, V18, P382, DOI 10.1128/AAC.18.3.382; NEU HC, 1965, J BIOL CHEM, V240, P3685; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEGEL EC, 1982, MUTAT RES, V93, P25, DOI 10.1016/0027-5107(82)90122-1; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Vanhove M, 1996, PROTEINS, V25, P104, DOI 10.1002/(SICI)1097-0134(199605)25:1<104::AID-PROT8>3.3.CO;2-H; WIEDEMANN B, 1989, J ANTIMICROB CHEMOTH, V24, P1	30	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29144	29150		10.1074/jbc.272.46.29144	http://dx.doi.org/10.1074/jbc.272.46.29144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360991	hybrid			2022-12-27	WOS:A1997YF68400050
J	Tachibana, I; Bodorova, J; Berditchevski, F; Zutter, MM; Hemler, ME				Tachibana, I; Bodorova, J; Berditchevski, F; Zutter, MM; Hemler, ME			NAG-2, a novel transmembrane-4 superfamily (TM4SF) protein that complexes with integrins and other TM4SF proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-VIRUS TYPE-1; MHC CLASS-II; MONOCLONAL-ANTIBODIES; T-CELLS; TYROSINE PHOSPHORYLATION; MEMBRANE GLYCOPROTEIN; SYNCYTIUM FORMATION; SEQUENCE-ANALYSIS; B-LYMPHOCYTES; C33 ANTIGEN	Transmembrane-4 superfamily (TM4SF) proteins form complexes with integrins and other cell-surface proteins. To further characterize the major proteins present in a typical TM4SF protein complex, we raised monoclonal antibodies against proteins co-immunoprecipitated with CD81 from MDA-MB-435 breast cancer cells. Only two types of cell-surface proteins were recognized by our 35 selected antibodies. These included an integrin (alpha(6) beta(1)) and three different TM4SF proteins (CD9, CD63, and NAG-2). The protein NAG-P (novel anti gen-a) is a previously unknown 30-kDa cell-surface protein. Using an expression cloning protocol, cDNA encoding NAG-2 was isolated. When aligned with other TM4SF proteins, the deduced amino acid sequence of NAG-2 showed most identity (34%) to CD53. Flow cytometry, Northern blotting, and immunohistochemistry showed that NAG-2 is widely present in multiple tissues and cell types but is absent from brain, lymphoid cells, and platelets, Within various tissues, strongest staining was seen on fibroblasts, endothelial cells, follicular dendritic cells, and mesothelial cells. In nonstringent detergent, NAG-2 protein was co-immunoprecipitated with other TM4SF members (CD9 and CD81) and integrins (alpha(3) beta(1) and alpha(6) beta(1)). Also, two-color immunofluorescence showed that NAG-S was co-localized with CD81 on the surface of spread HT1080 cells. These results confirm the presence of NAG-S in specific TM4SF.TM4SF and TM4SF-integrin complexes.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [R01CA070275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NCI NIH HHS [CA70275] Funding Source: Medline; NIGMS NIH HHS [GM38903] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; CARMO AM, 1995, EUR J IMMUNOL, V25, P2090, DOI 10.1002/eji.1830250743; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; GIL ML, 1992, J IMMUNOL, V148, P2826; Gwynn B, 1996, GENOMICS, V35, P389, DOI 10.1006/geno.1996.0375; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; IMAI T, 1993, J IMMUNOL, V151, P6470; Jones PH, 1996, CELL ADHES COMMUN, V4, P297, DOI 10.3109/15419069609010773; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; Mannion BA, 1996, J IMMUNOL, V157, P2039; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; PASQUALINI R, 1993, J CELL SCI, V105, P101; Pujades C, 1996, BIOCHEM J, V313, P899, DOI 10.1042/bj3130899; Radford KJ, 1996, BIOCHEM BIOPH RES CO, V222, P13, DOI 10.1006/bbrc.1996.0690; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SCHICK MR, 1993, J IMMUNOL, V151, P1918; Schmidt C, 1996, J NEUROSCI RES, V43, P12, DOI 10.1002/jnr.490430103; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; Skubitz KM, 1996, J IMMUNOL, V157, P3617; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; Szollosi J, 1996, J IMMUNOL, V157, P2939; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; Tomlinson MG, 1996, J MOL EVOL, V43, P312; TOOTHILL VJ, 1990, J IMMUNOL, V145, P283; TRAVIS GH, 1991, GENOMICS, V10, P733, DOI 10.1016/0888-7543(91)90457-P; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WICE BM, 1995, J BIOL CHEM, V270, P21907, DOI 10.1074/jbc.270.37.21907; WRIGHT MD, 1990, J IMMUNOL, V144, P3195; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; YU J, 1994, J CELL BIOL, V125, P171, DOI 10.1083/jcb.125.1.171; ZUTTER MM, 1991, BLOOD, V77, P2231	51	81	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29181	29189		10.1074/jbc.272.46.29181	http://dx.doi.org/10.1074/jbc.272.46.29181			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360996	hybrid			2022-12-27	WOS:A1997YF68400055
J	King, SL; Kamata, T; Cunningham, JA; Emsley, J; Liddington, RC; Takada, Y; Bergelson, JM				King, SL; Kamata, T; Cunningham, JA; Emsley, J; Liddington, RC; Takada, Y; Bergelson, JM			Echovirus 1 interaction with the human very late antigen-2 (integrin alpha 2 beta 1) I domain - Identification of two independent virus contact sites distinct from the metal, ion-dependent adhesion site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; LIGAND-BINDING SITES; A-DOMAIN; INTERCELLULAR-ADHESION; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; VLA-2; PROTEINS; COLLAGEN	The human integrin very late antigen (VLA)-2 (CD49b/CD29) mediates interactions with collagen and is the receptor for echovirus 1. Binding sites for both collagen and echovirus 1 have been mapped to the I domain within the alpha 2 subunit of the VLA-2 alpha 2 beta 1 heterodimer. Although murine VLA-2 interacts with collagen, it does not bind virus. We have used isolated human-murine chimeric I domains expressed as glutathione S-transferase fusion proteins in Escherichia coli to identify two groups of amino acids, 199-201 and 212-216, independently involved in virus attachment. These residues are distinct from the metal ion-dependent adhesion site previously demonstrated to be essential for VLA-2 interactions with collagen. Mutations in three metal ion-dependent adhesion site residues that abolish adhesion to collagen had no effect on virus binding. These results confirm that different sites within the I domain are responsible for VLA-2 interaction with extracellular matrix proteins and with viral ligands.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV INFECT DIS, BOSTON, MA 02115 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Scripps Research Institute; University of Leicester			emsley, jonas/A-8509-2016	emsley, jonas/0000-0002-8949-8030; takada, yoshikazu/0000-0001-5481-9589	NIAID NIH HHS [AI35667] Funding Source: Medline; NIGMS NIH HHS [GM47157, GM49899] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049899, R01GM047157] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGELSON JM, 1993, J VIROL, V67, P6847, DOI 10.1128/JVI.67.11.6847-6852.1993; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; COLOMBATTI A, 1991, BLOOD, V77, P2305; EDELMAN JM, 1994, CELL ADHES COMMUN, V2, P131, DOI 10.3109/15419069409004432; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; HAHN WC, 1993, GENE, V127, P267, DOI 10.1016/0378-1119(93)90731-H; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; Kamata T, 1996, J BIOL CHEM, V271, P19008, DOI 10.1074/jbc.271.31.19008; KING SL, 1995, J VIROL, V69, P3237, DOI 10.1128/JVI.69.5.3237-3239.1995; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PISCHEL KD, 1987, J IMMUNOL, V138, P226; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; SANTOSO S, 1991, THROMB HAEMOSTASIS, V65, P678; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; TUCKWELL D, 1995, J CELL SCI, V108, P1629; vanKooyk Y, 1996, J EXP MED, V183, P1247, DOI 10.1084/jem.183.3.1247; Zhang L, 1996, J BIOL CHEM, V271, P29953, DOI 10.1074/jbc.271.47.29953; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211; ZYLSTRA S, 1986, CANCER RES, V46, P6446	32	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28518	28522		10.1074/jbc.272.45.28518	http://dx.doi.org/10.1074/jbc.272.45.28518			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353313	hybrid			2022-12-27	WOS:A1997YF21900053
J	Lachowicz, A; VanGoor, P; Katzur, AC; Bonhomme, G; Stojilkovic, SS				Lachowicz, A; VanGoor, P; Katzur, AC; Bonhomme, G; Stojilkovic, SS			Uncoupling of calcium mobilization and entry pathways in endothelin-stimulated pituitary lactotrophs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; FREE CA-2+ CONCENTRATIONS; RAT ANTERIOR-PITUITARY; PROLACTIN SECRETION; INOSITOL PHOSPHATE; NONEXCITABLE CELLS; INDUCED SPIKE; AR42J CELLS; CA2+ ENTRY; OSCILLATIONS	In cells expressing Ca2+-mobilizing receptors, InsP(3)- induced Ca2+ release from intracellular stores is commonly associated with extracellular Ca2+ influx. Operation of these two Ca2+ signaling pathways mediates thyrotropin-releasing hormone (TRH) and angiotensin II (AII)-induced prolactin secretion from rat pituitary lactotrophs. After an initial hyperpolarization induced by Ca2+ mobilization from the endoplasmic reticulum (ER), these agonists generated an increase in the steady-state firing of action potentials, further facilitating extracellular Ca2+ influx and prolactin release. Like TRH and AII, endothelin-l (ET-1) also induced a rapid release of Ca2+ from the ER and a concomitant spike prolactin secretion during the first 3-5 min of stimulation, However, unlike TRH and AII actions, Ca2+ mobilization was not coupled to Ca2+ influx during sustained ET-1 stimulation, as ET-1 induced a long-lasting abolition of action potential firing, This lead to a depletion of the ER Ca2+ pool, a prolonged decrease in [Ca2+](i), and sustained inhibition of prolactin release. ET-l-induced inhibition and TRH/AII-induced stimulation of Ca2+ influx and hormone secretion were reduced in the presence of the L-type Ca2+ channel blocker, nifedipine, Basal [Ca2+](i) and prolactin release were also reduced in the presence of nifedipine. Furthermore, TRH-induced Ca2+ influx and secretion were abolished by ET-1, as TRH was unable to reactivate Ca2+ influx and prolactin release in ET-l-stimulated cells. Depolarization of the cells during sustained inhibitory action of ET-1, however, increased [Ca2+](i) and prolactin release, These results indicate that L-type Ca2+ channel represents a common Ca2+ influx pathway that controls basal [Ca2+](i) and secretion and is regulated by TRH/AII and ET-1 in an opposite manner, Thus, the receptor-mediated uncoupling of Ca2+ entry from Ca2+ mobilization provides an effective control mechanism in terminating the stimulatory action of ET-1. Moreover, it makes electrically active lactotrophs quiescent and unresponsive to other calcium-mobilizing agonists.	NICHHD,ERBB,UCS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ALBERT PR, 1984, J BIOL CHEM, V259, P5350; ALBERT PR, 1984, J BIOL CHEM, V259, P5827; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD SJ, 1991, NATURE, V352, P162; CESNJAJ M, 1995, MOL BIOL CELL, V9, P1037; CHAO HS, 1993, ENDOCRINOLOGY, V133, P505, DOI 10.1210/en.133.2.505; DUBINSKY JM, 1984, J GEN PHYSIOL, V83, P309, DOI 10.1085/jgp.83.3.309; DYMSHITZ J, 1992, NEUROENDOCRINOLOGY, V55, P724, DOI 10.1159/000126192; Gershengorn MC, 1996, PHYSIOL REV, V76, P175, DOI 10.1152/physrev.1996.76.1.175; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Hinkle PM, 1996, TRENDS ENDOCRIN MET, V7, P370, DOI 10.1016/S1043-2760(96)00188-9; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V183, P1090, DOI 10.1016/S0006-291X(05)80302-X; KANYICSKA B, 1991, BIOCHEM BIOPH RES CO, V174, P338, DOI 10.1016/0006-291X(91)90525-C; Kanyicska B, 1997, ENDOCRINOLOGY, V138, P3141, DOI 10.1210/en.138.8.3141; KANYICSKA B, 1993, AM J PHYSIOL, V265, pE601, DOI 10.1152/ajpendo.1993.265.4.E601; KANYICSKA B, 1995, ENDOCRINOLOGY, V136, P990, DOI 10.1210/en.136.3.990; KUKULJAN M, 1992, FEBS LETT, V301, P19, DOI 10.1016/0014-5793(92)80201-Q; LEWIS DL, 1988, ENDOCRINOLOGY, V123, P611, DOI 10.1210/endo-123-1-611; LI PZ, 1992, MOL ENDOCRINOL, V6, P1393, DOI 10.1210/me.6.9.1393; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; NELSON EJ, 1994, ENDOCRINOLOGY, V135, P1084, DOI 10.1210/en.135.3.1084; OZAWA S, 1986, PHYSIOL REV, V66, P887, DOI 10.1152/physrev.1986.66.4.887; OZAWA S, 1979, P NATL ACAD SCI USA, V76, P6017, DOI 10.1073/pnas.76.11.6017; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; RUTHERFORD RAD, 1993, BRIT J PHARMACOL, V109, P544, DOI 10.1111/j.1476-5381.1993.tb13605.x; SAMSON WK, 1990, BIOCHEM BIOPH RES CO, V169, P737, DOI 10.1016/0006-291X(90)90393-2; SAMSON WK, 1992, BIOCHEM BIOPH RES CO, V187, P590, DOI 10.1016/0006-291X(92)91235-I; SAMSON WK, 1992, ENDOCRINOLOGY, V130, P2964, DOI 10.1210/en.130.5.2964; Samson WK, 1995, ADV EXP MED BIOL, V395, P355; Sankaranarayanan S, 1996, AM J PHYSIOL-CELL PH, V271, pC1927, DOI 10.1152/ajpcell.1996.271.6.C1927; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; STOJILKOVIC SS, 1992, TRENDS PHARMACOL SCI, V13, P385, DOI 10.1016/0165-6147(92)90118-P; STOJILKOVIC SS, 1992, P NATL ACAD SCI USA, V89, P4081, DOI 10.1073/pnas.89.9.4081; STOJILKOVIC SS, 1991, J BIOL CHEM, V266, P10377; STOJILKOVIC SS, 1992, ENDOCRINOLOGY, V130, P465, DOI 10.1210/en.130.1.465; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; STOJILKOVIC SS, 1991, MOL PHARMACOL, V39, P762; STOJILKOVIC SS, 1988, J BIOL CHEM, V263, P13054; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TOMIC M, 1994, ENDOCRINOLOGY, V135, P1762, DOI 10.1210/en.135.5.1762; VILLALOBOS C, 1995, PFLUG ARCH EUR J PHY, V430, P923, DOI 10.1007/BF01837406; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WINIGER BP, 1988, BIOCHEM J, V255, P161, DOI 10.1042/bj2550161; ZHAO H, 1990, J BIOL CHEM, V265, P20856	47	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28308	28314		10.1074/jbc.272.45.28308	http://dx.doi.org/10.1074/jbc.272.45.28308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353286	hybrid			2022-12-27	WOS:A1997YF21900026
J	Leon, DA; Herberg, FW; Banky, P; Taylor, SS				Leon, DA; Herberg, FW; Banky, P; Taylor, SS			A stable alpha-helical domain at the N terminus of the RI alpha subunits of cAMP-dependent protein kinase is a novel dimerization/docking motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II REGULATORY SUBUNIT; A-KINASE; ANCHORING PROTEINS; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; BINDING DOMAINS; LEUCINE-ZIPPER; CYCLIC-GMP; LOCALIZATION; SITE	The RI alpha subunit of cAMP-dependent protein kinase is maintained as an asymmetric dimer by a dimerization motif at the N terminus, Based on resistance to proteolysis and expression as a discrete domain in Escherichia coli, this motif is defined as residues 12-61. This motif is chemically, kinetically, and thermally stable, The two endogenous interchain disulfide bonds between Cys(16) and Cys(37) in RI alpha are extremely resistant to reduction even in 8 M urea, indicating that they are well shielded from the reducing environment of the cell. The disulfide bonds were present in recombinant RI alpha as well as when the dimerization domain alone was expressed in E. coli, emphasizing the unusual stability of this motif and the disulfide bonds. Although 100 mM, dithiothreitol was sufficient to reduce the disulfide bonds, it did not abolish dimerization. In addition, a stable dimer also still formed when Cys(37) was replaced with His, confirming unambiguously the original antiparallel alignment of the disulfide bonds, Thus, both in vitro and in vivo, disulfide bonds are not required for dimerization. Circular dichroism of the dimerization domain indicated a high content of a thermostable alpha-helix. Based on the CD data, trypsin resistance of the fragment, location of the disulfide bonds, and amphipathic helix predictions, potential models are discussed, A new alignment of the dimerization domains of RI, RII, and cGMP-dependent protein kinase elucidates fundamental similarities as well as significant differences among these three domains.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; RUHR UNIV BOCHUM, INST BIOCHEM SUPRAMOL SYST, D-44780 BOCHUM, GERMANY	Howard Hughes Medical Institute; University of California System; University of California San Diego; Ruhr University Bochum			Herberg, Friedrich W/B-5572-2015	Herberg, Friedrich W/0000-0001-7117-7653	NIGMS NIH HHS [GM34921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; BUBIS J, 1987, J BIOL CHEM, V262, P14961; CARMICHAEL DF, 1982, J BIOL CHEM, V257, P440; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HEMMINGS BA, 1982, EUR J BIOCHEM, V127, P473; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; ImaizumiScherrer T, 1996, J CELL BIOL, V134, P1241, DOI 10.1083/jcb.134.5.1241; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEON DA, 1991, BIOCHEMISTRY-US, V30, P3035, DOI 10.1021/bi00226a008; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MONKEN CE, 1980, J BIOL CHEM, V255, P7067; MONKEN CE, 1985, ARCH BIOCHEM BIOPHYS, V240, P888, DOI 10.1016/0003-9861(85)90099-2; MUTZEL R, 1987, P NATL ACAD SCI USA, V84, P6, DOI 10.1073/pnas.84.1.6; REIMANN EM, 1986, BIOCHEMISTRY-US, V25, P119, DOI 10.1021/bi00349a018; RINGHEIM GE, 1990, J BIOL CHEM, V265, P4800; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASWAT LD, 1988, METHOD ENZYMOL, V159, P325; SARKAR D, 1984, J BIOL CHEM, V259, P9840; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; TAKIO K, 1982, P NATL ACAD SCI-BIOL, V79, P2544, DOI 10.1073/pnas.79.8.2544; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; TITANI K, 1981, PROTEIN PHOSPHORYLAT, P19; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WELDON SL, 1983, J BIOL CHEM, V258, P1129; ZICK SK, 1982, J BIOL CHEM, V257, P2287; ZOLLER MJ, 1979, J BIOL CHEM, V254, P8363	48	45	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28431	28437		10.1074/jbc.272.45.28431	http://dx.doi.org/10.1074/jbc.272.45.28431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353302	hybrid			2022-12-27	WOS:A1997YF21900042
J	Martin, G; Schoonjans, K; Lefebvre, AM; Staels, B; Auwerx, J				Martin, G; Schoonjans, K; Lefebvre, AM; Staels, B; Auwerx, J			Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPAR alpha and PPAR gamma activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCES ADIPOCYTE DIFFERENTIATION; HORMONE RECEPTOR SUPERFAMILY; INSULIN-SENSITIZING AGENT; PEROXISOME PROLIFERATOR; LIPID-METABOLISM; CDNA CLONING; PIOGLITAZONE; GLUCOSE; CELLS; BINDING	Intracellular fatty acid (FA) concentrations are in part determined by a regulated import/export system that is cent-rolled by two key proteins, i.e. fatty acid transport protein (FATP) and acyl-CoA synthetase (ACS), which respectively facilitate the transport of FAs across the cell membrane and their esterification to prevent their efflux, The aim of this investigation was to analyze the expression pattern of FATP and ACS and to determine whether their expression was altered by agents that affect FA metabolism through the activation of peroxisome proliferator-activated receptors (PPAR) such as the fibrates and thiazolidinediones, FATP mRNA was ubiquitously expressed, with highest levels being detected in adipose tissue, heart, brain, and testis. Fibrate treatment, which is known to preferentially activate PPAR gamma, induced FATP mRNA levels in rat liver and intestine and induced ACS mRNA levels in liver and kidney, The antidiabetic thiazolidinedione BRL 49653, which is a high-affinity ligand for the adipocyte-specific PPAR gamma form, caused a small induction of muscle but a robust induction of adipose tissue FATP mRNA levels. BRL 49653 did not affect liver FATP and had a tendency to decrease heart FATP mRNA levels, ACS mRNA levels in general showed a similar pattern after BRL 49653 as FATP except for the muscle where ACS mRNA was induced, This regulation of FATP and ACS expression by PPAR activators was shown to be at the transcriptional level and could also be reproduced in vitro in cell culture systems, In the hepatocyte cell lines AML-12 or Fa 32, fenofibric acid, but not BRL 49653, induced FATP and ACS mRNA levels, whereas in the 3T3-L1 preadipocyte cell line, the PPAR gamma ligand induced FATP and ACS mRNA levels quicker than fenofibric acid, Inducibility of ACS and FATP mRNA by PPAR alpha or gamma activators correlated with the tissue-specific distribution of the respective PPARs and was furthermore associated with a concomitant increase in FA uptake, Most interestingly, thiazolidinedione antidiabetic agents seem to favor adipocyte-specific FA uptake relative to muscle, perhaps underlying in part the beneficial effects of these agents on insulin-mediated glucose disposal.	INST PASTEUR, U325 INSERM, DEPT ATHEROSCLEROSE, F-59019 LILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503; Auwerx, Johan/0000-0002-5065-5393; Schoonjans, Kristina/0000-0003-1247-4265; Lefebvre, Anne-Marie/0000-0001-5644-0441				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; AMRI EZ, 1991, J LIPID RES, V32, P1449; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; APERLO C, 1995, GENE, V162, P297, DOI 10.1016/0378-1119(95)00196-D; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BERK PD, 1990, P NATL ACAD SCI USA, V87, P3484, DOI 10.1073/pnas.87.9.3484; Bjorntorp P, 1996, INT J OBESITY, V20, P291; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; BUCHANAN TA, 1995, J CLIN INVEST, V96, P354, DOI 10.1172/JCI118041; CASTLE CK, 1993, ARTERIOSCLER THROMB, V13, P302, DOI 10.1161/01.ATV.13.2.302; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GAILLARD D, 1989, BIOCHEM J, V257, P389, DOI 10.1042/bj2570389; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; HIRAGUN A, 1988, J CELL PHYSIOL, V134, P124, DOI 10.1002/jcp.1041340115; HIRSHMAN MF, 1995, BIOCHEM BIOPH RES CO, V208, P835, DOI 10.1006/bbrc.1995.1412; IKEDA H, 1990, ARZNEIMITTEL-FORSCH, V40-1, P156; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEFEBVRE AM, 1997, IN PRESS ARTERIOSCLE; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; Marin P, 1996, J CLIN ENDOCR METAB, V81, P1018, DOI 10.1210/jc.81.3.1018; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; Poirier H, 1996, EUR J BIOCHEM, V238, P368, DOI 10.1111/j.1432-1033.1996.0368z.x; RANDLE PJ, 1963, LANCET, V1, P785; Ren J, 1996, DIABETES, V45, P1822, DOI 10.2337/diabetes.45.12.1822; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SCHOONJANS K, 1993, EUR J BIOCHEM, V216, P615, DOI 10.1111/j.1432-1033.1993.tb18181.x; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schoonjans K, 1996, J LIPID RES, V37, P907; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; Shimomura I, 1996, AM J PHYSIOL-ENDOC M, V270, pE995, DOI 10.1152/ajpendo.1996.270.6.E995; SPARKS RL, 1991, J CELL PHYSIOL, V146, P101, DOI 10.1002/jcp.1041460114; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; TEBOUL L, 1995, J BIOL CHEM, V270, P28183, DOI 10.1074/jbc.270.47.28183; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	57	438	460	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28210	28217		10.1074/jbc.272.45.28210	http://dx.doi.org/10.1074/jbc.272.45.28210			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353271	hybrid			2022-12-27	WOS:A1997YF21900011
J	Rarick, HM; Tu, XH; Solaro, RJ; Martin, AF				Rarick, HM; Tu, XH; Solaro, RJ; Martin, AF			The C terminus of cardiac troponin I is essential for full inhibitory activity and Ca2+ sensitivity of rat myofibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE FIBERS; CALCIUM-BINDING SITES; BIOLOGICAL-ACTIVITY; THIOL MUTANTS; COMPLEX; RABBIT; ACTIN; PEPTIDE; MUTATION; SEQUENCE	Although the C terminus of troponin I is known to be important in myofilament Ca2+ regulation in skeletal muscle, the regulatory function of this region of cardiac troponin I (cTnI) has not been defined. To address this question, the following recombinant proteins were expressed in Escherichia coli and purified: mouse wildtype cTnI (WT cTnI; 211 residues), cTnI-(1-199) (missing 12 residues), cTnI-(1-188) (missing 23 residues), and cTnI-(1-151) (missing 60 residues), The inhibitory activity of cTnI and the mutants was tested in myofibrils, from which cTnI.cTnC was extracted by exchanging endogenous cardiac troponin with exogenous cTnT causing the Ca2+ sensitivity of the myofibrils to be lost, Addition of increasing amounts of exogenous WT cTnI or cTnI-(1-199) to cTnT-treated myofibrils at pCa 8 caused a concentration-dependent inhibition of the maximum ATPase activity, However, cTnI-(1-188) and cTnI-(l-151) inhibited this activity to about 75% and 50% of that of the WT cTnI, respectively, We also formed a complex of either WT cTnI or each of the mutants with cTnC, reconstituted the complex into the cTnT-treated myofibrils, and measured the Mg2+-ATPase activity as a function of pCa, We found that the cTnI-(1-188).cTnC complex only partially restored Ca2+ sensitivity, whereas the cTnI-(1-151).cTnC complex did not restore any Ca2+ sensitivity, Each cTnI C terminal deletion mutant was able to bind to cTnC, as shown by urea-polyacrylamide gel-shift analysis and size exclusion chromatography, Each mutant also co-sedimented with actin, Our results indicate that residues 152-199 (C-terminal to the inhibitory re gion) of cTnI are essential for full inhibitory activity and Ca2+ sensitivity of myofibrillar ATPase activity in the heart.			Rarick, HM (corresponding author), UNIV ILLINOIS,COLL MED MC901,DEPT PHYSIOL & BIOPHYS,835 S WOLCOTT AVE,CHICAGO,IL 60612, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049934, F32HL009009] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-49934, F32-HL-09009] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHANDRA M, 1997, IN PRESS BIOCHEMISTR; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6754, DOI 10.1021/bi9622276; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FARAH CS, 1994, J BIOL CHEM, V269, P5230; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GUO XD, 1994, J BIOL CHEM, V269, P15210; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; Jha PK, 1996, BIOCHEMISTRY-US, V35, P11026, DOI 10.1021/bi960406h; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; KLEERKOPER Q, 1995, BIOCHEMISTRY-US, V34, P13343, DOI 10.1021/bi00041a010; KOBAYASHI T, 1994, J BIOL CHEM, V269, P5725; KRUDY GA, 1994, J BIOL CHEM, V269, P23731; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NOZAKI S, 1980, CHEM LETT, V3, P345; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PAGANI ED, 1984, METHOD PHARMACOL, P49; Pan BS, 1996, J BIOL CHEM, V271, P817, DOI 10.1074/jbc.271.2.817; PAN BS, 1987, J BIOL CHEM, V262, P7839; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pearlstone JR, 1997, BIOCHEMISTRY-US, V36, P7601, DOI 10.1021/bi970200w; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; Rarick HM, 1996, J BIOL CHEM, V271, P27039, DOI 10.1074/jbc.271.43.27039; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Solaro R.J., 1995, PHYSL PATHOPHYSIOLOG, P355; SPYRACOPOULOS L, 1997, IN PRESS BIOCHEMISTR; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1989, BIOCHEMISTRY-US, V28, P5902, DOI 10.1021/bi00440a029; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VANEYK JE, 1993, FEBS LETT, V323, P223, DOI 10.1016/0014-5793(93)81344-Y; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; VANEYK JE, 1993, BIOCHEMISTRY-US, V30, P9974; WANG C, 1994, J MOL BIOL, V190, P509; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; Zhang R., 1995, Biophysical Journal, V68, pA165	48	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26887	26892		10.1074/jbc.272.43.26887	http://dx.doi.org/10.1074/jbc.272.43.26887			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341121	hybrid			2022-12-27	WOS:A1997YC65900017
J	Recio, JA; Aranda, A				Recio, JA; Aranda, A			Activation of the HIV-1 long terminal repeat by nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSCRIPTION FACTOR; TYPE-1 PROMOTER; GENE-EXPRESSION; FACTOR RECEPTOR; PC12 CELLS; IN-VITRO; PROTEIN; ENHANCER	The brain is an important target for the human immunodeficiency virus type 1 (HIV-1), We show here that nerve growth factor (NGF), which induces neuronal differentiation and survival, causes a strong activation of the HIV-1 long terminal repeat by a Ras/Raf-dependent mechanism in PC12 cells, Mutation of the kappa B sequences contained whithin the long terminal repeat reduces NGF-mediated stimulation, NGF does not activate NF-kappa B in PC12 cells, but rather increases binding of other nuclear factors to the kappa B sequences. Furthermore, a nuclear receptor response element contributes to the stimulatory effect of NGF, The retinoids receptors have been identified as components of the nuclear binding to the nuclear receptor response element in NGF-treated PC12 cells. These results reveal the importance of neurotrophins and nuclear receptor signaling pathways as specific activators of HIV-1 gene expression in neural cells.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Aranda, Ana/ABG-8820-2020	Aranda, Ana/0000-0002-8338-9589; Recio, Juan Angel/0000-0002-7320-3832				Bagetta G, 1996, P NATL ACAD SCI USA, V93, P928, DOI 10.1073/pnas.93.2.928; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CORBOY JR, 1992, SCIENCE, V258, P1804, DOI 10.1126/science.1465618; Cosgaya JM, 1996, ONCOGENE, V12, P2651; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DUBOISDALCQ M, 1995, CURR OPIN NEUROBIOL, V5, P647, DOI 10.1016/0959-4388(95)80071-9; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; LADIAS JAA, 1994, J BIOL CHEM, V269, P5944; LEE MO, 1994, P NATL ACAD SCI USA, V91, P5632, DOI 10.1073/pnas.91.12.5632; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; Sawaya BE, 1996, J BIOL CHEM, V271, P23572, DOI 10.1074/jbc.271.38.23572; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	27	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26807	26810		10.1074/jbc.272.43.26807	http://dx.doi.org/10.1074/jbc.272.43.26807			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341108	hybrid			2022-12-27	WOS:A1997YC65900004
J	Trejo, SR; Fahl, WE; Ratner, L				Trejo, SR; Fahl, WE; Ratner, L			The Tax protein of human T-cell leukemia virus type 1 mediates the transactivation of the c-sis/platelet-derived growth factor-B promoter through interactions with the zinc finger transcription factors Sp1 and NGFI-A/Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; ELEMENT-BINDING PROTEIN; HORMONE-RELATED PROTEIN; SIMIAN SARCOMA-VIRUS; HTLV-I; GENE-EXPRESSION; ALPHA-AMANITIN; DNA-BINDING; 21-BASE-PAIR REPEATS; REGULATORY ELEMENTS	Transcriptional up-regulation of the c-sis/platelet-derived growth factor-B (PDGF-B) proto-oncogene by the Tax protein of human T cell leukemia virus type 1 has been implicated as one possible mechanism of cellular transformation by human T-cell leukemia virus type 1. In previous work, we identified an essential site in the c-sis/PDGF-B promoter, Tax-responsive element 1 (TRE1), necessary for transactivation by Tax. We also identified Sp1, Sp3, and NGFI-AIEgr-1 as the primary nuclear transcription factors binding to TRE1 which mediate Tax responsiveness. In the present work, we have investigated the mechanism(s) whereby Tax transactivates the c-sis/PDGF-B proto-oncogene. In vitro transcription assays showed that Tax was able to significantly increase the transcriptional activity of a template containing the -257 to +74 region of the c-sis/ PDGF-B promoter. Electrophoretic mobility shift assay analysis showed that Tax increased the DNA binding activity of both Spl and NGFI-A/Egr-1 using a TRE1 probe. Analysis of Tax mutants showed that two mutants, IEXC29S and IEXL320G, were unable to significantly transactivate the c-sis/PDGF-B promoter. Finally, co-immunoprecipitation analysis revealed that Tax is able to stably bind to both Spl and NGFI-A/Egr-1. Interestingly, co-immunoprecipitation analysis also revealed that Tax mutant IEXC29S is unable to interact with NGFI-A/Egr1, whereas Tax mutant IEXL320G is able to interact with NGFI-A/Egr-1.	WASHINGTON UNIV, SCH MED, DIV MOL ONCOL, ST LOUIS, MO 63110 USA; UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53706 USA	Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison				Ratner, Lee/0000-0003-2744-7294	NCI NIH HHS [CA63417] Funding Source: Medline; NHLBI NIH HHS [5 T32 HL07088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063417] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BANGHAM CRM, 1988, EMBO J, V7, P4179, DOI 10.1002/j.1460-2075.1988.tb03314.x; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BHAGAVATI S, 1988, NEW ENGL J MED, V318, P1141, DOI 10.1056/NEJM198805053181801; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; CONNOR LM, 1993, VIROLOGY, V195, P569, DOI 10.1006/viro.1993.1408; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P1119, DOI 10.1093/nar/23.7.1119; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DUVALL JF, 1995, J VIROL, V69, P5077, DOI 10.1128/JVI.69.8.5077-5086.1995; EBERT SN, 1994, J BIOL CHEM, V269, P20885; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; Goustin AS, 1990, GROWTH FACTORS, V2, P189, DOI 10.3109/08977199009071505; HART CE, 1990, J INVEST DERMATOL, V94, pS53, DOI 10.1111/1523-1747.ep12875065; JACOB ST, 1970, NATURE, V225, P60, DOI 10.1038/225060b0; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; JOSEPHS SF, 1984, SCIENCE, V225, P636, DOI 10.1126/science.6740330; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KRAMER B, 1995, J INFLAMM, V45, P183; KUDO S, 1994, EUR J BIOCHEM, V223, P319, DOI 10.1111/j.1432-1033.1994.tb18997.x; Langton B., 1988, MED VIROL, V8, P295; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; LIANG Y, 1996, ONCOGENE, V12, P1; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PANTAZIS P, 1987, ONCOGENE, V1, P285; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PIRAS G, 1994, J VIROL, V68, P6170, DOI 10.1128/JVI.68.10.6170-6179.1994; RATNER L, 1989, NUCLEIC ACIDS RES, V17, P4101, DOI 10.1093/nar/17.11.4101; RATNER L, 1988, MEDICINE, V67, P401, DOI 10.1097/00005792-198811000-00004; ROSS R, 1978, CELL, V14, P203, DOI 10.1016/0092-8674(78)90107-1; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1990, GENE DEV, V4, P1875; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Trejo SR, 1996, J BIOL CHEM, V271, P14584, DOI 10.1074/jbc.271.24.14584; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YIN MJ, 1995, J VIROL, V69, P6209, DOI 10.1128/JVI.69.10.6209-6218.1995; YU CY, 1991, J BIOL CHEM, V266, P8907; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	68	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27411	27421		10.1074/jbc.272.43.27411	http://dx.doi.org/10.1074/jbc.272.43.27411			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341193	hybrid			2022-12-27	WOS:A1997YC65900089
J	Barik, S; Taylor, RE; Chakrabarti, D				Barik, S; Taylor, RE; Chakrabarti, D			Identification, cloning, and mutational analysis of the casein kinase 1 cDNA of the malaria parasite, Plasmodium falciparum - Stage-specific expression of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED PROTEIN-KINASE; ERYTHROCYTE-MEMBRANE; MOLECULAR-CLONING; SURFACE-ANTIGEN; PHOSPHORYLATION; YEAST; PURIFICATION; SEQUENCE; CELL; PHOSPHOPROTEINS	The cDNA for casein kinase 1 (CK1) of Plasmodium falciparum was cloned, sequenced, and expressed in bacteria, The single major open reading frame of the 1,2-kilobase pair cDNA coded for a 324-amino acid polypeptide of similar to 37 kDa, the predicted sequence of which showed strong identity with known CK1 isoforms, The purified recombinant enzyme exhibited properties characteristic of CK1, such as inhibition by CK1-7, the ability to phosphorylate a highly specific peptide substrate, and a strong preference for ATP over GTP, A casein kinase activity, partially purified from soluble extracts of P. falciparum by affinity chromatography through CK1-7 columns displayed identical properties, The activity showed a stage-specific expression in the parasite, in the order trophozoite > ring much greater than schizont. Northern analysis indicated the existence of two major CK1 mRNAs, 2.4 and 3.2 kilobase pairs long, the levels of which mere in the order ring > schizont > trophozoite. Mutagenesis of recombinant CK1 defined important amino acid residues and their potential role in the conformation of the enzyme, The malarial CK1 appeared to be the one of the smallest and perhaps the most primitive CK1 enzymes known, containing little sequence information beyond the minimal catalytic domain.	UNIV CENT FLORIDA, DEPT MOL BIOL & MICROBIOL, ORLANDO, FL 32816 USA	State University System of Florida; University of Central Florida	Barik, S (corresponding author), UNIV S ALABAMA, DEPT BIOCHEM & MOL BIOL, MOBILE, AL 36688 USA.							[Anonymous], 1991, MALARIA OBSTACLES OP; Ansai T, 1996, J BIOL CHEM, V271, P24401, DOI 10.1074/jbc.271.40.24401; Barik S, 1996, Subcell Biochem, V26, P115; BARIK S, 1995, METH NEUROSCI, V26, P309; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; CHAKRABARTI D, 1993, P NATL ACAD SCI USA, V90, P12020, DOI 10.1073/pnas.90.24.12020; CHAKRABARTI D, 1994, MOL BIOCHEM PARASIT, V66, P97, DOI 10.1016/0166-6851(94)90039-6; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CHISHTI AH, 1994, BLOOD, V83, P3339; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; Eadie GS, 1942, J BIOL CHEM, V146, P85; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HALDAR K, 1985, J BIOL CHEM, V260, P4969; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KEARNEY PH, 1994, BIOCHEM BIOPH RES CO, V203, P231, DOI 10.1006/bbrc.1994.2172; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LUSTIGMAN S, 1990, MOL BIOCHEM PARASIT, V38, P261, DOI 10.1016/0166-6851(90)90029-L; MAZUMDER B, 1994, VIROLOGY, V205, P93, DOI 10.1006/viro.1994.1623; MEGGIO F, 1991, FEBS LETT, V283, P303, DOI 10.1016/0014-5793(91)80614-9; MILNE DM, 1992, ONCOGENE, V7, P1361; MURRAY MC, 1989, MOL BIOCHEM PARASIT, V34, P229, DOI 10.1016/0166-6851(89)90051-0; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SUETTERLIN BW, 1991, MOL BIOCHEM PARASIT, V46, P113, DOI 10.1016/0166-6851(91)90205-K; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Tuazon P. T., 1991, ADV 2 MESSENGER PHOS, V23, P123; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; WANG PC, 1994, J BIOL CHEM, V269, P12014; WISER MF, 1987, EXP PARASITOL, V64, P328, DOI 10.1016/0014-4894(87)90043-9; WISER MF, 1985, MOL BIOCHEM PARASIT, V17, P179, DOI 10.1016/0166-6851(85)90017-9; WISER MF, 1983, J CELL BIOCHEM, V2, P305; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x	41	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26132	26138		10.1074/jbc.272.42.26132	http://dx.doi.org/10.1074/jbc.272.42.26132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334178	hybrid			2022-12-27	WOS:A1997YB13900012
J	Otto, C; Reichardt, HM; Schutz, G				Otto, C; Reichardt, HM; Schutz, G			Absence of glucocorticoid receptor-beta in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; GENE; LOCALIZATION; PROTEINS; ISOFORM; SITE; CDNA	Two human glucocorticoid receptor (GR) isoforms, GR alpha and GR beta, are derived from the same gene by alternative splicing involving exon 9 of the GR locus, The non-ligand binding isoform GR beta was proposed to act as a transdominant negative inhibitor of GR alpha, thus modulating glucocorticoid responsiveness of target tissues, To study GR beta in mice we characterized the genomic region around exon 9 of the murine GR gene. Sequence analysis revealed that the presumed exon 9 beta contained an open reading frame of 59 amino acids, In contrast, human exon 9 beta encoded only 15 amino acids, Using reverse transcriptase polymerase chain reaction the ab absence of GR beta mRNA was demonstrated in all adult mouse tissues examined, To exclude the possibility that the polymerase chain reaction conditions employed were not suitable for the amplification of GR beta mRNA, we synthesized an artificial template corresponding to the presumed GRP mRNA spanning exons 7, 8, and 9 beta, Various amounts of this template were added to brain cDNA preparations and as little as 25 molecules were detectable under the polymerase chain reaction conditions chosen, Since GR beta is not conserved across species its physiological significance in humans appears questionable.	GERMAN CANC RES CTR,DIV MOL BIOL CELL 1,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Reichardt, Holger/AAF-3048-2020	Reichardt, Holger/0000-0003-4647-057X				BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; deCastro M, 1996, MOL MED, V2, P597, DOI 10.1007/BF03401643; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; Hecht K, 1997, J BIOL CHEM, V272, P26659, DOI 10.1074/jbc.272.42.26659; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; STRAHLE U, 1992, P NATL ACAD SCI USA, V89, P6731, DOI 10.1073/pnas.89.15.6731; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	21	83	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26665	26668		10.1074/jbc.272.42.26665	http://dx.doi.org/10.1074/jbc.272.42.26665			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334249	hybrid			2022-12-27	WOS:A1997YB13900083
J	Sheikh, MS; Carrier, F; Papathanasiou, MA; Hollander, MC; Zhan, QM; Yu, K; Fornace, AJ				Sheikh, MS; Carrier, F; Papathanasiou, MA; Hollander, MC; Zhan, QM; Yu, K; Fornace, AJ			Identification of several human homologs of hamster DNA damage-inducible transcripts - Cloning and characterization of a novel UV-inducible cDNA that codes for a putative RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION FACTOR-5; CELL NUCLEAR ANTIGEN; MESSENGER-RNA; RECOGNITION MOTIF; MAMMALIAN-CELLS; EXCISION-REPAIR; LEUKEMIA-CELLS; GENE; INDUCTION; GROWTH	Low Patio hybridization subtraction technique was previously used in this laboratory to enrich and isolate a number of low abundance UV-inducible hamster transcripts (Fornace, A. J., Jr., Alamo, I. J., and Hollander, M. C. (1988) Proc. Natl. Acad, Sci. U. S. A. 85, 8800-8804) that led to the identification and cloning of five important hamster and human GADD genes (Fornace, A. J., Jr., Nebert, D. W., Hollander, M. C,, Luethy, J. D., Papathanasiou, M., Fargnoli, J., and Holbrook, N. J. (1989) Mol, Cell. Biol. 9, 4196-4205), In this study we have characterized the remaining DNA damage-inducible (DDI) transcripts. Of the 24 DDI clones, 3 clones (A13, A20, and A113) representing different regions of the same hamster cDNA exhibited near perfect homology to human p21(WAF1/CIP1) cDNA. The DDI clones A26, A88, and A99 displayed very high sequence homologies with the human proliferating nuclear antigen, rat translation initiation factor-5 (eIF-5), and human thrombomodulin, respectively, whereas clones A29 and A121 matched with express sequence tagged sequences of unknown identity, The DDI clones A18, 106, and A107 were different isolates of the same hamster cDNA (hereafter referred to as A18) and displayed high sequence homology with the members in the heterogeneous ribonucleoprotein (hnRNP) family, Using the hamster A18 partial-length cDNA as a probe, we screened human fibroblast cDNA library and isolated the corresponding full-length human cDNA. The deduced amino acid sequence revealed that the putative protein contains all the canonical features of a novel glycine-rich hnRNP. The A18 mRNA levels mere specifically increased in response to DNA damage induced by UV irradiation or UV mimetic agents, Thus the putative A18 hnRNP is the first hnRNP whose mRNA is specifically regulated in response to UV-induced DNA damage; accordingly, it may play some role in repair of W-type DNA damage.			Sheikh, MS (corresponding author), NCI, MOL PHARMACOL LAB, NIH, BLDG 37, RM 5D02, BETHESDA, MD 20892 USA.		Carrier, France/C-3063-2008; Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Carrier, France/0000-0002-5517-5284				BAE IS, 1995, CANCER RES, V55, P2387; BIAMONTI G, 1994, NUCLEIC ACIDS RES, V22, P1996, DOI 10.1093/nar/22.11.1996; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; CONWAY EM, 1994, J BIOL CHEM, V269, P22804; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARGNOLI J, 1990, ANAL BIOCHEM, V187, P364, DOI 10.1016/0003-2697(90)90471-K; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GOMEZ J, 1988, NATURE, V334, P262, DOI 10.1038/334262a0; HARPER JW, 1993, CELL, V75, P805; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1996, NUCLEIC ACIDS RES, V12, P387; HOLLANDER MC, 1994, DNA REPAIR MECH IMPA, P221; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KUMAR A, 1986, J BIOL CHEM, V261, P1266; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Nishiyama H, 1997, J CELL BIOL, V137, P899, DOI 10.1083/jcb.137.4.899; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REBAGLIATI M, 1989, CELL, V58, P231, DOI 10.1016/0092-8674(89)90834-9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SHIRAI T, 1988, J BIOCHEM-TOKYO, V103, P281, DOI 10.1093/oxfordjournals.jbchem.a122261; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1995, INT J ONCOL, V6, P937; ZHANG W, 1995, CANCER RES, V55, P668	47	80	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26720	26726		10.1074/jbc.272.42.26720	http://dx.doi.org/10.1074/jbc.272.42.26720			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334257	hybrid			2022-12-27	WOS:A1997YB13900091
J	Hug, H; Strand, S; Grambihler, A; Galle, J; Hack, V; Stremmel, W; Krammer, PH; Galle, PR				Hug, H; Strand, S; Grambihler, A; Galle, J; Hack, V; Stremmel, W; Krammer, PH; Galle, PR			Communication - Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; T-CELL; SUPEROXIDE-DISMUTASE; INDUCED APOPTOSIS; FAS LIGAND; DEATH; INHIBITOR; RECEPTOR; DAMAGE	Oxidative stress has been associated with the induction of programmed cell death, The CD95 ligand/receptor system is a specific mediator of apoptosis. We have used the model of drug-induced apoptosis to assess whether the CD95 ligand mRNA is induced by reactive oxygen intermediates. Treatment of HepG2 hepatoma cells with bleomycin induced the production of reactive oxygen intermediates and, as an additional parameter of oxidative stress, resulted in glutathione (GSH) depletion, In parallel, CD95 ligand mRNA expression was induced, In a similar fashion CD95 ligand mRNA expression increased after treatment with H2O2. Additional treatment with the antioxidant and GSH precursor N-acetylcysteine resulted in partial restoration of intracellular GSH levels and in reduced induction of CD95 ligand mRNA, Induction of CD95 ligand mRNA by bleomycin was further reduced by combined treatment with N-acetylcysteine and deferoxamine. These data suggest a direct role of oxygen radicals in the induction of the CD95 ligand.	UNIV HEIDELBERG HOSP,DEPT GASTROENTEROL,D-69115 HEIDELBERG,GERMANY; ZMBH,CTR BIOL MOL,D-69120 HEIDELBERG,GERMANY; UNIV WURZBURG,DEPT MED,DIV NEPHROL,D-97080 WURZBURG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,TUMOR IMMUNOL PROGRAMME,PHK,DIV IMMUNOCHEM,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ)			Galle, Peter R/T-5292-2018	Galle, Peter R/0000-0001-8294-0992; Stremmel, Wolfgang/0000-0002-8545-1753				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AN J, 1992, MUTAT RES, V270, P167, DOI 10.1016/0027-5107(92)90127-N; AN J, 1993, MUTAT RES, V289, P215, DOI 10.1016/0027-5107(93)90072-N; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GALLE J, 1995, CIRCULATION, V92, P1582, DOI 10.1161/01.CIR.92.6.1582; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Kilinc Cumhur, 1993, Journal of Basic and Clinical Physiology and Pharmacology, V4, P249; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PETER ME, 1995, INT IMMUNOL, V7, P1873, DOI 10.1093/intimm/7.11.1873; SATO N, 1995, J IMMUNOL, V154, P3194; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; STRASSER A, 1995, NATURE, V373, P385, DOI 10.1038/373385a0; SUDA T, 1995, J IMMUNOL, V154, P3806; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; Williams MS, 1996, J IMMUNOL, V157, P2395; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139	29	159	165	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28191	28193		10.1074/jbc.272.45.28191	http://dx.doi.org/10.1074/jbc.272.45.28191			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353266	hybrid			2022-12-27	WOS:A1997YF21900006
J	Irminger, JC; Verchere, CB; Meyer, K; Halban, PA				Irminger, JC; Verchere, CB; Meyer, K; Halban, PA			Proinsulin targeting to the regulated pathway is not impaired in carboxypeptidase E-deficient Cpe(fat)/Cpe(fat) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEINS; SORTING SIGNAL; CELLS; PROOPIOMELANOCORTIN; IDENTIFICATION; CONVERSION; INSULIN; CLEAVAGE; GRANULES; MUTATION	Sorting of proinsulin from the trans-Golgi network to secretory granules is critical for its conversion to insulin as well as for regulated insulin secretion. The proinsulin sorting mechanism is unknown. Recently, carboxypeptidase E (CPE) was proposed as a sorting receptor for prohormones. To know whether CPE is implicated in proinsulin sorting, pancreatic islets were isolated from CPE-deficient Cpe(fat)/Cpe(fat) mice and Cpe(fat)/+ controls, pulse-labeled ([H-3]leucine), and then chased in basal medium (90 min) to examine constitutive secretion followed by medium with secretagogues (60 min) to stimulate regulated secretion. Secretion of labeled proinsulin via the constitutive pathway was <2% even in Cpe(fat)/Cpe(fat) islets. After a 150-min chase, only 13% of radioactivity remained as proinsulin in Cpe(fat)/+ islets compared with 46% in Cpe(fat)/Cpe(fat) islets, reflecting slower conversion. Regulated secretion was stimulated to an equal extent from Cpe(fat)/+ and Cpe(fat)/Cpe(fat) mice with 20% of the total content of labeled (pro)insulin released during the 60-min stimulatory period. It is concluded that in CPE-deficient Cpe(fat)/ Cpe(fat) mice, proinsulin is efficiently routed to the regulated pathway and its release can be effectively stimulated by secretagogues. CPE is thus not essential for sorting proinsulin to granules.			Irminger, JC (corresponding author), UNIV GENEVA,LABS RECH LOUIS JEANTET,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.							CASTLE AM, 1992, J BIOL CHEM, V267, P13093; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; GORR SU, 1995, FEBS LETT, V361, P8, DOI 10.1016/0014-5793(95)00142-V; GUEST PC, 1995, MOL CELL ENDOCRINOL, V113, P99, DOI 10.1016/0303-7207(95)03619-I; HALBAN PA, 1994, BIOCHEM J, V299, P1; IRMINGER JC, 1994, J BIOL CHEM, V269, P1756; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; ROY P, 1991, MOL CELL ENDOCRINOL, V82, P237, DOI 10.1016/0303-7207(91)90037-S; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; Shen FS, 1997, P NATL ACAD SCI USA, V94, P5314, DOI 10.1073/pnas.94.10.5314; SIZONENKO SV, 1991, BIOCHEM J, V278, P621, DOI 10.1042/bj2780621; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; Thiele C, 1997, CURR BIOL, V7, pR496, DOI 10.1016/S0960-9822(06)00247-8	25	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27532	27534		10.1074/jbc.272.44.27532	http://dx.doi.org/10.1074/jbc.272.44.27532			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346885	hybrid			2022-12-27	WOS:A1997YD47300011
J	Raso, V; Brown, M; McGrath, J				Raso, V; Brown, M; McGrath, J			Intracellular targeting with low pH-triggered bispecific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; HUMAN-MALIGNANT MESOTHELIOMA; DIPHTHERIA-TOXIN; CELL-LINE; ENTRY; RICIN; DELIVERY; BEARING; ANTIGEN; IMMUNOTOXINS	Bispecific antibodies were designed to deliver a reversibly bound ligand into target cells and then spontaneously release it upon passage into acidified vesicles, These reagents were assembled by coupling monoclonal antibodies that recognize acid-sensitive epitopes on diphtheria toxin to cell type-specific monoclonal antibodies, The dual binding capacity of the bispecific antibodies was confirmed by delivery of I-125-diphtheria toxin to target molecules present on intact cells, Bispecific antibodies directed against transferrin receptors on human cells were loaded with toxin and tested for cytotoxicity. The mutant diphtheria toxins CRM107 and CRM45 were used since their inability to bind cell. receptors renders them ordinarily nontoxic, Their full cytotoxic potential, however, was restored via bispecific antibody-mediated delivery and release within low pH intracellular vesicles, Cytotoxicity was shown to be spe cific by blocking receptor sites and to be acidification-dependent by protection using NH4Cl to raise endosomal pH. Kinetics for inhibition of cellular protein synthesis was identical for native diphtheria toxin and the bispecific antibody CRM107 combination. The rate of inhibition (t(1/2) = 20 min) indicated that release of CRM107 from the antibody combining site was fast, and its toxic action was unimpeded by this delivery mechanism.			Raso, V (corresponding author), BOSTON BIOMED RES INST, 20 STANIFORD ST, BOSTON, MA 02114 USA.				NATIONAL CANCER INSTITUTE [R01CA049856, R01CA049254] Funding Source: NIH RePORTER; NCI NIH HHS [CA49856, CA49254] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHA P, 1983, J BIOL CHEM, V258, P1565; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BRENNAN M, 1985, SCIENCE, V229, P81, DOI 10.1126/science.3925553; CARROLL SF, 1988, METHOD ENZYMOL, V165, P68; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CIEPLAK W, 1988, BIOCHEM BIOPH RES CO, V157, P747, DOI 10.1016/S0006-291X(88)80313-9; COLOMBATTI M, 1986, J BIOL CHEM, V261, P3030; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; GEISOW MJ, 1984, EXP CELL RES, V150, P29, DOI 10.1016/0014-4827(84)90698-0; GEISOW MJ, 1984, EXP CELL RES, V150, P36, DOI 10.1016/0014-4827(84)90699-2; GIGLIOTTI F, 1984, J INFECT DIS, V149, P43, DOI 10.1093/infdis/149.1.43; GLENNIE MJ, 1988, J IMMUNOL, V141, P3662; GREENFIELD L, 1987, SCIENCE, V238, P536, DOI 10.1126/science.3498987; GRIFFIN T, 1993, JNCI-J NATL CANCER I, V85, P292, DOI 10.1093/jnci/85.4.292; GRIFFIN TW, 1987, CANCER RES, V47, P4266; KIM K, 1965, J BACTERIOL, V90, P1552, DOI 10.1128/JB.90.6.1552-1556.1965; LAIRD W, 1976, J VIROL, V19, P220, DOI 10.1128/JVI.19.1.220-227.1976; MILNE JC, 1994, J BIOL CHEM, V269, P20607; NISONOFF A, 1961, ARCH BIOCHEM BIOPHYS, V93, P460, DOI 10.1016/0003-9861(61)90296-X; OVERLY CC, 1995, P NATL ACAD SCI USA, V92, P3156, DOI 10.1073/pnas.92.8.3156; RAPPUOLI R, 1983, J CHROMATOGR, V268, P543, DOI 10.1016/S0021-9673(01)95457-3; RASO V, 1984, J BIOL CHEM, V259, P1143; RASO V, 1982, IMMUNOL REV, V62, P93, DOI 10.1111/j.1600-065X.1982.tb00391.x; RASO V, 1981, CANCER RES, V41, P2073; Raso V, 1997, J BIOL CHEM, V272, P27618, DOI 10.1074/jbc.272.44.27618; RASO V, 1982, CANCER RES, V42, P457; RASO VA, 1984, RECEPTOR MEDIATED TA, V82, P119; REALE FR, 1987, CANCER RES, V47, P3199; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; VANRENSWOUDE J, 1982, P NATL ACAD SCI-BIOL, V79, P6186; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; Youle R J, 1991, Semin Cell Biol, V2, P39; ZUCKER DR, 1984, MOL IMMUNOL, V21, P785, DOI 10.1016/0161-5890(84)90165-2	37	4	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27623	27628		10.1074/jbc.272.44.27623	http://dx.doi.org/10.1074/jbc.272.44.27623			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346900	hybrid			2022-12-27	WOS:A1997YD47300026
J	Thomas, M; Chedin, S; Carles, C; Riva, M; Famulok, M; Sentenac, A				Thomas, M; Chedin, S; Carles, C; Riva, M; Famulok, M; Sentenac, A			Selective targeting and inhibition of yeast RNA polymerase II by RNA aptamers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SELECTION; SACCHAROMYCES-CEREVISIAE; ELONGATION COMPLEX; TERNARY COMPLEXES; RECEPTOR-BINDING; LARGEST SUBUNIT; GROWTH-FACTOR; AMINO-ACIDS; L-ARGININE; DNA	To probe the complex nucleic acid binding domains of yeast RNA polymerase II (Pol II), we have isolated in the presence of heparin RNA molecules that selectively bind to yeast Pol II. A class of RNA molecules was found to bind and strongly interfere with enzyme-DNA interaction but not with RNA chain elongation, Remarkably, one selected RNA ligand was a specific inhibitor of Saccharomyces cerevisiae Pol II. S. cerevisiae Pol I and Pol III and Pol II from Schizosaccharomyces pombe or wheat germ cells were not affected. Photocross-linking experiments showed that the RNA ligand preferentially interacted with B220, the largest subunit of Pol II and, to a lesser extent, with B150, the second largest subunit, The selected RNA was expressed in yeast cells under the control of a Pol III promoter, Yeast cells that expressed the anti-Pol II aptamer grew normally, However, a cell growth defect was observed when expressing the RNA aptamer in cells having an artificially reduced level of Pol II.	CEA SACLAY, SERV BIOCHIM & GENET MOL, F-91191 GIF SUR YVETTE, FRANCE; UNIV MUNICH, GENZENTRUM, INST BIOCHEM, D-1377 MUNICH, GERMANY	CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Munich								Archambault J, 1996, GENETICS, V142, P737; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BREAKER RR, 1994, BIOCHEMISTRY-US, V33, P11980, DOI 10.1021/bi00205a037; BUHLER JM, 1974, J BIOL CHEM, V249, P5963; BUSBY S, 1981, EUR J BIOCHEM, V118, P443, DOI 10.1111/j.1432-1033.1981.tb05540.x; CAMIER S, 1995, P NATL ACAD SCI USA, V92, P9338, DOI 10.1073/pnas.92.20.9338; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHAN CL, 1994, RAV S MOL C, V3, P297; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DEZELEE S, 1972, FEBS LETT, V21, P1, DOI 10.1016/0014-5793(72)80148-0; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1994, J AM CHEM SOC, V116, P1698, DOI 10.1021/ja00084a010; FOX CF, 1965, J BIOL CHEM, V240, P2101; Geiger A, 1996, NUCLEIC ACIDS RES, V24, P1029, DOI 10.1093/nar/24.6.1029; GIVER L, 1993, NUCLEIC ACIDS RES, V21, P5509, DOI 10.1093/nar/21.23.5509; GOOD PD, 1994, GENE, V151, P209, DOI 10.1016/0378-1119(94)90658-0; HUAIFENG M, 1983, EUR J BIOCHEM, V131, P113, DOI 10.1111/j.1432-1033.1983.tb07237.x; HUET J, 1985, J BIOL CHEM, V260, P5304; JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028; JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P11227, DOI 10.1073/pnas.90.23.11227; Jiang F, 1996, NATURE, V382, P183, DOI 10.1038/382183a0; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; King RA, 1996, CELL, V87, P893, DOI 10.1016/S0092-8674(00)81996-0; KRAKOW J, 1970, TRANSCRIPTION GENETI, V35, P78; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KUBIK MF, 1994, NUCLEIC ACIDS RES, V22, P2619, DOI 10.1093/nar/22.13.2619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landick R, 1996, SCIENCE, V273, P202, DOI 10.1126/science.273.5272.202; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; Liu KB, 1996, EMBO J, V15, P150, DOI 10.1002/j.1460-2075.1996.tb00343.x; LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; NIEUWLANDT D, 1995, BIOCHEMISTRY-US, V34, P5651, DOI 10.1021/bi00016a041; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Sentenac A, 1982, MOL BIOL YEAST SACCH, P561; SEVERINOV K, 1994, J BIOL CHEM, V269, P31701; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Williamson JR, 1996, NATURE, V382, P112, DOI 10.1038/382112a0	44	63	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27980	27986		10.1074/jbc.272.44.27980	http://dx.doi.org/10.1074/jbc.272.44.27980			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346949	Green Published, hybrid			2022-12-27	WOS:A1997YD47300075
J	Adelman, K; Orsini, G; Kolb, A; Graziani, L; Brody, EN				Adelman, K; Orsini, G; Kolb, A; Graziani, L; Brody, EN			The interaction between the AsiA protein of bacteriophage T4 and the sigma(70) subunit of Escherichia coli RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; OPEN-COMPLEX-FORMATION; TRANSCRIPTION INITIATION; MIDDLE PROMOTERS; SIGMA-70 SUBUNIT; MOTA PROTEIN; DNA; SPECIFICITY; RECOGNITION; BINDING	The AsiA protein of bacteriophage T4 binds to the sigma 70 subunit of Escherichia coli RNA polymerase and plays a dual regulatory role during T4 development: (i) inhibition of host and phage early transcription, and (ii) coactivation of phage middle-mode transcription, which also requires the T4 DNA binding transcriptional activator, MotA. We report that the interaction between AsiA and sigma(70) occurs with a 1:1 stoichiometry, When preincubated with RNA polymerase, AsiA is a potent inhibitor of open complex formation at the lac UV5 promoter, whereas it does not perturb preformed open or intermediate promoter complexes. DNase I footprinting and electrophoretic mobility shift analyses of RNA polymerase-DNA complexes formed at the T4 early promoter P15.0 show that AsiA blocks the initial RNA polymerase binding step that leads to the formation of specific closed promoter complexes, A contrasting result is obtained on the T4 middle promoter PrIIB2, where AsiA stimulates the formation of both closed complexes and open complexes, Therefore, we propose that AsiA modulates initial DNA binding by the RNA polymerase, switching promoter usage at the level of closed complex formation.	UNIV PARIS 06, CNRS, UPR 9061, CTR GENET MOL, LAB ASSOCIE, F-91198 GIF SUR YVETTE, FRANCE; INST PASTEUR, CNRS, URA 1149, UNITE PHYSICOCHIM MACROMOL BIOL, F-75724 PARIS 15, FRANCE; SUNY BUFFALO, DEPT CHEM, BUFFALO, NY 14260 USA; UNIV COLORADO, DEPT MOL CELLULAR & DEV BIOL, BOULDER, CO 80309 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Colorado System; University of Colorado Boulder				Adelman, Karen/0000-0001-5364-334X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050700] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50700] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRODY EN, 1995, FEMS MICROBIOL LETT, V128, P1; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BUCKLE M, 1992, EMBO J, V11, P2619, DOI 10.1002/j.1460-2075.1992.tb05327.x; BUCKLE M, 1994, TRANSCRIPTION MECH R, P207; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Burns HD, 1996, BIOCHEM J, V317, P305, DOI 10.1042/bj3170305; Busby S, 1994, Methods Mol Biol, V30, P397; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GUILD N, 1988, J MOL BIOL, V199, P241, DOI 10.1016/0022-2836(88)90311-7; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HINTON DM, 1991, J BIOL CHEM, V266, P18034; Hinton DM, 1996, J MOL BIOL, V256, P235, DOI 10.1006/jmbi.1996.0082; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MACDONALD PM, 1984, GENETICS, V106, P17; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCOY M I M, 1979, Biochimica et Biophysica Acta, V562, P149; Mosig Gisela, 1994, P127; ORSINI G, 1993, J BACTERIOL, V175, P85, DOI 10.1128/JB.175.1.85-93.1993; OUHAMMOUCH M, 1995, P NATL ACAD SCI USA, V92, P1451, DOI 10.1073/pnas.92.5.1451; OUHAMMOUCH M, 1994, J BACTERIOL, V176, P5194, DOI 10.1128/jb.176.16.5194.1994; OZOLINE ON, 1995, NUCLEIC ACIDS RES, V23, P4533, DOI 10.1093/nar/23.22.4533; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; RICHET E, 1991, J MOL BIOL, V218, P529; SCHAEFFER F, 1982, EMBO J, V1, P99, DOI 10.1002/j.1460-2075.1982.tb01131.x; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STEVENS A, 1977, BIOCHIM BIOPHYS ACTA, V475, P193, DOI 10.1016/0005-2787(77)90355-0; Stevens A., 1976, RNA POLYMERASE, P617; Stitt Barbara, 1994, P142; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; TRAVERS AA, 1987, CRIT REV BIOCHEM MOL, V22, P181, DOI 10.3109/10409238709101483; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; WILKENS K, 1994, MOL BIOL BACTERIOP T, V4, P132; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	43	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27435	27443		10.1074/jbc.272.43.27435	http://dx.doi.org/10.1074/jbc.272.43.27435			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341196	hybrid			2022-12-27	WOS:A1997YC65900092
J	Carranco, R; Almoguera, C; Jordano, J				Carranco, R; Almoguera, C; Jordano, J			A plant small heat shock protein gene expressed during zygotic embryogenesis but noninducible by heat stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL REGULATION; SEED MATURATION; MESSENGER-RNAS; WATER-STRESS; PROMOTER; ELEMENTS; PEA; LOCALIZATION; DROSOPHILA; INDUCTION	A small heat shack protein (sHSP) gene from sunflower, Ha hsp17.6 G1, showed expression patterns that differ from what is known for members of this gene family. The mRNAs of this gene accumulated in seeds during late desiccation stages of zygotic embryogenesis but not in response to heat shock in vegetative tissues, The failure to respond to heat shock was independent of the developmental stage after germination and shock temperature. Nuclear run-on analyses demonstrated that transcription from the Ha hsp17.6 G1 promoter is not induced by heat shock, This agrees with the presence, in this promoter, of sequences with little similarity to heat shock elements, Our results show an evolutionary divergence, in the regulation of plant sHSP genes, which has originated stress-responsive genes and nonresponsive members within this gene family, We discuss implications for mechanisms controlling the developmental regulation of sHSP genes in plants.	CSIC, INST RECURSOS NAT & AGROBIOL, E-41080 SEVILLE, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS)			Carranco, Raúl/GXG-1194-2022; Almoguera, Concepción/J-7026-2014; Jordano, Juan/J-5829-2012	Carranco, Raúl/0000-0001-9359-9793; Almoguera, Concepción/0000-0002-7961-6507; Jordano, Juan/0000-0002-2583-4453				ALMOGUERA C, 1992, PLANT MOL BIOL, V19, P781, DOI 10.1007/BF00027074; ALMOGUERA C, 1995, PLANT PHYSIOL, V107, P765, DOI 10.1104/pp.107.3.765; ALMOGUERA C, 1993, PLANT J, V4, P947, DOI 10.1046/j.1365-313X.1993.04060947.x; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BARROS MD, 1992, PLANT MOL BIOL, V19, P665, DOI 10.1007/BF00026792; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Coca MA, 1996, PLANT MOL BIOL, V31, P863, DOI 10.1007/BF00019473; COCA MA, 1994, PLANT MOL BIOL, V25, P479, DOI 10.1007/BF00043876; DEROCHER A, 1995, PLANT MOL BIOL, V27, P441, DOI 10.1007/BF00019312; DEROCHER AE, 1994, PLANT J, V5, P93, DOI 10.1046/j.1365-313X.1994.5010093.x; EDINGTON BV, 1990, MOL CELL BIOL, V10, P4886, DOI 10.1128/MCB.10.9.4886; FERNANDES M, 1994, NUCLEIC ACIDS RES, V22, P167, DOI 10.1093/nar/22.2.167; Fernandes M., 1994, BIOL HEAT SHOCK PROT, P375; GURLEY WB, 1991, BIOCHEMISTRY-US, V30, P1, DOI 10.1021/bi00215a001; HUBEL A, 1994, PLANT MOL BIOL, V26, P353, DOI 10.1007/BF00039545; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; KRISHNA P, 1992, PLANT PHYSIOL, V100, P1772, DOI 10.1104/pp.100.4.1772; LUTHE DS, 1980, PLANT PHYSIOL, V65, P305, DOI 10.1104/pp.65.2.305; MITTLER R, 1994, PLANT J, V5, P397, DOI 10.1111/j.1365-313X.1994.00397.x; Never L, 1996, CELL STRESS CHAPERON, V1, P215, DOI 10.1379/1466-1268(1996)001<0215:THWCAP>2.3.CO;2; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; Prandl R, 1996, PLANT MOL BIOL, V31, P157, DOI 10.1007/BF00020615; PRANDL R, 1995, PLANT MOL BIOL, V28, P73, DOI 10.1007/BF00042039; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; WANNER LA, 1991, PLANT CELL, V3, P1289, DOI 10.1105/tpc.3.12.1289; Waters ER, 1996, J EXP BOT, V47, P325, DOI 10.1093/jxb/47.3.325; Wehmeyer N, 1996, PLANT PHYSIOL, V112, P747, DOI 10.1104/pp.112.2.747; WISTOW G, 1995, BBA-GENE STRUCT EXPR, V1263, P105, DOI 10.1016/0167-4781(95)00087-W; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0; ZURNIEDEN U, 1995, PLANTA, V196, P530	32	50	59	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27470	27475		10.1074/jbc.272.43.27470	http://dx.doi.org/10.1074/jbc.272.43.27470			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341201	hybrid			2022-12-27	WOS:A1997YC65900097
J	Okada, N; Watarai, M; Ozeri, V; Hanski, E; Caparon, M; Sasakawa, C				Okada, N; Watarai, M; Ozeri, V; Hanski, E; Caparon, M; Sasakawa, C			A matrix form of fibronectin mediates enhanced binding of Streptococcus pyogenes to host tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; PROTEIN-F; SURFACE PROTEIN; EXTRACELLULAR-MATRIX; MULTIPLE BINDING; ESCHERICHIA-COLI; ADHERENCE; RECEPTOR; ADHESINS; DOMAIN	The pathogenic Gram-positive bacterium Streptococcus pyogenes (group A streptococcus) binds to fibronectin via protein P. In this study, we have investigated the binding properties of protein F to various multimeric tissue forms of fibronectin that appear on cell surfaces and in the extracellular matrix, We show that binding of S. pyogenes through protein F is more efficient to an in vitro-derived polymerized form of fibronectin (superfibronectin) than to soluble fibronectin immobilized ins a solid phase, In addition, Chinese hamster ovary cells overexpressing the alpha(5) beta(1) integrin produced an increased amount of a fibronectin matrix and consequently bound a higher number of S. pyogenes cells. Inhibition and direct binding assays using purified Proteins demonstrated that binding to a fibronectin matrix involved both domains of protein F (UR and RD2) that have previously been implicated in interactions with fibronectin, Using intact S. pyogenes bacteria in which various domains of protein F were expressed as hybrids with the surface-exposed region of an unrelated protein, we revealed that, in contrast to the predominantly UR-mediated binding to soluble fibronectin, the maximal binding to the fibronectin matrix required RD2 inn addition to UR. Since in some infections a pyogenes may initially encounter a matrix form of fibronectin, these results suggest that UR and RD2 may be important for the initiation of streptococcal infectious processes.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT CLIN MICROBIOL,IL-91010 JERUSALEM,ISRAEL; WASHINGTON UNIV,SCH MED,DEPT MOL MICROBIOL,ST LOUIS,MO 63110	Hebrew University of Jerusalem; Washington University (WUSTL)	Okada, N (corresponding author), UNIV TOKYO,INST MED SCI,DEPT BACTERIOL,MINATO KU,4-6-1 SHIROKANEDAI,TOKYO 108,JAPAN.		hanski, emanuel/M-2696-2018	hanski, emanuel/0000-0001-5054-0628				BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; CAPARON MG, 1992, J BACTERIOL, V174, P5693, DOI 10.1128/JB.174.17.5693-5701.1992; COURTNEY HS, 1994, INFECT IMMUN, V62, P3937, DOI 10.1128/IAI.62.9.3937-3946.1994; COURTNEY HS, 1992, CURR MICROBIOL, V25, P245, DOI 10.1007/BF01575856; FOGG GC, 1994, MOL MICROBIOL, V11, P671, DOI 10.1111/j.1365-2958.1994.tb00345.x; FRICK IM, 1995, EMBO J, V14, P1674, DOI 10.1002/j.1460-2075.1995.tb07156.x; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HANSKI E, 1995, METHOD ENZYMOL, V253, P269; HANSKI E, 1992, P NATL ACAD SCI USA, V89, P6172, DOI 10.1073/pnas.89.13.6172; HASTY DL, 1992, INFECT IMMUN, V60, P2147, DOI 10.1128/IAI.60.6.2147-2152.1992; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KREIKEMEYER B, 1995, MOL MICROBIOL, V17, P137, DOI 10.1111/j.1365-2958.1995.mmi_17010137.x; Lee JY, 1996, INFECT IMMUN, V64, P413, DOI 10.1128/IAI.64.2.413-421.1996; LOWRANCE JH, 1988, INFECT IMMUN, V56, P2279, DOI 10.1128/IAI.56.9.2279-2285.1988; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; NATANSON S, 1995, J INFECT DIS, V171, P871, DOI 10.1093/infdis/171.4.871; OKADA N, 1994, J CLIN INVEST, V94, P965, DOI 10.1172/JCI117463; Ozeri V, 1996, EMBO J, V15, P989, DOI 10.1002/j.1460-2075.1996.tb00435.x; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; PATTI JM, 1994, CURR OPIN CELL BIOL, V6, P752, DOI 10.1016/0955-0674(94)90104-X; PEAKE P, 1993, INFECT IMMUN, V61, P4828, DOI 10.1128/IAI.61.11.4828-4834.1993; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; RAKONJAC JV, 1995, INFECT IMMUN, V63, P622, DOI 10.1128/IAI.63.2.622-631.1995; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SCHMIDT KH, 1993, FEMS IMMUNOL MED MIC, V7, P135; SCHULZEKOOPS H, 1993, INFECT IMMUN, V61, P2513, DOI 10.1128/IAI.61.6.2513-2519.1993; SCOTT JR, 1974, VIROLOGY, V62, P344, DOI 10.1016/0042-6822(74)90397-3; SCOTT JR, 1986, J EXP MED, V164, P1641, DOI 10.1084/jem.164.5.1641; SELA S, 1993, MOL MICROBIOL, V10, P1049, DOI 10.1111/j.1365-2958.1993.tb00975.x; SIMPSON WA, 1987, REV INFECT DIS, V9, pS351; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x; TALAY SR, 1992, INFECT IMMUN, V60, P3837, DOI 10.1128/IAI.60.9.3837-3844.1992; TALAY SR, 1991, MOL MICROBIOL, V5, P1727, DOI 10.1111/j.1365-2958.1991.tb01921.x; TAMURA GS, 1995, MOL MICROBIOL, V15, P581, DOI 10.1111/j.1365-2958.1995.tb02271.x; VONDERFLIER M, 1995, INFECT IMMUN, V63, P4317; WANNAMAKER LW, 1970, NEW ENGL J MED, V282, P23, DOI 10.1056/NEJM197001082820206; Watarai M, 1996, J EXP MED, V183, P991, DOI 10.1084/jem.183.3.991; WESTERLUND B, 1989, FEBS LETT, V243, P199, DOI 10.1016/0014-5793(89)80129-2	42	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26978	26984		10.1074/jbc.272.43.26978	http://dx.doi.org/10.1074/jbc.272.43.26978			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341135	hybrid			2022-12-27	WOS:A1997YC65900031
J	Miyamoto, Y; Imamoto, N; Sekimoto, T; Tachibana, T; Seki, T; Tada, S; Enomoto, T; Yoneda, Y				Miyamoto, Y; Imamoto, N; Sekimoto, T; Tachibana, T; Seki, T; Tada, S; Enomoto, T; Yoneda, Y			Differential modes of nuclear localization signal (NLS) recognition by three distinct classes of NLS receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; AMINO-ACID MOTIF; PROTEIN IMPORT; HUMAN HOMOLOG; HELA-CELLS; IDENTIFICATION; BINDING; INTERACTS; TRANSPORT; RAN/TC4	The targeting of karyophilic proteins to nuclear pores is mediated via the formation of a nuclear pore-targeting complex, through the interaction of nuclear localization signal (NLS) with its NLS receptor. Recently, a novel human protein, Qip1, was identified from a yeast two-hybrid system with DNA helicase Q1. This study demonstrates that Qip1 is a novel third class of NLS receptor that efficiently recognizes the NLS of the helicase Q1. Moreover, the data obtained in this study show that the specific interaction between Qip1 and the NLS of the helicase Q1 requires its upstream sequence of the minimal essential NLS. By using purified recombinant proteins alone in the digitonin-permeabilized cell-free transport system, it was demonstrated that the two known human NLS receptors, Rch1 and NPI-1, are able to transport all the tested NLS substrates into the nucleus, while Qip1 most efficiently transports the helicase Q1-NLS substrates, which contain its upstream sequence in so far as we have examined the system. Furthermore, in HeLa cell crude cytosol, it was found that endogenous Rch1 binds to all the tested NLS substrates, while the binding of endogenous NPI-1 is restricted to only some NLSs, despite the fact that NPI-1 itself shows binding activity to a variety of NLSs. These results indicate that at least three structurally and functionally distinct NLS receptors exist in the human single cell population, and suggest that the nuclear import of karyophilic proteins may be controlled in a complex manner at the NLS recognition step by the existence of a variety of NLS receptors with various specificities to each NLS.	OSAKA UNIV, SCH MED, DEPT ANAT & CELL BIOL, SUITA, OSAKA 565, JAPAN; UNIV TOKYO, FAC PHARMACEUT SCI, DEPT PHYSIOL CHEM, BUNKYO KU, TOKYO 113, JAPAN; TOHOKU UNIV, FAC PHARMACEUT SCI, DEPT MOL CELL BIOL, AOBA KU, SENDAI, MIYAGI 98077, JAPAN	Osaka University; University of Tokyo; Tohoku University			Imamoto, Naoko/A-7458-2015	Imamoto, Naoko/0000-0002-2886-3022; Miyamoto, Yoichi/0000-0003-4016-1119				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Hicks GR, 1996, PLANT CELL, V8, P1337, DOI 10.1105/tpc.8.8.1337; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SEKI M, 1994, J BIOCHEM-TOKYO, V115, P523, DOI 10.1093/oxfordjournals.jbchem.a124369; Seki T, 1997, BIOCHEM BIOPH RES CO, V234, P48, DOI 10.1006/bbrc.1997.6535; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; Tada S, 1996, CELL STRUCT FUNCT, V21, P123, DOI 10.1247/csf.21.123; TOROK I, 1995, J CELL BIOL, V129, P1473, DOI 10.1083/jcb.129.6.1473; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3; Yoneda Y, 1996, ARCH HISTOL CYTOL, V59, P97, DOI 10.1679/aohc.59.97	50	149	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26375	26381		10.1074/jbc.272.42.26375	http://dx.doi.org/10.1074/jbc.272.42.26375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334211	hybrid			2022-12-27	WOS:A1997YB13900045
J	Palaparti, A; Baratz, A; Stifani, S				Palaparti, A; Baratz, A; Stifani, S			The groucho/transducin-like enhancer of split transcriptional repressors interact with the genetically defined a amino-terminal silencing domain of histone H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX REPRESSOR; DROSOPHILA-ENHANCER; SACCHAROMYCES-CEREVISIAE; COREPRESSOR COMPLEX; CHROMATIN STRUCTURE; GROUCHO TRANSCRIPT; GLUCOSE REPRESSION; BHLH PROTEINS; GENE-PRODUCT; WRPW MOTIF	Groucho is a transcriptional repressor implicated in Notch signaling and involved in neural development and segmentation in Drosophila. We are investigating the molecular mechanisms underlying the functions of Groucho and its mammalian homologs, the transducin-like Enhancer of split (TLE) proteins, We report that Groucho/TLEs are associated with chromatin in live cells and that they co-purify with isolated histones. Affinity chromatography and far Western blotting studies show further that native Groucho/TLE proteins interact specifically with histone H3 and not with other core histones. This interaction is mediated by the H8 aminoterminal domain previously shown by genetic analysis in yeast to be essential for the role of H3 in transcriptional silencing, We also demonstrate that Groucho/TLEs form oligomeric structures in vivo, These combined findings suggest that transcription complexes containing Groucho/TLEs may associate with chromatin through interactions with the amino terminus of histone H3 and that these interactions may be propagated along the chromosome due to the ability of Groucho/TLEs to participate in higher order structures.	MCGILL UNIV,MONTREAL NEUROL INST,CTR NEURONAL SURVIVAL,MONTREAL,PQ H3A 2B4,CANADA	McGill University				Stifani, Stefano/0000-0002-2376-7701				ANDERSSON LO, 1972, FEBS LETT, V20, P199, DOI 10.1016/0014-5793(72)80793-2; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; AXEL R, 1973, P NATL ACAD SCI USA, V70, P2029, DOI 10.1073/pnas.70.7.2029; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; DECELIS JF, 1995, DEVELOPMENT, V121, P3467; DEHNI G, 1995, MECH DEVELOP, V53, P369, DOI 10.1016/0925-4773(95)00452-1; DELIDAKIS C, 1991, GENETICS, V129, P803; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; FISCHERVIZE JA, 1992, DEVELOPMENT, V115, P89; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Heitzler P, 1996, DEVELOPMENT, V122, P161; Hubbard EJA, 1996, SCIENCE, V273, P112, DOI 10.1126/science.273.5271.112; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; KAGEYAMA R, 1995, CRIT REV NEUROBIOL, V9, P177; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KNUST E, 1992, GENETICS, V132, P505; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Koop KE, 1996, MECH DEVELOP, V59, P73, DOI 10.1016/0925-4773(96)00582-5; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; MALLO M, 1995, DEV DYNAM, V204, P338, DOI 10.1002/aja.1002040311; MALLO M, 1993, MECH DEVELOP, V42, P67, DOI 10.1016/0925-4773(93)90099-J; MIYASAKA H, 1993, EUR J BIOCHEM, V216, P343, DOI 10.1111/j.1432-1033.1993.tb18151.x; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pinto M, 1996, J BIOL CHEM, V271, P33026, DOI 10.1074/jbc.271.51.33026; ROTH SY, 1995, CURR OPIN GENET DEV, V5, P168, DOI 10.1016/0959-437X(95)80004-2; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHMIDT CJ, 1993, J BIOL CHEM, V268, P25681; SCHRONS H, 1992, GENETICS, V132, P481; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; VANDERWE.DR, 1971, FEBS LETT, V14, P333, DOI 10.1016/0014-5793(71)80294-6; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; Varanasi US, 1996, MOL CELL BIOL, V16, P6707; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307	47	130	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26604	26610		10.1074/jbc.272.42.26604	http://dx.doi.org/10.1074/jbc.272.42.26604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334241	hybrid			2022-12-27	WOS:A1997YB13900075
J	Sun, B; Murray, NR; Fields, AP				Sun, B; Murray, NR; Fields, AP			A role for nuclear phosphatidylinositol-specific phospholipase C in the G(2)/M phase transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN LEUKEMIC-CELLS; RAT-LIVER NUCLEI; LAMIN-B; DIFFERENTIATION; ACTIVATION; PHOSPHORYLATION; PROLIFERATION; INHIBITION; INDUCTION	Protein kinase C (PKC) is activated at the nucleus during the G(2) phase of cell cycle, where it is required for mitosis, However, the mechanisms controlling cell cycle-dependent activation of nuclear PKC are not known, We now report that nuclear levels of the major physiologic PKC activator diacylglycerol (DAG) fluctuate during cell cycle. Specifically, nuclear DAG levels in G(2)/M phase cells are 2.5-3-fold higher than in G(1) phase cells, In synchronized cells, nuclear DAG levels rise to a peak coincident with the G(2)/M phase transition and return to basal levels in G(1) phase cells, This increase in DAG level is sufficient to stimulate beta(II) PKC-mediated phosphorylation of its mitotic nuclear envelope substrate lamin B in vitro, Isolated nuclei from G(2) phase cells contain an active phospholipase activity capable of generating DAG in vitro, Nuclear phospholipase activity is inhibited by the selective phosphatidylinositol-specific phospholipase C (PI-PLC) inhibitor 1-O-octadeyl-2-O-methyl-sn-glycero-3-phosphocholine and neomycin sulfate, but not by the phosphatidylcholine-PLC selective inhibitor D609 or inhibitors of phospholipase D-mediated DAG generation, Treatment of synchronized cells with 1-O-octadeyl-2-O-methyl-sn-glycero-3-phosphocholine leads to decreased nuclear PI-PLC activity and cell cycle blockade in the G(2) phase, suggesting a role for nuclear PI-PLC in the G(2)/M phase transition, Our data are consistent with the hypothesis that nuclear PI-PLC generates DAG to activate nuclear beta(II) PKC, whose activity is required for mitosis.	UNIV TEXAS,MED BRANCH,SEALY CTR ONCOL & HEMATOL,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston								ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; CLEMENS MJ, 1992, J CELL SCI, V103, P881; DIOMEDE L, 1994, INT J CANCER, V57, P645, DOI 10.1002/ijc.2910570506; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1995, BIOCHEM J, V312, P63, DOI 10.1042/bj3120063; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; GOSS VL, 1994, J BIOL CHEM, V269, P19074; HEESBEEN EC, 1993, LEUKEMIA RES, V17, P143, DOI 10.1016/0145-2126(93)90059-T; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; KURIKI H, 1992, J BIOCHEM-TOKYO, V111, P283, DOI 10.1093/oxfordjournals.jbchem.a123750; LISCOVITCH M, 1991, BIOCHEM J, V279, P319, DOI 10.1042/bj2790319; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; MURRAY NR, 1997, PROTEIN KINASE C, P97; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; OKAMOTO S, 1987, CANCER RES, V47, P2599; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PAPPU AS, 1983, NEUROCHEM RES, V8, P1565, DOI 10.1007/BF00964158; POWIS G, 1992, CANCER RES, V52, P2835; PRIESS JE, 1987, METHOD ENZYMOL, V141, P294; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; TOKER A, 1994, J BIOL CHEM, V269, P32358; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156	36	106	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26313	26317		10.1074/jbc.272.42.26313	http://dx.doi.org/10.1074/jbc.272.42.26313			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334202	hybrid			2022-12-27	WOS:A1997YB13900036
J	Zhang, Y; Scandura, JM; VanNostrand, WE; Walsh, PN				Zhang, Y; Scandura, JM; VanNostrand, WE; Walsh, PN			The mechanism by which heparin promotes the inhibition of coagulation factor XIa by protease nexin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; ANTITHROMBIN-III; HUMAN PLATELETS; ALPHA-1-PROTEASE INHIBITOR; SLOW-BINDING; FACTOR-XA; THROMBIN; PURIFICATION	Previous kinetic studies have shown that protease nexin-2 is a potent, reversible, and competitive inhibitor of factor XIa. Here we show that high molecular weight heparin potentiates the ability of protease nexin-2 to inhibit factor XIa with a parabolic concentration dependence, predominantly because of an increase of the association rate constant with little perturbation of the dissociation rate constant. No effect on factor XIa inhibition by protease nexin-a was observed with heparin preparations of 6-22 saccharide units (0.1 nM-10 mu M), whereas heparin preparations with 32-64 saccharide units potentiated factor XIa inhibition by protease nexin-2 in a size-and concentration-dependent manner. We propose a model wherein heparin exerts this effect by providing a template for the assembly of factor XIa-protease nexin-a complexes, and only heparin polymers consisting of greater than 32 saccharide units (M-r similar to 10,000) are sufficiently long to provide a template to which factor XIa and protease nexin-a molecules can bind simultaneously. Heparin-mediated enhancement of factor XIa inhibition by protease nexin-2 was partially abrogated by high molecular weight kininogen, suggesting that high molecular weight kininogen may play a role in regulating factor XIa activity.	TEMPLE UNIV,SCH MED,SOL SHERRY THROMBOSIS RES CTR,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MED,PHILADELPHIA,PA 19140; SUNY STONY BROOK,DEPT MED,STONY BROOK,NY 11794	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Scandura, Joseph/0000-0002-9525-143X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056153, R01HL046213, P50HL045486] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45486, HL56153, HL46213] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEELER DL, 1986, BLOOD, V67, P1488; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BROEKMAN MJ, 1975, BRIT J HAEMATOL, V31, P51, DOI 10.1111/j.1365-2141.1975.tb00831.x; BUSH AI, 1990, J BIOL CHEM, V265, P15977; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HOLMER E, 1981, BIOCHEM J, V193, P395, DOI 10.1042/bj1930395; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOMIYAMA Y, 1992, THROMB RES, V66, P397, DOI 10.1016/0049-3848(92)90289-M; LANE DA, 1986, J BIOL CHEM, V261, P3980; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MELHADO LL, 1982, J AM CHEM SOC, V104, P7299, DOI 10.1021/ja00389a065; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; SALVESEN G, 1994, HEMOSTASIS THROMBOSI; Scandura JM, 1997, BIOCHEMISTRY-US, V36, P412, DOI 10.1021/bi9612576; SCOTT CF, 1982, J CLIN INVEST, V69, P844, DOI 10.1172/JCI110524; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANNOSTRAND WE, 1995, THROMB RES, V78, P43, DOI 10.1016/0049-3848(95)00033-X; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; WALSH PN, 1987, J CLIN INVEST, V80, P1578, DOI 10.1172/JCI113244	33	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26139	26144		10.1074/jbc.272.42.26139	http://dx.doi.org/10.1074/jbc.272.42.26139			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334179	hybrid			2022-12-27	WOS:A1997YB13900013
J	Kruttgen, A; Heymach, JV; Kahle, PJ; Shooter, EM				Kruttgen, A; Heymach, JV; Kahle, PJ; Shooter, EM			The role of the nerve growth factor carboxyl terminus in receptor binding and conformational stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTROPHIN RECEPTOR; BIOLOGICAL-ACTIVITY; TYROSINE KINASE; SIGNAL-TRANSDUCTION; NEURONAL SURVIVAL; AFFINITY RECEPTOR; TRK; NGF; CELLS; DIFFERENTIATION	The role of the nerve growth factor (NGF) carboxyl terminus in the function of NGF is not well understood, Previous work showed that deletion of residues 112-120 abolished NGF bioactivity. Several mutagenesis studies, however, have localized the binding sites of the two NGF receptors, p75 and TrkA to other regions of the NGF molecule, To investigate the role of the NGF COOH terminus, Foe performed a detailed structure-function analysis of this region by deleting stepwise each of the nine COOH-terminal residues as well as constructing six point mutants, We found that point mutations within the 111-115 region, but not deletion of residues 116-120, significantly decreased NGF bioactivity, as determined by TrkA tyrosine phosphorylation and neurite outgrowth from PC12 cells. Mutation of the absolutely conserved Leu(112) led to severely disrupted p75 binding on A875 cells but had only a modest effect on TrkA binding to MG87-TrkA fibroblasts, This suggests that the p75 binding surface is more extended than previously believed and includes not only charged residues within loops 1 and 5 but also spatially discontinuous, uncharged residues in a region where the NH2 and COOH termini are in close proximity, Unexpectedly, deletion of COOH-terminal residues beyond Ala(116) led to significantly decreased stability, These results demonstrate that residues 111-115, but not residues 116-120, are important for both the structural stability and biological activity of NGF.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Heymach, John/AAG-2361-2019; Kruttgen, Alexander P/E-9232-2010	Heymach, John/0000-0001-9068-8942; 	NICHD NIH HHS [HD07249] Funding Source: Medline; NINDS NIH HHS [NS07158, NS04270] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON M, 1994, J BIOL CHEM, V269, P926; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARKER PA, 1994, NEURON, V13, P1; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; BRADSHAW RA, 1994, PROTEIN SCI, V3, P1901, DOI 10.1002/pro.5560031102; BURTON LE, 1992, J NEUROCHEM, V59, P1937, DOI 10.1111/j.1471-4159.1992.tb11030.x; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHAPMAN BS, 1995, PROTEIN SCI, V4, P1696, DOI 10.1002/pro.5560040905; DRINKWATER CC, 1993, J BIOL CHEM, V268, P23202; DRINKWATER CC, 1991, P ROY SOC B-BIOL SCI, V246, P307, DOI 10.1098/rspb.1991.0159; HEYMACH JV, 1995, J BIOL CHEM, V270, P12297, DOI 10.1074/jbc.270.20.12297; Heymach JV, 1996, J BIOL CHEM, V271, P25430, DOI 10.1074/jbc.271.41.25430; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1995, TRENDS BIOTECHNOL, V13, P217, DOI 10.1016/S0167-7799(00)88949-0; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KULLANDER K, 1994, J NEUROSCI RES, V39, P195, DOI 10.1002/jnr.490390210; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LUO Y, 1992, J BIOL CHEM, V267, P12275; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; ROVELLI G, 1993, P NATL ACAD SCI USA, V90, P8717, DOI 10.1073/pnas.90.18.8717; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; Shamovsky IL, 1996, J AM CHEM SOC, V118, P9743, DOI 10.1021/ja9611194; SHIH A, 1994, J BIOL CHEM, V269, P27679; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; SUTER U, 1992, J NEUROSCI, V12, P306; TIMM DE, 1994, PROTEIN SCI, V3, P451; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; ZIMMERMANN A, 1981, P NATL ACAD SCI-BIOL, V78, P4611, DOI 10.1073/pnas.78.7.4611	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29222	29228		10.1074/jbc.272.46.29222	http://dx.doi.org/10.1074/jbc.272.46.29222			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361001	hybrid			2022-12-27	WOS:A1997YF68400060
J	LopezRodriguez, C; Botella, L; Corbi, AL				LopezRodriguez, C; Botella, L; Corbi, AL			CCAAT-enhancer-binding proteins (C/EBP) regulate the tissue specific activity of the CD11c integrin gene promoter through functional interactions with Sp1 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID CELL-DIFFERENTIATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTOR; P150,95 CD11C/CD18; MONOCLONAL-ANTIBODIES; TEMPORAL EXPRESSION; HUMAN-MONOCYTES; FAMILY MEMBERS; T-CELLS	The CD11c/CD18 integrin binds Lipopolysaccharide, fibrinogen, and heparin, and mediates leukocyte adhesion, spreading, and migration, CD11c/CD18 is primarily found on myeloid cells and its expression is regulated during myeloid differentiation by transcriptional mechanisms acting on the CD11c gene promoter, We now describe that CCAAT/enhancer-binding proteins (C/EBP) contribute to the basal. tissue-specific and developmentally regulated activity of the CD11c promoter, A C/EBP-binding site within the CD11c promoter (CEBP-80) is bound by CEBP alpha in undifferentiated U937 cells and by C/EBP alpha- and C/EBP beta-containing dimers in phorbol 12-myristate 13-acetate-differentiating cells, and its disruption decreased the CD11c promoter activity in a cell type-dependent manner, C/EBP alpha transactivated the CD11c promoter through the CEBP-80 element, and C/EBP alpha transactivation was also dependent on the Sp1-70- and Sp1-120 Spl binding sites. The -90/-50 fragment from the CD11c promoter, containing the adjacent CEBP-80, Sp1-70, and AP1-60 sites, differentially enhanced the activity of the minimal prolactin promoter in hematopoietic and epithelial cells, Altogether, these results demonstrate that C/EBP factors participate in the tissue-restricted and regulated expression of the CD11c/CD18 integrin through functional interactions with Sp1, suggest that Spl-related factors modulate C/EBP alpha transcriptional activity on the CD11c promoter, and demonstrate the existence of a composite regulatory element recognized by C/EBP, Spl, and AP-1 factors and whose enhancing effects are cell-type dependent.	CONSEJO SUPER INVEST CIENT,INST PARASITOL & BIOMED LOPEZ NEYRA,GRANADA 18001,SPAIN; HOSP PRINCESA,MADRID 28006,SPAIN; CONSEJO SUPER INVEST CIENT,CTR INVEST BIOL,MADRID 28006,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Hospital de La Princesa; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Botella, Luisa M/L-1392-2014; Corbi, Angel/B-7194-2011; Corbí, Angel L./ABC-8146-2020; Lopez-Rodriguez, C/G-4482-2014	Corbi, Angel/0000-0003-1980-5733; Corbí, Angel L./0000-0003-1980-5733; Lopez-Rodriguez, C/0000-0002-2311-2406				ANDERSON DC, 1986, J IMMUNOL, V137, P15; BELLON T, 1994, EUR J IMMUNOL, V24, P41, DOI 10.1002/eji.1830240107; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; Blackford J, 1996, EUR J IMMUNOL, V26, P525, DOI 10.1002/eji.1830260304; CHADBURN A, 1992, HEMATOL PATHOL, V6, P193; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Corbi AL, 1997, LEUKEMIA LYMPHOMA, V25, P415, DOI 10.3109/10428199709039028; CORBI AL, 1996, LEUKOCYTE INTEGRINS; DELAHERA A, 1988, EUR J IMMUNOL, V18, P1131; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; ERNST P, 1995, IMMUNITY, V2, P311, DOI 10.1016/1074-7613(95)90139-6; ESKRA L, 1991, VET IMMUNOL IMMUNOP, V29, P213, DOI 10.1016/0165-2427(91)90015-5; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; FREITAG SO, 1992, SCIENCE, V256, P379; HANSON CA, 1990, BLOOD, V76, P2360; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HOGG N, 1986, EUR J IMMUNOL, V16, P240, DOI 10.1002/eji.1830160306; HULEATT JW, 1995, J IMMUNOL, V154, P5684; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; KEIZER GD, 1987, EUR J IMMUNOL, V17, P1317, DOI 10.1002/eji.1830170915; KEIZER GD, 1987, J IMMUNOL, V138, P3130; Kramer A, 1996, J BIOL CHEM, V271, P6579; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; LopezRodriguez C, 1996, J IMMUNOL, V156, P3780; LopezRodriguez C, 1995, EUR J IMMUNOL, V25, P3496, DOI 10.1002/eji.1830251243; MAVILIO F, 1987, BLOOD, V69, P160; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; Noti JD, 1996, MOL CELL BIOL, V16, P2940; NUEDA A, 1995, CELL IMMUNOL, V164, P163, DOI 10.1006/cimm.1995.1157; NUEDA A, 1993, J BIOL CHEM, V268, P19305; Osada S, 1996, J BIOL CHEM, V271, P3891; POSTIGO AA, 1991, J EXP MED, V174, P1313, DOI 10.1084/jem.174.6.1313; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; RUBIO MA, 1995, BLOOD, V86, P3715, DOI 10.1182/blood.V86.10.3715.bloodjournal86103715; SARIBAN E, 1988, BLOOD, V71, P488; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTING R, 1985, BLOOD, V65, P974; SCOTT LM, 1992, BLOOD, V80, P1725; STACKER SA, 1991, J IMMUNOL, V146, P648; TEVELDE AA, 1987, IMMUNOLOGY, V61, P261; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; YAMADA A, 1991, J IMMUNOL, V146, P53; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	51	61	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29120	29126		10.1074/jbc.272.46.29120	http://dx.doi.org/10.1074/jbc.272.46.29120			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360988	hybrid, Green Published			2022-12-27	WOS:A1997YF68400047
J	Moller, JV; Ning, G; Maunsbach, AB; Fujimoto, K; Asai, K; Juul, B; Lee, YJ; deGracia, AG; Falson, P; leMaire, M				Moller, JV; Ning, G; Maunsbach, AB; Fujimoto, K; Asai, K; Juul, B; Lee, YJ; deGracia, AG; Falson, P; leMaire, M			Probing of the membrane topology of sarcoplasmic reticulum Ca2+-ATPase with sequence-specific antibodies - Evidence for plasticity of the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; AMINO-ACID-SEQUENCE; CATALYTIC SUBUNIT; CA2+ BINDING; IMMUNOELECTRON MICROSCOPY; TRANSMEMBRANE TOPOLOGY; NONIONIC DETERGENT; COMPLEMENTARY-DNA; CATION OCCLUSION; CA-2+ TRANSPORT	The topology of Ca2+-ATPase in sarcoplasmic reticulum (SR) vesicles was investigated with the aid of sequence-specific antibodies, produced against oligopeptides corresponding to sequences close to the membranous portions of the protein, The antisera in competitive enzyme-linked immunosorbent assays only reacted with intact SR vesicles to a limited extent, but most epitopic regions were exposed by low concentrations of nondenaturing detergent, octaethylene glycol dodecyl ether (C12E8) or after removal of cytosolic regions by proteinase K, In particular, these treatments exposed the loop regions in the C-terminal domain, including L7-8, the loop region located between transmembrane segments M7 and M8, with a putative intravesicular position, which had immunochemical properties very similar to those of the C terminus with a documented cytosolic exposure, In contrast to this, the reactivity of the N-terminal intravesicular loop regions L1-2 and L3-4 was only increased by C12E8 treatment but not by proteinase K proteolysis, Complexation of Ca2+-ATPase with beta,gamma-CrATP stabilized the C-terminal domain of Ca2+-ATPase against proteinase K proteolysis and reaction with most of the antisera, but immunoreactivity was maintained by the L6-7 and L7-8 loops, Immunoelectron microscopic analyses of vesicles following negative staining, thin sectioning, and the SDS-digested freeze-fracture labeling method suggested that the L7-8 epitope, in contrast to L6-7 and the C terminus, can be exposed on either the intravesicular or cytosolic side of the membrane. A preponderant intravesicular location of L7-8 in intact vesicles is suggested by the susceptibility of this region to proteolytic cleavage after disruption of the vesicular barrier with C12E8 and in symmetrically reconstituted Ca2+-ATPase proteoliposomes. In conclusion, our data suggest an adaptable membrane insertion of the C-terminal Ca2+-ATPase domain, which under some conditions permits sliding of M8 through the membrane with cytosolic exposure of L7-8, of possible functional significance in connection with Ca2+ translocation, On the technical side, our data emphasize that extreme caution is needed when using nondenaturing detergents or other treatments like EGTA at alkaline pH to open up vesicles for probing of intravesicular location with antibodies.	AARHUS UNIV, INST ANAT, DEPT CELL BIOL, DK-8000 AARHUS C, DENMARK; CTR ETUD SACLAY, CEA, DEPT BIOL CELLULAIRE & MOL, SECT BIOPHYS PROT & MEMBRANES, F-91191 GIF SUR YVETTE, FRANCE; CTR ETUD SACLAY, CNRS, URA 2096, F-91191 GIF SUR YVETTE, FRANCE; KYOTO UNIV, FAC MED, DEPT ANAT, SAKYO KU, KYOTO 60601, JAPAN	Aarhus University; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Kyoto University	Moller, JV (corresponding author), AARHUS UNIV, DEPT BIOPHYS, OLE WORMS ALLE 185, DK-8000 AARHUS C, DENMARK.			Falson, Pierre/0000-0002-9760-4577				ANDERSEN JP, 1983, EUR J BIOCHEM, V134, P205, DOI 10.1111/j.1432-1033.1983.tb07552.x; ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BESANCON M, 1992, ACTA PHYSIOL SCAND, V146, P77; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; Canfield VA, 1996, BIOCHEMISTRY-US, V35, P14165, DOI 10.1021/bi961851f; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COAN C, 1994, BIOCHEMISTRY-US, V33, P3722, DOI 10.1021/bi00178a032; CORNELIUS F, 1995, HDB NONMEDICAL APPL, P219; DEFORESTA B, 1989, BIOCHEMISTRY-US, V28, P2558, DOI 10.1021/bi00432a032; DUNAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1496, DOI 10.1021/bi00548a037; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FAMBROUGH DM, 1997, IN PRESS ANN NY ACAD; Fiedler B, 1996, J BIOL CHEM, V271, P29312, DOI 10.1074/jbc.271.46.29312; Fujimoto K, 1997, HISTOCHEM CELL BIOL, V107, P87, DOI 10.1007/s004180050092; Fujimoto K, 1996, FEBS LETT, V395, P29, DOI 10.1016/0014-5793(96)01002-2; FUJIMOTO K, 1995, J CELL SCI, V108, P3443; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; GREEN NM, 1985, BIOCHEM J, V231, P425, DOI 10.1042/bj2310425; GREEN NM, 1994, SODIUM PUMP, P110; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HEEGAARD CW, 1990, J BIOL CHEM, V265, P12020; Inesi G, 1995, BIOSCIENCE REP, V15, P327, DOI 10.1007/BF01788365; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KRAGHHANSEN U, 1993, BIOCHEMISTRY-US, V32, P1648, DOI 10.1021/bi00057a032; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE M, 1987, BIOCHEMISTRY-US, V26, P4803, DOI 10.1021/bi00389a030; LEMAIRE M, 1993, ANAL BIOCHEM, V214, P50, DOI 10.1006/abio.1993.1455; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LEVY D, 1990, J BIOL CHEM, V265, P19524; LIN JL, 1995, J BIOL CHEM, V270, P6942, DOI 10.1074/jbc.270.12.6942; Lutsenko S, 1997, J BIOL CHEM, V272, P5249, DOI 10.1074/jbc.272.8.5249; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MATTHEWS I, 1989, BIOCHEM BIOPH RES CO, V161, P683, DOI 10.1016/0006-291X(89)92653-3; Maunsbach AB, 1997, J AM SOC NEPHROL, V8, P1; MEIS LD, 1971, J BIOL CHEM, V246, P4759; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MOLLER JV, 1991, SODIUM PUMP RECENT D, P259; NING G, 1993, FEBS LETT, V336, P521, DOI 10.1016/0014-5793(93)80868-U; NING G, 1994, ACTA HISTOCHEM CYTOC, V27, P347, DOI 10.1267/ahc.27.347; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; OVCHINNIKOV YA, 1987, TRENDS BIOCHEM SCI, V12, P434, DOI 10.1016/0968-0004(87)90210-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; Qiu XQ, 1996, J GEN PHYSIOL, V107, P313, DOI 10.1085/jgp.107.3.313; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SKRIVER E, 1994, SODIUM PUMP, P354; SMITH DL, 1993, J BIOL CHEM, V268, P22469; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1992, J BIOL CHEM, V267, P25739; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; YOON KL, 1994, J BIOL CHEM, V269, P28249; ZHANG JT, 1995, BIOCHEMISTRY-US, V34, P9159, DOI 10.1021/bi00028a027	80	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29015	29032		10.1074/jbc.272.46.29015	http://dx.doi.org/10.1074/jbc.272.46.29015			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360975	hybrid			2022-12-27	WOS:A1997YF68400034
J	Blystone, SD; Williams, MP; Slater, SE; Brown, EJ				Blystone, SD; Williams, MP; Slater, SE; Brown, EJ			Requirement of integrin beta(3) tyrosine 747 for beta(3) tyrosine phosphorylation and regulation of alpha(v)beta(3) avidity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUT SIGNAL-TRANSDUCTION; GLYCOPROTEIN-IIB-IIIA; CYTOPLASMIC DOMAINS; PLATELET-AGGREGATION; NPXY MOTIF; RECEPTOR; ADHESION; SUBUNIT; EXPRESSION; ALPHA	Leukocytes and platelets require stimulation for optimal beta(3) integrin receptor function, whereas beta(3) function is constitutive in many other cells, The molecular mechanisms that enhance integrin function in stimulated hematopoietic cells are poorly understood. Phosphorylation of the beta(3) cytoplasmic tail is a recently described but prevalent phenomenon, with unknown effects on gp, function. Here, we show that mutation of the beta(3) cytoplasmic tail tyrosine 747 to phenylalanine (Y747F) prevents beta(3) tyrosine phosphorylation in two cell lines. Whereas this mutation has no effect on alpha(v) beta(3)-mediated adhesion in a cell with constitutive beta(3) function, it completely abolishes adhesion and clot retraction by a cell that requires stimulation for beta(3) function. Ligand-induced conformational change as detected by LIBS-1 antibody occurs normally in Y747F mutant alpha(v) beta(3). Thus, tyrosine 747 of beta(3) is required for stimulation of alpha(v) beta(3)-mediated adhesion, probably due to its phosphorylation, Because the motif in beta(3) required for tyrosine phosphorylation is shared by several integrin beta-chains, this maybe a conserved mechanism for regulation of integrin-dependent adhesion.			Blystone, SD (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MED, DIV INFECT DIS, CAMPUS BOS 8051, ST LOUIS, MO 63110 USA.							BALLARD LL, 1991, CLIN EXP IMMUNOL, V84, P336; Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; CARLOS TM, 1994, BLOOD, V84, P2068; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CHEN YP, 1994, J BIOL CHEM, V269, P18307; DENICHILO MO, 1993, P NATL ACAD SCI USA, V90, P2517, DOI 10.1073/pnas.90.6.2517; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GEIGER B, 1992, COLD SPRING HARB SYM, V57, P631, DOI 10.1101/SQB.1992.057.01.069; GINSBERG MH, 1990, BLOOD, V76, P2017; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; JIANG YL, 1994, AM J PHYSIOL-CELL PH, V267, pC1112, DOI 10.1152/ajpcell.1994.267.4.C1112; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	26	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28757	28761		10.1074/jbc.272.45.28757	http://dx.doi.org/10.1074/jbc.272.45.28757			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353346	hybrid			2022-12-27	WOS:A1997YF21900086
J	Burgaya, F; Toutant, M; Studler, JM; Costa, A; LeBert, M; Gelman, M; Girault, JA				Burgaya, F; Toutant, M; Studler, JM; Costa, A; LeBert, M; Gelman, M; Girault, JA			Alternatively spliced focal adhesion kinase in rat brain with increased autophosphorylation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; XENOPUS-LAEVIS; PP125(FAK); EXPRESSION; PHOSPHORYLATION; BINDING; LOCALIZATION; HIPPOCAMPUS; PP60(SRC)	pp125 focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase transducing signals initiated by integrin engagement and G protein-coupled receptors, is highly expressed in brain. FAR from brain had a higher molecular weight and an increased autophosphorylation activity, than from other tissues, In addition to a 9-base insertion in the 3'-coding region, which defines FAK(+), rat striatal FAK mRNAs contained several additional short exons, coding for peptides of 28, 6, and 7 residues, respectively (termed boxes 28, 6, and 7), surrounding the autophosphorylated Tyr-397. In transfected COS 7 cells, the presence of boxes 6 and 7 conferred an increased overall tyrosine phosphorylation, a higher phosphorylation of Tyr-397 assessed with a phosphorylation state-specific antibody, and a more active autophosphorylation in immune precipitates. The presence of box 28 did not alter further these parameters, Two-dimensional phosphopeptide maps of hippocampal FAK were identical to those of FAR+6,7. The presence of the various exons did not alter the interaction of FAK with c-Src, n-Src; or Fyn. Thus, several splice isoforms of FAK are preferentially expressed in rat brain, some of which have an increased autophosphorylation activity, suggesting that FAR may have specific properties in neurons.	COLL FRANCE, INSERM U114, CHAIRE NEUROPHARMACOL, F-75231 PARIS 05, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France			Le Bert, Marc/AAR-4577-2021; Girault, Jean-Antoine/F-7518-2013	Le Bert, Marc/0000-0002-5945-3800; Girault, Jean-Antoine/0000-0002-7900-1705				ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; ARREGUI CO, 1994, J NEUROSCI, V14, P6967; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; Boxall AR, 1996, NEURON, V16, P805, DOI 10.1016/S0896-6273(00)80100-2; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; Burgaya F, 1996, MOL BRAIN RES, V37, P63, DOI 10.1016/0169-328X(95)00273-U; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; Derkinderen P, 1996, SCIENCE, V273, P1719, DOI 10.1126/science.273.5282.1719; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; Guan JL, 1996, INT REV CYTOL, V168, P81, DOI 10.1016/S0074-7696(08)60883-9; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HENS MD, 1995, DEV BIOL, V170, P274, DOI 10.1006/dbio.1995.1214; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1997, J CELL SCI, V110, P401; ILLC D, 1995, NATURE, V377, P539; Kojima N, 1997, P NATL ACAD SCI USA, V94, P4761, DOI 10.1073/pnas.94.9.4761; Malik RK, 1996, BBA-REV CANCER, V1287, P73, DOI 10.1016/0304-419X(96)00008-X; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; Schaller MD, 1996, J ENDOCRINOL, V150, P1, DOI 10.1677/joe.0.1500001; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Serpente N, 1996, MOL CELL NEUROSCI, V7, P391, DOI 10.1006/mcne.1996.0028; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Stevens GR, 1996, J NEUROSCI RES, V46, P445, DOI 10.1002/(SICI)1097-4547(19961115)46:4<445::AID-JNR6>3.3.CO;2-D; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; Worley TL, 1996, NEUROREPORT, V7, P1133, DOI 10.1097/00001756-199604260-00006; ZHANG XA, 1995, GENE, V160, P219, DOI 10.1016/0378-1119(95)00153-W	33	42	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28720	28725		10.1074/jbc.272.45.28720	http://dx.doi.org/10.1074/jbc.272.45.28720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353341	hybrid			2022-12-27	WOS:A1997YF21900081
J	Singh, N; Zanusso, G; Chen, SG; Fujioka, H; Richardson, S; Gambetti, P; Petersen, RB				Singh, N; Zanusso, G; Chen, SG; Fujioka, H; Richardson, S; Gambetti, P; Petersen, RB			Prion protein aggregation reverted by low temperature in transfected cells carrying a prion protein gene mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ANCHOR ATTACHMENT; CULTURED-CELLS; LINKED OLIGOSACCHARIDES; BIOCHEMICAL-PROPERTIES; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; TRUNCATED FORMS; QUALITY-CONTROL; ATP HYDROLYSIS; SCRAPIE	Prion diseases are characterized by the conversion of the normal cellular prion protein (PrPC), a glycoprotein that is anchored to the cell membrane by a glycosylphosphatidylinositol moiety, into an isoform that is protease-resistant (PrPres) and pathogenic. In inherited prion diseases, mutations in the prion protein (PrPM) engender the conversion of PrPM into PrPres. We developed a cell model of Gerstmann-Straussler-Scheinker disease, a neurodegenerative condition characterized by PrPM-containing amyloid deposits and neuronal loss, by expressing the Gerstmann-Straussler-Scheinker haplotype Q217R-129V in human neuroblastoma cells, By comparison to PrPC, this genotype results in the following alterations of PrPM: 1) expression of an aberrant form lacking the glycosylphosphatidylinositol anchor, 2) increased aggregation and protease resistance, and 3) impaired transport to the cell surface, Most of these alterations are temperature sensitive, indicating that they are due to misfolding of PrPM.	CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106	Case Western Reserve University			Zanusso, Gianluigi/K-2823-2018; Petersen, Robert/B-5075-2011; Chen, Shu G./AAK-7301-2021; Chen, Shu/Z-2943-2019; Chen, Shu G./O-4750-2014	Zanusso, Gianluigi/0000-0001-5199-6264; Petersen, Robert/0000-0002-3154-0072; Chen, Shu G./0000-0001-7180-3001; Chen, Shu G./0000-0001-7180-3001				BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; DEARMOND SJ, 1995, AM J PATHOL, V146, P785; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Fra A, 1993, Subcell Biochem, V21, P143; GOLDFARB LG, 1989, AM J HUM GENET S, V45, P189; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MORAN P, 1991, J BIOL CHEM, V266, P1250; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; Oda K, 1996, BIOCHEM J, V316, P623, DOI 10.1042/bj3160623; PARCHI P, 1996, SEMIN VIROL, V7, P1; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; PRUSINER SB, 1994, P NATL ACAD SCI USA, V91, P4611, DOI 10.1073/pnas.91.11.4611; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; Singh N, 1996, J BIOL CHEM, V271, P12879, DOI 10.1074/jbc.271.22.12879; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P7299, DOI 10.1021/bi9517704	46	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28461	28470		10.1074/jbc.272.45.28461	http://dx.doi.org/10.1074/jbc.272.45.28461			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353306	hybrid			2022-12-27	WOS:A1997YF21900046
J	Thinakaran, G; Harris, CL; Ratovitski, T; Davenport, F; Slunt, HH; Price, DL; Borchelt, DR; Sisodia, SS				Thinakaran, G; Harris, CL; Ratovitski, T; Davenport, F; Slunt, HH; Price, DL; Borchelt, DR; Sisodia, SS			Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; IN-VIVO; MUTATIONS; PROTEINS; SYSTEM; GENE; APP; ACCUMULATION; EXPRESSION	Mutations in two related genes, PS1 and PS2, account for the majority of early onset cases of familial Alzheimer's disease, PS1 and PS2 are homologous polytopic membrane proteins that are processed endoproteolytically into two fragments in vivo. In the present report we examine the fate of endogenous PS1 and PS2 after overexpression of human PS1 or PS2 in mouse N2a neuroblastoma cell lines and human PS1 in transgenic mice. Remarkably, in N2a cell lines and in brains of transgenic mice expressing human PS1, accumulation of human PSI derivatives is accompanied by a compensatory, and highly selective, decrease in the steady-state levels of murine PSI and PS2 derivatives. Similarly, the levels of murine PS1 derivatives are diminished in cultured cells overexpressing human PS2, To define the minimal sequence requirements for ''replacement'' we expressed familial Alzheimer's disease-linked and experimental deletion variants of PSI, These studies revealed that compromised accumulation of murine PS1 and PS2 derivatives resulting from overexpression of human PS1 occurs in a manner independent of endoproteolytic cleavage, Our results are consistent with a model in which the abundance of PS1 and PS2 fragments is regulated coordinately by competition for limiting cellular factor(s).	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Thinakaran, G (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV NEUROPATHOL,558 ROSS BLDG,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.				NIA NIH HHS [1PO1 AG14248] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG014248] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baumeister R, 1997, Genes Funct, V1, P149; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Busfield Frances, 1995, P59, DOI 10.1016/B978-012286965-5/50006-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lee MK, 1997, NAT MED, V3, P756, DOI 10.1038/nm0797-756; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; PRICE BD, 1992, J CELL PHYSIOL, V152, P545, DOI 10.1002/jcp.1041520314; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SCHELLENBERG GD, 1995, P NATL ACAD SCI USA, V92, P8552, DOI 10.1073/pnas.92.19.8552; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Sherrington R, 1996, HUM MOL GENET, V5, P985, DOI 10.1093/hmg/5.7.985; SISODIA S S, 1990, New Biologist, V2, P66; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; THINAKARAN G, 1995, J NEUROSCI, V15, P6314; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wisniewski HM, 1973, PROGR NEUROPATHOLOGY, V2, P1	38	286	291	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28415	28422		10.1074/jbc.272.45.28415	http://dx.doi.org/10.1074/jbc.272.45.28415			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353300	hybrid			2022-12-27	WOS:A1997YF21900040
J	Bourguignon, LYW; Zhu, HB; Chu, A; Iida, N; Zhang, L; Hung, MC				Bourguignon, LYW; Zhu, HB; Chu, A; Iida, N; Zhang, L; Hung, MC			Interaction between the adhesion receptor, CD44, and the oncogene product, p185(HER2), promotes human ovarian tumor cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA TRANSMEMBRANE GLYCOPROTEIN; MEMBRANE-CYTOSKELETON INTERACTION; SIGNAL-TRANSDUCTION; HYALURONAN-BINDING; CANCER CELLS; EXPRESSION; PROTEIN; DOMAIN; GP85; METASTASIS	In this study we have examined the interaction between CD44s (the standard form) and the p185(HER2) proto-oncogene in the ovarian carcinoma cell line. Surface biotinylation followed by wheat germ agglutinin column chromatography and anti-CD44-mediated immunoprecipitation indicate that both CD44s and p185(HER2) are expressed on the cell surface and most importantly, that these two molecules are physically linked to each other via interchain disulfide bonds, We have also determined that hyaluronic acid stimulates CD44s-associated p185(HER2) tyrosine kinase activity, leading to an increase in the ovarian carcinoma cell growth, After transfection of the ovarian carcinoma cell line with the adenovirus 5 EIA gene, which is known to repress p185(HER2) expression, we observed that both surface CD44s expression and CD44s-mediated cell adhesion to hyaluronic acid are significantly reduced in the transfectant cells compared with the control cells. These data suggest that down-regulation of p185(HER2) blocks CD44s expression and subsequent adhesion function, Our findings also indicate that the CD44s-p185(HER2) interaction is both functionally coupled and biosynthetically regulated, We believe that direct ''cross-talk'' between these two surface molecules (i.e, CD44s and the p185(HER2)) may be one of the most important signaling events in human ovarian carcinoma development.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	Bourguignon, LYW (corresponding author), UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,1600 NW 10TH AVE,MIAMI,FL 33101, USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA066163, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [CA58880, CA66163] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; BANERJEE SD, 1992, J CELL BIOL, V119, P643, DOI 10.1083/jcb.119.3.643; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; Bourguignon LYW, 1996, CURR TOP MEMBR, V43, P293; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; Bourguignon LYW, 1995, J NEURO-ONCOL, V26, P201, DOI 10.1007/BF01052623; CANNISTRA SA, 1995, CLIN CANCER RES, V1, P333; CANNISTRA SA, 1993, CANCER RES, V53, P3830; CARTER WG, 1988, J BIOL CHEM, V263, P4193; GUNTHERT U, 1991, CANCER RES, V51, P5292; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KNUDSON W, 1989, CIBA FDN S, V143, P150; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIAO HX, 1995, J IMMUNOL, V155, P3938; Liu D, 1996, J EXP MED, V183, P1987, DOI 10.1084/jem.183.5.1987; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P22073; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; PAULI BU, 1988, HUM PATHOL, V19, P628, DOI 10.1016/S0046-8177(88)80168-0; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PIVER MS, 1991, SEMIN ONCOL, V18, P177; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; UNDERHILL C, 1992, J CELL SCI, V103, P293; West D. C., 1989, CIBA F SYMP, V143, P201; Xia WY, 1997, CLIN CANCER RES, V3, P3; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1993, CANCER RES, V53, P891; Zhu D, 1996, ONCOGENE, V12, P2309	38	193	200	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27913	27918		10.1074/jbc.272.44.27913	http://dx.doi.org/10.1074/jbc.272.44.27913			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346940	hybrid			2022-12-27	WOS:A1997YD47300066
J	Dai, Y; Wang, CC				Dai, Y; Wang, CC			A mutant truncated protein disulfide isomerase with no chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROLYL 4-HYDROXYLASE; SITE-DIRECTED MUTAGENESIS; ENDOPLASMIC-RETICULUM; BETA-SUBUNIT; PEPTIDE BINDING; THIOREDOXIN; POLYPEPTIDE; AGGREGATION; RESIDENT; LYSOZYME	A mutant human protein disulfide isomerase with the COOH-terminal 51 amino acid residues deleted (abb'a') has been expressed in Escherichia coli. Its secondary structures are very similar to those of the native bovine enzyme. The mutant enzyme shows neither peptide binding ability nor chaperone activity in assisting the refolding of denatured D-glyceraldehyde-3-phosphate dehydrogenase but keeps most of the catalytic activities for reduction of insulin and isomerization of scrambled ribonuclease. It assists the reactivation of denatured and reduced proteins containing disulfide bonds, acid phospholipase A(2), and lysozyme to different levels, which are significantly lower than those by the native bovine enzyme.	ACAD SINICA,INST BIOPHYS,NATL LAB BIOMACROMOL,BEIJING 100101,PEOPLES R CHINA	Chinese Academy of Sciences; Institute of Biophysics, CAS								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CAI H, 1994, J BIOL CHEM, V269, P24550; Darby NJ, 1996, BIOCHEMISTRY-US, V35, P10517, DOI 10.1021/bi960763s; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gao Y, 1997, J BIOTECHNOL, V54, P105, DOI 10.1016/S0168-1656(97)01695-7; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; Hayano T, 1995, FEBS LETT, V377, P505, DOI 10.1016/0014-5793(95)01410-1; HUA QX, 1984, BIOCHIM BIOPHYS ACTA, V189, P234; KEMMINK J, 1995, PROTEIN SCI, V4, P2587, DOI 10.1002/pro.5560041216; KOIVU J, 1987, J BIOL CHEM, V262, P6447; Koivunen P, 1996, BIOCHEM J, V316, P599, DOI 10.1042/bj3160599; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; Lamberg A, 1996, BIOCHEM J, V315, P533, DOI 10.1042/bj3150533; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LIANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P240, DOI 10.1016/0167-4838(90)90211-W; LILIE H, 1994, J BIOL CHEM, V269, P14290; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; NOIVA R, 1994, PROTEIN EXPRES PURIF, V5, P1, DOI 10.1006/prep.1994.1001; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PUIG A, 1994, J BIOL CHEM, V269, P7764; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; VUORI K, 1992, J BIOL CHEM, V267, P7211; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; WANG CC, 1997, PROLYL HYDROXYLASE P; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801; Wu X.-f., 1984, Acta Biochimica et Biophysica Sinica, V16, P664; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651; Zheng WD, 1997, ARCH BIOCHEM BIOPHYS, V337, P326, DOI 10.1006/abbi.1996.9783	39	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27572	27576		10.1074/jbc.272.44.27572	http://dx.doi.org/10.1074/jbc.272.44.27572			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346892	hybrid			2022-12-27	WOS:A1997YD47300018
J	Hofmeister, R; Wiegmann, K; Korherr, C; Bernardo, K; Kronke, M; Falk, W				Hofmeister, R; Wiegmann, K; Korherr, C; Bernardo, K; Kronke, M; Falk, W			Activation of acid sphingomyelinase by interleukin-1 (IL-1) requires the IL-1 receptor accessory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; CELL-FREE SYSTEM; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; NEUTRAL SPHINGOMYELINASE; GROWTH SUPPRESSION; GENE-EXPRESSION; CYTO-TOXICITY; T-CELLS	The cytokine interleukin-1 (IL-1) plays an important role in inflammation and regulation of immune responses, but the mechanisms of its signal transduction and cell activation processes are incompletely understood. Ceramide generated by sphingomyelinases (SMases) is known to function as an important second messenger molecule in the signaling pathway of IL-1 and tumor necrosis factor. To investigate the activation of SMases by IL-1, we used an IL-1 receptor type I (IL-1RI)-positive EL4 thymoma cell line, which is defective in IL-1R accessory protein (IL-1RAcP) expression. In this cell line (EL4D6/76), tumor necrosis factor induced ligand/receptor internalization, NF kappa B nuclear translocation, IL-2 production, and the activation of neutral (N)-SMase and acid (A)-SMase. In contrast, stimulation with IL-1 resulted only in the activation of N-SMase whereas ligand/receptor internalization, NF kappa B translocation, IL-2 production, and activation of A-SMase were not detected. Transfection of this functionally defective EL4D6/76 with IL-1RAcP cDNA restored these functions. These data suggest that A-SMase activity is strongly linked with the internalization of IL-1RI mediated by IL-1RAcP and that A-SMase and N-SMase are activated by different pathways.	UNIV REGENSBURG,DEPT INTERNAL MED 1,D-93042 REGENSBURG,GERMANY; CHRISTIAN ALBRECHTS UNIV KIEL,INST IMMUNOL,D-24105 KIEL,GERMANY	University of Regensburg; University of Kiel								Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; ANDRIEU N, 1995, J BIOL CHEM, V270, P24518, DOI 10.1074/jbc.270.41.24518; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BRADLEY JR, 1993, J IMMUNOL, V150, P5544; BROOKS JW, 1994, EUR CYTOKINE NETW, V5, P547; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; FALK W, 1994, LYMPHOKINE CYTOK RES, V13, P167; FALK W, 1989, LYMPHOKINE RES, V8, P263; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; Hofmeister R, 1996, J INFLAMM, V47, P151; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; KULL FC, 1981, CANCER RES, V41, P4885; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LIU J, 1994, J BIOL CHEM, V269, P3047; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SIMS JE, 1994, EUR CYTOKINE NETW, V5, P539; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SUFFYS P, 1987, BIOCHEM BIOPH RES CO, V149, P735, DOI 10.1016/0006-291X(87)90429-3; VONHOEGEN I, 1989, EUR J IMMUNOL, V19, P329; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	52	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27730	27736		10.1074/jbc.272.44.27730	http://dx.doi.org/10.1074/jbc.272.44.27730			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346915	hybrid			2022-12-27	WOS:A1997YD47300041
J	Shworak, NW; Liu, J; Fritze, LMS; Schwartz, JJ; Zhang, LJ; Logeart, D; Rosenberg, RD				Shworak, NW; Liu, J; Fritze, LMS; Schwartz, JJ; Zhang, LJ; Logeart, D; Rosenberg, RD			Molecular cloning and expression of mouse and human cDNAs encoding heparan sulfate D-glucosaminyl 3-O-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEACETYLASE N-SULFOTRANSFERASE; ANTITHROMBIN-BINDING SEQUENCE; AORTIC ENDOTHELIAL-CELLS; HAMSTER OVARY CELLS; HEPARINLIKE MOLECULES; ENDOPLASMIC-RETICULUM; ANTI-THROMBIN; HIGH-AFFINITY; PURIFICATION; BIOSYNTHESIS	The cellular rate of anticoagulant heparan sulfate proteoglycan (HSPG(act)) generation is determined by the level of a kinetically limiting microsomal activity, HSact conversion activity, which is predominantly composed of the long sought heparan sulfate D-glucosaminyl 3-O-sulfotransferase (3-OST) (Shworak, N. W., Fritze, L. M. S., Liu, J., Butler, L. D., and Rosenberg, R. D. (1996) J. Biol. Chem. 271, 27063-27071; Liu, J., Shworak, N. W., Fritze, L. M. S., Edelberg, J. M., and Rosenberg, R. D. (1996) J. Biol. Chem. 271, 27072-27082). Mouse 3-OST cDNAs were isolated by proteolyzing the purified enzyme with Lys-C, sequencing the resultant peptides as well as the existing amino terminus, employing degenerate polymerase chain reaction primers corresponding to the sequences of the peptides as well as the amino terminus to amplify a fragment from LTA cDNA, and utilizing the resultant probe to obtain full-length enzyme cDNAs from a lambda Zap Express LTA cDNA library. Human 3-OST cDNAs were isolated by searching the expressed sequence tag data bank with the mouse sequence, identifying a partial-length human cDNA and utilizing the clone as a probe to isolate a full-length enzyme cDNA from a lambda TriplEx human brain cDNA library. The expression of wild-type mouse 3-OST as well as protein A-tagged mouse enzyme by transient transfection of COS-7 cells and the expression of both wildtype mouse and human 3-OST by in vitro transcription/ translation demonstrate that the two cDNAs directly encode both HSact conversion and 3-OST activities, The mouse 3-OST cDNAs exhibit three different size classes because of a 5'-untranslated region of variable length, which results from the insertion of 0-1629 base pairs (bp) between residues 216 and 217; however, all cDNAs contain the same open reading frame of 933 bp. The length of the 3'-untranslated region ranges from 301 to 430 bp. The nucleic acid sequence of mouse and human 3-OST cDNAs are similar to 85% similar, encoding novel 311- and 307-amino acid proteins of 35,876 and 35,750 daltons, respectively, that are 93% similar. The encoded enzymes are predicted to be intraluminal Golgi residents, pre-sumably interacting via their C-terminal regions with an integral membrane protein. Both 3-OST species exhibit five potential N-glycosylation sites, which account for the apparent discrepancy between the molecular masses of the encoded enzyme (similar to 34 kDa) and the previously purified enzyme (similar to 46 kDa). The two 3-OST species also exhibit similar to 50% similarity with all previously identified forms of the heparan biosynthetic enzyme N-deacetylase/N-sulfotransferase, which suggests that heparan biosynthetic enzymes share a common sulfotransferase domain.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Shworak, Nicholas/AAJ-6770-2020; Logeart-Avramoglou, Delphine/N-7390-2017	Shworak, Nicholas/0000-0001-7783-4634; Logeart-Avramoglou, Delphine/0000-0002-2052-9425	NHLBI NIH HHS [HL-41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES DA, 1991, J BIOL CHEM, V266, P14277; ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Favaloro J, 1980, Methods Enzymol, V65, P718; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1991, BIOCHIM BIOPHYS ACTA, V1133, P9; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HONG WJ, 1993, BIOESSAYS, V15, P231, DOI 10.1002/bies.950150403; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIND T, 1993, J BIOL CHEM, V268, P20705; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MARCUM JA, 1985, BIOCHEM BIOPH RES CO, V126, P365, DOI 10.1016/0006-291X(85)90615-1; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1986, AM J PHYSIOL, V250, pN879; MONTGOMERY RI, 1992, P NATL ACAD SCI USA, V89, P11327, DOI 10.1073/pnas.89.23.11327; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; ROSENBERG RD, 1978, ANNU REV MED, V29, P367, DOI 10.1146/annurev.me.29.020178.002055; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; STONE KL, 1990, METHOD ENZYMOL, V193, P389, DOI 10.1016/0076-6879(90)93429-O; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; WEIS K, 1994, J BIOL CHEM, V269, P19142; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOUNG JDE, 1987, P NATL ACAD SCI USA, V84, P9175, DOI 10.1073/pnas.84.24.9175; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313	68	139	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28008	28019		10.1074/jbc.272.44.28008	http://dx.doi.org/10.1074/jbc.272.44.28008			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346953	hybrid			2022-12-27	WOS:A1997YD47300079
J	Sies, H; Sharov, VS; Klotz, LO; Briviba, K				Sies, H; Sharov, VS; Klotz, LO; Briviba, K			Glutathione peroxidase protects against peroxynitrite-mediated oxidations - A new function for selenoproteins as peroxynitrite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE NITRATION; NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; CARBON-DIOXIDE; EBSELEN; INACTIVATION; 2-(METHYLSELENO)BENZANILIDE; SELENOMETHIONINE; HYDROPEROXIDES; MECHANISM	There is a requirement for cellular defense against excessive peroxynitrite generation to protect against DNA strand breaks and mutations and against interference with protein tyrosine-based signaling and other protein functions due to formation of 3-nitrotyrosine. Here, we demonstrate a role of selenium-containing enzymes catalyzing peroxynitrite reduction using glutathione peroxidase (GPx) as an example, GPx protected against the oxidation of dihydrorhodamine 123 by peroxynitrite more effectively than ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one), a selenoorganic compound exhibiting a high second-order rate constant for the reaction with peroxynitrite, 2 x 10(6) m(-1) s(-1). Carboxymethylation of selenocysteine in GPx by iodoacetate led to the loss of ''classical'' glutathione peroxidase activity but maintained protection against peroxynitrite-mediated oxidation. The maintenance of protection by GPx against peroxynitrite requires GSH as reductant. When peroxynitrite was infused to maintain a 0.2 mu M steady-state concentration, GPx in the presence of GSH, but neither GPx nor GSH alone, effectively inhibited the hydroxylation of benzoate by peroxynitrite, Under these steady-state conditions peroxynitrite did not cause the loss of classical GPx activity. GPx, like selenomethionine, protected against protein 3-nitrotyrosine formation in human fibroblast lysates, shown in Western blots, The formation of nitrite rather than nitrate from peroxynitrite was enhanced by GPx or by selenomethionine. The results demonstrate a novel function of GPx and potentially of other selenoproteins containing selenocysteine or selenomethionine, in the GSH-dependent maintenance of a defense line against peroxynitrite-mediated oxidations, as a peroxynitrite reductase.			Sies, H (corresponding author), UNIV DUSSELDORF,INST PHYSIOL CHEM 1,POSTFACH 101007,D-40001 DUSSELDORF,GERMANY.		Sies, Helmut/ABE-7355-2020; Klotz, Lars Oliver/AAC-5051-2019; Sies, Helmut/B-7266-2008	Klotz, Lars Oliver/0000-0002-1261-8911; Sies, Helmut/0000-0002-1000-3198; Briviba, Karlis/0000-0003-3338-7515				ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; Back TG, 1997, J AM CHEM SOC, V119, P2079, DOI 10.1021/ja963602k; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1996, NITRIC OXIDE PRINCIP, P1, DOI DOI 10.1016/B978-012435555-2/50002-4; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; Briviba K, 1996, BIOCHEM J, V319, P13, DOI 10.1042/bj3190013; BURK RF, 1995, HEPATOLOGY, V21, P561; CHRISTISON J, 1994, BIOCHEM J, V304, P341, DOI 10.1042/bj3040341; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; FISCHER H, 1987, B SOC CHIM BELG, V96, P757; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; Fukuyama N, 1997, FREE RADICAL BIO MED, V22, P771, DOI 10.1016/S0891-5849(96)00401-7; GLASS RS, 1989, J ORG CHEM, V54, P1092, DOI 10.1021/jo00266a018; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; Masumoto H, 1996, CHEM RES TOXICOL, V9, P1057, DOI 10.1021/tx9600560; Masumoto H, 1996, CHEM RES TOXICOL, V9, P262, DOI 10.1021/tx950115u; MASUMOTO H, 1996, FEBS LETT, V98, P179; MULLER A, 1984, BIOCHEM PHARMACOL, V33, P3235, DOI 10.1016/0006-2952(84)90083-2; NIKAWA T, 1994, BIOCHEM PHARMACOL, V47, P1007, DOI 10.1016/0006-2952(94)90411-1; Padmaja S, 1996, FREE RADICAL BIO MED, V21, P317, DOI 10.1016/0891-5849(96)00132-3; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1991, J BIOL CHEM, V266, P4244; Roussyn I, 1996, ARCH BIOCHEM BIOPHYS, V330, P216, DOI 10.1006/abbi.1996.0245; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; Sies H, 1997, Adv Pharmacol, V38, P229; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Szabo C, 1997, J BIOL CHEM, V272, P9030; VERDON CP, 1995, ANAL BIOCHEM, V224, P502, DOI 10.1006/abio.1995.1079; Whiteman M, 1996, FREE RADICAL RES, V25, P275, DOI 10.3109/10715769609149052; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X; ZIEGLER DM, 1992, CHEM RES TOXICOL, V5, P163, DOI 10.1021/tx00026a004	40	390	402	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27812	27817		10.1074/jbc.272.44.27812	http://dx.doi.org/10.1074/jbc.272.44.27812			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346926	hybrid			2022-12-27	WOS:A1997YD47300052
J	Chuang, LF; Killam, KF; Chuang, RY				Chuang, LF; Killam, KF; Chuang, RY			Induction and activation of mitogen-activated protein kinases of human lymphocytes as one of the signaling pathways of the immunomodulatory effects of morphine sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PERIPHERAL-BLOOD; RECEPTOR GENE-EXPRESSION; T-CELL; PHOSPHORYLATION; IDENTIFICATION; INSULIN; HIV-1; MEK; PURIFICATION; COMPLEX	Morphine sulfate causes immunomodulatory and immunosuppressive effects in human, In this study, the signaling pathway involved in these morphine effects was studied, Addition of morphine sulfate to human CEMx174 lymphocytic cells resulted in increased ex pression of mitogen-activated protein kinase cascade proteins, Morphine enhanced the cellular levels of ERK1 (44 kDa), ERK2 (42 kDa), a 54-kDa ERK, MEK1 (45 kDa), and MEKK (78 kDa), A time-dependent increase in the activated (Thr and Tyr dually phosphorylated) state of ERK1 and ERK2 was also observed, Naloxone, a morphine antagonist, reversed the observed morphine effects, implicating a mu opioid receptor-mediated process. These findings suggest that mitogen activated protein kinases are important intermediates in signal transduction pathways initiated by morphine receptors in immune cells.	UNIV CALIF DAVIS,SCH MED,DEPT MED PHARMACOL & TOXICOL,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010433, R01DA005901] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 10433, DA 05901] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROWN SM, 1974, ARCH INTERN MED, V134, P1001, DOI 10.1001/archinte.134.6.1001; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Chuang L F, 1993, In Vivo, V7, P159; CHUANG LF, 1993, BIOCHEM BIOPH RES CO, V195, P1165, DOI 10.1006/bbrc.1993.2167; Chuang LF, 1997, ADDICT BIOL, V2, P421, DOI 10.1080/13556219772471; CHUANG LF, 1995, BIOCHEM BIOPH RES CO, V209, P1003, DOI 10.1006/bbrc.1995.1597; CHUANG LF, 1994, BIOCHEM BIOPH RES CO, V202, P1291, DOI 10.1006/bbrc.1994.2071; CHUANG TK, 1995, BIOCHEM BIOPH RES CO, V216, P922, DOI 10.1006/bbrc.1995.2709; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DONAHOE RM, 1988, ADV BIOCHEM PSYCHOPH, V44, P145; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; GOWDA SD, 1989, J IMMUNOL, V142, P773; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PETERSON PK, 1990, AIDS, V4, P869, DOI 10.1097/00002030-199009000-00006; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; VOELKERDING KV, 1995, ONCOGENE, V10, P515	24	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26815	26817		10.1074/jbc.272.43.26815	http://dx.doi.org/10.1074/jbc.272.43.26815			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341110	hybrid			2022-12-27	WOS:A1997YC65900006
J	Deloulme, JC; Prichard, L; Delattre, O; Storm, DR				Deloulme, JC; Prichard, L; Delattre, O; Storm, DR			The prooncoprotein EWS binds calmodulin and is phosphorylated by protein kinase C through an IQ domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING FACTOR PSF; NUCLEAR MATRIX; CELL-NUCLEUS; PREMESSENGER RNA; SENSITIVE METHOD; HNRNP PROTEINS; CDNA CLONING; EWING FAMILY; NEUROMODULIN; IDENTIFICATION	A growing family of proteins is regulated by protein kinase C and calmodulin through IQ domains, a regulatory motif originally identified in neuromodulin (Alexander, K. A., Wakim, B. T., Doyle, G. S., Walsh, K. A., and Storm, D. R. (1988) J. Biol. Chem, 263, 7544-7549). Here we report that EWS, a nuclear RNA-binding proonco-protein, contains an IQ domain, is phosphorylated by protein kinase C, and interacts with calmodulin, Interestingly, PKC phosphorylation of EWS inhibits its binding to RNA homopolymers, and conversely, RNA binding to EWS interferes with PKC phosphorylation, Several other RNA-binding proteins, including TLS/FUS and PSF, co-purify with EWS, PKC phosphorylation of these proteins also inhibits their binding to RNA in vitro. These data suggest that PKC may regulate interactions of EWS and other RNA-binding proteins with their RNA targets and that IQ domains may provide a regulatory link between Ca2+ signal transduction pathways and RNA processing.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; INST CURIE, INSERM, U434, F-75231 PARIS 05, FRANCE	University of Washington; University of Washington Seattle; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Deloulme, Jean Christophe/P-6858-2017	Deloulme, Jean Christophe/0000-0002-2234-5865; delattre, olivier/0000-0002-8730-2276	NINDS NIH HHS [NS 20498] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020498] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BACHS O, 1987, J BIOL CHEM, V262, P10786; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; BOSSER R, 1995, MOL CELL BIOL, V15, P661; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brill S, 1996, MOL CELL BIOL, V16, P4869; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; BUELT MK, 1994, J BIOL CHEM, V269, P29367; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CALVIO C, 1995, RNA, V1, P724; Chao S, 1996, MOL BRAIN RES, V40, P195, DOI 10.1016/0169-328X(96)00049-6; CHAPMAN ER, 1991, PROG BRAIN RES, V89, P37; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIVECHA N, 1994, CELL CALCIUM, V16, P297, DOI 10.1016/0143-4160(94)90093-0; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Gamby C, 1996, J BIOL CHEM, V271, P26698, DOI 10.1074/jbc.271.43.26698; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; GERENDASY DD, 1994, J MOL NEUROSCI, V5, P133, DOI 10.1007/BF02736729; GETZENBERG RH, 1994, J CELL BIOCHEM, V55, P22, DOI 10.1002/jcb.240550105; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IDRISS H, 1994, BIOCHEMISTRY-US, V33, P11382, DOI 10.1021/bi00203a037; Irvine R F, 1992, Semin Cell Biol, V3, P225, DOI 10.1016/1043-4682(92)90024-P; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIN C, 1994, CELL CALCIUM, V16, P247, DOI 10.1016/0143-4160(94)90088-4; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; Mattern KA, 1996, J CELL BIOCHEM, V62, P275, DOI 10.1002/(SICI)1097-4644(199608)62:2<275::AID-JCB15>3.0.CO;2-K; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MAY WA, 1993, MOL CELL BIOL, V13, P7397; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; NEEL VA, 1994, DEVELOPMENT, V120, P2235; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; Petrova TV, 1996, J BIOL CHEM, V271, P26646, DOI 10.1074/jbc.271.43.26646; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Schalinske KL, 1996, J BIOL CHEM, V271, P7168, DOI 10.1074/jbc.271.12.7168; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SERRATOSA J, 1988, BIOCHEM BIOPH RES CO, V150, P1162, DOI 10.1016/0006-291X(88)90751-6; SHEU FS, 1994, MOL BRAIN RES, V21, P62, DOI 10.1016/0169-328X(94)90378-6; SHEU FS, 1995, ARCH BIOCHEM BIOPHYS, V316, P335, DOI 10.1006/abbi.1995.1045; Slemmon JR, 1996, J BIOL CHEM, V271, P15911, DOI 10.1074/jbc.271.27.15911; TAKAGI T, 1990, J BIOL CHEM, V265, P19721; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRICHE TJ, 1997, ENCY CANC, V1, P652; vanDriel R, 1995, INT REV CYTOL, V162A, P151; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; ZINI N, 1995, HISTOCHEM CELL BIOL, V103, P447, DOI 10.1007/BF01457544; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	74	63	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27369	27377		10.1074/jbc.272.43.27369	http://dx.doi.org/10.1074/jbc.272.43.27369			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341188	hybrid			2022-12-27	WOS:A1997YC65900084
J	Dharmavaram, RM; Liu, G; Mowers, SD; Jimenez, SA				Dharmavaram, RM; Liu, G; Mowers, SD; Jimenez, SA			Detection and characterization of Sp1 binding activity in human chondrocytes and its alterations during chondrocyte dedifferentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; COLLAGEN GENE; ARTICULAR CHONDROCYTES; PROCOLLAGEN GENE; ALGINATE BEADS; NUCLEAR FACTOR; CELL-SHAPE; 1ST INTRON; PROMOTER; CARTILAGE	We have detected DNA binding activity for a synthetic oligonucleotide containing an Sp1 consensus sequence in nuclear extracts from human chondrocytes. Changes in the levels of Sp1 oligonucleotide binding activity were examined in nuclear extracts from freshly isolated human chondrocytes, from chondrocytes that had beets cultured under conditions that allowed the maintenance of a chondrocyte-specific phenotype on plastic dishes coated with the hydrogel poly(2-hydroxyethyl methacrylate), and from chondrocytes induced to dedifferentiate into fibroblast-like cells by passage in monolayer culture on plastic substrate, It was observed that Spl binding was 2-3-fold greater in nuclear extracts from dedifferentiated chondrocytes than in nuclear extracts from either freshly isolated chondrocytes or from cells cultured in suspension. The Sp1 binding activity was specific, since it was competed by unlabeled Sp1 but not by AP1 or AP2, The addition of a polyclonal antibody against Sp1 to nuclear extracts from freshly isolated chondrocytes or to extracts isolate from chondrocytes cultured in monolayer decreased the binding of Sp1 by similar to 85%, However, when the same experiment was carried out with nuclear extracts prepared from cells cultured on poly(2-hydroxyethyl methacrylate)-coated plates, only a very slight inhibition of Sp1 binding was observed, When fragments of the COL2A1 promoter containing putative Spl binding sites amplified by polymerase chain reaction were examined, it was found that the amounts of DNA-protein complex formed with nuclear extracts from dedifferentiated chondrocytes were 2-3-fold greater than the amounts formed with nuclear extracts from freshly isolated chondrocytes or from cells cultured in suspension, Quantitation of DNA binding activity by titration experiments demonstrated that nuclear extracts from fibroblast-like cells contained approximately 2-fold greater Sp-1 specific binding activity than nuclear extracts from chondrocytes. The direct role of Sp1 in type II collagen gene transcription was demonstrated by co-transfection experiments of COL2A1 promoter-CAT constructs in Drosophila Schneider line L2 cells that lack Sp1 homologs. This is the first demonstration of Sp1 binding activity in human chondrocytes and of differences in Sp1 DNA binding activity between differentiated and dedifferentiated chondrocytes.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT MED, DIV RHEUMATOL, PHILADELPHIA, PA 19107 USA	Jefferson University				Jimenez, Sergio/0000-0001-5213-1203	NIAMS NIH HHS [AR39740, AR07583] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740, T32AR007583] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARCHER CW, 1990, J CELL SCI, V97, P361; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BENYA PD, 1979, ARCH BIOCHEM BIOPHYS, V192, P327, DOI 10.1016/0003-9861(79)90100-0; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EYRE DR, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P119; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HAUSELMANN HJ, 1994, J CELL SCI, V107, P17; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JIANPING Y, 1996, MOL CELL BIOL, V16, P157; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; Jimenez SA, 1997, MATRIX BIOL, V16, P29, DOI 10.1016/S0945-053X(97)90114-1; KUETTNER KE, 1982, J CELL BIOL, V93, P751, DOI 10.1083/jcb.93.3.751; LIYE L, 1995, GENE, V164, P229; MAATTA A, 1993, BIOCHEM J, V294, P365, DOI 10.1042/bj2940365; MALLEINGERIN F, 1990, DIFFERENTIATION, V43, P204, DOI 10.1111/j.1432-0436.1990.tb00447.x; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; REFOJO MF, 1965, J APPL POLYM SCI, V9, P2425, DOI 10.1002/app.1965.070090707; REGINATO AM, 1994, ARTHRITIS RHEUM, V37, P1338, DOI 10.1002/art.1780370912; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SIERON AL, 1993, J BIOL CHEM, V268, P21232; VIKKULA M, 1992, BIOCHEM J, V285, P287, DOI 10.1042/bj2850287; VONDERMARK K, 1977, NATURE, V267, P531, DOI 10.1038/267531a0; VONDERMARK K, 1986, CONNECTIVE TISSUE BI, P272; WANG LQ, 1991, J BIOL CHEM, V266, P19878; WICHTERLE O, 1960, NATURE, V185, P117, DOI 10.1038/185117a0	36	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26918	26925		10.1074/jbc.272.43.26918	http://dx.doi.org/10.1074/jbc.272.43.26918			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341126	hybrid, Green Published			2022-12-27	WOS:A1997YC65900022
J	Karlsson, NG; Herrmann, A; Karlsson, H; Johansson, MEV; Carlstedt, I; Hansson, GC				Karlsson, NG; Herrmann, A; Karlsson, H; Johansson, MEV; Carlstedt, I; Hansson, GC			The glycosylation of rat intestinal Muc2 mucin varies between rat strains and the small and large intestine - A study of O-linked oligosaccharides by a mass spectrometric approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SMALL-INTESTINE; MOLECULAR-CLONING; INSOLUBLE MUCIN; EPITHELIAL-CELLS; TERMINAL REGION; GLYCOSPHINGOLIPIDS; CHROMATOGRAPHY; IDENTIFICATION; GLYCOPROTEINS; APOPROTEIN	The large glycosylated domains obtained from the rat intestinal mucin Muc2 were isolated from the large and small intestine of the inbred rat strains GOT-W and GOT-BW. The expression of the rat Muc2 in the large intestine was confirmed immunochemically and by Northern blotting. Released oligosaccharides were structurally characterized by gas chromatography-mass spectrometry (neutral and sialylated species) or by tandem mass spectrometry (sulfated species), and a total of 63 structures was assigned. The large intestinal oligosaccharides were found to be identical between the strains, while the small intestinal glycosylation differed. Until now, detailed structural analysis of oligosaccharides isolated from a single mucin core or mucin domain with different origin have not been performed, and the information of different mucin glycoforms has been limited to immunochemistry. Blood group A-determinants (Gal-NAc alpha 1-3(Fuc alpha 1-2)Gal beta 1-, and structures related to the blood group Sd(a)/Cad-related epitope NeuAc/NeuGc alpha 1-3(GalNAc beta 1-4)Gal beta 1-were found in GOT-BW small intestine, and also in both large intestines. Blood group H-determinants and NeuAc/NeuGc alpha 1-3Gal beta 1- were found in all samples. Core 1 (Gal beta 1-3GalNAc alpha 1-), core 2 (Gal beta 1-3(GlcNAc beta 1-6)GalNAc alpha 1-), core 3 (GlcNAc beta 1-3GalNAc alpha 1-), and core 4 (GlcNAc beta 1-3(GlcNAc beta 1-6)GalNAc alpha 1- were also found in all the samples. The large intestine were enriched in sulfated oligosaccharides and the small intestine contained higher amounts of sialylated species. Sulfation were found exclusively on C-6 of GlcNAc.	LUND UNIV,SECT MOL PATHOGENESIS,DEPT CELL & MOL BIOL,S-22100 LUND,SWEDEN	Lund University	Karlsson, NG (corresponding author), GOTHENBURG UNIV,DEPT MED BIOCHEM,MEDICINAREGATAN 9,S-41390 GOTHENBURG,SWEDEN.		Hansson, Gunnar C/A-1236-2009; Hansson, Gunnar C./AAF-7324-2019; Karlsson, Niclas/G-5235-2013; Johansson, Malin E. V./HCH-7451-2022	Hansson, Gunnar C/0000-0002-1900-1869; Hansson, Gunnar C./0000-0002-1900-1869; Karlsson, Niclas/0000-0002-3045-2628; Johansson, Malin E. V./0000-0002-4237-6677				ANGSTROM J, 1987, BIOCHIM BIOPHYS ACTA, V926, P79, DOI 10.1016/0304-4165(87)90184-X; ASKER N, 1995, BIOCHEM J, V308, P873, DOI 10.1042/bj3080873; BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; BLANCHARD D, 1983, J BIOL CHEM, V258, P7691; BREIMER ME, 1982, J BIOL CHEM, V257, P50; CARLSSON HE, 1978, CARBOHYD RES, V64, P181, DOI 10.1016/S0008-6215(00)83699-X; CARLSTEDT I, 1993, J BIOL CHEM, V268, P18771; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; CIUCANO I, 1984, CARBOHYD RES, V131, P207; CORFIELD AP, 1993, GLYCOCONJUGATE J, V10, P72, DOI 10.1007/BF00731190; CORFIELD AP, 1988, CLIN SCI, V74, P71, DOI 10.1042/cs0740071; DAKOUR J, 1987, ANAL BIOCHEM, V161, P140, DOI 10.1016/0003-2697(87)90663-4; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GUM JR, 1994, J BIOL CHEM, V269, P2440; HANSSON GC, 1984, BIOCHIM BIOPHYS ACTA, V792, P281, DOI 10.1016/0005-2760(84)90195-4; HANSSON GC, 1983, J BIOL CHEM, V258, P9612; HANSSON GC, 1994, BIOCHEM BIOPH RES CO, V198, P181, DOI 10.1006/bbrc.1994.1026; HANSSON GC, 1991, CARBOHYD RES, V221, P179, DOI 10.1016/0008-6215(91)80055-R; HANSSON GC, 1988, MOL IMMUNOLOGY COMPL, P465; Karlsson NG, 1996, GLYCOCONJUGATE J, V13, P823, DOI 10.1007/BF00702346; KARLSSON NG, 1995, ANAL BIOCHEM, V224, P538, DOI 10.1006/abio.1995.1084; KARLSSON NG, 1995, GLYCOCONJUGATE J, V12, P69, DOI 10.1007/BF00731871; Karlsson NG, 1996, J MASS SPECTROM, V31, P560; KLEIN A, 1993, EUR J BIOCHEM, V211, P491, DOI 10.1111/j.1432-1033.1993.tb17575.x; LARSON G, 1987, CARBOHYD RES, V161, P14430; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; OHMORI H, 1994, J BIOL CHEM, V269, P17833; SMITH AC, 1986, CLIN GASTROENTEROL, V15, P805; SMITH EL, 1975, BIOCHIM BIOPHYS ACTA, V388, P171, DOI 10.1016/0005-2760(75)90121-6; SOH CPC, 1989, GLYCOCONJUGATE J, V6, P319, DOI 10.1007/BF01047851; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WATKINS WM, 1995, BLOOD CEL B, V6, P351; XU G, 1992, BIOCHEM BIOPH RES CO, V183, P821, DOI 10.1016/0006-291X(92)90557-2; XU GQ, 1992, J BIOL CHEM, V267, P5401; YANG HJ, 1971, J BIOL CHEM, V246, P1192	37	55	56	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27025	27034		10.1074/jbc.272.43.27025	http://dx.doi.org/10.1074/jbc.272.43.27025			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341141	hybrid			2022-12-27	WOS:A1997YC65900037
J	Micheva, KD; Kay, BK; McPherson, PS				Micheva, KD; Kay, BK; McPherson, PS			Synaptojanin forms two separate complexes in the nerve terminal - Interactions with endophilin and amphiphysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; SRC HOMOLOGY-3 DOMAINS; I PROTEIN-I; SYNAPTIC VESICLES; SYNAPSIN-I; BINDING-SITE; SH3 DOMAINS; DYNAMIN; ENDOCYTOSIS; MEMBRANE	Endophilin is a recently discovered src homology 3 domain-containing protein that is a major in vitro binding partner for synaptojanin. To further characterize endophilin, we generated an antipeptide antibody. Endophilin is enriched in the brain, and immunofluorescence analysis reveals a high concentration of the protein in synaptic terminals, where it colocalizes with synaptojanin. In vitro binding assays demonstrate that endophilin binds through its src homology 3 domain to synaptojanin, and immunoprecipitation analysis with the antiendophilin antibody reveals that endophilin is stably associated with synaptojanin in the nerve terminal. Immunoprecipitation with an antibody against amphiphysin I and II, which interact through their src homology 3 domains with dynamin and synaptojanin at sites distinct from those for endophilin, reveals a second stable complex, which includes dynamin and synaptojanin but excludes endophilin. These data demonstrate that synaptojanin is present in two separate complexes in the nerve terminal and support an important role for endophilin in the regulation of synaptojanin function.	MCGILL UNIV,MONTREAL NEUROL INST,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	McGill University; University of North Carolina; University of North Carolina Chapel Hill			Micheva, Kristina/ABH-6913-2020	Micheva, Kristina/0000-0003-1138-3732				Blackstad TW, 1961, J COMP NEUROL, V117, P113; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JUNG MW, 1993, HIPPOCAMPUS, V3, P165, DOI 10.1002/hipo.450030209; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MCPHERSON PS, 1990, J BIOL CHEM, V265, P1854; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; SHARP AH, 1993, J NEUROSCI, V13, P3051; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Woscholski R, 1997, J BIOL CHEM, V272, P9625	45	112	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27239	27245		10.1074/jbc.272.43.27239	http://dx.doi.org/10.1074/jbc.272.43.27239			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341169	hybrid			2022-12-27	WOS:A1997YC65900065
J	Sun, WM; Williams, CH; Massey, V				Sun, WM; Williams, CH; Massey, V			The role of glycine 99 in L-lactate monooxygenase from Mycobacterium smegmatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SPINACH GLYCOLATE OXIDASE; AMINO-ACID-SEQUENCE; ACTIVE-SITE; ESCHERICHIA-COLI; TRANSITION-STATE; BAKERS-YEAST; FLAVOCYTOCHROME-B2; MECHANISM; DEHYDROGENASE	Glycine 99 in L-lactate monooxygenase (LMO) from Mycobacterium smegmatis was mutated to serine and threonine, and the resultant mutants were studied extensively to explore the role of this residue in maintaining monooxygenase activity and in controlling the reactivity with molecular oxygen. Both mutants were observed to lose monooxygenase activity completely and generate H2O2 and pyruvate as reaction products. However, the mutants have much lower activities than a true L-lactate oxidase. The oxygen reactivities of the reduced and semiquinone forms of the mutant enzymes were significantly different from those of wild type enzyme. These results confirm our previous suggestion that the electronic interactions in the active site are a crucial factor that governs the oxygen reactivity of the enzyme (Sun, W., Williams, C. H., Jr., and Massey, V. (1996) J. Biol. Chem. 271, 17226-17233). In addition, the mutants cause a dramatic decrease of the rate of flavin reduction by L-lactate compared with the wild type enzyme, mainly due to the much lower stabilization of the transition state.	DEPT VET AFFAIRS MED CTR,ANN ARBOR,MI 48105		Sun, WM (corresponding author), UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NIGMS NIH HHS [GM 11106, GM 21444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CEDERLUND E, 1988, EUR J BIOCHEM, V173, P523, DOI 10.1111/j.1432-1033.1988.tb14029.x; CHOONG YS, 1980, J BIOL CHEM, V255, P8672; CLARK WM, 1960, OXIDATION REDUCTION, P504; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GHISLA S, 1975, J BIOL CHEM, V250, P577; GHISLA S, 1979, J BIOL CHEM, V254, P662; GHISLA S, 1977, J BIOL CHEM, V252, P6729; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; GIEGEL DA, 1990, J BIOL CHEM, V265, P6626; HAYAISHI O, 1957, J AM CHEM SOC, V79, P4809, DOI 10.1021/ja01574a060; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE KHD, 1991, J BIOL CHEM, V266, P20877; LEDERER F, 1985, EUR J BIOCHEM, V152, P419, DOI 10.1111/j.1432-1033.1985.tb09213.x; LEDERER F, 1991, CHEM BIOCH FLAVOENZY, V2, P153; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; MAEDAYORITA K, 1995, BIOCHIMIE, V77, P631, DOI 10.1016/0300-9084(96)88178-8; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1977, J BIOL CHEM, V252, P5612; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MUH U, 1994, J BIOL CHEM, V269, P7982; MUH U, 1994, J BIOL CHEM, V269, P7994; MUH U, 1994, J BIOL CHEM, V269, P7989; MULLER F, 1969, J BIOL CHEM, V244, P4007; MULLER F, 1972, Z NATURFORSCH PT B, VB 27, P1023; SMEKAL O, 1993, BIOCHEM J, V290, P103, DOI 10.1042/bj2900103; STANKOVICH M, 1983, BIOCHEMISTRY-US, V22, P4466, DOI 10.1021/bi00288a018; SULLIVAN PA, 1977, BIOCHEM J, V165, P375, DOI 10.1042/bj1650375; SULLIVAN PA, 1968, BIOCHEM J, V110, P363, DOI 10.1042/bj1100363; Sun WM, 1996, J BIOL CHEM, V271, P17226, DOI 10.1074/jbc.271.29.17226; TSOU AY, 1990, BIOCHEMISTRY-US, V29, P9856, DOI 10.1021/bi00494a015; VOLOKITA M, 1987, J BIOL CHEM, V262, P15825; WALSH C, 1973, J BIOL CHEM, V248, P7049; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629; Yorita K, 1996, J BIOL CHEM, V271, P28300, DOI 10.1074/jbc.271.45.28300	36	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27065	27076		10.1074/jbc.272.43.27065	http://dx.doi.org/10.1074/jbc.272.43.27065			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341146	hybrid			2022-12-27	WOS:A1997YC65900042
J	Gum, JR; Ho, JJL; Pratt, WS; Hicks, JW; Hill, AS; Vinall, LE; Roberton, AM; Swallow, DM; Kim, YS				Gum, JR; Ho, JJL; Pratt, WS; Hicks, JW; Hill, AS; Vinall, LE; Roberton, AM; Swallow, DM; Kim, YS			MUC3 human intestinal mucin - Analysis of gene structure, the carboxyl terminus, and a novel upstream repetitive region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; MOLECULAR-CLONING; COLON-CANCER; EPITHELIAL MUCIN; EXPRESSION; CDNA; SEQUENCE; GROWTH; CELLS; RICH	MUC3 is a large mucin glycoprotein expressed by the human intestine and gall bladder. in this manuscript, we present details of the deduced protein structure of MUC3. The MUC3 carboxyl-terminal domain is 617 residues in length, including 511 residues of a non-repetitive mucin-like domain (27% Thr, 22% Ser and 11% Pro) and a 106-residue Cys-rich domain with homology to the epidermal growth factor (EGF) - like structural motifs found in many proteins. The region of MUGS located upstream of the previously described. 51-base pair (bp) tandem repeats, which encode a major Ser and Thr-rich domain, consists of a second type of repetitive structure with an imperfect periodicity of approximately 1125 bp. This domain is also mucin-like and appears to be considerably larger than 2000 residues (6000 bp), The MUC3 gene itself is large and complex, using pulse field gel electrophoresis and blot analysis, the smallest fragment found that contained all human genomic DNA hybridizing 60 the 51-bp tandem repeat probe was 200 kilobases with restriction enzyme SwaI. Both PvuII and PstI produced two sets of hybridizing fragments that were hypervariable within the human population with a pattern suggestive of both a variation in the number of tandem repeats (VNTR) and sequence polymorphism These fragments varied independently of each other, bat no genetic recombination was detected in a study of 40 human families. Thus, the MUC3 gene encodes a very large glycoprotein with a structure very different from that of any mucin currently described.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT VET AFFAIRS MED CTR,GASTROINTESTINAL RES LAB 151M2,SAN FRANCISCO,CA 94121; UNIV LONDON UNIV COLL,GALTON LAB,MRC,HUMAN BIOCHEM GENET UNIT,LONDON NW1 2HE,ENGLAND	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of London; University College London	Gum, JR (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94121, USA.				NATIONAL CANCER INSTITUTE [R01CA024321] Funding Source: NIH RePORTER; NCI NIH HHS [CA 24321] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN A, 1981, PHYSL GASTROINTESTIN, P627; ASKER N, 1995, BIOCHEM J, V308, P873, DOI 10.1042/bj3080873; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BAECKSTROM D, 1994, J BIOL CHEM, V269, P14430; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; Carlstedt I, 1995, BIOCHEM SOC T, V23, P845, DOI 10.1042/bst0230845; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; DUPERAT VG, 1995, BIOCHEM J, V305, P211, DOI 10.1042/bj3050211; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FOX MF, 1992, ANN HUM GENET, V56, P281, DOI 10.1111/j.1469-1809.1992.tb01154.x; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GREEN F, 1987, GENE, V57, P101, DOI 10.1016/0378-1119(87)90181-8; Gress TM, 1996, ONCOGENE, V13, P1819; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1991, J BIOL CHEM, V266, P22733; Gum JR, 1995, BIOCHEM SOC T, V23, P795, DOI 10.1042/bst0230795; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILL AS, 1995, CYTOGENET CELL GENET, V71, P25; HO SB, 1993, CANCER RES, V53, P641; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; JEFFREY GP, 1994, GASTROENTEROLOGY, V106, P336, DOI 10.1016/0016-5085(94)90590-8; KLOMP LWJ, 1995, BIOCHEM J, V308, P831, DOI 10.1042/bj3080831; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LAN MS, 1990, J BIOL CHEM, V265, P15294; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; LESUFFLEUR T, 1993, J CELL SCI, V106, P771; MCCOOL DJ, 1994, BIOCHEM J, V302, P111, DOI 10.1042/bj3020111; McGuckin MA, 1996, BIOCHEM CELL BIOL, V74, P87, DOI 10.1139/o96-009; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; NARDELLI J, 1988, PANCREAS, V3, P631, DOI 10.1097/00006676-198812000-00002; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; SANDS BE, 1995, J BIOL CHEM, V270, P9353, DOI 10.1074/jbc.270.16.9353; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; Shankar V, 1997, AM J RESP CELL MOL, V16, P232, DOI 10.1165/ajrcmb.16.3.9070607; Sheehan JK, 1996, BIOCHEM J, V315, P1055, DOI 10.1042/bj3151055; Spurr N. K., 1994, European Journal of Human Genetics, V2, P193; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; Toribara NW, 1997, J BIOL CHEM, V272, P16398, DOI 10.1074/jbc.272.26.16398	49	84	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26678	26686		10.1074/jbc.272.42.26678	http://dx.doi.org/10.1074/jbc.272.42.26678			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334251	hybrid			2022-12-27	WOS:A1997YB13900085
J	Summers, H; Fleming, A; Frappier, L				Summers, H; Fleming, A; Frappier, L			Requirements for Epstein-Barr nuclear antigen 1 (EBNA1)-induced permanganate sensitivity of the Epstein-Barr virus latent origin of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; EBNA1; ORIP; SITES; DOMAINS; CELLS; IDENTIFICATION; PURIFICATION; DISTORTION; MECHANISM	Epstein-Barr nuclear antigen 1 (EBNA1) activates DNA replication from the Epstein-Barr virus latent origin of DNA replication, oriP. EBNA1 binds cooperatively to four recognition sites in the dyad symmetry (DS) element of oriP, causing alterations in the origin DNA structure, which can be detected by the increased sensitivity of one Thy residue in two of the binding sites to permanganate oxidation. To better understand the significance of this EBNA1-induced origin distortion we have investigated the DNA sequence and EBNA1 amino acid requirements far permanganate sensitivity. We have shown that the EBNA1. DNA binding and dimerization domains are sufficient to induce permanganate sensitivity and that amino acids 463-467, which form an extended chain that, travels along the minor groove of the EBNA1 recognition site, play an important role in generating the DNA distortion. The EBNA1-induced permanganate sensitivity is independent of cooperative interactions between EBNA1 molecules on the origin and requires a specific sequence within the EBNA1 binding site. Using synthetic EBNA1 binding sites, we found that the inversion of a single AT base pair in the EBNA1 recognition sequence is sufficient to confer EBNA1-induced permanganate sensitivity. These studies indicate that permanganate oxidation can detect very minor alterations in DNA structure.	MCMASTER UNIV,INST MOL BIOL & BIOTECHNOL,CANC RES GRP,HAMILTON,ON L8N 3Z5,CANADA	McMaster University								ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; BOROWIEC JA, 1991, J VIROL, V65, P1228, DOI 10.1128/JVI.65.3.1228-1235.1991; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BRUSH GS, 1996, DNA REPLICATION EUKA, P1; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P45; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FRAPPIER L, 1992, J VIROL, V66, P1786, DOI 10.1128/JVI.66.3.1786-1790.1992; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FRAPPIER L, 1994, J BIOL CHEM, V269, P1057; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GOLDSMITH K, 1993, J VIROL, V67, P3418, DOI 10.1128/JVI.67.6.3418-3426.1993; HARRISON S, 1994, J VIROL, V68, P1913, DOI 10.1128/JVI.68.3.1913-1925.1994; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; IIDA S, 1970, BIOCHIM BIOPHYS ACTA, V213, P1, DOI 10.1016/0005-2787(70)90002-X; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; Laine A, 1995, J BIOL CHEM, V270, P30914, DOI 10.1074/jbc.270.52.30914; MACKEY D, 1995, J VIROL, V69, P6199, DOI 10.1128/JVI.69.10.6199-6208.1995; NILLER HH, 1995, J BIOL CHEM, V270, P12864, DOI 10.1074/jbc.270.21.12864; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Summers H, 1996, J VIROL, V70, P1228, DOI 10.1128/JVI.70.2.1228-1231.1996; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WYSOKENSKI DA, 1989, J VIROL, V63, P2657, DOI 10.1128/JVI.63.6.2657-2666.1989; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	33	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26434	26440		10.1074/jbc.272.42.26434	http://dx.doi.org/10.1074/jbc.272.42.26434			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334219	hybrid			2022-12-27	WOS:A1997YB13900053
J	Kuriki, T; Stewart, DC; Preiss, J				Kuriki, T; Stewart, DC; Preiss, J			Construction of chimeric enzymes out of maize endosperm branching enzymes I and II: Activity and properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-STEAROTHERMOPHILUS; CATALYTIC MECHANISM; AMYLOLYTIC ENZYMES; RICE ENDOSPERM; ALPHA-AMYLASES; ZEA-MAYS; STARCH; EXPRESSION; RESOLUTION	Branching enzyme I and II isoforms from maize endosperm (mBE I and mBE II, respectively) have quite different properties, and to elucidate the domain(s) that determines the differences, chimeric genes consisting of part mBE I and part mBE II were constructed. When expressed under the control of the T7 promoter in Escherichia coli, several of the chimeric enzymes were inactive, The only fully active chimeric enzyme was mBE II-I BspHI, in which the carboxyl-terminal part of mBE II was exchanged for that of mBE I at a BspHI restriction site and was purified to homogeneity and characterized, Another chimeric enzyme, mBE I-II HindIII, in which the amino-terminal end of mBE II was replaced with that of mBE I, had very little activity and was only partially characterized, The purified mBE II-I BspHI exhibited higher activity than wild-type mBE I and mBE II when assayed by the phosphorylase a stimulation assay. mBE II-I BspHI had substrate specificity (preference for amylose rather than amylopectin) and catalytic capacity similar to mBE I, despite the fact that only the carboxyl terminus was from mBE I, suggesting that the carboxyl terminus may be involved in determining substrate specificity and catalytic capacity, In chain transfer experiments, mBE II-I BspHI transferred more short chains (with a degree of polymerization of around 6) in a fashion similar to mBE II, In contrast, mBE I-II HindIII transferred more long chains (with a degree of polymerization of around 11-12), similar to mBE I, suggesting that the amino terminus of mBEs may play a role in the size of oligosaccharide chain transferred, This study challenges the notion that the catalytic centers for branching enzymes are exclusively located in the central portion of the enzyme; it suggests instead that the amino and carboxyl termini may also be involved in determining substrate preference, catalytic capacity, and chain length transfer.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University								BABA T, 1991, BIOCHEM BIOPH RES CO, V181, P87, DOI 10.1016/S0006-291X(05)81385-3; BHATTACHARYYA MK, 1990, CELL, V60, P115, DOI 10.1016/0092-8674(90)90721-P; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BOYER CD, 1978, CARBOHYD RES, V61, P321, DOI 10.1016/S0008-6215(00)84492-4; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cao HP, 1996, J PROTEIN CHEM, V15, P291, DOI 10.1007/BF01887118; FISHER DK, 1993, PLANT PHYSIOL, V102, P1045, DOI 10.1104/pp.102.3.1045; GUAN HP, 1994, CELL MOL BIOL, V40, P981; GUAN HP, 1994, PLANT PHYSIOL, V104, P1449, DOI 10.1104/pp.104.4.1449; GUAN HP, 1995, P NATL ACAD SCI USA, V92, P964, DOI 10.1073/pnas.92.4.964; GUAN HP, 1993, PLANT PHYSIOL, V102, P1269, DOI 10.1104/pp.102.4.1269; HAWKER JS, 1974, ARCH BIOCHEM BIOPHYS, V160, P530, DOI 10.1016/0003-9861(74)90430-5; JESPERSEN HM, 1991, BIOCHEM J, V280, P51, DOI 10.1042/bj2800051; JESPERSEN HM, 1993, J PROTEIN CHEM, V12, P791, DOI 10.1007/BF01024938; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KOSSMANN J, 1991, MOL GEN GENET, V203, P237; Kubota M., 1991, DENPUN KAGAKU, V38, P141; Kuriki T, 1996, J PROTEIN CHEM, V15, P305, DOI 10.1007/BF01887119; KURIKI T, 1991, J BACTERIOL, V173, P6147, DOI 10.1128/jb.173.19.6147-6152.1991; KURIKI T, 1988, J BACTERIOL, V170, P1554, DOI 10.1128/jb.170.4.1554-1559.1988; KURIKI T, 1995, ENZYME CHEM MOL BIOL, P87; KURIKI T, 1992, TRENDS GLYCOSCI GLYC, V4, P567; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MIZUNO K, 1993, J BIOL CHEM, V268, P19084; NAKAMURA A, 1992, FEBS LETT, V296, P37, DOI 10.1016/0014-5793(92)80398-Z; NAKAMURA Y, 1992, PHYSIOL PLANTARUM, V84, P329, DOI 10.1111/j.1399-3054.1992.tb04672.x; NAKAMURA Y, 1992, PLANT PHYSIOL, V99, P1265, DOI 10.1104/pp.99.3.1265; POULSEN P, 1993, PLANT PHYSIOL, V102, P1053, DOI 10.1104/pp.102.3.1053; Preiss J., 1996, PHOTOASSIMILATE DIST, V3, p63?96; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; ROMEO T, 1988, GENE, V70, P363, DOI 10.1016/0378-1119(88)90208-9; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH AM, 1988, PLANTA, V175, P270, DOI 10.1007/BF00392437; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STROKOPYTOV B, 1995, BIOCHEMISTRY-US, V34, P2234, DOI 10.1021/bi00007a018; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; TAKATA H, 1994, APPL ENVIRON MICROB, V60, P3096, DOI 10.1128/AEM.60.9.3096-3104.1994; TAKATA H, 1992, J BIOL CHEM, V267, P18447; TAKEDA Y, 1993, CARBOHYD RES, V240, P253, DOI 10.1016/0008-6215(93)84188-C	43	82	87	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28999	29004		10.1074/jbc.272.46.28999	http://dx.doi.org/10.1074/jbc.272.46.28999			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360973	hybrid			2022-12-27	WOS:A1997YF68400032
J	Ray, BK; Ray, A				Ray, BK; Ray, A			Induction of serum amyloid A (SAA) gene by SAA-activating sequence-binding factor (SAF) in monocyte/macrophage cells - Evidence for a functional synergy between SAF and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A GENE; MESSENGER-RNA; MOLECULAR-CLONING; FAMILY PROTEINS; EXPRESSION; C/EBP; APOLIPOPROTEIN; TRANSCRIPTION; LIVER; PARTICIPATION	Serum amyloid A (SAA) is a plasma protein that is associated with many inflammatory diseases including amyloidosis, arthritis, and atherosclerosis. SAA level is significantly increased during inflammatory condition, and such abnormal expression of this protein is linked to the pathogenesis of the above-mentioned diseases, A promoter element, designated as SAA-activating sequence (SAS), located between -280 and -226 has been implicated in the induction mechanism and a nuclear factor, SAS-binding factor (SAF), has been shown to bind to this region, In this report, using a cloned SAF gene in transient transfection assay. we provide evidence that SAF potentiates SAA gene expression through SAS element. Furthermore, we show that during lipopolysaccharide-mediated induction of SAF, het eromeric complex with transcription factor Sp1 is formed, Transfection assays using both transcription factor genes have demonstrated that SAF-Sp1 heteromer is a highly potent transactivator of SAA expression.	UNIV MISSOURI,DEPT VET PATHOBIOL,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK049205, R01DK049205] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49205] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BETTS JC, 1993, J BIOL CHEM, V268, P25624; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; JIANG SL, 1995, J IMMUNOL, V154, P825; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LIANG JS, 1995, J LIPID RES, V36, P37; LIAO F, 1994, J CLIN INVEST, V94, P877, DOI 10.1172/JCI117409; LOWELL CA, 1986, J BIOL CHEM, V261, P8442; Lozanski G, 1996, CYTOKINE, V8, P534, DOI 10.1006/cyto.1996.0072; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSIS AJ, 1993, BIOCHEM PHARMACOL, V46, P2119, DOI 10.1016/0006-2952(93)90599-R; MALLE E, 1993, ATHEROSCLEROSIS, V102, P131, DOI 10.1016/0021-9150(93)90155-N; MEEK RL, 1994, P NATL ACAD SCI USA, V91, P3186, DOI 10.1073/pnas.91.8.3186; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Ray A, 1996, MOL CELL BIOL, V16, P1584; Ray Alpana, 1993, Gene Expression, V3, P151; Ray BK, 1997, BIOCHEMISTRY-US, V36, P4662, DOI 10.1021/bi9624595; RIENHOFF HY, 1988, MOL CELL BIOL, V8, P3710, DOI 10.1128/MCB.8.9.3710; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; Sambrook J., 2002, MOL CLONING LAB MANU; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; STEINMETZ A, 1989, BIOCHIM BIOPHYS ACTA, V1006, P173, DOI 10.1016/0005-2760(89)90192-6; URIELISHOVAL S, 1994, AM J PATHOL, V145, P650	33	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28948	28953		10.1074/jbc.272.46.28948	http://dx.doi.org/10.1074/jbc.272.46.28948			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360966	hybrid			2022-12-27	WOS:A1997YF68400025
J	Shen, ZC; JacobsLorena, M				Shen, ZC; JacobsLorena, M			Characterization of a novel gut-specific chitinase gene from the human malaria vector Anopheles gambiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOSQUITO PERITROPHIC MEMBRANE; BACILLUS-CIRCULANS WL-12; MANDUCA-SEXTA L; PARASITE CHITINASE; MOLTING FLUID; AEDES-AEGYPTI; INTEGUMENT; MECHANISM; INHIBITOR; ALIGNMENT	Chitinases that function in the molting of the larval exoskeleton have been characterized previously, However, chitinase expression in an adult insect gut has not been described. Here we report on the initial characterization and cloning of a novel chitinase gene that is expressed specifically in the midgut of adult Anopheles gambiae females, Upon feeding, chitinase is secreted into the gut lumen as an inactive pro enzyme that is later activated by trypsin. Thus, temporal regulation of chitinase activity is tightly coupled to the temporal pattern of trypsin secretion, The enzyme may play a role in structuring the chitin-containing extracellular peritrophic matrix, whose formation is also induced by feeding, A chitinase cDNA was cloned from a library enriched for gut-specific sequences, The open reading frame encodes a 525-amino acid protein comprised of a putative catalytic domain at the N terminus, a putative chitin-binding domain at the C terminus, and a threonine/serine/proline-rich amino acid stretch in between them, Northern analysis indicates that this chitinase is expressed exclusively in the guts of adult females and not in adult carcasses or in any larval or pupal tissues, The present findings suggest the possibility of using this chitinase as an antigen for a malaria transmission-blocking vaccine.			Shen, ZC (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT GENET,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BILLINGSLEY PF, 1992, J PARASITOL, V78, P430, DOI 10.2307/3283640; Elvin CM, 1996, J BIOL CHEM, V271, P8925, DOI 10.1074/jbc.271.15.8925; ESCOTT GM, 1995, INFECT IMMUN, V63, P4770, DOI 10.1128/IAI.63.12.4770-4773.1995; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; FUKAMIZO T, 1985, INSECT BIOCHEM, V15, P1, DOI 10.1016/0020-1790(85)90037-X; HENRISSAT B, 1990, Protein Sequences and Data Analysis, V3, P523; Higgins D G, 1994, Methods Mol Biol, V25, P307; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; HUMPHREYS AM, 1984, J GEN MICROBIOL, V130, P1359; Jacobs-Lorena Marcelo, 1996, P318; KOGA D, 1989, INSECT BIOCHEM, V19, P123, DOI 10.1016/0020-1790(89)90082-6; KOGA D, 1983, INSECT BIOCHEM, V13, P295, DOI 10.1016/0020-1790(83)90052-5; KOGA D, 1982, INSECT BIOCHEM, V12, P493, DOI 10.1016/0020-1790(82)90017-8; KRAMER KJ, 1993, INSECT BIOCHEM MOLEC, V23, P691, DOI 10.1016/0965-1748(93)90043-R; KRISHNAN A, 1994, J BIOL CHEM, V269, P20971; Lemos FJA, 1996, INSECT BIOCHEM MOLEC, V26, P651, DOI 10.1016/S0965-1748(96)00014-8; Moskalyk LA, 1996, INSECT MOL BIOL, V5, P261, DOI 10.1111/j.1365-2583.1996.tb00100.x; PETERS W, 1992, ZOOPHYSIOLOGY PERITR, V130; Regev A, 1996, APPL ENVIRON MICROB, V62, P3581, DOI 10.1128/AEM.62.10.3581-3586.1996; SAKUDA S, 1986, TETRAHEDRON LETT, V27, P2475, DOI 10.1016/S0040-4039(00)84560-8; Shahabuddin M, 1996, INFECT IMMUN, V64, P739, DOI 10.1128/IAI.64.3.739-743.1996; SHAHABUDDIN M, 1993, P NATL ACAD SCI USA, V90, P4266, DOI 10.1073/pnas.90.9.4266; Tellam R. L., 1996, P86; TRUDEL J, 1989, ANAL BIOCHEM, V178, P362, DOI 10.1016/0003-2697(89)90653-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATANABE T, 1993, J BIOL CHEM, V268, P18567; WATANABE T, 1994, BIOSCI BIOTECH BIOCH, V58, P2283, DOI 10.1271/bbb.58.2283; Watanabe T, 1996, MOL MAR BIOL BIOTECH, V5, P299	29	108	124	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28895	28900		10.1074/jbc.272.46.28895	http://dx.doi.org/10.1074/jbc.272.46.28895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360958	hybrid			2022-12-27	WOS:A1997YF68400017
J	Chang, YWE; Traugh, JA				Chang, YWE; Traugh, JA			Phosphorylation of elongation factor 1 and ribosomal protein S6 by multipotential S6 kinase and insulin stimulation of translational elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; MATURATION-PROMOTING FACTOR; FACTOR-I; RABBIT RETICULOCYTES; INITIATION-FACTORS; EXCHANGE ACTIVITY; CHAIN ELONGATION; PHORBOL ESTERS; MESSENGER-RNA; PURIFICATION	Stimulation of protein synthesis in response to insulin is concomitant with increased phosphorylation of initiation factors 4B and 4G and ribosomal protein S6 (Morley, S. J., and Traugh, J. A. (1993) Biochimie 75, 985-989) and is due at least in part to multipotential S6 kinase. When elongation factor 1 (EF-1) from rabbit reticulocytes was examined as substrate for multipotential S6 kinase, up to 1 mol/mol of phosphate was incorporated into the alpha, beta, and delta subunits. Phosphorylation of EF-1 resulted in a 2-2.6-fold stimulation of EF-1 activity, as measured by poly(U)-directed polyphenylalanine synthesis. The rate of elongation was also stimulated by approximately a-fold with 80 S ribosomes phosphorylated on S6 by multipotential S6 kinase. When the rates of elongation in extracts from serum-fed 3T3-L1 cells and cells serum-deprived for 1.5 h were compared, a 40% decrease was observed upon serum deprivation. The addition of insulin to serum-deprived cells for 15 min stimulated elongation to a rate equivalent to that of serum-fed cells. Similar results were obtained with partially purified EF-1, with both EF-1 and ribosomes contributing to stimulation of elongation. These data are consistent with a ribosomal transit time of 3.2 min for serum-deprived cells and 1.6 min following the addition of insulin for 15 min. Taken together, the data suggest that insulin stimulation involves coordinate regulation of EF-1 and ribosomes through phosphorylation by multipotential S6 kinase.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521	University of California System; University of California Riverside					NIGMS NIH HHS [GM26738] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEC G, 1994, J BIOL CHEM, V269, P2086; BEC G, 1989, J BIOL CHEM, V264, P21131; Bensen ES, 1996, BBA-PROTEIN STRUCT M, V1292, P249, DOI 10.1016/0167-4838(95)00209-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKHARD SJ, 1983, J BIOL CHEM, V258, P4003; DEVER TE, 1989, J BIOL CHEM, V264, P20518; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FLOYD GA, 1979, EUR J BIOCHEM, V96, P277, DOI 10.1111/j.1432-1033.1979.tb13038.x; HASSELL JA, 1976, BIOCHEMISTRY-US, V15, P1375, DOI 10.1021/bi00652a004; HASSELL JA, 1973, BIOCHIM BIOPHYS ACTA, V324, P545, DOI 10.1016/0005-2787(73)90213-X; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JANSSEN GMC, 1988, J BIOL CHEM, V263, P1773; JANSSEN GMC, 1988, J BIOL CHEM, V263, P11063; JANSSEN GMC, 1991, J BIOL CHEM, V266, P14885; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; JEFFREY IW, 1993, BIOCHIMIE, V75, P791, DOI 10.1016/0300-9084(93)90129-G; KHATRA BS, 1991, ARCH BIOCHEM BIOPHYS, V284, P186, DOI 10.1016/0003-9861(91)90282-N; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBBEN TH, 1983, J BIOL CHEM, V258, P3992; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MERRICK WC, 1975, J BIOL CHEM, V250, P2620; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1993, BIOCHIMIE, V75, P985, DOI 10.1016/0300-9084(93)90149-M; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; MULNERLORILLON O, 1994, J BIOL CHEM, V269, P20201; NIELSEN PJ, 1980, J CELL PHYSIOL, V104, P269, DOI 10.1002/jcp.1041040302; PALEN E, 1987, J BIOL CHEM, V262, P3518; PALEN E, 1990, FEBS LETT, V274, P12, DOI 10.1016/0014-5793(90)81317-H; PALEN E, 1994, BIOCHEMISTRY-US, V33, P8515, DOI 10.1021/bi00194a016; PENDERGAST AM, 1985, J BIOL CHEM, V260, P1769; PERISIC O, 1983, J BIOL CHEM, V258, P9589; PERISIC O, 1985, FEBS LETT, V183, P215, DOI 10.1016/0014-5793(85)80779-1; PETERS HI, 1995, EUR J BIOCHEM, V234, P550, DOI 10.1111/j.1432-1033.1995.550_b.x; PROUD CG, 1994, MOL BIOL REP, V19, P161, DOI 10.1007/BF00986958; Redpath NT, 1996, EMBO J, V15, P2291, DOI 10.1002/j.1460-2075.1996.tb00582.x; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; ROSENBERRY TL, 1989, J BIOL CHEM, V264, P7096; RYAZANOV AG, 1991, FEBS LETT, V285, P170, DOI 10.1016/0014-5793(91)80798-8; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAHARA SM, 1982, EUR J BIOCHEM, V126, P395; TREVILLYAN JM, 1985, J BIOL CHEM, V260, P3041; TSURUGA M, 1993, BIOSCI BIOTECH BIOCH, V57, P1740; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; VANDAMME HTF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P241, DOI 10.1016/0167-4781(90)90174-Z; VENEMA RC, 1991, J BIOL CHEM, V266, P12574; VENEMA RC, 1991, J BIOL CHEM, V266, P11993; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; YOSHIZAWA F, 1995, BIOSCI BIOTECH BIOCH, V59, P348, DOI 10.1271/bbb.59.348	51	47	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28252	28257		10.1074/jbc.272.45.28252	http://dx.doi.org/10.1074/jbc.272.45.28252			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353277	hybrid			2022-12-27	WOS:A1997YF21900017
J	McKay, RT; Tripet, BP; Hodges, RS; Sykes, BD				McKay, RT; Tripet, BP; Hodges, RS; Sykes, BD			Interaction of the second binding region of troponin I with the regulatory domain of skeletal muscle troponin C as determined by NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTO-CROSS-LINKING; INHIBITORY REGION; BIOLOGICAL-ACTIVITY; CALCIUM-BINDING; PEPTIDE COMPLEX; RABBIT; CONTRACTION; TROPOMYOSIN; PROTEINS; AFFINITY	Two dimensional H-1,(1)5N-heteronuclear single quantum correlation NMR was used to monitor the resonance frequency changes of the backbone amide groups belonging to the N-15-labeled regulatory domain of calcium saturated troponin C (N-TnC) upon addition of synthetic skeletal N-acetyl-troponin I 115-131-amide peptide (TnI(115-131)). Utilizing the change in amide chemical shifts, the dissociation constant for 1:1 binding of TnI(115-131) to N-TnC in low salt and 100 mM KCl samples was determined to be 28 +/- 4 and 24 +/- 4 mu M, respectively. The off rate of TnI(115-131) was determined to be 300 s(-1) from observed N-TnC backbone amide H-1,N-15-heteronuclear single quantum correlation cross-peak line widths, which is on the order of the calcium off rates (Li, M. X., Gagne, S. M., Tsuda, S., Kay, C. M., Smillie, L. B., and Sykes, B. D. (1995) Biochemistry 34, 8330-8340), and agrees with kinetic expectations for biological regulation of muscle contraction. The TnI(115-131) binding site on N-TnC was determined by mapping of chemical shift changes onto the N-TnC NMR structure and was demonstrated to be in the ''hydrophobic pocket'' (Gagne, S. M., Tsuda, S., Li, M. X., Smillie, L. B., and Sykes, B. D. (1995) Nat. Struct. Biol. 2, 784-789).	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	University of Alberta				McKay, Ryan/0000-0002-0255-159X				BAKER JR, 1996, ACAD AM ENCY VERSION; CAMPBELL AP, 1992, BIOCHIM BIOPHYS ACTA, V1160, P35, DOI 10.1016/0167-4838(92)90036-D; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOUDUSSE A, 1995, P NATL ACAD SCI USA, V92, P10644, DOI 10.1073/pnas.92.23.10644; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jha PK, 1996, BIOCHEMISTRY-US, V35, P11026, DOI 10.1021/bi960406h; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kobayashi T, 1996, BBA-PROTEIN STRUCT M, V1294, P25, DOI 10.1016/0167-4838(95)00258-8; KOBAYASHI T, 1995, BIOCHEMISTRY-US, V34, P10946, DOI 10.1021/bi00034a029; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; NGAI SM, 1994, J BIOL CHEM, V269, P2165; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P8233, DOI 10.1021/bi00193a009; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; PEARLSTONE JR, 1995, BIOCHEMISTRY-US, V34, P6932, DOI 10.1021/bi00021a004; Pearlstone JR, 1997, BIOCHEMISTRY-US, V36, P7601, DOI 10.1021/bi970200w; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P9703, DOI 10.1021/bi00155a025; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; PEARLSTONE JR, 1997, BIOPHYS J, V72, P331; PEARLSTONE JR, 1995, BIOPHYS J, V68, P166; POTTER JD, 1982, CALCIUM CELL FUNCTIO, V2, P145; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHAW GS, 1991, J AM CHEM SOC, V113, P5557, DOI 10.1021/ja00015a006; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; SLUPSKY CM, 1992, PROTEIN SCI, V1, P1595, DOI 10.1002/pro.5560011207; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SLUPSKY CM, 1995, BIOCHEMISTRY-US, V34, P7365, DOI 10.1021/bi00022a009; Sutherland I. O, 1971, ANNUAL REPORTS NMR S, V4, P71; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VANEYK JE, 1991, BIOCHEMISTRY-US, V30, P9974, DOI 10.1021/bi00105a023; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; Wolfram S., 1996, MATH BOOK	51	89	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28494	28500		10.1074/jbc.272.45.28494	http://dx.doi.org/10.1074/jbc.272.45.28494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353310	hybrid			2022-12-27	WOS:A1997YF21900050
J	Brezillon, S; Zahn, JM; Pierrot, D; Gaillard, D; Hinnrasky, J; Millart, H; Klossek, JM; Tummler, B; Puchelle, E				Brezillon, S; Zahn, JM; Pierrot, D; Gaillard, D; Hinnrasky, J; Millart, H; Klossek, JM; Tummler, B; Puchelle, E			ATP depletion induces a loss of respiratory epithelium functional integrity and down-regulates CFTR (cystic fibrosis transmembrane conductance regulator) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL PROPERTIES; NASAL EPITHELIUM; PROTEIN-KINASES; CELLS; GENE; IDENTIFICATION; DIFFERENTIATION; CHANNEL; MEMBRANE; TISSUES	To mimic the effect of ischemia on the integrity of airway epithelium and expression of cystic fibrosis transmembrane conductance regulator (CFTR), we induced an ATP depletion of the respiratory epithelium from upper airway cells (nasal tissue) and human bronchial epithelial 16HBE14o(-) cell line. Histological analysis showed that 2 h of ATP depletion led to a loss of the epithelium integrity at the interface between basal cells and columnar cells. The expression of connexin 43 (Cx43, subunit of the gap junctions) and desmoplakins 1 and 2 (DPs 1 and 2, major components of the desmosomes) proteins was inhibited. After 90 min of ATP depletion, a significant decrease of the transepithelial resistance (25%) was observed but was reversible. Similar results were obtained with the 16HBE14o(-) human bronchial epithelial cell line. ATP depletion led to actin filaments depolymerization. The expression of the mature CFTR (170 kDa) and fodrin proteins at the apical domain of the ciliated cells was down-regulated. The steady-state levels of CFTR, Cx43, DPs 1 and 2 mRNAs, semiquantified by RT-polymerase chain reaction kinetics, remained constant throughout ATP depletion in nasal tissue as in the homogeneous cell population of 16HBE14o(-) human bronchial epithelial cell line. This suggests that the down-regulation of these proteins might be posttranscriptional. The intercellular diffusion through gap junctions of Lucifer dye was completely inhibited after 90 min of ATP depletion but was reversible. The volume-dependent and the cAMP-dependent chloride secretion were inhibited in a nonreversible way. Taken together, these results suggest that an ATP depletion in human airway epithelium, mimicking ischemia, may induce a marked alteration in the junctional complexes and cytoskeleton structure concomitantly with a loss of apical CFTR expression and chloride secretion function.	UNIV REIMS,CHR MAISON BLANCHE,INSERM,U314,IFR 53,F-51092 REIMS,FRANCE; CHU MAISON BLANCHE,LAB PHARMACOL TOXICOL,IFR 53,F-51092 REIMS,FRANCE; CHU JEAN BERNARD,SERV OTORHINOLARYNGOL & CHIRURG CERVICO FACIALE,F-86021 POITIERS,FRANCE; KLIN FORSCHERGRP,D-30623 HANNOVER,GERMANY	CHU de Reims; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Reims Champagne-Ardenne; CHU de Reims; CHU Poitiers; Universite de Poitiers				BREZILLON, stephane/0000-0001-7954-8340				BACALLAO R, 1994, J CELL SCI, V107, P3301; BERGER HA, 1993, J BIOL CHEM, V268, P2037; Brezillon S, 1997, HUM PATHOL, V28, P944, DOI 10.1016/S0046-8177(97)90010-1; BREZILLON S, 1995, LAB INVEST, V72, P191; CHEVILLARD M, 1991, CELL TISSUE RES, V264, P49, DOI 10.1007/BF00305721; DECHECCHI MC, 1993, J BIOL CHEM, V268, P11321; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DUPUIT F, 1995, J CLIN INVEST, V96, P1601, DOI 10.1172/JCI118199; EGAN TM, 1991, LUNG SCI FDN, P2205; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; GOODMAN P, 1993, COMPUT MED IMAG GRAP, V17, P133, DOI 10.1016/0895-6111(93)90055-R; GORDON RE, 1982, EXP LUNG RES, V3, P46; HANSEN M, 1993, J CELL SCI, V106, P995; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; Herard AL, 1996, AM J RESP CELL MOL, V15, P624, DOI 10.1165/ajrcmb.15.5.8918369; HUG T, 1995, PFLUG ARCH EUR J PHY, V429, P682, DOI 10.1007/BF00373989; HULLRYDE EA, 1983, J CHROMATOGR, V275, P411, DOI 10.1016/S0378-4347(00)84388-1; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lau AF, 1996, J BIOENERG BIOMEMBR, V28, P359, DOI 10.1007/BF02110112; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; Li XL, 1996, J BIOL CHEM, V271, P15695, DOI 10.1074/jbc.271.26.15695; Ma JJ, 1996, J BIOL CHEM, V271, P7351, DOI 10.1074/jbc.271.13.7351; MANDEL LJ, 1994, J CELL SCI, V107, P3315; MATTHEWS JB, 1994, SURGERY, V116, P150; Molitoris BA, 1996, KIDNEY INT, V49, P1592, DOI 10.1038/ki.1996.231; MOLITORIS BA, 1993, AM J PHYSIOL, V265, pF693, DOI 10.1152/ajprenal.1993.265.5.F693; MONTEFORT S, 1993, EUR RESPIR J, V6, P1257; MORRIS AP, 1992, J BIOL CHEM, V267, P5575; Nurko S, 1996, AM J PHYSIOL-RENAL, V270, pF39, DOI 10.1152/ajprenal.1996.270.1.F39; PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485, DOI 10.1165/ajrcmb/7.5.485; Reddy MM, 1996, AM J PHYSIOL-CELL PH, V271, pC35, DOI 10.1152/ajpcell.1996.271.1.C35; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Wersto RP, 1996, P NATL ACAD SCI USA, V93, P1167, DOI 10.1073/pnas.93.3.1167; XIE JX, 1995, J BIOL CHEM, V270, P28084	38	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27830	27838		10.1074/jbc.272.44.27830	http://dx.doi.org/10.1074/jbc.272.44.27830			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346929	hybrid			2022-12-27	WOS:A1997YD47300055
J	Cameron, AM; Nucifora, FC; Fung, ET; Livingston, DJ; Aldape, RA; Ross, CA; Snyder, SH				Cameron, AM; Nucifora, FC; Fung, ET; Livingston, DJ; Aldape, RA; Ross, CA; Snyder, SH			FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; RYANODINE RECEPTOR; CYCLOSPORINE-A; FKBP12-FK506-CALCINEURIN COMPLEX; PROTEIN; FKBP-12; IDENTIFICATION; IMMUNOPHILINS; ACTIVATION; ISOMERASE	The immunophilin FKBP12 is one of the most abundant and conserved proteins in biology. It is the primary receptor for the immunosuppressant actions of the drug FK506 in whose presence FKBP12 binds to and inhibits calcineurin, disrupting interleukin formation in lymphocytes. The physiologic functions of FKBP12 are less clear, although the protein has been demonstrated to physiologically interact with the inositol 1,4,5-trisphosphate receptor (IP3R), the ryanodine receptor, and the type 1 transforming growth factor beta receptor. We now report that FKBP12 binds the IP3R at residues 1400-1401, a leucyl-prolyl dipeptide epitope that structurally resembles FK506. We further demonstrate that binding to IP3R at this site enables FKBP12 to interact with calcineurin, presumably to anchor the phosphatase to IP3R and modulate the receptor's phosphorylation status. We propose that FK506 promotes an FKBP12-calcineurin interaction by mimicking structurally similar dipeptide epitopes present within proteins that use FKBP12 to anchor calcineurin to the appropriate physiologic substrates.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			NUCIFORA, FREDERICK/X-2364-2019					ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; FUTER O, 1995, J BIOL CHEM, V270, P18935, DOI 10.1074/jbc.270.32.18935; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; IKEDA Y, 1994, J AM CHEM SOC, V116, P4143, DOI 10.1021/ja00088a086; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LODISH HF, 1991, J BIOL CHEM, V266, P14835; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6	29	187	194	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27582	27588		10.1074/jbc.272.44.27582	http://dx.doi.org/10.1074/jbc.272.44.27582			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346894	hybrid			2022-12-27	WOS:A1997YD47300020
J	Fygenson, DK; Goodman, MF				Fygenson, DK; Goodman, MF			Appendix - Gel kinetic analysis of polymerase fidelity in the presence of multiple enzyme DNA encounters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV SO CALIF,DEPT BIOL SCI,HEDCO MOL BIOL LABS,LOS ANGELES,CA 90089	University of Southern California			Fygenson, Deborah/U-3105-2017	Fygenson, Deborah/0000-0002-5681-3938	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042554, R37GM021422, R01GM021422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21422, GM42554] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; GOODMAN R, 1988, INTRO STOCHASTIC MOD, P157; PETRUSKA J, 1985, J BIOL CHEM, V260, P7533	4	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27931	27935		10.1074/jbc.272.44.27931	http://dx.doi.org/10.1074/jbc.272.44.27931			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346942	Green Submitted, hybrid			2022-12-27	WOS:A1997YD47300068
J	Lindner, RA; Kapur, A; Carver, JA				Lindner, RA; Kapur, A; Carver, JA			The interaction of the molecular chaperone, alpha-crystallin, with molten globule states of bovine alpha-lactalbumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL CHARACTERIZATION; PROTEINS; SPECTROSCOPY; SPECIFICITY	Small heat shock proteins function in a chaperone-like manner to prevent the precipitation of proteins under conditions of stress (e.g. heat). alpha-Crystallin, the major mammalian lens protein, is a small heat shock protein. The mechanism of chaperone action of these proteins is poorly understood. In this paper, the conformational state of a protein when it forms a high molecular weight complex with alpha-crystallin is investigated by examining, using NMR spectroscopy and size exclusion high performance liquid chromatography, the interaction of alpha-crystallin with alpha-lactalbumin and its various intermediately folded (molten globule) states. The complex is formed following reduction of alpha-lactalbumin by dithiothreitol in the presence of alpha-crystallin, and this interaction has been monitored in real time by H-1 NMR spectroscopy. It is concluded that alpha-crystallin interacts with a disordered molten globule state of alpha-lactalbumin while it is on an irreversible pathway toward aggregation and precipitation. alpha-Crystallin does not interact, however, with molten globule states of alpha-lactalbumin that are stable in solution, e.g. the reduced and carboxy-amidated species. It is proposed that alpha-crystallin distinguishes between the various molten globule states of alpha-lactalbumin on the basis of the lifetimes of these states, i.e. the protein must be in a disordered molten globule state for a significant length of time and on the pathway to aggregation and precipitation for interaction to occur.	UNIV WOLLONGONG,DEPT CHEM,WOLLONGONG,NSW 2522,AUSTRALIA	University of Wollongong			Carver, John Adrian/J-3825-2014	Carver, John Adrian/0000-0002-2441-8108				ALEXANDRESCU AT, 1992, EUR J BIOCHEM, V210, P699, DOI 10.1111/j.1432-1033.1992.tb17471.x; Arai M, 1996, FOLD DES, V1, P275, DOI 10.1016/S1359-0278(96)00041-7; AUGUSTEYN RC, 1988, BIOCHIM BIOPHYS ACTA, V957, P192, DOI 10.1016/0167-4838(88)90272-5; BALBACH J, 1995, NAT STRUCT BIOL, V2, P865, DOI 10.1038/nsb1095-865; BOELENS WC, 1995, MOL BIOL REP, V21, P75, DOI 10.1007/BF00986495; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; CARVER JA, 1994, BBA-PROTEIN STRUCT M, V1204, P195, DOI 10.1016/0167-4838(94)90009-4; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; Carver JA, 1996, EXP EYE RES, V63, P639, DOI 10.1006/exer.1996.0158; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CREIGHTON TE, 1993, CURR BIOL, V3, P234; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; Dobson CM., 1992, CURR OPIN STRUC BIOL, V2, P6; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KILBY GW, 1995, EXP EYE RES, V60, P465, DOI 10.1016/S0014-4835(05)80061-2; KUWAJIMA K, 1990, BIOCHEMISTRY-US, V29, P8240, DOI 10.1021/bi00488a007; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; REDFIELD C, 1994, NAT STRUCT BIOL, V1, P23, DOI 10.1038/nsb0194-23	27	103	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27722	27729		10.1074/jbc.272.44.27722	http://dx.doi.org/10.1074/jbc.272.44.27722			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346914	hybrid			2022-12-27	WOS:A1997YD47300040
J	Sinnegger, MJ; Wang, ZY; Grabner, M; Hering, S; Striessnig, J; Glossmann, H; Mitterdorfer, J				Sinnegger, MJ; Wang, ZY; Grabner, M; Hering, S; Striessnig, J; Glossmann, H; Mitterdorfer, J			Nine L-type amino acid residues confer full 1,4-dihydropyridine sensitivity to the neuronal calcium channel alpha(1A) subunit - Role of L-type MET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY DIHYDROPYRIDINE BINDING; VOLTAGE-DEPENDENT MODULATION; MOLECULAR DETERMINANTS; SKELETAL-MUSCLE; CA2+ CHANNELS; FUNCTIONAL EXPRESSION; ALPHA-1 SUBUNIT; IVS6 SEGMENT; ANTAGONISTS; RECEPTOR	Pharmacological modulation by 1,4-dihydropyridines is a central feature of L-type calcium channels, Recently, eight L-type amino acid residues in transmembrane segments IIIS5, IIIS6, and IVS6 of the calcium channel alpha(1) subunit were identified to substantially contribute to 1,4-dihydropyridine sensitivity, To determine whether these eight L-type residues (Thr(1066), Gln(1070), Ile(1180), Ile(1183), Tyr(1490), Met(1491), Ile(1497), and Ile(1498), alpha(1C-a) numbering) are sufficient to form a high affinity 1,4-dihydropyridine binding site in a non-L-type calcium channel, we transferred them to the 1,4-dihydropyridine-insensitive alpha(1A) subunit using site-directed mutagenesis, 1,4-Dihydropyridine agonist and antagonist modulation of barium inward currents mediated by the mutant alpha(1A) subunits, coexpressed with alpha(2) delta and beta(1a) subunits in Xenopus laevis oocytes, was investigated with the two-microelectrode voltage clamp technique, The resulting mutant alpha(1A-DHPi) displayed low sensitivity for 1,4-dihydropyridines. Analysis of the 1,4-dihydropyridine binding region of an ancestral L-type alpha(1) subunit previously cloned from Musca domestica body wall muscle led to the identification of Met(1188) (alpha(1C-a) numbering) as an additional critical constituent of the L-type 1,4-dihydropyridine binding domain, The introduction of this residue into alpha(1A-DHpi) restored full sensitivity for 1,4-dihydropyridines. It also transferred functional properties considered hallmarks of 1,4-dihydropyridine agonist and antagonist effects (i.e. stereoselectivity, voltage dependence of drug modulation, and agonist-induced shift in the voltage-dependence of activation), Our gain-of-function mutants provide an excellent model for future studies of the structure-activity relationship of 1,4-dihydropyridines to obtain critical structural information for the development of drugs for neuronal, non-L-type calcium channels.	UNIV INNSBRUCK, INST BIOCHEM PHARMACOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck			Striessnig, Joerg/S-9334-2017; Glossmann, Hartmut/AAL-9790-2020	Striessnig, Joerg/0000-0002-9406-7120; glossmann, hartmut h./0000-0002-7392-3266; Brauns, Martina/0000-0002-0547-2731				BEAN BP, 1984, P NATL ACAD SCI-BIOL, V81, P6388, DOI 10.1073/pnas.81.20.6388; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Brauns T, 1997, BIOCHEMISTRY-US, V36, P3625, DOI 10.1021/bi9613584; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Durell SR, 1996, NEUROPHARMACOLOGY, V35, P761, DOI 10.1016/0028-3908(96)00097-4; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLOSSMANN H, 1990, REV PHYSIOL BIOCH P, V114, P1; GRABNER M, 1994, FEBS LETT, V339, P189, DOI 10.1016/0014-5793(94)80413-3; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KAMP TJ, 1989, CIRC RES, V64, P338, DOI 10.1161/01.RES.64.2.338; KASS RS, 1987, CIRC RES, V61, P1; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILJANICH GP, 1995, ANNU REV PHARMACOL, V35, P707, DOI 10.1146/annurev.pa.35.040195.003423; MITTERDORFER J, 1995, BIOCHEMISTRY-US, V34, P9350, DOI 10.1021/bi00029a010; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PETERSON BZ, 1995, J BIOL CHEM, V270, P18201, DOI 10.1074/jbc.270.31.18201; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGUINETTI MC, 1986, J GEN PHYSIOL, V88, P369, DOI 10.1085/jgp.88.3.369; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; TRIGGLE DJ, 1992, CLEV CLIN J MED, V59, P617; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	43	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27686	27693		10.1074/jbc.272.44.27686	http://dx.doi.org/10.1074/jbc.272.44.27686			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346909	hybrid			2022-12-27	WOS:A1997YD47300035
J	Cullen, PJ; Kaufman, CK; Bowman, WC; Kranz, RG				Cullen, PJ; Kaufman, CK; Bowman, WC; Kranz, RG			Characterization of the Rhodobacter capsulatus housekeeping RNA polymerase - In vitro transcription of photosynthesis and other genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RPOB GENE; SUPEROPERONAL ORGANIZATION; RHODOPSEUDOMONAS-CAPSULATA; PROMOTER RECOGNITION; SIGMA-70 SUBUNIT; OMEGA SUBUNIT; EXPRESSION; BACTERIAL; MUTAGENESIS; INVITRO	To begin to characterize biochemically the transcriptional activation systems in photosynthetic bacteria, the Rhodobacter capsulatus RNA polymerase (RNAP) that contains the sigma(70)) was purified and characterized using two classical sigma(70) type promotes, the bacteriophage T7A1 and the RNA I promoters. Transcription from these promoters was sensitive to rifampicin, RNase, and monoclonal antibody 2G10 (directed against the Escherichia coli sigma(70) subunit). Specific transcripts were detected in vitro for R. capsulatus cytochrome c(2) (cycA) and fructose-inducible (fruB) promoters and genes induced in photosynthesis (puf and puc) and bacteriochlorophyll biosynthesis (bchC). Alignment of these natural promoters activated by R. capsulatus RNAP/sigma(70) indicated a preference for the sequence TTGAC at the -35 region for strong in vitro transcription. To test the -35 recognition pattern, the R. capsulatus nifA1 promoter, which exhibits only three of the five consensus nucleotides at the -35 region, was mutated to four and five of the consensus nucleotides. Although the nifA1 wild type promoter showed no transcription, the double mutated promoter exhibited high levels of in vitro transcription by the purified R. capsulatus RNAP/sigma(70) enzyme. Similarities and differences between the RNAPs and the promoters of R. capsulatus and E. coli are discussed.	WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130	Washington University (WUSTL)			, Charles/ABC-8259-2020	Kaufman, Charles/0000-0003-3122-1677				AVTGES P, 1985, MOL GEN GENET, V201, P353; BALBAS P, 1986, GENE, V50, P3, DOI 10.1016/0378-1119(86)90307-0; BALDWIN TO, 1984, FOCUS, V6, P7; BAUER CE, 1991, MOL GEN GENET, V228, P433, DOI 10.1007/BF00260637; BAUER CE, 1988, J BIOL CHEM, V263, P4820; Bauer CE, 1996, CELL, V85, P5, DOI 10.1016/S0092-8674(00)81074-0; BAUER CE, 1995, ANOXYGENIC PHOTOSYNT, P1221; BECKMAN DL, 1992, GENE DEV, V6, P268, DOI 10.1101/gad.6.2.268; Breyer MJ, 1997, J BACTERIOL, V179, P1404, DOI 10.1128/jb.179.4.1404-1408.1997; BUGGY JJ, 1994, J BACTERIOL, V176, P6936, DOI 10.1128/JB.176.22.6936-6943.1994; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; DUPORT C, 1994, GENE, V145, P103, DOI 10.1016/0378-1119(94)90330-1; FORREST ME, 1987, FEBS LETT, V212, P28, DOI 10.1016/0014-5793(87)81550-8; FOSTERHARTNETT D, 1992, MOL MICROBIOL, V6, P1049, DOI 10.1111/j.1365-2958.1992.tb02170.x; FOSTERHARTNETT D, 1994, J BACTERIOL, V176, P6175, DOI 10.1128/jb.176.20.6175-6187.1994; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GENTRY D, 1991, J BACTERIOL, V173, P3901, DOI 10.1128/JB.173.12.3901-3903.1991; GENTRY DR, 1986, GENE, V48, P33, DOI 10.1016/0378-1119(86)90349-5; GROSS C, 1976, J BACTERIOL, V128, P382, DOI 10.1128/JB.128.1.382-389.1976; HEISLER LM, 1993, J BIOL CHEM, V268, P25369; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; KANSY JW, 1989, J BIOL CHEM, V264, P13751; KARLS RK, 1993, J BACTERIOL, V175, P7629, DOI 10.1128/JB.175.23.7629-7638.1993; Kranz R. G., 1995, Anoxygenic photosynthetic bacteria., P1191; MA D, 1993, J BACTERIOL, V175, P2037, DOI 10.1128/JB.175.7.2037-2045.1993; MARRS B, 1974, P NATL ACAD SCI USA, V71, P971, DOI 10.1073/pnas.71.3.971; Masepohl B, 1996, ARCH MICROBIOL, V165, P80, DOI 10.1007/s002030050301; Miller J.H., 1972, EXPT MOL GENETICS; MOSLEY CS, 1994, J BACTERIOL, V176, P7566, DOI 10.1128/JB.176.24.7566-7573.1994; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; PONNAMPALAM SN, 1995, J BACTERIOL, V177, P2990, DOI 10.1128/jb.177.11.2990-2997.1995; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; SCOTT JR, 1984, MICROBIOL REV, V48, P1; SEVERINOV K, 1994, MOL GEN GENET, V244, P120, DOI 10.1007/BF00283512; SGANGA MW, 1992, CELL, V68, P945, DOI 10.1016/0092-8674(92)90037-D; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; WIGGS JL, 1979, CELL, V16, P97; YEN HC, 1977, ARCH BIOCHEM BIOPHYS, V181, P411, DOI 10.1016/0003-9861(77)90246-6; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558; YOUVAN DC, 1985, P NATL ACAD SCI USA, V82, P58, DOI 10.1073/pnas.82.1.58	46	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27266	27273		10.1074/jbc.272.43.27266	http://dx.doi.org/10.1074/jbc.272.43.27266			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341173	hybrid			2022-12-27	WOS:A1997YC65900069
J	Foger, B; SantamarinaFojo, S; Shamburek, RD; Parrot, CL; Talley, GD; Brewer, HB				Foger, B; SantamarinaFojo, S; Shamburek, RD; Parrot, CL; Talley, GD; Brewer, HB			Plasma phospholipid transfer protein - Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRANSFER PROTEINS; APOLIPOPROTEIN-A-I; GENE; EXCHANGE; SUBPOPULATIONS; REPLACEMENT; CONVERSION; EXPRESSION; MECHANISM; VECTORS	In vitro studies have shown that plasma phospholipid transfer protein (PLTP) converts isolated human high density lipoprotein-3 (HDL,) into larger HDL particles and generates lipid poor apoA-I containing nascent HDL, To evaluate the role of PLTP in vivo we generated recombinant adenovirus vectors containing either human PLTP cDNA (rPLTP.AdV) or the reporter luciferase cDNA as a control. After intravenous infusion of 4 x 10(7) plaque-forming units (low dose) and 4 x 10(8) plaque forming units (high dose) of rPLTP.AdV into mice, PLTP activity in plasma increased from base-line levels of 8.4 +/- 0.2 to 108 +/- 17 and from 8.9 +/- 0.6 to 352 +/- 31 mu mol/ml/h, respectively, on day 4 (both p < 0.001). Thus, both low and high doses of rPLTP.AdV led to pronounced overexpression of human PLTP in mice. On day 4 after treatment, mice treated with low and high doses of rPLTP.AdV showed decreased HDL cholesterol (-54% and -91%) and apoA-I (-64% and -98%) (all p < 0.05). Kinetic studies revealed that the fractional catabolic rates of HDL labeled with [H-3] phosphatidylcholine, [C-14]phosphatidylcholine ether, [H-3]cholesteryl ether, and I-125-labeled mouse apoA-I were increased by 8.5-, 8.7-, 3.8-, and 2.8-fold, respectively, in mice treated with low dose rPLTP.AdV (all p < 0.001). After injection of labeled HDL, mice treated with rPLTP.AdV showed an increased accumulation of labeled PC ether (+304%) and cholesteryl ether (+92%) in the liver (both p < 0.05), Two-dimensional gel electrophoresis of plasma 5 min after injection of HDL labeled with I-125 apoA-I demonstrated increased levels of newly generated pre-beta-HDL in mice overexpressing PLTP, In conclusion, HDL remodeling mediated by PLTP generates nascent, lipid-poor apoA-I in vivo and accelerates the hepatic uptake of HDL surface and core lipids in mice treated with rPLTP.AdV. Accelerated catabolism of HDL in mice overexpressing PLTP leads to low HDL levels. Our data indicate an important role for PLTP in modulating reverse cholesterol transport in vivo.			Foger, B (corresponding author), NHLBI,MOL DIS BRANCH,NIH,BLDG 10,ROOM 7N102,10 CTR DR,MSC 1666,BETHESDA,MD 20892, USA.							ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; ALBERS JJ, 1984, ARTERIOSCLEROSIS, V4, P49, DOI 10.1161/01.ATV.4.1.49; Albers JJ, 1996, CURR OPIN LIPIDOL, V7, P88, DOI 10.1097/00041433-199604000-00007; ApplebaumBowden D, 1996, J CLIN INVEST, V97, P799, DOI 10.1172/JCI118479; Barter PJ, 1996, ATHEROSCLEROSIS, V121, P1, DOI 10.1016/0021-9150(95)05675-0; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BERMAN M, 1978, DHEW PUBLICATION, V78, P180; Cheung MC, 1996, BBA-LIPID LIPID MET, V1303, P103, DOI 10.1016/0005-2760(96)00082-3; DAMEN J, 1982, BIOCHIM BIOPHYS ACTA, V712, P444, DOI 10.1016/0005-2760(82)90271-5; DAY JR, 1994, J BIOL CHEM, V269, P9388; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FIELDING CJ, 1995, J LIPID RES, V36, P211; FOLCH J, 1957, J BIOL CHEM, V226, P497; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREGG RE, 1984, J LIPID RES, V25, P1167; Halperin G, 1986, Methods Enzymol, V129, P816; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; JIANG XC, 1995, J BIOL CHEM, V270, P17133, DOI 10.1074/jbc.270.29.17133; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KOPFLER WP, 1994, CIRCULATION, V90, P1319, DOI 10.1161/01.CIR.90.3.1319; KOSTNER GM, 1995, BIOCHEM J, V305, P659, DOI 10.1042/bj3050659; KOZAR RA, 1993, J SURG RES, V55, P548, DOI 10.1006/jsre.1993.1182; Lusa S, 1996, BIOCHEM J, V313, P275, DOI 10.1042/bj3130275; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MORTON RE, 1981, J BIOL CHEM, V256, P1992; Murdoch SJ, 1996, BBA-LIPID LIPID MET, V1303, P222, DOI 10.1016/0005-2760(96)00105-1; NICHOLS AV, 1987, J LIPID RES, V28, P719; Nishida HI, 1997, J BIOL CHEM, V272, P6959, DOI 10.1074/jbc.272.11.6959; POWNALL HJ, 1991, J LIPID RES, V32, P793; PUSSINEN P, 1995, J LIPID RES, V36, P975; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; Shamburek RD, 1996, AM J PHYSIOL-ENDOC M, V271, pE1073, DOI 10.1152/ajpendo.1996.271.6.E1073; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; TALL AR, 1983, J BIOL CHEM, V258, P2174; TALL AR, 1985, J LIPID RES, V26, P842; TALL AR, 1993, J LIPID RES, V34, P1255; TALL AR, 1983, J LIPID RES, V24, P277; Tollefson J H, 1986, Methods Enzymol, V129, P797; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TU AY, 1993, J BIOL CHEM, V268, P23098; TU AY, 1995, BIOCHEM BIOPH RES CO, V207, P552, DOI 10.1006/bbrc.1995.1223; vonEckardstein A, 1996, BBA-LIPID LIPID MET, V1301, P255, DOI 10.1016/0005-2760(96)00050-1; WHITMORE TE, 1995, GENOMICS, V28, P599, DOI 10.1006/geno.1995.1198	48	130	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27393	27400		10.1074/jbc.272.43.27393	http://dx.doi.org/10.1074/jbc.272.43.27393			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341191	hybrid			2022-12-27	WOS:A1997YC65900087
J	Hanada, T; Lin, LH; Chandy, KG; Oh, SS; Chishti, AH				Hanada, T; Lin, LH; Chandy, KG; Oh, SS; Chishti, AH			Human homologue of the Drosophila discs large tumor suppressor binds to p56(lck) tyrosine kinase and shaker type Kv1.3 potassium channel in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MICE LACKING; K+ CHANNELS; IN-VITRO; RECEPTOR; ACTIVATION; PROTEINS; FAMILY; DOMAINS; ASSOCIATION	Human homologue of the Drosophila discs large tumor suppressor protein (hDlg) belongs to a newly discovered family of proteins termed MAGUKs that appear to have structural as well as signaling functions, Consistent with the multi-domain organization of MAGUKs, hDlg consists of three copies of the PDZ (PSD-95/Discs large/zO-1) domain, an SH3 motif, and a guanylate ki nase-like domain, In addition, the hDlg contains an amino-terminal proline-rich domain that is absent in other MAGUKs. To explore the role of hDlg in cell signaling pathways, we used human T lymphocytes as a model system to investigate interaction of hDlg with known tyrosine kinases, In human T lymphocyte cell lines, binding properties of hDlg were studied by immunoprecipitation, immunoblotting, and immune complex kinase assays. Our results show that protein tyrosine kinase activity is associated with the immunoprecipitates of hDlg, Immunoblotting experiments revealed that the immunoprecipitates of hDlg contain p56(lck), a member of the Src family of tyrosine kinases, The specificity of the interaction is demonstrated by the lack of p59(fyn) tyrosine kinase and phosphotidylinositol 3-kinase in the hDlg immunoprecipitates, Direct interaction between hDlg and p56(lck) is demonstrated using glutathione S-transferase fusion proteins of hDlg and recombinant p56(lck) expressed in the baculovirus infected Sf9 cells, The p56(lck) binding site was localized within the aminoterminal segment of hDlg containing proline-rich domain, In addition, we show in vivo association of hDlg with Kv1.3 channel, which was expressed in T lymphocytes as an epitope-tagged protein using a vaccinia virus expression system, Taken together, these results provide the first evidence of a direct interaction between hDlg and p56(lck) tyrosine kinase and suggest a novel function of hDlg in coupling tyrosine kinase and voltage-gated potassium channel in T lymphocytes.	TUFTS UNIV,SCH MED,ST ELIZABETHS MED CTR,TUMOR CELL BIOL LAB,BOSTON,MA 02135; UNIV CALIF IRVINE,DEPT MICROBIOL,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT MOL GENET,IRVINE,CA 92697	St. Elizabeth's Medical Center; Tufts University; University of California System; University of California Irvine; University of California System; University of California Irvine					NCI NIH HHS [CA66263] Funding Source: Medline; NIAID NIH HHS [AI24783] Funding Source: Medline; NIGMS NIH HHS [GM-OD54872-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM054872] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; CAI YC, 1993, J BIOL CHEM, V268, P23720; CHANDY KG, 1984, J EXP MED, V160, P369, DOI 10.1084/jem.160.2.369; CHANDY KG, 1993, SEMIN NEUROSCI, V5, P125; CHANDY KG, 1995, HDB RECEPTORS CHANNE, V1; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Gibson S, 1996, J BIOL CHEM, V271, P7079, DOI 10.1074/jbc.271.12.7079; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kim AC, 1996, GENOMICS, V31, P223, DOI 10.1006/geno.1996.0035; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Koo GC, 1997, J IMMUNOL, V158, P5120; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NGUYEN QA, 1996, MOL PHARMACOL, V50, P1672; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; Rader RK, 1996, J IMMUNOL, V156, P1425; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Spencer RH, 1997, J BIOL CHEM, V272, P2389; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Taher TEI, 1996, J BIOL CHEM, V271, P2863, DOI 10.1074/jbc.271.5.2863; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Weissenhorn W, 1996, EUR J BIOCHEM, V238, P440, DOI 10.1111/j.1432-1033.1996.0440z.x; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	42	101	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26899	26904		10.1074/jbc.272.43.26899	http://dx.doi.org/10.1074/jbc.272.43.26899			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341123	hybrid			2022-12-27	WOS:A1997YC65900019
J	Koslov, ER; Maupin, P; Pradhan, D; Morrow, JS; Rimm, DL				Koslov, ER; Maupin, P; Pradhan, D; Morrow, JS; Rimm, DL			alpha-catenin can form asymmetric homodimeric complexes and/or heterodimeric complexes with beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; RECOMBINANT PROTEINS; ACTIN-BINDING; CELL-ADHESION; F-ACTIN; CADHERIN; VINCULIN; ASSOCIATION; EXPRESSION	The cadherin-based transmembrane cell-cell adhesive complex is thought to be composed of a cadherin molecule, a beta-catenin, and an alpha-catenin, which connects the complex to the cytoskeleton. The precise stoichiometry of this complex remains uncertain. We have used a series of recombinant molecules and biophysical techniques to assess the multimeric state of human alpha- and beta-catenin in vitro and then visualized them by electron microscopy after rotary shadowing. Calculated solution molecular masses are 213 kDa for alpha-catenin, 73 kDa for beta-catenin, and 186 kDa for both, This suggests that alpha-catenin exists as a homodimer in solution, beta-catenin is a monomer, and when both are present, they form alpha/beta-catenin heterodimers. Go-precipitation and surface plasmon resonance assays localize the site of alpha-catenin dimerization to the NH2-terminal 228 amino acids. This region encompasses a high-affinity (K-d = 100 nM) binding site for beta-catenin that lies between residues 54 and 157. We anticipate that the oligomeric state of alpha-catenin and the relative stoichiometry of the components in the membrane adhesion complex will be dynamic and regulated by beta-catenin, cell adhesion, and probably other factors as well.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; JOHNS HOPKINS UNIV,SCH MED,DEPT ANAT & CELL BIOL,BALTIMORE,MD 21205	Yale University; Johns Hopkins University			Pradhan, Debabrata/W-5476-2019; Aljarah, Ali/Q-7105-2016	Pradhan, Debabrata/0000-0003-4995-6882; Rimm, David/0000-0001-5820-4397; Aljarah, Ali/0000-0003-0535-090X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26338] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERLE H, 1994, J CELL SCI, V107, P3655; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nieset JE, 1997, J CELL SCI, V110, P1013; Obama H, 1997, J BIOL CHEM, V272, P11017; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; RIMM DL, 1994, BIOCHEM BIOPH RES CO, V203, P1691, DOI 10.1006/bbrc.1994.2381; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0	25	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27301	27306		10.1074/jbc.272.43.27301	http://dx.doi.org/10.1074/jbc.272.43.27301			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341178	hybrid			2022-12-27	WOS:A1997YC65900074
J	Louis, HA; Pino, JD; Schmeichel, KL; Pomies, P; Beckerle, MC				Louis, HA; Pino, JD; Schmeichel, KL; Pomies, P; Beckerle, MC			Comparison of three members of the cysteine-rich protein family reveals functional conservation and divergent patterns of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIM-DOMAIN PROTEINS; ZINC-FINGER MOTIF; MOLECULAR CHARACTERIZATION; SMOOTH-MUSCLE; ALPHA-ACTININ; ZYXIN; BINDING; CYTOSKELETON; FIBROBLASTS; SITES	Members of the cysteine-rich protein (CRP) family are evolutionarily conserved proteins that have been implicated in the processes of cell proliferation and differentiation. Tn particular, one CRP family member has been shown to be an essential regulator of cardiac and skeletal muscle development, Each of the three vertebrate CRP isoforms characterized to date is composed of two copies of the zinc-binding LIM domain with associated glycine-rich repeats. In this study, we have addressed the biological significance of the CRF multigene family by comparing the subcellular distributions, biochemical properties, and expression patterns of CRP1, CRP2, and CRP3/MLP. Our data reveal that all three CRP family members, when expressed in adherent fibroblasts, associate specifically with the actin cytoskeleton. Moreover, all three GRP isoforms are capable of interacting with the cytoskeletal proteins alpha-actinin and zyxin. Together, these observations suggest that CRP family members may exhibit overlapping cellular functions, Differences between the three CRPs are evident in their protein expression patterns In chick embryos, CRP1 expression is detected in a variety of organs enriched in smooth muscle, CRP2 is restricted to arteries and fibroblasts., CRP3/MLP is dominant in organs enriched in striated muscle, CRP isoform expression is also developmentally regulated in the chick. Our findings suggest that the three CRP family members perform similar functions in different muscle derivatives, The demonstration that all members of the CRP family are associated with cytoskeletal components that have been implicated in the assembly and organization of filamentous actin suggests that CRPs contribute to muscle cell differentiation via effects on cytoarchitecture.	UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah			Pomiès, Pascal/AAC-8037-2020	Pomiès, Pascal/0000-0002-5301-6087	NATIONAL CANCER INSTITUTE [P30CA042014, T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM014832] Funding Source: NIH RePORTER; NCI NIH HHS [CA42014, CA09602] Funding Source: Medline; NIGMS NIH HHS [5F31GM14832-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Banks WJ, 1974, HISTOLOGY COMP ORGAN; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; CLEVELAND DW, 1985, ANNU REV BIOCHEM, V54, P331, DOI 10.1146/annurev.bi.54.070185.001555; COX RD, 1992, DEV BIOL, V149, P228, DOI 10.1016/0012-1606(92)90279-P; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DENAC M, 1987, COMP BIOCHEM PHYS C, V87, P325, DOI 10.1016/0742-8413(87)90016-8; DOOLITTLE RF, 1987, URFS ORFS PRIMER ANA; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; GOLSTEYN R, 1997, IN PRESS J CELL SCI; Harlow E., 1988, ANTIBODIES LAB MANUA; Hasson T, 1996, J BIOL CHEM, V271, P16431, DOI 10.1074/jbc.271.28.16431; Herman IM, 1993, CURR OPIN CELL BIOL, V5, P48, DOI 10.1016/S0955-0674(05)80007-9; Jain MK, 1996, J BIOL CHEM, V271, P10194, DOI 10.1074/jbc.271.17.10194; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; King AS, 1989, FORM FUNCTION BIRDS; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; MARUYAMA K, 1965, J BIOCHEM-TOKYO, V58, P13, DOI 10.1093/oxfordjournals.jbchem.a128158; MCCLURE DB, 1982, GROWTH CELLS HORMONA; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; Moore DD, 1995, GLOB MOB SURV; NIX DA, 1997, IN PRESS J CELL BIOL; PATCH LA, 1995, J CELL SCI, V108, P1371; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PerezAlvarado GC, 1996, J MOL BIOL, V257, P153, DOI 10.1006/jmbi.1996.0153; PODLUBNAYA ZA, 1975, J MOL BIOL, V92, P357, DOI 10.1016/0022-2836(75)90234-X; POMIES P, 1997, IN PRESS J CELL BIOL; RAFF EC, 1984, J CELL BIOL, V99, P1, DOI 10.1083/jcb.99.1.1; RUBENSTEIN PA, 1990, BIOESSAYS, V12, P309, DOI 10.1002/bies.950120702; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; Schmeichel KL, 1997, MOL BIOL CELL, V8, P219, DOI 10.1091/mbc.8.2.219; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Sisson S, 1953, ANATOMY DOMESTIC ANI, V3; Stronach BE, 1996, J CELL BIOL, V134, P1179, DOI 10.1083/jcb.134.5.1179; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISKIRCHEN R, 1995, J BIOL CHEM, V270, P28946, DOI 10.1074/jbc.270.48.28946; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; WU RY, 1994, J BIOL CHEM, V269, P25085	54	168	179	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27484	27491		10.1074/jbc.272.43.27484	http://dx.doi.org/10.1074/jbc.272.43.27484			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341203	hybrid			2022-12-27	WOS:A1997YC65900099
J	Meech, R; Mackenzie, PI				Meech, R; Mackenzie, PI			UDP-glucuronosyltransferase, the role of the amino terminus in dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INACTIVATION ANALYSIS; PEPTIDASE CLEAVAGE SITE; LIVER; BILIRUBIN; FORM; TESTOSTERONE; GLUCURONIDE; EXPRESSION; VARIANT; PHENOL	UDP-glucuronosyltransferases (UGTs) comprise an important enzyme system in mammals that is involved in detoxification of a variety of small hydrophobic compounds of both endogenous and exogenous origin, Some evidence suggests that these enzymes may function as oligomers; however, little is known about the domain of interaction or the mechanism of oligomerization, In this work, evidence for a functional dimerization between UGTs is provided by studies on mutated forms of UGTSB1. When two inactive forms of UGT2B1 were coexpressed in cell culture, catalytic activity was restored, indicating that UGT2B1 forms functional dimers. To delineate the dimerization domain, inactive fusion proteins containing the amino-or carboxyl-terminal domains of UGT2B1 were generated and expressed with active UGT2B1, Expression of a fusion protein containing only the amino-terminal half of UGT2B1 with active UGT2B1 caused a reduction in UGT2B1 catalytic activity, This reduction in activity was not observed when UGT2B1 was co-expressed with a fusion protein containing only the carboxyl terminal half of UGT2B1, strongly suggesting that the amino-terminal domain is involved in dimerization. Truncation of the immediate amino terminus of UGT2B1 abolished UGT2B1 activity and dimer formation. Activity was also abolished by an L4R substitution in this region of the mature protein, which is highly conserved in the UGT family. These results indicate that UGTs can interact through their amino-terminal domains to form catalytically active dimers. Possible mechanisms resulting in the formation and stabilization of the UGT2B1 dimer are discussed.	FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT CLIN PHARMACOL,SCH MED,BEDFORD PK,SA 5042,AUSTRALIA	Flinders University South Australia				Meech, Robyn/0000-0002-6831-0801; Mackenzie, Peter/0000-0002-0697-6878				BRENNAN SO, 1990, P NATL ACAD SCI USA, V87, P26, DOI 10.1073/pnas.87.1.26; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; DALY M, 1990, FEBS LETT, V273, P87, DOI 10.1016/0014-5793(90)81057-U; GSCHAIDMEIER H, 1994, BIOCHEM PHARMACOL, V48, P1545, DOI 10.1016/0006-2952(94)90198-8; Ikushiro S, 1997, BIOCHEMISTRY-US, V36, P7154, DOI 10.1021/bi9702344; Koiwai O, 1996, HUM MOL GENET, V5, P645, DOI 10.1093/hmg/5.5.645; MACKENZIE PI, 1984, ARCH BIOCHEM BIOPHYS, V231, P487, DOI 10.1016/0003-9861(84)90412-0; MACKENZIE PI, 1986, J BIOL CHEM, V261, P6119; MACKENZIE PI, 1987, J BIOL CHEM, V262, P9744; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MACKENZIE PI, 1995, REV BIOCHEM TOXICOL, V11, P29; MACKENZIE PI, 1990, FRONTIERS BIOTRANSFO, V2, P211; MATERN H, 1982, J BIOL CHEM, V257, P7422; Meech R, 1996, DNA CELL BIOL, V15, P489, DOI 10.1089/dna.1996.15.489; MORTLOCK D, 1993, J TISSUE CULTURE MET, V15, P176; OWENS IS, 1992, PHARMACOGENETICS, V2, P93, DOI 10.1097/00008571-199206000-00001; PETERS WHM, 1984, J BIOL CHEM, V259, P1701; PRITCHARD M, 1994, MOL PHARMACOL, V45, P42; RITTER JK, 1992, J BIOL CHEM, V267, P3257; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH PC, 1990, DRUG METAB DISPOS, V18, P639; WILLIAMS AM, 1992, BIOCHEM PHARMACOL, V43, P745, DOI 10.1016/0006-2952(92)90239-F	24	97	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26913	26917		10.1074/jbc.272.43.26913	http://dx.doi.org/10.1074/jbc.272.43.26913			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341125	hybrid			2022-12-27	WOS:A1997YC65900021
J	Barrett, MG; Belinsky, GS; Tashjian, AH				Barrett, MG; Belinsky, GS; Tashjian, AH			A new action of parathyroid hormone - Receptor-mediated stimulation of extracellular acidification in human osteoblast-like SaOS-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BONE-RESORPTION; ALKALINE-PHOSPHATASE; SARCOMA CELLS; INTRACELLULAR CALCIUM; SIGNAL-TRANSDUCTION; COUPLED RECEPTOR; DOWN-REGULATION; UMR-106 CELLS; LINE UMR-106	The major physiological function of parathyroid hormone (PTH) is the maintenance of Ca2+/P-i homeostasis via the parathyroid hormone/parathyroid hormone-related protein receptor (PTHR) in kidney and bone, An important consequence of PTHR activation in bone is enhanced local acidification of the extracellular space. Agonist activation of some seven transmembrane-domain receptors increases the extracellular acidification rate (ECAR). We utilized microphysiometry to investigate PTH-stimulated, receptor-mediated increases in ECAR in human osteoblast-like SaOS-2 cells, PTH-(1-34) elicited a large, acute, dose-dependent increase in ECAR with an EC50 of about 2 nM. The PTH-induced increase in ECAR was specific to cells expressing the PTHR, and was inhibited by PTHR antagonists. Rapid, partial, homologous desensitization of the PTH-induced increase in ECAR was observed. Incubation of SaOS-2 cells with 8-bromo-cyclic AMP neither mimicked nor abrogated the PTH effect, and PTH stimulated an acute increase in ECAR in cAMP-resistant SaOS-2 Ca#4A cells. Stimulation of ECAR by PTH was independent of transient increases in cytosolic free calcium, Both inhibition and down-regulation of PKC reduced the PTH-induced increase in ECAR. inhibition of Na+/H+ exchange did not affect the PTH-induced ECAR response. me conclude that PTH caused a receptor-mediated, concentration-dependent, increase in ECAR, which was not dependent on the cAMP/PKA signaling pathway or the Na+/H+ exchanger but involved the action of PKC, Thus, acid production in bone, a physiologically important action of PTH, is not confined to osteoclasts as previously considered but is also mediated by osteoblasts.	HARVARD UNIV, SCH PUBL HLTH, DEPT MOL & CELLULAR TOXICOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 10206, DK 46655] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046655, R01DK010206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1994, ENDOCRINOLOGY, V135, P2588, DOI 10.1210/en.135.6.2588; Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756-3282(95)00486-6; ATKINS D, 1975, J ENDOCRINOL, V64, P573, DOI 10.1677/joe.0.0640573; AURBACH GD, 1985, WILLIAMS TXB ENDOCRI, P1153; Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; AZARANI A, 1995, J BIOL CHEM, V270, P23166, DOI 10.1074/jbc.270.39.23166; Baron R, 1995, ACTA ORTHOP SCAND, V66, P66, DOI 10.3109/17453679509157650; BERGWITZ C, 1994, BBA-MOL CELL RES, V1222, P447, DOI 10.1016/0167-4889(94)90053-1; BIDWELL JP, 1991, ENDOCRINOLOGY, V128, P1021, DOI 10.1210/endo-128-2-1021; BLIND E, 1995, ENDOCRINOLOGY, V136, P4271, DOI 10.1210/en.136.10.4271; Bliziotes M, 1996, J BONE MINER RES, V11, P820; BOLAND CJ, 1986, ENDOCRINOLOGY, V118, P980, DOI 10.1210/endo-118-3-980; BUSHINSKY DA, 1994, MINER ELECTROL METAB, V20, P40; Bushinsky DA, 1996, AM J PHYSIOL-RENAL, V271, pF216, DOI 10.1152/ajprenal.1996.271.1.F216; CHIO CL, 1994, J BIOL CHEM, V269, P11813; CHIO CL, 1994, MOL PHARMACOL, V45, P51; DresnerPollak R, 1996, J BONE MINER RES, V11, P1061; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; FELIX R, 1978, AM J PHYSIOL, V234, pC51, DOI 10.1152/ajpcell.1978.234.1.C51; FERRIER J, 1992, BONE MINER, V19, P103, DOI 10.1016/0169-6009(92)90919-5; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; FUKAYAMA S, 1991, CELL REGUL, V2, P889, DOI 10.1091/mbc.2.11.889; FUKAYAMA S, 1988, ENDOCRINOLOGY, V123, P2841, DOI 10.1210/endo-123-6-2841; FUKAYAMA S, 1992, ENDOCRINOLOGY, V131, P1757, DOI 10.1210/en.131.4.1757; GRAHAM CS, 1992, BIOCHEM J, V288, P137, DOI 10.1042/bj2880137; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA A, 1994, AM J PHYSIOL, V266, pC1083, DOI 10.1152/ajpcell.1994.266.4.C1083; HALDIMANN B, 1977, AM J PHYSIOL, V232, pE535, DOI 10.1152/ajpendo.1977.232.6.E535; HERRMANNERLEE MPM, 1977, EUR J PHARMACOL, V46, P51, DOI 10.1016/0014-2999(77)90143-1; HOHMANN EL, 1984, ENDOCRINOLOGY, V114, P1321, DOI 10.1210/endo-114-4-1321; IVEY JL, 1976, J CLIN INVEST, V58, P1327, DOI 10.1172/JCI108588; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAJI H, 1992, BIOCHEM BIOPH RES CO, V182, P1356, DOI 10.1016/0006-291X(92)91882-Q; KAJI H, 1993, HORM METAB RES, V25, P421, DOI 10.1055/s-2007-1002136; KRAMER IM, 1989, J BIOL CHEM, V264, P5876; KRUG E, 1987, J BIOL CHEM, V262, P11852; LEE SK, 1994, J BONE MINER RES, V9, P781; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MITCHELL J, 1990, ENDOCRINOLOGY, V126, P2650, DOI 10.1210/endo-126-5-2650; Monroe JJ, 1996, AM J PHYSIOL-CELL PH, V270, pC1277, DOI 10.1152/ajpcell.1996.270.5.C1277; OWICKI JC, 1992, BIOSENS BIOELECTRON, V7, P255, DOI 10.1016/0956-5663(92)87004-9; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; PITCHFORD S, 1995, AM J PHYSIOL-CELL PH, V268, pC936, DOI 10.1152/ajpcell.1995.268.4.C936; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; RICHARDSON UI, 1976, J CELL PHYSIOL, V88, P287, DOI 10.1002/jcp.1040880304; SCHLESINGER PH, 1994, MINER ELECTROL METAB, V20, P31; SUGIMOTO T, 1986, CALCIFIED TISSUE INT, V39, P171, DOI 10.1007/BF02555114; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; VAES G, 1968, J CELL BIOL, V39, P676, DOI 10.1083/jcb.39.3.676; VIGNERY A, 1978, CALC TISS RES, V26, P23, DOI 10.1007/BF02013229; WHITFIELD JF, 1995, TRENDS PHARMACOL SCI, V16, P382, DOI 10.1016/S0165-6147(00)89079-3; WILTINK A, 1993, CELL CALCIUM, V14, P591, DOI 10.1016/0143-4160(93)90059-F	54	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26346	26353		10.1074/jbc.272.42.26346	http://dx.doi.org/10.1074/jbc.272.42.26346			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334207	hybrid			2022-12-27	WOS:A1997YB13900041
J	Bi, WM; Wu, L; Coustry, F; deCrombrugghe, B; Maity, SN				Bi, WM; Wu, L; Coustry, F; deCrombrugghe, B; Maity, SN			DNA binding specificity of the CCAAT-binding factor CBF/NF-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR NF-Y; TRANSCRIPTION FACTOR; B-SUBUNIT; FUNCTIONAL DOMAINS; SEQUENCE IDENTITY; COLLAGEN PROMOTER; UBIQUITOUS FACTOR; HISTONE FOLD; YEAST HAP2; C-SUBUNIT	CBF is a heterotrimeric protein that binds to DNA containing CCAAT motifs, Here we have analyzed interactions of recombinant CBF with DNA using hydroxyl radical footprinting and methylation interference assays, In the CBF-DNA complex, three separate DNA regions are protected from hydroxyl radical cleavage, one located over and immediately adjacent to the CCAAT motif itself and the other two located on both sides of the CCAAT motif, The methylation interference assay showed, however, that only in the CCAAT motif region methylation of bases was able to interfere with the for mation of a CBF-DNA complex, suggesting that CBF makes sequence-specific contacts only in the CCAAT motif region, To further determine the specific DNA sequences necessary for CBF binding, we employed a polymerase chain reaction-mediated random binding site selection method, This analysis showed that CBF binding to DNA requires the CCAAT sequence and other specific sequences immediately flanking both ends of the CCAAT motif, We also showed that the nature of the flanking nucleotide sequences affects the affinity of CBF for DNA, Interestingly, most of the CCAAT motifs present in various higher eukaryotic promoters correspond to the CBF binding sites that were selected, consistent with the hypothesis that these motifs are binding sites for CBF and, hence, that CBF could regulate transcription of numerous eukaryotic genes.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center				Maity, Sankar/0000-0002-2387-6545	NCI NIH HHS [CA49515] Funding Source: Medline; NIAMS NIH HHS [AR43660] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043660] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; BALDWIN AS, 1994, CURRENT PROTOCOL S25; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Hasegawa T, 1996, NUCLEIC ACIDS RES, V24, P3253, DOI 10.1093/nar/24.16.3253; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; Hung HL, 1996, J BIOL CHEM, V271, P2323, DOI 10.1074/jbc.271.4.2323; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; Kim IS, 1996, MOL CELL BIOL, V16, P4003; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P8286; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MAXAM AM, 1980, METHOD ENZYMOL, V65, P497; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; ROY B, 1995, MOL CELL BIOL, V15, P2263; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Tezuka KI, 1996, J BIOL CHEM, V271, P22713, DOI 10.1074/jbc.271.37.22713; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VANHUISJDUIJNEN RH, 1990, EMBO J, V10, P3119; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x	38	93	99	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26562	26572		10.1074/jbc.272.42.26562	http://dx.doi.org/10.1074/jbc.272.42.26562			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334236	hybrid			2022-12-27	WOS:A1997YB13900070
J	Hara, K; Yonezawa, K; Kozlowski, MT; Sugimoto, T; Andrabi, K; Weng, QP; Kasuga, M; Nishimoto, I; Avruch, J				Hara, K; Yonezawa, K; Kozlowski, MT; Sugimoto, T; Andrabi, K; Weng, QP; Kasuga, M; Nishimoto, I; Avruch, J			Regulation of eIF-4E BP1 phosphorylation by mTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMALIAN PROTEIN; SERINE RESIDUE; RAPAMYCIN; YEAST; COMPLEX; TARGET; FKBP12-RAPAMYCIN; FKBP12	The proteins eIF-4E BP1 and p70 S6 kinase each undergo an insulin/mitogen-stimulated phosphorylation in situ that is partially inhibited by rapamycin. Previous work has established that the protein known as mTOR/RAFT-1/FRAP is the target through which the rapamycin.FKBP12 complex acts to dephosphorylate/deactivate the p70 S6 kinase; thus, some mTOR mutants that have lost the ability to bind to the rapamycin.FKBP12 complex in vitro can protect the p70 S6 kinase against rapamycin-induced dephosphorylation/deactivation in situ, We show herein that such mTOR mutants also protect eIF-4E BP1 against rapamycin-induced dephosphorylation, and for both p70 S6 kinase and eIF-4E BP1, such protection requires that the rapamycin-resistant mTOR variant retains an active catalytic domain, In contrast, mutants of p70 S6 kinase rendered intrinsically resistant to inhibition by rapamycin in situ are not able to protect coexpressed eIF-4E BP1 from rapamycin-induced dephosphorylation. We conclude that mTOR is an upstream regulator of eIF-4E BP1 as well as the p70 S6 kinase; moreover, these two mTOR targets are regulated in a parallel rather than sequential manner.	MASSACHUSETTS GEN HOSP,DIABET UNIT,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; KOBE UNIV,BIOSIGNAL RES CTR,KOBE,HYOGO 657,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,KOBE,HYOGO 657,JAPAN; KEIO UNIV,SCH MED,DEPT PHARMACOL & NEUROSCI,TOKYO 160,JAPAN	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Kobe University; Kobe University; Keio University				andrabi, Khurshid/0000-0003-0314-5662	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776, R37DK017776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK17776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarcon CM, 1996, GENE DEV, V10, P279, DOI 10.1101/gad.10.3.279; AZIPIAZU I, 1996, J BIOL CHEM, V271, P5033; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; DIGGLE TA, 1996, BIOCHEM J, V315, P146; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REINHARD G, 1994, EMBO J, V1, P1557; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STAN R, 1994, J BIOL CHEM, V269, P32027; WENG QP, 1995, MOL CELL BIOL, V15, P2333; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	33	393	402	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26457	26463		10.1074/jbc.272.42.26457	http://dx.doi.org/10.1074/jbc.272.42.26457			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334222	hybrid, Green Published			2022-12-27	WOS:A1997YB13900056
J	Krieg, J; Glasner, W; Vicentini, A; Doucey, MA; Loffler, A; Hess, D; Hofsteenge, J				Krieg, J; Glasner, W; Vicentini, A; Doucey, MA; Loffler, A; Hess, D; Hofsteenge, J			C-mannosylation of human RNase 2 is an intracellular process performed by a variety of cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-PROTOPLASTS; U-S; GLYCOSYLATION; EXPRESSION; TRYPTOPHAN; PROTEINS; PURIFICATION; RIBONUCLEASE; RECEPTOR; RESIDUE	C-2-alpha-Mannosyltryptophan was discovered in RNase 2 from human urine, representing a novel way of attaching carbohydrate to a protein, Here, we have addressed two questions related to the biosynthesis of this modification: (i) is C-mannosylation part of the normal intracellular biosynthetic route, and (ii) how general is it, i.e. which organisms perform this kind of glycosylation? To answer the first question, RNase 2, which is identical to the eosinophil-derived neurotoxin, was isolated from intracellular stores of cultured human HL-60 cells. The enzyme was C-mannosylated at Trp-7, showing that the modification occurs intracellularly, before secretion of the protein, The second question was investigated by immunological and chemical analysis of RNase 2 purified from the supernatant of transiently transformed cells from different organisms, This revealed that C-mannosylation occurs in cells from man, green monkey, pig, mouse, and hamster, The observation that pig kidney cells contain the machinery for C-mannosylation of Trp-7 of human RNase 2 but that the homologous RNase from porcine kidney is not a substrate, since it does not contain a tryptophan at position 7, strongly suggests that C-mannosylated proteins other than RNase 2 exist, Recombinant RNase 2 isolated from insect cells, plant protoplasts, and Escherichia coli was not C-mannosylated, These results not only form the basis for further studies on the biochemical aspects of C-mannosylation but also have implications for the choice of cells for production of recombinant glycoproteins.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ASSELBERGS FAM, 1993, ANAL BIOCHEM, V209, P327, DOI 10.1006/abio.1993.1128; BEINTEMA JJ, 1988, BIOCHEMISTRY-US, V27, P4530, DOI 10.1021/bi00412a046; BELOCOPITOW E, 1977, MOL CELL BIOCHEM, V16, P127, DOI 10.1007/BF01732053; CHAZENBALK GD, 1995, J BIOL CHEM, V270, P1543, DOI 10.1074/jbc.270.4.1543; DEBEER T, 1995, BIOCHEMISTRY-US, V34, P11785, DOI 10.1021/bi00037a016; DELMER DP, 1978, PLANT PHYSIOL, V61, P25, DOI 10.1104/pp.61.1.25; DURACK DT, 1979, P NATL ACAD SCI USA, V76, P1443, DOI 10.1073/pnas.76.3.1443; ETCHEVERRY T, 1995, PROTEIN ENG, P163; FISCHKOFF SA, 1984, J EXP MED, V160, P179, DOI 10.1084/jem.160.1.179; FISCHKOFF SA, 1986, BLOOD, V68, P185; FOMINAYA JM, 1988, BIOCHIM BIOPHYS ACTA, V954, P216, DOI 10.1016/0167-4838(88)90074-X; GADE G, 1992, BIOCHEM BIOPH RES CO, V189, P1303, DOI 10.1016/0006-291X(92)90215-7; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; Gordon MH, 1933, BRIT MED J, V1933, P641, DOI 10.1136/bmj.1.3771.641; HOFSTEENGE J, 1994, BIOCHEMISTRY-US, V33, P13524, DOI 10.1021/bi00250a003; Hofsteenge J, 1996, TECHNIQUES PROTEIN C, V7, P163; Hohn T, 1996, P NATL ACAD SCI USA, V93, P8334, DOI 10.1073/pnas.93.16.8334; IRIE M, 1988, J BIOCHEM-TOKYO, V104, P289, DOI 10.1093/oxfordjournals.jbchem.a122460; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; Loffler A, 1996, BIOCHEMISTRY-US, V35, P12005, DOI 10.1021/bi9610515; NEWTON DL, 1994, J BIOL CHEM, V269, P26739; RIBO M, 1994, BIOL CHEM H-S, V375, P357; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT TGM, 1993, PROTEIN ENG, V6, P109, DOI 10.1093/protein/6.1.109; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHNEIDER I, 1964, J EXP ZOOL, V156, P91, DOI 10.1002/jez.1401560107; SNYDER MR, 1997, RIBONUCLEASES STRUCT, P425; STANLEY P, 1995, FASEB J, V9, P1436, DOI 10.1096/fasebj.9.14.7589985; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; TIFFANY HL, 1995, J LEUKOCYTE BIOL, V58, P49	31	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26687	26692		10.1074/jbc.272.42.26687	http://dx.doi.org/10.1074/jbc.272.42.26687			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334252	hybrid			2022-12-27	WOS:A1997YB13900086
J	Yoshimura, Y; Yamauchi, T				Yoshimura, Y; Yamauchi, T			Phosphorylation-dependent reversible association of Ca2+/calmodulin-dependent protein kinase II with the postsynaptic densities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; MOLECULAR-CLONING; ALPHA-SUBUNIT; BETA-SUBUNIT; MUTANT MICE; PURIFICATION; AUTOPHOSPHORYLATION; TRANSLOCATION; THREONINE-286; EXPRESSION	The association of soluble Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) with postsynaptic densities (PSDs) was determined by activity assay, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and immunoblotting of the enzyme. Soluble CaM kinase II was autophosphorylated with ATP in the presence of Ca2+ and calmodulin, and then it was incubated with PSDs, Autophosphorylated CaM kinase II rt as precipitated with PSDs by centrifugation. The kinase that was not autophosphorylated did not precipitate with PSDs, These results indicate that the soluble previously autophosphorylated CaM kinase II associates with PSDs and forms PSD-CaM kinase II complex. A maximum of about GO mu g of soluble CaM kinase II bound to 1 mg of PSD protein under the experimental conditions. Ca2+-independent activity generated by autophosphorylation of the kinase was retained in the PSD-CaM kinase II complex, The CaM kinase II thus associated with PSDs phosphorylated a number of PSD proteins in both the absence and presence of Ca2+. When the CaM kinase II-PSD complex was incubated at 30 degrees C, its Ca2+-independent activity was gradually decreased. This decrease was correlated with dephosphorylation of the kinase and its release from PSD-CaM kinase II complex, These results indicate that CaM kinase IT reversibly translocates to PSDs in a phosphorylation-dependent manner.	UNIV TOKUSHIMA, FAC PHARMACEUT SCI, DEPT BIOCHEM, TOKUSHIMA 770, JAPAN	Tokushima University								BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; FONG YL, 1989, J BIOL CHEM, V264, P16759; GOIDENRING JR, 1984, J NEUROCHEM, V42, P1077; GOLDENRING JR, 1983, J BIOL CHEM, V258, P2632; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; ICHIKAWA T, 1992, J CHEM NEUROANAT, V5, P383, DOI 10.1016/0891-0618(92)90054-T; ICHINOSE M, 1990, BRAIN RES, V533, P137, DOI 10.1016/0006-8993(90)91806-R; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; KENNEDY MB, 1981, P NATL ACAD SCI-BIOL, V78, P1293, DOI 10.1073/pnas.78.2.1293; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; OCHIISHI T, 1993, BRAIN RES, V610, P97, DOI 10.1016/0006-8993(93)91222-E; OHSAKO S, 1991, J BIOCHEM-TOKYO, V109, P137, DOI 10.1093/oxfordjournals.jbchem.a123334; RICH D P, 1990, Molecular and Cellular Neuroscience, V1, P107; RICH DP, 1989, J NEUROCHEM, V53, P807, DOI 10.1111/j.1471-4159.1989.tb11777.x; SAHYOUN N, 1985, J BIOL CHEM, V260, P1230; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SUGIURA H, 1992, BRAIN RES, V593, P97, DOI 10.1016/0006-8993(92)91269-K; SUZUKI T, 1994, J NEUROCHEM, V63, P1529, DOI 10.1046/j.1471-4159.1994.63041529.x; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; WAXHAM MN, 1990, P NATL ACAD SCI USA, V87, P1273, DOI 10.1073/pnas.87.4.1273; WU K, 1986, J NEUROCHEM, V46, P831, DOI 10.1111/j.1471-4159.1986.tb13047.x; WU K, 1992, P NATL ACAD SCI USA, V89, P3015, DOI 10.1073/pnas.89.7.3015; YAMAUCHI T, 1980, FEBS LETT, V116, P141, DOI 10.1016/0014-5793(80)80628-4; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x; Yoshimura Y, 1996, J BIOCHEM, V119, P268	42	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26354	26359		10.1074/jbc.272.42.26354	http://dx.doi.org/10.1074/jbc.272.42.26354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334208	hybrid			2022-12-27	WOS:A1997YB13900042
J	Dong, LQ; Du, HY; Porter, SG; Kolakowski, LF; Lee, AV; Mandarino, J; Fan, JB; Yee, D; Liu, F				Dong, LQ; Du, HY; Porter, SG; Kolakowski, LF; Lee, AV; Mandarino, J; Fan, JB; Yee, D; Liu, F			Cloning, chromosome localization, expression, and characterization of an Src homology 2 and pleckstrin homology domain-containing insulin receptor binding protein hGrb10 gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; SIGNAL-TRANSDUCTION; BREAST-CANCER; PH DOMAINS; GRB-IR; GROWTH; CELLS; IDENTIFICATION; EFFICIENCY; ACTIVATION	hGrb10 alpha (previously named Grb-IR) is a Src-homology 2 domain-containing protein that binds with high affinity to the tyrosine-phosphorylated insulin receptor and insulin-like growth factor-1 receptor, At least two isoforms of human Grb10, (hGrb10 alpha and hGrb10 beta), which differ in the pleckstrin homology (PEI) domain and the N-terminal sequence, have previously been identified in insulin target tissues such as human skeletal muscle and fat cells, Here we report the cloning of the third isoform of the hGrb10 family (hGrb10 gamma) from human skeletal muscle and its localization to human chromosome 7, We have also determined the human chromosome localization of Grb7 to 17q21-q22 and Grb14 to chromosome 2, hGrb10 gamma contains an intact PEI domain and an N-terminal sequence that is present in hGrb10 gamma but absent in hGrb10 beta, RNase protection assays and Western blot analysis showed that hGrb10 alpha and hGrb10 gamma are differentially expressed in insulin target cells including skeletal muscle, liver, and adipocyte cells, hGrb10 gamma is also expressed in HeLa cells and various breast cancer cell lines, The protein bound with high affinity to the insulin receptor in cells, and the interaction was dependent on the tyrosine phosphorylation of the receptor, hGrb10 gamma also underwent insulin-stimulated membrane translocation and serine phosphorylation, hGrb10 gamma phosphorylation was inhibited by PD98059, a specific inhibitor of mitogen-activated protein kinase kinase, and wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase, Taken together, our data suggest that hGrb10 isoforms are potential downstream signaling components of the insulin receptor tyrosine kinase and that the PH domain may play an important role in the involvement of these isoforms in signal transduction pathways initiated by insulin and other growth factors.	UNIV TEXAS,HLTH SCI CTR,DEPT PHARMACOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284; STANFORD UNIV,SCH MED,STANFORD HUMAN GENOME CTR,PALO ALTO,CA 94304	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Stanford University				Yee, Douglas/0000-0002-3387-4009; Lee, Adrian/0000-0001-9917-514X				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DELALUNA S, 1988, GENE, V62, P121; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EHRENBORG E, 1992, GENOMICS, V12, P497, DOI 10.1016/0888-7543(92)90440-4; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; INGLEY E, 1994, J CELL BIOCHEM, V56, P436, DOI 10.1002/jcb.240560403; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LIU F, 1994, BIOCHEM J, V298, P471, DOI 10.1042/bj2980471; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Morrione A, 1996, CANCER RES, V56, P3165; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1610; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WHITE MF, 1994, J BIOL CHEM, V269, P1; YANG H, 1995, MOL ENDOCRINOL, V9, P1380, DOI 10.1210/me.9.10.1380; YEE D, 1988, CANCER RES, V48, P6691	33	65	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29104	29112		10.1074/jbc.272.46.29104	http://dx.doi.org/10.1074/jbc.272.46.29104			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360986	hybrid			2022-12-27	WOS:A1997YF68400045
J	Borges, E; Pendl, G; Eytner, R; Steegmaier, M; Zollner, O; Vestweber, D				Borges, E; Pendl, G; Eytner, R; Steegmaier, M; Zollner, O; Vestweber, D			The binding of T cell-expressed P-selectin glycoprotein ligand-1 to E- and P-selectin is differentially regulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUTANEOUS LYMPHOCYTE ANTIGEN; NECROSIS-FACTOR-ALPHA; LEWIS-X ANTIGEN; HUMAN NEUTROPHILS; HOMING RECEPTOR; ENDOTHELIAL SELECTINS; MONOCLONAL-ANTIBODY; TYROSINE SULFATION; ADHESION MOLECULE; AMINO-TERMINUS	The HECA452 carbohydrate epitope, also termed cutaneous lymphocyte antigen, is known to bind to E-selectin and defines a human T cell subset preferentially found in inflamed skin, Activated T cells can express a functional form of the P-selectin glycoprotein ligand-l (PSGL-1), the major ligand known for P-selectin. Here we show that PSGL-1 can exist in two forms, of which only one carries the HECA452 epitope and binds to E-selectin, while the other only binds to P-selectin, We have analyzed the glycoprotein ligands for E- and P-selectin on the mouse CD8(+) T cell clone 4G3 at 4, 8, and 12 days after antigen-specific activation, Only at day 4 did the cells bind to E-selectin, whereas cells at all three activation stages bound to P-selectin, Expression of the HECA452 epitope correlated with E-selectin binding, In affinity isolation experiments, PSGL-1 was isolated as the major ligand by E-selectin-IgG and by P-selectin-IgG; however, PSGL-1 only bound to E-selectin at day 4, whereas it bound to P-selectin at all three activation stages, Immunoprecipitated PSGL-1 from cells at day 4, but not from cells at days 8 and 12, was recognized in immunoblots by monoclonal antibody HECA452. In immunoblots of total extracts of cells at day 4, HECA452 recognized a 240/140-kDa pair of protein bands as the major antigen, These bands could be completely removed by depletion of cell extracts with anti-PSGL-1 antibodies, Our data suggest that the carbohydrate requirements for binding of PSGL-1 to P-selectin differ from those necessary for binding to E-selectin. Furthermore, we conclude that the major glycoprotein carrier for the HECA452 epitope on activated 463 cells is PSGL-1.	UNIV MUNSTER,INST CELL BIOL,ZMBE,D-48149 MUNSTER,GERMANY	University of Munster				Vestweber, Dietmar/0000-0002-3517-732X				ALON R, 1994, J CELL BIOL, V127, P1485, DOI 10.1083/jcb.127.5.1485; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BORGES E, 1994, J IMMUNOL METHODS, V173, P253, DOI 10.1016/0022-1759(94)90304-2; Borges E, 1997, J EXP MED, V185, P573, DOI 10.1084/jem.185.3.573; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; DAMLE NK, 1992, EUR J IMMUNOL, V22, P1789, DOI 10.1002/eji.1830220718; DEBOER OJ, 1994, IMMUNOLOGY, V81, P359; DUIJVESTIJN AM, 1988, AM J PATHOL, V130, P147; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; Gotsch U, 1997, J CELL SCI, V110, P583; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu L, 1996, IMMUNOLOGY, V88, P207, DOI 10.1111/j.1365-2567.1996.tb00006.x; LOWE JB, 1997, SELECTINS INITATORS, V3, P143; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; OHMORI K, 1993, BLOOD, V82, P2797; PATEL KD, 1995, J CLIN INVEST, V96, P1887, DOI 10.1172/JCI118234; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1993, J IMMUNOL, V150, P1122; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; ROSSITER H, 1994, EUR J IMMUNOL, V24, P205, DOI 10.1002/eji.1830240132; ROTZSCHKE O, 1991, EUR J IMMUNOL, V21, P2891, DOI 10.1002/eji.1830211136; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA M, 1993, BIOCHEM BIOPH RES CO, V193, P337, DOI 10.1006/bbrc.1993.1629; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; TAMATANI T, 1995, AM J PHYSIOL-HEART C, V269, pH1282, DOI 10.1152/ajpheart.1995.269.4.H1282; Tipping PG, 1996, EUR J IMMUNOL, V26, P454, DOI 10.1002/eji.1830260228; VACHINO G, 1995, J BIOL CHEM, V270, P21966, DOI 10.1074/jbc.270.37.21966; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Vestweber D, 1996, J CELL BIOCHEM, V61, P585, DOI 10.1002/(SICI)1097-4644(19960616)61:4<585::AID-JCB12>3.0.CO;2-F; VESTWEBER D, 1997, SELECTIONS INITIATOR; WELLER A, 1992, J BIOL CHEM, V267, P15176; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002	43	79	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28786	28792		10.1074/jbc.272.45.28786	http://dx.doi.org/10.1074/jbc.272.45.28786			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353350	hybrid			2022-12-27	WOS:A1997YF21900090
J	Mahmud, I; Ueda, N; Yamaguchi, H; Yamashita, R; Yamamoto, S; Kanaoka, Y; Urade, Y; Hayaishi, O				Mahmud, I; Ueda, N; Yamaguchi, H; Yamashita, R; Yamamoto, S; Kanaoka, Y; Urade, Y; Hayaishi, O			Prostaglandin D synthase in human megakaryoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D SYNTHETASE; CDNA CLONING; D-ISOMERASE; BETA-TRACE; PURIFICATION; LINE; IDENTIFICATION; PROTEIN; CMK	The cytosol fraction of human platelets did not convert prostaglandin (PG) H-2 to PGD(2). However, a homogenate of human megakaryoblastic CMK cells (precursor cells of platelets) produced PGD(2) from PGH(2). The PGD synthase activity was localized in the cytosol of CMK cells, and absolutely required glutathione. The catalytic properties and Western and Northern blottings indicated that the enzyme was PGD synthase of the hematopoietic type rather than the lipocalin type, When CMK cells were differentiated to megakaryocytes with phorbol ester along with induction of cyclooxygenase-l, the PGD synthase activity increased about 2-fold for 2 days and then decreased. In another human megakaryoblastic cell line, Dami, the PGD synthase increased about 10-fold by the addition of phorbol ester. Thus, the PGD synthase, which was undetectable in platelets, appeared during differentiation of megakaryoblasts to megakaryocytes.	UNIV TOKUSHIMA,SCH MED,DEPT BIOCHEM,TOKUSHIMA 770,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; OSAKA BIOSCI INST,DEPT MOL BEHAV BIOL,SUITA,OSAKA 565,JAPAN	Tokushima University; Tokushima University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTHAZELHOF E, 1979, BIOCHIM BIOPHYS ACTA, V572, P43, DOI 10.1016/0005-2760(79)90198-X; ENDO T, 1995, AM J RESP CELL MOL, V12, P358, DOI 10.1165/ajrcmb.12.3.7873203; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1991, FATTY ACIDS, V47, P1; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GREENBERG SM, 1988, BLOOD, V72, P1968; HAYAISHI O, 1991, FASEB J, V5, P2575, DOI 10.1096/fasebj.5.11.1907936; HOFFMANN A, 1993, J NEUROCHEM, V61, P451; KANAOKA Y, 1996, FATTY ACIDS S1, V55, P123; KOMATSU N, 1989, BLOOD, V74, P42; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SHEPPARD KA, 1992, BIOCHIM BIOPHYS ACTA, V1133, P223, DOI 10.1016/0167-4889(92)90073-K; TAKAHASHI Y, 1992, BIOCHEM BIOPH RES CO, V182, P433, DOI 10.1016/0006-291X(92)91750-K; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; Ueda N, 1997, BBA-LIPID LIPID MET, V1344, P103, DOI 10.1016/S0005-2760(96)00131-2; URADE Y, 1989, J IMMUNOL, V143, P2982; URADE Y, 1987, J BIOL CHEM, V262, P3820; URADE Y, 1995, J LIPID MEDIAT CELL, V12, P257, DOI 10.1016/0929-7855(95)00032-L; URADE Y, 1985, J BIOL CHEM, V260, P2410; URADE Y, 1990, J BIOL CHEM, V265, P371; WATANABE K, 1994, BIOCHEM BIOPH RES CO, V203, P1110, DOI 10.1006/bbrc.1994.2297; WATANABE T, 1982, J BIOL CHEM, V257, P4847; Yamashima T, 1997, J NEUROSCI, V17, P2376	27	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28263	28266		10.1074/jbc.272.45.28263	http://dx.doi.org/10.1074/jbc.272.45.28263			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353279	hybrid			2022-12-27	WOS:A1997YF21900019
J	Moeck, GS; Coulton, JW; Postle, K				Moeck, GS; Coulton, JW; Postle, K			Cell envelope signaling in Escherichia coli - Ligand binding to the ferrichrome-iron receptor FhuA promotes interaction with the energy-transducing protein TonB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE TRANSPORT; INDUCED CONFORMATIONAL CHANGE; CONSENSUS PENTAPEPTIDE; VITAMIN-B12 TRANSPORT; ENTEROBACTIN RECEPTOR; CYTOPLASMIC MEMBRANE; BTUB451 MUTATION; GENE ENCODES; K-12; SUPPRESSION	The ferrichrome-iron receptor of Escherichia coli is FhuA, an outer membrane protein that is dependent upon the energy coupling protein TonB to enable active transport of specific hydroxamate siderophores, infection by certain phages, and cell killing by the protein antibiotics colicin M and microcin 25. In vivo cross-linking studies were performed to establish at the biochemical level the interaction between FhuA and TonB. In an E. coli strain in which both proteins were expressed from the chromosome, a high molecular mass complex was detected when the ferrichrome homologue ferricrocin was added immediately prior to addition of crosslinker, The complex included both proteins; it was absent from strains of E. coli that were devoid of either FhuA or TonB, and it was detected with anti-FhuA and anti-TonB monoclonal antibodies, These results indicate that, in vivo, the binding of ferricrocin to FhuA enhances complex formation between the receptor and TonB, An in vitro system was established with which to examine the FhuA-TonB interaction, Incubation of TonB with histidine-tagged FhuA followed by addition of Ni2+-nitrilotriacetate-agarose led to the specific recovery of both TonB and FhuA. Addition of ferricrocin or colicin M to FhuA in this system greatly increased the coupling between FhuA and TonB, Conversely, a monoclonal antibody that binds near the N terminus of FhuA reduced the retention of TonB by histidine-tagged FhuA. These studies demonstrate the significance of ligand binding at the external surface of the cell to mediate signal transduction across the outer membrane.	MCGILL UNIV, DEPT MICROBIOL & IMMUNOL, MONTREAL, PQ H3A 2B4, CANADA; WASHINGTON STATE UNIV, DEPT MICROBIOL, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	McGill University; Washington State University; Washington State University				Postle, Kathleen/0000-0001-9451-777X				ANTON M, 1993, MOL GEN GENET, V239, P371, DOI 10.1007/BF00276935; BASSFORD PJ, 1976, J BACTERIOL, V128, P242, DOI 10.1128/JB.128.1.242-247.1976; BELL PE, 1990, J BACTERIOL, V172, P3826, DOI 10.1128/jb.172.7.3826-3829.1990; Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; BRADBEER C, 1976, J BACTERIOL, V128, P99, DOI 10.1128/JB.128.1.99-104.1976; BRADBEER C, 1993, J BACTERIOL, V175, P3146, DOI 10.1128/JB.175.10.3146-3150.1993; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; BRINKLEY M, 1992, BIOCONJUGATE CHEM, V3, P2, DOI 10.1021/bc00013a001; CARMEL G, 1990, J BACTERIOL, V172, P1861, DOI 10.1128/jb.172.4.1861-1869.1990; CARMEL G, 1991, J BACTERIOL, V173, P4394, DOI 10.1128/JB.173.14.4394-4403.1991; COULTON JW, 1986, J BACTERIOL, V165, P181, DOI 10.1128/jb.165.1.181-192.1986; Earhart C.F., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1075; GUDMUNDSDOTTIR A, 1989, J BACTERIOL, V171, P6526, DOI 10.1128/jb.171.12.6526-6533.1989; GUNTER K, 1990, FEBS LETT, V274, P85, DOI 10.1016/0014-5793(90)81335-L; HANCOCK REW, 1976, J BACTERIOL, V125, P409, DOI 10.1128/JB.125.2.409-415.1976; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; HELLER KJ, 1988, GENE, V64, P147, DOI 10.1016/0378-1119(88)90488-X; HILL CW, 1981, P NATL ACAD SCI-BIOL, V78, P7069, DOI 10.1073/pnas.78.11.7069; INGHAM C, 1990, J BACTERIOL, V172, P3577, DOI 10.1128/jb.172.7.3577-3583.1990; JAROSIK GP, 1994, INFECT IMMUN, V62, P2470, DOI 10.1128/IAI.62.6.2470-2477.1994; JASKULA JC, 1994, J BACTERIOL, V176, P2326, DOI 10.1128/JB.176.8.2326-2338.1994; Jiang XQ, 1997, SCIENCE, V276, P1261, DOI 10.1126/science.276.5316.1261; KADNER RJ, 1995, J BACTERIOL, V177, P4829, DOI 10.1128/jb.177.17.4829-4835.1995; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KOEBNIK R, 1993, MOL GEN GENET, V237, P152, DOI 10.1007/BF00282796; LARSEN RA, 1994, MOL MICROBIOL, V13, P627, DOI 10.1111/j.1365-2958.1994.tb00457.x; LARSEN RA, 1993, MOL MICROBIOL, V10, P943, DOI 10.1111/j.1365-2958.1993.tb00966.x; Larsen RA, 1997, J BACTERIOL, V179, P3213, DOI 10.1128/jb.179.10.3213-3221.1997; Larsen RA, 1996, J BACTERIOL, V178, P1363, DOI 10.1128/jb.178.5.1363-1373.1996; Letellier L, 1997, J BIOL CHEM, V272, P8836; LeVier K, 1996, J BACTERIOL, V178, P7265, DOI 10.1128/jb.178.24.7265-7275.1996; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; LIU J, 1994, BIOCHEMISTRY-US, V33, P13274, DOI 10.1021/bi00249a014; Locher KP, 1997, J BIOL CHEM, V272, P1448, DOI 10.1074/jbc.272.3.1448; Means G.E., 1971, CHEM MODIFICATION PR; MOECK GS, 1995, J BACTERIOL, V177, P6118, DOI 10.1128/jb.177.21.6118-6125.1995; Moeck GS, 1996, MOL MICROBIOL, V22, P459, DOI 10.1046/j.1365-2958.1996.00112.x; Mondigler M, 1996, VIROLOGY, V219, P19, DOI 10.1006/viro.1996.0218; MONDIGLER M, 1995, FEMS MICROBIOL LETT, V130, P293; NAU CD, 1989, J BACTERIOL, V171, P1041, DOI 10.1128/jb.171.2.1041-1047.1989; NIKAIDO H, 1994, METHOD ENZYMOL, V235, P225; Plancon L, 1997, J BIOL CHEM, V272, P16868, DOI 10.1074/jbc.272.27.16868; Poole K, 1996, MICROBIOL-UK, V142, P1449, DOI 10.1099/13500872-142-6-1449; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; POSTLE K, 1983, P NATL ACAD SCI-BIOL, V80, P5235, DOI 10.1073/pnas.80.17.5235; REYNOLDS PR, 1980, J BIOL CHEM, V255, P4313; SALOMON RA, 1992, J BACTERIOL, V174, P7428, DOI 10.1128/jb.174.22.7428-7435.1992; SCHOFFLER H, 1989, MOL GEN GENET, V217, P378, DOI 10.1007/BF02464907; SCHRAMM E, 1987, J BACTERIOL, V169, P3350, DOI 10.1128/jb.169.7.3350-3357.1987; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; SKARE JT, 1993, J BIOL CHEM, V268, P16302; SUN TP, 1986, J BACTERIOL, V165, P107, DOI 10.1128/jb.165.1.107-115.1986; TUCKMAN M, 1992, J BACTERIOL, V174, P320, DOI 10.1128/jb.174.1.320-323.1992; YELTON DE, 1981, HYBRIDOMA, V1, P5, DOI 10.1089/hyb.1.1981.1.5	56	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28391	28397		10.1074/jbc.272.45.28391	http://dx.doi.org/10.1074/jbc.272.45.28391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353297	hybrid			2022-12-27	WOS:A1997YF21900037
J	Unkles, SE; Smith, J; Kanan, GJMM; Millar, LJ; Heck, IS; Boxer, DH; Kinghorn, JR				Unkles, SE; Smith, J; Kanan, GJMM; Millar, LJ; Heck, IS; Boxer, DH; Kinghorn, JR			The Aspergillus nidulans cnxABC locus is a single gene encoding two catalytic domains required for synthesis of precursor Z, an intermediate in molybdenum cofactor biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLYBDOPTERIN BIOSYNTHESIS; NITRATE ASSIMILATION; CONVERTING FACTOR; EARLY STEPS; CONTAINS; CLONING; CHLA; NIIA	The Aspergillus nidulans complex locus, cnxABC, has been shown to be required for the synthesis of precursor Z, an intermediate in the molybdopterin cofactor pathway. The locus was isolated by chromosome walking a physical distance of 65-kilobase pairs from the brlA gene and defines a single transcript that encodes, most likely, a difunctional protein with two catalytic domains, CNXA and CNXC. Mutations (cnxA) affecting the CNXA domain, mutants (cnxC) in the CNXC domain, and frameshift (cnxB) mutants disrupting both domains have greatly reduced levels of precursor Z compared with the wild type. The CNXA domain is similar at the amino acid level to the Escherichia coli moaA gene product, while CNXC is similar to the E. coli moaC product, with both E. coli products encoded by different cistrons. In the wild type, precursor Z levels are 3-4 times higher in nitrate-grown cells than in those grown on ammonium, and there is an approximately parallel increase in the 2.4-kilobase pair transcript following growth on nitrate, suggesting nitrate induction of this early section of the pathway. Analysis of the deduced amino acid sequence of several mutants has identified residues critical for the function of the protein. In the CNXA section of the protein, insertion of three amino acid residues into a domain thought to bind an iron-sulfur cofactor leads to a null phenotype as judged by complete loss of activity of the molybdoenzyme, nitrate reductase. More specifically, a mutant has been characterized in which tyrosine replaces cysteine 345, one of several cysteine residues probably involved in binding the cofactor. This supports the proposition that these residues play an essential catalytic role. An insertion of seven amino acids between residues valine 139 and serine 140, leads to a temperature-sensitive phenotype, suggesting a conformational change affecting the catalytic activity of the CNXA region only. A single base pair deletion leading to an in frame stop codon in the CNXC region, which causes a null phenotype, effectively deletes the last 20 amino acid residues of the protein, indicating that these residues are necessary for catalytic function.	MONASH UNIV,DEPT MICROBIOL,CLAYTON,VIC 3168,AUSTRALIA; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	Monash University; University of Dundee	Unkles, SE (corresponding author), UNIV ST ANDREWS,SCH ENVIRONM & EVOLUTIONARY BIOL,ST ANDREWS KY16 9TH,FIFE,SCOTLAND.							Arst HN, 1996, MOL MICROBIOL, V19, P1019; ARST HN, 1982, J GEN MICROBIOL, V128, P1083; BRODY H, 1991, NUCLEIC ACIDS RES, V19, P3105, DOI 10.1093/nar/19.11.3105; Clutterbuck A.J, 1974, HDB GENETICS, V1, P447; COVE DJ, 1963, NATURE, V198, P262, DOI 10.1038/198262a0; COVE DJ, 1979, BIOL REV, V54, P291, DOI 10.1111/j.1469-185X.1979.tb01014.x; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; GEMS DH, 1993, CURR GENET, V24, P520, DOI 10.1007/BF00351716; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; HARTLEY MJ, 1970, GENET RES, V16, P123, DOI 10.1017/S0016672300002330; HOFF T, 1995, J BIOL CHEM, V270, P6100, DOI 10.1074/jbc.270.11.6100; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; JOHNSTONE IL, 1985, EMBO J, V4, P1307, DOI 10.1002/j.1460-2075.1985.tb03777.x; MACCABE AP, 1990, EMBO J, V9, P279, DOI 10.1002/j.1460-2075.1990.tb08106.x; PATEMAN JA, 1964, NATURE, V201, P58, DOI 10.1038/201058a0; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; PUNT PJ, 1995, MOL CELL BIOL, V15, P5688; RAJAGOPALAN KV, 1997, NITROGEN ASSIMILATIO; RIVERS SL, 1993, MOL MICROBIOL, V8, P1071, DOI 10.1111/j.1365-2958.1993.tb01652.x; SCAZZOCC.C, 1974, J LESS-COMMON MET, V36, P461, DOI 10.1016/0022-5088(74)90130-1; SCAZZOCCHIO C, 1980, MOLYBDENUM MOLYBDENU, P489; SUAREZ T, 1995, EMBO J, V14, P1453, DOI 10.1002/j.1460-2075.1995.tb07132.x; TOMSETT AB, 1989, NITROGEN PHOSPHORUS, P33; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082	29	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28381	28390		10.1074/jbc.272.45.28381	http://dx.doi.org/10.1074/jbc.272.45.28381			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353296	hybrid, Green Published			2022-12-27	WOS:A1997YF21900036
J	Abdollah, S; MaciasSilva, M; Tsukazaki, T; Hayashi, H; Attisano, L; Wrana, JL				Abdollah, S; MaciasSilva, M; Tsukazaki, T; Hayashi, H; Attisano, L; Wrana, JL			T beta RI phosphorylation of Smad2 on Ser(465) and Ser(467) is required for Smad2-Smad4 complex formation and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; GLYCOGEN-SYNTHASE KINASE-3; MAD-RELATED PROTEIN; RECEPTOR COMPLEX; ACTS DOWNSTREAM; DROSOPHILA; PATHWAY; FAMILY; TRANSDUCTION; ACTIVATION	Mothers against Dpp-related or Smad proteins are essential components of serine/threonine kinase receptor signaling pathways that are regulated by phosphorylation. Recently, it was demonstrated that Smad2 interacts transiently with and is a direct substrate of the transforming growth factor-beta (TGF-beta) type I receptor, T beta RI. Phosphorylation sites on Smad2 were localized to a carboxyl-terminal fragment containing three serine residues at positions 464, 465, and 467. In this report, we show that T beta RI specifically phosphorylates Smad2 on serines 465 and 467. Serine 464 is not a site of phosphorylation, but is important for efficient phosphorylation of Smad2. Phosphorylation at both sites is required to mediate association of Smad2 with Smad4 in mammalian cells, while in yeast, Smad2 interacts directly with Smad4 and does not require phosphorylation. Mutation of either serine residue 465 or 467 prevents dissociation of Smad2 from activated T beta RI and blocks TGF-beta-dependent signaling and Smad2 transcriptional activity. These results indicate that receptor-dependent phosphorylation of Smad2 on serines 465 and 467 is required in mammalian cells to permit association with Smad4 and to propagate TGF-beta signals.	HOSP SICK CHILDREN, PROGRAM DEV BIOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DIV GASTROENTEROL, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT MED GENET & MICROBIOL, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, DEPT ANAT & CELL BIOL, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto			Wrana, Jeffrey/F-8857-2013	Macias-Silva, Marina/0000-0002-3972-0983				Attisano L, 1996, MOL CELL BIOL, V16, P1066; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN RH, 1994, J BIOL CHEM, V269, P22868; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CANCER SURV, V27, P41; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAFTERY LA, 1995, GENETICS, V139, P241; Sambrook J., MOL CLONING LAB MANU; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SMITH DB, 1990, CURRENT PROTOCOLS MO; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Woodgett JR, 1991, METHOD ENZYMOL, V200, P564; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	41	396	419	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27678	27685		10.1074/jbc.272.44.27678	http://dx.doi.org/10.1074/jbc.272.44.27678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346908	hybrid			2022-12-27	WOS:A1997YD47300034
J	Fasshauer, D; Otto, H; Eliason, WK; Jahn, R; Brunger, AT				Fasshauer, D; Otto, H; Eliason, WK; Jahn, R; Brunger, AT			Structural changes are associated with soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; LIGHT-SCATTERING; IN-VITRO; T-SNARE; SYNTAXIN; SNAP-25; TRANSPORT; PALMITOYLATION; SPECIFICITY; POLYMERASE	SNAP-25, syntaxin, and synaptobrevin play a key role in the regulated exocytosis of synaptic vesicles, but their mechanism of action is not understood. In vitro, the proteins spontaneously assemble into a ternary complex that can be dissociated by the ATPase N-ethylmaleimide-sensitive fusion protein and the cofactors alpha-, beta-, and gamma-SNAP. Since the structural changes associated with these reactions probably form the basis of membrane fusion, we have embarked on biophysical studies aimed at elucidating such changes in vitro using recombinant proteins. All proteins were purified in a monomeric form. Syntaxin showed significant alpha-helicity, whereas SNAP-25 and synaptobrevin exhibited characteristics of largely unstructured proteins. Formation of the ternary complex induced dramatic increases in alpha-helicity and in thermal stability. This suggests that structure is induced in SNAP-25 and synaptobrevin upon complex formation. In addition, the stoichiometry changed from 2:1 in the syntaxin-SNAP-25 complex to 1:1:1 in the ternary complex. We propose that the transition from largely unstructured monomers to a tightly packed, energetically favored ternary complex connecting two membranes is a key step in overcoming energy barriers for membrane fusion.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,DEPT BIOCHEM & MOL BIOPHYS,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University; Yale University			Fasshauer, Dirk/B-1563-2013	Fasshauer, Dirk/0000-0002-1040-4282; Brunger, Axel/0000-0001-5121-2036; Jahn, Reinhard/0000-0003-1542-3498	NIGMS NIH HHS [GM54160-01] Funding Source: Medline; NINDS NIH HHS [5 RO1 NS33709-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033709] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Augustine GJ, 1996, ANNU REV PHARMACOL, V36, P659, DOI 10.1146/annurev.pa.36.040196.003303; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Calakos N, 1996, PHYSIOL REV, V76, P1; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hao JC, 1997, J NEUROSCI, V17, P1596; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HESS DT, 1992, J NEUROSCI, V12, P4634; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S	30	276	283	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28036	28041		10.1074/jbc.272.44.28036	http://dx.doi.org/10.1074/jbc.272.44.28036			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346956	hybrid			2022-12-27	WOS:A1997YD47300082
J	Chen, CM; Xie, Y; Stevenson, MA; Auron, PE; Calderwood, SK				Chen, CM; Xie, Y; Stevenson, MA; Auron, PE; Calderwood, SK			Heat shock factor 1 represses Ras-induced transcriptional activation of the c-fos gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; PROMOTER ELEMENTS; HSP70 GENE; EXPRESSION; PROTEIN; BINDING; PHOSPHORYLATION; ONCOGENES; CELLS; EUKARYOTES	Heat shock factor 1, the critical molecular regulator of the stress response is conserved throughout eukaryotic organisms and activates the transcription of heat shock genes. We now show that heat shock factor 1 inhibits the expression of c-fos, an immediate early gene that controls responses to extracellular stimuli for growth and differentiation. Heat shock factor 1 inhibits the transcription of the c-fos gene and antagonizes the activating effects of the signal transducing protein Has on the c-fos promoter and on the promoter of another Has responsive gene uPA. This property was specific for heat shock factor 1; c-fos repression was not seen with the structurally related protein heat shock factor 2, Repression involved different molecular mechanisms compared with those involved in transcriptional activation by heat shock factor 1 and specifically did not require binding to the c-fos promoter. Thus, in addition to its known role as a transcriptional activator of the cellular heat shock response, heat shock factor 1 also antagonizes the expression of Fos, a key component of the ubiquitous AP-1 transcription factor complex and as such could influence multiple aspects of cell regulation.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,CTR BLOOD RES,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School					NCI NIH HHS [CA4707, CA50642, CA31303] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050642, P01CA031303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; BOS JL, 1989, CANCER RES, V49, P4682; Cahill CM, 1996, J BIOL CHEM, V271, P24874; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; COLETTA F, 1990, BIOCHEM BIOPH RES CO, V168, P1013; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; GEORGOPOLIS C, 1993, ANN REV CELL BIOL, V22, P631; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gray S, 1996, GENE DEV, V10, P700, DOI 10.1101/gad.10.6.700; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HRUGER MJ, 1996, INFECT DIS N AM, V10, P1; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; METZ R, 1991, ONCOGENE, V6, P2165; Oesterreich S, 1996, BIOCHEM BIOPH RES CO, V222, P155, DOI 10.1006/bbrc.1996.0714; OPPERMANN J, 1989, NATURE, V341, P125; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAL GD, 1988, NUCLEIC ACIDS RES, V16, P9878; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Yang BS, 1996, MOL CELL BIOL, V16, P538	38	69	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26803	26806		10.1074/jbc.272.43.26803	http://dx.doi.org/10.1074/jbc.272.43.26803			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341107	hybrid			2022-12-27	WOS:A1997YC65900003
J	Chu, P; Murray, S; Lissin, D; vonZastrow, M				Chu, P; Murray, S; Lissin, D; vonZastrow, M			delta and kappa opioid receptors are differentially regulated by dynamin-dependent endocytosis when activated by the same alkaloid agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; PROTEIN-KINASE-C; OPIATE RECEPTOR; MOLECULAR MECHANISMS; DOWN-REGULATION; INTERNALIZATION; DESENSITIZATION; SEQUESTRATION; RESENSITIZATION; MUTANT	Many alkaloid drugs used as analgesics activate multiple opioid receptors. Mechanisms that distinguish the actions of these drugs on the regulation of individual mu, delta, and kappa receptors are not understood. We have observed that individual cloned opioid receptors differ Significantly in their regulation by rapid endocytosis in the presence of alkaloid drug etorphine, a potent agonist of mu, delta, and kappa opioid receptors. Internalization of epitope-tagged delta opioid receptors from the plasma membrane is detectable within 10 min in the presence of etorphine. In contrast, kappa receptors expressed in the same cells remain in the plasma membrane and are not internalized for greater than or equal to 60 min, even when cells are exposed to saturating concentrations of etorphine. The rapid internalization of delta receptors is specifically inhibited in cells expressing K44E mutant dynamin I, suggesting that type-specific internalization of opioid receptors is mediated by clathrin-coated pits. Examination of a series of chimeric mutant kappa/delta receptors indicates that at least two receptor domains, including the highly divergent carboxyl-termindi cytoplasmic tail, determine the type specificity of this endocytic mechanism. We conclude that structurally homologous opioid receptors are differentially sorted by clathrin-mediated endocytosis following-activation by the same agonist ligand. These studies identify a fundamental mechanism of receptor regulation mediating type-specific effects of analgesic drugs that activate more than one type of opioid receptor.	UNIV CALIF SAN FRANCISCO,NINA IRELAND LAB,LANGLEY PORTER INST,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR NEUROBIOL & PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019552] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00218] Funding Source: Medline; NIMH NIH HHS [MH19552] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Akil H, 1996, NIDA Res Monogr, V161, P127; Baba T, 1995, COLD SPRING HARB SYM, V60, P235, DOI 10.1101/SQB.1995.060.01.027; Blake AD, 1996, CHEM BIOL, V3, P967, DOI 10.1016/S1074-5521(96)90163-5; Blake AD, 1997, J BIOL CHEM, V272, P782, DOI 10.1074/jbc.272.2.782; Bohm SK, 1996, J BIOL CHEM, V271, P22003; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Evans CJ, 1993, BIOL BASIS SUBSTANCE, P31; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HUGHES J, 1977, BRIT MED BULL, V33, P157, DOI 10.1093/oxfordjournals.bmb.a071416; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Krueger KM, 1997, J BIOL CHEM, V272, P5; LAW PY, 1984, J BIOL CHEM, V259, P4096; Law PY, 1997, MOL PHARMACOL, V51, P152, DOI 10.1124/mol.51.1.152; LAW PY, 1982, MOL PHARMACOL, V72, P1; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; Mostafapour S, 1996, RECEPT SIGNAL TRANS, V6, P151; PEI G, 1995, MOL PHARMACOL, V48, P173; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Raynor K, 1996, NIDA Res Monogr, V161, P83; Reisine T, 1996, ANN NY ACAD SCI, V780, P168, DOI 10.1111/j.1749-6632.1996.tb15121.x; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	35	133	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27124	27130		10.1074/jbc.272.43.27124	http://dx.doi.org/10.1074/jbc.272.43.27124			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341153	hybrid			2022-12-27	WOS:A1997YC65900049
J	VazquezPrado, J; Medina, LD; GarciaSainz, JA				VazquezPrado, J; Medina, LD; GarciaSainz, JA			Activation of endothelin ETA receptors induces phosphorylation of alpha(1b)-adrenoreceptors in rat-1 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; INOSITOL PHOSPHOLIPID-METABOLISM; PHORBOL-MYRISTATE ACETATE; KINASE-C ISOFORMS; ADRENERGIC-RECEPTOR; ALPHA-1-ADRENERGIC RECEPTORS; TYROSINE PHOSPHORYLATION; LYSOPHOSPHATIDIC ACID; REGULATORY PROTEINS; CROSS-TALK	The effect of endothelin-l on the phosphorylation of alpha(1b)-adrenoreceptors, transfected into rat-1 fibroblasts, was studied, Basal alpha(1b)-adrenoreceptor phosphorylation was markedly increased by endothelin-l, norepinephrine, and phorbol esters, The effect of endothelin-l was dose dependent (EC50 approximate to 1 nM), reached its maximum 5 min after stimulation, and was inhibited by BQ-123, an antagonist selective for ETA receptors. Endothelin-1-induced alpha(1b)-adrenoreceptor phosphorylation was attenuated by staurosporine or genistein and essentially abolished when both inhibitors were used together. The effect of norepinephrine. was not modified by either staurosporine or genistein alone, and it was only partially inhibited when both were used together. These data suggest the participation of protein kinase C and tyrosine kinase(s) in endothelin-l-induced receptor phosphorylation. However, phosphoaminoacid analysis revealed the presence of phosphoserine and traces of phosphothreonine, but not of phosphotyrosine, suggesting that the putative tyrosine kinase(s), activated by endothelin, could act in a step previous to receptor phosphorylation. The effect of endothelin-1 on alpha(1b)-adrenoreceptor phosphorylation was not mediated through pertussis toxin-sensitive G proteins. Calcium mobilization induced by norepinephrine was diminished by endothelin-l, Norepinephrine and endothelin-1 increased [S-35]GTP gamma S binding to control membranes. The effect of norepinephrine was abolished in membranes obtained from cells pretreated with endothelin-l. Interestingly, genistein plus staurosporine inhibited this effect of the endothelial peptide, Endothelin-l did not induce alpha(1b)-adrenoreceptor internalization, Our data indicate that activation of ETA receptors by endothelin-1 induces alpha(1b)-adrenoreceptor phosphorylation and alters G protein coupling.	NATL AUTONOMOUS UNIV MEXICO,INST FISIOL CELULAR,DEPT CELL BIOL,MEXICO CITY 04510,DF,MEXICO; UNIV AUTONOMA METROPOLITANA IZTAPALAPA,DEPT REPROD BIOL,DIV CBS,MEXICO CITY 09340,DF,MEXICO	Universidad Nacional Autonoma de Mexico; Universidad Autonoma Metropolitana - Mexico			GARCIA-SAINZ, JESUS ADOLFO/A-5389-2008; VAZQUEZ-PRADO, JOSE/C-1630-2017	GARCIA-SAINZ, JESUS ADOLFO/0000-0002-5235-0657; VAZQUEZ-PRADO, JOSE/0000-0001-5797-6643				AMBAR I, 1993, EUR J PHARM-MOLEC PH, V245, P31, DOI 10.1016/0922-4106(93)90166-7; BEELER JF, 1995, BIOCHEM J, V305, P73, DOI 10.1042/bj3050073; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BERTI L, 1994, J BIOL CHEM, V269, P3381; BOUVIER M, 1987, J BIOL CHEM, V262, P3106; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHAU LY, 1993, J NEUROCHEM, V60, P454, DOI 10.1111/j.1471-4159.1993.tb03172.x; Chen X, 1995, BIOCHEM BIOPH RES CO, V217, P445, DOI 10.1006/bbrc.1995.2796; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; CLERK A, 1994, J BIOL CHEM, V269, P32848; COOPER RH, 1985, J BIOL CHEM, V260, P3281; CORVERA S, 1986, J BIOL CHEM, V261, P520; CORVERA S, 1984, BIOCHEM BIOPH RES CO, V119, P1128, DOI 10.1016/0006-291X(84)90892-1; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DAMRON DS, 1993, J BIOL CHEM, V268, P27335; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Diviani D, 1996, J BIOL CHEM, V271, P5049; DONOSO MV, 1994, BRIT J PHARMACOL, V111, P473, DOI 10.1111/j.1476-5381.1994.tb14761.x; FONSECA MI, 1995, J BIOL CHEM, V270, P8902, DOI 10.1074/jbc.270.15.8902; GARCIASAINZ JA, 1989, AM J PHYSIOL, V256, pC384, DOI 10.1152/ajpcell.1989.256.2.C384; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HABER E, 1994, NATURE, V370, P252, DOI 10.1038/370252a0; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HIEBLE JP, 1995, PHARMACOL REV, V47, P267; JAMES AF, 1994, NATURE, V370, P297, DOI 10.1038/370297a0; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; LYNCH CJ, 1985, J BIOL CHEM, V260, P2844; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MATTINGLY RR, 1992, J BIOL CHEM, V267, P7470; MINNEMAN KP, 1994, ANNU REV PHARMACOL, V34, P117; Nambi P, 1996, J PHARMACOL EXP THER, V277, P1567; ONO K, 1994, NATURE, V370, P301, DOI 10.1038/370301a0; PACHTER JA, 1993, BIOCHEM J, V294, P153, DOI 10.1042/bj2940153; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; SAVILLE MK, 1994, BIOCHEM J, V301, P407, DOI 10.1042/bj3010407; SEKURA RD, 1983, J BIOL CHEM, V258, P4647; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VazquezPrado J, 1996, MOL PHARMACOL, V50, P17; WIELAND T, 1994, METHOD ENZYMOL, V237, P3; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZUZAGA JL, 1996, EMBO J, V15, P6220	50	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27330	27337		10.1074/jbc.272.43.27330	http://dx.doi.org/10.1074/jbc.272.43.27330			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341183	hybrid			2022-12-27	WOS:A1997YC65900079
J	Zhang, SH; Kobayashi, R; Graves, PR; PiwnicaWorms, H; Tonks, NK				Zhang, SH; Kobayashi, R; Graves, PR; PiwnicaWorms, H; Tonks, NK			Serine phosphorylation-dependent association of the band 4.1-related protein-tyrosine phosphatase PTPH1 with 14-3-3 beta protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL-ASSOCIATED PROTEINS; MULTIPLE SIGNALING PATHWAYS; SEQUENCE HOMOLOGY; IN-VIVO; T-CELLS; 14-3-3-PROTEINS; KINASE; CLONING; IDENTIFICATION; EXPRESSION	PTPH1 is a human protein-tyrosine phosphatase with homology to the band 4.1 superfamily of cytoskeletal-associated proteins. PTPH1 was found to associate with 14-3-3 beta using a yeast two-hybrid screen, and its interaction could be reconstituted in vitro using recombinant proteins. Examination of the interaction between 14-3-3 beta and various deletion mutants of PTPH1 by two-hybrid tests suggested that the integrity of the PTP is important for this binding. Although both PTPH1 and Raf-1 form complexes with 14-3-3 beta, they appear to do so independently, Binding of 14-3-3 beta to PTPH1 in vitro was abolished by pretreating PTPH1 with potato acid phosphatase and was greatly enhanced by pretreating with Cdc25C-associated protein kinase. Thus the association between PTPH1 and 14-3-3 beta is phosphorylation-dependent. Two novel motifs (RSLSVE)-V-359 and (RVDSEP)-E-853 in PTPH1 were identified as major 14-3-3 beta-binding sites, both of which are distinct from the consensus binding motif RSXSXP recently found in Raf-l. Mutation of Ser(359) and Ser(853) to alanine significantly reduced the association between 14-3-3 beta and PTPH1. Furthermore, association of PTPH1 and 14-3-3 beta was detected in several cell lines and was regulated in response to extracellular signals. These results raise the possibility that 14-3-3 beta may function as an adaptor molecule in the regulation of PTPH1 and may provide a link between serine/threonine and tyrosine phosphorylation-dependent signaling pathways.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Washington University (WUSTL)			Piwnica-Worms, Helen/C-5214-2012		NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018428] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840] Funding Source: Medline; NIGMS NIH HHS [GM18428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; LABBE D, 1994, FEBS LETT, V356, P351, DOI 10.1016/0014-5793(94)01305-5; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; OGG S, 1994, J BIOL CHEM, V269, P30461; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SAHIN M, 1995, P NATL ACAD SCI USA, V92, P7859, DOI 10.1073/pnas.92.17.7859; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SAWADA M, 1994, BIOCHEM BIOPH RES CO, V203, P479, DOI 10.1006/bbrc.1994.2207; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; SMITH AL, 1995, BIOCHEM BIOPH RES CO, V209, P959, DOI 10.1006/bbrc.1995.1591; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG SH, 1995, J BIOL CHEM, V270, P20067, DOI 10.1074/jbc.270.34.20067; ZHANG SH, 1994, J BIOL CHEM, V269, P17593	49	87	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27281	27287		10.1074/jbc.272.43.27281	http://dx.doi.org/10.1074/jbc.272.43.27281			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341175	hybrid			2022-12-27	WOS:A1997YC65900071
J	Banik, U; Wang, GA; Wagner, PD; Kaufman, S				Banik, U; Wang, GA; Wagner, PD; Kaufman, S			Interaction of phosphorylated tryptophan hydroxylase with 14-3-3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; BIOSPECIFIC INTERACTION ANALYSIS; HIGH-LEVEL EXPRESSION; RAT BRAIN-STEM; TYROSINE-HYDROXYLASE; ACTIVATOR PROTEIN; ESCHERICHIA-COLI; PHENYLALANINE-HYDROXYLASE; CEREBROSPINAL-FLUID; MOLECULAR-CLONING	Rabbit brain tryptophan hydroxylase (TPH) has been expressed in insect cells (Spodoptera frugiperda) as a histidine-tagged enzyme. The specific activity of the purified fusion enzyme is 80 nmol of 5-hydroxytryptophan/min/mg. Multifunctional regulatory 14-3-3 proteins were purified from fresh bovine brain. Phosphorylation and 14-3-3 proteins play important roles in the regulation of TPH activity. We have found that phosphorylation of TPH by cAMP-dependent protein kinase increased the activity of the hydroxylase by 25-30% and that 14-3-3 proteins increased the hydroxylase activity of phosphorylated TPH by similar to 45%. Under these conditions, the 14-3-3 proteins were not phosphorylated, and unphosphorylated TPH was not activated by 14-3-3 proteins. Surface plasmon resonance analysis demonstrated that 14-3-3 proteins bind to phosphorylated TPH with an affinity constant (K-a) of 4.5 x 10(7) M-1. Binding studies using affinity chromatography also showed that 14-3-3 proteins interact with phosphorylated TPH. The dephosphorylation of TPH by protein phosphatase-l was inhibited by 14-3-3 proteins. Our results demonstrate that 14-3-3 proteins form a complex with phosphorylated brain TPH, thereby increasing its enzymatic activity and inhibiting its dephosphorylation.	NCI, BIOCHEM LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Banik, U (corresponding author), NIMH, NEUROCHEM LAB, NIH, BLDG 36, RM 3D30, BETHESDA, MD 20892 USA.							AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; ATKINSON J, 1987, J NEUROCHEM, V49, P1241, DOI 10.1111/j.1471-4159.1987.tb10016.x; BOSTON PF, 1982, J NEUROCHEM, V38, P1466, DOI 10.1111/j.1471-4159.1982.tb07927.x; BOSTON PF, 1982, J NEUROCHEM, V38, P1475, DOI 10.1111/j.1471-4159.1982.tb07928.x; Brown S-L, 1991, ROLE SEROTONIN PSYCH; CHEN FS, 1994, FEBS LETT, V347, P128, DOI 10.1016/0014-5793(94)00520-6; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FISHER DB, 1973, J BIOL CHEM, V248, P4345; FITZPATRICK PF, 1990, J BIOL CHEM, V265, P2042; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FRIEDMAN PA, 1972, J BIOL CHEM, V247, P4165; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FUNAKOSHI H, 1991, J BIOL CHEM, V266, P15614; GOLDEN RN, 1990, PSYCHIAT ANN, V20, P558, DOI 10.3928/0048-5713-19901001-05; Goldman ER, 1997, BIOCHEMISTRY-US, V36, P49, DOI 10.1021/bi961769k; HASEGAWA H, 1987, METHOD ENZYMOL, V142, P88; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1987, FEBS LETT, V219, P79, DOI 10.1016/0014-5793(87)81194-8; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; JEQUIER E, 1967, MOL PHARMACOL, V3, P274; JOHANSEN PA, 1995, J NEUROCHEM, V65, P882; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KAUFMAN S, 1970, METHODS ENZYMOL    A, V17, P603; Kaufman S., 1974, MOL MECH OXYGEN ACTI, P285; KIM KS, 1991, MOL BRAIN RES, V9, P277; Kuhn DM, 1997, J NEUROCHEM, V68, P2220; KUHN DM, 1980, J BIOL CHEM, V255, P4137; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MAKITA Y, 1990, FEBS LETT, V268, P185, DOI 10.1016/0014-5793(90)81004-8; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NAKATA H, 1982, EUR J BIOCHEM, V122, P41, DOI 10.1111/j.1432-1033.1982.tb05845.x; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PHILLIPS RS, 1984, J BIOL CHEM, V259, P2474; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; SHIMAN R, 1970, METHODS ENZYMOLOGY A, V17, P609; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STOLL J, 1990, GENOMICS, V7, P88, DOI 10.1016/0888-7543(90)90522-V; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; TANJI M, 1994, J NEUROCHEM, V63, P1908; TIPPER JP, 1994, ARCH BIOCHEM BIOPHYS, V315, P445, DOI 10.1006/abbi.1994.1523; TONG JH, 1975, J BIOL CHEM, V250, P4152; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; VRANA KE, 1994, LIFE SCI, V55, P1045, DOI 10.1016/0024-3205(94)00639-3; WANG YH, 1991, P NATL ACAD SCI USA, V88, P8779, DOI 10.1073/pnas.88.19.8779; WHITAKERAZMITIA PM, 1990, ANN NY ACAD SCI, V600, P315, DOI 10.1111/j.1749-6632.1990.tb16892.x; WU YN, 1992, BIOCHEM J, V285, P697, DOI 10.1042/bj2850697; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YAMAUCHI T, 1981, BIOCHEM BIOPH RES CO, V100, P807, DOI 10.1016/S0006-291X(81)80246-X; YAMAUCHI T, 1979, ARCH BIOCHEM BIOPHYS, V198, P219, DOI 10.1016/0003-9861(79)90413-2; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404; YANG XJ, 1994, P NATL ACAD SCI USA, V91, P6659, DOI 10.1073/pnas.91.14.6659; Zoche M, 1996, BIOCHEMISTRY-US, V35, P8742, DOI 10.1021/bi960445t	64	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26219	26225		10.1074/jbc.272.42.26219	http://dx.doi.org/10.1074/jbc.272.42.26219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334190	hybrid			2022-12-27	WOS:A1997YB13900024
J	Basuyaux, JP; Ferreira, E; Stehelin, D; Buttice, G				Basuyaux, JP; Ferreira, E; Stehelin, D; Buttice, G			The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA-dependent and -independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN STROMELYSIN GENE; BINDING MOTIF; AP-1 SITE; FAMILY; EXPRESSION; INHIBITION; PROMOTER; ERG; TPA; TRANSACTIVATION	The transcription factors Fos,Jun, and Ets regulate the expression of human stromelysin-1 and collagenase-1 genes, Recently, we found that ERG, an Ets family member, activates collagenase-1 gene but not stromely-sin-1 by physically interacting with c-Fos/c-Jun, Interestingly, ERG binds to stromelysin-1 promoter and represses its activation by ETS2. Here, to investigate the molecular mechanism of this regulation, we have used an in vitro protein-protein interaction assay and studied the transcription factor interactions of ETS2. We found that ETS2 could weakly associate with in vitro synthesized ETS1, c-Fos, and c-Jun and strongly with c-Fos/c-Jun complex and ERG via several distinct ETS2: domains including the C-terminal region that contains the DNA-binding domain, Strikingly, these interactions were stabilized in vitro by DNA as they were inhibited by ethidium bromide, Both the N-terminal region, comprising the transactivation domain, and the C-terminal region of ETS2 associated with ERG and, interestingly, the interaction of ERG through the transactivation domain of ETS2 was DNA-independent, The DNA-dependent interaction of ETS2 with c-Fos/c-Jun was enhanced by specific DNA fragments requiring two Ets-binding-sites of the stromelysin-1 promoter, Using the two hybrid system, we also demonstrated that ETS2 interacts with c-Jun or ERG in vivo.	INST BIOL,CNRS IFR3,F-59021 LILLE,FRANCE					Buttice', Giovanna/0000-0001-6550-5585				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KURAS L, 1995, MOL CELL BIOL, V15, P208, DOI 10.1128/MCB.15.1.208; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; Min W, 1996, MOL CELL BIOL, V16, P359; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; QUINONES S, 1989, J BIOL CHEM, V264, P8339; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	37	96	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26188	26195		10.1074/jbc.272.42.26188	http://dx.doi.org/10.1074/jbc.272.42.26188			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334186	hybrid			2022-12-27	WOS:A1997YB13900020
J	Kelm, RJ; Elder, PK; Strauch, AR; Getz, MJ				Kelm, RJ; Elder, PK; Strauch, AR; Getz, MJ			Sequence of cDNAs encoding components of vascular actin single-stranded DNA-binding factor 2 establish identity to Pur alpha and Pur beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CELLULAR PROTEINS YB-1; FAR UPSTREAM ELEMENT; GENE PROMOTER; C-MYC; STIMULATES TRANSCRIPTION; ATHEROMATOUS PLAQUE; IDENTIFICATION; FIBROBLASTS; ENHANCER	Transcriptional repression of the mouse vascular smooth muscle cu-actin gene in fibroblasts and myoblasts is mediated, in part, by the interaction of two single-stranded DNA binding activities with opposite strands of an essential transcription enhancer factor-1 recognition element (Sun, S., Stoflet, E. S., Cogan, J. G., Strauch, A. R., and Getz, M. J. (1995) Mol. Cell. Biol. 15, 2429-2436). One of these activities, previously designated vascular actin single-stranded DNA-binding factor 2 includes two distinct polypeptides (p44 and p46) which specifically interact with the purine rich strand of both the enhancer and a related element in a protein coding exon of the gene (Kelm, R. J., Jr., Sun, S., Strauch, A. R., and Getz, M. J. (1996) J. Biol. Chem. 271, 24278-24285). Expression screening of a mouse lung cDNA library with a vascular actin single-stranded DNA-binding factor 2 recognition element has now resulted in the isolation of two distinct cDNA clones that encode p46 and p44, One of these proteins is identical to Pur alpha, a retinoblastoma-binding; protein previously implicated in both transcriptional activation and DNA replication, The other is a related family member, presumably Pur beta, Comparative band shift and Southwestern blot analyses conducted with cellular p46, p44, and cloned Pur proteins synthesized in vitro and in vivo, establish identity of p46 with Pur alpha and p44 with Pur beta. This study implicates Pur alpha and/or Pur beta in the control of vascular smooth muscle alpha-actin gene transcription.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; OHIO STATE UNIV,COLL MED,DEPT ANAT CELL BIOL & NEUROBIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,BIOCHEM PROGRAM,COLUMBUS,OH 43210	Mayo Clinic; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NHLBI NIH HHS [R01 HL54281] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELBASSET EM, 1991, NEUROSCI LETT, V125, P117, DOI 10.1016/0304-3940(91)90005-E; ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; BABAEV VR, 1990, AM J PATHOL, V136, P1031; BAZAR L, 1995, J BIOL CHEM, V270, P8241, DOI 10.1074/jbc.270.14.8241; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; BETZ E, 1991, J CELL PHYSIOL, V147, P385, DOI 10.1002/jcp.1041470302; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; COGAN JG, 1994, MOL BIOL CELL, V5, P950; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; Duncan R, 1996, MOL CELL BIOL, V16, P2274; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; HAAS S, 1995, J BIOL CHEM, V270, P12503, DOI 10.1074/jbc.270.21.12503; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; HERAULT Y, 1993, CELL MOL BIOL RES, V39, P717; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Jurk M, 1996, NUCLEIC ACIDS RES, V24, P2799, DOI 10.1093/nar/24.14.2799; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; KOCHER O, 1991, LAB INVEST, V65, P459; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LECAIN E, 1991, J NEUROSCI RES, V28, P601, DOI 10.1002/jnr.490280417; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MIN BH, 1990, J BIOL CHEM, V265, P16667; PAN WT, 1990, J BIOL CHEM, V265, P7022; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; SCHURCH W, 1992, HISTOLOGY PATHOLOGIS, P109; SEALEY L, 1987, MOL CELL BIOL, V7, P787, DOI 10.1128/MCB.7.2.787; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; Skalli O., 1988, MOL CELLULAR BIOL WO; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; WILKISON WO, 1990, J BIOL CHEM, V265, P477	45	73	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26727	26733		10.1074/jbc.272.42.26727	http://dx.doi.org/10.1074/jbc.272.42.26727			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334258	hybrid			2022-12-27	WOS:A1997YB13900092
J	Trumbore, MW; Wang, RH; Enkemann, SA; Berger, SL				Trumbore, MW; Wang, RH; Enkemann, SA; Berger, SL			Prothymosin alpha in vivo contains phosphorylated glutamic acid residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; BINDS HISTONES; RAT THYMUS; IN-VITRO; C-MYC; GENE; EXPRESSION; PROTEIN; NUCLEOPLASMIN; LOCALIZATION	Human and monkey prothymosin alpha contain activated carbonyl groups on glutamic acid residues. Three lines of evidence indicate the existence of unusual phosphates. 1) Prothymosin alpha continued to be metabolically labeled with [P-32]orthophosphoric acid despite a mutation at Ser(1), the sole site of phosphate in purified bovine prothymosin alpha (Sburlati, A. R., De La Rosa, A., Batey D. W., Kurys, G. L., Manrow, R. E., Pannell, L. K., Martin, B. M., Sheeley, D. M., and Berger, S. L. (1993) Biochemistry 32, 4587-4596), 2) Immediately upon cell lysis, the pH stability curves of metabolically label ed native [P-32]prothymosin alpha or a [P-32]histidine-tagged variant resembled the pH stability curve of acetyl phosphate. 3) After a brief incubation at pH ?, these curves changed from a pattern diagnostic for an acyl phosphate to that characteristic of a serine or threonine phosphate, an observation consistent with transfer of phosphate in vitro. Our data indicate that most of prothymosin alpha's phosphates are subject instantaneously to hydrolysis, based on the observation that greater than 90% of the phosphate initially found at pH 7 disappeared at the extremes of pH. Rapid loss of phosphate was not affected by the presence of phosphatase inhibitors including 50 mM sodium fluoride, 1 mM okadaic acid, and 0.5 mM calyculin A. The amount of phosphate missing could not be ascertained, but the trifling amount recovered on Ser or Thr depended heavily on conditions favoring the transient survival of labile phosphate. Further analysis using COS cells lysed in the presence of sodium borohydride showed that: 1) phosphate recovered on prothymosin alpha decreased 8-fold when lysates were treated with borohydride; 2) the reagent caused 4-8 glutamic acid residues/molecule to vanish; 3) using [H-3]NaBH4, label was introduced into proline, a product derived from reductive cleavage of phosphoglutamate; and 4) [H-3]proline was localized almost exclusively to a peptide with pronounced homology to the histone binding site of nucleoplasmin, a chromatin remodeling protein found in Xenopus laevis. Our data demonstrate that prothymosin a is energy-rich by virtue of stoichiometric amounts of glutamyl phosphate.	NCI, SECT GENES & GENE PROD, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANTHONY RS, 1972, J BIOL CHEM, V247, P2120; Appleby JL, 1996, CELL, V86, P845, DOI 10.1016/S0092-8674(00)80158-0; BARCIA MG, 1992, FEBS LETT, V312, P152, DOI 10.1016/0014-5793(92)80924-6; BERGER SL, 1994, ANAL BIOCHEM, V222, P1, DOI 10.1006/abio.1994.1445; BLACK S, 1955, J BIOL CHEM, V213, P27; BURGLIN TR, 1987, GENE DEV, V1, P97, DOI 10.1101/gad.1.1.97; BUSTELO XR, 1991, J BIOL CHEM, V266, P1443; COHENSOLAL L, 1979, BIOCHEM J, V177, P81, DOI 10.1042/bj1770081; COHENSOLAL L, 1979, P NATL ACAD SCI USA, V76, P4327, DOI 10.1073/pnas.76.9.4327; COHENSOLAL L, 1985, ANAL BIOCHEM, V151, P82, DOI 10.1016/0003-2697(85)90055-7; COTTAM GL, 1969, BIOCHEM BIOPH RES CO, V35, P895, DOI 10.1016/0006-291X(69)90708-6; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DELAMO FF, 1995, FEBS LETT, V359, P15, DOI 10.1016/0014-5793(94)01427-3; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; Dingwall C, 1990, Semin Cell Biol, V1, P11; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DOSIL M, 1990, FEBS LETT, V269, P373, DOI 10.1016/0014-5793(90)81196-U; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; FRILLINGOS S, 1991, MOL CELL BIOCHEM, V108, P85; GAST K, 1995, BIOCHEMISTRY-US, V34, P13211, DOI 10.1021/bi00040a037; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1391, DOI 10.1073/pnas.81.5.1391; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1008, DOI 10.1073/pnas.81.4.1008; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Jencks W. P., 1976, HDB BIOCH MOL BIOL, V1, P296; KAHLENBERG A, 1968, ARCH BIOCHEM BIOPHYS, V126, P331, DOI 10.1016/0003-9861(68)90589-4; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOSHLAND DE, 1993, SCIENCE, V262, P532, DOI 10.1126/science.8211179; KOSHLAND DE, 1952, J AM CHEM SOC, V74, P2286, DOI 10.1021/ja01129a035; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; KUBOTA S, 1995, EUR J BIOCHEM, V233, P48, DOI 10.1111/j.1432-1033.1995.048_1.x; LANDAIS JC, 1989, CONNECT TISSUE RES, V19, P1, DOI 10.3109/03008208909016810; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; MALIN EL, 1989, ANAL BIOCHEM, V181, P315, DOI 10.1016/0003-2697(89)90249-2; MANROW RE, 1993, J MOL BIOL, V234, P281, DOI 10.1006/jmbi.1993.1583; MANROW RE, 1991, J BIOL CHEM, V266, P3916; MARDH S, 1971, BIOCHIM BIOPHYS ACTA, V251, P419, DOI 10.1016/0005-2795(71)90131-0; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; MORI M, 1993, ONCOGENE, V8, P2821; PAPAMARCAKI T, 1994, FEBS LETT, V345, P71, DOI 10.1016/0014-5793(94)00439-0; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; POST RL, 1973, ORG ENERGY TRANSDUCI, P25; ROBSON E, 1993, HISTOCHEM J, V25, P497; Sburlati A R, 1990, Protein Expr Purif, V1, P184, DOI 10.1016/1046-5928(90)90014-P; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SBURLATI AR, 1993, BIOCHEMISTRY-US, V32, P4587, DOI 10.1021/bi00068a015; SEALY L, 1986, BIOCHEMISTRY-US, V25, P3064, DOI 10.1021/bi00358a049; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; SUZUKI F, 1969, J BIOCHEM, V66, P767, DOI 10.1093/oxfordjournals.jbchem.a129206; Vareli K, 1996, EUR J BIOCHEM, V238, P799, DOI 10.1111/j.1432-1033.1996.0799w.x; Wang RH, 1997, J BIOL CHEM, V272, P26405, DOI 10.1074/jbc.272.42.26405; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	59	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26394	26404		10.1074/jbc.272.42.26394	http://dx.doi.org/10.1074/jbc.272.42.26394			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334214	hybrid			2022-12-27	WOS:A1997YB13900048
J	Wu, WJ; Leonard, DA; ACerione, R; Manor, D				Wu, WJ; Leonard, DA; ACerione, R; Manor, D			Interaction between Cdc42Hs and RhoGDI is mediated through the Rho insert region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEINS; GUANINE-NUCLEOTIDE EXCHANGE; WISKOTT-ALDRICH SYNDROME; RASGAP-RELATED PROTEIN; DBL ONCOGENE PRODUCT; ACTIN POLYMERIZATION; KINASE; IDENTIFICATION; RAC	Members of the Rho subfamily of GTP binding proteins contain a region of amino acid sequence (residues 122-134) that is absent from other Ras-like proteins and is termed the Rho insert region, To address the functional role of this domain, we have constructed a Cdc42Hs/Ras chimera in which loop 8 from Ha-Ras was substituted for the region in Cdc42Hs that contains the 13-amino acid insert region, Our data indicate that the insert region of Cdc42Hs is not essential for its interactions with various target/effector molecules or for interactions with the guanine nucleotide exchange factor, Dbl, or the Cdc42 GTPase-activating protein (GAP), However, the regulation of GDP dissociation and GTP hydrolysis on Cdc42Hs by the Rho GDP-dissociation inhibitor (GDI) is extremely sensitive to changes in the insert region, such that a Cdc42Hs/Ha-Ras chimera that lacks this insert is no longer susceptible to a GDI-induced inhibition of GDP dissociation and GTP hydrolysis, The insensitivity to GDI activity is not due to the inability of the GDI molecule to bind to the Cdc42Hs/Ha-Ras chimera, and in fact, the GDI is fully capable of stimulating the release of this chimera from membranes.	CORNELL UNIV,CTR VET MED,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University					NEI NIH HHS [EY06429] Funding Source: Medline; NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Best A, 1996, J BIOL CHEM, V271, P3756; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CERIONE RA, 1996, CURR OPIN CELL BIOL, V8, P205; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEONARD D, 1992, J BIOL CHEM, V267, P22860; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Nomanbhoy TK, 1996, BIOCHEMISTRY-US, V35, P4602, DOI 10.1021/bi951743d; OLSON ME, 1995, SCIENCE, V269, P53; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; SUTCLIFF M, 1995, PROTEIN PEPTIDE LETT, V1, P84; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; UEDA T, 1990, J BIOL CHEM, V265, P9373; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517	36	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26153	26158		10.1074/jbc.272.42.26153	http://dx.doi.org/10.1074/jbc.272.42.26153			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334181	hybrid			2022-12-27	WOS:A1997YB13900015
